<SEC-DOCUMENT>0001140361-15-018544.txt : 20150508
<SEC-HEADER>0001140361-15-018544.hdr.sgml : 20150508
<ACCEPTANCE-DATETIME>20150508170039
ACCESSION NUMBER:		0001140361-15-018544
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		10
CONFORMED PERIOD OF REPORT:	20150331
FILED AS OF DATE:		20150508
DATE AS OF CHANGE:		20150508

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			BIOTIME INC
		CENTRAL INDEX KEY:			0000876343
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				943127919
		STATE OF INCORPORATION:			CA
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-12830
		FILM NUMBER:		15847687

	BUSINESS ADDRESS:	
		STREET 1:		1301 HARBOR BAY PARKWAY
		CITY:			ALAMEDA
		STATE:			CA
		ZIP:			94502
		BUSINESS PHONE:		5105213390

	MAIL ADDRESS:	
		STREET 1:		1301 HARBOR BAY PARKWAY
		CITY:			ALAMEDA
		STATE:			CA
		ZIP:			94502
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>form10q.htm
<DESCRIPTION>BIOTIME INC 10-Q 3-31-2015
<TEXT>
<html>
<head>
<title></title>
<!--Licensed to: Summit Financial Printing, LLC
    Document created using EDGARfilings PROfile 3.3.0.0
    Copyright 1995 - 2015 Summit Financial Printing, LLC.  All rights reserved.-->
</head>
<body style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt" bgcolor="#ffffff" text="#000000">
<div>
<hr style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center; BACKGROUND-COLOR: #ffffff; HEIGHT: 10px; COLOR: #ffffff; MARGIN-LEFT: auto; BORDER-TOP: black 4px solid; MARGIN-RIGHT: auto">
</div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 14pt">UNITED STATES</div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 14pt">SECURITIES AND EXCHANGE COMMISSION</div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 12pt">Washington, D.C. 20549</div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">&#160;</div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 18pt; FONT-WEIGHT: bold">FORM 10-Q</div>

<div>&#160;</div>

<div>
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt" id="c7cbca3c478a457eb8b94b97e258f943" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr style="VERTICAL-ALIGN: top">
<td style="WIDTH: 18pt; VERTICAL-ALIGN: top; align: right">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#9746;</div>
</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top; align: left">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</div>
</td>
</tr>
</table>
</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">For the quarterly period ended March 31, 2015</div>

<div><br>
</div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">OR</div>

<div><br>
</div>

<div>
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt" id="498f4e0a4b174c218c9a0b524d79e715" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr style="VERTICAL-ALIGN: top">
<td style="WIDTH: 18pt; VERTICAL-ALIGN: top; align: right">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#9744;</div>
</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top; align: left">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</div>
</td>
</tr>
</table>
</div>

<div><br>
</div>

<div style="TEXT-ALIGN: justify; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">For the transition period from _________ to ________</div>

<div style="TEXT-ALIGN: justify"><br>
</div>

<div style="TEXT-ALIGN: justify; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">Commission file number<font style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold"> 1-12830</font></div>

<div><br>
</div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 24pt; FONT-WEIGHT: bold">BioTime, Inc.</div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">(Exact name of registrant as specified in its charter)</div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">&#160;</div>

<table style="WIDTH: 100%; BORDER-COLLAPSE: collapse; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt" id="74cd1c5269e94000ac38464e7a0b77c7" border="0" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 49.01%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">California</div>
</td>
<td style="WIDTH: 1.99%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</div>
</td>
<td style="WIDTH: 49%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">94-3127919</div>
</td>
</tr>

<tr>
<td style="WIDTH: 49.01%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">(State or other jurisdiction of incorporation or organization)</div>
</td>
<td style="WIDTH: 1.99%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">&#160;</div>
</td>
<td style="WIDTH: 49%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">(IRS Employer Identification No.)</div>
</td>
</tr>
</table>

<div style="TEXT-ALIGN: justify; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">&#160;</div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">1301 Harbor Bay Parkway, Suite 100</div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Alameda, California 94502</div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">(Address of principal executive offices)</div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">&#160;</div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(510) 521-3390</div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">(Registrant's telephone number, including area code)</div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">&#160;</div>

<div style="TEXT-ALIGN: justify; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.<font face="Wingdings 2"> </font><font style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">&#9746;</font> Yes&#160;&#160;&#160;&#160;<font style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">&#9744;</font> No</div>

<div style="TEXT-ALIGN: justify; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">&#160;</div>

<div style="TEXT-ALIGN: justify; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">Indicate by check mark whether the registrant has submitted electronically and posted on its corporate website, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).<font face="Wingdings"> </font><font style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">&#9746;</font> Yes&#160;&#160;&#160;&#160;<font style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">&#9744;</font> No</div>

<div style="TEXT-ALIGN: justify; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">&#160;</div>

<div style="TEXT-ALIGN: justify; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; and &#8220;smaller reporting company&#8221; in Rule 12b-2 of the Exchange Act.</div>

<div style="TEXT-ALIGN: justify; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">&#160;</div>

<table style="WIDTH: 100%; BORDER-COLLAPSE: collapse; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt" id="1f5a3ac86d0e4cacbb81ad56f721e017" border="0" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 22.19%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">Large accelerated filer</div>
</td>
<td style="WIDTH: 2.21%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">&#9744;</div>
</td>
<td style="WIDTH: 45.8%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">&#160;</div>
</td>
<td style="WIDTH: 27.6%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">Accelerated filer</div>
</td>
<td style="WIDTH: 2.2%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">&#9746;</div>
</td>
</tr>

<tr>
<td style="WIDTH: 22.19%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">Non-accelerated filer</div>
</td>
<td style="WIDTH: 2.21%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">&#9744;</div>
</td>
<td style="WIDTH: 45.8%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">(Do not check if a smaller reporting company)</div>
</td>
<td style="WIDTH: 27.6%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">Smaller reporting company </div>
</td>
<td style="WIDTH: 2.2%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">&#9744;</div>
</td>
</tr>
</table>

<div style="TEXT-ALIGN: justify; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">&#160;</div>

<div style="TEXT-ALIGN: justify; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).<font style="FONT-FAMILY: Wingdings; FONT-SIZE: 10pt"> o</font> Yes<font style="FONT-FAMILY: 'Wingdings 2', serif; FONT-SIZE: 10pt"> T</font> No</div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">&#160;</div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">APPLICABLE ONLY TO CORPORATE ISSUERS:</div>

<div><br>
</div>

<div style="TEXT-ALIGN: justify; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">Indicate the number of shares outstanding of each of the issuer's classes of common stock, as of the latest practicable date: 83,266,153 common shares, no par<font style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt"> value, as of May 1</font><font style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">, 2015</font></div>

<div style="TEXT-ALIGN: justify; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">&#160;</div>

<div style="TEXT-ALIGN: justify; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">
<hr style="BORDER-BOTTOM: black 4px solid; TEXT-ALIGN: center; BACKGROUND-COLOR: #ffffff; HEIGHT: 10px; COLOR: #ffffff; MARGIN-LEFT: auto; BORDER-TOP: black 1px solid; MARGIN-RIGHT: auto">
</div>

<div style="MARGIN-TOP: 10pt; MARGIN-BOTTOM: 10pt; CLEAR: both" id="DSPFPageBreakArea">
<hr style="BORDER-RIGHT-WIDTH: 0px; BACKGROUND-COLOR: #000000; PAGE-BREAK-AFTER: always; MARGIN: 4px 0px; WIDTH: 100%; BORDER-TOP-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; HEIGHT: 2px; COLOR: #000000; CLEAR: both; BORDER-LEFT-WIDTH: 0px" id="DSPFPageBreak" noshade="noshade">
</div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">PART 1--FINANCIAL INFORMATION</div>

<div><br>
</div>

<div style="TEXT-ALIGN: justify; FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman', Times, serif; MARGIN-LEFT: 0.1pt; FONT-SIZE: 10pt; MARGIN-RIGHT: 0.1pt">Statements made in this Form 10-Q that are not historical facts may constitute forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those discussed. Words such as &#8220;expects,&#8221; &#8220;may,&#8221; &#8220;will,&#8221; &#8220;anticipates,&#8221; &#8220;intends,&#8221; &#8220;plans,&#8221; &#8220;believes,&#8221; &#8220;seeks,&#8221; &#8220;estimates,&#8221; and similar expressions identify forward-looking statements. See &#8220;Risk Factors.&#8221;</div>

<div><br>
</div>

<div style="TEXT-ALIGN: justify; FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman', Times, serif; MARGIN-LEFT: 0.1pt; FONT-SIZE: 10pt; MARGIN-RIGHT: 0.1pt">References to &#8220;we&#8221; means BioTime, Inc. and its subsidiaries unless the context otherwise indicates.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: justify; FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">The description or discussion, in this Form 10-Q, of any contract or agreement is a summary only and is qualified in all respects by reference to the full text of the applicable contract or agreement.</div>

<div style="TEXT-ALIGN: justify; FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">&#160;</div>

<div style="MARGIN-TOP: 10pt; MARGIN-BOTTOM: 10pt; CLEAR: both" id="DSPFPageBreakArea">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 8pt" id="DSPFPageNumberArea">2</div>

<hr style="BORDER-RIGHT-WIDTH: 0px; BACKGROUND-COLOR: #000000; PAGE-BREAK-AFTER: always; MARGIN: 4px 0px; WIDTH: 100%; BORDER-TOP-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; HEIGHT: 2px; COLOR: #000000; CLEAR: both; BORDER-LEFT-WIDTH: 0px" id="DSPFPageBreak" noshade="noshade">
</div>

<div style="TEXT-ALIGN: left">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt" id="c505e344a02a4c38b2c642cd985c9d6a" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 36pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top; FONT-WEIGHT: bold; align: right">Item 1.</td>
<td style="TEXT-ALIGN: left; WIDTH: auto; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top">&#160;<font style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Financial Statements</font></td>
</tr>
</table>
</div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">BIOTIME, INC. AND SUBSIDIARIES</div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">CONDENSED CONSOLIDATED BALANCE SHEETS</div>

<div style="TEXT-ALIGN: center"><br>
</div>

<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt" id="0c3c04096da448cd8a1648ba9e92332a" cellspacing="0" cellpadding="0">
<tr>
<td style="PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; WHITE-SPACE: nowrap; VERTICAL-ALIGN: bottom" colspan="2">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">March 31, </div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">2015</div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">(Unaudited)</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; VERTICAL-ALIGN: bottom" valign="bottom" colspan="2">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">December 31,</div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">2014</div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">(Note 1)</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman', Times, serif; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt; FONT-WEIGHT: bold">ASSETS</div>
</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2"></td>
<td style="TEXT-ALIGN: left; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2"></td>
<td style="TEXT-ALIGN: left; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman', Times, serif; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">CURRENT ASSETS</div>
</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2"></td>
<td style="TEXT-ALIGN: left; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2"></td>
<td style="TEXT-ALIGN: left; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman', Times, serif; MARGIN-LEFT: 16.2pt; FONT-SIZE: 10pt">Cash and cash equivalents</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">$</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">25,829,533</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">$</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">29,486,909</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman', Times, serif; MARGIN-LEFT: 16.2pt; FONT-SIZE: 10pt">Trade accounts and grants receivable, net</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">866,180</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">1,041,856</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman', Times, serif; MARGIN-LEFT: 16.2pt; FONT-SIZE: 10pt">Inventory</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">299,308</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">266,022</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman', Times, serif; MARGIN-LEFT: 16.2pt; FONT-SIZE: 10pt">Landlord receivable</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">277,206</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">377,981</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman', Times, serif; MARGIN-LEFT: 16.2pt; FONT-SIZE: 10pt">Prepaid expenses and other current assets</div>
</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">1,271,895</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">1,231,789</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman', Times, serif; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">Total current assets</div>
</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">28,544,122</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">32,404,557</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman', Times, serif; MARGIN-LEFT: 16.2pt; FONT-SIZE: 10pt">Equipment, net and construction in progress (see Note 4)</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">2,864,669</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">2,857,846</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman', Times, serif; MARGIN-LEFT: 16.2pt; FONT-SIZE: 10pt">Deferred license and consulting fees</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">309,458</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">336,833</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman', Times, serif; MARGIN-LEFT: 16.2pt; FONT-SIZE: 10pt">Deposits</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">443,003</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">443,289</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman', Times, serif; MARGIN-LEFT: 16.2pt; FONT-SIZE: 10pt">Other long-term assets</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">7,916</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">9,985</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman', Times, serif; MARGIN-LEFT: 16.2pt; FONT-SIZE: 10pt">Intangible assets, net</div>
</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">37,534,302</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">38,848,396</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #cceeff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman', Times, serif; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">TOTAL ASSETS</div>
</td>
<td style="PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">$</div>
</td>
<td style="BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">69,703,470</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">$</div>
</td>
<td style="BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">74,900,906</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman', Times, serif; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt; FONT-WEIGHT: bold">LIABILITIES AND SHAREHOLDERS' EQUITY</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman', Times, serif; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">CURRENT LIABILITIES</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman', Times, serif; MARGIN-LEFT: 16.2pt; FONT-SIZE: 10pt">Accounts payable and accrued liabilities</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">$</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">6,322,407</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">$</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">6,803,173</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman', Times, serif; MARGIN-LEFT: 16.2pt; FONT-SIZE: 10pt">Capital lease liability, current portion</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">57,500</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">57,500</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman', Times, serif; MARGIN-LEFT: 16.2pt; FONT-SIZE: 10pt">Related party convertible debt, net of discount</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">169,908</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">60,237</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman', Times, serif; MARGIN-LEFT: 16.2pt; FONT-SIZE: 10pt">Deferred grant income</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">1,474,300</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">-</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman', Times, serif; MARGIN-LEFT: 16.2pt; FONT-SIZE: 10pt">Deferred license and subscription revenue, current portion</div>
</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">178,546</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">208,357</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman', Times, serif; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">Total current liabilities</div>
</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">8,202,661</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">7,129,267</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman', Times, serif; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">LONG-TERM LIABILITIES</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman', Times, serif; MARGIN-LEFT: 16.2pt; FONT-SIZE: 10pt">Deferred tax liabilities, net</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">3,337,662</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">4,514,362</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman', Times, serif; MARGIN-LEFT: 16.2pt; FONT-SIZE: 10pt">Deferred rent liabilities, net of current portion</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">34,967</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">97,280</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman', Times, serif; MARGIN-LEFT: 16.2pt; FONT-SIZE: 10pt">Lease liability</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">560,970</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">377,981</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman', Times, serif; MARGIN-LEFT: 16.2pt; FONT-SIZE: 10pt">Capital lease, net of current portion</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">17,307</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">31,290</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman', Times, serif; MARGIN-LEFT: 16.2pt; FONT-SIZE: 10pt">Other long-term liabilities</div>
</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">38,119</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">27,961</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman', Times, serif; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">Total long-term liabilities</div>
</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">3,989,025</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">5,048,874</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman', Times, serif; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">Commitments and contingencies</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman', Times, serif; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">SHAREHOLDERS' EQUITY</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman', Times, serif; MARGIN-LEFT: 16.2pt; FONT-SIZE: 10pt">Series A Convertible Preferred Stock, no par value, authorized 2,000,000 shares as of March 31, 2015 and December 31, 2014; 70,000 issued and outstanding as of March 31, 2015 and December 31, 2014</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">3,500,000</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">3,500,000</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman', Times, serif; MARGIN-LEFT: 16.2pt; FONT-SIZE: 10pt">Common shares, no par value, authorized 125,000,000 shares as of March 31, 2015 and December 31, 2014; 83,210,775 issued and 78,316,833 outstanding as of March 31, 2015 and 83,121,698 issued and 78,227,756 outstanding at December 31, 2014</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">234,751,802</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">234,842,998</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman', Times, serif; MARGIN-LEFT: 16.2pt; FONT-SIZE: 10pt">Contributed capital</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">7,145</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">7,145</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman', Times, serif; MARGIN-LEFT: 16.2pt; FONT-SIZE: 10pt">Accumulated other comprehensive income</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">238,820</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">185,835</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman', Times, serif; MARGIN-LEFT: 16.2pt; FONT-SIZE: 10pt">Accumulated deficit</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">(192,357,575</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">)</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">(182,190,207</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">)</div>
</td>
</tr>

<tr>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman', Times, serif; MARGIN-LEFT: 16.2pt; FONT-SIZE: 10pt">Treasury stock at cost: 4,893,942 shares at March 31, 2015 and at December 31, 2014</div>
</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">(19,889,788</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">)</div>
</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">(19,889,788</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">)</div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman', Times, serif; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">BioTime, Inc. shareholders' equity</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">26,250,404</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">36,455,983</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman', Times, serif; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">Non-controlling interest</div>
</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">31,261,380</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">26,266,782</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman', Times, serif; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">Total shareholders' equity</div>
</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">57,511,784</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">62,722,765</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #ffffff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman', Times, serif; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY</div>
</td>
<td style="PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">$</div>
</td>
<td style="BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">69,703,470</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">$</div>
</td>
<td style="BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">74,900,906</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>
</table>

<div><br>
</div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">See accompanying notes to the condensed consolidated interim financial statements.</div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">&#160;</div>

<div><br>
</div>

<div style="MARGIN-TOP: 10pt; MARGIN-BOTTOM: 10pt; CLEAR: both" id="DSPFPageBreakArea">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 8pt" id="DSPFPageNumberArea">3</div>

<hr style="BORDER-RIGHT-WIDTH: 0px; BACKGROUND-COLOR: #000000; PAGE-BREAK-AFTER: always; MARGIN: 4px 0px; WIDTH: 100%; BORDER-TOP-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; HEIGHT: 2px; COLOR: #000000; CLEAR: both; BORDER-LEFT-WIDTH: 0px" id="DSPFPageBreak" noshade="noshade">
</div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">BIOTIME, INC. AND SUBSIDIARIES</div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(UNAUDITED)</div>

<div style="TEXT-ALIGN: center"><br>
</div>

<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt" id="fb56fd380ca94916aba7ffbd6ae0e437" cellspacing="0" cellpadding="0">
<tr>
<td style="PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; VERTICAL-ALIGN: bottom" valign="bottom" colspan="6">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">Three Months Ended</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; WHITE-SPACE: nowrap; VERTICAL-ALIGN: bottom" colspan="2">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">March 31, </div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">2015</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; VERTICAL-ALIGN: bottom" valign="bottom" colspan="2">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">March 31, </div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">2014</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2"></td>
<td style="TEXT-ALIGN: left; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2"></td>
<td style="TEXT-ALIGN: left; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman', Times, serif; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt; FONT-WEIGHT: bold">REVENUES:</div>
</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2"></td>
<td style="TEXT-ALIGN: left; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2"></td>
<td style="TEXT-ALIGN: left; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman', Times, serif; MARGIN-LEFT: 16.2pt; FONT-SIZE: 10pt">License fees</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">$</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">319,146</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">$</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">294,504</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman', Times, serif; MARGIN-LEFT: 16.2pt; FONT-SIZE: 10pt">Royalties from product sales</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">156,550</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">97,886</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman', Times, serif; MARGIN-LEFT: 16.2pt; FONT-SIZE: 10pt">Grant income</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">698,839</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">575,659</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman', Times, serif; MARGIN-LEFT: 16.2pt; FONT-SIZE: 10pt">Sale of research products and services</div>
</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">89,919</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">98,586</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman', Times, serif; MARGIN-LEFT: 25.2pt; FONT-SIZE: 10pt">Total revenues</div>
</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">1,264,454</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">1,066,635</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman', Times, serif; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">Cost of sales</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">(264,167</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">)</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">(131,914</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">)</div>
</td>
</tr>

<tr>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman', Times, serif; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">Gross Profit</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">1,000,287</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">934,721</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman', Times, serif; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt; FONT-WEIGHT: bold">OPERATING EXPENSES:</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman', Times, serif; MARGIN-LEFT: 16.2pt; FONT-SIZE: 10pt">Research and development</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">9,323,510</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">8,405,393</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman', Times, serif; MARGIN-LEFT: 16.2pt; FONT-SIZE: 10pt">General and administrative</div>
</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">5,178,800</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">3,667,171</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman', Times, serif; MARGIN-LEFT: 16.2pt; FONT-SIZE: 10pt">Total operating expenses</div>
</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">14,502,310</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">12,072,564</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman', Times, serif; MARGIN-LEFT: 16.2pt; FONT-SIZE: 10pt">Loss from operations</div>
</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">(13,502,023</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">)</div>
</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">(11,137,843</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">)</div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman', Times, serif; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt; FONT-WEIGHT: bold">OTHER INCOME/(EXPENSES):</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman', Times, serif; MARGIN-LEFT: 16.2pt; FONT-SIZE: 10pt">Interest expense, net</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">(25,461</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">)&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">(8,384</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">)</div>
</td>
</tr>

<tr>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman', Times, serif; MARGIN-LEFT: 16.2pt; FONT-SIZE: 10pt">Other income/(expense), net</div>
</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">(239,453</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">)</div>
</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">69,170</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman', Times, serif; MARGIN-LEFT: 25.2pt; FONT-SIZE: 10pt">Total other income/(expenses), net</div>
</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">(264,914</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">)</div>
</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">60,786</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman', Times, serif; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">LOSS BEFORE INCOME TAX BENEFITS</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">(13,766,937</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">)</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">(11,077,057</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">)</div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman', Times, serif; MARGIN-LEFT: 25.2pt; FONT-SIZE: 10pt">Deferred income tax benefit</div>
</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">1,176,882</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">1,349,026</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman', Times, serif; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">NET LOSS</div>
</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">(12,590,055</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">)</div>
</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">(9,728,031</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">)</div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman', Times, serif; MARGIN-LEFT: 25.2pt; FONT-SIZE: 10pt">Net loss attributable to non-controlling interest</div>
</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">2,422,687</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">1,629,017</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #ffffff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman', Times, serif; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt; FONT-WEIGHT: bold">NET LOSS ATTRIBUTABLE TO BIOTIME, INC.</div>
</td>
<td style="PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">$</div>
</td>
<td style="BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">(10,167,368</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">)</div>
</td>
<td style="PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">$</div>
</td>
<td style="BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">(8,099,014</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">)</div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #ffffff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman', Times, serif; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">BASIC AND DILUTED NET LOSS PER COMMON SHARE</div>
</td>
<td style="PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">$</div>
</td>
<td style="BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">(0.13</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">)</div>
</td>
<td style="PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">$</div>
</td>
<td style="BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">(0.14</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">)</div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr style="HEIGHT: 16px">
<td style="PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #ffffff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman', Times, serif; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">WEIGHTED AVERAGE NUMBER OF COMMON STOCK OUTSTANDING: BASIC AND DILUTED</div>
</td>
<td style="PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">78,261,788</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">58,257,427</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>
</table>

<div style="TEXT-ALIGN: justify; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">&#160;</div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">See accompanying notes to the condensed consolidated interim financial statements.</div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">&#160;</div>

<div style="MARGIN-TOP: 10pt; MARGIN-BOTTOM: 10pt; CLEAR: both" id="DSPFPageBreakArea">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 8pt" id="DSPFPageNumberArea">4</div>

<hr style="BORDER-RIGHT-WIDTH: 0px; BACKGROUND-COLOR: #000000; PAGE-BREAK-AFTER: always; MARGIN: 4px 0px; WIDTH: 100%; BORDER-TOP-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; HEIGHT: 2px; COLOR: #000000; CLEAR: both; BORDER-LEFT-WIDTH: 0px" id="DSPFPageBreak" noshade="noshade">
</div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">BIOTIME, INC. AND SUBSIDIARIES</div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(UNAUDITED)</div>

<div><br>
</div>

<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt" id="1853e3a7462043efa3b1ff58ac8726e4" cellspacing="0" cellpadding="0">
<tr>
<td style="PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; VERTICAL-ALIGN: bottom" valign="bottom" colspan="6">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">Three Months Ended</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; VERTICAL-ALIGN: bottom" valign="bottom" colspan="2">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">March 31, 2015</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; VERTICAL-ALIGN: bottom" valign="bottom" colspan="2">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">March 31, 2014</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman', Times, serif; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt; FONT-WEIGHT: bold">NET LOSS</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">$</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">(12,590,055</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">)</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">$</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">(9,728,031</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">)</div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman', Times, serif; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">Other comprehensive income/(loss), net of tax:</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr style="HEIGHT: 14px">
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman', Times, serif; MARGIN-LEFT: 16.2pt; FONT-SIZE: 10pt">Change in foreign currency translation and other comprehensive income/(loss) from equity investments:</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom"></td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">&#160;</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom"></td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">&#160;</div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman', Times, serif; MARGIN-LEFT: 25.2pt; FONT-SIZE: 10pt">Unrealized loss on exchange translation in foreign subsidiaries</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;(53,323</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">)&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">(104,590</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">)&#160;</td>
</tr>

<tr>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman', Times, serif; MARGIN-LEFT: 18pt; FONT-SIZE: 10pt">Unrealized gain/(loss) on available-for-sale securities, net of taxes</div>
</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">338</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">(2,650</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">)</div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman', Times, serif; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt; FONT-WEIGHT: bold">COMPREHENSIVE LOSS</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">(12,643,040</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">)</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">(9,835,271</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">)</div>
</td>
</tr>

<tr>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman', Times, serif; MARGIN-LEFT: 16.2pt; FONT-SIZE: 10pt">Less: Comprehensive loss attributable to non-controlling interest</div>
</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">2,422,687</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">&#160;</div>
</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">1,629,017</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">&#160;</div>
</td>
</tr>

<tr>
<td style="PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #ffffff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman', Times, serif; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt; FONT-WEIGHT: bold">COMPREHENSIVE LOSS ATTRIBUTABLE TO BIOTIME, INC. COMMON SHAREHOLDERS</div>
</td>
<td style="PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">$</div>
</td>
<td style="BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">(10,220,353</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">)</div>
</td>
<td style="PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">$</div>
</td>
<td style="BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">(8,206,254</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">)</div>
</td>
</tr>
</table>

<div><br>
</div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">See accompanying notes to the condensed consolidated interim financial statements.</div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">&#160;</div>

<div><br>
</div>

<div style="MARGIN-TOP: 10pt; MARGIN-BOTTOM: 10pt; CLEAR: both" id="DSPFPageBreakArea">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 8pt" id="DSPFPageNumberArea">5</div>

<hr style="BORDER-RIGHT-WIDTH: 0px; BACKGROUND-COLOR: #000000; PAGE-BREAK-AFTER: always; MARGIN: 4px 0px; WIDTH: 100%; BORDER-TOP-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; HEIGHT: 2px; COLOR: #000000; CLEAR: both; BORDER-LEFT-WIDTH: 0px" id="DSPFPageBreak" noshade="noshade">
</div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">BIOTIME, INC. AND SUBSIDIARIES</div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(UNAUDITED)</div>

<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt" id="f9ab03adaa194770b4e305119a9146ae" cellspacing="0" cellpadding="0">
<tr>
<td style="PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; VERTICAL-ALIGN: bottom" valign="bottom" colspan="6">
<div style="TEXT-ALIGN: left"></div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">Three Months Ended</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; VERTICAL-ALIGN: bottom" valign="bottom" colspan="2">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">March 31, 2015</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; VERTICAL-ALIGN: bottom" valign="bottom" colspan="2">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">March 31, 2014</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman', Times, serif; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">CASH FLOWS FROM OPERATING ACTIVITIES:</div>
</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2"></td>
<td style="TEXT-ALIGN: left; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2"></td>
<td style="TEXT-ALIGN: left; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman', Times, serif; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">Net loss attributable to BioTime, Inc.</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">$</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">(10,167,368</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">)</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">$</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">(8,099,014</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">)</div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman', Times, serif; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">Net loss allocable to non-controlling interest</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">(2,422,687</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">)</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">(1,629,017</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">)</div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman', Times, serif; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">Adjustments to reconcile net loss attributable to BioTime, Inc. to net cash used in operating activities:</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman', Times, serif; MARGIN-LEFT: 16.2pt; FONT-SIZE: 10pt">Depreciation expense</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">262,600</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">256,945</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman', Times, serif; MARGIN-LEFT: 16.2pt; FONT-SIZE: 10pt">Amortization of intangible assets</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">1,314,094</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">1,367,998</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman', Times, serif; MARGIN-LEFT: 16.2pt; FONT-SIZE: 10pt">Amortization of deferred consulting fees</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">-</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">16,279</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman', Times, serif; MARGIN-LEFT: 16.2pt; FONT-SIZE: 10pt">Amortization of deferred license fees</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">27,375</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">27,375</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman', Times, serif; MARGIN-LEFT: 16.2pt; FONT-SIZE: 10pt">Amortization of deferred license, royalty and subscription revenues</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">-</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">(280</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">)</div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman', Times, serif; MARGIN-LEFT: 16.2pt; FONT-SIZE: 10pt">Amortization of prepaid rent in common stock</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">21,146</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">21,146</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman', Times, serif; MARGIN-LEFT: 16.2pt; FONT-SIZE: 10pt">Stock-based compensation</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">1,914,407</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">801,554</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman', Times, serif; MARGIN-LEFT: 16.2pt; FONT-SIZE: 10pt">Amortization of discount on related party convertible debt</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">49,697</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">-</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman', Times, serif; MARGIN-LEFT: 16.2pt; FONT-SIZE: 10pt">Accrued interest on convertible debt</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">3,531</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">-</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman', Times, serif; MARGIN-LEFT: 16.2pt; FONT-SIZE: 10pt">Loss on sale or write-off of equipment</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">-</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">8,576</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman', Times, serif; MARGIN-LEFT: 16.2pt; FONT-SIZE: 10pt">Deferred income tax benefit</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">(1,176,882</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">)</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">(1,349,026</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">)</div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman', Times, serif; MARGIN-LEFT: 16.2pt; FONT-SIZE: 10pt">Deferred grant income</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">1,474,300</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">-</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman', Times, serif; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">Changes in operating assets and liabilities:</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman', Times, serif; MARGIN-LEFT: 16.2pt; FONT-SIZE: 10pt">Accounts receivable, net</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">(56,598</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">)</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">(24,441</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">)</div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman', Times, serif; MARGIN-LEFT: 16.2pt; FONT-SIZE: 10pt">Grant receivable</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">228,191</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">202,122</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman', Times, serif; MARGIN-LEFT: 16.2pt; FONT-SIZE: 10pt">Inventory</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">(33,286</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">)</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">(57,894</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">)</div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman', Times, serif; MARGIN-LEFT: 16.2pt; FONT-SIZE: 10pt">Prepaid expenses and other current assets</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">(60,769</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">)</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">(375,224</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">)</div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman', Times, serif; MARGIN-LEFT: 16.2pt; FONT-SIZE: 10pt">Accounts payable and accrued liabilities</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">(365,175</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">)</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">(1,276,211</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">)</div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman', Times, serif; MARGIN-LEFT: 16.2pt; FONT-SIZE: 10pt">Other long-term liabilities</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">10,727</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">(185,717</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">)</div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman', Times, serif; MARGIN-LEFT: 16.2pt; FONT-SIZE: 10pt">Deferred rent liabilities</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">(62,313</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">)</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">(5,040</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">)</div>
</td>
</tr>

<tr>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman', Times, serif; MARGIN-LEFT: 16.2pt; FONT-SIZE: 10pt">Deferred revenues</div>
</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">(29,811</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">)</div>
</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">(57,402</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">)</div>
</td>
</tr>

<tr>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman', Times, serif; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">Net cash used in operating activities</div>
</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">(9,068,821</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">)</div>
</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">(10,357,271</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">)</div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman', Times, serif; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">CASH FLOWS FROM INVESTING ACTIVITIES:</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman', Times, serif; MARGIN-LEFT: 16.2pt; FONT-SIZE: 10pt">Purchase of equipment</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">(77,007</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">)</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">(231,921</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">)</div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman', Times, serif; MARGIN-LEFT: 16.2pt; FONT-SIZE: 10pt">Payments on construction in progress (see Note 4)</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">(296,382</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">)</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">-</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman', Times, serif; MARGIN-LEFT: 16.2pt; FONT-SIZE: 10pt">Proceeds from the sale of equipment</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">-</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">4,000</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman', Times, serif; MARGIN-LEFT: 16.2pt; FONT-SIZE: 10pt">Security deposit paid, net</div>
</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">-</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">(299,697</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">)</div>
</td>
</tr>

<tr>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman', Times, serif; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">Cash used in investing activities</div>
</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">(373,389</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">)</div>
</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">(527,618</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">)</div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman', Times, serif; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">CASH FLOWS FROM FINANCING ACTIVITIES:</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman', Times, serif; MARGIN-LEFT: 16.2pt; FONT-SIZE: 10pt">Proceeds from exercises of stock options</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">346,713</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">58,500</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman', Times, serif; MARGIN-LEFT: 16.2pt; FONT-SIZE: 10pt">Proceeds from sale of preferred stock</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">-</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">3,500,000</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman', Times, serif; MARGIN-LEFT: 16.2pt; FONT-SIZE: 10pt">Proceeds from issuance of common shares</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">-</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">8,182,559</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman', Times, serif; MARGIN-LEFT: 16.2pt; FONT-SIZE: 10pt">Fees paid on sale of common shares</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">-</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">(212,046</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">)</div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman', Times, serif; MARGIN-LEFT: 16.2pt; FONT-SIZE: 10pt">Proceeds from sale of treasury stock and subsidiary warrants</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">-</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">599,472</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr style="HEIGHT: 12px">
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 76%; MARGIN-LEFT: 9pt; VERTICAL-ALIGN: bottom" valign="bottom">&#160;&#160;&#160; Reimbursement from landlord on construction in progress (see Note 4)</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom"></td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom"></td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">283,764</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap"></td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom"></td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom"></td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">-</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap"></td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman', Times, serif; MARGIN-LEFT: 16.2pt; FONT-SIZE: 10pt">Repayment of capital lease obligation</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">(13,983</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">)</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">-</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman', Times, serif; MARGIN-LEFT: 16.2pt; FONT-SIZE: 10pt">Proceeds from sale of common shares of subsidiary</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">5,499,995</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">-</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman', Times, serif; MARGIN-LEFT: 16.2pt; FONT-SIZE: 10pt">Fees paid on sale of common shares of subsidiary</div>
</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">(432,631</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">)</div>
</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">-</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman', Times, serif; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">Net cash provided by financing activities</div>
</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">5,683,858</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">12,128,485</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman', Times, serif; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">Effect of exchange rate changes on cash and cash equivalents</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">100,976</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">(101,240</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">)</div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman', Times, serif; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">NET CHANGE IN CASH AND CASH EQUIVALENTS:</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">(3,657,376</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">)</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">1,142,356</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman', Times, serif; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">CASH AND CASH EQUIVALENTS:</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman', Times, serif; MARGIN-LEFT: 16.2pt; FONT-SIZE: 10pt">At beginning of the period</div>
</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">29,486,909</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">5,495,478</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #cceeff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman', Times, serif; MARGIN-LEFT: 16.2pt; FONT-SIZE: 10pt">At end of the period</div>
</td>
<td style="PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">$</div>
</td>
<td style="BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">25,829,533</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">$</div>
</td>
<td style="BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">6,637,834</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>
</table>

<div><br>
</div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">See accompanying notes to the condensed consolidated interim financial statements.</div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">&#160;</div>

<div style="MARGIN-TOP: 10pt; MARGIN-BOTTOM: 10pt; CLEAR: both" id="DSPFPageBreakArea">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 8pt" id="DSPFPageNumberArea">6</div>

<hr style="BORDER-RIGHT-WIDTH: 0px; BACKGROUND-COLOR: #000000; PAGE-BREAK-AFTER: always; MARGIN: 4px 0px; WIDTH: 100%; BORDER-TOP-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; HEIGHT: 2px; COLOR: #000000; CLEAR: both; BORDER-LEFT-WIDTH: 0px" id="DSPFPageBreak" noshade="noshade">
</div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">BIOTIME, INC.</div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS</div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(UNAUDITED)</div>

<div style="TEXT-ALIGN: center"><br>
</div>

<div style="TEXT-ALIGN: justify">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt" id="6bb2c3443f604ba0959ae9b627be3877" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 18pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top; FONT-WEIGHT: bold; align: right">1.</td>
<td style="TEXT-ALIGN: justify; WIDTH: auto; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top; FONT-WEIGHT: bold">Organization, Basis of Presentation, and Liquidity</td>
</tr>
</table>
</div>

<div style="TEXT-ALIGN: justify"><br>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman', Times, serif; MARGIN-LEFT: 0.1pt; FONT-SIZE: 10pt; MARGIN-RIGHT: 0.1pt"><font style="FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">General &#8211; </font><font style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">BioTime is a biotechnology company focused on the field of regenerative medicine; specifically human embryonic stem (&#8220;hES&#8221;) cell and induced pluripotent stem (&#8220;iPS&#8221;) cell technology. Regenerative medicine refers to therapies based on stem cell technology that are designed to rebuild cell and tissue function lost due to degenerative disease or injury. hES and iPS cells provide a means of manufacturing every cell type in the human body and therefore show considerable promise for the development of a number of new therapeutic products. BioTime and its subsidiaries are developing stem cell products for research and therapeutic use. BioTime&#8217;s primary therapeutic products are based on its </font><font style="FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">HyStem</font><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup><font style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt"> hydrogel technology and include </font><font style="FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">Renevia</font><font style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">&#8482; a product currently in clinical trials in Europe to facilitate cell transplantation; </font><font style="FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">ReGlyde</font><font style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">&#8482; a product under development for tendon surgery applications; and </font><font style="FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">Premvia</font><font style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">&#8482; for which 510(k) certification has been received for use in wound-management. Asterias Biotherapeutics, Inc. (&#8220;Asterias,&#8221; </font>NYSE MKT: AST<font style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">) is developing pluripotent stem-cell based therapies in neurology and oncology, including AST-OPC1 neural cells in spinal cord injury, and AST-VAC2, a pluripotent stem cell-derived cancer vaccine. OncoCyte Corporation (&#8220;OncoCyte&#8221;) is developing products and technologies to diagnose cancer. ES Cell International Pte Ltd. (&#8220;ESI&#8221;), a Singapore private limited company, is providing its National Institutes of Health (&#8220;NIH&#8221;) approved hES cell lines, manufactured under current good manufacturing practices (&#8216;cGMP&#8221;), to pre-researchers focused on clinical applications through BioTime&#8217;s </font><font style="FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">ESI BIO</font><font style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt"> division. OrthoCyte Corporation (&#8220;OrthoCyte&#8221;) is developing therapies to treat orthopedic disorders, diseases and injuries. ReCyte Therapeutics, Inc. (&#8220;ReCyte Therapeutics&#8221;) is developing therapies to treat a variety of cardiovascular and related ischemic disorders, as well as related products for research. Cell Cure Neurosciences Ltd. (&#8220;Cell Cure Neurosciences&#8221;) is an Israel-based biotechnology company focused on developing stem cell-based therapies for retinal and neurological disorders, including the development of retinal pigment epithelial cells for the treatment of macular degeneration. Research products and services are marketed through LifeMap Sciences Inc. and BioTime&#8217;s </font><font style="FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">ESI BIO</font><font style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt"> division. LifeMap Sciences, Inc. (&#8220;LifeMap Sciences&#8221;) markets, sells and distributes </font><font style="FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">GeneCards</font><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup><font style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">, the leading human gene database and an integrated database suite that includes </font><font style="FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">GeneCards</font><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup><font style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">, the </font><font style="FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">LifeMap Discovery</font><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup><font style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt"> database of embryonic development, stem cell research and regenerative medicine, and </font><font style="FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">MalaCards</font><font style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">&#8482;, the human disease database, and the analysis tools </font><font style="FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">VarElect</font><font style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">&#8482;, a powerful, yet easy-to-use application for prioritizing gene variants resulting from next generation sequencing experiments, and </font><font style="FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">GeneAnalytics</font><font style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">&#8482;, a novel gene set analysis tool. LifeMap Sciences&#8217; subsidiary LifeMap Solutions, Inc. (&#8220;LifeMap Solutions&#8221;) is developing mobile health software products in partnership with the Icahn Institute for Genomics and Multiscale Biology.</font></div>

<div><br>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman', Times, serif; MARGIN-LEFT: 0.1pt; FONT-SIZE: 10pt; MARGIN-RIGHT: 0.1pt">BioTime is focusing a portion of its efforts in the field of regenerative medicine on the development and sale of advanced human stem cell products and technologies that can be used by researchers at universities and other institutions, at companies in the bioscience and biopharmaceutical industries, and at other companies that provide research products to companies in those industries. These products are developed internally or in conjunction with BioTime&#8217;s subsidiaries and marketed through BioTime&#8217;s <font style="FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">ESI BIO</font> division. Products for the research market generally can be sold without regulatory (United States Food and Drug Administration (&#8220;FDA&#8221;)) approval, and are therefore relatively near-term business opportunities when compared to therapeutic products.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">BioTime previously developed blood plasma volume expanders and related technology for use in surgery, emergency trauma treatment and other applications. BioTime&#8217;s operating revenues are now derived primarily from research grants, from licensing fees and advertising from the marketing of the LifeMap Sciences database products, and from the sale of products for research.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">The unaudited condensed consolidated interim balance sheet as of March 31, 2015, the unaudited condensed consolidated interim statements of operations and statements of comprehensive loss for the three months ended March 31, 2015 and 2014, and the unaudited condensed consolidated interim statements of cash flows for the three months ended March 31, 2015 and 2014 have been prepared by BioTime&#8217;s management in accordance with the instructions from Form 10-Q and Regulation S-X. In the opinion of management, all adjustments (consisting only of normal recurring adjustments) necessary to present fairly the financial position, results of operations, and cash flows at March 31, 2015 have been made. The consolidated balance sheet as of December 31, 2014 is derived from the Company&#8217;s annual audited financial statements as of that date. The results of operations for the three months ended March 31, 2015 are not necessarily indicative of the operating results anticipated for the full year of 2015.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">Certain information and footnote disclosures normally included in consolidated financial statements prepared in accordance with U.S. generally accepted accounting principles have been condensed or omitted as permitted by regulations of the Securities and Exchange Commission (&#8220;SEC&#8221;) except for the consolidated balance sheet as of December 31, 2014, which was derived from audited financial statements. Certain previously furnished amounts have been reclassified to conform with presentations made during the current periods. It is suggested that these condensed consolidated interim financial statements be read in conjunction with the annual audited consolidated financial statements and notes thereto included in BioTime&#8217;s Annual Report on Form 10-K for the year ended December 31, 2014.</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">&#160;</div>

<div style="MARGIN-TOP: 10pt; MARGIN-BOTTOM: 10pt; CLEAR: both" id="DSPFPageBreakArea">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 8pt" id="DSPFPageNumberArea">7</div>

<hr style="BORDER-RIGHT-WIDTH: 0px; BACKGROUND-COLOR: #000000; PAGE-BREAK-AFTER: always; MARGIN: 4px 0px; WIDTH: 100%; BORDER-TOP-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; HEIGHT: 2px; COLOR: #000000; CLEAR: both; BORDER-LEFT-WIDTH: 0px" id="DSPFPageBreak" noshade="noshade">
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">Use of estimates</font> &#8211; The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the U.S. ("GAAP") requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">Principles of consolidation</font> &#8211; BioTime&#8217;s consolidated financial statements include the accounts of its subsidiaries. The following table reflects BioTime&#8217;s ownership, directly or through one or more subsidiaries, of the outstanding shares of its subsidiaries as of March 31, 2015.</div>

<div><br>
</div>

<table style="WIDTH: 100%; BORDER-COLLAPSE: collapse; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt" id="06f2f60e6e5b47db823df41a216b9c42" border="0" cellspacing="0" cellpadding="0">
<tr>
<td style="BORDER-LEFT: #000000 2px solid; WIDTH: 23.28%; VERTICAL-ALIGN: top; BORDER-TOP: #000000 2px solid">
<div style="TEXT-ALIGN: left">&#160;</div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Subsidiary</div>
</td>
<td style="BORDER-LEFT: #000000 2px solid; WIDTH: 57%; VERTICAL-ALIGN: top; BORDER-TOP: #000000 2px solid">
<div style="TEXT-ALIGN: left">&#160;</div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Field of Business</div>
</td>
<td style="BORDER-LEFT: #000000 2px solid; WIDTH: 10%; VERTICAL-ALIGN: top; BORDER-TOP: #000000 2px solid">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">BioTime</div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">Ownership</div>
</td>
<td style="BORDER-LEFT: #000000 2px solid; WIDTH: 10%; VERTICAL-ALIGN: top; BORDER-TOP: #000000 2px solid; BORDER-RIGHT: #000000 2px solid">
<div style="TEXT-ALIGN: left">&#160;</div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Country</div>
</td>
</tr>

<tr>
<td style="BORDER-LEFT: #000000 2px solid; BACKGROUND-COLOR: #cceeff; WIDTH: 23.28%; VERTICAL-ALIGN: top; BORDER-TOP: #000000 2px solid">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.7pt; FONT-FAMILY: 'Times New Roman', Times, serif; MARGIN-LEFT: 7.7pt; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">Asterias Biotherapeutics, Inc. (</font>NYSE MKT: AST)</div>
</td>
<td style="BORDER-LEFT: #000000 2px solid; BACKGROUND-COLOR: #cceeff; WIDTH: 57%; VERTICAL-ALIGN: top; BORDER-TOP: #000000 2px solid">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">Research, development and commercialization of human therapeutic products from stem cells, focused initially in the fields of neurology and oncology</div>
</td>
<td style="BORDER-LEFT: #000000 2px solid; BACKGROUND-COLOR: #cceeff; WIDTH: 10%; VERTICAL-ALIGN: top; BORDER-TOP: #000000 2px solid">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">67.5%</div>
</td>
<td style="BORDER-LEFT: #000000 2px solid; BACKGROUND-COLOR: #cceeff; WIDTH: 10%; VERTICAL-ALIGN: top; BORDER-TOP: #000000 2px solid; BORDER-RIGHT: #000000 2px solid">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">USA</div>
</td>
</tr>

<tr>
<td style="BORDER-LEFT: #000000 2px solid; BACKGROUND-COLOR: #ffffff; WIDTH: 23.28%; VERTICAL-ALIGN: top; BORDER-TOP: #000000 2px solid">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.7pt; FONT-FAMILY: 'Times New Roman', Times, serif; MARGIN-LEFT: 7.7pt; FONT-SIZE: 10pt">BioTime Asia, Limited</div>
</td>
<td style="BORDER-LEFT: #000000 2px solid; BACKGROUND-COLOR: #ffffff; WIDTH: 57%; VERTICAL-ALIGN: top; BORDER-TOP: #000000 2px solid">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">Stem cell products for research</div>
</td>
<td style="BORDER-LEFT: #000000 2px solid; BACKGROUND-COLOR: #ffffff; WIDTH: 10%; VERTICAL-ALIGN: top; BORDER-TOP: #000000 2px solid">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">81%</div>
</td>
<td style="BORDER-LEFT: #000000 2px solid; BACKGROUND-COLOR: #ffffff; WIDTH: 10%; VERTICAL-ALIGN: top; BORDER-TOP: #000000 2px solid; BORDER-RIGHT: #000000 2px solid">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">Hong Kong</div>
</td>
</tr>

<tr>
<td style="BORDER-LEFT: #000000 2px solid; BACKGROUND-COLOR: #cceeff; WIDTH: 23.28%; VERTICAL-ALIGN: top; BORDER-TOP: #000000 2px solid">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.7pt; FONT-FAMILY: 'Times New Roman', Times, serif; MARGIN-LEFT: 7.7pt; FONT-SIZE: 10pt">Cell Cure Neurosciences Ltd.</div>
</td>
<td style="BORDER-LEFT: #000000 2px solid; BACKGROUND-COLOR: #cceeff; WIDTH: 57%; VERTICAL-ALIGN: top; BORDER-TOP: #000000 2px solid">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">Age-related macular degeneration</div>
</td>
<td style="BORDER-LEFT: #000000 2px solid; BACKGROUND-COLOR: #cceeff; WIDTH: 10%; VERTICAL-ALIGN: top; BORDER-TOP: #000000 2px solid">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">62.5%(1)</div>
</td>
<td style="BORDER-LEFT: #000000 2px solid; BACKGROUND-COLOR: #cceeff; WIDTH: 10%; VERTICAL-ALIGN: top; BORDER-TOP: #000000 2px solid; BORDER-RIGHT: #000000 2px solid">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">Israel</div>
</td>
</tr>

<tr>
<td style="BORDER-LEFT: #000000 2px solid; BACKGROUND-COLOR: #ffffff; WIDTH: 23.28%; VERTICAL-ALIGN: top; BORDER-TOP: #000000 2px solid">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.7pt; FONT-FAMILY: 'Times New Roman', Times, serif; MARGIN-LEFT: 7.7pt; FONT-SIZE: 10pt">ES Cell International Pte Ltd</div>
</td>
<td style="BORDER-LEFT: #000000 2px solid; BACKGROUND-COLOR: #ffffff; WIDTH: 57%; VERTICAL-ALIGN: top; BORDER-TOP: #000000 2px solid">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">Stem cell products for research, including clinical grade cell lines produced under cGMP</div>
</td>
<td style="BORDER-LEFT: #000000 2px solid; BACKGROUND-COLOR: #ffffff; WIDTH: 10%; VERTICAL-ALIGN: top; BORDER-TOP: #000000 2px solid">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">100%</div>
</td>
<td style="BORDER-LEFT: #000000 2px solid; BACKGROUND-COLOR: #ffffff; WIDTH: 10%; VERTICAL-ALIGN: top; BORDER-TOP: #000000 2px solid; BORDER-RIGHT: #000000 2px solid">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">Singapore</div>
</td>
</tr>

<tr>
<td style="BORDER-LEFT: #000000 2px solid; BACKGROUND-COLOR: #cceeff; WIDTH: 23.28%; VERTICAL-ALIGN: top; BORDER-TOP: #000000 2px solid">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.7pt; FONT-FAMILY: 'Times New Roman', Times, serif; MARGIN-LEFT: 7.7pt; FONT-SIZE: 10pt">LifeMap Sciences, Inc.</div>
</td>
<td style="BORDER-LEFT: #000000 2px solid; BACKGROUND-COLOR: #cceeff; WIDTH: 57%; VERTICAL-ALIGN: top; BORDER-TOP: #000000 2px solid">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">Biomedical, gene, disease, and stem cell databases and tools</div>
</td>
<td style="BORDER-LEFT: #000000 2px solid; BACKGROUND-COLOR: #cceeff; WIDTH: 10%; VERTICAL-ALIGN: top; BORDER-TOP: #000000 2px solid">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">75.8%</div>
</td>
<td style="BORDER-LEFT: #000000 2px solid; BACKGROUND-COLOR: #cceeff; WIDTH: 10%; VERTICAL-ALIGN: top; BORDER-TOP: #000000 2px solid; BORDER-RIGHT: #000000 2px solid">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">USA</div>
</td>
</tr>

<tr>
<td style="BORDER-LEFT: #000000 2px solid; BACKGROUND-COLOR: #ffffff; WIDTH: 23.28%; VERTICAL-ALIGN: top; BORDER-TOP: #000000 2px solid">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.7pt; FONT-FAMILY: 'Times New Roman', Times, serif; MARGIN-LEFT: 7.7pt; FONT-SIZE: 10pt">LifeMap Sciences, Ltd.</div>
</td>
<td style="BORDER-LEFT: #000000 2px solid; BACKGROUND-COLOR: #ffffff; WIDTH: 57%; VERTICAL-ALIGN: top; BORDER-TOP: #000000 2px solid">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">Biomedical, gene, disease, and stem cell databases and tools</div>
</td>
<td style="BORDER-LEFT: #000000 2px solid; BACKGROUND-COLOR: #ffffff; WIDTH: 10%; VERTICAL-ALIGN: top; BORDER-TOP: #000000 2px solid">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">(2)</div>
</td>
<td style="BORDER-LEFT: #000000 2px solid; BACKGROUND-COLOR: #ffffff; WIDTH: 10%; VERTICAL-ALIGN: top; BORDER-TOP: #000000 2px solid; BORDER-RIGHT: #000000 2px solid">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">Israel</div>
</td>
</tr>

<tr>
<td style="BORDER-LEFT: #000000 2px solid; BACKGROUND-COLOR: #cceeff; WIDTH: 23.28%; VERTICAL-ALIGN: top; BORDER-TOP: #000000 2px solid">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.7pt; FONT-FAMILY: 'Times New Roman', Times, serif; MARGIN-LEFT: 7.7pt; FONT-SIZE: 10pt">LifeMap Solutions, Inc.</div>
</td>
<td style="BORDER-LEFT: #000000 2px solid; BACKGROUND-COLOR: #cceeff; WIDTH: 57%; VERTICAL-ALIGN: top; BORDER-TOP: #000000 2px solid">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">Mobile health software</div>
</td>
<td style="BORDER-LEFT: #000000 2px solid; BACKGROUND-COLOR: #cceeff; WIDTH: 10%; VERTICAL-ALIGN: top; BORDER-TOP: #000000 2px solid">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">(2)</div>
</td>
<td style="BORDER-LEFT: #000000 2px solid; BACKGROUND-COLOR: #cceeff; WIDTH: 10%; VERTICAL-ALIGN: top; BORDER-TOP: #000000 2px solid; BORDER-RIGHT: #000000 2px solid">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">USA</div>
</td>
</tr>

<tr>
<td style="BORDER-LEFT: #000000 2px solid; BACKGROUND-COLOR: #ffffff; WIDTH: 23.28%; VERTICAL-ALIGN: top; BORDER-TOP: #000000 2px solid">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.7pt; FONT-FAMILY: 'Times New Roman', Times, serif; MARGIN-LEFT: 7.7pt; FONT-SIZE: 10pt">OncoCyte Corporation</div>
</td>
<td style="BORDER-LEFT: #000000 2px solid; BACKGROUND-COLOR: #ffffff; WIDTH: 57%; VERTICAL-ALIGN: top; BORDER-TOP: #000000 2px solid">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">Cancer diagnostics</div>
</td>
<td style="BORDER-LEFT: #000000 2px solid; BACKGROUND-COLOR: #ffffff; WIDTH: 10%; VERTICAL-ALIGN: top; BORDER-TOP: #000000 2px solid">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">75.3%</div>
</td>
<td style="BORDER-LEFT: #000000 2px solid; BACKGROUND-COLOR: #ffffff; WIDTH: 10%; VERTICAL-ALIGN: top; BORDER-TOP: #000000 2px solid; BORDER-RIGHT: #000000 2px solid">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">USA</div>
</td>
</tr>

<tr>
<td style="BORDER-LEFT: #000000 2px solid; BACKGROUND-COLOR: #cceeff; WIDTH: 23.28%; VERTICAL-ALIGN: top; BORDER-TOP: #000000 2px solid">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.7pt; FONT-FAMILY: 'Times New Roman', Times, serif; MARGIN-LEFT: 7.7pt; FONT-SIZE: 10pt">OrthoCyte Corporation</div>
</td>
<td style="BORDER-LEFT: #000000 2px solid; BACKGROUND-COLOR: #cceeff; WIDTH: 57%; VERTICAL-ALIGN: top; BORDER-TOP: #000000 2px solid">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">Orthopedic diseases, including chronic back pain and osteoarthritis</div>
</td>
<td style="BORDER-LEFT: #000000 2px solid; BACKGROUND-COLOR: #cceeff; WIDTH: 10%; VERTICAL-ALIGN: top; BORDER-TOP: #000000 2px solid">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">100%(3)</div>
</td>
<td style="BORDER-LEFT: #000000 2px solid; BACKGROUND-COLOR: #cceeff; WIDTH: 10%; VERTICAL-ALIGN: top; BORDER-TOP: #000000 2px solid; BORDER-RIGHT: #000000 2px solid">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">USA</div>
</td>
</tr>

<tr>
<td style="BORDER-BOTTOM: #000000 2px solid; BORDER-LEFT: #000000 2px solid; BACKGROUND-COLOR: #ffffff; WIDTH: 23.28%; VERTICAL-ALIGN: top; BORDER-TOP: #000000 2px solid">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.7pt; FONT-FAMILY: 'Times New Roman', Times, serif; MARGIN-LEFT: 7.7pt; FONT-SIZE: 10pt">ReCyte Therapeutics, Inc.</div>
</td>
<td style="BORDER-BOTTOM: #000000 2px solid; BORDER-LEFT: #000000 2px solid; BACKGROUND-COLOR: #ffffff; WIDTH: 57%; VERTICAL-ALIGN: top; BORDER-TOP: #000000 2px solid">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">Vascular disorders, including cardiovascular-related diseases, ischemic conditions, vascular injuries</div>

<div>&#160;</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">Stem cell-derived endothelial and cardiovascular related progenitor cells that have applications in research, drug testing, and therapeutics</div>
</td>
<td style="BORDER-BOTTOM: #000000 2px solid; BORDER-LEFT: #000000 2px solid; BACKGROUND-COLOR: #ffffff; WIDTH: 10%; VERTICAL-ALIGN: top; BORDER-TOP: #000000 2px solid">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">94.8%</div>
</td>
<td style="BORDER-BOTTOM: #000000 2px solid; BORDER-LEFT: #000000 2px solid; BACKGROUND-COLOR: #ffffff; WIDTH: 10%; VERTICAL-ALIGN: top; BORDER-TOP: #000000 2px solid; BORDER-RIGHT: #000000 2px solid">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">USA</div>
</td>
</tr>
</table>

<div><br>
</div>

<div style="TEXT-ALIGN: left">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt" id="d1552f8f9b6b4b5e99d66eadbfefef70" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 18pt"></td>
<td style="WIDTH: 18pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top; align: right">(1)</td>
<td style="TEXT-ALIGN: left; WIDTH: auto; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top">Includes shares owned by <font style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">BioTime, Asterias, and ESI.</font></td>
</tr>
</table>
</div>

<div style="TEXT-ALIGN: left">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt" id="d0ce758a17cf445185c0ee9c32331a95" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 18pt"></td>
<td style="WIDTH: 18pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top; align: right">(2)</td>
<td style="TEXT-ALIGN: left; WIDTH: auto; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top">LifeMap Sciences, Ltd. and LifeMap Solutions, Inc. are wholly-owned subsidiaries of LifeMap Sciences, Inc.</td>
</tr>
</table>
</div>

<div style="TEXT-ALIGN: left">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt" id="2c2fd67907354658a7cf6a80b4f04c5a" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 18pt"></td>
<td style="WIDTH: 18pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top; align: right">(3)</td>
<td style="TEXT-ALIGN: left; WIDTH: auto; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top">Includes shares owned by BioTime and Asterias.</td>
</tr>
</table>
</div>

<div><br>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">All material intercompany accounts and transactions have been eliminated in consolidation. The consolidated financial statements are presented in accordance with GAAP and with the accounting and reporting requirements of SEC Regulation S-X. As of March 31, 2015, BioTime consolidated Asterias, ReCyte Therapeutics, OncoCyte, OrthoCyte, ESI, Cell Cure Neurosciences, BioTime Asia, Limited (&#8220;BioTime Asia&#8221;), LifeMap Sciences, LifeMap Sciences, Ltd., and LifeMap Solutions, Inc. as BioTime has the ability to control their operating and financial decisions and policies through its ownership, and the non-controlling interest is reflected as a separate element of shareholders' equity on BioTime&#8217;s consolidated balance sheets.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">Liquidity</font> &#8211; Since inception, BioTime has incurred significant operating losses and has funded its operations primarily through the issuance of equity securities, payments from research grants, royalties from product sales and sales of research products and services. At March 31, 2015, BioTime had an accumulated deficit of $192,357,575, working capital of $20,341,461 and shareholders&#8217; equity of $57,511,784. BioTime has evaluated its projected cash flows for it and its subsidiaries and believes that its cash and cash equivalents of $25,829,533 as of March 31, 2015, will be sufficient to fund its operations at least through 2015. However, clinical trials being conducted by BioTime&#8217;s subsidiaries, Asterias and Cell Cure Neurosciences will be funded in part with funds from grants and not from cash on hand. If Asterias or Cell Cure Neurosciences were to lose its grant funding it may be required to delay, postpone, or cancel its clinical trials or limit the number of clinical trial sites, or otherwise reduce or curtail its operations unless it is able to obtain from another source adequate financing that could be used for its clinical trial.</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">&#160;</div>

<div><br>
</div>

<div style="MARGIN-TOP: 10pt; MARGIN-BOTTOM: 10pt; CLEAR: both" id="DSPFPageBreakArea">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 8pt" id="DSPFPageNumberArea">8</div>

<hr style="BORDER-RIGHT-WIDTH: 0px; BACKGROUND-COLOR: #000000; PAGE-BREAK-AFTER: always; MARGIN: 4px 0px; WIDTH: 100%; BORDER-TOP-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; HEIGHT: 2px; COLOR: #000000; CLEAR: both; BORDER-LEFT-WIDTH: 0px" id="DSPFPageBreak" noshade="noshade">
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">Certain significant risks and uncertainties</font> &#8211; The operations of BioTime and its subsidiaries are subject to a number of factors that can affect their operating results and financial condition. Such factors include but are not limited to, the following: the results of clinical trials of their respective therapeutic product and medical device candidates; their ability to obtain FDA and foreign regulatory approval to market their respective therapeutic and medical device product candidates; their ability to develop new stem cell research products and technologies; competition from products manufactured and sold or being developed by other companies; the price and demand for their products; their ability to obtain additional financing and the terms of any such financing that may be obtained; their ability to negotiate favorable licensing or other manufacturing and marketing agreements for their products; the availability of ingredients used in their products; and the availability of reimbursement for the cost of their therapeutic and diagnostic products and medical devices (and related treatment) from government health administration authorities, private health coverage insurers, and other organizations.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: justify">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt" id="1876e599ab2440efb72626612b137bb2" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 18pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top; FONT-WEIGHT: bold; align: right">2.</td>
<td style="TEXT-ALIGN: justify; WIDTH: auto; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top; FONT-WEIGHT: bold">Summary of Significant Accounting Policies</td>
</tr>
</table>
</div>

<div><br>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">Revenue recognition</font> &#8211; BioTime complies with ASC 605-10 and recognizes revenue when persuasive evidence of an arrangement exists, delivery has occurred or services have been rendered, the price is fixed or determinable, and collectability is reasonably assured. Grant income and the sale of research products and services are recognized as revenue when earned. Revenues from the sale of research products and services are primarily derived from the sale of hydrogels and stem cell products. Royalty revenues consist of product royalty payments. License fee revenues consist primarily of subscription and advertising revenue from LifeMap Sciences&#8217; online databases and are recognized based upon respective subscription or advertising periods. Other license fees under certain license agreements were recognized during prior periods when earned and reasonably estimable. Royalties earned on product sales are recognized as revenue in the quarter in which the royalty reports are received from the licensee, rather than the quarter in which the sales took place. When BioTime is entitled to receive up-front nonrefundable licensing or similar fees pursuant to agreements under which BioTime has no continuing performance obligations, the fees are recognized as revenues when collection is reasonably assured. When BioTime receives up-front nonrefundable licensing or similar fees pursuant to agreements under which BioTime does have continuing performance obligations, the fees are deferred and amortized ratably over the performance period. If the performance period cannot be reasonably estimated, BioTime amortizes nonrefundable fees over the life of the contract until such time that the performance period can be more reasonably estimated. Milestone payments, if any, related to scientific or technical achievements are recognized in income when the milestone is accomplished if (a) substantive effort was required to achieve the milestone, (b) the amount of the milestone payment appears reasonably commensurate with the effort expended, and (c) collection of the payment is reasonably assured.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">Cash and cash equivalents</font> &#8211; BioTime considers all highly liquid investments purchased with an original maturity of three months or less to be cash equivalents.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">Trade accounts and grants receivable, net</font> &#8211; Net trade receivables amounted to approximately $605,800 and $549,300 and grants receivable amounted to approximately $260,300 and $492,600 as of March 31, 2015 and December 31, 2014, respectively. Net trade receivables include allowance for doubtful accounts of approximately $100,500 as of March 31, 2015 and December 31, 2014 for those amounts deemed uncollectible by BioTime. BioTime evaluates the collectability of its receivables based on a variety of factors, including the length of time receivables are past due and significant one-time events and historical experience. An additional reserve for individual accounts will be recorded if BioTime becomes aware of a customer&#8217;s inability to meet its financial obligations, such as in the case of bankruptcy filings or deterioration in the customer&#8217;s operating results or financial position. If circumstances related to customers change, estimates of the recoverability of receivables would be further adjusted.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">Concentrations of credit risk</font> &#8211; Financial instruments that potentially subject BioTime to significant concentrations of credit risk consist primarily of cash and cash equivalents. BioTime limits the amount of credit exposure of cash balances by maintaining its accounts in high credit quality financial institutions. Cash equivalent deposits with financial institutions may occasionally exceed the limits of insurance on bank deposits; however, BioTime has not experienced any losses on such accounts.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">Inventory &#8211;</font> Inventories are stated at the lower of cost or market. Cost, which includes amounts related to materials, labor, and overhead, is determined in a manner which approximates the first-in, first-out (&#8220;FIFO&#8221;) method.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">Equipment, net and construction in progress</font>&#160;&#8211; Equipment is stated at cost. Equipment and construction in progress is being depreciated using the straight-line method over a period of 36 to 120 months. Construction in progress is not depreciated until the underlying asset is placed into service. See Note 4.</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">&#160;</div>

<div><br>
</div>

<div style="MARGIN-TOP: 10pt; MARGIN-BOTTOM: 10pt; CLEAR: both" id="DSPFPageBreakArea">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 8pt" id="DSPFPageNumberArea">9</div>

<hr style="BORDER-RIGHT-WIDTH: 0px; BACKGROUND-COLOR: #000000; PAGE-BREAK-AFTER: always; MARGIN: 4px 0px; WIDTH: 100%; BORDER-TOP-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; HEIGHT: 2px; COLOR: #000000; CLEAR: both; BORDER-LEFT-WIDTH: 0px" id="DSPFPageBreak" noshade="noshade">
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">Intangible assets, net</font> &#8211; Intangible assets with finite useful lives are amortized over their estimated useful lives and intangible assets with indefinite lives are not amortized but rather are tested at least annually for impairment. Acquired in-process research and development intangible assets are accounted for depending on whether they were acquired as part of an acquisition of a business, or as assets that do not constitute a business. When acquired in conjunction with the acquisition of a business, these assets are considered to be indefinite-lived until the completion or abandonment of the associated research and development efforts and are capitalized as an asset. If and when development is complete, the associated assets would be deemed finite-lived and would then be amortized based on their respective estimated useful lives at that point in time. However, when acquired in conjunction with an acquisition of assets that do not constitute a business (such as the acquisition of assets by Asterias from Geron Corporation), in accordance with the accounting rules in ASC 805-50, such intangible assets related to in-process research and development (&#8220;IPR&amp;D&#8221;) are expensed upon acquisition.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">Treasury stock &#8211;</font> BioTime accounts for BioTime common shares issued to subsidiaries for future potential working capital needs as treasury stock on the consolidated balance sheet. BioTime has registered the BioTime common shares held by its subsidiaries for sale under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;) to enhance the marketability of the shares.</div>

<div style="TEXT-ALIGN: justify"><br>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">Warrants to purchase common stock</font> &#8211; BioTime generally accounts for warrants issued in connection with equity financings as a component of equity. None of the warrants issued by BioTime as of March 31, 2015 include a conditional obligation to issue a variable number of shares; nor was there a deemed possibility that BioTime may need to settle the warrants in cash.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">Cost of sales</font> &#8211; BioTime accounts for the cost of research products acquired for sale and any royalties paid as a result of any revenues in accordance with the terms of the respective licensing agreements as cost of sales on the consolidated statement of operations and comprehensive loss.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">Patent costs &#8211;</font> Costs associated with obtaining patents on products or technology developed are expensed as research and development expenses when incurred.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">Reclassification</font> &#8211; Certain prior year amounts have been reclassified to conform to the current year presentation. Trade and grant receivables are now reported separately from prepaid expenses and other current assets.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">Research and development</font> &#8211; Research and development expenses consist of costs incurred for company-sponsored, collaborative and contracted research and development activities. These costs include direct and research-related overhead expenses including salaries, payroll taxes, consulting fees, research and laboratory fees, rent of research facilities, amortization of intangible assets, and license fees paid to third parties to acquire patents or licenses to use patents and other technology. BioTime expenses research and development costs as such costs are incurred.</div>

<div>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">General and administrative</font> - General and administrative expenses consist principally of compensation and related benefits, including stock-based compensation, for executive and corporate personnel; professional and consulting fees; and allocated overhead.</div>

<div>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">Foreign currency translation gain and other comprehensive loss, &#160;foreign currency transaction gains and losses&#160;&#8211;</font> In countries in which BioTime operates, where the functional currency is other than the U.S. dollar, assets and liabilities are translated using published exchange rates in effect at the consolidated balance sheet date. Revenues and expenses and cash flows are translated using an approximate weighted average exchange rate for the period. Resulting translation adjustments are recorded as a component of accumulated other comprehensive income or loss on the consolidated balance sheet. For the three months ended March 31, 2015 and 2014, other comprehensive loss includes losses of $52,985 and $107,240, respectively which is largely from foreign currency translation.</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 36pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </div>

<div style="TEXT-ALIGN: justify">
<div style="TEXT-ALIGN: justify; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">For transactions denominated in other than the functional currency of BioTime, transactional gains and losses are recorded in other income and expense included in the consolidated statements of operations. For the three months ended March 31, 2015 and 2014, foreign currency transaction loss amounted to $205,149 and $10,212, respectively.</div>

<div style="TEXT-ALIGN: justify; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </div>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">Income taxes &#8211;</font> BioTime accounts for income taxes in accordance with GAAP requirements, which prescribe the use of the asset and liability method, whereby deferred tax asset or liability account balances are calculated at the balance sheet date using current tax laws and rates in effect. Valuation allowances are established when necessary to reduce deferred tax assets when it is more likely than not that a portion or all of the deferred tax assets will not be realized. The FASB guidance also prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more-likely-than-not sustainable upon examination by taxing authorities. Beginning October 1, 2013, Asterias began filing separate U.S. federal income tax returns but effectively BioTime combined Asterias&#8217; tax provision with BioTime&#8217;s consolidated financial statements. For California, Asterias&#8217; activity for 2013 and 2014 have been included in BioTime&#8217;s combined tax return. BioTime recognizes accrued interest and penalties related to unrecognized tax benefits, if any,&#160;as income tax expense, however, no amounts were accrued for the payment of interest and penalties as of March 31, 2015 and 2014. BioTime files a U.S. federal income tax return as well as various state and foreign income tax returns. In general, BioTime is no longer subject to tax examination by major taxing authorities for years before 2010. Although the statute is closed for purposes of assessing additional income and tax in those years, the taxing authorities may still make adjustments to the net operating loss and credit carryforwards used in open years. Therefore the statute should be considered open as it relates to the net operating loss and credit carryforwards. Any potential examinations may include questioning the timing and amount of deductions, the nexus of income among various tax jurisdictions and compliance with U.S. federal, state and local and foreign tax laws. Management does not expect that the total amount of unrecognized tax benefits will materially change over the next year.</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">&#160;</div>

<div><br>
</div>

<div style="MARGIN-TOP: 10pt; MARGIN-BOTTOM: 10pt; CLEAR: both" id="DSPFPageBreakArea">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 8pt" id="DSPFPageNumberArea">10</div>

<hr style="BORDER-RIGHT-WIDTH: 0px; BACKGROUND-COLOR: #000000; PAGE-BREAK-AFTER: always; MARGIN: 4px 0px; WIDTH: 100%; BORDER-TOP-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; HEIGHT: 2px; COLOR: #000000; CLEAR: both; BORDER-LEFT-WIDTH: 0px" id="DSPFPageBreak" noshade="noshade">
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">An income tax benefit of approximately $1,177,000 was recorded for the three months ended March 31, 2015, of which approximately $1,251,000 of the benefit was related to federal offset by adjustment of $74,000 related to state taxes. For the same period in 2014, an income tax benefit of approximately $1,349,000 was recorded, of which approximately $1,151,000 of the benefit was related to federal and $198,000 was related to state taxes.</div>

<div>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">Asterias established deferred tax liabilities primarily related to its acquisition of certain intellectual property. It is more likely than not that the Asterias deferred tax assets are fully realizable since these income tax benefits are expected to be available to offset such Asterias deferred tax liabilities.</div>

<div>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <br>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">In June 2014, Asterias sold 5,000,000 BioTime shares which resulted in a taxable gain of approximately $10.3 million and a tax payable of $3.6 million. Asterias received the BioTime shares from BioTime as part of the consideration for the Asterias common stock and warrants issued to BioTime under an Asset Contribution Agreement among BioTime, Asterias, and Geron Corporation, a tax free transaction. This income tax liability was offset by available net operating losses, resulting in no cash income taxes due from that sale. This transaction was treated as a deemed distribution by Asterias and recorded against equity.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">Stock-based compensation</font>&#160;<font style="FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">&#8211;</font> BioTime follows accounting standards governing share-based payments, which require the measurement and recognition of compensation expense for all share-based payment awards made to directors and employees, including employee stock options, based on estimated fair values. Consistent with FASB guidelines, BioTime utilizes the Black-Scholes Merton option pricing model for valuing share-based payment awards. BioTime's determination of fair value of share-based payment awards on the date of grant using that option-pricing model is affected by BioTime's stock price as well as by assumptions regarding a number of highly complex and subjective variables. These variables include, but are not limited to, BioTime's expected stock price volatility over the term of the awards, and actual and projected employee stock option exercise behaviors; the expected term of options granted, derived from historical data on employee exercises and post-vesting employment termination behavior; and a risk-free interest rate is based on the U.S. Treasury rates in effect during the corresponding period of grant. Although the fair value of employee stock options is determined in accordance with&#160;FASB guidance, changes in the subjective assumptions can materially affect the estimated value.</div>

<div style="TEXT-ALIGN: justify"><br>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">Impairment of long-lived assets</font>&#160;<font style="FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">&#8211;</font> BioTime&#8217;s long-lived assets, including intangible assets, are reviewed annually for impairment and whenever events or changes in circumstances indicate that the carrying amount of an asset may not be fully recoverable. If an impairment indicator is present, BioTime will evaluate recoverability by a comparison of the carrying amount of the assets to future undiscounted net cash flows expected to be generated by the assets. If the assets are impaired, the impairment recognized is measured by the amount by which the carrying amount exceeds the estimated fair value of the assets.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">Deferred license and consulting fees</font> &#8211; Deferred license and consulting fees consist of the value of warrants issued to third parties for services, and deferred license fees paid to acquire rights to use the proprietary technologies of third parties. The value of the warrants is being amortized over the period the services are being provided, and the license fees are being amortized over the estimated useful lives of the licensed technologies or licensed research products. BioTime is applying a 10 year estimated useful life to the technologies and products that it is currently licensing. The estimation of the useful life any technology or product involves a significant degree of inherent uncertainty, since the outcome of research and development or the commercial life of a new product cannot be known with certainty at the time that the right to use the technology or product is acquired. BioTime will review the continued appropriateness of the 10 year estimated useful life for impairments that might occur earlier than the original expected useful lives. BioTime will review its amortization schedules for impairments that might occur earlier than the original expected useful lives. See Note 6.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">Loss per share</font> &#8211; BioTime applies the two-class method for calculating basic earnings per share. Under the two-class method, net income, if any, will be reduced by preferred stock dividends and the residual amount is allocated between common stock and other participating securities based on their participation rights. Participating securities are comprised of Series A convertible preferred stock and participate in dividends, whether declared or not. Basic earnings per share is calculated by dividing net income or loss attributable to BioTime common shareholders by the weighted average number of shares of common stock outstanding, net of unvested restricted stock subject to repurchase by BioTime, if any, during the period. For periods in which BioTime reported a net loss, the participating securities are not contractually obligated to share in the losses of BioTime, and accordingly, no losses have been allocated to the participating securities. Diluted earnings per share is calculated by dividing the net income or loss attributable to BioTime common shareholders by the weighted average number of common shares outstanding, adjusted for the effects of potentially dilutive common stock, which are comprised of stock options and warrants,&#160;using the treasury-stock method, and convertible preferred stock, using the if-converted method. Because BioTime reported losses attributable to common stockholders for all periods presented, all potentially dilutive common stock are antidilutive for those periods. Diluted net loss per share for the three months ended March 31, 2015 and 2014 excludes any effect from 4,893,942 treasury shares, 4,266,605 options and 9,194,679 warrants and 10,546,137 treasury shares, 5,491,301 options and 9,751,615 warrants, respectively, because their inclusion would be antidilutive.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">Fair value of financial instruments</font> &#8211; The fair value of BioTime&#8217;s assets and liabilities, which qualify as financial instruments under FASB guidance regarding disclosures about fair value of financial instruments, approximate the carrying amounts presented in the accompanying consolidated balance sheets. The carrying amounts of cash equivalents, accounts receivable, prepaid expenses and other current assets, accounts payable, accrued expenses and other current liabilities approximate fair values because of the short-term nature of these items.</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">&#160;</div>

<div><br>
</div>

<div style="MARGIN-TOP: 10pt; MARGIN-BOTTOM: 10pt; CLEAR: both" id="DSPFPageBreakArea">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 8pt" id="DSPFPageNumberArea">11</div>

<hr style="BORDER-RIGHT-WIDTH: 0px; BACKGROUND-COLOR: #000000; PAGE-BREAK-AFTER: always; MARGIN: 4px 0px; WIDTH: 100%; BORDER-TOP-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; HEIGHT: 2px; COLOR: #000000; CLEAR: both; BORDER-LEFT-WIDTH: 0px" id="DSPFPageBreak" noshade="noshade">
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman', serif; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman', serif; FONT-SIZE: 10pt">Recently Issued Accounting Pronouncements </font>&#8211; There have been no recent accounting pronouncements or changes in accounting pronouncements during the three months ended March 31, 2015, as compared to the recent accounting pronouncements described in BioTime's 2014 Annual Report on Form 10-K that are of significance or potential significance to BioTime.</div>

<div>&#160;</div>

<div>
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt" id="2e75a01ab9424374aa55f381f7d4fbd1" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 18pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top; FONT-WEIGHT: bold; align: right">3.</td>
<td style="TEXT-ALIGN: justify; WIDTH: auto; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top; FONT-WEIGHT: bold">Inventory</td>
</tr>
</table>
</div>

<div style="TEXT-ALIGN: justify"><br>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">BioTime held $286,513 and $253,227 of inventory of finished products on-site at its corporate headquarters in Alameda, California at March 31, 2015 and December 31, 2014, respectively. Finished goods products of $12,795 were held by a third party on consignment at March 31, 2015 and December 31, 2014.</div>

<div style="TEXT-ALIGN: justify"><br>
</div>

<div style="TEXT-ALIGN: justify">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt" id="8f9b8ab9e576460eb23a10d392033d13" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 18pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top; FONT-WEIGHT: bold; align: right">4.</td>
<td style="TEXT-ALIGN: justify; WIDTH: auto; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top; FONT-WEIGHT: bold">Equipment, net and construction in progress</td>
</tr>
</table>
</div>

<div style="TEXT-ALIGN: justify"><br>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">At March 31, 2015 and December 31, 2014, equipment, furniture and fixtures, and construction in progress were comprised of the following:</div>

<div><br>
</div>

<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt" id="e12b24c17ae7427f883045e159507e7b" cellspacing="0" cellpadding="0">
<tr>
<td style="PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; WHITE-SPACE: nowrap; VERTICAL-ALIGN: bottom" colspan="2">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">March 31, 2015</div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(Unaudited)</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; VERTICAL-ALIGN: bottom" valign="bottom" colspan="2">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">December 31,</div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2014</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman', Times, serif; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">Equipment, furniture and fixtures</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">$</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">4,928,857</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">$</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">4,870,516</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman', Times, serif; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">Construction in progress</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">606,641</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">405,730</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman', Times, serif; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">Accumulated depreciation</div>
</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">(2,670,829</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">)</div>
</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">(2,418,400</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">)</div>
</td>
</tr>

<tr>
<td style="PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #ffffff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman', Times, serif; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">Equipment, net&#160;and construction in progress</div>
</td>
<td style="PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">$</div>
</td>
<td style="BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">2,864,669</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">$</div>
</td>
<td style="BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">2,857,846</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>
</table>

<div style="TEXT-ALIGN: justify"><br>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman', Times, serif; MARGIN-LEFT: 0.1pt; FONT-SIZE: 10pt; MARGIN-RIGHT: 0.1pt">Equipment, furniture and fixtures, and construction in progress at March 31, 2015 include $115,000 financed by capital lease borrowings in June 2014 and $606,641 of construction in progress for Asterias&#8217; Fremont facility. Depreciation expense amounted to $262,600 and $256,945 for the three months ended March 31, 2015 and 2014, respectively. The difference between the depreciation expense recognized in the consolidated statement of operations and the increase in accumulated depreciation of $252,429&#160;in the consolidated balance sheet is partially attributed to the sale of partially depreciated assets and foreign currency rates.</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 36pt; MARGIN-LEFT: 0.1pt; MARGIN-RIGHT: 0.1pt"><br>
</div>

<div style="TEXT-ALIGN: justify; FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; MARGIN-RIGHT: 0.1pt">Construction in progress</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 36pt; MARGIN-LEFT: 0.1pt; MARGIN-RIGHT: 0.1pt"><br>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">Construction in progress of $606,641 as of March 31, 2015 entirely relates to the improvements for Asterias' Fremont facility. Under the terms of the lease agreement, the landlord has provided Asterias with a tenant improvement allowance of $4,400,000, which Asterias is using to construct a laboratory and production facility that can be used to produce human embryonic stem cell and related products under cGMP. Of the $606,641, $560,970 qualify for reimbursement under the tenant improvement allowance. As of March 31, 2015, we received $283,764 from the landlord. The facility is expected to be substantially completed and placed into service in the third quarter of 2015.</div>

<div style="TEXT-ALIGN: justify"><br>
</div>

<div style="TEXT-ALIGN: justify">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt" id="5dc282b3c7cd4483807e725336b5dd8a" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 18pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top; FONT-WEIGHT: bold; align: right">5.</td>
<td style="TEXT-ALIGN: justify; WIDTH: auto; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top; FONT-WEIGHT: bold">Intangible assets, net</td>
</tr>
</table>
</div>

<div><br>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">At March 31, 2015 and December 31, 2014, intangible assets and intangible assets net of amortization were comprised of the following:</div>

<div><br>
</div>

<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt" id="7602d9f04d9a42648e8a75c9c85526a4" cellspacing="0" cellpadding="0">
<tr>
<td style="PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; WHITE-SPACE: nowrap; VERTICAL-ALIGN: bottom" colspan="2">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">March 31, 2015</div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(Unaudited)</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; VERTICAL-ALIGN: bottom" valign="bottom" colspan="2">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">December 31,</div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2014</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman', Times, serif; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">Intangible assets</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">$</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">52,562,549</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">$</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">52,562,549</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman', Times, serif; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">Accumulated amortization</div>
</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">(15,028,247</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">)</div>
</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">(13,714,153</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">)</div>
</td>
</tr>

<tr>
<td style="PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #cceeff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman', Times, serif; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">Intangible assets, net</div>
</td>
<td style="PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">$</div>
</td>
<td style="BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">37,534,302</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">$</div>
</td>
<td style="BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">38,848,396</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>
</table>

<div style="TEXT-ALIGN: justify"><br>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">BioTime amortizes its intangible assets generally over an estimated period of 10 years on a straight line basis. BioTime recognized $1,314,094 and $1,367,998 in amortization expense of intangible assets, included in research and development,&#160;during the three months ended March 31, 2015 and 2014, respectively.</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">&#160;</div>

<div style="TEXT-ALIGN: justify"><br>
</div>

<div style="MARGIN-TOP: 10pt; MARGIN-BOTTOM: 10pt; CLEAR: both" id="DSPFPageBreakArea">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 8pt" id="DSPFPageNumberArea">12</div>

<hr style="BORDER-RIGHT-WIDTH: 0px; BACKGROUND-COLOR: #000000; PAGE-BREAK-AFTER: always; MARGIN: 4px 0px; WIDTH: 100%; BORDER-TOP-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; HEIGHT: 2px; COLOR: #000000; CLEAR: both; BORDER-LEFT-WIDTH: 0px" id="DSPFPageBreak" noshade="noshade">
</div>

<div style="TEXT-ALIGN: justify">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt" id="779ba13124f24bf89f02f0c64b6d54a0" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 18pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top; FONT-WEIGHT: bold; align: right">6.</td>
<td style="TEXT-ALIGN: justify; WIDTH: auto; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top; FONT-WEIGHT: bold">Royalty Obligation and Deferred License Fees</td>
</tr>
</table>
</div>

<div style="TEXT-ALIGN: justify"><br>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">BioTime amortizes deferred license fees over the estimated useful lives of the licensed technologies or licensed research products. BioTime is applying a 10 year estimated useful life to the technologies and products that it is currently licensing. The estimation of the useful life of any technology or product involves a significant degree of inherent uncertainty, since the outcome of research and development or the commercial life a new product cannot be known with certainty at the time that the right to use the technology or product is acquired. BioTime will review its amortization schedules for impairments that might occur earlier than the original expected useful lives.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">As of March 31, 2015, future amortization of deferred license fees described above was as follows:</div>

<div><br>
</div>

<table style="WIDTH: 50%; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt" id="b0e99b49bce6437d8ebfdbfa2c7a3170" border="0" cellspacing="0" cellpadding="0" align="center">
<tr>
<td style="BORDER-BOTTOM: #000000 2px solid; WIDTH: 38%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Year Ended December 31,</div>
</td>
<td style="PADDING-BOTTOM: 2px; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; WIDTH: 10%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Deferred</div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">License Fees</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 38%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">2015</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 10%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">$82,125</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr style="HEIGHT: 16px">
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 38%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">2016</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: center; BACKGROUND-COLOR: #ffffff; WIDTH: 10%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;109,500</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 38%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">2017</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: center; BACKGROUND-COLOR: #cceeff; WIDTH: 10%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;109,500</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 38%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">2018</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: center; BACKGROUND-COLOR: #ffffff; WIDTH: 10%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;73,667</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 38%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">2019</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: center; BACKGROUND-COLOR: #cceeff; WIDTH: 10%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;24,083</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 38%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">Thereafter</div>
</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: center; BACKGROUND-COLOR: #ffffff; WIDTH: 10%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;20,083</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #cceeff; WIDTH: 38%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">Total</div>
</td>
<td style="PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 10%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">$418,958</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>
</table>

<div><br>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">The current portion in the amount of $109,500 is included in prepaid expenses and other current assets. The noncurrent portion in the amount of $309,458 is included in deferred license and consulting fees.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: justify">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt" id="b67f1d917f5e4502b59784959c7cb595" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 18pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top; FONT-WEIGHT: bold; align: right">7.</td>
<td style="TEXT-ALIGN: justify; WIDTH: auto; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top; FONT-WEIGHT: bold">Accounts Payable and Accrued Liabilities</td>
</tr>
</table>
</div>

<div style="TEXT-ALIGN: justify"><br>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">At March 31, 2015 and December 31, 2014, accounts payable and accrued liabilities consisted of the following:</div>

<div><br>
</div>

<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt" id="0d73ea0ddd7441b09d2313e886cb88ae" cellspacing="0" cellpadding="0">
<tr>
<td style="PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; WHITE-SPACE: nowrap; VERTICAL-ALIGN: bottom" colspan="2">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">March 31, 2015</div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(Unaudited)</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; VERTICAL-ALIGN: bottom" valign="bottom" colspan="2">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">December 31,</div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2014</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman', Times, serif; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">Accounts payable</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">$</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">2,707,437</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">$</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">2,296,645</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman', Times, serif; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">Accrued expenses</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">3,092,030</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">3,125,023</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman', Times, serif; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">Accrued bonuses</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">240,689</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">964,189</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman', Times, serif; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">Other current liabilities</div>
</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">282,251</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">417,316</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #cceeff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman', Times, serif; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">Total</div>
</td>
<td style="PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">$</div>
</td>
<td style="BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">6,322,407</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">$</div>
</td>
<td style="BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">6,803,173</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>
</table>

<div><br>
</div>

<div style="TEXT-ALIGN: left">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt" id="3a256fe4f68e4daa9d4406b431543044" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 18pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top; FONT-WEIGHT: bold; align: right">8.</td>
<td style="TEXT-ALIGN: left; WIDTH: auto; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top; FONT-WEIGHT: bold">Related Party Transactions and Related Party Convertible Debt</td>
</tr>
</table>
</div>

<div><br>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">BioTime currently pays $5,050 per month for the use of approximately 900 square feet of office space in New York City, which is made available to BioTime on a month-by-month basis by one of its directors at his cost for use in conducting meetings and other business affairs.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">In February 2015, Asterias raised approximately $5.5 million in aggregate gross proceeds from the sale of 1,410,255 shares of Series A Common Stock at a price of $3.90 per share through an underwritten public offering and a private placement. Broadwood Partners, L.P., British &amp; American Investment Trust PLC and Pedro Lichtinger purchased an aggregate of 1,025,640 of the shares. Broadwood Partners, L.P. is BioTime&#8217;s largest shareholder and one of its directors, Neal C. Bradsher, is President, and one of Asterias&#8217; directors, Richard T. LeBuhn, is Senior Vice President, of Broadwood Capital, Inc., the investment manager of Broadwood Partners, L.P. Pedro Lichtinger is Asterias&#8217; Chief Executive Officer and a member of its Board of Directors. British &amp; American Investment Trust PLC is an affiliate of a stockholder of Asterias and BioTime.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">In July and September 2014, Cell Cure Neurosciences issued certain convertible notes (the &#8220;Convertible Notes&#8221;) to two Cell Cure Neurosciences shareholders other than BioTime in the principal amount of $470,876. One of the Cell Cure Neurosciences shareholders who acquired Convertible Notes is considered a related party.&#160;&#160; The functional currency of Cell Cure Neurosciences is the Israeli New Shekel, however the Convertible Notes are payable in United States dollars. The Convertible Notes bear a stated interest rate of 3% per annum. The total outstanding principal balance of the Convertible Notes, with accrued interest, is due and payable on various maturity dates in July and September 2017. The outstanding principal balance of the Convertible Notes with accrued interest is convertible into Cell Cure Neurosciences ordinary shares at a fixed conversion price of $20.00 per share, at the election of the holder, at any time prior to maturity. Any conversion of the Convertible Notes must be settled with Cell Cure Neurosciences ordinary shares and not with cash. The conversion feature of the Convertible Notes is not accounted for as an embedded derivative under the provisions of ASC 815,<font style="FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt"> Derivatives and Hedging</font> since it is not a freestanding financial instrument and the underlying Cell Cure Neurosciences ordinary shares are not readily convertible into cash. Accordingly, the Convertible Notes are accounted for under ASC 470-20,<font style="FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt"> Debt with Conversion and Other Options.</font> Under ASC 470-20, BioTime determined that a beneficial conversion feature (&#8220;BCF&#8221;) was present on the issuance dates of the Convertible Notes.</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">&#160;</div>

<div><br>
</div>

<div style="MARGIN-TOP: 10pt; MARGIN-BOTTOM: 10pt; CLEAR: both" id="DSPFPageBreakArea">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 8pt" id="DSPFPageNumberArea">13</div>

<hr style="BORDER-RIGHT-WIDTH: 0px; BACKGROUND-COLOR: #000000; PAGE-BREAK-AFTER: always; MARGIN: 4px 0px; WIDTH: 100%; BORDER-TOP-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; HEIGHT: 2px; COLOR: #000000; CLEAR: both; BORDER-LEFT-WIDTH: 0px" id="DSPFPageBreak" noshade="noshade">
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">A conversion feature is beneficial if, on the issuance dates, the effective conversion price is less than the fair value of the issuer&#8217;s capital stock. Since the effective conversion price of $20.00 per share is less than the estimated $41.00 per share fair value of Cell Cure Neurosciences ordinary shares on the dates the Convertible Notes were issued, a beneficial conversion feature equal to the intrinsic value is present. In accordance with ASC 470-20-30-8, if the intrinsic value of the BCF is greater than the proceeds allocated to the convertible instrument, the amount of the discount assigned to the BCF is limited to the amount of the proceeds allocated to the convertible instrument. The BCF is recorded as an addition to equity with a corresponding reduction to the carrying value of the convertible debt instrument. In the case of the Convertible Notes, this reduction represents a debt discount equal to the principal amount of $470,876 on the issuance dates. This debt discount will be amortized to interest expense using the effective interest method over the three-year term of the debt, representing an approximate effective annual interest rate of 23%. As of March 31, 2015, the carrying value of the Convertible Notes was $169,908, comprised of principal and accrued interest of $534,816, net of unamortized debt discount of $364,908.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: justify">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt" id="e0b0dac3cf0743748d5afe4e34bb7441" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 18pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top; FONT-WEIGHT: bold; align: right">9.</td>
<td style="TEXT-ALIGN: justify; WIDTH: auto; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top; FONT-WEIGHT: bold">Shareholders' Equity</td>
</tr>
</table>
</div>

<div><br>
</div>

<div style="TEXT-ALIGN: justify; FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">Preferred Shares</div>

<div style="TEXT-ALIGN: justify"><br>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">BioTime is authorized to issue 2,000,000 shares of preferred stock. The preferred shares may be issued in one or more series as the board of directors may by resolution determine. The board of directors is authorized to fix the number of shares of any series of preferred shares and to determine or alter the rights, preferences, privileges, and restrictions granted to or imposed on the preferred shares as a class, or upon any wholly unissued series of any preferred shares. The board of directors may, by resolution, increase or decrease (but not below the number of shares of such series then outstanding) the number of shares of any series of preferred shares subsequent to the issue of shares of that series.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">As of March 31, 2015, BioTime had 70,000 outstanding shares of Series A Convertible Preferred Stock (&#8220;Series A Preferred Stock&#8221;). The Series A Preferred Stock carries a cumulative annual 3% preferred dividend or $1.50 per share, in preference to BioTime common shares. Each share of Series A Preferred Stock is convertible, at the election of the holder, into BioTime common shares at a conversion price of $4.00 per share, a current conversion ratio of 12.5 common shares for each share of Series A Preferred Stock.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">In addition to the preferred dividend, the Series A Preferred Stock will be entitled to participate with BioTime common shares in any dividends or distributions on common shares (other than dividends and distributions of common shares resulting in an adjustment of the conversion price) as if all shares of Series A Preferred Stock were then converted into common shares.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">All outstanding Series A Preferred Stock will automatically be converted into common shares on March 4, 2019, or if holders of a majority of the outstanding shares of Series A Preferred Stock, voting as a class, approve or consent to a conversion. The conversion price is subject to prorata adjustment in the event of a subdivision or reclassification of the common shares into a greater number of shares, a stock dividend paid in common shares, or a stock combination or reclassification of the common shares into a smaller number of shares.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">The Series A Preferred Stock will be entitled to vote with common shares on all matters submitted to common shareholders for approval. Each share of Series A Preferred Stock will be entitled to a number of votes equal to the number of common shares into which it could then be converted. The Series A Preferred Stock will also vote as a separate class on certain matters affecting those shares.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">In the event of a liquidation or dissolution of BioTime, holders of Series A Preferred Stock will be entitled to receive payment of any accrued but unpaid preferred dividends before any assets may be distributed to holders of common shares. After payment of the accrued dividends, the Series A Preferred Stock will participate with the common shares in the distribution of any assets available to shareholders, as if the Series A Preferred Stock was then converted into common shares.</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">&#160;</div>

<div><br>
</div>

<div style="MARGIN-TOP: 10pt; MARGIN-BOTTOM: 10pt; CLEAR: both" id="DSPFPageBreakArea">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 8pt" id="DSPFPageNumberArea">14</div>

<hr style="BORDER-RIGHT-WIDTH: 0px; BACKGROUND-COLOR: #000000; PAGE-BREAK-AFTER: always; MARGIN: 4px 0px; WIDTH: 100%; BORDER-TOP-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; HEIGHT: 2px; COLOR: #000000; CLEAR: both; BORDER-LEFT-WIDTH: 0px" id="DSPFPageBreak" noshade="noshade">
</div>

<div style="TEXT-ALIGN: justify; FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">Common Shares</div>

<div><br>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">BioTime is authorized to issue 125,000,000 common shares with no par value. As of March 31, 2015, BioTime had 83,210,775 issued and 78,316,833 outstanding common shares. As of December 31, 2014, BioTime had 83,121,698 issued and 78,227,756 outstanding common shares. The difference of 4,893,942 common shares as of March 31, 2015 and December 31, 2014 is attributed to shares held by BioTime subsidiaries which are accounted for as treasury stock on the condensed consolidated balance sheet.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">During the three months ended March 31, 2015 and 2014, BioTime granted 440,000 and 1,205,000 options, respectively, under its 2012 Equity Incentive Plan.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">During the three months ended March 31, 2015, 89,077 options and no warrants were exercised.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt" id="7ded8079a7df456cb3514f6b0e7cb728" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 18pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top; FONT-WEIGHT: bold; align: right">10.</td>
<td style="TEXT-ALIGN: left; WIDTH: auto; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top; FONT-WEIGHT: bold">Sales of BioTime Common Shares by Subsidiaries</td>
</tr>
</table>
</div>

<div><br>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">Certain BioTime subsidiaries hold BioTime common shares that the subsidiaries received from BioTime in exchange for capital stock in the subsidiaries. The BioTime common shares held by subsidiaries are treated as treasury stock by BioTime and BioTime does not recognize a gain or loss on the sale of those shares by its subsidiaries.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">During June 2014, Asterias sold 5,000,000 of its BioTime common shares with warrants to purchase 5,000,000 shares of Asterias Series B common stock to two investors for $12,500,000 in cash. Broadwood Partners, L.P., purchased 1,000,000 of the BioTime common shares with 1,000,000 Asterias warrants and a trust previously established by George Karfunkel purchased 4,000,000 of the BioTime common shares with 4,000,000 Asterias warrants.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt" id="b5633f0494d34b44b2ef14ec174214e3" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 18pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top; FONT-WEIGHT: bold; align: right">11.</td>
<td style="TEXT-ALIGN: left; WIDTH: auto; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top; FONT-WEIGHT: bold">Segment Information</td>
</tr>
</table>
</div>

<div><br>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">BioTime's executive management team, as a group, represents the entity's chief operating decision makers. To date, BioTime&#8217;s executive management team has viewed BioTime&#8217;s operations as one segment that includes, the research and development of therapeutic products for oncology, orthopedics, retinal and neurological diseases and disorders, blood and vascular system diseases and disorders, blood plasma volume expansion, diagnostic products for the early detection of cancer, and hydrogel products that may be used in surgery, and products for human embryonic stem cell research. As a result, the financial information disclosed materially represents all of the financial information related to BioTime&#8217;s sole operating segment.</div>

<div style="TEXT-ALIGN: left"><br>
</div>

<div style="TEXT-ALIGN: justify">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt" id="bbb6450f10d24f70853ad9dff8702de1" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 18pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top; FONT-WEIGHT: bold; align: right">12.</td>
<td style="TEXT-ALIGN: justify; WIDTH: auto; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top; FONT-WEIGHT: bold">Subsequent Events</td>
</tr>
</table>
</div>

<div><br>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">In April 2015, Asterias received&#160;$1,062,023 from the California Institute for Regenerative Medicine as quarterly installment payment of a $14.3 million research grant awarded during 2014.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman', serif; FONT-SIZE: 10pt">On May 8, 2015, OncoCyte Corporation accepted subscriptions for 3,000,000 shares of its common stock for $3,300,000 in cash from two of its shareholders, including a subscription for 1,000,000 shares from George Karfunkel, a beneficial owner of more than 5% of the outstanding common shares of BioTime. Concurrently, BioTime purchased 3,000,000 shares of OncoCyte common stock in exchange for the cancelation of $3,300,000 of indebtedness owed to BioTime by OncoCyte, and OncoCyte delivered to BioTime a convertible promissory note (the &#8220;Note&#8221;) for an additional $3,300,000 of OncoCyte's indebtedness to BioTime. The Note will bear interest at the rate of 1% per annum and will mature and be payable on November 30, 2016. BioTime will have the right to convert the principal amount of the Note plus accrued interest into shares of OncoCyte common stock at a conversion price of $1.10 per share commencing on the earliest of November 8, 2016, or six months after OncoCyte completes an initial underwritten public offering of its common stock, or upon the occurrence of an &#8220;Event of Default&#8221; as defined in the Note. An Event of Default includes a failure of OncoCyte to pay any amount due on the Note or the commencement of bankruptcy proceedings by or against OncoCyte or the occurrence of certain insolvency related events, the dissolution or liquidation of OncoCyte, or any material breach or default by OncoCyte under any loan agreement, promissory note, or other instrument evidencing indebtedness payable to a third party. The conversion price is subject to pro rata adjustment in the event of a stock split, combination, reclassification, or similar event.</div>

<div style="TEXT-ALIGN: justify; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">&#160;</div>

<div style="MARGIN-TOP: 10pt; MARGIN-BOTTOM: 10pt; CLEAR: both" id="DSPFPageBreakArea">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 8pt" id="DSPFPageNumberArea">15</div>

<hr style="BORDER-RIGHT-WIDTH: 0px; BACKGROUND-COLOR: #000000; PAGE-BREAK-AFTER: always; MARGIN: 4px 0px; WIDTH: 100%; BORDER-TOP-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; HEIGHT: 2px; COLOR: #000000; CLEAR: both; BORDER-LEFT-WIDTH: 0px" id="DSPFPageBreak" noshade="noshade">
</div>

<div style="TEXT-ALIGN: justify">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt" id="2b7d5731b1f04baeab9cf334461be64c" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 36pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top; FONT-WEIGHT: bold; align: right">Item 2.</td>
<td style="TEXT-ALIGN: justify; WIDTH: auto; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top; FONT-WEIGHT: bold">Management's Discussion and Analysis of Financial Condition and Results of Operations</td>
</tr>
</table>
</div>

<div><br>
</div>

<div style="TEXT-ALIGN: justify; FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">The following Management's Discussion and Analysis of Financial Condition and Results of Operations is intended to provide information necessary to understand our Condensed Consolidated Financial Statements for the three months ended March 31, 2015 and 2014, and highlight certain other information which, in the opinion of management, will enhance a reader's understanding of our financial condition, changes in financial condition and results of operations. In particular, the discussion is intended to provide an analysis of significant trends and material changes in our financial position and the operating results of our business during the quarter ended March 31, 2015 as compared to the quarter ended March 31, 2014. This discussion should be read in conjunction with our Condensed Consolidated Financial Statements for the three months ended March 31, 2015 and 2014 and related notes included elsewhere in this Quarterly Report on Form 10-Q. These historical financial statements may not be indicative of our future performance. This Management's Discussion and Analysis of Financial Condition and Results of Operations contains a number of forward-looking statements, all of which are based on our current expectations and could be affected by the uncertainties and risks described throughout this report and in our Annual Report on Form 10-K, particularly in "Risk Factors."</div>

<div><br>
</div>

<div style="TEXT-ALIGN: justify; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Critical Accounting Policies</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 36pt"><br>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">Revenue recognition</font> &#8211; We comply with ASC 605-10 and recognize revenue when persuasive evidence of an arrangement exists, delivery has occurred or services have been rendered, the price is fixed or determinable, and collectability is reasonably assured. Grant income and the sale of research products and services are recognized as revenue when earned. Revenues from the sale of research products and services are primarily derived from the sale of hydrogels and stem cell products. Royalty revenues consist of product royalty payments. License fee revenues consist of fees under license agreements and are recognized when earned and reasonably estimable and also include subscription and advertising revenue from our online databases based upon respective subscription or advertising periods. We recognize revenue in the quarter in which the royalty reports are received rather than the quarter in which the sales took place. When we are entitled to receive up-front nonrefundable licensing or similar fees pursuant to agreements under which we have no continuing performance obligations, the fees are recognized as revenues when collection is reasonably assured. When we receive up-front nonrefundable licensing or similar fees pursuant to agreements under which we do have continuing performance obligations, the fees are deferred and amortized ratably over the performance period. If the performance period cannot be reasonably estimated, we amortize nonrefundable fees over the life of the contract until such time that the performance period can be more reasonably estimated. Milestone payments, if any, related to scientific or technical achievements are recognized in income when the milestone is accomplished if (a) substantive effort was required to achieve the milestone, (b) the amount of the milestone payment appears reasonably commensurate with the effort expended, and (c) collection of the payment is reasonably assured.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">Patent costs</font> &#8211; Costs associated with obtaining patents on products or technology developed are expensed as research and development expenses when incurred.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">Intangible assets, net</font> &#8211; Intangible assets<font style="FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">&#160;</font>with finite useful lives are amortized over estimated useful lives and intangible assets with indefinite lives are not amortized but rather are tested at least annually for impairment. Acquired in-process research and development intangible assets are accounted depending on whether they were acquired as part of an acquisition of a business, or assets that do not constitute a business. When acquired in conjunction with acquisition of a business, these assets are considered to be indefinite-lived until the completion or abandonment of the associated research and development efforts and are capitalized as an asset. If and when development is complete, the associated assets would be deemed finite-lived and would then be amortized based on their respective estimated useful lives at that point in time. However, when acquired in conjunction with an acquisition of assets that do not constitute a business (such as Asterias&#8217; acquisition of assets from Geron), in accordance with the accounting rules in ASC 805-50, such intangible assets related to IPR&amp;D are expensed upon acquisition.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">Research and development</font> &#8211; Research and development expenses consist of costs incurred for company-sponsored, collaborative and contracted research and development activities. These costs include direct and research-related overhead expenses including salaries, payroll taxes, consulting fees, research and laboratory fees, rent of research facilities, amortization of intangible assets, and license fees paid to third parties to acquire patents or licenses to use patents and other technology. BioTime expenses research and development costs as such costs are incurred.</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </div>

<div style="TEXT-ALIGN: justify; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">
<div style="TEXT-ALIGN: justify; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">General and administrative</font> - General and administrative expenses consist principally of compensation and related benefits, including stock-based compensation, for executive and corporate personnel; professional and consulting fees; and allocated overhead.</div>

<div style="TEXT-ALIGN: justify; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </div>
</div>

<div><br>
</div>

<div style="MARGIN-TOP: 10pt; MARGIN-BOTTOM: 10pt; CLEAR: both" id="DSPFPageBreakArea">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 8pt" id="DSPFPageNumberArea">16</div>

<hr style="BORDER-RIGHT-WIDTH: 0px; BACKGROUND-COLOR: #000000; PAGE-BREAK-AFTER: always; MARGIN: 4px 0px; WIDTH: 100%; BORDER-TOP-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; HEIGHT: 2px; COLOR: #000000; CLEAR: both; BORDER-LEFT-WIDTH: 0px" id="DSPFPageBreak" noshade="noshade">
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">Stock-based compensation</font> &#8211; We follow accounting standards governing share-based payments, which require the measurement and recognition of compensation expense for all share-based payment awards made to directors and employees, including employee stock options, based on estimated fair values. Consistent with FASB guidelines, we utilize the Black-Scholes Merton option pricing model for valuing share-based payment awards. Our determination of fair value of share-based payment awards on the date of grant using that option-pricing model is affected by the price of BioTime common shares as well as by assumptions regarding a number of highly complex and subjective variables. These variables include, but are not limited to, our expected stock price volatility over the term of the awards, and actual and projected employee stock option exercise behaviors; the expected term of options granted, derived from historical data on employee exercises and post-vesting employment termination behavior; and a risk-free interest rate is based on the U.S. Treasury rates in effect during the corresponding period of grant. Although the fair value of employee stock options is determined in accordance with recent FASB guidance, changes in the subjective assumptions can materially affect the estimated value.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">Treasury stock</font> &#8211; We account for BioTime common shares issued to subsidiaries for future potential working capital needs as treasury stock on the consolidated balance sheet. We have registered the BioTime common shares held by our subsidiaries for sale under the Securities Act to enhance the marketability of the shares.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">Impairment of long-lived assets &#8211;</font> Our long-lived assets, including intangible assets, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be fully recoverable. If an impairment indicator is present, we evaluate recoverability by a comparison of the carrying amount of the assets to future undiscounted net cash flows expected to be generated by the assets. If the assets are impaired, the impairment recognized is measured by the amount by which the carrying amount exceeds the estimated fair value of the assets.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">Deferred license and consulting fees</font> &#8211; Deferred license and consulting fees consist of the value of warrants issued to third parties for services, and deferred license fees paid to acquire rights to use the proprietary technologies of third parties. The value of the warrants is being amortized over the lives of the warrants, and deferred license fees over the estimated useful lives of the licensed technologies or licensed research products. We are applying a 10 year estimated useful life to the technologies and products that we are currently licensing. The estimation of the useful life any technology or product involves a significant degree of inherent uncertainty, since the outcome of research and development or the commercial life of a new product cannot be known with certainty at the time that the right to use the technology or product is acquired. We will review the continued appropriateness of the 10 year estimated useful life for impairments that might occur earlier than the original expected useful lives.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">Principles of consolidation &#8211;</font> Our consolidated financial statements include the accounts of our wholly-owned subsidiary ESI, and the accounts of our majority owned subsidiaries, Asterias, ReCyte Therapeutics, OncoCyte, OrthoCyte, BioTime Asia, Cell Cure Neurosciences, and LifeMap Sciences. All material intercompany accounts and transactions have been eliminated in consolidation. The consolidated financial statements are presented in accordance with accounting principles generally accepted in the U.S. and with the accounting and reporting requirements of SEC Regulation S-X.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: justify; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Results of Operations</div>

<div style="TEXT-ALIGN: justify"><br>
</div>

<div style="TEXT-ALIGN: justify; FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">Comparison of Three Months Ended March 31, 2015 and 2014</div>

<div style="TEXT-ALIGN: justify"><br>
</div>

<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt" id="3f8f4f78ca99479fadf015bdd616b61a" border="0" cellspacing="0" cellpadding="0">
<tr>
<td style="PADDING-BOTTOM: 2px; WIDTH: 52%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="PADDING-BOTTOM: 2px; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; VERTICAL-ALIGN: bottom" valign="bottom" colspan="6">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Three Months Ended March 31,</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; WIDTH: 4%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="PADDING-BOTTOM: 2px; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom" colspan="3">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">$ Increase/</div>
</td>
<td style="PADDING-BOTTOM: 2px; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom" colspan="3">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">% Increase/</div>
</td>
</tr>

<tr>
<td style="PADDING-BOTTOM: 2px; WIDTH: 52%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="PADDING-BOTTOM: 2px; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; VERTICAL-ALIGN: bottom" valign="bottom" colspan="3">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2015</div>
</td>
<td style="PADDING-BOTTOM: 2px; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; VERTICAL-ALIGN: bottom" valign="bottom" colspan="3">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2014</div>
</td>
<td style="PADDING-BOTTOM: 2px; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; VERTICAL-ALIGN: bottom" valign="bottom" colspan="3">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Decrease</div>
</td>
<td style="PADDING-BOTTOM: 2px; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; VERTICAL-ALIGN: bottom" valign="bottom" colspan="3">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Decrease</div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 52%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman', Times, serif; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">License fees</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">$</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 6%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">319,146</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 4%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">$</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 6%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">294,504</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 4%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">$</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 6%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">+24,642</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 4%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 6%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">+8</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 4%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">%</div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 52%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman', Times, serif; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">Royalty from product sales</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 6%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">156,550</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 4%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 6%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">97,886</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 4%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 6%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">+58,664</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 4%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 6%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">+60</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 4%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">%</div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 52%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman', Times, serif; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">Grant income</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 6%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">698,839</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 4%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 6%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">575,659</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 4%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 6%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">+123,180</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 4%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 6%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">+21</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 4%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">%</div>
</td>
</tr>

<tr>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 52%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman', Times, serif; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">Sales of research products and services</div>
</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 6%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">89,919</div>
</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 4%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 6%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">98,586</div>
</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 4%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 6%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">-8,667</div>
</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 4%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 6%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">-9</div>
</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 4%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">%</div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 52%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman', Times, serif; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">Total revenues</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 6%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">1,264,454</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 4%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 6%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">1,066,635</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 4%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 6%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">+197,819</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 4%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 6%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">+19</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 4%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">%</div>
</td>
</tr>

<tr>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 52%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman', Times, serif; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">Cost of sales</div>
</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 6%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">(264,167</div>
</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 4%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">)</div>
</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 6%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">(131,914</div>
</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 4%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">)</div>
</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 6%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">+132,253</div>
</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 4%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 6%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">+100</div>
</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 4%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">%</div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 52%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman', Times, serif; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">Total revenues, net</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 6%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">1,000,287</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 4%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 6%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">934,721</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 4%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 6%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">+65,566</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 4%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 6%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">+7</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 4%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">%</div>
</td>
</tr>
</table>

<div style="TEXT-ALIGN: justify"><br>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">Our license fee revenues amounted to $319,146 and $294,504 for the three months ended March 31, 2015 and 2014, respectively. License fee revenues for the three months ended March 31, 2015 and 2014 entirely represents subscription and advertising revenues from LifeMap Science&#8217;s online database business primarily related to its<font style="FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt"> GeneCards</font><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup> database.</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">&#160;</div>

<div><br>
</div>

<div style="MARGIN-TOP: 10pt; MARGIN-BOTTOM: 10pt; CLEAR: both" id="DSPFPageBreakArea">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 8pt" id="DSPFPageNumberArea">17</div>

<hr style="BORDER-RIGHT-WIDTH: 0px; BACKGROUND-COLOR: #000000; PAGE-BREAK-AFTER: always; MARGIN: 4px 0px; WIDTH: 100%; BORDER-TOP-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; HEIGHT: 2px; COLOR: #000000; CLEAR: both; BORDER-LEFT-WIDTH: 0px" id="DSPFPageBreak" noshade="noshade">
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">Our royalty revenues from product sales for the three months ended March 31, 2015 primarily consist of $101,747 of royalties earned by Asterias under various license agreements. Royalty revenues on sales of<font style="FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt"> Hextend</font><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup> made by Hospira, Inc. and CJ HealthCare Corporation (&#8220;CJ Health&#8221;) during the period beginning October 1, 2014 and ending December 31, 2014 were $54,803 compared with $35,905 for the three months ended March 31, 2014. Despite the increase in the royalties on sales of <font style="FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">Hextend</font><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174; </sup>earned during the first quarter of 2015, the blood volume expander market has contracted over the past several years as hospitals shifted their purchases to albumin products. Hospira has reported that they have seen a rapid decline in the price of hetastarch-based plasma expanders in the market which could continue to have a negative impact on revenues from the sale of<font style="FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt"> Hextend</font><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup>. The FDA also required certain new safety labeling changes for the entire class of hydroxyethyl starch products, including <font style="FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">Hextend</font><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup> which may have contributed to the decline in <font style="FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">Hextend</font><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174; </sup>sales.<br>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">Total grant revenue for the first three months in 2015 increased by approximately 21% to $698,839. Grant revenue in the first three months of 2015 included $677,313 to Asterias from the California Institute for Regenerative Medicine (&#8220;CIRM&#8221;), and $104,668 from three grants awarded to us by the National Institutes of Health (''NIH'') that will expire at various time during 2016. This revenue was offset in part by an $83,142 adjustment to a grant from the Office of the Chief Scientist of Israel (&#8220;OCS&#8221;).</div>

<div><br>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">Cost of sales for the first three months in 2015 increased by approximately $132,253 due to an increase in cost of sales of in the various streams of revenues other than grant income.</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </div>

<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt" id="47950497de3f4da9b53aa5e2401087e5" border="0" cellspacing="0" cellpadding="0">
<tr>
<td style="PADDING-BOTTOM: 2px; WIDTH: 52%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="PADDING-BOTTOM: 2px; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; WHITE-SPACE: nowrap; VERTICAL-ALIGN: bottom" colspan="7">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Three Months Ended </div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">March 31,&#160;</div>
</td>
<td style="PADDING-BOTTOM: 2px; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom" colspan="3">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">$ Increase/</div>
</td>
<td style="PADDING-BOTTOM: 2px; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom" colspan="3">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">% Increase/</div>
</td>
</tr>

<tr>
<td style="PADDING-BOTTOM: 2px; WIDTH: 52%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="PADDING-BOTTOM: 2px; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; VERTICAL-ALIGN: bottom" valign="bottom" colspan="3">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2015</div>
</td>
<td style="PADDING-BOTTOM: 2px; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; VERTICAL-ALIGN: bottom" valign="bottom" colspan="3">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2014</div>
</td>
<td style="PADDING-BOTTOM: 2px; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; VERTICAL-ALIGN: bottom" valign="bottom" colspan="3">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Decrease</div>
</td>
<td style="PADDING-BOTTOM: 2px; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; VERTICAL-ALIGN: bottom" valign="bottom" colspan="3">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Decrease</div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 52%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman', Times, serif; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">Research and development expenses</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">$</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 6%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">(9,323,510</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 4%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">)</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">$</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 6%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">(8,405,393</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 4%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">)</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">$</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 6%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">+918,117</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 4%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 6%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">+11</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 4%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">%</div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 52%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman', Times, serif; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">General and administrative expenses</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 6%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">(5,178,800</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 4%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">)</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 6%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">(3,667,171</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 4%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">)</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 6%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">+1,511,629</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 4%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 6%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">+41</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 4%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">%</div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 52%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman', Times, serif; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">Interest expense, net</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 6%; VERTICAL-ALIGN: bottom" valign="bottom">(25,461</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 4%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">)&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 6%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">(8,384</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 4%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">)</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 6%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">+17,077</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 4%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 6%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">+204</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 4%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">%</div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 52%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman', Times, serif; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">Other income/(expense), net</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 6%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">(239,453</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 4%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">)</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 6%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">69,170</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 4%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 6%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">-308,263</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 4%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 6%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">-446</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 4%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">%</div>
</td>
</tr>
</table>

<div><br>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">Research and development expenses &#8211;</font> Research and development expenses increased approximately 11% to $9,323,510 for the three months ended March 31, 2015, from $8,405,393 for the three months ended March 31, 2014. The increase is largely due to the continued ramp-up of the Asterias and LifeMap Solutions product development programs, OncoCyte&#8217;s clinical trial work to develop its<font style="FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt"> PanC-Dx&#8482;</font> cancer diagnostics, and increased activity of BioTime&#8217;s <font style="FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">ESI BIO</font> division. Those increases were partially offset by a reduction in development expenses of BioTime&#8217;s <font style="FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">HyStem</font> hydrogel products, and reductions in OrthoCyte and ReCyte Therapeutics research activities. Employee compensation, including stock-based compensation and related costs allocated to research and development expenses increased by $591,016, contract manufacturing related expenses increased by $324,536, outside research and services primarily related to our regulatory and clinical trials of<font style="FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt"> Renevia</font>&#8482;, AST-OPC1, and<font style="FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt"> PanC-Dx&#8482;</font> cancer diagnostics increased by $95,229, rent and facilities maintenance related expenses allocated to research and development increased by $101,002, equipment rental and equipment maintenance related expenses allocated to research and development increased by $70,677, laboratory and supplies expenses increased by $53,842, and travel and entertainment related expenses increased by $50,938. These increases are in part offset by a decrease of $53,842 in amortization of intangible assets as a result of an adjustment to reduce the gross cost of the intangible assets by $2,157,369 with a corresponding reduction to the accumulated amortization balance of $269,671 during the fourth quarter in 2014, a decrease of $357,387 in Cell Cure related expenses, and a decrease of $56,949 in ESI related expenses.</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">&#160;</div>

<div><br>
</div>

<div style="MARGIN-TOP: 10pt; MARGIN-BOTTOM: 10pt; CLEAR: both" id="DSPFPageBreakArea">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 8pt" id="DSPFPageNumberArea">18</div>

<hr style="BORDER-RIGHT-WIDTH: 0px; BACKGROUND-COLOR: #000000; PAGE-BREAK-AFTER: always; MARGIN: 4px 0px; WIDTH: 100%; BORDER-TOP-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; HEIGHT: 2px; COLOR: #000000; CLEAR: both; BORDER-LEFT-WIDTH: 0px" id="DSPFPageBreak" noshade="noshade">
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">The following table shows the amount of our total research and development expenses allocated to our primary research and development projects during the three months ended March 31, 2015 and 2014.</div>

<div><br>
</div>

<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt" id="f6e1656b3932412ab66344070d67034b" border="0" cellspacing="0" cellpadding="0">
<tr>
<td style="PADDING-BOTTOM: 2px; WIDTH: 25%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="PADDING-BOTTOM: 2px; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom"></td>
<td style="PADDING-BOTTOM: 2px; WIDTH: 26%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;&#160;</td>
<td style="PADDING-BOTTOM: 2px; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; VERTICAL-ALIGN: bottom" valign="bottom" colspan="7">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Amount</font><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(1)</sup></div>
</td>
<td style="PADDING-BOTTOM: 2px; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; VERTICAL-ALIGN: bottom" valign="bottom" colspan="7">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Percent</div>
</td>
</tr>

<tr>
<td style="BORDER-BOTTOM: #000000 2px solid; WIDTH: 25%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: center; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman', Times, serif; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Company</div>
</td>
<td style="PADDING-BOTTOM: 2px; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom"></td>
<td style="BORDER-BOTTOM: #000000 2px solid; WIDTH: 26%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Program</div>
</td>
<td style="PADDING-BOTTOM: 2px; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; VERTICAL-ALIGN: bottom" valign="bottom" colspan="3">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2015</div>
</td>
<td style="PADDING-BOTTOM: 2px; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; VERTICAL-ALIGN: bottom" valign="bottom" colspan="3">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2014</div>
</td>
<td style="PADDING-BOTTOM: 2px; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; VERTICAL-ALIGN: bottom" valign="bottom" colspan="3">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2015</div>
</td>
<td style="PADDING-BOTTOM: 2px; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; VERTICAL-ALIGN: bottom" valign="bottom" colspan="3">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2014</div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 25%; VERTICAL-ALIGN: top" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman', Times, serif; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">Asterias Biotherapeutics</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: top" valign="bottom"></td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 26%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -9.9pt; FONT-FAMILY: 'Times New Roman', Times, serif; MARGIN-LEFT: 9.9pt; FONT-SIZE: 10pt">hESC-based cell therapy programs</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">$</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 6%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">3,592,615</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 4%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">$</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 6%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">2,599,146</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 4%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 6%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">38.5</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 4%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">%</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 6%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">30.9</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 4%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">%</div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 25%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman', Times, serif; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">BioTime</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom"></td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 26%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -9.9pt; FONT-FAMILY: 'Times New Roman', Times, serif; MARGIN-LEFT: 9.9pt; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">Hextend</font><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup></div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">$</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 6%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">13,224</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 4%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">$</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 6%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">12,160</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 4%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 6%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">0.1</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 4%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">%</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 6%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">0.1</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 4%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">%</div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 25%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman', Times, serif; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">BioTime</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom"></td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 26%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -9.9pt; FONT-FAMILY: 'Times New Roman', Times, serif; MARGIN-LEFT: 9.9pt; FONT-SIZE: 10pt">3D Culture</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">$</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 6%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">-</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 4%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">$</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 6%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">25,078</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 4%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 6%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">0.0</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 4%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">%</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 6%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">0.3</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 4%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">%</div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 25%; VERTICAL-ALIGN: top" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman', Times, serif; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">BioTime and ESI</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: top" valign="bottom"></td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 26%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -9.9pt; FONT-FAMILY: 'Times New Roman', Times, serif; MARGIN-LEFT: 9.9pt; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">PureStem</font><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup> hEPCs, cGMP hES cell lines, and related research products</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">$</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 6%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">1,126,027</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 4%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">$</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 6%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">823,451</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 4%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 6%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">12.1</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 4%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">%</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 6%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">9.8</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 4%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">%</div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 25%; VERTICAL-ALIGN: top" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman', Times, serif; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">BioTime</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: top" valign="bottom"></td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 26%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -9.9pt; FONT-FAMILY: 'Times New Roman', Times, serif; MARGIN-LEFT: 9.9pt; FONT-SIZE: 10pt">Hydrogel products and<font style="FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt"> HyStem</font><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;"> &#174;</sup> research</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">$</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 6%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">980,290</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 4%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">$</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 6%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">1,315,231</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 4%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 6%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">10.5</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 4%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">%</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 6%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">15.7</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 4%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">%</div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 25%; VERTICAL-ALIGN: top" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman', Times, serif; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">Cell Cure Neurosciences</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: top" valign="bottom"></td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 26%; VERTICAL-ALIGN: top" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -9.9pt; FONT-FAMILY: 'Times New Roman', Times, serif; MARGIN-LEFT: 9.9pt; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">OpRegen</font><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup>,<font style="FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt"> OpRegen</font><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;"> &#174;</sup><font style="FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt"> -Plus</font> , and neurological disease therapies</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">$</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 6%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">906,630</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 4%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">$</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 6%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">1,261,054</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 4%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 6%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">9.7</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 4%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">%</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 6%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">15.0</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 4%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">%</div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 25%; VERTICAL-ALIGN: top" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman', Times, serif; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">LifeMap Sciences</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: top" valign="bottom"></td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 26%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -9.9pt; FONT-FAMILY: 'Times New Roman', Times, serif; MARGIN-LEFT: 9.9pt; FONT-SIZE: 10pt">Database development and sales</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">$</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 6%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">1,219,048</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 4%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">$</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 6%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">781,424</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 4%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 6%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">13.1</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 4%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">%</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 6%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">9.3</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 4%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">%</div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 25%; VERTICAL-ALIGN: top" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman', Times, serif; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">OncoCyte</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: top" valign="bottom"></td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 26%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -9.9pt; FONT-FAMILY: 'Times New Roman', Times, serif; MARGIN-LEFT: 9.9pt; FONT-SIZE: 10pt">Cancer therapy and diagnostics and therapy</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">$</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 6%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">1,028,888</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 4%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">$</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 6%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">929,725</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 4%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 6%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">11.0</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 4%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">%</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 6%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">11.1</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 4%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">%</div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 25%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman', Times, serif; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">OrthoCyte</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom"></td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 26%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -9.9pt; FONT-FAMILY: 'Times New Roman', Times, serif; MARGIN-LEFT: 9.9pt; FONT-SIZE: 10pt">Orthopedic therapy</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">$</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 6%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">180,494</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 4%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">$</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 6%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">224,716</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 4%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 6%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">2.0</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 4%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">%</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 6%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">2.7</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 4%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">%</div>
</td>
</tr>

<tr>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 25%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman', Times, serif; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">ReCyte Therapeutics</div>
</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom"></td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 26%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -9.9pt; FONT-FAMILY: 'Times New Roman', Times, serif; MARGIN-LEFT: 9.9pt; FONT-SIZE: 10pt">Cardiovascular therapy</div>
</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">$</div>
</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 6%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">276,294</div>
</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 4%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">$</div>
</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 6%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">433,408</div>
</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 4%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 6%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">3.0</div>
</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 4%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">%</div>
</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 6%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">5.1</div>
</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 4%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">%</div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 25%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman', Times, serif; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">Total</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom"></td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 26%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">$</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 6%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">9,323,510</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 4%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">$</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 6%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">8,405,393</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 4%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 6%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">100.0</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 4%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">%</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 6%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">100.0</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 4%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">%</div>
</td>
</tr>
</table>

<div><br>
</div>

<div style="TEXT-ALIGN: justify">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt" id="83958a36ba3b4c6a941a24d683c8ae1a" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 18pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top; align: right">(1)</td>
<td style="TEXT-ALIGN: justify; WIDTH: auto; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top">Amount also includes research and development expenses incurred directly by the subsidiary and certain general research and development expenses, such as lab supplies, lab expenses, rent allocated, and insurance allocated to research and development expenses, incurred directly by BioTime on behalf of the subsidiary and allocated to the subsidiary.</td>
</tr>
</table>
</div>

<div><br>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">General and administrative expenses &#8211;</font> General and administrative expenses increased to $5,178,800 for the three months ended March 31, 2015 from $3,667,171 for the three months ended March 31, 2014. The largest increases occurred at Asterias which increased staffing, and at LifeMap Sciences reflecting the increased staffing of its LifeMap Solutions subsidiary. The increase is primarily attributable to an increase of $764,977 in employee compensation, including employee bonus accruals, stock-based compensation and related costs allocated to general and administrative expenses, an increase of $104,750 in general consulting expenses, an increase of $262,982 in stock-based compensation to general consultants expenses, an increase of $240,929 in accounting, audit and tax related expense, an increase in $108,114 in investor and public relations related expenses, an increase of $199,490 in legal expenses, and an increase of $97,000 in outside directors compensation expenses. These increases are in part offset by a decrease of $164,755 in stock-based compensation to our independent directors, and a decrease of $61,301in Asterias&#8217; state corporation and franchise taxes.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">General and administrative expenses include employee and director compensation allocated to general and administrative expenses, consulting fees other than those paid for science-related consulting, facilities and equipment rent and maintenance related expenses, insurance costs allocated to general and administrative expenses, stock exchange-related costs, depreciation expense, shipping expenses, marketing costs, legal and accounting costs, and other miscellaneous expenses which are allocated to general and administrative expense.</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">&#160;</div>

<div><br>
</div>

<div style="MARGIN-TOP: 10pt; MARGIN-BOTTOM: 10pt; CLEAR: both" id="DSPFPageBreakArea">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 8pt" id="DSPFPageNumberArea">19</div>

<hr style="BORDER-RIGHT-WIDTH: 0px; BACKGROUND-COLOR: #000000; PAGE-BREAK-AFTER: always; MARGIN: 4px 0px; WIDTH: 100%; BORDER-TOP-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; HEIGHT: 2px; COLOR: #000000; CLEAR: both; BORDER-LEFT-WIDTH: 0px" id="DSPFPageBreak" noshade="noshade">
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">The following table shows the amount of our general and administrative expenses and those related to our subsidiaries during the three months ended March 31, 2015 and 2014.</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt"><br>
</div>

<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt" id="658cc532b58b42a48073518f4dd87bee" border="0" cellspacing="0" cellpadding="0">
<tr>
<td style="PADDING-BOTTOM: 2px; WIDTH: 52%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="PADDING-BOTTOM: 2px; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; VERTICAL-ALIGN: bottom" valign="bottom" colspan="7">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Amount<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(1)</sup></div>
</td>
<td style="PADDING-BOTTOM: 2px; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; VERTICAL-ALIGN: bottom" valign="bottom" colspan="7">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Percent</div>
</td>
</tr>

<tr>
<td style="BORDER-BOTTOM: #000000 2px solid; WIDTH: 52%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman', Times, serif; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Company</div>
</td>
<td style="PADDING-BOTTOM: 2px; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; VERTICAL-ALIGN: bottom" valign="bottom" colspan="3">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2015</div>
</td>
<td style="PADDING-BOTTOM: 2px; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; VERTICAL-ALIGN: bottom" valign="bottom" colspan="3">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2014</div>
</td>
<td style="PADDING-BOTTOM: 2px; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; VERTICAL-ALIGN: bottom" valign="bottom" colspan="3">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2015</div>
</td>
<td style="PADDING-BOTTOM: 2px; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; VERTICAL-ALIGN: bottom" valign="bottom" colspan="3">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2014</div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 52%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman', Times, serif; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">BioTime</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">$</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 6%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">1,015,070</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 4%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">$</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 6%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">1,220,539</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 4%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 6%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">19.6</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 4%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">%</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 6%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">33.3</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 4%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">%</div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 52%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman', Times, serif; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">Asterias Biotherapeutics</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">$</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 6%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">1,672,150</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 4%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">$</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 6%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">1,094,474</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 4%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 6%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">32.3</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 4%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">%</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 6%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">29.8</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 4%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">%</div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 52%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman', Times, serif; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">BioTime Asia</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">$</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 6%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">369</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 4%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">$</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 6%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">2,132</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 4%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 6%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">0.0</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 4%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">%</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 6%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">0.0</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 4%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">%</div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 52%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman', Times, serif; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">Cell Cure Neurosciences</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">$</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 6%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">148,648</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 4%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">$</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 6%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">196,915</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 4%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 6%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">2.8</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 4%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">%</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 6%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">5.4</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 4%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">%</div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 52%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman', Times, serif; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">ESI</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">$</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 6%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">71,859</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 4%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">$</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 6%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">51,144</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 4%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 6%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">1.4</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 4%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">%</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 6%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">1.4</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 4%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">%</div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 52%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman', Times, serif; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">LifeMap Sciences</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">$</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 6%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">1,717,385</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 4%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">$</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 6%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">611,168</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 4%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 6%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">33.2</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 4%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">%</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 6%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">16.7</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 4%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">%</div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 52%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman', Times, serif; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">OncoCyte</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">$</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 6%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">250,072</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 4%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">$</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 6%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">205,336</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 4%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 6%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">4.8</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 4%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">%</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 6%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">5.6</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 4%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">%</div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 52%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman', Times, serif; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">OrthoCyte</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">$</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 6%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">178,657</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 4%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">$</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 6%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">146,451</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 4%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 6%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">3.5</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 4%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">%</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 6%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">4.0</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 4%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">%</div>
</td>
</tr>

<tr>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 52%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman', Times, serif; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">ReCyte Therapeutics</div>
</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">$</div>
</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 6%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">124,590</div>
</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 4%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">$</div>
</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 6%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">139,012</div>
</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 4%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 6%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">2.4</div>
</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 4%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">%</div>
</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 6%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">3.8</div>
</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 4%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">%</div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 52%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman', Times, serif; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">Total</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">$</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 6%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">5,178,800</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 4%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">$</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 6%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">3,667,171</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 4%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 6%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">100.0</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 4%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">%</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 6%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">100.0</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 4%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">%</div>
</td>
</tr>
</table>

<div><br>
</div>

<div style="TEXT-ALIGN: justify">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt" id="8465c33a6771477c8e04fd00c6ccfd51" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 18pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top; align: right">(1)</td>
<td style="TEXT-ALIGN: justify; WIDTH: auto; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top">Amount also includes general and administrative expenses incurred directly by the subsidiary and allocations from BioTime for certain general overhead expenses</td>
</tr>
</table>
</div>

<div><br>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">Interest income/(expense) &#8211;</font> During the three months ended March 31, 2015 and 2014, we incurred $25,461 and $8,384&#160;of net interest expense, respectively. </div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">&#160;</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">Other income/(expense) &#8211;</font> Other expense in 2015 consists primarily of $104,986 and $101,011 of foreign currency transaction losses recognized by ESI and by Cell Cure Neurosciences, respectively, and a $30,348 increase in leasehold improvement liability related to a Cell Cure lease. Other income in 2014 consists primarily of $127,368 in gain on embedded derivatives earned by Cell Cure Neurosciences through a research contract, based in U.S. dollars, with an Israeli company, offset by a $31,582 decrease in leasehold improvement liability due to the early termination of a Cell Cure lease, $17,881 in charitable donations made, and $10,212 of foreign currency transaction expense.</div>

<div>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <br>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">Income Taxes &#8211; </font>An income tax benefit of approximately $1,177,000 was recorded for the three months ended March 31, 2015, of which approximately $1,251,000 of the benefit was related to federal offset by adjustment of $74,000 related to state taxes.&#160; For the same period in 2014, an income tax benefit of approximately $1,349,000 was recorded, of which approximately $1,151,000 of the benefit was related to federal and $198,000 was related to state taxes.<br>
 &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </div>

<div style="TEXT-ALIGN: justify; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Liquidity and Capital Resources</div>

<div><br>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">At March 31, 2015, we had $25,829,533 of cash and cash equivalents on hand of which $8,984,466 was held by Asterias and other subsidiaries.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">We have outstanding warrants to purchase 9,194,679 of our common shares at an exercise price of $5.00 per share that will expire on dates ranging from January 13, 2016 through September 30, 2018. We will receive $45,975,395 if all of the warrants are exercised. There can be no assurance that the warrants will be exercised.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">Asterias has outstanding warrants to purchase 3,500,000 shares of Asterias' common stock at an exercise price of $5.00 per share that will expire on September 30, 2016, and warrants to purchase 5,000,000 shares of Asterias' common stock at an exercise price of $2.34 per share that will expire on June 15, 2015. Asterias will receive $29,200,000 if all of the warrants are exercised. There can be no assurance that the warrants will be exercised.</div>

<div>&#160;</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman', serif; FONT-SIZE: 10pt">On May 8, 2015, OncoCyte Corporation accepted subscriptions for 3,000,000 shares of its common stock for $3,300,000 in cash from two of its shareholders, including a subscription for 1,000,000 shares from George Karfunkel, a beneficial owner of more than 5% of the outstanding common shares of BioTime.&#160; See Note 12 to condensed consolidated financial statements.</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</div>

<div><br>
</div>

<div style="MARGIN-TOP: 10pt; MARGIN-BOTTOM: 10pt; CLEAR: both" id="DSPFPageBreakArea">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 8pt" id="DSPFPageNumberArea">20</div>

<hr style="BORDER-RIGHT-WIDTH: 0px; BACKGROUND-COLOR: #000000; PAGE-BREAK-AFTER: always; MARGIN: 4px 0px; WIDTH: 100%; BORDER-TOP-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; HEIGHT: 2px; COLOR: #000000; CLEAR: both; BORDER-LEFT-WIDTH: 0px" id="DSPFPageBreak" noshade="noshade">
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">Asterias was awarded a $14.3 million Strategic Partnership III grant by CIRM to help fund its clinical development of AST-OPC1. The grant will provide funding for Asterias to conduct a Phase I/IIa clinical trial of AST-OPC1 in subjects with complete cervical spinal cord injury, and for product development efforts to refine and scale manufacturing methods to support eventual commercialization. CIRM will disburse the grant funds to Asterias through July 1, 2018 in accordance with a quarterly disbursement schedule, subject to Asterias attaining certain progress and safety milestones. Asterias received the first payment during October 2014 in the amount of $916,554. In January 2015, Asterias received the second payment from CIRM in the amount of $2,269,515. In April 2015, Asterias received the third payment from CIRM in the amount of $1,062,023. As the balance of the distributions of the CIRM grant are subject to meeting certain progress and go/no-go milestones, there can be no assurance that Asterias will receive the entire amount granted.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">&#160;</font>During September 2014, Asterias entered into a Clinical Trial and Option Agreement (the &#8220;CRUK Agreement&#8221;) with Cancer Research UK (&#8220;CRUK&#8221;) and Cancer Research Technology Limited (&#8220;CRT&#8221;), a wholly-owned subsidiary of CRUK, pursuant to which CRUK has agreed to fund Phase I/IIa clinical development of Asterias&#8217; AST-VAC2 product candidate. Asterias will, at its own cost, complete process development and manufacturing scale-up of the AST-VAC2 manufacturing process and will transfer the resulting cGMP compatible process to CRUK. CRUK will, at its own cost, manufacture the clinical grade AST-VAC2 and will carry out the Phase I/IIa clinical trial of AST-VAC2 in cancer patients both resected early-stage and advanced forms of lung cancer. Asterias will have an exclusive first option to obtain a license to use the data from the clinical trial. If Asterias exercises that option it will be obligated to make payments upon the execution of the License Agreement, upon the achievement of various milestones, and then royalties on sales of products, and if Asterias sublicenses product development or commercialization rights to a third party, Asterias would pay CRT a share of any sublicense revenues that Asterias receives from the third party, with CRT&#8217;s share varying from a high of 40% in the case of a sublicense entered into prior to commencement of a Phase II clinical trial, to substantially lower rates in the case of a sublicense entered into at various later stages of clinical development but prior to completion of a Phase III clinical trial, and as low as 7.5% in the case of a sublicense entered into after completion of a Phase III clinical trial. In connection with the CRUK Agreement, Asterias sublicensed to CRUK for use in the clinical trials and product manufacturing process certain patents that have been licensed or sublicensed to Asterias by third parties. Asterias would also be obligated to make payments to those licensors and sublicensors upon the achievement of various milestones, and then royalties on sales of products if AST-VAC2 is successfully developed and commercialized.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: justify; FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Cash generated by operations</div>

<div><br>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">During the three months ended March 31, 2015, we received $3,016,336 of cash from operations. Our sources of that cash primarily consisted of $467,455 from the sale of research products and subscription and advertisement revenues, $2,269,515 in a grant payment to Asterias from CIRM, and $131,814 in grant payments from the NIH. We also received $147,552 in royalty revenues on product sales by licensees.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: justify; FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Cash used in operations</div>

<div><br>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">During the three months ended March 31, 2015, our total research and development expenditures were $9,323,510 and our general and administrative expenditures were $5,178,800. Net loss attributable to BioTime for the three months ended March 31, 2015 amounted to $10,167,368. Net cash used in operating activities during this period amounted to $9,068,821. The difference between the net loss and net cash used in operating activities during the three months ended March 31, 2015 was primarily attributable to </font>$1,914,407 in stock-based compensation paid to employees, consultants and directors, amortization of $1,314,094 in intangible assets, $262,600 in depreciation expenses, $1,474,300 in deferred grant income, and $228,191 in grant receivables. This overall difference was offset to some extent by $1,176,882 in deferred income tax benefit, $365,175 in accounts payable and accrued liabilities, $62,313 in deferred rent liabilities, $60,769 in prepaid expenses and other current assets, and net loss of $2,422,687 allocable to the non-controlling interest in our subsidiaries.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: justify; FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Cash flows from investing activities</div>

<div><br>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">During the three months ended March 31, 2015, we used $373,389 for investing activities. The primary components of this cash were purchases of equipment of $77,007 and payments on construction in progress of $296,382.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: justify; FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Cash generated by financing activities</div>

<div><br>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">During the three months ended March 31, 2015, Asterias raised approximately $5.5 million in aggregate gross proceeds from the sale of 1,410,255 shares of its common stock at a price of $3.90 per share through an underwritten public offering and a private placement. Broadwood Partners, L.P., British &amp; American Investment Trust PLC and Pedro Lichtinger purchased an aggregate of 1,025,640 of the shares. Broadwood Partners, L.P. is BioTime&#8217;s largest shareholder and one of its directors, Neal C. Bradsher, is President, and one of Asterias&#8217; directors, Richard T. LeBuhn, is Senior Vice President, of Broadwood Capital, Inc., the investment manager of Broadwood Partners, L.P. Pedro Lichtinger is Asterias&#8217; Chief Executive Officer and a member of its Board of Directors. British &amp; American Investment Trust PLC is an affiliate of a stockholder that owns more than 5% of the outstanding shares of Asterias common stock.</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">&#160;</div>

<div><br>
</div>

<div style="MARGIN-TOP: 10pt; MARGIN-BOTTOM: 10pt; CLEAR: both" id="DSPFPageBreakArea">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 8pt" id="DSPFPageNumberArea">21</div>

<hr style="BORDER-RIGHT-WIDTH: 0px; BACKGROUND-COLOR: #000000; PAGE-BREAK-AFTER: always; MARGIN: 4px 0px; WIDTH: 100%; BORDER-TOP-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; HEIGHT: 2px; COLOR: #000000; CLEAR: both; BORDER-LEFT-WIDTH: 0px" id="DSPFPageBreak" noshade="noshade">
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">BioTime </font>also received $346,713 in cash from the exercise of stock options by employees at a weighted average exercise price of $3.89 per share.</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">&#160;</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">Asterias received $283,764 from the landlord on reimbursable construction in progress. See Note&#160;4 to condensed consolidated financial statements.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: justify; FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Contractual obligations</div>

<div><br>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">As of March 31, 2015, our contractual obligations for the next five years and thereafter were as follows:</div>

<div style="TEXT-ALIGN: left"><br>
</div>

<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt" id="a5c2fd3c6080427f8f846e57f54096fb" border="0" cellspacing="0" cellpadding="0">
<tr>
<td style="PADDING-BOTTOM: 2px; WIDTH: 40%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="PADDING-BOTTOM: 2px; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom"></td>
<td style="BORDER-BOTTOM: #000000 2px solid; VERTICAL-ALIGN: bottom" valign="bottom" colspan="18">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Principal Payments Due by Period</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; WIDTH: 4%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BORDER-BOTTOM: #000000 2px solid; WIDTH: 40%; VERTICAL-ALIGN: bottom" valign="bottom">
<div>&#160;</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman', Times, serif; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Contractual Obligations<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(1)</sup></div>
</td>
<td style="PADDING-BOTTOM: 2px; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom"></td>
<td style="BORDER-BOTTOM: #000000 2px solid; VERTICAL-ALIGN: bottom" valign="bottom" colspan="3">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Total</div>
</td>
<td style="PADDING-BOTTOM: 2px; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom"></td>
<td style="BORDER-BOTTOM: #000000 2px solid; VERTICAL-ALIGN: bottom" valign="bottom" colspan="3">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Less Than

<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">1 Year</div>
</div>
</td>
<td style="PADDING-BOTTOM: 2px; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom"></td>
<td style="BORDER-BOTTOM: #000000 2px solid; VERTICAL-ALIGN: bottom" valign="bottom" colspan="3">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">1-3 Years</div>
</td>
<td style="PADDING-BOTTOM: 2px; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom"></td>
<td style="BORDER-BOTTOM: #000000 2px solid; VERTICAL-ALIGN: bottom" valign="bottom" colspan="3">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">4-5 Years</div>
</td>
<td style="PADDING-BOTTOM: 2px; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom"></td>
<td style="BORDER-BOTTOM: #000000 2px solid; VERTICAL-ALIGN: bottom" valign="bottom" colspan="3">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">After</div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">5 Years</div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 40%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman', Times, serif; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">Operating leases<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(2)</sup></div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">$</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 6%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">10,785,793</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 4%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 6%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">1,250,534</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 4%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 6%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">2,764,870</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 4%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 6%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">2,736,456</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 4%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 6%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">4,033,933</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 4%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 40%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman', Times, serif; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">Capital lease<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(3)</sup></div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">$</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 6%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">84,673</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 4%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 6%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">47,629</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 4%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 6%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">37,044</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 4%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 6%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">-</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 4%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 6%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">-</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 4%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>
</table>

<div><br>
</div>

<div style="TEXT-ALIGN: left">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt" id="ee1da28e21c2468c84ace6628c732ca5" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 18pt"></td>
<td style="WIDTH: 18pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top; align: right">(1)</td>
<td style="TEXT-ALIGN: left; WIDTH: auto; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top">This table does not include payments to key employees that could arise if they were involuntary terminated or if their employment terminated following a change in control.</td>
</tr>
</table>
</div>

<div style="TEXT-ALIGN: left">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt" id="c6bbec02421f49ccb3755c861f75ea0b" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 18pt"></td>
<td style="WIDTH: 18pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top; align: right">(2)</td>
<td style="TEXT-ALIGN: left; WIDTH: auto; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top">Includes the lease of our principal office and laboratory facilities in Alameda, California, and leases of the offices and laboratory facilities of our subsidiaries Asterias, LifeMap Sciences, and Cell Cure Neurosciences. Also includes three operating leases for lab equipment.</td>
</tr>
</table>
</div>

<div style="TEXT-ALIGN: left">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt" id="a4611ce4a7074d49baa9397ff83ad87e" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 18pt"></td>
<td style="WIDTH: 18pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top; align: right">(3)</td>
<td style="TEXT-ALIGN: left; WIDTH: auto; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top">Includes one capital lease for lab equipment.</td>
</tr>
</table>
</div>

<div><br>
</div>

<div style="TEXT-ALIGN: justify; FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Future capital needs</div>

<div><br>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">The operations of our subsidiary Asterias will continue to result in an increase in our operating expenses and losses on a consolidated basis, and will increase our need for additional capital on an ongoing basis. Asterias&#8217; research and development efforts will involve substantial expenses that will add to our losses on a consolidated basis for the near future. Also, Asterias is now a public company and will be incurring costs associated with audits of its financial statements, filing annual, quarterly, and other periodic reports with the SEC, holding annual shareholder meetings, and public relations and investor relations. These costs incurred by Asterias will be in addition to those incurred by BioTime for similar purposes.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">We and our subsidiaries will need to continue to sell BioTime common shares from time to time, and our subsidiaries will also seek to raise capital through the sale of their capital stock. We and our subsidiaries will also seek funding for our research and development programs from other sources such as research grants and other arrangements with third parties.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">We have consolidated the sales and marketing of our research products in a new <font style="FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">ESI BIO</font> division. We have shifted our sales and marketing efforts from the BioTime website to a new <font style="FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">ESI BIO</font> website based effort and utilized more sales personnel. We also plan to expand our product offerings. This effort will require additional expenditures for the development of new research products and the addition of assets and personnel for sales and marketing purposes.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">The amount and pace of research and development work that we and our subsidiaries can do or sponsor, and our ability to commence and complete the clinical trials that are required in order for us to obtain FDA and foreign regulatory approval of products, depend upon the amount of money we and our subsidiaries have. Future research and clinical study costs are not presently determinable due to many factors, including the inherent uncertainty of these costs and the uncertainty as to timing, source, and amount of capital that will become available for our projects.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">The market value and the volatility of our stock price, as well as general market conditions, could impact our ability to raise capital on favorable terms, or at all. Any equity financing that we or our subsidiaries obtain may further dilute or otherwise impair the ownership interests of our current shareholders. If we and our subsidiaries fail to generate positive cash flows or fail to obtain additional capital when required, we and our subsidiaries could modify, delay or abandon some or all of our respective research and development programs.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">Because our revenues are not presently sufficient to cover our operating expenses, we will continue to need to obtain additional equity capital or debt in order to finance our operations. The future availability and terms of equity or debt financing are uncertain. The unavailability or inadequacy of financing or revenues to meet future capital needs could force us to modify, curtail, delay, or suspend some or all aspects of our planned operations. Sales of additional equity securities by us or our subsidiaries could result in the dilution of the interests of present shareholders.</div>

<div>&#160;</div>

<div style="MARGIN-TOP: 10pt; MARGIN-BOTTOM: 10pt; CLEAR: both" id="DSPFPageBreakArea">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 8pt" id="DSPFPageNumberArea">22</div>

<hr style="BORDER-RIGHT-WIDTH: 0px; BACKGROUND-COLOR: #000000; PAGE-BREAK-AFTER: always; MARGIN: 4px 0px; WIDTH: 100%; BORDER-TOP-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; HEIGHT: 2px; COLOR: #000000; CLEAR: both; BORDER-LEFT-WIDTH: 0px" id="DSPFPageBreak" noshade="noshade">
</div>

<div style="TEXT-ALIGN: justify">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt" id="2d7b62cdec7b47aa9cbf52100aa29eea" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 36pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top; FONT-WEIGHT: bold; align: right">Item 3.</td>
<td style="TEXT-ALIGN: justify; WIDTH: auto; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top; FONT-WEIGHT: bold">Quantitative and Qualitative Disclosures about Market Risk</td>
</tr>
</table>
</div>

<div style="TEXT-ALIGN: justify"><br>
</div>

<div style="TEXT-ALIGN: justify; FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">Foreign Currency Exchange Risk</div>

<div><br>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">We are exposed to some foreign exchange currency risks because we have subsidiaries that are located in foreign countries. We do not engage in foreign currency hedging activities. Because we translate foreign currencies into United States dollars for reporting purposes, currency fluctuations have an impact on our financial results. We believe that our exposure to currency exchange fluctuation risk is mitigated by the fact that our foreign subsidiaries pay their financial obligations almost exclusively in their local currency. As of March 31, 2015, currency exchange rates did not have a material impact on our intercompany transactions with our foreign subsidiaries. However, a weakening of the dollar against the foreign exchange used in the home countries of our foreign subsidiaries could increase our cost of providing additional financing to our foreign subsidiaries in the future. Conversely, a strengthening of the dollar would decrease our cost of making additional investments in those subsidiaries.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: justify; FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">Credit Risk</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 36pt"><br>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">We place some of our cash in U.S. banks and invest most of our cash in money market funds. Deposits with banks may temporarily exceed the amount of insurance provided on such deposits. We will monitor the cash balances in the accounts and adjust the cash balances as appropriate, but if the amount of a deposit at any time exceeds the federally insured amount at a bank, the uninsured portion of the deposit could be lost, in whole or in part, if the bank were to fail. Our investments in money market funds are not insured or guaranteed by the United States government or any of its agencies.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">Our foreign subsidiaries deposit their cash in local banks, but if the amount of a deposit at any time exceeds the amount at a bank under the national banking insurance laws, the uninsured portion of the deposit could be lost, in whole or in part, if the bank were to fail.<font style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">&#160;</font></div>

<div><br>
</div>

<div style="TEXT-ALIGN: justify; FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">Interest Rate Risk</div>

<div style="TEXT-ALIGN: justify"><br>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">We invest most of our cash in money market funds. The primary objective of our investments will be to preserve principal and liquidity while earning a return on our invested capital, without incurring significant risks. Our future investment income is not guaranteed and may fall short of expectations due to changes in prevailing interest rates, or we may suffer losses in principal if the net asset value of a money market fund falls below $1 per share.</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 36pt"><br>
</div>

<div style="TEXT-ALIGN: justify">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt" id="700ecf0e7c6c48f6baec80b5269fd377" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 36pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top; FONT-WEIGHT: bold; align: right">Item 4.</td>
<td style="TEXT-ALIGN: justify; WIDTH: auto; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top; FONT-WEIGHT: bold">Controls and Procedures</td>
</tr>
</table>
</div>

<div style="TEXT-ALIGN: justify"><br>
</div>

<div style="TEXT-ALIGN: justify; FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">Evaluation of Disclosure Controls and Procedures</div>

<div style="TEXT-ALIGN: justify"><br>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">It is management&#8217;s responsibility to establish and maintain adequate internal control over all financial reporting pursuant to Rule 13a-15 under the Securities Exchange Act of 1934 (&#8220;Exchange Act&#8221;). Our management, including our principal executive officer and our principal financial officer, have reviewed and evaluated the effectiveness of our disclosure controls and procedures as of the end of our fourth quarter. Following this review and evaluation<font style="FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt"> ,</font> management collectively determined that our disclosure controls and procedures are effective to ensure that information required to be disclosed by us in reports that we file or submit under the Exchange Act (i) is recorded, processed, summarized and reported within the time periods specified in SEC rules and forms; and (ii) is accumulated and communicated to management, including our chief executive officer and our chief financial officer, as appropriate to allow timely decisions regarding required disclosure.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: justify; FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">Changes in Internal Control over Financial Reporting</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">There were no changes in our internal control over financial reporting that occurred during the period covered by this Quarterly Report on Form 10-Q that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">&#160;</div>

<div><br>
</div>

<div style="MARGIN-TOP: 10pt; MARGIN-BOTTOM: 10pt; CLEAR: both" id="DSPFPageBreakArea">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 8pt" id="DSPFPageNumberArea">23</div>

<hr style="BORDER-RIGHT-WIDTH: 0px; BACKGROUND-COLOR: #000000; PAGE-BREAK-AFTER: always; MARGIN: 4px 0px; WIDTH: 100%; BORDER-TOP-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; HEIGHT: 2px; COLOR: #000000; CLEAR: both; BORDER-LEFT-WIDTH: 0px" id="DSPFPageBreak" noshade="noshade">
</div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">PART II - OTHER INFORMATION</div>

<div><br>
</div>

<div style="TEXT-ALIGN: justify">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt" id="c16a60c3a66742f38b2def6b3fb4c572" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 36pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top; FONT-WEIGHT: bold; align: right">Item 1.</td>
<td style="TEXT-ALIGN: justify; WIDTH: auto; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top; FONT-WEIGHT: bold">Legal Proceedings.</td>
</tr>
</table>
</div>

<div style="TEXT-ALIGN: justify"><br>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">From time to time, we and our subsidiaries may be involved in routine litigation incidental to the conduct of our business. We are not presently a party to any pending litigation.</div>

<div><br>
</div>

<div>
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt" id="6263ae866cde47f9986917a3a7067897" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr style="VERTICAL-ALIGN: top">
<td style="WIDTH: 36pt; VERTICAL-ALIGN: top; align: right">
<div style="TEXT-ALIGN: justify; TEXT-INDENT: -36pt; FONT-FAMILY: 'Times New Roman', Times, serif; MARGIN-LEFT: 36pt; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Item 1A.</div>
</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top; align: left">
<div style="TEXT-ALIGN: justify; TEXT-INDENT: -36pt; FONT-FAMILY: 'Times New Roman', Times, serif; MARGIN-LEFT: 36pt; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Risk Factors</div>
</td>
</tr>
</table>
</div>

<div style="TEXT-ALIGN: justify"><br>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">Our business is subject to various risks, including those described below. You should consider the following risk factors, together with all of the other information included in this report, which could materially adversely affect our proposed operations, our business prospects, and financial condition, and the value of an investment in our business. There may be other factors that are not mentioned here or of which we are not presently aware that could also affect our business operations and prospects.</div>

<div style="TEXT-ALIGN: justify"><br>
</div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Risks Related to Our Business Operations</div>

<div style="TEXT-ALIGN: justify"><br>
</div>

<div style="TEXT-ALIGN: justify; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">We have incurred operating losses since inception and we do not know if we will attain profitability</div>

<div style="TEXT-ALIGN: justify"><br>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">Our comprehensive net losses for the three months ended March 31, 2015 and for the fiscal years ended December 31, 2014, 2013, and 2012 were $10,220,353, $36,288,724, $43,760,366, and $21,362,524, respectively, and we had an accumulated deficit of $192,357,575 as of March 31, 2015 and $182,190,207, $145,778,547, and $101,895,712, as of December 31, 2014, 2013, and 2012, respectively. We primarily finance our operations through the sale of equity securities, licensing fees, royalties on product sales by our licensees, research grants, and subscription fees and advertising revenue from database products. Ultimately, our ability to generate sufficient operating revenue to earn a profit depends upon our and our subsidiaries&#8217; success in developing and marketing or licensing products and technology.</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 36pt"><br>
</div>

<div style="TEXT-ALIGN: justify; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">We will spend a substantial amount of our capital on research and development but we might not succeed in developing products and technologies that are useful in medicine</div>

<div><br>
</div>

<div style="TEXT-ALIGN: justify">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt" id="a2b650655196421984cb758428b6aba3" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 18pt"></td>
<td style="WIDTH: 18pt; FONT-FAMILY: Symbol, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top; align: right">&#183;</td>
<td style="TEXT-ALIGN: justify; WIDTH: auto; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top">We are attempting to develop new medical products and technologies.</td>
</tr>
</table>
</div>

<div><br>
</div>

<div style="TEXT-ALIGN: justify">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt" id="d85af8cdbbea473cb94a9d893cc3bed5" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 18pt"></td>
<td style="WIDTH: 18pt; FONT-FAMILY: Symbol, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top; align: right">&#183;</td>
<td style="TEXT-ALIGN: justify; WIDTH: auto; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top">Many of our experimental products and technologies have not been applied in human medicine and have only been used in laboratory studies <font style="FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">in vitro</font> or in animals. These new products and technologies might not prove to be safe and efficacious in the human medical applications for which they were developed.</td>
</tr>
</table>
</div>

<div><br>
</div>

<div style="TEXT-ALIGN: justify">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt" id="da1b79c2961a4242aff0b100d9a7c00b" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 18pt"></td>
<td style="WIDTH: 18pt; FONT-FAMILY: Symbol, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top; align: right">&#183;</td>
<td style="TEXT-ALIGN: justify; WIDTH: auto; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top">The experimentation we are doing is costly, time consuming, and uncertain as to its results. We incurred research and development expenses amounting to $9,323,510, during the three months ended March 31, 2015, and $37,532,624, $26,609,423, and $18,116,688, during the fiscal years ended December 31, 2014, 2013, and 2012, respectively, excluding $17,458,766 charged as in process research and development expenses during 2013 in accordance with ASC 805-50 on account of Asterias&#8217; acquisition of certain assets from Geron.</td>
</tr>
</table>
</div>

<div><br>
</div>

<div style="TEXT-ALIGN: justify">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt" id="5d0f5d7248dd45b687299e45dbc3cca5" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 18pt"></td>
<td style="WIDTH: 18pt; FONT-FAMILY: Symbol, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top; align: right">&#183;</td>
<td style="TEXT-ALIGN: justify; WIDTH: auto; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top">If we are successful in developing a new technology or product, refinement of the new technology or product and definition of the practical applications and limitations of the technology or product may take years and require the expenditure of large sums of money. Future clinical trials of new therapeutic products, particularly those products that are regulated as drugs or biological, will be very expensive and will take years to complete. We may not have the financial resources to fund clinical trials on our own and we may have to enter into licensing or collaborative arrangements with larger, well-capitalized pharmaceutical companies in order to bear the cost. Any such arrangements may be dilutive to our ownership or economic interest in the products we develop, and we might have to accept a royalty payment on the sale of the product rather than receiving the gross revenues from product sales.</td>
</tr>
</table>
</div>

<div><br>
</div>

<div style="TEXT-ALIGN: justify; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">The amount and pace of research and development work that we and our subsidiaries can do or sponsor, and our ability to commence and complete clinical trials required to obtain regulatory approval to market our therapeutic and medical device products, depends upon the amount of money we have</div>

<div><br>
</div>

<div style="TEXT-ALIGN: justify">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt" id="63c8ff98a00b42fc9dbb13a10b382318" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 18pt"></td>
<td style="WIDTH: 18pt; FONT-FAMILY: Symbol, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top; align: right">&#183;</td>
<td style="TEXT-ALIGN: justify; WIDTH: auto; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top">At March 31, 2015, we had $25,829,533 of cash and cash equivalents on hand, of which $8,984,466 was held by Asterias and other subsidiaries. Although Asterias raised an additional $5,500,000 of equity capital during February 2015, there can be no assurance that we or our subsidiaries will be able to raise additional funds on favorable terms or at all, or that any funds raised will be sufficient to permit us or our subsidiaries to develop and market our products and technology. Unless we and our subsidiaries are able to generate sufficient revenue or raise additional funds when needed, it is likely that we will be unable to continue our planned activities, even if we make progress in our research and development projects.</td>
</tr>
</table>
</div>

<div>&#160;</div>

<div style="MARGIN-TOP: 10pt; MARGIN-BOTTOM: 10pt; CLEAR: both" id="DSPFPageBreakArea">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 8pt" id="DSPFPageNumberArea">24</div>

<hr style="BORDER-RIGHT-WIDTH: 0px; BACKGROUND-COLOR: #000000; PAGE-BREAK-AFTER: always; MARGIN: 4px 0px; WIDTH: 100%; BORDER-TOP-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; HEIGHT: 2px; COLOR: #000000; CLEAR: both; BORDER-LEFT-WIDTH: 0px" id="DSPFPageBreak" noshade="noshade">
</div>

<div style="TEXT-ALIGN: justify">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt" id="4f0b67b2e84d457ea38300ecdd12db56" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 18pt"></td>
<td style="WIDTH: 18pt; FONT-FAMILY: Symbol, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top; align: right">&#183;</td>
<td style="TEXT-ALIGN: justify; WIDTH: auto; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top">We may have to postpone or limit the pace of our research and development work and planned clinical trials of our product candidates unless our cash resources increase through a growth in revenues or additional equity investment or borrowing.</td>
</tr>
</table>
</div>

<div style="TEXT-ALIGN: justify; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">&#160;</div>

<div style="TEXT-ALIGN: justify">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt" id="61f515986e214874bfec0920085b59b8" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 36pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top; FONT-WEIGHT: bold; align: right">Item 2.</td>
<td style="TEXT-ALIGN: justify; WIDTH: auto; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top; FONT-WEIGHT: bold">Unregistered Sales of Equity Securities and Use of Proceeds</td>
</tr>
</table>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 36pt"><br>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">
<div style="TEXT-ALIGN: justify; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">None.</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">&#160;</div>
</div>

<div style="TEXT-ALIGN: justify">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt" id="4d4de870f23745679824c516eefd3e68" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 36pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top; FONT-WEIGHT: bold; align: right">Item 3.</td>
<td style="TEXT-ALIGN: justify; WIDTH: auto; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top; FONT-WEIGHT: bold">Default Upon Senior Securities</td>
</tr>
</table>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 36pt"><br>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">None.</div>

<div style="TEXT-ALIGN: justify"><br>
</div>

<div style="TEXT-ALIGN: justify">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt" id="7cdace4cb2594350a540d36fe93ac411" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 36pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top; FONT-WEIGHT: bold; align: right">Item 4.</td>
<td style="TEXT-ALIGN: justify; WIDTH: auto; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top; FONT-WEIGHT: bold">Mine Safety Disclosures</td>
</tr>
</table>
</div>

<div style="TEXT-ALIGN: justify"><br>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">Not Applicable.</div>

<div style="TEXT-ALIGN: justify"><br>
</div>

<div style="TEXT-ALIGN: justify">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt" id="0fd812dbe1a5464f9f8a0e5e26e9df79" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 36pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top; FONT-WEIGHT: bold; align: right">Item 5.</td>
<td style="TEXT-ALIGN: justify; WIDTH: auto; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top; FONT-WEIGHT: bold">Other Information</td>
</tr>
</table>
</div>

<div><br>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">
<div style="TEXT-ALIGN: justify; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">Our Board of Directors has set Friday, July 10, 2015 as the date of our next annual meeting of shareholders. Any shareholder who desires to submit a proposal for consideration and approval by the shareholders at the annual meeting and who wishes to have that proposal included in our proxy statement under SEC Rule 14a-8, must submit their proposal to us a reasonable time prior to the date that we begin to print and mail our proxy statement for the annual meeting. We expect to begin printing and mailing our proxy statement on or before June 8, 2015.</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">&#160;</div>
</div>

<div><br>
</div>

<div style="MARGIN-TOP: 10pt; MARGIN-BOTTOM: 10pt; CLEAR: both" id="DSPFPageBreakArea">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 8pt" id="DSPFPageNumberArea">25</div>

<hr style="BORDER-RIGHT-WIDTH: 0px; BACKGROUND-COLOR: #000000; PAGE-BREAK-AFTER: always; MARGIN: 4px 0px; WIDTH: 100%; BORDER-TOP-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; HEIGHT: 2px; COLOR: #000000; CLEAR: both; BORDER-LEFT-WIDTH: 0px" id="DSPFPageBreak" noshade="noshade">
</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt" id="5644241bacda4c23aa2007e34c7f2ec3" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr style="VERTICAL-ALIGN: top">
<td style="WIDTH: 36pt; VERTICAL-ALIGN: top; align: right">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Item 6.</div>
</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top; align: left">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Exhibits</div>
</td>
</tr>
</table>
</div>

<div>&#160;</div>

<table style="WIDTH: 100%; BORDER-COLLAPSE: collapse; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt" id="4d76ad88f3324dd398d07f671475d6bf" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 8.98%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">Exhibit</div>
</td>
<td style="WIDTH: 91.02%; VERTICAL-ALIGN: bottom">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 8.98%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">Numbers</div>
</td>
<td style="WIDTH: 91.02%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">Description</div>
</td>
</tr>

<tr>
<td style="WIDTH: 8.98%; VERTICAL-ALIGN: bottom">&#160;</td>
<td style="WIDTH: 91.02%; VERTICAL-ALIGN: bottom">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 8.98%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">3.1</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 91.02%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">Articles of Incorporation with all amendments.(1)</div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 8.98%; VERTICAL-ALIGN: bottom">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 91.02%; VERTICAL-ALIGN: bottom">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 8.98%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">3.2</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 91.02%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">By-Laws, as Amended. (2)</div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 8.98%; VERTICAL-ALIGN: bottom">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 91.02%; VERTICAL-ALIGN: bottom">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 8.98%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">4.1</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 91.02%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">Specimen of Series A Convertible Preferred Stock Certificate (3)</div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 8.98%; VERTICAL-ALIGN: top">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 91.02%; VERTICAL-ALIGN: top">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 8.98%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">4.2</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 91.02%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">Certificate of Determination of Series A Convertible Preferred Stock (3)</div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 8.98%; VERTICAL-ALIGN: top">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 91.02%; VERTICAL-ALIGN: top">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 8.98%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">10.1</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 91.02%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">Form of Subscription Agreement, dated February 4, 2015, by and among Asterias Biotherapeutics, Inc. and the investors named therein (4)</div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 8.98%; VERTICAL-ALIGN: top">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 91.02%; VERTICAL-ALIGN: top">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 8.98%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">10.2</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 91.02%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">First Amendment to Co-Development and Option Agreement, dated March 7, 2015, between Icahn School of Medicine at Mount Sinai and LifeMap Solutions, Inc. (Portions of this exhibit have been omitted pursuant to a request for confidential treatment)*</div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 8.98%; VERTICAL-ALIGN: top">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 91.02%; VERTICAL-ALIGN: top">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 8.98%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">31</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 91.02%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">Rule 13a-14(a)/15d-14(a) Certification.*</div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 8.98%; VERTICAL-ALIGN: bottom">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 91.02%; VERTICAL-ALIGN: bottom">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 8.98%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">32</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 91.02%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">Section 1350 Certification.*</div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 8.98%; VERTICAL-ALIGN: bottom">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 91.02%; VERTICAL-ALIGN: bottom">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 8.98%; VERTICAL-ALIGN: bottom">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">101</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 91.02%; VERTICAL-ALIGN: bottom">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">Interactive Data File</div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 8.98%; VERTICAL-ALIGN: bottom">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 91.02%; VERTICAL-ALIGN: bottom">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 8.98%; VERTICAL-ALIGN: bottom">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">101.INS</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 91.02%; VERTICAL-ALIGN: bottom">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">XBRL Instance Document *</div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 8.98%; VERTICAL-ALIGN: bottom">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 91.02%; VERTICAL-ALIGN: bottom">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 8.98%; VERTICAL-ALIGN: bottom">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">101.SCH</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 91.02%; VERTICAL-ALIGN: bottom">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">XBRL Taxonomy Extension Schema *</div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 8.98%; VERTICAL-ALIGN: bottom">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 91.02%; VERTICAL-ALIGN: bottom">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 8.98%; VERTICAL-ALIGN: bottom">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">101.CAL</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 91.02%; VERTICAL-ALIGN: bottom">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">XBRL Taxonomy Extension Calculation Linkbase *</div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 8.98%; VERTICAL-ALIGN: bottom">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 91.02%; VERTICAL-ALIGN: bottom">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 8.98%; VERTICAL-ALIGN: bottom">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">101.LAB</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 91.02%; VERTICAL-ALIGN: bottom">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">XBRL Taxonomy Extension Label Linkbase *</div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 8.98%; VERTICAL-ALIGN: bottom">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 91.02%; VERTICAL-ALIGN: bottom">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 8.98%; VERTICAL-ALIGN: bottom">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">101.PRE</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 91.02%; VERTICAL-ALIGN: bottom">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">XBRL Taxonomy Extension Presentation Linkbase *</div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 8.98%; VERTICAL-ALIGN: bottom">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 91.02%; VERTICAL-ALIGN: bottom">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 8.98%; VERTICAL-ALIGN: bottom">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">101.DEF</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 91.02%; VERTICAL-ALIGN: bottom">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">XBRL Taxonomy Extension Definition Document *</div>
</td>
</tr>
</table>

<div><br>
</div>

<div style="TEXT-ALIGN: justify">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt" id="b83fb28eb92744c89dfc57ed8cbe1764" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 27pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top; align: right">(1)</td>
<td style="TEXT-ALIGN: justify; WIDTH: auto; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top">Incorporated by reference to BioTime&#8217;s Annual Report on Form 10-K/A-1 for the year ended December 31, 2013 filed with the Securities and Exchange Commission on April 29, 2014.</td>
</tr>
</table>
</div>

<div style="TEXT-ALIGN: justify"><br>
</div>

<div style="TEXT-ALIGN: justify">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt" id="8449fbf4a9d94add97f6410a777e7dd3" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 27pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top; align: right">(2)</td>
<td style="TEXT-ALIGN: justify; WIDTH: auto; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top">Incorporated by reference to Registration Statement on Form S-1, File Number 33-48717 and Post-Effective Amendment No. 1 thereto filed with the Securities and Exchange Commission on June 22, 1992, and August 27, 1992, respectively.</td>
</tr>
</table>
</div>

<div style="TEXT-ALIGN: justify"><br>
</div>

<div style="TEXT-ALIGN: justify">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt" id="2c5f8608028047a6b12f767fe17ca377" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 27pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top; align: right">(3)</td>
<td style="TEXT-ALIGN: justify; WIDTH: auto; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top">Incorporated by reference to BioTime&#8217;s Current Report on Form 8-K filed with the Securities and Exchange Commission on March 5, 2014.</td>
</tr>
</table>
</div>

<div style="TEXT-ALIGN: justify"><br>
</div>

<div style="TEXT-ALIGN: justify">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt" id="bd00bd9a89d147228d4fe97f330e34e1" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 27pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top; align: right">(4)</td>
<td style="TEXT-ALIGN: justify; WIDTH: auto; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top">Incorporated by reference to BioTime&#8217;s Annual Report on Form 10-K for the year ended December 31, 2014 filed with the Securities and Exchange Commission on March 11, 2015.</td>
</tr>
</table>
</div>

<div style="TEXT-ALIGN: justify"><br>
</div>

<div style="TEXT-ALIGN: justify">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt" id="81722dbdb8444ad48b5ee5d381b603e3" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 27pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top; align: right">*</td>
<td style="TEXT-ALIGN: justify; WIDTH: auto; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top">Filed herewith</td>
</tr>
</table>
</div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</div>

<div style="MARGIN-TOP: 10pt; MARGIN-BOTTOM: 10pt; CLEAR: both" id="DSPFPageBreakArea">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 8pt" id="DSPFPageNumberArea">26</div>

<hr style="BORDER-RIGHT-WIDTH: 0px; BACKGROUND-COLOR: #000000; PAGE-BREAK-AFTER: always; MARGIN: 4px 0px; WIDTH: 100%; BORDER-TOP-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; HEIGHT: 2px; COLOR: #000000; CLEAR: both; BORDER-LEFT-WIDTH: 0px" id="DSPFPageBreak" noshade="noshade">
</div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">SIGNATURES</div>

<div><br>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 36pt"><br>
</div>

<table style="WIDTH: 100%; BORDER-COLLAPSE: collapse; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt" id="cd7129de779944ef9c732c1e17353657" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 51.06%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 40.44%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">BIOTIME, INC.</div>
</td>
<td style="WIDTH: 8.5%; VERTICAL-ALIGN: top">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 51.06%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 40.44%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 8.5%; VERTICAL-ALIGN: top">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 51.06%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">Date: May 8, 2015</div>
</td>
<td style="BORDER-BOTTOM: #000000 2px solid; WIDTH: 40.44%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">/s/ Michael D. West</div>
</td>
<td style="WIDTH: 8.5%; VERTICAL-ALIGN: top">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 51.06%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 40.44%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">Michael D. West</div>
</td>
<td style="WIDTH: 8.5%; VERTICAL-ALIGN: top">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 51.06%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 40.44%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">Chief Executive Officer</div>
</td>
<td style="WIDTH: 8.5%; VERTICAL-ALIGN: top">&#160;</td>
</tr>
</table>

<div style="TEXT-ALIGN: justify"><br>
</div>

<table style="WIDTH: 100%; BORDER-COLLAPSE: collapse; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt" id="d98dd26d570744fdb9ce2a49126683a6" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 51.06%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">Date: May 8, 2015</div>
</td>
<td style="BORDER-BOTTOM: #000000 2px solid; WIDTH: 40.44%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">/s/ Robert W. Peabody</div>
</td>
<td style="WIDTH: 8.5%; VERTICAL-ALIGN: top">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 51.06%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 40.44%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">Robert W. Peabody</div>
</td>
<td style="WIDTH: 8.5%; VERTICAL-ALIGN: top">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 51.06%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 40.44%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">Chief Financial Officer</div>
</td>
<td style="WIDTH: 8.5%; VERTICAL-ALIGN: top">&#160;</td>
</tr>
</table>

<div>&#160;</div>

<div style="MARGIN-TOP: 10pt; MARGIN-BOTTOM: 10pt; CLEAR: both" id="DSPFPageBreakArea">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 8pt" id="DSPFPageNumberArea">27</div>

<hr style="BORDER-RIGHT-WIDTH: 0px; BACKGROUND-COLOR: #000000; PAGE-BREAK-AFTER: always; MARGIN: 4px 0px; WIDTH: 100%; BORDER-TOP-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; HEIGHT: 2px; COLOR: #000000; CLEAR: both; BORDER-LEFT-WIDTH: 0px" id="DSPFPageBreak" noshade="noshade">
</div>

<table style="WIDTH: 100%; BORDER-COLLAPSE: collapse; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt" id="63701febd5934b1781d8ab5914ee6677" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 8.98%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">Exhibit</div>
</td>
<td style="WIDTH: 91.02%; VERTICAL-ALIGN: bottom">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 8.98%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">Numbers</div>
</td>
<td style="WIDTH: 91.02%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">Description</div>
</td>
</tr>

<tr>
<td style="WIDTH: 8.98%; VERTICAL-ALIGN: bottom">&#160;</td>
<td style="WIDTH: 91.02%; VERTICAL-ALIGN: bottom">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 8.98%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">3.1</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 91.02%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">Articles of Incorporation with all amendments.(1)</div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 8.98%; VERTICAL-ALIGN: bottom">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 91.02%; VERTICAL-ALIGN: bottom">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 8.98%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">3.2</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 91.02%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">By-Laws, as Amended. (2)</div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 8.98%; VERTICAL-ALIGN: bottom">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 91.02%; VERTICAL-ALIGN: bottom">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 8.98%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">4.1</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 91.02%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">Specimen of Series A Convertible Preferred Stock Certificate (3)</div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 8.98%; VERTICAL-ALIGN: top">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 91.02%; VERTICAL-ALIGN: top">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 8.98%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">4.2</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 91.02%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">Certificate of Determination of Series A Convertible Preferred Stock (3)</div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 8.98%; VERTICAL-ALIGN: top">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 91.02%; VERTICAL-ALIGN: top">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 8.98%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">10.1</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 91.02%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">Form of Subscription Agreement, dated February 4, 2015, by and among Asterias Biotherapeutics, Inc. and the investors named therein (4)</div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 8.98%; VERTICAL-ALIGN: top">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 91.02%; VERTICAL-ALIGN: top">&#160;</td>
</tr>

<tr style="HEIGHT: 28px">
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 8.98%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt"><a href="ex10_2.htm">10.2</a></div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 91.02%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">First Amendment to Co-Development and Option Agreement, dated March 7, 2015, between Icahn School of Medicine at Mount Sinai and LifeMap Solutions, Inc. (Portions of this exhibit have been omitted pursuant to a request for confidential treatment)*</div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 8.98%; VERTICAL-ALIGN: top">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 91.02%; VERTICAL-ALIGN: top">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 8.98%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt"><a href="ex31.htm">31</a></div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 91.02%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">Rule 13a-14(a)/15d-14(a) Certification.*</div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 8.98%; VERTICAL-ALIGN: bottom">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 91.02%; VERTICAL-ALIGN: bottom">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 8.98%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt"><a href="ex32.htm">32</a></div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 91.02%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">Section 1350 Certification.*</div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 8.98%; VERTICAL-ALIGN: bottom">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 91.02%; VERTICAL-ALIGN: bottom">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 8.98%; VERTICAL-ALIGN: bottom">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">101</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 91.02%; VERTICAL-ALIGN: bottom">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">Interactive Data File</div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 8.98%; VERTICAL-ALIGN: bottom">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 91.02%; VERTICAL-ALIGN: bottom">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 8.98%; VERTICAL-ALIGN: bottom">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">101.INS</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 91.02%; VERTICAL-ALIGN: bottom">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">XBRL Instance Document *</div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 8.98%; VERTICAL-ALIGN: bottom">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 91.02%; VERTICAL-ALIGN: bottom">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 8.98%; VERTICAL-ALIGN: bottom">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">101.SCH</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 91.02%; VERTICAL-ALIGN: bottom">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">XBRL Taxonomy Extension Schema *</div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 8.98%; VERTICAL-ALIGN: bottom">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 91.02%; VERTICAL-ALIGN: bottom">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 8.98%; VERTICAL-ALIGN: bottom">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">101.CAL</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 91.02%; VERTICAL-ALIGN: bottom">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">XBRL Taxonomy Extension Calculation Linkbase *</div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 8.98%; VERTICAL-ALIGN: bottom">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 91.02%; VERTICAL-ALIGN: bottom">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 8.98%; VERTICAL-ALIGN: bottom">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">101.LAB</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 91.02%; VERTICAL-ALIGN: bottom">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">XBRL Taxonomy Extension Label Linkbase *</div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 8.98%; VERTICAL-ALIGN: bottom">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 91.02%; VERTICAL-ALIGN: bottom">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 8.98%; VERTICAL-ALIGN: bottom">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">101.PRE</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 91.02%; VERTICAL-ALIGN: bottom">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">XBRL Taxonomy Extension Presentation Linkbase *</div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 8.98%; VERTICAL-ALIGN: bottom">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 91.02%; VERTICAL-ALIGN: bottom">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 8.98%; VERTICAL-ALIGN: bottom">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">101.DEF</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 91.02%; VERTICAL-ALIGN: bottom">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">XBRL Taxonomy Extension Definition Document *</div>
</td>
</tr>
</table>

<div><br>
</div>

<div style="TEXT-ALIGN: justify">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt" id="04aaf252e2fb4a9b8bcf44ef0d0bc62c" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 27pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top; align: right">(1)</td>
<td style="TEXT-ALIGN: justify; WIDTH: auto; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top">Incorporated by reference to BioTime&#8217;s Annual Report on Form 10-K/A-1 for the year ended December 31, 2013 filed with the Securities and Exchange Commission on April 29, 2014.</td>
</tr>
</table>
</div>

<div style="TEXT-ALIGN: justify"><br>
</div>

<div style="TEXT-ALIGN: justify">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt" id="6461289591814fb39145be499966aed4" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 27pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top; align: right">(2)</td>
<td style="TEXT-ALIGN: justify; WIDTH: auto; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top">Incorporated by reference to Registration Statement on Form S-1, File Number 33-48717 and Post-Effective Amendment No. 1 thereto filed with the Securities and Exchange Commission on June 22, 1992, and August 27, 1992, respectively.</td>
</tr>
</table>
</div>

<div style="TEXT-ALIGN: justify"><br>
</div>

<div style="TEXT-ALIGN: justify">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt" id="0549ff665a754db6aa2a955a84432179" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 27pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top; align: right">(3)</td>
<td style="TEXT-ALIGN: justify; WIDTH: auto; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top">Incorporated by reference to BioTime&#8217;s Current Report on Form 8-K filed with the Securities and Exchange Commission on March 5, 2014.</td>
</tr>
</table>
</div>

<div style="TEXT-ALIGN: justify"><br>
</div>

<div style="TEXT-ALIGN: justify">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt" id="1d5e97800e2f4034a10f4bd2bdd604fa" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 27pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top; align: right">(4)</td>
<td style="TEXT-ALIGN: justify; WIDTH: auto; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top">Incorporated by reference to BioTime&#8217;s Annual Report on Form 10-K for the year ended December 31, 2014 filed with the Securities and Exchange Commission on March 11, 2015.</td>
</tr>
</table>
</div>

<div style="TEXT-ALIGN: justify"><br>
</div>

<div style="TEXT-ALIGN: justify">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt" id="ef68f954d69e46fe89965d761d624245" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 27pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top; align: right">*</td>
<td style="TEXT-ALIGN: justify; WIDTH: auto; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top">Filed herewith</td>
</tr>
</table>
</div>

<div>&#160;</div>

<div>
<div style="TEXT-ALIGN: center">&#160;</div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 8pt">28</div>

<div style="TEXT-ALIGN: center">
<hr style="TEXT-ALIGN: center; BACKGROUND-COLOR: #000000; HEIGHT: 2px; COLOR: #000000; MARGIN-LEFT: auto; MARGIN-RIGHT: auto" noshade="noshade">
</div>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>2
<FILENAME>ex10_2.htm
<DESCRIPTION>EXHIBIT 10.2
<TEXT>
<html>
<head>
<title></title>
<!--Licensed to: Summit Financial Printing, LLC
    Document created using EDGARfilings PROfile 3.3.0.0
    Copyright 1995 - 2015 Summit Financial Printing, LLC.  All rights reserved.-->
</head>
<body style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif" bgcolor="#ffffff" text="#000000">
<div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; FONT-STYLE: normal; TEXT-ALIGN: right">
<hr style="HEIGHT: 4px; COLOR: #000000; TEXT-ALIGN: center; MARGIN-LEFT: auto; BACKGROUND-COLOR: #000000; MARGIN-RIGHT: auto" noshade="noshade">
 Exhibit 10.2</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic; TEXT-ALIGN: justify">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic; TEXT-ALIGN: justify">Certain information has been omitted under a request for confidential treatment, and the omitted information has been filed with the Commission.&#160; Confidential portions are marked [**].</div>

<div><br>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center">FIRST AMENDMENT TO CO-DEVELOPMENT AND OPTION AGREEMENT</div>

<div><br>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center">Between</div>

<div><br>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; MARGIN-LEFT: 63.55pt; MARGIN-RIGHT: 45pt"><u>Icahn School of Medicine at Mount Sinai</u></div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; MARGIN-LEFT: 63.55pt; MARGIN-RIGHT: 45pt">a nonprofit education corporation organized and existing under the laws of the State of New York, having a principal place of business of One Gustave L. Levy Place, New York, New York 10029 (hereinafter, &#8220;<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Mount Sinai</font>&#8221;)</div>

<div><br>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; MARGIN-LEFT: 63.55pt; MARGIN-RIGHT: 45pt">and</div>

<div><br>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; MARGIN-LEFT: 63.55pt; MARGIN-RIGHT: 45pt"><u>LifeMap Solutions, Inc.</u></div>

<div><br>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center">a corporation organized and existing under the laws of Delaware, having a place of business at 1301 Bay Harbor Parkway, Suite 100, Alameda, CA 94502</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; MARGIN-LEFT: 63.55pt; MARGIN-RIGHT: 45pt">(hereinafter, <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">&#8220;LifeMap&#8221;</font>)</div>

<div><br>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-LEFT: 72pt; TEXT-INDENT: -72pt">WHEREAS:</div>

<div><br>
</div>

<div style="TEXT-ALIGN: justify">
<table id="2e1f5463373f4acebb685515f0b1fbb8" class="DSPFListTable" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; VERTICAL-ALIGN: top; WIDTH: 72pt; align: right">(A)</td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; VERTICAL-ALIGN: top; TEXT-ALIGN: justify; WIDTH: auto">Mount Sinai and LifeMap are parties to a certain Co-development and Option Agreement dated May 1, 2014 (&#8220;<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">the Co-development and Option</font>&#160;<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Agreement</font>&#8221;);</td>
</tr>
</table>
</div>

<div><br>
</div>

<div style="TEXT-ALIGN: justify">
<table id="a777f29f5bda416788a2bec43ba6244c" class="DSPFListTable" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; VERTICAL-ALIGN: top; WIDTH: 72pt; align: right">(B)</td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; VERTICAL-ALIGN: top; TEXT-ALIGN: justify; WIDTH: auto">Mount Sinai and LifeMap wish to extend the timeframe for negotiating and entering into a definitive license agreement in accordance with Exhibit E of the Co-development and Option Agreement;</td>
</tr>
</table>
</div>

<div><br>
</div>

<div style="TEXT-ALIGN: justify">
<table id="1ab2f0eded6f4fcea6361b22371dc5b4" class="DSPFListTable" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; VERTICAL-ALIGN: top; WIDTH: 72pt; align: right">(C)</td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; VERTICAL-ALIGN: top; TEXT-ALIGN: justify; WIDTH: auto">Mount Sinai and LifeMap wish to add Attachment A-1 defining a specific project undertaken to fulfill the Development Activities, as defined in the Co-development and Option Agreement;</td>
</tr>
</table>
</div>

<div><br>
</div>

<div style="TEXT-ALIGN: justify">
<table id="3d48561363854483b1e33971ae4a145e" class="DSPFListTable" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; VERTICAL-ALIGN: top; WIDTH: 72pt; align: right">(D)</td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; VERTICAL-ALIGN: top; TEXT-ALIGN: justify; WIDTH: auto">Mount Sinai and LifeMap wish to update Attachment D with specific Mount Sinai Background Intellectual Property, and terms and conditions relating thereto, to be utilized as part of the Development Activities;</td>
</tr>
</table>
</div>

<div><br>
</div>

<div style="TEXT-ALIGN: justify">
<table id="4a83e4b4c73e45b085d5b6e341922431" class="DSPFListTable" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; VERTICAL-ALIGN: top; WIDTH: 72pt; align: right">(E)</td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; VERTICAL-ALIGN: top; TEXT-ALIGN: justify; WIDTH: auto">Mount Sinai and LifeMap wish to amend the Field of Use definition in the Co-development and Option Agreement and clauses related thereto;.and</td>
</tr>
</table>
</div>

<div><br>
</div>

<div style="TEXT-ALIGN: justify">
<table id="80c24923d39a4a658fae2128e66b3d72" class="DSPFListTable" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; VERTICAL-ALIGN: top; WIDTH: 72pt; align: right">(F)</td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; VERTICAL-ALIGN: top; TEXT-ALIGN: justify; WIDTH: auto">Mount Sinai and LifeMap wish to amend Clause 6.1 of the Co-development and Option Agreement to include Developed Intellectual Property in the license grant.</td>
</tr>
</table>
</div>

<div><br>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify">NOW, THEREFORE, THE PARTIES AGREE AS FOLLOWS:</div>

<div><br>
</div>

<div style="TEXT-ALIGN: justify">
<table id="0ba07769feba481fb15a973b45bac3f7" class="DSPFListTable" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-VARIANT: normal; VERTICAL-ALIGN: top; FONT-WEIGHT: normal; FONT-STYLE: normal; WIDTH: 36pt; align: right">1.</td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; VERTICAL-ALIGN: top; TEXT-ALIGN: justify; WIDTH: auto">Capitalised terms in this Amendment that are defined in the Co-development and Option Agreement shall have the same meaning attributed to them therein, unless otherwise defined in this Amendment.</td>
</tr>
</table>
</div>

<div><br>
</div>

<div style="TEXT-ALIGN: justify">
<table id="4381397d8a7c41a2885309e256d1a2c3" class="DSPFListTable" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; VERTICAL-ALIGN: top; WIDTH: 36pt; align: right">2.</td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; VERTICAL-ALIGN: top; TEXT-ALIGN: justify; WIDTH: auto">The preamble hereto shall form an integral part of this Amendment.</td>
</tr>
</table>
</div>

<div><br>
</div>

<div style="TEXT-ALIGN: justify">
<table id="5abcc968ac4f4a08908eda02d0fbf309" class="DSPFListTable" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; VERTICAL-ALIGN: top; WIDTH: 36pt; align: right">3.</td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; VERTICAL-ALIGN: top; TEXT-ALIGN: justify; WIDTH: auto">The Co-development and Option Agreement and this Amendment shall be read as one and shall represent the complete current understanding between the parties with respect to the subject matters hereof.</td>
</tr>
</table>
</div>

<div><br>
</div>

<div style="TEXT-ALIGN: justify">
<table id="80fb582377dd4e888e9bb3095f3f63fa" class="DSPFListTable" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; VERTICAL-ALIGN: top; WIDTH: 36pt; align: right">4.</td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; VERTICAL-ALIGN: top; TEXT-ALIGN: justify; WIDTH: auto">Subject only to the modifications contained herein, the provisions of the Co-development and Option Agreement shall remain unaltered and in full force and effect.</td>
</tr>
</table>
</div>

<div><br>
 &#160;</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
<hr id="DSPFPageBreak" style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; PAGE-BREAK-AFTER: always; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; WIDTH: 100%; BACKGROUND-COLOR: #000000" noshade="noshade">
<div id="DSPFPageNumberArea" style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center">- 2 -</div>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic; TEXT-ALIGN: justify; MARGIN-LEFT: 36pt">Certain information has been omitted under a request for confidential treatment, and the omitted information has been filed with the Commission. Confidential portions are marked [**].</div>

<div><br>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify; MARGIN-LEFT: 36pt"><u>Definitions</u></div>

<div><br>
</div>

<div style="TEXT-ALIGN: justify">
<table id="22821a463b7c42d0912138c82abd1dbc" class="DSPFListTable" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; VERTICAL-ALIGN: top; WIDTH: 36pt; align: right">5.</td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; VERTICAL-ALIGN: top; TEXT-ALIGN: justify; WIDTH: auto">It is hereby agreed that, as of the date of full execution hereof, Clause 1.7 shall read in its entirety as follows:</td>
</tr>
</table>
</div>

<div><br>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-LEFT: 36pt">&#8220;<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; FONT-STYLE: italic">Development Activities</font> means the collaborative research and co-development program described in <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Attachments A</font> and <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">A-1</font> to this Agreement, which are hereby incorporated into and made a part of this Agreement.&#8221;</div>

<div><br>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify; MARGIN-LEFT: 40.5pt; TEXT-INDENT: -4.5pt"><u>Expansion of the Option Term</u></div>

<div><br>
</div>

<div style="TEXT-ALIGN: justify">
<table id="4f046368421d407487a45176e01865f5" class="DSPFListTable" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; VERTICAL-ALIGN: top; WIDTH: 36pt; align: right">6.</td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; VERTICAL-ALIGN: top; TEXT-ALIGN: justify; WIDTH: auto">It is hereby agreed that, as of the date of full execution hereof, the last sentence in Clause 7.1 of the Co-development and Option Agreement shall be replaced with:</td>
</tr>
</table>
</div>

<div><br>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">&#8220;The Parties agree that they will use good faith efforts to begin negotiations on a license, as discussed above, within sixty (60) days of the Effective Date, and shall use reasonable efforts to agree on a form of license, based substantially on the terms attached hereto as Attachment E, on or before <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">[**]</font>.&#8221;</div>

<div><br>
</div>

<div style="TEXT-ALIGN: justify">
<table id="a9679d44d28c45acaf34c4f0c705dded" class="DSPFListTable" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; VERTICAL-ALIGN: top; WIDTH: 36pt; align: right">7.</td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; VERTICAL-ALIGN: top; TEXT-ALIGN: justify; WIDTH: auto">It is hereby agreed that, as of the date of full execution hereof, the first sentence in Clause 7.2 of the Co-development and Option Agreement shall be replaced with:</td>
</tr>
</table>
</div>

<div><br>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">&#8220;If LifeMap and Mount Sinai fail to execute a license agreement <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">[**]</font>, or such additional time period as the Parties shall reasonably agree in writing, either Party may initiate a mediation process through which the Parties shall endeavor to arrive at a mutually agreeable license agreement in accordance with the provisions set forth in <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Attachment E</font>, with the assistance of a sole mediator to be agreed upon by the Parties, or if the Parties are unable to agree on a mediator, one shall be appointed by the American Arbitration Association, or other similar association mutually agreed upon.&#8221;</div>

<div><br>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify; MARGIN-LEFT: 36pt"><u>Attachment A-1</u></div>

<div><br>
</div>

<div style="TEXT-ALIGN: justify">
<table id="b2da080121604804b98da8fcbf991369" class="DSPFListTable" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; VERTICAL-ALIGN: top; WIDTH: 36pt; align: right">8.</td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; VERTICAL-ALIGN: top; TEXT-ALIGN: justify; WIDTH: auto">It is hereby agreed that, as of the date of full execution hereof, the following is added as Attachment A-1 of the Co-development and Option Agreement:</td>
</tr>
</table>
</div>

<div><br>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">&#8220;As part of the Development Activities, the Parties have undertaken a project to demonstrate the potential feasibility of using a smartphone application for improving clinical asthma management (&#8220;Asthma App&#8221;), and such project may include a clinical study approved by the Mount Sinai IRB to be conducted by Mount Sinai researchers and/or clinicians. The Asthma App will include educational materials and is meant to educate patients about asthma, treatments, and the importance of adherence and will include reminders to patients to take their medications and will monitor adherence. It will assess the patient's disease condition at intake and at monthly intervals over six (6) months using a quality of life questionnaire.&#160; The Asthma App is intended for clinical research use only and will be given away for free in the Apple Store and is intended to pioneer a new approach to performing clinical studies on a very large scale at low cost by leveraging the power of mobile applications for cost-effective patient recruiting, e-consenting, and study participation.&#160; This project is part of a relationship with Apple, Inc. and the Parties have entered into a three-party Framework and Source Code License Agreement by and between Mount Sinai, LifeMap, and Apple, Inc. effective February 16, 2015 whereby the Parties provide Apple, Inc with specifications to build an iOS application layer focused on asthma and Apple, Inc provides the Parties with access to a third-party coding contractor and access to Apple Inc.&#8217;s proprietary framework(s) of health and fitness research-related application programming interfaces for the iOS operating system and proprietary, content-neutral implementation software.&#160; The Parties acknowledge and agree that the posting of the Asthma App in the Apple Store for the purposes of clinical research in accordance with the project described in this Attachment A-1 does not constitute commercial use and LifeMap does not require a commercial license in accordance with Exhibit E to Mount Sinai&#8217;s interest in and to the Asthma App for such clinical research.&#160; Notwithstanding the foregoing, the Parties acknowledge and agree that any use other than the foregoing of the Asthma App by LifeMap would require such commercial license to Mount Sinai&#8217;s interest in and to the Asthma App.&#8221;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">&#160;</div>

<div><br>
</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
<hr id="DSPFPageBreak" style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; PAGE-BREAK-AFTER: always; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; WIDTH: 100%; BACKGROUND-COLOR: #000000" noshade="noshade">
<div id="DSPFPageNumberArea" style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center">- 3 -</div>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic; TEXT-ALIGN: justify">Certain information has been omitted under a request for confidential treatment, and the omitted information has been filed with the Commission. Confidential portions are marked [**].</div>

<div><br>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify; MARGIN-LEFT: 36pt"><u>Attachment D</u></div>

<div style="TEXT-ALIGN: justify; MARGIN-LEFT: 36pt; TEXT-INDENT: -36pt"><br>
</div>

<div style="TEXT-ALIGN: justify">
<table id="aa44cc3ae30040a28fdaa73dda17a9a3" class="DSPFListTable" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; VERTICAL-ALIGN: top; WIDTH: 36pt; align: right">9.</td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; VERTICAL-ALIGN: top; TEXT-ALIGN: justify; WIDTH: auto">It is hereby agreed that, as of the date of full execution hereof, the following is added to Exhibit D of the Co-development and Option Agreement:</td>
</tr>
</table>
</div>

<div><br>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-LEFT: 36pt">&#8220;The Parties hereby add the following as Mount Sinai Background Intellectual Property:</div>

<div><br>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-LEFT: 36pt">&#8220;Educational videos about asthma and asthma inhalers licensed to LifeMap (&#8220;Licensed Content&#8221;) by the MS/NJH Administrative Services, LLC in accordance with the Non-Exclusive License Agreement by and between LifeMap and MS/NJH Administrative Services, LLC, effective March 6, 2015.&#160; The Parties acknowledge and agree that such Licensed Content is solely intended for use in the Development Activities outlined in Attachment A-1.&#160; The Parties further acknowledge and agree that such Licensed Content is separate from the class of Mount Sinai Background Intellectual Property for which LifeMap is granted an option to license in accordance with Section 7.1 and Attachment E.&#160; Should LifeMap desire additional rights, including commercial use, in and to the Licensed Content, such license shall be negotiated at the discretion of the MS/NJH Administrative Services, LLC and shall be subject to its own terms and conditions independent of those outlined in Attachment E.&#8221;</div>

<div><br>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify; MARGIN-LEFT: 36pt"><u>Amendment of the Field of Use</u></div>

<div><br>
</div>

<div style="TEXT-ALIGN: justify">
<table id="23f67258318241fb82686f940bf162c8" class="DSPFListTable" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; VERTICAL-ALIGN: top; WIDTH: 36pt; align: right">10.</td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; VERTICAL-ALIGN: top; TEXT-ALIGN: justify; WIDTH: auto">It is hereby agreed that, as of the date of full execution hereof, Clause 1.12 of the Co-development and Option Agreement, shall be replaced by the following:</td>
</tr>
</table>
</div>

<div><br>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">&#8220;<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; FONT-STYLE: italic">Field of Use</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic">&#160;</font>means (i) Consumer applications (including, for clarity, Internet, Web-based, mobile user and Mobile User Applications, databases and software products), <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; BACKGROUND-COLOR: #ffffff">based on interpretation and/or presentation of Wide Scale Health Related Information; </font>and (ii)&#160;Consumer and/or research applications (including, for clarity, Internet, Web-based, mobile user and Mobile User Applications, databases and software products) that utilize clinical data and other information&#160;of individuals&#160;relating to human disease, health and/or wellness for monitoring and maintenance of Asthma and <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; BACKGROUND-COLOR: #ffffff">Chronic Obstructive Pulmonary Disease</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">.&#8221;</font></div>

<div><br>
</div>

<div style="TEXT-ALIGN: justify">
<table id="39e5c7b812fa4a6b883e6283d37c2e7a" class="DSPFListTable" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; VERTICAL-ALIGN: top; WIDTH: 36pt; align: right">11.</td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; VERTICAL-ALIGN: top; TEXT-ALIGN: justify; WIDTH: auto">It is hereby agreed that, as of the date of full execution hereof, in Attachment E of the Co-development and Option Agreement, the first paragraph of the Field of Use definition shall be replaced with:</td>
</tr>
</table>
</div>

<div><br>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">&#8220;Consumer applications (including, for clarity, Internet, Web-based, mobile user and Mobile User Applications, databases and software products), <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; BACKGROUND-COLOR: #ffffff">based (i) on interpretation and/or presentation of Wide Scale Health Related Information; </font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">and (ii)&#160;</font>Consumer and/or research applications (including, for clarity, Internet, Web-based, mobile user and Mobile User Applications, databases and software products) that utilize clinical data and other information&#160;of individuals&#160;relating to human disease, health and/or wellness for monitoring and maintenance of Asthma and <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; BACKGROUND-COLOR: #ffffff">Chronic Obstructive Pulmonary Disease</font>.<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; BACKGROUND-COLOR: #ffffff">&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; BACKGROUND-COLOR: #ffffff">Wide Scale Health Related Information is defined as one or more components of genetic information, </font>clinical data and other information<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; BACKGROUND-COLOR: #ffffff"> of individuals </font>relating to human disease, health and/or wellness, in which the genetic information component (if such component is available) <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">[**]</font>.&#160; As an example:&#8221;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">&#160;</div>

<div><br>
</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
<hr id="DSPFPageBreak" style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; PAGE-BREAK-AFTER: always; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; WIDTH: 100%; BACKGROUND-COLOR: #000000" noshade="noshade">
<div id="DSPFPageNumberArea" style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center">- 4 -</div>
</div>

<div style="TEXT-ALIGN: justify">
<table id="9d227f0754284d489f58286b3fbd434f" class="DSPFListTable" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; VERTICAL-ALIGN: top; WIDTH: 36pt; BACKGROUND-COLOR: #ffffff; align: right">12.</td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; VERTICAL-ALIGN: top; TEXT-ALIGN: justify; WIDTH: auto; BACKGROUND-COLOR: #ffffff">It is hereby agreed that, as of the date of full execution hereof, Clause 7.4 of the Co-development and Option Agreement shall be replaced in its entirety by the following:</td>
</tr>
</table>
</div>

<div><br>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">&#8220;During the term hereof, neither Mount Sinai nor any Affiliate of Mount Sinai will knowingly enter into any agreement with a commercial third party with respect to activities that are within the Field of Use defined in Section 1.12 (i) where such agreement would commit a Committed Participant to participate in such activities; provided, however ,that the Parties acknowledge and agree that a Committed Participant can recuse him/herself from the Development Activities at any time during the term hereof.&#160; The Parties further acknowledge and agree that following such recusal, Mount Sinai is free to enter into any agreement with a commercial third party with respect to activities that are within the Field of Use defined in Section 1.12 (i) where such agreement commits the recused Committed Participant to participate in such activities; provided that the recused Committed Participant will not utilize the Results in part or in whole for activities in the Field of Use defined in Section 1.12 (i) with any commercial third party other than as may permitted under the definitive license agreement in accordance with <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Attachment E</font>.&#8221;</div>

<div><br>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify; MARGIN-LEFT: 36pt"><u>Amendment to Clause 6.1</u></div>

<div><br>
</div>

<div style="TEXT-ALIGN: justify">
<table id="806724721e374741a3788b3e094ee31b" class="DSPFListTable" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; VERTICAL-ALIGN: top; WIDTH: 36pt; align: right">13.</td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; VERTICAL-ALIGN: top; TEXT-ALIGN: justify; WIDTH: auto">It is hereby agreed that, as of the date of full execution hereof, Clause 6.1 of the Co-development and Option Agreement, shall be replaced by the following:</td>
</tr>
</table>
</div>

<div><br>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">Each Party hereby grants the other Party a world-wide, royalty-free, non-exclusive, non-sublicenseable (except to Affiliates) license, during the term of this Agreement, to use such Party&#8217;s Developed Intellectual Property and Background Intellectual Property, as listed in <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Attachment D</font>, as may be amended in a writing executed by the Parties from time to time, solely to the extent necessary to undertake the Development Activities</div>

<div><br>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; MARGIN-LEFT: 18pt">SIGNATURES TO FOLLOW</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; MARGIN-LEFT: 18pt">&#160;</div>

<div><br>
</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
<hr id="DSPFPageBreak" style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; PAGE-BREAK-AFTER: always; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; WIDTH: 100%; BACKGROUND-COLOR: #000000" noshade="noshade">
<div id="DSPFPageNumberArea" style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center">- 5 -</div>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify">IN WITNESS WHEREOF, the parties have duly executed this Amendment as of the dates indicated below.</div>

<div><br>
</div>

<table id="6579c6d01f01459ea48be1bc5a5247b1" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; BORDER-COLLAPSE: collapse; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 48.15%" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify; MARGIN-LEFT: 28.35pt; TEXT-INDENT: -28.35pt">For&#160;&#160; ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 3.7%">&#160;</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 48.15%" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify; MARGIN-LEFT: 28.35pt; TEXT-INDENT: -28.35pt">for&#160;&#160; LIFEMAP SOLUTIONS, INC.</div>
</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 14.81%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify">Signature</div>
</td>
<td style="VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 2px solid; WIDTH: 33.33%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">s/</font> Sybil Lombillo</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 3.7%">&#160;</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 12.96%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify">Signature</div>
</td>
<td style="VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 2px solid; WIDTH: 35.19%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">s/Kenneth Elsner</div>
</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 14.81%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify">Name</div>
</td>
<td style="VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 2px solid; WIDTH: 33.33%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">Sybil Lombillo, Ph.D., J.D.</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 3.7%">&#160;</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 12.96%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify">Name</div>
</td>
<td style="BORDER-TOP: #000000 2px solid; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 2px solid; WIDTH: 35.19%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">Kenneth Elsner</div>
</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 14.81%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify">Title</div>
</td>
<td style="BORDER-TOP: #000000 2px solid; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; WIDTH: 33.33%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">Director, Intellectual Property</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">and Asset Development</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 3.7%">&#160;</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 12.96%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify">Title</div>
</td>
<td style="BORDER-TOP: #000000 2px solid; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; WIDTH: 35.19%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">CFO</div>
</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 14.81%">&#160;</td>
<td style="BORDER-TOP: #000000 2px solid; VERTICAL-ALIGN: top; WIDTH: 33.33%">&#160;</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 3.7%">&#160;</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 12.96%">&#160;</td>
<td style="BORDER-TOP: #000000 2px solid; VERTICAL-ALIGN: top; WIDTH: 35.19%">&#160;</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 14.81%">&#160;</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 33.33%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center">March 7, 2015</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 3.7%">&#160;</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 12.96%">&#160;</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 35.19%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center">3/7/15</div>
</td>
</tr>
</table>

<div><br>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify">READ AND ACKNOWLEDGED:</div>

<div><br>
</div>

<table id="c452443f61354225a071112d3b75aef8" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; BORDER-COLLAPSE: collapse; WIDTH: 100%" cellspacing="0" cellpadding="0" border="0">
<tr>
<td style="VERTICAL-ALIGN: top; BORDER-BOTTOM: black 2px solid; WIDTH: 20%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">s/Eric Schadt</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 80%">&#160;</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 20%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify">Eric Schadt</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 80%">&#160;</td>
</tr>
</table>

<div>&#160;</div>

<div><br>
<hr style="HEIGHT: 2px; COLOR: #000000; TEXT-ALIGN: center; MARGIN-LEFT: auto; BACKGROUND-COLOR: #000000; MARGIN-RIGHT: auto" noshade="noshade">
</div>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31
<SEQUENCE>3
<FILENAME>ex31.htm
<DESCRIPTION>EXHIBIT 31
<TEXT>
<html>
<head>
<title></title>
<!--Licensed to: Summit Financial Printing, LLC
    Document created using EDGARfilings PROfile 3.3.0.0
    Copyright 1995 - 2015 Summit Financial Printing, LLC.  All rights reserved.-->
</head>
<body style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif" bgcolor="#ffffff" text="#000000">
<div>
<hr style="HEIGHT: 4px; COLOR: #000000; TEXT-ALIGN: center; MARGIN-LEFT: auto; BACKGROUND-COLOR: #000000; MARGIN-RIGHT: auto" noshade="noshade">
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: right">Exhibit 31</div>

<div><br>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center">CERTIFICATIONS</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">I, Michael D. West, certify that:</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">1. I have reviewed this quarterly report on Form 10-Q of BioTime, Inc.</div>

<div><br>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</div>

<div><br>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</div>

<div><br>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">4. The registrant&#8217;s other certifying officers and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rule 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</div>

<div><br>
</div>

<div style="TEXT-ALIGN: justify">
<table id="bc253332302740d9998aa19d2bfe9959" class="DSPFListTable" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; VERTICAL-ALIGN: top; WIDTH: 27pt; align: right">(a)</td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; VERTICAL-ALIGN: top; TEXT-ALIGN: justify; WIDTH: auto">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which the periodic reports are being prepared;</td>
</tr>
</table>
</div>

<div><br>
</div>

<div style="TEXT-ALIGN: justify">
<table id="e17895d5f630458cad9e24179cd6ea1c" class="DSPFListTable" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; VERTICAL-ALIGN: top; WIDTH: 27pt; align: right">(b)</td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; VERTICAL-ALIGN: top; TEXT-ALIGN: justify; WIDTH: auto">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</td>
</tr>
</table>
</div>

<div style="TEXT-ALIGN: justify"><br>
</div>

<div style="TEXT-ALIGN: justify">
<table id="272ff8ee57d84bf8acd1134f26951570" class="DSPFListTable" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; VERTICAL-ALIGN: top; WIDTH: 27pt; align: right">(c)</td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; VERTICAL-ALIGN: top; TEXT-ALIGN: justify; WIDTH: auto">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</td>
</tr>
</table>
</div>

<div><br>
</div>

<div style="TEXT-ALIGN: justify">
<table id="3a7199483d784bbdb2513c3e861c85bc" class="DSPFListTable" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; VERTICAL-ALIGN: top; WIDTH: 27pt; align: right">(d)</td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; VERTICAL-ALIGN: top; TEXT-ALIGN: justify; WIDTH: auto">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting.</td>
</tr>
</table>
</div>

<div><br>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">5. The registrant's other certifying officers and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of registrant's board of directors (or persons performing the equivalent functions):</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">&#160;</div>

<div style="TEXT-ALIGN: justify">
<table id="5c51c099b07740ceb2a7bfd54e810dc3" class="DSPFListTable" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; VERTICAL-ALIGN: top; WIDTH: 27pt; align: right">(a)</td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; VERTICAL-ALIGN: top; TEXT-ALIGN: justify; WIDTH: auto">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">&#160;</div>

<div style="TEXT-ALIGN: justify">
<table id="7b04946a4d31492299fad1e78a5fa3e1" class="DSPFListTable" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; VERTICAL-ALIGN: top; WIDTH: 27pt; align: right">(b)</td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; VERTICAL-ALIGN: top; TEXT-ALIGN: justify; WIDTH: auto">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">&#160;</div>

<table id="aaeeaf4c8f654b10a17ee1fd2d7af684" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; BORDER-COLLAPSE: collapse; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 23.9%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Date: May 8, 2015</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 76.1%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;</div>
</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 23.9%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 76.1%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;</div>
</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 2px solid; WIDTH: 23.9%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic; TEXT-ALIGN: left">/s/ Michael D. West</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 76.1%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;</div>
</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 23.9%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Michael D. West</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 76.1%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;</div>
</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 23.9%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Chief Executive Officer</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 76.1%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;</div>
</td>
</tr>
</table>

<div style="TEXT-ALIGN: center"><br>
 &#160;</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
<hr id="DSPFPageBreak" style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; PAGE-BREAK-AFTER: always; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; WIDTH: 100%; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: right">Exhibit 31</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: right">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center">CERTIFICATIONS</div>

<div style="TEXT-ALIGN: left"><br>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">I, Robert W. Peabody, certify that:</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">1. I have reviewed this quarterly report on Form 10-Q of BioTime, Inc.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">4. The registrant&#8217;s other certifying officers and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rule 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">&#160;</div>

<div style="TEXT-ALIGN: justify">
<table id="950c1f01c204459c94209e613e09361e" class="DSPFListTable" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; VERTICAL-ALIGN: top; WIDTH: 27pt; align: right">(a)</td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; VERTICAL-ALIGN: top; TEXT-ALIGN: justify; WIDTH: auto">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which the periodic reports are being prepared;</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">&#160;</div>

<div style="TEXT-ALIGN: justify">
<table id="e7d5ce80ff414389a24d5cfa2c617138" class="DSPFListTable" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; VERTICAL-ALIGN: top; WIDTH: 27pt; align: right">(b)</td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; VERTICAL-ALIGN: top; TEXT-ALIGN: justify; WIDTH: auto">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">&#160;</div>

<div style="TEXT-ALIGN: justify">
<table id="b675110747224ed48edf15b4f6a8d363" class="DSPFListTable" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; VERTICAL-ALIGN: top; WIDTH: 27pt; align: right">(c)</td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; VERTICAL-ALIGN: top; TEXT-ALIGN: justify; WIDTH: auto">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">&#160;</div>

<div style="TEXT-ALIGN: justify">
<table id="fe5b6ef346bb433594536187956929ff" class="DSPFListTable" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; VERTICAL-ALIGN: top; WIDTH: 27pt; align: right">(d)</td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; VERTICAL-ALIGN: top; TEXT-ALIGN: justify; WIDTH: auto">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting.</td>
</tr>
</table>
</div>

<div><br>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">5. The registrant's other certifying officers and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of registrant's board of directors (or persons performing the equivalent functions):</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">&#160;</div>

<div style="TEXT-ALIGN: justify">
<table id="91e94b58aaab4a319d36fbc83db05067" class="DSPFListTable" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; VERTICAL-ALIGN: top; WIDTH: 27pt; align: right">(a)</td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; VERTICAL-ALIGN: top; TEXT-ALIGN: justify; WIDTH: auto">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">&#160;</div>

<div style="TEXT-ALIGN: justify">
<table id="8799b7c740f84f7d893d99a48a90d0b1" class="DSPFListTable" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; VERTICAL-ALIGN: top; WIDTH: 27pt; align: right">(b)</td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; VERTICAL-ALIGN: top; TEXT-ALIGN: justify; WIDTH: auto">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">&#160;</div>

<table id="b12a86e4592044a9b26bb1931cc698d6" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; BORDER-COLLAPSE: collapse; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 24%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Date: May 8, 2015</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 76%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;</div>
</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 24%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 76%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;</div>
</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 2px solid; WIDTH: 24%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic; TEXT-ALIGN: left">/s/ Robert W. Peabody</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 76%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;</div>
</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 24%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Robert W. Peabody</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 76%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;</div>
</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 24%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Chief Financial Officer</div>
</td>
</tr>
</table>

<div>&#160;</div>

<div>&#160;</div>

<div>
<hr style="HEIGHT: 2px; COLOR: #000000; TEXT-ALIGN: center; MARGIN-LEFT: auto; BACKGROUND-COLOR: #000000; MARGIN-RIGHT: auto" noshade="noshade">
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32
<SEQUENCE>4
<FILENAME>ex32.htm
<DESCRIPTION>EXHIBIT 32
<TEXT>
<html>
<head>
<title></title>
<!--Licensed to: Summit Financial Printing, LLC
    Document created using EDGARfilings PROfile 3.3.0.0
    Copyright 1995 - 2015 Summit Financial Printing, LLC.  All rights reserved.-->
</head>
<body style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt" bgcolor="#ffffff" text="#000000">
<div>
<hr style="BACKGROUND-COLOR: #000000; COLOR: #000000; HEIGHT: 4px; MARGIN-LEFT: auto; MARGIN-RIGHT: auto; text-align: center; TEXT-ALIGN: center" noshade="noshade">
</div>

<div style="TEXT-ALIGN: right; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Exhibit 32</div>

<div><br>
</div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,</div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">AS ADOPTED PURSUANT TO</div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</div>

<div><br>
</div>

<div style="TEXT-ALIGN: justify; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">In connection with the Quarterly Report on Form 10-Q of BioTime, Inc. (the &#8220;Company&#8221;) for the quarter ended March 31, 2015 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), we, Michael D. West, Chief Executive Officer, and Robert W. Peabody, Chief Financial Officer of the Company, certify pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:</div>

<div style="TEXT-ALIGN: justify; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">&#160;</div>

<div style="TEXT-ALIGN: justify">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt" id="ecf56ed24c3f4e33811f6e0bc6110f3d" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 27pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top; align: right">1.</td>
<td style="TEXT-ALIGN: justify; WIDTH: auto; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top">The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and</td>
</tr>
</table>
</div>

<div><br>
</div>

<div style="TEXT-ALIGN: justify">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt" id="0828242d1a4f432da7e0523063b2b9fb" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 27pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top; align: right">2.</td>
<td style="TEXT-ALIGN: justify; WIDTH: auto; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</td>
</tr>
</table>
</div>

<div style="TEXT-ALIGN: justify; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">&#160;</div>

<table style="WIDTH: 100%; BORDER-COLLAPSE: collapse; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt" id="34cf48f0760545b2bf19fd85e1cbca10" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 100%; VERTICAL-ALIGN: top" colspan="2">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">Date: May 8, 2015</div>
</td>
</tr>

<tr>
<td style="WIDTH: 25%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">&#160;</div>
</td>
<td style="WIDTH: 75%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">&#160;</div>
</td>
</tr>

<tr>
<td style="BORDER-BOTTOM: #000000 2px solid; WIDTH: 25%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">/s/ Michael D. West</div>
</td>
<td style="WIDTH: 75%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">&#160;</div>
</td>
</tr>

<tr>
<td style="WIDTH: 100%; VERTICAL-ALIGN: top" colspan="2">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">Michael D. West</div>
</td>
</tr>

<tr>
<td style="WIDTH: 100%; VERTICAL-ALIGN: top" colspan="2">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">Chief Executive Officer</div>
</td>
</tr>
</table>

<div><br>
</div>

<table style="WIDTH: 100%; BORDER-COLLAPSE: collapse; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt" id="4444cff8a57f4da988f7ef4851acdacf" cellspacing="0" cellpadding="0">
<tr>
<td style="BORDER-BOTTOM: #000000 2px solid; WIDTH: 25%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">/s/ Robert W. Peabody</div>
</td>
<td style="WIDTH: 75%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">&#160;</div>
</td>
</tr>

<tr>
<td style="WIDTH: 100%; VERTICAL-ALIGN: top" colspan="2">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">Robert W. Peabody</div>
</td>
</tr>

<tr>
<td style="WIDTH: 100%; VERTICAL-ALIGN: top" colspan="2">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">Chief Financial Officer</div>
</td>
</tr>
</table>

<div>&#160;</div>

<div>&#160;</div>

<div>
<hr style="BACKGROUND-COLOR: #000000; COLOR: #000000; HEIGHT: 2px; MARGIN-LEFT: auto; MARGIN-RIGHT: auto; text-align: center; TEXT-ALIGN: center" noshade="noshade">
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>5
<FILENAME>btx-20150331.xml
<DESCRIPTION>XBRL INSTANCE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--Generated by EDGARfilings PROfile 3.3.0.0 Copyright 1995 - 2015 Summit Financial Printing, LLC. All rights reserved.-->
<xbrl xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2014-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2014-01-31" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:country="http://xbrl.sec.gov/country/2013-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2014-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2011-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2011-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2014-01-31" xmlns:btx="http://biotimeinc.com/20150331" xmlns="http://www.xbrl.org/2003/instance">
  <link:schemaRef xlink:type="simple" xlink:href="btx-20150331.xsd" />
  <xbrli:context id="c20150101to20150331">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000876343</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20150501">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000876343</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-05-01</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20141231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000876343</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20150331">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000876343</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20140101to20140331">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000876343</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20131231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000876343</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20140331">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000876343</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20150331_LegalEntityAxis_LifemapSciencesIncMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000876343</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">btx:LifemapSciencesIncMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20150331_LegalEntityAxis_BiotimeAsiaLimitedMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000876343</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">btx:BiotimeAsiaLimitedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20150331_LegalEntityAxis_CellCureNeurosciencesLtdMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000876343</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">btx:CellCureNeurosciencesLtdMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20150331_LegalEntityAxis_RecyteTherapeuticsIncMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000876343</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">btx:RecyteTherapeuticsIncMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20150331_LegalEntityAxis_OrthocyteCorporationMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000876343</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">btx:OrthocyteCorporationMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20150331_LegalEntityAxis_AsteriasBiotherapeuticsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000876343</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">btx:AsteriasBiotherapeuticsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20150331_LegalEntityAxis_EsCellInternationalPteLtdMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000876343</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">btx:EsCellInternationalPteLtdMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20150331_LegalEntityAxis_LifemapSolutionsIncMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000876343</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">btx:LifemapSolutionsIncMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20150331_LegalEntityAxis_OncocyteCorporationMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000876343</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">btx:OncocyteCorporationMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20150331_LegalEntityAxis_LifemapSciencesLtdMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000876343</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">btx:LifemapSciencesLtdMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20150331_StatementEquityComponentsAxis_ParentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000876343</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20150101to20150331_PropertyPlantAndEquipmentByTypeAxis_EquipmentMember_RangeAxis_MinimumMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000876343</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20150101to20150331_PropertyPlantAndEquipmentByTypeAxis_EquipmentMember_RangeAxis_MaximumMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000876343</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20140601to20140630">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000876343</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-06-01</xbrli:startDate>
      <xbrli:endDate>2014-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20140630">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000876343</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20150101to20150331_FiniteLivedIntangibleAssetsByMajorClassAxis_TechnologyBasedIntangibleAssetsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000876343</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TechnologyBasedIntangibleAssetsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20150101to20150331_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_EmployeeStockOptionMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000876343</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20140101to20140331_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_TreasuryStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000876343</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20140101to20140331_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_EmployeeStockOptionMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000876343</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20150101to20150331_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_TreasuryStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000876343</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20150101to20150331_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_WarrantMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000876343</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20140101to20140331_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_WarrantMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000876343</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20150201to20150228_RelatedPartyTransactionAxis_CommonClassAMember_RelatedPartyTransactionsByRelatedPartyAxis_AsteriasBiotherapeuticsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000876343</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">btx:AsteriasBiotherapeuticsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-02-01</xbrli:startDate>
      <xbrli:endDate>2015-02-28</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20150228_RelatedPartyTransactionAxis_CommonClassAMember_RelatedPartyTransactionsByRelatedPartyAxis_AsteriasBiotherapeuticsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000876343</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">btx:AsteriasBiotherapeuticsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-02-28</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20150101to20150331_RelatedPartyTransactionsByRelatedPartyAxis_CellCureNeurosciencesLtdMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000876343</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">btx:CellCureNeurosciencesLtdMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20150331_RelatedPartyTransactionsByRelatedPartyAxis_CellCureNeurosciencesLtdMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000876343</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">btx:CellCureNeurosciencesLtdMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20150331_StatementClassOfStockAxis_SeriesAPreferredStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000876343</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20150101to20150331_StatementClassOfStockAxis_SeriesAPreferredStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000876343</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20150101to20150331_RelatedPartyTransactionAxis_CommonStockMember_RelatedPartyTransactionsByRelatedPartyAxis_AsteriasBiotherapeuticsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000876343</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">btx:AsteriasBiotherapeuticsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20150331_RelatedPartyTransactionAxis_WarrantMember_RelatedPartyTransactionsByRelatedPartyAxis_MajorityShareholderMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000876343</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:MajorityShareholderMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20150331_RelatedPartyTransactionAxis_WarrantMember_RelatedPartyTransactionsByRelatedPartyAxis_DirectorMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000876343</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:DirectorMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20150331_RelatedPartyTransactionAxis_CommonStockMember_RelatedPartyTransactionsByRelatedPartyAxis_MajorityShareholderMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000876343</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:MajorityShareholderMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20150331_RelatedPartyTransactionAxis_CommonClassBMember_RelatedPartyTransactionsByRelatedPartyAxis_AsteriasBiotherapeuticsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000876343</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">btx:AsteriasBiotherapeuticsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20150331_RelatedPartyTransactionAxis_CommonStockMember_RelatedPartyTransactionsByRelatedPartyAxis_DirectorMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000876343</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:DirectorMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20150430to20150430_LegalEntityAxis_AsteriasBiotherapeuticsMember_MajorCustomersAxis_CaliforniaInstituteOfRegenerativeMedicineMember_SubsequentEventTypeAxis_SubsequentEventMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000876343</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">btx:CaliforniaInstituteOfRegenerativeMedicineMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">btx:AsteriasBiotherapeuticsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-04-30</xbrli:startDate>
      <xbrli:endDate>2015-04-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20150430_LegalEntityAxis_AsteriasBiotherapeuticsMember_MajorCustomersAxis_CaliforniaInstituteOfRegenerativeMedicineMember_SubsequentEventTypeAxis_SubsequentEventMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000876343</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">btx:CaliforniaInstituteOfRegenerativeMedicineMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">btx:AsteriasBiotherapeuticsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-04-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20150508to20150508_LegalEntityAxis_OncocyteCorporationMember_SubsequentEventTypeAxis_SubsequentEventMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000876343</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">btx:OncocyteCorporationMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-05-08</xbrli:startDate>
      <xbrli:endDate>2015-05-08</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20150508to20150508_LegalEntityAxis_OncocyteCorporationMember_RelatedPartyTransactionsByRelatedPartyAxis_MajorityShareholderMember_SubsequentEventTypeAxis_SubsequentEventMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000876343</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:MajorityShareholderMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">btx:OncocyteCorporationMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-05-08</xbrli:startDate>
      <xbrli:endDate>2015-05-08</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20150508_LegalEntityAxis_OncocyteCorporationMember_RelatedPartyTransactionsByRelatedPartyAxis_MajorityShareholderMember_SubsequentEventTypeAxis_SubsequentEventMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000876343</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:MajorityShareholderMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">btx:OncocyteCorporationMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-05-08</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20150508to20150508_DebtInstrumentAxis_ConvertibleNotesPayableMember_LegalEntityAxis_OncocyteCorporationMember_SubsequentEventTypeAxis_SubsequentEventMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000876343</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">btx:OncocyteCorporationMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-05-08</xbrli:startDate>
      <xbrli:endDate>2015-05-08</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20150508_DebtInstrumentAxis_ConvertibleNotesPayableMember_LegalEntityAxis_OncocyteCorporationMember_SubsequentEventTypeAxis_SubsequentEventMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000876343</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">btx:OncocyteCorporationMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-05-08</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20150101to20150331_DebtInstrumentAxis_ConvertibleNotesPayableMember_LegalEntityAxis_OncocyteCorporationMember_SubsequentEventTypeAxis_SubsequentEventMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000876343</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">btx:OncocyteCorporationMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:unit id="U001">
    <xbrli:measure>xbrli:shares</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="U002">
    <xbrli:measure>iso4217:USD</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="U003">
    <xbrli:divide>
      <xbrli:unitNumerator>
        <xbrli:measure>iso4217:USD</xbrli:measure>
      </xbrli:unitNumerator>
      <xbrli:unitDenominator>
        <xbrli:measure>xbrli:shares</xbrli:measure>
      </xbrli:unitDenominator>
    </xbrli:divide>
  </xbrli:unit>
  <xbrli:unit id="U004">
    <xbrli:measure>xbrli:pure</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="U005">
    <xbrli:measure>utr:sqft</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="U006">
    <xbrli:measure>btx:Investor</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="U007">
    <xbrli:measure>btx:Segment</xbrli:measure>
  </xbrli:unit>
  <!--Amendment Flag-->
  <dei:AmendmentFlag contextRef="c20150101to20150331">false</dei:AmendmentFlag>
  <!--Current Fiscal Year End Date-->
  <dei:CurrentFiscalYearEndDate contextRef="c20150101to20150331">--12-31</dei:CurrentFiscalYearEndDate>
  <!--Document Period End Date-->
  <dei:DocumentPeriodEndDate contextRef="c20150101to20150331">2015-03-31</dei:DocumentPeriodEndDate>
  <!--Entity Well-known Seasoned Issuer-->
  <dei:EntityWellKnownSeasonedIssuer contextRef="c20150101to20150331">No</dei:EntityWellKnownSeasonedIssuer>
  <!--Entity Voluntary Filers-->
  <dei:EntityVoluntaryFilers contextRef="c20150101to20150331">No</dei:EntityVoluntaryFilers>
  <!--Entity Current Reporting Status-->
  <dei:EntityCurrentReportingStatus contextRef="c20150101to20150331">Yes</dei:EntityCurrentReportingStatus>
  <!--Entity Filer Category-->
  <dei:EntityFilerCategory contextRef="c20150101to20150331">Accelerated Filer</dei:EntityFilerCategory>
  <!--Entity Registrant Name-->
  <dei:EntityRegistrantName contextRef="c20150101to20150331">BIOTIME INC</dei:EntityRegistrantName>
  <!--Entity Central Index Key-->
  <dei:EntityCentralIndexKey contextRef="c20150101to20150331">0000876343</dei:EntityCentralIndexKey>
  <!--Entity Common Stock, Shares Outstanding-->
  <dei:EntityCommonStockSharesOutstanding contextRef="c20150501" unitRef="U001" decimals="0">83266153</dei:EntityCommonStockSharesOutstanding>
  <!--Document Fiscal Year Focus-->
  <dei:DocumentFiscalYearFocus contextRef="c20150101to20150331">2015</dei:DocumentFiscalYearFocus>
  <!--Document Fiscal Period Focus-->
  <dei:DocumentFiscalPeriodFocus contextRef="c20150101to20150331">Q1</dei:DocumentFiscalPeriodFocus>
  <!--Document Type-->
  <dei:DocumentType contextRef="c20150101to20150331">10-Q</dei:DocumentType>
  <!--Area of Land-->
  <us-gaap:AreaOfLand contextRef="c20150331" unitRef="U005" decimals="0">900</us-gaap:AreaOfLand>
  <!--Accounts Payable and Accrued Liabilities, Current-->
  <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="c20150331" unitRef="U002" decimals="0">6322407</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
  <!--Accounts Payable and Accrued Liabilities, Current-->
  <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="c20141231" unitRef="U002" decimals="0">6803173</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
  <!--Accounts Payable and Accrued Liabilities Disclosure [Text Block]-->
  <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock contextRef="c20150101to20150331">&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;div style="text-align: justify;"&gt;&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 100%;"&gt;&lt;tr&gt;&lt;td style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 18pt; vertical-align: top; font-weight: bold; align: right;"&gt;7.&lt;/td&gt;&lt;td style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: auto; vertical-align: top; font-weight: bold; text-align: justify;"&gt;Accounts Payable and Accrued Liabilities&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align: justify;"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; text-indent: 36pt;"&gt;At March 31, 2015 and December 31, 2014, accounts payable and accrued liabilities consisted of the following:&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 100%;"&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="vertical-align: bottom; white-space: nowrap; border-bottom: #000000 2px solid;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; text-align: center;"&gt;March 31, 2015&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; text-align: center;"&gt;(Unaudited)&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; text-align: center;"&gt;December 31,&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; text-align: center;"&gt;2014&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="width: 76%; vertical-align: bottom; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;"&gt;Accounts payable&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;2,707,437&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;2,296,645&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="width: 76%; vertical-align: bottom; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;"&gt;Accrued expenses&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;3,092,030&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;3,125,023&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="width: 76%; vertical-align: bottom; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;"&gt;Accrued bonuses&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;240,689&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;964,189&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="width: 76%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;"&gt;Other current liabilities&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;282,251&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;417,316&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="width: 76%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;"&gt;Total&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;6,322,407&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;6,803,173&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
  <!--Accounts Receivable, Net, Current-->
  <us-gaap:AccountsReceivableNetCurrent contextRef="c20150331" unitRef="U002" decimals="0">605800</us-gaap:AccountsReceivableNetCurrent>
  <!--Accounts Receivable, Net, Current-->
  <us-gaap:AccountsReceivableNetCurrent contextRef="c20141231" unitRef="U002" decimals="0">549300</us-gaap:AccountsReceivableNetCurrent>
  <!--Accounts payable-->
  <us-gaap:AccountsPayableCurrent contextRef="c20141231" unitRef="U002" decimals="0">2296645</us-gaap:AccountsPayableCurrent>
  <!--Accounts payable-->
  <us-gaap:AccountsPayableCurrent contextRef="c20150331" unitRef="U002" decimals="0">2707437</us-gaap:AccountsPayableCurrent>
  <!--Accrued expenses-->
  <us-gaap:AccruedLiabilitiesCurrent contextRef="c20141231" unitRef="U002" decimals="0">3125023</us-gaap:AccruedLiabilitiesCurrent>
  <!--Accrued expenses-->
  <us-gaap:AccruedLiabilitiesCurrent contextRef="c20150331" unitRef="U002" decimals="0">3092030</us-gaap:AccruedLiabilitiesCurrent>
  <!--Accrued Bonuses, Current-->
  <us-gaap:AccruedBonusesCurrent contextRef="c20141231" unitRef="U002" decimals="0">964189</us-gaap:AccruedBonusesCurrent>
  <!--Accrued Bonuses, Current-->
  <us-gaap:AccruedBonusesCurrent contextRef="c20150331" unitRef="U002" decimals="0">240689</us-gaap:AccruedBonusesCurrent>
  <!--Accumulated Depreciation, Depletion and Amortization, Property, Plant and Equipment, Period Increase (Decrease)-->
  <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipmentPeriodIncreaseDecrease contextRef="c20150101to20150331" unitRef="U002" decimals="0">252429</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipmentPeriodIncreaseDecrease>
  <!--Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment-->
  <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c20150331" unitRef="U002" decimals="0">2670829</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
  <!--Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment-->
  <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c20141231" unitRef="U002" decimals="0">2418400</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
  <!--Accumulated other comprehensive income-->
  <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c20150331" unitRef="U002" decimals="0">238820</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
  <!--Accumulated other comprehensive income-->
  <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c20141231" unitRef="U002" decimals="0">185835</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
  <!--Contributed capital-->
  <us-gaap:AdditionalPaidInCapital contextRef="c20150331" unitRef="U002" decimals="0">7145</us-gaap:AdditionalPaidInCapital>
  <!--Contributed capital-->
  <us-gaap:AdditionalPaidInCapital contextRef="c20141231" unitRef="U002" decimals="0">7145</us-gaap:AdditionalPaidInCapital>
  <!--Allowance for Doubtful Accounts Receivable, Current-->
  <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent contextRef="c20141231" unitRef="U002" decimals="0">100500</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
  <!--Allowance for Doubtful Accounts Receivable, Current-->
  <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent contextRef="c20150331" unitRef="U002" decimals="0">100500</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
  <!--Amortization of Deferred Charges-->
  <us-gaap:AmortizationOfDeferredCharges contextRef="c20150101to20150331" unitRef="U002" decimals="0">0</us-gaap:AmortizationOfDeferredCharges>
  <!--Amortization of Deferred Charges-->
  <us-gaap:AmortizationOfDeferredCharges contextRef="c20140101to20140331" unitRef="U002" decimals="0">-280</us-gaap:AmortizationOfDeferredCharges>
  <!--Amortization of intangible assets-->
  <us-gaap:AmortizationOfIntangibleAssets contextRef="c20140101to20140331" unitRef="U002" decimals="0">1367998</us-gaap:AmortizationOfIntangibleAssets>
  <!--Amortization of intangible assets-->
  <us-gaap:AmortizationOfIntangibleAssets contextRef="c20150101to20150331" unitRef="U002" decimals="0">1314094</us-gaap:AmortizationOfIntangibleAssets>
  <!--Amortization of Debt Discount (Premium)-->
  <us-gaap:AmortizationOfDebtDiscountPremium contextRef="c20140101to20140331" unitRef="U002" decimals="0">0</us-gaap:AmortizationOfDebtDiscountPremium>
  <!--Amortization of Debt Discount (Premium)-->
  <us-gaap:AmortizationOfDebtDiscountPremium contextRef="c20150101to20150331" unitRef="U002" decimals="0">49697</us-gaap:AmortizationOfDebtDiscountPremium>
  <!--Anti-dilutive shares excluded from computation of diluted loss per share (in shares)-Stock Options [Member]-->
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c20150101to20150331_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_EmployeeStockOptionMember" unitRef="U001" decimals="0">4266605</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <!--Anti-dilutive shares excluded from computation of diluted loss per share (in shares)-Treasury Stock [Member]-->
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c20140101to20140331_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_TreasuryStockMember" unitRef="U001" decimals="0">10546137</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <!--Anti-dilutive shares excluded from computation of diluted loss per share (in shares)-Stock Options [Member]-->
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c20140101to20140331_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_EmployeeStockOptionMember" unitRef="U001" decimals="0">5491301</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <!--Anti-dilutive shares excluded from computation of diluted loss per share (in shares)-Treasury Stock [Member]-->
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c20150101to20150331_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_TreasuryStockMember" unitRef="U001" decimals="0">4893942</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <!--Anti-dilutive shares excluded from computation of diluted loss per share (in shares)-Warrant [Member]-->
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c20150101to20150331_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_WarrantMember" unitRef="U001" decimals="0">9194679</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <!--Anti-dilutive shares excluded from computation of diluted loss per share (in shares)-Warrant [Member]-->
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c20140101to20140331_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_WarrantMember" unitRef="U001" decimals="0">9751615</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <!--Assets-->
  <us-gaap:Assets contextRef="c20141231" unitRef="U002" decimals="0">74900906</us-gaap:Assets>
  <!--Assets-->
  <us-gaap:Assets contextRef="c20150331" unitRef="U002" decimals="0">69703470</us-gaap:Assets>
  <!--Assets, Current-->
  <us-gaap:AssetsCurrent contextRef="c20141231" unitRef="U002" decimals="0">32404557</us-gaap:AssetsCurrent>
  <!--Assets, Current-->
  <us-gaap:AssetsCurrent contextRef="c20150331" unitRef="U002" decimals="0">28544122</us-gaap:AssetsCurrent>
  <!--Repayment of capital lease obligation-->
  <us-gaap:CapitalLeasesIncomeStatementAmortizationExpense contextRef="c20140101to20140331" unitRef="U002" decimals="0">0</us-gaap:CapitalLeasesIncomeStatementAmortizationExpense>
  <!--Repayment of capital lease obligation-->
  <us-gaap:CapitalLeasesIncomeStatementAmortizationExpense contextRef="c20150101to20150331" unitRef="U002" decimals="0">-13983</us-gaap:CapitalLeasesIncomeStatementAmortizationExpense>
  <!--Capital lease liability, current portion-->
  <us-gaap:CapitalLeaseObligationsCurrent contextRef="c20150331" unitRef="U002" decimals="0">57500</us-gaap:CapitalLeaseObligationsCurrent>
  <!--Capital lease liability, current portion-->
  <us-gaap:CapitalLeaseObligationsCurrent contextRef="c20141231" unitRef="U002" decimals="0">57500</us-gaap:CapitalLeaseObligationsCurrent>
  <!--Capital-Parent [Member]-->
  <us-gaap:Capital contextRef="c20150331_StatementEquityComponentsAxis_ParentMember" unitRef="U002" decimals="0">20341461</us-gaap:Capital>
  <!--Equipment, furniture , and fixtures included in capital lease borrowings-->
  <us-gaap:CapitalLeaseObligations contextRef="c20140630" unitRef="U002" decimals="0">115000</us-gaap:CapitalLeaseObligations>
  <!--Cash and Cash Equivalents, Policy [Policy Text Block]-->
  <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="c20150101to20150331">&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; text-indent: 36pt;"&gt;&lt;font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;"&gt;Cash and cash equivalents&lt;/font&gt; &amp;#8211; BioTime considers all highly liquid investments purchased with an original maturity of three months or less to be cash equivalents.&lt;/div&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
  <!--Cash and Cash Equivalents, Period Increase (Decrease)-->
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="c20150101to20150331" unitRef="U002" decimals="0">-3657376</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <!--Cash and Cash Equivalents, Period Increase (Decrease)-->
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="c20140101to20140331" unitRef="U002" decimals="0">1142356</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <!--Cash and Cash Equivalents, at Carrying Value-->
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c20141231" unitRef="U002" decimals="0">29486909</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <!--Cash and Cash Equivalents, at Carrying Value-->
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c20150331" unitRef="U002" decimals="0">25829533</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <!--Cash and Cash Equivalents, at Carrying Value-->
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c20131231" unitRef="U002" decimals="0">5495478</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <!--Cash and Cash Equivalents, at Carrying Value-->
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c20140331" unitRef="U002" decimals="0">6637834</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <!--Cash and Cash Equivalents, at Carrying Value-Parent [Member]-->
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c20150331_StatementEquityComponentsAxis_ParentMember" unitRef="U002" decimals="0">25829533</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <!--Number of warrants issued (in shares)-Warrant [Member]-George Karfunkel [Member]-->
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight contextRef="c20150331_RelatedPartyTransactionAxis_WarrantMember_RelatedPartyTransactionsByRelatedPartyAxis_MajorityShareholderMember" unitRef="U001" decimals="0">4000000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
  <!--Number of warrants issued (in shares)-Warrant [Member]-Broadwood Partners, LP [Member]-->
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight contextRef="c20150331_RelatedPartyTransactionAxis_WarrantMember_RelatedPartyTransactionsByRelatedPartyAxis_DirectorMember" unitRef="U001" decimals="0">1000000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
  <!--Commitments and contingencies-->
  <us-gaap:CommitmentsAndContingencies contextRef="c20141231" unitRef="U002" xsi:nil="true" />
  <!--Commitments and contingencies-->
  <us-gaap:CommitmentsAndContingencies contextRef="c20150331" unitRef="U002" xsi:nil="true" />
  <!--Common shares, no par value, authorized 125,000,000 shares as of March 31, 2015 and December 31, 2014; 83,210,775 issued and 78,316,833 outstanding as of March 31, 2015 and 83,121,698 issued and 78,227,756 outstanding at December 31, 2014-->
  <us-gaap:CommonStockValue contextRef="c20150331" unitRef="U002" decimals="0">234751802</us-gaap:CommonStockValue>
  <!--Common shares, no par value, authorized 125,000,000 shares as of March 31, 2015 and December 31, 2014; 83,210,775 issued and 78,316,833 outstanding as of March 31, 2015 and 83,121,698 issued and 78,227,756 outstanding at December 31, 2014-->
  <us-gaap:CommonStockValue contextRef="c20141231" unitRef="U002" decimals="0">234842998</us-gaap:CommonStockValue>
  <!--Common shares, issued (in shares)-->
  <us-gaap:CommonStockSharesIssued contextRef="c20141231" unitRef="U001" decimals="0">83121698</us-gaap:CommonStockSharesIssued>
  <!--Common shares, issued (in shares)-->
  <us-gaap:CommonStockSharesIssued contextRef="c20150331" unitRef="U001" decimals="0">83210775</us-gaap:CommonStockSharesIssued>
  <!--Common shares, authorized (in shares)-->
  <us-gaap:CommonStockSharesAuthorized contextRef="c20150331" unitRef="U001" decimals="0">125000000</us-gaap:CommonStockSharesAuthorized>
  <!--Common shares, authorized (in shares)-->
  <us-gaap:CommonStockSharesAuthorized contextRef="c20141231" unitRef="U001" decimals="0">125000000</us-gaap:CommonStockSharesAuthorized>
  <!--Common shares, par value (in dollars per share)-->
  <us-gaap:CommonStockNoParValue contextRef="c20150331" unitRef="U003" decimals="INF">0</us-gaap:CommonStockNoParValue>
  <!--Common shares, par value (in dollars per share)-->
  <us-gaap:CommonStockNoParValue contextRef="c20141231" unitRef="U003" decimals="INF">0</us-gaap:CommonStockNoParValue>
  <!--Common shares, outstanding (in shares)-->
  <us-gaap:CommonStockSharesOutstanding contextRef="c20141231" unitRef="U001" decimals="0">78227756</us-gaap:CommonStockSharesOutstanding>
  <!--Common shares, outstanding (in shares)-->
  <us-gaap:CommonStockSharesOutstanding contextRef="c20150331" unitRef="U001" decimals="0">78316833</us-gaap:CommonStockSharesOutstanding>
  <!--Comprehensive Income (Loss), Net of Tax, Attributable to Parent-->
  <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c20150101to20150331" unitRef="U002" decimals="0">-12643040</us-gaap:ComprehensiveIncomeNetOfTax>
  <!--Comprehensive Income (Loss), Net of Tax, Attributable to Parent-->
  <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c20140101to20140331" unitRef="U002" decimals="0">-9835271</us-gaap:ComprehensiveIncomeNetOfTax>
  <!--Concentration Risk, Credit Risk, Policy [Policy Text Block]-->
  <us-gaap:ConcentrationRiskCreditRisk contextRef="c20150101to20150331">&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;div&gt;&lt;font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;"&gt;Concentrations of credit risk&lt;/font&gt; &amp;#8211; Financial instruments that potentially subject BioTime to significant concentrations of credit risk consist primarily of cash and cash equivalents. BioTime limits the amount of credit exposure of cash balances by maintaining its accounts in high credit quality financial institutions. Cash equivalent deposits with financial institutions may occasionally exceed the limits of insurance on bank deposits; however, BioTime has not experienced any losses on such accounts&lt;/div&gt;&lt;/div&gt;</us-gaap:ConcentrationRiskCreditRisk>
  <!--Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Table Text Block]-->
  <us-gaap:ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTextBlock contextRef="c20150101to20150331">&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;div&gt;The following table reflects BioTime&amp;#8217;s ownership, directly or through one or more subsidiaries, of the outstanding shares of its subsidiaries as of March 31, 2015.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 100%; border-collapse: collapse;"&gt;&lt;tr&gt;&lt;td style="border-top: #000000 2px solid; width: 23.28%; vertical-align: top; border-left: #000000 2px solid;"&gt;&lt;div style="text-align: left;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; text-align: center;"&gt;Subsidiary&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top: #000000 2px solid; width: 57%; vertical-align: top; border-left: #000000 2px solid;"&gt;&lt;div style="text-align: left;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; text-align: center;"&gt;Field of Business&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top: #000000 2px solid; width: 10%; vertical-align: top; border-left: #000000 2px solid;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;"&gt;BioTime&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;"&gt;Ownership&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top: #000000 2px solid; border-right: #000000 2px solid; width: 10%; vertical-align: top; border-left: #000000 2px solid;"&gt;&lt;div style="text-align: left;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; text-align: center;"&gt;Country&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-top: #000000 2px solid; width: 23.28%; vertical-align: top; border-left: #000000 2px solid; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; margin-left: 7.7pt; text-indent: -7.7pt;"&gt;&lt;font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;Asterias Biotherapeutics, Inc. (&lt;/font&gt;NYSE MKT: AST)&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top: #000000 2px solid; width: 57%; vertical-align: top; border-left: #000000 2px solid; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;"&gt;Research, development and commercialization of human therapeutic products from stem cells, focused initially in the fields of neurology and oncology&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top: #000000 2px solid; width: 10%; vertical-align: top; border-left: #000000 2px solid; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;"&gt;67.5%&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top: #000000 2px solid; border-right: #000000 2px solid; width: 10%; vertical-align: top; border-left: #000000 2px solid; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;"&gt;USA&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-top: #000000 2px solid; width: 23.28%; vertical-align: top; border-left: #000000 2px solid; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; margin-left: 7.7pt; text-indent: -7.7pt;"&gt;BioTime Asia, Limited&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top: #000000 2px solid; width: 57%; vertical-align: top; border-left: #000000 2px solid; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;"&gt;Stem cell products for research&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top: #000000 2px solid; width: 10%; vertical-align: top; border-left: #000000 2px solid; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;"&gt;81%&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top: #000000 2px solid; border-right: #000000 2px solid; width: 10%; vertical-align: top; border-left: #000000 2px solid; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;"&gt;Hong Kong&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-top: #000000 2px solid; width: 23.28%; vertical-align: top; border-left: #000000 2px solid; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; margin-left: 7.7pt; text-indent: -7.7pt;"&gt;Cell Cure Neurosciences Ltd.&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top: #000000 2px solid; width: 57%; vertical-align: top; border-left: #000000 2px solid; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;"&gt;Age-related macular degeneration&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top: #000000 2px solid; width: 10%; vertical-align: top; border-left: #000000 2px solid; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;"&gt;62.5%(1)&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top: #000000 2px solid; border-right: #000000 2px solid; width: 10%; vertical-align: top; border-left: #000000 2px solid; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;"&gt;Israel&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-top: #000000 2px solid; width: 23.28%; vertical-align: top; border-left: #000000 2px solid; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; margin-left: 7.7pt; text-indent: -7.7pt;"&gt;ES Cell International Pte Ltd&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top: #000000 2px solid; width: 57%; vertical-align: top; border-left: #000000 2px solid; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;"&gt;Stem cell products for research, including clinical grade cell lines produced under cGMP&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top: #000000 2px solid; width: 10%; vertical-align: top; border-left: #000000 2px solid; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;"&gt;100%&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top: #000000 2px solid; border-right: #000000 2px solid; width: 10%; vertical-align: top; border-left: #000000 2px solid; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;"&gt;Singapore&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-top: #000000 2px solid; width: 23.28%; vertical-align: top; border-left: #000000 2px solid; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; margin-left: 7.7pt; text-indent: -7.7pt;"&gt;LifeMap Sciences, Inc.&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top: #000000 2px solid; width: 57%; vertical-align: top; border-left: #000000 2px solid; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;"&gt;Biomedical, gene, disease, and stem cell databases and tools&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top: #000000 2px solid; width: 10%; vertical-align: top; border-left: #000000 2px solid; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;"&gt;75.8%&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top: #000000 2px solid; border-right: #000000 2px solid; width: 10%; vertical-align: top; border-left: #000000 2px solid; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;"&gt;USA&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-top: #000000 2px solid; width: 23.28%; vertical-align: top; border-left: #000000 2px solid; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; margin-left: 7.7pt; text-indent: -7.7pt;"&gt;LifeMap Sciences, Ltd.&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top: #000000 2px solid; width: 57%; vertical-align: top; border-left: #000000 2px solid; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;"&gt;Biomedical, gene, disease, and stem cell databases and tools&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top: #000000 2px solid; width: 10%; vertical-align: top; border-left: #000000 2px solid; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;"&gt;(2)&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top: #000000 2px solid; border-right: #000000 2px solid; width: 10%; vertical-align: top; border-left: #000000 2px solid; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;"&gt;Israel&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-top: #000000 2px solid; width: 23.28%; vertical-align: top; border-left: #000000 2px solid; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; margin-left: 7.7pt; text-indent: -7.7pt;"&gt;LifeMap Solutions, Inc.&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top: #000000 2px solid; width: 57%; vertical-align: top; border-left: #000000 2px solid; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;"&gt;Mobile health software&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top: #000000 2px solid; width: 10%; vertical-align: top; border-left: #000000 2px solid; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;"&gt;(2)&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top: #000000 2px solid; border-right: #000000 2px solid; width: 10%; vertical-align: top; border-left: #000000 2px solid; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;"&gt;USA&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-top: #000000 2px solid; width: 23.28%; vertical-align: top; border-left: #000000 2px solid; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; margin-left: 7.7pt; text-indent: -7.7pt;"&gt;OncoCyte Corporation&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top: #000000 2px solid; width: 57%; vertical-align: top; border-left: #000000 2px solid; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;"&gt;Cancer diagnostics&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top: #000000 2px solid; width: 10%; vertical-align: top; border-left: #000000 2px solid; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;"&gt;75.3%&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top: #000000 2px solid; border-right: #000000 2px solid; width: 10%; vertical-align: top; border-left: #000000 2px solid; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;"&gt;USA&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-top: #000000 2px solid; width: 23.28%; vertical-align: top; border-left: #000000 2px solid; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; margin-left: 7.7pt; text-indent: -7.7pt;"&gt;OrthoCyte Corporation&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top: #000000 2px solid; width: 57%; vertical-align: top; border-left: #000000 2px solid; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;"&gt;Orthopedic diseases, including chronic back pain and osteoarthritis&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top: #000000 2px solid; width: 10%; vertical-align: top; border-left: #000000 2px solid; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;"&gt;100%(3)&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top: #000000 2px solid; border-right: #000000 2px solid; width: 10%; vertical-align: top; border-left: #000000 2px solid; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;"&gt;USA&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-top: #000000 2px solid; width: 23.28%; vertical-align: top; border-bottom: #000000 2px solid; border-left: #000000 2px solid; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; margin-left: 7.7pt; text-indent: -7.7pt;"&gt;ReCyte Therapeutics, Inc.&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top: #000000 2px solid; width: 57%; vertical-align: top; border-bottom: #000000 2px solid; border-left: #000000 2px solid; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;"&gt;Vascular disorders, including cardiovascular-related diseases, ischemic conditions, vascular injuries&lt;/div&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;"&gt;Stem cell-derived endothelial and cardiovascular related progenitor cells that have applications in research, drug testing, and therapeutics&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top: #000000 2px solid; width: 10%; vertical-align: top; border-bottom: #000000 2px solid; border-left: #000000 2px solid; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;"&gt;94.8%&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top: #000000 2px solid; border-right: #000000 2px solid; width: 10%; vertical-align: top; border-bottom: #000000 2px solid; border-left: #000000 2px solid; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;"&gt;USA&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: left;"&gt;&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 100%;"&gt;&lt;tr&gt;&lt;td style="width: 18pt;"&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 18pt; vertical-align: top; align: right;"&gt;(1)&lt;/td&gt;&lt;td style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: auto; vertical-align: top; text-align: left;"&gt;Includes shares owned by &lt;font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;BioTime, Asterias, and ESI.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align: left;"&gt;&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 100%;"&gt;&lt;tr&gt;&lt;td style="width: 18pt;"&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 18pt; vertical-align: top; align: right;"&gt;(2)&lt;/td&gt;&lt;td style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: auto; vertical-align: top; text-align: left;"&gt;LifeMap Sciences, Ltd. and LifeMap Solutions, Inc. are wholly-owned subsidiaries of LifeMap Sciences, Inc.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align: left;"&gt;&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 100%;"&gt;&lt;tr&gt;&lt;td style="width: 18pt;"&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 18pt; vertical-align: top; align: right;"&gt;(3)&lt;/td&gt;&lt;td style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: auto; vertical-align: top; text-align: left;"&gt;Includes shares owned by BioTime and Asterias.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTextBlock>
  <!--Construction in progress-->
  <us-gaap:ConstructionInProgressGross contextRef="c20141231" unitRef="U002" decimals="0">405730</us-gaap:ConstructionInProgressGross>
  <!--Construction in progress-->
  <us-gaap:ConstructionInProgressGross contextRef="c20150331" unitRef="U002" decimals="0">606641</us-gaap:ConstructionInProgressGross>
  <!--Amount of convertible note-Cell Cure Neurosciences, Ltd. [Member]-->
  <us-gaap:ConvertibleDebt contextRef="c20150331_RelatedPartyTransactionsByRelatedPartyAxis_CellCureNeurosciencesLtdMember" unitRef="U002" decimals="0">534816</us-gaap:ConvertibleDebt>
  <!--Carrying value of convertible notes-Cell Cure Neurosciences, Ltd. [Member]-->
  <us-gaap:ConvertibleNotesPayableCurrent contextRef="c20150331_RelatedPartyTransactionsByRelatedPartyAxis_CellCureNeurosciencesLtdMember" unitRef="U002" decimals="0">169908</us-gaap:ConvertibleNotesPayableCurrent>
  <!--Cost of sales-->
  <us-gaap:CostOfSalesPolicyTextBlock contextRef="c20150101to20150331">&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; text-indent: 36pt;"&gt;&lt;font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;"&gt;Cost of sales&lt;/font&gt; &amp;#8211; BioTime accounts for the cost of research products acquired for sale and any royalties paid as a result of any revenues in accordance with the terms of the respective licensing agreements as cost of sales on the consolidated statement of operations and comprehensive loss.&lt;/div&gt;&lt;/div&gt;</us-gaap:CostOfSalesPolicyTextBlock>
  <!--Cost of Revenue-->
  <us-gaap:CostOfRevenue contextRef="c20150101to20150331" unitRef="U002" decimals="0">264167</us-gaap:CostOfRevenue>
  <!--Cost of Revenue-->
  <us-gaap:CostOfRevenue contextRef="c20140101to20140331" unitRef="U002" decimals="0">131914</us-gaap:CostOfRevenue>
  <!--Common stock purchased in exchange for cancelation of indebtedness (in shares)-Subsequent Event [Member]-OncoCyte Corporation [Member]-->
  <us-gaap:DebtConversionConvertedInstrumentSharesIssued1 contextRef="c20150508to20150508_LegalEntityAxis_OncocyteCorporationMember_SubsequentEventTypeAxis_SubsequentEventMember" unitRef="U001" decimals="0">3000000</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
  <!--Common stock purchased in exchange for cancelation of indebtedness, value-OncoCyte Corporation [Member]-Subsequent Event [Member]-Convertible Notes Payable [Member]-->
  <us-gaap:DebtConversionConvertedInstrumentAmount1 contextRef="c20150508to20150508_DebtInstrumentAxis_ConvertibleNotesPayableMember_LegalEntityAxis_OncocyteCorporationMember_SubsequentEventTypeAxis_SubsequentEventMember" unitRef="U002" decimals="0">3300000</us-gaap:DebtConversionConvertedInstrumentAmount1>
  <!--Common stock purchased in exchange for cancelation of indebtedness, value-Subsequent Event [Member]-OncoCyte Corporation [Member]-->
  <us-gaap:DebtConversionConvertedInstrumentAmount1 contextRef="c20150508to20150508_LegalEntityAxis_OncocyteCorporationMember_SubsequentEventTypeAxis_SubsequentEventMember" unitRef="U002" decimals="0">3300000</us-gaap:DebtConversionConvertedInstrumentAmount1>
  <!--Accrued interest is payable period-Cell Cure Neurosciences, Ltd. [Member]-->
  <us-gaap:DebtInstrumentTerm contextRef="c20150101to20150331_RelatedPartyTransactionsByRelatedPartyAxis_CellCureNeurosciencesLtdMember">P3Y</us-gaap:DebtInstrumentTerm>
  <!--Conversion price (in dollars per share)-Cell Cure Neurosciences, Ltd. [Member]-->
  <us-gaap:DebtInstrumentConvertibleConversionPrice1 contextRef="c20150331_RelatedPartyTransactionsByRelatedPartyAxis_CellCureNeurosciencesLtdMember" unitRef="U003" decimals="2">20.00</us-gaap:DebtInstrumentConvertibleConversionPrice1>
  <!--Conversion price (in dollars per share)-OncoCyte Corporation [Member]-Subsequent Event [Member]-Convertible Notes Payable [Member]-->
  <us-gaap:DebtInstrumentConvertibleConversionPrice1 contextRef="c20150508_DebtInstrumentAxis_ConvertibleNotesPayableMember_LegalEntityAxis_OncocyteCorporationMember_SubsequentEventTypeAxis_SubsequentEventMember" unitRef="U003" decimals="2">1.10</us-gaap:DebtInstrumentConvertibleConversionPrice1>
  <!--Effective annual interest rate (in hundredths)-Cell Cure Neurosciences, Ltd. [Member]-->
  <us-gaap:DebtInstrumentInterestRateEffectivePercentage contextRef="c20150331_RelatedPartyTransactionsByRelatedPartyAxis_CellCureNeurosciencesLtdMember" unitRef="U004" decimals="INF">0.23</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
  <!--Unamortized debt discount-Cell Cure Neurosciences, Ltd. [Member]-->
  <us-gaap:DebtInstrumentUnamortizedDiscount contextRef="c20150331_RelatedPartyTransactionsByRelatedPartyAxis_CellCureNeurosciencesLtdMember" unitRef="U002" decimals="0">364908</us-gaap:DebtInstrumentUnamortizedDiscount>
  <!--Stated interest rate (in hundredths)-Cell Cure Neurosciences, Ltd. [Member]-->
  <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="c20150331_RelatedPartyTransactionsByRelatedPartyAxis_CellCureNeurosciencesLtdMember" unitRef="U004" decimals="INF">0.03</us-gaap:DebtInstrumentInterestRateStatedPercentage>
  <!--Stated interest rate (in hundredths)-OncoCyte Corporation [Member]-Subsequent Event [Member]-Convertible Notes Payable [Member]-->
  <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="c20150508_DebtInstrumentAxis_ConvertibleNotesPayableMember_LegalEntityAxis_OncocyteCorporationMember_SubsequentEventTypeAxis_SubsequentEventMember" unitRef="U004" decimals="INF">0.01</us-gaap:DebtInstrumentInterestRateStatedPercentage>
  <!--Debt instrument maturity date-OncoCyte Corporation [Member]-Subsequent Event [Member]-Convertible Notes Payable [Member]-->
  <us-gaap:DebtInstrumentMaturityDate contextRef="c20150101to20150331_DebtInstrumentAxis_ConvertibleNotesPayableMember_LegalEntityAxis_OncocyteCorporationMember_SubsequentEventTypeAxis_SubsequentEventMember">2016-11-30</us-gaap:DebtInstrumentMaturityDate>
  <!--Deferred Costs-->
  <us-gaap:DeferredCostsCurrentAndNoncurrent contextRef="c20150331" unitRef="U002" decimals="0">418958</us-gaap:DeferredCostsCurrentAndNoncurrent>
  <!--Deferred Charges, Policy [Policy Text Block]-->
  <us-gaap:DeferredChargesPolicyTextBlock contextRef="c20150101to20150331">&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; text-indent: 36pt;"&gt;&lt;font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;"&gt;Deferred license and consulting fees&lt;/font&gt; &amp;#8211; Deferred license and consulting fees consist of the value of warrants issued to third parties for services, and deferred license fees paid to acquire rights to use the proprietary technologies of third parties. The value of the warrants is being amortized over the period the services are being provided, and the license fees are being amortized over the estimated useful lives of the licensed technologies or licensed research products. BioTime is applying a 10 year estimated useful life to the technologies and products that it is currently licensing. The estimation of the useful life any technology or product involves a significant degree of inherent uncertainty, since the outcome of research and development or the commercial life of a new product cannot be known with certainty at the time that the right to use the technology or product is acquired. BioTime will review the continued appropriateness of the 10 year estimated useful life for impairments that might occur earlier than the original expected useful lives. BioTime will review its amortization schedules for impairments that might occur earlier than the original expected useful lives. See Note 6.&lt;/div&gt;&lt;/div&gt;</us-gaap:DeferredChargesPolicyTextBlock>
  <!--Deferred Federal Income Tax Expense (Benefit)-->
  <us-gaap:DeferredFederalIncomeTaxExpenseBenefit contextRef="c20140101to20140331" unitRef="U002" decimals="0">1151000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
  <!--Deferred Federal Income Tax Expense (Benefit)-->
  <us-gaap:DeferredFederalIncomeTaxExpenseBenefit contextRef="c20150101to20150331" unitRef="U002" decimals="0">1251000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
  <!--Deferred income tax benefit-->
  <us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="c20140101to20140331" unitRef="U002" decimals="0">-1349026</us-gaap:DeferredIncomeTaxExpenseBenefit>
  <!--Deferred income tax benefit-->
  <us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="c20150101to20150331" unitRef="U002" decimals="0">-1176882</us-gaap:DeferredIncomeTaxExpenseBenefit>
  <!--Deferred State and Local Income Tax Expense (Benefit)-->
  <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit contextRef="c20140101to20140331" unitRef="U002" decimals="0">198000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
  <!--Deferred State and Local Income Tax Expense (Benefit)-->
  <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit contextRef="c20150101to20150331" unitRef="U002" decimals="0">74000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
  <!--Deferred rent liabilities, net of current portion-->
  <us-gaap:DeferredRentCreditNoncurrent contextRef="c20141231" unitRef="U002" decimals="0">97280</us-gaap:DeferredRentCreditNoncurrent>
  <!--Deferred rent liabilities, net of current portion-->
  <us-gaap:DeferredRentCreditNoncurrent contextRef="c20150331" unitRef="U002" decimals="0">34967</us-gaap:DeferredRentCreditNoncurrent>
  <!--Deferred Revenue Disclosure [Text Block]-->
  <us-gaap:DeferredRevenueDisclosureTextBlock contextRef="c20150101to20150331">&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;div style="text-align: justify;"&gt;&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 100%;"&gt;&lt;tr&gt;&lt;td style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 18pt; vertical-align: top; font-weight: bold; align: right;"&gt;6.&lt;/td&gt;&lt;td style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: auto; vertical-align: top; font-weight: bold; text-align: justify;"&gt;Royalty Obligation and Deferred License Fees&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align: justify;"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; text-indent: 36pt;"&gt;BioTime amortizes deferred license fees over the estimated useful lives of the licensed technologies or licensed research products. BioTime is applying a 10 year estimated useful life to the technologies and products that it is currently licensing. The estimation of the useful life of any technology or product involves a significant degree of inherent uncertainty, since the outcome of research and development or the commercial life a new product cannot be known with certainty at the time that the right to use the technology or product is acquired. BioTime will review its amortization schedules for impairments that might occur earlier than the original expected useful lives.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; text-indent: 36pt;"&gt;As of March 31, 2015, future amortization of deferred license fees described above was as follows:&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;table align="center" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 50%;"&gt;&lt;tr&gt;&lt;td valign="bottom" style="width: 38%; vertical-align: bottom; border-bottom: #000000 2px solid;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; text-align: center;"&gt;Year Ended December 31,&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 10%; vertical-align: bottom; border-bottom: #000000 2px solid;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; text-align: center;"&gt;Deferred&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; text-align: center;"&gt;License Fees&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="width: 38%; vertical-align: bottom; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;"&gt;2015&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 10%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;"&gt;$82,125&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 16px;"&gt;&lt;td valign="bottom" style="width: 38%; vertical-align: bottom; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;"&gt;2016&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 10%; vertical-align: bottom; text-align: center; background-color: #ffffff;"&gt;&amp;#160;109,500&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="width: 38%; vertical-align: bottom; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;"&gt;2017&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 10%; vertical-align: bottom; text-align: center; background-color: #cceeff;"&gt;&amp;#160;109,500&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="width: 38%; vertical-align: bottom; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;"&gt;2018&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 10%; vertical-align: bottom; text-align: center; background-color: #ffffff;"&gt;&amp;#160;73,667&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="width: 38%; vertical-align: bottom; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;"&gt;2019&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 10%; vertical-align: bottom; text-align: center; background-color: #cceeff;"&gt;&amp;#160;24,083&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="width: 38%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;"&gt;Thereafter&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 10%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: center; background-color: #ffffff;"&gt;&amp;#160;20,083&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="width: 38%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;"&gt;Total&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 10%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;"&gt;$418,958&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; text-indent: 36pt;"&gt;The current portion in the amount of $109,500 is included in prepaid expenses and other current assets. The noncurrent portion in the amount of $309,458 is included in deferred license and consulting fees.&lt;/div&gt;&lt;/div&gt;</us-gaap:DeferredRevenueDisclosureTextBlock>
  <!--Deferred license and subscription revenue, current portion-->
  <us-gaap:DeferredRevenueCurrent contextRef="c20141231" unitRef="U002" decimals="0">208357</us-gaap:DeferredRevenueCurrent>
  <!--Deferred license and subscription revenue, current portion-->
  <us-gaap:DeferredRevenueCurrent contextRef="c20150331" unitRef="U002" decimals="0">178546</us-gaap:DeferredRevenueCurrent>
  <!--Deferred tax liabilities, net-->
  <us-gaap:DeferredTaxLiabilitiesNoncurrent contextRef="c20150331" unitRef="U002" decimals="0">3337662</us-gaap:DeferredTaxLiabilitiesNoncurrent>
  <!--Deferred tax liabilities, net-->
  <us-gaap:DeferredTaxLiabilitiesNoncurrent contextRef="c20141231" unitRef="U002" decimals="0">4514362</us-gaap:DeferredTaxLiabilitiesNoncurrent>
  <!--Deposits Assets, Noncurrent-->
  <us-gaap:DepositsAssetsNoncurrent contextRef="c20150331" unitRef="U002" decimals="0">443003</us-gaap:DepositsAssetsNoncurrent>
  <!--Deposits Assets, Noncurrent-->
  <us-gaap:DepositsAssetsNoncurrent contextRef="c20141231" unitRef="U002" decimals="0">443289</us-gaap:DepositsAssetsNoncurrent>
  <!--Depreciation expense-->
  <us-gaap:Depreciation contextRef="c20140101to20140331" unitRef="U002" decimals="0">256945</us-gaap:Depreciation>
  <!--Depreciation expense-->
  <us-gaap:Depreciation contextRef="c20150101to20150331" unitRef="U002" decimals="0">262600</us-gaap:Depreciation>
  <!--BASIC AND DILUTED NET LOSS PER COMMON SHARE (in dollars per share)-->
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="c20150101to20150331" unitRef="U003" decimals="2">-0.13</us-gaap:EarningsPerShareBasicAndDiluted>
  <!--BASIC AND DILUTED NET LOSS PER COMMON SHARE (in dollars per share)-->
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="c20140101to20140331" unitRef="U003" decimals="2">-0.14</us-gaap:EarningsPerShareBasicAndDiluted>
  <!--Earnings Per Share, Policy [Policy Text Block]-->
  <us-gaap:EarningsPerSharePolicyTextBlock contextRef="c20150101to20150331">&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; text-indent: 36pt;"&gt;&lt;font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;"&gt;Loss per share&lt;/font&gt; &amp;#8211; BioTime applies the two-class method for calculating basic earnings per share. Under the two-class method, net income, if any, will be reduced by preferred stock dividends and the residual amount is allocated between common stock and other participating securities based on their participation rights. Participating securities are comprised of Series A convertible preferred stock and participate in dividends, whether declared or not. Basic earnings per share is calculated by dividing net income or loss attributable to BioTime common shareholders by the weighted average number of shares of common stock outstanding, net of unvested restricted stock subject to repurchase by BioTime, if any, during the period. For periods in which BioTime reported a net loss, the participating securities are not contractually obligated to share in the losses of BioTime, and accordingly, no losses have been allocated to the participating securities. Diluted earnings per share is calculated by dividing the net income or loss attributable to BioTime common shareholders by the weighted average number of common shares outstanding, adjusted for the effects of potentially dilutive common stock, which are comprised of stock options and warrants, using the treasury-stock method, and convertible preferred stock, using the if-converted method. Because BioTime reported losses attributable to common stockholders for all periods presented, all potentially dilutive common stock are antidilutive for those periods. Diluted net loss per share for the three months ended March 31, 2015 and 2014 excludes any effect from 4,893,942 treasury shares, 4,266,605 options and 9,194,679 warrants and 10,546,137 treasury shares, 5,491,301 options and 9,751,615 warrants, respectively, because their inclusion would be antidilutive.&lt;/div&gt;&lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
  <!--Effect of exchange rate changes on cash and cash equivalents-->
  <us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents contextRef="c20140101to20140331" unitRef="U002" decimals="0">-101240</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents>
  <!--Effect of exchange rate changes on cash and cash equivalents-->
  <us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents contextRef="c20150101to20150331" unitRef="U002" decimals="0">100976</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents>
  <!--Ownership percentage on outstanding common shares (in hundredths)-George Karfunkel [Member]-OncoCyte Corporation [Member]-Subsequent Event [Member]-->
  <us-gaap:EquityMethodInvestmentOwnershipPercentage contextRef="c20150508_LegalEntityAxis_OncocyteCorporationMember_RelatedPartyTransactionsByRelatedPartyAxis_MajorityShareholderMember_SubsequentEventTypeAxis_SubsequentEventMember" unitRef="U004" decimals="2">0.05</us-gaap:EquityMethodInvestmentOwnershipPercentage>
  <!--Fair Value of Financial Instruments, Policy [Policy Text Block]-->
  <us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="c20150101to20150331">&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; text-indent: 36pt;"&gt;&lt;font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;"&gt;Fair value of financial instruments&lt;/font&gt; &amp;#8211; The fair value of BioTime&amp;#8217;s assets and liabilities, which qualify as financial instruments under FASB guidance regarding disclosures about fair value of financial instruments, approximate the carrying amounts presented in the accompanying consolidated balance sheets. The carrying amounts of cash equivalents, accounts receivable, prepaid expenses and other current assets, accounts payable, accrued expenses and other current liabilities approximate fair values because of the short-term nature of these items.&lt;/div&gt;&lt;/div&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
  <!--Intangible assets, useful life-Technology [Member]-->
  <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="c20150101to20150331_FiniteLivedIntangibleAssetsByMajorClassAxis_TechnologyBasedIntangibleAssetsMember">P10Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
  <!--Intangible assets, useful life-->
  <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="c20150101to20150331">P10Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
  <!--Finite-Lived Intangible Assets, Gross-->
  <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c20150331" unitRef="U002" decimals="0">52562549</us-gaap:FiniteLivedIntangibleAssetsGross>
  <!--Finite-Lived Intangible Assets, Gross-->
  <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c20141231" unitRef="U002" decimals="0">52562549</us-gaap:FiniteLivedIntangibleAssetsGross>
  <!--Finite-Lived Intangible Assets, Accumulated Amortization-->
  <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c20141231" unitRef="U002" decimals="0">13714153</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
  <!--Finite-Lived Intangible Assets, Accumulated Amortization-->
  <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c20150331" unitRef="U002" decimals="0">15028247</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
  <!--Finite-Lived Intangible Assets, Net-->
  <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c20150331" unitRef="U002" decimals="0">37534302</us-gaap:FiniteLivedIntangibleAssetsNet>
  <!--Finite-Lived Intangible Assets, Net-->
  <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c20141231" unitRef="U002" decimals="0">38848396</us-gaap:FiniteLivedIntangibleAssetsNet>
  <!--Foreign currency translation gain and other comprehensive loss-->
  <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock contextRef="c20150101to20150331">&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; text-indent: 36pt;"&gt;&lt;font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;"&gt;Foreign currency translation gain and other comprehensive loss, &amp;#160;foreign currency transaction gains and losses&amp;#160;&amp;#8211;&lt;/font&gt; In countries in which BioTime operates, where the functional currency is other than the U.S. dollar, assets and liabilities are translated using published exchange rates in effect at the consolidated balance sheet date. Revenues and expenses and cash flows are translated using an approximate weighted average exchange rate for the period. Resulting translation adjustments are recorded as a component of accumulated other comprehensive income or loss on the consolidated balance sheet. For the three months ended March 31, 2015 and 2014, other comprehensive loss includes losses of $52,985 and $107,240, respectively which is largely from foreign currency translation.&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 36pt;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; text-indent: 36pt;"&gt;For transactions denominated in other than the functional currency of BioTime, transactional gains and losses are recorded in other income and expense included in the consolidated statements of operations. For the three months ended March 31, 2015 and 2014, foreign currency transaction loss amounted to $205,149 and $10,212, respectively.&lt;/div&gt;&lt;/div&gt;</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
  <!--Foreign Currency Transaction Gain (Loss), before Tax-->
  <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax contextRef="c20150101to20150331" unitRef="U002" decimals="0">-205149</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
  <!--Foreign Currency Transaction Gain (Loss), before Tax-->
  <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax contextRef="c20140101to20140331" unitRef="U002" decimals="0">-10212</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
  <!--General and administrative-->
  <us-gaap:GeneralAndAdministrativeExpense contextRef="c20150101to20150331" unitRef="U002" decimals="0">5178800</us-gaap:GeneralAndAdministrativeExpense>
  <!--General and administrative-->
  <us-gaap:GeneralAndAdministrativeExpense contextRef="c20140101to20140331" unitRef="U002" decimals="0">3667171</us-gaap:GeneralAndAdministrativeExpense>
  <!--Goodwill and Intangible Assets, Policy [Policy Text Block]-->
  <us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock contextRef="c20150101to20150331">&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; text-indent: 36pt;"&gt;&lt;font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;"&gt;Intangible assets, net&lt;/font&gt; &amp;#8211; Intangible assets with finite useful lives are amortized over their estimated useful lives and intangible assets with indefinite lives are not amortized but rather are tested at least annually for impairment. Acquired in-process research and development intangible assets are accounted for depending on whether they were acquired as part of an acquisition of a business, or as assets that do not constitute a business. When acquired in conjunction with the acquisition of a business, these assets are considered to be indefinite-lived until the completion or abandonment of the associated research and development efforts and are capitalized as an asset. If and when development is complete, the associated assets would be deemed finite-lived and would then be amortized based on their respective estimated useful lives at that point in time. However, when acquired in conjunction with an acquisition of assets that do not constitute a business (such as the acquisition of assets by Asterias from Geron Corporation), in accordance with the accounting rules in ASC 805-50, such intangible assets related to in-process research and development (&amp;#8220;IPR&amp;amp;D&amp;#8221;) are expensed upon acquisition.&lt;/div&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock>
  <!--Grants Receivable, Current-->
  <us-gaap:GrantsReceivableCurrent contextRef="c20141231" unitRef="U002" decimals="0">492600</us-gaap:GrantsReceivableCurrent>
  <!--Grants Receivable, Current-->
  <us-gaap:GrantsReceivableCurrent contextRef="c20150331" unitRef="U002" decimals="0">260300</us-gaap:GrantsReceivableCurrent>
  <!--Grants Receivable-California Institute of Regenerative Medicine [Member]-Asterias Biotherapeutics [Member]-Subsequent Event [Member]-->
  <us-gaap:GrantsReceivable contextRef="c20150430_LegalEntityAxis_AsteriasBiotherapeuticsMember_MajorCustomersAxis_CaliforniaInstituteOfRegenerativeMedicineMember_SubsequentEventTypeAxis_SubsequentEventMember" unitRef="U002" decimals="-5">14300000</us-gaap:GrantsReceivable>
  <!--Gross Profit-->
  <us-gaap:GrossProfit contextRef="c20150101to20150331" unitRef="U002" decimals="0">1000287</us-gaap:GrossProfit>
  <!--Gross Profit-->
  <us-gaap:GrossProfit contextRef="c20140101to20140331" unitRef="U002" decimals="0">934721</us-gaap:GrossProfit>
  <!--Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]-->
  <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock contextRef="c20150101to20150331">&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; text-indent: 36pt;"&gt;&lt;font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;"&gt;Impairment of long-lived assets&lt;/font&gt;&amp;#160;&lt;font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;"&gt;&amp;#8211;&lt;/font&gt; BioTime&amp;#8217;s long-lived assets, including intangible assets, are reviewed annually for impairment and whenever events or changes in circumstances indicate that the carrying amount of an asset may not be fully recoverable. If an impairment indicator is present, BioTime will evaluate recoverability by a comparison of the carrying amount of the assets to future undiscounted net cash flows expected to be generated by the assets. If the assets are impaired, the impairment recognized is measured by the amount by which the carrying amount exceeds the estimated fair value of the assets.&lt;/div&gt;&lt;/div&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
  <!--Loss on sale or write-off of equipment-->
  <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse contextRef="c20140101to20140331" unitRef="U002" decimals="0">8576</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
  <!--Loss on sale or write-off of equipment-->
  <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse contextRef="c20150101to20150331" unitRef="U002" decimals="0">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
  <!--Income (Loss) from Continuing Operations before Income Taxes, Extraordinary Items, Noncontrolling Interest-->
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c20140101to20140331" unitRef="U002" decimals="0">-11077057</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
  <!--Income (Loss) from Continuing Operations before Income Taxes, Extraordinary Items, Noncontrolling Interest-->
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c20150101to20150331" unitRef="U002" decimals="0">-13766937</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
  <!--Income Tax, Policy [Policy Text Block]-->
  <us-gaap:IncomeTaxPolicyTextBlock contextRef="c20150101to20150331">&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; text-indent: 36pt;"&gt;&lt;font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;"&gt;Income taxes &amp;#8211;&lt;/font&gt; BioTime accounts for income taxes in accordance with GAAP requirements, which prescribe the use of the asset and liability method, whereby deferred tax asset or liability account balances are calculated at the balance sheet date using current tax laws and rates in effect. Valuation allowances are established when necessary to reduce deferred tax assets when it is more likely than not that a portion or all of the deferred tax assets will not be realized. The FASB guidance also prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more-likely-than-not sustainable upon examination by taxing authorities. Beginning October 1, 2013, Asterias began filing separate U.S. federal income tax returns but effectively BioTime combined Asterias&amp;#8217; tax provision with BioTime&amp;#8217;s consolidated financial statements. For California, Asterias&amp;#8217; activity for 2013 and 2014 have been included in BioTime&amp;#8217;s combined tax return. BioTime recognizes accrued interest and penalties related to unrecognized tax benefits, if any,&amp;#160;as income tax expense, however, no amounts were accrued for the payment of interest and penalties as of March 31, 2015 and 2014. BioTime files a U.S. federal income tax return as well as various state and foreign income tax returns. In general, BioTime is no longer subject to tax examination by major taxing authorities for years before 2010. Although the statute is closed for purposes of assessing additional income and tax in those years, the taxing authorities may still make adjustments to the net operating loss and credit carryforwards used in open years. Therefore the statute should be considered open as it relates to the net operating loss and credit carryforwards. Any potential examinations may include questioning the timing and amount of deductions, the nexus of income among various tax jurisdictions and compliance with U.S. federal, state and local and foreign tax laws. Management does not expect that the total amount of unrecognized tax benefits will materially change over the next year.&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; text-indent: 36pt;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; text-indent: 36pt;"&gt;An income tax benefit of approximately $1,177,000 was recorded for the three months ended March 31, 2015, of which approximately $1,251,000 of the benefit was related to federal offset by adjustment of $74,000 related to state taxes. For the same period in 2014, an income tax benefit of approximately $1,349,000 was recorded , of which approximately $1,151,000 of the benefit was related to federal and $198,000 was related to state taxes.&lt;/div&gt;&lt;div&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; text-indent: 36pt;"&gt;Asterias established deferred tax liabilities primarily related to its acquisition of certain intellectual property. It is more likely than not that the Asterias deferred tax assets are fully realizable since these income tax benefits are expected to be available to offset such Asterias deferred tax liabilities.&lt;/div&gt;&lt;div&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;br /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; text-indent: 36pt;"&gt;In June 2014, Asterias sold 5,000,000 BioTime shares which resulted in a taxable gain of approximately $10.3 million and a tax payable of $3.6 million. Asterias received the BioTime shares from BioTime as part of the consideration for the Asterias common stock and warrants issued to BioTime under an Asset Contribution Agreement among BioTime, Asterias, and Geron Corporation, a tax free transaction. This income tax liability was offset by available net operating losses, resulting in no cash income taxes due from that sale. This transaction was treated as a deemed distribution by Asterias and recorded against equity.&lt;/div&gt;&lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
  <!--Increase (Decrease) in Accounts Receivable-->
  <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c20150101to20150331" unitRef="U002" decimals="0">56598</us-gaap:IncreaseDecreaseInAccountsReceivable>
  <!--Increase (Decrease) in Accounts Receivable-->
  <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c20140101to20140331" unitRef="U002" decimals="0">24441</us-gaap:IncreaseDecreaseInAccountsReceivable>
  <!--Other long term liabilities-->
  <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities contextRef="c20140101to20140331" unitRef="U002" decimals="0">-185717</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
  <!--Other long term liabilities-->
  <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities contextRef="c20150101to20150331" unitRef="U002" decimals="0">10727</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
  <!--Accounts payable and accrued liabilities-->
  <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="c20140101to20140331" unitRef="U002" decimals="0">-1276211</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
  <!--Accounts payable and accrued liabilities-->
  <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="c20150101to20150331" unitRef="U002" decimals="0">-365175</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
  <!--Deferred revenues-->
  <us-gaap:IncreaseDecreaseInDeferredRevenue contextRef="c20150101to20150331" unitRef="U002" decimals="0">-29811</us-gaap:IncreaseDecreaseInDeferredRevenue>
  <!--Deferred revenues-->
  <us-gaap:IncreaseDecreaseInDeferredRevenue contextRef="c20140101to20140331" unitRef="U002" decimals="0">-57402</us-gaap:IncreaseDecreaseInDeferredRevenue>
  <!--Increase (Decrease) in Inventories-->
  <us-gaap:IncreaseDecreaseInInventories contextRef="c20140101to20140331" unitRef="U002" decimals="0">57894</us-gaap:IncreaseDecreaseInInventories>
  <!--Increase (Decrease) in Inventories-->
  <us-gaap:IncreaseDecreaseInInventories contextRef="c20150101to20150331" unitRef="U002" decimals="0">33286</us-gaap:IncreaseDecreaseInInventories>
  <!--Increase (Decrease) in Prepaid Expense and Other Assets-->
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c20140101to20140331" unitRef="U002" decimals="0">375224</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <!--Increase (Decrease) in Prepaid Expense and Other Assets-->
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c20150101to20150331" unitRef="U002" decimals="0">60769</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <!--Intangible Assets, Net (Excluding Goodwill)-->
  <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="c20150331" unitRef="U002" decimals="0">37534302</us-gaap:IntangibleAssetsNetExcludingGoodwill>
  <!--Intangible Assets, Net (Excluding Goodwill)-->
  <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="c20141231" unitRef="U002" decimals="0">38848396</us-gaap:IntangibleAssetsNetExcludingGoodwill>
  <!--Intangible Assets Disclosure [Text Block]-->
  <us-gaap:IntangibleAssetsDisclosureTextBlock contextRef="c20150101to20150331">&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;div style="text-align: justify;"&gt;&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 100%;"&gt;&lt;tr&gt;&lt;td style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 18pt; vertical-align: top; font-weight: bold; align: right;"&gt;5.&lt;/td&gt;&lt;td style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: auto; vertical-align: top; font-weight: bold; text-align: justify;"&gt;Intangible assets, net&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; text-indent: 36pt;"&gt;At March 31, 2015 and December 31, 2014, intangible assets and intangible assets net of amortization were comprised of the following:&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 100%;"&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="vertical-align: bottom; white-space: nowrap; border-bottom: #000000 2px solid;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; text-align: center;"&gt;March 31, 2015&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; text-align: center;"&gt;(Unaudited)&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; text-align: center;"&gt;December 31,&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; text-align: center;"&gt;2014&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="width: 76%; vertical-align: bottom; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;"&gt;Intangible assets&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;52,562,549&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;52,562,549&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="width: 76%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;"&gt;Accumulated amortization&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;(15,028,247&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;(13,714,153&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="width: 76%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;"&gt;Intangible assets, net&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;37,534,302&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;38,848,396&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="text-align: justify;"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; text-indent: 36pt;"&gt;BioTime amortizes its intangible assets generally over an estimated period of 10 years on a straight line basis. BioTime recognized $1,314,094 and $1,367,998 in amortization expense of intangible assets, included in research and development,&amp;#160;during the three months ended March 31, 2015 and 2014, respectively.&lt;/div&gt;&lt;/div&gt;</us-gaap:IntangibleAssetsDisclosureTextBlock>
  <!--Intangible Assets, Costs Incurred to Renew or Extend, Policy [Policy Text Block]-->
  <us-gaap:IntangibleAssetsFiniteLivedPolicyCostsIncurredToRenewOrExtend contextRef="c20150101to20150331">&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; text-indent: 36pt;"&gt;&lt;font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;"&gt;Patent costs &amp;#8211;&lt;/font&gt; Costs associated with obtaining patents on products or technology developed are expensed as research and development expenses when incurred.&lt;/div&gt;&lt;/div&gt;</us-gaap:IntangibleAssetsFiniteLivedPolicyCostsIncurredToRenewOrExtend>
  <!--Interest expense, net-->
  <us-gaap:InterestIncomeExpenseNet contextRef="c20140101to20140331" unitRef="U002" decimals="0">-8384</us-gaap:InterestIncomeExpenseNet>
  <!--Interest expense, net-->
  <us-gaap:InterestIncomeExpenseNet contextRef="c20150101to20150331" unitRef="U002" decimals="0">-25461</us-gaap:InterestIncomeExpenseNet>
  <!--Inventory-->
  <us-gaap:InventoryNet contextRef="c20141231" unitRef="U002" decimals="0">266022</us-gaap:InventoryNet>
  <!--Inventory-->
  <us-gaap:InventoryNet contextRef="c20150331" unitRef="U002" decimals="0">299308</us-gaap:InventoryNet>
  <!--Inventory, Policy [Policy Text Block]-->
  <us-gaap:InventoryPolicyTextBlock contextRef="c20150101to20150331">&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; text-indent: 36pt;"&gt;&lt;font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;"&gt;Inventory &amp;#8211;&lt;/font&gt; Inventories are stated at the lower of cost or market. Cost, which includes amounts related to materials, labor, and overhead, is determined in a manner which approximates the first-in, first-out (&amp;#8220;FIFO&amp;#8221;) method.&lt;/div&gt;&lt;/div&gt;</us-gaap:InventoryPolicyTextBlock>
  <!--Inventory, Finished Goods, Net of Reserves-->
  <us-gaap:InventoryFinishedGoodsNetOfReserves contextRef="c20150331" unitRef="U002" decimals="0">286513</us-gaap:InventoryFinishedGoodsNetOfReserves>
  <!--Inventory, Finished Goods, Net of Reserves-->
  <us-gaap:InventoryFinishedGoodsNetOfReserves contextRef="c20141231" unitRef="U002" decimals="0">253227</us-gaap:InventoryFinishedGoodsNetOfReserves>
  <!--Inventory Disclosure [Text Block]-->
  <us-gaap:InventoryDisclosureTextBlock contextRef="c20150101to20150331">&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;div style="text-align: justify;"&gt;&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 100%;"&gt;&lt;tr&gt;&lt;td style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 18pt; vertical-align: top; font-weight: bold; align: right;"&gt;3.&lt;/td&gt;&lt;td style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: auto; vertical-align: top; font-weight: bold; text-align: justify;"&gt;Inventory&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align: justify;"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; text-indent: 36pt;"&gt;BioTime held $286,513 and $253,227 of inventory of finished products on-site at its corporate headquarters in Alameda, California at March 31, 2015 and December 31, 2014, respectively. Finished goods products of $12,795 were held by a third party on consignment at March 31, 2015 and December 31, 2014.&lt;/div&gt;&lt;/div&gt;</us-gaap:InventoryDisclosureTextBlock>
  <!--Leasehold improvements for Asterias' facility-->
  <us-gaap:LeaseholdImprovementsGross contextRef="c20150331" unitRef="U002" decimals="0">606641</us-gaap:LeaseholdImprovementsGross>
  <!--Liabilities, Current-->
  <us-gaap:LiabilitiesCurrent contextRef="c20141231" unitRef="U002" decimals="0">7129267</us-gaap:LiabilitiesCurrent>
  <!--Liabilities, Current-->
  <us-gaap:LiabilitiesCurrent contextRef="c20150331" unitRef="U002" decimals="0">8202661</us-gaap:LiabilitiesCurrent>
  <!--Liabilities and Equity-->
  <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c20141231" unitRef="U002" decimals="0">74900906</us-gaap:LiabilitiesAndStockholdersEquity>
  <!--Liabilities and Equity-->
  <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c20150331" unitRef="U002" decimals="0">69703470</us-gaap:LiabilitiesAndStockholdersEquity>
  <!--Liabilities, Noncurrent-->
  <us-gaap:LiabilitiesNoncurrent contextRef="c20150331" unitRef="U002" decimals="0">3989025</us-gaap:LiabilitiesNoncurrent>
  <!--Liabilities, Noncurrent-->
  <us-gaap:LiabilitiesNoncurrent contextRef="c20141231" unitRef="U002" decimals="0">5048874</us-gaap:LiabilitiesNoncurrent>
  <!--License fees-->
  <us-gaap:LicensesRevenue contextRef="c20150101to20150331" unitRef="U002" decimals="0">319146</us-gaap:LicensesRevenue>
  <!--License fees-->
  <us-gaap:LicensesRevenue contextRef="c20140101to20140331" unitRef="U002" decimals="0">294504</us-gaap:LicensesRevenue>
  <!--Capital lease, net of current portion-->
  <us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent contextRef="c20141231" unitRef="U002" decimals="0">31290</us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent>
  <!--Capital lease, net of current portion-->
  <us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent contextRef="c20150331" unitRef="U002" decimals="0">17307</us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent>
  <!--BioTime Ownership (in hundredths)-LifeMap Sciences, Inc. [Member]-->
  <us-gaap:MinorityInterestOwnershipPercentageByParent contextRef="c20150331_LegalEntityAxis_LifemapSciencesIncMember" unitRef="U004" decimals="3">0.758</us-gaap:MinorityInterestOwnershipPercentageByParent>
  <!--BioTime Ownership (in hundredths)-BioTime Asia, Limited [Member]-->
  <us-gaap:MinorityInterestOwnershipPercentageByParent contextRef="c20150331_LegalEntityAxis_BiotimeAsiaLimitedMember" unitRef="U004" decimals="2">0.81</us-gaap:MinorityInterestOwnershipPercentageByParent>
  <!--BioTime Ownership (in hundredths)-Cell Cure Neurosciences, Ltd. [Member]-->
  <us-gaap:MinorityInterestOwnershipPercentageByParent contextRef="c20150331_LegalEntityAxis_CellCureNeurosciencesLtdMember" unitRef="U004" decimals="3" id="Item-1">0.625</us-gaap:MinorityInterestOwnershipPercentageByParent>
  <!--BioTime Ownership (in hundredths)-ReCyte Therapeutics, Inc. [Member]-->
  <us-gaap:MinorityInterestOwnershipPercentageByParent contextRef="c20150331_LegalEntityAxis_RecyteTherapeuticsIncMember" unitRef="U004" decimals="3">0.948</us-gaap:MinorityInterestOwnershipPercentageByParent>
  <!--BioTime Ownership (in hundredths)-OrthoCyte Corporation [Member]-->
  <us-gaap:MinorityInterestOwnershipPercentageByParent contextRef="c20150331_LegalEntityAxis_OrthocyteCorporationMember" unitRef="U004" decimals="0" id="Item-2">1</us-gaap:MinorityInterestOwnershipPercentageByParent>
  <!--BioTime Ownership (in hundredths)-Asterias Biotherapeutics [Member]-->
  <us-gaap:MinorityInterestOwnershipPercentageByParent contextRef="c20150331_LegalEntityAxis_AsteriasBiotherapeuticsMember" unitRef="U004" decimals="3">0.675</us-gaap:MinorityInterestOwnershipPercentageByParent>
  <!--BioTime Ownership (in hundredths)-ES Cell International Pte., Ltd. [Member]-->
  <us-gaap:MinorityInterestOwnershipPercentageByParent contextRef="c20150331_LegalEntityAxis_EsCellInternationalPteLtdMember" unitRef="U004" decimals="0">1</us-gaap:MinorityInterestOwnershipPercentageByParent>
  <!--BioTime Ownership (in hundredths)-LifeMap Solutions, Inc [Member]-->
  <us-gaap:MinorityInterestOwnershipPercentageByParent contextRef="c20150331_LegalEntityAxis_LifemapSolutionsIncMember" unitRef="U004" decimals="0" id="Item-3">0</us-gaap:MinorityInterestOwnershipPercentageByParent>
  <!--BioTime Ownership (in hundredths)-OncoCyte Corporation [Member]-->
  <us-gaap:MinorityInterestOwnershipPercentageByParent contextRef="c20150331_LegalEntityAxis_OncocyteCorporationMember" unitRef="U004" decimals="3">0.753</us-gaap:MinorityInterestOwnershipPercentageByParent>
  <!--BioTime Ownership (in hundredths)-LifeMap Sciences, Ltd. [Member]-->
  <us-gaap:MinorityInterestOwnershipPercentageByParent contextRef="c20150331_LegalEntityAxis_LifemapSciencesLtdMember" unitRef="U004" decimals="0" id="Item-4">0</us-gaap:MinorityInterestOwnershipPercentageByParent>
  <!--Non-controlling interest-->
  <us-gaap:MinorityInterest contextRef="c20150331" unitRef="U002" decimals="0">31261380</us-gaap:MinorityInterest>
  <!--Non-controlling interest-->
  <us-gaap:MinorityInterest contextRef="c20141231" unitRef="U002" decimals="0">26266782</us-gaap:MinorityInterest>
  <!--Net loss attributable to BioTime, Inc.-->
  <us-gaap:NetIncomeLoss contextRef="c20150101to20150331" unitRef="U002" decimals="0">-10167368</us-gaap:NetIncomeLoss>
  <!--Net loss attributable to BioTime, Inc.-->
  <us-gaap:NetIncomeLoss contextRef="c20140101to20140331" unitRef="U002" decimals="0">-8099014</us-gaap:NetIncomeLoss>
  <!--Net Income (Loss) Available to Common Stockholders, Basic-->
  <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="c20150101to20150331" unitRef="U002" decimals="0">-10167368</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
  <!--Net Income (Loss) Available to Common Stockholders, Basic-->
  <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="c20140101to20140331" unitRef="U002" decimals="0">-8099014</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
  <!--Net Cash Provided by (Used in) Operating Activities, Continuing Operations-->
  <us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations contextRef="c20150101to20150331" unitRef="U002" decimals="0">-9068821</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
  <!--Net Cash Provided by (Used in) Operating Activities, Continuing Operations-->
  <us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations contextRef="c20140101to20140331" unitRef="U002" decimals="0">-10357271</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
  <!--Net Cash Provided by (Used in) Financing Activities, Continuing Operations-->
  <us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations contextRef="c20140101to20140331" unitRef="U002" decimals="0">12128485</us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations>
  <!--Net Cash Provided by (Used in) Financing Activities, Continuing Operations-->
  <us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations contextRef="c20150101to20150331" unitRef="U002" decimals="0">5683858</us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations>
  <!--Net Cash Provided by (Used in) Investing Activities, Continuing Operations-->
  <us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations contextRef="c20140101to20140331" unitRef="U002" decimals="0">-527618</us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations>
  <!--Net Cash Provided by (Used in) Investing Activities, Continuing Operations-->
  <us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations contextRef="c20150101to20150331" unitRef="U002" decimals="0">-373389</us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations>
  <!--Net loss attributable to non-controlling interest-->
  <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="c20140101to20140331" unitRef="U002" decimals="0">1629017</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
  <!--Net loss attributable to non-controlling interest-->
  <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="c20150101to20150331" unitRef="U002" decimals="0">2422687</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
  <!--New Accounting Pronouncements, Policy [Policy Text Block]-->
  <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="c20150101to20150331">&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; font-style: italic; text-align: justify; text-indent: 36pt;"&gt;&lt;font style="font-weight: normal;"&gt;Recently Issued Accounting Pronouncements &amp;#8211; &lt;/font&gt;&lt;font style="font-weight: normal; font-style: normal;"&gt;There have been no recent accounting pronouncements or changes in accounting pronouncments during the three months ended March 31, 2015, as compared to the recent accounting pronouncements described in the Comany's 2014 Annual Report on Form 10-K that are of significance or potential significance to the Company.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
  <!--Nonoperating Income (Expense)-->
  <us-gaap:NonoperatingIncomeExpense contextRef="c20140101to20140331" unitRef="U002" decimals="0">60786</us-gaap:NonoperatingIncomeExpense>
  <!--Nonoperating Income (Expense)-->
  <us-gaap:NonoperatingIncomeExpense contextRef="c20150101to20150331" unitRef="U002" decimals="0">-264914</us-gaap:NonoperatingIncomeExpense>
  <!--Number of operating segments-->
  <us-gaap:NumberOfOperatingSegments contextRef="c20150101to20150331" unitRef="U007" decimals="INF">1</us-gaap:NumberOfOperatingSegments>
  <!--Operating Expenses-->
  <us-gaap:OperatingExpenses contextRef="c20140101to20140331" unitRef="U002" decimals="0">12072564</us-gaap:OperatingExpenses>
  <!--Operating Expenses-->
  <us-gaap:OperatingExpenses contextRef="c20150101to20150331" unitRef="U002" decimals="0">14502310</us-gaap:OperatingExpenses>
  <!--Operating Income (Loss)-->
  <us-gaap:OperatingIncomeLoss contextRef="c20140101to20140331" unitRef="U002" decimals="0">-11137843</us-gaap:OperatingIncomeLoss>
  <!--Operating Income (Loss)-->
  <us-gaap:OperatingIncomeLoss contextRef="c20150101to20150331" unitRef="U002" decimals="0">-13502023</us-gaap:OperatingIncomeLoss>
  <!--Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]-->
  <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="c20150101to20150331">&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;div style="text-align: justify;"&gt;&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 100%;"&gt;&lt;tr&gt;&lt;td style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 18pt; vertical-align: top; font-weight: bold; align: right;"&gt;1.&lt;/td&gt;&lt;td style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: auto; vertical-align: top; font-weight: bold; text-align: justify;"&gt;Organization, Basis of Presentation, and Liquidity&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align: justify;"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; margin-left: 0.1pt; margin-right: 0.1pt; text-indent: 36pt;"&gt;&lt;font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;"&gt;General &amp;#8211; &lt;/font&gt;&lt;font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;BioTime is a biotechnology company focused on the field of regenerative medicine; specifically human embryonic stem (&amp;#8220;hES&amp;#8221;) cell and induced pluripotent stem (&amp;#8220;iPS&amp;#8221;) cell technology. Regenerative medicine refers to therapies based on stem cell technology that are designed to rebuild cell and tissue function lost due to degenerative disease or injury. hES and iPS cells provide a means of manufacturing every cell type in the human body and therefore show considerable promise for the development of a number of new therapeutic products. BioTime and its subsidiaries are developing stem cell products for research and therapeutic use. BioTime&amp;#8217;s primary therapeutic products are based on its &lt;/font&gt;&lt;font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;"&gt;HyStem&lt;/font&gt;&lt;sup style="font-size: smaller; vertical-align: text-top; line-height: 1;"&gt;&amp;#174;&lt;/sup&gt;&lt;font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt; hydrogel technology and include &lt;/font&gt;&lt;font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;"&gt;Renevia&lt;/font&gt;&lt;font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;&amp;#8482; a product currently in clinical trials in Europe to facilitate cell transplantation; &lt;/font&gt;&lt;font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;"&gt;ReGlyde&lt;/font&gt;&lt;font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;&amp;#8482; a product under development for tendon surgery applications; and &lt;/font&gt;&lt;font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;"&gt;Premvia&lt;/font&gt;&lt;font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;&amp;#8482; for which 510(k) certification has been received for use in wound-management. Asterias Biotherapeutics, Inc. (&amp;#8220;Asterias,&amp;#8221; &lt;/font&gt;NYSE MKT: AST&lt;font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;) is developing pluripotent stem-cell based therapies in neurology and oncology, including AST-OPC1 neural cells in spinal cord injury, and AST-VAC2, a pluripotent stem cell-derived cancer vaccine. OncoCyte Corporation (&amp;#8220;OncoCyte&amp;#8221;) is developing products and technologies to diagnose cancer. ES Cell International Pte Ltd. (&amp;#8220;ESI&amp;#8221;), a Singapore private limited company, is providing its National Institutes of Health (&amp;#8220;NIH&amp;#8221;) approved hES cell lines, manufactured under current good manufacturing practices (&amp;#8216;cGMP&amp;#8221;), to pre-researchers focused on clinical applications through BioTime&amp;#8217;s &lt;/font&gt;&lt;font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;"&gt;ESI BIO&lt;/font&gt;&lt;font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt; division. OrthoCyte Corporation (&amp;#8220;OrthoCyte&amp;#8221;) is developing therapies to treat orthopedic disorders, diseases and injuries. ReCyte Therapeutics, Inc. (&amp;#8220;ReCyte Therapeutics&amp;#8221;) is developing therapies to treat a variety of cardiovascular and related ischemic disorders, as well as related products for research. Cell Cure Neurosciences Ltd. (&amp;#8220;Cell Cure Neurosciences&amp;#8221;) is an Israel-based biotechnology company focused on developing stem cell-based therapies for retinal and neurological disorders, including the development of retinal pigment epithelial cells for the treatment of macular degeneration. Research products and services are marketed through LifeMap Sciences Inc. and BioTime&amp;#8217;s &lt;/font&gt;&lt;font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;"&gt;ESI BIO&lt;/font&gt;&lt;font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt; division. LifeMap Sciences, Inc. (&amp;#8220;LifeMap Sciences&amp;#8221;) markets, sells and distributes &lt;/font&gt;&lt;font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;"&gt;GeneCards&lt;/font&gt;&lt;sup style="font-size: smaller; vertical-align: text-top; line-height: 1;"&gt;&amp;#174;&lt;/sup&gt;&lt;font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;, the leading human gene database and an integrated database suite that includes &lt;/font&gt;&lt;font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;"&gt;GeneCards&lt;/font&gt;&lt;sup style="font-size: smaller; vertical-align: text-top; line-height: 1;"&gt;&amp;#174;&lt;/sup&gt;&lt;font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;, the &lt;/font&gt;&lt;font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;"&gt;LifeMap Discovery&lt;/font&gt;&lt;sup style="font-size: smaller; vertical-align: text-top; line-height: 1;"&gt;&amp;#174;&lt;/sup&gt;&lt;font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt; database of embryonic development, stem cell research and regenerative medicine, and &lt;/font&gt;&lt;font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;"&gt;MalaCards&lt;/font&gt;&lt;font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;&amp;#8482;, the human disease database, and the analysis tools &lt;/font&gt;&lt;font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;"&gt;VarElect&lt;/font&gt;&lt;font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;&amp;#8482;, a powerful, yet easy-to-use application for prioritizing gene variants resulting from next generation sequencing experiments, and &lt;/font&gt;&lt;font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;"&gt;GeneAnalytics&lt;/font&gt;&lt;font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;&amp;#8482;, a novel gene set analysis tool. LifeMap Sciences&amp;#8217; subsidiary LifeMap Solutions, Inc. (&amp;#8220;LifeMap Solutions&amp;#8221;) is developing mobile health software products in partnership with the Icahn Institute for Genomics and Multiscale Biology.&lt;/font&gt;&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; margin-left: 0.1pt; margin-right: 0.1pt; text-indent: 36pt;"&gt;BioTime is focusing a portion of its efforts in the field of regenerative medicine on the development and sale of advanced human stem cell products and technologies that can be used by researchers at universities and other institutions, at companies in the bioscience and biopharmaceutical industries, and at other companies that provide research products to companies in those industries. These products are developed internally or in conjunction with BioTime&amp;#8217;s subsidiaries and marketed through BioTime&amp;#8217;s &lt;font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;"&gt;ESI BIO&lt;/font&gt; division. Products for the research market generally can be sold without regulatory (United States Food and Drug Administration (&amp;#8220;FDA&amp;#8221;)) approval, and are therefore relatively near-term business opportunities when compared to therapeutic products.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; text-indent: 36pt;"&gt;BioTime previously developed blood plasma volume expanders and related technology for use in surgery, emergency trauma treatment and other applications. BioTime&amp;#8217;s operating revenues are now derived primarily from research grants, from licensing fees and advertising from the marketing of the LifeMap Sciences database products, and from the sale of products for research.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; text-indent: 36pt;"&gt;The unaudited condensed consolidated interim balance sheet as of March 31, 2015, the unaudited condensed consolidated interim statements of operations and statements of comprehensive loss for the three months ended March 31, 2015 and 2014, and the unaudited condensed consolidated interim statements of cash flows for the three months ended March 31, 2015 and 2014 have been prepared by BioTime&amp;#8217;s management in accordance with the instructions from Form 10-Q and Regulation S-X. In the opinion of management, all adjustments (consisting only of normal recurring adjustments) necessary to present fairly the financial position, results of operations, and cash flows at March 31, 2015 have been made. The consolidated balance sheet as of December 31, 2014 is derived from the Company&amp;#8217;s annual audited financial statements as of that date. The results of operations for the three months ended March 31, 2015 are not necessarily indicative of the operating results anticipated for the full year of 2015.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; text-indent: 36pt;"&gt;Certain information and footnote disclosures normally included in consolidated financial statements prepared in accordance with U.S. generally accepted accounting principles have been condensed or omitted as permitted by regulations of the Securities and Exchange Commission (&amp;#8220;SEC&amp;#8221;) except for the consolidated balance sheet as of December 31, 2014, which was derived from audited financial statements. Certain previously furnished amounts have been reclassified to conform with presentations made during the current periods. It is suggested that these condensed consolidated interim financial statements be read in conjunction with the annual audited consolidated financial statements and notes thereto included in BioTime&amp;#8217;s Annual Report on Form 10-K for the year ended December 31, 2014.&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; text-indent: 36pt;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; text-indent: 36pt;"&gt;&lt;font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;"&gt;Use of estimates&lt;/font&gt; &amp;#8211; The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the U.S. ("GAAP") requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; text-indent: 36pt;"&gt;&lt;font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;"&gt;Principles of consolidation&lt;/font&gt; &amp;#8211; BioTime&amp;#8217;s consolidated financial statements include the accounts of its subsidiaries. The following table reflects BioTime&amp;#8217;s ownership, directly or through one or more subsidiaries, of the outstanding shares of its subsidiaries as of March 31, 2015.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 100%; border-collapse: collapse;"&gt;&lt;tr&gt;&lt;td style="border-top: #000000 2px solid; width: 23.28%; vertical-align: top; border-left: #000000 2px solid;"&gt;&lt;div style="text-align: left;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; text-align: center;"&gt;Subsidiary&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top: #000000 2px solid; width: 57%; vertical-align: top; border-left: #000000 2px solid;"&gt;&lt;div style="text-align: left;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; text-align: center;"&gt;Field of Business&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top: #000000 2px solid; width: 10%; vertical-align: top; border-left: #000000 2px solid;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;"&gt;BioTime&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;"&gt;Ownership&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top: #000000 2px solid; border-right: #000000 2px solid; width: 10%; vertical-align: top; border-left: #000000 2px solid;"&gt;&lt;div style="text-align: left;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; text-align: center;"&gt;Country&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-top: #000000 2px solid; width: 23.28%; vertical-align: top; border-left: #000000 2px solid; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; margin-left: 7.7pt; text-indent: -7.7pt;"&gt;&lt;font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;Asterias Biotherapeutics, Inc. (&lt;/font&gt;NYSE MKT: AST)&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top: #000000 2px solid; width: 57%; vertical-align: top; border-left: #000000 2px solid; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;"&gt;Research, development and commercialization of human therapeutic products from stem cells, focused initially in the fields of neurology and oncology&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top: #000000 2px solid; width: 10%; vertical-align: top; border-left: #000000 2px solid; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;"&gt;67.5%&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top: #000000 2px solid; border-right: #000000 2px solid; width: 10%; vertical-align: top; border-left: #000000 2px solid; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;"&gt;USA&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-top: #000000 2px solid; width: 23.28%; vertical-align: top; border-left: #000000 2px solid; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; margin-left: 7.7pt; text-indent: -7.7pt;"&gt;BioTime Asia, Limited&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top: #000000 2px solid; width: 57%; vertical-align: top; border-left: #000000 2px solid; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;"&gt;Stem cell products for research&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top: #000000 2px solid; width: 10%; vertical-align: top; border-left: #000000 2px solid; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;"&gt;81%&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top: #000000 2px solid; border-right: #000000 2px solid; width: 10%; vertical-align: top; border-left: #000000 2px solid; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;"&gt;Hong Kong&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-top: #000000 2px solid; width: 23.28%; vertical-align: top; border-left: #000000 2px solid; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; margin-left: 7.7pt; text-indent: -7.7pt;"&gt;Cell Cure Neurosciences Ltd.&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top: #000000 2px solid; width: 57%; vertical-align: top; border-left: #000000 2px solid; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;"&gt;Age-related macular degeneration&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top: #000000 2px solid; width: 10%; vertical-align: top; border-left: #000000 2px solid; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;"&gt;62.5%(1)&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top: #000000 2px solid; border-right: #000000 2px solid; width: 10%; vertical-align: top; border-left: #000000 2px solid; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;"&gt;Israel&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-top: #000000 2px solid; width: 23.28%; vertical-align: top; border-left: #000000 2px solid; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; margin-left: 7.7pt; text-indent: -7.7pt;"&gt;ES Cell International Pte Ltd&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top: #000000 2px solid; width: 57%; vertical-align: top; border-left: #000000 2px solid; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;"&gt;Stem cell products for research, including clinical grade cell lines produced under cGMP&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top: #000000 2px solid; width: 10%; vertical-align: top; border-left: #000000 2px solid; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;"&gt;100%&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top: #000000 2px solid; border-right: #000000 2px solid; width: 10%; vertical-align: top; border-left: #000000 2px solid; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;"&gt;Singapore&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-top: #000000 2px solid; width: 23.28%; vertical-align: top; border-left: #000000 2px solid; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; margin-left: 7.7pt; text-indent: -7.7pt;"&gt;LifeMap Sciences, Inc.&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top: #000000 2px solid; width: 57%; vertical-align: top; border-left: #000000 2px solid; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;"&gt;Biomedical, gene, disease, and stem cell databases and tools&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top: #000000 2px solid; width: 10%; vertical-align: top; border-left: #000000 2px solid; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;"&gt;75.8%&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top: #000000 2px solid; border-right: #000000 2px solid; width: 10%; vertical-align: top; border-left: #000000 2px solid; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;"&gt;USA&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-top: #000000 2px solid; width: 23.28%; vertical-align: top; border-left: #000000 2px solid; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; margin-left: 7.7pt; text-indent: -7.7pt;"&gt;LifeMap Sciences, Ltd.&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top: #000000 2px solid; width: 57%; vertical-align: top; border-left: #000000 2px solid; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;"&gt;Biomedical, gene, disease, and stem cell databases and tools&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top: #000000 2px solid; width: 10%; vertical-align: top; border-left: #000000 2px solid; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;"&gt;(2)&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top: #000000 2px solid; border-right: #000000 2px solid; width: 10%; vertical-align: top; border-left: #000000 2px solid; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;"&gt;Israel&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-top: #000000 2px solid; width: 23.28%; vertical-align: top; border-left: #000000 2px solid; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; margin-left: 7.7pt; text-indent: -7.7pt;"&gt;LifeMap Solutions, Inc.&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top: #000000 2px solid; width: 57%; vertical-align: top; border-left: #000000 2px solid; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;"&gt;Mobile health software&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top: #000000 2px solid; width: 10%; vertical-align: top; border-left: #000000 2px solid; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;"&gt;(2)&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top: #000000 2px solid; border-right: #000000 2px solid; width: 10%; vertical-align: top; border-left: #000000 2px solid; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;"&gt;USA&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-top: #000000 2px solid; width: 23.28%; vertical-align: top; border-left: #000000 2px solid; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; margin-left: 7.7pt; text-indent: -7.7pt;"&gt;OncoCyte Corporation&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top: #000000 2px solid; width: 57%; vertical-align: top; border-left: #000000 2px solid; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;"&gt;Cancer diagnostics&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top: #000000 2px solid; width: 10%; vertical-align: top; border-left: #000000 2px solid; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;"&gt;75.3%&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top: #000000 2px solid; border-right: #000000 2px solid; width: 10%; vertical-align: top; border-left: #000000 2px solid; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;"&gt;USA&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-top: #000000 2px solid; width: 23.28%; vertical-align: top; border-left: #000000 2px solid; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; margin-left: 7.7pt; text-indent: -7.7pt;"&gt;OrthoCyte Corporation&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top: #000000 2px solid; width: 57%; vertical-align: top; border-left: #000000 2px solid; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;"&gt;Orthopedic diseases, including chronic back pain and osteoarthritis&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top: #000000 2px solid; width: 10%; vertical-align: top; border-left: #000000 2px solid; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;"&gt;100%(3)&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top: #000000 2px solid; border-right: #000000 2px solid; width: 10%; vertical-align: top; border-left: #000000 2px solid; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;"&gt;USA&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-top: #000000 2px solid; width: 23.28%; vertical-align: top; border-bottom: #000000 2px solid; border-left: #000000 2px solid; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; margin-left: 7.7pt; text-indent: -7.7pt;"&gt;ReCyte Therapeutics, Inc.&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top: #000000 2px solid; width: 57%; vertical-align: top; border-bottom: #000000 2px solid; border-left: #000000 2px solid; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;"&gt;Vascular disorders, including cardiovascular-related diseases, ischemic conditions, vascular injuries&lt;/div&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;"&gt;Stem cell-derived endothelial and cardiovascular related progenitor cells that have applications in research, drug testing, and therapeutics&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top: #000000 2px solid; width: 10%; vertical-align: top; border-bottom: #000000 2px solid; border-left: #000000 2px solid; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;"&gt;94.8%&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top: #000000 2px solid; border-right: #000000 2px solid; width: 10%; vertical-align: top; border-bottom: #000000 2px solid; border-left: #000000 2px solid; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;"&gt;USA&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: left;"&gt;&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 100%;"&gt;&lt;tr&gt;&lt;td style="width: 18pt;"&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 18pt; vertical-align: top; align: right;"&gt;(1)&lt;/td&gt;&lt;td style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: auto; vertical-align: top; text-align: left;"&gt;Includes shares owned by &lt;font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;BioTime, Asterias, and ESI.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align: left;"&gt;&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 100%;"&gt;&lt;tr&gt;&lt;td style="width: 18pt;"&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 18pt; vertical-align: top; align: right;"&gt;(2)&lt;/td&gt;&lt;td style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: auto; vertical-align: top; text-align: left;"&gt;LifeMap Sciences, Ltd. and LifeMap Solutions, Inc. are wholly-owned subsidiaries of LifeMap Sciences, Inc.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align: left;"&gt;&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 100%;"&gt;&lt;tr&gt;&lt;td style="width: 18pt;"&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 18pt; vertical-align: top; align: right;"&gt;(3)&lt;/td&gt;&lt;td style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: auto; vertical-align: top; text-align: left;"&gt;Includes shares owned by BioTime and Asterias.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; text-indent: 36pt;"&gt;All material intercompany accounts and transactions have been eliminated in consolidation. The consolidated financial statements are presented in accordance with GAAP and with the accounting and reporting requirements of SEC Regulation S-X. As of March 31, 2015, BioTime consolidated Asterias, ReCyte Therapeutics, OncoCyte, OrthoCyte, ESI, Cell Cure Neurosciences, BioTime Asia, Limited (&amp;#8220;BioTime Asia&amp;#8221;), LifeMap Sciences, LifeMap Sciences, Ltd., and LifeMap Solutions, Inc. as BioTime has the ability to control their operating and financial decisions and policies through its ownership, and the non-controlling interest is reflected as a separate element of shareholders' equity on BioTime&amp;#8217;s consolidated balance sheets.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; text-indent: 36pt;"&gt;&lt;font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;"&gt;Liquidity&lt;/font&gt; &amp;#8211; Since inception, BioTime has incurred significant operating losses and has funded its operations primarily through the issuance of equity securities, payments from research grants, royalties from product sales and sales of research products and services. At March 31, 2015, BioTime had an accumulated deficit of $192,357,575, working capital of $20,341,461 and shareholders&amp;#8217; equity of $57,511,784. BioTime has evaluated its projected cash flows for it and its subsidiaries and believes that its cash and cash equivalents of $25,829,533 as of March 31, 2015, will be sufficient to fund its operations at least through 2015. However, clinical trials being conducted by BioTime&amp;#8217;s subsidiaries, Asterias and Cell Cure Neurosciences will be funded in part with funds from grants and not from cash on hand. If Asterias or Cell Cure Neurosciences were to lose its grant funding it may be required to delay, postpone, or cancel its clinical trials or limit the number of clinical trial sites, or otherwise reduce or curtail its operations unless it is able to obtain from another source adequate financing that could be used for its clinical trial.&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; text-indent: 36pt;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; text-indent: 36pt;"&gt;&lt;font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;"&gt;Certain significant risks and uncertainties&lt;/font&gt; &amp;#8211; The operations of BioTime and its subsidiaries are subject to a number of factors that can affect their operating results and financial condition. Such factors include but are not limited to, the following: the results of clinical trials of their respective therapeutic product and medical device candidates; their ability to obtain FDA and foreign regulatory approval to market their respective therapeutic and medical device product candidates; their ability to develop new stem cell research products and technologies; competition from products manufactured and sold or being developed by other companies; the price and demand for their products; their ability to obtain additional financing and the terms of any such financing that may be obtained; their ability to negotiate favorable licensing or other manufacturing and marketing agreements for their products; the availability of ingredients used in their products; and the availability of reimbursement for the cost of their therapeutic and diagnostic products and medical devices (and related treatment) from government health administration authorities, private health coverage insurers, and other organizations.&lt;/div&gt;&lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
  <!--Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax-->
  <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c20140101to20140331" unitRef="U002" decimals="0">-107240</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
  <!--Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax-->
  <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c20150101to20150331" unitRef="U002" decimals="0">-53167</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
  <!--Other Assets, Noncurrent-->
  <us-gaap:OtherAssetsNoncurrent contextRef="c20150331" unitRef="U002" decimals="0">7916</us-gaap:OtherAssetsNoncurrent>
  <!--Other Assets, Noncurrent-->
  <us-gaap:OtherAssetsNoncurrent contextRef="c20141231" unitRef="U002" decimals="0">9985</us-gaap:OtherAssetsNoncurrent>
  <!--Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss) Arising During Period, Net of Tax-->
  <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax contextRef="c20140101to20140331" unitRef="U002" decimals="0">-104590</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
  <!--Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss) Arising During Period, Net of Tax-->
  <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax contextRef="c20150101to20150331" unitRef="U002" decimals="0">-53323</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
  <!--Other Comprehensive Income (Loss), Unrealized Holding Gain (Loss) on Securities Arising During Period, Net of Tax-->
  <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="c20140101to20140331" unitRef="U002" decimals="0">-2650</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
  <!--Other Comprehensive Income (Loss), Unrealized Holding Gain (Loss) on Securities Arising During Period, Net of Tax-->
  <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="c20150101to20150331" unitRef="U002" decimals="0">338</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
  <!--Other income/(expense), net-->
  <us-gaap:OtherNonoperatingIncome contextRef="c20150101to20150331" unitRef="U002" decimals="0">-239453</us-gaap:OtherNonoperatingIncome>
  <!--Other income/(expense), net-->
  <us-gaap:OtherNonoperatingIncome contextRef="c20140101to20140331" unitRef="U002" decimals="0">69170</us-gaap:OtherNonoperatingIncome>
  <!--Other Liabilities, Noncurrent-->
  <us-gaap:OtherLiabilitiesNoncurrent contextRef="c20141231" unitRef="U002" decimals="0">27961</us-gaap:OtherLiabilitiesNoncurrent>
  <!--Other Liabilities, Noncurrent-->
  <us-gaap:OtherLiabilitiesNoncurrent contextRef="c20150331" unitRef="U002" decimals="0">38119</us-gaap:OtherLiabilitiesNoncurrent>
  <!--Other Inventory, Materials, Supplies and Merchandise under Consignment, Gross-->
  <us-gaap:OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment contextRef="c20150331" unitRef="U002" decimals="0">12795</us-gaap:OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment>
  <!--Other Inventory, Materials, Supplies and Merchandise under Consignment, Gross-->
  <us-gaap:OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment contextRef="c20141231" unitRef="U002" decimals="0">12795</us-gaap:OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment>
  <!--Other Accrued Liabilities, Current-->
  <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="c20150331" unitRef="U002" decimals="0">282251</us-gaap:OtherAccruedLiabilitiesCurrent>
  <!--Other Accrued Liabilities, Current-->
  <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="c20141231" unitRef="U002" decimals="0">417316</us-gaap:OtherAccruedLiabilitiesCurrent>
  <!--COMPREHENSIVE LOSS ATTRIBUTABLE TO BIOTIME, INC. COMMON SHAREHOLDERS-->
  <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest contextRef="c20140101to20140331" unitRef="U002" decimals="0">-8206254</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest>
  <!--COMPREHENSIVE LOSS ATTRIBUTABLE TO BIOTIME, INC. COMMON SHAREHOLDERS-->
  <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest contextRef="c20150101to20150331" unitRef="U002" decimals="0">-10220353</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest>
  <!--Payments for Rent-->
  <us-gaap:PaymentsForRent contextRef="c20150101to20150331" unitRef="U002" decimals="0">5050</us-gaap:PaymentsForRent>
  <!--Payments for Capital Improvements-->
  <us-gaap:PaymentsForCapitalImprovements contextRef="c20140101to20140331" unitRef="U002" decimals="0">0</us-gaap:PaymentsForCapitalImprovements>
  <!--Payments for Capital Improvements-->
  <us-gaap:PaymentsForCapitalImprovements contextRef="c20150101to20150331" unitRef="U002" decimals="0">296382</us-gaap:PaymentsForCapitalImprovements>
  <!--Payments to Acquire Property, Plant, and Equipment-->
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c20140101to20140331" unitRef="U002" decimals="0">231921</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <!--Payments to Acquire Property, Plant, and Equipment-->
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c20150101to20150331" unitRef="U002" decimals="0">77007</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <!--Series A Convertible Preferred Shares, par value (in dollars per share)-->
  <us-gaap:PreferredStockNoParValue contextRef="c20150331" unitRef="U003" decimals="INF">0</us-gaap:PreferredStockNoParValue>
  <!--Series A Convertible Preferred Shares, par value (in dollars per share)-->
  <us-gaap:PreferredStockNoParValue contextRef="c20141231" unitRef="U003" decimals="INF">0</us-gaap:PreferredStockNoParValue>
  <!--Preferred stock dividend rate (in hundredths)-Series A Preferred Stock [Member]-->
  <us-gaap:PreferredStockDividendRatePercentage contextRef="c20150101to20150331_StatementClassOfStockAxis_SeriesAPreferredStockMember" unitRef="U004" decimals="INF">0.03</us-gaap:PreferredStockDividendRatePercentage>
  <!--Series A Convertible Preferred shares, no par value, authorized 2,000,000 shares as of March 31, 2015 and December 31, 2014; 70,000 issued and outstanding as of March 31, 2015 and December 31, 2014-->
  <us-gaap:PreferredStockValue contextRef="c20141231" unitRef="U002" decimals="0">3500000</us-gaap:PreferredStockValue>
  <!--Series A Convertible Preferred shares, no par value, authorized 2,000,000 shares as of March 31, 2015 and December 31, 2014; 70,000 issued and outstanding as of March 31, 2015 and December 31, 2014-->
  <us-gaap:PreferredStockValue contextRef="c20150331" unitRef="U002" decimals="0">3500000</us-gaap:PreferredStockValue>
  <!--Series A Convertible Preferred Shares, issued (in shares)-->
  <us-gaap:PreferredStockSharesIssued contextRef="c20141231" unitRef="U001" decimals="0">70000</us-gaap:PreferredStockSharesIssued>
  <!--Series A Convertible Preferred Shares, issued (in shares)-->
  <us-gaap:PreferredStockSharesIssued contextRef="c20150331" unitRef="U001" decimals="0">70000</us-gaap:PreferredStockSharesIssued>
  <!--Series A Convertible Preferred Shares, authorized (in shares)-->
  <us-gaap:PreferredStockSharesAuthorized contextRef="c20141231" unitRef="U001" decimals="0">2000000</us-gaap:PreferredStockSharesAuthorized>
  <!--Series A Convertible Preferred Shares, authorized (in shares)-->
  <us-gaap:PreferredStockSharesAuthorized contextRef="c20150331" unitRef="U001" decimals="0">2000000</us-gaap:PreferredStockSharesAuthorized>
  <!--Preferred share dividend (in dollars per shares)-Series A Preferred Stock [Member]-->
  <us-gaap:PreferredStockDividendRatePerDollarAmount contextRef="c20150101to20150331_StatementClassOfStockAxis_SeriesAPreferredStockMember" unitRef="U003" decimals="INF">1.50</us-gaap:PreferredStockDividendRatePerDollarAmount>
  <!--Series A Convertible Preferred shares outstanding (in shares)-->
  <us-gaap:PreferredStockSharesOutstanding contextRef="c20150331" unitRef="U001" decimals="0">70000</us-gaap:PreferredStockSharesOutstanding>
  <!--Series A Convertible Preferred shares outstanding (in shares)-->
  <us-gaap:PreferredStockSharesOutstanding contextRef="c20141231" unitRef="U001" decimals="0">70000</us-gaap:PreferredStockSharesOutstanding>
  <!--Series A Convertible Preferred shares outstanding (in shares)-Series A Preferred Stock [Member]-->
  <us-gaap:PreferredStockSharesOutstanding contextRef="c20150331_StatementClassOfStockAxis_SeriesAPreferredStockMember" unitRef="U001" decimals="0">70000</us-gaap:PreferredStockSharesOutstanding>
  <!--Prepaid expenses and other current assets-->
  <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c20150331" unitRef="U002" decimals="0">1271895</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
  <!--Prepaid expenses and other current assets-->
  <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c20141231" unitRef="U002" decimals="0">1231789</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
  <!--Reclassification, Policy [Policy Text Block]-->
  <us-gaap:PriorPeriodReclassificationAdjustmentDescription contextRef="c20150101to20150331">&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; text-indent: 36pt;"&gt;&lt;font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;"&gt;Reclassification&lt;/font&gt; &amp;#8211; Certain prior year amounts have been reclassified to conform to the current year presentation. Trade and grant receivables are now reported separately from prepaid expenses and other current assets.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:PriorPeriodReclassificationAdjustmentDescription>
  <!--Principal and accumulated interest-Cell Cure Neurosciences, Ltd. [Member]-->
  <us-gaap:ProceedsFromConvertibleDebt contextRef="c20150101to20150331_RelatedPartyTransactionsByRelatedPartyAxis_CellCureNeurosciencesLtdMember" unitRef="U002" decimals="0">470876</us-gaap:ProceedsFromConvertibleDebt>
  <!--Proceeds from sale of common shares of subsidiary-->
  <us-gaap:ProceedsFromMinorityShareholders contextRef="c20140101to20140331" unitRef="U002" decimals="0">0</us-gaap:ProceedsFromMinorityShareholders>
  <!--Proceeds from sale of common shares of subsidiary-->
  <us-gaap:ProceedsFromMinorityShareholders contextRef="c20150101to20150331" unitRef="U002" decimals="0">5499995</us-gaap:ProceedsFromMinorityShareholders>
  <!--Proceeds from sale of preferred stock-->
  <us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock contextRef="c20150101to20150331" unitRef="U002" decimals="0">0</us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock>
  <!--Proceeds from sale of preferred stock-->
  <us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock contextRef="c20140101to20140331" unitRef="U002" decimals="0">3500000</us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock>
  <!--Proceeds from issuance of common shares-->
  <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c20140101to20140331" unitRef="U002" decimals="0">8182559</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <!--Proceeds from issuance of common shares-->
  <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c20150101to20150331" unitRef="U002" decimals="0">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <!--Proceeds from issuance of common shares-Asterias Biotherapeutics [Member]-Common Class A [Member]-->
  <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c20150201to20150228_RelatedPartyTransactionAxis_CommonClassAMember_RelatedPartyTransactionsByRelatedPartyAxis_AsteriasBiotherapeuticsMember" unitRef="U002" decimals="-5">5500000</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <!--Proceeds from Stock Options Exercised-->
  <us-gaap:ProceedsFromStockOptionsExercised contextRef="c20140101to20140331" unitRef="U002" decimals="0">58500</us-gaap:ProceedsFromStockOptionsExercised>
  <!--Proceeds from Stock Options Exercised-->
  <us-gaap:ProceedsFromStockOptionsExercised contextRef="c20150101to20150331" unitRef="U002" decimals="0">346713</us-gaap:ProceedsFromStockOptionsExercised>
  <!--Proceeds from sale of BioTime stock-Asterias Biotherapeutics [Member]-BioTime Common Stock [Member]-->
  <us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesEquity contextRef="c20150101to20150331_RelatedPartyTransactionAxis_CommonStockMember_RelatedPartyTransactionsByRelatedPartyAxis_AsteriasBiotherapeuticsMember" unitRef="U002" decimals="0">12500000</us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesEquity>
  <!--Proceeds from sale of treasury stock and subsidiary warrants-->
  <us-gaap:ProceedsFromSaleOfTreasuryStock contextRef="c20140101to20140331" unitRef="U002" decimals="0">599472</us-gaap:ProceedsFromSaleOfTreasuryStock>
  <!--Proceeds from sale of treasury stock and subsidiary warrants-->
  <us-gaap:ProceedsFromSaleOfTreasuryStock contextRef="c20150101to20150331" unitRef="U002" decimals="0">0</us-gaap:ProceedsFromSaleOfTreasuryStock>
  <!--Proceeds from the sale of equipment-->
  <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment contextRef="c20150101to20150331" unitRef="U002" decimals="0">0</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
  <!--Proceeds from the sale of equipment-->
  <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment contextRef="c20140101to20140331" unitRef="U002" decimals="0">4000</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
  <!--NET LOSS-->
  <us-gaap:ProfitLoss contextRef="c20140101to20140331" unitRef="U002" decimals="0">-9728031</us-gaap:ProfitLoss>
  <!--NET LOSS-->
  <us-gaap:ProfitLoss contextRef="c20150101to20150331" unitRef="U002" decimals="0">-12590055</us-gaap:ProfitLoss>
  <!--Property, Plant and Equipment, Policy [Policy Text Block]-->
  <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="c20150101to20150331">&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; text-indent: 36pt;"&gt;&lt;font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;"&gt;Equipment, net and construction in progress&lt;/font&gt;&amp;#160;&amp;#8211; Equipment is stated at cost. Equipment and construction in progress is being depreciated using the straight-line method over a period of 36 to 120 months. Construction in progress is not depreciated until the underlying asset is placed into service. See Note 4.&lt;/div&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
  <!--Property, Plant and Equipment, Useful Life-Equipment [Member]-Minimum [Member]-->
  <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c20150101to20150331_PropertyPlantAndEquipmentByTypeAxis_EquipmentMember_RangeAxis_MinimumMember">P36M</us-gaap:PropertyPlantAndEquipmentUsefulLife>
  <!--Property, Plant and Equipment, Useful Life-Equipment [Member]-Maximum [Member]-->
  <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c20150101to20150331_PropertyPlantAndEquipmentByTypeAxis_EquipmentMember_RangeAxis_MaximumMember">P120M</us-gaap:PropertyPlantAndEquipmentUsefulLife>
  <!--Property, Plant and Equipment, Gross-->
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="c20150331" unitRef="U002" decimals="0">4928857</us-gaap:PropertyPlantAndEquipmentGross>
  <!--Property, Plant and Equipment, Gross-->
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="c20141231" unitRef="U002" decimals="0">4870516</us-gaap:PropertyPlantAndEquipmentGross>
  <!--Equipment, net and construction in progress (see Note 4)-->
  <us-gaap:PropertyPlantAndEquipmentNet contextRef="c20141231" unitRef="U002" decimals="0">2857846</us-gaap:PropertyPlantAndEquipmentNet>
  <!--Equipment, net and construction in progress (see Note 4)-->
  <us-gaap:PropertyPlantAndEquipmentNet contextRef="c20150331" unitRef="U002" decimals="0">2864669</us-gaap:PropertyPlantAndEquipmentNet>
  <!--Property, Plant and Equipment [Table Text Block]-->
  <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="c20150101to20150331">&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; text-indent: 36pt;"&gt;At March 31, 2015 and December 31, 2014, equipment, furniture and fixtures, and construction in progress were comprised of the following:&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 100%;"&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="vertical-align: bottom; white-space: nowrap; border-bottom: #000000 2px solid;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; text-align: center;"&gt;March 31, 2015&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; text-align: center;"&gt;(Unaudited)&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; text-align: center;"&gt;December 31,&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; text-align: center;"&gt;2014&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="width: 76%; vertical-align: bottom; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;"&gt;Equipment, furniture and fixtures&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;4,928,857&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;4,870,516&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="width: 76%; vertical-align: bottom; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;"&gt;Construction in progress&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;606,641&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;405,730&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="width: 76%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;"&gt;Accumulated depreciation&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;(2,670,829&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;(2,418,400&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="width: 76%; vertical-align: bottom; padding-bottom: 4px; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;"&gt;Equipment net,&amp;#160;and construction in progress&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;2,864,669&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;2,857,846&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
  <!--Property, Plant and Equipment Disclosure [Text Block]-->
  <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="c20150101to20150331">&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;div style="text-align: justify;"&gt;&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 100%;"&gt;&lt;tr&gt;&lt;td style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 18pt; vertical-align: top; font-weight: bold; align: right;"&gt;4.&lt;/td&gt;&lt;td style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: auto; vertical-align: top; font-weight: bold; text-align: justify;"&gt;Equipment, net and construction in progress&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align: justify;"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; text-indent: 36pt;"&gt;At March 31, 2015 and December 31, 2014, equipment, furniture and fixtures, and construction in progress were comprised of the following:&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 100%;"&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="vertical-align: bottom; white-space: nowrap; border-bottom: #000000 2px solid;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; text-align: center;"&gt;March 31, 2015&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; text-align: center;"&gt;(Unaudited)&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; text-align: center;"&gt;December 31,&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; text-align: center;"&gt;2014&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="width: 76%; vertical-align: bottom; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;"&gt;Equipment, furniture and fixtures&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;4,928,857&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;4,870,516&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="width: 76%; vertical-align: bottom; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;"&gt;Construction in progress&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;606,641&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;405,730&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="width: 76%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;"&gt;Accumulated depreciation&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;(2,670,829&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;(2,418,400&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="width: 76%; vertical-align: bottom; padding-bottom: 4px; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;"&gt;Equipment net,&amp;#160;and construction in progress&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;2,864,669&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;2,857,846&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="text-align: justify;"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; margin-left: 0.1pt; margin-right: 0.1pt; text-indent: 36pt;"&gt;Equipment, furniture and fixtures, and construction in progress at March 31, 2015 include $115,000 financed by capital lease borrowings in June 2014 and $606,641 of construction in progress for Asterias&amp;#8217; Fremont facility. Depreciation expense amounted to $262,600 and $256,945 for the three months ended March 31, 2015 and 2014, respectively. The difference between the depreciation expense recognized in the consolidated statement of operations and the increase in accumulated depreciation of $252,429 in the consolidated balance sheet is partially attributed to the sale of partially depreciated assets and foreign currency rates.&lt;/div&gt;&lt;div style="text-align: justify; margin-left: 0.1pt; margin-right: 0.1pt; text-indent: 36pt;"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic; text-align: justify; margin-right: 0.1pt;"&gt;Construction in progress&lt;/div&gt;&lt;div style="text-align: justify; margin-left: 0.1pt; margin-right: 0.1pt; text-indent: 36pt;"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; text-indent: 36pt;"&gt;Construction in progress of $606,641 as of March 31, 2015 entirely relates to the improvements for Asterias' Fremont facility. Under the terms of the lease agreement, the landlord has provided Asterias with a tenant improvement allowance of $4,400,000, which Asterias is using to construct a laboratory and production facility that can be used to produce human embryonic stem cell and related products under cGMP. Of the $606,641, $560,970 qualify for reimbursement under the tenant improvement allowance. As of March 31, 2015, we received $283,764 from the landlord. The facility is expected to be substantially completed and placed into service in the third quarter of 2015.&lt;/div&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
  <!--Related Party Transactions Disclosure [Text Block]-->
  <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="c20150101to20150331">&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;div style="text-align: left;"&gt;&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 100%;"&gt;&lt;tr&gt;&lt;td style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 18pt; vertical-align: top; font-weight: bold; align: right;"&gt;8.&lt;/td&gt;&lt;td style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: auto; vertical-align: top; font-weight: bold; text-align: left;"&gt;Related Party Transactions and Related Party Convertible Debt&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; text-indent: 36pt;"&gt;BioTime currently pays $5,050 per month for the use of approximately 900 square feet of office space in New York City, which is made available to BioTime on a month-by-month basis by one of its directors at his cost for use in conducting meetings and other business affairs.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; text-indent: 36pt;"&gt;In February 2015, Asterias raised approximately $5.5 million in aggregate gross proceeds from the sale of 1,410,255 shares of Series A Common Stock at a price of $3.90 per share through an underwritten public offering and a private placement. Broadwood Partners, L.P., British &amp;amp; American Investment Trust PLC and Pedro Lichtinger purchased an aggregate of 1,025,640 of the shares. Broadwood Partners, L.P. is BioTime&amp;#8217;s largest shareholder and one of its directors, Neal C. Bradsher, is President, and one of Asterias&amp;#8217; directors, Richard T. LeBuhn, is Senior Vice President, of Broadwood Capital, Inc., the investment manager of Broadwood Partners, L.P. Pedro Lichtinger is Asterias&amp;#8217; Chief Executive Officer and a member of its Board of Directors. British &amp;amp; American Investment Trust PLC is an affiliate of a stockholder of Asterias and BioTime.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; text-indent: 36pt;"&gt;In July and September 2014, Cell Cure Neurosciences issued certain convertible notes (the &amp;#8220;Convertible Notes&amp;#8221;) to two Cell Cure Neurosciences shareholders other than BioTime in the principal amount of $470,876. One of the Cell Cure Neurosciences shareholders who acquired Convertible Notes is considered a related party.&amp;#160;&amp;#160; The functional currency of Cell Cure Neurosciences is the Israeli New Shekel, however the Convertible Notes are payable in United States dollars. The Convertible Notes bear a stated interest rate of 3% per annum. The total outstanding principal balance of the Convertible Notes, with accrued interest, is due and payable on various maturity dates in July and September 2017. The outstanding principal balance of the Convertible Notes with accrued interest is convertible into Cell Cure Neurosciences ordinary shares at a fixed conversion price of $20.00 per share, at the election of the holder, at any time prior to maturity. Any conversion of the Convertible Notes must be settled with Cell Cure Neurosciences ordinary shares and not with cash. The conversion feature of the Convertible Notes is not accounted for as an embedded derivative under the provisions of ASC 815,&lt;font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;"&gt; Derivatives and Hedging&lt;/font&gt; since it is not a freestanding financial instrument and the underlying Cell Cure Neurosciences ordinary shares are not readily convertible into cash. Accordingly, the Convertible Notes are accounted for under ASC 470-20,&lt;font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;"&gt; Debt with Conversion and Other Options.&lt;/font&gt; Under ASC 470-20, BioTime determined that a beneficial conversion feature (&amp;#8220;BCF&amp;#8221;) was present on the issuance dates of the Convertible Notes.&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; text-indent: 36pt;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; text-indent: 36pt;"&gt;A conversion feature is beneficial if, on the issuance dates, the effective conversion price is less than the fair value of the issuer&amp;#8217;s capital stock. Since the effective conversion price of $20.00 per share is less than the estimated $41.00 per share fair value of Cell Cure Neurosciences ordinary shares on the dates the Convertible Notes were issued, a beneficial conversion feature equal to the intrinsic value is present. In accordance with ASC 470-20-30-8, if the intrinsic value of the BCF is greater than the proceeds allocated to the convertible instrument, the amount of the discount assigned to the BCF is limited to the amount of the proceeds allocated to the convertible instrument. The BCF is recorded as an addition to equity with a corresponding reduction to the carrying value of the convertible debt instrument. In the case of the Convertible Notes, this reduction represents a debt discount equal to the principal amount of $470,876 on the issuance dates. This debt discount will be amortized to interest expense using the effective interest method over the three-year term of the debt, representing an approximate effective annual interest rate of 23%. As of March 31, 2015, the carrying value of the Convertible Notes was $169,908, comprised of principal and accrued interest of $534,816, net of unamortized debt discount of $364,908.&lt;/div&gt;&lt;/div&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
  <!--Research and development-->
  <us-gaap:ResearchAndDevelopmentExpense contextRef="c20150101to20150331" unitRef="U002" decimals="0">9323510</us-gaap:ResearchAndDevelopmentExpense>
  <!--Research and development-->
  <us-gaap:ResearchAndDevelopmentExpense contextRef="c20140101to20140331" unitRef="U002" decimals="0">8405393</us-gaap:ResearchAndDevelopmentExpense>
  <!--Research and Development Expense, Policy [Policy Text Block]-->
  <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="c20150101to20150331">&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; text-indent: 36pt;"&gt;&lt;font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;"&gt;Research and development&lt;/font&gt; &amp;#8211; Research and development expenses consist of costs incurred for company-sponsored, collaborative and contracted research and development activities. These costs include direct and research-related overhead expenses including salaries, payroll taxes, consulting fees, research and laboratory fees, rent of research facilities, amortization of intangible assets, and license fees paid to third parties to acquire patents or licenses to use patents and other technology. BioTime expenses research and development costs as such costs are incurred.&lt;/div&gt;&lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
  <!--Accumulated deficit-->
  <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c20141231" unitRef="U002" decimals="0">-182190207</us-gaap:RetainedEarningsAccumulatedDeficit>
  <!--Accumulated deficit-->
  <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c20150331" unitRef="U002" decimals="0">-192357575</us-gaap:RetainedEarningsAccumulatedDeficit>
  <!--Accumulated deficit-Parent [Member]-->
  <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c20150331_StatementEquityComponentsAxis_ParentMember" unitRef="U002" decimals="0">-192357575</us-gaap:RetainedEarningsAccumulatedDeficit>
  <!--Grant income-->
  <us-gaap:RevenueFromGrants contextRef="c20150101to20150331" unitRef="U002" decimals="0">698839</us-gaap:RevenueFromGrants>
  <!--Grant income-->
  <us-gaap:RevenueFromGrants contextRef="c20140101to20140331" unitRef="U002" decimals="0">575659</us-gaap:RevenueFromGrants>
  <!--Grant income-California Institute of Regenerative Medicine [Member]-Asterias Biotherapeutics [Member]-Subsequent Event [Member]-->
  <us-gaap:RevenueFromGrants contextRef="c20150430to20150430_LegalEntityAxis_AsteriasBiotherapeuticsMember_MajorCustomersAxis_CaliforniaInstituteOfRegenerativeMedicineMember_SubsequentEventTypeAxis_SubsequentEventMember" unitRef="U002" decimals="0">1062023</us-gaap:RevenueFromGrants>
  <!--Revenue Recognition, Policy [Policy Text Block]-->
  <us-gaap:RevenueRecognitionPolicyTextBlock contextRef="c20150101to20150331">&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; text-indent: 36pt;"&gt;&lt;font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;"&gt;Revenue recognition&lt;/font&gt; &amp;#8211; BioTime complies with ASC 605-10 and recognizes revenue when persuasive evidence of an arrangement exists, delivery has occurred or services have been rendered, the price is fixed or determinable, and collectability is reasonably assured. Grant income and the sale of research products and services are recognized as revenue when earned. Revenues from the sale of research products and services are primarily derived from the sale of hydrogels and stem cell products. Royalty revenues consist of product royalty payments. License fee revenues consist primarily of subscription and advertising revenue from LifeMap Sciences&amp;#8217; online databases and are recognized based upon respective subscription or advertising periods. Other license fees under certain license agreements were recognized during prior periods when earned and reasonably estimable. Royalties earned on product sales are recognized as revenue in the quarter in which the royalty reports are received from the licensee, rather than the quarter in which the sales took place. When BioTime is entitled to receive up-front nonrefundable licensing or similar fees pursuant to agreements under which BioTime has no continuing performance obligations, the fees are recognized as revenues when collection is reasonably assured. When BioTime receives up-front nonrefundable licensing or similar fees pursuant to agreements under which BioTime does have continuing performance obligations, the fees are deferred and amortized ratably over the performance period. If the performance period cannot be reasonably estimated, BioTime amortizes nonrefundable fees over the life of the contract until such time that the performance period can be more reasonably estimated. Milestone payments, if any, related to scientific or technical achievements are recognized in income when the milestone is accomplished if (a) substantive effort was required to achieve the milestone, (b) the amount of the milestone payment appears reasonably commensurate with the effort expended, and (c) collection of the payment is reasonably assured.&lt;/div&gt;&lt;/div&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
  <!--Royalties from product sales-->
  <us-gaap:RoyaltyRevenue contextRef="c20150101to20150331" unitRef="U002" decimals="0">156550</us-gaap:RoyaltyRevenue>
  <!--Royalties from product sales-->
  <us-gaap:RoyaltyRevenue contextRef="c20140101to20140331" unitRef="U002" decimals="0">97886</us-gaap:RoyaltyRevenue>
  <!--Sale of stock, number of shares issued in transaction (in shares)-Asterias Biotherapeutics [Member]-Common Class A [Member]-->
  <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction contextRef="c20150201to20150228_RelatedPartyTransactionAxis_CommonClassAMember_RelatedPartyTransactionsByRelatedPartyAxis_AsteriasBiotherapeuticsMember" unitRef="U001" decimals="0">1410255</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
  <!--Sale of stock, number of shares issued in transaction (in shares)-Subsequent Event [Member]-OncoCyte Corporation [Member]-->
  <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction contextRef="c20150508to20150508_LegalEntityAxis_OncocyteCorporationMember_SubsequentEventTypeAxis_SubsequentEventMember" unitRef="U001" decimals="0">3000000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
  <!--Sale of stock, number of shares issued in transaction (in shares)-George Karfunkel [Member]-OncoCyte Corporation [Member]-Subsequent Event [Member]-->
  <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction contextRef="c20150508to20150508_LegalEntityAxis_OncocyteCorporationMember_RelatedPartyTransactionsByRelatedPartyAxis_MajorityShareholderMember_SubsequentEventTypeAxis_SubsequentEventMember" unitRef="U001" decimals="0">1000000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
  <!--Sale of stock consideration received-Subsequent Event [Member]-OncoCyte Corporation [Member]-->
  <us-gaap:SaleOfStockConsiderationReceivedPerTransaction contextRef="c20150508to20150508_LegalEntityAxis_OncocyteCorporationMember_SubsequentEventTypeAxis_SubsequentEventMember" unitRef="U002" decimals="0">3300000</us-gaap:SaleOfStockConsiderationReceivedPerTransaction>
  <!--Sale of research products and services-->
  <us-gaap:SalesRevenueGoodsNet contextRef="c20140101to20140331" unitRef="U002" decimals="0">98586</us-gaap:SalesRevenueGoodsNet>
  <!--Sale of research products and services-->
  <us-gaap:SalesRevenueGoodsNet contextRef="c20150101to20150331" unitRef="U002" decimals="0">89919</us-gaap:SalesRevenueGoodsNet>
  <!--Revenue, Net-->
  <us-gaap:SalesRevenueNet contextRef="c20150101to20150331" unitRef="U002" decimals="0">1264454</us-gaap:SalesRevenueNet>
  <!--Revenue, Net-->
  <us-gaap:SalesRevenueNet contextRef="c20140101to20140331" unitRef="U002" decimals="0">1066635</us-gaap:SalesRevenueNet>
  <!--Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]-->
  <us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock contextRef="c20150101to20150331">&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; text-indent: 36pt;"&gt;At March 31, 2015 and December 31, 2014, accounts payable and accrued liabilities consisted of the following:&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 100%;"&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="vertical-align: bottom; white-space: nowrap; border-bottom: #000000 2px solid;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; text-align: center;"&gt;March 31, 2015&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; text-align: center;"&gt;(Unaudited)&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; text-align: center;"&gt;December 31,&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; text-align: center;"&gt;2014&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="width: 76%; vertical-align: bottom; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;"&gt;Accounts payable&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;2,707,437&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;2,296,645&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="width: 76%; vertical-align: bottom; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;"&gt;Accrued expenses&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;3,092,030&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;3,125,023&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="width: 76%; vertical-align: bottom; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;"&gt;Accrued bonuses&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;240,689&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;964,189&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="width: 76%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;"&gt;Other current liabilities&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;282,251&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;417,316&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="width: 76%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;"&gt;Total&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;6,322,407&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;6,803,173&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock>
  <!--Schedule of Finite-Lived Intangible Assets [Table Text Block]-->
  <us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock contextRef="c20150101to20150331">&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; text-indent: 36pt;"&gt;At March 31, 2015 and December 31, 2014, intangible assets and intangible assets net of amortization were comprised of the following:&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 100%;"&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="vertical-align: bottom; white-space: nowrap; border-bottom: #000000 2px solid;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; text-align: center;"&gt;March 31, 2015&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; text-align: center;"&gt;(Unaudited)&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; text-align: center;"&gt;December 31,&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; text-align: center;"&gt;2014&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="width: 76%; vertical-align: bottom; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;"&gt;Intangible assets&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;52,562,549&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;52,562,549&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="width: 76%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;"&gt;Accumulated amortization&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;(15,028,247&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;(13,714,153&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="width: 76%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;"&gt;Intangible assets, net&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;37,534,302&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;38,848,396&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock>
  <!--Segment Reporting Disclosure [Text Block]-->
  <us-gaap:SegmentReportingDisclosureTextBlock contextRef="c20150101to20150331">&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;div style="text-align: left;"&gt;&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 100%;"&gt;&lt;tr&gt;&lt;td style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 18pt; vertical-align: top; font-weight: bold; align: right;"&gt;11.&lt;/td&gt;&lt;td style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: auto; vertical-align: top; font-weight: bold; text-align: left;"&gt;Segment Information&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; text-indent: 36pt;"&gt;BioTime's executive management team, as a group, represents the entity's chief operating decision makers. To date, BioTime&amp;#8217;s executive management team has viewed BioTime&amp;#8217;s operations as one segment that includes, the research and development of therapeutic products for oncology, orthopedics, retinal and neurological diseases and disorders, blood and vascular system diseases and disorders, blood plasma volume expansion, diagnostic products for the early detection of cancer, and hydrogel products that may be used in surgery, and products for human embryonic stem cell research. As a result, the financial information disclosed materially represents all of the financial information related to BioTime&amp;#8217;s sole operating segment.&lt;/div&gt;&lt;/div&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
  <!--Selling, General and Administrative Expenses, Policy [Policy Text Block]-->
  <us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock contextRef="c20150101to20150331">&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; text-indent: 36pt;"&gt;&lt;font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;"&gt;General and administrative&lt;/font&gt; - General and administrative expenses consist principally of compensation and related benefits, including stock-based compensation, for executive and corporate personnel; professional and consulting fees; and allocated overhead.&lt;/div&gt;&lt;/div&gt;</us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock>
  <!--Stock-based compensation-->
  <us-gaap:ShareBasedCompensation contextRef="c20150101to20150331" unitRef="U002" decimals="0">1914407</us-gaap:ShareBasedCompensation>
  <!--Stock-based compensation-->
  <us-gaap:ShareBasedCompensation contextRef="c20140101to20140331" unitRef="U002" decimals="0">801554</us-gaap:ShareBasedCompensation>
  <!--Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross-->
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="c20150101to20150331" unitRef="U001" decimals="0">440000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <!--Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross-->
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="c20140101to20140331" unitRef="U001" decimals="0">1205000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <!--Share Price-Asterias Biotherapeutics [Member]-Common Class A [Member]-->
  <us-gaap:SharePrice contextRef="c20150228_RelatedPartyTransactionAxis_CommonClassAMember_RelatedPartyTransactionsByRelatedPartyAxis_AsteriasBiotherapeuticsMember" unitRef="U003" decimals="2">3.90</us-gaap:SharePrice>
  <!--Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]-->
  <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="c20150101to20150331">&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; text-indent: 36pt;"&gt;&lt;font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;"&gt;Stock-based compensation&lt;/font&gt;&amp;#160;&lt;font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;"&gt;&amp;#8211;&lt;/font&gt; BioTime follows accounting standards governing share-based payments, which require the measurement and recognition of compensation expense for all share-based payment awards made to directors and employees, including employee stock options, based on estimated fair values. Consistent with FASB guidelines, BioTime utilizes the Black-Scholes Merton option pricing model for valuing share-based payment awards. BioTime's determination of fair value of share-based payment awards on the date of grant using that option-pricing model is affected by BioTime's stock price as well as by assumptions regarding a number of highly complex and subjective variables. These variables include, but are not limited to, BioTime's expected stock price volatility over the term of the awards, and actual and projected employee stock option exercise behaviors; the expected term of options granted, derived from historical data on employee exercises and post-vesting employment termination behavior; and a risk-free interest rate is based on the U.S. Treasury rates in effect during the corresponding period of grant. Although the fair value of employee stock options is determined in accordance with&amp;#160;FASB guidance, changes in the subjective assumptions can materially affect the estimated value.&lt;/div&gt;&lt;/div&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
  <!--Number of shares purchased (in shares)-Asterias Biotherapeutics [Member]-Common Class A [Member]-->
  <us-gaap:SharesIssued contextRef="c20150228_RelatedPartyTransactionAxis_CommonClassAMember_RelatedPartyTransactionsByRelatedPartyAxis_AsteriasBiotherapeuticsMember" unitRef="U001" decimals="0">1025640</us-gaap:SharesIssued>
  <!--Number of shares purchased (in shares)-BioTime Common Stock [Member]-George Karfunkel [Member]-->
  <us-gaap:SharesIssued contextRef="c20150331_RelatedPartyTransactionAxis_CommonStockMember_RelatedPartyTransactionsByRelatedPartyAxis_MajorityShareholderMember" unitRef="U001" decimals="0">4000000</us-gaap:SharesIssued>
  <!--Number of shares purchased (in shares)-Asterias Biotherapeutics [Member]-Asterias Series B Common Stock [Member]-->
  <us-gaap:SharesIssued contextRef="c20150331_RelatedPartyTransactionAxis_CommonClassBMember_RelatedPartyTransactionsByRelatedPartyAxis_AsteriasBiotherapeuticsMember" unitRef="U001" decimals="0">5000000</us-gaap:SharesIssued>
  <!--Number of shares purchased (in shares)-Broadwood Partners, LP [Member]-BioTime Common Stock [Member]-->
  <us-gaap:SharesIssued contextRef="c20150331_RelatedPartyTransactionAxis_CommonStockMember_RelatedPartyTransactionsByRelatedPartyAxis_DirectorMember" unitRef="U001" decimals="0">1000000</us-gaap:SharesIssued>
  <!--Summary of Significant Accounting Policies-->
  <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="c20150101to20150331">&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;div style="text-align: justify;"&gt;&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 100%;"&gt;&lt;tr&gt;&lt;td style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 18pt; vertical-align: top; font-weight: bold; align: right;"&gt;2.&lt;/td&gt;&lt;td style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: auto; vertical-align: top; font-weight: bold; text-align: justify;"&gt;Summary of Significant Accounting Policies&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; text-indent: 36pt;"&gt;&lt;font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;"&gt;Revenue recognition&lt;/font&gt; &amp;#8211; BioTime complies with ASC 605-10 and recognizes revenue when persuasive evidence of an arrangement exists, delivery has occurred or services have been rendered, the price is fixed or determinable, and collectability is reasonably assured. Grant income and the sale of research products and services are recognized as revenue when earned. Revenues from the sale of research products and services are primarily derived from the sale of hydrogels and stem cell products. Royalty revenues consist of product royalty payments. License fee revenues consist primarily of subscription and advertising revenue from LifeMap Sciences&amp;#8217; online databases and are recognized based upon respective subscription or advertising periods. Other license fees under certain license agreements were recognized during prior periods when earned and reasonably estimable. Royalties earned on product sales are recognized as revenue in the quarter in which the royalty reports are received from the licensee, rather than the quarter in which the sales took place. When BioTime is entitled to receive up-front nonrefundable licensing or similar fees pursuant to agreements under which BioTime has no continuing performance obligations, the fees are recognized as revenues when collection is reasonably assured. When BioTime receives up-front nonrefundable licensing or similar fees pursuant to agreements under which BioTime does have continuing performance obligations, the fees are deferred and amortized ratably over the performance period. If the performance period cannot be reasonably estimated, BioTime amortizes nonrefundable fees over the life of the contract until such time that the performance period can be more reasonably estimated. Milestone payments, if any, related to scientific or technical achievements are recognized in income when the milestone is accomplished if (a) substantive effort was required to achieve the milestone, (b) the amount of the milestone payment appears reasonably commensurate with the effort expended, and (c) collection of the payment is reasonably assured.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; text-indent: 36pt;"&gt;&lt;font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;"&gt;Cash and cash equivalents&lt;/font&gt; &amp;#8211; BioTime considers all highly liquid investments purchased with an original maturity of three months or less to be cash equivalents.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; text-indent: 36pt;"&gt;&lt;font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;"&gt;Trade accounts and grants receivable, net&lt;/font&gt; &amp;#8211; Net trade receivables amounted to approximately $605,800 and $549,300 and grants receivable amounted to approximately $260,300 and $492,600 as of March 31, 2015 and December 31, 2014, respectively. Net trade receivables include allowance for doubtful accounts of approximately $100,500 as of March 31, 2015 and December 31, 2014 for those amounts deemed uncollectible by BioTime. BioTime evaluates the collectability of its receivables based on a variety of factors, including the length of time receivables are past due and significant one-time events and historical experience. An additional reserve for individual accounts will be recorded if BioTime becomes aware of a customer&amp;#8217;s inability to meet its financial obligations, such as in the case of bankruptcy filings or deterioration in the customer&amp;#8217;s operating results or financial position. If circumstances related to customers change, estimates of the recoverability of receivables would be further adjusted.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; text-indent: 36pt;"&gt;&lt;font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;"&gt;Concentrations of credit risk&lt;/font&gt; &amp;#8211; Financial instruments that potentially subject BioTime to significant concentrations of credit risk consist primarily of cash and cash equivalents. BioTime limits the amount of credit exposure of cash balances by maintaining its accounts in high credit quality financial institutions. Cash equivalent deposits with financial institutions may occasionally exceed the limits of insurance on bank deposits; however, BioTime has not experienced any losses on such accounts.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; text-indent: 36pt;"&gt;&lt;font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;"&gt;Inventory &amp;#8211;&lt;/font&gt; Inventories are stated at the lower of cost or market. Cost, which includes amounts related to materials, labor, and overhead, is determined in a manner which approximates the first-in, first-out (&amp;#8220;FIFO&amp;#8221;) method.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; text-indent: 36pt;"&gt;&lt;font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;"&gt;Equipment, net and construction in progress&lt;/font&gt;&amp;#160;&amp;#8211; Equipment is stated at cost. Equipment and construction in progress is being depreciated using the straight-line method over a period of 36 to 120 months. Construction in progress is not depreciated until the underlying asset is placed into service. See Note 4.&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; text-indent: 36pt;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; text-indent: 36pt;"&gt;&lt;font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;"&gt;Intangible assets, net&lt;/font&gt; &amp;#8211; Intangible assets with finite useful lives are amortized over their estimated useful lives and intangible assets with indefinite lives are not amortized but rather are tested at least annually for impairment. Acquired in-process research and development intangible assets are accounted for depending on whether they were acquired as part of an acquisition of a business, or as assets that do not constitute a business. When acquired in conjunction with the acquisition of a business, these assets are considered to be indefinite-lived until the completion or abandonment of the associated research and development efforts and are capitalized as an asset. If and when development is complete, the associated assets would be deemed finite-lived and would then be amortized based on their respective estimated useful lives at that point in time. However, when acquired in conjunction with an acquisition of assets that do not constitute a business (such as the acquisition of assets by Asterias from Geron Corporation), in accordance with the accounting rules in ASC 805-50, such intangible assets related to in-process research and development (&amp;#8220;IPR&amp;amp;D&amp;#8221;) are expensed upon acquisition.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; text-indent: 36pt;"&gt;&lt;font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;"&gt;Treasury stock &amp;#8211;&lt;/font&gt; BioTime accounts for BioTime common shares issued to subsidiaries for future potential working capital needs as treasury stock on the consolidated balance sheet. BioTime has registered the BioTime common shares held by its subsidiaries for sale under the Securities Act of 1933, as amended (the &amp;#8220;Securities Act&amp;#8221;) to enhance the marketability of the shares.&lt;/div&gt;&lt;div style="text-align: justify;"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; text-indent: 36pt;"&gt;&lt;font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;"&gt;Warrants to purchase common stock&lt;/font&gt; &amp;#8211; BioTime generally accounts for warrants issued in connection with equity financings as a component of equity. None of the warrants issued by BioTime as of March 31, 2015 include a conditional obligation to issue a variable number of shares; nor was there a deemed possibility that BioTime may need to settle the warrants in cash.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; text-indent: 36pt;"&gt;&lt;font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;"&gt;Cost of sales&lt;/font&gt; &amp;#8211; BioTime accounts for the cost of research products acquired for sale and any royalties paid as a result of any revenues in accordance with the terms of the respective licensing agreements as cost of sales on the consolidated statement of operations and comprehensive loss.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; text-indent: 36pt;"&gt;&lt;font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;"&gt;Patent costs &amp;#8211;&lt;/font&gt; Costs associated with obtaining patents on products or technology developed are expensed as research and development expenses when incurred.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; text-indent: 36pt;"&gt;&lt;font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;"&gt;Reclassification&lt;/font&gt; &amp;#8211; Certain prior year amounts have been reclassified to conform to the current year presentation. Trade and grant receivables are now reported separately from prepaid expenses and other current assets.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; text-indent: 36pt;"&gt;&lt;font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;"&gt;Research and development&lt;/font&gt; &amp;#8211; Research and development expenses consist of costs incurred for company-sponsored, collaborative and contracted research and development activities. These costs include direct and research-related overhead expenses including salaries, payroll taxes, consulting fees, research and laboratory fees, rent of research facilities, amortization of intangible assets, and license fees paid to third parties to acquire patents or licenses to use patents and other technology. BioTime expenses research and development costs as such costs are incurred.&lt;/div&gt;&lt;div&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; text-indent: 36pt;"&gt;&lt;font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;"&gt;General and administrative&lt;/font&gt; - General and administrative expenses consist principally of compensation and related benefits, including stock-based compensation, for executive and corporate personnel; professional and consulting fees; and allocated overhead.&lt;/div&gt;&lt;div&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; text-indent: 36pt;"&gt;&lt;font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;"&gt;Foreign currency translation gain and other comprehensive loss, &amp;#160;foreign currency transaction gains and losses&amp;#160;&amp;#8211;&lt;/font&gt; In countries in which BioTime operates, where the functional currency is other than the U.S. dollar, assets and liabilities are translated using published exchange rates in effect at the consolidated balance sheet date. Revenues and expenses and cash flows are translated using an approximate weighted average exchange rate for the period. Resulting translation adjustments are recorded as a component of accumulated other comprehensive income or loss on the consolidated balance sheet. For the three months ended March 31, 2015 and 2014, other comprehensive loss includes losses of $52,985 and $107,240, respectively which is largely from foreign currency translation.&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 36pt;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/div&gt;&lt;div style="text-align: justify;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; text-indent: 36pt;"&gt;For transactions denominated in other than the functional currency of BioTime, transactional gains and losses are recorded in other income and expense included in the consolidated statements of operations. For the three months ended March 31, 2015 and 2014, foreign currency transaction loss amounted to $205,149 and $10,212, respectively.&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; text-indent: 36pt;"&gt;&lt;font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;"&gt;Income taxes &amp;#8211;&lt;/font&gt; BioTime accounts for income taxes in accordance with GAAP requirements, which prescribe the use of the asset and liability method, whereby deferred tax asset or liability account balances are calculated at the balance sheet date using current tax laws and rates in effect. Valuation allowances are established when necessary to reduce deferred tax assets when it is more likely than not that a portion or all of the deferred tax assets will not be realized. The FASB guidance also prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more-likely-than-not sustainable upon examination by taxing authorities. Beginning October 1, 2013, Asterias began filing separate U.S. federal income tax returns but effectively BioTime combined Asterias&amp;#8217; tax provision with BioTime&amp;#8217;s consolidated financial statements. For California, Asterias&amp;#8217; activity for 2013 and 2014 have been included in BioTime&amp;#8217;s combined tax return. BioTime recognizes accrued interest and penalties related to unrecognized tax benefits, if any,&amp;#160;as income tax expense, however, no amounts were accrued for the payment of interest and penalties as of March 31, 2015 and 2014. BioTime files a U.S. federal income tax return as well as various state and foreign income tax returns. In general, BioTime is no longer subject to tax examination by major taxing authorities for years before 2010. Although the statute is closed for purposes of assessing additional income and tax in those years, the taxing authorities may still make adjustments to the net operating loss and credit carryforwards used in open years. Therefore the statute should be considered open as it relates to the net operating loss and credit carryforwards. Any potential examinations may include questioning the timing and amount of deductions, the nexus of income among various tax jurisdictions and compliance with U.S. federal, state and local and foreign tax laws. Management does not expect that the total amount of unrecognized tax benefits will materially change over the next year.&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; text-indent: 36pt;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; text-indent: 36pt;"&gt;An income tax benefit of approximately $1,177,000 was recorded for the three months ended March 31, 2015, of which approximately $1,251,000 of the benefit was related to federal offset by adjustment of $74,000 related to state taxes. For the same period in 2014, an income tax benefit of approximately $1,349,000 was recorded , of which approximately $1,151,000 of the benefit was related to federal and $198,000 was related to state taxes.&lt;/div&gt;&lt;div&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; text-indent: 36pt;"&gt;Asterias established deferred tax liabilities primarily related to its acquisition of certain intellectual property. It is more likely than not that the Asterias deferred tax assets are fully realizable since these income tax benefits are expected to be available to offset such Asterias deferred tax liabilities.&lt;/div&gt;&lt;div&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;br /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; text-indent: 36pt;"&gt;In June 2014, Asterias sold 5,000,000 BioTime shares which resulted in a taxable gain of approximately $10.3 million and a tax payable of $3.6 million. Asterias received the BioTime shares from BioTime as part of the consideration for the Asterias common stock and warrants issued to BioTime under an Asset Contribution Agreement among BioTime, Asterias, and Geron Corporation, a tax free transaction. This income tax liability was offset by available net operating losses, resulting in no cash income taxes due from that sale. This transaction was treated as a deemed distribution by Asterias and recorded against equity.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; text-indent: 36pt;"&gt;&lt;font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;"&gt;Stock-based compensation&lt;/font&gt;&amp;#160;&lt;font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;"&gt;&amp;#8211;&lt;/font&gt; BioTime follows accounting standards governing share-based payments, which require the measurement and recognition of compensation expense for all share-based payment awards made to directors and employees, including employee stock options, based on estimated fair values. Consistent with FASB guidelines, BioTime utilizes the Black-Scholes Merton option pricing model for valuing share-based payment awards. BioTime's determination of fair value of share-based payment awards on the date of grant using that option-pricing model is affected by BioTime's stock price as well as by assumptions regarding a number of highly complex and subjective variables. These variables include, but are not limited to, BioTime's expected stock price volatility over the term of the awards, and actual and projected employee stock option exercise behaviors; the expected term of options granted, derived from historical data on employee exercises and post-vesting employment termination behavior; and a risk-free interest rate is based on the U.S. Treasury rates in effect during the corresponding period of grant. Although the fair value of employee stock options is determined in accordance with&amp;#160;FASB guidance, changes in the subjective assumptions can materially affect the estimated value.&lt;/div&gt;&lt;div style="text-align: justify;"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; text-indent: 36pt;"&gt;&lt;font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;"&gt;Impairment of long-lived assets&lt;/font&gt;&amp;#160;&lt;font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;"&gt;&amp;#8211;&lt;/font&gt; BioTime&amp;#8217;s long-lived assets, including intangible assets, are reviewed annually for impairment and whenever events or changes in circumstances indicate that the carrying amount of an asset may not be fully recoverable. If an impairment indicator is present, BioTime will evaluate recoverability by a comparison of the carrying amount of the assets to future undiscounted net cash flows expected to be generated by the assets. If the assets are impaired, the impairment recognized is measured by the amount by which the carrying amount exceeds the estimated fair value of the assets.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; text-indent: 36pt;"&gt;&lt;font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;"&gt;Deferred license and consulting fees&lt;/font&gt; &amp;#8211; Deferred license and consulting fees consist of the value of warrants issued to third parties for services, and deferred license fees paid to acquire rights to use the proprietary technologies of third parties. The value of the warrants is being amortized over the period the services are being provided, and the license fees are being amortized over the estimated useful lives of the licensed technologies or licensed research products. BioTime is applying a 10 year estimated useful life to the technologies and products that it is currently licensing. The estimation of the useful life any technology or product involves a significant degree of inherent uncertainty, since the outcome of research and development or the commercial life of a new product cannot be known with certainty at the time that the right to use the technology or product is acquired. BioTime will review the continued appropriateness of the 10 year estimated useful life for impairments that might occur earlier than the original expected useful lives. BioTime will review its amortization schedules for impairments that might occur earlier than the original expected useful lives. See Note 6.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; text-indent: 36pt;"&gt;&lt;font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;"&gt;Loss per share&lt;/font&gt; &amp;#8211; BioTime applies the two-class method for calculating basic earnings per share. Under the two-class method, net income, if any, will be reduced by preferred stock dividends and the residual amount is allocated between common stock and other participating securities based on their participation rights. Participating securities are comprised of Series A convertible preferred stock and participate in dividends, whether declared or not. Basic earnings per share is calculated by dividing net income or loss attributable to BioTime common shareholders by the weighted average number of shares of common stock outstanding, net of unvested restricted stock subject to repurchase by BioTime, if any, during the period. For periods in which BioTime reported a net loss, the participating securities are not contractually obligated to share in the losses of BioTime, and accordingly, no losses have been allocated to the participating securities. Diluted earnings per share is calculated by dividing the net income or loss attributable to BioTime common shareholders by the weighted average number of common shares outstanding, adjusted for the effects of potentially dilutive common stock, which are comprised of stock options and warrants, using the treasury-stock method, and convertible preferred stock, using the if-converted method. Because BioTime reported losses attributable to common stockholders for all periods presented, all potentially dilutive common stock are antidilutive for those periods. Diluted net loss per share for the three months ended March 31, 2015 and 2014 excludes any effect from 4,893,942 treasury shares, 4,266,605 options and 9,194,679 warrants and 10,546,137 treasury shares, 5,491,301 options and 9,751,615 warrants, respectively, because their inclusion would be antidilutive.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; text-indent: 36pt;"&gt;&lt;font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;"&gt;Fair value of financial instruments&lt;/font&gt; &amp;#8211; The fair value of BioTime&amp;#8217;s assets and liabilities, which qualify as financial instruments under FASB guidance regarding disclosures about fair value of financial instruments, approximate the carrying amounts presented in the accompanying consolidated balance sheets. The carrying amounts of cash equivalents, accounts receivable, prepaid expenses and other current assets, accounts payable, accrued expenses and other current liabilities approximate fair values because of the short-term nature of these items.&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; text-indent: 36pt;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; font-style: italic; text-align: justify; text-indent: 36pt;"&gt;&lt;font style="font-weight: normal;"&gt;Recently Issued Accounting Pronouncements &amp;#8211; &lt;/font&gt;&lt;font style="font-weight: normal; font-style: normal;"&gt;There have been no recent accounting pronouncements or changes in accounting pronouncments during the three months ended March 31, 2015, as compared to the recent accounting pronouncements described in the Comany's 2014 Annual Report on Form 10-K that are of significance or potential significance to the Company.&lt;/font&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; text-indent: 36pt;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
  <!--Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period-->
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="c20150101to20150331" unitRef="U001" decimals="0">89077</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <!--Stockholders' Equity Attributable to Parent-->
  <us-gaap:StockholdersEquity contextRef="c20150331" unitRef="U002" decimals="0">26250404</us-gaap:StockholdersEquity>
  <!--Stockholders' Equity Attributable to Parent-->
  <us-gaap:StockholdersEquity contextRef="c20141231" unitRef="U002" decimals="0">36455983</us-gaap:StockholdersEquity>
  <!--Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest-->
  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c20141231" unitRef="U002" decimals="0">62722765</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
  <!--Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest-->
  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c20150331" unitRef="U002" decimals="0">57511784</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
  <!--Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest-Parent [Member]-->
  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c20150331_StatementEquityComponentsAxis_ParentMember" unitRef="U002" decimals="0">57511784</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
  <!--Stockholders' Equity Note Disclosure [Text Block]-->
  <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="c20150101to20150331">&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;div style="text-align: justify;"&gt;&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 100%;"&gt;&lt;tr&gt;&lt;td style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 18pt; vertical-align: top; font-weight: bold; align: right;"&gt;9.&lt;/td&gt;&lt;td style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: auto; vertical-align: top; font-weight: bold; text-align: justify;"&gt;Shareholders' Equity&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic; text-align: justify;"&gt;Preferred Shares&lt;/div&gt;&lt;div style="text-align: justify;"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; text-indent: 36pt;"&gt;BioTime is authorized to issue 2,000,000 shares of preferred stock. The preferred shares may be issued in one or more series as the board of directors may by resolution determine. The board of directors is authorized to fix the number of shares of any series of preferred shares and to determine or alter the rights, preferences, privileges, and restrictions granted to or imposed on the preferred shares as a class, or upon any wholly unissued series of any preferred shares. The board of directors may, by resolution, increase or decrease (but not below the number of shares of such series then outstanding) the number of shares of any series of preferred shares subsequent to the issue of shares of that series.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; text-indent: 36pt;"&gt;As of March 31, 2015, BioTime had 70,000 outstanding shares of Series A Convertible Preferred Stock (&amp;#8220;Series A Preferred Stock&amp;#8221;). The Series A Preferred Stock carries a cumulative annual 3% preferred dividend or $1.50 per share, in preference to BioTime common shares. Each share of Series A Preferred Stock is convertible, at the election of the holder, into BioTime common shares at a conversion price of $4.00 per share, a current conversion ratio of 12.5 common shares for each share of Series A Preferred Stock.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; text-indent: 36pt;"&gt;In addition to the preferred dividend, the Series A Preferred Stock will be entitled to participate with BioTime common shares in any dividends or distributions on common shares (other than dividends and distributions of common shares resulting in an adjustment of the conversion price) as if all shares of Series A Preferred Stock were then converted into common shares.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; text-indent: 36pt;"&gt;All outstanding Series A Preferred Stock will automatically be converted into common shares on March 4, 2019, or if holders of a majority of the outstanding shares of Series A Preferred Stock, voting as a class, approve or consent to a conversion. The conversion price is subject to prorata adjustment in the event of a subdivision or reclassification of the common shares into a greater number of shares, a stock dividend paid in common shares, or a stock combination or reclassification of the common shares into a smaller number of shares.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; text-indent: 36pt;"&gt;The Series A Preferred Stock will be entitled to vote with common shares on all matters submitted to common shareholders for approval. Each share of Series A Preferred Stock will be entitled to a number of votes equal to the number of common shares into which it could then be converted. The Series A Preferred Stock will also vote as a separate class on certain matters affecting those shares.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; text-indent: 36pt;"&gt;In the event of a liquidation or dissolution of BioTime, holders of Series A Preferred Stock will be entitled to receive payment of any accrued but unpaid preferred dividends before any assets may be distributed to holders of common shares. After payment of the accrued dividends, the Series A Preferred Stock will participate with the common shares in the distribution of any assets available to shareholders, as if the Series A Preferred Stock was then converted into common shares.&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; text-indent: 36pt;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic; text-align: justify;"&gt;Common Shares&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; text-indent: 36pt;"&gt;BioTime is authorized to issue 125,000,000 common shares with no par value. As of March 31, 2015, BioTime had 83,210,775 issued and 78,316,833 outstanding common shares. As of December 31, 2014, BioTime had 83,121,698 issued and 78,227,756 outstanding common shares. The difference of 4,893,942 common shares as of March 31, 2015 and December 31, 2014 is attributed to shares held by BioTime subsidiaries which are accounted for as treasury stock on the condensed consolidated balance sheet.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; text-indent: 36pt;"&gt;During the three months ended March 31, 2015 and 2014, BioTime granted 440,000 and 1,205,000 options, respectively, under its 2012 Equity Incentive Plan.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; text-indent: 36pt;"&gt;During the three months ended March 31, 2015, 89,077 options and no warrants were exercised.&lt;/div&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
  <!--Subsequent Events [Text Block]-->
  <us-gaap:SubsequentEventsTextBlock contextRef="c20150101to20150331">&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;div style="text-align: justify;"&gt;&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 100%;"&gt;&lt;tr&gt;&lt;td style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 18pt; vertical-align: top; font-weight: bold; align: right;"&gt;12.&lt;/td&gt;&lt;td style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: auto; vertical-align: top; font-weight: bold; text-align: justify;"&gt;Subsequent Events&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; text-indent: 36pt;"&gt;In April 2015, Asterias received $1,062,023 from the California Institute for Regenerative Medicine as quarterly installment payment of a $14.3 million research grant awarded during 2014.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; text-indent: 36pt;"&gt;On May 8, 2015, OncoCyte Corporation&amp;#160;accepted subscriptions for&amp;#160;3,000,000 shares of its common stock to two for $3,300,000 in cash from two of its shareholders, including&amp;#160;a subscription for 1,000,000 shares&amp;#160;from George Karfunkel, a beneficial owner of more than 5% of the outstanding common shares of BioTime. Concurrently, BioTime purchased&amp;#160;3,000,000 shares of OncoCyte common stock in exchange for the cancelation of $3,300,000 of indebtedness owed to BioTime by OncoCyte, and OncoCyte delivered to BioTime a convertible promissory note (the &amp;#8220;Note&amp;#8221;) for an additional $3,300,000 of OncoCyte&amp;#8217;s indebtedness to BioTime. The Note will bear interest at the rate of 1% per annum and will mature and be payable on November 30, 2016. BioTime will have the right to convert the principal amount of the Note plus accrued interest into shares of OncoCyte common stock at a conversion price of $1.10 per share commencing on the earliest of November 8, 2016, or six months after OncoCyte completes an initial underwritten public offering of its common stock, or upon the occurrence of an &amp;#8220;Event of Default&amp;#8221; as defined in the Note. An Event of Default includes a failure of OncoCyte to pay any amount due on the Note or the commencement of bankruptcy proceedings by or against OncoCyte or the occurrence of certain insolvency related events, the dissolution or liquidation of OncoCyte, or any material breach or default by OncoCyte under any loan agreement, promissory note, or other instrument evidencing indebtedness payable to a third party. The conversion price is subject to pro rata adjustment in the event of a stock split, combination, reclassification, or similar event.&lt;/div&gt;&lt;/div&gt;</us-gaap:SubsequentEventsTextBlock>
  <!--Trade accounts and grants receivable, net-->
  <us-gaap:TradeAndOtherAccountsReceivablePolicy contextRef="c20150101to20150331">&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; text-indent: 36pt;"&gt;&lt;font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;"&gt;Trade accounts and grants receivable, net&lt;/font&gt; &amp;#8211; Net trade receivables amounted to approximately $605,800 and $549,300 and grants receivable amounted to approximately $260,300 and $492,600 as of March 31, 2015 and December 31, 2014, respectively. Net trade receivables include allowance for doubtful accounts of approximately $100,500 as of March 31, 2015 and December 31, 2014 for those amounts deemed uncollectible by BioTime. BioTime evaluates the collectability of its receivables based on a variety of factors, including the length of time receivables are past due and significant one-time events and historical experience. An additional reserve for individual accounts will be recorded if BioTime becomes aware of a customer&amp;#8217;s inability to meet its financial obligations, such as in the case of bankruptcy filings or deterioration in the customer&amp;#8217;s operating results or financial position. If circumstances related to customers change, estimates of the recoverability of receivables would be further adjusted.&lt;/div&gt;&lt;/div&gt;</us-gaap:TradeAndOtherAccountsReceivablePolicy>
  <!--Treasury stock (in shares)-->
  <us-gaap:TreasuryStockShares contextRef="c20141231" unitRef="U001" decimals="0">4893942</us-gaap:TreasuryStockShares>
  <!--Treasury stock (in shares)-->
  <us-gaap:TreasuryStockShares contextRef="c20150331" unitRef="U001" decimals="0">4893942</us-gaap:TreasuryStockShares>
  <!--Treasury Stock, Value-->
  <us-gaap:TreasuryStockValue contextRef="c20150331" unitRef="U002" decimals="0">19889788</us-gaap:TreasuryStockValue>
  <!--Treasury Stock, Value-->
  <us-gaap:TreasuryStockValue contextRef="c20141231" unitRef="U002" decimals="0">19889788</us-gaap:TreasuryStockValue>
  <!--Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued-->
  <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued contextRef="c20140331" unitRef="U002" decimals="0">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
  <!--Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued-->
  <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued contextRef="c20150331" unitRef="U002" decimals="0">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
  <!--Weighted Average Number of Shares Outstanding, Basic and Diluted-->
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="c20150101to20150331" unitRef="U001" decimals="0">78261788</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <!--Weighted Average Number of Shares Outstanding, Basic and Diluted-->
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="c20140101to20140331" unitRef="U001" decimals="0">58257427</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <!--Schedule Of Expected Amortization Deferred License Expense [Table Text Block]-->
  <btx:ScheduleOfExpectedAmortizationDeferredLicenseExpenseTableTextBlock contextRef="c20150101to20150331">&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; text-indent: 36pt;"&gt;As of March 31, 2015, future amortization of deferred license fees described above was as follows:&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;table align="center" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 50%;"&gt;&lt;tr&gt;&lt;td valign="bottom" style="width: 38%; vertical-align: bottom; border-bottom: #000000 2px solid;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; text-align: center;"&gt;Year Ended December 31,&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 10%; vertical-align: bottom; border-bottom: #000000 2px solid;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; text-align: center;"&gt;Deferred&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; text-align: center;"&gt;License Fees&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="width: 38%; vertical-align: bottom; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;"&gt;2015&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 10%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;"&gt;$82,125&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 16px;"&gt;&lt;td valign="bottom" style="width: 38%; vertical-align: bottom; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;"&gt;2016&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 10%; vertical-align: bottom; text-align: center; background-color: #ffffff;"&gt;&amp;#160;109,500&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="width: 38%; vertical-align: bottom; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;"&gt;2017&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 10%; vertical-align: bottom; text-align: center; background-color: #cceeff;"&gt;&amp;#160;109,500&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="width: 38%; vertical-align: bottom; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;"&gt;2018&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 10%; vertical-align: bottom; text-align: center; background-color: #ffffff;"&gt;&amp;#160;73,667&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="width: 38%; vertical-align: bottom; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;"&gt;2019&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 10%; vertical-align: bottom; text-align: center; background-color: #cceeff;"&gt;&amp;#160;24,083&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="width: 38%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;"&gt;Thereafter&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 10%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: center; background-color: #ffffff;"&gt;&amp;#160;20,083&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="width: 38%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;"&gt;Total&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 10%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;"&gt;$418,958&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</btx:ScheduleOfExpectedAmortizationDeferredLicenseExpenseTableTextBlock>
  <!--Deferred license and consulting fees classified as noncurrent-->
  <btx:DeferredLicenseAndConsultingFeesClassifiedAsNoncurrent contextRef="c20150331" unitRef="U002" decimals="0">309458</btx:DeferredLicenseAndConsultingFeesClassifiedAsNoncurrent>
  <!--Prepaid expenses in other current Assets-->
  <btx:PrepaidExpensesInOtherCurrentAssets contextRef="c20150331" unitRef="U002" decimals="0">109500</btx:PrepaidExpensesInOtherCurrentAssets>
  <!--Deferred License Fees Amortization Expense Year Two-->
  <btx:DeferredLicenseFeesAmortizationExpenseYearTwo contextRef="c20150331" unitRef="U002" decimals="0">109500</btx:DeferredLicenseFeesAmortizationExpenseYearTwo>
  <!--Deferred License Fees Amortization Expense Year Three-->
  <btx:DeferredLicenseFeesAmortizationExpenseYearThree contextRef="c20150331" unitRef="U002" decimals="0">109500</btx:DeferredLicenseFeesAmortizationExpenseYearThree>
  <!--Deferred License Fees Amortization Expense Due In Remainder Of Fiscal Year-->
  <btx:DeferredLicenseFeesAmortizationExpenseDueInRemainderOfFiscalYear contextRef="c20150331" unitRef="U002" decimals="0">82125</btx:DeferredLicenseFeesAmortizationExpenseDueInRemainderOfFiscalYear>
  <!--Deferred License Fees Amortization Expense After Year Five-->
  <btx:DeferredLicenseFeesAmortizationExpenseAfterYearFive contextRef="c20150331" unitRef="U002" decimals="0">20083</btx:DeferredLicenseFeesAmortizationExpenseAfterYearFive>
  <!--Deferred License Fees Amortization Expense Year Four-->
  <btx:DeferredLicenseFeesAmortizationExpenseYearFour contextRef="c20150331" unitRef="U002" decimals="0">73667</btx:DeferredLicenseFeesAmortizationExpenseYearFour>
  <!--Deferred License Fees Amortization Expense Year Five-->
  <btx:DeferredLicenseFeesAmortizationExpenseYearFive contextRef="c20150331" unitRef="U002" decimals="0">24083</btx:DeferredLicenseFeesAmortizationExpenseYearFive>
  <!--Treasury stock [Policy Text Block]-->
  <btx:TreasuryStockPolicyTextBlock contextRef="c20150101to20150331">&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; text-indent: 36pt;"&gt;&lt;font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;"&gt;Treasury stock &amp;#8211;&lt;/font&gt; BioTime accounts for BioTime common shares issued to subsidiaries for future potential working capital needs as treasury stock on the consolidated balance sheet. BioTime has registered the BioTime common shares held by its subsidiaries for sale under the Securities Act of 1933, as amended (the &amp;#8220;Securities Act&amp;#8221;) to enhance the marketability of the shares.&lt;/div&gt;&lt;/div&gt;</btx:TreasuryStockPolicyTextBlock>
  <!--Warrants to purchase common stock [Policy Text Block]-->
  <btx:WarrantsToPurchaseCommonStockPolicyTextBlock contextRef="c20150101to20150331">&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; text-indent: 36pt;"&gt;&lt;font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;"&gt;Warrants to purchase common stock&lt;/font&gt; &amp;#8211; BioTime generally accounts for warrants issued in connection with equity financings as a component of equity. None of the warrants issued by BioTime as of March 31, 2015 include a conditional obligation to issue a variable number of shares; nor was there a deemed possibility that BioTime may need to settle the warrants in cash.&lt;/div&gt;&lt;/div&gt;</btx:WarrantsToPurchaseCommonStockPolicyTextBlock>
  <!--Tax payable on sale of subsidiary shares-->
  <btx:TaxPayableOnSaleOfSubsidiaryShares contextRef="c20140630" unitRef="U002" decimals="-5">3600000</btx:TaxPayableOnSaleOfSubsidiaryShares>
  <!--Taxable Gain On Sale Of Subsidiary Shares-->
  <btx:TaxableGainOnSaleOfSubsidiaryShares contextRef="c20140630" unitRef="U002" decimals="-5">10300000</btx:TaxableGainOnSaleOfSubsidiaryShares>
  <!--Estimated fair market value-Cell Cure Neurosciences, Ltd. [Member]-->
  <btx:EstimatedFairMarketValue contextRef="c20150101to20150331_RelatedPartyTransactionsByRelatedPartyAxis_CellCureNeurosciencesLtdMember" unitRef="U003" decimals="2">41.00</btx:EstimatedFairMarketValue>
  <!--Number of Cell Cure Neurosciences investors-Cell Cure Neurosciences, Ltd. [Member]-->
  <btx:NumberOfCellCureNeurosciencesInvestors contextRef="c20150101to20150331_RelatedPartyTransactionsByRelatedPartyAxis_CellCureNeurosciencesLtdMember" unitRef="U006" decimals="INF">2</btx:NumberOfCellCureNeurosciencesInvestors>
  <!--Preferred shares, Convertible, Conversion Ratio-Series A Preferred Stock [Member]-->
  <btx:PreferredSharesConvertibleConversionRatio contextRef="c20150101to20150331_StatementClassOfStockAxis_SeriesAPreferredStockMember" unitRef="U004" decimals="1">12.5</btx:PreferredSharesConvertibleConversionRatio>
  <!--Share conversion price (in dollars per share)-Series A Preferred Stock [Member]-->
  <btx:PricePerShareOfOptionsToPurchaseCompany contextRef="c20150331_StatementClassOfStockAxis_SeriesAPreferredStockMember" unitRef="U003" decimals="INF">4.00</btx:PricePerShareOfOptionsToPurchaseCompany>
  <!--Warrants exercised-->
  <btx:WarrantsExercised contextRef="c20150101to20150331" unitRef="U001" decimals="0">0</btx:WarrantsExercised>
  <!--Related party convertible debt, net of discount-->
  <btx:RelatedPartyConvertibleDebtNetOfDiscount contextRef="c20141231" unitRef="U002" decimals="0">60237</btx:RelatedPartyConvertibleDebtNetOfDiscount>
  <!--Related party convertible debt, net of discount-->
  <btx:RelatedPartyConvertibleDebtNetOfDiscount contextRef="c20150331" unitRef="U002" decimals="0">169908</btx:RelatedPartyConvertibleDebtNetOfDiscount>
  <!--Trade accounts and grants receivable net current-->
  <btx:TradeAccountsAndGrantsReceivableNetCurrent contextRef="c20150331" unitRef="U002" decimals="0">866180</btx:TradeAccountsAndGrantsReceivableNetCurrent>
  <!--Trade accounts and grants receivable net current-->
  <btx:TradeAccountsAndGrantsReceivableNetCurrent contextRef="c20141231" unitRef="U002" decimals="0">1041856</btx:TradeAccountsAndGrantsReceivableNetCurrent>
  <!--Deferred license and consulting fees-->
  <btx:DeferredLicenseAndConsultingFees contextRef="c20150331" unitRef="U002" decimals="0">309458</btx:DeferredLicenseAndConsultingFees>
  <!--Deferred license and consulting fees-->
  <btx:DeferredLicenseAndConsultingFees contextRef="c20141231" unitRef="U002" decimals="0">336833</btx:DeferredLicenseAndConsultingFees>
  <!--Landlord Liabilities Noncurrent-->
  <btx:LandlordLiabilitiesNoncurrent contextRef="c20150331" unitRef="U002" decimals="0">560970</btx:LandlordLiabilitiesNoncurrent>
  <!--Landlord Liabilities Noncurrent-->
  <btx:LandlordLiabilitiesNoncurrent contextRef="c20141231" unitRef="U002" decimals="0">377981</btx:LandlordLiabilitiesNoncurrent>
  <!--Deferred grant income-->
  <btx:DeferredGrantIncome contextRef="c20150331" unitRef="U002" decimals="0">1474300</btx:DeferredGrantIncome>
  <!--Deferred grant income-->
  <btx:DeferredGrantIncome contextRef="c20141231" unitRef="U002" decimals="0">0</btx:DeferredGrantIncome>
  <!--Tenant Allowance Receivable-->
  <btx:TenantAllowanceReceivable contextRef="c20150331" unitRef="U002" decimals="0">277206</btx:TenantAllowanceReceivable>
  <!--Tenant Allowance Receivable-->
  <btx:TenantAllowanceReceivable contextRef="c20141231" unitRef="U002" decimals="0">377981</btx:TenantAllowanceReceivable>
  <!--Tenant Improvement Allowance Reimbursement Under Lease Agreement-->
  <btx:TenantImprovementAllowanceReimbursementUnderLeaseAgreement contextRef="c20150331" unitRef="U002" decimals="0">560970</btx:TenantImprovementAllowanceReimbursementUnderLeaseAgreement>
  <!--Tenant Improvement Allowance Under Lease Agreement-->
  <btx:TenantImprovementAllowanceUnderLeaseAgreement contextRef="c20150331" unitRef="U002" decimals="0">4400000</btx:TenantImprovementAllowanceUnderLeaseAgreement>
  <!--Fees paid on sale of common shares of subsidiary-->
  <btx:FeesPaidOnSaleOfCommonSharesOfSubsidiary contextRef="c20140101to20140331" unitRef="U002" decimals="0">0</btx:FeesPaidOnSaleOfCommonSharesOfSubsidiary>
  <!--Fees paid on sale of common shares of subsidiary-->
  <btx:FeesPaidOnSaleOfCommonSharesOfSubsidiary contextRef="c20150101to20150331" unitRef="U002" decimals="0">432631</btx:FeesPaidOnSaleOfCommonSharesOfSubsidiary>
  <!--Amortization of Stock Based Prepaid Rent-->
  <btx:AmortizationOfStockBasedPrepaidRent contextRef="c20150101to20150331" unitRef="U002" decimals="0">21146</btx:AmortizationOfStockBasedPrepaidRent>
  <!--Amortization of Stock Based Prepaid Rent-->
  <btx:AmortizationOfStockBasedPrepaidRent contextRef="c20140101to20140331" unitRef="U002" decimals="0">21146</btx:AmortizationOfStockBasedPrepaidRent>
  <!--Accrued interest on convertible debt-->
  <btx:AccruedInterestOnConvertibleDebt contextRef="c20140101to20140331" unitRef="U002" decimals="0">0</btx:AccruedInterestOnConvertibleDebt>
  <!--Accrued interest on convertible debt-->
  <btx:AccruedInterestOnConvertibleDebt contextRef="c20150101to20150331" unitRef="U002" decimals="0">-3531</btx:AccruedInterestOnConvertibleDebt>
  <!--Amortization of deferred license fees-->
  <btx:AmortizationOfDeferredLicenseFees contextRef="c20150101to20150331" unitRef="U002" decimals="0">27375</btx:AmortizationOfDeferredLicenseFees>
  <!--Amortization of deferred license fees-->
  <btx:AmortizationOfDeferredLicenseFees contextRef="c20140101to20140331" unitRef="U002" decimals="0">27375</btx:AmortizationOfDeferredLicenseFees>
  <!--Increase (decrease) in Grant receivable-->
  <btx:IncreaseDecreaseInGrantReceivable contextRef="c20150101to20150331" unitRef="U002" decimals="0">-228191</btx:IncreaseDecreaseInGrantReceivable>
  <!--Increase (decrease) in Grant receivable-->
  <btx:IncreaseDecreaseInGrantReceivable contextRef="c20140101to20140331" unitRef="U002" decimals="0">-202122</btx:IncreaseDecreaseInGrantReceivable>
  <!--Amortization of deferred consulting fees-->
  <btx:AmortizationOfDeferredConsultingFees contextRef="c20150101to20150331" unitRef="U002" decimals="0">0</btx:AmortizationOfDeferredConsultingFees>
  <!--Amortization of deferred consulting fees-->
  <btx:AmortizationOfDeferredConsultingFees contextRef="c20140101to20140331" unitRef="U002" decimals="0">16279</btx:AmortizationOfDeferredConsultingFees>
  <!--Increase (Decrease) in Deferred Rent Liabilities-->
  <btx:IncreaseDecreaseInDeferredRentLiabilities contextRef="c20140101to20140331" unitRef="U002" decimals="0">5040</btx:IncreaseDecreaseInDeferredRentLiabilities>
  <!--Increase (Decrease) in Deferred Rent Liabilities-->
  <btx:IncreaseDecreaseInDeferredRentLiabilities contextRef="c20150101to20150331" unitRef="U002" decimals="0">62313</btx:IncreaseDecreaseInDeferredRentLiabilities>
  <!--Proceeds From Deferred Grant Income-->
  <btx:ProceedsFromDeferredGrantIncome contextRef="c20150101to20150331" unitRef="U002" decimals="0">1474300</btx:ProceedsFromDeferredGrantIncome>
  <!--Proceeds From Deferred Grant Income-->
  <btx:ProceedsFromDeferredGrantIncome contextRef="c20140101to20140331" unitRef="U002" decimals="0">0</btx:ProceedsFromDeferredGrantIncome>
  <!--Proceeds from Construction in Progress-->
  <btx:ProceedsFromConstructionInProgress contextRef="c20140101to20140331" unitRef="U002" decimals="0">0</btx:ProceedsFromConstructionInProgress>
  <!--Proceeds from Construction in Progress-->
  <btx:ProceedsFromConstructionInProgress contextRef="c20150101to20150331" unitRef="U002" decimals="0">283764</btx:ProceedsFromConstructionInProgress>
  <!--Security deposit received-->
  <btx:SecurityDepositReceived contextRef="c20150101to20150331" unitRef="U002" decimals="0">0</btx:SecurityDepositReceived>
  <!--Security deposit received-->
  <btx:SecurityDepositReceived contextRef="c20140101to20140331" unitRef="U002" decimals="0">-299697</btx:SecurityDepositReceived>
  <!--Fees paid on sale of common shares-->
  <btx:FeesPaidOnSaleOfCommonShares contextRef="c20150101to20150331" unitRef="U002" decimals="0">0</btx:FeesPaidOnSaleOfCommonShares>
  <!--Fees paid on sale of common shares-->
  <btx:FeesPaidOnSaleOfCommonShares contextRef="c20140101to20140331" unitRef="U002" decimals="0">212046</btx:FeesPaidOnSaleOfCommonShares>
  <!--Shares sold by third party-->
  <btx:SharesSoldByThirdParty contextRef="c20140601to20140630" unitRef="U001" decimals="0">5000000</btx:SharesSoldByThirdParty>
  <!--Shares sold by third party-Asterias Biotherapeutics [Member]-BioTime Common Stock [Member]-->
  <btx:SharesSoldByThirdParty contextRef="c20150101to20150331_RelatedPartyTransactionAxis_CommonStockMember_RelatedPartyTransactionsByRelatedPartyAxis_AsteriasBiotherapeuticsMember" unitRef="U001" decimals="0">5000000</btx:SharesSoldByThirdParty>
  <!--Number of Investors-Asterias Biotherapeutics [Member]-BioTime Common Stock [Member]-->
  <btx:NumberOfInvestors contextRef="c20150101to20150331_RelatedPartyTransactionAxis_CommonStockMember_RelatedPartyTransactionsByRelatedPartyAxis_AsteriasBiotherapeuticsMember" unitRef="U006" decimals="INF">2</btx:NumberOfInvestors>
  <!--Number of Investors-Subsequent Event [Member]-OncoCyte Corporation [Member]-->
  <btx:NumberOfInvestors contextRef="c20150508to20150508_LegalEntityAxis_OncocyteCorporationMember_SubsequentEventTypeAxis_SubsequentEventMember" unitRef="U006" decimals="INF">2</btx:NumberOfInvestors>
  <!--Sales of BioTime Common Shares by Subsidiaries [Text Block]-->
  <btx:SalesOfBiotimeCommonSharesBySubsidiariesTextBlock contextRef="c20150101to20150331">&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;div style="text-align: left;"&gt;&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 100%;"&gt;&lt;tr&gt;&lt;td style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 18pt; vertical-align: top; font-weight: bold; align: right;"&gt;10.&lt;/td&gt;&lt;td style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: auto; vertical-align: top; font-weight: bold; text-align: left;"&gt;Sales of BioTime Common Shares by Subsidiaries&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; text-indent: 36pt;"&gt;Certain BioTime subsidiaries hold BioTime common shares that the subsidiaries received from BioTime in exchange for capital stock in the subsidiaries. The BioTime common shares held by subsidiaries are treated as treasury stock by BioTime and BioTime does not recognize a gain or loss on the sale of those shares by its subsidiaries.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; text-indent: 36pt;"&gt;During June 2014, Asterias sold 5,000,000 of its BioTime common shares with warrants to purchase 5,000,000 shares of Asterias Series B common stock to two investors for $12,500,000 in cash. Broadwood Partners, L.P., purchased 1,000,000 of the BioTime common shares with 1,000,000 Asterias warrants and a trust previously established by George Karfunkel purchased 4,000,000 of the BioTime common shares with 4,000,000 Asterias warrants.&lt;/div&gt;&lt;/div&gt;</btx:SalesOfBiotimeCommonSharesBySubsidiariesTextBlock>
  <link:footnoteLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:footnote xlink:label="Footnote-Item-1" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Includes shares owned by BioTime, Asterias, and ESI.</link:footnote>
    <link:loc xlink:href="#Item-1" xlink:label="Item-1_lbl" xlink:type="locator" />
    <link:footnoteArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Item-1_lbl" xlink:to="Footnote-Item-1" xlink:type="arc" />
    <link:footnote xlink:label="Footnote-Item-2" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Includes shares owned by BioTime and Asterias.</link:footnote>
    <link:loc xlink:href="#Item-2" xlink:label="Item-2_lbl" xlink:type="locator" />
    <link:footnoteArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Item-2_lbl" xlink:to="Footnote-Item-2" xlink:type="arc" />
    <link:footnote xlink:label="Footnote-Item-3" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">LifeMap Sciences, Ltd. and LifeMap Solutions, Inc. are wholly-owned subsidiaries of LifeMap Sciences, Inc.</link:footnote>
    <link:loc xlink:href="#Item-3" xlink:label="Item-3_lbl" xlink:type="locator" />
    <link:footnoteArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Item-3_lbl" xlink:to="Footnote-Item-3" xlink:type="arc" />
    <link:loc xlink:href="#Item-4" xlink:label="Item-4_lbl" xlink:type="locator" />
    <link:footnoteArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Item-4_lbl" xlink:to="Footnote-Item-3" xlink:type="arc" />
  </link:footnoteLink>
</xbrl>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>btx-20150331.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--Generated by EDGARfilings PROfile 3.3.0.0 Copyright 1995 - 2015 Summit Financial Printing, LLC. All rights reserved.-->
<xs:schema targetNamespace="http://biotimeinc.com/20150331" elementFormDefault="qualified" xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:btx="http://biotimeinc.com/20150331" xmlns:us-types="http://fasb.org/us-types/2014-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:dei="http://xbrl.sec.gov/dei/2014-01-31">
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xlink:type="simple" xlink:href="btx-20150331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="btx-20150331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="btx-20150331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="btx-20150331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:roleType roleURI="http://biotimeinc.com/role/DocumentAndEntityInformation" id="DocumentAndEntityInformation">
        <link:definition>000100 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biotimeinc.com/role/CondensedConsolidatedBalanceSheetsUnaudited" id="CondensedConsolidatedBalanceSheetsUnaudited">
        <link:definition>010000 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biotimeinc.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" id="CondensedConsolidatedBalanceSheetsUnauditedParenthetical">
        <!--Parent Role: CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)-->
        <link:definition>010100 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biotimeinc.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited" id="CondensedConsolidatedStatementsOfOperationsUnaudited">
        <link:definition>020000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biotimeinc.com/role/CondensedConsolidatedStatementsOfComprehensiveLossUnaudited" id="CondensedConsolidatedStatementsOfComprehensiveLossUnaudited">
        <link:definition>030000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (UNAUDITED)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biotimeinc.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" id="CondensedConsolidatedStatementsOfCashFlowsUnaudited">
        <link:definition>040000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biotimeinc.com/role/OrganizationBasisOfPresentationAndLiquidity" id="OrganizationBasisOfPresentationAndLiquidity">
        <link:definition>060100 - Disclosure - Organization, Basis of Presentation, and Liquidity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biotimeinc.com/role/SummaryOfSignificantAccountingPolicies" id="SummaryOfSignificantAccountingPolicies">
        <link:definition>060200 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biotimeinc.com/role/Inventory" id="Inventory">
        <link:definition>060300 - Disclosure - Inventory</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biotimeinc.com/role/EquipmentNetAndConstructionInProgress" id="EquipmentNetAndConstructionInProgress">
        <link:definition>060400 - Disclosure - Equipment, net and construction in progress</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biotimeinc.com/role/IntangibleAssetsNet" id="IntangibleAssetsNet">
        <link:definition>060500 - Disclosure - Intangible assets, net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biotimeinc.com/role/RoyaltyObligationAndDeferredLicenseFees" id="RoyaltyObligationAndDeferredLicenseFees">
        <link:definition>060600 - Disclosure - Royalty Obligation and Deferred License Fees</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biotimeinc.com/role/AccountsPayableAndAccruedLiabilities" id="AccountsPayableAndAccruedLiabilities">
        <link:definition>060700 - Disclosure - Accounts Payable and Accrued Liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biotimeinc.com/role/RelatedPartyTransactionsAndRelatedPartyConvertibleDebt" id="RelatedPartyTransactionsAndRelatedPartyConvertibleDebt">
        <link:definition>060800 - Disclosure - Related Party Transactions and Related Party Convertible Debt</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biotimeinc.com/role/ShareholdersEquity" id="ShareholdersEquity">
        <link:definition>060900 - Disclosure - Shareholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biotimeinc.com/role/SalesOfBiotimeCommonSharesBySubsidiaries" id="SalesOfBiotimeCommonSharesBySubsidiaries">
        <link:definition>061000 - Disclosure - Sales of BioTime Common Shares by Subsidiaries</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biotimeinc.com/role/SegmentInformation" id="SegmentInformation">
        <link:definition>061100 - Disclosure - Segment Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biotimeinc.com/role/SubsequentEvents" id="SubsequentEvents">
        <link:definition>061200 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biotimeinc.com/role/SummaryOfSignificantAccountingPoliciesPolicies" id="SummaryOfSignificantAccountingPoliciesPolicies">
        <!--Parent Role: Summary of Significant Accounting Policies-->
        <link:definition>070200 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biotimeinc.com/role/OrganizationBasisOfPresentationAndLiquidityTables" id="OrganizationBasisOfPresentationAndLiquidityTables">
        <!--Parent Role: Organization, Basis of Presentation, and Liquidity-->
        <link:definition>080100 - Disclosure - Organization, Basis of Presentation and Liquidity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biotimeinc.com/role/EquipmentNetAndConstructionInProgressTables" id="EquipmentNetAndConstructionInProgressTables">
        <!--Parent Role: Equipment, net and construction in progress-->
        <link:definition>080400 - Disclosure - Equipment, net and construction in progress (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biotimeinc.com/role/IntangibleAssetsNetTables" id="IntangibleAssetsNetTables">
        <!--Parent Role: Intangible assets, net-->
        <link:definition>080500 - Disclosure - Intangible assets, net (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biotimeinc.com/role/RoyaltyObligationAndDeferredLicenseFeesTables" id="RoyaltyObligationAndDeferredLicenseFeesTables">
        <!--Parent Role: Royalty Obligation and Deferred License Fees-->
        <link:definition>080601 - Disclosure - Royalty Obligation and Deferred License Fees (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biotimeinc.com/role/AccountsPayableAndAccruedLiabilitiesTables" id="AccountsPayableAndAccruedLiabilitiesTables">
        <!--Parent Role: Accounts Payable and Accrued Liabilities-->
        <link:definition>080700 - Disclosure - Accounts Payable and Accrued Liabilities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biotimeinc.com/role/OrganizationBasisOfPresentationAndLiquidityDetails" id="OrganizationBasisOfPresentationAndLiquidityDetails">
        <!--Parent Role: Organization, Basis of Presentation, and Liquidity-->
        <link:definition>090100 - Disclosure - Organization, Basis of Presentation and Liquidity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biotimeinc.com/role/SummaryOfSignificantAccountingPoliciesDetails" id="SummaryOfSignificantAccountingPoliciesDetails">
        <!--Parent Role: Summary of Significant Accounting Policies-->
        <link:definition>090200 - Disclosure - Summary of Significant Accounting Policies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biotimeinc.com/role/InventoryDetails" id="InventoryDetails">
        <!--Parent Role: Inventory-->
        <link:definition>090300 - Disclosure - Inventory (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biotimeinc.com/role/EquipmentNetAndConstructionInProgressDetails" id="EquipmentNetAndConstructionInProgressDetails">
        <!--Parent Role: Equipment, net and construction in progress-->
        <link:definition>090400 - Disclosure - Equipment, net and construction in progress (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biotimeinc.com/role/IntangibleAssetsNetDetails" id="IntangibleAssetsNetDetails">
        <!--Parent Role: Intangible assets, net-->
        <link:definition>090500 - Disclosure - Intangible assets, net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biotimeinc.com/role/RoyaltyObligationAndDeferredLicenseFeesDetails" id="RoyaltyObligationAndDeferredLicenseFeesDetails">
        <!--Parent Role: Royalty Obligation and Deferred License Fees-->
        <link:definition>090602 - Disclosure - Royalty Obligation and Deferred License Fees (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biotimeinc.com/role/AccountsPayableAndAccruedLiabilitiesDetails" id="AccountsPayableAndAccruedLiabilitiesDetails">
        <!--Parent Role: Accounts Payable and Accrued Liabilities-->
        <link:definition>090700 - Disclosure - Accounts Payable and Accrued Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biotimeinc.com/role/RelatedPartyTransactionsAndRelatedPartyConvertibleDebtDetails" id="RelatedPartyTransactionsAndRelatedPartyConvertibleDebtDetails">
        <!--Parent Role: Related Party Transactions and Related Party Convertible Debt-->
        <link:definition>090800 - Disclosure - Related Party Transactions and Related Party Convertible Debt (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biotimeinc.com/role/ShareholdersEquityDetails" id="ShareholdersEquityDetails">
        <!--Parent Role: Shareholders' Equity-->
        <link:definition>090900 - Disclosure - Shareholders' Equity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biotimeinc.com/role/SalesOfBiotimeCommonSharesBySubsidiariesDetails" id="SalesOfBiotimeCommonSharesBySubsidiariesDetails">
        <!--Parent Role: Sales of BioTime Common Shares by Subsidiaries-->
        <link:definition>091000 - Disclosure - Sales of BioTime Common Shares by Subsidiaries (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biotimeinc.com/role/SegmentInformationDetails" id="SegmentInformationDetails">
        <!--Parent Role: Segment Information-->
        <link:definition>091100 - Disclosure - Segment Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biotimeinc.com/role/SubsequentEventsDetails" id="SubsequentEventsDetails">
        <!--Parent Role: Subsequent Events-->
        <link:definition>091200 - Disclosure - Subsequent Events (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:import namespace="http://fasb.org/us-gaap/2014-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/dei/2014-01-31" schemaLocation="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/invest/2013-01-31" schemaLocation="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/country/2013-01-31" schemaLocation="http://xbrl.sec.gov/country/2013/country-2013-01-31.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/currency/2014-01-31" schemaLocation="http://xbrl.sec.gov/currency/2014/currency-2014-01-31.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/exch/2014-01-31" schemaLocation="http://xbrl.sec.gov/exch/2014/exch-2014-01-31.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/naics/2011-01-31" schemaLocation="http://xbrl.sec.gov/naics/2011/naics-2011-01-31.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/sic/2011-01-31" schemaLocation="http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd" />
  <xs:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xs:import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/stpr/2011-01-31" schemaLocation="http://xbrl.sec.gov/stpr/2011/stpr-2011-01-31.xsd" />
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xs:import namespace="http://www.xbrl.org/2004/ref" schemaLocation="http://www.xbrl.org/2004/ref-2004-08-10.xsd" />
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xs:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
  <xs:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />
  <xs:import namespace="http://fasb.org/us-types/2014-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2014/elts/us-types-2014-01-31.xsd" />
  <xs:import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" />
  <xs:element name="SalesOfBioTimeCommonSharesBySubsidiariesAbstract" id="btx_SalesOfBioTimeCommonSharesBySubsidiariesAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="SalesOfBiotimeCommonSharesBySubsidiariesTextBlock" id="btx_SalesOfBiotimeCommonSharesBySubsidiariesTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="NumberOfInvestors" id="btx_NumberOfInvestors" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="SharesSoldByThirdParty" id="btx_SharesSoldByThirdParty" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="AsteriasBiotherapeuticsMember" id="btx_AsteriasBiotherapeuticsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="FeesPaidOnSaleOfCommonShares" id="btx_FeesPaidOnSaleOfCommonShares" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" />
  <xs:element name="SecurityDepositReceived" id="btx_SecurityDepositReceived" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" />
  <xs:element name="ProceedsFromConstructionInProgress" id="btx_ProceedsFromConstructionInProgress" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" />
  <xs:element name="ProceedsFromDeferredGrantIncome" id="btx_ProceedsFromDeferredGrantIncome" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" />
  <xs:element name="IncreaseDecreaseInDeferredRentLiabilities" id="btx_IncreaseDecreaseInDeferredRentLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" />
  <xs:element name="AmortizationOfDeferredConsultingFees" id="btx_AmortizationOfDeferredConsultingFees" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" />
  <xs:element name="IncreaseDecreaseInGrantReceivable" id="btx_IncreaseDecreaseInGrantReceivable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" />
  <xs:element name="AmortizationOfDeferredLicenseFees" id="btx_AmortizationOfDeferredLicenseFees" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" />
  <xs:element name="AccruedInterestOnConvertibleDebt" id="btx_AccruedInterestOnConvertibleDebt" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" />
  <xs:element name="AmortizationOfStockBasedPrepaidRent" id="btx_AmortizationOfStockBasedPrepaidRent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" />
  <xs:element name="FeesPaidOnSaleOfCommonSharesOfSubsidiary" id="btx_FeesPaidOnSaleOfCommonSharesOfSubsidiary" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" />
  <xs:element name="TenantImprovementAllowanceUnderLeaseAgreement" id="btx_TenantImprovementAllowanceUnderLeaseAgreement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" />
  <xs:element name="TenantImprovementAllowanceReimbursementUnderLeaseAgreement" id="btx_TenantImprovementAllowanceReimbursementUnderLeaseAgreement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" />
  <xs:element name="LifemapSolutionsIncMember" id="btx_LifemapSolutionsIncMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="RecyteTherapeuticsIncMember" id="btx_RecyteTherapeuticsIncMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="EsCellInternationalPteLtdMember" id="btx_EsCellInternationalPteLtdMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="LifemapSciencesLtdMember" id="btx_LifemapSciencesLtdMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="LifemapSciencesIncMember" id="btx_LifemapSciencesIncMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="OncocyteCorporationMember" id="btx_OncocyteCorporationMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="BiotimeAsiaLimitedMember" id="btx_BiotimeAsiaLimitedMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="CellCureNeurosciencesLtdMember" id="btx_CellCureNeurosciencesLtdMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="OrthocyteCorporationMember" id="btx_OrthocyteCorporationMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="TenantAllowanceReceivable" id="btx_TenantAllowanceReceivable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" />
  <xs:element name="DeferredGrantIncome" id="btx_DeferredGrantIncome" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" />
  <xs:element name="LandlordLiabilitiesNoncurrent" id="btx_LandlordLiabilitiesNoncurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" />
  <xs:element name="DeferredLicenseAndConsultingFees" id="btx_DeferredLicenseAndConsultingFees" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" />
  <xs:element name="TradeAccountsAndGrantsReceivableNetCurrent" id="btx_TradeAccountsAndGrantsReceivableNetCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" />
  <xs:element name="RelatedPartyConvertibleDebtNetOfDiscount" id="btx_RelatedPartyConvertibleDebtNetOfDiscount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" />
  <xs:element name="CaliforniaInstituteOfRegenerativeMedicineMember" id="btx_CaliforniaInstituteOfRegenerativeMedicineMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="EquityIncentivePlanMember" id="btx_EquityIncentivePlanMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="WarrantsExercised" id="btx_WarrantsExercised" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="PricePerShareOfOptionsToPurchaseCompany" id="btx_PricePerShareOfOptionsToPurchaseCompany" type="num:perShareItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" />
  <xs:element name="StockOptionPlan2002Member" id="btx_StockOptionPlan2002Member" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="PreferredSharesConvertibleConversionRatio" id="btx_PreferredSharesConvertibleConversionRatio" type="xbrli:pureItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="DocumentAndEntityInformationAbstract" id="btx_DocumentAndEntityInformationAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="NumberOfCellCureNeurosciencesInvestors" id="btx_NumberOfCellCureNeurosciencesInvestors" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="EstimatedFairMarketValue" id="btx_EstimatedFairMarketValue" type="num:perShareItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="TaxableGainOnSaleOfSubsidiaryShares" id="btx_TaxableGainOnSaleOfSubsidiaryShares" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" />
  <xs:element name="DeferredLicenseAndConsultingFeesAbstract" id="btx_DeferredLicenseAndConsultingFeesAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="TaxPayableOnSaleOfSubsidiaryShares" id="btx_TaxPayableOnSaleOfSubsidiaryShares" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" />
  <xs:element name="WarrantsToPurchaseCommonStockPolicyTextBlock" id="btx_WarrantsToPurchaseCommonStockPolicyTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="TreasuryStockPolicyTextBlock" id="btx_TreasuryStockPolicyTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="DeferredLicenseFeesAmortizationExpenseYearFive" id="btx_DeferredLicenseFeesAmortizationExpenseYearFive" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" />
  <xs:element name="DeferredLicenseFeesAmortizationExpenseYearFour" id="btx_DeferredLicenseFeesAmortizationExpenseYearFour" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" />
  <xs:element name="DeferredLicenseFeesAmortizationExpenseAfterYearFive" id="btx_DeferredLicenseFeesAmortizationExpenseAfterYearFive" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" />
  <xs:element name="DeferredLicenseFeesAmortizationExpenseDueInRemainderOfFiscalYear" id="btx_DeferredLicenseFeesAmortizationExpenseDueInRemainderOfFiscalYear" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" />
  <xs:element name="DeferredLicenseFeesAmortizationExpenseYearThree" id="btx_DeferredLicenseFeesAmortizationExpenseYearThree" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" />
  <xs:element name="DeferredLicenseFeesAmortizationExpenseYearTwo" id="btx_DeferredLicenseFeesAmortizationExpenseYearTwo" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" />
  <xs:element name="PrepaidExpensesInOtherCurrentAssets" id="btx_PrepaidExpensesInOtherCurrentAssets" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" />
  <xs:element name="DeferredLicenseAndConsultingFeesClassifiedAsNoncurrent" id="btx_DeferredLicenseAndConsultingFeesClassifiedAsNoncurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" />
  <xs:element name="ScheduleOfExpectedAmortizationDeferredLicenseExpenseTableTextBlock" id="btx_ScheduleOfExpectedAmortizationDeferredLicenseExpenseTableTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>7
<FILENAME>btx-20150331_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--Generated by EDGARfilings PROfile 3.3.0.0 Copyright 1995 - 2015 Summit Financial Printing, LLC. All rights reserved.-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <link:roleRef roleURI="http://biotimeinc.com/role/AccountsPayableAndAccruedLiabilitiesDetails" xlink:type="simple" xlink:href="btx-20150331.xsd#AccountsPayableAndAccruedLiabilitiesDetails" />
  <link:roleRef roleURI="http://biotimeinc.com/role/RoyaltyObligationAndDeferredLicenseFeesDetails" xlink:type="simple" xlink:href="btx-20150331.xsd#RoyaltyObligationAndDeferredLicenseFeesDetails" />
  <link:roleRef roleURI="http://biotimeinc.com/role/IntangibleAssetsNetDetails" xlink:type="simple" xlink:href="btx-20150331.xsd#IntangibleAssetsNetDetails" />
  <link:roleRef roleURI="http://biotimeinc.com/role/EquipmentNetAndConstructionInProgressDetails" xlink:type="simple" xlink:href="btx-20150331.xsd#EquipmentNetAndConstructionInProgressDetails" />
  <link:roleRef roleURI="http://biotimeinc.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" xlink:type="simple" xlink:href="btx-20150331.xsd#CondensedConsolidatedStatementsOfCashFlowsUnaudited" />
  <link:roleRef roleURI="http://biotimeinc.com/role/CondensedConsolidatedStatementsOfComprehensiveLossUnaudited" xlink:type="simple" xlink:href="btx-20150331.xsd#CondensedConsolidatedStatementsOfComprehensiveLossUnaudited" />
  <link:roleRef roleURI="http://biotimeinc.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited" xlink:type="simple" xlink:href="btx-20150331.xsd#CondensedConsolidatedStatementsOfOperationsUnaudited" />
  <link:roleRef roleURI="http://biotimeinc.com/role/CondensedConsolidatedBalanceSheetsUnaudited" xlink:type="simple" xlink:href="btx-20150331.xsd#CondensedConsolidatedBalanceSheetsUnaudited" />
  <link:calculationLink xlink:type="extended" xlink:role="http://biotimeinc.com/role/CondensedConsolidatedBalanceSheetsUnaudited">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Assets" xlink:label="Assets" xlink:title="Assets" />
    <link:loc xlink:type="locator" xlink:href="btx-20150331.xsd#btx_DeferredLicenseAndConsultingFees" xlink:label="DeferredLicenseAndConsultingFees" xlink:title="DeferredLicenseAndConsultingFees" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Assets" xlink:to="DeferredLicenseAndConsultingFees" xlink:title="calculation: Assets to DeferredLicenseAndConsultingFees" order="3.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="IntangibleAssetsNetExcludingGoodwill" xlink:title="IntangibleAssetsNetExcludingGoodwill" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Assets" xlink:to="IntangibleAssetsNetExcludingGoodwill" xlink:title="calculation: Assets to IntangibleAssetsNetExcludingGoodwill" order="6.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="OtherAssetsNoncurrent" xlink:title="OtherAssetsNoncurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Assets" xlink:to="OtherAssetsNoncurrent" xlink:title="calculation: Assets to OtherAssetsNoncurrent" order="4.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="PropertyPlantAndEquipmentNet" xlink:title="PropertyPlantAndEquipmentNet" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Assets" xlink:to="PropertyPlantAndEquipmentNet" xlink:title="calculation: Assets to PropertyPlantAndEquipmentNet" order="2.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="AssetsCurrent" xlink:title="AssetsCurrent" />
    <link:loc xlink:type="locator" xlink:href="btx-20150331.xsd#btx_TenantAllowanceReceivable" xlink:label="TenantAllowanceReceivable" xlink:title="TenantAllowanceReceivable" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="AssetsCurrent" xlink:to="TenantAllowanceReceivable" xlink:title="calculation: AssetsCurrent to TenantAllowanceReceivable" order="3.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="PrepaidExpenseAndOtherAssetsCurrent" xlink:title="PrepaidExpenseAndOtherAssetsCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="AssetsCurrent" xlink:to="PrepaidExpenseAndOtherAssetsCurrent" xlink:title="calculation: AssetsCurrent to PrepaidExpenseAndOtherAssetsCurrent" order="4.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="CashAndCashEquivalentsAtCarryingValue" xlink:title="CashAndCashEquivalentsAtCarryingValue" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="AssetsCurrent" xlink:to="CashAndCashEquivalentsAtCarryingValue" xlink:title="calculation: AssetsCurrent to CashAndCashEquivalentsAtCarryingValue" order="0.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InventoryNet" xlink:label="InventoryNet" xlink:title="InventoryNet" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="AssetsCurrent" xlink:to="InventoryNet" xlink:title="calculation: AssetsCurrent to InventoryNet" order="2.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20150331.xsd#btx_TradeAccountsAndGrantsReceivableNetCurrent" xlink:label="TradeAccountsAndGrantsReceivableNetCurrent" xlink:title="TradeAccountsAndGrantsReceivableNetCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="AssetsCurrent" xlink:to="TradeAccountsAndGrantsReceivableNetCurrent" xlink:title="calculation: AssetsCurrent to TradeAccountsAndGrantsReceivableNetCurrent" order="1.0" weight="1.0" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Assets" xlink:to="AssetsCurrent" xlink:title="calculation: Assets to AssetsCurrent" order="1.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DepositsAssetsNoncurrent" xlink:label="DepositsAssetsNoncurrent" xlink:title="DepositsAssetsNoncurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Assets" xlink:to="DepositsAssetsNoncurrent" xlink:title="calculation: Assets to DepositsAssetsNoncurrent" order="5.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="LiabilitiesAndStockholdersEquity" xlink:title="LiabilitiesAndStockholdersEquity" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="LiabilitiesCurrent" xlink:title="LiabilitiesCurrent" />
    <link:loc xlink:type="locator" xlink:href="btx-20150331.xsd#btx_RelatedPartyConvertibleDebtNetOfDiscount" xlink:label="RelatedPartyConvertibleDebtNetOfDiscount" xlink:title="RelatedPartyConvertibleDebtNetOfDiscount" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LiabilitiesCurrent" xlink:to="RelatedPartyConvertibleDebtNetOfDiscount" xlink:title="calculation: LiabilitiesCurrent to RelatedPartyConvertibleDebtNetOfDiscount" order="4.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="AccountsPayableAndAccruedLiabilitiesCurrent" xlink:title="AccountsPayableAndAccruedLiabilitiesCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LiabilitiesCurrent" xlink:to="AccountsPayableAndAccruedLiabilitiesCurrent" xlink:title="calculation: LiabilitiesCurrent to AccountsPayableAndAccruedLiabilitiesCurrent" order="1.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="DeferredRevenueCurrent" xlink:title="DeferredRevenueCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LiabilitiesCurrent" xlink:to="DeferredRevenueCurrent" xlink:title="calculation: LiabilitiesCurrent to DeferredRevenueCurrent" order="3.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CapitalLeaseObligationsCurrent" xlink:label="CapitalLeaseObligationsCurrent" xlink:title="CapitalLeaseObligationsCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LiabilitiesCurrent" xlink:to="CapitalLeaseObligationsCurrent" xlink:title="calculation: LiabilitiesCurrent to CapitalLeaseObligationsCurrent" order="2.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20150331.xsd#btx_DeferredGrantIncome" xlink:label="DeferredGrantIncome" xlink:title="DeferredGrantIncome" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LiabilitiesCurrent" xlink:to="DeferredGrantIncome" xlink:title="calculation: LiabilitiesCurrent to DeferredGrantIncome" order="5.0" weight="1.0" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LiabilitiesAndStockholdersEquity" xlink:to="LiabilitiesCurrent" xlink:title="calculation: LiabilitiesAndStockholdersEquity to LiabilitiesCurrent" order="1.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:title="StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="StockholdersEquity" xlink:title="StockholdersEquity" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TreasuryStockValue" xlink:label="TreasuryStockValue" xlink:title="TreasuryStockValue" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="StockholdersEquity" xlink:to="TreasuryStockValue" xlink:title="calculation: StockholdersEquity to TreasuryStockValue" order="6.0" weight="-1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="RetainedEarningsAccumulatedDeficit" xlink:title="RetainedEarningsAccumulatedDeficit" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="StockholdersEquity" xlink:to="RetainedEarningsAccumulatedDeficit" xlink:title="calculation: StockholdersEquity to RetainedEarningsAccumulatedDeficit" order="5.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockValue" xlink:label="CommonStockValue" xlink:title="CommonStockValue" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="StockholdersEquity" xlink:to="CommonStockValue" xlink:title="calculation: StockholdersEquity to CommonStockValue" order="2.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:title="AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="StockholdersEquity" xlink:to="AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:title="calculation: StockholdersEquity to AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="4.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="AdditionalPaidInCapital" xlink:title="AdditionalPaidInCapital" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="StockholdersEquity" xlink:to="AdditionalPaidInCapital" xlink:title="calculation: StockholdersEquity to AdditionalPaidInCapital" order="3.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="PreferredStockValue" xlink:title="PreferredStockValue" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="StockholdersEquity" xlink:to="PreferredStockValue" xlink:title="calculation: StockholdersEquity to PreferredStockValue" order="1.0" weight="1.0" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="StockholdersEquity" xlink:title="calculation: StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest to StockholdersEquity" order="1.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MinorityInterest" xlink:label="MinorityInterest" xlink:title="MinorityInterest" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="MinorityInterest" xlink:title="calculation: StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest to MinorityInterest" order="2.0" weight="1.0" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LiabilitiesAndStockholdersEquity" xlink:to="StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:title="calculation: LiabilitiesAndStockholdersEquity to StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" order="3.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="LiabilitiesNoncurrent" xlink:title="LiabilitiesNoncurrent" />
    <link:loc xlink:type="locator" xlink:href="btx-20150331.xsd#btx_LandlordLiabilitiesNoncurrent" xlink:label="LandlordLiabilitiesNoncurrent" xlink:title="LandlordLiabilitiesNoncurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LiabilitiesNoncurrent" xlink:to="LandlordLiabilitiesNoncurrent" xlink:title="calculation: LiabilitiesNoncurrent to LandlordLiabilitiesNoncurrent" order="2.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent" xlink:label="DeferredRentCreditNoncurrent" xlink:title="DeferredRentCreditNoncurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LiabilitiesNoncurrent" xlink:to="DeferredRentCreditNoncurrent" xlink:title="calculation: LiabilitiesNoncurrent to DeferredRentCreditNoncurrent" order="1.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:label="LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:title="LongTermDebtAndCapitalLeaseObligationsCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LiabilitiesNoncurrent" xlink:to="LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:title="calculation: LiabilitiesNoncurrent to LongTermDebtAndCapitalLeaseObligationsCurrent" order="3.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxLiabilitiesNoncurrent" xlink:label="DeferredTaxLiabilitiesNoncurrent" xlink:title="DeferredTaxLiabilitiesNoncurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LiabilitiesNoncurrent" xlink:to="DeferredTaxLiabilitiesNoncurrent" xlink:title="calculation: LiabilitiesNoncurrent to DeferredTaxLiabilitiesNoncurrent" order="0.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="OtherLiabilitiesNoncurrent" xlink:title="OtherLiabilitiesNoncurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LiabilitiesNoncurrent" xlink:to="OtherLiabilitiesNoncurrent" xlink:title="calculation: LiabilitiesNoncurrent to OtherLiabilitiesNoncurrent" order="4.0" weight="1.0" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LiabilitiesAndStockholdersEquity" xlink:to="LiabilitiesNoncurrent" xlink:title="calculation: LiabilitiesAndStockholdersEquity to LiabilitiesNoncurrent" order="2.0" weight="1.0" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://biotimeinc.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProfitLoss" xlink:label="ProfitLoss" xlink:title="ProfitLoss" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="DeferredIncomeTaxExpenseBenefit" xlink:title="DeferredIncomeTaxExpenseBenefit" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ProfitLoss" xlink:to="DeferredIncomeTaxExpenseBenefit" xlink:title="calculation: ProfitLoss to DeferredIncomeTaxExpenseBenefit" order="0.0" weight="-1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:title="IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="OperatingIncomeLoss" xlink:title="OperatingIncomeLoss" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="OperatingExpenses" xlink:title="OperatingExpenses" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="ResearchAndDevelopmentExpense" xlink:title="ResearchAndDevelopmentExpense" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="OperatingExpenses" xlink:to="ResearchAndDevelopmentExpense" xlink:title="calculation: OperatingExpenses to ResearchAndDevelopmentExpense" order="0.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="GeneralAndAdministrativeExpense" xlink:title="GeneralAndAdministrativeExpense" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="OperatingExpenses" xlink:to="GeneralAndAdministrativeExpense" xlink:title="calculation: OperatingExpenses to GeneralAndAdministrativeExpense" order="1.0" weight="1.0" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="OperatingIncomeLoss" xlink:to="OperatingExpenses" xlink:title="calculation: OperatingIncomeLoss to OperatingExpenses" order="0.0" weight="-1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_GrossProfit" xlink:label="GrossProfit" xlink:title="GrossProfit" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SalesRevenueNet" xlink:label="SalesRevenueNet" xlink:title="SalesRevenueNet" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LicensesRevenue" xlink:label="LicensesRevenue" xlink:title="LicensesRevenue" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="SalesRevenueNet" xlink:to="LicensesRevenue" xlink:title="calculation: SalesRevenueNet to LicensesRevenue" order="0.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RevenueFromGrants" xlink:label="RevenueFromGrants" xlink:title="RevenueFromGrants" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="SalesRevenueNet" xlink:to="RevenueFromGrants" xlink:title="calculation: SalesRevenueNet to RevenueFromGrants" order="2.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SalesRevenueGoodsNet" xlink:label="SalesRevenueGoodsNet" xlink:title="SalesRevenueGoodsNet" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="SalesRevenueNet" xlink:to="SalesRevenueGoodsNet" xlink:title="calculation: SalesRevenueNet to SalesRevenueGoodsNet" order="3.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RoyaltyRevenue" xlink:label="RoyaltyRevenue" xlink:title="RoyaltyRevenue" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="SalesRevenueNet" xlink:to="RoyaltyRevenue" xlink:title="calculation: SalesRevenueNet to RoyaltyRevenue" order="1.0" weight="1.0" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="GrossProfit" xlink:to="SalesRevenueNet" xlink:title="calculation: GrossProfit to SalesRevenueNet" order="0.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CostOfRevenue" xlink:label="CostOfRevenue" xlink:title="CostOfRevenue" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="GrossProfit" xlink:to="CostOfRevenue" xlink:title="calculation: GrossProfit to CostOfRevenue" order="1.0" weight="-1.0" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="OperatingIncomeLoss" xlink:to="GrossProfit" xlink:title="calculation: OperatingIncomeLoss to GrossProfit" order="1.0" weight="1.0" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="OperatingIncomeLoss" xlink:title="calculation: IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest to OperatingIncomeLoss" order="0.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="NonoperatingIncomeExpense" xlink:title="NonoperatingIncomeExpense" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="InterestIncomeExpenseNet" xlink:title="InterestIncomeExpenseNet" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NonoperatingIncomeExpense" xlink:to="InterestIncomeExpenseNet" xlink:title="calculation: NonoperatingIncomeExpense to InterestIncomeExpenseNet" order="0.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="OtherNonoperatingIncome" xlink:title="OtherNonoperatingIncome" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NonoperatingIncomeExpense" xlink:to="OtherNonoperatingIncome" xlink:title="calculation: NonoperatingIncomeExpense to OtherNonoperatingIncome" order="1.0" weight="1.0" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="NonoperatingIncomeExpense" xlink:title="calculation: IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest to NonoperatingIncomeExpense" order="1.0" weight="1.0" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ProfitLoss" xlink:to="IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:title="calculation: ProfitLoss to IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="1.0" weight="1.0" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://biotimeinc.com/role/CondensedConsolidatedStatementsOfComprehensiveLossUnaudited">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="ComprehensiveIncomeNetOfTax" xlink:title="ComprehensiveIncomeNetOfTax" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProfitLoss" xlink:label="ProfitLoss" xlink:title="ProfitLoss" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ComprehensiveIncomeNetOfTax" xlink:to="ProfitLoss" xlink:title="calculation: ComprehensiveIncomeNetOfTax to ProfitLoss" order="0.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:label="OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:title="OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ComprehensiveIncomeNetOfTax" xlink:to="OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:title="calculation: ComprehensiveIncomeNetOfTax to OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" order="1.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:title="OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ComprehensiveIncomeNetOfTax" xlink:to="OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:title="calculation: ComprehensiveIncomeNetOfTax to OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" order="2.0" weight="1.0" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://biotimeinc.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:title="CashAndCashEquivalentsPeriodIncreaseDecrease" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:title="NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="NetIncomeLossAttributableToNoncontrollingInterest" xlink:title="NetIncomeLossAttributableToNoncontrollingInterest" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="NetIncomeLossAttributableToNoncontrollingInterest" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivitiesContinuingOperations to NetIncomeLossAttributableToNoncontrollingInterest" order="15.0" weight="-1.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20150331.xsd#btx_AmortizationOfStockBasedPrepaidRent" xlink:label="AmortizationOfStockBasedPrepaidRent" xlink:title="AmortizationOfStockBasedPrepaidRent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="AmortizationOfStockBasedPrepaidRent" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivitiesContinuingOperations to AmortizationOfStockBasedPrepaidRent" order="13.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="DeferredIncomeTaxExpenseBenefit" xlink:title="DeferredIncomeTaxExpenseBenefit" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="DeferredIncomeTaxExpenseBenefit" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivitiesContinuingOperations to DeferredIncomeTaxExpenseBenefit" order="17.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Depreciation" xlink:label="Depreciation" xlink:title="Depreciation" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="Depreciation" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivitiesContinuingOperations to Depreciation" order="2.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20150331.xsd#btx_IncreaseDecreaseInGrantReceivable" xlink:label="IncreaseDecreaseInGrantReceivable" xlink:title="IncreaseDecreaseInGrantReceivable" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="IncreaseDecreaseInGrantReceivable" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivitiesContinuingOperations to IncreaseDecreaseInGrantReceivable" order="22.0" weight="-1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="NetIncomeLoss" xlink:title="NetIncomeLoss" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="NetIncomeLoss" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivitiesContinuingOperations to NetIncomeLoss" order="0.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AmortizationOfDeferredCharges" xlink:label="AmortizationOfDeferredCharges" xlink:title="AmortizationOfDeferredCharges" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="AmortizationOfDeferredCharges" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivitiesContinuingOperations to AmortizationOfDeferredCharges" order="11.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:title="IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivitiesContinuingOperations to IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" order="26.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="IncreaseDecreaseInAccountsReceivable" xlink:title="IncreaseDecreaseInAccountsReceivable" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="IncreaseDecreaseInAccountsReceivable" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivitiesContinuingOperations to IncreaseDecreaseInAccountsReceivable" order="21.0" weight="-1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="AmortizationOfDebtDiscountPremium" xlink:title="AmortizationOfDebtDiscountPremium" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="AmortizationOfDebtDiscountPremium" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivitiesContinuingOperations to AmortizationOfDebtDiscountPremium" order="4.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:label="ImpairmentOfLongLivedAssetsHeldForUse" xlink:title="ImpairmentOfLongLivedAssetsHeldForUse" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="ImpairmentOfLongLivedAssetsHeldForUse" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivitiesContinuingOperations to ImpairmentOfLongLivedAssetsHeldForUse" order="19.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20150331.xsd#btx_AmortizationOfDeferredLicenseFees" xlink:label="AmortizationOfDeferredLicenseFees" xlink:title="AmortizationOfDeferredLicenseFees" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="AmortizationOfDeferredLicenseFees" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivitiesContinuingOperations to AmortizationOfDeferredLicenseFees" order="9.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:label="IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:title="IncreaseDecreaseInOtherNoncurrentLiabilities" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivitiesContinuingOperations to IncreaseDecreaseInOtherNoncurrentLiabilities" order="28.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="AmortizationOfIntangibleAssets" xlink:title="AmortizationOfIntangibleAssets" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="AmortizationOfIntangibleAssets" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivitiesContinuingOperations to AmortizationOfIntangibleAssets" order="3.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="IncreaseDecreaseInInventories" xlink:title="IncreaseDecreaseInInventories" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="IncreaseDecreaseInInventories" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivitiesContinuingOperations to IncreaseDecreaseInInventories" order="23.0" weight="-1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="IncreaseDecreaseInDeferredRevenue" xlink:title="IncreaseDecreaseInDeferredRevenue" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="IncreaseDecreaseInDeferredRevenue" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivitiesContinuingOperations to IncreaseDecreaseInDeferredRevenue" order="27.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:title="IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivitiesContinuingOperations to IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="24.0" weight="-1.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20150331.xsd#btx_AmortizationOfDeferredConsultingFees" xlink:label="AmortizationOfDeferredConsultingFees" xlink:title="AmortizationOfDeferredConsultingFees" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="AmortizationOfDeferredConsultingFees" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivitiesContinuingOperations to AmortizationOfDeferredConsultingFees" order="8.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="ShareBasedCompensation" xlink:title="ShareBasedCompensation" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="ShareBasedCompensation" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivitiesContinuingOperations to ShareBasedCompensation" order="16.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20150331.xsd#btx_AccruedInterestOnConvertibleDebt" xlink:label="AccruedInterestOnConvertibleDebt" xlink:title="AccruedInterestOnConvertibleDebt" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="AccruedInterestOnConvertibleDebt" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivitiesContinuingOperations to AccruedInterestOnConvertibleDebt" order="6.0" weight="-1.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20150331.xsd#btx_IncreaseDecreaseInDeferredRentLiabilities" xlink:label="IncreaseDecreaseInDeferredRentLiabilities" xlink:title="IncreaseDecreaseInDeferredRentLiabilities" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="IncreaseDecreaseInDeferredRentLiabilities" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivitiesContinuingOperations to IncreaseDecreaseInDeferredRentLiabilities" order="12.0" weight="-1.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20150331.xsd#btx_ProceedsFromDeferredGrantIncome" xlink:label="ProceedsFromDeferredGrantIncome" xlink:title="ProceedsFromDeferredGrantIncome" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="ProceedsFromDeferredGrantIncome" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivitiesContinuingOperations to ProceedsFromDeferredGrantIncome" order="14.0" weight="1.0" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:title="calculation: CashAndCashEquivalentsPeriodIncreaseDecrease to NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" order="1.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:label="NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:title="NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" />
    <link:loc xlink:type="locator" xlink:href="btx-20150331.xsd#btx_SecurityDepositReceived" xlink:label="SecurityDepositReceived" xlink:title="SecurityDepositReceived" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:to="SecurityDepositReceived" xlink:title="calculation: NetCashProvidedByUsedInInvestingActivitiesContinuingOperations to SecurityDepositReceived" order="4.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="PaymentsToAcquirePropertyPlantAndEquipment" xlink:title="PaymentsToAcquirePropertyPlantAndEquipment" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:to="PaymentsToAcquirePropertyPlantAndEquipment" xlink:title="calculation: NetCashProvidedByUsedInInvestingActivitiesContinuingOperations to PaymentsToAcquirePropertyPlantAndEquipment" order="1.0" weight="-1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:title="ProceedsFromSaleOfPropertyPlantAndEquipment" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:to="ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:title="calculation: NetCashProvidedByUsedInInvestingActivitiesContinuingOperations to ProceedsFromSaleOfPropertyPlantAndEquipment" order="2.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaymentsForCapitalImprovements" xlink:label="PaymentsForCapitalImprovements" xlink:title="PaymentsForCapitalImprovements" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:to="PaymentsForCapitalImprovements" xlink:title="calculation: NetCashProvidedByUsedInInvestingActivitiesContinuingOperations to PaymentsForCapitalImprovements" order="5.0" weight="-1.0" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:title="calculation: CashAndCashEquivalentsPeriodIncreaseDecrease to NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" order="2.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:label="EffectOfExchangeRateOnCashAndCashEquivalents" xlink:title="EffectOfExchangeRateOnCashAndCashEquivalents" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="EffectOfExchangeRateOnCashAndCashEquivalents" xlink:title="calculation: CashAndCashEquivalentsPeriodIncreaseDecrease to EffectOfExchangeRateOnCashAndCashEquivalents" order="4.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:label="NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:title="NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" />
    <link:loc xlink:type="locator" xlink:href="btx-20150331.xsd#btx_ProceedsFromConstructionInProgress" xlink:label="ProceedsFromConstructionInProgress" xlink:title="ProceedsFromConstructionInProgress" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="ProceedsFromConstructionInProgress" xlink:title="calculation: NetCashProvidedByUsedInFinancingActivitiesContinuingOperations to ProceedsFromConstructionInProgress" order="6.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromSaleOfTreasuryStock" xlink:label="ProceedsFromSaleOfTreasuryStock" xlink:title="ProceedsFromSaleOfTreasuryStock" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="ProceedsFromSaleOfTreasuryStock" xlink:title="calculation: NetCashProvidedByUsedInFinancingActivitiesContinuingOperations to ProceedsFromSaleOfTreasuryStock" order="4.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="ProceedsFromStockOptionsExercised" xlink:title="ProceedsFromStockOptionsExercised" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="ProceedsFromStockOptionsExercised" xlink:title="calculation: NetCashProvidedByUsedInFinancingActivitiesContinuingOperations to ProceedsFromStockOptionsExercised" order="0.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="ProceedsFromIssuanceOfCommonStock" xlink:title="ProceedsFromIssuanceOfCommonStock" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="ProceedsFromIssuanceOfCommonStock" xlink:title="calculation: NetCashProvidedByUsedInFinancingActivitiesContinuingOperations to ProceedsFromIssuanceOfCommonStock" order="2.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CapitalLeasesIncomeStatementAmortizationExpense" xlink:label="CapitalLeasesIncomeStatementAmortizationExpense" xlink:title="CapitalLeasesIncomeStatementAmortizationExpense" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="CapitalLeasesIncomeStatementAmortizationExpense" xlink:title="calculation: NetCashProvidedByUsedInFinancingActivitiesContinuingOperations to CapitalLeasesIncomeStatementAmortizationExpense" order="8.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20150331.xsd#btx_FeesPaidOnSaleOfCommonSharesOfSubsidiary" xlink:label="FeesPaidOnSaleOfCommonSharesOfSubsidiary" xlink:title="FeesPaidOnSaleOfCommonSharesOfSubsidiary" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="FeesPaidOnSaleOfCommonSharesOfSubsidiary" xlink:title="calculation: NetCashProvidedByUsedInFinancingActivitiesContinuingOperations to FeesPaidOnSaleOfCommonSharesOfSubsidiary" order="7.0" weight="-1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromMinorityShareholders" xlink:label="ProceedsFromMinorityShareholders" xlink:title="ProceedsFromMinorityShareholders" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="ProceedsFromMinorityShareholders" xlink:title="calculation: NetCashProvidedByUsedInFinancingActivitiesContinuingOperations to ProceedsFromMinorityShareholders" order="5.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:label="ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:title="ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:title="calculation: NetCashProvidedByUsedInFinancingActivitiesContinuingOperations to ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" order="1.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20150331.xsd#btx_FeesPaidOnSaleOfCommonShares" xlink:label="FeesPaidOnSaleOfCommonShares" xlink:title="FeesPaidOnSaleOfCommonShares" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="FeesPaidOnSaleOfCommonShares" xlink:title="calculation: NetCashProvidedByUsedInFinancingActivitiesContinuingOperations to FeesPaidOnSaleOfCommonShares" order="3.0" weight="-1.0" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:title="calculation: CashAndCashEquivalentsPeriodIncreaseDecrease to NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" order="3.0" weight="1.0" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://biotimeinc.com/role/EquipmentNetAndConstructionInProgressDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="PropertyPlantAndEquipmentNet" xlink:title="PropertyPlantAndEquipmentNet" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="PropertyPlantAndEquipmentGross" xlink:title="PropertyPlantAndEquipmentGross" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="PropertyPlantAndEquipmentNet" xlink:to="PropertyPlantAndEquipmentGross" xlink:title="calculation: PropertyPlantAndEquipmentNet to PropertyPlantAndEquipmentGross" order="1.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConstructionInProgressGross" xlink:label="ConstructionInProgressGross" xlink:title="ConstructionInProgressGross" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="PropertyPlantAndEquipmentNet" xlink:to="ConstructionInProgressGross" xlink:title="calculation: PropertyPlantAndEquipmentNet to ConstructionInProgressGross" order="0.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:title="AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="PropertyPlantAndEquipmentNet" xlink:to="AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:title="calculation: PropertyPlantAndEquipmentNet to AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="2.0" weight="-1.0" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://biotimeinc.com/role/IntangibleAssetsNetDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="FiniteLivedIntangibleAssetsNet" xlink:title="FiniteLivedIntangibleAssetsNet" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:title="FiniteLivedIntangibleAssetsAccumulatedAmortization" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="FiniteLivedIntangibleAssetsNet" xlink:to="FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:title="calculation: FiniteLivedIntangibleAssetsNet to FiniteLivedIntangibleAssetsAccumulatedAmortization" order="2.0" weight="-1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="FiniteLivedIntangibleAssetsGross" xlink:title="FiniteLivedIntangibleAssetsGross" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="FiniteLivedIntangibleAssetsNet" xlink:to="FiniteLivedIntangibleAssetsGross" xlink:title="calculation: FiniteLivedIntangibleAssetsNet to FiniteLivedIntangibleAssetsGross" order="1.0" weight="1.0" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://biotimeinc.com/role/RoyaltyObligationAndDeferredLicenseFeesDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredCostsCurrentAndNoncurrent" xlink:label="DeferredCostsCurrentAndNoncurrent" xlink:title="DeferredCostsCurrentAndNoncurrent" />
    <link:loc xlink:type="locator" xlink:href="btx-20150331.xsd#btx_DeferredLicenseFeesAmortizationExpenseDueInRemainderOfFiscalYear" xlink:label="DeferredLicenseFeesAmortizationExpenseDueInRemainderOfFiscalYear" xlink:title="DeferredLicenseFeesAmortizationExpenseDueInRemainderOfFiscalYear" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="DeferredCostsCurrentAndNoncurrent" xlink:to="DeferredLicenseFeesAmortizationExpenseDueInRemainderOfFiscalYear" xlink:title="calculation: DeferredCostsCurrentAndNoncurrent to DeferredLicenseFeesAmortizationExpenseDueInRemainderOfFiscalYear" order="0.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20150331.xsd#btx_DeferredLicenseFeesAmortizationExpenseYearFour" xlink:label="DeferredLicenseFeesAmortizationExpenseYearFour" xlink:title="DeferredLicenseFeesAmortizationExpenseYearFour" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="DeferredCostsCurrentAndNoncurrent" xlink:to="DeferredLicenseFeesAmortizationExpenseYearFour" xlink:title="calculation: DeferredCostsCurrentAndNoncurrent to DeferredLicenseFeesAmortizationExpenseYearFour" order="3.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20150331.xsd#btx_DeferredLicenseFeesAmortizationExpenseYearThree" xlink:label="DeferredLicenseFeesAmortizationExpenseYearThree" xlink:title="DeferredLicenseFeesAmortizationExpenseYearThree" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="DeferredCostsCurrentAndNoncurrent" xlink:to="DeferredLicenseFeesAmortizationExpenseYearThree" xlink:title="calculation: DeferredCostsCurrentAndNoncurrent to DeferredLicenseFeesAmortizationExpenseYearThree" order="2.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20150331.xsd#btx_DeferredLicenseFeesAmortizationExpenseAfterYearFive" xlink:label="DeferredLicenseFeesAmortizationExpenseAfterYearFive" xlink:title="DeferredLicenseFeesAmortizationExpenseAfterYearFive" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="DeferredCostsCurrentAndNoncurrent" xlink:to="DeferredLicenseFeesAmortizationExpenseAfterYearFive" xlink:title="calculation: DeferredCostsCurrentAndNoncurrent to DeferredLicenseFeesAmortizationExpenseAfterYearFive" order="5.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20150331.xsd#btx_DeferredLicenseFeesAmortizationExpenseYearFive" xlink:label="DeferredLicenseFeesAmortizationExpenseYearFive" xlink:title="DeferredLicenseFeesAmortizationExpenseYearFive" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="DeferredCostsCurrentAndNoncurrent" xlink:to="DeferredLicenseFeesAmortizationExpenseYearFive" xlink:title="calculation: DeferredCostsCurrentAndNoncurrent to DeferredLicenseFeesAmortizationExpenseYearFive" order="4.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20150331.xsd#btx_DeferredLicenseFeesAmortizationExpenseYearTwo" xlink:label="DeferredLicenseFeesAmortizationExpenseYearTwo" xlink:title="DeferredLicenseFeesAmortizationExpenseYearTwo" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="DeferredCostsCurrentAndNoncurrent" xlink:to="DeferredLicenseFeesAmortizationExpenseYearTwo" xlink:title="calculation: DeferredCostsCurrentAndNoncurrent to DeferredLicenseFeesAmortizationExpenseYearTwo" order="1.0" weight="1.0" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://biotimeinc.com/role/AccountsPayableAndAccruedLiabilitiesDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="AccountsPayableAndAccruedLiabilitiesCurrent" xlink:title="AccountsPayableAndAccruedLiabilitiesCurrent" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccruedBonusesCurrent" xlink:label="AccruedBonusesCurrent" xlink:title="AccruedBonusesCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="AccruedBonusesCurrent" xlink:title="calculation: AccountsPayableAndAccruedLiabilitiesCurrent to AccruedBonusesCurrent" order="3.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="OtherAccruedLiabilitiesCurrent" xlink:title="OtherAccruedLiabilitiesCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="OtherAccruedLiabilitiesCurrent" xlink:title="calculation: AccountsPayableAndAccruedLiabilitiesCurrent to OtherAccruedLiabilitiesCurrent" order="4.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="AccountsPayableCurrent" xlink:title="AccountsPayableCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="AccountsPayableCurrent" xlink:title="calculation: AccountsPayableAndAccruedLiabilitiesCurrent to AccountsPayableCurrent" order="1.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="AccruedLiabilitiesCurrent" xlink:title="AccruedLiabilitiesCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="AccruedLiabilitiesCurrent" xlink:title="calculation: AccountsPayableAndAccruedLiabilitiesCurrent to AccruedLiabilitiesCurrent" order="2.0" weight="1.0" />
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>8
<FILENAME>btx-20150331_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--Generated by EDGARfilings PROfile 3.3.0.0 Copyright 1995 - 2015 Summit Financial Printing, LLC. All rights reserved.-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:t1="http://xbrl.org/2005/xbrldt">
  <link:roleRef roleURI="http://biotimeinc.com/role/SubsequentEventsDetails" xlink:type="simple" xlink:href="btx-20150331.xsd#SubsequentEventsDetails" />
  <link:roleRef roleURI="http://biotimeinc.com/role/SegmentInformationDetails" xlink:type="simple" xlink:href="btx-20150331.xsd#SegmentInformationDetails" />
  <link:roleRef roleURI="http://biotimeinc.com/role/SalesOfBiotimeCommonSharesBySubsidiariesDetails" xlink:type="simple" xlink:href="btx-20150331.xsd#SalesOfBiotimeCommonSharesBySubsidiariesDetails" />
  <link:roleRef roleURI="http://biotimeinc.com/role/ShareholdersEquityDetails" xlink:type="simple" xlink:href="btx-20150331.xsd#ShareholdersEquityDetails" />
  <link:roleRef roleURI="http://biotimeinc.com/role/RelatedPartyTransactionsAndRelatedPartyConvertibleDebtDetails" xlink:type="simple" xlink:href="btx-20150331.xsd#RelatedPartyTransactionsAndRelatedPartyConvertibleDebtDetails" />
  <link:roleRef roleURI="http://biotimeinc.com/role/AccountsPayableAndAccruedLiabilitiesDetails" xlink:type="simple" xlink:href="btx-20150331.xsd#AccountsPayableAndAccruedLiabilitiesDetails" />
  <link:roleRef roleURI="http://biotimeinc.com/role/RoyaltyObligationAndDeferredLicenseFeesDetails" xlink:type="simple" xlink:href="btx-20150331.xsd#RoyaltyObligationAndDeferredLicenseFeesDetails" />
  <link:roleRef roleURI="http://biotimeinc.com/role/IntangibleAssetsNetDetails" xlink:type="simple" xlink:href="btx-20150331.xsd#IntangibleAssetsNetDetails" />
  <link:roleRef roleURI="http://biotimeinc.com/role/EquipmentNetAndConstructionInProgressDetails" xlink:type="simple" xlink:href="btx-20150331.xsd#EquipmentNetAndConstructionInProgressDetails" />
  <link:roleRef roleURI="http://biotimeinc.com/role/InventoryDetails" xlink:type="simple" xlink:href="btx-20150331.xsd#InventoryDetails" />
  <link:roleRef roleURI="http://biotimeinc.com/role/SummaryOfSignificantAccountingPoliciesDetails" xlink:type="simple" xlink:href="btx-20150331.xsd#SummaryOfSignificantAccountingPoliciesDetails" />
  <link:roleRef roleURI="http://biotimeinc.com/role/OrganizationBasisOfPresentationAndLiquidityDetails" xlink:type="simple" xlink:href="btx-20150331.xsd#OrganizationBasisOfPresentationAndLiquidityDetails" />
  <link:roleRef roleURI="http://biotimeinc.com/role/AccountsPayableAndAccruedLiabilitiesTables" xlink:type="simple" xlink:href="btx-20150331.xsd#AccountsPayableAndAccruedLiabilitiesTables" />
  <link:roleRef roleURI="http://biotimeinc.com/role/RoyaltyObligationAndDeferredLicenseFeesTables" xlink:type="simple" xlink:href="btx-20150331.xsd#RoyaltyObligationAndDeferredLicenseFeesTables" />
  <link:roleRef roleURI="http://biotimeinc.com/role/IntangibleAssetsNetTables" xlink:type="simple" xlink:href="btx-20150331.xsd#IntangibleAssetsNetTables" />
  <link:roleRef roleURI="http://biotimeinc.com/role/EquipmentNetAndConstructionInProgressTables" xlink:type="simple" xlink:href="btx-20150331.xsd#EquipmentNetAndConstructionInProgressTables" />
  <link:roleRef roleURI="http://biotimeinc.com/role/OrganizationBasisOfPresentationAndLiquidityTables" xlink:type="simple" xlink:href="btx-20150331.xsd#OrganizationBasisOfPresentationAndLiquidityTables" />
  <link:roleRef roleURI="http://biotimeinc.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="btx-20150331.xsd#SummaryOfSignificantAccountingPoliciesPolicies" />
  <link:roleRef roleURI="http://biotimeinc.com/role/SubsequentEvents" xlink:type="simple" xlink:href="btx-20150331.xsd#SubsequentEvents" />
  <link:roleRef roleURI="http://biotimeinc.com/role/SegmentInformation" xlink:type="simple" xlink:href="btx-20150331.xsd#SegmentInformation" />
  <link:roleRef roleURI="http://biotimeinc.com/role/SalesOfBiotimeCommonSharesBySubsidiaries" xlink:type="simple" xlink:href="btx-20150331.xsd#SalesOfBiotimeCommonSharesBySubsidiaries" />
  <link:roleRef roleURI="http://biotimeinc.com/role/ShareholdersEquity" xlink:type="simple" xlink:href="btx-20150331.xsd#ShareholdersEquity" />
  <link:roleRef roleURI="http://biotimeinc.com/role/RelatedPartyTransactionsAndRelatedPartyConvertibleDebt" xlink:type="simple" xlink:href="btx-20150331.xsd#RelatedPartyTransactionsAndRelatedPartyConvertibleDebt" />
  <link:roleRef roleURI="http://biotimeinc.com/role/AccountsPayableAndAccruedLiabilities" xlink:type="simple" xlink:href="btx-20150331.xsd#AccountsPayableAndAccruedLiabilities" />
  <link:roleRef roleURI="http://biotimeinc.com/role/RoyaltyObligationAndDeferredLicenseFees" xlink:type="simple" xlink:href="btx-20150331.xsd#RoyaltyObligationAndDeferredLicenseFees" />
  <link:roleRef roleURI="http://biotimeinc.com/role/IntangibleAssetsNet" xlink:type="simple" xlink:href="btx-20150331.xsd#IntangibleAssetsNet" />
  <link:roleRef roleURI="http://biotimeinc.com/role/EquipmentNetAndConstructionInProgress" xlink:type="simple" xlink:href="btx-20150331.xsd#EquipmentNetAndConstructionInProgress" />
  <link:roleRef roleURI="http://biotimeinc.com/role/Inventory" xlink:type="simple" xlink:href="btx-20150331.xsd#Inventory" />
  <link:roleRef roleURI="http://biotimeinc.com/role/SummaryOfSignificantAccountingPolicies" xlink:type="simple" xlink:href="btx-20150331.xsd#SummaryOfSignificantAccountingPolicies" />
  <link:roleRef roleURI="http://biotimeinc.com/role/OrganizationBasisOfPresentationAndLiquidity" xlink:type="simple" xlink:href="btx-20150331.xsd#OrganizationBasisOfPresentationAndLiquidity" />
  <link:roleRef roleURI="http://biotimeinc.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" xlink:type="simple" xlink:href="btx-20150331.xsd#CondensedConsolidatedStatementsOfCashFlowsUnaudited" />
  <link:roleRef roleURI="http://biotimeinc.com/role/CondensedConsolidatedStatementsOfComprehensiveLossUnaudited" xlink:type="simple" xlink:href="btx-20150331.xsd#CondensedConsolidatedStatementsOfComprehensiveLossUnaudited" />
  <link:roleRef roleURI="http://biotimeinc.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited" xlink:type="simple" xlink:href="btx-20150331.xsd#CondensedConsolidatedStatementsOfOperationsUnaudited" />
  <link:roleRef roleURI="http://biotimeinc.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" xlink:type="simple" xlink:href="btx-20150331.xsd#CondensedConsolidatedBalanceSheetsUnauditedParenthetical" />
  <link:roleRef roleURI="http://biotimeinc.com/role/CondensedConsolidatedBalanceSheetsUnaudited" xlink:type="simple" xlink:href="btx-20150331.xsd#CondensedConsolidatedBalanceSheetsUnaudited" />
  <link:roleRef roleURI="http://biotimeinc.com/role/DocumentAndEntityInformation" xlink:type="simple" xlink:href="btx-20150331.xsd#DocumentAndEntityInformation" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" />
  <link:definitionLink xlink:type="extended" xlink:role="http://biotimeinc.com/role/DocumentAndEntityInformation" />
  <link:definitionLink xlink:type="extended" xlink:role="http://biotimeinc.com/role/CondensedConsolidatedBalanceSheetsUnaudited" />
  <link:definitionLink xlink:type="extended" xlink:role="http://biotimeinc.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" />
  <link:definitionLink xlink:type="extended" xlink:role="http://biotimeinc.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited" />
  <link:definitionLink xlink:type="extended" xlink:role="http://biotimeinc.com/role/CondensedConsolidatedStatementsOfComprehensiveLossUnaudited" />
  <link:definitionLink xlink:type="extended" xlink:role="http://biotimeinc.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" />
  <link:definitionLink xlink:type="extended" xlink:role="http://biotimeinc.com/role/OrganizationBasisOfPresentationAndLiquidity" />
  <link:definitionLink xlink:type="extended" xlink:role="http://biotimeinc.com/role/SummaryOfSignificantAccountingPolicies" />
  <link:definitionLink xlink:type="extended" xlink:role="http://biotimeinc.com/role/Inventory" />
  <link:definitionLink xlink:type="extended" xlink:role="http://biotimeinc.com/role/EquipmentNetAndConstructionInProgress" />
  <link:definitionLink xlink:type="extended" xlink:role="http://biotimeinc.com/role/IntangibleAssetsNet" />
  <link:definitionLink xlink:type="extended" xlink:role="http://biotimeinc.com/role/RoyaltyObligationAndDeferredLicenseFees" />
  <link:definitionLink xlink:type="extended" xlink:role="http://biotimeinc.com/role/AccountsPayableAndAccruedLiabilities" />
  <link:definitionLink xlink:type="extended" xlink:role="http://biotimeinc.com/role/RelatedPartyTransactionsAndRelatedPartyConvertibleDebt" />
  <link:definitionLink xlink:type="extended" xlink:role="http://biotimeinc.com/role/ShareholdersEquity" />
  <link:definitionLink xlink:type="extended" xlink:role="http://biotimeinc.com/role/SalesOfBiotimeCommonSharesBySubsidiaries" />
  <link:definitionLink xlink:type="extended" xlink:role="http://biotimeinc.com/role/SegmentInformation" />
  <link:definitionLink xlink:type="extended" xlink:role="http://biotimeinc.com/role/SubsequentEvents" />
  <link:definitionLink xlink:type="extended" xlink:role="http://biotimeinc.com/role/SummaryOfSignificantAccountingPoliciesPolicies" />
  <link:definitionLink xlink:type="extended" xlink:role="http://biotimeinc.com/role/OrganizationBasisOfPresentationAndLiquidityTables" />
  <link:definitionLink xlink:type="extended" xlink:role="http://biotimeinc.com/role/EquipmentNetAndConstructionInProgressTables" />
  <link:definitionLink xlink:type="extended" xlink:role="http://biotimeinc.com/role/IntangibleAssetsNetTables" />
  <link:definitionLink xlink:type="extended" xlink:role="http://biotimeinc.com/role/RoyaltyObligationAndDeferredLicenseFeesTables" />
  <link:definitionLink xlink:type="extended" xlink:role="http://biotimeinc.com/role/AccountsPayableAndAccruedLiabilitiesTables" />
  <link:definitionLink xlink:type="extended" xlink:role="http://biotimeinc.com/role/OrganizationBasisOfPresentationAndLiquidityDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MinorityInterestLineItems" xlink:label="MinorityInterestLineItems" xlink:title="MinorityInterestLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:label="MinorityInterestOwnershipPercentageByParent" xlink:title="MinorityInterestOwnershipPercentageByParent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="MinorityInterestLineItems" xlink:to="MinorityInterestOwnershipPercentageByParent" xlink:title="definition: MinorityInterestLineItems to MinorityInterestOwnershipPercentageByParent" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="RetainedEarningsAccumulatedDeficit" xlink:title="RetainedEarningsAccumulatedDeficit" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="MinorityInterestLineItems" xlink:to="RetainedEarningsAccumulatedDeficit" xlink:title="definition: MinorityInterestLineItems to RetainedEarningsAccumulatedDeficit" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Capital" xlink:label="Capital" xlink:title="Capital" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="MinorityInterestLineItems" xlink:to="Capital" xlink:title="definition: MinorityInterestLineItems to Capital" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:title="StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="MinorityInterestLineItems" xlink:to="StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:title="definition: MinorityInterestLineItems to StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="CashAndCashEquivalentsAtCarryingValue" xlink:title="CashAndCashEquivalentsAtCarryingValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="MinorityInterestLineItems" xlink:to="CashAndCashEquivalentsAtCarryingValue" xlink:title="definition: MinorityInterestLineItems to CashAndCashEquivalentsAtCarryingValue" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MinorityInterestTable" xlink:label="MinorityInterestTable" xlink:title="MinorityInterestTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="MinorityInterestLineItems" xlink:to="MinorityInterestTable" xlink:title="definition: MinorityInterestLineItems to MinorityInterestTable" order="6.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="LegalEntityAxis" xlink:title="LegalEntityAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="MinorityInterestTable" xlink:to="LegalEntityAxis" xlink:title="definition: MinorityInterestTable to LegalEntityAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="EntityDomain" xlink:title="EntityDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="LegalEntityAxis" xlink:to="EntityDomain" xlink:title="definition: LegalEntityAxis to EntityDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="EntityDomain_2" xlink:title="EntityDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="LegalEntityAxis" xlink:to="EntityDomain_2" xlink:title="definition: LegalEntityAxis to EntityDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20150331.xsd#btx_AsteriasBiotherapeuticsMember" xlink:label="AsteriasBiotherapeuticsMember" xlink:title="AsteriasBiotherapeuticsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EntityDomain" xlink:to="AsteriasBiotherapeuticsMember" xlink:title="definition: EntityDomain to AsteriasBiotherapeuticsMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20150331.xsd#btx_BiotimeAsiaLimitedMember" xlink:label="BiotimeAsiaLimitedMember" xlink:title="BiotimeAsiaLimitedMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EntityDomain" xlink:to="BiotimeAsiaLimitedMember" xlink:title="definition: EntityDomain to BiotimeAsiaLimitedMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20150331.xsd#btx_CellCureNeurosciencesLtdMember" xlink:label="CellCureNeurosciencesLtdMember" xlink:title="CellCureNeurosciencesLtdMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EntityDomain" xlink:to="CellCureNeurosciencesLtdMember" xlink:title="definition: EntityDomain to CellCureNeurosciencesLtdMember" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20150331.xsd#btx_EsCellInternationalPteLtdMember" xlink:label="EsCellInternationalPteLtdMember" xlink:title="EsCellInternationalPteLtdMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EntityDomain" xlink:to="EsCellInternationalPteLtdMember" xlink:title="definition: EntityDomain to EsCellInternationalPteLtdMember" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20150331.xsd#btx_LifemapSciencesIncMember" xlink:label="LifemapSciencesIncMember" xlink:title="LifemapSciencesIncMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EntityDomain" xlink:to="LifemapSciencesIncMember" xlink:title="definition: EntityDomain to LifemapSciencesIncMember" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20150331.xsd#btx_LifemapSciencesLtdMember" xlink:label="LifemapSciencesLtdMember" xlink:title="LifemapSciencesLtdMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EntityDomain" xlink:to="LifemapSciencesLtdMember" xlink:title="definition: EntityDomain to LifemapSciencesLtdMember" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20150331.xsd#btx_LifemapSolutionsIncMember" xlink:label="LifemapSolutionsIncMember" xlink:title="LifemapSolutionsIncMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EntityDomain" xlink:to="LifemapSolutionsIncMember" xlink:title="definition: EntityDomain to LifemapSolutionsIncMember" order="7.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20150331.xsd#btx_OncocyteCorporationMember" xlink:label="OncocyteCorporationMember" xlink:title="OncocyteCorporationMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EntityDomain" xlink:to="OncocyteCorporationMember" xlink:title="definition: EntityDomain to OncocyteCorporationMember" order="8.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20150331.xsd#btx_OrthocyteCorporationMember" xlink:label="OrthocyteCorporationMember" xlink:title="OrthocyteCorporationMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EntityDomain" xlink:to="OrthocyteCorporationMember" xlink:title="definition: EntityDomain to OrthocyteCorporationMember" order="9.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20150331.xsd#btx_RecyteTherapeuticsIncMember" xlink:label="RecyteTherapeuticsIncMember" xlink:title="RecyteTherapeuticsIncMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EntityDomain" xlink:to="RecyteTherapeuticsIncMember" xlink:title="definition: EntityDomain to RecyteTherapeuticsIncMember" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsidiariesMember" xlink:label="SubsidiariesMember" xlink:title="SubsidiariesMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EntityDomain" xlink:to="SubsidiariesMember" xlink:title="definition: EntityDomain to SubsidiariesMember" order="11.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="StatementEquityComponentsAxis" xlink:title="StatementEquityComponentsAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="MinorityInterestTable" xlink:to="StatementEquityComponentsAxis" xlink:title="definition: MinorityInterestTable to StatementEquityComponentsAxis" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="EquityComponentDomain" xlink:title="EquityComponentDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="StatementEquityComponentsAxis" xlink:to="EquityComponentDomain" xlink:title="definition: StatementEquityComponentsAxis to EquityComponentDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="EquityComponentDomain_2" xlink:title="EquityComponentDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="StatementEquityComponentsAxis" xlink:to="EquityComponentDomain_2" xlink:title="definition: StatementEquityComponentsAxis to EquityComponentDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ParentMember" xlink:label="ParentMember" xlink:title="ParentMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EquityComponentDomain" xlink:to="ParentMember" xlink:title="definition: EquityComponentDomain to ParentMember" order="1.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://biotimeinc.com/role/SummaryOfSignificantAccountingPoliciesDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:title="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:title="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:title="definition: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems to AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:title="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:title="definition: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems to ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="2.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:title="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:title="definition: ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable to AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="AntidilutiveSecuritiesNameDomain" xlink:title="AntidilutiveSecuritiesNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="AntidilutiveSecuritiesNameDomain" xlink:title="definition: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis to AntidilutiveSecuritiesNameDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="AntidilutiveSecuritiesNameDomain_2" xlink:title="AntidilutiveSecuritiesNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="AntidilutiveSecuritiesNameDomain_2" xlink:title="definition: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis to AntidilutiveSecuritiesNameDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TreasuryStockMember" xlink:label="TreasuryStockMember" xlink:title="TreasuryStockMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AntidilutiveSecuritiesNameDomain" xlink:to="TreasuryStockMember" xlink:title="definition: AntidilutiveSecuritiesNameDomain to TreasuryStockMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="EmployeeStockOptionMember" xlink:title="EmployeeStockOptionMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AntidilutiveSecuritiesNameDomain" xlink:to="EmployeeStockOptionMember" xlink:title="definition: AntidilutiveSecuritiesNameDomain to EmployeeStockOptionMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WarrantMember" xlink:label="WarrantMember" xlink:title="WarrantMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AntidilutiveSecuritiesNameDomain" xlink:to="WarrantMember" xlink:title="definition: AntidilutiveSecuritiesNameDomain to WarrantMember" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="FiniteLivedIntangibleAssetsLineItems" xlink:title="FiniteLivedIntangibleAssetsLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="FiniteLivedIntangibleAssetUsefulLife" xlink:title="FiniteLivedIntangibleAssetUsefulLife" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FiniteLivedIntangibleAssetsLineItems" xlink:to="FiniteLivedIntangibleAssetUsefulLife" xlink:title="definition: FiniteLivedIntangibleAssetsLineItems to FiniteLivedIntangibleAssetUsefulLife" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:title="ScheduleOfFiniteLivedIntangibleAssetsTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="FiniteLivedIntangibleAssetsLineItems" xlink:to="ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:title="definition: FiniteLivedIntangibleAssetsLineItems to ScheduleOfFiniteLivedIntangibleAssetsTable" order="2.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:title="FiniteLivedIntangibleAssetsByMajorClassAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:title="definition: ScheduleOfFiniteLivedIntangibleAssetsTable to FiniteLivedIntangibleAssetsByMajorClassAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:title="FiniteLivedIntangibleAssetsMajorClassNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:title="definition: FiniteLivedIntangibleAssetsByMajorClassAxis to FiniteLivedIntangibleAssetsMajorClassNameDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="FiniteLivedIntangibleAssetsMajorClassNameDomain_2" xlink:title="FiniteLivedIntangibleAssetsMajorClassNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="FiniteLivedIntangibleAssetsMajorClassNameDomain_2" xlink:title="definition: FiniteLivedIntangibleAssetsByMajorClassAxis to FiniteLivedIntangibleAssetsMajorClassNameDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TechnologyBasedIntangibleAssetsMember" xlink:label="TechnologyBasedIntangibleAssetsMember" xlink:title="TechnologyBasedIntangibleAssetsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="TechnologyBasedIntangibleAssetsMember" xlink:title="definition: FiniteLivedIntangibleAssetsMajorClassNameDomain to TechnologyBasedIntangibleAssetsMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="PropertyPlantAndEquipmentLineItems" xlink:title="PropertyPlantAndEquipmentLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="PropertyPlantAndEquipmentUsefulLife" xlink:title="PropertyPlantAndEquipmentUsefulLife" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="PropertyPlantAndEquipmentLineItems" xlink:to="PropertyPlantAndEquipmentUsefulLife" xlink:title="definition: PropertyPlantAndEquipmentLineItems to PropertyPlantAndEquipmentUsefulLife" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="ScheduleOfPropertyPlantAndEquipmentTable" xlink:title="ScheduleOfPropertyPlantAndEquipmentTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="PropertyPlantAndEquipmentLineItems" xlink:to="ScheduleOfPropertyPlantAndEquipmentTable" xlink:title="definition: PropertyPlantAndEquipmentLineItems to ScheduleOfPropertyPlantAndEquipmentTable" order="2.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="PropertyPlantAndEquipmentByTypeAxis" xlink:title="PropertyPlantAndEquipmentByTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="PropertyPlantAndEquipmentByTypeAxis" xlink:title="definition: ScheduleOfPropertyPlantAndEquipmentTable to PropertyPlantAndEquipmentByTypeAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="PropertyPlantAndEquipmentTypeDomain" xlink:title="PropertyPlantAndEquipmentTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="PropertyPlantAndEquipmentByTypeAxis" xlink:to="PropertyPlantAndEquipmentTypeDomain" xlink:title="definition: PropertyPlantAndEquipmentByTypeAxis to PropertyPlantAndEquipmentTypeDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="PropertyPlantAndEquipmentTypeDomain_2" xlink:title="PropertyPlantAndEquipmentTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="PropertyPlantAndEquipmentByTypeAxis" xlink:to="PropertyPlantAndEquipmentTypeDomain_2" xlink:title="definition: PropertyPlantAndEquipmentByTypeAxis to PropertyPlantAndEquipmentTypeDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquipmentMember" xlink:label="EquipmentMember" xlink:title="EquipmentMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="PropertyPlantAndEquipmentTypeDomain" xlink:to="EquipmentMember" xlink:title="definition: PropertyPlantAndEquipmentTypeDomain to EquipmentMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeAxis" xlink:label="RangeAxis" xlink:title="RangeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="RangeAxis" xlink:title="definition: ScheduleOfPropertyPlantAndEquipmentTable to RangeAxis" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeMember" xlink:label="RangeMember" xlink:title="RangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="RangeAxis" xlink:to="RangeMember" xlink:title="definition: RangeAxis to RangeMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeMember" xlink:label="RangeMember_2" xlink:title="RangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="RangeAxis" xlink:to="RangeMember_2" xlink:title="definition: RangeAxis to RangeMember_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MinimumMember" xlink:label="MinimumMember" xlink:title="MinimumMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RangeMember" xlink:to="MinimumMember" xlink:title="definition: RangeMember to MinimumMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MaximumMember" xlink:label="MaximumMember" xlink:title="MaximumMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RangeMember" xlink:to="MaximumMember" xlink:title="definition: RangeMember to MaximumMember" order="2.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://biotimeinc.com/role/InventoryDetails" />
  <link:definitionLink xlink:type="extended" xlink:role="http://biotimeinc.com/role/EquipmentNetAndConstructionInProgressDetails" />
  <link:definitionLink xlink:type="extended" xlink:role="http://biotimeinc.com/role/IntangibleAssetsNetDetails" />
  <link:definitionLink xlink:type="extended" xlink:role="http://biotimeinc.com/role/RoyaltyObligationAndDeferredLicenseFeesDetails" />
  <link:definitionLink xlink:type="extended" xlink:role="http://biotimeinc.com/role/AccountsPayableAndAccruedLiabilitiesDetails" />
  <link:definitionLink xlink:type="extended" xlink:role="http://biotimeinc.com/role/RelatedPartyTransactionsAndRelatedPartyConvertibleDebtDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="RelatedPartyTransactionLineItems" xlink:title="RelatedPartyTransactionLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaymentsForRent" xlink:label="PaymentsForRent" xlink:title="PaymentsForRent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RelatedPartyTransactionLineItems" xlink:to="PaymentsForRent" xlink:title="definition: RelatedPartyTransactionLineItems to PaymentsForRent" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AreaOfLand" xlink:label="AreaOfLand" xlink:title="AreaOfLand" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RelatedPartyTransactionLineItems" xlink:to="AreaOfLand" xlink:title="definition: RelatedPartyTransactionLineItems to AreaOfLand" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="ProceedsFromIssuanceOfCommonStock" xlink:title="ProceedsFromIssuanceOfCommonStock" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RelatedPartyTransactionLineItems" xlink:to="ProceedsFromIssuanceOfCommonStock" xlink:title="definition: RelatedPartyTransactionLineItems to ProceedsFromIssuanceOfCommonStock" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="SaleOfStockNumberOfSharesIssuedInTransaction" xlink:title="SaleOfStockNumberOfSharesIssuedInTransaction" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RelatedPartyTransactionLineItems" xlink:to="SaleOfStockNumberOfSharesIssuedInTransaction" xlink:title="definition: RelatedPartyTransactionLineItems to SaleOfStockNumberOfSharesIssuedInTransaction" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharePrice" xlink:label="SharePrice" xlink:title="SharePrice" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RelatedPartyTransactionLineItems" xlink:to="SharePrice" xlink:title="definition: RelatedPartyTransactionLineItems to SharePrice" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharesIssued" xlink:label="SharesIssued" xlink:title="SharesIssued" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RelatedPartyTransactionLineItems" xlink:to="SharesIssued" xlink:title="definition: RelatedPartyTransactionLineItems to SharesIssued" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20150331.xsd#btx_NumberOfCellCureNeurosciencesInvestors" xlink:label="NumberOfCellCureNeurosciencesInvestors" xlink:title="NumberOfCellCureNeurosciencesInvestors" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RelatedPartyTransactionLineItems" xlink:to="NumberOfCellCureNeurosciencesInvestors" xlink:title="definition: RelatedPartyTransactionLineItems to NumberOfCellCureNeurosciencesInvestors" order="7.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="DebtInstrumentInterestRateStatedPercentage" xlink:title="DebtInstrumentInterestRateStatedPercentage" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RelatedPartyTransactionLineItems" xlink:to="DebtInstrumentInterestRateStatedPercentage" xlink:title="definition: RelatedPartyTransactionLineItems to DebtInstrumentInterestRateStatedPercentage" order="8.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="DebtInstrumentConvertibleConversionPrice1" xlink:title="DebtInstrumentConvertibleConversionPrice1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RelatedPartyTransactionLineItems" xlink:to="DebtInstrumentConvertibleConversionPrice1" xlink:title="definition: RelatedPartyTransactionLineItems to DebtInstrumentConvertibleConversionPrice1" order="9.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20150331.xsd#btx_EstimatedFairMarketValue" xlink:label="EstimatedFairMarketValue" xlink:title="EstimatedFairMarketValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RelatedPartyTransactionLineItems" xlink:to="EstimatedFairMarketValue" xlink:title="definition: RelatedPartyTransactionLineItems to EstimatedFairMarketValue" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="ProceedsFromConvertibleDebt" xlink:title="ProceedsFromConvertibleDebt" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RelatedPartyTransactionLineItems" xlink:to="ProceedsFromConvertibleDebt" xlink:title="definition: RelatedPartyTransactionLineItems to ProceedsFromConvertibleDebt" order="11.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentTerm" xlink:label="DebtInstrumentTerm" xlink:title="DebtInstrumentTerm" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RelatedPartyTransactionLineItems" xlink:to="DebtInstrumentTerm" xlink:title="definition: RelatedPartyTransactionLineItems to DebtInstrumentTerm" order="12.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="DebtInstrumentInterestRateEffectivePercentage" xlink:title="DebtInstrumentInterestRateEffectivePercentage" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RelatedPartyTransactionLineItems" xlink:to="DebtInstrumentInterestRateEffectivePercentage" xlink:title="definition: RelatedPartyTransactionLineItems to DebtInstrumentInterestRateEffectivePercentage" order="13.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConvertibleNotesPayableCurrent" xlink:label="ConvertibleNotesPayableCurrent" xlink:title="ConvertibleNotesPayableCurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RelatedPartyTransactionLineItems" xlink:to="ConvertibleNotesPayableCurrent" xlink:title="definition: RelatedPartyTransactionLineItems to ConvertibleNotesPayableCurrent" order="14.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConvertibleDebt" xlink:label="ConvertibleDebt" xlink:title="ConvertibleDebt" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RelatedPartyTransactionLineItems" xlink:to="ConvertibleDebt" xlink:title="definition: RelatedPartyTransactionLineItems to ConvertibleDebt" order="15.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="DebtInstrumentUnamortizedDiscount" xlink:title="DebtInstrumentUnamortizedDiscount" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RelatedPartyTransactionLineItems" xlink:to="DebtInstrumentUnamortizedDiscount" xlink:title="definition: RelatedPartyTransactionLineItems to DebtInstrumentUnamortizedDiscount" order="16.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:title="ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="RelatedPartyTransactionLineItems" xlink:to="ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:title="definition: RelatedPartyTransactionLineItems to ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" order="17.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="RelatedPartyTransactionsByRelatedPartyAxis" xlink:title="RelatedPartyTransactionsByRelatedPartyAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="RelatedPartyTransactionsByRelatedPartyAxis" xlink:title="definition: ScheduleOfRelatedPartyTransactionsByRelatedPartyTable to RelatedPartyTransactionsByRelatedPartyAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="RelatedPartyDomain" xlink:title="RelatedPartyDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="RelatedPartyDomain" xlink:title="definition: RelatedPartyTransactionsByRelatedPartyAxis to RelatedPartyDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="RelatedPartyDomain_2" xlink:title="RelatedPartyDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="RelatedPartyDomain_2" xlink:title="definition: RelatedPartyTransactionsByRelatedPartyAxis to RelatedPartyDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20150331.xsd#btx_AsteriasBiotherapeuticsMember" xlink:label="AsteriasBiotherapeuticsMember" xlink:title="AsteriasBiotherapeuticsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RelatedPartyDomain" xlink:to="AsteriasBiotherapeuticsMember" xlink:title="definition: RelatedPartyDomain to AsteriasBiotherapeuticsMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20150331.xsd#btx_CellCureNeurosciencesLtdMember" xlink:label="CellCureNeurosciencesLtdMember" xlink:title="CellCureNeurosciencesLtdMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RelatedPartyDomain" xlink:to="CellCureNeurosciencesLtdMember" xlink:title="definition: RelatedPartyDomain to CellCureNeurosciencesLtdMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="RelatedPartyTransactionAxis" xlink:title="RelatedPartyTransactionAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="RelatedPartyTransactionAxis" xlink:title="definition: ScheduleOfRelatedPartyTransactionsByRelatedPartyTable to RelatedPartyTransactionAxis" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="RelatedPartyTransactionDomain" xlink:title="RelatedPartyTransactionDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="RelatedPartyTransactionAxis" xlink:to="RelatedPartyTransactionDomain" xlink:title="definition: RelatedPartyTransactionAxis to RelatedPartyTransactionDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="RelatedPartyTransactionDomain_2" xlink:title="RelatedPartyTransactionDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="RelatedPartyTransactionAxis" xlink:to="RelatedPartyTransactionDomain_2" xlink:title="definition: RelatedPartyTransactionAxis to RelatedPartyTransactionDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonClassAMember" xlink:label="CommonClassAMember" xlink:title="CommonClassAMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RelatedPartyTransactionDomain" xlink:to="CommonClassAMember" xlink:title="definition: RelatedPartyTransactionDomain to CommonClassAMember" order="1.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://biotimeinc.com/role/ShareholdersEquityDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="ClassOfStockLineItems" xlink:title="ClassOfStockLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:label="PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:title="PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfStockLineItems" xlink:to="PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:title="definition: ClassOfStockLineItems to PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:label="CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:title="CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfStockLineItems" xlink:to="CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:title="definition: ClassOfStockLineItems to CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="CommonStockSharesAuthorized" xlink:title="CommonStockSharesAuthorized" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfStockLineItems" xlink:to="CommonStockSharesAuthorized" xlink:title="definition: ClassOfStockLineItems to CommonStockSharesAuthorized" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockNoParValue" xlink:label="CommonStockNoParValue" xlink:title="CommonStockNoParValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfStockLineItems" xlink:to="CommonStockNoParValue" xlink:title="definition: ClassOfStockLineItems to CommonStockNoParValue" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="CommonStockSharesIssued" xlink:title="CommonStockSharesIssued" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfStockLineItems" xlink:to="CommonStockSharesIssued" xlink:title="definition: ClassOfStockLineItems to CommonStockSharesIssued" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="CommonStockSharesOutstanding" xlink:title="CommonStockSharesOutstanding" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfStockLineItems" xlink:to="CommonStockSharesOutstanding" xlink:title="definition: ClassOfStockLineItems to CommonStockSharesOutstanding" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TreasuryStockShares" xlink:label="TreasuryStockShares" xlink:title="TreasuryStockShares" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfStockLineItems" xlink:to="TreasuryStockShares" xlink:title="definition: ClassOfStockLineItems to TreasuryStockShares" order="7.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfStockLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:title="definition: ClassOfStockLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="8.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:title="StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfStockLineItems" xlink:to="StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:title="definition: ClassOfStockLineItems to StockIssuedDuringPeriodSharesStockOptionsExercised" order="9.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20150331.xsd#btx_WarrantsExercised" xlink:label="WarrantsExercised" xlink:title="WarrantsExercised" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfStockLineItems" xlink:to="WarrantsExercised" xlink:title="definition: ClassOfStockLineItems to WarrantsExercised" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="PreferredStockSharesAuthorized" xlink:title="PreferredStockSharesAuthorized" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfStockLineItems" xlink:to="PreferredStockSharesAuthorized" xlink:title="definition: ClassOfStockLineItems to PreferredStockSharesAuthorized" order="11.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="PreferredStockSharesOutstanding" xlink:title="PreferredStockSharesOutstanding" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfStockLineItems" xlink:to="PreferredStockSharesOutstanding" xlink:title="definition: ClassOfStockLineItems to PreferredStockSharesOutstanding" order="12.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockDividendRatePercentage" xlink:label="PreferredStockDividendRatePercentage" xlink:title="PreferredStockDividendRatePercentage" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfStockLineItems" xlink:to="PreferredStockDividendRatePercentage" xlink:title="definition: ClassOfStockLineItems to PreferredStockDividendRatePercentage" order="13.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockDividendRatePerDollarAmount" xlink:label="PreferredStockDividendRatePerDollarAmount" xlink:title="PreferredStockDividendRatePerDollarAmount" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfStockLineItems" xlink:to="PreferredStockDividendRatePerDollarAmount" xlink:title="definition: ClassOfStockLineItems to PreferredStockDividendRatePerDollarAmount" order="14.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20150331.xsd#btx_PricePerShareOfOptionsToPurchaseCompany" xlink:label="PricePerShareOfOptionsToPurchaseCompany" xlink:title="PricePerShareOfOptionsToPurchaseCompany" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfStockLineItems" xlink:to="PricePerShareOfOptionsToPurchaseCompany" xlink:title="definition: ClassOfStockLineItems to PricePerShareOfOptionsToPurchaseCompany" order="15.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20150331.xsd#btx_PreferredSharesConvertibleConversionRatio" xlink:label="PreferredSharesConvertibleConversionRatio" xlink:title="PreferredSharesConvertibleConversionRatio" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfStockLineItems" xlink:to="PreferredSharesConvertibleConversionRatio" xlink:title="definition: ClassOfStockLineItems to PreferredSharesConvertibleConversionRatio" order="16.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="ScheduleOfStockByClassTable" xlink:title="ScheduleOfStockByClassTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ClassOfStockLineItems" xlink:to="ScheduleOfStockByClassTable" xlink:title="definition: ClassOfStockLineItems to ScheduleOfStockByClassTable" order="17.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="StatementClassOfStockAxis" xlink:title="StatementClassOfStockAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfStockByClassTable" xlink:to="StatementClassOfStockAxis" xlink:title="definition: ScheduleOfStockByClassTable to StatementClassOfStockAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="ClassOfStockDomain" xlink:title="ClassOfStockDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="StatementClassOfStockAxis" xlink:to="ClassOfStockDomain" xlink:title="definition: StatementClassOfStockAxis to ClassOfStockDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="ClassOfStockDomain_2" xlink:title="ClassOfStockDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="StatementClassOfStockAxis" xlink:to="ClassOfStockDomain_2" xlink:title="definition: StatementClassOfStockAxis to ClassOfStockDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="SeriesAPreferredStockMember" xlink:title="SeriesAPreferredStockMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfStockDomain" xlink:to="SeriesAPreferredStockMember" xlink:title="definition: ClassOfStockDomain to SeriesAPreferredStockMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="LegalEntityAxis" xlink:title="LegalEntityAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfStockByClassTable" xlink:to="LegalEntityAxis" xlink:title="definition: ScheduleOfStockByClassTable to LegalEntityAxis" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="EntityDomain" xlink:title="EntityDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="LegalEntityAxis" xlink:to="EntityDomain" xlink:title="definition: LegalEntityAxis to EntityDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="EntityDomain_2" xlink:title="EntityDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="LegalEntityAxis" xlink:to="EntityDomain_2" xlink:title="definition: LegalEntityAxis to EntityDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20150331.xsd#btx_AsteriasBiotherapeuticsMember" xlink:label="AsteriasBiotherapeuticsMember" xlink:title="AsteriasBiotherapeuticsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EntityDomain" xlink:to="AsteriasBiotherapeuticsMember" xlink:title="definition: EntityDomain to AsteriasBiotherapeuticsMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20150331.xsd#btx_OrthocyteCorporationMember" xlink:label="OrthocyteCorporationMember" xlink:title="OrthocyteCorporationMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EntityDomain" xlink:to="OrthocyteCorporationMember" xlink:title="definition: EntityDomain to OrthocyteCorporationMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20150331.xsd#btx_OncocyteCorporationMember" xlink:label="OncocyteCorporationMember" xlink:title="OncocyteCorporationMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EntityDomain" xlink:to="OncocyteCorporationMember" xlink:title="definition: EntityDomain to OncocyteCorporationMember" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20150331.xsd#btx_RecyteTherapeuticsIncMember" xlink:label="RecyteTherapeuticsIncMember" xlink:title="RecyteTherapeuticsIncMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EntityDomain" xlink:to="RecyteTherapeuticsIncMember" xlink:title="definition: EntityDomain to RecyteTherapeuticsIncMember" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20150331.xsd#btx_LifemapSciencesIncMember" xlink:label="LifemapSciencesIncMember" xlink:title="LifemapSciencesIncMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EntityDomain" xlink:to="LifemapSciencesIncMember" xlink:title="definition: EntityDomain to LifemapSciencesIncMember" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20150331.xsd#btx_BiotimeAsiaLimitedMember" xlink:label="BiotimeAsiaLimitedMember" xlink:title="BiotimeAsiaLimitedMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EntityDomain" xlink:to="BiotimeAsiaLimitedMember" xlink:title="definition: EntityDomain to BiotimeAsiaLimitedMember" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="TitleOfIndividualAxis" xlink:title="TitleOfIndividualAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfStockByClassTable" xlink:to="TitleOfIndividualAxis" xlink:title="definition: ScheduleOfStockByClassTable to TitleOfIndividualAxis" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="TitleOfIndividualWithRelationshipToEntityDomain" xlink:title="TitleOfIndividualWithRelationshipToEntityDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="TitleOfIndividualAxis" xlink:to="TitleOfIndividualWithRelationshipToEntityDomain" xlink:title="definition: TitleOfIndividualAxis to TitleOfIndividualWithRelationshipToEntityDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="TitleOfIndividualWithRelationshipToEntityDomain_2" xlink:title="TitleOfIndividualWithRelationshipToEntityDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="TitleOfIndividualAxis" xlink:to="TitleOfIndividualWithRelationshipToEntityDomain_2" xlink:title="definition: TitleOfIndividualAxis to TitleOfIndividualWithRelationshipToEntityDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ChiefExecutiveOfficerMember" xlink:label="ChiefExecutiveOfficerMember" xlink:title="ChiefExecutiveOfficerMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="ChiefExecutiveOfficerMember" xlink:title="definition: TitleOfIndividualWithRelationshipToEntityDomain to ChiefExecutiveOfficerMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ExecutiveVicePresidentMember" xlink:label="ExecutiveVicePresidentMember" xlink:title="ExecutiveVicePresidentMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="ExecutiveVicePresidentMember" xlink:title="definition: TitleOfIndividualWithRelationshipToEntityDomain to ExecutiveVicePresidentMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="PlanNameAxis" xlink:title="PlanNameAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfStockByClassTable" xlink:to="PlanNameAxis" xlink:title="definition: ScheduleOfStockByClassTable to PlanNameAxis" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="PlanNameDomain" xlink:title="PlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="PlanNameAxis" xlink:to="PlanNameDomain" xlink:title="definition: PlanNameAxis to PlanNameDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="PlanNameDomain_2" xlink:title="PlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="PlanNameAxis" xlink:to="PlanNameDomain_2" xlink:title="definition: PlanNameAxis to PlanNameDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20150331.xsd#btx_EquityIncentivePlanMember" xlink:label="EquityIncentivePlanMember" xlink:title="EquityIncentivePlanMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="PlanNameDomain" xlink:to="EquityIncentivePlanMember" xlink:title="definition: PlanNameDomain to EquityIncentivePlanMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20150331.xsd#btx_StockOptionPlan2002Member" xlink:label="StockOptionPlan2002Member" xlink:title="StockOptionPlan2002Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="PlanNameDomain" xlink:to="StockOptionPlan2002Member" xlink:title="definition: PlanNameDomain to StockOptionPlan2002Member" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="AwardTypeAxis" xlink:title="AwardTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfStockByClassTable" xlink:to="AwardTypeAxis" xlink:title="definition: ScheduleOfStockByClassTable to AwardTypeAxis" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="AwardTypeAxis" xlink:to="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="definition: AwardTypeAxis to ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="AwardTypeAxis" xlink:to="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2" xlink:title="definition: AwardTypeAxis to ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="RestrictedStockMember" xlink:title="RestrictedStockMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="RestrictedStockMember" xlink:title="definition: ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain to RestrictedStockMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WarrantMember" xlink:label="WarrantMember" xlink:title="WarrantMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="WarrantMember" xlink:title="definition: ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain to WarrantMember" order="2.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://biotimeinc.com/role/SalesOfBiotimeCommonSharesBySubsidiariesDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="RelatedPartyTransactionLineItems" xlink:title="RelatedPartyTransactionLineItems" />
    <link:loc xlink:type="locator" xlink:href="btx-20150331.xsd#btx_SharesSoldByThirdParty" xlink:label="SharesSoldByThirdParty" xlink:title="SharesSoldByThirdParty" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RelatedPartyTransactionLineItems" xlink:to="SharesSoldByThirdParty" xlink:title="definition: RelatedPartyTransactionLineItems to SharesSoldByThirdParty" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20150331.xsd#btx_NumberOfInvestors" xlink:label="NumberOfInvestors" xlink:title="NumberOfInvestors" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RelatedPartyTransactionLineItems" xlink:to="NumberOfInvestors" xlink:title="definition: RelatedPartyTransactionLineItems to NumberOfInvestors" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity" xlink:label="ProceedsFromSaleOfAvailableForSaleSecuritiesEquity" xlink:title="ProceedsFromSaleOfAvailableForSaleSecuritiesEquity" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RelatedPartyTransactionLineItems" xlink:to="ProceedsFromSaleOfAvailableForSaleSecuritiesEquity" xlink:title="definition: RelatedPartyTransactionLineItems to ProceedsFromSaleOfAvailableForSaleSecuritiesEquity" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:title="ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RelatedPartyTransactionLineItems" xlink:to="ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:title="definition: RelatedPartyTransactionLineItems to ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharesIssued" xlink:label="SharesIssued" xlink:title="SharesIssued" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RelatedPartyTransactionLineItems" xlink:to="SharesIssued" xlink:title="definition: RelatedPartyTransactionLineItems to SharesIssued" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:title="ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="RelatedPartyTransactionLineItems" xlink:to="ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:title="definition: RelatedPartyTransactionLineItems to ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" order="6.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="RelatedPartyTransactionsByRelatedPartyAxis" xlink:title="RelatedPartyTransactionsByRelatedPartyAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="RelatedPartyTransactionsByRelatedPartyAxis" xlink:title="definition: ScheduleOfRelatedPartyTransactionsByRelatedPartyTable to RelatedPartyTransactionsByRelatedPartyAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="RelatedPartyDomain" xlink:title="RelatedPartyDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="RelatedPartyDomain" xlink:title="definition: RelatedPartyTransactionsByRelatedPartyAxis to RelatedPartyDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="RelatedPartyDomain_2" xlink:title="RelatedPartyDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="RelatedPartyDomain_2" xlink:title="definition: RelatedPartyTransactionsByRelatedPartyAxis to RelatedPartyDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20150331.xsd#btx_AsteriasBiotherapeuticsMember" xlink:label="AsteriasBiotherapeuticsMember" xlink:title="AsteriasBiotherapeuticsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RelatedPartyDomain" xlink:to="AsteriasBiotherapeuticsMember" xlink:title="definition: RelatedPartyDomain to AsteriasBiotherapeuticsMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DirectorMember" xlink:label="DirectorMember" xlink:title="DirectorMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RelatedPartyDomain" xlink:to="DirectorMember" xlink:title="definition: RelatedPartyDomain to DirectorMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MajorityShareholderMember" xlink:label="MajorityShareholderMember" xlink:title="MajorityShareholderMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RelatedPartyDomain" xlink:to="MajorityShareholderMember" xlink:title="definition: RelatedPartyDomain to MajorityShareholderMember" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="RelatedPartyTransactionAxis" xlink:title="RelatedPartyTransactionAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="RelatedPartyTransactionAxis" xlink:title="definition: ScheduleOfRelatedPartyTransactionsByRelatedPartyTable to RelatedPartyTransactionAxis" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="RelatedPartyTransactionDomain" xlink:title="RelatedPartyTransactionDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="RelatedPartyTransactionAxis" xlink:to="RelatedPartyTransactionDomain" xlink:title="definition: RelatedPartyTransactionAxis to RelatedPartyTransactionDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="RelatedPartyTransactionDomain_2" xlink:title="RelatedPartyTransactionDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="RelatedPartyTransactionAxis" xlink:to="RelatedPartyTransactionDomain_2" xlink:title="definition: RelatedPartyTransactionAxis to RelatedPartyTransactionDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockMember" xlink:label="CommonStockMember" xlink:title="CommonStockMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RelatedPartyTransactionDomain" xlink:to="CommonStockMember" xlink:title="definition: RelatedPartyTransactionDomain to CommonStockMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonClassBMember" xlink:label="CommonClassBMember" xlink:title="CommonClassBMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RelatedPartyTransactionDomain" xlink:to="CommonClassBMember" xlink:title="definition: RelatedPartyTransactionDomain to CommonClassBMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WarrantMember" xlink:label="WarrantMember" xlink:title="WarrantMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RelatedPartyTransactionDomain" xlink:to="WarrantMember" xlink:title="definition: RelatedPartyTransactionDomain to WarrantMember" order="3.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://biotimeinc.com/role/SegmentInformationDetails" />
  <link:definitionLink xlink:type="extended" xlink:role="http://biotimeinc.com/role/SubsequentEventsDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="SubsequentEventLineItems" xlink:title="SubsequentEventLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RevenueFromGrants" xlink:label="RevenueFromGrants" xlink:title="RevenueFromGrants" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SubsequentEventLineItems" xlink:to="RevenueFromGrants" xlink:title="definition: SubsequentEventLineItems to RevenueFromGrants" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_GrantsReceivable" xlink:label="GrantsReceivable" xlink:title="GrantsReceivable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SubsequentEventLineItems" xlink:to="GrantsReceivable" xlink:title="definition: SubsequentEventLineItems to GrantsReceivable" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="SaleOfStockNumberOfSharesIssuedInTransaction" xlink:title="SaleOfStockNumberOfSharesIssuedInTransaction" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SubsequentEventLineItems" xlink:to="SaleOfStockNumberOfSharesIssuedInTransaction" xlink:title="definition: SubsequentEventLineItems to SaleOfStockNumberOfSharesIssuedInTransaction" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20150331.xsd#btx_NumberOfInvestors" xlink:label="NumberOfInvestors" xlink:title="NumberOfInvestors" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SubsequentEventLineItems" xlink:to="NumberOfInvestors" xlink:title="definition: SubsequentEventLineItems to NumberOfInvestors" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedPerTransaction" xlink:label="SaleOfStockConsiderationReceivedPerTransaction" xlink:title="SaleOfStockConsiderationReceivedPerTransaction" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SubsequentEventLineItems" xlink:to="SaleOfStockConsiderationReceivedPerTransaction" xlink:title="definition: SubsequentEventLineItems to SaleOfStockConsiderationReceivedPerTransaction" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="EquityMethodInvestmentOwnershipPercentage" xlink:title="EquityMethodInvestmentOwnershipPercentage" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SubsequentEventLineItems" xlink:to="EquityMethodInvestmentOwnershipPercentage" xlink:title="definition: SubsequentEventLineItems to EquityMethodInvestmentOwnershipPercentage" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="DebtConversionConvertedInstrumentSharesIssued1" xlink:title="DebtConversionConvertedInstrumentSharesIssued1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SubsequentEventLineItems" xlink:to="DebtConversionConvertedInstrumentSharesIssued1" xlink:title="definition: SubsequentEventLineItems to DebtConversionConvertedInstrumentSharesIssued1" order="7.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="DebtConversionConvertedInstrumentAmount1" xlink:title="DebtConversionConvertedInstrumentAmount1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SubsequentEventLineItems" xlink:to="DebtConversionConvertedInstrumentAmount1" xlink:title="definition: SubsequentEventLineItems to DebtConversionConvertedInstrumentAmount1" order="8.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="DebtInstrumentInterestRateStatedPercentage" xlink:title="DebtInstrumentInterestRateStatedPercentage" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SubsequentEventLineItems" xlink:to="DebtInstrumentInterestRateStatedPercentage" xlink:title="definition: SubsequentEventLineItems to DebtInstrumentInterestRateStatedPercentage" order="9.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="DebtInstrumentMaturityDate" xlink:title="DebtInstrumentMaturityDate" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SubsequentEventLineItems" xlink:to="DebtInstrumentMaturityDate" xlink:title="definition: SubsequentEventLineItems to DebtInstrumentMaturityDate" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="DebtInstrumentConvertibleConversionPrice1" xlink:title="DebtInstrumentConvertibleConversionPrice1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SubsequentEventLineItems" xlink:to="DebtInstrumentConvertibleConversionPrice1" xlink:title="definition: SubsequentEventLineItems to DebtInstrumentConvertibleConversionPrice1" order="11.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="SubsequentEventTable" xlink:title="SubsequentEventTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="SubsequentEventLineItems" xlink:to="SubsequentEventTable" xlink:title="definition: SubsequentEventLineItems to SubsequentEventTable" order="12.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="SubsequentEventTypeAxis" xlink:title="SubsequentEventTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="SubsequentEventTable" xlink:to="SubsequentEventTypeAxis" xlink:title="definition: SubsequentEventTable to SubsequentEventTypeAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="SubsequentEventTypeDomain" xlink:title="SubsequentEventTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="SubsequentEventTypeAxis" xlink:to="SubsequentEventTypeDomain" xlink:title="definition: SubsequentEventTypeAxis to SubsequentEventTypeDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="SubsequentEventTypeDomain_2" xlink:title="SubsequentEventTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="SubsequentEventTypeAxis" xlink:to="SubsequentEventTypeDomain_2" xlink:title="definition: SubsequentEventTypeAxis to SubsequentEventTypeDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="SubsequentEventMember" xlink:title="SubsequentEventMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SubsequentEventTypeDomain" xlink:to="SubsequentEventMember" xlink:title="definition: SubsequentEventTypeDomain to SubsequentEventMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="LegalEntityAxis" xlink:title="LegalEntityAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="SubsequentEventTable" xlink:to="LegalEntityAxis" xlink:title="definition: SubsequentEventTable to LegalEntityAxis" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="EntityDomain" xlink:title="EntityDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="LegalEntityAxis" xlink:to="EntityDomain" xlink:title="definition: LegalEntityAxis to EntityDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="EntityDomain_2" xlink:title="EntityDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="LegalEntityAxis" xlink:to="EntityDomain_2" xlink:title="definition: LegalEntityAxis to EntityDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20150331.xsd#btx_AsteriasBiotherapeuticsMember" xlink:label="AsteriasBiotherapeuticsMember" xlink:title="AsteriasBiotherapeuticsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EntityDomain" xlink:to="AsteriasBiotherapeuticsMember" xlink:title="definition: EntityDomain to AsteriasBiotherapeuticsMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20150331.xsd#btx_OncocyteCorporationMember" xlink:label="OncocyteCorporationMember" xlink:title="OncocyteCorporationMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EntityDomain" xlink:to="OncocyteCorporationMember" xlink:title="definition: EntityDomain to OncocyteCorporationMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MajorCustomersAxis" xlink:label="MajorCustomersAxis" xlink:title="MajorCustomersAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="SubsequentEventTable" xlink:to="MajorCustomersAxis" xlink:title="definition: SubsequentEventTable to MajorCustomersAxis" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NameOfMajorCustomerDomain" xlink:label="NameOfMajorCustomerDomain" xlink:title="NameOfMajorCustomerDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="MajorCustomersAxis" xlink:to="NameOfMajorCustomerDomain" xlink:title="definition: MajorCustomersAxis to NameOfMajorCustomerDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NameOfMajorCustomerDomain" xlink:label="NameOfMajorCustomerDomain_2" xlink:title="NameOfMajorCustomerDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="MajorCustomersAxis" xlink:to="NameOfMajorCustomerDomain_2" xlink:title="definition: MajorCustomersAxis to NameOfMajorCustomerDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20150331.xsd#btx_CaliforniaInstituteOfRegenerativeMedicineMember" xlink:label="CaliforniaInstituteOfRegenerativeMedicineMember" xlink:title="CaliforniaInstituteOfRegenerativeMedicineMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="NameOfMajorCustomerDomain" xlink:to="CaliforniaInstituteOfRegenerativeMedicineMember" xlink:title="definition: NameOfMajorCustomerDomain to CaliforniaInstituteOfRegenerativeMedicineMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="DebtInstrumentAxis" xlink:title="DebtInstrumentAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="SubsequentEventTable" xlink:to="DebtInstrumentAxis" xlink:title="definition: SubsequentEventTable to DebtInstrumentAxis" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="DebtInstrumentNameDomain" xlink:title="DebtInstrumentNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="DebtInstrumentAxis" xlink:to="DebtInstrumentNameDomain" xlink:title="definition: DebtInstrumentAxis to DebtInstrumentNameDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="DebtInstrumentNameDomain_2" xlink:title="DebtInstrumentNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="DebtInstrumentAxis" xlink:to="DebtInstrumentNameDomain_2" xlink:title="definition: DebtInstrumentAxis to DebtInstrumentNameDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConvertibleNotesPayableMember" xlink:label="ConvertibleNotesPayableMember" xlink:title="ConvertibleNotesPayableMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentNameDomain" xlink:to="ConvertibleNotesPayableMember" xlink:title="definition: DebtInstrumentNameDomain to ConvertibleNotesPayableMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="RelatedPartyTransactionsByRelatedPartyAxis" xlink:title="RelatedPartyTransactionsByRelatedPartyAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="SubsequentEventTable" xlink:to="RelatedPartyTransactionsByRelatedPartyAxis" xlink:title="definition: SubsequentEventTable to RelatedPartyTransactionsByRelatedPartyAxis" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="RelatedPartyDomain" xlink:title="RelatedPartyDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="RelatedPartyDomain" xlink:title="definition: RelatedPartyTransactionsByRelatedPartyAxis to RelatedPartyDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="RelatedPartyDomain_2" xlink:title="RelatedPartyDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="RelatedPartyDomain_2" xlink:title="definition: RelatedPartyTransactionsByRelatedPartyAxis to RelatedPartyDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MajorityShareholderMember" xlink:label="MajorityShareholderMember" xlink:title="MajorityShareholderMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RelatedPartyDomain" xlink:to="MajorityShareholderMember" xlink:title="definition: RelatedPartyDomain to MajorityShareholderMember" order="1.0" />
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>9
<FILENAME>btx-20150331_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--Generated by EDGARfilings PROfile 3.3.0.0 Copyright 1995 - 2015 Summit Financial Printing, LLC. All rights reserved.-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" />
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:label="AmendmentFlag" xlink:title="AmendmentFlag" />
    <link:label xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_AmendmentFlag_lbl" xml:lang="en-US" id="dei_AmendmentFlag_lbl">Amendment Flag</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:title="label: AmendmentFlag to dei_AmendmentFlag_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="CurrentFiscalYearEndDate" xlink:title="CurrentFiscalYearEndDate" />
    <link:label xlink:type="resource" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US" id="dei_CurrentFiscalYearEndDate_lbl">Current Fiscal Year End Date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:title="label: CurrentFiscalYearEndDate to dei_CurrentFiscalYearEndDate_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="DocumentPeriodEndDate" xlink:title="DocumentPeriodEndDate" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US" id="dei_DocumentPeriodEndDate_lbl">Document Period End Date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:title="label: DocumentPeriodEndDate to dei_DocumentPeriodEndDate_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="EntityDomain" xlink:title="EntityDomain" />
    <link:label xlink:type="resource" xlink:label="dei_EntityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityDomain_lbl" xml:lang="en-US" id="dei_EntityDomain_lbl">Entity [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityDomain" xlink:to="dei_EntityDomain_lbl" xlink:title="label: EntityDomain to dei_EntityDomain_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="EntityWellKnownSeasonedIssuer" xlink:title="EntityWellKnownSeasonedIssuer" />
    <link:label xlink:type="resource" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US" id="dei_EntityWellKnownSeasonedIssuer_lbl">Entity Well-known Seasoned Issuer</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:title="label: EntityWellKnownSeasonedIssuer to dei_EntityWellKnownSeasonedIssuer_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="EntityVoluntaryFilers" xlink:title="EntityVoluntaryFilers" />
    <link:label xlink:type="resource" xlink:label="dei_EntityVoluntaryFilers_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US" id="dei_EntityVoluntaryFilers_lbl">Entity Voluntary Filers</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:title="label: EntityVoluntaryFilers to dei_EntityVoluntaryFilers_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="EntityCurrentReportingStatus" xlink:title="EntityCurrentReportingStatus" />
    <link:label xlink:type="resource" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US" id="dei_EntityCurrentReportingStatus_lbl">Entity Current Reporting Status</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:title="label: EntityCurrentReportingStatus to dei_EntityCurrentReportingStatus_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:label="EntityFilerCategory" xlink:title="EntityFilerCategory" />
    <link:label xlink:type="resource" xlink:label="dei_EntityFilerCategory_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityFilerCategory_lbl" xml:lang="en-US" id="dei_EntityFilerCategory_lbl">Entity Filer Category</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:title="label: EntityFilerCategory to dei_EntityFilerCategory_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:label="EntityRegistrantName" xlink:title="EntityRegistrantName" />
    <link:label xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityRegistrantName_lbl" xml:lang="en-US" id="dei_EntityRegistrantName_lbl">Entity Registrant Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:title="label: EntityRegistrantName to dei_EntityRegistrantName_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="EntityCentralIndexKey" xlink:title="EntityCentralIndexKey" />
    <link:label xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityCentralIndexKey_lbl" xml:lang="en-US" id="dei_EntityCentralIndexKey_lbl">Entity Central Index Key</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:title="label: EntityCentralIndexKey to dei_EntityCentralIndexKey_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="EntityCommonStockSharesOutstanding" xlink:title="EntityCommonStockSharesOutstanding" />
    <link:label xlink:type="resource" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US" id="dei_EntityCommonStockSharesOutstanding_lbl">Entity Common Stock, Shares Outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:title="label: EntityCommonStockSharesOutstanding to dei_EntityCommonStockSharesOutstanding_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="DocumentFiscalYearFocus" xlink:title="DocumentFiscalYearFocus" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US" id="dei_DocumentFiscalYearFocus_lbl">Document Fiscal Year Focus</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:title="label: DocumentFiscalYearFocus to dei_DocumentFiscalYearFocus_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="DocumentFiscalPeriodFocus" xlink:title="DocumentFiscalPeriodFocus" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US" id="dei_DocumentFiscalPeriodFocus_lbl">Document Fiscal Period Focus</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:title="label: DocumentFiscalPeriodFocus to dei_DocumentFiscalPeriodFocus_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="LegalEntityAxis" xlink:title="LegalEntityAxis" />
    <link:label xlink:type="resource" xlink:label="dei_LegalEntityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_LegalEntityAxis_lbl" xml:lang="en-US" id="dei_LegalEntityAxis_lbl">Legal Entity [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LegalEntityAxis" xlink:to="dei_LegalEntityAxis_lbl" xlink:title="label: LegalEntityAxis to dei_LegalEntityAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:label="DocumentType" xlink:title="DocumentType" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentType_lbl" xml:lang="en-US" id="dei_DocumentType_lbl">Document Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentType" xlink:to="dei_DocumentType_lbl" xlink:title="label: DocumentType to dei_DocumentType_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AreaOfLand" xlink:label="AreaOfLand" xlink:title="AreaOfLand" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AreaOfLand_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_AreaOfLand_lbl" xml:lang="en-US" id="us-gaap_AreaOfLand_lbl">Area of office space (in square feet)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AreaOfLand" xlink:to="us-gaap_AreaOfLand_lbl" xlink:title="label: AreaOfLand to us-gaap_AreaOfLand_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AreaOfLand_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AreaOfLand_lbl1" xml:lang="en-US" id="us-gaap_AreaOfLand_lbl1">Area of Land</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AreaOfLand" xlink:to="us-gaap_AreaOfLand_lbl1" xlink:title="label: AreaOfLand to us-gaap_AreaOfLand_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="AwardTypeAxis" xlink:title="AwardTypeAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AwardTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US" id="us-gaap_AwardTypeAxis_lbl">Award Type [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl" xlink:title="label: AwardTypeAxis to us-gaap_AwardTypeAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="AccountingPoliciesAbstract" xlink:title="AccountingPoliciesAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US" id="us-gaap_AccountingPoliciesAbstract_lbl">Summary of Significant Accounting Policies [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" xlink:title="label: AccountingPoliciesAbstract to us-gaap_AccountingPoliciesAbstract_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_AccountingPoliciesAbstract_lbl1" xml:lang="en-US" id="us-gaap_AccountingPoliciesAbstract_lbl1">Summary of Significant Accounting Policies [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl1" xlink:title="label: AccountingPoliciesAbstract to us-gaap_AccountingPoliciesAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="AccountsPayableAndAccruedLiabilitiesCurrent" xlink:title="AccountsPayableAndAccruedLiabilitiesCurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl" xml:lang="en-US" id="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl">Accounts payable and accrued liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl" xlink:title="label: AccountsPayableAndAccruedLiabilitiesCurrent to us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl1" xml:lang="en-US" id="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl1">Accounts payable and accrued liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl1" xlink:title="label: AccountsPayableAndAccruedLiabilitiesCurrent to us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl2" xml:lang="en-US" id="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl2">Accounts Payable and Accrued Liabilities, Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl2" xlink:title="label: AccountsPayableAndAccruedLiabilitiesCurrent to us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:title="AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xml:lang="en-US" id="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl">Accounts Payable and Accrued Liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xlink:title="label: AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock to us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl1" xml:lang="en-US" id="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl1">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl1" xlink:title="label: AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock to us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="AccountsReceivableNetCurrent" xlink:title="AccountsReceivableNetCurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_AccountsReceivableNetCurrent_lbl" xml:lang="en-US" id="us-gaap_AccountsReceivableNetCurrent_lbl">Trade receivable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent_lbl" xlink:title="label: AccountsReceivableNetCurrent to us-gaap_AccountsReceivableNetCurrent_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AccountsReceivableNetCurrent_lbl1" xml:lang="en-US" id="us-gaap_AccountsReceivableNetCurrent_lbl1">Accounts Receivable, Net, Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent_lbl1" xlink:title="label: AccountsReceivableNetCurrent to us-gaap_AccountsReceivableNetCurrent_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="AccountsPayableCurrent" xlink:title="AccountsPayableCurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US" id="us-gaap_AccountsPayableCurrent_lbl">Accounts payable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" xlink:title="label: AccountsPayableCurrent to us-gaap_AccountsPayableCurrent_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="AccruedLiabilitiesCurrent" xlink:title="AccruedLiabilitiesCurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US" id="us-gaap_AccruedLiabilitiesCurrent_lbl">Accrued expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:title="label: AccruedLiabilitiesCurrent to us-gaap_AccruedLiabilitiesCurrent_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccruedBonusesCurrent" xlink:label="AccruedBonusesCurrent" xlink:title="AccruedBonusesCurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AccruedBonusesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_AccruedBonusesCurrent_lbl" xml:lang="en-US" id="us-gaap_AccruedBonusesCurrent_lbl">Accrued bonuses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccruedBonusesCurrent" xlink:to="us-gaap_AccruedBonusesCurrent_lbl" xlink:title="label: AccruedBonusesCurrent to us-gaap_AccruedBonusesCurrent_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AccruedBonusesCurrent_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AccruedBonusesCurrent_lbl1" xml:lang="en-US" id="us-gaap_AccruedBonusesCurrent_lbl1">Accrued Bonuses, Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccruedBonusesCurrent" xlink:to="us-gaap_AccruedBonusesCurrent_lbl1" xlink:title="label: AccruedBonusesCurrent to us-gaap_AccruedBonusesCurrent_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipmentPeriodIncreaseDecrease" xlink:label="AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipmentPeriodIncreaseDecrease" xlink:title="AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipmentPeriodIncreaseDecrease" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipmentPeriodIncreaseDecrease_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipmentPeriodIncreaseDecrease_lbl" xml:lang="en-US" id="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipmentPeriodIncreaseDecrease_lbl">Increase in accumulated depreciation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipmentPeriodIncreaseDecrease" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipmentPeriodIncreaseDecrease_lbl" xlink:title="label: AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipmentPeriodIncreaseDecrease to us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipmentPeriodIncreaseDecrease_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipmentPeriodIncreaseDecrease_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipmentPeriodIncreaseDecrease_lbl1" xml:lang="en-US" id="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipmentPeriodIncreaseDecrease_lbl1">Accumulated Depreciation, Depletion and Amortization, Property, Plant and Equipment, Period Increase (Decrease)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipmentPeriodIncreaseDecrease" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipmentPeriodIncreaseDecrease_lbl1" xlink:title="label: AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipmentPeriodIncreaseDecrease to us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipmentPeriodIncreaseDecrease_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:title="AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US" id="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl">Accumulated depreciation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:title="label: AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment to us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl1" xml:lang="en-US" id="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl1">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl1" xlink:title="label: AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment to us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:title="AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xml:lang="en-US" id="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl">Accumulated other comprehensive income</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:title="label: AccumulatedOtherComprehensiveIncomeLossNetOfTax to us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="AdditionalPaidInCapital" xlink:title="AdditionalPaidInCapital" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US" id="us-gaap_AdditionalPaidInCapital_lbl">Contributed capital</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl" xlink:title="label: AdditionalPaidInCapital to us-gaap_AdditionalPaidInCapital_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:title="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" id="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl">Adjustments to reconcile net loss attributable to BioTime, Inc. to net cash used in operating activities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:title="label: AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:label="AllowanceForDoubtfulAccountsReceivableCurrent" xlink:title="AllowanceForDoubtfulAccountsReceivableCurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_lbl" xml:lang="en-US" id="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_lbl">Allowance for doubtful accounts</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AllowanceForDoubtfulAccountsReceivableCurrent" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_lbl" xlink:title="label: AllowanceForDoubtfulAccountsReceivableCurrent to us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_lbl1" xml:lang="en-US" id="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_lbl1">Allowance for Doubtful Accounts Receivable, Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AllowanceForDoubtfulAccountsReceivableCurrent" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_lbl1" xlink:title="label: AllowanceForDoubtfulAccountsReceivableCurrent to us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AmortizationOfDeferredCharges" xlink:label="AmortizationOfDeferredCharges" xlink:title="AmortizationOfDeferredCharges" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AmortizationOfDeferredCharges_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_AmortizationOfDeferredCharges_lbl" xml:lang="en-US" id="us-gaap_AmortizationOfDeferredCharges_lbl">Amortization of deferred license, royalty and subscription revenues</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AmortizationOfDeferredCharges" xlink:to="us-gaap_AmortizationOfDeferredCharges_lbl" xlink:title="label: AmortizationOfDeferredCharges to us-gaap_AmortizationOfDeferredCharges_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AmortizationOfDeferredCharges_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AmortizationOfDeferredCharges_lbl1" xml:lang="en-US" id="us-gaap_AmortizationOfDeferredCharges_lbl1">Amortization of Deferred Charges</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AmortizationOfDeferredCharges" xlink:to="us-gaap_AmortizationOfDeferredCharges_lbl1" xlink:title="label: AmortizationOfDeferredCharges to us-gaap_AmortizationOfDeferredCharges_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="AmortizationOfIntangibleAssets" xlink:title="AmortizationOfIntangibleAssets" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AmortizationOfIntangibleAssets_lbl" xml:lang="en-US" id="us-gaap_AmortizationOfIntangibleAssets_lbl">Amortization of intangible assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AmortizationOfIntangibleAssets" xlink:to="us-gaap_AmortizationOfIntangibleAssets_lbl" xlink:title="label: AmortizationOfIntangibleAssets to us-gaap_AmortizationOfIntangibleAssets_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="AmortizationOfDebtDiscountPremium" xlink:title="AmortizationOfDebtDiscountPremium" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_AmortizationOfDebtDiscountPremium_lbl" xml:lang="en-US" id="us-gaap_AmortizationOfDebtDiscountPremium_lbl">Amortization of discount on related party convertible debt</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AmortizationOfDebtDiscountPremium" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium_lbl" xlink:title="label: AmortizationOfDebtDiscountPremium to us-gaap_AmortizationOfDebtDiscountPremium_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AmortizationOfDebtDiscountPremium_lbl1" xml:lang="en-US" id="us-gaap_AmortizationOfDebtDiscountPremium_lbl1">Amortization of Debt Discount (Premium)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AmortizationOfDebtDiscountPremium" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium_lbl1" xlink:title="label: AmortizationOfDebtDiscountPremium to us-gaap_AmortizationOfDebtDiscountPremium_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:title="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xml:lang="en-US" id="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl">Antidilutive Securities [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:title="label: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis to us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:title="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xml:lang="en-US" id="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:title="label: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems to us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="AntidilutiveSecuritiesNameDomain" xlink:title="AntidilutiveSecuritiesNameDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xml:lang="en-US" id="us-gaap_AntidilutiveSecuritiesNameDomain_lbl">Antidilutive Securities, Name [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:title="label: AntidilutiveSecuritiesNameDomain to us-gaap_AntidilutiveSecuritiesNameDomain_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:title="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US" id="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl">Anti-dilutive shares excluded from computation of diluted loss per share (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:title="label: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount to us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Assets" xlink:label="Assets" xlink:title="Assets" />
    <link:label xlink:type="resource" xlink:label="us-gaap_Assets_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_Assets_lbl" xml:lang="en-US" id="us-gaap_Assets_lbl">TOTAL ASSETS</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Assets" xlink:to="us-gaap_Assets_lbl" xlink:title="label: Assets to us-gaap_Assets_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_Assets_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_Assets_lbl1" xml:lang="en-US" id="us-gaap_Assets_lbl1">Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Assets" xlink:to="us-gaap_Assets_lbl1" xlink:title="label: Assets to us-gaap_Assets_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="AssetsCurrentAbstract" xlink:title="AssetsCurrentAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US" id="us-gaap_AssetsCurrentAbstract_lbl">CURRENT ASSETS</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" xlink:title="label: AssetsCurrentAbstract to us-gaap_AssetsCurrentAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="AssetsAbstract" xlink:title="AssetsAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_AssetsAbstract_lbl" xml:lang="en-US" id="us-gaap_AssetsAbstract_lbl">ASSETS</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" xlink:title="label: AssetsAbstract to us-gaap_AssetsAbstract_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AssetsAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AssetsAbstract_lbl1" xml:lang="en-US" id="us-gaap_AssetsAbstract_lbl1">Assets [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl1" xlink:title="label: AssetsAbstract to us-gaap_AssetsAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="AssetsCurrent" xlink:title="AssetsCurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_AssetsCurrent_lbl" xml:lang="en-US" id="us-gaap_AssetsCurrent_lbl">Total current assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" xlink:title="label: AssetsCurrent to us-gaap_AssetsCurrent_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AssetsCurrent_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AssetsCurrent_lbl1" xml:lang="en-US" id="us-gaap_AssetsCurrent_lbl1">Assets, Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl1" xlink:title="label: AssetsCurrent to us-gaap_AssetsCurrent_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CapitalLeasesIncomeStatementAmortizationExpense" xlink:label="CapitalLeasesIncomeStatementAmortizationExpense" xlink:title="CapitalLeasesIncomeStatementAmortizationExpense" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CapitalLeasesIncomeStatementAmortizationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CapitalLeasesIncomeStatementAmortizationExpense_lbl" xml:lang="en-US" id="us-gaap_CapitalLeasesIncomeStatementAmortizationExpense_lbl">Repayment of capital lease obligation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CapitalLeasesIncomeStatementAmortizationExpense" xlink:to="us-gaap_CapitalLeasesIncomeStatementAmortizationExpense_lbl" xlink:title="label: CapitalLeasesIncomeStatementAmortizationExpense to us-gaap_CapitalLeasesIncomeStatementAmortizationExpense_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CapitalLeaseObligationsCurrent" xlink:label="CapitalLeaseObligationsCurrent" xlink:title="CapitalLeaseObligationsCurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CapitalLeaseObligationsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CapitalLeaseObligationsCurrent_lbl" xml:lang="en-US" id="us-gaap_CapitalLeaseObligationsCurrent_lbl">Capital lease liability, current portion</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CapitalLeaseObligationsCurrent" xlink:to="us-gaap_CapitalLeaseObligationsCurrent_lbl" xlink:title="label: CapitalLeaseObligationsCurrent to us-gaap_CapitalLeaseObligationsCurrent_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Capital" xlink:label="Capital" xlink:title="Capital" />
    <link:label xlink:type="resource" xlink:label="us-gaap_Capital_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_Capital_lbl" xml:lang="en-US" id="us-gaap_Capital_lbl">Working capital</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Capital" xlink:to="us-gaap_Capital_lbl" xlink:title="label: Capital to us-gaap_Capital_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_Capital_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_Capital_lbl1" xml:lang="en-US" id="us-gaap_Capital_lbl1">Capital</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Capital" xlink:to="us-gaap_Capital_lbl1" xlink:title="label: Capital to us-gaap_Capital_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CapitalLeaseObligations" xlink:label="CapitalLeaseObligations" xlink:title="CapitalLeaseObligations" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CapitalLeaseObligations_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CapitalLeaseObligations_lbl" xml:lang="en-US" id="us-gaap_CapitalLeaseObligations_lbl">Equipment, furniture , and fixtures included in capital lease borrowings</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CapitalLeaseObligations" xlink:to="us-gaap_CapitalLeaseObligations_lbl" xlink:title="label: CapitalLeaseObligations to us-gaap_CapitalLeaseObligations_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="CashAndCashEquivalentsPolicyTextBlock" xlink:title="CashAndCashEquivalentsPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US" id="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl">Cash and cash equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:title="label: CashAndCashEquivalentsPolicyTextBlock to us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl1" xml:lang="en-US" id="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl1">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl1" xlink:title="label: CashAndCashEquivalentsPolicyTextBlock to us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:title="CashAndCashEquivalentsPeriodIncreaseDecrease" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl" xml:lang="en-US" id="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl">NET CHANGE IN CASH AND CASH EQUIVALENTS:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl" xlink:title="label: CashAndCashEquivalentsPeriodIncreaseDecrease to us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl1" xml:lang="en-US" id="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl1">Cash and Cash Equivalents, Period Increase (Decrease)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl1" xlink:title="label: CashAndCashEquivalentsPeriodIncreaseDecrease to us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="CashAndCashEquivalentsAtCarryingValue" xlink:title="CashAndCashEquivalentsAtCarryingValue" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:title="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" id="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl">At end of the period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:title="label: CashAndCashEquivalentsAtCarryingValue to us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl1" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:title="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl1" xml:lang="en-US" id="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl1">At beginning of the period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl1" xlink:title="label: CashAndCashEquivalentsAtCarryingValue to us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl2" xml:lang="en-US" id="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl2">Cash and cash equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl2" xlink:title="label: CashAndCashEquivalentsAtCarryingValue to us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl2" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl3" xml:lang="en-US" id="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl3">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl3" xlink:title="label: CashAndCashEquivalentsAtCarryingValue to us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl3" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsAbstract" xlink:label="CashAndCashEquivalentsAbstract" xlink:title="CashAndCashEquivalentsAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CashAndCashEquivalentsAbstract_lbl" xml:lang="en-US" id="us-gaap_CashAndCashEquivalentsAbstract_lbl">CASH AND CASH EQUIVALENTS:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashAndCashEquivalentsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAbstract_lbl" xlink:title="label: CashAndCashEquivalentsAbstract to us-gaap_CashAndCashEquivalentsAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ChiefExecutiveOfficerMember" xlink:label="ChiefExecutiveOfficerMember" xlink:title="ChiefExecutiveOfficerMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ChiefExecutiveOfficerMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ChiefExecutiveOfficerMember_lbl" xml:lang="en-US" id="us-gaap_ChiefExecutiveOfficerMember_lbl">Michael D. West [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ChiefExecutiveOfficerMember" xlink:to="us-gaap_ChiefExecutiveOfficerMember_lbl" xlink:title="label: ChiefExecutiveOfficerMember to us-gaap_ChiefExecutiveOfficerMember_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="ClassOfStockLineItems" xlink:title="ClassOfStockLineItems" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ClassOfStockLineItems_lbl" xml:lang="en-US" id="us-gaap_ClassOfStockLineItems_lbl">Class of Stock [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClassOfStockLineItems" xlink:to="us-gaap_ClassOfStockLineItems_lbl" xlink:title="label: ClassOfStockLineItems to us-gaap_ClassOfStockLineItems_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:title="ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl" xml:lang="en-US" id="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl">Number of warrants issued (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl" xlink:title="label: ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight to us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="ClassOfStockDomain" xlink:title="ClassOfStockDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ClassOfStockDomain_lbl" xml:lang="en-US" id="us-gaap_ClassOfStockDomain_lbl">Class of Stock [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl" xlink:title="label: ClassOfStockDomain to us-gaap_ClassOfStockDomain_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="CommitmentsAndContingencies" xlink:title="CommitmentsAndContingencies" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US" id="us-gaap_CommitmentsAndContingencies_lbl">Commitments and contingencies</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" xlink:title="label: CommitmentsAndContingencies to us-gaap_CommitmentsAndContingencies_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonClassAMember" xlink:label="CommonClassAMember" xlink:title="CommonClassAMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommonClassAMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_CommonClassAMember_lbl" xml:lang="en-US" id="us-gaap_CommonClassAMember_lbl">Series A Common Stock [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonClassAMember" xlink:to="us-gaap_CommonClassAMember_lbl" xlink:title="label: CommonClassAMember to us-gaap_CommonClassAMember_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommonClassAMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CommonClassAMember_lbl1" xml:lang="en-US" id="us-gaap_CommonClassAMember_lbl1">Common Class A [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonClassAMember" xlink:to="us-gaap_CommonClassAMember_lbl1" xlink:title="label: CommonClassAMember to us-gaap_CommonClassAMember_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockMember" xlink:label="CommonStockMember" xlink:title="CommonStockMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CommonStockMember_lbl" xml:lang="en-US" id="us-gaap_CommonStockMember_lbl">BioTime Common Stock [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" xlink:title="label: CommonStockMember to us-gaap_CommonStockMember_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockValue" xlink:label="CommonStockValue" xlink:title="CommonStockValue" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CommonStockValue_lbl" xml:lang="en-US" id="us-gaap_CommonStockValue_lbl">Common shares, no par value, authorized 125,000,000 shares as of March 31, 2015 and December 31, 2014; 83,210,775 issued and 78,316,833 outstanding as of March 31, 2015 and 83,121,698 issued and 78,227,756 outstanding at December 31, 2014</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" xlink:title="label: CommonStockValue to us-gaap_CommonStockValue_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="CommonStockSharesIssued" xlink:title="CommonStockSharesIssued" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US" id="us-gaap_CommonStockSharesIssued_lbl">Common shares, shares issued (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" xlink:title="label: CommonStockSharesIssued to us-gaap_CommonStockSharesIssued_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CommonStockSharesIssued_lbl1" xml:lang="en-US" id="us-gaap_CommonStockSharesIssued_lbl1">Common shares, issued (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl1" xlink:title="label: CommonStockSharesIssued to us-gaap_CommonStockSharesIssued_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonClassBMember" xlink:label="CommonClassBMember" xlink:title="CommonClassBMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommonClassBMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CommonClassBMember_lbl" xml:lang="en-US" id="us-gaap_CommonClassBMember_lbl">Asterias Series B Common Stock [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonClassBMember" xlink:to="us-gaap_CommonClassBMember_lbl" xlink:title="label: CommonClassBMember to us-gaap_CommonClassBMember_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="CommonStockSharesAuthorized" xlink:title="CommonStockSharesAuthorized" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US" id="us-gaap_CommonStockSharesAuthorized_lbl">Common shares, authorized (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" xlink:title="label: CommonStockSharesAuthorized to us-gaap_CommonStockSharesAuthorized_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockNoParValue" xlink:label="CommonStockNoParValue" xlink:title="CommonStockNoParValue" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommonStockNoParValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CommonStockNoParValue_lbl" xml:lang="en-US" id="us-gaap_CommonStockNoParValue_lbl">Common shares, par value (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockNoParValue" xlink:to="us-gaap_CommonStockNoParValue_lbl" xlink:title="label: CommonStockNoParValue to us-gaap_CommonStockNoParValue_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="CommonStockSharesOutstanding" xlink:title="CommonStockSharesOutstanding" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US" id="us-gaap_CommonStockSharesOutstanding_lbl">Common shares, outstanding (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" xlink:title="label: CommonStockSharesOutstanding to us-gaap_CommonStockSharesOutstanding_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_CommonStockSharesOutstanding_lbl1" xml:lang="en-US" id="us-gaap_CommonStockSharesOutstanding_lbl1">Common shares, shares outstanding (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl1" xlink:title="label: CommonStockSharesOutstanding to us-gaap_CommonStockSharesOutstanding_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:label="CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:title="CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_lbl" xml:lang="en-US" id="us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_lbl">Common Shares [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_lbl" xlink:title="label: CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract to us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_lbl1" xml:lang="en-US" id="us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_lbl1">Common Stock, Number of Shares, Par Value and Other Disclosures [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_lbl1" xlink:title="label: CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract to us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="ComprehensiveIncomeNetOfTax" xlink:title="ComprehensiveIncomeNetOfTax" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xml:lang="en-US" id="us-gaap_ComprehensiveIncomeNetOfTax_lbl">COMPREHENSIVE LOSS</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:title="label: ComprehensiveIncomeNetOfTax to us-gaap_ComprehensiveIncomeNetOfTax_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ComprehensiveIncomeNetOfTax_lbl1" xml:lang="en-US" id="us-gaap_ComprehensiveIncomeNetOfTax_lbl1">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl1" xlink:title="label: ComprehensiveIncomeNetOfTax to us-gaap_ComprehensiveIncomeNetOfTax_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="ConcentrationRiskCreditRisk" xlink:title="ConcentrationRiskCreditRisk" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ConcentrationRiskCreditRisk_lbl" xml:lang="en-US" id="us-gaap_ConcentrationRiskCreditRisk_lbl">Concentrations of credit risk</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:title="label: ConcentrationRiskCreditRisk to us-gaap_ConcentrationRiskCreditRisk_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ConcentrationRiskCreditRisk_lbl1" xml:lang="en-US" id="us-gaap_ConcentrationRiskCreditRisk_lbl1">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl1" xlink:title="label: ConcentrationRiskCreditRisk to us-gaap_ConcentrationRiskCreditRisk_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTextBlock" xlink:label="ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTextBlock" xlink:title="ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTextBlock_lbl" xml:lang="en-US" id="us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTextBlock_lbl">BioTime's ownership of outstanding shares of its subsidiaries</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTextBlock" xlink:to="us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTextBlock_lbl" xlink:title="label: ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTextBlock to us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTextBlock_lbl1" xml:lang="en-US" id="us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTextBlock_lbl1">Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Table Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTextBlock" xlink:to="us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTextBlock_lbl1" xlink:title="label: ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTextBlock to us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConstructionInProgressGross" xlink:label="ConstructionInProgressGross" xlink:title="ConstructionInProgressGross" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ConstructionInProgressGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ConstructionInProgressGross_lbl" xml:lang="en-US" id="us-gaap_ConstructionInProgressGross_lbl">Construction in progress</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConstructionInProgressGross" xlink:to="us-gaap_ConstructionInProgressGross_lbl" xlink:title="label: ConstructionInProgressGross to us-gaap_ConstructionInProgressGross_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConvertibleNotesPayableMember" xlink:label="ConvertibleNotesPayableMember" xlink:title="ConvertibleNotesPayableMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ConvertibleNotesPayableMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ConvertibleNotesPayableMember_lbl" xml:lang="en-US" id="us-gaap_ConvertibleNotesPayableMember_lbl">Convertible Promissory Note [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConvertibleNotesPayableMember" xlink:to="us-gaap_ConvertibleNotesPayableMember_lbl" xlink:title="label: ConvertibleNotesPayableMember to us-gaap_ConvertibleNotesPayableMember_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ConvertibleNotesPayableMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ConvertibleNotesPayableMember_lbl1" xml:lang="en-US" id="us-gaap_ConvertibleNotesPayableMember_lbl1">Convertible Notes Payable [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConvertibleNotesPayableMember" xlink:to="us-gaap_ConvertibleNotesPayableMember_lbl1" xlink:title="label: ConvertibleNotesPayableMember to us-gaap_ConvertibleNotesPayableMember_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConvertibleDebt" xlink:label="ConvertibleDebt" xlink:title="ConvertibleDebt" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ConvertibleDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ConvertibleDebt_lbl" xml:lang="en-US" id="us-gaap_ConvertibleDebt_lbl">Amount of convertible note</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConvertibleDebt" xlink:to="us-gaap_ConvertibleDebt_lbl" xlink:title="label: ConvertibleDebt to us-gaap_ConvertibleDebt_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConvertibleNotesPayableCurrent" xlink:label="ConvertibleNotesPayableCurrent" xlink:title="ConvertibleNotesPayableCurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ConvertibleNotesPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ConvertibleNotesPayableCurrent_lbl" xml:lang="en-US" id="us-gaap_ConvertibleNotesPayableCurrent_lbl">Carrying value of convertible notes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConvertibleNotesPayableCurrent" xlink:to="us-gaap_ConvertibleNotesPayableCurrent_lbl" xlink:title="label: ConvertibleNotesPayableCurrent to us-gaap_ConvertibleNotesPayableCurrent_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CostOfSalesPolicyTextBlock" xlink:label="CostOfSalesPolicyTextBlock" xlink:title="CostOfSalesPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CostOfSalesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CostOfSalesPolicyTextBlock_lbl" xml:lang="en-US" id="us-gaap_CostOfSalesPolicyTextBlock_lbl">Cost of sales</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CostOfSalesPolicyTextBlock" xlink:to="us-gaap_CostOfSalesPolicyTextBlock_lbl" xlink:title="label: CostOfSalesPolicyTextBlock to us-gaap_CostOfSalesPolicyTextBlock_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CostOfRevenue" xlink:label="CostOfRevenue" xlink:title="CostOfRevenue" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CostOfRevenue_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_CostOfRevenue_lbl" xml:lang="en-US" id="us-gaap_CostOfRevenue_lbl">Cost of sales</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CostOfRevenue" xlink:to="us-gaap_CostOfRevenue_lbl" xlink:title="label: CostOfRevenue to us-gaap_CostOfRevenue_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CostOfRevenue_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CostOfRevenue_lbl1" xml:lang="en-US" id="us-gaap_CostOfRevenue_lbl1">Cost of Revenue</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CostOfRevenue" xlink:to="us-gaap_CostOfRevenue_lbl1" xlink:title="label: CostOfRevenue to us-gaap_CostOfRevenue_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="DebtConversionConvertedInstrumentSharesIssued1" xlink:title="DebtConversionConvertedInstrumentSharesIssued1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DebtConversionConvertedInstrumentSharesIssued1_lbl" xml:lang="en-US" id="us-gaap_DebtConversionConvertedInstrumentSharesIssued1_lbl">Common stock purchased in exchange for cancelation of indebtedness (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtConversionConvertedInstrumentSharesIssued1" xlink:to="us-gaap_DebtConversionConvertedInstrumentSharesIssued1_lbl" xlink:title="label: DebtConversionConvertedInstrumentSharesIssued1 to us-gaap_DebtConversionConvertedInstrumentSharesIssued1_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="DebtConversionConvertedInstrumentAmount1" xlink:title="DebtConversionConvertedInstrumentAmount1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DebtConversionConvertedInstrumentAmount1_lbl" xml:lang="en-US" id="us-gaap_DebtConversionConvertedInstrumentAmount1_lbl">Common stock purchased in exchange for cancelation of indebtedness, value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtConversionConvertedInstrumentAmount1" xlink:to="us-gaap_DebtConversionConvertedInstrumentAmount1_lbl" xlink:title="label: DebtConversionConvertedInstrumentAmount1 to us-gaap_DebtConversionConvertedInstrumentAmount1_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentTerm" xlink:label="DebtInstrumentTerm" xlink:title="DebtInstrumentTerm" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DebtInstrumentTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DebtInstrumentTerm_lbl" xml:lang="en-US" id="us-gaap_DebtInstrumentTerm_lbl">Accrued interest is payable period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentTerm" xlink:to="us-gaap_DebtInstrumentTerm_lbl" xlink:title="label: DebtInstrumentTerm to us-gaap_DebtInstrumentTerm_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="DebtInstrumentAxis" xlink:title="DebtInstrumentAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DebtInstrumentAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DebtInstrumentAxis_lbl" xml:lang="en-US" id="us-gaap_DebtInstrumentAxis_lbl">Debt Instrument [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentAxis_lbl" xlink:title="label: DebtInstrumentAxis to us-gaap_DebtInstrumentAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="DebtInstrumentConvertibleConversionPrice1" xlink:title="DebtInstrumentConvertibleConversionPrice1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_DebtInstrumentConvertibleConversionPrice1_lbl" xml:lang="en-US" id="us-gaap_DebtInstrumentConvertibleConversionPrice1_lbl">Debt instrument conversion price (in hundredths)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentConvertibleConversionPrice1" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1_lbl" xlink:title="label: DebtInstrumentConvertibleConversionPrice1 to us-gaap_DebtInstrumentConvertibleConversionPrice1_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DebtInstrumentConvertibleConversionPrice1_lbl1" xml:lang="en-US" id="us-gaap_DebtInstrumentConvertibleConversionPrice1_lbl1">Conversion price (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentConvertibleConversionPrice1" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1_lbl1" xlink:title="label: DebtInstrumentConvertibleConversionPrice1 to us-gaap_DebtInstrumentConvertibleConversionPrice1_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="DebtInstrumentInterestRateEffectivePercentage" xlink:title="DebtInstrumentInterestRateEffectivePercentage" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DebtInstrumentInterestRateEffectivePercentage_lbl" xml:lang="en-US" id="us-gaap_DebtInstrumentInterestRateEffectivePercentage_lbl">Effective annual interest rate (in hundredths)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentInterestRateEffectivePercentage" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage_lbl" xlink:title="label: DebtInstrumentInterestRateEffectivePercentage to us-gaap_DebtInstrumentInterestRateEffectivePercentage_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="DebtInstrumentNameDomain" xlink:title="DebtInstrumentNameDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DebtInstrumentNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DebtInstrumentNameDomain_lbl" xml:lang="en-US" id="us-gaap_DebtInstrumentNameDomain_lbl">Debt Instrument, Name [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentNameDomain" xlink:to="us-gaap_DebtInstrumentNameDomain_lbl" xlink:title="label: DebtInstrumentNameDomain to us-gaap_DebtInstrumentNameDomain_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="DebtInstrumentUnamortizedDiscount" xlink:title="DebtInstrumentUnamortizedDiscount" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DebtInstrumentUnamortizedDiscount_lbl" xml:lang="en-US" id="us-gaap_DebtInstrumentUnamortizedDiscount_lbl">Unamortized debt discount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentUnamortizedDiscount" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscount_lbl" xlink:title="label: DebtInstrumentUnamortizedDiscount to us-gaap_DebtInstrumentUnamortizedDiscount_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="DebtInstrumentInterestRateStatedPercentage" xlink:title="DebtInstrumentInterestRateStatedPercentage" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xml:lang="en-US" id="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl">Debt instrument interest rate (in hundredths)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentInterestRateStatedPercentage" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xlink:title="label: DebtInstrumentInterestRateStatedPercentage to us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl1" xml:lang="en-US" id="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl1">Stated interest rate (in hundredths)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentInterestRateStatedPercentage" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl1" xlink:title="label: DebtInstrumentInterestRateStatedPercentage to us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="DebtInstrumentMaturityDate" xlink:title="DebtInstrumentMaturityDate" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DebtInstrumentMaturityDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DebtInstrumentMaturityDate_lbl" xml:lang="en-US" id="us-gaap_DebtInstrumentMaturityDate_lbl">Debt instrument maturity date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentMaturityDate" xlink:to="us-gaap_DebtInstrumentMaturityDate_lbl" xlink:title="label: DebtInstrumentMaturityDate to us-gaap_DebtInstrumentMaturityDate_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredCostsCurrentAndNoncurrent" xlink:label="DeferredCostsCurrentAndNoncurrent" xlink:title="DeferredCostsCurrentAndNoncurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DeferredCostsCurrentAndNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_DeferredCostsCurrentAndNoncurrent_lbl" xml:lang="en-US" id="us-gaap_DeferredCostsCurrentAndNoncurrent_lbl">Total</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredCostsCurrentAndNoncurrent" xlink:to="us-gaap_DeferredCostsCurrentAndNoncurrent_lbl" xlink:title="label: DeferredCostsCurrentAndNoncurrent to us-gaap_DeferredCostsCurrentAndNoncurrent_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DeferredCostsCurrentAndNoncurrent_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DeferredCostsCurrentAndNoncurrent_lbl1" xml:lang="en-US" id="us-gaap_DeferredCostsCurrentAndNoncurrent_lbl1">Deferred Costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredCostsCurrentAndNoncurrent" xlink:to="us-gaap_DeferredCostsCurrentAndNoncurrent_lbl1" xlink:title="label: DeferredCostsCurrentAndNoncurrent to us-gaap_DeferredCostsCurrentAndNoncurrent_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredChargesPolicyTextBlock" xlink:label="DeferredChargesPolicyTextBlock" xlink:title="DeferredChargesPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DeferredChargesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_DeferredChargesPolicyTextBlock_lbl" xml:lang="en-US" id="us-gaap_DeferredChargesPolicyTextBlock_lbl">Deferred license and consulting fees</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredChargesPolicyTextBlock" xlink:to="us-gaap_DeferredChargesPolicyTextBlock_lbl" xlink:title="label: DeferredChargesPolicyTextBlock to us-gaap_DeferredChargesPolicyTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DeferredChargesPolicyTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DeferredChargesPolicyTextBlock_lbl1" xml:lang="en-US" id="us-gaap_DeferredChargesPolicyTextBlock_lbl1">Deferred Charges, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredChargesPolicyTextBlock" xlink:to="us-gaap_DeferredChargesPolicyTextBlock_lbl1" xlink:title="label: DeferredChargesPolicyTextBlock to us-gaap_DeferredChargesPolicyTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredRevenueDisclosureAbstract" xlink:label="DeferredRevenueDisclosureAbstract" xlink:title="DeferredRevenueDisclosureAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DeferredRevenueDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DeferredRevenueDisclosureAbstract_lbl" xml:lang="en-US" id="us-gaap_DeferredRevenueDisclosureAbstract_lbl">Royalty Obligation and Deferred License Fees [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredRevenueDisclosureAbstract" xlink:to="us-gaap_DeferredRevenueDisclosureAbstract_lbl" xlink:title="label: DeferredRevenueDisclosureAbstract to us-gaap_DeferredRevenueDisclosureAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="DeferredFederalIncomeTaxExpenseBenefit" xlink:title="DeferredFederalIncomeTaxExpenseBenefit" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl" xml:lang="en-US" id="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl">Deferred income tax benefit, federal</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredFederalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl" xlink:title="label: DeferredFederalIncomeTaxExpenseBenefit to us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl1" xml:lang="en-US" id="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl1">Deferred Federal Income Tax Expense (Benefit)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredFederalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl1" xlink:title="label: DeferredFederalIncomeTaxExpenseBenefit to us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredCostsAbstract" xlink:label="DeferredCostsAbstract" xlink:title="DeferredCostsAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DeferredCostsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_DeferredCostsAbstract_lbl" xml:lang="en-US" id="us-gaap_DeferredCostsAbstract_lbl">Amortization of deferred license fees [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredCostsAbstract" xlink:to="us-gaap_DeferredCostsAbstract_lbl" xlink:title="label: DeferredCostsAbstract to us-gaap_DeferredCostsAbstract_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DeferredCostsAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DeferredCostsAbstract_lbl1" xml:lang="en-US" id="us-gaap_DeferredCostsAbstract_lbl1">Deferred Costs [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredCostsAbstract" xlink:to="us-gaap_DeferredCostsAbstract_lbl1" xlink:title="label: DeferredCostsAbstract to us-gaap_DeferredCostsAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="DeferredIncomeTaxExpenseBenefit" xlink:title="DeferredIncomeTaxExpenseBenefit" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xml:lang="en-US" id="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl">Deferred income tax benefit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xlink:title="label: DeferredIncomeTaxExpenseBenefit to us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl1" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl1" xml:lang="en-US" id="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl1">Deferred income tax benefit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl1" xlink:title="label: DeferredIncomeTaxExpenseBenefit to us-gaap_DeferredIncomeTaxExpenseBenefit_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:title="DeferredStateAndLocalIncomeTaxExpenseBenefit" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl" xml:lang="en-US" id="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl">Deferred income tax benefit, state taxes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl" xlink:title="label: DeferredStateAndLocalIncomeTaxExpenseBenefit to us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl1" xml:lang="en-US" id="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl1">Deferred State and Local Income Tax Expense (Benefit)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl1" xlink:title="label: DeferredStateAndLocalIncomeTaxExpenseBenefit to us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent" xlink:label="DeferredRentCreditNoncurrent" xlink:title="DeferredRentCreditNoncurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DeferredRentCreditNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DeferredRentCreditNoncurrent_lbl" xml:lang="en-US" id="us-gaap_DeferredRentCreditNoncurrent_lbl">Deferred rent liabilities, net of current portion</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredRentCreditNoncurrent" xlink:to="us-gaap_DeferredRentCreditNoncurrent_lbl" xlink:title="label: DeferredRentCreditNoncurrent to us-gaap_DeferredRentCreditNoncurrent_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredRevenueDisclosureTextBlock" xlink:label="DeferredRevenueDisclosureTextBlock" xlink:title="DeferredRevenueDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DeferredRevenueDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_DeferredRevenueDisclosureTextBlock_lbl" xml:lang="en-US" id="us-gaap_DeferredRevenueDisclosureTextBlock_lbl">Royalty Obligation and Deferred License Fees</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredRevenueDisclosureTextBlock" xlink:to="us-gaap_DeferredRevenueDisclosureTextBlock_lbl" xlink:title="label: DeferredRevenueDisclosureTextBlock to us-gaap_DeferredRevenueDisclosureTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DeferredRevenueDisclosureTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DeferredRevenueDisclosureTextBlock_lbl1" xml:lang="en-US" id="us-gaap_DeferredRevenueDisclosureTextBlock_lbl1">Deferred Revenue Disclosure [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredRevenueDisclosureTextBlock" xlink:to="us-gaap_DeferredRevenueDisclosureTextBlock_lbl1" xlink:title="label: DeferredRevenueDisclosureTextBlock to us-gaap_DeferredRevenueDisclosureTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="DeferredRevenueCurrent" xlink:title="DeferredRevenueCurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DeferredRevenueCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DeferredRevenueCurrent_lbl" xml:lang="en-US" id="us-gaap_DeferredRevenueCurrent_lbl">Deferred license and subscription revenue, current portion</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredRevenueCurrent" xlink:to="us-gaap_DeferredRevenueCurrent_lbl" xlink:title="label: DeferredRevenueCurrent to us-gaap_DeferredRevenueCurrent_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxLiabilitiesNoncurrent" xlink:label="DeferredTaxLiabilitiesNoncurrent" xlink:title="DeferredTaxLiabilitiesNoncurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DeferredTaxLiabilitiesNoncurrent_lbl" xml:lang="en-US" id="us-gaap_DeferredTaxLiabilitiesNoncurrent_lbl">Deferred tax liabilities, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredTaxLiabilitiesNoncurrent" xlink:to="us-gaap_DeferredTaxLiabilitiesNoncurrent_lbl" xlink:title="label: DeferredTaxLiabilitiesNoncurrent to us-gaap_DeferredTaxLiabilitiesNoncurrent_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DepositsAssetsNoncurrent" xlink:label="DepositsAssetsNoncurrent" xlink:title="DepositsAssetsNoncurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DepositsAssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_DepositsAssetsNoncurrent_lbl" xml:lang="en-US" id="us-gaap_DepositsAssetsNoncurrent_lbl">Deposits</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DepositsAssetsNoncurrent" xlink:to="us-gaap_DepositsAssetsNoncurrent_lbl" xlink:title="label: DepositsAssetsNoncurrent to us-gaap_DepositsAssetsNoncurrent_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DepositsAssetsNoncurrent_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DepositsAssetsNoncurrent_lbl1" xml:lang="en-US" id="us-gaap_DepositsAssetsNoncurrent_lbl1">Deposits Assets, Noncurrent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DepositsAssetsNoncurrent" xlink:to="us-gaap_DepositsAssetsNoncurrent_lbl1" xlink:title="label: DepositsAssetsNoncurrent to us-gaap_DepositsAssetsNoncurrent_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Depreciation" xlink:label="Depreciation" xlink:title="Depreciation" />
    <link:label xlink:type="resource" xlink:label="us-gaap_Depreciation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_Depreciation_lbl" xml:lang="en-US" id="us-gaap_Depreciation_lbl">Depreciation expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Depreciation" xlink:to="us-gaap_Depreciation_lbl" xlink:title="label: Depreciation to us-gaap_Depreciation_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_Depreciation_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_Depreciation_lbl1" xml:lang="en-US" id="us-gaap_Depreciation_lbl1">Depreciation expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Depreciation" xlink:to="us-gaap_Depreciation_lbl1" xlink:title="label: Depreciation to us-gaap_Depreciation_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DirectorMember" xlink:label="DirectorMember" xlink:title="DirectorMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DirectorMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DirectorMember_lbl" xml:lang="en-US" id="us-gaap_DirectorMember_lbl">Broadwood Partners, LP [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DirectorMember" xlink:to="us-gaap_DirectorMember_lbl" xlink:title="label: DirectorMember to us-gaap_DirectorMember_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="EarningsPerShareBasicAndDiluted" xlink:title="EarningsPerShareBasicAndDiluted" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xml:lang="en-US" id="us-gaap_EarningsPerShareBasicAndDiluted_lbl">BASIC AND DILUTED NET LOSS PER COMMON SHARE (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EarningsPerShareBasicAndDiluted" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xlink:title="label: EarningsPerShareBasicAndDiluted to us-gaap_EarningsPerShareBasicAndDiluted_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="EarningsPerSharePolicyTextBlock" xlink:title="EarningsPerSharePolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US" id="us-gaap_EarningsPerSharePolicyTextBlock_lbl">Loss per share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:title="label: EarningsPerSharePolicyTextBlock to us-gaap_EarningsPerSharePolicyTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_EarningsPerSharePolicyTextBlock_lbl1" xml:lang="en-US" id="us-gaap_EarningsPerSharePolicyTextBlock_lbl1">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl1" xlink:title="label: EarningsPerSharePolicyTextBlock to us-gaap_EarningsPerSharePolicyTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:label="EffectOfExchangeRateOnCashAndCashEquivalents" xlink:title="EffectOfExchangeRateOnCashAndCashEquivalents" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_lbl" xml:lang="en-US" id="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_lbl">Effect of exchange rate changes on cash and cash equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EffectOfExchangeRateOnCashAndCashEquivalents" xlink:to="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_lbl" xlink:title="label: EffectOfExchangeRateOnCashAndCashEquivalents to us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="EmployeeStockOptionMember" xlink:title="EmployeeStockOptionMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_EmployeeStockOptionMember_lbl" xml:lang="en-US" id="us-gaap_EmployeeStockOptionMember_lbl">Stock Options [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl" xlink:title="label: EmployeeStockOptionMember to us-gaap_EmployeeStockOptionMember_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquipmentMember" xlink:label="EquipmentMember" xlink:title="EquipmentMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_EquipmentMember_lbl" xml:lang="en-US" id="us-gaap_EquipmentMember_lbl">Equipment [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EquipmentMember" xlink:to="us-gaap_EquipmentMember_lbl" xlink:title="label: EquipmentMember to us-gaap_EquipmentMember_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityAbstract" xlink:label="EquityAbstract" xlink:title="EquityAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_EquityAbstract_lbl" xml:lang="en-US" id="us-gaap_EquityAbstract_lbl">Shareholders' Equity [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl" xlink:title="label: EquityAbstract to us-gaap_EquityAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="EquityMethodInvestmentOwnershipPercentage" xlink:title="EquityMethodInvestmentOwnershipPercentage" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl" xml:lang="en-US" id="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl">Ownership percentage on outstanding common shares (in hundredths)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EquityMethodInvestmentOwnershipPercentage" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl" xlink:title="label: EquityMethodInvestmentOwnershipPercentage to us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="EquityComponentDomain" xlink:title="EquityComponentDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_EquityComponentDomain_lbl" xml:lang="en-US" id="us-gaap_EquityComponentDomain_lbl">Equity Component [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl" xlink:title="label: EquityComponentDomain to us-gaap_EquityComponentDomain_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ExecutiveVicePresidentMember" xlink:label="ExecutiveVicePresidentMember" xlink:title="ExecutiveVicePresidentMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ExecutiveVicePresidentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ExecutiveVicePresidentMember_lbl" xml:lang="en-US" id="us-gaap_ExecutiveVicePresidentMember_lbl">Robert W. Peabody [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ExecutiveVicePresidentMember" xlink:to="us-gaap_ExecutiveVicePresidentMember_lbl" xlink:title="label: ExecutiveVicePresidentMember to us-gaap_ExecutiveVicePresidentMember_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="FairValueOfFinancialInstrumentsPolicy" xlink:title="FairValueOfFinancialInstrumentsPolicy" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xml:lang="en-US" id="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl">Fair value of financial instruments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueOfFinancialInstrumentsPolicy" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xlink:title="label: FairValueOfFinancialInstrumentsPolicy to us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl1" xml:lang="en-US" id="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl1">Fair Value of Financial Instruments, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueOfFinancialInstrumentsPolicy" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl1" xlink:title="label: FairValueOfFinancialInstrumentsPolicy to us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="FiniteLivedIntangibleAssetUsefulLife" xlink:title="FiniteLivedIntangibleAssetUsefulLife" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl" xml:lang="en-US" id="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl">Intangible assets, useful life</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FiniteLivedIntangibleAssetUsefulLife" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl" xlink:title="label: FiniteLivedIntangibleAssetUsefulLife to us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl1" xml:lang="en-US" id="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl1">Intangible asset, useful life</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FiniteLivedIntangibleAssetUsefulLife" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl1" xlink:title="label: FiniteLivedIntangibleAssetUsefulLife to us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="FiniteLivedIntangibleAssetsGross" xlink:title="FiniteLivedIntangibleAssetsGross" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_FiniteLivedIntangibleAssetsGross_lbl" xml:lang="en-US" id="us-gaap_FiniteLivedIntangibleAssetsGross_lbl">Intangible assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FiniteLivedIntangibleAssetsGross" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross_lbl" xlink:title="label: FiniteLivedIntangibleAssetsGross to us-gaap_FiniteLivedIntangibleAssetsGross_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FiniteLivedIntangibleAssetsGross_lbl1" xml:lang="en-US" id="us-gaap_FiniteLivedIntangibleAssetsGross_lbl1">Finite-Lived Intangible Assets, Gross</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FiniteLivedIntangibleAssetsGross" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross_lbl1" xlink:title="label: FiniteLivedIntangibleAssetsGross to us-gaap_FiniteLivedIntangibleAssetsGross_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="FiniteLivedIntangibleAssetsLineItems" xlink:title="FiniteLivedIntangibleAssetsLineItems" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FiniteLivedIntangibleAssetsLineItems_lbl" xml:lang="en-US" id="us-gaap_FiniteLivedIntangibleAssetsLineItems_lbl">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsLineItems_lbl" xlink:title="label: FiniteLivedIntangibleAssetsLineItems to us-gaap_FiniteLivedIntangibleAssetsLineItems_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:title="FiniteLivedIntangibleAssetsAccumulatedAmortization" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xml:lang="en-US" id="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl">Accumulated amortization</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xlink:title="label: FiniteLivedIntangibleAssetsAccumulatedAmortization to us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl1" xml:lang="en-US" id="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl1">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl1" xlink:title="label: FiniteLivedIntangibleAssetsAccumulatedAmortization to us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="FiniteLivedIntangibleAssetsNet" xlink:title="FiniteLivedIntangibleAssetsNet" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xml:lang="en-US" id="us-gaap_FiniteLivedIntangibleAssetsNet_lbl">Intangible assets, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xlink:title="label: FiniteLivedIntangibleAssetsNet to us-gaap_FiniteLivedIntangibleAssetsNet_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FiniteLivedIntangibleAssetsNet_lbl1" xml:lang="en-US" id="us-gaap_FiniteLivedIntangibleAssetsNet_lbl1">Finite-Lived Intangible Assets, Net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_lbl1" xlink:title="label: FiniteLivedIntangibleAssetsNet to us-gaap_FiniteLivedIntangibleAssetsNet_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:title="FiniteLivedIntangibleAssetsMajorClassNameDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" xml:lang="en-US" id="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" xlink:title="label: FiniteLivedIntangibleAssetsMajorClassNameDomain to us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:title="FiniteLivedIntangibleAssetsByMajorClassAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xml:lang="en-US" id="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xlink:title="label: FiniteLivedIntangibleAssetsByMajorClassAxis to us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:label="FiniteLivedIntangibleAssetsNetAbstract" xlink:title="FiniteLivedIntangibleAssetsNetAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNetAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_FiniteLivedIntangibleAssetsNetAbstract_lbl" xml:lang="en-US" id="us-gaap_FiniteLivedIntangibleAssetsNetAbstract_lbl">Intangible assets, net [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FiniteLivedIntangibleAssetsNetAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNetAbstract_lbl" xlink:title="label: FiniteLivedIntangibleAssetsNetAbstract to us-gaap_FiniteLivedIntangibleAssetsNetAbstract_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNetAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FiniteLivedIntangibleAssetsNetAbstract_lbl1" xml:lang="en-US" id="us-gaap_FiniteLivedIntangibleAssetsNetAbstract_lbl1">Finite-Lived Intangible Assets, Net [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FiniteLivedIntangibleAssetsNetAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNetAbstract_lbl1" xlink:title="label: FiniteLivedIntangibleAssetsNetAbstract to us-gaap_FiniteLivedIntangibleAssetsNetAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:title="ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" xml:lang="en-US" id="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl">Foreign currency translation gain and other comprehensive loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" xlink:title="label: ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock to us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="ForeignCurrencyTransactionGainLossBeforeTax" xlink:title="ForeignCurrencyTransactionGainLossBeforeTax" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl" xml:lang="en-US" id="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl">Foreign currency transaction gain (loss)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ForeignCurrencyTransactionGainLossBeforeTax" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl" xlink:title="label: ForeignCurrencyTransactionGainLossBeforeTax to us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl1" xml:lang="en-US" id="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl1">Foreign Currency Transaction Gain (Loss), before Tax</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ForeignCurrencyTransactionGainLossBeforeTax" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl1" xlink:title="label: ForeignCurrencyTransactionGainLossBeforeTax to us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="GeneralAndAdministrativeExpense" xlink:title="GeneralAndAdministrativeExpense" />
    <link:label xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US" id="us-gaap_GeneralAndAdministrativeExpense_lbl">General and administrative</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:title="label: GeneralAndAdministrativeExpense to us-gaap_GeneralAndAdministrativeExpense_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:label="GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:title="GoodwillAndIntangibleAssetsPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_lbl" xml:lang="en-US" id="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_lbl">Intangible assets, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:to="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_lbl" xlink:title="label: GoodwillAndIntangibleAssetsPolicyTextBlock to us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_lbl1" xml:lang="en-US" id="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_lbl1">Goodwill and Intangible Assets, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:to="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_lbl1" xlink:title="label: GoodwillAndIntangibleAssetsPolicyTextBlock to us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:title="GoodwillAndIntangibleAssetsDisclosureAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl" xml:lang="en-US" id="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl">Intangible assets, net [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl" xlink:title="label: GoodwillAndIntangibleAssetsDisclosureAbstract to us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_GrantsReceivableCurrent" xlink:label="GrantsReceivableCurrent" xlink:title="GrantsReceivableCurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_GrantsReceivableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_GrantsReceivableCurrent_lbl" xml:lang="en-US" id="us-gaap_GrantsReceivableCurrent_lbl">Grants receivable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GrantsReceivableCurrent" xlink:to="us-gaap_GrantsReceivableCurrent_lbl" xlink:title="label: GrantsReceivableCurrent to us-gaap_GrantsReceivableCurrent_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_GrantsReceivableCurrent_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_GrantsReceivableCurrent_lbl1" xml:lang="en-US" id="us-gaap_GrantsReceivableCurrent_lbl1">Grants Receivable, Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GrantsReceivableCurrent" xlink:to="us-gaap_GrantsReceivableCurrent_lbl1" xlink:title="label: GrantsReceivableCurrent to us-gaap_GrantsReceivableCurrent_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_GrantsReceivable" xlink:label="GrantsReceivable" xlink:title="GrantsReceivable" />
    <link:label xlink:type="resource" xlink:label="us-gaap_GrantsReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_GrantsReceivable_lbl" xml:lang="en-US" id="us-gaap_GrantsReceivable_lbl">Grants receivable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GrantsReceivable" xlink:to="us-gaap_GrantsReceivable_lbl" xlink:title="label: GrantsReceivable to us-gaap_GrantsReceivable_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_GrantsReceivable_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_GrantsReceivable_lbl1" xml:lang="en-US" id="us-gaap_GrantsReceivable_lbl1">Grants Receivable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GrantsReceivable" xlink:to="us-gaap_GrantsReceivable_lbl1" xlink:title="label: GrantsReceivable to us-gaap_GrantsReceivable_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_GrossProfit" xlink:label="GrossProfit" xlink:title="GrossProfit" />
    <link:label xlink:type="resource" xlink:label="us-gaap_GrossProfit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_GrossProfit_lbl" xml:lang="en-US" id="us-gaap_GrossProfit_lbl">Gross Profit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GrossProfit" xlink:to="us-gaap_GrossProfit_lbl" xlink:title="label: GrossProfit to us-gaap_GrossProfit_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_GrossProfit_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_GrossProfit_lbl1" xml:lang="en-US" id="us-gaap_GrossProfit_lbl1">Gross Profit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GrossProfit" xlink:to="us-gaap_GrossProfit_lbl1" xlink:title="label: GrossProfit to us-gaap_GrossProfit_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:title="ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xml:lang="en-US" id="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl">Impairment of long-lived assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xlink:title="label: ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock to us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl1" xml:lang="en-US" id="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl1">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl1" xlink:title="label: ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock to us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:label="ImpairmentOfLongLivedAssetsHeldForUse" xlink:title="ImpairmentOfLongLivedAssetsHeldForUse" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl" xml:lang="en-US" id="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl">Loss on sale or write-off of equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ImpairmentOfLongLivedAssetsHeldForUse" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl" xlink:title="label: ImpairmentOfLongLivedAssetsHeldForUse to us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="IncomeStatementAbstract" xlink:title="IncomeStatementAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US" id="us-gaap_IncomeStatementAbstract_lbl">CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" xlink:title="label: IncomeStatementAbstract to us-gaap_IncomeStatementAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:title="IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xml:lang="en-US" id="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl">LOSS BEFORE INCOME TAX BENEFITS</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:title="label: IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest to us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl1" xml:lang="en-US" id="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl1">Income (Loss) from Continuing Operations before Income Taxes, Extraordinary Items, Noncontrolling Interest</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl1" xlink:title="label: IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest to us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="IncomeTaxDisclosureAbstract" xlink:title="IncomeTaxDisclosureAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US" id="us-gaap_IncomeTaxDisclosureAbstract_lbl">Income Taxes [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:title="label: IncomeTaxDisclosureAbstract to us-gaap_IncomeTaxDisclosureAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="IncomeTaxPolicyTextBlock" xlink:title="IncomeTaxPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US" id="us-gaap_IncomeTaxPolicyTextBlock_lbl">Income taxes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:title="label: IncomeTaxPolicyTextBlock to us-gaap_IncomeTaxPolicyTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncomeTaxPolicyTextBlock_lbl1" xml:lang="en-US" id="us-gaap_IncomeTaxPolicyTextBlock_lbl1">Income Tax, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl1" xlink:title="label: IncomeTaxPolicyTextBlock to us-gaap_IncomeTaxPolicyTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="IncreaseDecreaseInAccountsReceivable" xlink:title="IncreaseDecreaseInAccountsReceivable" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xml:lang="en-US" id="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl">Accounts receivable, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xlink:title="label: IncreaseDecreaseInAccountsReceivable to us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl1" xml:lang="en-US" id="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl1">Increase (Decrease) in Accounts Receivable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl1" xlink:title="label: IncreaseDecreaseInAccountsReceivable to us-gaap_IncreaseDecreaseInAccountsReceivable_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:label="IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:title="IncreaseDecreaseInOtherNoncurrentLiabilities" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_lbl" xml:lang="en-US" id="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_lbl">Other long term liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_lbl" xlink:title="label: IncreaseDecreaseInOtherNoncurrentLiabilities to us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:title="IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US" id="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl">Accounts payable and accrued liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xlink:title="label: IncreaseDecreaseInAccountsPayableAndAccruedLiabilities to us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="IncreaseDecreaseInDeferredRevenue" xlink:title="IncreaseDecreaseInDeferredRevenue" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl" xml:lang="en-US" id="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl">Deferred revenues</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInDeferredRevenue" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl" xlink:title="label: IncreaseDecreaseInDeferredRevenue to us-gaap_IncreaseDecreaseInDeferredRevenue_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="IncreaseDecreaseInOperatingCapitalAbstract" xlink:title="IncreaseDecreaseInOperatingCapitalAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US" id="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl">Changes in operating assets and liabilities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:title="label: IncreaseDecreaseInOperatingCapitalAbstract to us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="IncreaseDecreaseInInventories" xlink:title="IncreaseDecreaseInInventories" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_IncreaseDecreaseInInventories_lbl" xml:lang="en-US" id="us-gaap_IncreaseDecreaseInInventories_lbl">Inventory</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories_lbl" xlink:title="label: IncreaseDecreaseInInventories to us-gaap_IncreaseDecreaseInInventories_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncreaseDecreaseInInventories_lbl1" xml:lang="en-US" id="us-gaap_IncreaseDecreaseInInventories_lbl1">Increase (Decrease) in Inventories</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories_lbl1" xlink:title="label: IncreaseDecreaseInInventories to us-gaap_IncreaseDecreaseInInventories_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:title="IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US" id="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl">Prepaid expenses and other current assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:title="label: IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets to us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl1" xml:lang="en-US" id="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl1">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl1" xlink:title="label: IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets to us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="IntangibleAssetsNetExcludingGoodwill" xlink:title="IntangibleAssetsNetExcludingGoodwill" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" xml:lang="en-US" id="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl">Intangible assets, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IntangibleAssetsNetExcludingGoodwill" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" xlink:title="label: IntangibleAssetsNetExcludingGoodwill to us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl1" xml:lang="en-US" id="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl1">Intangible Assets, Net (Excluding Goodwill)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IntangibleAssetsNetExcludingGoodwill" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl1" xlink:title="label: IntangibleAssetsNetExcludingGoodwill to us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:label="IntangibleAssetsDisclosureTextBlock" xlink:title="IntangibleAssetsDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl" xml:lang="en-US" id="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl">Intangible assets, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IntangibleAssetsDisclosureTextBlock" xlink:to="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl" xlink:title="label: IntangibleAssetsDisclosureTextBlock to us-gaap_IntangibleAssetsDisclosureTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl1" xml:lang="en-US" id="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl1">Intangible Assets Disclosure [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IntangibleAssetsDisclosureTextBlock" xlink:to="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl1" xlink:title="label: IntangibleAssetsDisclosureTextBlock to us-gaap_IntangibleAssetsDisclosureTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicyCostsIncurredToRenewOrExtend" xlink:label="IntangibleAssetsFiniteLivedPolicyCostsIncurredToRenewOrExtend" xlink:title="IntangibleAssetsFiniteLivedPolicyCostsIncurredToRenewOrExtend" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicyCostsIncurredToRenewOrExtend_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_IntangibleAssetsFiniteLivedPolicyCostsIncurredToRenewOrExtend_lbl" xml:lang="en-US" id="us-gaap_IntangibleAssetsFiniteLivedPolicyCostsIncurredToRenewOrExtend_lbl">Patent costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IntangibleAssetsFiniteLivedPolicyCostsIncurredToRenewOrExtend" xlink:to="us-gaap_IntangibleAssetsFiniteLivedPolicyCostsIncurredToRenewOrExtend_lbl" xlink:title="label: IntangibleAssetsFiniteLivedPolicyCostsIncurredToRenewOrExtend to us-gaap_IntangibleAssetsFiniteLivedPolicyCostsIncurredToRenewOrExtend_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicyCostsIncurredToRenewOrExtend_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IntangibleAssetsFiniteLivedPolicyCostsIncurredToRenewOrExtend_lbl1" xml:lang="en-US" id="us-gaap_IntangibleAssetsFiniteLivedPolicyCostsIncurredToRenewOrExtend_lbl1">Intangible Assets, Costs Incurred to Renew or Extend, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IntangibleAssetsFiniteLivedPolicyCostsIncurredToRenewOrExtend" xlink:to="us-gaap_IntangibleAssetsFiniteLivedPolicyCostsIncurredToRenewOrExtend_lbl1" xlink:title="label: IntangibleAssetsFiniteLivedPolicyCostsIncurredToRenewOrExtend to us-gaap_IntangibleAssetsFiniteLivedPolicyCostsIncurredToRenewOrExtend_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="InterestIncomeExpenseNet" xlink:title="InterestIncomeExpenseNet" />
    <link:label xlink:type="resource" xlink:label="us-gaap_InterestIncomeExpenseNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_InterestIncomeExpenseNet_lbl" xml:lang="en-US" id="us-gaap_InterestIncomeExpenseNet_lbl">Interest expense, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InterestIncomeExpenseNet" xlink:to="us-gaap_InterestIncomeExpenseNet_lbl" xlink:title="label: InterestIncomeExpenseNet to us-gaap_InterestIncomeExpenseNet_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InventoryNet" xlink:label="InventoryNet" xlink:title="InventoryNet" />
    <link:label xlink:type="resource" xlink:label="us-gaap_InventoryNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_InventoryNet_lbl" xml:lang="en-US" id="us-gaap_InventoryNet_lbl">Inventory</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InventoryNet" xlink:to="us-gaap_InventoryNet_lbl" xlink:title="label: InventoryNet to us-gaap_InventoryNet_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="InventoryPolicyTextBlock" xlink:title="InventoryPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_InventoryPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_InventoryPolicyTextBlock_lbl" xml:lang="en-US" id="us-gaap_InventoryPolicyTextBlock_lbl">Inventory</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InventoryPolicyTextBlock" xlink:to="us-gaap_InventoryPolicyTextBlock_lbl" xlink:title="label: InventoryPolicyTextBlock to us-gaap_InventoryPolicyTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_InventoryPolicyTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_InventoryPolicyTextBlock_lbl1" xml:lang="en-US" id="us-gaap_InventoryPolicyTextBlock_lbl1">Inventory, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InventoryPolicyTextBlock" xlink:to="us-gaap_InventoryPolicyTextBlock_lbl1" xlink:title="label: InventoryPolicyTextBlock to us-gaap_InventoryPolicyTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="InventoryFinishedGoodsNetOfReserves" xlink:title="InventoryFinishedGoodsNetOfReserves" />
    <link:label xlink:type="resource" xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_InventoryFinishedGoodsNetOfReserves_lbl" xml:lang="en-US" id="us-gaap_InventoryFinishedGoodsNetOfReserves_lbl">Inventory of finished products on-site</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InventoryFinishedGoodsNetOfReserves" xlink:to="us-gaap_InventoryFinishedGoodsNetOfReserves_lbl" xlink:title="label: InventoryFinishedGoodsNetOfReserves to us-gaap_InventoryFinishedGoodsNetOfReserves_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_InventoryFinishedGoodsNetOfReserves_lbl1" xml:lang="en-US" id="us-gaap_InventoryFinishedGoodsNetOfReserves_lbl1">Inventory, Finished Goods, Net of Reserves</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InventoryFinishedGoodsNetOfReserves" xlink:to="us-gaap_InventoryFinishedGoodsNetOfReserves_lbl1" xlink:title="label: InventoryFinishedGoodsNetOfReserves to us-gaap_InventoryFinishedGoodsNetOfReserves_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="InventoryDisclosureTextBlock" xlink:title="InventoryDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_InventoryDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_InventoryDisclosureTextBlock_lbl" xml:lang="en-US" id="us-gaap_InventoryDisclosureTextBlock_lbl">Inventory</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InventoryDisclosureTextBlock" xlink:to="us-gaap_InventoryDisclosureTextBlock_lbl" xlink:title="label: InventoryDisclosureTextBlock to us-gaap_InventoryDisclosureTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_InventoryDisclosureTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_InventoryDisclosureTextBlock_lbl1" xml:lang="en-US" id="us-gaap_InventoryDisclosureTextBlock_lbl1">Inventory Disclosure [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InventoryDisclosureTextBlock" xlink:to="us-gaap_InventoryDisclosureTextBlock_lbl1" xlink:title="label: InventoryDisclosureTextBlock to us-gaap_InventoryDisclosureTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="InventoryDisclosureAbstract" xlink:title="InventoryDisclosureAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_InventoryDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_InventoryDisclosureAbstract_lbl" xml:lang="en-US" id="us-gaap_InventoryDisclosureAbstract_lbl">Inventory [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryDisclosureAbstract_lbl" xlink:title="label: InventoryDisclosureAbstract to us-gaap_InventoryDisclosureAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LeaseholdImprovementsGross" xlink:label="LeaseholdImprovementsGross" xlink:title="LeaseholdImprovementsGross" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LeaseholdImprovementsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LeaseholdImprovementsGross_lbl" xml:lang="en-US" id="us-gaap_LeaseholdImprovementsGross_lbl">Leasehold improvements for Asterias' facility</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LeaseholdImprovementsGross" xlink:to="us-gaap_LeaseholdImprovementsGross_lbl" xlink:title="label: LeaseholdImprovementsGross to us-gaap_LeaseholdImprovementsGross_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="LiabilitiesCurrent" xlink:title="LiabilitiesCurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US" id="us-gaap_LiabilitiesCurrent_lbl">Total current liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" xlink:title="label: LiabilitiesCurrent to us-gaap_LiabilitiesCurrent_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrent_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LiabilitiesCurrent_lbl1" xml:lang="en-US" id="us-gaap_LiabilitiesCurrent_lbl1">Liabilities, Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl1" xlink:title="label: LiabilitiesCurrent to us-gaap_LiabilitiesCurrent_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="LiabilitiesAndStockholdersEquity" xlink:title="LiabilitiesAndStockholdersEquity" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US" id="us-gaap_LiabilitiesAndStockholdersEquity_lbl">TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:title="label: LiabilitiesAndStockholdersEquity to us-gaap_LiabilitiesAndStockholdersEquity_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LiabilitiesAndStockholdersEquity_lbl1" xml:lang="en-US" id="us-gaap_LiabilitiesAndStockholdersEquity_lbl1">Liabilities and Equity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl1" xlink:title="label: LiabilitiesAndStockholdersEquity to us-gaap_LiabilitiesAndStockholdersEquity_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="LiabilitiesNoncurrent" xlink:title="LiabilitiesNoncurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LiabilitiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_LiabilitiesNoncurrent_lbl" xml:lang="en-US" id="us-gaap_LiabilitiesNoncurrent_lbl">Total long-term liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiabilitiesNoncurrent" xlink:to="us-gaap_LiabilitiesNoncurrent_lbl" xlink:title="label: LiabilitiesNoncurrent to us-gaap_LiabilitiesNoncurrent_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LiabilitiesNoncurrent_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LiabilitiesNoncurrent_lbl1" xml:lang="en-US" id="us-gaap_LiabilitiesNoncurrent_lbl1">Liabilities, Noncurrent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiabilitiesNoncurrent" xlink:to="us-gaap_LiabilitiesNoncurrent_lbl1" xlink:title="label: LiabilitiesNoncurrent to us-gaap_LiabilitiesNoncurrent_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="LiabilitiesCurrentAbstract" xlink:title="LiabilitiesCurrentAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US" id="us-gaap_LiabilitiesCurrentAbstract_lbl">CURRENT LIABILITIES</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:title="label: LiabilitiesCurrentAbstract to us-gaap_LiabilitiesCurrentAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="LiabilitiesNoncurrentAbstract" xlink:title="LiabilitiesNoncurrentAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LiabilitiesNoncurrentAbstract_lbl" xml:lang="en-US" id="us-gaap_LiabilitiesNoncurrentAbstract_lbl">LONG-TERM LIABILITIES</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract_lbl" xlink:title="label: LiabilitiesNoncurrentAbstract to us-gaap_LiabilitiesNoncurrentAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="LiabilitiesAndStockholdersEquityAbstract" xlink:title="LiabilitiesAndStockholdersEquityAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US" id="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl">LIABILITIES AND SHAREHOLDERS' EQUITY</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:title="label: LiabilitiesAndStockholdersEquityAbstract to us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl1" xml:lang="en-US" id="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl1">Liabilities and Equity [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl1" xlink:title="label: LiabilitiesAndStockholdersEquityAbstract to us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LicensesRevenue" xlink:label="LicensesRevenue" xlink:title="LicensesRevenue" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LicensesRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LicensesRevenue_lbl" xml:lang="en-US" id="us-gaap_LicensesRevenue_lbl">License fees</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LicensesRevenue" xlink:to="us-gaap_LicensesRevenue_lbl" xlink:title="label: LicensesRevenue to us-gaap_LicensesRevenue_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:label="LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:title="LongTermDebtAndCapitalLeaseObligationsCurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_lbl" xml:lang="en-US" id="us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_lbl">Capital lease, net of current portion</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:to="us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_lbl" xlink:title="label: LongTermDebtAndCapitalLeaseObligationsCurrent to us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MajorCustomersAxis" xlink:label="MajorCustomersAxis" xlink:title="MajorCustomersAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_MajorCustomersAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_MajorCustomersAxis_lbl" xml:lang="en-US" id="us-gaap_MajorCustomersAxis_lbl">Customer [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MajorCustomersAxis" xlink:to="us-gaap_MajorCustomersAxis_lbl" xlink:title="label: MajorCustomersAxis to us-gaap_MajorCustomersAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MajorityShareholderMember" xlink:label="MajorityShareholderMember" xlink:title="MajorityShareholderMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_MajorityShareholderMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_MajorityShareholderMember_lbl" xml:lang="en-US" id="us-gaap_MajorityShareholderMember_lbl">George Karfunkel [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MajorityShareholderMember" xlink:to="us-gaap_MajorityShareholderMember_lbl" xlink:title="label: MajorityShareholderMember to us-gaap_MajorityShareholderMember_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MaximumMember" xlink:label="MaximumMember" xlink:title="MaximumMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_MaximumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_MaximumMember_lbl" xml:lang="en-US" id="us-gaap_MaximumMember_lbl">Maximum [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MaximumMember" xlink:to="us-gaap_MaximumMember_lbl" xlink:title="label: MaximumMember to us-gaap_MaximumMember_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MinimumMember" xlink:label="MinimumMember" xlink:title="MinimumMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_MinimumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_MinimumMember_lbl" xml:lang="en-US" id="us-gaap_MinimumMember_lbl">Minimum [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MinimumMember" xlink:to="us-gaap_MinimumMember_lbl" xlink:title="label: MinimumMember to us-gaap_MinimumMember_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MinorityInterestLineItems" xlink:label="MinorityInterestLineItems" xlink:title="MinorityInterestLineItems" />
    <link:label xlink:type="resource" xlink:label="us-gaap_MinorityInterestLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_MinorityInterestLineItems_lbl" xml:lang="en-US" id="us-gaap_MinorityInterestLineItems_lbl">Noncontrolling Interest [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MinorityInterestLineItems" xlink:to="us-gaap_MinorityInterestLineItems_lbl" xlink:title="label: MinorityInterestLineItems to us-gaap_MinorityInterestLineItems_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MinorityInterestTable" xlink:label="MinorityInterestTable" xlink:title="MinorityInterestTable" />
    <link:label xlink:type="resource" xlink:label="us-gaap_MinorityInterestTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_MinorityInterestTable_lbl" xml:lang="en-US" id="us-gaap_MinorityInterestTable_lbl">Noncontrolling Interest [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MinorityInterestTable" xlink:to="us-gaap_MinorityInterestTable_lbl" xlink:title="label: MinorityInterestTable to us-gaap_MinorityInterestTable_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:label="MinorityInterestOwnershipPercentageByParent" xlink:title="MinorityInterestOwnershipPercentageByParent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByParent_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_MinorityInterestOwnershipPercentageByParent_lbl" xml:lang="en-US" id="us-gaap_MinorityInterestOwnershipPercentageByParent_lbl">BioTime Ownership (in hundredths)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MinorityInterestOwnershipPercentageByParent" xlink:to="us-gaap_MinorityInterestOwnershipPercentageByParent_lbl" xlink:title="label: MinorityInterestOwnershipPercentageByParent to us-gaap_MinorityInterestOwnershipPercentageByParent_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MinorityInterest" xlink:label="MinorityInterest" xlink:title="MinorityInterest" />
    <link:label xlink:type="resource" xlink:label="us-gaap_MinorityInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_MinorityInterest_lbl" xml:lang="en-US" id="us-gaap_MinorityInterest_lbl">Non-controlling interest</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MinorityInterest" xlink:to="us-gaap_MinorityInterest_lbl" xlink:title="label: MinorityInterest to us-gaap_MinorityInterest_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NameOfMajorCustomerDomain" xlink:label="NameOfMajorCustomerDomain" xlink:title="NameOfMajorCustomerDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NameOfMajorCustomerDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_NameOfMajorCustomerDomain_lbl" xml:lang="en-US" id="us-gaap_NameOfMajorCustomerDomain_lbl">Customer [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NameOfMajorCustomerDomain" xlink:to="us-gaap_NameOfMajorCustomerDomain_lbl" xlink:title="label: NameOfMajorCustomerDomain to us-gaap_NameOfMajorCustomerDomain_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:label="NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:title="NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_lbl" xml:lang="en-US" id="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_lbl">CASH FLOWS FROM FINANCING ACTIVITIES:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_lbl" xlink:title="label: NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract to us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="NetIncomeLoss" xlink:title="NetIncomeLoss" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US" id="us-gaap_NetIncomeLoss_lbl">Net loss attributable to BioTime, Inc.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" xlink:title="label: NetIncomeLoss to us-gaap_NetIncomeLoss_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:label="NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:title="NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_lbl" xml:lang="en-US" id="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_lbl">CASH FLOWS FROM OPERATING ACTIVITIES:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_lbl" xlink:title="label: NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract to us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="NetIncomeLossAvailableToCommonStockholdersBasic" xlink:title="NetIncomeLossAvailableToCommonStockholdersBasic" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xml:lang="en-US" id="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl">NET LOSS ATTRIBUTABLE TO BIOTIME, INC.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xlink:title="label: NetIncomeLossAvailableToCommonStockholdersBasic to us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl1" xml:lang="en-US" id="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl1">Net Income (Loss) Available to Common Stockholders, Basic</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl1" xlink:title="label: NetIncomeLossAvailableToCommonStockholdersBasic to us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:title="NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_lbl" xml:lang="en-US" id="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_lbl">Net cash used in operating activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_lbl" xlink:title="label: NetCashProvidedByUsedInOperatingActivitiesContinuingOperations to us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_lbl1" xml:lang="en-US" id="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_lbl1">Net Cash Provided by (Used in) Operating Activities, Continuing Operations</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_lbl1" xlink:title="label: NetCashProvidedByUsedInOperatingActivitiesContinuingOperations to us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:label="NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:title="NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_lbl" xml:lang="en-US" id="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_lbl">Net cash provided by financing activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_lbl" xlink:title="label: NetCashProvidedByUsedInFinancingActivitiesContinuingOperations to us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_lbl1" xml:lang="en-US" id="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_lbl1">Net Cash Provided by (Used in) Financing Activities, Continuing Operations</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_lbl1" xlink:title="label: NetCashProvidedByUsedInFinancingActivitiesContinuingOperations to us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:label="NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:title="NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_lbl" xml:lang="en-US" id="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_lbl">Cash used in investing activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_lbl" xlink:title="label: NetCashProvidedByUsedInInvestingActivitiesContinuingOperations to us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_lbl1" xml:lang="en-US" id="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_lbl1">Net Cash Provided by (Used in) Investing Activities, Continuing Operations</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_lbl1" xlink:title="label: NetCashProvidedByUsedInInvestingActivitiesContinuingOperations to us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:label="NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:title="NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_lbl" xml:lang="en-US" id="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_lbl">CASH FLOWS FROM INVESTING ACTIVITIES:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_lbl" xlink:title="label: NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract to us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="NetIncomeLossAttributableToNoncontrollingInterest" xlink:title="NetIncomeLossAttributableToNoncontrollingInterest" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_lbl" xml:lang="en-US" id="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_lbl">Net loss attributable to non-controlling interest</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetIncomeLossAttributableToNoncontrollingInterest" xlink:to="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_lbl" xlink:title="label: NetIncomeLossAttributableToNoncontrollingInterest to us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_lbl1" xml:lang="en-US" id="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_lbl1">Net loss attributable to non-controlling interest</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetIncomeLossAttributableToNoncontrollingInterest" xlink:to="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_lbl1" xlink:title="label: NetIncomeLossAttributableToNoncontrollingInterest to us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_lbl1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_lbl2" xml:lang="en-US" id="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_lbl2">Less: Comprehensive loss attributable to non-controlling interest</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetIncomeLossAttributableToNoncontrollingInterest" xlink:to="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_lbl2" xlink:title="label: NetIncomeLossAttributableToNoncontrollingInterest to us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_lbl2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:title="NewAccountingPronouncementsPolicyPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US" id="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl">Recently issued accounting pronouncements</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:title="label: NewAccountingPronouncementsPolicyPolicyTextBlock to us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl1" xml:lang="en-US" id="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl1">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl1" xlink:title="label: NewAccountingPronouncementsPolicyPolicyTextBlock to us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="NonoperatingIncomeExpense" xlink:title="NonoperatingIncomeExpense" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US" id="us-gaap_NonoperatingIncomeExpense_lbl">Total other income/(expenses), net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl" xlink:title="label: NonoperatingIncomeExpense to us-gaap_NonoperatingIncomeExpense_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_NonoperatingIncomeExpense_lbl1" xml:lang="en-US" id="us-gaap_NonoperatingIncomeExpense_lbl1">Nonoperating Income (Expense)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl1" xlink:title="label: NonoperatingIncomeExpense to us-gaap_NonoperatingIncomeExpense_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="NonoperatingIncomeExpenseAbstract" xlink:title="NonoperatingIncomeExpenseAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US" id="us-gaap_NonoperatingIncomeExpenseAbstract_lbl">OTHER INCOME/(EXPENSES):</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xlink:title="label: NonoperatingIncomeExpenseAbstract to us-gaap_NonoperatingIncomeExpenseAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="NumberOfOperatingSegments" xlink:title="NumberOfOperatingSegments" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_NumberOfOperatingSegments_lbl" xml:lang="en-US" id="us-gaap_NumberOfOperatingSegments_lbl">Number of operating segments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfOperatingSegments" xlink:to="us-gaap_NumberOfOperatingSegments_lbl" xlink:title="label: NumberOfOperatingSegments to us-gaap_NumberOfOperatingSegments_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="OperatingExpensesAbstract" xlink:title="OperatingExpensesAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US" id="us-gaap_OperatingExpensesAbstract_lbl">OPERATING EXPENSES:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" xlink:title="label: OperatingExpensesAbstract to us-gaap_OperatingExpensesAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="OperatingExpenses" xlink:title="OperatingExpenses" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_OperatingExpenses_lbl" xml:lang="en-US" id="us-gaap_OperatingExpenses_lbl">Total operating expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl" xlink:title="label: OperatingExpenses to us-gaap_OperatingExpenses_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingExpenses_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OperatingExpenses_lbl1" xml:lang="en-US" id="us-gaap_OperatingExpenses_lbl1">Operating Expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl1" xlink:title="label: OperatingExpenses to us-gaap_OperatingExpenses_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="OperatingIncomeLoss" xlink:title="OperatingIncomeLoss" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US" id="us-gaap_OperatingIncomeLoss_lbl">Loss from operations</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" xlink:title="label: OperatingIncomeLoss to us-gaap_OperatingIncomeLoss_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OperatingIncomeLoss_lbl1" xml:lang="en-US" id="us-gaap_OperatingIncomeLoss_lbl1">Operating Income (Loss)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl1" xlink:title="label: OperatingIncomeLoss to us-gaap_OperatingIncomeLoss_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:title="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US" id="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl">Organization, Basis of Presentation, and Liquidity [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:title="label: OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract to us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:title="OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xml:lang="en-US" id="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl">Organization, Basis of Presentation, and Liquidity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xlink:title="label: OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock to us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl1" xml:lang="en-US" id="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl1">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl1" xlink:title="label: OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock to us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:title="OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl" xml:lang="en-US" id="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl">Foreign currency gain (loss) included in comprehensive loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl" xlink:title="label: OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax to us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl1" xml:lang="en-US" id="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl1">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl1" xlink:title="label: OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax to us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="OtherAssetsNoncurrent" xlink:title="OtherAssetsNoncurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_OtherAssetsNoncurrent_lbl" xml:lang="en-US" id="us-gaap_OtherAssetsNoncurrent_lbl">Other long-term assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl" xlink:title="label: OtherAssetsNoncurrent to us-gaap_OtherAssetsNoncurrent_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OtherAssetsNoncurrent_lbl1" xml:lang="en-US" id="us-gaap_OtherAssetsNoncurrent_lbl1">Other Assets, Noncurrent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl1" xlink:title="label: OtherAssetsNoncurrent to us-gaap_OtherAssetsNoncurrent_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:label="OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:title="OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_lbl" xml:lang="en-US" id="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_lbl">Other comprehensive income/(loss), net of tax:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_lbl" xlink:title="label: OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract to us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxAbstract" xlink:label="OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxAbstract" xlink:title="OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxAbstract_lbl" xml:lang="en-US" id="us-gaap_OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxAbstract_lbl">Change in foreign currency translation and other comprehensive income/(loss) from equity investments:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxAbstract_lbl" xlink:title="label: OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxAbstract to us-gaap_OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:label="OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:title="OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_lbl" xml:lang="en-US" id="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_lbl">Unrealized loss on exchange translation in foreing subsidiaries</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_lbl" xlink:title="label: OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax to us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_lbl1" xml:lang="en-US" id="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_lbl1">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss) Arising During Period, Net of Tax</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_lbl1" xlink:title="label: OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax to us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:title="OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl" xml:lang="en-US" id="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl">Unrealized gain/(loss) on available-for-sale securities, net of taxes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl" xlink:title="label: OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax to us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl1" xml:lang="en-US" id="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl1">Other Comprehensive Income (Loss), Unrealized Holding Gain (Loss) on Securities Arising During Period, Net of Tax</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl1" xlink:title="label: OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax to us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="OtherNonoperatingIncome" xlink:title="OtherNonoperatingIncome" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingIncome_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OtherNonoperatingIncome_lbl" xml:lang="en-US" id="us-gaap_OtherNonoperatingIncome_lbl">Other income/(expense), net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherNonoperatingIncome" xlink:to="us-gaap_OtherNonoperatingIncome_lbl" xlink:title="label: OtherNonoperatingIncome to us-gaap_OtherNonoperatingIncome_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="OtherLiabilitiesNoncurrent" xlink:title="OtherLiabilitiesNoncurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_OtherLiabilitiesNoncurrent_lbl" xml:lang="en-US" id="us-gaap_OtherLiabilitiesNoncurrent_lbl">Other long term liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherLiabilitiesNoncurrent" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_lbl" xlink:title="label: OtherLiabilitiesNoncurrent to us-gaap_OtherLiabilitiesNoncurrent_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OtherLiabilitiesNoncurrent_lbl1" xml:lang="en-US" id="us-gaap_OtherLiabilitiesNoncurrent_lbl1">Other Liabilities, Noncurrent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherLiabilitiesNoncurrent" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_lbl1" xlink:title="label: OtherLiabilitiesNoncurrent to us-gaap_OtherLiabilitiesNoncurrent_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment" xlink:label="OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment" xlink:title="OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment_lbl" xml:lang="en-US" id="us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment_lbl">Inventory held by third party on consignment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment" xlink:to="us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment_lbl" xlink:title="label: OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment to us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment_lbl1" xml:lang="en-US" id="us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment_lbl1">Other Inventory, Materials, Supplies and Merchandise under Consignment, Gross</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment" xlink:to="us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment_lbl1" xlink:title="label: OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment to us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="OtherAccruedLiabilitiesCurrent" xlink:title="OtherAccruedLiabilitiesCurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xml:lang="en-US" id="us-gaap_OtherAccruedLiabilitiesCurrent_lbl">Other accrued liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:title="label: OtherAccruedLiabilitiesCurrent to us-gaap_OtherAccruedLiabilitiesCurrent_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OtherAccruedLiabilitiesCurrent_lbl1" xml:lang="en-US" id="us-gaap_OtherAccruedLiabilitiesCurrent_lbl1">Other Accrued Liabilities, Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl1" xlink:title="label: OtherAccruedLiabilitiesCurrent to us-gaap_OtherAccruedLiabilitiesCurrent_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest" xlink:label="OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest" xlink:title="OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest_lbl" xml:lang="en-US" id="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest_lbl">COMPREHENSIVE LOSS ATTRIBUTABLE TO BIOTIME, INC. COMMON SHAREHOLDERS</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest_lbl" xlink:title="label: OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest to us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ParentMember" xlink:label="ParentMember" xlink:title="ParentMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ParentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ParentMember_lbl" xml:lang="en-US" id="us-gaap_ParentMember_lbl">Parent [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ParentMember" xlink:to="us-gaap_ParentMember_lbl" xlink:title="label: ParentMember to us-gaap_ParentMember_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="PayablesAndAccrualsAbstract" xlink:title="PayablesAndAccrualsAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PayablesAndAccrualsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PayablesAndAccrualsAbstract_lbl" xml:lang="en-US" id="us-gaap_PayablesAndAccrualsAbstract_lbl">Accounts Payable and Accrued Liabilities [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PayablesAndAccrualsAbstract" xlink:to="us-gaap_PayablesAndAccrualsAbstract_lbl" xlink:title="label: PayablesAndAccrualsAbstract to us-gaap_PayablesAndAccrualsAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaymentsForRent" xlink:label="PaymentsForRent" xlink:title="PaymentsForRent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PaymentsForRent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_PaymentsForRent_lbl" xml:lang="en-US" id="us-gaap_PaymentsForRent_lbl">Rent per month</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PaymentsForRent" xlink:to="us-gaap_PaymentsForRent_lbl" xlink:title="label: PaymentsForRent to us-gaap_PaymentsForRent_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PaymentsForRent_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PaymentsForRent_lbl1" xml:lang="en-US" id="us-gaap_PaymentsForRent_lbl1">Payments for Rent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PaymentsForRent" xlink:to="us-gaap_PaymentsForRent_lbl1" xlink:title="label: PaymentsForRent to us-gaap_PaymentsForRent_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaymentsForCapitalImprovements" xlink:label="PaymentsForCapitalImprovements" xlink:title="PaymentsForCapitalImprovements" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PaymentsForCapitalImprovements_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_PaymentsForCapitalImprovements_lbl" xml:lang="en-US" id="us-gaap_PaymentsForCapitalImprovements_lbl">Payments on construction in progress (see Note 4)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PaymentsForCapitalImprovements" xlink:to="us-gaap_PaymentsForCapitalImprovements_lbl" xlink:title="label: PaymentsForCapitalImprovements to us-gaap_PaymentsForCapitalImprovements_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PaymentsForCapitalImprovements_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PaymentsForCapitalImprovements_lbl1" xml:lang="en-US" id="us-gaap_PaymentsForCapitalImprovements_lbl1">Payments for Capital Improvements</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PaymentsForCapitalImprovements" xlink:to="us-gaap_PaymentsForCapitalImprovements_lbl1" xlink:title="label: PaymentsForCapitalImprovements to us-gaap_PaymentsForCapitalImprovements_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="PaymentsToAcquirePropertyPlantAndEquipment" xlink:title="PaymentsToAcquirePropertyPlantAndEquipment" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US" id="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl">Purchase of equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:title="label: PaymentsToAcquirePropertyPlantAndEquipment to us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl1" xml:lang="en-US" id="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl1">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl1" xlink:title="label: PaymentsToAcquirePropertyPlantAndEquipment to us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="PlanNameDomain" xlink:title="PlanNameDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PlanNameDomain_lbl" xml:lang="en-US" id="us-gaap_PlanNameDomain_lbl">Plan Name [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl" xlink:title="label: PlanNameDomain to us-gaap_PlanNameDomain_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="PlanNameAxis" xlink:title="PlanNameAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PlanNameAxis_lbl" xml:lang="en-US" id="us-gaap_PlanNameAxis_lbl">Plan Name [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl" xlink:title="label: PlanNameAxis to us-gaap_PlanNameAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockNoParValue" xlink:label="PreferredStockNoParValue" xlink:title="PreferredStockNoParValue" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PreferredStockNoParValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PreferredStockNoParValue_lbl" xml:lang="en-US" id="us-gaap_PreferredStockNoParValue_lbl">Series A Convertible Preferred Shares, par value (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreferredStockNoParValue" xlink:to="us-gaap_PreferredStockNoParValue_lbl" xlink:title="label: PreferredStockNoParValue to us-gaap_PreferredStockNoParValue_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockDividendRatePercentage" xlink:label="PreferredStockDividendRatePercentage" xlink:title="PreferredStockDividendRatePercentage" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PreferredStockDividendRatePercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PreferredStockDividendRatePercentage_lbl" xml:lang="en-US" id="us-gaap_PreferredStockDividendRatePercentage_lbl">Preferred stock dividend rate (in hundredths)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreferredStockDividendRatePercentage" xlink:to="us-gaap_PreferredStockDividendRatePercentage_lbl" xlink:title="label: PreferredStockDividendRatePercentage to us-gaap_PreferredStockDividendRatePercentage_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="PreferredStockValue" xlink:title="PreferredStockValue" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PreferredStockValue_lbl" xml:lang="en-US" id="us-gaap_PreferredStockValue_lbl">Series A Convertible Preferred shares, no par value, authorized 2,000,000 shares as of March 31, 2015 and December 31, 2014; 70,000 issued and outstanding as of March 31, 2015 and December 31, 2014</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl" xlink:title="label: PreferredStockValue to us-gaap_PreferredStockValue_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:label="PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:title="PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_lbl" xml:lang="en-US" id="us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_lbl">Preferred Shares [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_lbl" xlink:title="label: PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract to us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_lbl1" xml:lang="en-US" id="us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_lbl1">Preferred Stock, Number of Shares, Par Value and Other Disclosures [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_lbl1" xlink:title="label: PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract to us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="PreferredStockSharesIssued" xlink:title="PreferredStockSharesIssued" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US" id="us-gaap_PreferredStockSharesIssued_lbl">Series A Convertible Preferred Shares, issued (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl" xlink:title="label: PreferredStockSharesIssued to us-gaap_PreferredStockSharesIssued_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="PreferredStockSharesAuthorized" xlink:title="PreferredStockSharesAuthorized" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US" id="us-gaap_PreferredStockSharesAuthorized_lbl">Series A Convertible Preferred Shares, authorized (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:title="label: PreferredStockSharesAuthorized to us-gaap_PreferredStockSharesAuthorized_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_PreferredStockSharesAuthorized_lbl1" xml:lang="en-US" id="us-gaap_PreferredStockSharesAuthorized_lbl1">Preferred shares, shares authorized (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl1" xlink:title="label: PreferredStockSharesAuthorized to us-gaap_PreferredStockSharesAuthorized_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockDividendRatePerDollarAmount" xlink:label="PreferredStockDividendRatePerDollarAmount" xlink:title="PreferredStockDividendRatePerDollarAmount" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PreferredStockDividendRatePerDollarAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PreferredStockDividendRatePerDollarAmount_lbl" xml:lang="en-US" id="us-gaap_PreferredStockDividendRatePerDollarAmount_lbl">Preferred share dividend (in dollars per shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreferredStockDividendRatePerDollarAmount" xlink:to="us-gaap_PreferredStockDividendRatePerDollarAmount_lbl" xlink:title="label: PreferredStockDividendRatePerDollarAmount to us-gaap_PreferredStockDividendRatePerDollarAmount_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="PreferredStockSharesOutstanding" xlink:title="PreferredStockSharesOutstanding" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US" id="us-gaap_PreferredStockSharesOutstanding_lbl">Series A Convertible Preferred shares outstanding (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:title="label: PreferredStockSharesOutstanding to us-gaap_PreferredStockSharesOutstanding_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="PrepaidExpenseAndOtherAssetsCurrent" xlink:title="PrepaidExpenseAndOtherAssetsCurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US" id="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl">Prepaid expenses and other current assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:title="label: PrepaidExpenseAndOtherAssetsCurrent to us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:label="PriorPeriodReclassificationAdjustmentDescription" xlink:title="PriorPeriodReclassificationAdjustmentDescription" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PriorPeriodReclassificationAdjustmentDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_PriorPeriodReclassificationAdjustmentDescription_lbl" xml:lang="en-US" id="us-gaap_PriorPeriodReclassificationAdjustmentDescription_lbl">Reclassification</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PriorPeriodReclassificationAdjustmentDescription" xlink:to="us-gaap_PriorPeriodReclassificationAdjustmentDescription_lbl" xlink:title="label: PriorPeriodReclassificationAdjustmentDescription to us-gaap_PriorPeriodReclassificationAdjustmentDescription_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PriorPeriodReclassificationAdjustmentDescription_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PriorPeriodReclassificationAdjustmentDescription_lbl1" xml:lang="en-US" id="us-gaap_PriorPeriodReclassificationAdjustmentDescription_lbl1">Reclassification, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PriorPeriodReclassificationAdjustmentDescription" xlink:to="us-gaap_PriorPeriodReclassificationAdjustmentDescription_lbl1" xlink:title="label: PriorPeriodReclassificationAdjustmentDescription to us-gaap_PriorPeriodReclassificationAdjustmentDescription_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="ProceedsFromConvertibleDebt" xlink:title="ProceedsFromConvertibleDebt" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ProceedsFromConvertibleDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ProceedsFromConvertibleDebt_lbl" xml:lang="en-US" id="us-gaap_ProceedsFromConvertibleDebt_lbl">Principal and accumulated interest</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromConvertibleDebt" xlink:to="us-gaap_ProceedsFromConvertibleDebt_lbl" xlink:title="label: ProceedsFromConvertibleDebt to us-gaap_ProceedsFromConvertibleDebt_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromMinorityShareholders" xlink:label="ProceedsFromMinorityShareholders" xlink:title="ProceedsFromMinorityShareholders" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ProceedsFromMinorityShareholders_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ProceedsFromMinorityShareholders_lbl" xml:lang="en-US" id="us-gaap_ProceedsFromMinorityShareholders_lbl">Proceeds from sale of common shares of subsidiary</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromMinorityShareholders" xlink:to="us-gaap_ProceedsFromMinorityShareholders_lbl" xlink:title="label: ProceedsFromMinorityShareholders to us-gaap_ProceedsFromMinorityShareholders_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:label="ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:title="ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_lbl" xml:lang="en-US" id="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_lbl">Proceeds from sale of preferred stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:to="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_lbl" xlink:title="label: ProceedsFromIssuanceOfPreferredStockAndPreferenceStock to us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="ProceedsFromIssuanceOfCommonStock" xlink:title="ProceedsFromIssuanceOfCommonStock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US" id="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl">Proceeds from issuance of common shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:title="label: ProceedsFromIssuanceOfCommonStock to us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="ProceedsFromStockOptionsExercised" xlink:title="ProceedsFromStockOptionsExercised" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ProceedsFromStockOptionsExercised_lbl" xml:lang="en-US" id="us-gaap_ProceedsFromStockOptionsExercised_lbl">Proceeds from exercises of stock options</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:title="label: ProceedsFromStockOptionsExercised to us-gaap_ProceedsFromStockOptionsExercised_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ProceedsFromStockOptionsExercised_lbl1" xml:lang="en-US" id="us-gaap_ProceedsFromStockOptionsExercised_lbl1">Proceeds from Stock Options Exercised</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl1" xlink:title="label: ProceedsFromStockOptionsExercised to us-gaap_ProceedsFromStockOptionsExercised_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity" xlink:label="ProceedsFromSaleOfAvailableForSaleSecuritiesEquity" xlink:title="ProceedsFromSaleOfAvailableForSaleSecuritiesEquity" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity_lbl" xml:lang="en-US" id="us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity_lbl">Proceeds from sale of BioTime stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromSaleOfAvailableForSaleSecuritiesEquity" xlink:to="us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity_lbl" xlink:title="label: ProceedsFromSaleOfAvailableForSaleSecuritiesEquity to us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromSaleOfTreasuryStock" xlink:label="ProceedsFromSaleOfTreasuryStock" xlink:title="ProceedsFromSaleOfTreasuryStock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ProceedsFromSaleOfTreasuryStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ProceedsFromSaleOfTreasuryStock_lbl" xml:lang="en-US" id="us-gaap_ProceedsFromSaleOfTreasuryStock_lbl">Proceeds from sale of treasury stock and subsidiary warrants</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromSaleOfTreasuryStock" xlink:to="us-gaap_ProceedsFromSaleOfTreasuryStock_lbl" xlink:title="label: ProceedsFromSaleOfTreasuryStock to us-gaap_ProceedsFromSaleOfTreasuryStock_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:title="ProceedsFromSaleOfPropertyPlantAndEquipment" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_lbl" xml:lang="en-US" id="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_lbl">Proceeds from the sale of equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:to="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_lbl" xlink:title="label: ProceedsFromSaleOfPropertyPlantAndEquipment to us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProfitLoss" xlink:label="ProfitLoss" xlink:title="ProfitLoss" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_ProfitLoss_lbl" xml:lang="en-US" id="us-gaap_ProfitLoss_lbl">NET LOSS</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl" xlink:title="label: ProfitLoss to us-gaap_ProfitLoss_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ProfitLoss_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ProfitLoss_lbl1" xml:lang="en-US" id="us-gaap_ProfitLoss_lbl1">NET LOSS</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl1" xlink:title="label: ProfitLoss to us-gaap_ProfitLoss_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="PropertyPlantAndEquipmentPolicyTextBlock" xlink:title="PropertyPlantAndEquipmentPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xml:lang="en-US" id="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl">Equipment, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:title="label: PropertyPlantAndEquipmentPolicyTextBlock to us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl1" xml:lang="en-US" id="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl1">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl1" xlink:title="label: PropertyPlantAndEquipmentPolicyTextBlock to us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="PropertyPlantAndEquipmentUsefulLife" xlink:title="PropertyPlantAndEquipmentUsefulLife" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xml:lang="en-US" id="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl">Equipment useful life</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:title="label: PropertyPlantAndEquipmentUsefulLife to us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl1" xml:lang="en-US" id="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl1">Property, Plant and Equipment, Useful Life</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl1" xlink:title="label: PropertyPlantAndEquipmentUsefulLife to us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:label="PropertyPlantAndEquipmentNetAbstract" xlink:title="PropertyPlantAndEquipmentNetAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNetAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PropertyPlantAndEquipmentNetAbstract_lbl" xml:lang="en-US" id="us-gaap_PropertyPlantAndEquipmentNetAbstract_lbl">Equipment, furniture and fixtures [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PropertyPlantAndEquipmentNetAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNetAbstract_lbl" xlink:title="label: PropertyPlantAndEquipmentNetAbstract to us-gaap_PropertyPlantAndEquipmentNetAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="PropertyPlantAndEquipmentGross" xlink:title="PropertyPlantAndEquipmentGross" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_PropertyPlantAndEquipmentGross_lbl" xml:lang="en-US" id="us-gaap_PropertyPlantAndEquipmentGross_lbl">Equipment, furniture and fixtures</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:title="label: PropertyPlantAndEquipmentGross to us-gaap_PropertyPlantAndEquipmentGross_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PropertyPlantAndEquipmentGross_lbl1" xml:lang="en-US" id="us-gaap_PropertyPlantAndEquipmentGross_lbl1">Property, Plant and Equipment, Gross</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl1" xlink:title="label: PropertyPlantAndEquipmentGross to us-gaap_PropertyPlantAndEquipmentGross_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="PropertyPlantAndEquipmentNet" xlink:title="PropertyPlantAndEquipmentNet" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US" id="us-gaap_PropertyPlantAndEquipmentNet_lbl">Equipment net, and construction in progress</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:title="label: PropertyPlantAndEquipmentNet to us-gaap_PropertyPlantAndEquipmentNet_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PropertyPlantAndEquipmentNet_lbl1" xml:lang="en-US" id="us-gaap_PropertyPlantAndEquipmentNet_lbl1">Equipment, net and construction in progress (see Note 4)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl1" xlink:title="label: PropertyPlantAndEquipmentNet to us-gaap_PropertyPlantAndEquipmentNet_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="PropertyPlantAndEquipmentAbstract" xlink:title="PropertyPlantAndEquipmentAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xml:lang="en-US" id="us-gaap_PropertyPlantAndEquipmentAbstract_lbl">Equipment, net, and construction in progress [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xlink:title="label: PropertyPlantAndEquipmentAbstract to us-gaap_PropertyPlantAndEquipmentAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="PropertyPlantAndEquipmentTextBlock" xlink:title="PropertyPlantAndEquipmentTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US" id="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl">Equipment, furniture and fixtures</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:title="label: PropertyPlantAndEquipmentTextBlock to us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl1" xml:lang="en-US" id="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl1">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl1" xlink:title="label: PropertyPlantAndEquipmentTextBlock to us-gaap_PropertyPlantAndEquipmentTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="PropertyPlantAndEquipmentTypeDomain" xlink:title="PropertyPlantAndEquipmentTypeDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xml:lang="en-US" id="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl">Property, Plant and Equipment, Type [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xlink:title="label: PropertyPlantAndEquipmentTypeDomain to us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="PropertyPlantAndEquipmentByTypeAxis" xlink:title="PropertyPlantAndEquipmentByTypeAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xml:lang="en-US" id="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl">Property, Plant and Equipment, Type [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:title="label: PropertyPlantAndEquipmentByTypeAxis to us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="PropertyPlantAndEquipmentDisclosureTextBlock" xlink:title="PropertyPlantAndEquipmentDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xml:lang="en-US" id="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl">Equipment, net, and construction in progress</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xlink:title="label: PropertyPlantAndEquipmentDisclosureTextBlock to us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl1" xml:lang="en-US" id="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl1">Property, Plant and Equipment Disclosure [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl1" xlink:title="label: PropertyPlantAndEquipmentDisclosureTextBlock to us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="PropertyPlantAndEquipmentLineItems" xlink:title="PropertyPlantAndEquipmentLineItems" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US" id="us-gaap_PropertyPlantAndEquipmentLineItems_lbl">Property, Plant and Equipment [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:title="label: PropertyPlantAndEquipmentLineItems to us-gaap_PropertyPlantAndEquipmentLineItems_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeAxis" xlink:label="RangeAxis" xlink:title="RangeAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RangeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_RangeAxis_lbl" xml:lang="en-US" id="us-gaap_RangeAxis_lbl">Range [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RangeAxis" xlink:to="us-gaap_RangeAxis_lbl" xlink:title="label: RangeAxis to us-gaap_RangeAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeMember" xlink:label="RangeMember" xlink:title="RangeMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RangeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_RangeMember_lbl" xml:lang="en-US" id="us-gaap_RangeMember_lbl">Range [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RangeMember" xlink:to="us-gaap_RangeMember_lbl" xlink:title="label: RangeMember to us-gaap_RangeMember_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="RelatedPartyTransactionsDisclosureTextBlock" xlink:title="RelatedPartyTransactionsDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xml:lang="en-US" id="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl">Related Party Transactions and Related Party Convertible Debt</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:title="label: RelatedPartyTransactionsDisclosureTextBlock to us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl1" xml:lang="en-US" id="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl1">Related Party Transactions Disclosure [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl1" xlink:title="label: RelatedPartyTransactionsDisclosureTextBlock to us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="RelatedPartyTransactionDomain" xlink:title="RelatedPartyTransactionDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_RelatedPartyTransactionDomain_lbl" xml:lang="en-US" id="us-gaap_RelatedPartyTransactionDomain_lbl">Related Party Transaction [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RelatedPartyTransactionDomain" xlink:to="us-gaap_RelatedPartyTransactionDomain_lbl" xlink:title="label: RelatedPartyTransactionDomain to us-gaap_RelatedPartyTransactionDomain_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="RelatedPartyTransactionAxis" xlink:title="RelatedPartyTransactionAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_RelatedPartyTransactionAxis_lbl" xml:lang="en-US" id="us-gaap_RelatedPartyTransactionAxis_lbl">Related Party Transaction [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionAxis_lbl" xlink:title="label: RelatedPartyTransactionAxis to us-gaap_RelatedPartyTransactionAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="RelatedPartyTransactionLineItems" xlink:title="RelatedPartyTransactionLineItems" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_RelatedPartyTransactionLineItems_lbl" xml:lang="en-US" id="us-gaap_RelatedPartyTransactionLineItems_lbl">Related Party Transaction [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionLineItems_lbl" xlink:title="label: RelatedPartyTransactionLineItems to us-gaap_RelatedPartyTransactionLineItems_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="RelatedPartyTransactionsByRelatedPartyAxis" xlink:title="RelatedPartyTransactionsByRelatedPartyAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xml:lang="en-US" id="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl">Related Party [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:title="label: RelatedPartyTransactionsByRelatedPartyAxis to us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="RelatedPartyDomain" xlink:title="RelatedPartyDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RelatedPartyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_RelatedPartyDomain_lbl" xml:lang="en-US" id="us-gaap_RelatedPartyDomain_lbl">Related Party [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyDomain_lbl" xlink:title="label: RelatedPartyDomain to us-gaap_RelatedPartyDomain_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="RelatedPartyTransactionsAbstract" xlink:title="RelatedPartyTransactionsAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_RelatedPartyTransactionsAbstract_lbl" xml:lang="en-US" id="us-gaap_RelatedPartyTransactionsAbstract_lbl">Related Party Transactions and Related Party Convertible Debt [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl" xlink:title="label: RelatedPartyTransactionsAbstract to us-gaap_RelatedPartyTransactionsAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="ResearchAndDevelopmentExpense" xlink:title="ResearchAndDevelopmentExpense" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US" id="us-gaap_ResearchAndDevelopmentExpense_lbl">Research and development</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:title="label: ResearchAndDevelopmentExpense to us-gaap_ResearchAndDevelopmentExpense_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="ResearchAndDevelopmentExpensePolicy" xlink:title="ResearchAndDevelopmentExpensePolicy" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US" id="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl">Research and development</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:title="label: ResearchAndDevelopmentExpensePolicy to us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl1" xml:lang="en-US" id="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl1">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl1" xlink:title="label: ResearchAndDevelopmentExpensePolicy to us-gaap_ResearchAndDevelopmentExpensePolicy_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="RestrictedStockMember" xlink:title="RestrictedStockMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RestrictedStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_RestrictedStockMember_lbl" xml:lang="en-US" id="us-gaap_RestrictedStockMember_lbl">Restricted Stock [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RestrictedStockMember" xlink:to="us-gaap_RestrictedStockMember_lbl" xlink:title="label: RestrictedStockMember to us-gaap_RestrictedStockMember_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="RetainedEarningsAccumulatedDeficit" xlink:title="RetainedEarningsAccumulatedDeficit" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US" id="us-gaap_RetainedEarningsAccumulatedDeficit_lbl">Accumulated deficit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:title="label: RetainedEarningsAccumulatedDeficit to us-gaap_RetainedEarningsAccumulatedDeficit_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_RetainedEarningsAccumulatedDeficit_lbl1" xml:lang="en-US" id="us-gaap_RetainedEarningsAccumulatedDeficit_lbl1">Accumulated deficit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl1" xlink:title="label: RetainedEarningsAccumulatedDeficit to us-gaap_RetainedEarningsAccumulatedDeficit_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RevenueFromGrants" xlink:label="RevenueFromGrants" xlink:title="RevenueFromGrants" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RevenueFromGrants_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_RevenueFromGrants_lbl" xml:lang="en-US" id="us-gaap_RevenueFromGrants_lbl">Revenue from grants</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RevenueFromGrants" xlink:to="us-gaap_RevenueFromGrants_lbl" xlink:title="label: RevenueFromGrants to us-gaap_RevenueFromGrants_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RevenueFromGrants_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_RevenueFromGrants_lbl1" xml:lang="en-US" id="us-gaap_RevenueFromGrants_lbl1">Grant income</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RevenueFromGrants" xlink:to="us-gaap_RevenueFromGrants_lbl1" xlink:title="label: RevenueFromGrants to us-gaap_RevenueFromGrants_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="RevenueRecognitionPolicyTextBlock" xlink:title="RevenueRecognitionPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xml:lang="en-US" id="us-gaap_RevenueRecognitionPolicyTextBlock_lbl">Revenue recognition</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RevenueRecognitionPolicyTextBlock" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xlink:title="label: RevenueRecognitionPolicyTextBlock to us-gaap_RevenueRecognitionPolicyTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_RevenueRecognitionPolicyTextBlock_lbl1" xml:lang="en-US" id="us-gaap_RevenueRecognitionPolicyTextBlock_lbl1">Revenue Recognition, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RevenueRecognitionPolicyTextBlock" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock_lbl1" xlink:title="label: RevenueRecognitionPolicyTextBlock to us-gaap_RevenueRecognitionPolicyTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RoyaltyRevenue" xlink:label="RoyaltyRevenue" xlink:title="RoyaltyRevenue" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RoyaltyRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_RoyaltyRevenue_lbl" xml:lang="en-US" id="us-gaap_RoyaltyRevenue_lbl">Royalties from product sales</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RoyaltyRevenue" xlink:to="us-gaap_RoyaltyRevenue_lbl" xlink:title="label: RoyaltyRevenue to us-gaap_RoyaltyRevenue_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="SaleOfStockNumberOfSharesIssuedInTransaction" xlink:title="SaleOfStockNumberOfSharesIssuedInTransaction" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xml:lang="en-US" id="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl">Sale of stock, number of shares issued in transaction (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xlink:title="label: SaleOfStockNumberOfSharesIssuedInTransaction to us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl1" xml:lang="en-US" id="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl1">Shares sold (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl1" xlink:title="label: SaleOfStockNumberOfSharesIssuedInTransaction to us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedPerTransaction" xlink:label="SaleOfStockConsiderationReceivedPerTransaction" xlink:title="SaleOfStockConsiderationReceivedPerTransaction" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SaleOfStockConsiderationReceivedPerTransaction_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SaleOfStockConsiderationReceivedPerTransaction_lbl" xml:lang="en-US" id="us-gaap_SaleOfStockConsiderationReceivedPerTransaction_lbl">Sale of stock consideration received</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SaleOfStockConsiderationReceivedPerTransaction" xlink:to="us-gaap_SaleOfStockConsiderationReceivedPerTransaction_lbl" xlink:title="label: SaleOfStockConsiderationReceivedPerTransaction to us-gaap_SaleOfStockConsiderationReceivedPerTransaction_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SalesRevenueGoodsNet" xlink:label="SalesRevenueGoodsNet" xlink:title="SalesRevenueGoodsNet" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SalesRevenueGoodsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SalesRevenueGoodsNet_lbl" xml:lang="en-US" id="us-gaap_SalesRevenueGoodsNet_lbl">Sale of research products and services</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SalesRevenueGoodsNet" xlink:to="us-gaap_SalesRevenueGoodsNet_lbl" xlink:title="label: SalesRevenueGoodsNet to us-gaap_SalesRevenueGoodsNet_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SalesRevenueNet" xlink:label="SalesRevenueNet" xlink:title="SalesRevenueNet" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SalesRevenueNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_SalesRevenueNet_lbl" xml:lang="en-US" id="us-gaap_SalesRevenueNet_lbl">Total revenues</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SalesRevenueNet" xlink:to="us-gaap_SalesRevenueNet_lbl" xlink:title="label: SalesRevenueNet to us-gaap_SalesRevenueNet_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SalesRevenueNet_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SalesRevenueNet_lbl1" xml:lang="en-US" id="us-gaap_SalesRevenueNet_lbl1">Revenue, Net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SalesRevenueNet" xlink:to="us-gaap_SalesRevenueNet_lbl1" xlink:title="label: SalesRevenueNet to us-gaap_SalesRevenueNet_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SalesRevenueNetAbstract" xlink:label="SalesRevenueNetAbstract" xlink:title="SalesRevenueNetAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SalesRevenueNetAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_SalesRevenueNetAbstract_lbl" xml:lang="en-US" id="us-gaap_SalesRevenueNetAbstract_lbl">REVENUES:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SalesRevenueNetAbstract" xlink:to="us-gaap_SalesRevenueNetAbstract_lbl" xlink:title="label: SalesRevenueNetAbstract to us-gaap_SalesRevenueNetAbstract_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SalesRevenueNetAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SalesRevenueNetAbstract_lbl1" xml:lang="en-US" id="us-gaap_SalesRevenueNetAbstract_lbl1">Revenue, Net [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SalesRevenueNetAbstract" xlink:to="us-gaap_SalesRevenueNetAbstract_lbl1" xlink:title="label: SalesRevenueNetAbstract to us-gaap_SalesRevenueNetAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:title="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xml:lang="en-US" id="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:title="label: ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable to us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:title="ScheduleOfFiniteLivedIntangibleAssetsTable" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_lbl" xml:lang="en-US" id="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_lbl">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_lbl" xlink:title="label: ScheduleOfFiniteLivedIntangibleAssetsTable to us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:label="ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:title="ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl" xml:lang="en-US" id="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl">Accounts payable and accrued liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl" xlink:title="label: ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock to us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl1" xml:lang="en-US" id="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl1">Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl1" xlink:title="label: ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock to us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:label="ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:title="ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl" xml:lang="en-US" id="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl">Intangible assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl" xlink:title="label: ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock to us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl1" xml:lang="en-US" id="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl1">Schedule of Finite-Lived Intangible Assets [Table Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl1" xlink:title="label: ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock to us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:title="ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xml:lang="en-US" id="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xlink:title="label: ScheduleOfRelatedPartyTransactionsByRelatedPartyTable to us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="ScheduleOfPropertyPlantAndEquipmentTable" xlink:title="ScheduleOfPropertyPlantAndEquipmentTable" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xml:lang="en-US" id="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl">Schedule of Property, Plant and Equipment [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:title="label: ScheduleOfPropertyPlantAndEquipmentTable to us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="ScheduleOfStockByClassTable" xlink:title="ScheduleOfStockByClassTable" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleOfStockByClassTable_lbl" xml:lang="en-US" id="us-gaap_ScheduleOfStockByClassTable_lbl">Schedule of Stock by Class [Table</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfStockByClassTable" xlink:to="us-gaap_ScheduleOfStockByClassTable_lbl" xlink:title="label: ScheduleOfStockByClassTable to us-gaap_ScheduleOfStockByClassTable_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SegmentReportingAbstract" xlink:label="SegmentReportingAbstract" xlink:title="SegmentReportingAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SegmentReportingAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SegmentReportingAbstract_lbl" xml:lang="en-US" id="us-gaap_SegmentReportingAbstract_lbl">Segment Information [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingAbstract_lbl" xlink:title="label: SegmentReportingAbstract to us-gaap_SegmentReportingAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="SegmentReportingDisclosureTextBlock" xlink:title="SegmentReportingDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_SegmentReportingDisclosureTextBlock_lbl" xml:lang="en-US" id="us-gaap_SegmentReportingDisclosureTextBlock_lbl">Segment Information</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SegmentReportingDisclosureTextBlock" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock_lbl" xlink:title="label: SegmentReportingDisclosureTextBlock to us-gaap_SegmentReportingDisclosureTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SegmentReportingDisclosureTextBlock_lbl1" xml:lang="en-US" id="us-gaap_SegmentReportingDisclosureTextBlock_lbl1">Segment Reporting Disclosure [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SegmentReportingDisclosureTextBlock" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock_lbl1" xlink:title="label: SegmentReportingDisclosureTextBlock to us-gaap_SegmentReportingDisclosureTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:label="SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:title="SellingGeneralAndAdministrativeExpensesPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_lbl" xml:lang="en-US" id="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_lbl">General and administrative</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_lbl" xlink:title="label: SellingGeneralAndAdministrativeExpensesPolicyTextBlock to us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_lbl1" xml:lang="en-US" id="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_lbl1">Selling, General and Administrative Expenses, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_lbl1" xlink:title="label: SellingGeneralAndAdministrativeExpensesPolicyTextBlock to us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="SeriesAPreferredStockMember" xlink:title="SeriesAPreferredStockMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SeriesAPreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SeriesAPreferredStockMember_lbl" xml:lang="en-US" id="us-gaap_SeriesAPreferredStockMember_lbl">Series A Preferred Stock [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SeriesAPreferredStockMember" xlink:to="us-gaap_SeriesAPreferredStockMember_lbl" xlink:title="label: SeriesAPreferredStockMember to us-gaap_SeriesAPreferredStockMember_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="ShareBasedCompensation" xlink:title="ShareBasedCompensation" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensation_lbl">Stock-based compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" xlink:title="label: ShareBasedCompensation to us-gaap_ShareBasedCompensation_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl">Stock options granted (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl1">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharePrice" xlink:label="SharePrice" xlink:title="SharePrice" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SharePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_SharePrice_lbl" xml:lang="en-US" id="us-gaap_SharePrice_lbl">Stock price (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharePrice" xlink:to="us-gaap_SharePrice_lbl" xlink:title="label: SharePrice to us-gaap_SharePrice_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SharePrice_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SharePrice_lbl1" xml:lang="en-US" id="us-gaap_SharePrice_lbl1">Share Price</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharePrice" xlink:to="us-gaap_SharePrice_lbl1" xlink:title="label: SharePrice to us-gaap_SharePrice_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:title="ShareBasedCompensationOptionAndIncentivePlansPolicy" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl">Stock-based compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:title="label: ShareBasedCompensationOptionAndIncentivePlansPolicy to us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl1">Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl1" xlink:title="label: ShareBasedCompensationOptionAndIncentivePlansPolicy to us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl">Equity Award [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xlink:title="label: ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain to us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharesIssued" xlink:label="SharesIssued" xlink:title="SharesIssued" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SharesIssued_lbl" xml:lang="en-US" id="us-gaap_SharesIssued_lbl">Number of shares purchased (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharesIssued" xlink:to="us-gaap_SharesIssued_lbl" xlink:title="label: SharesIssued to us-gaap_SharesIssued_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SharesIssued_lbl1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_SharesIssued_lbl1" xml:lang="en-US" id="us-gaap_SharesIssued_lbl1">Number of shares purchased (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharesIssued" xlink:to="us-gaap_SharesIssued_lbl1" xlink:title="label: SharesIssued to us-gaap_SharesIssued_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="SignificantAccountingPoliciesTextBlock" xlink:title="SignificantAccountingPoliciesTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US" id="us-gaap_SignificantAccountingPoliciesTextBlock_lbl">Summary of Significant Accounting Policies</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:title="label: SignificantAccountingPoliciesTextBlock to us-gaap_SignificantAccountingPoliciesTextBlock_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:title="StatementOfIncomeAndComprehensiveIncomeAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_lbl" xml:lang="en-US" id="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_lbl">CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (UNAUDITED) [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_lbl" xlink:title="label: StatementOfIncomeAndComprehensiveIncomeAbstract to us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="StatementOfCashFlowsAbstract" xlink:title="StatementOfCashFlowsAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US" id="us-gaap_StatementOfCashFlowsAbstract_lbl">CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited) [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:title="label: StatementOfCashFlowsAbstract to us-gaap_StatementOfCashFlowsAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="StatementEquityComponentsAxis" xlink:title="StatementEquityComponentsAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US" id="us-gaap_StatementEquityComponentsAxis_lbl">Equity Components [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" xlink:title="label: StatementEquityComponentsAxis to us-gaap_StatementEquityComponentsAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="StatementOfFinancialPositionAbstract" xlink:title="StatementOfFinancialPositionAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US" id="us-gaap_StatementOfFinancialPositionAbstract_lbl">CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:title="label: StatementOfFinancialPositionAbstract to us-gaap_StatementOfFinancialPositionAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="StatementClassOfStockAxis" xlink:title="StatementClassOfStockAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StatementClassOfStockAxis_lbl" xml:lang="en-US" id="us-gaap_StatementClassOfStockAxis_lbl">Class of Stock [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl" xlink:title="label: StatementClassOfStockAxis to us-gaap_StatementClassOfStockAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:title="StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US" id="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl">Options exercised (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:title="label: StockIssuedDuringPeriodSharesStockOptionsExercised to us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl1" xml:lang="en-US" id="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl1">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl1" xlink:title="label: StockIssuedDuringPeriodSharesStockOptionsExercised to us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:label="StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:title="StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_lbl" xml:lang="en-US" id="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_lbl">SHAREHOLDERS' EQUITY</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_lbl" xlink:title="label: StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract to us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="StockholdersEquity" xlink:title="StockholdersEquity" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" id="us-gaap_StockholdersEquity_lbl">BioTime, Inc. shareholders' equity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" xlink:title="label: StockholdersEquity to us-gaap_StockholdersEquity_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StockholdersEquity_lbl1" xml:lang="en-US" id="us-gaap_StockholdersEquity_lbl1">Stockholders' Equity Attributable to Parent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl1" xlink:title="label: StockholdersEquity to us-gaap_StockholdersEquity_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:title="StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl" xml:lang="en-US" id="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl">Shareholders' equity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl" xlink:title="label: StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest to us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl1" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl1" xml:lang="en-US" id="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl1">Total shareholders' equity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl1" xlink:title="label: StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest to us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl2" xml:lang="en-US" id="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl2">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl2" xlink:title="label: StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest to us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="StockholdersEquityNoteDisclosureTextBlock" xlink:title="StockholdersEquityNoteDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US" id="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl">Shareholders' Equity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:title="label: StockholdersEquityNoteDisclosureTextBlock to us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl1" xml:lang="en-US" id="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl1">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl1" xlink:title="label: StockholdersEquityNoteDisclosureTextBlock to us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="SubsequentEventsTextBlock" xlink:title="SubsequentEventsTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US" id="us-gaap_SubsequentEventsTextBlock_lbl">Subsequent Events</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl" xlink:title="label: SubsequentEventsTextBlock to us-gaap_SubsequentEventsTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SubsequentEventsTextBlock_lbl1" xml:lang="en-US" id="us-gaap_SubsequentEventsTextBlock_lbl1">Subsequent Events [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl1" xlink:title="label: SubsequentEventsTextBlock to us-gaap_SubsequentEventsTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="SubsequentEventsAbstract" xlink:title="SubsequentEventsAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US" id="us-gaap_SubsequentEventsAbstract_lbl">Subsequent Events [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl" xlink:title="label: SubsequentEventsAbstract to us-gaap_SubsequentEventsAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="SubsequentEventTable" xlink:title="SubsequentEventTable" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SubsequentEventTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SubsequentEventTable_lbl" xml:lang="en-US" id="us-gaap_SubsequentEventTable_lbl">Subsequent Event [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTable_lbl" xlink:title="label: SubsequentEventTable to us-gaap_SubsequentEventTable_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="SubsequentEventLineItems" xlink:title="SubsequentEventLineItems" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SubsequentEventLineItems_lbl" xml:lang="en-US" id="us-gaap_SubsequentEventLineItems_lbl">Subsequent Event [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventLineItems_lbl" xlink:title="label: SubsequentEventLineItems to us-gaap_SubsequentEventLineItems_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="SubsequentEventMember" xlink:title="SubsequentEventMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SubsequentEventMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US" id="us-gaap_SubsequentEventMember_lbl">Subsequent Event [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl" xlink:title="label: SubsequentEventMember to us-gaap_SubsequentEventMember_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="SubsequentEventTypeDomain" xlink:title="SubsequentEventTypeDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SubsequentEventTypeDomain_lbl" xml:lang="en-US" id="us-gaap_SubsequentEventTypeDomain_lbl">Subsequent Event Type [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain_lbl" xlink:title="label: SubsequentEventTypeDomain to us-gaap_SubsequentEventTypeDomain_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="SubsequentEventTypeAxis" xlink:title="SubsequentEventTypeAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SubsequentEventTypeAxis_lbl" xml:lang="en-US" id="us-gaap_SubsequentEventTypeAxis_lbl">Subsequent Event Type [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl" xlink:title="label: SubsequentEventTypeAxis to us-gaap_SubsequentEventTypeAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsidiariesMember" xlink:label="SubsidiariesMember" xlink:title="SubsidiariesMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SubsidiariesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SubsidiariesMember_lbl" xml:lang="en-US" id="us-gaap_SubsidiariesMember_lbl">Subsidiaries [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SubsidiariesMember" xlink:to="us-gaap_SubsidiariesMember_lbl" xlink:title="label: SubsidiariesMember to us-gaap_SubsidiariesMember_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TechnologyBasedIntangibleAssetsMember" xlink:label="TechnologyBasedIntangibleAssetsMember" xlink:title="TechnologyBasedIntangibleAssetsMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_TechnologyBasedIntangibleAssetsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_TechnologyBasedIntangibleAssetsMember_lbl" xml:lang="en-US" id="us-gaap_TechnologyBasedIntangibleAssetsMember_lbl">Technology [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TechnologyBasedIntangibleAssetsMember" xlink:to="us-gaap_TechnologyBasedIntangibleAssetsMember_lbl" xlink:title="label: TechnologyBasedIntangibleAssetsMember to us-gaap_TechnologyBasedIntangibleAssetsMember_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="TitleOfIndividualAxis" xlink:title="TitleOfIndividualAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_TitleOfIndividualAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_TitleOfIndividualAxis_lbl" xml:lang="en-US" id="us-gaap_TitleOfIndividualAxis_lbl">Title of Individual [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TitleOfIndividualAxis" xlink:to="us-gaap_TitleOfIndividualAxis_lbl" xlink:title="label: TitleOfIndividualAxis to us-gaap_TitleOfIndividualAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="TitleOfIndividualWithRelationshipToEntityDomain" xlink:title="TitleOfIndividualWithRelationshipToEntityDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xml:lang="en-US" id="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_lbl">Relationship to Entity [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xlink:title="label: TitleOfIndividualWithRelationshipToEntityDomain to us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:label="TradeAndOtherAccountsReceivablePolicy" xlink:title="TradeAndOtherAccountsReceivablePolicy" />
    <link:label xlink:type="resource" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_TradeAndOtherAccountsReceivablePolicy_lbl" xml:lang="en-US" id="us-gaap_TradeAndOtherAccountsReceivablePolicy_lbl">Trade accounts and grants receivable, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TradeAndOtherAccountsReceivablePolicy" xlink:to="us-gaap_TradeAndOtherAccountsReceivablePolicy_lbl" xlink:title="label: TradeAndOtherAccountsReceivablePolicy to us-gaap_TradeAndOtherAccountsReceivablePolicy_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TreasuryStockShares" xlink:label="TreasuryStockShares" xlink:title="TreasuryStockShares" />
    <link:label xlink:type="resource" xlink:label="us-gaap_TreasuryStockShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_TreasuryStockShares_lbl" xml:lang="en-US" id="us-gaap_TreasuryStockShares_lbl">Treasury stock (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TreasuryStockShares" xlink:to="us-gaap_TreasuryStockShares_lbl" xlink:title="label: TreasuryStockShares to us-gaap_TreasuryStockShares_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TreasuryStockMember" xlink:label="TreasuryStockMember" xlink:title="TreasuryStockMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_TreasuryStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_TreasuryStockMember_lbl" xml:lang="en-US" id="us-gaap_TreasuryStockMember_lbl">Treasury Shares [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TreasuryStockMember" xlink:to="us-gaap_TreasuryStockMember_lbl" xlink:title="label: TreasuryStockMember to us-gaap_TreasuryStockMember_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_TreasuryStockMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_TreasuryStockMember_lbl1" xml:lang="en-US" id="us-gaap_TreasuryStockMember_lbl1">Treasury Stock [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TreasuryStockMember" xlink:to="us-gaap_TreasuryStockMember_lbl1" xlink:title="label: TreasuryStockMember to us-gaap_TreasuryStockMember_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TreasuryStockValue" xlink:label="TreasuryStockValue" xlink:title="TreasuryStockValue" />
    <link:label xlink:type="resource" xlink:label="us-gaap_TreasuryStockValue_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_TreasuryStockValue_lbl" xml:lang="en-US" id="us-gaap_TreasuryStockValue_lbl">Treasury stock at cost: 4,893,942 shares at March 31, 2015 and at December 31, 2014</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TreasuryStockValue" xlink:to="us-gaap_TreasuryStockValue_lbl" xlink:title="label: TreasuryStockValue to us-gaap_TreasuryStockValue_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_TreasuryStockValue_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_TreasuryStockValue_lbl1" xml:lang="en-US" id="us-gaap_TreasuryStockValue_lbl1">Treasury Stock, Value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TreasuryStockValue" xlink:to="us-gaap_TreasuryStockValue_lbl1" xlink:title="label: TreasuryStockValue to us-gaap_TreasuryStockValue_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:label="UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:title="UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" />
    <link:label xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_lbl" xml:lang="en-US" id="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_lbl">Accrued interest and penalties</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_lbl" xlink:title="label: UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued to us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_lbl1" xml:lang="en-US" id="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_lbl1">Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_lbl1" xlink:title="label: UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued to us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WarrantMember" xlink:label="WarrantMember" xlink:title="WarrantMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_WarrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_WarrantMember_lbl" xml:lang="en-US" id="us-gaap_WarrantMember_lbl">Asterias Warrants [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WarrantMember" xlink:to="us-gaap_WarrantMember_lbl" xlink:title="label: WarrantMember to us-gaap_WarrantMember_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_WarrantMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_WarrantMember_lbl1" xml:lang="en-US" id="us-gaap_WarrantMember_lbl1">Warrant [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WarrantMember" xlink:to="us-gaap_WarrantMember_lbl1" xlink:title="label: WarrantMember to us-gaap_WarrantMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_WarrantMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_WarrantMember_lbl2" xml:lang="en-US" id="us-gaap_WarrantMember_lbl2">Warrants [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WarrantMember" xlink:to="us-gaap_WarrantMember_lbl2" xlink:title="label: WarrantMember to us-gaap_WarrantMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:title="WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
    <link:label xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xml:lang="en-US" id="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl">WEIGHTED AVERAGE NUMBER OF COMMON STOCK OUTSTANDING: BASIC AND DILUTED (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xlink:title="label: WeightedAverageNumberOfShareOutstandingBasicAndDiluted to us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl1" xml:lang="en-US" id="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl1">Weighted Average Number of Shares Outstanding, Basic and Diluted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl1" xlink:title="label: WeightedAverageNumberOfShareOutstandingBasicAndDiluted to us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl1" />
    <link:loc xlink:type="locator" xlink:href="btx-20150331.xsd#btx_ScheduleOfExpectedAmortizationDeferredLicenseExpenseTableTextBlock" xlink:label="ScheduleOfExpectedAmortizationDeferredLicenseExpenseTableTextBlock" xlink:title="ScheduleOfExpectedAmortizationDeferredLicenseExpenseTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="btx_ScheduleOfExpectedAmortizationDeferredLicenseExpenseTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_ScheduleOfExpectedAmortizationDeferredLicenseExpenseTableTextBlock_lbl" xml:lang="en-US" id="btx_ScheduleOfExpectedAmortizationDeferredLicenseExpenseTableTextBlock_lbl">Tabular disclosure of the estimated aggregate amortization expense for deferred license fees subject to amortization for each of the five succeeding fiscal years.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfExpectedAmortizationDeferredLicenseExpenseTableTextBlock" xlink:to="btx_ScheduleOfExpectedAmortizationDeferredLicenseExpenseTableTextBlock_lbl" xlink:title="label: ScheduleOfExpectedAmortizationDeferredLicenseExpenseTableTextBlock to btx_ScheduleOfExpectedAmortizationDeferredLicenseExpenseTableTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_ScheduleOfExpectedAmortizationDeferredLicenseExpenseTableTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_ScheduleOfExpectedAmortizationDeferredLicenseExpenseTableTextBlock_lbl1" xml:lang="en-US" id="btx_ScheduleOfExpectedAmortizationDeferredLicenseExpenseTableTextBlock_lbl1">Schedule Of Expected Amortization Deferred License Expense [Table Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfExpectedAmortizationDeferredLicenseExpenseTableTextBlock" xlink:to="btx_ScheduleOfExpectedAmortizationDeferredLicenseExpenseTableTextBlock_lbl1" xlink:title="label: ScheduleOfExpectedAmortizationDeferredLicenseExpenseTableTextBlock to btx_ScheduleOfExpectedAmortizationDeferredLicenseExpenseTableTextBlock_lbl1" />
    <link:label xlink:type="resource" xlink:label="btx_ScheduleOfExpectedAmortizationDeferredLicenseExpenseTableTextBlock_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="btx_ScheduleOfExpectedAmortizationDeferredLicenseExpenseTableTextBlock_lbl2" xml:lang="en-US" id="btx_ScheduleOfExpectedAmortizationDeferredLicenseExpenseTableTextBlock_lbl2">Amortization of deferred license fees</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfExpectedAmortizationDeferredLicenseExpenseTableTextBlock" xlink:to="btx_ScheduleOfExpectedAmortizationDeferredLicenseExpenseTableTextBlock_lbl2" xlink:title="label: ScheduleOfExpectedAmortizationDeferredLicenseExpenseTableTextBlock to btx_ScheduleOfExpectedAmortizationDeferredLicenseExpenseTableTextBlock_lbl2" />
    <link:loc xlink:type="locator" xlink:href="btx-20150331.xsd#btx_DeferredLicenseAndConsultingFeesClassifiedAsNoncurrent" xlink:label="DeferredLicenseAndConsultingFeesClassifiedAsNoncurrent" xlink:title="DeferredLicenseAndConsultingFeesClassifiedAsNoncurrent" />
    <link:label xlink:type="resource" xlink:label="btx_DeferredLicenseAndConsultingFeesClassifiedAsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_DeferredLicenseAndConsultingFeesClassifiedAsNoncurrent_lbl" xml:lang="en-US" id="btx_DeferredLicenseAndConsultingFeesClassifiedAsNoncurrent_lbl">Carrying amounts as of the balance sheet of noncurrent deferred license and consulting fees, which consists of the value of warrants issued to third parties for services and to the minority shareholder in BioTime Asia for consulting services, and deferred license fees paid to acquire rights to use the proprietary technologies of third parties.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredLicenseAndConsultingFeesClassifiedAsNoncurrent" xlink:to="btx_DeferredLicenseAndConsultingFeesClassifiedAsNoncurrent_lbl" xlink:title="label: DeferredLicenseAndConsultingFeesClassifiedAsNoncurrent to btx_DeferredLicenseAndConsultingFeesClassifiedAsNoncurrent_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_DeferredLicenseAndConsultingFeesClassifiedAsNoncurrent_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_DeferredLicenseAndConsultingFeesClassifiedAsNoncurrent_lbl1" xml:lang="en-US" id="btx_DeferredLicenseAndConsultingFeesClassifiedAsNoncurrent_lbl1">Deferred license and consulting fees classified as noncurrent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredLicenseAndConsultingFeesClassifiedAsNoncurrent" xlink:to="btx_DeferredLicenseAndConsultingFeesClassifiedAsNoncurrent_lbl1" xlink:title="label: DeferredLicenseAndConsultingFeesClassifiedAsNoncurrent to btx_DeferredLicenseAndConsultingFeesClassifiedAsNoncurrent_lbl1" />
    <link:label xlink:type="resource" xlink:label="btx_DeferredLicenseAndConsultingFeesClassifiedAsNoncurrent_lbl2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="btx_DeferredLicenseAndConsultingFeesClassifiedAsNoncurrent_lbl2" xml:lang="en-US" id="btx_DeferredLicenseAndConsultingFeesClassifiedAsNoncurrent_lbl2">Deferred license and consulting fees in noncurrent assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredLicenseAndConsultingFeesClassifiedAsNoncurrent" xlink:to="btx_DeferredLicenseAndConsultingFeesClassifiedAsNoncurrent_lbl2" xlink:title="label: DeferredLicenseAndConsultingFeesClassifiedAsNoncurrent to btx_DeferredLicenseAndConsultingFeesClassifiedAsNoncurrent_lbl2" />
    <link:loc xlink:type="locator" xlink:href="btx-20150331.xsd#btx_PrepaidExpensesInOtherCurrentAssets" xlink:label="PrepaidExpensesInOtherCurrentAssets" xlink:title="PrepaidExpensesInOtherCurrentAssets" />
    <link:label xlink:type="resource" xlink:label="btx_PrepaidExpensesInOtherCurrentAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_PrepaidExpensesInOtherCurrentAssets_lbl" xml:lang="en-US" id="btx_PrepaidExpensesInOtherCurrentAssets_lbl">Carrying amounts as of the balance sheet of related prepaid expenses which are classified in other current assets on the balance sheet.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PrepaidExpensesInOtherCurrentAssets" xlink:to="btx_PrepaidExpensesInOtherCurrentAssets_lbl" xlink:title="label: PrepaidExpensesInOtherCurrentAssets to btx_PrepaidExpensesInOtherCurrentAssets_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_PrepaidExpensesInOtherCurrentAssets_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_PrepaidExpensesInOtherCurrentAssets_lbl1" xml:lang="en-US" id="btx_PrepaidExpensesInOtherCurrentAssets_lbl1">Prepaid expenses in other current Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PrepaidExpensesInOtherCurrentAssets" xlink:to="btx_PrepaidExpensesInOtherCurrentAssets_lbl1" xlink:title="label: PrepaidExpensesInOtherCurrentAssets to btx_PrepaidExpensesInOtherCurrentAssets_lbl1" />
    <link:label xlink:type="resource" xlink:label="btx_PrepaidExpensesInOtherCurrentAssets_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="btx_PrepaidExpensesInOtherCurrentAssets_lbl2" xml:lang="en-US" id="btx_PrepaidExpensesInOtherCurrentAssets_lbl2">Prepaid expenses in other current assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PrepaidExpensesInOtherCurrentAssets" xlink:to="btx_PrepaidExpensesInOtherCurrentAssets_lbl2" xlink:title="label: PrepaidExpensesInOtherCurrentAssets to btx_PrepaidExpensesInOtherCurrentAssets_lbl2" />
    <link:loc xlink:type="locator" xlink:href="btx-20150331.xsd#btx_DeferredLicenseFeesAmortizationExpenseYearTwo" xlink:label="DeferredLicenseFeesAmortizationExpenseYearTwo" xlink:title="DeferredLicenseFeesAmortizationExpenseYearTwo" />
    <link:label xlink:type="resource" xlink:label="btx_DeferredLicenseFeesAmortizationExpenseYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_DeferredLicenseFeesAmortizationExpenseYearTwo_lbl" xml:lang="en-US" id="btx_DeferredLicenseFeesAmortizationExpenseYearTwo_lbl">Amount of amortization expense expected to be recognized during the second fiscal year following the latest fiscal year for deferred license fee.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredLicenseFeesAmortizationExpenseYearTwo" xlink:to="btx_DeferredLicenseFeesAmortizationExpenseYearTwo_lbl" xlink:title="label: DeferredLicenseFeesAmortizationExpenseYearTwo to btx_DeferredLicenseFeesAmortizationExpenseYearTwo_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_DeferredLicenseFeesAmortizationExpenseYearTwo_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_DeferredLicenseFeesAmortizationExpenseYearTwo_lbl1" xml:lang="en-US" id="btx_DeferredLicenseFeesAmortizationExpenseYearTwo_lbl1">Deferred License Fees Amortization Expense Year Two</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredLicenseFeesAmortizationExpenseYearTwo" xlink:to="btx_DeferredLicenseFeesAmortizationExpenseYearTwo_lbl1" xlink:title="label: DeferredLicenseFeesAmortizationExpenseYearTwo to btx_DeferredLicenseFeesAmortizationExpenseYearTwo_lbl1" />
    <link:label xlink:type="resource" xlink:label="btx_DeferredLicenseFeesAmortizationExpenseYearTwo_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="btx_DeferredLicenseFeesAmortizationExpenseYearTwo_lbl2" xml:lang="en-US" id="btx_DeferredLicenseFeesAmortizationExpenseYearTwo_lbl2">2016</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredLicenseFeesAmortizationExpenseYearTwo" xlink:to="btx_DeferredLicenseFeesAmortizationExpenseYearTwo_lbl2" xlink:title="label: DeferredLicenseFeesAmortizationExpenseYearTwo to btx_DeferredLicenseFeesAmortizationExpenseYearTwo_lbl2" />
    <link:loc xlink:type="locator" xlink:href="btx-20150331.xsd#btx_DeferredLicenseFeesAmortizationExpenseYearThree" xlink:label="DeferredLicenseFeesAmortizationExpenseYearThree" xlink:title="DeferredLicenseFeesAmortizationExpenseYearThree" />
    <link:label xlink:type="resource" xlink:label="btx_DeferredLicenseFeesAmortizationExpenseYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_DeferredLicenseFeesAmortizationExpenseYearThree_lbl" xml:lang="en-US" id="btx_DeferredLicenseFeesAmortizationExpenseYearThree_lbl">Amount of amortization expense expected to be recognized during the third fiscal year following the latest fiscal year for deferred license fee.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredLicenseFeesAmortizationExpenseYearThree" xlink:to="btx_DeferredLicenseFeesAmortizationExpenseYearThree_lbl" xlink:title="label: DeferredLicenseFeesAmortizationExpenseYearThree to btx_DeferredLicenseFeesAmortizationExpenseYearThree_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_DeferredLicenseFeesAmortizationExpenseYearThree_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_DeferredLicenseFeesAmortizationExpenseYearThree_lbl1" xml:lang="en-US" id="btx_DeferredLicenseFeesAmortizationExpenseYearThree_lbl1">Deferred License Fees Amortization Expense Year Three</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredLicenseFeesAmortizationExpenseYearThree" xlink:to="btx_DeferredLicenseFeesAmortizationExpenseYearThree_lbl1" xlink:title="label: DeferredLicenseFeesAmortizationExpenseYearThree to btx_DeferredLicenseFeesAmortizationExpenseYearThree_lbl1" />
    <link:label xlink:type="resource" xlink:label="btx_DeferredLicenseFeesAmortizationExpenseYearThree_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="btx_DeferredLicenseFeesAmortizationExpenseYearThree_lbl2" xml:lang="en-US" id="btx_DeferredLicenseFeesAmortizationExpenseYearThree_lbl2">2017</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredLicenseFeesAmortizationExpenseYearThree" xlink:to="btx_DeferredLicenseFeesAmortizationExpenseYearThree_lbl2" xlink:title="label: DeferredLicenseFeesAmortizationExpenseYearThree to btx_DeferredLicenseFeesAmortizationExpenseYearThree_lbl2" />
    <link:loc xlink:type="locator" xlink:href="btx-20150331.xsd#btx_DeferredLicenseFeesAmortizationExpenseDueInRemainderOfFiscalYear" xlink:label="DeferredLicenseFeesAmortizationExpenseDueInRemainderOfFiscalYear" xlink:title="DeferredLicenseFeesAmortizationExpenseDueInRemainderOfFiscalYear" />
    <link:label xlink:type="resource" xlink:label="btx_DeferredLicenseFeesAmortizationExpenseDueInRemainderOfFiscalYear_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_DeferredLicenseFeesAmortizationExpenseDueInRemainderOfFiscalYear_lbl" xml:lang="en-US" id="btx_DeferredLicenseFeesAmortizationExpenseDueInRemainderOfFiscalYear_lbl">Amount of amortization expense expected to be recognized during in the remainder of the fiscal year following the latest fiscal year ended for deferred license fee.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredLicenseFeesAmortizationExpenseDueInRemainderOfFiscalYear" xlink:to="btx_DeferredLicenseFeesAmortizationExpenseDueInRemainderOfFiscalYear_lbl" xlink:title="label: DeferredLicenseFeesAmortizationExpenseDueInRemainderOfFiscalYear to btx_DeferredLicenseFeesAmortizationExpenseDueInRemainderOfFiscalYear_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_DeferredLicenseFeesAmortizationExpenseDueInRemainderOfFiscalYear_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_DeferredLicenseFeesAmortizationExpenseDueInRemainderOfFiscalYear_lbl1" xml:lang="en-US" id="btx_DeferredLicenseFeesAmortizationExpenseDueInRemainderOfFiscalYear_lbl1">Deferred License Fees Amortization Expense Due In Remainder Of Fiscal Year</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredLicenseFeesAmortizationExpenseDueInRemainderOfFiscalYear" xlink:to="btx_DeferredLicenseFeesAmortizationExpenseDueInRemainderOfFiscalYear_lbl1" xlink:title="label: DeferredLicenseFeesAmortizationExpenseDueInRemainderOfFiscalYear to btx_DeferredLicenseFeesAmortizationExpenseDueInRemainderOfFiscalYear_lbl1" />
    <link:label xlink:type="resource" xlink:label="btx_DeferredLicenseFeesAmortizationExpenseDueInRemainderOfFiscalYear_lbl2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="btx_DeferredLicenseFeesAmortizationExpenseDueInRemainderOfFiscalYear_lbl2" xml:lang="en-US" id="btx_DeferredLicenseFeesAmortizationExpenseDueInRemainderOfFiscalYear_lbl2">2015</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredLicenseFeesAmortizationExpenseDueInRemainderOfFiscalYear" xlink:to="btx_DeferredLicenseFeesAmortizationExpenseDueInRemainderOfFiscalYear_lbl2" xlink:title="label: DeferredLicenseFeesAmortizationExpenseDueInRemainderOfFiscalYear to btx_DeferredLicenseFeesAmortizationExpenseDueInRemainderOfFiscalYear_lbl2" />
    <link:loc xlink:type="locator" xlink:href="btx-20150331.xsd#btx_DeferredLicenseFeesAmortizationExpenseAfterYearFive" xlink:label="DeferredLicenseFeesAmortizationExpenseAfterYearFive" xlink:title="DeferredLicenseFeesAmortizationExpenseAfterYearFive" />
    <link:label xlink:type="resource" xlink:label="btx_DeferredLicenseFeesAmortizationExpenseAfterYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_DeferredLicenseFeesAmortizationExpenseAfterYearFive_lbl" xml:lang="en-US" id="btx_DeferredLicenseFeesAmortizationExpenseAfterYearFive_lbl">Amount of amortization expense expected to be recognized after the fifth fiscal year following the latest fiscal year for deferred license fee.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredLicenseFeesAmortizationExpenseAfterYearFive" xlink:to="btx_DeferredLicenseFeesAmortizationExpenseAfterYearFive_lbl" xlink:title="label: DeferredLicenseFeesAmortizationExpenseAfterYearFive to btx_DeferredLicenseFeesAmortizationExpenseAfterYearFive_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_DeferredLicenseFeesAmortizationExpenseAfterYearFive_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_DeferredLicenseFeesAmortizationExpenseAfterYearFive_lbl1" xml:lang="en-US" id="btx_DeferredLicenseFeesAmortizationExpenseAfterYearFive_lbl1">Deferred License Fees Amortization Expense After Year Five</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredLicenseFeesAmortizationExpenseAfterYearFive" xlink:to="btx_DeferredLicenseFeesAmortizationExpenseAfterYearFive_lbl1" xlink:title="label: DeferredLicenseFeesAmortizationExpenseAfterYearFive to btx_DeferredLicenseFeesAmortizationExpenseAfterYearFive_lbl1" />
    <link:label xlink:type="resource" xlink:label="btx_DeferredLicenseFeesAmortizationExpenseAfterYearFive_lbl2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="btx_DeferredLicenseFeesAmortizationExpenseAfterYearFive_lbl2" xml:lang="en-US" id="btx_DeferredLicenseFeesAmortizationExpenseAfterYearFive_lbl2">Thereafter</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredLicenseFeesAmortizationExpenseAfterYearFive" xlink:to="btx_DeferredLicenseFeesAmortizationExpenseAfterYearFive_lbl2" xlink:title="label: DeferredLicenseFeesAmortizationExpenseAfterYearFive to btx_DeferredLicenseFeesAmortizationExpenseAfterYearFive_lbl2" />
    <link:loc xlink:type="locator" xlink:href="btx-20150331.xsd#btx_DeferredLicenseFeesAmortizationExpenseYearFour" xlink:label="DeferredLicenseFeesAmortizationExpenseYearFour" xlink:title="DeferredLicenseFeesAmortizationExpenseYearFour" />
    <link:label xlink:type="resource" xlink:label="btx_DeferredLicenseFeesAmortizationExpenseYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_DeferredLicenseFeesAmortizationExpenseYearFour_lbl" xml:lang="en-US" id="btx_DeferredLicenseFeesAmortizationExpenseYearFour_lbl">Amount of amortization expense expected to be recognized during the fourth fiscal year following the latest fiscal year for deferred license fee.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredLicenseFeesAmortizationExpenseYearFour" xlink:to="btx_DeferredLicenseFeesAmortizationExpenseYearFour_lbl" xlink:title="label: DeferredLicenseFeesAmortizationExpenseYearFour to btx_DeferredLicenseFeesAmortizationExpenseYearFour_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_DeferredLicenseFeesAmortizationExpenseYearFour_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_DeferredLicenseFeesAmortizationExpenseYearFour_lbl1" xml:lang="en-US" id="btx_DeferredLicenseFeesAmortizationExpenseYearFour_lbl1">Deferred License Fees Amortization Expense Year Four</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredLicenseFeesAmortizationExpenseYearFour" xlink:to="btx_DeferredLicenseFeesAmortizationExpenseYearFour_lbl1" xlink:title="label: DeferredLicenseFeesAmortizationExpenseYearFour to btx_DeferredLicenseFeesAmortizationExpenseYearFour_lbl1" />
    <link:label xlink:type="resource" xlink:label="btx_DeferredLicenseFeesAmortizationExpenseYearFour_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="btx_DeferredLicenseFeesAmortizationExpenseYearFour_lbl2" xml:lang="en-US" id="btx_DeferredLicenseFeesAmortizationExpenseYearFour_lbl2">2018</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredLicenseFeesAmortizationExpenseYearFour" xlink:to="btx_DeferredLicenseFeesAmortizationExpenseYearFour_lbl2" xlink:title="label: DeferredLicenseFeesAmortizationExpenseYearFour to btx_DeferredLicenseFeesAmortizationExpenseYearFour_lbl2" />
    <link:loc xlink:type="locator" xlink:href="btx-20150331.xsd#btx_DeferredLicenseFeesAmortizationExpenseYearFive" xlink:label="DeferredLicenseFeesAmortizationExpenseYearFive" xlink:title="DeferredLicenseFeesAmortizationExpenseYearFive" />
    <link:label xlink:type="resource" xlink:label="btx_DeferredLicenseFeesAmortizationExpenseYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_DeferredLicenseFeesAmortizationExpenseYearFive_lbl" xml:lang="en-US" id="btx_DeferredLicenseFeesAmortizationExpenseYearFive_lbl">Amount of amortization expense expected to be recognized during the fifth fiscal year following the latest fiscal year for deferred license fee.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredLicenseFeesAmortizationExpenseYearFive" xlink:to="btx_DeferredLicenseFeesAmortizationExpenseYearFive_lbl" xlink:title="label: DeferredLicenseFeesAmortizationExpenseYearFive to btx_DeferredLicenseFeesAmortizationExpenseYearFive_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_DeferredLicenseFeesAmortizationExpenseYearFive_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_DeferredLicenseFeesAmortizationExpenseYearFive_lbl1" xml:lang="en-US" id="btx_DeferredLicenseFeesAmortizationExpenseYearFive_lbl1">Deferred License Fees Amortization Expense Year Five</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredLicenseFeesAmortizationExpenseYearFive" xlink:to="btx_DeferredLicenseFeesAmortizationExpenseYearFive_lbl1" xlink:title="label: DeferredLicenseFeesAmortizationExpenseYearFive to btx_DeferredLicenseFeesAmortizationExpenseYearFive_lbl1" />
    <link:label xlink:type="resource" xlink:label="btx_DeferredLicenseFeesAmortizationExpenseYearFive_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="btx_DeferredLicenseFeesAmortizationExpenseYearFive_lbl2" xml:lang="en-US" id="btx_DeferredLicenseFeesAmortizationExpenseYearFive_lbl2">2019</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredLicenseFeesAmortizationExpenseYearFive" xlink:to="btx_DeferredLicenseFeesAmortizationExpenseYearFive_lbl2" xlink:title="label: DeferredLicenseFeesAmortizationExpenseYearFive to btx_DeferredLicenseFeesAmortizationExpenseYearFive_lbl2" />
    <link:loc xlink:type="locator" xlink:href="btx-20150331.xsd#btx_TreasuryStockPolicyTextBlock" xlink:label="TreasuryStockPolicyTextBlock" xlink:title="TreasuryStockPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="btx_TreasuryStockPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_TreasuryStockPolicyTextBlock_lbl" xml:lang="en-US" id="btx_TreasuryStockPolicyTextBlock_lbl">Disclosure of accounting policy for an entity's treasury stock, including common shares issued to subsidiaries for future potential working capital needs.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TreasuryStockPolicyTextBlock" xlink:to="btx_TreasuryStockPolicyTextBlock_lbl" xlink:title="label: TreasuryStockPolicyTextBlock to btx_TreasuryStockPolicyTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_TreasuryStockPolicyTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_TreasuryStockPolicyTextBlock_lbl1" xml:lang="en-US" id="btx_TreasuryStockPolicyTextBlock_lbl1">Treasury stock [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TreasuryStockPolicyTextBlock" xlink:to="btx_TreasuryStockPolicyTextBlock_lbl1" xlink:title="label: TreasuryStockPolicyTextBlock to btx_TreasuryStockPolicyTextBlock_lbl1" />
    <link:label xlink:type="resource" xlink:label="btx_TreasuryStockPolicyTextBlock_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="btx_TreasuryStockPolicyTextBlock_lbl2" xml:lang="en-US" id="btx_TreasuryStockPolicyTextBlock_lbl2">Treasury stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TreasuryStockPolicyTextBlock" xlink:to="btx_TreasuryStockPolicyTextBlock_lbl2" xlink:title="label: TreasuryStockPolicyTextBlock to btx_TreasuryStockPolicyTextBlock_lbl2" />
    <link:loc xlink:type="locator" xlink:href="btx-20150331.xsd#btx_WarrantsToPurchaseCommonStockPolicyTextBlock" xlink:label="WarrantsToPurchaseCommonStockPolicyTextBlock" xlink:title="WarrantsToPurchaseCommonStockPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="btx_WarrantsToPurchaseCommonStockPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_WarrantsToPurchaseCommonStockPolicyTextBlock_lbl" xml:lang="en-US" id="btx_WarrantsToPurchaseCommonStockPolicyTextBlock_lbl">Disclosure of accounting policy for an entity's warrants to purchase common stock, including common shares issued to subsidiaries for future potential working capital needs.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WarrantsToPurchaseCommonStockPolicyTextBlock" xlink:to="btx_WarrantsToPurchaseCommonStockPolicyTextBlock_lbl" xlink:title="label: WarrantsToPurchaseCommonStockPolicyTextBlock to btx_WarrantsToPurchaseCommonStockPolicyTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_WarrantsToPurchaseCommonStockPolicyTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_WarrantsToPurchaseCommonStockPolicyTextBlock_lbl1" xml:lang="en-US" id="btx_WarrantsToPurchaseCommonStockPolicyTextBlock_lbl1">Warrants to purchase common stock [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WarrantsToPurchaseCommonStockPolicyTextBlock" xlink:to="btx_WarrantsToPurchaseCommonStockPolicyTextBlock_lbl1" xlink:title="label: WarrantsToPurchaseCommonStockPolicyTextBlock to btx_WarrantsToPurchaseCommonStockPolicyTextBlock_lbl1" />
    <link:label xlink:type="resource" xlink:label="btx_WarrantsToPurchaseCommonStockPolicyTextBlock_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="btx_WarrantsToPurchaseCommonStockPolicyTextBlock_lbl2" xml:lang="en-US" id="btx_WarrantsToPurchaseCommonStockPolicyTextBlock_lbl2">Warrants to purchase common stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WarrantsToPurchaseCommonStockPolicyTextBlock" xlink:to="btx_WarrantsToPurchaseCommonStockPolicyTextBlock_lbl2" xlink:title="label: WarrantsToPurchaseCommonStockPolicyTextBlock to btx_WarrantsToPurchaseCommonStockPolicyTextBlock_lbl2" />
    <link:loc xlink:type="locator" xlink:href="btx-20150331.xsd#btx_TaxPayableOnSaleOfSubsidiaryShares" xlink:label="TaxPayableOnSaleOfSubsidiaryShares" xlink:title="TaxPayableOnSaleOfSubsidiaryShares" />
    <link:label xlink:type="resource" xlink:label="btx_TaxPayableOnSaleOfSubsidiaryShares_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_TaxPayableOnSaleOfSubsidiaryShares_lbl" xml:lang="en-US" id="btx_TaxPayableOnSaleOfSubsidiaryShares_lbl">Refers to the tax payable on sale of subsidiary shares.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TaxPayableOnSaleOfSubsidiaryShares" xlink:to="btx_TaxPayableOnSaleOfSubsidiaryShares_lbl" xlink:title="label: TaxPayableOnSaleOfSubsidiaryShares to btx_TaxPayableOnSaleOfSubsidiaryShares_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_TaxPayableOnSaleOfSubsidiaryShares_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_TaxPayableOnSaleOfSubsidiaryShares_lbl1" xml:lang="en-US" id="btx_TaxPayableOnSaleOfSubsidiaryShares_lbl1">Tax payable on sale of subsidiary shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TaxPayableOnSaleOfSubsidiaryShares" xlink:to="btx_TaxPayableOnSaleOfSubsidiaryShares_lbl1" xlink:title="label: TaxPayableOnSaleOfSubsidiaryShares to btx_TaxPayableOnSaleOfSubsidiaryShares_lbl1" />
    <link:label xlink:type="resource" xlink:label="btx_TaxPayableOnSaleOfSubsidiaryShares_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="btx_TaxPayableOnSaleOfSubsidiaryShares_lbl2" xml:lang="en-US" id="btx_TaxPayableOnSaleOfSubsidiaryShares_lbl2">Tax payable on sale of subsidiary shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TaxPayableOnSaleOfSubsidiaryShares" xlink:to="btx_TaxPayableOnSaleOfSubsidiaryShares_lbl2" xlink:title="label: TaxPayableOnSaleOfSubsidiaryShares to btx_TaxPayableOnSaleOfSubsidiaryShares_lbl2" />
    <link:loc xlink:type="locator" xlink:href="btx-20150331.xsd#btx_DeferredLicenseAndConsultingFeesAbstract" xlink:label="DeferredLicenseAndConsultingFeesAbstract" xlink:title="DeferredLicenseAndConsultingFeesAbstract" />
    <link:label xlink:type="resource" xlink:label="btx_DeferredLicenseAndConsultingFeesAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_DeferredLicenseAndConsultingFeesAbstract_lbl1" xml:lang="en-US" id="btx_DeferredLicenseAndConsultingFeesAbstract_lbl1">Deferred license and consulting fees [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredLicenseAndConsultingFeesAbstract" xlink:to="btx_DeferredLicenseAndConsultingFeesAbstract_lbl1" xlink:title="label: DeferredLicenseAndConsultingFeesAbstract to btx_DeferredLicenseAndConsultingFeesAbstract_lbl1" />
    <link:label xlink:type="resource" xlink:label="btx_DeferredLicenseAndConsultingFeesAbstract_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="btx_DeferredLicenseAndConsultingFeesAbstract_lbl2" xml:lang="en-US" id="btx_DeferredLicenseAndConsultingFeesAbstract_lbl2">Deferred license and consulting fees [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredLicenseAndConsultingFeesAbstract" xlink:to="btx_DeferredLicenseAndConsultingFeesAbstract_lbl2" xlink:title="label: DeferredLicenseAndConsultingFeesAbstract to btx_DeferredLicenseAndConsultingFeesAbstract_lbl2" />
    <link:loc xlink:type="locator" xlink:href="btx-20150331.xsd#btx_TaxableGainOnSaleOfSubsidiaryShares" xlink:label="TaxableGainOnSaleOfSubsidiaryShares" xlink:title="TaxableGainOnSaleOfSubsidiaryShares" />
    <link:label xlink:type="resource" xlink:label="btx_TaxableGainOnSaleOfSubsidiaryShares_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_TaxableGainOnSaleOfSubsidiaryShares_lbl" xml:lang="en-US" id="btx_TaxableGainOnSaleOfSubsidiaryShares_lbl">Refers to the taxable gain on the sale of subsidiary shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TaxableGainOnSaleOfSubsidiaryShares" xlink:to="btx_TaxableGainOnSaleOfSubsidiaryShares_lbl" xlink:title="label: TaxableGainOnSaleOfSubsidiaryShares to btx_TaxableGainOnSaleOfSubsidiaryShares_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_TaxableGainOnSaleOfSubsidiaryShares_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_TaxableGainOnSaleOfSubsidiaryShares_lbl1" xml:lang="en-US" id="btx_TaxableGainOnSaleOfSubsidiaryShares_lbl1">Taxable Gain On Sale Of Subsidiary Shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TaxableGainOnSaleOfSubsidiaryShares" xlink:to="btx_TaxableGainOnSaleOfSubsidiaryShares_lbl1" xlink:title="label: TaxableGainOnSaleOfSubsidiaryShares to btx_TaxableGainOnSaleOfSubsidiaryShares_lbl1" />
    <link:label xlink:type="resource" xlink:label="btx_TaxableGainOnSaleOfSubsidiaryShares_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="btx_TaxableGainOnSaleOfSubsidiaryShares_lbl2" xml:lang="en-US" id="btx_TaxableGainOnSaleOfSubsidiaryShares_lbl2">Taxable gain on sale of subsidiary shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TaxableGainOnSaleOfSubsidiaryShares" xlink:to="btx_TaxableGainOnSaleOfSubsidiaryShares_lbl2" xlink:title="label: TaxableGainOnSaleOfSubsidiaryShares to btx_TaxableGainOnSaleOfSubsidiaryShares_lbl2" />
    <link:loc xlink:type="locator" xlink:href="btx-20150331.xsd#btx_EstimatedFairMarketValue" xlink:label="EstimatedFairMarketValue" xlink:title="EstimatedFairMarketValue" />
    <link:label xlink:type="resource" xlink:label="btx_EstimatedFairMarketValue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_EstimatedFairMarketValue_lbl" xml:lang="en-US" id="btx_EstimatedFairMarketValue_lbl">Refers to the price per share of the estimated fair market value feature embedded in the debt instrument.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EstimatedFairMarketValue" xlink:to="btx_EstimatedFairMarketValue_lbl" xlink:title="label: EstimatedFairMarketValue to btx_EstimatedFairMarketValue_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_EstimatedFairMarketValue_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_EstimatedFairMarketValue_lbl1" xml:lang="en-US" id="btx_EstimatedFairMarketValue_lbl1">Estimated fair market value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EstimatedFairMarketValue" xlink:to="btx_EstimatedFairMarketValue_lbl1" xlink:title="label: EstimatedFairMarketValue to btx_EstimatedFairMarketValue_lbl1" />
    <link:label xlink:type="resource" xlink:label="btx_EstimatedFairMarketValue_lbl2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="btx_EstimatedFairMarketValue_lbl2" xml:lang="en-US" id="btx_EstimatedFairMarketValue_lbl2">Estimated fair market value (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EstimatedFairMarketValue" xlink:to="btx_EstimatedFairMarketValue_lbl2" xlink:title="label: EstimatedFairMarketValue to btx_EstimatedFairMarketValue_lbl2" />
    <link:loc xlink:type="locator" xlink:href="btx-20150331.xsd#btx_NumberOfCellCureNeurosciencesInvestors" xlink:label="NumberOfCellCureNeurosciencesInvestors" xlink:title="NumberOfCellCureNeurosciencesInvestors" />
    <link:label xlink:type="resource" xlink:label="btx_NumberOfCellCureNeurosciencesInvestors_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_NumberOfCellCureNeurosciencesInvestors_lbl" xml:lang="en-US" id="btx_NumberOfCellCureNeurosciencesInvestors_lbl">Refers to number of cell cure neurosciences investors.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfCellCureNeurosciencesInvestors" xlink:to="btx_NumberOfCellCureNeurosciencesInvestors_lbl" xlink:title="label: NumberOfCellCureNeurosciencesInvestors to btx_NumberOfCellCureNeurosciencesInvestors_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_NumberOfCellCureNeurosciencesInvestors_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_NumberOfCellCureNeurosciencesInvestors_lbl1" xml:lang="en-US" id="btx_NumberOfCellCureNeurosciencesInvestors_lbl1">Number of Cell Cure Neurosciences investors</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfCellCureNeurosciencesInvestors" xlink:to="btx_NumberOfCellCureNeurosciencesInvestors_lbl1" xlink:title="label: NumberOfCellCureNeurosciencesInvestors to btx_NumberOfCellCureNeurosciencesInvestors_lbl1" />
    <link:label xlink:type="resource" xlink:label="btx_NumberOfCellCureNeurosciencesInvestors_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="btx_NumberOfCellCureNeurosciencesInvestors_lbl2" xml:lang="en-US" id="btx_NumberOfCellCureNeurosciencesInvestors_lbl2">Number of Cell Cure Neurosciences investors</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfCellCureNeurosciencesInvestors" xlink:to="btx_NumberOfCellCureNeurosciencesInvestors_lbl2" xlink:title="label: NumberOfCellCureNeurosciencesInvestors to btx_NumberOfCellCureNeurosciencesInvestors_lbl2" />
    <link:loc xlink:type="locator" xlink:href="btx-20150331.xsd#btx_DocumentAndEntityInformationAbstract" xlink:label="DocumentAndEntityInformationAbstract" xlink:title="DocumentAndEntityInformationAbstract" />
    <link:label xlink:type="resource" xlink:label="btx_DocumentAndEntityInformationAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_DocumentAndEntityInformationAbstract_lbl1" xml:lang="en-US" id="btx_DocumentAndEntityInformationAbstract_lbl1">Document and Entity Information [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="btx_DocumentAndEntityInformationAbstract_lbl1" xlink:title="label: DocumentAndEntityInformationAbstract to btx_DocumentAndEntityInformationAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="btx-20150331.xsd#btx_PreferredSharesConvertibleConversionRatio" xlink:label="PreferredSharesConvertibleConversionRatio" xlink:title="PreferredSharesConvertibleConversionRatio" />
    <link:label xlink:type="resource" xlink:label="btx_PreferredSharesConvertibleConversionRatio_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_PreferredSharesConvertibleConversionRatio_lbl" xml:lang="en-US" id="btx_PreferredSharesConvertibleConversionRatio_lbl">The ratio applied to the debt for purposes of determining the number of shares of the equity security into which the debt will be converted.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreferredSharesConvertibleConversionRatio" xlink:to="btx_PreferredSharesConvertibleConversionRatio_lbl" xlink:title="label: PreferredSharesConvertibleConversionRatio to btx_PreferredSharesConvertibleConversionRatio_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_PreferredSharesConvertibleConversionRatio_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_PreferredSharesConvertibleConversionRatio_lbl1" xml:lang="en-US" id="btx_PreferredSharesConvertibleConversionRatio_lbl1">Preferred shares, Convertible, Conversion Ratio</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreferredSharesConvertibleConversionRatio" xlink:to="btx_PreferredSharesConvertibleConversionRatio_lbl1" xlink:title="label: PreferredSharesConvertibleConversionRatio to btx_PreferredSharesConvertibleConversionRatio_lbl1" />
    <link:label xlink:type="resource" xlink:label="btx_PreferredSharesConvertibleConversionRatio_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="btx_PreferredSharesConvertibleConversionRatio_lbl2" xml:lang="en-US" id="btx_PreferredSharesConvertibleConversionRatio_lbl2">Common stock conversion ratio</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreferredSharesConvertibleConversionRatio" xlink:to="btx_PreferredSharesConvertibleConversionRatio_lbl2" xlink:title="label: PreferredSharesConvertibleConversionRatio to btx_PreferredSharesConvertibleConversionRatio_lbl2" />
    <link:loc xlink:type="locator" xlink:href="btx-20150331.xsd#btx_StockOptionPlan2002Member" xlink:label="StockOptionPlan2002Member" xlink:title="StockOptionPlan2002Member" />
    <link:label xlink:type="resource" xlink:label="btx_StockOptionPlan2002Member_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_StockOptionPlan2002Member_lbl" xml:lang="en-US" id="btx_StockOptionPlan2002Member_lbl">Name of stock option plan originating in 2002.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockOptionPlan2002Member" xlink:to="btx_StockOptionPlan2002Member_lbl" xlink:title="label: StockOptionPlan2002Member to btx_StockOptionPlan2002Member_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_StockOptionPlan2002Member_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_StockOptionPlan2002Member_lbl1" xml:lang="en-US" id="btx_StockOptionPlan2002Member_lbl1">Stock Option Plan 2002 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockOptionPlan2002Member" xlink:to="btx_StockOptionPlan2002Member_lbl1" xlink:title="label: StockOptionPlan2002Member to btx_StockOptionPlan2002Member_lbl1" />
    <link:loc xlink:type="locator" xlink:href="btx-20150331.xsd#btx_PricePerShareOfOptionsToPurchaseCompany" xlink:label="PricePerShareOfOptionsToPurchaseCompany" xlink:title="PricePerShareOfOptionsToPurchaseCompany" />
    <link:label xlink:type="resource" xlink:label="btx_PricePerShareOfOptionsToPurchaseCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_PricePerShareOfOptionsToPurchaseCompany_lbl" xml:lang="en-US" id="btx_PricePerShareOfOptionsToPurchaseCompany_lbl">Price of a single share of a number of saleable stocks of a company.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PricePerShareOfOptionsToPurchaseCompany" xlink:to="btx_PricePerShareOfOptionsToPurchaseCompany_lbl" xlink:title="label: PricePerShareOfOptionsToPurchaseCompany to btx_PricePerShareOfOptionsToPurchaseCompany_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_PricePerShareOfOptionsToPurchaseCompany_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_PricePerShareOfOptionsToPurchaseCompany_lbl1" xml:lang="en-US" id="btx_PricePerShareOfOptionsToPurchaseCompany_lbl1">Share conversion price (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PricePerShareOfOptionsToPurchaseCompany" xlink:to="btx_PricePerShareOfOptionsToPurchaseCompany_lbl1" xlink:title="label: PricePerShareOfOptionsToPurchaseCompany to btx_PricePerShareOfOptionsToPurchaseCompany_lbl1" />
    <link:loc xlink:type="locator" xlink:href="btx-20150331.xsd#btx_WarrantsExercised" xlink:label="WarrantsExercised" xlink:title="WarrantsExercised" />
    <link:label xlink:type="resource" xlink:label="btx_WarrantsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_WarrantsExercised_lbl" xml:lang="en-US" id="btx_WarrantsExercised_lbl">Number of warrants exercised during the period that is attributable to transactions involving issuance of stock not separately disclosed.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WarrantsExercised" xlink:to="btx_WarrantsExercised_lbl" xlink:title="label: WarrantsExercised to btx_WarrantsExercised_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_WarrantsExercised_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_WarrantsExercised_lbl1" xml:lang="en-US" id="btx_WarrantsExercised_lbl1">Warrants exercised</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WarrantsExercised" xlink:to="btx_WarrantsExercised_lbl1" xlink:title="label: WarrantsExercised to btx_WarrantsExercised_lbl1" />
    <link:label xlink:type="resource" xlink:label="btx_WarrantsExercised_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="btx_WarrantsExercised_lbl2" xml:lang="en-US" id="btx_WarrantsExercised_lbl2">Warrants exercised (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WarrantsExercised" xlink:to="btx_WarrantsExercised_lbl2" xlink:title="label: WarrantsExercised to btx_WarrantsExercised_lbl2" />
    <link:loc xlink:type="locator" xlink:href="btx-20150331.xsd#btx_EquityIncentivePlanMember" xlink:label="EquityIncentivePlanMember" xlink:title="EquityIncentivePlanMember" />
    <link:label xlink:type="resource" xlink:label="btx_EquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_EquityIncentivePlanMember_lbl" xml:lang="en-US" id="btx_EquityIncentivePlanMember_lbl">Name of equity incentive plan originating in 2012 plan.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EquityIncentivePlanMember" xlink:to="btx_EquityIncentivePlanMember_lbl" xlink:title="label: EquityIncentivePlanMember to btx_EquityIncentivePlanMember_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_EquityIncentivePlanMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_EquityIncentivePlanMember_lbl1" xml:lang="en-US" id="btx_EquityIncentivePlanMember_lbl1">2012 Equity Incentive Plan [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EquityIncentivePlanMember" xlink:to="btx_EquityIncentivePlanMember_lbl1" xlink:title="label: EquityIncentivePlanMember to btx_EquityIncentivePlanMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="btx_EquityIncentivePlanMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="btx_EquityIncentivePlanMember_lbl2" xml:lang="en-US" id="btx_EquityIncentivePlanMember_lbl2">2012 Equity Incentive Plan [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EquityIncentivePlanMember" xlink:to="btx_EquityIncentivePlanMember_lbl2" xlink:title="label: EquityIncentivePlanMember to btx_EquityIncentivePlanMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="btx-20150331.xsd#btx_CaliforniaInstituteOfRegenerativeMedicineMember" xlink:label="CaliforniaInstituteOfRegenerativeMedicineMember" xlink:title="CaliforniaInstituteOfRegenerativeMedicineMember" />
    <link:label xlink:type="resource" xlink:label="btx_CaliforniaInstituteOfRegenerativeMedicineMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_CaliforniaInstituteOfRegenerativeMedicineMember_lbl" xml:lang="en-US" id="btx_CaliforniaInstituteOfRegenerativeMedicineMember_lbl">Represents one of the major customers of the entity.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CaliforniaInstituteOfRegenerativeMedicineMember" xlink:to="btx_CaliforniaInstituteOfRegenerativeMedicineMember_lbl" xlink:title="label: CaliforniaInstituteOfRegenerativeMedicineMember to btx_CaliforniaInstituteOfRegenerativeMedicineMember_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_CaliforniaInstituteOfRegenerativeMedicineMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_CaliforniaInstituteOfRegenerativeMedicineMember_lbl1" xml:lang="en-US" id="btx_CaliforniaInstituteOfRegenerativeMedicineMember_lbl1">California Institute of Regenerative Medicine [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CaliforniaInstituteOfRegenerativeMedicineMember" xlink:to="btx_CaliforniaInstituteOfRegenerativeMedicineMember_lbl1" xlink:title="label: CaliforniaInstituteOfRegenerativeMedicineMember to btx_CaliforniaInstituteOfRegenerativeMedicineMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="btx_CaliforniaInstituteOfRegenerativeMedicineMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="btx_CaliforniaInstituteOfRegenerativeMedicineMember_lbl2" xml:lang="en-US" id="btx_CaliforniaInstituteOfRegenerativeMedicineMember_lbl2">CIRM [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CaliforniaInstituteOfRegenerativeMedicineMember" xlink:to="btx_CaliforniaInstituteOfRegenerativeMedicineMember_lbl2" xlink:title="label: CaliforniaInstituteOfRegenerativeMedicineMember to btx_CaliforniaInstituteOfRegenerativeMedicineMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="btx-20150331.xsd#btx_RelatedPartyConvertibleDebtNetOfDiscount" xlink:label="RelatedPartyConvertibleDebtNetOfDiscount" xlink:title="RelatedPartyConvertibleDebtNetOfDiscount" />
    <link:label xlink:type="resource" xlink:label="btx_RelatedPartyConvertibleDebtNetOfDiscount_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_RelatedPartyConvertibleDebtNetOfDiscount_lbl" xml:lang="en-US" id="btx_RelatedPartyConvertibleDebtNetOfDiscount_lbl">Convertible debt that the issuer (lender) can convert at any time before maturity. Convertible debt is a financial instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RelatedPartyConvertibleDebtNetOfDiscount" xlink:to="btx_RelatedPartyConvertibleDebtNetOfDiscount_lbl" xlink:title="label: RelatedPartyConvertibleDebtNetOfDiscount to btx_RelatedPartyConvertibleDebtNetOfDiscount_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_RelatedPartyConvertibleDebtNetOfDiscount_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_RelatedPartyConvertibleDebtNetOfDiscount_lbl1" xml:lang="en-US" id="btx_RelatedPartyConvertibleDebtNetOfDiscount_lbl1">Related party convertible debt, net of discount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RelatedPartyConvertibleDebtNetOfDiscount" xlink:to="btx_RelatedPartyConvertibleDebtNetOfDiscount_lbl1" xlink:title="label: RelatedPartyConvertibleDebtNetOfDiscount to btx_RelatedPartyConvertibleDebtNetOfDiscount_lbl1" />
    <link:label xlink:type="resource" xlink:label="btx_RelatedPartyConvertibleDebtNetOfDiscount_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="btx_RelatedPartyConvertibleDebtNetOfDiscount_lbl2" xml:lang="en-US" id="btx_RelatedPartyConvertibleDebtNetOfDiscount_lbl2">Related party convertible debt, net of discount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RelatedPartyConvertibleDebtNetOfDiscount" xlink:to="btx_RelatedPartyConvertibleDebtNetOfDiscount_lbl2" xlink:title="label: RelatedPartyConvertibleDebtNetOfDiscount to btx_RelatedPartyConvertibleDebtNetOfDiscount_lbl2" />
    <link:loc xlink:type="locator" xlink:href="btx-20150331.xsd#btx_TradeAccountsAndGrantsReceivableNetCurrent" xlink:label="TradeAccountsAndGrantsReceivableNetCurrent" xlink:title="TradeAccountsAndGrantsReceivableNetCurrent" />
    <link:label xlink:type="resource" xlink:label="btx_TradeAccountsAndGrantsReceivableNetCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_TradeAccountsAndGrantsReceivableNetCurrent_lbl" xml:lang="en-US" id="btx_TradeAccountsAndGrantsReceivableNetCurrent_lbl">Amount due from customers or clients for goods or services that have been delivered or sold in the normal course of business within one year or the normal operating cycle, if longer, net of allowance for doubtful accounts, and the amounts due under the terms of governmental, corporate, or foundation grants.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TradeAccountsAndGrantsReceivableNetCurrent" xlink:to="btx_TradeAccountsAndGrantsReceivableNetCurrent_lbl" xlink:title="label: TradeAccountsAndGrantsReceivableNetCurrent to btx_TradeAccountsAndGrantsReceivableNetCurrent_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_TradeAccountsAndGrantsReceivableNetCurrent_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_TradeAccountsAndGrantsReceivableNetCurrent_lbl1" xml:lang="en-US" id="btx_TradeAccountsAndGrantsReceivableNetCurrent_lbl1">Trade accounts and grants receivable net current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TradeAccountsAndGrantsReceivableNetCurrent" xlink:to="btx_TradeAccountsAndGrantsReceivableNetCurrent_lbl1" xlink:title="label: TradeAccountsAndGrantsReceivableNetCurrent to btx_TradeAccountsAndGrantsReceivableNetCurrent_lbl1" />
    <link:label xlink:type="resource" xlink:label="btx_TradeAccountsAndGrantsReceivableNetCurrent_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="btx_TradeAccountsAndGrantsReceivableNetCurrent_lbl2" xml:lang="en-US" id="btx_TradeAccountsAndGrantsReceivableNetCurrent_lbl2">Trade accounts and grants receivable, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TradeAccountsAndGrantsReceivableNetCurrent" xlink:to="btx_TradeAccountsAndGrantsReceivableNetCurrent_lbl2" xlink:title="label: TradeAccountsAndGrantsReceivableNetCurrent to btx_TradeAccountsAndGrantsReceivableNetCurrent_lbl2" />
    <link:loc xlink:type="locator" xlink:href="btx-20150331.xsd#btx_DeferredLicenseAndConsultingFees" xlink:label="DeferredLicenseAndConsultingFees" xlink:title="DeferredLicenseAndConsultingFees" />
    <link:label xlink:type="resource" xlink:label="btx_DeferredLicenseAndConsultingFees_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_DeferredLicenseAndConsultingFees_lbl" xml:lang="en-US" id="btx_DeferredLicenseAndConsultingFees_lbl">Carrying amounts as of the balance sheet of deferred license and consulting fees, which consists of the value of warrants issued to third parties for services and to the minority shareholder in BioTime Asia for consulting services, and deferred license fees paid to acquire rights to use the proprietary technologies of third parties.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredLicenseAndConsultingFees" xlink:to="btx_DeferredLicenseAndConsultingFees_lbl" xlink:title="label: DeferredLicenseAndConsultingFees to btx_DeferredLicenseAndConsultingFees_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_DeferredLicenseAndConsultingFees_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_DeferredLicenseAndConsultingFees_lbl1" xml:lang="en-US" id="btx_DeferredLicenseAndConsultingFees_lbl1">Deferred license and consulting fees</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredLicenseAndConsultingFees" xlink:to="btx_DeferredLicenseAndConsultingFees_lbl1" xlink:title="label: DeferredLicenseAndConsultingFees to btx_DeferredLicenseAndConsultingFees_lbl1" />
    <link:loc xlink:type="locator" xlink:href="btx-20150331.xsd#btx_LandlordLiabilitiesNoncurrent" xlink:label="LandlordLiabilitiesNoncurrent" xlink:title="LandlordLiabilitiesNoncurrent" />
    <link:label xlink:type="resource" xlink:label="btx_LandlordLiabilitiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_LandlordLiabilitiesNoncurrent_lbl" xml:lang="en-US" id="btx_LandlordLiabilitiesNoncurrent_lbl">The aggregate carrying amount, as of the balance sheet date, of noncurrent liabilities related to a lease agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LandlordLiabilitiesNoncurrent" xlink:to="btx_LandlordLiabilitiesNoncurrent_lbl" xlink:title="label: LandlordLiabilitiesNoncurrent to btx_LandlordLiabilitiesNoncurrent_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_LandlordLiabilitiesNoncurrent_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_LandlordLiabilitiesNoncurrent_lbl1" xml:lang="en-US" id="btx_LandlordLiabilitiesNoncurrent_lbl1">Landlord Liabilities Noncurrent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LandlordLiabilitiesNoncurrent" xlink:to="btx_LandlordLiabilitiesNoncurrent_lbl1" xlink:title="label: LandlordLiabilitiesNoncurrent to btx_LandlordLiabilitiesNoncurrent_lbl1" />
    <link:label xlink:type="resource" xlink:label="btx_LandlordLiabilitiesNoncurrent_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="btx_LandlordLiabilitiesNoncurrent_lbl2" xml:lang="en-US" id="btx_LandlordLiabilitiesNoncurrent_lbl2">Lease liability</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LandlordLiabilitiesNoncurrent" xlink:to="btx_LandlordLiabilitiesNoncurrent_lbl2" xlink:title="label: LandlordLiabilitiesNoncurrent to btx_LandlordLiabilitiesNoncurrent_lbl2" />
    <link:loc xlink:type="locator" xlink:href="btx-20150331.xsd#btx_DeferredGrantIncome" xlink:label="DeferredGrantIncome" xlink:title="DeferredGrantIncome" />
    <link:label xlink:type="resource" xlink:label="btx_DeferredGrantIncome_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_DeferredGrantIncome_lbl" xml:lang="en-US" id="btx_DeferredGrantIncome_lbl">The carrying amount of consideration received or receivable as of the balance sheet date on grant awards that were not recognized as revenue in conformity with GAAP, and which are expected to be recognized as such within one year or the normal operating cycle, if longer.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredGrantIncome" xlink:to="btx_DeferredGrantIncome_lbl" xlink:title="label: DeferredGrantIncome to btx_DeferredGrantIncome_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_DeferredGrantIncome_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_DeferredGrantIncome_lbl1" xml:lang="en-US" id="btx_DeferredGrantIncome_lbl1">Deferred grant income</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredGrantIncome" xlink:to="btx_DeferredGrantIncome_lbl1" xlink:title="label: DeferredGrantIncome to btx_DeferredGrantIncome_lbl1" />
    <link:loc xlink:type="locator" xlink:href="btx-20150331.xsd#btx_TenantAllowanceReceivable" xlink:label="TenantAllowanceReceivable" xlink:title="TenantAllowanceReceivable" />
    <link:label xlink:type="resource" xlink:label="btx_TenantAllowanceReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_TenantAllowanceReceivable_lbl" xml:lang="en-US" id="btx_TenantAllowanceReceivable_lbl">Amount of tenant allowance due from lessor to lessee per the lease agreement to cover building improvements and or construction costs.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TenantAllowanceReceivable" xlink:to="btx_TenantAllowanceReceivable_lbl" xlink:title="label: TenantAllowanceReceivable to btx_TenantAllowanceReceivable_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_TenantAllowanceReceivable_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_TenantAllowanceReceivable_lbl1" xml:lang="en-US" id="btx_TenantAllowanceReceivable_lbl1">Tenant Allowance Receivable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TenantAllowanceReceivable" xlink:to="btx_TenantAllowanceReceivable_lbl1" xlink:title="label: TenantAllowanceReceivable to btx_TenantAllowanceReceivable_lbl1" />
    <link:label xlink:type="resource" xlink:label="btx_TenantAllowanceReceivable_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="btx_TenantAllowanceReceivable_lbl2" xml:lang="en-US" id="btx_TenantAllowanceReceivable_lbl2">Landlord receivable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TenantAllowanceReceivable" xlink:to="btx_TenantAllowanceReceivable_lbl2" xlink:title="label: TenantAllowanceReceivable to btx_TenantAllowanceReceivable_lbl2" />
    <link:loc xlink:type="locator" xlink:href="btx-20150331.xsd#btx_OrthocyteCorporationMember" xlink:label="OrthocyteCorporationMember" xlink:title="OrthocyteCorporationMember" />
    <link:label xlink:type="resource" xlink:label="btx_OrthocyteCorporationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_OrthocyteCorporationMember_lbl" xml:lang="en-US" id="btx_OrthocyteCorporationMember_lbl">Another company which is controlled, directly or indirectly, by its parent. The usual condition for control is ownership of a majority (over 50%) of the outstanding voting stock. The power to control may also exist with a lesser percentage of ownership, for example, by contract, lease, agreement with other stockholders or by court decree.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OrthocyteCorporationMember" xlink:to="btx_OrthocyteCorporationMember_lbl" xlink:title="label: OrthocyteCorporationMember to btx_OrthocyteCorporationMember_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_OrthocyteCorporationMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_OrthocyteCorporationMember_lbl1" xml:lang="en-US" id="btx_OrthocyteCorporationMember_lbl1">OrthoCyte Corporation [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OrthocyteCorporationMember" xlink:to="btx_OrthocyteCorporationMember_lbl1" xlink:title="label: OrthocyteCorporationMember to btx_OrthocyteCorporationMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="btx_OrthocyteCorporationMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="btx_OrthocyteCorporationMember_lbl2" xml:lang="en-US" id="btx_OrthocyteCorporationMember_lbl2">OrthoCyte Corporation [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OrthocyteCorporationMember" xlink:to="btx_OrthocyteCorporationMember_lbl2" xlink:title="label: OrthocyteCorporationMember to btx_OrthocyteCorporationMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="btx-20150331.xsd#btx_CellCureNeurosciencesLtdMember" xlink:label="CellCureNeurosciencesLtdMember" xlink:title="CellCureNeurosciencesLtdMember" />
    <link:label xlink:type="resource" xlink:label="btx_CellCureNeurosciencesLtdMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_CellCureNeurosciencesLtdMember_lbl" xml:lang="en-US" id="btx_CellCureNeurosciencesLtdMember_lbl">Another company which is controlled, directly or indirectly, by its parent. The usual condition for control is ownership of a majority (over 50%) of the outstanding voting stock. The power to control may also exist with a lesser percentage of ownership, for example, by contract, lease, agreement with other stockholders or by court decree.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CellCureNeurosciencesLtdMember" xlink:to="btx_CellCureNeurosciencesLtdMember_lbl" xlink:title="label: CellCureNeurosciencesLtdMember to btx_CellCureNeurosciencesLtdMember_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_CellCureNeurosciencesLtdMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_CellCureNeurosciencesLtdMember_lbl1" xml:lang="en-US" id="btx_CellCureNeurosciencesLtdMember_lbl1">Cell Cure Neurosciences, Ltd. [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CellCureNeurosciencesLtdMember" xlink:to="btx_CellCureNeurosciencesLtdMember_lbl1" xlink:title="label: CellCureNeurosciencesLtdMember to btx_CellCureNeurosciencesLtdMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="btx_CellCureNeurosciencesLtdMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="btx_CellCureNeurosciencesLtdMember_lbl2" xml:lang="en-US" id="btx_CellCureNeurosciencesLtdMember_lbl2">Cell Cure Neurosciences, Ltd. [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CellCureNeurosciencesLtdMember" xlink:to="btx_CellCureNeurosciencesLtdMember_lbl2" xlink:title="label: CellCureNeurosciencesLtdMember to btx_CellCureNeurosciencesLtdMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="btx-20150331.xsd#btx_BiotimeAsiaLimitedMember" xlink:label="BiotimeAsiaLimitedMember" xlink:title="BiotimeAsiaLimitedMember" />
    <link:label xlink:type="resource" xlink:label="btx_BiotimeAsiaLimitedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_BiotimeAsiaLimitedMember_lbl" xml:lang="en-US" id="btx_BiotimeAsiaLimitedMember_lbl">Another company which is controlled, directly or indirectly, by its parent. The usual condition for control is ownership of a majority (over 50%) of the outstanding voting stock. The power to control may also exist with a lesser percentage of ownership, for example, by contract, lease, agreement with other stockholders or by court decree.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BiotimeAsiaLimitedMember" xlink:to="btx_BiotimeAsiaLimitedMember_lbl" xlink:title="label: BiotimeAsiaLimitedMember to btx_BiotimeAsiaLimitedMember_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_BiotimeAsiaLimitedMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_BiotimeAsiaLimitedMember_lbl1" xml:lang="en-US" id="btx_BiotimeAsiaLimitedMember_lbl1">BioTime Asia, Limited [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BiotimeAsiaLimitedMember" xlink:to="btx_BiotimeAsiaLimitedMember_lbl1" xlink:title="label: BiotimeAsiaLimitedMember to btx_BiotimeAsiaLimitedMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="btx_BiotimeAsiaLimitedMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="btx_BiotimeAsiaLimitedMember_lbl2" xml:lang="en-US" id="btx_BiotimeAsiaLimitedMember_lbl2">BioTime Asia, Limited [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BiotimeAsiaLimitedMember" xlink:to="btx_BiotimeAsiaLimitedMember_lbl2" xlink:title="label: BiotimeAsiaLimitedMember to btx_BiotimeAsiaLimitedMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="btx-20150331.xsd#btx_OncocyteCorporationMember" xlink:label="OncocyteCorporationMember" xlink:title="OncocyteCorporationMember" />
    <link:label xlink:type="resource" xlink:label="btx_OncocyteCorporationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_OncocyteCorporationMember_lbl" xml:lang="en-US" id="btx_OncocyteCorporationMember_lbl">Another company which is controlled, directly or indirectly, by its parent. The usual condition for control is ownership of a majority (over 50%) of the outstanding voting stock. The power to control may also exist with a lesser percentage of ownership, for example, by contract, lease, agreement with other stockholders or by court decree.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OncocyteCorporationMember" xlink:to="btx_OncocyteCorporationMember_lbl" xlink:title="label: OncocyteCorporationMember to btx_OncocyteCorporationMember_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_OncocyteCorporationMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_OncocyteCorporationMember_lbl1" xml:lang="en-US" id="btx_OncocyteCorporationMember_lbl1">OncoCyte Corporation [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OncocyteCorporationMember" xlink:to="btx_OncocyteCorporationMember_lbl1" xlink:title="label: OncocyteCorporationMember to btx_OncocyteCorporationMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="btx_OncocyteCorporationMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="btx_OncocyteCorporationMember_lbl2" xml:lang="en-US" id="btx_OncocyteCorporationMember_lbl2">OncoCyte Corporation [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OncocyteCorporationMember" xlink:to="btx_OncocyteCorporationMember_lbl2" xlink:title="label: OncocyteCorporationMember to btx_OncocyteCorporationMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="btx-20150331.xsd#btx_LifemapSciencesIncMember" xlink:label="LifemapSciencesIncMember" xlink:title="LifemapSciencesIncMember" />
    <link:label xlink:type="resource" xlink:label="btx_LifemapSciencesIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_LifemapSciencesIncMember_lbl" xml:lang="en-US" id="btx_LifemapSciencesIncMember_lbl">Another company which is controlled, directly or indirectly, by its parent. The usual condition for control is ownership of a majority (over 50%) of the outstanding voting stock. The power to control may also exist with a lesser percentage of ownership, for example, by contract, lease, agreement with other stockholders or by court decree.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LifemapSciencesIncMember" xlink:to="btx_LifemapSciencesIncMember_lbl" xlink:title="label: LifemapSciencesIncMember to btx_LifemapSciencesIncMember_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_LifemapSciencesIncMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_LifemapSciencesIncMember_lbl1" xml:lang="en-US" id="btx_LifemapSciencesIncMember_lbl1">LifeMap Sciences, Inc. [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LifemapSciencesIncMember" xlink:to="btx_LifemapSciencesIncMember_lbl1" xlink:title="label: LifemapSciencesIncMember to btx_LifemapSciencesIncMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="btx_LifemapSciencesIncMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="btx_LifemapSciencesIncMember_lbl2" xml:lang="en-US" id="btx_LifemapSciencesIncMember_lbl2">LifeMap Sciences, Inc. [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LifemapSciencesIncMember" xlink:to="btx_LifemapSciencesIncMember_lbl2" xlink:title="label: LifemapSciencesIncMember to btx_LifemapSciencesIncMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="btx-20150331.xsd#btx_LifemapSciencesLtdMember" xlink:label="LifemapSciencesLtdMember" xlink:title="LifemapSciencesLtdMember" />
    <link:label xlink:type="resource" xlink:label="btx_LifemapSciencesLtdMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_LifemapSciencesLtdMember_lbl" xml:lang="en-US" id="btx_LifemapSciencesLtdMember_lbl">Another company which is controlled, directly or indirectly, by its parent. The usual condition for control is ownership of a majority (over 50%) of the outstanding voting stock. The power to control may also exist with a lesser percentage of ownership, for example, by contract, lease, agreement with other stockholders or by court decree.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LifemapSciencesLtdMember" xlink:to="btx_LifemapSciencesLtdMember_lbl" xlink:title="label: LifemapSciencesLtdMember to btx_LifemapSciencesLtdMember_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_LifemapSciencesLtdMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_LifemapSciencesLtdMember_lbl1" xml:lang="en-US" id="btx_LifemapSciencesLtdMember_lbl1">LifeMap Sciences, Ltd. [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LifemapSciencesLtdMember" xlink:to="btx_LifemapSciencesLtdMember_lbl1" xlink:title="label: LifemapSciencesLtdMember to btx_LifemapSciencesLtdMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="btx_LifemapSciencesLtdMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="btx_LifemapSciencesLtdMember_lbl2" xml:lang="en-US" id="btx_LifemapSciencesLtdMember_lbl2">LifeMap Sciences, Ltd. [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LifemapSciencesLtdMember" xlink:to="btx_LifemapSciencesLtdMember_lbl2" xlink:title="label: LifemapSciencesLtdMember to btx_LifemapSciencesLtdMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="btx-20150331.xsd#btx_EsCellInternationalPteLtdMember" xlink:label="EsCellInternationalPteLtdMember" xlink:title="EsCellInternationalPteLtdMember" />
    <link:label xlink:type="resource" xlink:label="btx_EsCellInternationalPteLtdMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_EsCellInternationalPteLtdMember_lbl" xml:lang="en-US" id="btx_EsCellInternationalPteLtdMember_lbl">Another company which is controlled, directly or indirectly, by its parent. The usual condition for control is ownership of a majority (over 50%) of the outstanding voting stock. The power to control may also exist with a lesser percentage of ownership, for example, by contract, lease, agreement with other stockholders or by court decree.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EsCellInternationalPteLtdMember" xlink:to="btx_EsCellInternationalPteLtdMember_lbl" xlink:title="label: EsCellInternationalPteLtdMember to btx_EsCellInternationalPteLtdMember_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_EsCellInternationalPteLtdMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_EsCellInternationalPteLtdMember_lbl1" xml:lang="en-US" id="btx_EsCellInternationalPteLtdMember_lbl1">ES Cell International Pte., Ltd. [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EsCellInternationalPteLtdMember" xlink:to="btx_EsCellInternationalPteLtdMember_lbl1" xlink:title="label: EsCellInternationalPteLtdMember to btx_EsCellInternationalPteLtdMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="btx_EsCellInternationalPteLtdMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="btx_EsCellInternationalPteLtdMember_lbl2" xml:lang="en-US" id="btx_EsCellInternationalPteLtdMember_lbl2">ES Cell International Pte., Ltd. [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EsCellInternationalPteLtdMember" xlink:to="btx_EsCellInternationalPteLtdMember_lbl2" xlink:title="label: EsCellInternationalPteLtdMember to btx_EsCellInternationalPteLtdMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="btx-20150331.xsd#btx_RecyteTherapeuticsIncMember" xlink:label="RecyteTherapeuticsIncMember" xlink:title="RecyteTherapeuticsIncMember" />
    <link:label xlink:type="resource" xlink:label="btx_RecyteTherapeuticsIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_RecyteTherapeuticsIncMember_lbl" xml:lang="en-US" id="btx_RecyteTherapeuticsIncMember_lbl">Another company which is controlled, directly or indirectly, by its parent. The usual condition for control is ownership of a majority (over 50%) of the outstanding voting stock. The power to control may also exist with a lesser percentage of ownership, for example, by contract, lease, agreement with other stockholders or by court decree.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RecyteTherapeuticsIncMember" xlink:to="btx_RecyteTherapeuticsIncMember_lbl" xlink:title="label: RecyteTherapeuticsIncMember to btx_RecyteTherapeuticsIncMember_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_RecyteTherapeuticsIncMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_RecyteTherapeuticsIncMember_lbl1" xml:lang="en-US" id="btx_RecyteTherapeuticsIncMember_lbl1">ReCyte Therapeutics, Inc. [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RecyteTherapeuticsIncMember" xlink:to="btx_RecyteTherapeuticsIncMember_lbl1" xlink:title="label: RecyteTherapeuticsIncMember to btx_RecyteTherapeuticsIncMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="btx_RecyteTherapeuticsIncMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="btx_RecyteTherapeuticsIncMember_lbl2" xml:lang="en-US" id="btx_RecyteTherapeuticsIncMember_lbl2">ReCyte Therapeutics, Inc. [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RecyteTherapeuticsIncMember" xlink:to="btx_RecyteTherapeuticsIncMember_lbl2" xlink:title="label: RecyteTherapeuticsIncMember to btx_RecyteTherapeuticsIncMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="btx-20150331.xsd#btx_LifemapSolutionsIncMember" xlink:label="LifemapSolutionsIncMember" xlink:title="LifemapSolutionsIncMember" />
    <link:label xlink:type="resource" xlink:label="btx_LifemapSolutionsIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_LifemapSolutionsIncMember_lbl" xml:lang="en-US" id="btx_LifemapSolutionsIncMember_lbl">Another company which is controlled, directly or indirectly, by its parent. The usual condition for control is ownership of a majority (over 50%) of the outstanding voting stock. The power to control may also exist with a lesser percentage of ownership, for example, by contract, lease, agreement with other stockholders or by court decree.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LifemapSolutionsIncMember" xlink:to="btx_LifemapSolutionsIncMember_lbl" xlink:title="label: LifemapSolutionsIncMember to btx_LifemapSolutionsIncMember_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_LifemapSolutionsIncMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_LifemapSolutionsIncMember_lbl1" xml:lang="en-US" id="btx_LifemapSolutionsIncMember_lbl1">LifeMap Solutions, Inc [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LifemapSolutionsIncMember" xlink:to="btx_LifemapSolutionsIncMember_lbl1" xlink:title="label: LifemapSolutionsIncMember to btx_LifemapSolutionsIncMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="btx_LifemapSolutionsIncMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="btx_LifemapSolutionsIncMember_lbl2" xml:lang="en-US" id="btx_LifemapSolutionsIncMember_lbl2">LifeMap Solutions, Inc. [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LifemapSolutionsIncMember" xlink:to="btx_LifemapSolutionsIncMember_lbl2" xlink:title="label: LifemapSolutionsIncMember to btx_LifemapSolutionsIncMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="btx-20150331.xsd#btx_TenantImprovementAllowanceReimbursementUnderLeaseAgreement" xlink:label="TenantImprovementAllowanceReimbursementUnderLeaseAgreement" xlink:title="TenantImprovementAllowanceReimbursementUnderLeaseAgreement" />
    <link:label xlink:type="resource" xlink:label="btx_TenantImprovementAllowanceReimbursementUnderLeaseAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_TenantImprovementAllowanceReimbursementUnderLeaseAgreement_lbl" xml:lang="en-US" id="btx_TenantImprovementAllowanceReimbursementUnderLeaseAgreement_lbl">Amount of quality for reimbursement under the tenant improvement allowance to lease agreement which use to construct a laboratory and production facility.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TenantImprovementAllowanceReimbursementUnderLeaseAgreement" xlink:to="btx_TenantImprovementAllowanceReimbursementUnderLeaseAgreement_lbl" xlink:title="label: TenantImprovementAllowanceReimbursementUnderLeaseAgreement to btx_TenantImprovementAllowanceReimbursementUnderLeaseAgreement_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_TenantImprovementAllowanceReimbursementUnderLeaseAgreement_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_TenantImprovementAllowanceReimbursementUnderLeaseAgreement_lbl1" xml:lang="en-US" id="btx_TenantImprovementAllowanceReimbursementUnderLeaseAgreement_lbl1">Tenant Improvement Allowance Reimbursement Under Lease Agreement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TenantImprovementAllowanceReimbursementUnderLeaseAgreement" xlink:to="btx_TenantImprovementAllowanceReimbursementUnderLeaseAgreement_lbl1" xlink:title="label: TenantImprovementAllowanceReimbursementUnderLeaseAgreement to btx_TenantImprovementAllowanceReimbursementUnderLeaseAgreement_lbl1" />
    <link:label xlink:type="resource" xlink:label="btx_TenantImprovementAllowanceReimbursementUnderLeaseAgreement_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="btx_TenantImprovementAllowanceReimbursementUnderLeaseAgreement_lbl2" xml:lang="en-US" id="btx_TenantImprovementAllowanceReimbursementUnderLeaseAgreement_lbl2">Amount qualifying for reimbursement under the tenant improvement allowance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TenantImprovementAllowanceReimbursementUnderLeaseAgreement" xlink:to="btx_TenantImprovementAllowanceReimbursementUnderLeaseAgreement_lbl2" xlink:title="label: TenantImprovementAllowanceReimbursementUnderLeaseAgreement to btx_TenantImprovementAllowanceReimbursementUnderLeaseAgreement_lbl2" />
    <link:loc xlink:type="locator" xlink:href="btx-20150331.xsd#btx_TenantImprovementAllowanceUnderLeaseAgreement" xlink:label="TenantImprovementAllowanceUnderLeaseAgreement" xlink:title="TenantImprovementAllowanceUnderLeaseAgreement" />
    <link:label xlink:type="resource" xlink:label="btx_TenantImprovementAllowanceUnderLeaseAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_TenantImprovementAllowanceUnderLeaseAgreement_lbl" xml:lang="en-US" id="btx_TenantImprovementAllowanceUnderLeaseAgreement_lbl">Amount of allowance for tenant related to lease agreement which use to construct a laboratory and production facility.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TenantImprovementAllowanceUnderLeaseAgreement" xlink:to="btx_TenantImprovementAllowanceUnderLeaseAgreement_lbl" xlink:title="label: TenantImprovementAllowanceUnderLeaseAgreement to btx_TenantImprovementAllowanceUnderLeaseAgreement_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_TenantImprovementAllowanceUnderLeaseAgreement_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_TenantImprovementAllowanceUnderLeaseAgreement_lbl1" xml:lang="en-US" id="btx_TenantImprovementAllowanceUnderLeaseAgreement_lbl1">Tenant Improvement Allowance Under Lease Agreement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TenantImprovementAllowanceUnderLeaseAgreement" xlink:to="btx_TenantImprovementAllowanceUnderLeaseAgreement_lbl1" xlink:title="label: TenantImprovementAllowanceUnderLeaseAgreement to btx_TenantImprovementAllowanceUnderLeaseAgreement_lbl1" />
    <link:label xlink:type="resource" xlink:label="btx_TenantImprovementAllowanceUnderLeaseAgreement_lbl2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="btx_TenantImprovementAllowanceUnderLeaseAgreement_lbl2" xml:lang="en-US" id="btx_TenantImprovementAllowanceUnderLeaseAgreement_lbl2">Tenant improvement allowance under lease agreement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TenantImprovementAllowanceUnderLeaseAgreement" xlink:to="btx_TenantImprovementAllowanceUnderLeaseAgreement_lbl2" xlink:title="label: TenantImprovementAllowanceUnderLeaseAgreement to btx_TenantImprovementAllowanceUnderLeaseAgreement_lbl2" />
    <link:loc xlink:type="locator" xlink:href="btx-20150331.xsd#btx_FeesPaidOnSaleOfCommonSharesOfSubsidiary" xlink:label="FeesPaidOnSaleOfCommonSharesOfSubsidiary" xlink:title="FeesPaidOnSaleOfCommonSharesOfSubsidiary" />
    <link:label xlink:type="resource" xlink:label="btx_FeesPaidOnSaleOfCommonSharesOfSubsidiary_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_FeesPaidOnSaleOfCommonSharesOfSubsidiary_lbl" xml:lang="en-US" id="btx_FeesPaidOnSaleOfCommonSharesOfSubsidiary_lbl">The cash outflow associated with fee paid on sale of common shares of subsidiary during the period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FeesPaidOnSaleOfCommonSharesOfSubsidiary" xlink:to="btx_FeesPaidOnSaleOfCommonSharesOfSubsidiary_lbl" xlink:title="label: FeesPaidOnSaleOfCommonSharesOfSubsidiary to btx_FeesPaidOnSaleOfCommonSharesOfSubsidiary_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_FeesPaidOnSaleOfCommonSharesOfSubsidiary_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_FeesPaidOnSaleOfCommonSharesOfSubsidiary_lbl1" xml:lang="en-US" id="btx_FeesPaidOnSaleOfCommonSharesOfSubsidiary_lbl1">Fees paid on sale of common shares of subsidiary</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FeesPaidOnSaleOfCommonSharesOfSubsidiary" xlink:to="btx_FeesPaidOnSaleOfCommonSharesOfSubsidiary_lbl1" xlink:title="label: FeesPaidOnSaleOfCommonSharesOfSubsidiary to btx_FeesPaidOnSaleOfCommonSharesOfSubsidiary_lbl1" />
    <link:label xlink:type="resource" xlink:label="btx_FeesPaidOnSaleOfCommonSharesOfSubsidiary_lbl2" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="btx_FeesPaidOnSaleOfCommonSharesOfSubsidiary_lbl2" xml:lang="en-US" id="btx_FeesPaidOnSaleOfCommonSharesOfSubsidiary_lbl2">Fees paid on sale of common shares of subsidiary</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FeesPaidOnSaleOfCommonSharesOfSubsidiary" xlink:to="btx_FeesPaidOnSaleOfCommonSharesOfSubsidiary_lbl2" xlink:title="label: FeesPaidOnSaleOfCommonSharesOfSubsidiary to btx_FeesPaidOnSaleOfCommonSharesOfSubsidiary_lbl2" />
    <link:loc xlink:type="locator" xlink:href="btx-20150331.xsd#btx_AmortizationOfStockBasedPrepaidRent" xlink:label="AmortizationOfStockBasedPrepaidRent" xlink:title="AmortizationOfStockBasedPrepaidRent" />
    <link:label xlink:type="resource" xlink:label="btx_AmortizationOfStockBasedPrepaidRent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_AmortizationOfStockBasedPrepaidRent_lbl" xml:lang="en-US" id="btx_AmortizationOfStockBasedPrepaidRent_lbl">The aggregate amount of recurring noncash expense charged against earnings in the period to allocate the cost of amortization of stock based prepaid rent.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AmortizationOfStockBasedPrepaidRent" xlink:to="btx_AmortizationOfStockBasedPrepaidRent_lbl" xlink:title="label: AmortizationOfStockBasedPrepaidRent to btx_AmortizationOfStockBasedPrepaidRent_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_AmortizationOfStockBasedPrepaidRent_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_AmortizationOfStockBasedPrepaidRent_lbl1" xml:lang="en-US" id="btx_AmortizationOfStockBasedPrepaidRent_lbl1">Amortization of Stock Based Prepaid Rent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AmortizationOfStockBasedPrepaidRent" xlink:to="btx_AmortizationOfStockBasedPrepaidRent_lbl1" xlink:title="label: AmortizationOfStockBasedPrepaidRent to btx_AmortizationOfStockBasedPrepaidRent_lbl1" />
    <link:label xlink:type="resource" xlink:label="btx_AmortizationOfStockBasedPrepaidRent_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="btx_AmortizationOfStockBasedPrepaidRent_lbl2" xml:lang="en-US" id="btx_AmortizationOfStockBasedPrepaidRent_lbl2">Amortization of prepaid rent in common stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AmortizationOfStockBasedPrepaidRent" xlink:to="btx_AmortizationOfStockBasedPrepaidRent_lbl2" xlink:title="label: AmortizationOfStockBasedPrepaidRent to btx_AmortizationOfStockBasedPrepaidRent_lbl2" />
    <link:loc xlink:type="locator" xlink:href="btx-20150331.xsd#btx_AccruedInterestOnConvertibleDebt" xlink:label="AccruedInterestOnConvertibleDebt" xlink:title="AccruedInterestOnConvertibleDebt" />
    <link:label xlink:type="resource" xlink:label="btx_AccruedInterestOnConvertibleDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_AccruedInterestOnConvertibleDebt_lbl" xml:lang="en-US" id="btx_AccruedInterestOnConvertibleDebt_lbl">Refers to accrued amount unpaid interest on the convertible debt instrument for the period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccruedInterestOnConvertibleDebt" xlink:to="btx_AccruedInterestOnConvertibleDebt_lbl" xlink:title="label: AccruedInterestOnConvertibleDebt to btx_AccruedInterestOnConvertibleDebt_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_AccruedInterestOnConvertibleDebt_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_AccruedInterestOnConvertibleDebt_lbl1" xml:lang="en-US" id="btx_AccruedInterestOnConvertibleDebt_lbl1">Accrued interest on convertible debt</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccruedInterestOnConvertibleDebt" xlink:to="btx_AccruedInterestOnConvertibleDebt_lbl1" xlink:title="label: AccruedInterestOnConvertibleDebt to btx_AccruedInterestOnConvertibleDebt_lbl1" />
    <link:label xlink:type="resource" xlink:label="btx_AccruedInterestOnConvertibleDebt_lbl2" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="btx_AccruedInterestOnConvertibleDebt_lbl2" xml:lang="en-US" id="btx_AccruedInterestOnConvertibleDebt_lbl2">Accrued interest on convertible debt</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccruedInterestOnConvertibleDebt" xlink:to="btx_AccruedInterestOnConvertibleDebt_lbl2" xlink:title="label: AccruedInterestOnConvertibleDebt to btx_AccruedInterestOnConvertibleDebt_lbl2" />
    <link:loc xlink:type="locator" xlink:href="btx-20150331.xsd#btx_AmortizationOfDeferredLicenseFees" xlink:label="AmortizationOfDeferredLicenseFees" xlink:title="AmortizationOfDeferredLicenseFees" />
    <link:label xlink:type="resource" xlink:label="btx_AmortizationOfDeferredLicenseFees_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_AmortizationOfDeferredLicenseFees_lbl" xml:lang="en-US" id="btx_AmortizationOfDeferredLicenseFees_lbl">The aggregate amount of recurring noncash expense charged against earnings in the period to allocate the cost of deferred license fees.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AmortizationOfDeferredLicenseFees" xlink:to="btx_AmortizationOfDeferredLicenseFees_lbl" xlink:title="label: AmortizationOfDeferredLicenseFees to btx_AmortizationOfDeferredLicenseFees_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_AmortizationOfDeferredLicenseFees_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_AmortizationOfDeferredLicenseFees_lbl1" xml:lang="en-US" id="btx_AmortizationOfDeferredLicenseFees_lbl1">Amortization of deferred license fees</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AmortizationOfDeferredLicenseFees" xlink:to="btx_AmortizationOfDeferredLicenseFees_lbl1" xlink:title="label: AmortizationOfDeferredLicenseFees to btx_AmortizationOfDeferredLicenseFees_lbl1" />
    <link:label xlink:type="resource" xlink:label="btx_AmortizationOfDeferredLicenseFees_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="btx_AmortizationOfDeferredLicenseFees_lbl2" xml:lang="en-US" id="btx_AmortizationOfDeferredLicenseFees_lbl2">Amortization of deferred license fees</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AmortizationOfDeferredLicenseFees" xlink:to="btx_AmortizationOfDeferredLicenseFees_lbl2" xlink:title="label: AmortizationOfDeferredLicenseFees to btx_AmortizationOfDeferredLicenseFees_lbl2" />
    <link:loc xlink:type="locator" xlink:href="btx-20150331.xsd#btx_IncreaseDecreaseInGrantReceivable" xlink:label="IncreaseDecreaseInGrantReceivable" xlink:title="IncreaseDecreaseInGrantReceivable" />
    <link:label xlink:type="resource" xlink:label="btx_IncreaseDecreaseInGrantReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_IncreaseDecreaseInGrantReceivable_lbl" xml:lang="en-US" id="btx_IncreaseDecreaseInGrantReceivable_lbl">The increase (decrease) during the reporting period for amounts due under the terms of governmental, corporate, or foundation grants.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInGrantReceivable" xlink:to="btx_IncreaseDecreaseInGrantReceivable_lbl" xlink:title="label: IncreaseDecreaseInGrantReceivable to btx_IncreaseDecreaseInGrantReceivable_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_IncreaseDecreaseInGrantReceivable_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_IncreaseDecreaseInGrantReceivable_lbl1" xml:lang="en-US" id="btx_IncreaseDecreaseInGrantReceivable_lbl1">Increase (decrease) in Grant receivable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInGrantReceivable" xlink:to="btx_IncreaseDecreaseInGrantReceivable_lbl1" xlink:title="label: IncreaseDecreaseInGrantReceivable to btx_IncreaseDecreaseInGrantReceivable_lbl1" />
    <link:label xlink:type="resource" xlink:label="btx_IncreaseDecreaseInGrantReceivable_lbl2" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="btx_IncreaseDecreaseInGrantReceivable_lbl2" xml:lang="en-US" id="btx_IncreaseDecreaseInGrantReceivable_lbl2">Grant receivable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInGrantReceivable" xlink:to="btx_IncreaseDecreaseInGrantReceivable_lbl2" xlink:title="label: IncreaseDecreaseInGrantReceivable to btx_IncreaseDecreaseInGrantReceivable_lbl2" />
    <link:loc xlink:type="locator" xlink:href="btx-20150331.xsd#btx_AmortizationOfDeferredConsultingFees" xlink:label="AmortizationOfDeferredConsultingFees" xlink:title="AmortizationOfDeferredConsultingFees" />
    <link:label xlink:type="resource" xlink:label="btx_AmortizationOfDeferredConsultingFees_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_AmortizationOfDeferredConsultingFees_lbl" xml:lang="en-US" id="btx_AmortizationOfDeferredConsultingFees_lbl">The aggregate amount of recurring noncash expense charged against earnings in the period to allocate the cost of deferred consulting fees.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AmortizationOfDeferredConsultingFees" xlink:to="btx_AmortizationOfDeferredConsultingFees_lbl" xlink:title="label: AmortizationOfDeferredConsultingFees to btx_AmortizationOfDeferredConsultingFees_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_AmortizationOfDeferredConsultingFees_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_AmortizationOfDeferredConsultingFees_lbl1" xml:lang="en-US" id="btx_AmortizationOfDeferredConsultingFees_lbl1">Amortization of deferred consulting fees</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AmortizationOfDeferredConsultingFees" xlink:to="btx_AmortizationOfDeferredConsultingFees_lbl1" xlink:title="label: AmortizationOfDeferredConsultingFees to btx_AmortizationOfDeferredConsultingFees_lbl1" />
    <link:loc xlink:type="locator" xlink:href="btx-20150331.xsd#btx_IncreaseDecreaseInDeferredRentLiabilities" xlink:label="IncreaseDecreaseInDeferredRentLiabilities" xlink:title="IncreaseDecreaseInDeferredRentLiabilities" />
    <link:label xlink:type="resource" xlink:label="btx_IncreaseDecreaseInDeferredRentLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_IncreaseDecreaseInDeferredRentLiabilities_lbl" xml:lang="en-US" id="btx_IncreaseDecreaseInDeferredRentLiabilities_lbl">The increase (decrease) during the reporting period in the amount due that is the result of the cumulative difference between actual rent due and rental income recognized on a straight-line basis.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInDeferredRentLiabilities" xlink:to="btx_IncreaseDecreaseInDeferredRentLiabilities_lbl" xlink:title="label: IncreaseDecreaseInDeferredRentLiabilities to btx_IncreaseDecreaseInDeferredRentLiabilities_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_IncreaseDecreaseInDeferredRentLiabilities_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_IncreaseDecreaseInDeferredRentLiabilities_lbl1" xml:lang="en-US" id="btx_IncreaseDecreaseInDeferredRentLiabilities_lbl1">Increase (Decrease) in Deferred Rent Liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInDeferredRentLiabilities" xlink:to="btx_IncreaseDecreaseInDeferredRentLiabilities_lbl1" xlink:title="label: IncreaseDecreaseInDeferredRentLiabilities to btx_IncreaseDecreaseInDeferredRentLiabilities_lbl1" />
    <link:label xlink:type="resource" xlink:label="btx_IncreaseDecreaseInDeferredRentLiabilities_lbl2" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="btx_IncreaseDecreaseInDeferredRentLiabilities_lbl2" xml:lang="en-US" id="btx_IncreaseDecreaseInDeferredRentLiabilities_lbl2">Deferred rent liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInDeferredRentLiabilities" xlink:to="btx_IncreaseDecreaseInDeferredRentLiabilities_lbl2" xlink:title="label: IncreaseDecreaseInDeferredRentLiabilities to btx_IncreaseDecreaseInDeferredRentLiabilities_lbl2" />
    <link:loc xlink:type="locator" xlink:href="btx-20150331.xsd#btx_ProceedsFromDeferredGrantIncome" xlink:label="ProceedsFromDeferredGrantIncome" xlink:title="ProceedsFromDeferredGrantIncome" />
    <link:label xlink:type="resource" xlink:label="btx_ProceedsFromDeferredGrantIncome_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_ProceedsFromDeferredGrantIncome_lbl" xml:lang="en-US" id="btx_ProceedsFromDeferredGrantIncome_lbl">The cash inflow from deferred grant awarded during the period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromDeferredGrantIncome" xlink:to="btx_ProceedsFromDeferredGrantIncome_lbl" xlink:title="label: ProceedsFromDeferredGrantIncome to btx_ProceedsFromDeferredGrantIncome_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_ProceedsFromDeferredGrantIncome_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_ProceedsFromDeferredGrantIncome_lbl1" xml:lang="en-US" id="btx_ProceedsFromDeferredGrantIncome_lbl1">Proceeds From Deferred Grant Income</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromDeferredGrantIncome" xlink:to="btx_ProceedsFromDeferredGrantIncome_lbl1" xlink:title="label: ProceedsFromDeferredGrantIncome to btx_ProceedsFromDeferredGrantIncome_lbl1" />
    <link:label xlink:type="resource" xlink:label="btx_ProceedsFromDeferredGrantIncome_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="btx_ProceedsFromDeferredGrantIncome_lbl2" xml:lang="en-US" id="btx_ProceedsFromDeferredGrantIncome_lbl2">Deferred grant income</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromDeferredGrantIncome" xlink:to="btx_ProceedsFromDeferredGrantIncome_lbl2" xlink:title="label: ProceedsFromDeferredGrantIncome to btx_ProceedsFromDeferredGrantIncome_lbl2" />
    <link:loc xlink:type="locator" xlink:href="btx-20150331.xsd#btx_ProceedsFromConstructionInProgress" xlink:label="ProceedsFromConstructionInProgress" xlink:title="ProceedsFromConstructionInProgress" />
    <link:label xlink:type="resource" xlink:label="btx_ProceedsFromConstructionInProgress_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_ProceedsFromConstructionInProgress_lbl" xml:lang="en-US" id="btx_ProceedsFromConstructionInProgress_lbl">Refers to proceeds from landlord on construction in progress.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromConstructionInProgress" xlink:to="btx_ProceedsFromConstructionInProgress_lbl" xlink:title="label: ProceedsFromConstructionInProgress to btx_ProceedsFromConstructionInProgress_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_ProceedsFromConstructionInProgress_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_ProceedsFromConstructionInProgress_lbl1" xml:lang="en-US" id="btx_ProceedsFromConstructionInProgress_lbl1">Proceeds from Construction in Progress</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromConstructionInProgress" xlink:to="btx_ProceedsFromConstructionInProgress_lbl1" xlink:title="label: ProceedsFromConstructionInProgress to btx_ProceedsFromConstructionInProgress_lbl1" />
    <link:label xlink:type="resource" xlink:label="btx_ProceedsFromConstructionInProgress_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="btx_ProceedsFromConstructionInProgress_lbl2" xml:lang="en-US" id="btx_ProceedsFromConstructionInProgress_lbl2">Reimbursement from landlord on construction in progress (see Note 4)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromConstructionInProgress" xlink:to="btx_ProceedsFromConstructionInProgress_lbl2" xlink:title="label: ProceedsFromConstructionInProgress to btx_ProceedsFromConstructionInProgress_lbl2" />
    <link:label xlink:type="resource" xlink:label="btx_ProceedsFromConstructionInProgress_lbl3" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="btx_ProceedsFromConstructionInProgress_lbl3" xml:lang="en-US" id="btx_ProceedsFromConstructionInProgress_lbl3">Reimbursement from landlord on construction in progress</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromConstructionInProgress" xlink:to="btx_ProceedsFromConstructionInProgress_lbl3" xlink:title="label: ProceedsFromConstructionInProgress to btx_ProceedsFromConstructionInProgress_lbl3" />
    <link:loc xlink:type="locator" xlink:href="btx-20150331.xsd#btx_SecurityDepositReceived" xlink:label="SecurityDepositReceived" xlink:title="SecurityDepositReceived" />
    <link:label xlink:type="resource" xlink:label="btx_SecurityDepositReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_SecurityDepositReceived_lbl" xml:lang="en-US" id="btx_SecurityDepositReceived_lbl">The net cash inflow/(outflow) associated with security deposit received during the period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SecurityDepositReceived" xlink:to="btx_SecurityDepositReceived_lbl" xlink:title="label: SecurityDepositReceived to btx_SecurityDepositReceived_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_SecurityDepositReceived_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_SecurityDepositReceived_lbl1" xml:lang="en-US" id="btx_SecurityDepositReceived_lbl1">Security deposit received</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SecurityDepositReceived" xlink:to="btx_SecurityDepositReceived_lbl1" xlink:title="label: SecurityDepositReceived to btx_SecurityDepositReceived_lbl1" />
    <link:label xlink:type="resource" xlink:label="btx_SecurityDepositReceived_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="btx_SecurityDepositReceived_lbl2" xml:lang="en-US" id="btx_SecurityDepositReceived_lbl2">Security deposit paid, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SecurityDepositReceived" xlink:to="btx_SecurityDepositReceived_lbl2" xlink:title="label: SecurityDepositReceived to btx_SecurityDepositReceived_lbl2" />
    <link:loc xlink:type="locator" xlink:href="btx-20150331.xsd#btx_FeesPaidOnSaleOfCommonShares" xlink:label="FeesPaidOnSaleOfCommonShares" xlink:title="FeesPaidOnSaleOfCommonShares" />
    <link:label xlink:type="resource" xlink:label="btx_FeesPaidOnSaleOfCommonShares_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_FeesPaidOnSaleOfCommonShares_lbl" xml:lang="en-US" id="btx_FeesPaidOnSaleOfCommonShares_lbl">The cash outflow associated with fee paid on sale of common shares during the period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FeesPaidOnSaleOfCommonShares" xlink:to="btx_FeesPaidOnSaleOfCommonShares_lbl" xlink:title="label: FeesPaidOnSaleOfCommonShares to btx_FeesPaidOnSaleOfCommonShares_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_FeesPaidOnSaleOfCommonShares_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_FeesPaidOnSaleOfCommonShares_lbl1" xml:lang="en-US" id="btx_FeesPaidOnSaleOfCommonShares_lbl1">Fees paid on sale of common shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FeesPaidOnSaleOfCommonShares" xlink:to="btx_FeesPaidOnSaleOfCommonShares_lbl1" xlink:title="label: FeesPaidOnSaleOfCommonShares to btx_FeesPaidOnSaleOfCommonShares_lbl1" />
    <link:label xlink:type="resource" xlink:label="btx_FeesPaidOnSaleOfCommonShares_lbl2" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="btx_FeesPaidOnSaleOfCommonShares_lbl2" xml:lang="en-US" id="btx_FeesPaidOnSaleOfCommonShares_lbl2">Fees paid on sale of common stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FeesPaidOnSaleOfCommonShares" xlink:to="btx_FeesPaidOnSaleOfCommonShares_lbl2" xlink:title="label: FeesPaidOnSaleOfCommonShares to btx_FeesPaidOnSaleOfCommonShares_lbl2" />
    <link:loc xlink:type="locator" xlink:href="btx-20150331.xsd#btx_AsteriasBiotherapeuticsMember" xlink:label="AsteriasBiotherapeuticsMember" xlink:title="AsteriasBiotherapeuticsMember" />
    <link:label xlink:type="resource" xlink:label="btx_AsteriasBiotherapeuticsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_AsteriasBiotherapeuticsMember_lbl" xml:lang="en-US" id="btx_AsteriasBiotherapeuticsMember_lbl">Another company which is controlled, directly or indirectly, by its parent. The usual condition for control is ownership of a majority (over 50%) of the outstanding voting stock. The power to control may also exist with a lesser percentage of ownership, for example, by contract, lease, agreement with other stockholders or by court decree.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AsteriasBiotherapeuticsMember" xlink:to="btx_AsteriasBiotherapeuticsMember_lbl" xlink:title="label: AsteriasBiotherapeuticsMember to btx_AsteriasBiotherapeuticsMember_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_AsteriasBiotherapeuticsMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_AsteriasBiotherapeuticsMember_lbl1" xml:lang="en-US" id="btx_AsteriasBiotherapeuticsMember_lbl1">Asterias Biotherapeutics [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AsteriasBiotherapeuticsMember" xlink:to="btx_AsteriasBiotherapeuticsMember_lbl1" xlink:title="label: AsteriasBiotherapeuticsMember to btx_AsteriasBiotherapeuticsMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="btx_AsteriasBiotherapeuticsMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="btx_AsteriasBiotherapeuticsMember_lbl2" xml:lang="en-US" id="btx_AsteriasBiotherapeuticsMember_lbl2">Asterias Biotherapeutics, Inc.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AsteriasBiotherapeuticsMember" xlink:to="btx_AsteriasBiotherapeuticsMember_lbl2" xlink:title="label: AsteriasBiotherapeuticsMember to btx_AsteriasBiotherapeuticsMember_lbl2" />
    <link:label xlink:type="resource" xlink:label="btx_AsteriasBiotherapeuticsMember_lbl3" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="btx_AsteriasBiotherapeuticsMember_lbl3" xml:lang="en-US" id="btx_AsteriasBiotherapeuticsMember_lbl3">Asterias Biotherapeutics [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AsteriasBiotherapeuticsMember" xlink:to="btx_AsteriasBiotherapeuticsMember_lbl3" xlink:title="label: AsteriasBiotherapeuticsMember to btx_AsteriasBiotherapeuticsMember_lbl3" />
    <link:loc xlink:type="locator" xlink:href="btx-20150331.xsd#btx_SharesSoldByThirdParty" xlink:label="SharesSoldByThirdParty" xlink:title="SharesSoldByThirdParty" />
    <link:label xlink:type="resource" xlink:label="btx_SharesSoldByThirdParty_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_SharesSoldByThirdParty_lbl" xml:lang="en-US" id="btx_SharesSoldByThirdParty_lbl">The number of shares sold by third parities during the period reported.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharesSoldByThirdParty" xlink:to="btx_SharesSoldByThirdParty_lbl" xlink:title="label: SharesSoldByThirdParty to btx_SharesSoldByThirdParty_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_SharesSoldByThirdParty_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_SharesSoldByThirdParty_lbl1" xml:lang="en-US" id="btx_SharesSoldByThirdParty_lbl1">Shares sold by third party</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharesSoldByThirdParty" xlink:to="btx_SharesSoldByThirdParty_lbl1" xlink:title="label: SharesSoldByThirdParty to btx_SharesSoldByThirdParty_lbl1" />
    <link:label xlink:type="resource" xlink:label="btx_SharesSoldByThirdParty_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="btx_SharesSoldByThirdParty_lbl2" xml:lang="en-US" id="btx_SharesSoldByThirdParty_lbl2">Number of shares sold (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharesSoldByThirdParty" xlink:to="btx_SharesSoldByThirdParty_lbl2" xlink:title="label: SharesSoldByThirdParty to btx_SharesSoldByThirdParty_lbl2" />
    <link:label xlink:type="resource" xlink:label="btx_SharesSoldByThirdParty_lbl3" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="btx_SharesSoldByThirdParty_lbl3" xml:lang="en-US" id="btx_SharesSoldByThirdParty_lbl3">Number of shares sold by subsidiary (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharesSoldByThirdParty" xlink:to="btx_SharesSoldByThirdParty_lbl3" xlink:title="label: SharesSoldByThirdParty to btx_SharesSoldByThirdParty_lbl3" />
    <link:loc xlink:type="locator" xlink:href="btx-20150331.xsd#btx_NumberOfInvestors" xlink:label="NumberOfInvestors" xlink:title="NumberOfInvestors" />
    <link:label xlink:type="resource" xlink:label="btx_NumberOfInvestors_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_NumberOfInvestors_lbl" xml:lang="en-US" id="btx_NumberOfInvestors_lbl">Refers to number of investors.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfInvestors" xlink:to="btx_NumberOfInvestors_lbl" xlink:title="label: NumberOfInvestors to btx_NumberOfInvestors_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_NumberOfInvestors_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_NumberOfInvestors_lbl1" xml:lang="en-US" id="btx_NumberOfInvestors_lbl1">Number of Investors</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfInvestors" xlink:to="btx_NumberOfInvestors_lbl1" xlink:title="label: NumberOfInvestors to btx_NumberOfInvestors_lbl1" />
    <link:label xlink:type="resource" xlink:label="btx_NumberOfInvestors_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="btx_NumberOfInvestors_lbl2" xml:lang="en-US" id="btx_NumberOfInvestors_lbl2">Number of investors</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfInvestors" xlink:to="btx_NumberOfInvestors_lbl2" xlink:title="label: NumberOfInvestors to btx_NumberOfInvestors_lbl2" />
    <link:label xlink:type="resource" xlink:label="btx_NumberOfInvestors_lbl3" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="btx_NumberOfInvestors_lbl3" xml:lang="en-US" id="btx_NumberOfInvestors_lbl3">Sale of stock, number of shareholders</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfInvestors" xlink:to="btx_NumberOfInvestors_lbl3" xlink:title="label: NumberOfInvestors to btx_NumberOfInvestors_lbl3" />
    <link:loc xlink:type="locator" xlink:href="btx-20150331.xsd#btx_SalesOfBiotimeCommonSharesBySubsidiariesTextBlock" xlink:label="SalesOfBiotimeCommonSharesBySubsidiariesTextBlock" xlink:title="SalesOfBiotimeCommonSharesBySubsidiariesTextBlock" />
    <link:label xlink:type="resource" xlink:label="btx_SalesOfBiotimeCommonSharesBySubsidiariesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_SalesOfBiotimeCommonSharesBySubsidiariesTextBlock_lbl" xml:lang="en-US" id="btx_SalesOfBiotimeCommonSharesBySubsidiariesTextBlock_lbl">Refers to sales of BioTime Common Shares by Subsidiaries.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SalesOfBiotimeCommonSharesBySubsidiariesTextBlock" xlink:to="btx_SalesOfBiotimeCommonSharesBySubsidiariesTextBlock_lbl" xlink:title="label: SalesOfBiotimeCommonSharesBySubsidiariesTextBlock to btx_SalesOfBiotimeCommonSharesBySubsidiariesTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_SalesOfBiotimeCommonSharesBySubsidiariesTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_SalesOfBiotimeCommonSharesBySubsidiariesTextBlock_lbl1" xml:lang="en-US" id="btx_SalesOfBiotimeCommonSharesBySubsidiariesTextBlock_lbl1">Sales of BioTime Common Shares by Subsidiaries [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SalesOfBiotimeCommonSharesBySubsidiariesTextBlock" xlink:to="btx_SalesOfBiotimeCommonSharesBySubsidiariesTextBlock_lbl1" xlink:title="label: SalesOfBiotimeCommonSharesBySubsidiariesTextBlock to btx_SalesOfBiotimeCommonSharesBySubsidiariesTextBlock_lbl1" />
    <link:label xlink:type="resource" xlink:label="btx_SalesOfBiotimeCommonSharesBySubsidiariesTextBlock_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="btx_SalesOfBiotimeCommonSharesBySubsidiariesTextBlock_lbl2" xml:lang="en-US" id="btx_SalesOfBiotimeCommonSharesBySubsidiariesTextBlock_lbl2">Sales of BioTime Common Shares by Subsidiaries</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SalesOfBiotimeCommonSharesBySubsidiariesTextBlock" xlink:to="btx_SalesOfBiotimeCommonSharesBySubsidiariesTextBlock_lbl2" xlink:title="label: SalesOfBiotimeCommonSharesBySubsidiariesTextBlock to btx_SalesOfBiotimeCommonSharesBySubsidiariesTextBlock_lbl2" />
    <link:loc xlink:type="locator" xlink:href="btx-20150331.xsd#btx_SalesOfBioTimeCommonSharesBySubsidiariesAbstract" xlink:label="SalesOfBioTimeCommonSharesBySubsidiariesAbstract" xlink:title="SalesOfBioTimeCommonSharesBySubsidiariesAbstract" />
    <link:label xlink:type="resource" xlink:label="btx_SalesOfBioTimeCommonSharesBySubsidiariesAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_SalesOfBioTimeCommonSharesBySubsidiariesAbstract_lbl1" xml:lang="en-US" id="btx_SalesOfBioTimeCommonSharesBySubsidiariesAbstract_lbl1">Sales of BioTime Common Shares by Subsidiaries [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SalesOfBioTimeCommonSharesBySubsidiariesAbstract" xlink:to="btx_SalesOfBioTimeCommonSharesBySubsidiariesAbstract_lbl1" xlink:title="label: SalesOfBioTimeCommonSharesBySubsidiariesAbstract to btx_SalesOfBioTimeCommonSharesBySubsidiariesAbstract_lbl1" />
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>10
<FILENAME>btx-20150331_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--Generated by EDGARfilings PROfile 3.3.0.0 Copyright 1995 - 2015 Summit Financial Printing, LLC. All rights reserved.-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" />
  <link:roleRef roleURI="http://biotimeinc.com/role/SubsequentEventsDetails" xlink:type="simple" xlink:href="btx-20150331.xsd#SubsequentEventsDetails" />
  <link:roleRef roleURI="http://biotimeinc.com/role/SegmentInformationDetails" xlink:type="simple" xlink:href="btx-20150331.xsd#SegmentInformationDetails" />
  <link:roleRef roleURI="http://biotimeinc.com/role/SalesOfBiotimeCommonSharesBySubsidiariesDetails" xlink:type="simple" xlink:href="btx-20150331.xsd#SalesOfBiotimeCommonSharesBySubsidiariesDetails" />
  <link:roleRef roleURI="http://biotimeinc.com/role/ShareholdersEquityDetails" xlink:type="simple" xlink:href="btx-20150331.xsd#ShareholdersEquityDetails" />
  <link:roleRef roleURI="http://biotimeinc.com/role/RelatedPartyTransactionsAndRelatedPartyConvertibleDebtDetails" xlink:type="simple" xlink:href="btx-20150331.xsd#RelatedPartyTransactionsAndRelatedPartyConvertibleDebtDetails" />
  <link:roleRef roleURI="http://biotimeinc.com/role/AccountsPayableAndAccruedLiabilitiesDetails" xlink:type="simple" xlink:href="btx-20150331.xsd#AccountsPayableAndAccruedLiabilitiesDetails" />
  <link:roleRef roleURI="http://biotimeinc.com/role/RoyaltyObligationAndDeferredLicenseFeesDetails" xlink:type="simple" xlink:href="btx-20150331.xsd#RoyaltyObligationAndDeferredLicenseFeesDetails" />
  <link:roleRef roleURI="http://biotimeinc.com/role/IntangibleAssetsNetDetails" xlink:type="simple" xlink:href="btx-20150331.xsd#IntangibleAssetsNetDetails" />
  <link:roleRef roleURI="http://biotimeinc.com/role/EquipmentNetAndConstructionInProgressDetails" xlink:type="simple" xlink:href="btx-20150331.xsd#EquipmentNetAndConstructionInProgressDetails" />
  <link:roleRef roleURI="http://biotimeinc.com/role/InventoryDetails" xlink:type="simple" xlink:href="btx-20150331.xsd#InventoryDetails" />
  <link:roleRef roleURI="http://biotimeinc.com/role/SummaryOfSignificantAccountingPoliciesDetails" xlink:type="simple" xlink:href="btx-20150331.xsd#SummaryOfSignificantAccountingPoliciesDetails" />
  <link:roleRef roleURI="http://biotimeinc.com/role/OrganizationBasisOfPresentationAndLiquidityDetails" xlink:type="simple" xlink:href="btx-20150331.xsd#OrganizationBasisOfPresentationAndLiquidityDetails" />
  <link:roleRef roleURI="http://biotimeinc.com/role/AccountsPayableAndAccruedLiabilitiesTables" xlink:type="simple" xlink:href="btx-20150331.xsd#AccountsPayableAndAccruedLiabilitiesTables" />
  <link:roleRef roleURI="http://biotimeinc.com/role/RoyaltyObligationAndDeferredLicenseFeesTables" xlink:type="simple" xlink:href="btx-20150331.xsd#RoyaltyObligationAndDeferredLicenseFeesTables" />
  <link:roleRef roleURI="http://biotimeinc.com/role/IntangibleAssetsNetTables" xlink:type="simple" xlink:href="btx-20150331.xsd#IntangibleAssetsNetTables" />
  <link:roleRef roleURI="http://biotimeinc.com/role/EquipmentNetAndConstructionInProgressTables" xlink:type="simple" xlink:href="btx-20150331.xsd#EquipmentNetAndConstructionInProgressTables" />
  <link:roleRef roleURI="http://biotimeinc.com/role/OrganizationBasisOfPresentationAndLiquidityTables" xlink:type="simple" xlink:href="btx-20150331.xsd#OrganizationBasisOfPresentationAndLiquidityTables" />
  <link:roleRef roleURI="http://biotimeinc.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="btx-20150331.xsd#SummaryOfSignificantAccountingPoliciesPolicies" />
  <link:roleRef roleURI="http://biotimeinc.com/role/SubsequentEvents" xlink:type="simple" xlink:href="btx-20150331.xsd#SubsequentEvents" />
  <link:roleRef roleURI="http://biotimeinc.com/role/SegmentInformation" xlink:type="simple" xlink:href="btx-20150331.xsd#SegmentInformation" />
  <link:roleRef roleURI="http://biotimeinc.com/role/SalesOfBiotimeCommonSharesBySubsidiaries" xlink:type="simple" xlink:href="btx-20150331.xsd#SalesOfBiotimeCommonSharesBySubsidiaries" />
  <link:roleRef roleURI="http://biotimeinc.com/role/ShareholdersEquity" xlink:type="simple" xlink:href="btx-20150331.xsd#ShareholdersEquity" />
  <link:roleRef roleURI="http://biotimeinc.com/role/RelatedPartyTransactionsAndRelatedPartyConvertibleDebt" xlink:type="simple" xlink:href="btx-20150331.xsd#RelatedPartyTransactionsAndRelatedPartyConvertibleDebt" />
  <link:roleRef roleURI="http://biotimeinc.com/role/AccountsPayableAndAccruedLiabilities" xlink:type="simple" xlink:href="btx-20150331.xsd#AccountsPayableAndAccruedLiabilities" />
  <link:roleRef roleURI="http://biotimeinc.com/role/RoyaltyObligationAndDeferredLicenseFees" xlink:type="simple" xlink:href="btx-20150331.xsd#RoyaltyObligationAndDeferredLicenseFees" />
  <link:roleRef roleURI="http://biotimeinc.com/role/IntangibleAssetsNet" xlink:type="simple" xlink:href="btx-20150331.xsd#IntangibleAssetsNet" />
  <link:roleRef roleURI="http://biotimeinc.com/role/EquipmentNetAndConstructionInProgress" xlink:type="simple" xlink:href="btx-20150331.xsd#EquipmentNetAndConstructionInProgress" />
  <link:roleRef roleURI="http://biotimeinc.com/role/Inventory" xlink:type="simple" xlink:href="btx-20150331.xsd#Inventory" />
  <link:roleRef roleURI="http://biotimeinc.com/role/SummaryOfSignificantAccountingPolicies" xlink:type="simple" xlink:href="btx-20150331.xsd#SummaryOfSignificantAccountingPolicies" />
  <link:roleRef roleURI="http://biotimeinc.com/role/OrganizationBasisOfPresentationAndLiquidity" xlink:type="simple" xlink:href="btx-20150331.xsd#OrganizationBasisOfPresentationAndLiquidity" />
  <link:roleRef roleURI="http://biotimeinc.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" xlink:type="simple" xlink:href="btx-20150331.xsd#CondensedConsolidatedStatementsOfCashFlowsUnaudited" />
  <link:roleRef roleURI="http://biotimeinc.com/role/CondensedConsolidatedStatementsOfComprehensiveLossUnaudited" xlink:type="simple" xlink:href="btx-20150331.xsd#CondensedConsolidatedStatementsOfComprehensiveLossUnaudited" />
  <link:roleRef roleURI="http://biotimeinc.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited" xlink:type="simple" xlink:href="btx-20150331.xsd#CondensedConsolidatedStatementsOfOperationsUnaudited" />
  <link:roleRef roleURI="http://biotimeinc.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" xlink:type="simple" xlink:href="btx-20150331.xsd#CondensedConsolidatedBalanceSheetsUnauditedParenthetical" />
  <link:roleRef roleURI="http://biotimeinc.com/role/CondensedConsolidatedBalanceSheetsUnaudited" xlink:type="simple" xlink:href="btx-20150331.xsd#CondensedConsolidatedBalanceSheetsUnaudited" />
  <link:roleRef roleURI="http://biotimeinc.com/role/DocumentAndEntityInformation" xlink:type="simple" xlink:href="btx-20150331.xsd#DocumentAndEntityInformation" />
  <link:presentationLink xlink:type="extended" xlink:role="http://biotimeinc.com/role/DocumentAndEntityInformation">
    <link:loc xlink:type="locator" xlink:href="btx-20150331.xsd#btx_DocumentAndEntityInformationAbstract" xlink:label="DocumentAndEntityInformationAbstract" xlink:title="DocumentAndEntityInformationAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:label="EntityRegistrantName" xlink:title="EntityRegistrantName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="EntityRegistrantName" xlink:title="presentation: DocumentAndEntityInformationAbstract to EntityRegistrantName" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="EntityCentralIndexKey" xlink:title="EntityCentralIndexKey" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="EntityCentralIndexKey" xlink:title="presentation: DocumentAndEntityInformationAbstract to EntityCentralIndexKey" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="CurrentFiscalYearEndDate" xlink:title="CurrentFiscalYearEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="CurrentFiscalYearEndDate" xlink:title="presentation: DocumentAndEntityInformationAbstract to CurrentFiscalYearEndDate" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="EntityWellKnownSeasonedIssuer" xlink:title="EntityWellKnownSeasonedIssuer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="EntityWellKnownSeasonedIssuer" xlink:title="presentation: DocumentAndEntityInformationAbstract to EntityWellKnownSeasonedIssuer" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="EntityVoluntaryFilers" xlink:title="EntityVoluntaryFilers" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="EntityVoluntaryFilers" xlink:title="presentation: DocumentAndEntityInformationAbstract to EntityVoluntaryFilers" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="EntityCurrentReportingStatus" xlink:title="EntityCurrentReportingStatus" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="EntityCurrentReportingStatus" xlink:title="presentation: DocumentAndEntityInformationAbstract to EntityCurrentReportingStatus" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:label="EntityFilerCategory" xlink:title="EntityFilerCategory" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="EntityFilerCategory" xlink:title="presentation: DocumentAndEntityInformationAbstract to EntityFilerCategory" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="EntityCommonStockSharesOutstanding" xlink:title="EntityCommonStockSharesOutstanding" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="EntityCommonStockSharesOutstanding" xlink:title="presentation: DocumentAndEntityInformationAbstract to EntityCommonStockSharesOutstanding" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="DocumentFiscalYearFocus" xlink:title="DocumentFiscalYearFocus" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="DocumentFiscalYearFocus" xlink:title="presentation: DocumentAndEntityInformationAbstract to DocumentFiscalYearFocus" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="DocumentFiscalPeriodFocus" xlink:title="DocumentFiscalPeriodFocus" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="DocumentFiscalPeriodFocus" xlink:title="presentation: DocumentAndEntityInformationAbstract to DocumentFiscalPeriodFocus" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:label="DocumentType" xlink:title="DocumentType" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="DocumentType" xlink:title="presentation: DocumentAndEntityInformationAbstract to DocumentType" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:label="AmendmentFlag" xlink:title="AmendmentFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="AmendmentFlag" xlink:title="presentation: DocumentAndEntityInformationAbstract to AmendmentFlag" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="DocumentPeriodEndDate" xlink:title="DocumentPeriodEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="DocumentPeriodEndDate" xlink:title="presentation: DocumentAndEntityInformationAbstract to DocumentPeriodEndDate" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://biotimeinc.com/role/CondensedConsolidatedBalanceSheetsUnaudited">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="StatementOfFinancialPositionAbstract" xlink:title="StatementOfFinancialPositionAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="AssetsAbstract" xlink:title="AssetsAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="AssetsCurrentAbstract" xlink:title="AssetsCurrentAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="CashAndCashEquivalentsAtCarryingValue" xlink:title="CashAndCashEquivalentsAtCarryingValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsCurrentAbstract" xlink:to="CashAndCashEquivalentsAtCarryingValue" xlink:title="presentation: AssetsCurrentAbstract to CashAndCashEquivalentsAtCarryingValue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="btx-20150331.xsd#btx_TradeAccountsAndGrantsReceivableNetCurrent" xlink:label="TradeAccountsAndGrantsReceivableNetCurrent" xlink:title="TradeAccountsAndGrantsReceivableNetCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsCurrentAbstract" xlink:to="TradeAccountsAndGrantsReceivableNetCurrent" xlink:title="presentation: AssetsCurrentAbstract to TradeAccountsAndGrantsReceivableNetCurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InventoryNet" xlink:label="InventoryNet" xlink:title="InventoryNet" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsCurrentAbstract" xlink:to="InventoryNet" xlink:title="presentation: AssetsCurrentAbstract to InventoryNet" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="btx-20150331.xsd#btx_TenantAllowanceReceivable" xlink:label="TenantAllowanceReceivable" xlink:title="TenantAllowanceReceivable" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsCurrentAbstract" xlink:to="TenantAllowanceReceivable" xlink:title="presentation: AssetsCurrentAbstract to TenantAllowanceReceivable" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="PrepaidExpenseAndOtherAssetsCurrent" xlink:title="PrepaidExpenseAndOtherAssetsCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsCurrentAbstract" xlink:to="PrepaidExpenseAndOtherAssetsCurrent" xlink:title="presentation: AssetsCurrentAbstract to PrepaidExpenseAndOtherAssetsCurrent" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="AssetsCurrent" xlink:title="AssetsCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsCurrentAbstract" xlink:to="AssetsCurrent" xlink:title="presentation: AssetsCurrentAbstract to AssetsCurrent" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsAbstract" xlink:to="AssetsCurrentAbstract" xlink:title="presentation: AssetsAbstract to AssetsCurrentAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="PropertyPlantAndEquipmentNet" xlink:title="PropertyPlantAndEquipmentNet" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsAbstract" xlink:to="PropertyPlantAndEquipmentNet" xlink:title="presentation: AssetsAbstract to PropertyPlantAndEquipmentNet" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="btx-20150331.xsd#btx_DeferredLicenseAndConsultingFees" xlink:label="DeferredLicenseAndConsultingFees" xlink:title="DeferredLicenseAndConsultingFees" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsAbstract" xlink:to="DeferredLicenseAndConsultingFees" xlink:title="presentation: AssetsAbstract to DeferredLicenseAndConsultingFees" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DepositsAssetsNoncurrent" xlink:label="DepositsAssetsNoncurrent" xlink:title="DepositsAssetsNoncurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsAbstract" xlink:to="DepositsAssetsNoncurrent" xlink:title="presentation: AssetsAbstract to DepositsAssetsNoncurrent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="OtherAssetsNoncurrent" xlink:title="OtherAssetsNoncurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsAbstract" xlink:to="OtherAssetsNoncurrent" xlink:title="presentation: AssetsAbstract to OtherAssetsNoncurrent" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="IntangibleAssetsNetExcludingGoodwill" xlink:title="IntangibleAssetsNetExcludingGoodwill" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsAbstract" xlink:to="IntangibleAssetsNetExcludingGoodwill" xlink:title="presentation: AssetsAbstract to IntangibleAssetsNetExcludingGoodwill" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Assets" xlink:label="Assets" xlink:title="Assets" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsAbstract" xlink:to="Assets" xlink:title="presentation: AssetsAbstract to Assets" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="AssetsAbstract" xlink:title="presentation: StatementOfFinancialPositionAbstract to AssetsAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="LiabilitiesAndStockholdersEquityAbstract" xlink:title="LiabilitiesAndStockholdersEquityAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="LiabilitiesCurrentAbstract" xlink:title="LiabilitiesCurrentAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="AccountsPayableAndAccruedLiabilitiesCurrent" xlink:title="AccountsPayableAndAccruedLiabilitiesCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesCurrentAbstract" xlink:to="AccountsPayableAndAccruedLiabilitiesCurrent" xlink:title="presentation: LiabilitiesCurrentAbstract to AccountsPayableAndAccruedLiabilitiesCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CapitalLeaseObligationsCurrent" xlink:label="CapitalLeaseObligationsCurrent" xlink:title="CapitalLeaseObligationsCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesCurrentAbstract" xlink:to="CapitalLeaseObligationsCurrent" xlink:title="presentation: LiabilitiesCurrentAbstract to CapitalLeaseObligationsCurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="btx-20150331.xsd#btx_RelatedPartyConvertibleDebtNetOfDiscount" xlink:label="RelatedPartyConvertibleDebtNetOfDiscount" xlink:title="RelatedPartyConvertibleDebtNetOfDiscount" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesCurrentAbstract" xlink:to="RelatedPartyConvertibleDebtNetOfDiscount" xlink:title="presentation: LiabilitiesCurrentAbstract to RelatedPartyConvertibleDebtNetOfDiscount" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="btx-20150331.xsd#btx_DeferredGrantIncome" xlink:label="DeferredGrantIncome" xlink:title="DeferredGrantIncome" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesCurrentAbstract" xlink:to="DeferredGrantIncome" xlink:title="presentation: LiabilitiesCurrentAbstract to DeferredGrantIncome" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="DeferredRevenueCurrent" xlink:title="DeferredRevenueCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesCurrentAbstract" xlink:to="DeferredRevenueCurrent" xlink:title="presentation: LiabilitiesCurrentAbstract to DeferredRevenueCurrent" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="LiabilitiesCurrent" xlink:title="LiabilitiesCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesCurrentAbstract" xlink:to="LiabilitiesCurrent" xlink:title="presentation: LiabilitiesCurrentAbstract to LiabilitiesCurrent" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesAndStockholdersEquityAbstract" xlink:to="LiabilitiesCurrentAbstract" xlink:title="presentation: LiabilitiesAndStockholdersEquityAbstract to LiabilitiesCurrentAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="LiabilitiesNoncurrentAbstract" xlink:title="LiabilitiesNoncurrentAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxLiabilitiesNoncurrent" xlink:label="DeferredTaxLiabilitiesNoncurrent" xlink:title="DeferredTaxLiabilitiesNoncurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesNoncurrentAbstract" xlink:to="DeferredTaxLiabilitiesNoncurrent" xlink:title="presentation: LiabilitiesNoncurrentAbstract to DeferredTaxLiabilitiesNoncurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent" xlink:label="DeferredRentCreditNoncurrent" xlink:title="DeferredRentCreditNoncurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesNoncurrentAbstract" xlink:to="DeferredRentCreditNoncurrent" xlink:title="presentation: LiabilitiesNoncurrentAbstract to DeferredRentCreditNoncurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="btx-20150331.xsd#btx_LandlordLiabilitiesNoncurrent" xlink:label="LandlordLiabilitiesNoncurrent" xlink:title="LandlordLiabilitiesNoncurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesNoncurrentAbstract" xlink:to="LandlordLiabilitiesNoncurrent" xlink:title="presentation: LiabilitiesNoncurrentAbstract to LandlordLiabilitiesNoncurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:label="LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:title="LongTermDebtAndCapitalLeaseObligationsCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesNoncurrentAbstract" xlink:to="LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:title="presentation: LiabilitiesNoncurrentAbstract to LongTermDebtAndCapitalLeaseObligationsCurrent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="OtherLiabilitiesNoncurrent" xlink:title="OtherLiabilitiesNoncurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesNoncurrentAbstract" xlink:to="OtherLiabilitiesNoncurrent" xlink:title="presentation: LiabilitiesNoncurrentAbstract to OtherLiabilitiesNoncurrent" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="LiabilitiesNoncurrent" xlink:title="LiabilitiesNoncurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesNoncurrentAbstract" xlink:to="LiabilitiesNoncurrent" xlink:title="presentation: LiabilitiesNoncurrentAbstract to LiabilitiesNoncurrent" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesAndStockholdersEquityAbstract" xlink:to="LiabilitiesNoncurrentAbstract" xlink:title="presentation: LiabilitiesAndStockholdersEquityAbstract to LiabilitiesNoncurrentAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="CommitmentsAndContingencies" xlink:title="CommitmentsAndContingencies" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesAndStockholdersEquityAbstract" xlink:to="CommitmentsAndContingencies" xlink:title="presentation: LiabilitiesAndStockholdersEquityAbstract to CommitmentsAndContingencies" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:label="StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:title="StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="PreferredStockValue" xlink:title="PreferredStockValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="PreferredStockValue" xlink:title="presentation: StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract to PreferredStockValue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockValue" xlink:label="CommonStockValue" xlink:title="CommonStockValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="CommonStockValue" xlink:title="presentation: StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract to CommonStockValue" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="AdditionalPaidInCapital" xlink:title="AdditionalPaidInCapital" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="AdditionalPaidInCapital" xlink:title="presentation: StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract to AdditionalPaidInCapital" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:title="AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:title="presentation: StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract to AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="RetainedEarningsAccumulatedDeficit" xlink:title="RetainedEarningsAccumulatedDeficit" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="RetainedEarningsAccumulatedDeficit" xlink:title="presentation: StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract to RetainedEarningsAccumulatedDeficit" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TreasuryStockValue" xlink:label="TreasuryStockValue" xlink:title="TreasuryStockValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="TreasuryStockValue" xlink:title="presentation: StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract to TreasuryStockValue" order="5.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="StockholdersEquity" xlink:title="StockholdersEquity" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="StockholdersEquity" xlink:title="presentation: StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract to StockholdersEquity" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MinorityInterest" xlink:label="MinorityInterest" xlink:title="MinorityInterest" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="MinorityInterest" xlink:title="presentation: StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract to MinorityInterest" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:title="StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:title="presentation: StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract to StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesAndStockholdersEquityAbstract" xlink:to="StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:title="presentation: LiabilitiesAndStockholdersEquityAbstract to StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="LiabilitiesAndStockholdersEquity" xlink:title="LiabilitiesAndStockholdersEquity" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesAndStockholdersEquityAbstract" xlink:to="LiabilitiesAndStockholdersEquity" xlink:title="presentation: LiabilitiesAndStockholdersEquityAbstract to LiabilitiesAndStockholdersEquity" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="LiabilitiesAndStockholdersEquityAbstract" xlink:title="presentation: StatementOfFinancialPositionAbstract to LiabilitiesAndStockholdersEquityAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://biotimeinc.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="StatementOfFinancialPositionAbstract" xlink:title="StatementOfFinancialPositionAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="LiabilitiesAndStockholdersEquityAbstract" xlink:title="LiabilitiesAndStockholdersEquityAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:label="StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:title="StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockNoParValue" xlink:label="PreferredStockNoParValue" xlink:title="PreferredStockNoParValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="PreferredStockNoParValue" xlink:title="presentation: StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract to PreferredStockNoParValue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="PreferredStockSharesAuthorized" xlink:title="PreferredStockSharesAuthorized" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="PreferredStockSharesAuthorized" xlink:title="presentation: StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract to PreferredStockSharesAuthorized" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="PreferredStockSharesIssued" xlink:title="PreferredStockSharesIssued" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="PreferredStockSharesIssued" xlink:title="presentation: StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract to PreferredStockSharesIssued" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="PreferredStockSharesOutstanding" xlink:title="PreferredStockSharesOutstanding" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="PreferredStockSharesOutstanding" xlink:title="presentation: StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract to PreferredStockSharesOutstanding" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockNoParValue" xlink:label="CommonStockNoParValue" xlink:title="CommonStockNoParValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="CommonStockNoParValue" xlink:title="presentation: StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract to CommonStockNoParValue" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="CommonStockSharesAuthorized" xlink:title="CommonStockSharesAuthorized" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="CommonStockSharesAuthorized" xlink:title="presentation: StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract to CommonStockSharesAuthorized" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="CommonStockSharesIssued" xlink:title="CommonStockSharesIssued" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="CommonStockSharesIssued" xlink:title="presentation: StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract to CommonStockSharesIssued" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="CommonStockSharesOutstanding" xlink:title="CommonStockSharesOutstanding" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="CommonStockSharesOutstanding" xlink:title="presentation: StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract to CommonStockSharesOutstanding" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TreasuryStockShares" xlink:label="TreasuryStockShares" xlink:title="TreasuryStockShares" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="TreasuryStockShares" xlink:title="presentation: StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract to TreasuryStockShares" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesAndStockholdersEquityAbstract" xlink:to="StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:title="presentation: LiabilitiesAndStockholdersEquityAbstract to StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="LiabilitiesAndStockholdersEquityAbstract" xlink:title="presentation: StatementOfFinancialPositionAbstract to LiabilitiesAndStockholdersEquityAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://biotimeinc.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="IncomeStatementAbstract" xlink:title="IncomeStatementAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SalesRevenueNetAbstract" xlink:label="SalesRevenueNetAbstract" xlink:title="SalesRevenueNetAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LicensesRevenue" xlink:label="LicensesRevenue" xlink:title="LicensesRevenue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SalesRevenueNetAbstract" xlink:to="LicensesRevenue" xlink:title="presentation: SalesRevenueNetAbstract to LicensesRevenue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RoyaltyRevenue" xlink:label="RoyaltyRevenue" xlink:title="RoyaltyRevenue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SalesRevenueNetAbstract" xlink:to="RoyaltyRevenue" xlink:title="presentation: SalesRevenueNetAbstract to RoyaltyRevenue" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RevenueFromGrants" xlink:label="RevenueFromGrants" xlink:title="RevenueFromGrants" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SalesRevenueNetAbstract" xlink:to="RevenueFromGrants" xlink:title="presentation: SalesRevenueNetAbstract to RevenueFromGrants" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SalesRevenueGoodsNet" xlink:label="SalesRevenueGoodsNet" xlink:title="SalesRevenueGoodsNet" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SalesRevenueNetAbstract" xlink:to="SalesRevenueGoodsNet" xlink:title="presentation: SalesRevenueNetAbstract to SalesRevenueGoodsNet" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SalesRevenueNet" xlink:label="SalesRevenueNet" xlink:title="SalesRevenueNet" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SalesRevenueNetAbstract" xlink:to="SalesRevenueNet" xlink:title="presentation: SalesRevenueNetAbstract to SalesRevenueNet" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="SalesRevenueNetAbstract" xlink:title="presentation: IncomeStatementAbstract to SalesRevenueNetAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CostOfRevenue" xlink:label="CostOfRevenue" xlink:title="CostOfRevenue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="CostOfRevenue" xlink:title="presentation: IncomeStatementAbstract to CostOfRevenue" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_GrossProfit" xlink:label="GrossProfit" xlink:title="GrossProfit" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="GrossProfit" xlink:title="presentation: IncomeStatementAbstract to GrossProfit" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="OperatingExpensesAbstract" xlink:title="OperatingExpensesAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="ResearchAndDevelopmentExpense" xlink:title="ResearchAndDevelopmentExpense" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingExpensesAbstract" xlink:to="ResearchAndDevelopmentExpense" xlink:title="presentation: OperatingExpensesAbstract to ResearchAndDevelopmentExpense" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="GeneralAndAdministrativeExpense" xlink:title="GeneralAndAdministrativeExpense" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingExpensesAbstract" xlink:to="GeneralAndAdministrativeExpense" xlink:title="presentation: OperatingExpensesAbstract to GeneralAndAdministrativeExpense" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="OperatingExpenses" xlink:title="OperatingExpenses" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingExpensesAbstract" xlink:to="OperatingExpenses" xlink:title="presentation: OperatingExpensesAbstract to OperatingExpenses" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="OperatingExpensesAbstract" xlink:title="presentation: IncomeStatementAbstract to OperatingExpensesAbstract" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="OperatingIncomeLoss" xlink:title="OperatingIncomeLoss" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="OperatingIncomeLoss" xlink:title="presentation: IncomeStatementAbstract to OperatingIncomeLoss" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="NonoperatingIncomeExpenseAbstract" xlink:title="NonoperatingIncomeExpenseAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="InterestIncomeExpenseNet" xlink:title="InterestIncomeExpenseNet" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NonoperatingIncomeExpenseAbstract" xlink:to="InterestIncomeExpenseNet" xlink:title="presentation: NonoperatingIncomeExpenseAbstract to InterestIncomeExpenseNet" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="OtherNonoperatingIncome" xlink:title="OtherNonoperatingIncome" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NonoperatingIncomeExpenseAbstract" xlink:to="OtherNonoperatingIncome" xlink:title="presentation: NonoperatingIncomeExpenseAbstract to OtherNonoperatingIncome" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="NonoperatingIncomeExpense" xlink:title="NonoperatingIncomeExpense" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NonoperatingIncomeExpenseAbstract" xlink:to="NonoperatingIncomeExpense" xlink:title="presentation: NonoperatingIncomeExpenseAbstract to NonoperatingIncomeExpense" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="NonoperatingIncomeExpenseAbstract" xlink:title="presentation: IncomeStatementAbstract to NonoperatingIncomeExpenseAbstract" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:title="IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:title="presentation: IncomeStatementAbstract to IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="DeferredIncomeTaxExpenseBenefit" xlink:title="DeferredIncomeTaxExpenseBenefit" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="DeferredIncomeTaxExpenseBenefit" xlink:title="presentation: IncomeStatementAbstract to DeferredIncomeTaxExpenseBenefit" order="7.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProfitLoss" xlink:label="ProfitLoss" xlink:title="ProfitLoss" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="ProfitLoss" xlink:title="presentation: IncomeStatementAbstract to ProfitLoss" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="NetIncomeLossAttributableToNoncontrollingInterest" xlink:title="NetIncomeLossAttributableToNoncontrollingInterest" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="NetIncomeLossAttributableToNoncontrollingInterest" xlink:title="presentation: IncomeStatementAbstract to NetIncomeLossAttributableToNoncontrollingInterest" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="NetIncomeLossAvailableToCommonStockholdersBasic" xlink:title="NetIncomeLossAvailableToCommonStockholdersBasic" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="NetIncomeLossAvailableToCommonStockholdersBasic" xlink:title="presentation: IncomeStatementAbstract to NetIncomeLossAvailableToCommonStockholdersBasic" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="EarningsPerShareBasicAndDiluted" xlink:title="EarningsPerShareBasicAndDiluted" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="EarningsPerShareBasicAndDiluted" xlink:title="presentation: IncomeStatementAbstract to EarningsPerShareBasicAndDiluted" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:title="WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:title="presentation: IncomeStatementAbstract to WeightedAverageNumberOfShareOutstandingBasicAndDiluted" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://biotimeinc.com/role/CondensedConsolidatedStatementsOfComprehensiveLossUnaudited">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:title="StatementOfIncomeAndComprehensiveIncomeAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProfitLoss" xlink:label="ProfitLoss" xlink:title="ProfitLoss" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="ProfitLoss" xlink:title="presentation: StatementOfIncomeAndComprehensiveIncomeAbstract to ProfitLoss" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:label="OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:title="OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxAbstract" xlink:label="OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxAbstract" xlink:title="OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:label="OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:title="OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxAbstract" xlink:to="OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:title="presentation: OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxAbstract to OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:title="OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxAbstract" xlink:to="OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:title="presentation: OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxAbstract to OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxAbstract" xlink:title="presentation: OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract to OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="ComprehensiveIncomeNetOfTax" xlink:title="ComprehensiveIncomeNetOfTax" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="ComprehensiveIncomeNetOfTax" xlink:title="presentation: OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract to ComprehensiveIncomeNetOfTax" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="NetIncomeLossAttributableToNoncontrollingInterest" xlink:title="NetIncomeLossAttributableToNoncontrollingInterest" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="NetIncomeLossAttributableToNoncontrollingInterest" xlink:title="presentation: OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract to NetIncomeLossAttributableToNoncontrollingInterest" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest" xlink:label="OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest" xlink:title="OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest" xlink:title="presentation: OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract to OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:title="presentation: StatementOfIncomeAndComprehensiveIncomeAbstract to OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://biotimeinc.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="StatementOfCashFlowsAbstract" xlink:title="StatementOfCashFlowsAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:label="NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:title="NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="NetIncomeLoss" xlink:title="NetIncomeLoss" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="NetIncomeLoss" xlink:title="presentation: NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract to NetIncomeLoss" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="NetIncomeLossAttributableToNoncontrollingInterest" xlink:title="NetIncomeLossAttributableToNoncontrollingInterest" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="NetIncomeLossAttributableToNoncontrollingInterest" xlink:title="presentation: NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract to NetIncomeLossAttributableToNoncontrollingInterest" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:title="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Depreciation" xlink:label="Depreciation" xlink:title="Depreciation" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="Depreciation" xlink:title="presentation: AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to Depreciation" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="AmortizationOfIntangibleAssets" xlink:title="AmortizationOfIntangibleAssets" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="AmortizationOfIntangibleAssets" xlink:title="presentation: AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to AmortizationOfIntangibleAssets" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="btx-20150331.xsd#btx_AmortizationOfDeferredConsultingFees" xlink:label="AmortizationOfDeferredConsultingFees" xlink:title="AmortizationOfDeferredConsultingFees" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="AmortizationOfDeferredConsultingFees" xlink:title="presentation: AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to AmortizationOfDeferredConsultingFees" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="btx-20150331.xsd#btx_AmortizationOfDeferredLicenseFees" xlink:label="AmortizationOfDeferredLicenseFees" xlink:title="AmortizationOfDeferredLicenseFees" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="AmortizationOfDeferredLicenseFees" xlink:title="presentation: AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to AmortizationOfDeferredLicenseFees" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AmortizationOfDeferredCharges" xlink:label="AmortizationOfDeferredCharges" xlink:title="AmortizationOfDeferredCharges" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="AmortizationOfDeferredCharges" xlink:title="presentation: AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to AmortizationOfDeferredCharges" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="btx-20150331.xsd#btx_AmortizationOfStockBasedPrepaidRent" xlink:label="AmortizationOfStockBasedPrepaidRent" xlink:title="AmortizationOfStockBasedPrepaidRent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="AmortizationOfStockBasedPrepaidRent" xlink:title="presentation: AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to AmortizationOfStockBasedPrepaidRent" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="ShareBasedCompensation" xlink:title="ShareBasedCompensation" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="ShareBasedCompensation" xlink:title="presentation: AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to ShareBasedCompensation" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="AmortizationOfDebtDiscountPremium" xlink:title="AmortizationOfDebtDiscountPremium" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="AmortizationOfDebtDiscountPremium" xlink:title="presentation: AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to AmortizationOfDebtDiscountPremium" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="btx-20150331.xsd#btx_AccruedInterestOnConvertibleDebt" xlink:label="AccruedInterestOnConvertibleDebt" xlink:title="AccruedInterestOnConvertibleDebt" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="AccruedInterestOnConvertibleDebt" xlink:title="presentation: AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to AccruedInterestOnConvertibleDebt" order="8.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:label="ImpairmentOfLongLivedAssetsHeldForUse" xlink:title="ImpairmentOfLongLivedAssetsHeldForUse" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="ImpairmentOfLongLivedAssetsHeldForUse" xlink:title="presentation: AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to ImpairmentOfLongLivedAssetsHeldForUse" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="DeferredIncomeTaxExpenseBenefit" xlink:title="DeferredIncomeTaxExpenseBenefit" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="DeferredIncomeTaxExpenseBenefit" xlink:title="presentation: AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to DeferredIncomeTaxExpenseBenefit" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="btx-20150331.xsd#btx_ProceedsFromDeferredGrantIncome" xlink:label="ProceedsFromDeferredGrantIncome" xlink:title="ProceedsFromDeferredGrantIncome" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="ProceedsFromDeferredGrantIncome" xlink:title="presentation: AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to ProceedsFromDeferredGrantIncome" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="IncreaseDecreaseInOperatingCapitalAbstract" xlink:title="IncreaseDecreaseInOperatingCapitalAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="IncreaseDecreaseInAccountsReceivable" xlink:title="IncreaseDecreaseInAccountsReceivable" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="IncreaseDecreaseInAccountsReceivable" xlink:title="presentation: IncreaseDecreaseInOperatingCapitalAbstract to IncreaseDecreaseInAccountsReceivable" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="btx-20150331.xsd#btx_IncreaseDecreaseInGrantReceivable" xlink:label="IncreaseDecreaseInGrantReceivable" xlink:title="IncreaseDecreaseInGrantReceivable" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="IncreaseDecreaseInGrantReceivable" xlink:title="presentation: IncreaseDecreaseInOperatingCapitalAbstract to IncreaseDecreaseInGrantReceivable" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="IncreaseDecreaseInInventories" xlink:title="IncreaseDecreaseInInventories" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="IncreaseDecreaseInInventories" xlink:title="presentation: IncreaseDecreaseInOperatingCapitalAbstract to IncreaseDecreaseInInventories" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:title="IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:title="presentation: IncreaseDecreaseInOperatingCapitalAbstract to IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:title="IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:title="presentation: IncreaseDecreaseInOperatingCapitalAbstract to IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:label="IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:title="IncreaseDecreaseInOtherNoncurrentLiabilities" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:title="presentation: IncreaseDecreaseInOperatingCapitalAbstract to IncreaseDecreaseInOtherNoncurrentLiabilities" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="btx-20150331.xsd#btx_IncreaseDecreaseInDeferredRentLiabilities" xlink:label="IncreaseDecreaseInDeferredRentLiabilities" xlink:title="IncreaseDecreaseInDeferredRentLiabilities" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="IncreaseDecreaseInDeferredRentLiabilities" xlink:title="presentation: IncreaseDecreaseInOperatingCapitalAbstract to IncreaseDecreaseInDeferredRentLiabilities" order="6.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="IncreaseDecreaseInDeferredRevenue" xlink:title="IncreaseDecreaseInDeferredRevenue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="IncreaseDecreaseInDeferredRevenue" xlink:title="presentation: IncreaseDecreaseInOperatingCapitalAbstract to IncreaseDecreaseInDeferredRevenue" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="IncreaseDecreaseInOperatingCapitalAbstract" xlink:title="presentation: AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to IncreaseDecreaseInOperatingCapitalAbstract" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:title="presentation: NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract to AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:title="NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:title="presentation: NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract to NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:title="presentation: StatementOfCashFlowsAbstract to NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:label="NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:title="NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="PaymentsToAcquirePropertyPlantAndEquipment" xlink:title="PaymentsToAcquirePropertyPlantAndEquipment" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="PaymentsToAcquirePropertyPlantAndEquipment" xlink:title="presentation: NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract to PaymentsToAcquirePropertyPlantAndEquipment" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaymentsForCapitalImprovements" xlink:label="PaymentsForCapitalImprovements" xlink:title="PaymentsForCapitalImprovements" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="PaymentsForCapitalImprovements" xlink:title="presentation: NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract to PaymentsForCapitalImprovements" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:title="ProceedsFromSaleOfPropertyPlantAndEquipment" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:title="presentation: NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract to ProceedsFromSaleOfPropertyPlantAndEquipment" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="btx-20150331.xsd#btx_SecurityDepositReceived" xlink:label="SecurityDepositReceived" xlink:title="SecurityDepositReceived" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="SecurityDepositReceived" xlink:title="presentation: NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract to SecurityDepositReceived" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:label="NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:title="NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:title="presentation: NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract to NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:title="presentation: StatementOfCashFlowsAbstract to NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:label="NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:title="NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="ProceedsFromStockOptionsExercised" xlink:title="ProceedsFromStockOptionsExercised" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="ProceedsFromStockOptionsExercised" xlink:title="presentation: NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract to ProceedsFromStockOptionsExercised" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:label="ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:title="ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:title="presentation: NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract to ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="ProceedsFromIssuanceOfCommonStock" xlink:title="ProceedsFromIssuanceOfCommonStock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="ProceedsFromIssuanceOfCommonStock" xlink:title="presentation: NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract to ProceedsFromIssuanceOfCommonStock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="btx-20150331.xsd#btx_FeesPaidOnSaleOfCommonShares" xlink:label="FeesPaidOnSaleOfCommonShares" xlink:title="FeesPaidOnSaleOfCommonShares" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="FeesPaidOnSaleOfCommonShares" xlink:title="presentation: NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract to FeesPaidOnSaleOfCommonShares" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromSaleOfTreasuryStock" xlink:label="ProceedsFromSaleOfTreasuryStock" xlink:title="ProceedsFromSaleOfTreasuryStock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="ProceedsFromSaleOfTreasuryStock" xlink:title="presentation: NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract to ProceedsFromSaleOfTreasuryStock" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="btx-20150331.xsd#btx_ProceedsFromConstructionInProgress" xlink:label="ProceedsFromConstructionInProgress" xlink:title="ProceedsFromConstructionInProgress" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="ProceedsFromConstructionInProgress" xlink:title="presentation: NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract to ProceedsFromConstructionInProgress" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CapitalLeasesIncomeStatementAmortizationExpense" xlink:label="CapitalLeasesIncomeStatementAmortizationExpense" xlink:title="CapitalLeasesIncomeStatementAmortizationExpense" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="CapitalLeasesIncomeStatementAmortizationExpense" xlink:title="presentation: NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract to CapitalLeasesIncomeStatementAmortizationExpense" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromMinorityShareholders" xlink:label="ProceedsFromMinorityShareholders" xlink:title="ProceedsFromMinorityShareholders" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="ProceedsFromMinorityShareholders" xlink:title="presentation: NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract to ProceedsFromMinorityShareholders" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="btx-20150331.xsd#btx_FeesPaidOnSaleOfCommonSharesOfSubsidiary" xlink:label="FeesPaidOnSaleOfCommonSharesOfSubsidiary" xlink:title="FeesPaidOnSaleOfCommonSharesOfSubsidiary" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="FeesPaidOnSaleOfCommonSharesOfSubsidiary" xlink:title="presentation: NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract to FeesPaidOnSaleOfCommonSharesOfSubsidiary" order="8.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:label="NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:title="NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:title="presentation: NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract to NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:title="presentation: StatementOfCashFlowsAbstract to NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:label="EffectOfExchangeRateOnCashAndCashEquivalents" xlink:title="EffectOfExchangeRateOnCashAndCashEquivalents" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="EffectOfExchangeRateOnCashAndCashEquivalents" xlink:title="presentation: StatementOfCashFlowsAbstract to EffectOfExchangeRateOnCashAndCashEquivalents" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:title="CashAndCashEquivalentsPeriodIncreaseDecrease" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:title="presentation: StatementOfCashFlowsAbstract to CashAndCashEquivalentsPeriodIncreaseDecrease" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsAbstract" xlink:label="CashAndCashEquivalentsAbstract" xlink:title="CashAndCashEquivalentsAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="CashAndCashEquivalentsAtCarryingValue" xlink:title="CashAndCashEquivalentsAtCarryingValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CashAndCashEquivalentsAbstract" xlink:to="CashAndCashEquivalentsAtCarryingValue" xlink:title="presentation: CashAndCashEquivalentsAbstract to CashAndCashEquivalentsAtCarryingValue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="CashAndCashEquivalentsAtCarryingValue_2" xlink:title="CashAndCashEquivalentsAtCarryingValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CashAndCashEquivalentsAbstract" xlink:to="CashAndCashEquivalentsAtCarryingValue_2" xlink:title="presentation: CashAndCashEquivalentsAbstract to CashAndCashEquivalentsAtCarryingValue" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="CashAndCashEquivalentsAbstract" xlink:title="presentation: StatementOfCashFlowsAbstract to CashAndCashEquivalentsAbstract" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://biotimeinc.com/role/OrganizationBasisOfPresentationAndLiquidity">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:title="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:title="OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:title="presentation: OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract to OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://biotimeinc.com/role/SummaryOfSignificantAccountingPolicies">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="AccountingPoliciesAbstract" xlink:title="AccountingPoliciesAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="SignificantAccountingPoliciesTextBlock" xlink:title="SignificantAccountingPoliciesTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="SignificantAccountingPoliciesTextBlock" xlink:title="presentation: AccountingPoliciesAbstract to SignificantAccountingPoliciesTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://biotimeinc.com/role/Inventory">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="InventoryDisclosureAbstract" xlink:title="InventoryDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="InventoryDisclosureTextBlock" xlink:title="InventoryDisclosureTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InventoryDisclosureAbstract" xlink:to="InventoryDisclosureTextBlock" xlink:title="presentation: InventoryDisclosureAbstract to InventoryDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://biotimeinc.com/role/EquipmentNetAndConstructionInProgress">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="PropertyPlantAndEquipmentAbstract" xlink:title="PropertyPlantAndEquipmentAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="PropertyPlantAndEquipmentDisclosureTextBlock" xlink:title="PropertyPlantAndEquipmentDisclosureTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentAbstract" xlink:to="PropertyPlantAndEquipmentDisclosureTextBlock" xlink:title="presentation: PropertyPlantAndEquipmentAbstract to PropertyPlantAndEquipmentDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://biotimeinc.com/role/IntangibleAssetsNet">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:title="GoodwillAndIntangibleAssetsDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:label="IntangibleAssetsDisclosureTextBlock" xlink:title="IntangibleAssetsDisclosureTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="IntangibleAssetsDisclosureTextBlock" xlink:title="presentation: GoodwillAndIntangibleAssetsDisclosureAbstract to IntangibleAssetsDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://biotimeinc.com/role/RoyaltyObligationAndDeferredLicenseFees">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredRevenueDisclosureAbstract" xlink:label="DeferredRevenueDisclosureAbstract" xlink:title="DeferredRevenueDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredRevenueDisclosureTextBlock" xlink:label="DeferredRevenueDisclosureTextBlock" xlink:title="DeferredRevenueDisclosureTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredRevenueDisclosureAbstract" xlink:to="DeferredRevenueDisclosureTextBlock" xlink:title="presentation: DeferredRevenueDisclosureAbstract to DeferredRevenueDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://biotimeinc.com/role/AccountsPayableAndAccruedLiabilities">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="PayablesAndAccrualsAbstract" xlink:title="PayablesAndAccrualsAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:title="AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PayablesAndAccrualsAbstract" xlink:to="AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:title="presentation: PayablesAndAccrualsAbstract to AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://biotimeinc.com/role/RelatedPartyTransactionsAndRelatedPartyConvertibleDebt">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="RelatedPartyTransactionsAbstract" xlink:title="RelatedPartyTransactionsAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="RelatedPartyTransactionsDisclosureTextBlock" xlink:title="RelatedPartyTransactionsDisclosureTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsAbstract" xlink:to="RelatedPartyTransactionsDisclosureTextBlock" xlink:title="presentation: RelatedPartyTransactionsAbstract to RelatedPartyTransactionsDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://biotimeinc.com/role/ShareholdersEquity">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityAbstract" xlink:label="EquityAbstract" xlink:title="EquityAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="StockholdersEquityNoteDisclosureTextBlock" xlink:title="StockholdersEquityNoteDisclosureTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityAbstract" xlink:to="StockholdersEquityNoteDisclosureTextBlock" xlink:title="presentation: EquityAbstract to StockholdersEquityNoteDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://biotimeinc.com/role/SalesOfBiotimeCommonSharesBySubsidiaries">
    <link:loc xlink:type="locator" xlink:href="btx-20150331.xsd#btx_SalesOfBioTimeCommonSharesBySubsidiariesAbstract" xlink:label="SalesOfBioTimeCommonSharesBySubsidiariesAbstract" xlink:title="SalesOfBioTimeCommonSharesBySubsidiariesAbstract" />
    <link:loc xlink:type="locator" xlink:href="btx-20150331.xsd#btx_SalesOfBiotimeCommonSharesBySubsidiariesTextBlock" xlink:label="SalesOfBiotimeCommonSharesBySubsidiariesTextBlock" xlink:title="SalesOfBiotimeCommonSharesBySubsidiariesTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SalesOfBioTimeCommonSharesBySubsidiariesAbstract" xlink:to="SalesOfBiotimeCommonSharesBySubsidiariesTextBlock" xlink:title="presentation: SalesOfBioTimeCommonSharesBySubsidiariesAbstract to SalesOfBiotimeCommonSharesBySubsidiariesTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://biotimeinc.com/role/SegmentInformation">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SegmentReportingAbstract" xlink:label="SegmentReportingAbstract" xlink:title="SegmentReportingAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="SegmentReportingDisclosureTextBlock" xlink:title="SegmentReportingDisclosureTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SegmentReportingAbstract" xlink:to="SegmentReportingDisclosureTextBlock" xlink:title="presentation: SegmentReportingAbstract to SegmentReportingDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://biotimeinc.com/role/SubsequentEvents">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="SubsequentEventsAbstract" xlink:title="SubsequentEventsAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="SubsequentEventsTextBlock" xlink:title="SubsequentEventsTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsAbstract" xlink:to="SubsequentEventsTextBlock" xlink:title="presentation: SubsequentEventsAbstract to SubsequentEventsTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://biotimeinc.com/role/SummaryOfSignificantAccountingPoliciesPolicies">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="AccountingPoliciesAbstract" xlink:title="AccountingPoliciesAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="RevenueRecognitionPolicyTextBlock" xlink:title="RevenueRecognitionPolicyTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="RevenueRecognitionPolicyTextBlock" xlink:title="presentation: AccountingPoliciesAbstract to RevenueRecognitionPolicyTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="CashAndCashEquivalentsPolicyTextBlock" xlink:title="CashAndCashEquivalentsPolicyTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="CashAndCashEquivalentsPolicyTextBlock" xlink:title="presentation: AccountingPoliciesAbstract to CashAndCashEquivalentsPolicyTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:label="TradeAndOtherAccountsReceivablePolicy" xlink:title="TradeAndOtherAccountsReceivablePolicy" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="TradeAndOtherAccountsReceivablePolicy" xlink:title="presentation: AccountingPoliciesAbstract to TradeAndOtherAccountsReceivablePolicy" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="ConcentrationRiskCreditRisk" xlink:title="ConcentrationRiskCreditRisk" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="ConcentrationRiskCreditRisk" xlink:title="presentation: AccountingPoliciesAbstract to ConcentrationRiskCreditRisk" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="InventoryPolicyTextBlock" xlink:title="InventoryPolicyTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="InventoryPolicyTextBlock" xlink:title="presentation: AccountingPoliciesAbstract to InventoryPolicyTextBlock" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="PropertyPlantAndEquipmentPolicyTextBlock" xlink:title="PropertyPlantAndEquipmentPolicyTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="PropertyPlantAndEquipmentPolicyTextBlock" xlink:title="presentation: AccountingPoliciesAbstract to PropertyPlantAndEquipmentPolicyTextBlock" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:label="GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:title="GoodwillAndIntangibleAssetsPolicyTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:title="presentation: AccountingPoliciesAbstract to GoodwillAndIntangibleAssetsPolicyTextBlock" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="btx-20150331.xsd#btx_TreasuryStockPolicyTextBlock" xlink:label="TreasuryStockPolicyTextBlock" xlink:title="TreasuryStockPolicyTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="TreasuryStockPolicyTextBlock" xlink:title="presentation: AccountingPoliciesAbstract to TreasuryStockPolicyTextBlock" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="btx-20150331.xsd#btx_WarrantsToPurchaseCommonStockPolicyTextBlock" xlink:label="WarrantsToPurchaseCommonStockPolicyTextBlock" xlink:title="WarrantsToPurchaseCommonStockPolicyTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="WarrantsToPurchaseCommonStockPolicyTextBlock" xlink:title="presentation: AccountingPoliciesAbstract to WarrantsToPurchaseCommonStockPolicyTextBlock" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CostOfSalesPolicyTextBlock" xlink:label="CostOfSalesPolicyTextBlock" xlink:title="CostOfSalesPolicyTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="CostOfSalesPolicyTextBlock" xlink:title="presentation: AccountingPoliciesAbstract to CostOfSalesPolicyTextBlock" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicyCostsIncurredToRenewOrExtend" xlink:label="IntangibleAssetsFiniteLivedPolicyCostsIncurredToRenewOrExtend" xlink:title="IntangibleAssetsFiniteLivedPolicyCostsIncurredToRenewOrExtend" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="IntangibleAssetsFiniteLivedPolicyCostsIncurredToRenewOrExtend" xlink:title="presentation: AccountingPoliciesAbstract to IntangibleAssetsFiniteLivedPolicyCostsIncurredToRenewOrExtend" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:label="PriorPeriodReclassificationAdjustmentDescription" xlink:title="PriorPeriodReclassificationAdjustmentDescription" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="PriorPeriodReclassificationAdjustmentDescription" xlink:title="presentation: AccountingPoliciesAbstract to PriorPeriodReclassificationAdjustmentDescription" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="ResearchAndDevelopmentExpensePolicy" xlink:title="ResearchAndDevelopmentExpensePolicy" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="ResearchAndDevelopmentExpensePolicy" xlink:title="presentation: AccountingPoliciesAbstract to ResearchAndDevelopmentExpensePolicy" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:label="SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:title="SellingGeneralAndAdministrativeExpensesPolicyTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:title="presentation: AccountingPoliciesAbstract to SellingGeneralAndAdministrativeExpensesPolicyTextBlock" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:title="ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:title="presentation: AccountingPoliciesAbstract to ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="IncomeTaxPolicyTextBlock" xlink:title="IncomeTaxPolicyTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="IncomeTaxPolicyTextBlock" xlink:title="presentation: AccountingPoliciesAbstract to IncomeTaxPolicyTextBlock" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:title="ShareBasedCompensationOptionAndIncentivePlansPolicy" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:title="presentation: AccountingPoliciesAbstract to ShareBasedCompensationOptionAndIncentivePlansPolicy" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:title="ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:title="presentation: AccountingPoliciesAbstract to ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredChargesPolicyTextBlock" xlink:label="DeferredChargesPolicyTextBlock" xlink:title="DeferredChargesPolicyTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="DeferredChargesPolicyTextBlock" xlink:title="presentation: AccountingPoliciesAbstract to DeferredChargesPolicyTextBlock" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="EarningsPerSharePolicyTextBlock" xlink:title="EarningsPerSharePolicyTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="EarningsPerSharePolicyTextBlock" xlink:title="presentation: AccountingPoliciesAbstract to EarningsPerSharePolicyTextBlock" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="FairValueOfFinancialInstrumentsPolicy" xlink:title="FairValueOfFinancialInstrumentsPolicy" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="FairValueOfFinancialInstrumentsPolicy" xlink:title="presentation: AccountingPoliciesAbstract to FairValueOfFinancialInstrumentsPolicy" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:title="NewAccountingPronouncementsPolicyPolicyTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:title="presentation: AccountingPoliciesAbstract to NewAccountingPronouncementsPolicyPolicyTextBlock" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://biotimeinc.com/role/OrganizationBasisOfPresentationAndLiquidityTables">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:title="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTextBlock" xlink:label="ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTextBlock" xlink:title="ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTextBlock" xlink:title="presentation: OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract to ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://biotimeinc.com/role/EquipmentNetAndConstructionInProgressTables">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="PropertyPlantAndEquipmentAbstract" xlink:title="PropertyPlantAndEquipmentAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="PropertyPlantAndEquipmentTextBlock" xlink:title="PropertyPlantAndEquipmentTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentAbstract" xlink:to="PropertyPlantAndEquipmentTextBlock" xlink:title="presentation: PropertyPlantAndEquipmentAbstract to PropertyPlantAndEquipmentTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://biotimeinc.com/role/IntangibleAssetsNetTables">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:title="GoodwillAndIntangibleAssetsDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:label="ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:title="ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:title="presentation: GoodwillAndIntangibleAssetsDisclosureAbstract to ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://biotimeinc.com/role/RoyaltyObligationAndDeferredLicenseFeesTables">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredRevenueDisclosureAbstract" xlink:label="DeferredRevenueDisclosureAbstract" xlink:title="DeferredRevenueDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="btx-20150331.xsd#btx_ScheduleOfExpectedAmortizationDeferredLicenseExpenseTableTextBlock" xlink:label="ScheduleOfExpectedAmortizationDeferredLicenseExpenseTableTextBlock" xlink:title="ScheduleOfExpectedAmortizationDeferredLicenseExpenseTableTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredRevenueDisclosureAbstract" xlink:to="ScheduleOfExpectedAmortizationDeferredLicenseExpenseTableTextBlock" xlink:title="presentation: DeferredRevenueDisclosureAbstract to ScheduleOfExpectedAmortizationDeferredLicenseExpenseTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://biotimeinc.com/role/AccountsPayableAndAccruedLiabilitiesTables">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="PayablesAndAccrualsAbstract" xlink:title="PayablesAndAccrualsAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:label="ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:title="ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PayablesAndAccrualsAbstract" xlink:to="ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:title="presentation: PayablesAndAccrualsAbstract to ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://biotimeinc.com/role/OrganizationBasisOfPresentationAndLiquidityDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:title="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MinorityInterestTable" xlink:label="MinorityInterestTable" xlink:title="MinorityInterestTable" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="LegalEntityAxis" xlink:title="LegalEntityAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="EntityDomain" xlink:title="EntityDomain" />
    <link:loc xlink:type="locator" xlink:href="btx-20150331.xsd#btx_AsteriasBiotherapeuticsMember" xlink:label="AsteriasBiotherapeuticsMember" xlink:title="AsteriasBiotherapeuticsMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EntityDomain" xlink:to="AsteriasBiotherapeuticsMember" xlink:title="presentation: EntityDomain to AsteriasBiotherapeuticsMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="btx-20150331.xsd#btx_BiotimeAsiaLimitedMember" xlink:label="BiotimeAsiaLimitedMember" xlink:title="BiotimeAsiaLimitedMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EntityDomain" xlink:to="BiotimeAsiaLimitedMember" xlink:title="presentation: EntityDomain to BiotimeAsiaLimitedMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="btx-20150331.xsd#btx_CellCureNeurosciencesLtdMember" xlink:label="CellCureNeurosciencesLtdMember" xlink:title="CellCureNeurosciencesLtdMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EntityDomain" xlink:to="CellCureNeurosciencesLtdMember" xlink:title="presentation: EntityDomain to CellCureNeurosciencesLtdMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="btx-20150331.xsd#btx_EsCellInternationalPteLtdMember" xlink:label="EsCellInternationalPteLtdMember" xlink:title="EsCellInternationalPteLtdMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EntityDomain" xlink:to="EsCellInternationalPteLtdMember" xlink:title="presentation: EntityDomain to EsCellInternationalPteLtdMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="btx-20150331.xsd#btx_LifemapSciencesIncMember" xlink:label="LifemapSciencesIncMember" xlink:title="LifemapSciencesIncMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EntityDomain" xlink:to="LifemapSciencesIncMember" xlink:title="presentation: EntityDomain to LifemapSciencesIncMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="btx-20150331.xsd#btx_LifemapSciencesLtdMember" xlink:label="LifemapSciencesLtdMember" xlink:title="LifemapSciencesLtdMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EntityDomain" xlink:to="LifemapSciencesLtdMember" xlink:title="presentation: EntityDomain to LifemapSciencesLtdMember" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="btx-20150331.xsd#btx_LifemapSolutionsIncMember" xlink:label="LifemapSolutionsIncMember" xlink:title="LifemapSolutionsIncMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EntityDomain" xlink:to="LifemapSolutionsIncMember" xlink:title="presentation: EntityDomain to LifemapSolutionsIncMember" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="btx-20150331.xsd#btx_OncocyteCorporationMember" xlink:label="OncocyteCorporationMember" xlink:title="OncocyteCorporationMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EntityDomain" xlink:to="OncocyteCorporationMember" xlink:title="presentation: EntityDomain to OncocyteCorporationMember" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="btx-20150331.xsd#btx_OrthocyteCorporationMember" xlink:label="OrthocyteCorporationMember" xlink:title="OrthocyteCorporationMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EntityDomain" xlink:to="OrthocyteCorporationMember" xlink:title="presentation: EntityDomain to OrthocyteCorporationMember" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="btx-20150331.xsd#btx_RecyteTherapeuticsIncMember" xlink:label="RecyteTherapeuticsIncMember" xlink:title="RecyteTherapeuticsIncMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EntityDomain" xlink:to="RecyteTherapeuticsIncMember" xlink:title="presentation: EntityDomain to RecyteTherapeuticsIncMember" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsidiariesMember" xlink:label="SubsidiariesMember" xlink:title="SubsidiariesMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EntityDomain" xlink:to="SubsidiariesMember" xlink:title="presentation: EntityDomain to SubsidiariesMember" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LegalEntityAxis" xlink:to="EntityDomain" xlink:title="presentation: LegalEntityAxis to EntityDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="MinorityInterestTable" xlink:to="LegalEntityAxis" xlink:title="presentation: MinorityInterestTable to LegalEntityAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="StatementEquityComponentsAxis" xlink:title="StatementEquityComponentsAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="EquityComponentDomain" xlink:title="EquityComponentDomain" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ParentMember" xlink:label="ParentMember" xlink:title="ParentMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityComponentDomain" xlink:to="ParentMember" xlink:title="presentation: EquityComponentDomain to ParentMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementEquityComponentsAxis" xlink:to="EquityComponentDomain" xlink:title="presentation: StatementEquityComponentsAxis to EquityComponentDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="MinorityInterestTable" xlink:to="StatementEquityComponentsAxis" xlink:title="presentation: MinorityInterestTable to StatementEquityComponentsAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MinorityInterestLineItems" xlink:label="MinorityInterestLineItems" xlink:title="MinorityInterestLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:label="MinorityInterestOwnershipPercentageByParent" xlink:title="MinorityInterestOwnershipPercentageByParent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="MinorityInterestLineItems" xlink:to="MinorityInterestOwnershipPercentageByParent" xlink:title="presentation: MinorityInterestLineItems to MinorityInterestOwnershipPercentageByParent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="RetainedEarningsAccumulatedDeficit" xlink:title="RetainedEarningsAccumulatedDeficit" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="MinorityInterestLineItems" xlink:to="RetainedEarningsAccumulatedDeficit" xlink:title="presentation: MinorityInterestLineItems to RetainedEarningsAccumulatedDeficit" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Capital" xlink:label="Capital" xlink:title="Capital" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="MinorityInterestLineItems" xlink:to="Capital" xlink:title="presentation: MinorityInterestLineItems to Capital" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:title="StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="MinorityInterestLineItems" xlink:to="StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:title="presentation: MinorityInterestLineItems to StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="CashAndCashEquivalentsAtCarryingValue" xlink:title="CashAndCashEquivalentsAtCarryingValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="MinorityInterestLineItems" xlink:to="CashAndCashEquivalentsAtCarryingValue" xlink:title="presentation: MinorityInterestLineItems to CashAndCashEquivalentsAtCarryingValue" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="MinorityInterestTable" xlink:to="MinorityInterestLineItems" xlink:title="presentation: MinorityInterestTable to MinorityInterestLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="MinorityInterestTable" xlink:title="presentation: OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract to MinorityInterestTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://biotimeinc.com/role/SummaryOfSignificantAccountingPoliciesDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="AccountingPoliciesAbstract" xlink:title="AccountingPoliciesAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="AccountsReceivableNetCurrent" xlink:title="AccountsReceivableNetCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="AccountsReceivableNetCurrent" xlink:title="presentation: AccountingPoliciesAbstract to AccountsReceivableNetCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_GrantsReceivableCurrent" xlink:label="GrantsReceivableCurrent" xlink:title="GrantsReceivableCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="GrantsReceivableCurrent" xlink:title="presentation: AccountingPoliciesAbstract to GrantsReceivableCurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:label="AllowanceForDoubtfulAccountsReceivableCurrent" xlink:title="AllowanceForDoubtfulAccountsReceivableCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="AllowanceForDoubtfulAccountsReceivableCurrent" xlink:title="presentation: AccountingPoliciesAbstract to AllowanceForDoubtfulAccountsReceivableCurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="ScheduleOfPropertyPlantAndEquipmentTable" xlink:title="ScheduleOfPropertyPlantAndEquipmentTable" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="PropertyPlantAndEquipmentByTypeAxis" xlink:title="PropertyPlantAndEquipmentByTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="PropertyPlantAndEquipmentTypeDomain" xlink:title="PropertyPlantAndEquipmentTypeDomain" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquipmentMember" xlink:label="EquipmentMember" xlink:title="EquipmentMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentTypeDomain" xlink:to="EquipmentMember" xlink:title="presentation: PropertyPlantAndEquipmentTypeDomain to EquipmentMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentByTypeAxis" xlink:to="PropertyPlantAndEquipmentTypeDomain" xlink:title="presentation: PropertyPlantAndEquipmentByTypeAxis to PropertyPlantAndEquipmentTypeDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="PropertyPlantAndEquipmentByTypeAxis" xlink:title="presentation: ScheduleOfPropertyPlantAndEquipmentTable to PropertyPlantAndEquipmentByTypeAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeAxis" xlink:label="RangeAxis" xlink:title="RangeAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeMember" xlink:label="RangeMember" xlink:title="RangeMember" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MinimumMember" xlink:label="MinimumMember" xlink:title="MinimumMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangeMember" xlink:to="MinimumMember" xlink:title="presentation: RangeMember to MinimumMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MaximumMember" xlink:label="MaximumMember" xlink:title="MaximumMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangeMember" xlink:to="MaximumMember" xlink:title="presentation: RangeMember to MaximumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangeAxis" xlink:to="RangeMember" xlink:title="presentation: RangeAxis to RangeMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="RangeAxis" xlink:title="presentation: ScheduleOfPropertyPlantAndEquipmentTable to RangeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="PropertyPlantAndEquipmentLineItems" xlink:title="PropertyPlantAndEquipmentLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="PropertyPlantAndEquipmentUsefulLife" xlink:title="PropertyPlantAndEquipmentUsefulLife" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentLineItems" xlink:to="PropertyPlantAndEquipmentUsefulLife" xlink:title="presentation: PropertyPlantAndEquipmentLineItems to PropertyPlantAndEquipmentUsefulLife" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="PropertyPlantAndEquipmentLineItems" xlink:title="presentation: ScheduleOfPropertyPlantAndEquipmentTable to PropertyPlantAndEquipmentLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="ScheduleOfPropertyPlantAndEquipmentTable" xlink:title="presentation: AccountingPoliciesAbstract to ScheduleOfPropertyPlantAndEquipmentTable" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:title="OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:title="presentation: AccountingPoliciesAbstract to OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="ForeignCurrencyTransactionGainLossBeforeTax" xlink:title="ForeignCurrencyTransactionGainLossBeforeTax" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="ForeignCurrencyTransactionGainLossBeforeTax" xlink:title="presentation: AccountingPoliciesAbstract to ForeignCurrencyTransactionGainLossBeforeTax" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="IncomeTaxDisclosureAbstract" xlink:title="IncomeTaxDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:label="UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:title="UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:title="presentation: IncomeTaxDisclosureAbstract to UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="DeferredIncomeTaxExpenseBenefit" xlink:title="DeferredIncomeTaxExpenseBenefit" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="DeferredIncomeTaxExpenseBenefit" xlink:title="presentation: IncomeTaxDisclosureAbstract to DeferredIncomeTaxExpenseBenefit" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="DeferredFederalIncomeTaxExpenseBenefit" xlink:title="DeferredFederalIncomeTaxExpenseBenefit" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="DeferredFederalIncomeTaxExpenseBenefit" xlink:title="presentation: IncomeTaxDisclosureAbstract to DeferredFederalIncomeTaxExpenseBenefit" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:title="DeferredStateAndLocalIncomeTaxExpenseBenefit" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:title="presentation: IncomeTaxDisclosureAbstract to DeferredStateAndLocalIncomeTaxExpenseBenefit" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="btx-20150331.xsd#btx_SharesSoldByThirdParty" xlink:label="SharesSoldByThirdParty" xlink:title="SharesSoldByThirdParty" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="SharesSoldByThirdParty" xlink:title="presentation: IncomeTaxDisclosureAbstract to SharesSoldByThirdParty" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="btx-20150331.xsd#btx_TaxableGainOnSaleOfSubsidiaryShares" xlink:label="TaxableGainOnSaleOfSubsidiaryShares" xlink:title="TaxableGainOnSaleOfSubsidiaryShares" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="TaxableGainOnSaleOfSubsidiaryShares" xlink:title="presentation: IncomeTaxDisclosureAbstract to TaxableGainOnSaleOfSubsidiaryShares" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="btx-20150331.xsd#btx_TaxPayableOnSaleOfSubsidiaryShares" xlink:label="TaxPayableOnSaleOfSubsidiaryShares" xlink:title="TaxPayableOnSaleOfSubsidiaryShares" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="TaxPayableOnSaleOfSubsidiaryShares" xlink:title="presentation: IncomeTaxDisclosureAbstract to TaxPayableOnSaleOfSubsidiaryShares" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="IncomeTaxDisclosureAbstract" xlink:title="presentation: AccountingPoliciesAbstract to IncomeTaxDisclosureAbstract" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="btx-20150331.xsd#btx_DeferredLicenseAndConsultingFeesAbstract" xlink:label="DeferredLicenseAndConsultingFeesAbstract" xlink:title="DeferredLicenseAndConsultingFeesAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:title="ScheduleOfFiniteLivedIntangibleAssetsTable" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:title="FiniteLivedIntangibleAssetsByMajorClassAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:title="FiniteLivedIntangibleAssetsMajorClassNameDomain" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TechnologyBasedIntangibleAssetsMember" xlink:label="TechnologyBasedIntangibleAssetsMember" xlink:title="TechnologyBasedIntangibleAssetsMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="TechnologyBasedIntangibleAssetsMember" xlink:title="presentation: FiniteLivedIntangibleAssetsMajorClassNameDomain to TechnologyBasedIntangibleAssetsMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:title="presentation: FiniteLivedIntangibleAssetsByMajorClassAxis to FiniteLivedIntangibleAssetsMajorClassNameDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:title="presentation: ScheduleOfFiniteLivedIntangibleAssetsTable to FiniteLivedIntangibleAssetsByMajorClassAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="FiniteLivedIntangibleAssetsLineItems" xlink:title="FiniteLivedIntangibleAssetsLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="FiniteLivedIntangibleAssetUsefulLife" xlink:title="FiniteLivedIntangibleAssetUsefulLife" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FiniteLivedIntangibleAssetsLineItems" xlink:to="FiniteLivedIntangibleAssetUsefulLife" xlink:title="presentation: FiniteLivedIntangibleAssetsLineItems to FiniteLivedIntangibleAssetUsefulLife" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="FiniteLivedIntangibleAssetsLineItems" xlink:title="presentation: ScheduleOfFiniteLivedIntangibleAssetsTable to FiniteLivedIntangibleAssetsLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredLicenseAndConsultingFeesAbstract" xlink:to="ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:title="presentation: DeferredLicenseAndConsultingFeesAbstract to ScheduleOfFiniteLivedIntangibleAssetsTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="DeferredLicenseAndConsultingFeesAbstract" xlink:title="presentation: AccountingPoliciesAbstract to DeferredLicenseAndConsultingFeesAbstract" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:title="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:title="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="AntidilutiveSecuritiesNameDomain" xlink:title="AntidilutiveSecuritiesNameDomain" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TreasuryStockMember" xlink:label="TreasuryStockMember" xlink:title="TreasuryStockMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AntidilutiveSecuritiesNameDomain" xlink:to="TreasuryStockMember" xlink:title="presentation: AntidilutiveSecuritiesNameDomain to TreasuryStockMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="EmployeeStockOptionMember" xlink:title="EmployeeStockOptionMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AntidilutiveSecuritiesNameDomain" xlink:to="EmployeeStockOptionMember" xlink:title="presentation: AntidilutiveSecuritiesNameDomain to EmployeeStockOptionMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WarrantMember" xlink:label="WarrantMember" xlink:title="WarrantMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AntidilutiveSecuritiesNameDomain" xlink:to="WarrantMember" xlink:title="presentation: AntidilutiveSecuritiesNameDomain to WarrantMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="AntidilutiveSecuritiesNameDomain" xlink:title="presentation: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis to AntidilutiveSecuritiesNameDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:title="presentation: ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable to AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:title="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:title="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:title="presentation: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems to AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:title="presentation: ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable to AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:title="presentation: AccountingPoliciesAbstract to ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://biotimeinc.com/role/InventoryDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="InventoryDisclosureAbstract" xlink:title="InventoryDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="InventoryFinishedGoodsNetOfReserves" xlink:title="InventoryFinishedGoodsNetOfReserves" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InventoryDisclosureAbstract" xlink:to="InventoryFinishedGoodsNetOfReserves" xlink:title="presentation: InventoryDisclosureAbstract to InventoryFinishedGoodsNetOfReserves" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment" xlink:label="OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment" xlink:title="OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InventoryDisclosureAbstract" xlink:to="OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment" xlink:title="presentation: InventoryDisclosureAbstract to OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://biotimeinc.com/role/EquipmentNetAndConstructionInProgressDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="PropertyPlantAndEquipmentAbstract" xlink:title="PropertyPlantAndEquipmentAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:label="PropertyPlantAndEquipmentNetAbstract" xlink:title="PropertyPlantAndEquipmentNetAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="PropertyPlantAndEquipmentGross" xlink:title="PropertyPlantAndEquipmentGross" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentNetAbstract" xlink:to="PropertyPlantAndEquipmentGross" xlink:title="presentation: PropertyPlantAndEquipmentNetAbstract to PropertyPlantAndEquipmentGross" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConstructionInProgressGross" xlink:label="ConstructionInProgressGross" xlink:title="ConstructionInProgressGross" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentNetAbstract" xlink:to="ConstructionInProgressGross" xlink:title="presentation: PropertyPlantAndEquipmentNetAbstract to ConstructionInProgressGross" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:title="AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentNetAbstract" xlink:to="AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:title="presentation: PropertyPlantAndEquipmentNetAbstract to AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="PropertyPlantAndEquipmentNet" xlink:title="PropertyPlantAndEquipmentNet" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentNetAbstract" xlink:to="PropertyPlantAndEquipmentNet" xlink:title="presentation: PropertyPlantAndEquipmentNetAbstract to PropertyPlantAndEquipmentNet" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentAbstract" xlink:to="PropertyPlantAndEquipmentNetAbstract" xlink:title="presentation: PropertyPlantAndEquipmentAbstract to PropertyPlantAndEquipmentNetAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CapitalLeaseObligations" xlink:label="CapitalLeaseObligations" xlink:title="CapitalLeaseObligations" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentAbstract" xlink:to="CapitalLeaseObligations" xlink:title="presentation: PropertyPlantAndEquipmentAbstract to CapitalLeaseObligations" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LeaseholdImprovementsGross" xlink:label="LeaseholdImprovementsGross" xlink:title="LeaseholdImprovementsGross" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentAbstract" xlink:to="LeaseholdImprovementsGross" xlink:title="presentation: PropertyPlantAndEquipmentAbstract to LeaseholdImprovementsGross" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Depreciation" xlink:label="Depreciation" xlink:title="Depreciation" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentAbstract" xlink:to="Depreciation" xlink:title="presentation: PropertyPlantAndEquipmentAbstract to Depreciation" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipmentPeriodIncreaseDecrease" xlink:label="AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipmentPeriodIncreaseDecrease" xlink:title="AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipmentPeriodIncreaseDecrease" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentAbstract" xlink:to="AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipmentPeriodIncreaseDecrease" xlink:title="presentation: PropertyPlantAndEquipmentAbstract to AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipmentPeriodIncreaseDecrease" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="btx-20150331.xsd#btx_TenantImprovementAllowanceUnderLeaseAgreement" xlink:label="TenantImprovementAllowanceUnderLeaseAgreement" xlink:title="TenantImprovementAllowanceUnderLeaseAgreement" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentAbstract" xlink:to="TenantImprovementAllowanceUnderLeaseAgreement" xlink:title="presentation: PropertyPlantAndEquipmentAbstract to TenantImprovementAllowanceUnderLeaseAgreement" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="btx-20150331.xsd#btx_TenantImprovementAllowanceReimbursementUnderLeaseAgreement" xlink:label="TenantImprovementAllowanceReimbursementUnderLeaseAgreement" xlink:title="TenantImprovementAllowanceReimbursementUnderLeaseAgreement" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentAbstract" xlink:to="TenantImprovementAllowanceReimbursementUnderLeaseAgreement" xlink:title="presentation: PropertyPlantAndEquipmentAbstract to TenantImprovementAllowanceReimbursementUnderLeaseAgreement" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="btx-20150331.xsd#btx_ProceedsFromConstructionInProgress" xlink:label="ProceedsFromConstructionInProgress" xlink:title="ProceedsFromConstructionInProgress" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentAbstract" xlink:to="ProceedsFromConstructionInProgress" xlink:title="presentation: PropertyPlantAndEquipmentAbstract to ProceedsFromConstructionInProgress" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://biotimeinc.com/role/IntangibleAssetsNetDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:title="GoodwillAndIntangibleAssetsDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:label="FiniteLivedIntangibleAssetsNetAbstract" xlink:title="FiniteLivedIntangibleAssetsNetAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="FiniteLivedIntangibleAssetsGross" xlink:title="FiniteLivedIntangibleAssetsGross" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FiniteLivedIntangibleAssetsNetAbstract" xlink:to="FiniteLivedIntangibleAssetsGross" xlink:title="presentation: FiniteLivedIntangibleAssetsNetAbstract to FiniteLivedIntangibleAssetsGross" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:title="FiniteLivedIntangibleAssetsAccumulatedAmortization" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FiniteLivedIntangibleAssetsNetAbstract" xlink:to="FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:title="presentation: FiniteLivedIntangibleAssetsNetAbstract to FiniteLivedIntangibleAssetsAccumulatedAmortization" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="FiniteLivedIntangibleAssetsNet" xlink:title="FiniteLivedIntangibleAssetsNet" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FiniteLivedIntangibleAssetsNetAbstract" xlink:to="FiniteLivedIntangibleAssetsNet" xlink:title="presentation: FiniteLivedIntangibleAssetsNetAbstract to FiniteLivedIntangibleAssetsNet" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="FiniteLivedIntangibleAssetsNetAbstract" xlink:title="presentation: GoodwillAndIntangibleAssetsDisclosureAbstract to FiniteLivedIntangibleAssetsNetAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="FiniteLivedIntangibleAssetUsefulLife" xlink:title="FiniteLivedIntangibleAssetUsefulLife" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="FiniteLivedIntangibleAssetUsefulLife" xlink:title="presentation: GoodwillAndIntangibleAssetsDisclosureAbstract to FiniteLivedIntangibleAssetUsefulLife" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="AmortizationOfIntangibleAssets" xlink:title="AmortizationOfIntangibleAssets" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="AmortizationOfIntangibleAssets" xlink:title="presentation: GoodwillAndIntangibleAssetsDisclosureAbstract to AmortizationOfIntangibleAssets" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://biotimeinc.com/role/RoyaltyObligationAndDeferredLicenseFeesDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredRevenueDisclosureAbstract" xlink:label="DeferredRevenueDisclosureAbstract" xlink:title="DeferredRevenueDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="FiniteLivedIntangibleAssetUsefulLife" xlink:title="FiniteLivedIntangibleAssetUsefulLife" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredRevenueDisclosureAbstract" xlink:to="FiniteLivedIntangibleAssetUsefulLife" xlink:title="presentation: DeferredRevenueDisclosureAbstract to FiniteLivedIntangibleAssetUsefulLife" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredCostsAbstract" xlink:label="DeferredCostsAbstract" xlink:title="DeferredCostsAbstract" />
    <link:loc xlink:type="locator" xlink:href="btx-20150331.xsd#btx_DeferredLicenseFeesAmortizationExpenseDueInRemainderOfFiscalYear" xlink:label="DeferredLicenseFeesAmortizationExpenseDueInRemainderOfFiscalYear" xlink:title="DeferredLicenseFeesAmortizationExpenseDueInRemainderOfFiscalYear" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredCostsAbstract" xlink:to="DeferredLicenseFeesAmortizationExpenseDueInRemainderOfFiscalYear" xlink:title="presentation: DeferredCostsAbstract to DeferredLicenseFeesAmortizationExpenseDueInRemainderOfFiscalYear" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="btx-20150331.xsd#btx_DeferredLicenseFeesAmortizationExpenseYearTwo" xlink:label="DeferredLicenseFeesAmortizationExpenseYearTwo" xlink:title="DeferredLicenseFeesAmortizationExpenseYearTwo" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredCostsAbstract" xlink:to="DeferredLicenseFeesAmortizationExpenseYearTwo" xlink:title="presentation: DeferredCostsAbstract to DeferredLicenseFeesAmortizationExpenseYearTwo" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="btx-20150331.xsd#btx_DeferredLicenseFeesAmortizationExpenseYearThree" xlink:label="DeferredLicenseFeesAmortizationExpenseYearThree" xlink:title="DeferredLicenseFeesAmortizationExpenseYearThree" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredCostsAbstract" xlink:to="DeferredLicenseFeesAmortizationExpenseYearThree" xlink:title="presentation: DeferredCostsAbstract to DeferredLicenseFeesAmortizationExpenseYearThree" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="btx-20150331.xsd#btx_DeferredLicenseFeesAmortizationExpenseYearFour" xlink:label="DeferredLicenseFeesAmortizationExpenseYearFour" xlink:title="DeferredLicenseFeesAmortizationExpenseYearFour" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredCostsAbstract" xlink:to="DeferredLicenseFeesAmortizationExpenseYearFour" xlink:title="presentation: DeferredCostsAbstract to DeferredLicenseFeesAmortizationExpenseYearFour" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="btx-20150331.xsd#btx_DeferredLicenseFeesAmortizationExpenseYearFive" xlink:label="DeferredLicenseFeesAmortizationExpenseYearFive" xlink:title="DeferredLicenseFeesAmortizationExpenseYearFive" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredCostsAbstract" xlink:to="DeferredLicenseFeesAmortizationExpenseYearFive" xlink:title="presentation: DeferredCostsAbstract to DeferredLicenseFeesAmortizationExpenseYearFive" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="btx-20150331.xsd#btx_DeferredLicenseFeesAmortizationExpenseAfterYearFive" xlink:label="DeferredLicenseFeesAmortizationExpenseAfterYearFive" xlink:title="DeferredLicenseFeesAmortizationExpenseAfterYearFive" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredCostsAbstract" xlink:to="DeferredLicenseFeesAmortizationExpenseAfterYearFive" xlink:title="presentation: DeferredCostsAbstract to DeferredLicenseFeesAmortizationExpenseAfterYearFive" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredCostsCurrentAndNoncurrent" xlink:label="DeferredCostsCurrentAndNoncurrent" xlink:title="DeferredCostsCurrentAndNoncurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredCostsAbstract" xlink:to="DeferredCostsCurrentAndNoncurrent" xlink:title="presentation: DeferredCostsAbstract to DeferredCostsCurrentAndNoncurrent" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredRevenueDisclosureAbstract" xlink:to="DeferredCostsAbstract" xlink:title="presentation: DeferredRevenueDisclosureAbstract to DeferredCostsAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="btx-20150331.xsd#btx_PrepaidExpensesInOtherCurrentAssets" xlink:label="PrepaidExpensesInOtherCurrentAssets" xlink:title="PrepaidExpensesInOtherCurrentAssets" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredRevenueDisclosureAbstract" xlink:to="PrepaidExpensesInOtherCurrentAssets" xlink:title="presentation: DeferredRevenueDisclosureAbstract to PrepaidExpensesInOtherCurrentAssets" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="btx-20150331.xsd#btx_DeferredLicenseAndConsultingFeesClassifiedAsNoncurrent" xlink:label="DeferredLicenseAndConsultingFeesClassifiedAsNoncurrent" xlink:title="DeferredLicenseAndConsultingFeesClassifiedAsNoncurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredRevenueDisclosureAbstract" xlink:to="DeferredLicenseAndConsultingFeesClassifiedAsNoncurrent" xlink:title="presentation: DeferredRevenueDisclosureAbstract to DeferredLicenseAndConsultingFeesClassifiedAsNoncurrent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://biotimeinc.com/role/AccountsPayableAndAccruedLiabilitiesDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="PayablesAndAccrualsAbstract" xlink:title="PayablesAndAccrualsAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="AccountsPayableCurrent" xlink:title="AccountsPayableCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PayablesAndAccrualsAbstract" xlink:to="AccountsPayableCurrent" xlink:title="presentation: PayablesAndAccrualsAbstract to AccountsPayableCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="AccruedLiabilitiesCurrent" xlink:title="AccruedLiabilitiesCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PayablesAndAccrualsAbstract" xlink:to="AccruedLiabilitiesCurrent" xlink:title="presentation: PayablesAndAccrualsAbstract to AccruedLiabilitiesCurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccruedBonusesCurrent" xlink:label="AccruedBonusesCurrent" xlink:title="AccruedBonusesCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PayablesAndAccrualsAbstract" xlink:to="AccruedBonusesCurrent" xlink:title="presentation: PayablesAndAccrualsAbstract to AccruedBonusesCurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="OtherAccruedLiabilitiesCurrent" xlink:title="OtherAccruedLiabilitiesCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PayablesAndAccrualsAbstract" xlink:to="OtherAccruedLiabilitiesCurrent" xlink:title="presentation: PayablesAndAccrualsAbstract to OtherAccruedLiabilitiesCurrent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="AccountsPayableAndAccruedLiabilitiesCurrent" xlink:title="AccountsPayableAndAccruedLiabilitiesCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PayablesAndAccrualsAbstract" xlink:to="AccountsPayableAndAccruedLiabilitiesCurrent" xlink:title="presentation: PayablesAndAccrualsAbstract to AccountsPayableAndAccruedLiabilitiesCurrent" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://biotimeinc.com/role/RelatedPartyTransactionsAndRelatedPartyConvertibleDebtDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="RelatedPartyTransactionsAbstract" xlink:title="RelatedPartyTransactionsAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:title="ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="RelatedPartyTransactionsByRelatedPartyAxis" xlink:title="RelatedPartyTransactionsByRelatedPartyAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="RelatedPartyDomain" xlink:title="RelatedPartyDomain" />
    <link:loc xlink:type="locator" xlink:href="btx-20150331.xsd#btx_AsteriasBiotherapeuticsMember" xlink:label="AsteriasBiotherapeuticsMember" xlink:title="AsteriasBiotherapeuticsMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyDomain" xlink:to="AsteriasBiotherapeuticsMember" xlink:title="presentation: RelatedPartyDomain to AsteriasBiotherapeuticsMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="btx-20150331.xsd#btx_CellCureNeurosciencesLtdMember" xlink:label="CellCureNeurosciencesLtdMember" xlink:title="CellCureNeurosciencesLtdMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyDomain" xlink:to="CellCureNeurosciencesLtdMember" xlink:title="presentation: RelatedPartyDomain to CellCureNeurosciencesLtdMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="RelatedPartyDomain" xlink:title="presentation: RelatedPartyTransactionsByRelatedPartyAxis to RelatedPartyDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="RelatedPartyTransactionsByRelatedPartyAxis" xlink:title="presentation: ScheduleOfRelatedPartyTransactionsByRelatedPartyTable to RelatedPartyTransactionsByRelatedPartyAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="RelatedPartyTransactionAxis" xlink:title="RelatedPartyTransactionAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="RelatedPartyTransactionDomain" xlink:title="RelatedPartyTransactionDomain" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonClassAMember" xlink:label="CommonClassAMember" xlink:title="CommonClassAMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionDomain" xlink:to="CommonClassAMember" xlink:title="presentation: RelatedPartyTransactionDomain to CommonClassAMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionAxis" xlink:to="RelatedPartyTransactionDomain" xlink:title="presentation: RelatedPartyTransactionAxis to RelatedPartyTransactionDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="RelatedPartyTransactionAxis" xlink:title="presentation: ScheduleOfRelatedPartyTransactionsByRelatedPartyTable to RelatedPartyTransactionAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="RelatedPartyTransactionLineItems" xlink:title="RelatedPartyTransactionLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaymentsForRent" xlink:label="PaymentsForRent" xlink:title="PaymentsForRent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionLineItems" xlink:to="PaymentsForRent" xlink:title="presentation: RelatedPartyTransactionLineItems to PaymentsForRent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AreaOfLand" xlink:label="AreaOfLand" xlink:title="AreaOfLand" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionLineItems" xlink:to="AreaOfLand" xlink:title="presentation: RelatedPartyTransactionLineItems to AreaOfLand" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="ProceedsFromIssuanceOfCommonStock" xlink:title="ProceedsFromIssuanceOfCommonStock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionLineItems" xlink:to="ProceedsFromIssuanceOfCommonStock" xlink:title="presentation: RelatedPartyTransactionLineItems to ProceedsFromIssuanceOfCommonStock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="SaleOfStockNumberOfSharesIssuedInTransaction" xlink:title="SaleOfStockNumberOfSharesIssuedInTransaction" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionLineItems" xlink:to="SaleOfStockNumberOfSharesIssuedInTransaction" xlink:title="presentation: RelatedPartyTransactionLineItems to SaleOfStockNumberOfSharesIssuedInTransaction" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharePrice" xlink:label="SharePrice" xlink:title="SharePrice" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionLineItems" xlink:to="SharePrice" xlink:title="presentation: RelatedPartyTransactionLineItems to SharePrice" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharesIssued" xlink:label="SharesIssued" xlink:title="SharesIssued" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionLineItems" xlink:to="SharesIssued" xlink:title="presentation: RelatedPartyTransactionLineItems to SharesIssued" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="btx-20150331.xsd#btx_NumberOfCellCureNeurosciencesInvestors" xlink:label="NumberOfCellCureNeurosciencesInvestors" xlink:title="NumberOfCellCureNeurosciencesInvestors" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionLineItems" xlink:to="NumberOfCellCureNeurosciencesInvestors" xlink:title="presentation: RelatedPartyTransactionLineItems to NumberOfCellCureNeurosciencesInvestors" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="DebtInstrumentInterestRateStatedPercentage" xlink:title="DebtInstrumentInterestRateStatedPercentage" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionLineItems" xlink:to="DebtInstrumentInterestRateStatedPercentage" xlink:title="presentation: RelatedPartyTransactionLineItems to DebtInstrumentInterestRateStatedPercentage" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="DebtInstrumentConvertibleConversionPrice1" xlink:title="DebtInstrumentConvertibleConversionPrice1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionLineItems" xlink:to="DebtInstrumentConvertibleConversionPrice1" xlink:title="presentation: RelatedPartyTransactionLineItems to DebtInstrumentConvertibleConversionPrice1" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="btx-20150331.xsd#btx_EstimatedFairMarketValue" xlink:label="EstimatedFairMarketValue" xlink:title="EstimatedFairMarketValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionLineItems" xlink:to="EstimatedFairMarketValue" xlink:title="presentation: RelatedPartyTransactionLineItems to EstimatedFairMarketValue" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="ProceedsFromConvertibleDebt" xlink:title="ProceedsFromConvertibleDebt" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionLineItems" xlink:to="ProceedsFromConvertibleDebt" xlink:title="presentation: RelatedPartyTransactionLineItems to ProceedsFromConvertibleDebt" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentTerm" xlink:label="DebtInstrumentTerm" xlink:title="DebtInstrumentTerm" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionLineItems" xlink:to="DebtInstrumentTerm" xlink:title="presentation: RelatedPartyTransactionLineItems to DebtInstrumentTerm" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="DebtInstrumentInterestRateEffectivePercentage" xlink:title="DebtInstrumentInterestRateEffectivePercentage" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionLineItems" xlink:to="DebtInstrumentInterestRateEffectivePercentage" xlink:title="presentation: RelatedPartyTransactionLineItems to DebtInstrumentInterestRateEffectivePercentage" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConvertibleNotesPayableCurrent" xlink:label="ConvertibleNotesPayableCurrent" xlink:title="ConvertibleNotesPayableCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionLineItems" xlink:to="ConvertibleNotesPayableCurrent" xlink:title="presentation: RelatedPartyTransactionLineItems to ConvertibleNotesPayableCurrent" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConvertibleDebt" xlink:label="ConvertibleDebt" xlink:title="ConvertibleDebt" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionLineItems" xlink:to="ConvertibleDebt" xlink:title="presentation: RelatedPartyTransactionLineItems to ConvertibleDebt" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="DebtInstrumentUnamortizedDiscount" xlink:title="DebtInstrumentUnamortizedDiscount" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionLineItems" xlink:to="DebtInstrumentUnamortizedDiscount" xlink:title="presentation: RelatedPartyTransactionLineItems to DebtInstrumentUnamortizedDiscount" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="RelatedPartyTransactionLineItems" xlink:title="presentation: ScheduleOfRelatedPartyTransactionsByRelatedPartyTable to RelatedPartyTransactionLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsAbstract" xlink:to="ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:title="presentation: RelatedPartyTransactionsAbstract to ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://biotimeinc.com/role/ShareholdersEquityDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityAbstract" xlink:label="EquityAbstract" xlink:title="EquityAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="ScheduleOfStockByClassTable" xlink:title="ScheduleOfStockByClassTable" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="StatementClassOfStockAxis" xlink:title="StatementClassOfStockAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="ClassOfStockDomain" xlink:title="ClassOfStockDomain" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="SeriesAPreferredStockMember" xlink:title="SeriesAPreferredStockMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassOfStockDomain" xlink:to="SeriesAPreferredStockMember" xlink:title="presentation: ClassOfStockDomain to SeriesAPreferredStockMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementClassOfStockAxis" xlink:to="ClassOfStockDomain" xlink:title="presentation: StatementClassOfStockAxis to ClassOfStockDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockByClassTable" xlink:to="StatementClassOfStockAxis" xlink:title="presentation: ScheduleOfStockByClassTable to StatementClassOfStockAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="LegalEntityAxis" xlink:title="LegalEntityAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="EntityDomain" xlink:title="EntityDomain" />
    <link:loc xlink:type="locator" xlink:href="btx-20150331.xsd#btx_AsteriasBiotherapeuticsMember" xlink:label="AsteriasBiotherapeuticsMember" xlink:title="AsteriasBiotherapeuticsMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EntityDomain" xlink:to="AsteriasBiotherapeuticsMember" xlink:title="presentation: EntityDomain to AsteriasBiotherapeuticsMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="btx-20150331.xsd#btx_OrthocyteCorporationMember" xlink:label="OrthocyteCorporationMember" xlink:title="OrthocyteCorporationMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EntityDomain" xlink:to="OrthocyteCorporationMember" xlink:title="presentation: EntityDomain to OrthocyteCorporationMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="btx-20150331.xsd#btx_OncocyteCorporationMember" xlink:label="OncocyteCorporationMember" xlink:title="OncocyteCorporationMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EntityDomain" xlink:to="OncocyteCorporationMember" xlink:title="presentation: EntityDomain to OncocyteCorporationMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="btx-20150331.xsd#btx_RecyteTherapeuticsIncMember" xlink:label="RecyteTherapeuticsIncMember" xlink:title="RecyteTherapeuticsIncMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EntityDomain" xlink:to="RecyteTherapeuticsIncMember" xlink:title="presentation: EntityDomain to RecyteTherapeuticsIncMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="btx-20150331.xsd#btx_LifemapSciencesIncMember" xlink:label="LifemapSciencesIncMember" xlink:title="LifemapSciencesIncMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EntityDomain" xlink:to="LifemapSciencesIncMember" xlink:title="presentation: EntityDomain to LifemapSciencesIncMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="btx-20150331.xsd#btx_BiotimeAsiaLimitedMember" xlink:label="BiotimeAsiaLimitedMember" xlink:title="BiotimeAsiaLimitedMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EntityDomain" xlink:to="BiotimeAsiaLimitedMember" xlink:title="presentation: EntityDomain to BiotimeAsiaLimitedMember" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LegalEntityAxis" xlink:to="EntityDomain" xlink:title="presentation: LegalEntityAxis to EntityDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockByClassTable" xlink:to="LegalEntityAxis" xlink:title="presentation: ScheduleOfStockByClassTable to LegalEntityAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="TitleOfIndividualAxis" xlink:title="TitleOfIndividualAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="TitleOfIndividualWithRelationshipToEntityDomain" xlink:title="TitleOfIndividualWithRelationshipToEntityDomain" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ChiefExecutiveOfficerMember" xlink:label="ChiefExecutiveOfficerMember" xlink:title="ChiefExecutiveOfficerMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="ChiefExecutiveOfficerMember" xlink:title="presentation: TitleOfIndividualWithRelationshipToEntityDomain to ChiefExecutiveOfficerMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ExecutiveVicePresidentMember" xlink:label="ExecutiveVicePresidentMember" xlink:title="ExecutiveVicePresidentMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="ExecutiveVicePresidentMember" xlink:title="presentation: TitleOfIndividualWithRelationshipToEntityDomain to ExecutiveVicePresidentMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TitleOfIndividualAxis" xlink:to="TitleOfIndividualWithRelationshipToEntityDomain" xlink:title="presentation: TitleOfIndividualAxis to TitleOfIndividualWithRelationshipToEntityDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockByClassTable" xlink:to="TitleOfIndividualAxis" xlink:title="presentation: ScheduleOfStockByClassTable to TitleOfIndividualAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="PlanNameAxis" xlink:title="PlanNameAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="PlanNameDomain" xlink:title="PlanNameDomain" />
    <link:loc xlink:type="locator" xlink:href="btx-20150331.xsd#btx_EquityIncentivePlanMember" xlink:label="EquityIncentivePlanMember" xlink:title="EquityIncentivePlanMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PlanNameDomain" xlink:to="EquityIncentivePlanMember" xlink:title="presentation: PlanNameDomain to EquityIncentivePlanMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="btx-20150331.xsd#btx_StockOptionPlan2002Member" xlink:label="StockOptionPlan2002Member" xlink:title="StockOptionPlan2002Member" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PlanNameDomain" xlink:to="StockOptionPlan2002Member" xlink:title="presentation: PlanNameDomain to StockOptionPlan2002Member" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PlanNameAxis" xlink:to="PlanNameDomain" xlink:title="presentation: PlanNameAxis to PlanNameDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockByClassTable" xlink:to="PlanNameAxis" xlink:title="presentation: ScheduleOfStockByClassTable to PlanNameAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="AwardTypeAxis" xlink:title="AwardTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="RestrictedStockMember" xlink:title="RestrictedStockMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="RestrictedStockMember" xlink:title="presentation: ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain to RestrictedStockMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WarrantMember" xlink:label="WarrantMember" xlink:title="WarrantMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="WarrantMember" xlink:title="presentation: ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain to WarrantMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AwardTypeAxis" xlink:to="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="presentation: AwardTypeAxis to ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockByClassTable" xlink:to="AwardTypeAxis" xlink:title="presentation: ScheduleOfStockByClassTable to AwardTypeAxis" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="ClassOfStockLineItems" xlink:title="ClassOfStockLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:label="PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:title="PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="PreferredStockSharesAuthorized" xlink:title="PreferredStockSharesAuthorized" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="PreferredStockSharesAuthorized" xlink:title="presentation: PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract to PreferredStockSharesAuthorized" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="PreferredStockSharesOutstanding" xlink:title="PreferredStockSharesOutstanding" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="PreferredStockSharesOutstanding" xlink:title="presentation: PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract to PreferredStockSharesOutstanding" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockDividendRatePercentage" xlink:label="PreferredStockDividendRatePercentage" xlink:title="PreferredStockDividendRatePercentage" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="PreferredStockDividendRatePercentage" xlink:title="presentation: PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract to PreferredStockDividendRatePercentage" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockDividendRatePerDollarAmount" xlink:label="PreferredStockDividendRatePerDollarAmount" xlink:title="PreferredStockDividendRatePerDollarAmount" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="PreferredStockDividendRatePerDollarAmount" xlink:title="presentation: PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract to PreferredStockDividendRatePerDollarAmount" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="btx-20150331.xsd#btx_PricePerShareOfOptionsToPurchaseCompany" xlink:label="PricePerShareOfOptionsToPurchaseCompany" xlink:title="PricePerShareOfOptionsToPurchaseCompany" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="PricePerShareOfOptionsToPurchaseCompany" xlink:title="presentation: PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract to PricePerShareOfOptionsToPurchaseCompany" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="btx-20150331.xsd#btx_PreferredSharesConvertibleConversionRatio" xlink:label="PreferredSharesConvertibleConversionRatio" xlink:title="PreferredSharesConvertibleConversionRatio" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="PreferredSharesConvertibleConversionRatio" xlink:title="presentation: PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract to PreferredSharesConvertibleConversionRatio" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassOfStockLineItems" xlink:to="PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:title="presentation: ClassOfStockLineItems to PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:label="CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:title="CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="CommonStockSharesAuthorized" xlink:title="CommonStockSharesAuthorized" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="CommonStockSharesAuthorized" xlink:title="presentation: CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract to CommonStockSharesAuthorized" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockNoParValue" xlink:label="CommonStockNoParValue" xlink:title="CommonStockNoParValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="CommonStockNoParValue" xlink:title="presentation: CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract to CommonStockNoParValue" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="CommonStockSharesIssued" xlink:title="CommonStockSharesIssued" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="CommonStockSharesIssued" xlink:title="presentation: CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract to CommonStockSharesIssued" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="CommonStockSharesOutstanding" xlink:title="CommonStockSharesOutstanding" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="CommonStockSharesOutstanding" xlink:title="presentation: CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract to CommonStockSharesOutstanding" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TreasuryStockShares" xlink:label="TreasuryStockShares" xlink:title="TreasuryStockShares" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="TreasuryStockShares" xlink:title="presentation: CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract to TreasuryStockShares" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:title="presentation: CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:title="StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:title="presentation: CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract to StockIssuedDuringPeriodSharesStockOptionsExercised" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="btx-20150331.xsd#btx_WarrantsExercised" xlink:label="WarrantsExercised" xlink:title="WarrantsExercised" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="WarrantsExercised" xlink:title="presentation: CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract to WarrantsExercised" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassOfStockLineItems" xlink:to="CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:title="presentation: ClassOfStockLineItems to CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockByClassTable" xlink:to="ClassOfStockLineItems" xlink:title="presentation: ScheduleOfStockByClassTable to ClassOfStockLineItems" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityAbstract" xlink:to="ScheduleOfStockByClassTable" xlink:title="presentation: EquityAbstract to ScheduleOfStockByClassTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://biotimeinc.com/role/SalesOfBiotimeCommonSharesBySubsidiariesDetails">
    <link:loc xlink:type="locator" xlink:href="btx-20150331.xsd#btx_SalesOfBioTimeCommonSharesBySubsidiariesAbstract" xlink:label="SalesOfBioTimeCommonSharesBySubsidiariesAbstract" xlink:title="SalesOfBioTimeCommonSharesBySubsidiariesAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:title="ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="RelatedPartyTransactionsByRelatedPartyAxis" xlink:title="RelatedPartyTransactionsByRelatedPartyAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="RelatedPartyDomain" xlink:title="RelatedPartyDomain" />
    <link:loc xlink:type="locator" xlink:href="btx-20150331.xsd#btx_AsteriasBiotherapeuticsMember" xlink:label="AsteriasBiotherapeuticsMember" xlink:title="AsteriasBiotherapeuticsMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyDomain" xlink:to="AsteriasBiotherapeuticsMember" xlink:title="presentation: RelatedPartyDomain to AsteriasBiotherapeuticsMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DirectorMember" xlink:label="DirectorMember" xlink:title="DirectorMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyDomain" xlink:to="DirectorMember" xlink:title="presentation: RelatedPartyDomain to DirectorMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MajorityShareholderMember" xlink:label="MajorityShareholderMember" xlink:title="MajorityShareholderMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyDomain" xlink:to="MajorityShareholderMember" xlink:title="presentation: RelatedPartyDomain to MajorityShareholderMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="RelatedPartyDomain" xlink:title="presentation: RelatedPartyTransactionsByRelatedPartyAxis to RelatedPartyDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="RelatedPartyTransactionsByRelatedPartyAxis" xlink:title="presentation: ScheduleOfRelatedPartyTransactionsByRelatedPartyTable to RelatedPartyTransactionsByRelatedPartyAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="RelatedPartyTransactionAxis" xlink:title="RelatedPartyTransactionAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="RelatedPartyTransactionDomain" xlink:title="RelatedPartyTransactionDomain" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockMember" xlink:label="CommonStockMember" xlink:title="CommonStockMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionDomain" xlink:to="CommonStockMember" xlink:title="presentation: RelatedPartyTransactionDomain to CommonStockMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonClassBMember" xlink:label="CommonClassBMember" xlink:title="CommonClassBMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionDomain" xlink:to="CommonClassBMember" xlink:title="presentation: RelatedPartyTransactionDomain to CommonClassBMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WarrantMember" xlink:label="WarrantMember" xlink:title="WarrantMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionDomain" xlink:to="WarrantMember" xlink:title="presentation: RelatedPartyTransactionDomain to WarrantMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionAxis" xlink:to="RelatedPartyTransactionDomain" xlink:title="presentation: RelatedPartyTransactionAxis to RelatedPartyTransactionDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="RelatedPartyTransactionAxis" xlink:title="presentation: ScheduleOfRelatedPartyTransactionsByRelatedPartyTable to RelatedPartyTransactionAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="RelatedPartyTransactionLineItems" xlink:title="RelatedPartyTransactionLineItems" />
    <link:loc xlink:type="locator" xlink:href="btx-20150331.xsd#btx_SharesSoldByThirdParty" xlink:label="SharesSoldByThirdParty" xlink:title="SharesSoldByThirdParty" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionLineItems" xlink:to="SharesSoldByThirdParty" xlink:title="presentation: RelatedPartyTransactionLineItems to SharesSoldByThirdParty" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="btx-20150331.xsd#btx_NumberOfInvestors" xlink:label="NumberOfInvestors" xlink:title="NumberOfInvestors" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionLineItems" xlink:to="NumberOfInvestors" xlink:title="presentation: RelatedPartyTransactionLineItems to NumberOfInvestors" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity" xlink:label="ProceedsFromSaleOfAvailableForSaleSecuritiesEquity" xlink:title="ProceedsFromSaleOfAvailableForSaleSecuritiesEquity" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionLineItems" xlink:to="ProceedsFromSaleOfAvailableForSaleSecuritiesEquity" xlink:title="presentation: RelatedPartyTransactionLineItems to ProceedsFromSaleOfAvailableForSaleSecuritiesEquity" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:title="ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionLineItems" xlink:to="ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:title="presentation: RelatedPartyTransactionLineItems to ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharesIssued" xlink:label="SharesIssued" xlink:title="SharesIssued" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionLineItems" xlink:to="SharesIssued" xlink:title="presentation: RelatedPartyTransactionLineItems to SharesIssued" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="RelatedPartyTransactionLineItems" xlink:title="presentation: ScheduleOfRelatedPartyTransactionsByRelatedPartyTable to RelatedPartyTransactionLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SalesOfBioTimeCommonSharesBySubsidiariesAbstract" xlink:to="ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:title="presentation: SalesOfBioTimeCommonSharesBySubsidiariesAbstract to ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://biotimeinc.com/role/SegmentInformationDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SegmentReportingAbstract" xlink:label="SegmentReportingAbstract" xlink:title="SegmentReportingAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="NumberOfOperatingSegments" xlink:title="NumberOfOperatingSegments" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SegmentReportingAbstract" xlink:to="NumberOfOperatingSegments" xlink:title="presentation: SegmentReportingAbstract to NumberOfOperatingSegments" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://biotimeinc.com/role/SubsequentEventsDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="SubsequentEventsAbstract" xlink:title="SubsequentEventsAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="SubsequentEventTable" xlink:title="SubsequentEventTable" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="SubsequentEventTypeAxis" xlink:title="SubsequentEventTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="SubsequentEventTypeDomain" xlink:title="SubsequentEventTypeDomain" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="SubsequentEventMember" xlink:title="SubsequentEventMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventTypeDomain" xlink:to="SubsequentEventMember" xlink:title="presentation: SubsequentEventTypeDomain to SubsequentEventMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventTypeAxis" xlink:to="SubsequentEventTypeDomain" xlink:title="presentation: SubsequentEventTypeAxis to SubsequentEventTypeDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventTable" xlink:to="SubsequentEventTypeAxis" xlink:title="presentation: SubsequentEventTable to SubsequentEventTypeAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="LegalEntityAxis" xlink:title="LegalEntityAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="EntityDomain" xlink:title="EntityDomain" />
    <link:loc xlink:type="locator" xlink:href="btx-20150331.xsd#btx_AsteriasBiotherapeuticsMember" xlink:label="AsteriasBiotherapeuticsMember" xlink:title="AsteriasBiotherapeuticsMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EntityDomain" xlink:to="AsteriasBiotherapeuticsMember" xlink:title="presentation: EntityDomain to AsteriasBiotherapeuticsMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="btx-20150331.xsd#btx_OncocyteCorporationMember" xlink:label="OncocyteCorporationMember" xlink:title="OncocyteCorporationMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EntityDomain" xlink:to="OncocyteCorporationMember" xlink:title="presentation: EntityDomain to OncocyteCorporationMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LegalEntityAxis" xlink:to="EntityDomain" xlink:title="presentation: LegalEntityAxis to EntityDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventTable" xlink:to="LegalEntityAxis" xlink:title="presentation: SubsequentEventTable to LegalEntityAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MajorCustomersAxis" xlink:label="MajorCustomersAxis" xlink:title="MajorCustomersAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NameOfMajorCustomerDomain" xlink:label="NameOfMajorCustomerDomain" xlink:title="NameOfMajorCustomerDomain" />
    <link:loc xlink:type="locator" xlink:href="btx-20150331.xsd#btx_CaliforniaInstituteOfRegenerativeMedicineMember" xlink:label="CaliforniaInstituteOfRegenerativeMedicineMember" xlink:title="CaliforniaInstituteOfRegenerativeMedicineMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NameOfMajorCustomerDomain" xlink:to="CaliforniaInstituteOfRegenerativeMedicineMember" xlink:title="presentation: NameOfMajorCustomerDomain to CaliforniaInstituteOfRegenerativeMedicineMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="MajorCustomersAxis" xlink:to="NameOfMajorCustomerDomain" xlink:title="presentation: MajorCustomersAxis to NameOfMajorCustomerDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventTable" xlink:to="MajorCustomersAxis" xlink:title="presentation: SubsequentEventTable to MajorCustomersAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="DebtInstrumentAxis" xlink:title="DebtInstrumentAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="DebtInstrumentNameDomain" xlink:title="DebtInstrumentNameDomain" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConvertibleNotesPayableMember" xlink:label="ConvertibleNotesPayableMember" xlink:title="ConvertibleNotesPayableMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentNameDomain" xlink:to="ConvertibleNotesPayableMember" xlink:title="presentation: DebtInstrumentNameDomain to ConvertibleNotesPayableMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentAxis" xlink:to="DebtInstrumentNameDomain" xlink:title="presentation: DebtInstrumentAxis to DebtInstrumentNameDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventTable" xlink:to="DebtInstrumentAxis" xlink:title="presentation: SubsequentEventTable to DebtInstrumentAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="RelatedPartyTransactionsByRelatedPartyAxis" xlink:title="RelatedPartyTransactionsByRelatedPartyAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="RelatedPartyDomain" xlink:title="RelatedPartyDomain" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MajorityShareholderMember" xlink:label="MajorityShareholderMember" xlink:title="MajorityShareholderMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyDomain" xlink:to="MajorityShareholderMember" xlink:title="presentation: RelatedPartyDomain to MajorityShareholderMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="RelatedPartyDomain" xlink:title="presentation: RelatedPartyTransactionsByRelatedPartyAxis to RelatedPartyDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventTable" xlink:to="RelatedPartyTransactionsByRelatedPartyAxis" xlink:title="presentation: SubsequentEventTable to RelatedPartyTransactionsByRelatedPartyAxis" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="SubsequentEventLineItems" xlink:title="SubsequentEventLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RevenueFromGrants" xlink:label="RevenueFromGrants" xlink:title="RevenueFromGrants" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventLineItems" xlink:to="RevenueFromGrants" xlink:title="presentation: SubsequentEventLineItems to RevenueFromGrants" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_GrantsReceivable" xlink:label="GrantsReceivable" xlink:title="GrantsReceivable" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventLineItems" xlink:to="GrantsReceivable" xlink:title="presentation: SubsequentEventLineItems to GrantsReceivable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="SaleOfStockNumberOfSharesIssuedInTransaction" xlink:title="SaleOfStockNumberOfSharesIssuedInTransaction" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventLineItems" xlink:to="SaleOfStockNumberOfSharesIssuedInTransaction" xlink:title="presentation: SubsequentEventLineItems to SaleOfStockNumberOfSharesIssuedInTransaction" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="btx-20150331.xsd#btx_NumberOfInvestors" xlink:label="NumberOfInvestors" xlink:title="NumberOfInvestors" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventLineItems" xlink:to="NumberOfInvestors" xlink:title="presentation: SubsequentEventLineItems to NumberOfInvestors" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedPerTransaction" xlink:label="SaleOfStockConsiderationReceivedPerTransaction" xlink:title="SaleOfStockConsiderationReceivedPerTransaction" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventLineItems" xlink:to="SaleOfStockConsiderationReceivedPerTransaction" xlink:title="presentation: SubsequentEventLineItems to SaleOfStockConsiderationReceivedPerTransaction" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="EquityMethodInvestmentOwnershipPercentage" xlink:title="EquityMethodInvestmentOwnershipPercentage" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventLineItems" xlink:to="EquityMethodInvestmentOwnershipPercentage" xlink:title="presentation: SubsequentEventLineItems to EquityMethodInvestmentOwnershipPercentage" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="DebtConversionConvertedInstrumentSharesIssued1" xlink:title="DebtConversionConvertedInstrumentSharesIssued1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventLineItems" xlink:to="DebtConversionConvertedInstrumentSharesIssued1" xlink:title="presentation: SubsequentEventLineItems to DebtConversionConvertedInstrumentSharesIssued1" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="DebtConversionConvertedInstrumentAmount1" xlink:title="DebtConversionConvertedInstrumentAmount1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventLineItems" xlink:to="DebtConversionConvertedInstrumentAmount1" xlink:title="presentation: SubsequentEventLineItems to DebtConversionConvertedInstrumentAmount1" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="DebtInstrumentInterestRateStatedPercentage" xlink:title="DebtInstrumentInterestRateStatedPercentage" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventLineItems" xlink:to="DebtInstrumentInterestRateStatedPercentage" xlink:title="presentation: SubsequentEventLineItems to DebtInstrumentInterestRateStatedPercentage" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="DebtInstrumentMaturityDate" xlink:title="DebtInstrumentMaturityDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventLineItems" xlink:to="DebtInstrumentMaturityDate" xlink:title="presentation: SubsequentEventLineItems to DebtInstrumentMaturityDate" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="DebtInstrumentConvertibleConversionPrice1" xlink:title="DebtInstrumentConvertibleConversionPrice1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventLineItems" xlink:to="DebtInstrumentConvertibleConversionPrice1" xlink:title="presentation: SubsequentEventLineItems to DebtInstrumentConvertibleConversionPrice1" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventTable" xlink:to="SubsequentEventLineItems" xlink:title="presentation: SubsequentEventTable to SubsequentEventLineItems" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsAbstract" xlink:to="SubsequentEventTable" xlink:title="presentation: SubsequentEventsAbstract to SubsequentEventTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>11
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0`!@`(````(0!)FSNX\0$``,,7```3``@"6T-O;G1E;G1?5'EP97-=
M+GAM;""B!`(HH``"````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M``````````````````````````````````````#,F-%.VS`4AN\G\0Z1;U'C
MV@$&J"D7,"X'TN`!//NTB>K8EFU8^_8[2:%"J&M5K1+GIE$;^_Q?+>63\D]N
MEITM7B&FUKN:B7+,"G#:F];-:_;\=#^Z9$7*RAEEO8.:K2"QF^G)M\G3*D`J
M<+=+-6MR#M><)]U`IU+I`SB\,_.Q4QF_QCD/2B_4'+@<CR^X]BZ#RZ/<SV#3
MR1W,U(O-Q8\E_KPFB6`3*V[7"_NLFJD0;*M51E+^ZLRGE-%;0HD[AS6I:4,Z
M10S&MR;T=_X=\+;O`8\FM@:*1Q7S3]4A!E]:_L?'Q6_O%^7N(5LH_6S6:C!>
MOW1X`F4*$91)#4#N;#E<RTZU[IU[1_ZP./'A(HX,TO^_8?"!')((1T6$XXP(
MQSD1C@LB'-^)<%P2X;@BPB'&5$"H&%504:J@XE1!1:J"BE4%%:T**EX55,0J
MJ)A54C&KI&)62<6LDHI9)16S2BIFE53,*JF855(QJZ1BUHJ*62LJ9JVHF+6B
M8M:*BEDK*F:MOLJL&2M*X,/G_S\OPY@]'5G**POIR.^UZZ'[DAL5P?S*$<O<
MHP-\G+V'0RNK;QML-8]\")NYN_*Q:GV,/B0LG2,<#O#>*O>[1P$'0<PM;'KE
M;?WL)A$+Z\,#/Q7$T%?B!LR6;#Y4\-._````__\#`%!+`P04``8`"````"$`
MM54P(_4```!,`@``"P`(`E]R96QS+RYR96QS(*($`BB@``(`````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M`````````(R2ST[#,`S&[TB\0^3[ZFY("*&ENTQ(NR%4'L`D[A^UC:,D0/?V
MA`."2F/;T?;GSS];WN[F:50?'&(O3L.Z*$&Q,V)[UVIXK9]6#Z!B(F=I%,<:
MCAQA5]W>;%]XI)2;8M?[J+*+BQJZE/PC8C0=3Q0+\>QRI9$P4<IA:-&3&:AE
MW)3E/8:_'E`M/-7!:@@'>P>J/OH\^;*W-$UO>"_F?6*73HQ`GA,[RW;E0V8+
MJ<_;J)I"RTF#%?.<TQ')^R)C`YXFVEQ/]/^V.'$B2XG02.#S/-^*<T#KZX$N
MGVBI^+W./.*GA.%-9/AAP<4/5%\```#__P,`4$L#!!0`!@`(````(0`&;0M)
M"`(``,`6```:``@!>&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;',@H@0!**``
M`0``````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M``````````````````````````````````````````"\F,UNVS`0A.\%^@X"
M[S7-7<=)BL@YM"B0:YL^`"'1EA!9$DCVQV]?PFVH&F@F/1![,<`53`V&R_E(
MW=W_/`[5=^=#/XVU,JNUJMS83&T_'FKU]?'3NQM5A6C'U@[3Z&IU<D'=[]Z^
MN?OL!AO3GT+7SZ%*LXRA5EV,\WNM0].YHPVK:79C>K*?_-'&-/0'/=OFR1Z<
MIO5ZJ_W?<ZC=Q9S50ULK_]`:5M7C:4ZO?GWR:;_O&_=Q:KX=W1C_\0[]8_)/
MH7,NIDFM/[A8JUP*^OS$\"II5OH%.<D/63DW2`YMA>70%LGAVY)R0F>]:[]$
MGYHQ+`MV449JR)14D_MD49)+?UJ'#)+#&V$YO$%RKH757",QAH35&()RI,TQ
MT!VZ$G:'KI`[+!W)#".9BT9RB*<A,2[CX?<8V2'=NKASI8%@(!`HG2=$<4EK
MN%1%^93C?^F67'HFPBV2(\TGB"?IQH%]8\2M@=Z0-+H)HINE(X=AYG!16L9T
M=W#+CCH/]?D7+M&F:-(T=F@^=+8?%R&YA':T-*@AIXVT&@/ED/2Q@>"Q@8H>
M&W+P+PV32\\L@#<YELY?Q@%<=#ME*UYVQT!P&VEP&PANEL83X^Q+MDI^(H%P
MDEXIN%!&&MP&>D/2X"8(;BH*[O_8Y`2ON2R=.0PSAZ7QR1"?TKC"M!).G$QR
M??'=>?<+``#__P,`4$L#!!0`!@`(````(0":Z#'B@P,``*P+```/````>&PO
M=V]R:V)O;VLN>&ULE)91;]HP%(7?)^T_1'E?0Q)@;56HH#`-J:-58>UC9!(#
M5A.;VDXI^_6[#B6]B:.H?0(G^.3<<S]?<G7]EJ7.*Y6*"3YP_;..ZU`>BX3Q
MS<#]N_SUX]QUE"8\(:G@=.`>J'*OA]^_7>V%?%X)\>R``%<#=ZOU[M+S5+RE
M&5%G8D<YW%D+F1$-2[GQU$Y2DJ@MI3I+O:#3Z7L98=P]*ES*SVB(]9K%="+B
M/*-<'T4D38D&^VK+=LH=7JU92A^/%3EDMYN3#'R_I:Z3$J6G"=,T&;@]6(H]
MK5R0^6Z<LQ3N7H2=T/6&99'WTDGHFN2I7D)Y)W7(*^@&0=_\TD3QR.A>?6PR
M2^?MB?%$[,U/(=I#N0K!P+ZX]<02O87[G4ZGO/:;LLU6GRZ"O(?TBP3A.<6G
MPXOR3HE$T*EHRC73AVC&C^DS`2TTJ<^@,M]UY"6#+W*6^,8X5KFYFT^F\\5T
M$L&WQ=WM;#):PF(\NAW-;Z9()4`JP==4P$!I)D0R1=Z?,+-8@J<_V$P7J70_
M:>9=!9N!\,MD>E^3@3C*FOI(IB`#UW0G-X2S?P6NT9@HIB*QCNXE54`S02KA
M3R3SL^YFD6<9D0>S=\$VG,&9(%Q'HS@6.==8!DYO6=1Y76;&7^&Q0A[PC@NT
MXZ*^8_J2LYTY>1&GNF`MAG.G91Z;`XADN@![^6"_4]>90;5\PU8IC8A25"NC
MA[=7,+4X?1`'D@+A=ZN4;8YA&NXG=$VEI%@'@^I;I+X'IJ)[<B"%&5"!BS*G
M272+=3"IOH7J@YE`L.6>2'"UE(0K4B2B3$98![/J6[`NMD32K4@3F%Z1R5KC
MUG0QH;Z%Z(*DM,!IS,22932Z$5DF>%2(*FP"(^I;C"[HINCPQ_BH-!:#Z3>0
MN5+T)3>$3`U<E>=B&'V+QG:H\4GM8D9]"]+V0X:%>IA2F,^U<=A.>T4(\QI8
MO#;B'BT-<CB@'J8UL&AMI[YB!^,:6+BV8U\1PKP&%J_M2>.I&&!V85%+NKWW
M%2$,[_&O%P_8<J3!,-"$I3C>`*,+BYJ']FY7/&"0`PODYFXW^,$8!Q;&[>W&
M?D*,,2QJA;6WNR*$,0XMC-O'7(4;W.[0(KEASC7T*\04PZ)65ON\J[C!S(06
MQ0T#K\%-#],#;V]U-WEM\#5)8&["8O!Z!;SP,A>3-(:W3/-1O*9U>_WC'/%.
M+]K#_P```/__`P!02P,$%``&``@````A`,0'>7%"!0``.Q,``!@```!X;"]W
M;W)K<VAE971S+W-H965T-"YX;6R46%UOJS@0?5]I_P/B/<$V8'#4]*I0=?=*
M>Z75:C^>*7$2U!`BH!_WW^^8<<`VV[NA#VU##F>.9\;''W=?/NJ3]R;;KFK.
M6Y^NB>_)<]GLJO-AZ__UY],J];VN+\Z[XM2<Y=;_+CO_R_W//]V]-^U+=Y2R
M]X#AW&W]8]]?-D'0E4=9%]VZN<@S?+-OVKKHX6-["+I+*XO=\%)]"A@A/*B+
MZNPCPZ:]A:/9[ZM2/C;E:RW//9*T\E3TH+\[5I?NRE:7M]#51?OR>EF537T!
MBN?J5/7?!U+?J\O-U\.Y:8OG$XS[@T9%>>4>/LSHZZILFZ[9]VN@"U#H?,PB
M$`$PW=_M*AB!2KO7ROW6?Z";G'$_N+\;$O1W)=\[XW^O.S;OO[35[K?J+"';
M4"=5@>>F>5'0KSOU"%X.9F\_#17XO?5V<E^\GOH_FO=?974X]E#N&$:D!K;9
M?7^470D9!9HUBQ53V9Q``/SVZDJU!F2D^!C^OE>[_KCU0[Z.$Q)2@'O/LNN?
M*D7I>^5KUS?U/PBBF@I)F"8)0;W^GMU*$J"@87R/15_<W[7-NP=-`R&[2Z%:
MD&Z`6`TLA/2@C'&HGXT4AJA('A3+UH=NA]<[*,_;?1+?!6^0T5)#LCF$VHC\
MBE"%`'6C1!BW*?&_<WY5HL!*B:J!DI;A`^`>I3$G[AR1\!%B*8$$W:Y$@;=^
M9`1.DI$6M2$$&T:)S8T'5F!@N3VP`D,5S<"I$Q@A8JA42`6-I@$/RG(3P$04
MDVADL(1!]]XN3($=86*DQ8P@A`_":,SCF-B`W`2()$TGX98NOD27`MNZ4B=L
MAA#4Q46:AH[PW`3$"2B?`):P9(DP!7:$.9,F0P@*2X6@4U@LI/F]2.//\J46
M*L,&?CS'%-B1Y<RI#"&ZCHQ'43PU$`JS$(1S'DZ.865,+)&FP(ZTT.Z@#"$H
M;072*'>F96XAZ#`_1@Y+&@6GO#UM`]H1YV0ETQB=.$((2UUU%D2$4<*FGK#5
M*4.]N:@4[1<F_FB4Z501G)T:8QB6^<0.OLBU*7JPZ5E&I^K@B,'4B)"%,75F
M::YI$))&)`[%5'U;GG+:VW.#OFS)<\J24<1@[)B"-9&9/!,2<I[0Y+/2*?^]
M71ZZM27/=7R*&-U88.@LG*?/PC"2L)A/#6KG;Y'QJZV2.RT=H\HT!@6N:`@*
M0>,X[]`T'!"E89)&$\B6N&@-H&C@D(&Q_853OTQCS/;'MX8G=O!%/D_G1B^F
MSM#M;SKYBL41=Q"Y9M$93,/TL]HM,GLZ=WOANKW&Z,@LA`W#5!1=.=/ON:#)
ME%P[<8OLGL[]WICQ.G&6G8/APW;';2L3PDEB>(\ECBWR^P%M^[UP(F<:,W9]
MPKD('6O)'1`E24+B"61+7&3Z#$W?=`[AFK[&H$1*$YZF3OUS&Q)&@K!/]F5L
MT;(PH)T,3L187HVY9I#%@I#8&4-N@T3"4CAZC4U@)U"9M&&]UQ/1C[=$#*W=
M2N14(:T4,:B418SQV=JN:72N.1.$3BRV3.75RV6BPULRW96"(08/!RM*8'\4
M<@>4VZ"4"%`Z];:MU%DJ;DSH?,D0[I*ASLZPK,"&2)TX5V1-7=>9(R+84QD_
MGS6!LW8HS1%$^Y\FP-7`S"YU-P$97%,HT5CB)&5<;17&5D2SM#!QRN(D8FX?
MX%T%GN5KV1YD+D^GSBN;5W4/P2`EX]/QCN2!J7.Q\SR#NY/AHB$8OX"KBTMQ
MD-^*]E"=.^\D]T!)U@EDH,7+#_S0-Y?A!N&YZ>'28OCW")=4$HZR9`W@?=/T
MUP_J5#]>>]W_"P``__\#`%!+`P04``8`"````"$`0J!F`<L"``"C!P``&0``
M`'AL+W=O<FMS:&5E=',O<VAE970S,2YX;6R45<MNVS`0O!?H/Q"\1P_J91F6
M@\1!V@`-4!1]G&F)LHA(HD#2<?+W78JV;,E!:U],49X=SLXN5XO;MZ9&KTPJ
M+MH,^XZ'$6MS4?!VD^%?/Q]O9A@I3=N"UJ)E&7YG"M\N/W]:[(1\415C&@%#
MJS)<:=W-75?E%6NH<D3'6OBG%+*A&K9RXZI.,EKT04WM$L^+W8;R%EN&N;R$
M0Y0ES]F#R+<-:[4ED:RF&O2KBG?JP-;DE]`U5+YLNYM<-!U0K'G-]7M/BE&3
MSY\VK9!T74/>;WY(\P-WOSFC;W@NA1*E=H#.M4+/<T[=U`6FY:+@D(&Q'4E6
M9OC.GZ\2["X7O3^_.=NIDV>D*K'[(GGQC;<,S(8RF0*LA7@QT*?"O()@]RSZ
ML2_`=XD*5M)MK7^(W5?&-Y6&:D>0D,EK7KP_,)6#H4#CD,@PY:(&`?"+&FXZ
M`PRA;_VZXX6N,AS$3I1X@0]PM&9*/W)#B5&^55HT?RS(WU-9$K(G@75/XI.K
M28(]":Q'$C*+_"C^OQ37IM6[]$`U72ZDV"'H/!"N.FKZV)\#L[$G`),_M@=\
M,3%W)J@/!;2"DKXN@S19N*]0AWR/N3_'D#%B]0$B'"`NZ!M$@F_7BS1!&0XQ
M&D22Q!_X^T3N+<;6W62V.GDQ4@#6G"KXMST&##:.3@XF)UM,VIM'$B\)@XF!
MJQ&"I'$<1@/'2!ND>+DV`YYJ.[IN7;&8V!;62XD7>,/)/6(U0L!-\,@QOY$V
MN".7:S/@J;9CSE:;Q5AM)/3B63J1=@I(X]`_`8R4Q=<H,^"QLB"=C0^^MYB]
MLADAT:395J>`T$\"/QX81LJ2L;++KJ0)FBH<Z*UU%F);+@X(N#=MN1%B!C,N
MF9;5SED[03JZ8<]4;GBK4,U*N&:>DX#]TDY9N]&BZR?%6FB8COUC!1]#!I?-
M<P!<"J$/&S/'A\_K\B\```#__P,`4$L#!!0`!@`(````(0")*)UB0@,``/\)
M```9````>&PO=V]R:W-H965T<R]S:&5E=#,P+GAM;)Q676^;,!1]G[3_@'@O
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ME(H2`H!/J^*F-2`C]+G]WO-,%RL[B)UHY@4$X-:&*7W/#:5MI3NE1?4'0:2C
M0A*_(X'OCH1$3NA'L_D$%A<C:@W>44W72RGV%G0-:*J&FAXD"V`^.,,X>J]O
M606/AN3&L*QL:'=PH:`^3^L@"9;N$^0T[3"WB('/'D-ZA`O1]"%!&,.07D_R
M0=F`C;))N@GE%O\8ROBORP1C&>,\@,ZX+&<VK>QP8`(*T/-C!(AI^V#D"W9-
M]V7`$-!`*$B.1E`(,=!!?4:#^!C,2!M`0^UI9LVFL=D@"4_,(N;<;#P6O)Q5
M`S9F3>/X'HE.-'`Y:9?G/G1[OS[R.'N/I`$/)..>$E.+RW$K2;PD\KP>,-(T
M-_S@^%RV:<`#S6.I4!.7_ZV9O$?3@`>:\]X&:N(R:LZ"^*WV(7`PIOMLT0/1
MY$2T6T=5/_3FQZMBE%QBKHS)V6W11O5X'/SXM*X=J)/VWI9^UR5$\-(92Y^F
MN@.A=$CF271$C&V;"V1@>]IA)6;7V'Z0'$\*EKL#80R7^AJFZ?_$\-JM=58"
M!.%Q#KPD/,L#SF$<4Q636_:)E:6R4K$S,Y;`H>S_[>?_C=].\'X!QF]#M^P;
ME5M>*ZMD.6SUG!G<5Q('.#YHT;1#<",T#-[V9P$O6@Q&B><`.!="'Q[,*T+_
MZK;^"P``__\#`%!+`P04``8`"````"$`.:8+)C4#```&"0``&0```'AL+W=O
M<FMS:&5E=',O<VAE970R.2YX;6R4EDN/FS`4A?>5^A\0^P',(X$H9#2`IAVI
ME:JJC[4#)E@#&-G.9.;?]QH'`J2/=),$Y_CD\[G7=K;WKTUMO!`N*&MC$UF.
M:9`V9P5M#['Y_=OC76@:0N*VP#5K26R^$6'>[]Z_VYX8?Q85(=(`AU;$9B5E
MM[%MD5>DP<)B'6GAFY+Q!DMXY`=;=)S@HI_4U+;K."N[P;0UM<.&W^+!RI+F
M)&/YL2&MU":<U%@"OZAH)P:W)K_%KL'\^=C=Y:SIP&)/:RK?>E/3:/+-TZ%E
M'.]K6/<K\G$^>/</5_8-S3D3K)06V-D:]'K-D1W9X+3;%A16H&(W."EC\P%M
MLM"T=]L^GQ^4G,3DLR$J=OK`:?&)M@3"AC*I`NP9>U;2IT(-P63[:O9C7X`O
MW"A(B8^U_,I.'PD]5!*J'<""U+HVQ5M&1`Z!@HWE!LHI9S4`P*O14-49$`A^
M[=]/M)!5;'J!M49.Y*W!94^$?*3*TC3RHY"L^:E%Z&RE3=RSB0?TY^]=*U@[
M'H+?O-7$/YO`^\7$#0,4K/[M8NME]2EE6.+=EK.3`9T'X*+#JH_1!IR'>/1B
MQL#^E!<$I4P>E$MLPI:!*`34^&7G16AKOT!A\K,FN=8L%.F@4%50MID>Z+.T
M@7>$ACRGT+^OY<"FQ(IM<$WT`'B/L.X<-;U6K%=S278M<?U1,H.%HM\.J\2Q
M"86XL/G1Z-NGDFB-;E854[H<R"8#,Q3PO1U%B:';IRC!HF*)UD1]Q0-7->*2
M-M62"VWVUSDS7-@;M^,J\1)W4==$:U8][AT*'#=T_?4\W51K)KSS2=X:^2CP
MQDDSX-7_`"OQ'-A;-%FB)9H7SAO/]YS%DE(MF>#.YH2A'WK1Q79&N_X?6B5>
MT$8+ED1K(*^Q>;W5,MY!,^S&;#(PHU/W[^1@^OL>5^(Y'4*7[:BWC=;H7D4>
M\IUHH4CGBM4ZBL*QSOI`THH^;0VK[QU]HC:$'TA*ZEH8.3NJ.\6%3AM'Q^ON
MP55GT6(\01LX_V#<'K^`:ZC#!_(9\P-MA5&3$BP=2]T[7%]D^D&RKC_']TS"
M!=1_K.#_!H&CP;%`7#(FAP?U`^,_F-TO````__\#`%!+`P04``8`"````"$`
M>;^[?3P$``!/#@``&0```'AL+W=O<FMS:&5E=',O<VAE970R."YX;6R<5UMO
MLT80?:_4_X!XCV&YV[+]*5S2?E(K554OSQC6-@JP%HOCY-]WEL%X=VECIR]Q
M&)\Y/F=F]L+ZVWM3&V^TXQ5K-R99V*9!VX*557O8F'_^\?(4F0;O\[;,:];2
MC?E!N?EM^^,/ZPOK7OF1TMX`AI9OS&/?GU:6Q8LC;7*^8"?:PC=[UC5Y#X_=
MP>*GCN;ED-34EF/;@=7D56LBPZI[A(/M]U5!4U:<&]KV2-+1.N]!/S]6)WYE
M:XI'Z)J\>SV?G@K6G(!B5]55_S&0FD93K+X?6M;ENQI\OQ,O+Z[<P\.,OJF*
MCG&V[Q=`9Z'0N>>EM;2`:;LN*W`@RFYT=+\QG\DJ(YYI;==#@?ZJZ(5+_QO\
MR"X_=57Y2]52J#;T271@Q]BK@'XO10B2K5GVR]"!WSJCI/O\7/>_L\O/M#H<
M>VBW#XZ$L57YD5)>0$6!9N'X@JE@-0B`OT93B=&`BN3OP^>E*OOCQG2#A1_:
M+@&XL:.\?ZD$I6D49]ZSYF\$D9$*29R1Q`7UX_?.ETF\D00^;R1.Y!,_^((4
M$#WX@<^)Y9X/"VLRE#C-^WR[[MC%@+D%U_R4BU5`5D!XK2U68JKV?Q4;JBQ(
MG@7+QH0%!W7D,"%O6S=RUM8;=+48,?$<0U1$<D6(%@K:%`/8"!'(I(`%!B87
MT!W9Q;]/QE6L``NQUY^),0#<DWI->S)'A($J/IU#'$^%9'.(Z]]JH!B",9,-
MB;:XL'`^-R:2-B8,U^3#C5Q50XP87":BI(D>2/5`)@44C?!#LL;/M0DP>)"T
M.>Y2TX:8Y3`_WM*)(C]4$0DB;NI3)24*;9]H?<FD%$4]#/OCZ@584^_=.C<,
M:XR88%`?V$&@`Q($2.+E#,_V0]=6[692AJ(]^(IV`=:U:_,=(P:U/SE!:$>.
MUIP$(9)Z-<<CD6?K^J4<17^HZG]LND62ZL.-M!46(P9].%'@!8%N`Q&2#37%
M#R-/GR`I17$A[A?:UGE_C8HDW86OMCU&S$UCH@=2/9!A`(T3XMM2*Q3-R_^C
M623IFK4BQ8CY9/H1<#.5ZH%,"BB:"6Q\<J$_WV@&M*J6$'T7'$'CH`1.(-5K
M6,V)BO"#I:=U*1T1-T>9'%$=B'-+&I4[#O"4D_=*-])VPI@@:'3@.]YLP8Z(
MF[YT%LGDB*I8G%62XL>6*,$33E4>:=,]@E"Y!YN&/*QC\9%'EJY'LI%FP*C2
MQ7FE2?=@)[U3=)&ECHT;:9M'3!"$TOW`7H;:CI>,"%DYYMPBF8Q1E8NS2E-^
M?T>!J_=,^5+3%8\@/%N=R`T#;>M,%(26GHY?RB9FYRK>W_%RV=#N0!-:U]PH
MV%G<S1TX%Z?H]-[P[(A;F!:/R0JN@A"WIB_@.G_*#_37O#M4+3=JN@=*>Q%"
M6SM\(<"'GIV&*^V.]7"1'_X]PHL;A8N.O0#PGK'^^B!^8'H5W/X#``#__P,`
M4$L#!!0`!@`(````(0`M&B@T9`(``+X%```9````>&PO=V]R:W-H965T<R]S
M:&5E=#(W+GAM;)246V_;(!B&[R?M/R#N:WR(<U*<JDV5K=(J3=,.UP3C&-48
M"\CIW^\#$B]IJBV[L8W]\O!^)\_N][)!6ZZ-4&V!DRC&B+=,E:)=%_C']^7=
M&"-C:5O21K6\P`=N\/W\XX?93NE74W-N$1!:4^#:VFY*B&$UE]1$JN,M?*F4
MEM3"4J^)Z32GI=\D&Y+&\9!(*EH<"%-]"T-5E6#\2;&-Y*T-$,T;:L&_J45G
M3C3);L%)JE\WW1U3L@/$2C3"'CP4(\FFS^M6:;IJ(.Y],J#LQ/:+*[P43"NC
M*AL!C@2CUS%/R(0`:3XK!43@THXTKPK\D$P7`TSF,Y^?GX+OS-DS,K7:?=*B
M_"):#LF&,KD"K)1Z==+GTKV"S>1J]](7X*M&):_HIK'?U.XS%^O:0K5S",C%
M-2T/3]PP2"A@HC1W)*8:,`!7)(7K#$@(W?O[3I2V+G`VC/)1G"4@1RMN[%(X
M)$9L8ZR2OX(H.:(")#U"X'Z$).E_0[(C!.Y_(.DX3_+AOZV0$);/TA.U=#[3
M:H>@\\"XZ:CKXV0*Y/?3`OEPV@<G]EL@8@.EW,ZST61&MI!_=M0\7FO22\7B
M'<6@EQ#PU9N#?-UNSHD+/,"H-Y=F2<_U`3P&3:BSBVAQ]N+B9$C%[2<[,?3%
MV<G9.'YS<M!,?-+2\3!/LDO!XD*09VDZZ@47SB#`<V>NGS.8BK\7SFUZZ_!M
M;H(F.$S2T23OS_>Y@R%UC/>^!W]A!$-S=73-7ZA>B]:@AE?@,8Y&,"\Z#&!8
M6-7Y9EHI"X/C'VOX3W*H2QR!N%+*GA9NQ/L_[_PW````__\#`%!+`P04``8`
M"````"$`&PM+A.4&``!('@``&0```'AL+W=O<FMS:&5E=',O<VAE970R-BYX
M;6R46=N.VD@0?5]I_P'Y/>#V%=`P4:`[NY%VI=5J+\\>,(,5P,CV9)*_WVJ7
M#575+)@\9(;#J>)4=76?9OST\?MA/_J65W51'A>>&OO>*#^NRTUQ?%UX?__U
M^</4&]5-=MQD^_*8+[P?>>U]?/[YIZ?WLOI:[_*\&4&&8[WP=DUSFD\F]7J7
M'[)Z7)[R([RS+:M#UL#+ZG52GZH\V[1!A_TD\/UD<LB*HX<9YM60'.5V6ZQS
M7:[?#OFQP215OL\:T%_OBE/=9SNLAZ0[9-77M].'=7DX08J78E\T/]JDWNBP
MGG]Y/995]K*'NK^K*%OWN=L73OI#L:[*NMPV8T@W0:%NS;/);`*9GI\V!51@
MVSZJ\NW"^Z3F)DR]R?-3VZ!_BOR])K^/ZEWY_DM5;'XKCCET&];)KL!+67ZU
MU"\;"T'PQ(G^W*[`']5HDV^SMWWS9_G^:UZ\[AI8[A@JLH7--S]T7J^AHY!F
M',0VT[K<@P#X?W0H[&A`1[+O[<_W8M/L%EZ8C./4#Q701R]YW7PN;$IOM'ZK
MF_+P+Y)4EPJ3!%T2^-DE4?$X"N)T^DB6L,L27;($#TL!T6T]\+.7$HR#::SB
MY'Y!$VQ.VVN=-=GS4U6^CV"`H?SZE-GMH.:0N6\RMN3<]O_K.K3;)OEDLRP\
MV'G0T!I&Y=MS&,V>)M]@>=<=9XD<^/_"B7W.6;EY%&?HGF'7VWZTZ=/:48*:
MSH7!BM'"KD]-K]^2K?X^ZQ(!+E9(6;F<0(AU&6G"*<:E!-&9P@J"(:(%V94*
M85/=+LP&+3R8NW/3U6QZSM]V<(D<W$*VI2L):`D8`C"-\$%4XVUME@PU$&UA
M+#JX1`[1AL"LG;'$CZ>^&"$M(PR-B*-92"*8=IC^X=HM66H/15^10[0CD+3:
M@\2G2MJ5T#+"T(AH!C&7:IGVY!'MEBRU7V8.9P(Y1#L"J%WY?DR4H'8986Y$
M,.TIUSYLKFT0G^LPCD7_D4-JD("6@"$`TVCO%.*4O+_W;)#LL]C^2^00C0A@
MGS_$H4I27I5F!.6G0729B78E#,G)BICQ(FYO3DN6XH64)7*(>`0Z\8$?*VD"
MFC&4'RBQX0W)R<0K..KH$MQ6W[+E?,ASKR,1_0ZB'<10A"NT3D2&Y(Y"]"U^
M^CF6B22JL$>LQXJ%U^K&F^;\IC1*92UHN&XT+*I[)C=>FW'A4=D8U4V&4FDR
MG8J5UUU4SX$+A!^([6)H9MY\ZTC#B[!L,=V)Z.92(8E6@0@JA/L?G(,B2'=!
M'45=H1B:E]=@G8K4,.PD5.AO(.UL\6$BKBK+CD1KP3`4FD97*J$$N#0X#$.3
M\D*L;3U>")H=+T0,R=)^`8"50]E@0O8?/R!7'>52JW800Q$NW;K6X]+1Z[AT
M>1U0W!#!_:]H1P[5+A'3Y6DY7+MUK\>UH^=Q[?(ZH)"$UZX0KB%7I!/OQ!M!
M%W0IQE"$2[>>];AT=#H85#+ZSF%$[+#5M5(2T0YB*,*56H,B2N^<\FAGO+GB
M4%LJXGF=PAZAA0GWU4Z8H0@3'3QDGBU;GH[2/#O297%7#J(=Q%"$*[361=IJ
MS[X(]OKM]@9H>'P`I(EV)*JT]\G^ZYYV.(8B7*FPRX%*7=L,4W%R+0,D4:74
M-Z/I+)Q%XD3475#G.'X<)2H4HV)H8EX,3"9M^YUV6[88C%1:38`D6H1$M,,Q
M%.$*K0T]/AAH7G<&`TE4J41T(!%#$:[TBNL-&.$KKN<.!I*H4D1PU:,@2>"[
M,/=!;?\H=+'*:*9"7ZR5Z2AM7EZ+=1W2]3MS@1X%RWPYAU,QI\M`&MG*0;2#
M&(IPA5?,;D"WT:3NS(5TLE4@$>T@AB)<Z15O&Z`438KWU#DPI).M`D1P+F9J
M%B6I.`\UIZ2Q2I08'=-1KLS%0^X77'&_5%Z+.A*=[=[]+L>S1`R-8MVV7\OI
MY`Z[1+=1XOMB(KJR[$A$J8-H!S$4X4J%Y=W>8R%Z%IN'1-XD.A)5V%L=V9K.
MGQ2<,$,1+OJ*^]D*[XB_YG[RCADZ[N<@VD$,1;A2ZSKD"!LX"#9*#(+SAZ40
M2;3-$M$.QU"$*[4>0Y3>Z24Z$GP@.6R=496VM0I[A(:)^=%G4K_S#$6X:.LN
M1/3`]J(G<?'BMK(,D43;*Q'M<`Q%N%+A90.5HEU!URYM=@?!\;10(MI!#$6X
M4N%I=P8!38GWTAD$Z5PK>&1G)QPZ>BDL%;=[?29=!J$/`P1%XX,[?)ATR*O7
M?)7O]_5H7;[9AW(!_)7[C)X?&'X*[",6@:_4'![KV+SG-^`YWBE[S7_/JM?B
M6(_V^192^N,45%?X)!!?-.6I?83U4C;P!*_]=0=/;'-XBN&/@;PMRZ9_83_@
M_`SX^3\```#__P,`4$L#!!0`!@`(````(0"9S-L%#@@```DG```9````>&PO
M=V]R:W-H965T<R]S:&5E=#(U+GAM;)Q:76_B2A9\7VG_`^)]`+L-ABC)U>#N
MWKW276FUVH]G`DZ"!G"$R63FW^]IG\8^'QDP-R,-2;FZ4W7Z=)<AOO_MQWXW
M^%X>ZVUU>!@FH\EP4![6U69[>'D8_N??_LM\.*A/J\-FM:L.Y</P9UD/?WO\
MZU_N/ZKCM_JU+$\#F.%0/PQ?3Z>WN_&X7K^6^U4]JM[*`UQYKH[[U0E^/+Z,
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MVDG2.`F\QDG2;)1DDUF8X\(X$\?!:QR7C;)TFL^;7WYA8!8'PNM-OQ#D-&[A
M]3PN[2-T%L?!ZWE<,LJ3R<+DGSH<8Y6;1;.KT^KQ_EA]#&`G0!WKMU785\D=
M3'9>+;3:KM^OE@]*'B;Y&F9IYH*5J:'GOC^:='$__@Y]LHZ<)7)@F[><E#.*
M,R.L9)C6ZFG3C(]QFI+/.,5KBC&3EC.&0K35@'ZAU?B\9\^F`_EA""O>&C(F
M:>=M'"R1@WT>+!42L!)P$O`$8&*A2?N+#6382D3L5"X04A;-\GU)%JF9YO"/
M&RJ0U!FR?-0\31:3=)+S44Z.\@1@GJ":_3T%,O=DC.BI)7)FC2EPDR3Y7+10
M@11BB8Z9I7F:YC-1!B?'>`(P0[`;^QL*9&XH%<V\1`KZ2:?S=#$UAA>[0`KQ
MP\8LLOEL,1%K[RAE-C/YW(@J><J89HMIEL_;W\L<PRG2WW$@<\=&^EDBI_-3
M2,!*P$G`$X")S6\1&\C7-CQRB%@)6`DX"7@",+'A%HF<U9=/IT#FE54;'BG8
M2[_<\$CJ#%D).`EX`C#]BUOT!S+7;V1/+I$3-\/$9$DV$P=P@10B7P).`IX`
M3'X"]T+]Z]^PI0%Y.D72Q>,I<H@%A3B%>(IP%R$.>W=1@N$)QW4;<NI(BAP,
MCE^<29%#3>#,'>(4QU.$FPB9V-\$)B@U88PXT9<)B=DFNPN%6(4XA7B*<,TA
M\_IKQH2$6&D+K^\N$B1U-2P48A7B%.(IPC6'6.NO&4.0UUD&6(*DF6DB>3*:
MY=,)_1*Y4T1^Y]$JQ"G$4X0["CG6WQ&F'G<D;FZ6X=T-'%6=PD(A5B%.(9XB
M7'-(K_Z:,>NN=`X)Q-CM$K&)1)Q"/$6XYA!B_35CY/$ZJ\Y!4MLY<WG6)R0X
MXQL(B3C%\13A%D*.$0OAO9&!#+B<NPFF'[?2W2KAVX)(HBU#0C-JEXA3HSQ%
MN/808D3[%<T8>5=:AN1B;!F)V$0B3B&>(DQS*O*U>2^:AT\)KI2\&2BC5G9/
M)+7=`Q\%M/>O:.?,X&40=\HVLKJE<PKQ%.$61?CV:ZE4A[#)NG>PV%*1U.DJ
M%&(5XA3B*<*UWY2Y*<8IKZ78L,M(HIIE"EO%<0KQ%.&:81OVWP9I8%_M(R3%
M/A*.BCA%Y\@JQ"G$4X3KA_K=H#^PA?Y,*%RF2.H4%@JQ"G$*\13AFF]*V+"[
M0?.5/E$)&X=U+JQ"G$(\1;CF$'6]C\L4@Y$?\>J\05)[WN33.;W-F8AU*>*D
MU)'*7\7Q%.&.0O+U=X0YR1QE\LU**L.T4(A5B%.(IPC7+`+W<FBEF(]7.D>&
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M\2HK028^6+&1U97`*<13A-L+L4>"^4H*8$@R3YE\UVYDDA8*L0IQ"O$489JS
MF]*V85\[<B*IJV&A$*L0IQ!/$:[YIK3-,#99G=5=3R2U1\XBRQ?T2T1!$?F=
M1ZL0IQ!/$>Y(9/'ESLEB`.,#".%OO$L-%1JR&G(:\@SB,J&(M,&;_0N']8U_
MNL_"-")LC?C08WDF@=?VR$H6<E=WK/8O^!IR&O(,XB9#/I)=_&=-8LRRMI-W
M.,LLDKA)\2ZHZ%B=R7;@&7*:Y1G$38K4_K,F/XES>:8NX=&?9KFY21GI'>OL
MR&K(:2@\612GAX%H$I\4PH=.]N7QI2S*W:X>K*OW\!30%/X,T*+XA-(RN2N:
MW23PKUD*CRZEX4$?<07Z$ZZ83Z]D<"7[],KT_"#4N)T.'D1Z6[V4_U@=7[:'
M>K`KGT'B!.YYAH,C/LJ$/YRJM^9QEZ?J!(\@-=^^PB-G)>S^R0C(SU5U.O\0
M"M$^Q/;X?P```/__`P!02P,$%``&``@````A`$@](^4>!0``@!,``!D```!X
M;"]W;W)K<VAE971S+W-H965T,S(N>&ULE)A;;ZLX$,??5]KO@'@_`7/)34F.
M&JSN'FF/M%KMY9D2)T$-.`+:M-]^QQX#MDD3TH>V&?X>?IX9SP16WS^*D_/.
MJCKGY=HE$]]U6)GQ75X>UNX_?S]_F[M.W:3E+CWQDJW=3U:[WS>__K*Z\.JU
M/C+6.."AK-?NL6G.2\^KLR,KTGK"SZR$*WM>%6D#'ZN#5Y\KEN[DHN+D!;X_
M]8HT+UWTL*S&^.#[?9XQRK.W@I4-.JG8*6V`OS[FY[KU5F1CW!5I]?IV_I;Q
MX@PN7O)3WGQ*IZY39,L?AY)7Z<L)]OU!HC1K?<L/`_=%GE6\YOMF`NX\!!WN
M>>$M//"T6>URV($(NU.Q_=I](DL:Q*ZW6<D`_9NS2ZW][]1'?OFMRG=_Y"6#
M:$.>1`9>.'\5TA\[88+%WF#UL\S`GY6S8_OT[=3\Q2^_L_QP;"#=,>Q(;&RY
M^Z2LSB"BX&:"&!D_`0#\=HI<E`9$)/V0?R_YKCFNW7`ZB6=^2$#NO+"Z><Z%
M2]?)WNJ&%_^AB`BHSDF@G(1`KZX'#SN)E!/XVSJ))U$0S^8C4#S<EHP239MT
MLZKXQ8'2`_#ZG(I")DOPW(8'-],%[*MXP1Z%DR?A9>W"F8%0U)#D]TVX6*R\
M=TA,IC3;H8:8BJ15B-`)MQ0-\+MW&_O=(@^VT.T#0JSOXWIZ6UPA%KCMC;9H
MT&\4=+>1*$F[I$>934T)'4HBO]^B00N%,)Y6B`U:-.BTD=^'!7GM150S&"B0
M]/$H0KQVX7>7D,BW(K5%C3S2B&(;J&8P4.!`C4<18CB,!DIH9F2+FH4LR-C7
M2@?!\')/2C6#`39]!$R(;;#(`D--+,$6@]RU5]ORI)K!X)J97.+PAM`A;Q>_
M6&3RD7!N\:$&^>S*PFM3R3XG\R".K9-.V]7`;^"*F6KUFONX8I&)&_FQA8N:
M/I&);:":P4!:F$BW(R?$]ZH?-1J*;:":P4`AD+G'PR-7F?$9IE.)-*J!A2H+
MYC6.??'3A=D$%6U9R^/MH!&A-@$CWVJ=6R72`7%9;Z%*@X`D(CY4WA>`HA./
M!\2^;7:26>=9MHHM05&/DPPL5%D@D'(`3OIC889/=&*-;MRI)=B_34K[V"J1
M3HG+>@M5&A5&".(T^BK/HD\_#HK=70<-!_V%:",`>_'`0G6+&4#1IC6N._6'
M31UN>&-FB6^$4*1]F)*!A>H6DT>T9XUG9$*QJ>MQBOR^9%39M9U?5)0U:!/2
M7NSFA&XQ$45+UA#OA`P;N(%&^B)1:&H.A++:_8EO#=^$:&-`+J&ZQ<03[7D\
M'C9S$Z__HJ7P4(2S/[#@$Z+-`\6F64PVT:\UMI'9Q2YO,EH)W!(4(6-D[2!1
M5_N:I+K%8`RLT7$[O5)M=61B96^K1-@FHID_M[_N)DJA\>D6D^^AB1%<F1C$
M_@:E1'!N^V--^GD@DYITHNZ$Z!83T9H9X](<7)D=Q!YN2C1M3TI@Q3I1`CV2
MVK@Q,:&B]&J\DVFAMC-MC[8`16H@3!<+WQHKB5+H?+A&6DP^:V;<X1O.BHA8
M=]\&*$*^.(SF=H`3I=#Y<,T5OH=FAWC$'\3/[M%*A*<XG$97XF=/%_'&HYLW
M&#]\@8&/Y@6K#BQAIU/M9/Q-O)R(H,EVUN[%R5,HGF`M^Y8LX4%Z:$^"97)-
M3X,E/!N"WNL<P?N/<WI@/]/JD)>U<V)[0/`G,X"N\`T*?FCX6;Y`>.$-O/F0
M_Q[A31>#1W=_`N(]YTW[0=R@>W>V^1\``/__`P!02P,$%``&``@````A`.!4
MGV.L!```61$``!D```!X;"]W;W)K<VAE971S+W-H965T,S,N>&ULG)C;CJ,X
M$(;O5]IW0-Q/P$".2C)J0+T[THZT6NW.7!/B)*@!1T!WNM]^JUP<;)/))-,7
MW4GQN_+YMUT5]_KS>Y%;;[RJ,U%N;#9Q;8N7J=AGY7%C__?O\Z>%;=5-4NZ3
M7)1\8W_PVOZ\_?VW]454+_6)\\:"#&6]L4]-<UXY3IV>>)'4$W'F)3PYB*I(
M&GA;'9WZ7/%D+P<5N>.Y[LPIDJRT*<.JNB>'.!RRE,<B?2UXV5"2BN=)`_SU
M*3O77;8BO2==D50OK^=/J2C.D&*7Y5GS(9/:5I&NOAQ+426['.;]SH(D[7++
M-Z/T1996HA:'9@+I'`(=SWGI+!W(M%WO,Y@!VFY5_+"QG]@J]ICM;-?2H&\9
MO]3*:ZL^B<L?5;;_*RLYN`WKA"NP$^(%I5_V&(+!SFCTLUR!ORMKSP_):][\
M(RY_\NQX:F"YIS`CG-AJ_Q'S.@5'(<W$FV*F5.0``+^M(L.M`8XD[_+O)=LW
MIXWMSR;3N>LSD%L[7C?/&::TK?2U;D3QG41R1GT2KTWB`WW[W'LX2=`F@;]#
M$F\Q9=/9SU$<FI9T*4Z:9+NNQ,6"K0?@]3G!C<Q6D+FSAR;3&_8CO\`H3/*$
M638VG!FPHH9%?ML&GKMVWF!ATE83CC5,5T2=`E<!T\84D%XZP-M#@Y\J]/6U
M[-A0C&Q=UI`"D+N']0R0L6(^TR7Q6.(%O42#A46_'Q;%&QL6HF<+/,.FD#2T
M6=&FR`S$2D!#@;PJ"BZV#R?JMG\X"'0:DF%82)J97'DH</C3FR&7,B+%`!W?
M&J)!PS%['!H'Z="SI4X4DH28YU>(Z;E"_.,!&N],Y[UM+HK-]?8-4-(,()$9
MB)6`AC)_!`7%NF5S<^>1A"R#^B?7V5QHT@RT\>U!&B\V7:,8_7Q_XB"#VV`*
M2;*4V]-X%M$SA?>Z6.-<_@HG#M(Y`Z5DR%,2DH8,7O@><^?SJ;X;(I(HO/H8
MYK'9<M&/T;`9G/7'_96C3'"#*FQ%[6E:^&RV\(U]'+4:!=T8Y7DPW:'0ZNS8
M"Y2]<?M8,>H<:M&:#^69O&XUA!PLEOXR,,I:U$I48DI\?9`.C!WB?F#J)RIP
MX`U6M,0D:C\\N%*SF*I@GHM'M-\+,DG<2N2<=&#L&O<#H]K<%7/]LT)&(@)>
M+&$WZX*H%:@&TY`K>-@P[L>C]@+)E$8Z'(O6SZXIX1<6PZ>(=0^[[PVQ&M&=
MP\YP/QKU$1W-;$[X%17L'8R)1I%8C>@\V`_NYZ'N`=-5K#(K/U-:C#0O&D5B
M-:+S8`M0>.[[WL&H<:@^C7IXJZ$-=JV)MX+!QUB-Z)18^!^GI':A4@:^L9="
M1J*93QUHXHY*(PE43"6B8V*]?QR3NH2..5ID$D%5Q@/!)D:1CQ@]5RF5B$;I
M_5*KD:.,HN(;13EL1=3-C:(>M0\51#6B(S[44;QQ1PG,#A>VHBGY!U<\H]SU
MS_N:HD:(CFZR=$<K>'7D$<_SVDK%*]Y2/4C=1_L;]).'MQLC'K(5W*@@[O0/
MX&)[3H[\:U(=L[*V<GZ`E.YD#L6FHJLQO6G$6=X,=Z*!*ZU\>8)_87"X;+@3
M$!^$:+HW^`']/T6V_P,``/__`P!02P,$%``&``@````A`*$95C@[!```MQ``
M`!D```!X;"]W;W)K<VAE971S+W-H965T,S0N>&ULG%A;C^HV$'ZOU/\0Y?V0
M*[`@PM'":MLCM5)5]?(<$@/1)G%DFV7WWW?L,<$V+(3N0Y8,GV>^N?A+S.+[
M1U-[[X3QBK:9'XU"WR-M0<NJW67^WW^]?GOR/2[RMLQKVI+,_R3<_[[\^:?%
MD;(WOB=$>."AY9F_%Z*;!P$O]J3)^8AVI(5OMI0UN8!;M@MXQTA>JD5-'<1A
M.`F:O&I]]#!G0WS0[;8JR`LM#@UI!3IAI,X%\.?[JN,G;TTQQ%V3L[=#]ZV@
M30<N-E5=B4_EU/>:8OYCUU*6;VK(^R-*\^+D6]U<N&^J@E%.MV($[@(D>IGS
M+)@%X&FY*"O(0);=8V2;^<_1?!V/_6"Y4`7ZIR)';GSV^)X>?V%5^5O5$J@V
M]$EV8$/IFX3^**4)%@<7JU]5!_Y@7DFV^:$6?]+CKZ3:[06T>PP9R<3FY><+
MX054%-R,D$9!:R``5Z^IY&A`1?(/]?]8E6*?^<ED-)Z&201P;T.X>*VD2]\K
M#ES0YE\$19)4[R363A)@K[\?C])X/'T:X"5`1BK!EUSDRP6C1P^F!F+R+I<S
M&,W!\_6,@(7$/DMPYL-4`UD.;7A?IDFZ"-ZA=(7&K!`#UQZ3C$,;L[[$1#TB
M`&(].\AY.#L)ENQDT23=U<E@4CD'4I@U8DRZ\74J4)SA5"38HN(:UF@PXZ;)
M^'KD])'($ISY<.W+GX;GC+`NB%'[!8M@&*SRPW`.SUF"8;#-R,FDSP@C(V:B
M1F<<JC\;L4:$XF91F=A4Y`Y,8!_?GE>YR*4TM0.N$&,4PS!8#*8V@]N1)?A>
M&Q!C1#8,5F3Y&!F\1R78S=EM`V*,R&BXWA>+RNP1*A+L4GERRH\8@\K)(-7E
M/+@6B0@:/[P@"NW2F#DT-,C@H2TS-:N@L/:PVGRDGAD-DL.9PB#?'I$(5=#:
M,*FCE"L-,GGA,F6Q63PDEA$*WVVAT"`S.BZ[$ET*FE.#^QLT0AFT:A"Z(Z)!
M)@M<-F!>(REMC]-"0;1HI<Z38Z5<9[Y)ZRL=E>\*)HL[@X$:>*<UAE"BB*L@
MFH\]&/]+.Z,KXGG9&D,L-0NT8&LB1^)M6HZ@#I/T"$72;LU9)_`QHT%F:[[2
MUN@A<57H>[JN069T0W#M&CRDI]$504T35\E.`GIZ#5KK90-:$CO".JPE:I4C
ML*G[6JA!1E%,BU64V)'3V[M%H>^U1(/,Z%_):.S(Z,`:H"Y:8WFQ6Y1K2S&T
M!5N3WMHML92\AX5,K7);<W[-Q-VB069Q9+!K4A([<GJG-:B'MX5,N;2+@LL4
M'WLP'I)1>;1R7S\N=HL&F;GCLELMP7,B'J,:PG9D3>J:>P4]R#-@#&\,O;4_
MGSXG\ESBV%?Q?*7L0?\%'!N[?$=^S]FN:KE7DRVX#$=38,7PX(DW@G;J\+:A
M`@Z,ZN,>?B`@<.X)1P#>4BI.-Q`XZ']R6/X'``#__P,`4$L#!!0`!@`(````
M(0#^&@7*M08``/`;```8````>&PO=V]R:W-H965T<R]S:&5E=#(N>&ULG%G;
M;N,V$'TOT'\P])Y8O(@B@SB+E1;;+M`"1='+LV++L;"V94C*9O?O.Q09DS-*
M?&D"Q+%].#H\,YQ#4?<?ON^VLV]UUS?M?I&PVS29U?MENVKV3XOD[[\^W^AD
MU@_5?E5MVWV]2'[4??+AX>>?[E_:[FN_J>MA!A'V_2+9#,/A;C[OEYMZ5_6W
M[:'>PS?KMMM5`[SMGN;]H:NKU3AHMYWS-%7S7=7L$Q?AKKLD1KM>-\OZ4[M\
MWM7[P07IZFTU`/]^TQSZUVB[Y27A=E7W]?EPLVQW!PCQV&R;X<<8-)GMEG=?
MGO9M5SUN8=[?F:R6K[''-Y/PNV;9M7V['FXAW-P1G<[9S,T<(CW<KQJ8@95]
MUM7K1?*1W94R3>8/]Z-`_S3U2Q_]/^LW[<LO7;/ZK=G7H#;DR6;@L6V_6NB7
ME?T(!L\GHS^/&?BCFZWJ=?6\'?YL7WZMFZ?-`.G.8$9V8G>K'Y_J?@F*0IA;
MGME(RW8+!.#O;-?8T@!%JN_CZTNS&C:+1*C;+$\%`_CLL>Z'SXT-F<R6S_W0
M[OYU(.9#N2#<!X%7'X3QJX,('P1>0Q"N,Y:I\U3F;EJC2I^JH7JX[]J7&90>
M$.\/E2UD=@>1K3P"1'Y;'M#%COEH!XU#`=U#3K\]<'$__P9I6'I(\08$(\HW
M$/((F0.](T>0+>9XFIL%+Q*9S`*W[!AVI%\XB,NVG4\9?8`N#()<?F$+!O'B
M"RMR80<Q3K%,<Y,)HEN)($9J95)SC(+(P11C<I=ES@XB)/-C>*>.@ZB1I%:*
MZ10#RAC`4LET%N:)&,("B1F>SIL%$V8:7[AP$,>,&R-2`B@10*F4\V,$1$Q=
M0\R"";&0$2>9@WAB><[3(,@(*&.`R'.CV=O$<DSLLIS:09B@("DK',019#QG
MVI`U46*$8+D.DT3:66.,&L;II%HPH19F[K1S$*^=SJ1D4=:<>C%$<)G*+`M%
MB\@93.XR_>P@0C+4C2/I(*\DE50JJ.,X8D26:QEJ`%%DT%TO%W!$$W*D910>
MX]B)U,B,K@N,$$I';0>3(W9P.KO,M?"XY8G0PIUR'N/(22G2E-`O*8*_5WGL
M*A\8T40Y4O2%QSARN6$A92ZIZ'MC=!B/5;--^^(UP5R+1ZJ1"Q<>XU.:9P*$
M(S598HS64@L3XF""Q"O.I'5J$B*L-Y_6V`24@?V0S$G3*5F,R:5)4Q,U1DSP
M*JNP^S=8L1#^Z/&"E'SA,9')QY_@BQ,[N*QKL*DO"-(4"H]Q:52"0^\B0I88
MHF%?F8<%@FD2<SB3Q*DK2)*@@L5-/\NSE`#*$P!,C9C"A0I.W4%2=V!Q[V?*
MF(GG(P18?E2JF"/QAC/R34U!D@58L+CG,YG;YG:T==]`'"0;-U/A2T2,$T.X
M3+QQ%&YO,A2.6Z0>X\H/'#V+/,GQ0PB>:O&>L?*KC&%$$W+4&#S&D=,\Y;#5
M).HA2,ZXX2HL'ZSA5=;`W7X_[A\RM':O771/X+6*/L$7OZK]\VG[IVDI/,:W
M?R%RI4CQE0@B,R9%!,'T;!N.W.G"^G+-.W8I&<3W&CF,IRE-E!TO60PP.8]N
M)3#%J]J_O=LE&S9)V[_'.&J92L&A:'&Y*)[\B3TY)_9PNG&,:%+ZU!8\QET:
M^OW$%!``3AI,((]UN\H2^-02LA#8IS2V!*$9(]Q+'\1QY[F)%BVF1BSAC&I3
M*\A(-RAX;`7":)-RLFA+!,E2J74>V@ZF=Y4;\*D;9&1!%AX#577<E&2D(9>G
M,8B@/82)5^UI_48TWA%E8>8NM1X3[8CB3_#%2;>W+<.</142T]N!C&2H\!B_
MZF#'`3]D89Z$8)JDZUN:+(4,G!'+-?*XM44G&%XLA_%E#IO;#,Y!2,I+04!:
MPJE$Z$28ZU4F(:8F$3FSI^@PCF+.J(.5/L8;WV-B_\L>Q-0>Z%UGX3&O&FHP
M>9KJV!_@'`GV'T<$)FF;=>1A9Q+L6CM*,.ECA7`81^Z&&0Y;'_@]7G[4N"0H
MS1ETG:A=8Y+$*&PYRO/5.+V/4$2G0CC,D:S6)M>AT#S7TR!,]2KC$%/CB-J^
MK\;8.#B<2*=P3D/5C#%"P3&.T:%%8H)7V8>8VD>T&_($D7TPKIB(MB->PA@#
MDU`JUV'18X)7&8B8&H@*,_<$'<8E&4J1P8Y]HF",43SG/%>A9A%!>*B"ELQE
MV[YQ%-Z^*$*B\!AWC/W.O3_"O'/O[Y[9N*<1A^JI_KWJGII]/]O6:U@YZ6T.
M:Z=S3VS<FZ$]C$\='ML!GK2,_V[@R5H-1_CI+8#7;3N\OK'/A([/ZA[^`P``
M__\#`%!+`P04``8`"````"$`;5D?W1\#```>"@``&````'AL+W=O<FMS:&5E
M=',O<VAE970S+GAM;)R6VVZC,!"&[U?:=T#<-V!(($1)JH:JNY5VI=5J#]<.
MF&`5,++=IGW['=LYV3ELTUZ4$/_S\\V,,V9Z^]HVW@OA@K)NYJ-!Z'ND*UA)
MN]7,__WKX6;L>T+BKL0-Z\C,?R/"OYU__C1=,_XD:D*D!PZ=F/FUE/TD"$11
MDQ:+`>M)!RL5XRV6<,M7@>@YP:4.:IL@"L,D:#'M?.,PX>_Q8%5%"W+/BN>6
M=-*8<-)@"?RBIKW8NK7%>^Q:S)^>^YN"M3U8+&E#Y9LV];VVF#RN.L;QLH&\
M7]$0%UMO?7-DW]*",\$J.0"[P(`>YYP%60!.\VE)(0-5=H^3:N;?H4F.D!_,
MI[I`?RA9BX//GJC9^@NGY3?:$:@V]$EU8,G8DY(^ENHK"`Z.HA]T!WYPKR05
M?F[D3[;^2NBJEM#N$62D$IN4;_=$%%!1L!E$(^54L`8`X+_74K4UH"+X55_7
MM)3US(^3P2@-8P1R;TF$?*#*TO>*9R%9^]>(=$8[DVAC`M>-"8JN-HDW)G#=
MFT3C$1HE_T<)3%JZ2O=8XOF4L[4'6P_`18_51D83<%;E&9XM#]1%Q=RI(!T*
M:@$]?9DGHVGP`FTH-I+%L22R%?D)Q7`G"0!OQPAE.V0\W;HMFQ)##KZW8QOM
M;37^PDA,MU4^^<$7UH.A((</5L6)80=>!E!!H#L`2))=7@;`2#)=N=!>RT^O
M65B0W/58*LC!2NU'+XPDT5@PIM2?K<@O*2Q$V$+7(ZH@!W%L`RR,Q""F)P#/
MKUMXR4?P5)"#ESEX1G(>[_RZA9=^!$\%V7BIT[Z%D9S>=Z?7+"QU)A[,BLL_
M`R5V<)!3+2,QU8)QJC><@YQ?UEAXV35X2NS@.0-J820&;QQ'*$Q39\KEM@1%
M*,GV.]:"0S`W#HOWOEFBHQS,V*GB1K/9=.,8)>/8T>2.)HH@E?U0LD&=$^%R
ME^'H/JJC.VXW&@,X'&=Q-G1*K=X`E,UIB<$S)[PYNWJ\(M\Q7]%.>`VI8"R'
M@Q1^^MR<[^9&LEZ?44LFX5S6'VMX#R,P\,,!B"O&Y/9&O4'LWNSF_P```/__
M`P!02P,$%``&``@````A`/_X&FL45```T08!`!0```!X;"]S:&%R9613=')I
M;F=S+GAM;.R=V6Y<2;:>[PWX'3:$.FX)2++$24--!UD4I:);(M4D5=T-PQ>;
MF9OD[LKIY"`5^ZHO_`:^L0$;*/@!_!#U*/TD_OZU(F)/F22KVHVV@<8YIXZ8
MN7?$BA5K^-<0D5_]ZX_C4?:QF"_*Z>3K1SO;3Q]EQ60P'9:3ZZ\??;AXO?7B
M4;98YI-A/II.BJ\?W1:+1__ZS;__=U\M%LN,=R>+KQ_=+)>S+S[_?#&X*<;Y
M8GLZ*R9\<S6=C_,E?\ZO/U_,YD4^7-P4Q7(\^GSWZ=-GGX_S<O(H&TQ7D^77
MCUX</'N4K2;EOZV*0_]D_]GS1]]\M2B_^6KYS:OI8#4N)LL,,K*CR;)<WF;'
M$Q\?LK_Z?/G-5Y_K47]\+WLWG2QO%CPZ+(;M;]_E\^UL;Z>7[3[=.6A_><],
MV7_J7RZ6\WRP_,_M-P-99\5UJ2<@]B0?%^VGOCT^O3A^=Y0=GQRVOPH#'++.
M>3YB?</BQ^RWQ6W[N</5?,XSV>MR,>"Y/Q;Y7`O-7N7+SG1AS-\7H]'6#Y/I
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M"MZZ'!6];%(LVS,<3SXRWAJI>8O=&$WGP]H`[7??SXM97@ZSXD>,UP)AD:F9
M+F^*>38("I<O%L4::J=+M/#N9XY8[$R;:&0[$Z83S,1JL,1^9>4DF\VGU\CH
M(GN\*(KL9+HLLOTUW+\J4/YA-BH'HC*-M!J9KET57;5ZA28NRB[=I[8V;/KU
MUK*8C[/UJSM&YR?7)1P/#ZQE_,7I1?_MIFT/0O'VN/_M\=OCB^.CCF2@U++Y
MBVR6WVIS;5GL_WQE2\TORU&Y++M+.\QGI9@_PJ85\,0?O.VEW3`;U/4/9\7(
M#,@LG^-(!E/$!ENEB8?%9=BCZ54VQ,"*KK:HO"K"+IA4LGF#:=?0IX?J6[58
M72X&\W)FFSXOD-85DAQE9P.U%PT!BZM<PXZWIR=OMBZ.SMYE=_`ZT;7,?TPL
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M[.X^[ST_>-8<99EU^-A=/7"MO%P)D`S<'K4?P;RMQBLW.<&C3,>S>7&#"2\_
M%AL,2/VM87%5#LJ.(;H`4R]60+*%8$Z6+[%EB^47V7[OQ<N]WLO]W20FRW4R
MPO/W+N_;<GI1CI'"XPF.W_;X9CH:`@!_8RY\V4%H)]/)EI1G/AV-A/_*"5I:
M++K$FUE[R(CN76HV+>N?O,K.+TX/?WN/OOT*V/,>I$CL4"Q+P/5&&'1^MR*?
M!T5.6IP]QL4/X4@^Q\NAEK;NCG]_X+`UBZ!Q;:S%KQTL*-.O'\BG;RC.'8.U
MK,4OY5#K]8=QHO72_2MNO5"W+'<LK:6.=SRY02[/+T#E[T#0Y]GIZ^ST_=%9
M_^(8O`X8/^E_>'4,9-\HD?6H=K]M@<Z.OC\Z^7!T_D7[B[<!1ZX#CF?3VQQ8
MB;^ZFD_'`JA#X&JV`+1W(/L;"WC7(Z%S7I"7P@@0JN*HPDCN9Q?%_"-$=$9T
MUQTP4N?;0^R<QMQ`S!0<_7X^O>J:S,#4DS?9T1_>*R+J\N0LTJD(8`A(&TT-
MN[=Y]Z:8$(B.'*P.Q^7$XOXE%KW]I*^%K`AQJTQBC#':S[T5W<;L\"PQ0ON9
MTXOOCLZ4/CA]=_3YX[B()YV=!;B;V8V3K<5W#J5\VSY_',AZLO;1L`8+&EHO
M+-:_\?;T_#S[]NCUZ9FE.Z`WN^C_@4].CEX?7YRW%Y:PIH^>"9]>PN(UFWAR
M=)%I]/80)\4R&XF'^=)]L@43RRF`ZF$^*0Z<]2\NSHZ__7#1__8M5)]F(6V#
M&SPYW&Y/^VW__/C0?-*KX[<?%%>G<5!A(NYW[TY/B+'!AP_T`[\_.G[SG0;J
M?X\->'.4G7QX]RU#817B:/)^V>F'"VS&R:OCDS=?$,RWR?A;+1!SO0?3HB;'
MWQ\9QQ]BB1YDW.X9>G.:[?"&>%28*2/]5Y37DQ""#&XS9=T6P"Q%U+7H?0W6
M^ORQQ.2)ZYHR$82!)5'@P@.`CC)]F("T1@;!3;Z8H/AQX)349XU4H>,*]<IA
MF0OPMP6F-MPU2=!(C<C^F)<C2>T6J]N2=<L6!3&6A;\I0$(UNH-V.=J>]BWI
MA2\(/>K8\V]2E^Z4=RM.$MY:J-0F\F'2TS__+GO]]O3W#W*-A]73K\].WT7'
MB@_H'UX<?V\IB<Z6;[0E#43<IKX__-,J"%&&W2%?-26`9!?)5JTW38WA](Z>
MM`S9:D%(@415?H.T<_G11*%#+ED>)BM=^(,A[Q`W5DKVS_X,SA-DWLSMW/<"
M88BGGUC5XHZ44[\U47HOYD+6P8W[7NIE<P,DMZ;;ZS(I'3UK#PF++,=GV0PX
M.PB1JZ*G]MHM<[QU26*)N`Z5(58SQK6?:\\1DT89VCR_,\_4&2DDO&+`I!%@
M=",WU7[GK;P=SYFEF,ZS3UB*8FMZ=25P),.V%KFX#5VTA,NRF\;<6IJD(V@I
M5W=/+M818?50F_+D[MNII3L>M'Q99Y>EJ?<J3'O4MDTX/OG^Z/P"/WJ737B_
M`KXJU7@7<]_GMYY%\NW[Y4E>@.N@*(8!"0*XPN[>L:'G[B-N@:N6["5]5`[7
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M[-M\49INO5>(C5,7`B9OS"AO*:B#0KM9NE\^PL;2]UP5^A@,__4O_S4+D(8$
M:Y9GER6EK,'-9#J:7JO6,I[E$S98U5+V&ED7)Z[*8F1+GA=DW"U,)B\Z+H9D
M/2?%E]EB!K8A!9J/1K?9S6J<@[_'E_/;Z:0<8%&*<?;XKW_Y'S='YW_]R_]\
MDE$A]JB\G)"Q8);9"`0]@PZJYNGI\GWMZ8K$[8P*?I<&?#G89R&`IA"81"_6
MP]&!W*](L&FK@7B.!"O91(SR@C@%.@P17JY*UIIH7%HV*KM:3;P4""!?9L-5
MH8>'=4H`%E9,P<N7DS^1]=W.6+#M,DNQ`;%GKD3P?5P0#$F*8-;J"OL."Y1Z
M`$ZP#>+0D@JT((`VP'EZ.1TZNM(2"\57Y!:GGX1"B&58M4ID3#&&%(5?]FHM
M0Z+I\FRRLL(#_YX4GP*WBA7YU)3XV4XB(AFE-EG9%['5>69Y%Y%<,9>IE8+"
M,S)W2B=I#-\3GP7!2A/\]2__74PIQVI<J#^4AM)D:1]%RG>WY^RF:R6BK?]]
MSW\$P_I8T8G*,E\_6JS07J_E/?J<OI,_^\?/MP_TYP!I-^Z,:9C9T2?SUZ3$
M_9E#(LG+>:E/K_)QB43;B+LVCCIH"O^`C-)TK@\_-P*6W_S\OSM4Q7EW;)*_
MR[3J\?EB,<L'+`5/K'Q=\>B;[.9V2,6Z0(PJ[;;=G`Q&*\KW9^C0QS+_ZW_Y
M7XA$X':L%K)DH6_*`U)IXO8R'QD:/5K-B78D^DBLBKYFT$U8%=O/\)%NW;YD
M_#>CVV'1'']%S\R\GK-S*<6>2DE7\VL)?SZ;$8>8D5Q\:?J#W1P'6B59GVY*
MLI0'.T\?_R!C0LPDTV-I!=`?=KP0M%<G`CJM%Y`X+>@3Q>+A%OJ67YM?W\[Z
MR"Z+6TC>:])'L?58Y109K?A(#].5G?SQ_"A[]]N++ZBE7SR1`0W:)3UH6[$M
MTV*771]<R@,=DP(VFKG5AA"`VA\]OM+6:"A&WSI]?[ACC[(#&LE>7<SPO/RM
M7@FW,NY'],+W_<-=_NK086]OP7CCQT#@2[7+@4SW=G;*](>W^.7#Z9P"M[-1
M"X]?F,ENK33JN:EVE"^M3D:QS*\G4SCN,VUG&,%#B8AE/"<V`4MXSY1OET-G
M\M'YL:81]>>L/X<0&3):27AJ5%+X92>#;X)/T8Z*53())W'08WHVRB6U/K.L
MWY$36M[8+IX<?V?K0+:PP`PFTVS[@Y"KN%Y98;YT,8VE\^LI[4/5][;5ZC!3
M5ER#_[?!FW?OG7R6CPIN1=,GAU3SI$FAZA*.U9M/5]<WT>2:180?2FG"RX^E
M^O[8ICE%YO7[%+]9LU&5V$&9D/`R(\5P@P[CN=4_@1Q!9$__E//"MLO@RWVQ
MFW*U-N6%>52SWCR;5&/-MP^C(4?\F("D'DYHD,^'Y?1COAA0@IT;`3$NI[\#
M<]ND%&7])&GB_\?'DJ^HNYUM%[K#%9)T(H5;T"B`Z"\JJ3.I[#X0UP"(.5[,
M\V(4L@SW(J6:+4@^,;Q;;8332)D!'1"SHS$P2UO;D<H8\&XT,Q:-P+,YY4\-
M,"NO[:."/IN;@K1`-!6:1>_9GL>WQKFSN((MDJPS7,;FLH\Y>[SS#X54,,KJ
MV_*J>)?/LO/(4Y,)+2=@RPU2W'ZO)DSMKVP7?&)D;F$&4!/`(J\=L),"M8>(
M3XA3_XD&`/H]VW<ZKLR1.&X47LZ&^3*7,S*I0[:5QJ)!2MN:OEJ0:4=H!(Q=
M_O[)9(')#M)S)D>1?:4^-.'V#OS[)RAM@M(D:-BP*D"L12AH>@K5HA<-+F%-
MT`=>P"*\RT>Y60&PIF^,2WWP:4FZ_6E911#@Z%8Q^7(Z!5=]G\^/1N0J['WP
MT_13,;]:C7K9+9E+W.+MUG*Z)0Q9\]N&*T$H-'Z1LA<F,"637PN=L"D!K^+\
MI/AQ:4\$@+4@V8$WTGLJ!A``$?MBY[0>6;6^*`1A+`)-$^1KY%/0X]I<P#99
MA*8YQOI6$=MM]34MXD+)S)-\>'HU?A>]7\V9C:<T>!*#.IQ:3*^6I,TLT/1H
M#T@[HU.3O,#BIIQEG_!%9H2.!_D-/C1B,F,9BR,\'3C0>*<:A9KD"_D-(>)0
MN\62UXX+!)\BW&=H2ES3-@'\"1L0)6'`X@J?Q_^'&&WQW1F+F->H29ZQ?A%:
M(?+A1\%D8*+E,BJ93%!#&Y4B*T.^,II`7L(/S]^2)HL2+!S(MQR?P"#0ZZOG
M-8`WFY6!0;XS&L62,'HH+.:RC.C%7N//&9D[W+E!,IR^$BERBT*R&IA!JD8V
M,E$,949=X)=$02(L!GX&W%O3"L)7XVYG%S<`A>H%24!@'WRRF@@R2^0(\H!L
M4A)_BBD3$XBPB08,4K8R,J(#,.I/=\'P^QA_1)@3&0U,%U()FB9JPHXLZ(DS
MP:15B-5?J]N//G1UU%MLH4,0,.FUH+X8^&J^(@JK-8T@:`J*7K_J2T&>R!3`
MRQPC8?R&&4A=R,D8+F6KF7X"M/+V[<O50I$&@<E,DHLLF!A\HLG0-UQMXT+I
M%=9.S`Y:41V@">SA`6+XZ6K!3-5>7(ZT"F+QQ1B@C5Z3L,#(0*?)(:N+P#D)
ML!)^*4P.<7@/"UT0D4^\<H\BU-"D%NT25K.)!`SU?:OJHK%+R,`DIUP@UH-1
MS_PHQ6(I]K2-UKB-+'OBW7J@I/0J2SJ_A_*LA$;Z4/95*N][KX\P"?H@V;:(
M4I/[B6KLNY=&B.H?OS:N1*(ZFW#!%*MX($,"/U3+O^+4">)6,EE4C'),"HO<
MR$#Y.DY8K6WF==?UX`$Y*(.GE-?0<@.OF=GXT_Q2BEUULUI'050<`#VG&6@/
MUFDLTC!0_*[;K,Q!K'UGE=CZ*TFT'/_5:/K)TX,:Z>&S9S<Y"6?+[+`4O`V$
M8F#KXE;E=61_2&\0VQK+DS^2H0TG.J!!8O.:$W"93O48UT@LRR[(J9QO_6$;
MSV5B-)V1!W-'4\T!.Q2$UMH)'EL6EOR#!'""2+,M)`C'F&>241Q1T1>U%YY@
M'`A'%Y;YM+R!:@,DULHY+XL]H<K"`%8TA`9J[(5P16O/?6]J#,;^M[:QXM^8
MPSMFS9N"NDY`7[6;U#WCY;J;M.;0:P9FV?/)9`6]X912;04UB21R-P6%2.F(
MT[)V7:9_#Q04+/!DNDP\E4W!>UE>$,D)%J%NDIR/@#5J&#/3U:@48+\1V(]D
M!*_I$&)']0^Q/CE25E9G'$V"KJ;3)53@&8$U*!K)AT40`J/'4J_REDW>5QM=
M8U.2\S72_&'[?+OFY!#V8B9K(ZE?V;D(7`,17#FC%[2F.Y61PMR#PY;V$NDT
M#ACY'X9:HAJ$C2JR4+^.[OHH%O38>FH-RE"9=SP_.C3X2,$/>M+N-0SB@^2L
M%W*\GY"5Z"M,WNX2+&5\?%M@772+5ZLY?9\WXLW8SS!5FH!:XB079(_Y&M<+
MG8C`V`$L8Z1:W0+?`FH:DA5#AR60TF=IJY<(<7S'1,PJDUQ?TZ2FX00'>1+(
M5#&]P0B#3'B&M9L/B"1;%R6EB:0T?TO/&@.O'5`.6Y(I(`A.8;4AP+<YZG:T
M[RI,M1J8(J`<C>1OTX::;KBWZ)B(CJY\@`7H$6RARB,"5(*\8`TNX&YO>>#^
M-;C::(O4#VAF?;W`*Q2C\Q>52YK!N^*;*<[C1V_Z_?>/GL!BJJ]2T<JN2P[&
M^0\@ID2O`3RZ%L;>$^%;FWMU6V/BC^!43<)8C!_6,YM0:]:QORO3(+:P:GD,
MR=*F=TR.S%1&,W8_JT3S)MHJ-,9#H14--:N$VQ<D47?QIDY">=+\F!M-C`QP
M>EC"@WG$7PH7$L\Z0O"^LD:-K9;EJ)6DS8?<O[H@NK;"(`%FJMJ52G<M5QSK
MF'XRS;4"*2A=T;X5?71VQB;EZ+6'K\J%8QB6"(_E4#TYSXEL_4G?'!`N]EI8
MN,5RQ.CZ$81%:JMH$[06^'68=1XGZ#9SQ#K\MR&:\(Q3)S!H?WP:5]?^XE`V
M,2:NJF%BT4L`B]513F\F_YMUL/:@9U@]@4A8677GF^R#1(DI:(.D5S<IOL?8
MM6E2W..RE:+O!0%!Z$L`D2T9Q9RJ\=_B?1."F%#W2GFLKK5I_'#>;W\4C"!%
MP3+O$3Q8U:G]T'E*3ZT-$MJ/?\?QW>RW_*?]Q8;:@Q4GVL_VKU52`IEB8];E
M\-O//]O=/OB7QSN=`T=>S6@_?717>:[]\#W+K]<P4[6+8`[G.5#1QHIM87M9
M3*BS43[KS(.Z6A6P_44[IO-45OLIMM*:4Q2?RQFD`I<CY211*3?H89.E`]MC
M=6=4V7+C4S&/MIZP=VM3:>W!8NFU7I-M/W/H==Q0;56JL/W$:2P,WC6,/93*
M@58#;&PBQ4GU\%SFG%^D:3$T[L/`*1F_&R4_._/N/'WZ+X_W.M*WIEJXGD??
MQU(@GC+6)]WBRX8WRX5)+W@V$A^+AO@1.JOP,-B-5%Z,M<TVLY)@IT(Y^$:V
MSXIJ<J?-B?'ZKI"8`22L))L4JO2&_`QDUE,CPOQ"E,$N*KT$%I+K=Y&LF;\.
M0X^]90-X&1P+UKP>_O92'X./1<)LLWR&7`@&3L5W+2P)>%-T+5GSB<.DH]LM
M><=:WZ3B`/Q>>C&-":6=F>^CWFB(#J?S=A^K(=BH%A1XR#^4S5"+6G+\AG74
M?J*:O#(@%<)G]ZC=F.%T\!@2,SSFV.!^K.&9;G:.N0TK:]YZ9D%8TM:0\@R!
M,DFK:*O@5,";*6M#O)2UDPY]8VTS>J>%L+1CODV0')G68Y`U=?IH17I5\T"/
M9HSCWJ;*>#5-PP5::!<)T#>*\>0@FT6'M9\@8RZ3Z>FVD"48QK99<)+E=IT$
M*1"+R'1.61Z^)&`%CH(:`ENK,&=(\Z%B4#?B,W)O"*3&<NPF$%:#=R8N(+9-
M9\X4QP6(R(9#4T[UF8P34I1QM4TLIILNMHY:*UH*C.HBV4;@N^@(>NH$-3Q,
M%PS)0OW'@HYJ9\0D/E;XB4+2[F:]3T0/%7.4X&/Y6J>>IG-Q*,D5%YR!XE25
M>8UL@L<LO6K.5FQ$F%4_WA3ZET/R+)JS+&9K_?R'6&^Q>@!(?@;4R%%^U<0[
MO9I`E*A=A*.FQ!OM_%6=`6R*Y??2F7V.K^CTO4S29SLO=WM[!\][!\\/2"),
MYS^XSZ`_`ONA!W:?]O;V=WK[SW:<))G4L(WL63@S;T]JE)V=WO,7^RFO;0PM
M2/NOW*;`4U;P)\(%.%S+ORF3!$%:5#<$X,-+#!/06#)*FD"/V,MZWOY1:X5V
MH@]Z+W9?]@[V]M9&$*RTQ$Z2-%BLKL0+A9.HC[;>1J]M///I.A8%E:X>EN#*
MOJ/H24Z=RTY:77^7A7$07[JR5;:RKLU@*%HD6_DFB!MIC8+IU4./Y_59$!^7
M*AMI0F+/1,J8@Y)QL@_G=7R5')^"LXWSD>\0-]`+)!Q>V\C&'"V-?1KGMV)>
M,,]$SFKM'>6W/25>ES."OYXFL(8VO)"VJ\4EOK4V-5FJ6H-M\S'T%9]O0UE4
M]4EMNN@Q/=`V_$K9*Q^_MF&K"4J#TB,G*+4Z?"%O>FGY1\^)P1YBM&PQY?@+
MJ:$ATB-C%0PD2S0I\Z"=9:Y4I'`);2^D8Y5B1JUN:>;EX@<W+Q3X/.-FI:R8
MUZG1CL)%Q[%>%]@9)$@*I%75>Y/5$CU50W>LJU89EX8KP)180ESC5RXA8;_M
M['Q%LV@<#=-IW:_<!Q**4:A#Z"]<3KT$D_(%7]ANQ@E82W,[S9*Y9^(9.N!U
MM%ROQ'`YQK$FPR$>44A,/4NR-+02$2VN/D;-[87=I=AHK[)7=I"V5K>,Y4=Q
MS>M>890-E(@[+0JB>;Z3DA#`DU;_M*XSHV&^4S41#_`E2(4S>31CXI<;[L"2
M;:'A'3D485:<18/<U-0*F:1@3+(=\MFP_"W?)3GGS2'7&6K?>=F9&`G:S-1\
MZ$$![J!2$`VBD8&78]M6`<R%"0[PT?LT3!"#I?`-*H9KIIEP+1ZI">E?_I%^
M6BFL'ZN4L8%07Q)TU[K^-;]OHQ[*N6@LE/8VK"R>0U8+MA6:>`U#(KN_2*?'
MVAR)BPQGF-.["%?]K)/SDOW#1R#S/@K_35*M<:JP,PJY6X2FC-$>JX=CJ)2:
M$9^X1%RK:6IB@"KTEN3-BGNX/436!5,<VH'#H]9Q12,W:$AE%C6Q:B[G+C=:
MIO,W7:AUOAK#;./;>0U!]:OBR?N`(3M1XH/?W'@:9_G-&8Z6>\5@RV`*?C,-
MJ>5`37.`!_2YJI&F?WZ8/7MZL+7SU-877OHS7X<\+J426@A`=D`WNZX(`T,E
M6CZ%/#1(22?<O.&=;"_=DW`*[Z96%,[J`!"G7']D<)*=CQ",+V*]E3H')9B"
MXXK2$-<]=>*4/Z*^O#*D,Y2,_$22[GLP(&;$&D:#9GA:EUKR!&$;$)/1MK,W
M.G@G+$NJQI:FX6,%'C-FH7)3NA)U"LH2)S`B+6;P*O&J6EO]1*J+VR\<OT+(
M+!]N869BIT&D,IZQ<-DG*1(.&44K!`7A2'3*N2O@9`^T-]$`QV/3$5VKGVM@
MMP?2[Q!W&4\=WJSH8@S!KW1AG>2?SB5<LG=&1`$QNE,`%H)U@5W*U/2DM))@
M+=[Z^845(`A2DI=KS(L0U*?UH@$UL5-9C6#\,(=JWE`LHD2)U^G<+K+[E<&C
M]:ZQM:$LP:*9)8SL$N^;')0BB9>7(!#%R'LI4GB4)42>>R326FI-C$*Y""!%
M9<<:FOS0B60H[I?']>R]4QR.FT09"6M#)8@<Q0?\A]>@U@[J!)&`),TVHK%K
M._N]U#JB)W0(VUXN1X@A+A_9UW39:K;%YJ)&!+/$K'"WZV\6P)L1M6SC_VPE
M,^'108WKOBV^Q#BE3`,7W2%VA-PK^278CS_"<\FVI!.KF!-QQ7MSFIM7,11C
MYHU.9AF$"398A<:JPS(1F[_C.H=3),3,W2]>:KHWP33/+U5@@]AP,W5R;VXT
M:XQS&;;@16RK\]2_$C14P',I/6C)-6%F%0E3T$;3Y0F:NV\[D>8>D:8)?MSV
M4B=74,,E@88!'*JR`JU>K=Y`CFBQTM<Z@K:S=W2'<O(;2Q)-&"ED^1X"J.3[
MIYD=P+"S6G(;AA;MT$,^N%$P[%FQEDJBA\%#F/R(8TASF`T14JIM/!MYA9\Y
M'^=/S"9R<8:A<>\*Y9BW/(05>TU_PI2V.6F\7O;X\HE]Y*T"D6OI@;@\-?]A
M4C1DVA_(8`&X-B&_E`D,TUN1E22,N\?'`TZMN8N4(CC&2F.OUXLV$#G<=%=O
MO9KJ+@.#"Y](#]R4US<XX)$=.8:MZ3J=#*O`J6R%A5Y4AZAYR6'HW'*O%(8=
M9)(QJ)K%V$*+2[%&2$<[:]$))!]\9[`M0(?.N;=G:*X@W"C,(JR#PRV@!4`_
M6D<!:_H,A-1[P;6;4L3/#O9?]O;"'R&+X);$C.,=H^P^(SD41]DGD_1,?UA`
MT$S(VCR=U@?KS@IQX(CCO^M7$4-0MF3ZR6RI0/YPNKI<TGA4I;6%WF;XJVJ1
M%%9Z![^(HA`9*?'ARU8[#9JFTEL4004H55*G2G7%-)<G95N8#N*4!JG86CML
MW3C=%0)O#$(ZW"@EYE[I:\"M9%_VISZ.+,!,"2H=LM9^UG,/&)DM>T/(#@+T
M_0UX"GD=(*W>2R_P2PX1Z%O%>@*4'(SUO`>A-QC9&M4<\PMK>P(-2E1S(FU6
MI2XN^6R,F<VM[5W[0O\/<U+*MC2OL*]'4XK&U=\IWE3)B(:O-*.+3`6$@>*8
M>;[,)S_,5[,ES;97C#6Y1NH"M@;Y>*T\OE*?.R1;\,ZLT#L#<?4>M,*0V#AH
M_F90SKGHE!8S^*.]\P(6-,?5`#+MSBQ:?U/WB[:(#1-?<&=QH7Q:WS-.UM(0
M@AV@W8JGA0=USQ(8O&.X*,BS<[XBTZR!`M=EIJR2Z?[K1+SW:[I?,`\ULRL"
MO.X?TT81KK",NJ#@R^^89RV6-ALF@>H8LP3#+%7D"E'YB+``9,\:_B34-D)(
M^*,9MP3WU*[X/\$H"4<H$9D8R"YG81"PH87TU0[63P?0X=:\FAUMMAT.L>+Z
MMRR]29!'=$@,IIX)]>?)C$H1E?RR?;`XVK$=AQ@0QS3XEQF7#*!P9(<CMQT<
M<CK&#J](X93*P;EX[0&WYG(>U*LC!NDF>-OR^)>PNM3?NB`9$"<@$G4>Q[AJ
M*0FZ<*S)'V;P=^P4#%:5]T.;7TV\8_T0I#K*+Z<L0[LL<2:7@%/&Y<8@5HJ/
MW6"*"?U`H0NQ9H9][Z_*^6*Y54[H1[%_Z5"!G0XX?GUJ#9#C@D.V7>$_`H',
M),]^4YS)&E%=;$K6U!A\NV;^YY^4$D@OB,:**\K-<*XZCF;+D4BO&TAOQL3:
M#)U5:@KS;ZWSXBXOY0C@<LM"02?<>`,7`B!%H/>>*>S8V7T:>L7%_,WS";XB
MF=5L!C<UFP4:HUNI@;6[B3J+=\1WJ;"7@,C:@C1.U$F[OT9VL&"=*^^#(+6^
M<D"#7NA<(XEO>5BE/ES.D!5#T"X,$C92R]'TB4GUYQ$9Z7!C9A^>/F,J4#9%
M-;9X4(VO?#,VSTPC`J[2OS0FUF*\G1/-%!0HJ6^7<XF)&N\":"TG6XB&^L4Q
MO"$W(OFI=UAUR9,R!5/#=(8S"FY*&XK_Z"B8VDCB/_13*O+.XWQXJ!FQK]1.
M.21]K(-+CE>Y-2;TGUDQ@V=#[Z)9Z:'N\UP:^"1BY3`^DA2?#V%MF@:)1W#7
M]+=NGA!B!6?";6C0;,8<E,L*D:!+903C?B#42MRLDOQ9M$!:6NO`2V'FN'E"
MK#8H@H`R[C3HR$8^QZ-FXK\X'.YRLNLGQ0OX)>K,Y^H9"UT:&Z5L#F$+F3,/
MGFNSAH4ECQKPFLM76(\-:BX79MB)LYJD&8YG?7R%-+.(6)G8)-BRLDCB;(K\
MR`0)7VU7!4&C_LX-6R,@OCOWB@,_IJ$D.TR#VHZ4^2!XSU16M$S6FX*41[VG
MB68$&6U\3;TOPT>DZL7F"QZM"%?TG!*J+TBH'CSEL*EF[ZI-S7<\1.]D^H_?
MG_V'?#S[\I79?TF%!7V*J2QW5M.@CD&[4!RY(AL+IJ3-JIX+3CA!NAN=KV)-
M.!"Z@>Q^(A-])>7BE::F[%<K;A4"34?8U"F(3^P>.[&_28*+CVE6.LG4Z%^H
MP@0A`0I38'#70/9Q/9VT4EG3DN!&AU++J'H62OM6.V]`Z[%T<^?EWAY^6_X=
M^P57'^LY&-]\U+B/%2@F`%G25'K(X4(>(#ICZ4-G7F<K?A_N@Y,EB5&Q=-7X
MW=F=1I^YGR[0/A$F*+>-M)'KAE0W<ISV,;MC(;9R$035`;`)[6MI9A4(<=P<
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ME#K$GJ4#-^&Z)IFZPU`,\!2_'2V)&+Y>A%I_5`?Y,F$(QW'L;5BF;CV+F>GR
M\Q^K@F!O^ZB'K5J?CJ.F$QRQT4M(3(E\AC))2>O3PD--.DSI_GK-4C>`-"WY
M;!."2_,8IO$RD6]MY*G9=<D%TKJUH"I#BZP2B\K/*+9AU60Y7'@49@^$,S?N
M&U^'"XNM'1)<E6:S-@D_"F'#Q3%2QVV,GZ*CDW.-]U<A[G:Q-E7;_%8_-*+;
MXE7$U;I0-PFBTM26,2.5*@P`9\,*=#`[?NNF,$ZN/@YE6JP@'#"/YT;0WXX?
M]S@O%IDL+6Z[:4)3<H.6$*YB3CX(1J-2CU2XLJ]7L"9J3B4#E=)4_C!M8:)9
MS]>5Q5F,.AGZ"'\AB7&+.[*D7S/Z?^]_OFK]J.,;/W1E&UFOXR..6W:G!2>R
MUGV9&!9E'D.@DXN6J6!;)>SQ<N<@B9ZXNF1"?GP`(:H)GGSTFENA=7*$T.Y'
M#N+6%,0O/&-G29%/"?A'7RK^OB+(LDR)S=:26+^03KE;3!BJ%;7@_Y--Z_XL
MUNO07&0F.YSU3[?TZ_9[XT*P>1U_U,M^_@G.KKGG7Z8%?Z<1<$=2;DL->5[C
M6&'?"OLD[6.*9N71O:"L`[$'BB$+3VW3!D2&$J7D#IPNXHS:\3[_&1^!1?T<
MH,\=?GHN)I@PC+9&-M`S(;,5]4P[)MJXK-:((]Q3?UK(1DD>UF/B<)HY-1UH
MT4FX]8=E!?T$O#Q/APC%457&GX!<>1E(I!5CKDZ7!FDFT.*,)VDH=QN0D66-
M`XO_M0/G%JOB_CR_;>!'NI7P)K%&:JE=M]]HF5HUT"-MI?('YGHW\F-;)T?M
MF4;AR.%["Z>*/7[+P+J9;3Y7<N0EYAAIYCW8[;U\<6!;_-G.T^>]W7V".@QO
M*L($R4)2<$C<AAG\^GJ1Q:S`LG^@)K=-JO%/HNK*I#2E;L])!QI:TK].1S"@
M`923::B&0HW:FMD4#Y321P^[7A/F8&X13![JB$#"LQ:.5(#VUTG#^HT*ML7$
MPK$BQ.#$:>X^Z.WLOXP"P0_2[3;EX1^XN9L]>'O;CUW1##)M#H+"QOA3[$0[
M__%&YU+J)TYBJAQ0JYZA2S>L0C8(B?;1#&;#7E*XL$QVL,1$FZGE@7G#"S((
M\:<]C0H,>[SO!/.+I1ODH\'*G7:PHHUD@I]M=D/LQIV4E'[],O_DYAM4ZW["
M3?$V-W:I`]_L6ZRB^DSDN"CRNB6WQ%7CC@V0LGJMNVN(@0OY+_I3\6>LZ`=9
M"_,LRF9:*JMVZ13)0U!M8-S:`550U)OPF>2*_3B-@>SL=?_\V^R::[\M0\'-
MNG[YAVT)J^#IJB]0EI,KGLF<2`'MUN@%*1V+%^./*'E14QL8T@DH=]+"QF@:
M@WNGTP@B'S['(B%(EY/OEAF5W[+0`:V2H-CG$C)[@?L#N%8A:K2JRQ&+20MM
MP;8$?A(3-]R8(QNO"&MX1%PFG2DN;XG+6^+5@B\!#%:GM[19\2,W,/N=L2JC
M0:T<7*TO%."=KFT_'2RG^DE-_^GPO>I8'//1#PI[5%@E(0'N1Z+\,H"K@M0Q
M'*O4"99I>91-2-J[Q!%3(0PQNX$;O*1O;ICRDNJE,T;J>BV[#<."[O"\U8@;
ML&'-/BV<FX<("C9OHA/(,>NIT4.@AOM"VW"4>R8/\IBU3DV6H*C-[')S[D"O
M:(Q[%Q<3I$UM1%@0^T5?`BE@%]LD>0%[<XNN@%,M*[JBVRSNL*T\[C]8W!(I
MO9]_`F#4>!J`4*\J)=);%N/\4'KPV;5""7/H)9*.;2"(&?AR`Y*H(C*V78N[
M9[LQ9NEB667"N%7+M<BX$/U0;45!2LCR@W(]]JGJHY@1UJ<?MD4>8ZD:W=`.
MM&1ZG/])*^Y(MFVU$AJJWVE^[?M32D+<:6P7!HM)TG-56)A/]\VP]V(?F4MT
MFD7#'AEUXAEI3=4-$9:A_15%YL>EQC:=ER36$*2LWH+&,74%<4-&'5IJ:9`S
MH?>AZDAP_\P<H;C-"=KY+?21!AQ6;>H\/_&)S3S2QJBUUA>'`0SM!=(B773/
M.NTUR1B%->MDL#C]%Q*A+I';6GZ\MC4ZIZ`KA/R\"+<ULG*.0@M>LU!J),92
M%N="+%:C>BL+4A;.0BY]1(A,?@TY\R2O1^$2XW7/\H)+BC0T(BI6@<CQILI=
MFPVQ"TN"C=+EF+);>D[QIX?38I>NO==X\ICTXZ4;SFDK0@ID6=V@0WMPP$O[
M==>*]HT:[9TQL82.%?06$2\1.[NYVE*"T\%6_=2\)]J"B3"9K*(<!OQLI[?S
M_+G]:K+WZ84(19)LO*ZWG:V+'BA"7@6@7XN??.3=@QT;F2<T5B3")W)(@NQ&
M)\`/,^EZ33Q-)=P:_+/G^S9*S03Z5K`PW9/].I"ZH#H1J^8HE4<T^8/9L$?C
MFGX\NL&&NU:W\XM6)[GA@.2+VAR)`_7E?-7*[&Q&KO_H;]J41I>I(G["@0UT
M%I&J'!J))FI#NBFLMJ_>G=,H=\=V=;DAZU]6YQB)(B+O)6U^Q_>@1LE=(JQ!
M3,Q08.]TYYCH$%`T^(/)Q@;P+F:YYG6BHS5<W4)IZ<<)A<*"*%N.<?WL-59T
M5/<?M['M+<6[_L<5!3#7I;02<C##K/J]\HAF0DW4\TE@&'+-CH<,A1IC+:>%
M3K=-Q=/M/?46CRRJD%TWBPH*L;=D!/:VG\4G<!PJ>.JG(T!"WOJO?6[1846$
M^!G/`CQQD&Z*HB_S."8:NS0LCJ`J.DISJ^*95Q79XSBR%TZQ,WVEO-2:0V8-
M]*JE]./9"CDJW$]XIX*7('1&[Q35(W"_4L]O+7,@)PW:J(EDE"/]FI;<73*A
M\;<RU\""D/H/I0!,I4X:J+>M&A<%50>HL=#<%D4%^A)L]AH]7I=$<2Q3)IP7
MBI/<"%)Q`8N>.*OE"KY:FV=N:1#\HQ5D.WIPOB&?[&G,R'\_,6H`.K8;8'\X
MC"&<XZ?<+/#06?.0G*XZY:.L0D#`/?40+1(;#XHA/(((*2$><+7!/D6DI@#-
M.:QO%4+L#CNDQHLZ.ENKP0OPQO36:C'P/OS^2/P0P*&.A/!K<#VB>D%,I$IH
M2)@`O$FO$IAF!$#RIC!U`I``,/220EW.F]G/;$2.(9N*B,%L4IH1M\MLG0^(
M<_GD'5:5&7Q.V>B!>#>><F;-5JFY-G`SK#1!_]]4C7VI2E31*T6\@UTAOZDK
M*O6D5P]CWQPHR@FD*ZM.()KAYY3A##(7E@L=SD@]K#Q+BC2$-%#G>+4<C13Z
M-0S66S\*'1KW#1H69%W8M1!2J-87R_:P_\*\1?H@HE?VC4A6B1@AP?IQYXJ^
MY$KJA')Y,'SS,Z;DH!V-40&/)DP-T4/`KB@B0I5;U#]QC>%*A+5R!!;5'6#X
MM<N""B_MS7X&.F!4.(=EM3F"W#GOE4L`^EM#EQF%6M\WFY2;6`9A3E.XC!,,
M+;=TW$&<=9HL@Z)Y4G8AT!(*/)GZD3E<A?%+T:<E#=CAI`427@/HJ8.GE:FJ
MWZJ'P<$AD6ZW_:U:*TVP\"?UL*XII&NYB`FNI!N>84-;&<"??TKJIWB"XJLU
M=\MVVT[69*@N@QP_PE28<Q,DJ8[=UY3>]+UC+(]3XZ($1,%O[%>S2DS#9EI2
MI/-(O90'VYO-EL@9(DR'1EE\8L$;>B9-`I7Z4\.R?D[-FATX<U@MOMD''VZ)
M%=:*)1[%J::$UDNLQ<`3`VL6%$J++BO(%AKCY9R.[<FJ@1-6VQ6TA`?LUHS]
MAYPJ2V"'#N(Y"_-)JO2$AAJ9!K/U0-2%#&*`#5WB)(9&G87`H>D+3*"?I2`7
M"Z\4E]>J3TG9\08LQ+,7>HXYJ\%L.=6?QGU?FE117]066LL'L=+@P:H!G9$,
M[]Y.+ULVH,9E;TIWC[#.O40&^$H[PO<J_@9IK/?+$@ECU=H-+)G^H`<-G)$!
M"TPW>=<?:T#8\J;>2B`<%YJ8@V%,B#\2UFA$B'T'G+>ZH5C)AB@A+_XHP-"/
M)-G]T$7XA4:%+493;4ZS^^Z"([TU,MG@P.16JW.,4S57I-CVV%]@>ONY3[?N
M>JA!OU1QX\C5]K&8JN4Z,#.,(S-?7U5JN*CUJT"$]70ECRXU`KB'#G*N[O9[
MFM=,>`47/2G5F";X)^\4,XWWBU5"W0&#Y^3!,^=K&%I0.M"?UL04ZAE+XW.C
M`+DW)QG-QWM:HWGC7`J_O22?PE#E1,5MD!*5;6^!6G)>,H5]NE$4CV^/RFZD
M)IEZ*TE(.RA6D$O%_\;CGN`'KNR(Q%1'2G^@WXEZNVX62+/&TK8=K$I6T"2R
M+I`;ULF&A*;Q:I?,L+FE-EE&G?"]ZH6TJ`NYQL'XKR&X5;M[(Z54E:V1B<!2
MCZ4Q?GF!#GAS8X(`"H9:LIK.+R93EW:-/5E/J$7^?B+`T:(N$AQ:V_#_?0+2
M^89G'4OV5M5U\(&#TV8!$-&7"=`2EY^F6]84%VIT!HYCI4TJ#TSAYD98HZQE
M;<3M[(.=PE\WB!],\2`LY?(]!8BC\/J9675\V57AEY!9B&`GZDC..>#2T`AM
M.&/GQE^:F]IF+HOE)_U,HR07S7+0*=WTHO-,C5EV+;L64EU!UH!>Q!VUYQC%
M;>AV]G[3VS):0M$X5$01'3P'3\+.OAP%KG=9JOVUO30S&6E(X4%"*+MC0]@7
MJ,%J=52/S;#$]%PP&Q';P'[+U5<%47RBC::%RDV'`!B)]_3YTH-82T)@T&(`
M%1E7N[XL>N].WTB[GU<KC^][?+=:6KP*#2X`/+"R\\&PB7V$!"L&^C;5RAFT
M1X:CP[5HIY*;<'F#I"%VJ;R6B83K4R0%1C8;?U(?IJP7D0J*X$"CML]->=".
M"H[)P*C9D1`$$Q[ZFR$>CEF(I[E$AH9T%QH8&8,7I0-8_@@3;(4;>ZSJ/ZTD
M-SB5311M9Z]*?F6)J;N*=\?.B[:_^^['/0^WB-8W/9[7-",B8KSN:6!C%H\/
MP-FA%J>H,XXE^8F-!1WU<GF)49ST*`*37NB[TE3Q[,&6/QX[#O3X'6I9'Z&\
MV@I/PO=P]HZZ\"#'Z">-2<(59""6SZ-FU5<4+@1,694HL9@&(7@K:Y-LN9<S
MF5BBJP@2W^1)J-]!5QBS$I@H\C7;[T\+#]9.WF-E6>:&LB>1KU6L9(<YZ.FM
M:Q8N[_=>O-SKO=S?30QWU4#%]GN[SYYQV/T@9GIX>9B][.V\W.\]>_XR[9I]
MO,,A]/UGO9V]Y]V!#GK[+W<X0K_3&N@Y=8IG.P=IH&93#OF)L%>(`U;=\E!>
M1H^%OSH/.P[S=4I!R;)5Q?7Z^6&U75\@;,W(.A@!"T9#!*65QXPFOB'*MAW,
MO5*V9L,$Q%MX@4;$C>F\#ND<Q6+(':T;;,RESHLV"5E+-+9I!H+S"P#,?+5B
MIA12(@_!P"D'8,WA\B<HQ89>12"0N-$93YZA><08#FA,XLB8ZI;"T-C]T-;X
MVOLAF6Z?6*=!R%XZ:`B=?Z&OOK8'#394?%-=W%4<JF5(J!//E_YK6[2,P&N)
M`U^@;!S_''<O`CLC=3_13?_'GE+O^T+%NO><,6/1@W`M21`?AJQ\`GYB;@-$
M!ND]]JO^'MI>2SP$1M:?4QY*B>[TRR+WJCK<\^.#AC:".[J7D&'H^4J"<CCE
MC/,MF4EK(NEO_M$/`]NR8S"S.F$_$,:N#&#SFT`44\R8HZ.O\;CW[1V7I$6<
M8Z?&/MM]\8R[6/?,_GRV>[#7V]U]+GH(LN"?S@OP!SKDC5\AZL%Y3;9TY:;B
M&X%[?/Q,)R3LIPR'X1HF@R']$87;(3TW5?^-7EIC8U^QXV,U&>UYE]%^TY11
M"HY4Z&>CI:#A5!($?D8WXO.76$'B/GY-T8_#469*"0268>=AQ>;0XO4@&CH<
M3D?#'<X%5[KV?/A7K6)O\U6$S=WPVG?OV+]?,DR;A/Y#.:^BS4R,HKU?O_-C
M.B^"N9Q._Y;MNHM\VPC9RQ00R(Q4]W^V">/7`L,/$'5NMZ_+1?NU&B_6D]E^
MX;/V!X<8\G6'^]O/8<!2"W<Z@$_JHOW<8ZZV>?Y4=PJWO^DLC$?W=U[T]I\^
M;3^:EB7DJH:O.UB]\=U?N7-=Y?3B58&2[5A9.+AI/",15CBA;3<?D[<B$V\_
M"&.ZGZK+;EV>/04)[0-@%".MY[K!PEA.5'?>:SHR"4#BZ21Z`E[%VP^4-PI>
M+G0*01'V\;/=9^%Z(;B&27L&,CM(Z/M>)V"T>DD<,4_M[N[5_8=Y="D''M+C
M;,EU72`233@.74))IV9$$`W08&TA9HK@1^CL@BLVO<:$ZSHY;$$QWFVM\(F5
MK!`YVGVY=I)F,[`2Y8JV+9*+(-V9IAE5!=:(U3-I73Q4`W%@Y^:Q%*O-=$SE
M)M4RJJ,P6%W[_W!WKKM19=D=?Y7Z0*MIR3B^&Y)1)&-@0F*P1;DS&J%\L"D#
M5HSM<;FZ@Y2'X5EXLOS^:^W;V?N<4V4ZBD:19J3&=?9M[76_[9H5PW>(V*(]
M5/EG>*KPG0;%01I\1)6?>Q"E<,64I:5JT8W<BK%[MX)Y07)VA9V*#F*"Q?RS
M:79WZB%.2-@$%XM=F-_%6TWI*G9$S,H!BKIMW)_LTQ#@M+Y_SG*(0EQY9:'D
MK(@\R#2A=JC'4]@`DE3HZ#PTF`;'_3M$G3VBF]][)D`<&F5JMIA[DR2E:](?
M>!6&%I*NV='?RZARC9(/>G0]V]^81(5<`.:BBPZV/EZX,@8*97#HCKLR'I#(
M<Q4R.M`[MM?V]W9B$@+^@W`%3FCI]``N.1HY.##`22*72D!CR1AU>U#4"O@1
M[S9ZX]/@>8]TX;I`4$VT/6B\?7[P=1L:D_'X_H`UY07YCYK=KBQ1FZ";;;C]
MJY9C=Z24**K@[M*'2M/F%,VN"X92KE1_]U@<?^LIU3_[[4]<((^7;NYNUS]%
M#3/,C&$F';$]:B[R5ZT?\"CBH&[#"Q+!@2V=$X+1-9A[VIKJR!%;^)P+EDOJ
MXS:[VWBV8W#6/_?VUYX]>RI\*(^<^#5+-5N,45/#*;"W/UB`A'Z(F6$;ZI$P
M-1ACA]OCU!#41J8HVU'H9?N*%),_,G8$N]N;[(^YV?V)+_2$BQ2I`;;Z]?]3
M?$HT^G<9HOK[B4_]7X9]:@+H%T$A@M^A?RZR'ZFS88^0QC&K'#S^%U+2_K%>
M\:^XI2<OS8,X9K)$\JV'CU'S]V^;&[Q1TAH*W[_M;Z_M[37,^?NW+7C?TX8S
MGRHP>O:1%)1Z>4:@N?2,4#9[_3'3Y'=:):=@S=%+EA([*!NU/4OW"2:$:<*W
MJ[JW7!.@`V^((.,3&5IJFZ5V=N'MW:6:>Y6.("V\R%QHU-;@JIH3[/($50WB
MC^96.\KESC505ATWPFY75B8P"-QO&)-HM4?^:'LL_7LZK-(&+28G%CQL@J?]
MASE[SM?Q+`[]?GYS37"@D4C'K([+KO5!UO.\"]TS3S!5OJK)2"[2U2F[/V-C
MI.CBBXOS^__5R49N*@K&G-P`U.;HT&L;NQL69I#9RNLHZ-`".Q`QK>X673RU
MG7U&0<)<&BG7HMZF<")R?)7'.+]%CQ5)O275X*^\M30YI*E1M"K`<LLX[62E
MQQV9EF2+/SG_^L1W86J2K/70[TB,N<A5O5>C5^B"K!SM5WME:5#'BFYPO:KS
M*J[5TID<V\XIBXT@0>L!?GT]>75Q?L?IOIJJG=.B:==G4>+"!8^I]VAW?3?F
M@&OYLT^8:)_D4OQT9V%[]>B[P.\7TI:SO<J34T1.MG9W0]1%<$SA9SREP&`R
MM6@LAA2%II8IRC=DG3_SN_)`)JX!J_Y"#S5#YW>Z,V/G4/.%`O9!5T-T%6@8
MK6F:W[0[,SEDQQ.7OKLYF_V.<]+BY'KUEI?;UD_624NSYQP_3ZR1V>2`E!*:
MZEY3WZ;427,"G-XM`/_)T:%-?W(QN[N9(!(^"^[030P&R\PI0,,I*,+9VL6O
MLJ%C"]7L,%**!W8C)AF0Q5,%5;[/VC;.PW.VASY<60,ASZXFAYK];$97!SI^
M,MT)FK%>QL!;*."$D='XE1\G81LOZG$J8C>34UYCN'B^^'QM4TQYZ1'<^W=A
M?S$=9\KG.#R[U6-C_K9ER)/+$,3I3BL':V>:AXB)Y(N8-'!E\^4V#^F7_G'R
M,C4S.39RE&D"X"$#\T^S)Q'0<][I-+;ZPEXU)M=64*&##KGVJ]PS2^LN60&&
M#2(QK<P;HK[A$OA#W)MM(%Q:(["@M']=0$':Y%2OU=LNW<`8>KDK]$\+B4JB
M]<1&KPE*\[R,4(DF<"6#?:M?8A\XDF1H,$6H]E#AH+<7"Z@T/(!1HA*ZOS%^
MRQ^*/`KRUO20D+>C"?X[@>#1CKRG^WLX*')OMI76X4%-1*#E^L]4J)$.9-L6
MFG+*6..H6O`KH([+0&)F754Y'L7LZ8;"MH9VP*PZB;__>VGL>OKY@M+K5(YK
MO[?;$=./PAMP_*H>IUR?JA#AS6HY)7PZ9>YV[+DT3>&*'0"C%:4.`K;X"WO=
M_LD$D+)XO_@47I)8/J2=01]=A`S429K5$#I*:8O*15S-B#;V$8\'@='&&DSR
MG(F\(<"5Y2^M;`!']WV'/[:W_JV%JT[WSY:'4=624R2CG&TJ-G6F(`>7`;HP
MAT7+L\S8VEA':N.=\`$PO'N#&^]76JUIY,).P_:SF8GJQ<XL4@?TKI@#!T\9
M)F2QSM`EI-I^;_E'MH?N9`@IFS/!&*!J'Z0@M,.\6/<C13XBX\'UP7/-$/1.
M@"-%0?80/AO8S6S&GXC22R0JAR4["M%WO'#?G`#6(12?$E[\^*TK%?]R,>-5
M!!+2X`AH'SA9PX*(>]P;*OG1SWW!?.-[0EU;U/-75X8,9]:Y,(K((XE7X<EJ
MAC8.+:G&*8FIETHFHN<N=!P&.C$L[0G6%8<^#Y?@5&:H):[MNO&Q/4@*U?]J
M"0_ER,@XBV;:'CS&(:I679:@VG.?ZI_Z_/"5\6R9K[=R8>'"AE!U#$D!*XAV
M(AVZ_4;BQ*P^.T#$'6ZLV,SE1ZIK^U9QN9V:/Y38[U3&//[\1<PXS7D)$3]-
M>OD+`3'^9(*3YM:&/SK;R`J<DWXV'3H6OG57!>E"'=:CG<WNM]T-K8IK`1H.
MZGXD,C^OBV8X1PG.GKLE1(LJ!C>QFU1=(M+M0\A6YSCAKJDU0,LP!,ZU[QFW
MGFQO/'D*,W?N#\YWI@D8`0H)0"CD,',9-)"]5H6X72=ODOA\OY&0%.[P8+)&
MX7U9"`=]R5A+H0`3P7GX2#A26#075=F2W<$/W8`SOC"SO,5>J>B:6&CBH/45
M_D9VN>0#1<OZ(DO5-9='V&A*]4FU##IE"8&9"#_G3-F5V#<*10U1G0@%H.?E
M\)LX^;)=F"U3)MAU<"'+]@RLJ%;UTZ3`PE+=.>.['<%9YA<3Q7_RFL>RO9+@
MTD=ESWN=UX*O3]31@`!2+G;3NDKV",=S&ZN3FI2)V6N3`"83E$K/UO9/0W$G
MAW0H/.K<T6&C)8I)/MK<>[;V;`.JZ"0P%&"5-5!W=!%3V=TF%7!SK\CTS<#K
M`E=?;^_M:)F&NTZ+S..?[2V"^Z]_JG))^KX9<5><I)QR&]@X9Z)\`0E"!R"%
MK<%O8T:3+8MIJG]"T)+8/I?UL4A3=\HJ_NBIL.%53^=IT@+--N2A"74B(4*G
M''%`KBLZC_94LA6M)`RO!1<=WC8'184X5+SZ>CUCFB.@S-G\?;G:4LW"+KI'
M\MU+-@.$M*@2LVC98RR08*85%EF^'I!04@#V/ECR&UUQL*C=%A:2*L<;%VEX
M'MD!RTS$D:VO3!`,#>RD7M%[!KZ(*,4M<\N'VC"&CE*Q%^1D61/L?`#]6D\S
M""BNAO30$KJ(@9ATP'JDW</O85"/5>,J+>G\@@=#!F%I_1#"7KA/KCJG0?\R
M.&K)#2C8"W.3SA*XK6,DMY51T50A7[DAI@/3.^M0=,3WSV>S"?:F,+O8;3'U
MU%'TH&,7G234=[>2M*ST8?6C5"^_@J$O+%74Z`#OZ!<U<Y,&'?B<;+FTFE4S
M7("3W,ZCS?7@:#0XZ.K"EY:=`K#B&6%B\H`YN'C;A!?:_!^2/(.;@HP*";;4
MS($?#ZSH%I7/5=E2.QVU2AI/=`\7GV/57JKG!D^DX"#L',:,D(N5SM/@A92B
M0N"+`;6`=EUU$$910H*=Z?U(N1.\OB:T&>J]!MV6,#_>*$@*P15M%?A#+N%Q
M9O2X<*3D<6)1U<!<@N(#84&Y&P2:6[<!CTG'RM+]13P9E1"UKH\6*A3WK$LC
M^8`RL#A#B,YM-5=PP.PEU8W#&;E$7BVPM>RE\Z1@]:XEZ#G-DT6*)^R9<5!.
MY&:Y\00]141_,.EY8)?`4&XF<Y>A;:U-?N,Y:OF#"SYM/FW(E^L$%F9K01@@
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M4N#`W,`1Y2&]FND*^-N#;C9DD<E_&A,HQ4RC2BYU97%M:-NR]-3RST98]P17
M,\GBC/S7<:'87>=",#,40"]7U_'CZHDUKR(\&FFAF3JK25+HCVES@;*+[7?"
M@'9'8>L0L[%QC1\&,-_P@<7[Y#+MY:<--1Z&L)I)F!HAHLAK5''7W3:)5RE'
M4EI7]ZQF;U/\`5C<CS%DTL45I+^12+A%_&]_?]>M%6PS9.+^4_*_]M:>;F]W
MV'IGO3A[F:XA:8',J!;8W*+*2KECKG&'!2B56-O?W1M;X-2N3I%#4\O`]%PL
MUMF+KHI?NXJJG:39G61%-WLW"*M8^!`W+^4YO5KD'*1U4^KZI>?G5Y+@!,(8
M1!0A/97S2I+U-V9O\.+%`O]1:.2X<F5=!K=U;&'%';J-"ST$Z,TU]9XV%=T=
MI-VZ$*H5S5VJD!QWMQ4,9KQ>JD"2*GU":ND?VNC:Y"G=`_>IB_$-V+9`TUAR
MZ0I0[+W3/DXX);':;C=>3(=Z9(--BYNJJ>EAHT><`(>!O<===-!#+"-A?1<S
MS;P21G0&!"9,)$#/N<0YX5:IE[X$9\<]&WE9.8\+KCB\NW#$Y_)[<[0+8<6H
M6MP%EG$NX4[\[]2L4SX_2\I'S_%V==V>^S$'OA1XNB!A5[F-(7Q*)0]%N@.T
M4S;4@\HM?'QY<ZJ@4/?(Q@$37B'X8^"_Z,B75=,4'@[<_7F:S=(=&*XHK4JY
MT.D0M+H1E4J1268$Q6UY@&,H8(X_(SU@;=T^G0Y=78[`[3E!_C9M,1U*]T(N
MO>4[()_I4K68X\Y@BY0_>ID9`/_SQ0UI"9-_.[NC]S[QU&(CUC!TQ8WD;YN-
M-%<XO?ADZL3K:^`D4Z.M[NGY9(3@`H"H!,S/HWB6@JUS?W'VQ42TU/&;Q6WA
M`G6/F&FS*B34,^ZI2`3VBFO&U7YU"[8X,4XJ*"(Q4DOL&%S4JAQ"KZ>P1QM0
M5J'`KXB_SP-(C`7@'%(3;+Q18@98E?AQP_-"G<XIAAUW9[<7U+-_P+P)97I"
M/G+Y;JYN/N%X(I7O,^O-+C\P'PV?L1^NG*\JDX!O[-5IM!ZYH)!W(`W_D+]>
M637G5\JRT1]_.YM_P&="./:K%3^,CR!9!X,#P^V*>(1\V"27<<VT/[L\^W1-
M`E2]89V48X*?<@*F""_).Q^4^Z(=?/Y*K@X/8.23&K2"YY-D*K.>D*\DIW!P
M#>G`9+B&(X+8]!1E+,B.=^B7@="$K8)0Z%4-^N*Y,E,Y^=6!HBQN)][^"6)2
M!)RC1`PX&"8M06^(`O0+6-$24';6O;3N8(THJS\8(1ZLB@-,XZLF>2R5D,!D
MJ/3:V-K.*6&'J<D[\I_;M`[>0KQW>&3)`V+_*`1OA';XD"4_0D$(%ZSX#``R
MTBPM"SCF3M'`-%X*-*MB(&O4QQ7/7/&1]MC`Y5C.B*\3`@K\3/#[&"HX_(IU
M>AC*9D'![]\P()2\8QT(YSQ9$'0-=O_]V[;8G;&\S/PE1"+K+=F]COMHFU8!
M'1X?8(0X"/*G:R@X;7.Y[,,$7=R`R8S,SGUY7B:2T*]Y-,A=QBQIAX29Q'+F
M[(<HKB>[/T7\*WTM\13NKF)`P#WK>AE<@FH?$OZ<14$_8!)XX[P&G5HS,157
M9"R'*RHORQ90$Y!0*\^Y#V^FI+YXF2JD$L1EG*3CO^`3>AE7[6J*SZ,#*+;!
MX:D9GA&\XRE'.2EBKM5;_F&A>EVA.>K2NY+=K<7%C&MW]IG7=,5*4T;O"$P2
M7X*'S4+6"@0!8>-;Q<W,75G*D'$H<QC`1!:$:<2Q\#4423YO581GI=ID-8#3
M9&O%N[&!5LEO0L)*==B4^[ON37)`U4W:ESZVO=Y>+>!3=7#-?"`9]>/YN_AO
MJ3N-8TWWNKE.$5'*V;%1F&-B9<'6$8O'!6]!Z70XIU>B>=S&G""2Y=*R.;/^
MRRU8`9ID%/`E_P]!9B;)4/ZH<*NB75O#`CP"!"_*6YHT;D&^95KB"\90]4_J
M!\X0`^")V!<9[O9>!M@=08BTN)[4G[.SV+Q$_3&N=*],ED[!%7&_K,7_/3RO
MW*X`';L8@*`51%,R98U-,L,YS]G?+6[O/RCR9-D`@!4G"TY5\"FT`$[+A$FZ
M!T22ZFD2MHB<06XP591#YNU$WFMEA!N_HU.(6-72CA@]2D^@W;B$05+'B!)P
M<HZQ@)K"$(`ET)7$&XQ'#;BZ$<GENE".4U*I3>PN^!S)QQVKO%=#I0X=1F(!
MKITV!$Z5#9(VWE\E\RUS_QI;F].V#)V`:XDN6*E374]PP&!:<,,"#*2-B)HN
MOGQ1%APW.B4+PYS(2+>#HFT''@#R.\D,/0G_U12TA_?9M+Z,K#X%^O#&S'()
M8@5$62Z\8*&FL'^J@MRC'UOWME>HC4`?BLMW(MT95E!V$,)R4]O<Q*2XE=QO
M0S[5D4WI5Y50@-ZQI[UVK58N8HSV'TH7P3N,OC[/G-`25UR1SWD8X;1HGM:R
MQ@"@J4(6IA'.%XA!!"'^)$8!-_1B#VA$#8LCR.0\5O2B5.5<YQ%L$9[==C.@
M/XMJ0C,R^T>9+Q3RI*[R!HU<=ME_*<7'*#"<B.,#[07JCQ@4=<FP@#3Y/^5G
M:*)(4$WU->%CU?$2\&>45'<1G'<,(S9I3Y6'8]98\!+@AE84U,;6OZ;^P!:U
MJ'_]2WPO6OPM]E,KU8)ZP`D"$;RWIT/KW]Y59%7__JHNBZ=4=?7W'NO97A=/
ME36_C;<#KC\_LOH)Y+M)T/K75\M[/-5#@`10DLX<_*&93<`UBRX]]<#C.UZ+
M"E7-Z'.JWA4)G$BI#N\*&U4=&7,7<C\^55.D><-K`G)A')N:.?]\>:N92K4R
MZPM"^M)[4V_K%/&2"J-XG$"]"HFZ*Z6W6RN1UI+%")L3#$RF>>5()[FE<.G!
M@,<BC/7V>GW!#<ONTH4S(^B^KYG)(!1?]Y>[#P'](17)@VL&F;*TOFYP@A]`
MHA<T^[V\FO\R>?SK],7D48--^-C78]^AIFB25^*1`?=Z;%DL&9BY#OW^2#;D
M:_6_:MH"3&7+A##,SR&=L,:Z$SZ!U[Q_8[IT,\5?*/O2>L&%6H]._BPH`?4H
M^EM0EN`<#;)$7GPLF\R(Y;&D"7HJELK]YT'ZH@)%#Z8=\2B33-.AO0[DP#+P
M?K8^..K]9G/HEU//:C<@^^MT"/>3^XOU)7,=77Z\>'-V.YF&&A0'P^#2[>?C
M.]UJ=IIF"#II`/S@BE%!+8W^X8_E':M=!(-?O]]N=O?NPD;#V"K$&)SD(1K@
M,G+:G+Q1]>/<RZ%KS,5'#K&YY;A3_TB]YRSV"1$?KG__,S(5I@SOY6F8O@\.
MXK.5YKF8W2S.[]4G.RI1]7PGX;&A-0L3X<]!ITN<=3)&XHVXMWC"8VDUOT1S
M*R9.W,(,B*7)^:3?ZTTT4YGFH)<)4:^*:>MQ04<XU5-9(ZXT.*Y5[J)6!NM?
M/LCX^F`]*0:FYW5B,JI+=O'"&"VE_$W'!XVQ.B5-TQ8%OUW$BKH@K+'PK*U4
MDM9H`#`J_[5AVQS<9+6!"%#%Z$TQVD?6^V5@Z<]8>1SV!GSPR1$7.9,@B,\H
M''@BP1BZ%%^3I4-;+]79>@?WCPV6QYXGS;YCI-;D"W<^(#L.B'RFQJA3GF:_
MPQH#1UYZ"],0M#ND=\[B/IG0+V,_ZQ-415M@%/^UQI.TB,-9UH(_E&D.0O"G
M7,`^!G`B@<(=,W+!GE\9"F,&3YNT_"%PG,9V^/1%'(!80?/AB\E_3]YPW5\6
M7U88-'*7VSQM9=RPOLS^)7FM<FS)S:V-@>ER[\?'R_AS_A2]%$.PO[ECO=\\
M*@9FA_LKUF/369>W39PLW7XQ67_7OQ%>F,9::[U1K7GD#'E9]_[&KHA=ON_E
MRM05$<(J6N/5\Q[I=XN_%YW%/%@;E;R?4SNP>C`B0#R!!$*<5T57I]2Z#1%2
MCSD=ZV/FV115E[1ZA@/W$9H'XJ,]Z"*7]8\T"ZMG?M=I.&9<)'8&DZ]!SI@^
M"Z>>IN:V:&=JK+44M7K&C9#VP^RA950)4'/++P@3=Z4+8AQO2L11DX@Q,7]2
M-U8!)=QA&6(HV)4(GD;[2`(_KF-^+0`=LH9M6>8J.K'T3[2Z9;<,%,>R:%(8
MH&AH4M_SNU#%C2V%L^"!S4*6H\/\;Q\;CQ-=+=8G]$2S8-[*^QD5I>]D!RH^
M88*BGO,``C??1MD;Q(2F@I?>.Z11C2+GD,^S-0^1;2%E1)4-18>,(?$8]`U3
MSY;*:\]HUF>AD#T+^V:?C088W72S,<4OCQJP/&&'(>FEAN84A0<=Y#+JPA8"
MTUY'C.'#E+TM+S!>S]7.]A)OK,(0J%ORL>%@_T]XD%>@K3;#20Z5H;*7_#WN
MOSY>H^OC88O!"+E?;V;UB&U_(KK^\TMK<"^+I;?D;AG$XEM:J=X.SDU8U`.@
MU\I^KA<,,@7&5W]:?TFO8&>50+935E=_:%B;O#`2_?(H+F,^\-'`>`/6#W=_
MS)^Z_LLK0Q[$+JKH!"G_:X/\D?1\S/`RX;MJC>!\73Y_-:[TD8X,=MT[ICS&
MS,R1`5%-3XF08Q2<=/:5OD[,*@/<MS?$K_)W%A?`6^O/RGB3#!UBA-R+P;J9
M/%CC&I;6^LZF-LJQN"AYZAT]A!.^[6(."YDU"/Z@S-+EJ"\5GY6;[G"9WSHN
M398)@B'QDTPI)%#T248JL'CFT(7F'0QR=EPY18>H:-/'50R@-?Q6V6;Z)B#A
M\]4D9F]*Y<D/GW_Y=&F?B;26P_+W&!];SDOJ9)\?/LG81*N?H2\3,W'V^IK#
MQ_6?,TXUN6V-=)HVJ6MIM:&@PL9DS`M*<EOR@N[6.ZM76Z(]DC01WW,V/KUT
M]^7E)9A7FF+YS>'K=V_2OY=O-GM0'N3UGL+-I.@:J6*PU<[!@*0PX=(_.B*1
MQB<,BD%SG'(7'OV?6>8@YJ>[G2\:'2H*:&-A68-EIU4V/,'OG&_6R1@9.<8?
MGYU:1;TCW1RU0NITQ7#GT9OC]T$RKA?)(2?T3\6-Z=(F4[Y40SZ4-<JF-HR(
MYY8X5L0W=GU8:*'(BYC@\U9I<D/L\H5:;>3\DH>9#O5@RZF3&JI\[1I4]<>%
M^,]V1R]D_F$^O__G_Q$```#__P,`4$L#!!0`!@`(````(0"?JB8G_`L``)UL
M```-````>&PO<W1Y;&5S+GAM;-1=:6_CR!']'B#_@>`D01:(+8FB+,EK>3'2
MF,D`D\DBXR`!LD%`4Y3--0\M1<W:&^2_IZIY58M74R+5SAAC2Y2ZZM6KHP\V
MR9OO7CQ7^6J'.R?P%^KH<J@JMF\%:\=_7*A_NS<N9JJRBTQ_;;J!;R_45WNG
M?G?[ZU_=[*)7U_[R9-N1`B+\W4)]BJ+M]6"PLYYLS]Q=!EO;AT\V0>B9$;P-
M'P>[;6B;ZQTV\MR!-AQ>#3S3\=58PK5GB0CQS/!YO[VP`F]K1LZ#XSK1*Y.E
M*IYU_?'1#T+SP06H+R/=M%+9[$U!O.=88;`+-M$EB!L$FXUCV464\\%\`))N
M;_R]9WC13K&"O1\M5"T[I,2??%POU"M5B4U>!6L`\;N?]D'T[6_B/^_^\.[=
M\-_??/O/O]KK?_WP^^)G/WRC#E(U1";XH%[FY;!6+'P<2QXD%MS>;`*?&`)>
M9P1=/_O!S[Z!GT$P@'GXM=N;W2_*5].%(R.$9P5N$"H1>!GL8T=\T[/C;ZQ,
MUWD('?S:QO0<]S4^K.$!%AC)]SP'W(0'![&&\^IY0#2I33.$P=DTQB/4)@],
M,O%@O4WFCR4V<;HFS;I.X8_3Q:RHMZLS7<6X*'!XBJ[,5T1/^/BP4`T#:LAH
M.$1:J<-Z4C9?#4'?V91=3<YFV=@8&]-.+>-BL>@W5#@VNJ2R0:'Q?OKA;'1V
MKZS*NJ0,GRL#,.&Z9=&!U*W)[ZF!/^>(DS-W:)UZ#`9PT7O7>?3C[G:WW\*(
MS@J=;83,I?1.+XO]#\O,KDJG&(S^1A%L,+&#;MIQW6R4-I[@.`:.W-[`@#&R
M0]^`-TKR^OYU"Z,8'\:VR-0@_E[#MQ]#\W6D,2[%&NP"UUDCBL<5&SLE?=?J
MZLY8W3&]!)DHB@JAAK&:]B#T;CE?=8]T-9]W+50SX*=CH>\G^-.Q4`/^K3KC
M-*E>>E<@,WE*Y.!<9W@YG<_GL]'5;#:;Z^.1KC.2'Y*(=ORU_6+C]*<SFHH(
M)H!@/I[-KS0`,M1G3-59$8P!P'0RF4U&<TV'_ZQZ]H^@:TXGJFRO$@22O$H0
M2/(J&VX/.JC\2:;`RH/D7"4()'F5()#DU6G'%7@JW:L$@22O$@22O,H6B3K,
M55C1DYRK!($DKQ($DKS:V>`SJ<!SZ5XE""1YE2`XMU?3:=7J[LY@2P;%D5EG
MX^-$%P[BV^MBLT:8ISX$X1HFZNGYA-$<YHCQL=L;U]Y$,",-G<<G_!L%6_C]
M$$01G*BXO5D[YF/@FRZ\'*0MTK\U+>%4#IRU6:C1DV,]@S)N>3CF)E;1EX:L
MZNDXF]"G^G"J3[2K>,+6D6K/7CM[KVA=IKLT+H%&Y+;9<,*AGRE)PB%?K1J@
M%Q+W";9@KF:>%FP`,9&&A&"++FS,5VY%;20MQ&PD#01M)"U$;834*4NNE,EU
ML(>SB(<.-HS9<,AF?:WCI5P@`5X2,8UMBGPV-BEAM+&-**<I>5!?"KFQU/"'
MC8Y++&UH4;2SH4&)E0TM1&WDXZ;4XFSI`LMS"9(#OKFOB\(@BDDI3^H0+M+'
MR_0T1P$-@!%M2'!#PZ8.1U0J<7T,!W[')O>C1!17:8#5$ML[/^VA]\SE@<-$
M\?48T:(0<N]F%(DV%44/@IF6GDGBU8@:T2Y6>1WP+N8@5790O8HEIXZR9+0*
M@U_+=MTO.!S]QR8;`<.B\NW-RX9L?8&=*;@W!'?6X$LX<Y.\C$>[\1N`6-5(
MJVRDF-NM^_IY[SW8H<$V*3$5["B>(<K?+=DP/7_/SK1Y-EL65V,QWX=!9%L1
MVT3%SNQ5X1E7X!DE@D3PG*)?K]`//`GS<8I^6'8M=2+P(E4_!)>P_B[C`;>+
M)4$-+J!!78>G2P2PN)8B`"?(0(#;VQ(.(#QE((!%BQ0!!&B.`.#41,4I>3`B
MU0QB(%<)^OM2"34FM9)3V:.55>47]-=8:7#E]R2:2;V%0,]IAC<U`$Y2655B
M9948XG;(M)P">%-#@0&];C==WJBJYDLCA!1=P)`S`F6@CI'NHI+47-"9`ZAG
M9-GA.(0$!98BV1``CA0(Q!$C2?WOB&*0U`/3:)#4!5,(7!]\QIR@GN!Z2$D8
M`(^4K,C'"2.NQS@C#02"K`I)HD&352(I!EDU,G>%)JM$$@BR*B3UA*P223'(
MJI'$%;)*)($`C$BID-03LDHDQ2"K1N:N&,LJD02"K`I)/#'NN40.Z+)IO(A*
MUD]A]VWU4B@X*)W^'_KJ9=.XD#JJFC2!K+1Y/'N*9X[@"S:7(E-IO*#0Q*L4
M<.U4>0I"YQ>89.*%A18<L$,5+T2-'(L>^3DTM_?V"TQ%X[.N+YL#`]GL,EDA
M%L?(+[.F6,^+'/W1N+1]P&TEFSESL-:O*HVT$>7BK`GR<P(6A)4L!<)+KK3S
M059)1*/EN"+4EO;R<#D>`PU:89.[!M%G"'24W%AS9/L*NG?I&(BKJL(%5W'X
M%%DFRT5I=:L,5^HL/#]/ZW#K:E*)#V`<B:^'>G("6WV@@4'#D=R<QW=0,X_$
MUPU;8V[65W1>?,(@#73AP&\+#A67U((F=.6%^TR8A2`7XD\N.&Y^+<W;,*<J
M<W8#N+?H;!ZR+&=790^/KM"-O7U""SW;6\H>8)<OW6\)G*Q0K"B*?"06.KVW
MQ!PL_TEQJU@2%_PJ-8G%,!?<_7^`N1`%4C&79Q4<[64>WZFVMB-!`>6XK,*G
MJ/"XM'$-0T0]+$H>J;XXI^@"$&#F\0C-1W_<[R)G\]IN10OI.6T5B5+0*83S
M1P4_.REX@>_4*GUR9`1THYQZ(UZ@:(0#U;QL\,[-(PM<B%3/2H8H2+83_.B8
M[8DTV"4]*"R?8ZH45]C&W$BHP%//,=.)<NJ.TV*F'LY;B9EZE((>*Y#6)F:X
MW"K6.1Z"<%]8@-3JW`:&=](3\%G5"[X3TYYS(>Z\X?O+\Q%843P;\(EDPE%N
M%Z6UD[,J-=>2D&""E_F@MAA+N9E'B"N46Z$NA]6X-NG*>[,P6#U?M"&M35U0
MD>(.\(G&505`OMZ]O71MP"<]7<M/[O%ENI`+(JC%\^7HOH1+G@)(/C:%X*0[
M(!H'MB+!^!8`<0SUDK["E(D$6K&[%8FTO,ZWV.S2X6BTR&MOJ$6+9<5B&X1D
MWF$6XK,<=67BM$D2N*E*-@2L!V%`)X3;C!I<6::<[<J"?5CDJE;^FM9LUY:"
M]UJ%6\</?ZM<*.\MC.'L]`%"?=@[+MP9"K=CX8XZ"Y8_`F\9'TSV0-7)RA9>
M-:S^1!:D8UM9("$>@&JPE$1E05?75A:HCV6-P5HB"R[X;2TK6_2$.[MRLB#/
MV^+*ACUCGON)(/=ZF1_9;G'"/9@L@HO*ROV(=93(`I/;RLK]"(ZCLL#DMK)R
M/P)"(DL')6UEY7X$+U!9$&YM965^U#''<[XF@MQ?E?J1CU7<VBF"B\K*_<C'
MZE@P5JFLW(]\K*+);7'E?@2IA"\=/F@K*_<C7R=TP3I!;<S]R',_$>3^L*+R
M$:\)1GPL)?<=O"(<X0A5A*-82NXU/LK'@E$>2\G]Q<>W+AC?L93<4R"/6*3#
M!^(693X:\^SJ@NPNS77:&_`!@_V,"`QXR(BU=^'A+P$^.H9M789[BE.#\$(5
M(4E/MO6LK.!.%)D@/A^P&Q41=/>R=4W?C(+P5<'MRIDXWND307%_#(*,(UZ"
M!F]%`/T)'K0#S_!1@)>D$^<(PH%C&S%9+O#TX+6+;<1`ZQ@-'W\X^&XC!EK'
M8OBBBN,G$3$?_>T^\Q!?2['K%A'QR?&?[34?.7R5T`"DB*3/]CX*S2S^^)32
M!(GYC/<OR63P)8+=CN1PS/@9;E>2DHC+9J08X`!>!/A?]A&A$5L1(9I@7;IW
M(KC)6IK$G`B$)8+C/H!+"#(1!Q5%4,;?S=#';.%2]R!&*RS*+\B`T?_Z);^7
M#>,]PD=1L;O<9/,!(&IM;\R]&]UG'R[4_/6?V>T+(9B2;WWO?`TB)F*AYJ\_
MX7TA(8MAQ0_*S:<=W&L0_BK[T%FH_[E;3N<?[@SM8C9<SB[TL3VYF$^6'RXF
M^FKYX8,Q'VK#U7^!,GQNUS4\^.F$YV*QYW?!)1DC_7KGPM.SPL38!/R7_-A"
M)6]B^.QF<``;3DRE1@QVV7/%;O\'``#__P,`4$L#!!0`!@`(````(0#[8J5M
ME`8``*<;```3````>&PO=&AE;64O=&AE;64Q+GAM;.Q93V_;-A2_#]AW('1O
M;2>V&P=UBMBQFZU-&\1NAQYIF9984Z)`TDE]&]KC@`'#NF&7`;OM,&PKT`*[
M=)\F6X>M`_H5]DA*LAC+2](&&];5AT0B?WS_W^,C=?7:@XBA0R(DY7';JUVN
M>HC$/A_3.&A[=X;]2QL>D@K'8\QX3-K>G$COVM;[[UW%FRHD$4&P/I:;N.V%
M2B6;E8KT81C+RSPA,<Q-N(BP@E<15,8"'P'=B%76JM5F)<(T]E",(R![>S*A
M/D%#3=+;RHCW&+S&2NH!GXF!)DV<%08[GM8T0LYEEPETB%G;`SYC?C0D#Y2'
M&)8*)MI>U?R\RM;5"MY,%S&U8FUA7=_\TG7I@O%TS?`4P2AG6NO76U=V<OH&
MP-0RKM?K=7NUG)X!8-\'3:TL19KU_D:MD]$L@.SC,NUNM5&MN_@"_?4EF5N=
M3J?12F6Q1`W(/M:7\!O59GU[S<$;D,4WEO#USG:WVW3P!F3QS25\_TJK67?Q
M!A0R&D^7T-JA_7Y*/8=,.-LMA6\`?*.:PA<HB(8\NC2+"8_5JEB+\'TN^@#0
M0(85C9&:)V2"?8CB+HY&@F+-`&\27)BQ0[Y<&M*\D/0%353;^S#!D!$+>J^>
M?__J^5/TZOF3XX?/CA_^=/SHT?'#'RTM9^$NCH/BPI???O;GUQ^C/YY^\_+Q
M%^5X6<3_^L,GO_S\>3D0,F@AT8LOG_SV[,F+KS[]_;O')?!M@4=%^)!&1*);
MY`@=\`AT,X9Q)2<C<;X5PQ!39P4.@78)Z9X*'>"M.69EN`YQC7=70/$H`UZ?
MW7=D'81BIF@)YQMAY`#W.&<=+DH-<$/S*EAX.(N#<N9B5L0=8'Q8QKN+8\>U
MO5D"53,+2L?VW9`X8NXS'"L<D)@HI.?XE)`2[>Y1ZMAUC_J"2SY1Z!Y%'4Q+
M33*D(R>0%HMV:01^F9?I#*YV;+-W%W4X*]-ZAQRZ2$@(S$J$'Q+FF/$ZGBD<
ME9$<XH@5#7X3J[!,R,%<^$5<3RKP=$`81[TQD;)LS6T!^A:<?@-#O2IU^QZ;
M1RY2*#HMHWD3<UY$[O!I-\114H8=T#@L8C^04PA1C/:Y*H/O<3=#]#OX`<<K
MW7V7$L?=IQ>".S1P1%H$B)Z9B1)?7B?<B=_!G$TP,54&2KI3J2,:_UW99A3J
MMN7PKFRWO6W8Q,J29_=$L5Z%^P^6Z!T\B_<)9,7R%O6N0K^KT-Y;7Z%7Y?+%
MU^5%*88JK1L2VVN;SCM:V7A/*&,#-6?DIC2]MX0-:-R'0;W.'#I)?A!+0GC4
MF0P,'%P@L%F#!%<?414.0IQ`WU[S-)%`IJ0#B1(NX;QHADMI:SST_LJ>-AOZ
M'&(KA\1JCX_M\+H>SHX;.1DC56#.M!FC=4W@K,S6KZ1$0;?785;30IV96\V(
M9HJBPRU769O8G,O!Y+EJ,)A;$SH;!/T06+D)QW[-&LX[F)&QMKOU4>86XX6+
M=)$,\9BD/M)Z+_NH9IR4Q<J2(EH/&PSZ['B*U0K<6IKL&W`[BY.*[.HKV&7>
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MH4(.52@)J=\7T#B8V@'1`E>\,`U!!7?4YK\@A_J_S3E+PZ0UG"35`0V0H+`?
MJ5`0L@]ER43?*<1JZ=YE2;*4D(FH@K@RL6*/R"%A0UT#FWIO]U`(H6ZJ25H&
M#.YD_+GO:0:-`MWD%//-J63YWFMSX)_N?&PR@U)N'38-36;_7,2\/5CLJG:]
M69[MO45%],2BS:IG60',"EM!*TW[UQ3AG%NMK5A+&J\U,N'`B\L:PV#>$"5P
MD83T']C_J/"9_>"A-]0A/X#:BN#[A28&80-1?<DV'D@72#LX@L;)#MI@TJ2L
M:=/625LMVZPON-/-^9XPMI;L+/X^I['SYLQEY^3B11H[M;!C:SNVTM3@V9,I
M"D.3["!C'&.^E!4_9O'1?7#T#GPVF#$E33#!IRJ!H8<>F#R`Y+<<S=*MOP``
M`/__`P!02P,$%``&``@````A`'JNRAB(!0``;Q8``!D```!X;"]W;W)K<VAE
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M$&EUOZD@`RR[UXKMTG^(%CS._&!U/Q3H[TJ\=<9GK]LW;[^TU>9[=110;=@G
MW(&GIGE&ZK<-0K`X<%8_#COP>^MMQ+9X.?1_-&^_BFJW[V&[4\@($UML?C#1
ME5!1"#.)4XQ4-@<0`*]>76%K0$6*]^']K=KT^Z6?9)-T%B81T+TGT?6/%8;T
MO?*EZYOZ'TF*5"@9)%9!$E"O_A_?'&2J@L"[#A)-P^P&(2!YR`;>SS'"L4("
M69FAT*SHB]5]V[QYT+V0>W<J\%Z(%A#X7&%9CTO-_ZOD4&L,\H!1EC[<=E#-
M#OKD=36=SN^#5]C;4G'6+B>R&?F9@1N)8=D9,,*FH;V(GSG81Y#3)3'8-C.Q
MCUOFK!_)J/]\Y?49T%>.[>OF+F.6V13F4J8IR9E+3BQK%D>)OHR5#33?^&R0
M;&5#@9P"C`)<`E!<O:-)>LG/T@8]/5X;DI<^O.JXJ<YYV/:UY,@;&OL@IP"C
M`#<`2QNT]'AM2(8186E++CE+;9(S'_8KF]_=):3-<Y.0SM(L)00F"3H[;@"6
M]LS6CK?F%+C7.QD7T1RF)`?)T0IR"C`*<`.P-,YLC=>U(?FSO9<<0QL%&`6X
M`5C:\"G`&&W7M2&9UHWNO>08VBC`))`-W1'!<`]C$H,;2RRQ\UO$(MD6FZ3D
M0FO),<12@$E`B9TF(?[9G<*--9;:"*S<K"WV9@+8]1H/JVS=TU0/%7F#*9(A
MW$&8@W`3L96B/XSN@DBZ"4R3*^-)D4R%<IE&F,/A)F(K1`LP%(ZLI30.>U@1
M`UI'DJ1UY0["'(0K1#:&;`O=%[9T=`E#^B?;+SW%ECRS.VX=29(IF2+,X?`+
M@H\>VDYLL>@1X\5*1['%WE&QANT,W9M'%&$.PA6BZDON.ULR6H,A>9P%X!,R
M&0]3ZD)K13+K;/C0D`QS.%PA8UH#'8-('S$AI,]85<]T\ZD)89B1JCI%6$01
MKI`Q54=#(=(_-]Y(VI`MG3SMK17)K+KA7JKJ%.'F*KL_T$T,I9_<?])[H$.O
M#3?#H%1Q*<(BBG`3L16B@Q@*1PXWZ3M6+5-GN!GFI)12A$44X0J1;1`-GJ?[
MRY(>_R^/&U81C\OT1!J$KA7):`,'80["%9(EP^-%.`FU==K"B>5AS;-/S3F6
M'F;5/*,/%8ID"G>LS^%P$[&5$NN[WK^Q=+/K_:M(ID)J@LSA<!.Q%4(];N_?
M&%?1)M!MIII`DDRE%&$JD.9PA<@?(,DU\XC1BFZ^]8955#K]`:%(6E;N(,Q!
MN$)T_^KI:-><N-XG7?&!VV7ZSE"UEJ29^ID]"TE&.1[#P([IC)B#<!.Q!:/9
MW%YI:5&PYWH<9W3(P>F:K2MW$.8@>":'J^"A&)^'HHF:<W+:A2&MNSQ_D\="
MM6AW(A>'0^>5S0N>K>&HO*"7<[^'!`]+"+Z.%G"(X^(,S@D_PM?Q8OU1G#Q>
MP!'%!W'B!9Q4`!Y<+@S'?:=B)WXKVEUU[+R#V(+D<#*#_6SE@:'\TC>GX;#K
MJ>GAH&_XN(>#70''"W"(YGO;ING/7_`"EZ/BU;\```#__P,`4$L#!!0`!@`(
M````(0"Q'+[U8`(``(H%```9````>&PO=V]R:W-H965T<R]S:&5E=#,U+GAM
M;)14RV[;,!"\%^@_$+Q'E&PY?L!RX#1(&Z`!BJ*/,TVM)"*B*)#T(W_?)6DK
M"1R@SH42J>',[NRNEC<'U9(=&"MU5]`L22F!3NA2=G5!?_^ZOYI18AWO2M[J
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M2).,0AA"MQ@`KD1)WQEH"#^$YUZ6KBGH:)Y,LW0^GB++!JR[EYZ2$K&U3JN_
M$93YH`:2T9$$GT>2;)+DH\ETEJ'H?UA8C"@D>,<=7RV-WA-L&M2T/?<MF"V0
M^?V,,`J/77MP0;&I,5B+5=BM\OQZR79HG3AB;B,&UP&3#0B&HH,RJEVN[,%>
MV1OB0[F-!Z]E1N_+C#\BX\%O9.+!:YD\G[XOE']$R(,+BNO@TCA]\2FF&#&A
MG]X8A\6^W#@/+BBF,0CE^6Q((`I%S"04]"6(J!EG(K:,`E/#%VA;2X3>^G[/
M\,YP.HSB>ARF:?B`H]#S&AZYJ65G20L57DT3W_LF#E/<.-V'AMQHAT,07AO\
MYP'6.TT07&GM3AL_KL-?=/4/``#__P,`4$L#!!0`!@`(````(0"X$[<AO`,`
M`)8,```8````>&PO=V]R:W-H965T<R]S:&5E=#$N>&ULE)=OCZ(P$,;?7W+?
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M@=-FE7!8`:;=D2Q=NUNRC$CH>IM5E:#?G)U5Y[NCCN+\2?+D"R\89!OJI.G^
M!\M8K%D"E7,=K,A>B&=\]0EN^1!$50(,HOXV8;8!1O':,-WO3<C'JFS?I).P
ME)XR_5V</S-^.&J(-(,T8#:6R=L#4S&4`6*-@QFZQB(#"_CKY!SW$Z21OAHZ
MGNCCVIV$X]G<GQ"0.WNF]"-'2]>)3TJ+_(\1D=K*F`2U"7R>Z^?AF$S]\`:/
M2>T!GXV'?Z6'9]94I>N!:KI927%V8+,"M2HI;GVR!-__YP22@=HMBM<N-!,L
M5T%A7C;^RGN!U,>U8F<4\+=5D+XB:A18/6!H02`QUX.@&$&P6$BV,S>Z<0,K
MKE$$%?4T@-*USWL8D(,N!NZ5"6S3RWG!E];NM+/J2>MN^(S"["X$CCHW>O'!
MI!O_<EP4`U\G[M2*:Q2P3=MZO*^[(HL:A5T/>.=Z$!3W04(+Q"AF5?KOYN%D
M:F4H:@0V1W@+!XK[''.+PRB0(]V,1B0836"#IKB51V31UT:-UD::WX*$XC[2
M73_,SBA@_6V-;)!&88/@S]K5S8OB/@BQN]=(+I$T"IMD<0L)BBT2:TKLC*1+
M0NR&;B0V"H%VO3XKE=J"L;;FKM;T:*Q&BUK-``<'7J=(UTT48L9DM[6)U;F[
M6M,9*O6=T'39)`A#,GM?3&_.D)OF;:6VLF1W>*TQ+1[X-F[4/A]D"&=A)T.7
M9QXQD[.7&;O):TVO8%;71:UF@'/3"";#&6S/D5VMZ>($5NM%K6:``Z_=D!U4
M]PL5V+V%9Q_0&)Q]M5<&-(UD0'/3.(:CX(#&:N-=K9E7'-/`7PPZ:S"&S:G/
M'&-R)@\L8EFFG%B<\!1'P*F]VQY+M^:\V#Z``UY)#^PKE0=>*"=C*;SJC^>P
M<&F.B.9"B[(Z).V%AJ-=]?4(YW\&O^'^&,2I$+JYP&2U_U%L_@$``/__`P!0
M2P,$%``&``@````A`,XPK3!]!0``J1,``!D```!X;"]W;W)K<VAE971S+W-H
M965T,C0N>&ULK%A=CZLV$'VOU/^`>+\!#($$);G:A!!`K515M^TS2YP$;8@C
M8+_^?<?8!FSG1MFJ+\MR,G/L.3.VQRR^?U1GXPW734DN2].9V*:!+P79EY?C
MTOSK1_QM9AI-FU_V^9E<\-+\Q(WY??7K+XMW4K\T)XQ;`Q@NS=(\M>TUM*RF
M..$J;R;DBB_PRX'45=[":WVTFFN-\WWG5)TM9-N^5>7EQ60,8?T(!SD<R@)'
MI'BM\*5E)#4^YRW,OSF5UT:P5<4C=%5>O[Q>OQ6DN@+%<WDNV\^.U#2J(DR/
M%U+GSV>(^\/Q\D)P=R\:?546-6G(H9T`G<4FJL<\M^86,*T6^Q(BH+(;-3XL
MS2<GS!QD6JM%)]#?)7YO1O\;S8F\[^IR_UMYP:`VY(EFX)F0%VJ:[BD$SI;F
M'7<9^*,V]OB0OY[;/\E[@LOCJ85T3R$B&EBX_XQP4X"B0#-!4\I4D#-,`/X:
M54E+`Q3)/[KG>[EO3TO3]2?3P'8=,#>><=/&):4TC>*U:4GU#S-R.!4C09P$
MGIP$!1/'LWW*<<?/Y7[PY'Z.\XB?Q_W@*<:;>&@:S+I)WQD0IM-%&_2.CPT(
MJZ7S@^?7!IQS1X<FEDMW+T2+I:?+=I2W^6I1DW<#EA`DH+GF=$$Z(243>6;!
M]IG_6>(AXY3EB=(L30@#<MI`M;ZM7#1;6&]0806W6>LVCFRQ$1:TG"AMI`);
M%8A58*<"B0JD*I"-``MDZ;6!LOL_M*$T5!L1U5H`@UA($4)8")=(!;8J$*O`
M3@42%4A5(!L!DA"PCC0A7"B6VYN!J`GJM31A+?4U@0(EXVMFX[)E3U.^T9!(
M0[8:$FO(3D,2#4DU)!LCD@00AB8!W0^_N$XH#6R%('0OBCN7D[_F-E"5O0T*
MU`KIC?H2T9"MAL0:LM.01$-2#<G&B"03*"+)=+]"J'6GA@ABS9%1/6A(I"%;
M#8DU9*<AB8:D&I*-$2E07PGT/^Z;E$96@",C!30D8LC4[C9:#]ES3RZA;6\@
MA(TYTG4,W=ZZTVB3'AD5GJOLXFEO)*BS,;6D$9R&4C$PC28!B-J>RN)E3:#`
MH<QO%(D+H;&3A9+("G%DI)"&1`R92FO(#125>B,12LR1D4H:=<(1.L.W%;(=
M1?NT_UVP9F-622#:+.N'[R#0#W+]F4#0`0F%*(NL$$?&QS$*7#GZ36\DYAEQ
M!'J+8>/Q;-EMRXP\5GLHL`-/U37F)D."=MI8R2-CI?)8:.[[WE2>3C8>2](6
MHI"TO5%D(PVIM:PA0[SQ3HT")=>;WJC7D"-N?]IO.>)U]>+:<V2[BJ8Q-V%]
M-#T%=QIQHA&G,C&TJ#92<IR-B25U:*OW!7DZ<UD?`4$"AFH)E/1L!JM>(0'-
M!XDX)(H*&OR9<BC&PF145()HZ*P2`0W<J7!D!3OW/4?ESH1)QRW+1%O#>ROT
MH2W,H2R*>@Q2RLN7BWO#'<%J4(\Y3D<%QJU\Q':D&4)3I<V*!=&HP@0T<"<<
M&G&G,K?G!*ZC3#(31!VWK![M)S7UX!K(]W^QO3U^&,"-5U.20U(=^LJIM1&.
M0ZU$')K2V8A+"]*V.V'E=^+Z+@(3Y1R)N8TWKLU^5B)SB6"Z.UXJK/AX,[@P
MJSLWO?=3%=AX3'%VCV<WNPK71[S!YW-C%.25WM$=RM;#[`-"XH=PEL/L5#P(
MX0C3\<P/X2#3<?@0\=35D,*SIA\H;MBO40CW#)UG[8;0?>OXDQ<^0<#Z#VLO
MA#[T!CX-H6V[@?OA^E8`&S_<W,(C/X0^2N>)@G![RS[V0^@?=/N='^XZW.H5
M@@\EU_R(?\_K8WEIC#,^0)+L[MROV:<6]M+R\_^9M/")I&L%3O!)#,,)8=-5
M=""D%2\PL-5_9%O]"P``__\#`%!+`P04``8`"````"$`=.<UEQ(%```U$@``
M&0```'AL+W=O<FMS:&5E=',O<VAE970R,BYX;6RL6$V/HS@0O:^T_P%QG_!-
M$I1DU(000+O2:C2S>Z:)DZ`..`*ZT_WOMXQM@NU,.K/:2[MYE%]1SU5E.XNO
M[]5)>T--6^)ZJ5L34]=07>!=61^6^H_O\9>9KK5=7N_R$Z[14O]`K?YU]?MO
MBPMN7MHC0IT&#'6[U(]==PX,HRV.J,K;"3ZC&M[L<5/E'3PV!Z,]-RC?]9.J
MDV&;IF]4>5GKE"%H'N'`^WU9H`@7KQ6J.TK2H%/>P?>WQ_+<<K:J>(2NRIN7
MU_.7`E=GH'@N3V7WT9/J6E4$Z:'&3?Y\@KC?+3<O.'?_H-!79='@%N^["=`9
M]$/5F.?&W`"FU6)70@1$=JU!^Z7^9`699>K&:M$+]'>)+NWH?ZT]XLNV*7=_
ME#4"M6&=R`H\8_Q"3-,=@6"RH<R.^Q7XJ]%V:)^_GKIO^)*@\G#L8+D]B(@$
M%NP^(M06H"C03&R/,!7X!!\`?[6J)*D!BN3O_7@I=]UQJ=OSR=0RY\X46)Y1
MV\4EH=2UXK7M</4/-;(8%26Q&0F,C,3Q)][4="SP>6^BPR;"R"9:WL2UO>GL
MLYDNFPDC=SFQ9Y[E^9^XA`_J`X:1NYP]YM)G,V%D,^W)S/-<?T:DNB//E$V$
MD;M\,$JHTOYC8?RU*.=L(HS<Y8-10K*RC""YR%+B;IP&3:D^0Z.\RU>+!E\T
M*'M(FO:<DR9B!826YR:5:LC6GR4K9"EA>2(T2QTD@#QLH<+>5H[M+XPWJ(J"
MV82JC25:K+D%*0%"&\G`1@9B&=C*0"(#J0QD(\``609MH%3^#VT(#=&&1Q5R
MX"J6+0G!+?B42`8V,A#+P%8&$AE(92`;`8(04/J"$+<;%\\%8KW4H>B'7+#=
MN1A@2&T<VJ+(4J\5)%*0C8+$"K)5D$1!4@7)QH@0.H0AA$[JPX$Z^<7Z(#0P
M$02^BN))Z1\R(TC'D9$I*K<>C(;<4)"-@L0*LE601$%2!<G&B*`3=%=!I_LI
M0JQ[.7@0(4-&":$@D8)L%"16D*V")`J2*D@V1H1`86<1`OV/#9/0B`HP9*2`
M@D04\<R^P[JV.7?%[-@,!ES8F"'VT'ZV"FTR(*/$<V8B=3H8<>IL3"UH!)OH
M#8TF9`ONCF7Q$F)(<$CS&TGB0&AT2R$DHD(,&2FD(!%%/*&&G*D8RF8PXJ'$
M#!FII%`G#"%?^+:R34O2/AW><]9LS"H(1$[VZJY[%>@[/O],(#@Z<84(BZ@0
M0\;[L"VWF?5@Q+\S8@@<1*Z-QY4:SX8:N33W/)L<XN2V'C.;ZPIM%6?)(\[2
M!YQE8V>"NA#'774?2C]"(HI+$5?LX?+./1@-XE+$<X8"W#`$>NE5;L\1<S1F
M1*1D^)'*=J64VRK>$L5;>M.;1)1]XDV0EQP357WA,L&JFR?OXZ7>,XIB<P@6
M>8C?D4Z4ZZO1H#:#/%$W.9>YE=_7,ERC'-<QI:6,F9$[RF;58<*I[CI,N15S
M.)NY,V<NA4/NH"3GJ$,J.;U3TA-[A9H#6J/3J=4*_$KNBQ:A&V!ZF4W\`%HU
MZ"'CTP`ZE(IG?@!]2L7A4OS4MT.))R27Y1OVH1W`^5'E"9T`3E<J_N0&3Q"P
M^B)T`SAFW,"]`';E&[@?A+<"6/O!^A8>^0%LDRI/-`U@8U#QV`]@>U#QK1]L
M>]P8%()+^SD_H#_SYE#6K79">U@DLV_K#;WVTX>.M?=GW,%UO>_T1_AY!L$Y
MV"1EM,>XXP_@V!A^\%G]"P``__\#`%!+`P04``8`"````"$`<`V3D+H%``#/
M%0``&0```'AL+W=O<FMS:&5E=',O<VAE970Q,2YX;6RLF-N.HS@0AN]7VG=`
MW$\(IW2".AEU0CAI5UJM9G>O:>(DJ$,<`7UZ^REC&[`K'76OYF:8_E+^;?\N
MF\+WW]^JD_%"ZJ:DYZ5I3Z:F0<X%W97GP]+\YT?T;6X:39N?=_F)GLG2?">-
M^7WU^V_WK[1^:HZ$M`8HG)NE>6S;2V!937$D5=Y,Z(6<X9<]K:N\A3_K@]5<
M:I+OND;5R7*FTYE5Y>79Y`I!_1D-NM^7!0EI\5R1<\M%:G+*6QA_<RPOC52K
MBL_(57G]]'SY5M#J`A*/Y:ELWSM1TZB*(#V<:9T_GF#>;[:7%U*[^P/)5V51
MTX;NVPG(67R@>,X+:V&!TNI^5\(,F.U&3?9+\\$.,MLSK=5]9]"_)7EM1O\W
MFB-]C>MR]T=Y)N`VK!-;@4=*GUAHNF,(&ENH==2MP%^UL2/[_/G4_DU?$U(>
MCBTLMP\S8A,+=N\A:0IP%&0FCL^4"GJ"`<"_1E6RU`!'\K?N^5KNVN/2=!:3
M.WNZ<.]`Y9$T;50R2=,HGIN65O_Q(%M(<1%'B+@P>OZ[.YOX=U/7ACYO-?1$
M0WB*AM[0^8T.0;4;-3SEJ.]N=C03#>`I.[H9#VI=!_"4'3B?&AGLJZXA/&5'
MGVJW$.W@*3N\/2,;4H6O',L9[CK8B$VS^(IW"13F;;ZZK^FK`;L2UK2YY&R/
MVP%3DZG#)?ID^BB7((F8R@.369HP7TB3!C;`R\J=W5LOD+.%"%GC$%N-V,@(
MEJ!,-=3!5@>1#F(=)#I(=9"-@`6N]-9`0O\*:Y@,LT;.:BW!X)6C&2$C9)-0
M!UL=1#J(=9#H(-5!-@**$;"C%2.N'RLR%5CTTH0L[%/!\1;J!-<\QN4'"%OJ
M#2(A(EM$(D1B1!)$4D2R,5&F#M/XPM19]-)TP<=^[F@;\!B_VR.^:LM&_G:U
MN3(N./.^,"X6W8U+)M1:D-$"(!(BLD4D0B1&)$$D120;$V6B<%8K$_V?YQ.3
M41T0!#9_OU:./]46I`^2QH6(;!&)$(D121!)$<G&1#$%7@J**;<W)(M6YR[(
M:/41"1'9(A(A$B.2()(BDHV),E%6H/Z"MQ.341T09.0`(B$G_K3;JIXS77AJ
M=FS[`)D=D2!.?]C'2#;IR2CQW+DJG?9!4CH;2RL>0;%PQ:,)J]S:8UD\K2DD
M.*3YE21Q86K\_<U$5(<$&3F$2,B)K^PA]TZ=RK8/DE.)!!FYA*030=@(7U;.
MU-:\3_O?I6HV5E4,8F7-38=^T,M'#D'I*BWJ9%2/)(*U&1TBJ*QA_4/#H00(
M94,8\]#0TTZ?K8CR>`;ZCC]S?/U5&LF@8:%BJ3YTF$ATL\-4:MWJ,)-!78>J
MT:R2PMOUBZEH,Q7-9XZ\\8O5\?6J232$*)D3H4"^VZ.M1/"N':SW735I(ZG%
M-I&L:!U/2\)81@T])E)^Z#&52.U1T\JDUD<]JDZS4@TY#9];,%RVYV5&?_X`
ML'GQ![6+-&\MT3B[]7)F,P3)=J%`OCH3E-R\0W_6[7#XT'0]=ZHM:22DO'%R
MBX&.DUM(W>PPE<,2'<[GWMQ=:!\IF=*A:CFK$9'E_I#<TO,KY^SX%!&EYMCG
M<?79'<<;&Z$0HRU&$48Q1@E&*4:9@E0O6*&J>^'",??5KT9>\"I))Y#R3O'U
M0ADN4[HS8LB+$*,M1A%&,48)1BE&[$9G&`3WA]_0\`_LBM0'LB&G4V,4])G=
MOM@+R/4>\ZNA]5T`Y0_L'9W;+MP9=:<(^L63MTG:+\D\@,(!:R6+`-Z7F&?S
M`-Z:F,-UU4.7GYK^FEUC78E?.P%\.V*=-4SAV@P>O.`!S+O2P`_@2^`*GP50
M#%_A\V!];0*;>;"YQL-Y`$4;U@D7`90IF$?S`(H5S.-Y$'?<ZAV"Z[1+?B!_
MYO6A/#?&B>QAP:?=Z5#S"SG^1RMJC4?:PD5:5W8<X>*4P#?PE!W?>TI;^0=T
M;/57L:N?````__\#`%!+`P04``8`"````"$`-D?Y1ZX&``!N&P``&0```'AL
M+W=O<FMS:&5E=',O<VAE970Q,"YX;6RLF=]OHS@0Q]]/NO\AXGU#2(`0U'35
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MCBU,MP4C8@-S]]_]HLE!47`S7UK,4UZ=H`/P=W8N66J`(MFWK;:"P.6^/<)_
M]MQ:+U8&F,\>BZ8-2^92F^4O35N=_^N-#.ZJ=V)R)W#E3LRY8UFF[:S!R8V&
M<+>+#E?><&G-#7-AL^`WVMF\'5PQX$W[-;>'*\99S9>.95AO18)UTO40KACI
M?4/;\(9PQ9#O&IH!*=!%9/]@R*G!Z?U,=HGA9VUV?U=7KS-8;3!7S35C:]=P
MF1-,B5[/(4E^E".0',S+`W.SU6#<,/T-)/;7^^5J=:=_A63,N<V.VABRA8<6
M+/.86U\%@0I"%40JB%60J"`5@`ZR#-HL?XTVS`W3!D>U0R"(I0B!%MC$5T&@
M@E`%D0IB%20J2`4@"0'KG23)"I)E>M_`G&"MMAHL<R$G3'F@N]YFU>\0;,H]
M0GQ"`D)"0B)"8D(20E*12!+`,#X@`6L%FR3H*FA@*1KT1E:W:A1]/+PGMA_7
ME=1#V`2E'MZ>'&;=]0Q3;,>),!6$^(0$A(2$1(3$A"2$I"*1!@K[N#30#VY9
MS(VL`">P'0BS9<NSY0U&*)Q/2$!(2$A$2$Q(0D@J$DD4>%A)HMR>?68MCYT3
M8?8)\0D)"`D)B0B)"4D(244B#935HK_@@<7<R`IP(BA`B-\3:]&OU>5BHZS7
M8##`[`@Y60[;?T3<Q@,1$\^1$R\9C-!U*KJ6-((R8D*C.:NOVF.9/^\J2'!(
M\XDD6<'0^D<Z<R(KQ(F@$"%^3RQY#:WEH02#$0XEY$10B;B..6$]A/)B82C:
M)\-]])J*7B6!6*5S4Z$OU?5'"D&UB1)U;F2-$,'<")O(1A;`&ZVPKSXBZ//8
MT%S(#0-N9?(,W"P=QU+4#=%FG*<(G8]%2(SH9KP$??%XSGIA&<J.F*)-%T^6
MF556XF*=2#A13F:NR-DC4WJ"FJ1N'*Q&.3E:#>LN,#@RNP2R%[:M.@K1I#_\
ML'HD0C2F9HQH])T@ZGV;"VN]4J8N19/.MRP3J[M$F?HGVD^N5Z.OWJ#80!%V
MB*1D-)=R3GFC%3;T.3+MP5>`"#9F(3_'6J3;-$*T`JD%*V6E1C1BC`W'B`DB
M.:)2/:5H]:.(LM*LOE.57AESW!AQV;]_ES1XQ2BJWB,E9Y55X_&&8#6JSAO*
MTZ7D48`--_T^Z-BF;2O[2X@V8AX/O<)X,5K=C)>@%<:SUHZI#"9%FXG<GBJ<
M#6O,;93\C:UAJ*2Q]SN#HW&;\RCR*0HH"BF**(HI2BA*)21G'RMIU>RSX5'T
MLX=M7AJ/J;-C;W'8UBFO`N7)X(U6J*)/44!12%%$44Q10E$J(5D?5MV*^KR1
M$[P8%F40Z^-N1_(,@GR*`HI"BB**8HH2BE()R6-FA:XXY@^>9@Q>,(MB<"3G
M!'EV#E9C3A`4H/MQL844113%%"44I1*2]8'-2=+GC9Q@YDH)P='8=<\@R*<H
MH"BD**(HIBBA*)60/&96MZHY\9%]HJ]_I8J`(SDGE*.&!^^@^6XRY@1!`;4*
M*8HHBBE**&(OPL=.]/KT+[;[]Y?GHGXJO.)T:F9Y]<)>6B_9R6#`_1OUG;'!
M5^KJG;4+ATP8G\H-$UJ8DW<LN-,]XD@;&^YTI0NY`V$@NZ?B.'"G*\B5-K'C
MPF&/MH@W+IQQ*$_!T12'KPD/W7:@^-^QKPP3?G9+%]X`4O^[E0OOQ2A_,-T'
MF"1Z8P<Z3<H$*DV*Y+B[*3^>XWI3W'=<.&C3N/[&A:,EY:'CP@&3\LAQHX[K
M@T+PM>.:/15_9O53>6EFI^(`B;7HJI6Z_U[2_VCY^?"Q:N$[1W=4/,)WK0).
M#`M631ZJJL4?$%@?OI3=_P\``/__`P!02P,$%``&``@````A`!>\.LK$`@``
M7@<``!@```!X;"]W;W)K<VAE971S+W-H965T.2YX;6RL5<MNVS`0O!?H/Q"\
M1\_8C@7+@>T@;8$6*(H^SC1%241$42#I./G[+JE'9=DI7*`72US-CF9G5^O5
M_8NHT#-3FLLZQ:$78,1J*C->%RG^\?WQY@XC;4B=D4K6+,6O3./[]?MWJZ-4
M3[IDS"!@J'6*2V.:Q/<U+9D@VI,-J^%)+I4@!HZJ\'6C&,E<DJC\*`CFOB"\
MQBU#HJ[AD'G.*7N0]"!8;5H2Q2IB0+\N>:-[-D&OH1-$/1V:&RI%`Q1[7G'S
MZD@Q$C3Y5-12D7T%=;^$MX3VW.YP1B\X55++W'A`Y[="SVM>^DL?F-:KC$,%
MUG:D6)[B39CLYMA?KYP_/SD[ZM$]TJ4\?E`\^\QK!F9#FVP#]E(^6>BGS(8@
MV3_+?G0-^*I0QG)RJ,PW>?S(>%$:Z/8,"K)U)=GK`],4#`4:+YI9)BHK$`"_
M2'`[&6`(>7'7(\],"7=+C/9,FT=NJ3"B!VVD^-4]["C:Y*A+AFN7O/068;",
M%Z#@+WEQEP?7+B^>>[-%$(>@\4*BWXIV'CP00]8K)8\(Y@KDZ8;8*0T3(.N+
M;U\]V/&6&V"#)=E8EA3#!P$%:^C@\SJZ6_G/X#KM(-MS2'B*V/4(VRQ0-T@$
M;_Z#1,MB)=H&6LW;/C#2/!'4(Z:"P*>QH,N#TEMCP2F^'5L33RK?MI@X',3M
MQI$3,X#H^G=;<(ICJ./MOK28F6M:/#&@?W8Q_406#-WULBS8R1IZT45&!HPC
M)V^:G[[)#6P`Z'^<6$MSJJ&+P!3^,2N.)HX,H&$FVKW2?E."J8+M6%5I1.7!
M[HP%^#I$AW6VB6RG)_$MK#EGP#0>);N+^#B!,3GGV=PF&[<NISRS9.?VUS0^
M[]:K/SR`]=:0@GTAJN"U1A7+H93`LSM)M0NR/1C9N`VREP86G+LMX7^,P><5
M>`#.I33]P1HV_#.N?P,``/__`P!02P,$%``&``@````A`)UI)3+I!P``^R<`
M`!@```!X;"]W;W)K<VAE971S+W-H965T."YX;6RL6MMNVS@0?5]@_\'0>VWK
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MG/!%GE9E7>Z;.<(MVD3=,:\6JP4BW=WN<HR`8)]5V7[CW?OK;7SM+>YN%4#_
MYME+;?P]JP_ERV]5OOLC/V5`&W6B"CR6Y1<R_;0C$9P7CO='58$_J]DNVR?/
MQ^:O\N7W+'\Z-"AWC!'1P-:[[Q^R.@6B"#,/8HJ4ED<D@)^S(J?6`"+)-_7[
M)=\UAXT77LWCZV7HPWSVF-7-QYQ">K/TN6[*XK_6R.]"M4&"+@A^=T'PUP7[
ML+/'[]$/7;0#4'A\2)KD[K8J7V9H,J18GQ-J67^-P!J(-HT>FM>0`204Y)ZB
M;#S,#@RZ1CF_WOFKZ]O%5Y0@[6P>!!O;8JLMJ')(K\\1L/R$'"D*Y4C5I*0?
MM&!(.F`):0N>$(#B"87H0;E[-$;DM/$B"Z,;^X$/K4W8]@DEN34E%B@(-#X'
M<D*O8EP7"M4:Q:J,'!&MD_VM!#$1S`0O@T/&*K&^.IW$@,*46$^ZLI]$/1PM
M5W.(1[8Q!;*SZ"3H3`.PE5VU;6_$^^3:3NPR!&1L/[R3&!"8$@L"6IC8-+X&
M7B/'3U'L%#J).7XL56S\O1$?_\K.ZO+XR=A^>"<QQF]*K/'[F'X<@'`%X4@$
M5!P["RVR,?`9!H,5!\$G6C-J<QD%9<T2H``0&3AH*R6R@2#.,IZF"'TUOA7\
MEOM`%?V,U"(;",X0@Y4#!*/--X#HF,],P"1#Q>%;WQ390`@$.:4A>LH<<.A$
M-@XA;XC>RL&!B,PHT1LX=+1GXM")S(8P138.Q$[&TU1#!!-FADN.?D]\`SL&
MRX@#T5LY0(SB1]\E2"TR@7B5(GV!(Z<M$RH2FZ,]!YI0Q!R*WLJ!8A15^BY7
M:I$)Q:ML2>5W>B(>WQ,JC@V$%MF3XXH!,5AQ(`(B.Z-=+T\.9<T2H``V6VHK
MERT#B2VG`.&RI0JM\C`[@FV*MX.5`\0HM@Q<MM0BHR,LD<42@<"6/E5IY/JI
MXK""]$1H`L%VOEOM*-1H%%W2^8MM([3(!.)5N@P$NIRPDU)A&`X]#YHX\+VD
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M,[ZB#E8.:`*W3]L)AQV7F[")],Z7.>TH]-HH>@]=>M<B@]XMD=4_D4#O_LWX
M2:?BV*VM118?!'R=&ZQXE2+B96,G/+%_5!B6&46&R,Z,+SS:T2U1)-'[A,VB
MBL-2D^@]X"N/=A12^SGT'KGTKD4V:'SA&:R<<@KT'E#U1S)5Y-*[%MFI\95G
ML')28_1^^<P5N2RN1<:4LT3VE"->97T]C7VBCJ$-]M$B&PJ^T@U6#A2,M-^`
MPN7FJ!.94)@B&PJ!B"?UA$O#D43#`5]8!RL'B%$T'+DTK$4F$)V5.VWIR/US
M>D)%LCE%B^R>X`OY8,6AB.%H)G>Y)Y0U2X`"*+Y%Z/:]I;82H!#(==KTB#LN
M-::'%ME0\)W#8.5`P>CU#2A<%HT[D=$5ELB:'K%$F1/.7BH.*XFT(P[X+D4[
M"E4:19FQ2YE:9`+160E/$RC3IX8=N7;$+F%JD=41(=^E#%9.1XPB3-SI\Q.`
M%IE`N(39WN2W-]=%5CUEV^QXK&=I^4RW]/$-+BM[<?L)P4,<X!L"U?N.)H0F
MI+.$HXF@B41-#(WZ%,#QN8)&G4P<S34TZBL&KHG@@T5(R"""#]8027,#C;J^
M=J*MH%E)/O$2&:A/(;A/3%]8*,RY)H(/]B52!O#!KE#2`&MLRB0-L,:F2-(`
M:^Q))`VPQOY!T(3PP3%5TL`'YSY)`ZS;DR,?:0BL<4J2?(`UCBB2!ECC."%H
M`OC@K96D@0]>.@F:$%CC!8^D`=;8H$L:8-U>RSGC`=9XOR#X!/#!JV9)`Q^\
M%I8TP!IO924-L`8-2QI@C3>8D@98XP6DH/'A@YLD20,?7/%(&F"-6QA)`ZQQ
M%R)H`F"-0XJD`=:X(Q`T/GQPLRMIX(-;6$D#K'$)*FF`-2XL)0VP]D6L?6"-
M5RVN#SZ1NI>?`@?!_H%:0))3TPCR^VA]+Y,7,I(2>D`=Q3*BBF(144.QA*B@
M*N"B[V]\>G5.GK+/2?64G^K9,=N#])=S>B]?M1]OM?\TY5E]T?18-OCH2OUY
MP$=V&3ZD6<YAO"_+1O\#1!?]9WMW_P,``/__`P!02P,$%``&``@````A`#5!
MDHE>"```BR8``!@```!X;"]W;W)K<VAE971S+W-H965T-RYX;6RL6M]OXD80
M?J_4_P'Q?H"QP8!"3H'=:T]JI:JZML\..,$*8&0[E[O_OC/[P]Z979*0Y!YZ
MO6]GAV^^G9T9@Z\^_SCL>]_SJB[*X[(?#4;]7G[<E-OB>+_L__/MRZ=9OU<W
MV7&;[<MCONS_S.O^Y^M??[EZ*JN'>I?G30\\'.ME?]<TI\5P6&]V^2&K!^4I
M/\+*75D=L@;^6=T/ZU.59UNUZ;`?CD>CZ?"0%<>^]K"H7N.CO+LK-KDH-X^'
M_-AH)U6^SQK@7^^*4VV]'3:O<7?(JH?'TZ=->3B!B]MB7S0_E=-^[[!9?+T_
MEE5VNX>X?T1)MK&^U3\\]X=B4Y5U>=<,P-U0$_5CG@_G0_!T?;4M(`*4O5?E
M=\O^3;202=P?7E\I@?XM\J?:^?]>O2N??JN*[1_%,0>UX9SP!&[+\@%-OVX1
M@LU#;_<7=0)_5;UM?I<][IN_RZ??\^)^U\!Q3R`B#&RQ_2GR>@.*@IO!>(*>
M-N4>",!_>X<"4P,4R7XL^PE\<+%M=LM^/!U,TE$<@7GO-J^;+P6Z[/<VCW53
M'O[31I%QI9V`I7("?QLGT6B0C"?I3'GQ=PXU"Q64R)KL^JHJGWJ0*?`Y]2G#
MO(L6X,U&HSVT\9T+#^)")S?H9=F'%`?F-9S)]^MH$ET-OX..&V.S"MA0B[6U
M0-'0K>"`=(`A!-!&,?Z0*-`+1F$_?V6!+JPQHVPM[!;!`>D`A'+L4XXA&<-I
M9'7&32IU')T9I96VB77"H(QK#Q$>(EV$\(0\Y0GR,D_<!(D-L3M$>4)HHXE.
M%Z:K70OO)P0A:UV"SPN(QHJ8/;"501RY/$1XB'01PF9*V>!]BJ=PKA=>*'1#
M>1H$;H`C:<QD:XUL>,)#I(L0ZBFE_KR0:$P)&L01TD.$AT@7(6RP7[+"-+]<
M1_1":1J$ZI@P'5NC5D</D2Y"F,\I\^=U1&-*T"".CAXB/$2Z"&$3@6A<R`32
M]\*$5&XH40M1*2=,RLZJU=*')($H?ZSY3B(\+V>$UHRF@1Q!K54'"1^2!**<
ML*@[G%37'%^>G9%N#E`GK38K"U%1IUQ4L]$-P(-DYPO<TP"PW#L!O""J:0XN
M3;=?J&:]CCQ(^)`D$.44Z#31Z`V9VC:?3E0#45%3+FIK93>*R(,D@6@`V!1>
M+ZII(:ZH!NI.=8V3)>9S!PD?D@2BG+#:.YPP4]_0CB+3-%RR;1]Q&]*,:]I:
M=9IZD+3N5924/_8'A_\+B6JZB4O3;3`F43U(1!XD"40Y8>5W.*&F;ZFHIH&X
M9-N>XFHZYYJV5IVF'B0C%Z+\L5<P_M%DD$*J-;MB\[`J(2"X*@&M8QC6S,1O
M&H[+WD#JX<M([4$B\B!)($(5:^IS5+^5IW-4X6G*<E5>:%,P$)1XJ^':AX2%
MH+)U0]>4#=S26B7HB]+'UO->I<?HA+'7$-9WA]>(Y8G9R*S8%"["5FRPE-8*
M<Z1]Q)MV8Q,-&UL1"SN%AUR37_;07I]L8]/;G&0S$%8.AQ`?/L)6K)L*:Y6J
M1Y'18)I.1NZ?+DR5U=+:PPUS/KMK)U0,;(M,C.A=8I@^ZXJA(;Q'#B%>B\=!
M*U9=A+&"I,;'^-%@QA)&6@/(P>[#TB[Y:/380#\T>M.1W>@U1%,A9;37XZ`5
MN\LB;.7=!N.+)$#:I0F5`%LXDR!Y5P*@0U80-$03(/5N0]#*NPW:RB0`DU'B
MEU3PX5@/G-,_E_O8ZEGH<?2>0F!F!_?T-<1.W\O]H)67^\;*%H)T,G/KP,@3
MP]B3/)B>$P-GC`\5PPPMKA@:HGDPZ^ZF[LKCD%7JB=%:82'XQ&Z*-$Y8(IR[
M`SB,L-C?5P31(;L#&J*)P*O7>ART8L&)SBH<NW$"?W67X.RYX\#SH;&;"<H]
M=PVQ<V=E:ST.6G5'IK)#&"MH<KH!I!/F1UH+4@/.A8]?%O+PWU4#E$-Z]`9B
M1\_+7]B*E[^P57>G]0A@K5Z5`?#TYDF0.`.W'8@"`[<SQ2HO+&YT#,48:G*7
MAS->^\Q&EAS\NALKR'Q][/,DG;M_F)K2VI///IL$;")\(5)_W,.ODC'2:3>O
M6ZA[W!`6FK=6TD)J(^G+<6`PFXXN?`Q23MBAZ#$+ZF/[:&&L<+CHSFG.RK*P
MOM3O3R;-7%^4/8X@O*I<GE-ZD`&1+-=5;"#U-*/[A0\)'Y($HEQQ9F!<\0*]
MD`5ZTB#<-*1_5M,_;5A$U6G6GT5L5UW9.R-*$GLY(XE/]2^0U!,`(:DAEZ1%
M0LU$Q';5)=DU)$H2>S(C^0HE=2<G)#7DDK2((LE*OHCMJDNR,Z(DL3LZ)%]0
M4/=20LY`SL-Y[$'"AR2!**=`$W[#SPFQWWHM1)KAG#75=6=E+YKP(4D@PC]A
M7?1Y394UK4H6<C3U(>%#DD"44Z"M17CE+OQI(=%=S,T`"U%160M:=U:MJ#XD
M"40#N*@K)7Y7LI`KJK'J(.%;20)13H&N]"91=><@HAJ(BLKFGS6\.Z$F:S<`
M#\(W+#HK'8!^8T*_7'#(J_M\G>_W=6]3/N+;$%"EKJ]:6+^JL4K&\*Z&ZCW>
M2FS?XN`KT7R!7QC"B?.5.%E@$PJMS&!%_:[O[0%O<.L">Y(1,%"MF.])\`T3
M)0]?B8`U_,`1\!8!-_CE(+0R@155ASUO4UA1<XNWDL**FB^\%8@4OOD-?`YL
M">Z`#4%[$":H2P2ZP*]U@4^(0!?]A:K'"LX9OH8,[(FCQ0KF'G]%P`I.1/X*
M3)YP9J$5>/7G)O@I2"S@:06T@O9PC$'_R>)&OUK$`X0S#!XAG*`>/-L-\"K0
M*;O/_\RJ^^)8]_;Y'5P./756^F4B,X*:;[9ORP9>`E)?<N_@I:\<WN<8X1<H
M=V79V'^`1L/V-;+K_P$``/__`P!02P,$%``&``@````A`-::Q8.]!P``XB$`
M`!@```!X;"]W;W)K<VAE971S+W-H965T-BYX;6R<6EUOV\H1?2_0_R#HW1;W
M@U^&[8N(0=H+]`)%T=[[3$NT3402!9*.DW_?6<Y(W!E2-.4\)#9Y.'MV9O:<
M)3?WO_W<[Q8_BKHIJ\/#4MT&RT5QV%3;\O#RL/S??[_=),M%T^:';;ZK#L7#
M\E?1+'][_/O?[M^K^GOS6A3M`B(<FH?E:]L>[U:K9O-:[//FMCH6![CS7-7[
MO(5?ZY=5<ZR+?-L]M-^M=!!$JWU>'I88X:Z>$Z-Z?BXWQ==J\[8O#BT&J8M=
MW@+_YK4\-J=H^\V<</N\_OYVO-E4^R.$>"IW9?NK"[I<[#=WO[\<JCI_VL&\
M?RJ;;TZQNU\&X??EIJZ:ZKF]A7`K)#J<<[I*5Q#I\7Y;P@Q<VA=U\?RP_*+N
MLC!8KA[ONP3]61;OC??SHGFMWO]1E]M_E8<"L@UU<A5XJJKO#OK[UEV"AU>#
MI[]U%?AWO=@6S_G;KOU/]?[/HGQY;:'<(<S(3>QN^^MKT6P@HQ#F5H<NTJ;:
M`0'X>[$O76M`1O*?W;_OY;9]?5B:Z#:,`Z,`OG@JFO9;Z4(N%YNWIJWV?R%(
M42@,HBF(`?9T7\\-LD)"W?R^YFW^>%]7[PMH&ABR.>:N!=4=!'83,Y`>I'&>
MZJ69PA1=D"\NRL,2NAT>;Z`\/QY5D-ZO?D!*-X19CV`X(CLA7"6`WIDC3-SG
M.)[T$Q4'=E1<$1RW-5Z`V&=N6HP[1,31&<*80(9\)J=L33-R#STLK4=`J>`<
M'TDB!EO'L<Z\"XP!A/$93(_LP%!/-K(2(R,F[8IVHP(5Q29*."9CF"1(TT#9
M,X31@V[VZ<U+D'N(TTSC<WC,#T(B9*FMUE$B(!F#J$@#R1["2$9#DA:>GLZE
M>TA64332&C%>%;T+C$',&4R/[,`\/4H9D1_$8'YTI*-`-%C&`&&4VO`<@3%S
MCN7IP30S!Y;,^L;`RB$&F2FC;)`*1,8149RF??\Q;BGG-J^YW$.28S]WY(B8
ML.LNF3B\1_PC'?>RQK@I$,WYB>O0DE6O.<B*0%34V,2"=C8!X-R<L'I%G9<X
MA7+,U:-?4<010>.IHPAX\T8G?6HY/:'O,^FA:G-Z?>,0/011"I6R(L>9N@S@
M')T>>RF<7A?*H65Y^\8A;@BBSDJ5M8'(;D9Q$)($*@S[M</I"5N8F<(1?]!]
MD8@F@I"#32,IS9E"@&P!SL^)\_STH92STFKI6V[[!3E&7B8TXGY&]Z=I"2?X
MH*JHYIR6M`!UDGRW"1*YS.@FU3.\M,M05]E#A^;-E@JE6!,&![Y1*HZ21##/
M!,;8--#]<N'EO,HEU-`FK!A\31@DJ&QLS<#!"#)=T$]9A$*-ASX^;Q&5E@Y+
M(,_<_2LL/?HJ+^C0O'Y*]^L<5R&!J(!A%'H>V2$RCM#6VGY%<';"#::;7H^X
M@);M12!DIW6BTGYL8H=A"!%HI?L.X.R$&7S`;F@"6GJ`]B7^QAB=]%U-Y!@B
MC!-OB\+).<GV9&R>S&H4>E\WC%"&-6&HOE$01\(N,HZ`S8#VFH2S=()\/4N4
M<<92<%AKQ!!+$X5JL"?A$*7C2*N^&3C/JTS!O2@+3PT'6?0]006QEH9*06@"
M*@GC2^\(^BIKZ-!R#8LV6Q/H5&-MY"X^XX@PL/T$>>:N,@B->W^_LE"7\_:?
M!,9_0;C1:>)5C58)0X2Q#2XMX:O<00_=00W7,((H=6G@[*OO*N+',"HP(=2_
M!_$$?LHG])A/#-8(@CR?H,>Z*XR%^]#B+]1IK>O0HL<&.D(@2E0<!X,])4=`
M$Z9>)CD]813SU,Z,&(;<G*T)1#1U&IG!=H0@DW9OKC*+#BT3V/<PK@,"R6&Q
MQ>@FTK:!MT7AB7."[PGP!W5U:$E+[CX,@B[0PIOG;+)-.F<FK.$#9D-+4$;N
M3`SWA-B81"R)C$-"\`35FS3G)RQA9LNA[`.1?O]FY![%(,A;E_X5SD)H_TP6
M(Z\'1GJ`01"6RM@H'G@`0X1)>+')KO(`,^(!1GH`@2XTF2__!FA=;G^A_S/3
M-^(#IF\36IT(NL#0-X!$)3H,^T[D!1;R_\$R0$6'1>:U5Q^9F)UD?^R]S^#-
MTP)5.O`^1#!F5EC"O-QU3PD)\?8.R)!`X[FCF\@P3%,;]\+("7[*%.R(*7CO
M)T000<A!)R:.A-9D%$9.@1.\RA,L;OU9;0<OIP2B\BF3)D*>,T),$W,J[;G"
MS-*BMG."8OBU11!5SZ;P1\A?1I!IAL(=9C(<<0DK*K>VS"6LT9'<$V0$F6;X
M*7]P'_>EPWK?OZG[$$0YC!*3A$)],HJ#$`7OL(E-^CSS+OR4A=@1"_&4@HCZ
M%J*"(/4^(W6(C,*<^C6`SPD77B2L,)&9%1\Q$RO-I`M]^CYW`^^*\`%;N&'&
M,/!U5INPA_!\"D^95FR+3L`V!%94<TT@;T/@7^&C7^47=L0OK/0+`F&-=&J3
M*)4GIAG#A#8-;=Q/@A&$LV^F+=/IZ=#"+@;OT@3"@T$=)CH-C=`==^3N%A9B
MHLC$B;<]1()XI(Y'SONB?BFR8K=K%IOJS1V7:SAR.5\]'^5_T>[T5EQ?PQ%_
M=QZ^.M^`$_9C_E+\D=<OY:%9[(IG"!G<QK"2:SRCQU_:ZM@==#]5+9RM=S^^
MPO^E*."<-;@%\'-5M:=?W-GS^7]G//X?``#__P,`4$L#!!0`!@`(````(0`M
M?ZQ!40,``'H)```8````>&PO=V]R:W-H965T<R]S:&5E=#4N>&ULG)9=;]HP
M%(;O)^T_1+DO<1P2"`*J0M6MTB9-TSZN3>*`U22.;%/:?[]S8A*24!#:34N<
M][Q^S@<V\_NW(G=>N=)"E@O7'Q'7X64B4U%N%^[O7T]W4]?1AI4IRV7)%^X[
MU^[]\O.G^4&J%[WCW#C@4.J%NS.FFGF>3G:\8'HD*U["FTRJ@AEX5%M/5XJS
MM`XJ<H\2$GD%$Z5K'6;J%@^992+ACS+9%[PTUD3QG!G@USM1Z<:M2&ZQ*YAZ
MV5=WB2PJL-B(7)CWVM1UBF3VO"VE8IL<\G[SQRQIO.N',_M")$IJF9D1V'D6
M]#SGV(L]<%K.4P$98-D=Q;.%^^#/UCYQO>6\+M`?P0^Z\]G1.WGXHD3Z390<
MJ@U]P@YLI'Q!Z7.*2Q#LG44_U1WXH9R49VR?FY_R\)6+[<Y`NT/("!.;I>^/
M7"=04;`9T1"=$ID#`/QU"H&C`15A;_7_@TC-;N$&T2B<D,`'N;/AVCP)M'2=
M9*^-+/Y:D7^TLB;T:!(`_?$]O=7$LT!U?H_,L.5<R8,#0P-;ZHKA"/HS,,;$
M`BB/Q6A3O90II(@F#^BR<&':(5Q#>UZ7/O'GWBN4-#EJ5A]H^HIUH\!.`%[+
M"(EW&3\N>H."8D3!)B#;RBZ`=\M&!_N>*R91*^F10(6Z)%BM\<4Q:(@P"'0=
M`)\,$%968T<'J=>=A1X!V'0)KM<"Q=#/SL[Q*3%;'2N)ZY[=P33&A(1AFWRM
M6?<T\81.86Y;28\.:M&EP_I$,$W7*3%H6)^@];>85M.I3V>A1Q"=$^`\7R?`
MH'Z=?#(>$%A-9`L5!@$=(*Y[`HB'4K86/<3)_R!BT!!QT*>5U80U8A!,V]UM
M%^W;8P(T"B_0X975.1"N%P[%0ZKAA%G-<5^?1N.`C$][6[:>)IX&(9U<F+"X
MC]><5]<Q,6B(.>F79V4U%I..*8VF`\6ZJ_`C&A/_I.@U&&ZB7@UO.R;JJ"'E
MH(FKHZCYOA)*21`.)[$OFE(2T?`TSA;57G7V*BBXVO(USW/M)'*/UQB%&6I7
MVROV@>*I.EA?X=6+ZU[[`FZ^BFWY=Z:VHM1.SC.P)*,)?&>5O3OM@Y%5?0%M
MI($[K_ZX@]\X',X_,@)Q)J5I'G"#]E?3\A\```#__P,`4$L#!!0`!@`(````
M(0`+22LV=00``.<.```9````>&PO=V]R:W-H965T<R]S:&5E=#(S+GAM;*Q7
MVXZC1A!]CY1_0+RO,6"PC6ROC&&2E392%&V29XS;-AJ@+9H9S_Q]JOIFNO$Z
MLU%>AN&XZG#J=/5M]?FMJ9U7TK&*MFO7GTQ=A[0E/53M:>W^^>WIT\)U6%^T
MAZ*F+5F[[X2YGS<__[2ZTNZ9G0GI'6!HV=H]]_TE\3Q6GDE3L`F]D!9^.=*N
M*7IX[4X>NW2D./"DIO:"Z33VFJ)J7<&0=!_AH,=C59*,EB\-:7M!TI&ZZ$$_
M.U<7IMB:\B-T3=$]OUP^E;2Y`,6^JJO^G9.Z3E,F7TXM[8I]#76_^;.B5-S\
M943?5&5'&3WV$Z#SA-!QS4MOZ0'39G6HH`*TW>G(<>UN_23W9ZZW67&#_JK(
ME0W^=]B97G_IJL/7JB7@-HP3CL">TF<,_7)`")*]4?83'X'?.^=`CL5+W?]!
MK[^2ZG3N8;@CJ`@+2P[O&6$E.`HTDR!"II+6(`#^.DV%K0&.%&_\>:T._7GM
MAO$DFD]#'\*=/6']4X64KE.^L)XV?XL@7U()DD"2P/,.R8/$4";"4R:B]@<)
M,YD`3YD0@&4/$H".UP?/AU_PA"_<YJSHB\VJHU<'>A<J9Y<"9X*?`(GR5WQ2
M._X]P\%I)-DBR]J%20=>,NB2UTT8S%?>*XQL*6/2<8QO1NQ4!`XCTF8VD`\`
M#PK05<#(_`]5(`M6H;Z?*N!65F!)5A$J);.!?``8DJ$G;,DAC/7]QE8^8]+:
MA>[0/@>1[;.("44+HXV[$9*-D'R(&#KA8_=T_F"#(`O,/3!#*_?]V#0SE4$P
MR#HHB)9FT$X':<M'2#Y$C&*@PX?%/#8;@[EF]:54(@-K1T@V0O(A8JB)?T0-
M!IMJ)&+8%4\MNW20*B(3"(BZF1Q;,S&7,0%?FX<3;6Y*%LO%9(YLYZI\3BF0
M@J`[QH:P+(C%`CG,2B02ZIFWD\C-Z4PB\!CHMJ9C+H*BL6X\#XR6N9ON;_3R
M/=VP3RCA2&(*E\B"+WG!U(\L]_7OVGV!1'.>L0A@&S)3<A$PXY4;W;(T2[AC
M\4`J!IM2!3(+E%1K\NWT[UJJ0"(0-'`\M.3*-+[W&G)]6,R&EC_6RZ--P0K2
MYEH+W>X6H"5+*`)5#S3+J#L>^[C!#/KD7T1CM"5:0#>;%Z9?._X%6,)YB\I=
M3N181L_,Q%PEWG$:MYB/BQ8;$BS%RK74EY!VVEYS;P$J)Y.0Y;3=S#+JGM.X
MX0Q$_Z>5Q)>[UK`6`8&_PPZPFUTF&J,@$F-HVT'K6#V7J\0[HX";CET0G#6!
M#E=&M<)\?)F$8_6HNR1D3LE1B^FHVV@)*/;Y[)_YBV5D9>$I'C\W'"IQ*A?'
MQ89T)[(C=<V<DK[@B1MFT6:E87$=2.,DG6-C6?@N3F!)'^-YG,":/<;A6K'E
M@VKQI'C=N!.?!@D<M,8\:9C`R6:,;V?)5EQ;[`_,$C@]C!/2*(%]''!/)\`U
MXU*<R&]%=ZI:YM3D"*9,^9[2B8N*>.GEWK*G/5PP^#9SA@LE@9/9%-OC2&FO
M7O`#^HJZ^0<``/__`P!02P,$%``&``@````A`)L$24-!!0``/1,``!D```!X
M;"]W;W)K<VAE971S+W-H965T,3(N>&ULK%C;CJ-&$'V/E']`O*^AL<$VLKT:
M#).LE$A1M+MY9G#;1@.T!<QXYN]3?8.^L%Y/E)>=]:&J^M3IZJJ&S>>WNG)>
M<=N5I-FZ:.:[#FX*<BB;T];]]O7QT\IUNCYO#GE%&KQUWW'G?M[]^LOF2MKG
M[HQQ[T"$IMNZY[Z_Q)[7%6=<Y]V,7'`#3XZDK?,>?K8GK[NT.#\PI[KR`M^/
MO#HO&Y='B-M[8I#CL2QP2HJ7&C<]#]+B*N^!?W<N+YV,5A?WA*OS]OGE\JD@
M]05"/)55V;^SH*Y3%_&74T/:_*F"O-_0(B]D;/;#"E^714LZ<NQG$,[C1.V<
MU][:@TB[S:&$#*CL3HN/6_<!Q5G@N]YNPP3Z7N)KI_S?Z<[D^EM;'OXH&PQJ
MPS[1'7@BY)F:?CE0")P]R_N1[<!?K7/`Q_REZO\FU]]Q>3KWL-TA9$03BP_O
M*>X*4!3"S(*01BI(!03@7Z<N:6F`(OD;^WLM#_UYZ\ZC6;CTYPC,G2?<]8\E
M#>DZQ4O7D_H?;H1$*!XD$$'@KP@2S&>K,%Q$JR5$N>$Y%Y[P][\OOQ!!X*\(
M@H(96O@13<%>W.,2,$73O,]WFY9<'2A32+*[Y+3H40R>4DH>81#W1]J"J#3(
M`XVR=>%\@6P=%,3K+@BCC?<*FU@(F\2V0;K%7EK0':-A4Q/(%,"#!(8L8!/^
MARQH%)J%7#^1@)*605E:2)?4!#(%T"C#[IN4YW`2IFM8ZDR=MB[LN:+S4J>4
M<)LYKU8JX]Y"4@O)5$3C"8M]G"=U@E,%N2M$S8+@1B$K%^/97CZ;]M<(0M6J
M!&\+2(T9,;EAB4`4N2PDM9!,130VD<Z&G2?HA>)(WGV@:!B=IT#@!"B2KO2]
MWP]&,KW40C(5T:@O=>JWA:3&.D&!*$):2&HAF8IH;.BP-AH3/1\?;$PTBDY3
M(+J.:T/'P6C0T4(R%=&8KW7FMW6DQCI!@2@Z6DAJ(9F*:&P0B*8*>9L.L];Y
M2$A3+/(-Q4:K03(!P5$9*S8R>GXFC0(V\=6>CFBS-RH`A3,Z7/MS63PG!,*"
MS41"<^@I8C#1($8^`IH/?7[/E@*K4?-40E"?"OM`SSH35N$$>]KW;[#_2BX_
M8@\3?*#/IP<T4JEJ@@2TXF/61Z'.:3\:2)]40.&2^:P"N.?H3IFP6#`%]/JA
MDT%)9$)NE;"8(RIA#BT"2=CL]6@P&`ES*(0SIJ@_-TD+1W;'TTD;4^LGI(=Q
M)0DD2$"#RL:4W8\&TB<54`A'\19I'GE*:3I4[E=:C"!5:0Z-2IOC@5Z2X32`
MP4B:0X;2"U-IX3BA-!TG]Y,6PV<DD"`!#4J;O7@T&$ES'T-IJZ:YU932=.HH
MI/FM]Z.M18PN-1<.@;YJ!5CU/EB-"7$H@EZME(Y1<QD2CA.[0(>1F1"\TT`X
MVBIEL_E`WQ3334U.0/J9M$ILL!J3XU"$6`-8H-4Z-+PRQ$VFMHH.-C,S90K(
MU'YRPL5X5--1)R8;%GMD0:D-91JD=1UZSS.Y+F`//GAG86'TF24A&%U*?9@G
M9;0:M+<A^F;.1J+2ZOF;-G\OK'%[PGM<59U3D!?Z%@U=8[<98/Z*GRQCN+K!
M,B:^BN%B-(&O8[BB3.`('H"B$T\"7WY%,-=`?IS`Y+5]]O"$#G/["=PS8)VI
M)_"QXH&5A;4*.$Q$2@*@-87/8WB)LE=^6$!\]CW#7"",X37"=DBB&.[H@'N#
M`WR\N.0G_&?>GLJF<RI\A&WQ6;]J^></_J,7EXHGTL-G"W:_.,-G*@PO@3YM
M!D=">OF#+C!\^-K]"P``__\#`%!+`P04``8`"````"$`H6Y5&GD#```I"P``
M&0```'AL+W=O<FMS:&5E=',O<VAE970Q-"YX;6RL5MN.FS`0?:_4?T"\;X#<
M@Y*L$E;;5FJEJNKEV0$GL18PLIW-[M]WQ@:*31IMJKZ$,!P?GSDSOBSO7XK<
M>Z9",EZN_&@0^AXM4YZQ\K#R?WQ_O)O[GE2DS$C.2[KR7ZGT[]?OWRW/7#S)
M(Z7*`X92KORC4E4<!#(]TH+(`:]H"5_V7!1$P:LX!+(2E&1Z4)$'PS"<!@5A
MI6\88O$6#K[?LY0^\/14T%(9$D%SHD"_/+)*-FQ%^A:Z@HBG4W67\J("BAW+
MF7K5I+Y7I/&G0\D%V>60]TLT)FG#K5]Z]`5+!9=\KP9`%QBA_9P7P2(`IO4R
M8Y`!VNX)NE_YFRA.HJ$?K)?:H)^,GF7GOR>/_/Q!L.PS*RFX#77""NPX?T+H
MIPQ#,#CHC7[4%?@JO(SNR2E7W_CY(V6'HX)R3R`C3"S.7A^H3,%1H!D,)\B4
M\AP$P*]7,&P-<(2\Z.>99>JX\D?3P606CB*`>SLJU2-#2M]+3U+QXI<!1365
M(1G6)/"L2>#?%?RHQL/SYDD#DX#VXX$HLEX*?O:@R4"BK`BV;!0#<6.$D=%:
M\S=GP!(DV2#+RH?5`4E+*.?S>CB;+8-G*$%:8[9]3&0CD@:!E0-YK4:PY3]H
M1!;4B-5$T=LFT!'M"&H0KB`PRA4T@AZ\W#V-1SAHY8\MC^;VA%N#&9D^09%)
M-V*9`D2W:\!!T*N0UY5"&=!$E]$1F#3?+H^W!,)"Z`J\;@Z"M;"V.G6D8T4W
M8LTTM6?2/1P"^L8F1AI;0QV!ONS8M;!KEK0@MTMFMJSK!B#8GKR.=`SH1BP#
M\%AR%O$(&_)&`Y#&UE!'+`/FH6-`"W(-6-BRKAN`8'OR.M(QH!NQ#(@@6=>!
M<;@80&UN]$`SV3J:D.U";_-""3!0R[7%X;[6*<]U'R)$.P+J4,>)!G5A-MRT
M.K/A:OA'*\SV![M%NRCA3*Z3[*R(^=!IB#^HMB/,26Q.GH**`TUHGDLOY2<\
M9:,1;#9MV%P!ME$(=P!]C/>^X.U`9][[,FSN#<X7N%!L=!Y.?(M4F)\;!Z*+
M^%$,6W(?OQG'&W-A<8DF<:)O$&Y\&L/.T2?:SN)D=BD^CQ-]=KD\BSA9(#YH
M/\!%I2('^H6(`RNEE],]6!P.9K`C"G/5,2^*5_K\WW$%5Q3]]PA74@K'3C@`
M\)YSU;S@!.TE=_T;``#__P,`4$L#!!0`!@`(````(0!N0.6>004``!`3```9
M````>&PO=V]R:W-H965T<R]S:&5E=#(Q+GAM;*Q86X^K-A!^K]3_@'@_X4X2
ME.1H$\)-K515I^TS2YP$;<`1L+=_WS&V`=O9-*WZLEZ^C+_Q?)X9&U;?/ZJ+
M]H::ML3U6K=FIJZANL"'LCZM]3]^1-\6NM9V>7W(+[A&:_T3M?KWS<\_K=YQ
M\]*>$>HT8*C;M7[NNFM@&&UQ1E7>SO`5U?#+$3=5WL%C<S+::X/R0S^INABV
M:?I&E9>U3AF"YA$.?#R6!0IQ\5JANJ,D#;KD':R_/9?7EK-5Q2-T5=Z\O%Z_
M%;BZ`L5S>2F[SYY4UZHB2$\U;O+G"\3]8;EYP;G[!X6^*HL&M_C8S8#.H`M5
M8UX:2P.8-JM#"1$0V;4&'=?ZDQ5DEJ4;FU4OT)\E>F\G_VOM&;_'37GXI:P1
MJ`W[1';@&>,78IH>"`23#65VU._`;XUV0,?\]=+]CM\35)[.'6RW!Q&1P(+#
M9XC:`A0%FIGM$:8"7V`!\%>K2I(:H$C^L=9M<%P>NO-:=_R9-S<="\RU9]1V
M44DH=:UX;3M<_46-^H@&$H>1P,A(+'=FN:9/..[,<]D\&+GSN_;`UB\61N['
MF]D+S_+^R9//9L+(9MICE'=6.&?S8.0>'XH,RJM?*8P/1;9D]C!R/P]&9D'*
M]*[(/X_$9M`,Z!,JS+M\LVKPNP95"GO<7G-2\U9`R'@J47F&Y/HJMR"I",L3
MH5GK$#BD30L%\;9Q;&]EO$$2%\QFJ]I8HL6.6Y",);2A#.QE()*!6`82&4AE
M()L`!L@R:`/E\7]H0VB(-CRJ+0=&L6Q)"&[!IX0RL)>!2`9B&4AD()6!;`((
M0D")*T(XD"RW^PW/"3)KK4.9#SEA.ZX8Z);:.+2SD"W?*4BH('L%B10D5I!$
M05(%R::((`&$<5."?UDGA`:Z+0@]$64IB<*,("TG1KYHM!N,AAQ1D+V"1`H2
M*TBB(*F"9%-$T`FZM*#3_10AUKT</(@M0R8)H2"A@NP5)%*06$$2!4D5))LB
M0J!PJ`B!_L?&26A$!1@R44!!0HIX9M]I7=M<2G6U'PRXL!%#[*$-Q0IM,B#3
MQ%N(B9<.1IPZFU(+&L$!>D.CV1Q$[<YE\;+%D."0YC>2Q('0Z-%"2$2%&#)1
M2$%"BGAB#<W%4/:#$0\E8LA$)84Z80A9X=O&-BU)^W3XG;-F4U9!('(A5T_?
M4:`?^/J50'#+X@H1%E$AADS/8]N1VLQN,.+K#!D"]Y&Q\;BF)!HU<EGN+>W%
MPI-TC9C)N$&QXBMYQ%<J^EK,3<^2^F`V]25H"U$(VMY(LHF&Q%K4D"*NT*I=
M^<8R&`T:,L09ZFS/$+?/%]_T?9DE8A;TJDY.P5CA313>5.!U36_N2%N537D%
M;<A-3Q"'=J\Q\1ZJS)Y%%(U#L"N3%)*O-Z/5(!N#7'_4C4-0/1,N1TS'B%L)
ME>Y*-1FK'A,^<?28<DCT*-UC,V[UE4=1:;!2E':L&6^!O,(?[X?P8BFG*H.D
M7)4J93=:C:I3+E?<+BF-]GSBDG:\A>_ZOM1,(FXSR6$.C<TTX=!=?RFWXOZ\
M^<*5@B&OUT0%M_='%:>OR_3MID+-">W0Y=)J!7XEK\*6#ZL?8/J>GO@!'&>@
MAHS/`^CB*I[Y`?1R%8?W_:<^2HEG2[X#W+#?V@'<M56>K1/`#53%G]S@"0)6
M?]BZ`5S%;N!>`#>7&[@?;&\%L/.#W2T\]`.X2J@\X3R`PU/%(S^`(U3%8S^(
M>]P8%(+O$=?\A'[-FU-9M]H%'6&3S+X#-?2+!GWHV!'XC#OX$M&?AF?X\H2@
M2YJDBHX8=_P!'!O#MZS-WP```/__`P!02P,$%``&``@````A`-LA9L3A!0``
M@A<``!D```!X;"]W;W)K<VAE971S+W-H965T,C`N>&ULK%C;CN)&$'V/E'^P
M_#[8;0,&!*P&[$E62J0HVB3/'M.`-9A&MN>R?Y_JF]U=;799L?.PLU,^/EV7
MT]7E7G[ZJ$[>&ZV;DIU7/AF%OD?/!=N5Y\/*_^?+T\/,]YHV/^_R$SO3E?^5
M-OZG]:^_+-]9_=(<*6T]8#@W*__8MI=%$#3%D59Y,V(7>H8G>U97>0M_UH>@
MN=0TWXF7JE,0A>$TJ/+R[$N&17T+!]OORX*FK'BMZ+F5)#4]Y2WXWQS+2Z/9
MJN(6NBJO7UXO#P6K+D#Q7)[*]JL@];VJ6'P^G%F=/Y\@[@\RS@O-+?YPZ*NR
MJ%G#]NT(Z`+IJ!OS/)@'P+1>[DJ(@*?=J^E^Y3^211;%?K!>B@3]6]+WQOB_
MUQS9^V]UN?NC/%/(-M2)5^"9L1<._;SC)G@Y<-Y^$A7XJ_9V=)^_GMJ_V?OO
MM#P<6RCW!"+B@2UV7U/:%)!1H!E%$\Y4L!,X`/]Z5<FE`1G)/U;^&!8N=^UQ
MY<?3T20)8P)P[YDV[5/)*7VO>&U:5OTG041121)`"A+XK4A(.!I'DV0F6-PW
M`^F%""K-VWR]K-F[!TJ!=9I+SG5'%L"FHY$,77S7PH.X.,DC9UGY(''PO(&:
MO*WC*%H&;Y#'0F$V+H;8B*U&\*1QVA0;,L,00`!=%-%/B8*S\"CT^AMMZ,-"
M06TU0K^28D-F&"R78]?E&,0X+".=9_Z2D$Z79S)!+FTD)I:"X6G<.I;4L62F
MQ?(3=(H%POW\08%P%E`Z)*/S/(YBN_X;!8(B&Z"Q#=IVH"[ECB4S+58PH'`<
M#)F,$C"WQ[)XV3!8&)8?*$(,JI9:YQPB%.W`1EE$TQ&8K6-)'4MF6BPGI]]V
M\@N[7',2.HCVDI/87DH+,73A6%)E`3%T%2!3)+!,@<:B39J[,/FVXS=EEW/8
M?DL+,:5#IB%2Q2`(]9=T$(1$F"D05,=(02]"JU+\3$?-,X%FKM2D"W6[M#B?
M';RT$$BYX<T$!3\(FMJ@5($2T9W#T329A.9/'Z%0<*;@\,M8..DXK33,W320
M>]+`^>PT2`N!7X8WL\X;N>D&07,;E$I0%*HTS)!&,O7<[$$DZ=5FQ4V@#^+Z
MWQ6X(+0C5R9;`0GR>CN,0ALW'4;A#:!15NF37A]V"OB)C+;`^)[:0W_"Q5<F
MN_H)W@3#*+P+%$K5'Z4QTT_MZE]1/>](./28W+'[!2&JOIP>4/6Q\-6+"(65
MKU&Z`R23F=D`0B<9:FU+!]-KR>#S`]+!?<E0`TG43V-$FFP=S/J]*;O`("IQ
MDM%Q\6'U`>V43)%$MA"N[0$^;J#8[VL#:GXQ8Y<FN\2X>6W)(`H%E_:HX=@5
MR6UUYU/,3XU=C45F[-*$ZH[:UI9_@\&I@5!]R80Z4H6*(M7_DPGBR33"*OU5
MV?-9"(5_G^SE<`6#<C==\IKSP*P98.:TOT&4T_X&4?V>EF>_7O$V!?"!":5@
M;,S4>@H:F*F-<97(L<N*6YKX5W%_Z,^<WJ?F-6LTF#G;77'-5-GGXV1N_J!L
M9LH=>^VK(H`\F1GX3J0<C;J\-$73KNA;HDS]-T6J3?,.E6F3>-$^E_D<@ZHR
M#7_P2X?O)>RJFH^2SHFM0D70-OHZS5%;3C67N%Q1,C.Y+._A>':\-[_3;M.4
M8+$SK4WBVT6>%ZXI=4V99;)]Y0,+RO3W/^3YR8)2JTSRSDA\MW<6T:?1^9QV
M3\VT]R#;R8%990P;Z]M2A2[I."E-II/:,G28I(K"VL/S_D"RG1R:(;Y[)0)W
M?8Z3TF0ZJ2W"2=3R4T5A.]F#I)/R0E#>G56T/M`M/9T:KV"O_+(/)L?ULC/+
MF\A-%,)5I!`\?D*2Q09V!/1X]"2%)WRON$^@)RVRP2=PX_DHS@O$M8&;4/&U
MC^T1N#6PPB9>P#60N_+C&/B''FS&"[AJ<5_83!9PNP'VH%L9;D`O^8'^F=>'
M\MQX)[J'I,E^5,L[5-6<U.7&,VOA[E/<<QSAKIO"-5;(1^L]8ZW^@R_0W9ZO
M_P<``/__`P!02P,$%``&``@````A`+?,Y%3+!0``814``!D```!X;"]W;W)K
M<VAE971S+W-H965T,3,N>&ULK%C;CJ,X$'U?:?\!\3[A3@!U>M0)(8!VI=5J
M=O>9)DZ".L01T-TS?[]E;!-?F&BF-2]-<U(^KCI5M@L_?/[:GHTWU/4-OJQ,
M9V&;!KK4>-]<CBOSGR_9I\@T^J&Z[*LSOJ"5^0WUYN?'WW][>,?=2W]":#"`
MX=*OS-,P7!/+ZNL3:JM^@:_H`K\<<-=6`[QV1ZN_=JC:CX/:L^7:=FBU57,Q
M*4/2_0@'/AR:&J6X?FW19:`D'3I7`_C?GYIKS]G:^D?HVJI[>;U^JG%[!8KG
MYMP,WT92TVCKI#A><%<]GR'NKXY?U9Q[?-'HVZ;N<(\/PP+H+.JH'G-LQ18P
M/3[L&XB`R&YTZ+`RGYRD='S3>GP8!?JW0>^]\+_1G_#[KFOV?S07!&I#GD@&
MGC%^(:;%GD`PV-)&9V,&_NJ,/3I4K^?A;_R>H^9X&B#=`41$`DOVWU+4UZ`H
MT"S<@##5^`P.P%^C;4AI@"+5U_'YWNR'T\KTPD6PM#T'S(UGU`]90RA-HW[M
M!]S^1XT<1D5)7$8"3T;BN@O'M\.?X/`8!SP_[HC/2.#)';GK.(0X1@]/9A\O
M?#=81F/T=R*&Y3,.A">?:.%&@1.,(=\9&+.!\&0#'7NQ=.S86X(3^D"+YFM,
M?UH-U>-#A]\-6%.0D?Y:D17J)`Z4#4\\I9A*X7N5`"5`6)X(S<J$,"#)/93O
MVZ.[M!^L-RBYFMFL=1M'MMAP"U)?A#95@:T*9"JP4X%<!0H5*`7``EDF;:`.
M?X4VA(9HPZ-:<T`02Q&"6_`AJ0IL52!3@9T*Y"I0J$`I`)(0L)@T(3PHEOG=
M@=<$&;4R80T)-:%D?$UM/+H/D)1O-"35D*V&9!JRTY!<0PH-*45$D@#"^(`$
M9!1LA:"KH(&Z+JA1,*Z:I5((_+?Y\9*'L.XE#^\GAUB/GO$26S-$2(6&I!JR
MU9!,0W8:DFM(H2&EB$B!ADJ@']RR"(VL`$-@.Q"RY2H9F8RX<*F&;#4DTY"=
MAN0:4FA(*2*2*$M%E/O9)]9R[`P1LJ\AJ89L-233D)V&Y!I2:$@I(E*@I./\
M!0<6H9$58(B@@(:D%`GL<:WZKAW[<G5L)P->'1E#W&G[WVFT^80(A>=%,G4Q
M&7'J4J26-(*N8$:C!6D-AE-3OZPQ%#B4^4R1>!`:/=()B:P00P2%-"2E2""M
M(4_9U;:3$0\E8XB@DD:=,X1X".V%[2C:%]/OG+44626!2*=S5Z$O^/H]A:`9
MY1*--+)&'(+<")N()^=R<[/BOJ8<`I]O`WWEK-@R*Y]6(/182U]5-^,VMSSM
M./FM"<DY='>^@G.Q^=PX#/U`#J;D-N-\LLRDLQ(7ZTS!B7(2<T5."OGR":ID
M?N-,5C<Y&>1-ZV[+K?RQ@#P[=FU/T3?C-O0;AS0D.P[=:C/GT(V\X!`CA\;?
M=I6LE]QF))>%(IW73PA%&S7H*WB\:X=!<MTIJ=K<K/C`E$/QQ+5E$"\R^`"+
M8CGG&3<1:VSR@'/G.G?!!]*"BD/?4;E+;C)33Z0]$V6B1_]/;FP.:_)$]2BD
ME%DH![UA`\&*1Y@R*+A5PI9!H4OWJ<AU`Z7KS3B16&63!YP[U[D+F=MWEIZC
M.%E*W'*1S?6P#GRFLU.![WD_?D3`C82V8!DDU6&HG&4;/O"V'Z4,"H@WTS>D
MOO^QAC@<Q0T]U_5MY73)&),OUN;DU4U=QG1WOH)[Q>:+X$)CJ2UKRD3GHXK3
M>Q;ZH=VB[H@VZ'SNC1J_DCL49PG>3S"]X%DO$^AYP#L%SZ,$3OX9/$[@P-/Q
M,DK@V--QN$!Z&NM6X5^3BZ49^[6;P.>@SK/V$OA(TO$G/WD"L?0?UD$"K?P,
M'B;0S<[@4;*>"V`3)9LY/(T2Z+ITGC1.H,_0\2Q*H-O0\5V4[$;<FA2""ZYK
M=41_5MVQN?3&&1T@>7#-`B73T2LR^C*P9N$9#W"U-?8-)[C*1'!ZV&1U'3`>
M^`M,;$V7HX__`P``__\#`%!+`P04``8`"````"$`8QP=:NT$``#;$P``&0``
M`'AL+W=O<FMS:&5E=',O<VAE970Q.2YX;6R<6%V/HS84?:_4_X!XWX#M?"O)
M:J:C:5?J2E75[CX3XB1H`$=`)C/_OM?8P;[&"5%?4(#[<7SNO<?$JZ\?11Z\
M\ZK.1+D.R2@.`UZF8I>5AW7X[S^O7^9A4#=)N4MR4?)U^,GK\.OFUU]6%U&]
MU4?.FP`BE/4Z/#;-:1E%=7KD15*/Q(F7\&8OJB)IX+8Z1/6IXLFN=2KRB,;Q
M-"J2K`Q5A&7U2`RQWV<I?Q'IN>!EHX)4/$\:P%\?LU-]C5:DCX0KDNKM?/J2
MBN($(;99GC6?;=`P*-+EMT,IJF2;P[H_R#A)K[';FU[X(DLK48M],X)PD0+:
M7_,B6D00:;/:9;`"27M0\?TZ?"++9\;":+-J"?J1\4MM_0[JH[C\7F6[/[.2
M`]M0)UF!K1!OTO3;3CX"YZCG_=I6X*\JV/%]<LZ;O\7E#YX=C@V4>P(KD@M;
M[CY?>)T"HQ!F1"<R4BIR``#7H,AD:P`CR<<ZI)`XVS7'=<BFH\DL9@3,@RVO
MF]=,A@R#]%PWHOBIC$@+2L5JH;TD3;)95>(20+W!NCXELGO($@)?,:D('<I;
M(`&=#/(DHZQ#:%3(7P.S[QL6SU;1.["1:IMG90/7SH9T%A&@Z2`!#!N2GYYK
M9FDL,TNZ))1G]<!.0_UI&$XC5\Z@IO?32:=U.+87L9AW\14"9=-6$*T+O.QU
MR83C>#&ZV0'7)4H_P&;E9+&;4]E`*$/N8M'A0C#`R(4Q&\0@G3`&.NW"JV4K
M$[AV$$!?.AL$8=J'\!`3TL]!X7:9,L$H;O39K(^"DL$.D%X8`XL-TXH*96.#
M8.0&%5+<W?F+P?-^&THO#(*Z':%,;`PT9OYR+#P8V"`&Z84Q,&*85D0H&PQB
M[`<AF7>9>*@I6D<'B-N;V@8#F=P`(H7*+<ETD`ZB]`V-*3'2H_C01AB'`8N&
MA#@ZV$KS`SB4`&(<IO`:AS+".,PH81Q2SUP^Z."<$.F&RS+OP5`V&(9I9`S#
M(Y_#ND4\XDE,!VHV^NI)K9G&,`!LCXWA@97[O,,&(Z8!-0YEA.BXI1O$HZ%T
M/%R5OH3.3?]I&!X-M28;T^$14?)`<_15=&[:3\/HJR@EIH,P#(^,LN'=G&@=
MA6GH-BU&>GQXI-2J'0;B:.E]&2=:0ZGY?+D^PDU@(*%LDNA>,TX&FZ!U@]&T
MTNI'.*NI",[J$<B'E)IJB<1TFRRJ[MH*0S$[+(8B=<S2IOMT4Z5Z:-WJ4?]C
MC?I4;P&@!E)HU;.I]8@<O?$U0!V1&TBFQ<U.YI$R:G9E3!ZLQB:OW6"&]WWY
M9T-*F9U5/8)K-T:4FKT/9W6$:V")6J_L9!YYHC=T@7KDB<Z&!T3+DYW5HT;4
M;"1XB1XU>FQ`M!Y9/!)B6E_/AT>.J-E*,!)'CF2)Z03J-,"ZUB4+!R-F7]8X
ME!$N^@VADE+LMMI#C+2.^"N"F5HK(-H&`S&J@@AA_U>[6D<'2*\TV@@C,;QA
M)(YTM:61LW6_-#!VO0\)2TTT(U=5L^?1]!'&X1.ZX3T$#DKZ.(S0:!P>Z6.N
M]*GS$G4H4?#JP'_C>5X'J3C+LQ`&IPG=T^Z<YJF=S-[S^?()-C(X"G#?4`)O
M9NU!2/<*CE9.R8%_3ZI#5M9!SO>0+A[);\I*'<ZHFT:<VF.2K6C@4*7]>81#
M-`Z'#;'\\[X7HKG>R..?[EAN\Q\```#__P,`4$L#!!0`!@`(````(0`JG>BL
MR@(``&L'```9````>&PO=V]R:W-H965T<R]S:&5E=#$W+GAM;*Q576^;,!1]
MG[3_@/Q>/O/1H)`JH>I6:9.F:1_/CC%@%3"RG:;]][NV@0625IFT%\"7X^-S
MS[U<UG<O=>4\4R$9;Q(4N#YR:$-XQIHB03]_/-S<(D<JW&2XX@U-T"N5Z&[S
M\</ZR,63+"E5#C`T,D&E4FWL>9*4M,;2Y2UMX$W.18T5+$7AR590G)E-=>6%
MOK_P:LP:9!EB<0T'SW-&Z#TGAYHVRI((6F$%^F7)6MFSU>0:NAJ+IT-[0WC=
M`L6>54R]&E+DU"1^+!HN\+Z"O%^"&28]MUF<T=>,""YYKER@\ZS0\YQ7WLH#
MILTZ8Y"!MMT1-$_0-HC3!?(V:^//+T:/\N39D24_?A(L^\(:"F9#F70!]IP_
M:>ACID.PV3O;_6`*\$TX&<WQH5+?^?$S946IH-IS2$CG%6>O]U02,!1HW'"N
MF0BO0`!<G9KIS@!#\(NY'UFFR@2%*W<9^*MH"2Q[*M4#TY3((0>I>/W;@H*.
MRI*$'0G<.Y*%.POGR]L`SGQO8]1MA'NW,5JX\Z4?O;'1L^J-&?=8X<U:\*,#
M#0;Z9(MUNP8QD/4N6,V#+V_9`GYHDJUF21!\&9"QA%(^;R+?7WO/X#_I,+MS
M3#!&I#U"EPWD#1K!G?^@4;-HC;J46O2N#_P5'4X$]8BI(##J5-#EENF]T>`$
MS4;>3#+?64QDFT.+2T\C(S.`Z/JS-3A!$>3Q3F$L:&[*%DR4I?W+RP0C9="Q
MURO38*-L*$<7.?'@-#(Z:3$^23=M.`?T/W:MIAEKZ"+0B"=^3;MB``UM88>,
M_:YJ*@J:TJJ2#N$'/4"6X.P0'6;;-M2=.(GO8.89`Z;Q,$XOXJ,8.N6<9SN+
MMV9V3GGF<6J&V32^Z&:M-[R`6=?B@G[%HF"-="J:0RJ^JX>;L-/2+A1OS139
M<P53SCR6\%.CT,2^"^"<<]4OM&'#;W+S!P``__\#`%!+`P04``8`"````"$`
M=>ZVQMD$``"P$P``&0```'AL+W=O<FMS:&5E=',O<VAE970Q-2YX;6RL6$UO
MXS80O1?H?Q!T7\N4_"7#]B)VD':!+E`4[>Y9EFE;B"0:HA(G_[Z/E*B0%./:
M1B]Q-#,</KT9/I%<?'TK<N^55CQCY=(G@Z'OT3)ENZP\+/U__G[Z,O,]7B?E
M+LE929?^.^7^U]6OORS.K'KF1TIK#QE*OO2/=7V:!P%/C[1(^("=:`G/GE5%
M4N.Q.@3\5-%D)P<5>1`.AY.@2++2;S+,JVMRL/T^2^DC2U\*6M9-DHKF20W\
M_)B=N,I6I->D*Y+J^>7T)67%"2FV69[5[S*I[Q7I_-NA9%6RS?'>;V24I"JW
M?.BE+[*T8ISMZP'2!0W0_CO'01P@TVJQR_`&@G:OHONE_T#FFW#B!ZN%).A'
M1L]<^]_C1W;^K<IV?V0E!=NHDZC`EK%G$?IM)TP8'/1&/\D*_%EY.[I/7O+Z
M+W;^G6:'8XURC_%&XL7FN_='RE,PBC2#<"PRI2P'`/SUBDRT!AA)WN3O.=O5
MQZ4?QKZWI;Q^RD0JWTM?>,V*GXV3M"F:P6$[&+_MX-%@2H9Q-`6""^.B=AQ^
MVW'19#">#B,"C(Z!00-:<O"8U,EJ4;&SA\8"/'Y*1)N2.9*IEV^F[NCXC`W0
M()(\B"Q+'RL"+\Q1PM=5.(L6P2MH3]N8=3^&F!$;%2&J!7@=1I#S/V`4601&
M44$!>JT,&F@+D(JP`8$H'9"[4Q0W(GCICPQN1N9$ZR8F:GI#@-OH%H,,)+I^
M;A&\]".\QX7"-$%C6;;8!+91/O=X`QCZ[GI@(E@"ZZK16C0*=(LQT\2<Z<Z>
M%5E,"*T%;:BQ-;88Z8+LIIB:J"XWA0@V)V\MVOOK%N/]Q9?'6K/A&&S=N&A%
M&A-#:S$)F%@$=$$V`5`]'=9E`D2P.7EKT0C0+08!!"*O3R4[(+Z=`9G'1*%,
M)@=3BX./*)L$(D1,*\YE%F2T!4`D@$GC045)DTF$4"AM-DE$=`<1C=)!*+KU
M2%J32<3,)J*+ZA%QDTB25N]T`+H$2L7>J"@'$98LWMT1G6)^$-&:3")LH21=
M5(\(H6-:C?ZC(T2TU1&M2>\(W61VA%,<L5YN%`?2ET=E,HB(AW9'?"J0Y":%
ME-$6$;HBMAVAFTPB'"I)9G<0T9=)TDF@]J&(>[N9+JK7$3<I)>E+I3+I'?&I
M6(8NL43_W-@0,HU9#V4R&R*T&N(CRN8AQ,#K5X:,M@"(!#!I/*BHOD2$+JV\
MHR%D'@M'IX)Z0U@;X(T:Z(!VDU:&?:U4)IT(73Z-E1$ZM')R^\*0:2P>.A'4
M>;`VNQLUT,&#D+6KI5*<="RI5":=AT^E$H=*8S;QS1C=L3#Z2BDSR[[4>;!W
MDA]1W<)H#JG-`:V@U8%N:)YS+V4OX@`:3K%'[\S-Z7@=AC@>R\]FSQ/!$XDO
M>L\S@F?D](SAD:?<WI@)//(8;GL(//@V..8A4WBF3L\,'GD6ZV6+X8E=8\(A
M$,BSO#TF%%<$LN:VAV`,-FLN;!B#C97+`T:Q^W%YP"CV("X/&,46P.4!H[A.
MZ'MPK_'@G@4#'/%K46B7':!<F!Y&R.\L"Q"Y`*U11V<\JN@L(FKH+"$J*`L8
M=-7`?<DI.=#O277(2N[E=(]V'@[$)4?5W+@T#S4[R2N)+:MQ8R+_/>)FC.)$
M/!P@>,]8K1[`:-#=M:W^!0``__\#`%!+`P04``8`"````"$`*$T$8O@"``"O
M"```&0```'AL+W=O<FMS:&5E=',O<VAE970Q-BYX;6RL5EUOFS`4?9^T_X#\
M7CY"\X5"JH2J6Z55FJ9]/#M@P"K&R'::]M_OV@8$)(M::2\AOAP?GWONM<WF
M[I55S@L1DO(Z1H'K(X?4*<]H7<3HU\^'FQ5RI,)UABM>DQB]$8GNMI\_;4Y<
M/,N2$.4`0RUC5"K51)XGTY(P+%W>D!K>Y%PPK&`H"D\V@N#,3&*5-_/]A<<P
MK9%EB,1[.'B>TY3<\_3(2*TLB2`55J!?EK21'1M+WT/'L'@^-C<I9PU0'&A%
MU9LA10Y+H\>BY@(?*LC[-;C%:<=M!F?TC*:"2YXK%^@\*_0\Y[6W]H!IN\DH
M9*!M=P3)8[0+HF2%O.W&^/.;DI,<_'=DR4]?!,V^T9J`V5`F78`#Y\\:^ICI
M$$SVSF8_F`)\%TY&<GRLU`]^^DIH42JH]AP2TGE%V=L]D2D8"C3N;*Z94EZ!
M`/AU&-6=`8;@5_,\T4R5,0H7[GSIAP'`G0.1ZH%J2N2D1ZDX^V-!04ME268M
M"3P[DJOXL,7#L\._>U'/)F#\N,<*;S>"GQSH,9`H&ZP[-HB`N#/"RNZM^9<S
M8(DFV6F6&,'F@*0E5/-E.ULO-MX+E"!M,?MS3#!&)!U"5P[D]1K!H/^@4;-H
MC;J:6O2^"PQ$3P1UB*D@,&HJ*(0>O-P]G4=Z4HQN1QXMQPON+2:T?:)%)L/(
MR!0@^K@&/0EZ%?*Z4B@+FILR!OY88=*]O$PP4@@[8:CPNCL:;)3UY6DC`R^&
MD=%*B_%*IHE#0'^PBS7-6$,;@<8<^+6:6-*#IFVR',NZ;H`&CQ=O(P,#AI&1
M`?I:FN[BQ<<-T#1C#6UD;,!Z8D`/Z@VP!Z\]:!@1!4E(54DGY4=]J*ZAM?IH
M?][O9GIK3N)[N`>,`=/X+$HNXL,(MLPYS^XVVIFM/^691XDYX*?Q190L+O#L
MEU&RO!1?M?>5UQ/!?='@@CQA4=!:.A7)(77?74)9A+UQ[$#QQAS#!Z[@IC!_
M2_@P(+#[?1?`.>>J&VB#^T^-[5\```#__P,`4$L#!!0`!@`(````(0!MXSUA
M`@,``)T(```9````>&PO=V]R:W-H965T<R]S:&5E=#$X+GAM;*Q6VVZC,!!]
M7VG_`?F]7$,N**1*J+I;:2NM5GMY=L`$JX"1[33MW^\,MP+)5JFT+R$>CH_/
MG!G;K&]?BMQX9E)Q48;$,6UBL#(6"2\/(?GU\_YF20RE:9G07)0L)*],D=O-
MYT_KDY!/*F-,&\!0JI!D6E>!9:DX8P55IJA8"6]2(0NJ82@/EJHDHTD]J<@M
MU[;G5D%Y21J&0%[#(=*4Q^Q.Q,>"E;HAD2RG&O2KC%>J8ROB:^@**I^.U4TL
MB@HH]CSG^K4F)481!P^'4DBZSR'O%V=&XXZ['IS1%SR60HE4FT!G-4+/<UY9
M*PN8-NN$0P9HNR%9&I*M$T1+8FW6M3^_.3NIP7]#9>+T1?+D&R\9F`UEP@+L
MA7A"Z$."(9ALG<V^KPOP71H)2^DQUS_$Z2OCATQ#M7U("/,*DM<[IF(P%&A,
MUT>F6.0@`'Z-@F-G@"'TI7Z>>**SD+@+TU_8G@-P8\^4ON=(28SXJ+0H_C0@
MIZ5J2-R6!)XMR<)TE[[CSY'DG8E>.Q&>[41O_K;Z^42K45^;<4<UW:RE.!G0
M8*!/513;U0F`K'.A8>A]^9<MX`>2;)$E)+`S(&,%I7S>>+:WMI[!_[C%[,XQ
MSA@1=0@L&\CK-8([_T$CLJ!&+"6*WG6!-]'N1%"'F`H"HX:"+K=,YPV"0S(;
M>3,;+[1K,%[3'"@N&D9&9@#1]6LC."0>Y/%.81J07Y?-F5K0O;Q,,%(&'7N]
M,@37ROIRM)&!!\/(:*7Y>"5LV@6`/]BTR#*6T$:@#P=V^>-:13UHVA6+L:KW
MNP+!X\7;R"#_8624/UY!DTT[LU<F*/N@!4@T5M%&QA;,)Q;TH-Z"YIAM3I:"
MR0.+6)XK(Q9'/$)7T%M]M#_=MR[NQ4E\!Z=^;<$T[@;11;P7P%XYY]G.@FV]
MUZ<\?A#5Q_DT/@^@LN<\NT40+2[%E^WM9/5$<#M4],`>J3SP4ADY2R%UV\3.
ME,W]T@RTJ.IS=R\TW`OUWPP^`QAL>]L$<"J$[@9H</]AL?D+``#__P,`4$L#
M!!0`!@`(````(0"Z4=OZ-0$``$`"```1``@!9&]C4')O<',O8V]R92YX;6P@
MH@0!**```0``````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M``````````````````````````````````````````````````"4D5%+PS`4
MA=\%_T/)>YNF<S)"FX'*GAP(3A3?8G+7!9LT)-%N_]ZLZVI%7X2\A'/NEW-/
MRN5>-\DG.*]:4R&2Y2@!(UJI3%VAI\TJ7:#$!VXD;UH#%3J`1TMV>5$*2T7K
MX,&U%EQ0X)-(,IX*6Z%=")9B[,4.-/=9=)@H;ENG>8A75V/+Q3NO`1=Y?HTU
M!"YYX/@(3.U(1`-2BA%I/US3`Z3`T(`&$SPF&<'?W@!.^S\'>F7BU"H<;-QI
MB#ME2W$21_?>J]'8=5W6S?H8,3_!+^O[QW[55)EC5P(0._;3<!_6L<JM`GES
M8/LWUR3>[TK\6RNEZ--1X8`'D$E\CY[2G97GV>W=9H58D9-YFL>SV!2$DIR2
MJ]<2GUW#/!N!>@CP+^)\0CP#6)_[YY^S+P```/__`P!02P,$%``&``@````A
M`!R$&OZ5````J0```!````!X;"]C86QC0VAA:6XN>&UL/(Y!"@(Q$`3O@G\(
M<W=G];"()%E0\`7Z@)`=32"9+)D@^GOCQ4M#T5#=>G[GI%Y4)18VL!]&4,2^
M+)&?!NZWZ^X(2IKCQ:7"9.!#`K/=;K1WR5^"BZRZ@<5`:&T](8H/E)T,927N
MS:/4[%K'^D19*[E%`E'+"0_C.&'N`K#:JVK@/(&*_0.H]$NT&O\C]@L``/__
M`P!02P,$%``&``@````A`$M/SC?Q`@``Q`D``!``"`%D;V-0<F]P<R]A<'`N
M>&UL(*($`2B@``$`````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````G%;;
M3N,P$'U?:?^ARCND7(16*`TJ;5=4`EJ1P#Y:;C)I+1P[V$Y%^/H=)_0&QA*\
M.9XY,V?&9V)'5Z\E[ZU!:2;%(#@Y[@<]$)G,F5@.@L?T[]&?H*<-%3GE4L`@
M:$`'5_'O7]%<R0J48:![&$+H0;`RIKH,0YVMH*3Z&,T"+854)37XJ9:A+`J6
MP5AF=0G"A*?]_D4(KP9$#OE1M0T8=!$OU^:G07.967[Z*6TJ)!Q'PZKB+*,&
MJXSO6*:DEH7I35XSX%&X;XR070)9K9AIXGX4[G]&248YC#!P7%"N(0IW&]$-
M4-NT.65*Q]':7*XA,U+U-'O#MIT&O0758.D,@C55C`J#M*Q;]]&N>:6-BO])
M]:Q7`$9'(3ITF^URWW=_S<[CLXO6`U>'GC9"QP0-AQQ39CCH63&GRC@HGUWL
M<VY9=(P[0IM3)*@-,A$&^T6FHCMM)O>9;VL8S>['D_MD,B:X2F:WT_$PQ8_K
MX>WP?C3Y`>3D.Y@DQ6QWWTKS#OE)FE,GM9E:4L'>6AV2:ZJ9)K(@<P4:YX$Z
M(4E=EE0UUB]A2\%P@E`[9)AELA;&"9F*-8:3JG%:)R\UJ^S\$0&F/;U,"M1=
MG=GI<$*F2$XLV8(#H5JC,"W4Z?D@&\I1";,%9\NN3*N/,12@%`[,5@M6^IV0
MWBO19$X;VJ9``&ZJ&G)RZX0\`*<&K5:Y#4D5%9JV[+6MQPE)5E3!2O(<?W7$
MML"XNY/@A+>'<LUDRDH@(UF64I`6?S"0VP(26+;MW*G?W<6D7FAXJ6WG)_:`
MOHCF/6^W%/VR<F/\,G!CG#H@J3TU=S%^.;B3^/7@QO@;X)Y%_V"Y,=O)0D4;
MRKB[:G]KOXKL&#%O%G]OW5G\O75C_,/F/@_'M'EK\4_=%SD^CYT_Q\?Q<WD?
M7)<?+LA;)I[U8Y7*,?Y\-B^`P\VH+3S'NW%CWVU$-WCY*VZ#C%;X.X5\X_/9
M8-\K3]VC+#XY/^Z?]?$ILK<7A;OG5_P?``#__P,`4$L!`BT`%``&``@````A
M`$F;.[CQ`0``PQ<``!,``````````````````````%M#;VYT96YT7U1Y<&5S
M72YX;6Q02P$"+0`4``8`"````"$`M54P(_4```!,`@``"P``````````````
M```J!```7W)E;',O+G)E;'-02P$"+0`4``8`"````"$`!FT+20@"``#`%@``
M&@````````````````!0!P``>&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-0
M2P$"+0`4``8`"````"$`FN@QXH,#``"L"P``#P````````````````"8"@``
M>&PO=V]R:V)O;VLN>&UL4$L!`BT`%``&``@````A`,0'>7%"!0``.Q,``!@`
M````````````````2`X``'AL+W=O<FMS:&5E=',O<VAE970T+GAM;%!+`0(M
M`!0`!@`(````(0!"H&8!RP(``*,'```9`````````````````,`3``!X;"]W
M;W)K<VAE971S+W-H965T,S$N>&UL4$L!`BT`%``&``@````A`(DHG6)"`P``
M_PD``!D`````````````````PA8``'AL+W=O<FMS:&5E=',O<VAE970S,"YX
M;6Q02P$"+0`4``8`"````"$`.:8+)C4#```&"0``&0`````````````````[
M&@``>&PO=V]R:W-H965T<R]S:&5E=#(Y+GAM;%!+`0(M`!0`!@`(````(0!Y
MO[M]/`0``$\.```9`````````````````*<=``!X;"]W;W)K<VAE971S+W-H
M965T,C@N>&UL4$L!`BT`%``&``@````A`"T:*#1D`@``O@4``!D`````````
M````````&B(``'AL+W=O<FMS:&5E=',O<VAE970R-RYX;6Q02P$"+0`4``8`
M"````"$`&PM+A.4&``!('@``&0````````````````"U)```>&PO=V]R:W-H
M965T<R]S:&5E=#(V+GAM;%!+`0(M`!0`!@`(````(0"9S-L%#@@```DG```9
M`````````````````-$K``!X;"]W;W)K<VAE971S+W-H965T,C4N>&UL4$L!
M`BT`%``&``@````A`$@](^4>!0``@!,``!D`````````````````%C0``'AL
M+W=O<FMS:&5E=',O<VAE970S,BYX;6Q02P$"+0`4``8`"````"$`X%2?8ZP$
M``!9$0``&0````````````````!K.0``>&PO=V]R:W-H965T<R]S:&5E=#,S
M+GAM;%!+`0(M`!0`!@`(````(0"A&58X.P0``+<0```9````````````````
M`$X^``!X;"]W;W)K<VAE971S+W-H965T,S0N>&UL4$L!`BT`%``&``@````A
M`/X:!<JU!@``\!L``!@`````````````````P$(``'AL+W=O<FMS:&5E=',O
M<VAE970R+GAM;%!+`0(M`!0`!@`(````(0!M61_='P,``!X*```8````````
M`````````*M)``!X;"]W;W)K<VAE971S+W-H965T,RYX;6Q02P$"+0`4``8`
M"````"$`__@::Q14``#1!@$`%```````````````````30``>&PO<VAA<F5D
M4W1R:6YG<RYX;6Q02P$"+0`4``8`"````"$`GZHF)_P+``"=;```#0``````
M``````````!&H0``>&PO<W1Y;&5S+GAM;%!+`0(M`!0`!@`(````(0#[8J5M
ME`8``*<;```3`````````````````&VM``!X;"]T:&5M92]T:&5M93$N>&UL
M4$L!`BT`%``&``@````A`'JNRAB(!0``;Q8``!D`````````````````,K0`
M`'AL+W=O<FMS:&5E=',O<VAE970S-BYX;6Q02P$"+0`4``8`"````"$`L1R^
M]6`"``"*!0``&0````````````````#QN0``>&PO=V]R:W-H965T<R]S:&5E
M=#,U+GAM;%!+`0(M`!0`!@`(````(0"X$[<AO`,``)8,```8````````````
M`````(B\``!X;"]W;W)K<VAE971S+W-H965T,2YX;6Q02P$"+0`4``8`"```
M`"$`SC"M,'T%``"I$P``&0````````````````!ZP```>&PO=V]R:W-H965T
M<R]S:&5E=#(T+GAM;%!+`0(M`!0`!@`(````(0!TYS67$@4``#42```9````
M`````````````"[&``!X;"]W;W)K<VAE971S+W-H965T,C(N>&UL4$L!`BT`
M%``&``@````A`'`-DY"Z!0``SQ4``!D`````````````````=\L``'AL+W=O
M<FMS:&5E=',O<VAE970Q,2YX;6Q02P$"+0`4``8`"````"$`-D?Y1ZX&``!N
M&P``&0````````````````!HT0``>&PO=V]R:W-H965T<R]S:&5E=#$P+GAM
M;%!+`0(M`!0`!@`(````(0`7O#K*Q`(``%X'```8`````````````````$W8
M``!X;"]W;W)K<VAE971S+W-H965T.2YX;6Q02P$"+0`4``8`"````"$`G6DE
M,ND'``#[)P``&`````````````````!'VP``>&PO=V]R:W-H965T<R]S:&5E
M=#@N>&UL4$L!`BT`%``&``@````A`#5!DHE>"```BR8``!@`````````````
M````9N,``'AL+W=O<FMS:&5E=',O<VAE970W+GAM;%!+`0(M`!0`!@`(````
M(0#6FL6#O0<``.(A```8`````````````````/KK``!X;"]W;W)K<VAE971S
M+W-H965T-BYX;6Q02P$"+0`4``8`"````"$`+7^L05$#``!Z"0``&```````
M``````````#M\P``>&PO=V]R:W-H965T<R]S:&5E=#4N>&UL4$L!`BT`%``&
M``@````A``M)*S9U!```YPX``!D`````````````````=/<``'AL+W=O<FMS
M:&5E=',O<VAE970R,RYX;6Q02P$"+0`4``8`"````"$`FP1)0T$%```]$P``
M&0`````````````````@_```>&PO=V]R:W-H965T<R]S:&5E=#$R+GAM;%!+
M`0(M`!0`!@`(````(0"A;E4:>0,``"D+```9`````````````````)@!`0!X
M;"]W;W)K<VAE971S+W-H965T,30N>&UL4$L!`BT`%``&``@````A`&Y`Y9Y!
M!0``$!,``!D`````````````````2`4!`'AL+W=O<FMS:&5E=',O<VAE970R
M,2YX;6Q02P$"+0`4``8`"````"$`VR%FQ.$%``""%P``&0``````````````
M``#`"@$`>&PO=V]R:W-H965T<R]S:&5E=#(P+GAM;%!+`0(M`!0`!@`(````
M(0"WS.14RP4``&$5```9`````````````````-@0`0!X;"]W;W)K<VAE971S
M+W-H965T,3,N>&UL4$L!`BT`%``&``@````A`&,<'6KM!```VQ,``!D`````
M````````````VA8!`'AL+W=O<FMS:&5E=',O<VAE970Q.2YX;6Q02P$"+0`4
M``8`"````"$`*IWHK,H"``!K!P``&0````````````````#^&P$`>&PO=V]R
M:W-H965T<R]S:&5E=#$W+GAM;%!+`0(M`!0`!@`(````(0!U[K;&V00``+`3
M```9`````````````````/\>`0!X;"]W;W)K<VAE971S+W-H965T,34N>&UL
M4$L!`BT`%``&``@````A`"A-!&+X`@``KP@``!D`````````````````#R0!
M`'AL+W=O<FMS:&5E=',O<VAE970Q-BYX;6Q02P$"+0`4``8`"````"$`;>,]
M80(#``"="```&0`````````````````^)P$`>&PO=V]R:W-H965T<R]S:&5E
M=#$X+GAM;%!+`0(M`!0`!@`(````(0"Z4=OZ-0$``$`"```1````````````
M`````'<J`0!D;V-0<F]P<R]C;W)E+GAM;%!+`0(M`!0`!@`(````(0`<A!K^
ME0```*D````0`````````````````.,L`0!X;"]C86QC0VAA:6XN>&UL4$L!
M`BT`%``&``@````A`$M/SC?Q`@``Q`D``!``````````````````IBT!`&1O
D8U!R;W!S+V%P<"YX;6Q02P4&`````"X`+@!K#```S3$!````
`
end

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0E3FAG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Shareholders' Equity (Details) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="2">3 Months Ended</th>
        <th class="th" colspan="1"></th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2015</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract', window );"><strong>Preferred Shares [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred shares, shares authorized (in shares)</a></td>
        <td class="nump"><a title="us-gaap_PreferredStockSharesAuthorized" onclick="toggleNextSibling(this);">2,000,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PreferredStockSharesAuthorized</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_PreferredStockSharesAuthorized" onclick="toggleNextSibling(this);">2,000,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PreferredStockSharesAuthorized</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Series A Convertible Preferred shares outstanding (in shares)</a></td>
        <td class="nump"><a title="us-gaap_PreferredStockSharesOutstanding" onclick="toggleNextSibling(this);">70,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PreferredStockSharesOutstanding</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_PreferredStockSharesOutstanding" onclick="toggleNextSibling(this);">70,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PreferredStockSharesOutstanding</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract', window );"><strong>Common Shares [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common shares, authorized (in shares)</a></td>
        <td class="nump"><a title="us-gaap_CommonStockSharesAuthorized" onclick="toggleNextSibling(this);">125,000,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CommonStockSharesAuthorized</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_CommonStockSharesAuthorized" onclick="toggleNextSibling(this);">125,000,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CommonStockSharesAuthorized</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockNoParValue', window );">Common shares, par value (in dollars per share)</a></td>
        <td class="nump"><a title="us-gaap_CommonStockNoParValue" onclick="toggleNextSibling(this);">$ 0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CommonStockNoParValue</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_CommonStockNoParValue" onclick="toggleNextSibling(this);">$ 0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CommonStockNoParValue</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common shares, shares issued (in shares)</a></td>
        <td class="nump"><a title="us-gaap_CommonStockSharesIssued" onclick="toggleNextSibling(this);">83,210,775</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CommonStockSharesIssued</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_CommonStockSharesIssued" onclick="toggleNextSibling(this);">83,121,698</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CommonStockSharesIssued</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common shares, shares outstanding (in shares)</a></td>
        <td class="nump"><a title="us-gaap_CommonStockSharesOutstanding" onclick="toggleNextSibling(this);">78,316,833</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CommonStockSharesOutstanding</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_CommonStockSharesOutstanding" onclick="toggleNextSibling(this);">78,227,756</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CommonStockSharesOutstanding</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockShares', window );">Treasury stock (in shares)</a></td>
        <td class="nump"><a title="us-gaap_TreasuryStockShares" onclick="toggleNextSibling(this);">4,893,942</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_TreasuryStockShares</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_TreasuryStockShares" onclick="toggleNextSibling(this);">4,893,942</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_TreasuryStockShares</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Stock options granted (in shares)</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" onclick="toggleNextSibling(this);">440,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</span><span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" onclick="toggleNextSibling(this);">1,205,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Options exercised (in shares)</a></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" onclick="toggleNextSibling(this);">89,077</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_WarrantsExercised', window );">Warrants exercised (in shares)</a></td>
        <td class="nump"><a title="btx_WarrantsExercised" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">btx_WarrantsExercised</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract', window );"><strong>Preferred Shares [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Series A Convertible Preferred shares outstanding (in shares)</a></td>
        <td class="nump"><a title="us-gaap_PreferredStockSharesOutstanding[us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember]" onclick="toggleNextSibling(this);">70,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PreferredStockSharesOutstanding<br>/ us-gaap_StatementClassOfStockAxis<br>= us-gaap_SeriesAPreferredStockMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockDividendRatePercentage', window );">Preferred stock dividend rate (in hundredths)</a></td>
        <td class="nump"><a title="us-gaap_PreferredStockDividendRatePercentage[us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember]" onclick="toggleNextSibling(this);">3.00%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PreferredStockDividendRatePercentage<br>/ us-gaap_StatementClassOfStockAxis<br>= us-gaap_SeriesAPreferredStockMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockDividendRatePerDollarAmount', window );">Preferred share dividend (in dollars per shares)</a></td>
        <td class="nump"><a title="us-gaap_PreferredStockDividendRatePerDollarAmount[us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember]" onclick="toggleNextSibling(this);">$ 1.50</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PreferredStockDividendRatePerDollarAmount<br>/ us-gaap_StatementClassOfStockAxis<br>= us-gaap_SeriesAPreferredStockMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_PricePerShareOfOptionsToPurchaseCompany', window );">Share conversion price (in dollars per share)</a></td>
        <td class="nump"><a title="btx_PricePerShareOfOptionsToPurchaseCompany[us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember]" onclick="toggleNextSibling(this);">$ 4.00</a><span style="display:none;white-space:normal;text-align:left;">btx_PricePerShareOfOptionsToPurchaseCompany<br>/ us-gaap_StatementClassOfStockAxis<br>= us-gaap_SeriesAPreferredStockMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_PreferredSharesConvertibleConversionRatio', window );">Common stock conversion ratio</a></td>
        <td class="nump"><a title="btx_PreferredSharesConvertibleConversionRatio[us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember]" onclick="toggleNextSibling(this);">12.5</a><span style="display:none;white-space:normal;text-align:left;">btx_PreferredSharesConvertibleConversionRatio<br>/ us-gaap_StatementClassOfStockAxis<br>= us-gaap_SeriesAPreferredStockMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btx_PreferredSharesConvertibleConversionRatio">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The ratio applied to the debt for purposes of determining the number of shares of the equity security into which the debt will be converted.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">btx_PreferredSharesConvertibleConversionRatio</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>btx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:pureItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btx_PricePerShareOfOptionsToPurchaseCompany">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Price of a single share of a number of saleable stocks of a company.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">btx_PricePerShareOfOptionsToPurchaseCompany</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>btx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btx_WarrantsExercised">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of warrants exercised during the period that is attributable to transactions involving issuance of stock not separately disclosed.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">btx_WarrantsExercised</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>btx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockNoParValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Face amount per share of no-par value common stock.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CommonStockNoParValue</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockDividendRatePercentage">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The percentage rate used to calculate dividend payments on preferred stock.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PreferredStockDividendRatePercentage</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockDividendRatePerDollarAmount">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount per share used to calculated dividend payments on preferred stock.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PreferredStockDividendRatePerDollarAmount</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Gross number of share options (or share units) granted during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of share options (or share units) exercised during the current period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28,29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(iv)(2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockShares">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28,29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_TreasuryStockShares</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	word-wrap: break-word;
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EEHBI">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>Organization, Basis of Presentation and Liquidity (Details) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="2">
          <div>Mar. 31, 2015</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestLineItems', window );"><strong>Noncontrolling Interest [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
        <td class="num"><a title="us-gaap_RetainedEarningsAccumulatedDeficit" onclick="toggleNextSibling(this);">$ (192,357,575)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_RetainedEarningsAccumulatedDeficit</span><span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="num"><a title="us-gaap_RetainedEarningsAccumulatedDeficit" onclick="toggleNextSibling(this);">$ (182,190,207)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_RetainedEarningsAccumulatedDeficit</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Shareholders' equity</a></td>
        <td class="nump"><a title="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" onclick="toggleNextSibling(this);">57,511,784</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</span><span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="nump"><a title="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" onclick="toggleNextSibling(this);">62,722,765</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
        <td class="nump"><a title="us-gaap_CashAndCashEquivalentsAtCarryingValue" onclick="toggleNextSibling(this);">25,829,533</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CashAndCashEquivalentsAtCarryingValue</span><span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="nump"><a title="us-gaap_CashAndCashEquivalentsAtCarryingValue" onclick="toggleNextSibling(this);">29,486,909</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CashAndCashEquivalentsAtCarryingValue</span><span></span></td>
        <td class="nump"><a title="us-gaap_CashAndCashEquivalentsAtCarryingValue" onclick="toggleNextSibling(this);">6,637,834</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CashAndCashEquivalentsAtCarryingValue</span><span></span></td>
        <td class="nump"><a title="us-gaap_CashAndCashEquivalentsAtCarryingValue" onclick="toggleNextSibling(this);">5,495,478</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CashAndCashEquivalentsAtCarryingValue</span><span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_ParentMember', window );">Parent [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestLineItems', window );"><strong>Noncontrolling Interest [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
        <td class="num"><a title="us-gaap_RetainedEarningsAccumulatedDeficit[us-gaap_StatementEquityComponentsAxis=us-gaap_ParentMember]" onclick="toggleNextSibling(this);">(192,357,575)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_RetainedEarningsAccumulatedDeficit<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_ParentMember</span><span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Capital', window );">Working capital</a></td>
        <td class="nump"><a title="us-gaap_Capital[us-gaap_StatementEquityComponentsAxis=us-gaap_ParentMember]" onclick="toggleNextSibling(this);">20,341,461</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_Capital<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_ParentMember</span><span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Shareholders' equity</a></td>
        <td class="nump"><a title="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest[us-gaap_StatementEquityComponentsAxis=us-gaap_ParentMember]" onclick="toggleNextSibling(this);">57,511,784</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_ParentMember</span><span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
        <td class="nump"><a title="us-gaap_CashAndCashEquivalentsAtCarryingValue[us-gaap_StatementEquityComponentsAxis=us-gaap_ParentMember]" onclick="toggleNextSibling(this);">$ 25,829,533</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CashAndCashEquivalentsAtCarryingValue<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_ParentMember</span><span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=btx_AsteriasBiotherapeuticsMember', window );">Asterias Biotherapeutics, Inc.</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestLineItems', window );"><strong>Noncontrolling Interest [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByParent', window );">BioTime Ownership (in hundredths)</a></td>
        <td class="nump"><a title="us-gaap_MinorityInterestOwnershipPercentageByParent[dei_LegalEntityAxis=btx_AsteriasBiotherapeuticsMember]" onclick="toggleNextSibling(this);">67.50%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_MinorityInterestOwnershipPercentageByParent<br>/ dei_LegalEntityAxis<br>= btx_AsteriasBiotherapeuticsMember</span><span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=btx_BiotimeAsiaLimitedMember', window );">BioTime Asia, Limited [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestLineItems', window );"><strong>Noncontrolling Interest [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByParent', window );">BioTime Ownership (in hundredths)</a></td>
        <td class="nump"><a title="us-gaap_MinorityInterestOwnershipPercentageByParent[dei_LegalEntityAxis=btx_BiotimeAsiaLimitedMember]" onclick="toggleNextSibling(this);">81.00%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_MinorityInterestOwnershipPercentageByParent<br>/ dei_LegalEntityAxis<br>= btx_BiotimeAsiaLimitedMember</span><span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=btx_CellCureNeurosciencesLtdMember', window );">Cell Cure Neurosciences, Ltd. [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestLineItems', window );"><strong>Noncontrolling Interest [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByParent', window );">BioTime Ownership (in hundredths)</a></td>
        <td class="nump"><a title="us-gaap_MinorityInterestOwnershipPercentageByParent[dei_LegalEntityAxis=btx_CellCureNeurosciencesLtdMember]" onclick="toggleNextSibling(this);">62.50%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_MinorityInterestOwnershipPercentageByParent<br>/ dei_LegalEntityAxis<br>= btx_CellCureNeurosciencesLtdMember</span><span></span></td>
        <td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=btx_EsCellInternationalPteLtdMember', window );">ES Cell International Pte., Ltd. [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestLineItems', window );"><strong>Noncontrolling Interest [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByParent', window );">BioTime Ownership (in hundredths)</a></td>
        <td class="nump"><a title="us-gaap_MinorityInterestOwnershipPercentageByParent[dei_LegalEntityAxis=btx_EsCellInternationalPteLtdMember]" onclick="toggleNextSibling(this);">100.00%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_MinorityInterestOwnershipPercentageByParent<br>/ dei_LegalEntityAxis<br>= btx_EsCellInternationalPteLtdMember</span><span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=btx_LifemapSciencesIncMember', window );">LifeMap Sciences, Inc. [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestLineItems', window );"><strong>Noncontrolling Interest [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByParent', window );">BioTime Ownership (in hundredths)</a></td>
        <td class="nump"><a title="us-gaap_MinorityInterestOwnershipPercentageByParent[dei_LegalEntityAxis=btx_LifemapSciencesIncMember]" onclick="toggleNextSibling(this);">75.80%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_MinorityInterestOwnershipPercentageByParent<br>/ dei_LegalEntityAxis<br>= btx_LifemapSciencesIncMember</span><span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=btx_LifemapSciencesLtdMember', window );">LifeMap Sciences, Ltd. [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestLineItems', window );"><strong>Noncontrolling Interest [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByParent', window );">BioTime Ownership (in hundredths)</a></td>
        <td class="nump"><a title="us-gaap_MinorityInterestOwnershipPercentageByParent[dei_LegalEntityAxis=btx_LifemapSciencesLtdMember]" onclick="toggleNextSibling(this);">0.00%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_MinorityInterestOwnershipPercentageByParent<br>/ dei_LegalEntityAxis<br>= btx_LifemapSciencesLtdMember</span><span></span></td>
        <td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=btx_LifemapSolutionsIncMember', window );">LifeMap Solutions, Inc. [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestLineItems', window );"><strong>Noncontrolling Interest [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByParent', window );">BioTime Ownership (in hundredths)</a></td>
        <td class="nump"><a title="us-gaap_MinorityInterestOwnershipPercentageByParent[dei_LegalEntityAxis=btx_LifemapSolutionsIncMember]" onclick="toggleNextSibling(this);">0.00%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_MinorityInterestOwnershipPercentageByParent<br>/ dei_LegalEntityAxis<br>= btx_LifemapSolutionsIncMember</span><span></span></td>
        <td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=btx_OncocyteCorporationMember', window );">OncoCyte Corporation [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestLineItems', window );"><strong>Noncontrolling Interest [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByParent', window );">BioTime Ownership (in hundredths)</a></td>
        <td class="nump"><a title="us-gaap_MinorityInterestOwnershipPercentageByParent[dei_LegalEntityAxis=btx_OncocyteCorporationMember]" onclick="toggleNextSibling(this);">75.30%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_MinorityInterestOwnershipPercentageByParent<br>/ dei_LegalEntityAxis<br>= btx_OncocyteCorporationMember</span><span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=btx_OrthocyteCorporationMember', window );">OrthoCyte Corporation [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestLineItems', window );"><strong>Noncontrolling Interest [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByParent', window );">BioTime Ownership (in hundredths)</a></td>
        <td class="nump"><a title="us-gaap_MinorityInterestOwnershipPercentageByParent[dei_LegalEntityAxis=btx_OrthocyteCorporationMember]" onclick="toggleNextSibling(this);">100.00%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_MinorityInterestOwnershipPercentageByParent<br>/ dei_LegalEntityAxis<br>= btx_OrthocyteCorporationMember</span><span></span></td>
        <td class="fn" style="border-bottom: 0px;"><sup>[3]</sup></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=btx_RecyteTherapeuticsIncMember', window );">ReCyte Therapeutics, Inc. [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestLineItems', window );"><strong>Noncontrolling Interest [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByParent', window );">BioTime Ownership (in hundredths)</a></td>
        <td class="nump"><a title="us-gaap_MinorityInterestOwnershipPercentageByParent[dei_LegalEntityAxis=btx_RecyteTherapeuticsIncMember]" onclick="toggleNextSibling(this);">94.80%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_MinorityInterestOwnershipPercentageByParent<br>/ dei_LegalEntityAxis<br>= btx_RecyteTherapeuticsIncMember</span><span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr>
        <td colspan="6"></td>
      </tr>
      <tr>
        <td colspan="6">
          <table class="outerFootnotes" width="100%">
            <tr class="outerFootnote">
              <td style="vertical-align: top;" valign="top">[1]</td>
              <td style="vertical-align: top;" valign="top">Includes shares owned by BioTime, Asterias, and ESI.</td>
            </tr>
            <tr class="outerFootnote">
              <td style="vertical-align: top;" valign="top">[2]</td>
              <td style="vertical-align: top;" valign="top">LifeMap Sciences, Ltd. and LifeMap Solutions, Inc. are wholly-owned subsidiaries of LifeMap Sciences, Inc.</td>
            </tr>
            <tr class="outerFootnote">
              <td style="vertical-align: top;" valign="top">[3]</td>
              <td style="vertical-align: top;" valign="top">Includes shares owned by BioTime and Asterias.</td>
            </tr>
          </table>
        </td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Capital">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of total capital as defined in the regulations.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 948<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6490092&amp;loc=d3e47304-110998<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 942<br><br> -SubTopic 505<br><br> -Section 50<br><br> -Paragraph 1H<br><br> -Subparagraph (c)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35709795&amp;loc=d3e65071-112826<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 942<br><br> -SubTopic 505<br><br> -Section 50<br><br> -Paragraph 1H<br><br> -Subparagraph (c)(2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35709795&amp;loc=d3e65071-112826<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 948<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -Subparagraph (c)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6490092&amp;loc=d3e47080-110998<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_Capital</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Cash<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Cash Equivalents<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 1<br><br> -Article 5<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 1<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3044-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_MinorityInterestLineItems</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestOwnershipPercentageByParent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The parent entity's interest in net assets of the subsidiary, expressed as a percentage.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_MinorityInterestOwnershipPercentageByParent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 31<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.31(a)(3))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 15<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7656940&amp;loc=SL4568447-111683<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 16<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7656940&amp;loc=SL4568740-111683<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -Section 55<br><br> -Paragraph 4I<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35736750&amp;loc=SL4590271-111686<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=btx_AsteriasBiotherapeuticsMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">dei_LegalEntityAxis=btx_AsteriasBiotherapeuticsMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=btx_BiotimeAsiaLimitedMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">dei_LegalEntityAxis=btx_BiotimeAsiaLimitedMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=btx_CellCureNeurosciencesLtdMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">dei_LegalEntityAxis=btx_CellCureNeurosciencesLtdMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=btx_EsCellInternationalPteLtdMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">dei_LegalEntityAxis=btx_EsCellInternationalPteLtdMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=btx_LifemapSciencesIncMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">dei_LegalEntityAxis=btx_LifemapSciencesIncMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=btx_LifemapSciencesLtdMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">dei_LegalEntityAxis=btx_LifemapSciencesLtdMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=btx_LifemapSolutionsIncMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">dei_LegalEntityAxis=btx_LifemapSolutionsIncMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=btx_OncocyteCorporationMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">dei_LegalEntityAxis=btx_OncocyteCorporationMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=btx_OrthocyteCorporationMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">dei_LegalEntityAxis=btx_OrthocyteCorporationMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=btx_RecyteTherapeuticsIncMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">dei_LegalEntityAxis=btx_RecyteTherapeuticsIncMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_ParentMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_ParentMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Inventory<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2015</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">Inventory</a></td>
        <td class="text"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="text-align: justify;"><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 100%;"><tr><td style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 18pt; vertical-align: top; font-weight: bold; align: right;">3.</td><td style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: auto; vertical-align: top; font-weight: bold; text-align: justify;">Inventory</td></tr></table></div><div style="text-align: justify;"><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; text-indent: 36pt;">BioTime held $286,513 and $253,227 of inventory of finished products on-site at its corporate headquarters in Alameda, California at March 31, 2015 and December 31, 2014, respectively. Finished goods products of $12,795 were held by a third party on consignment at March 31, 2015 and December 31, 2014.</div></div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for inventory. This may include, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the major classes of inventory, and the nature of the cost elements included in inventory. If inventory is stated above cost, accrued net losses on firm purchase commitments for inventory and losses resulting from valuing inventory at the lower-of-cost-or-market may also be included. For LIFO inventory, may disclose the amount and basis for determining the excess of replacement or current cost over stated LIFO value and the effects of a LIFO quantities liquidation that impacts net income.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.6)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 6<br><br> -Subparagraph a, b, c<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>16
<FILENAME>Financial_Report.xls
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xls
M[[N_34E-12U697)S:6]N.B`Q+C`-"E@M1&]C=6UE;G0M5'EP93H@5V]R:V)O
M;VL-"D-O;G1E;G0M5'EP93H@;75L=&EP87)T+W)E;&%T960[(&)O=6YD87)Y
M/2(M+2TM/5].97AT4&%R=%\S.3AB8C$R8E]E.&-A7S1B-V%?.&9A,%\R-C,Y
M9&8U83@Y,3`B#0H-"E1H:7,@9&]C=6UE;G0@:7,@82!3:6YG;&4@1FEL92!7
M96(@4&%G92P@86QS;R!K;F]W;B!A<R!A(%=E8B!!<F-H:79E(&9I;&4N("!)
M9B!Y;W4@87)E('-E96EN9R!T:&ES(&UE<W-A9V4L('EO=7(@8G)O=W-E<B!O
M<B!E9&ET;W(@9&]E<VXG="!S=7!P;W)T(%=E8B!!<F-H:79E(&9I;&5S+B`@
M4&QE87-E(&1O=VYL;V%D(&$@8G)O=W-E<B!T:&%T('-U<'!O<G1S(%=E8B!!
M<F-H:79E+"!S=6-H(&%S($UI8W)O<V]F="!);G1E<FYE="!%>'!L;W)E<BX-
M"@T*+2TM+2TM/5].97AT4&%R=%\S.3AB8C$R8E]E.&-A7S1B-V%?.&9A,%\R
M-C,Y9&8U83@Y,3`-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO,SDX
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M;V9T+6-O;3IO9F9I8V4Z97AC96PB('AM;&YS/3-$(FAT='`Z+R]W=W<N=S,N
M;W)G+U12+U)%0RUH=&UL-#`B/@T*/&AE860^#0H\;65T82!N86UE/3-$(D5X
M8V5L(%=O<FMB;V]K($9R86UE<V5T(CX-"@T*/&UE=&$@;F%M93TS1%!R;V=)
M9"!C;VYT96YT/3-$17AC96PN4VAE970^#0H\;&EN:R!R96P],T1&:6QE+4QI
M<W0@:')E9CTS1")7;W)K<VAE971S+V9I;&5L:7-T+GAM;"(^#0H-"CPA+2U;
M:68@9W1E(&US;R`Y73X\>&UL/@T*(#QX.D5X8V5L5V]R:V)O;VL^#0H@(#QX
M.D5X8V5L5V]R:W-H965T<SX-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@
M(#QX.DYA;64^1&]C=6UE;G1?86YD7T5N=&ET>5]);F9O<FUA=&EO/"]X.DYA
M;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T
M<R]3:&5E=#`Q+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@
M(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^0T].1$5.4T5$7T-/
M3E-/3$E$051%1%]"04Q!3D-%/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T
M4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#`R+FAT;6PB+SX-"B`@
M(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*
M("`@(#QX.DYA;64^0T].1$5.4T5$7T-/3E-/3$E$051%1%]"04Q!3D-%,3PO
M>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS
M:&5E=',O4VAE970P,RYH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^
M#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/D-/3D1%3E-%
M1%]#3TY33TQ)1$%4141?4U1!5$5-13PO>#I.86UE/@T*("`@(#QX.E=O<FMS
M:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970P-"YH=&UL(B\^
M#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E
M=#X-"B`@("`\>#I.86UE/D-/3D1%3E-%1%]#3TY33TQ)1$%4141?4U1!5$5-
M13$\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7
M;W)K<VAE971S+U-H965T,#4N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H
M965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y#3TY$
M14Y3141?0T].4T],241!5$5$7U-4051%344R/"]X.DYA;64^#0H@("`@/'@Z
M5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#`V+FAT
M;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R
M:W-H965T/@T*("`@(#QX.DYA;64^3W)G86YI>F%T:6]N7T)A<VES7V]F7U!R
M97-E;G1A/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968]
M,T0B5V]R:W-H965T<R]3:&5E=#`W+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O
M<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^
M4W5M;6%R>5]O9E]3:6=N:69I8V%N=%]!8V-O=6YT/"]X.DYA;64^#0H@("`@
M/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#`X
M+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L
M5V]R:W-H965T/@T*("`@(#QX.DYA;64^26YV96YT;W)Y/"]X.DYA;64^#0H@
M("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E
M=#`Y+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X
M8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^17%U:7!M96YT7VYE=%]A;F1?
M8V]N<W1R=6-T:6]N/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E
M($A2968],T0B5V]R:W-H965T<R]3:&5E=#$P+FAT;6PB+SX-"B`@(#PO>#I%
M>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX
M.DYA;64^26YT86YG:6)L95]A<W-E='-?;F5T/"]X.DYA;64^#0H@("`@/'@Z
M5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#$Q+FAT
M;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R
M:W-H965T/@T*("`@(#QX.DYA;64^4F]Y86QT>5]/8FQI9V%T:6]N7V%N9%]$
M969E<G)E/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968]
M,T0B5V]R:W-H965T<R]3:&5E=#$R+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O
M<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^
M06-C;W5N='-?4&%Y86)L95]A;F1?06-C<G5E9%],/"]X.DYA;64^#0H@("`@
M/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#$S
M+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L
M5V]R:W-H965T/@T*("`@(#QX.DYA;64^4F5L871E9%]087)T>5]4<F%N<V%C
M=&EO;G-?86YD/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2
M968],T0B5V]R:W-H965T<R]3:&5E=#$T+FAT;6PB+SX-"B`@(#PO>#I%>&-E
M;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA
M;64^4VAA<F5H;VQD97)S7T5Q=6ET>3PO>#I.86UE/@T*("`@(#QX.E=O<FMS
M:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970Q-2YH=&UL(B\^
M#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E
M=#X-"B`@("`\>#I.86UE/E-A;&5S7V]F7T)I;U1I;65?0V]M;6]N7U-H87)E
M<SPO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O
M<FMS:&5E=',O4VAE970Q-BYH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE
M970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/E-E9VUE
M;G1?26YF;W)M871I;VX\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R
M8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T,3<N:'1M;"(O/@T*("`@/"]X
M.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@
M/'@Z3F%M93Y3=6)S97%U96YT7T5V96YT<SPO>#I.86UE/@T*("`@(#QX.E=O
M<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970Q."YH=&UL
M(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS
M:&5E=#X-"B`@("`\>#I.86UE/E-U;6UA<GE?;V9?4VEG;FEF:6-A;G1?06-C
M;W5N=#$\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS
M1")7;W)K<VAE971S+U-H965T,3DN:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R
M:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y/
M<F=A;FEZ871I;VY?0F%S:7-?;V9?4')E<V5N=&$Q/"]X.DYA;64^#0H@("`@
M/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#(P
M+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L
M5V]R:W-H965T/@T*("`@(#QX.DYA;64^17%U:7!M96YT7VYE=%]A;F1?8V]N
M<W1R=6-T:6]N,3PO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(
M4F5F/3-$(E=O<FMS:&5E=',O4VAE970R,2YH=&UL(B\^#0H@("`\+W@Z17AC
M96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.
M86UE/DEN=&%N9VEB;&5?87-S971S7VYE=%]486)L97,\+W@Z3F%M93X-"B`@
M("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T
M,C(N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC
M96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y2;WEA;'1Y7T]B;&EG871I;VY?
M86YD7T1E9F5R<F4Q/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E
M($A2968],T0B5V]R:W-H965T<R]3:&5E=#(S+FAT;6PB+SX-"B`@(#PO>#I%
M>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX
M.DYA;64^06-C;W5N='-?4&%Y86)L95]A;F1?06-C<G5E9%],,3PO>#I.86UE
M/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O
M4VAE970R-"YH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\
M>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/D]R9V%N:7IA=&EO;E]"
M87-I<U]O9E]0<F5S96YT83(\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713
M;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T,C4N:'1M;"(O/@T*("`@
M/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@
M("`@/'@Z3F%M93Y3=6UM87)Y7V]F7U-I9VYI9FEC86YT7T%C8V]U;G0R/"]X
M.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H
M965T<R]3:&5E=#(V+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-
M"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^26YV96YT;W)Y
M7T1E=&%I;',\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E
M9CTS1")7;W)K<VAE971S+U-H965T,C<N:'1M;"(O/@T*("`@/"]X.D5X8V5L
M5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M
M93Y%<75I<&UE;G1?;F5T7V%N9%]C;VYS=')U8W1I;VXR/"]X.DYA;64^#0H@
M("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E
M=#(X+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X
M8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^26YT86YG:6)L95]A<W-E='-?
M;F5T7T1E=&%I;',\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@
M2%)E9CTS1")7;W)K<VAE971S+U-H965T,CDN:'1M;"(O/@T*("`@/"]X.D5X
M8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z
M3F%M93Y2;WEA;'1Y7T]B;&EG871I;VY?86YD7T1E9F5R<F4R/"]X.DYA;64^
M#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3
M:&5E=#,P+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX
M.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^06-C;W5N='-?4&%Y86)L
M95]A;F1?06-C<G5E9%],,CPO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O
M=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970S,2YH=&UL(B\^#0H@("`\
M+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@
M("`\>#I.86UE/E)E;&%T961?4&%R='E?5')A;G-A8W1I;VYS7V%N9#$\+W@Z
M3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE
M971S+U-H965T,S(N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*
M("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y3:&%R96AO;&1E
M<G-?17%U:71Y7T1E=&%I;',\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713
M;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T,S,N:'1M;"(O/@T*("`@
M/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@
M("`@/'@Z3F%M93Y386QE<U]O9E]":6]4:6UE7T-O;6UO;E]3:&%R97,Q/"]X
M.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H
M965T<R]3:&5E=#,T+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-
M"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^4V5G;65N=%])
M;F9O<FUA=&EO;E]$971A:6QS/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T
M4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#,U+FAT;6PB+SX-"B`@
M(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*
M("`@(#QX.DYA;64^4W5B<V5Q=65N=%]%=F5N='-?1&5T86EL<SPO>#I.86UE
M/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O
M4VAE970S-BYH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@(#PO
M>#I%>&-E;%=O<FMS:&5E=',^#0H@(#QX.E-T>6QE<VAE970@2%)E9CTS1")7
M;W)K<VAE971S+W)E<&]R="YC<W,B+SX-"B`@/'@Z06-T:79E4VAE970^,#PO
M>#I!8W1I=F53:&5E=#X-"B`@/'@Z4')O=&5C=%-T<G5C='5R93Y&86QS93PO
M>#I0<F]T96-T4W1R=6-T=7)E/@T*("`\>#I0<F]T96-T5VEN9&]W<SY&86QS
M93PO>#I0<F]T96-T5VEN9&]W<SX-"B`\+W@Z17AC96Q7;W)K8F]O:SX-"CPO
M>&UL/CPA6V5N9&EF72TM/@T*/"]H96%D/@T*("`\8F]D>3X-"B`@(#QP/E1H
M:7,@<&%G92!S:&]U;&0@8F4@;W!E;F5D('=I=&@@36EC<F]S;V9T($5X8V5L
M(%A0(&]R(&YE=V5R+CPO<#X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM
M+2T]7TYE>'1087)T7S,Y.&)B,3)B7V4X8V%?-&(W85\X9F$P7S(V,SED9C5A
M.#DQ,`T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B\S.3AB8C$R8E]E
M.&-A7S1B-V%?.&9A,%\R-C,Y9&8U83@Y,3`O5V]R:W-H965T<R]3:&5E=#`Q
M+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN
M=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA
M<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U
M:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S
M970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,]
M,T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S
M8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R
M97!O<G0@:60],T1)1#!%,4=!13X-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY$
M;V-U;65N="!A;F0@16YT:71Y($EN9F]R;6%T:6]N/&)R/CPO<W1R;VYG/CPO
M=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C,@36]N
M=&AS($5N9&5D/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A
M;CTS1#$^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1H/DUA<BX@,S$L(#(P,34\8G(^/"]T:#X-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&@^36%Y(#`Q+"`R,#$U/&)R/CPO=&@^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D1O8W5M96YT(&%N9"!%
M;G1I='D@26YF;W)M871I;VX@6T%B<W1R86-T73PO<W1R;VYG/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%;G1I='D@4F5G:7-T<F%N="!.
M86UE/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#Y"24]424U%($E.
M0SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^16YT:71Y($-E;G1R86P@26YD97@@2V5Y/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XP,#`P.#<V,S0S/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#=7)R96YT($9I<V-A;"!996%R
M($5N9"!$871E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XM+3$R
M+3,Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y%;G1I='D@5V5L;"UK;F]W;B!396%S;VYE9"!)<W-U97(\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/DYO/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%;G1I='D@5F]L=6YT87)Y
M($9I;&5R<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^3F\\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5N
M=&ET>2!#=7)R96YT(%)E<&]R=&EN9R!3=&%T=7,\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/EEE<SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^16YT:71Y($9I;&5R($-A=&5G;W)Y/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#Y!8V-E;&5R871E9"!&:6QE
M<CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^16YT:71Y($-O;6UO;B!3=&]C:RP@4VAA<F5S($]U='-T86YD:6YG/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XX,RPR-C8L,34S/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y$;V-U
M;65N="!&:7-C86P@665A<B!&;V-U<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^,C`Q-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^1&]C=6UE;G0@1FES8V%L(%!E<FEO9"!&;V-U<SPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^43$\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D1O8W5M96YT(%1Y
M<&4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/C$P+5$\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%M96YD
M;65N="!&;&%G/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#YF86QS
M93QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^1&]C=6UE;G0@4&5R:6]D($5N9"!$871E/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#Y-87(@,S$L#0H)"3(P,34\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H
M=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7S,Y.&)B,3)B7V4X8V%?-&(W85\X
M9F$P7S(V,SED9C5A.#DQ,`T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#
M.B\S.3AB8C$R8E]E.&-A7S1B-V%?.&9A,%\R-C,Y9&8U83@Y,3`O5V]R:W-H
M965T<R]3:&5E=#`R+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z
M('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C
M:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-
M151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT
M+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V
M87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#
M;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B
M;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%3S%!1SX-"B`@("`@(#QT<CX-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS
M1#$^/'-T<F]N9SY#3TY$14Y3140@0T].4T],241!5$5$($)!3$%.0T4@4TA%
M1513("A5;F%U9&ET960I("A54T0@)"D\8G(^/"]S=')O;F<^/"]T:#X-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&@^36%R+B`S,2P@,C`Q-3QB<CX\+W1H/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$T/&)R/CPO=&@^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D-54E)%3E0@
M05-31513/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/D-A<V@@86YD(&-A<V@@97%U:79A;&5N=',\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/B0@,C4L.#(Y+#4S,SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,CDL-#@V+#DP.3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5')A
M9&4@86-C;W5N=',@86YD(&=R86YT<R!R96-E:79A8FQE+"!N970\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C@V-BPQ.#`\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#`T,2PX-38\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DEN
M=F5N=&]R>3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,CDY+#,P
M.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C(V-BPP,C(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/DQA;F1L;W)D(')E8V5I=F%B;&4\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C(W-RPR,#8\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XS-S<L.3@Q/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0<F5P86ED(&5X<&5N
M<V5S(&%N9"!O=&AE<B!C=7)R96YT(&%S<V5T<SPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,2PR-S$L.#DU/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PR,S$L-S@Y/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F5U/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5&]T86P@8W5R
M<F5N="!A<W-E=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(X
M+#4T-"PQ,C(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XS,BPT,#0L-34W/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y%<75I<&UE;G0L(&YE="!A;F0@8V]N<W1R
M=6-T:6]N(&EN('!R;V=R97-S("AS964@3F]T92`T*3PO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,BPX-C0L-C8Y/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,BPX-3<L.#0V/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y$969E<G)E
M9"!L:6-E;G-E(&%N9"!C;VYS=6QT:6YG(&9E97,\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C,P.2PT-3@\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XS,S8L.#,S/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y$97!O<VET<SPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-#0S+#`P,SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0T,RPR.#D\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D]T
M:&5R(&QO;F<M=&5R;2!A<W-E=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C<L.3$V/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^.2PY.#4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/DEN=&%N9VEB;&4@87-S971S+"!N970\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,W+#4S-"PS,#(\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS."PX-#@L
M,SDV/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F5U/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^5$]404P@05-31513/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XV.2PW,#,L-#<P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^-S0L.3`P+#DP-CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY#55)214Y4($Q)
M04))3$E42453/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/D%C8V]U;G1S('!A>6%B;&4@86YD(&%C8W)U960@;&EA8FEL:71I
M97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C8L,S(R+#0P-SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C8L
M.#`S+#$W,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^0V%P:71A;"!L96%S92!L:6%B:6QI='DL(&-U<G)E;G0@<&]R
M=&EO;CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-3<L-3`P/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-3<L
M-3`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y296QA=&5D('!A<G1Y(&-O;G9E<G1I8FQE(&1E8G0L(&YE="!O9B!D
M:7-C;W5N=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,38Y+#DP
M.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C8P+#(S-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^1&5F97)R960@9W)A;G0@:6YC;VUE/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XQ+#0W-"PS,#`\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y$969E<G)E9"!L:6-E;G-E
M(&%N9"!S=6)S8W)I<'1I;VX@<F5V96YU92P@8W5R<F5N="!P;W)T:6]N/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ-S@L-30V/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C`X+#,U-SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O=3X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/E1O=&%L(&-U<G)E;G0@;&EA8FEL:71I97,\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C@L,C`R+#8V,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C<L,3(Y+#(V-SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY,3TY'
M+51%4DT@3$E!0DE,251)15,\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^1&5F97)R960@=&%X(&QI86)I;&ET:65S+"!N970\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,L,S,W+#8V,CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0L-3$T
M+#,V,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^1&5F97)R960@<F5N="!L:6%B:6QI=&EE<RP@;F5T(&]F(&-U<G)E
M;G0@<&]R=&EO;CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,S0L
M.38W/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^.3<L,C@P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y,96%S92!L:6%B:6QI='D\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C4V,"PY-S`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XS-S<L.3@Q/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#87!I=&%L(&QE87-E+"!N
M970@;V8@8W5R<F5N="!P;W)T:6]N/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XQ-RPS,#<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XS,2PR.3`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/D]T:&5R(&QO;F<@=&5R;2!L:6%B:6QI
M=&EE<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,S@L,3$Y/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C<L
M.38Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F5U/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^5&]T86P@;&]N9RUT97)M(&QI86)I;&ET:65S/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XS+#DX.2PP,C4\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU+#`T."PX-S0\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-O;6UI
M=&UE;G1S(&%N9"!C;VYT:6YG96YC:65S/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XF;F)S<#LF;F)S<#L\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XF;F)S<#LF;F)S<#L\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^
M4TA!4D5(3TQ$15)3)R!%455)5%D\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^4V5R:65S($$@0V]N=F5R=&EB;&4@4')E9F5R
M<F5D('-H87)E<RP@;F\@<&%R('9A;'5E+"!A=71H;W)I>F5D(#(L,#`P+#`P
M,"!S:&%R97,@87,@;V8@36%R8V@@,S$L(#(P,34@86YD($1E8V5M8F5R(#,Q
M+"`R,#$T.R`W,"PP,#`@:7-S=65D(&%N9"!O=71S=&%N9&EN9R!A<R!O9B!-
M87)C:"`S,2P@,C`Q-2!A;F0@1&5C96UB97(@,S$L(#(P,30\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C,L-3`P+#`P,#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,L-3`P+#`P,#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V]M
M;6]N('-H87)E<RP@;F\@<&%R('9A;'5E+"!A=71H;W)I>F5D(#$R-2PP,#`L
M,#`P('-H87)E<R!A<R!O9B!-87)C:"`S,2P@,C`Q-2!A;F0@1&5C96UB97(@
M,S$L(#(P,30[(#@S+#(Q,"PW-S4@:7-S=65D(&%N9"`W."PS,38L.#,S(&]U
M='-T86YD:6YG(&%S(&]F($UA<F-H(#,Q+"`R,#$U(&%N9"`X,RPQ,C$L-CDX
M(&ES<W5E9"!A;F0@-S@L,C(W+#<U-B!O=71S=&%N9&EN9R!A="!$96-E;6)E
M<B`S,2P@,C`Q-#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C,T
M+#<U,2PX,#(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XR,S0L.#0R+#DY.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^0V]N=')I8G5T960@8V%P:71A;#PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-RPQ-#4\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XW+#$T-3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^06-C=6UU
M;&%T960@;W1H97(@8V]M<')E:&5N<VEV92!I;F-O;64\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C(S."PX,C`\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ.#4L.#,U/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!8V-U;75L871E
M9"!D969I8VET/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@Q.3(L
M,S4W+#4W-2D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M/B@Q.#(L,3DP+#(P-RD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/E1R96%S=7)Y('-T;V-K(&%T(&-O<W0Z
M(#0L.#DS+#DT,B!S:&%R97,@870@36%R8V@@,S$L(#(P,34@86YD(&%T($1E
M8V5M8F5R(#,Q+"`R,#$T/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M/B@Q.2PX.#DL-S@X*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6T^*#$Y+#@X.2PW.#@I/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F]U/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0FEO5&EM92P@26YC+B!S:&%R
M96AO;&1E<G,G(&5Q=6ET>3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,C8L,C4P+#0P-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C,V+#0U-2PY.#,\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYO;BUC;VYT<F]L;&EN9R!I;G1E
M<F5S=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,S$L,C8Q+#,X
M,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C(V+#(V-BPW.#(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R;W4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y4;W1A;"!S:&%R96AO;&1E<G,G(&5Q=6ET>3PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-3<L-3$Q+#<X-#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C8R+#<R,BPW
M-C4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R974^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y43U1!3"!,24%"24Q)5$E%4R!!3D0@4U1/0TM(3TQ$15)3)R!%455)
M5%D\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@-CDL-S`S+#0W
M,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/B0@-S0L.3`P+#DP-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?
M3F5X=%!A<G1?,SDX8F(Q,F)?93AC85\T8C=A7SAF83!?,C8S.61F-6$X.3$P
M#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+S,Y.&)B,3)B7V4X8V%?
M-&(W85\X9F$P7S(V,SED9C5A.#DQ,"]7;W)K<VAE971S+U-H965T,#,N:'1M
M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L
M90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI
M(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS
M1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU
M=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H
M;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP
M=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R
M="!I9#TS1$E$,$5"04%%/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,3X\<W1R;VYG/D-/3D1%
M3E-%1"!#3TY33TQ)1$%4140@0D%,04Y#12!32$5%5%,@*%5N875D:71E9"D@
M*%!A<F5N=&AE=&EC86PI("A54T0@)"D\8G(^/"]S=')O;F<^/"]T:#X-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&@^36%R+B`S,2P@,C`Q-3QB<CX\+W1H/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$T/&)R/CPO=&@^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/E-(05)%2$],
M1$524R<@15%52519/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/E-E<FEE<R!!($-O;G9E<G1I8FQE(%!R969E<G)E9"!3:&%R
M97,L('!A<B!V86QU92`H:6X@9&]L;&%R<R!P97(@<VAA<F4I/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#`\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#`\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-E<FEE<R!!($-O;G9E
M<G1I8FQE(%!R969E<G)E9"!3:&%R97,L(&%U=&AO<FEZ960@*&EN('-H87)E
M<RD\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(L,#`P+#`P,#QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(L
M,#`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^4V5R:65S($$@0V]N=F5R=&EB;&4@4')E9F5R<F5D(%-H87)E
M<RP@:7-S=65D("AI;B!S:&%R97,I/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XW,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XW,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-E<FEE<R!!($-O;G9E<G1I8FQE(%!R
M969E<G)E9"!S:&%R97,@;W5T<W1A;F1I;F<@*&EN('-H87)E<RD\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C<P+#`P,#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C<P+#`P,#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V]M;6]N
M('-H87)E<RP@<&%R('9A;'5E("AI;B!D;VQL87)S('!E<B!S:&%R92D\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,#QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V]M;6]N('-H
M87)E<RP@875T:&]R:7IE9"`H:6X@<VAA<F5S*3PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,3(U+#`P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,C4L,#`P+#`P,#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V]M;6]N
M('-H87)E<RP@:7-S=65D("AI;B!S:&%R97,I/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XX,RPR,3`L-S<U/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^.#,L,3(Q+#8Y.#QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V]M;6]N('-H
M87)E<RP@;W5T<W1A;F1I;F<@*&EN('-H87)E<RD\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C<X+#,Q-BPX,S,\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XW."PR,C<L-S4V/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y4<F5A<W5R
M>2!S=&]C:R`H:6X@<VAA<F5S*3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^-"PX.3,L.30R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^-"PX.3,L.30R/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-
M"@T*+2TM+2TM/5].97AT4&%R=%\S.3AB8C$R8E]E.&-A7S1B-V%?.&9A,%\R
M-C,Y9&8U83@Y,3`-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO,SDX
M8F(Q,F)?93AC85\T8C=A7SAF83!?,C8S.61F-6$X.3$P+U=O<FMS:&5E=',O
M4VAE970P-"YH=&UL#0I#;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T
M960M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E
M=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H
M='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL
M.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I
M<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N
M="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L
M87-S/3-$<F5P;W)T(&ED/3-$240P15HS044^#0H@("`@("`\='(^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS
M=')O;F<^0T].1$5.4T5$($-/3E-/3$E$051%1"!35$%414U%3E13($]&($]0
M15)!5$E/3E,@*%5.055$251%1"D@*%531"`D*3QB<CX\+W-T<F]N9SX\+W1H
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,CXS($UO;G1H
M<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T:#Y-87(N(#,Q+"`R,#$U/&)R/CPO=&@^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1H/DUA<BX@,S$L(#(P,30\8G(^/"]T:#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^4D5614Y515,Z/"]S
M=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DQI8V5N
M<V4@9F5E<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`S,3DL
M,30V/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^)"`R.30L-3`T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y2;WEA;'1I97,@9G)O;2!P<F]D=6-T('-A;&5S/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ-38L-34P/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^.3<L.#@V/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y'
M<F%N="!I;F-O;64\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C8Y
M."PX,SD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XU-S4L-C4Y/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y386QE(&]F(')E<V5A<F-H('!R;V1U8W1S(&%N9"!S
M97)V:6-E<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^.#DL.3$Y
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M.3@L-3@V/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F]U/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^5&]T86P@<F5V96YU97,\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C$L,C8T+#0U-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C$L,#8V+#8S-3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V]S="!O9B!S86QE<SPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,C8T+#$V-RD\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@Q,S$L.3$T
M*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O=3X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/D=R;W-S(%!R;V9I=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,2PP,#`L,C@W/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^.3,T+#<R,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY/4$52051)3D<@15A014Y3
M15,Z/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/E)E<V5A<F-H(&%N9"!D979E;&]P;65N=#PO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^.2PS,C,L-3$P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^."PT,#4L,SDS/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y'96YE<F%L(&%N9"!A
M9&UI;FES=')A=&EV93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M-2PQ-S@L.#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,RPV-C<L,3<Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F]U/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^5&]T86P@;W!E<F%T:6YG(&5X<&5N<V5S
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ-"PU,#(L,S$P/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3(L
M,#<R+#4V-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E=3X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/DQO<W,@9G)O;2!O<&5R871I;VYS/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M/B@Q,RPU,#(L,#(S*3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#$Q+#$S-RPX-#,I/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R
M;VYG/D]42$52($E.0T]-12\H15A014Y315,I.CPO<W1R;VYG/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y);G1E<F5S="!E>'!E;G-E+"!N
M970\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#(U+#0V,2D\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@X+#,X
M-"D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/D]T:&5R(&EN8V]M92\H97AP96YS92DL(&YE=#PO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;3XH,C,Y+#0U,RD\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XV.2PQ-S`\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R974^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y4;W1A;"!O=&AE
M<B!I;F-O;64O*&5X<&5N<V5S*2P@;F5T/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M/B@R-C0L.3$T*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C8P+#<X-CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O=3X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DQ/4U,@0D5&3U)%($E.0T]-
M12!405@@0D5.149)5%,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^
M*#$S+#<V-BPY,S<I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;3XH,3$L,#<W+#`U-RD\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D1E9F5R<F5D(&EN8V]M92!T87@@
M8F5N969I=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PQ-S8L
M.#@R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,2PS-#DL,#(V/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F]U/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^3D54($Q/4U,\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6T^*#$R+#4Y,"PP-34I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;3XH.2PW,C@L,#,Q*3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3F5T(&QO<W,@871T
M<FEB=71A8FQE('1O(&YO;BUC;VYT<F]L;&EN9R!I;G1E<F5S=#PO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,BPT,C(L-C@W/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PV,CDL,#$W/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.
M150@3$]34R!!5%1224)55$%"3$4@5$\@0DE/5$E-12P@24Y#+CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;3XD("@Q,"PQ-C<L,S8X*3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^)"`H."PP.3DL
M,#$T*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^0D%324,@04Y$($1)3%54140@3D54($Q/4U,@4$52($-/34U/3B!3
M2$%212`H:6X@9&]L;&%R<R!P97(@<VAA<F4I/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M/B0@*#`N,3,I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;3XD("@P+C$T*3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5T5)1TA4140@059%4D%'
M12!.54U"15(@3T8@0T]-34].(%-43T-+($]55%-404Y$24Y'.B!"05-)0R!!
M3D0@1$E,551%1"`H:6X@<VAA<F5S*3PO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^-S@L,C8Q+#<X.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C4X+#(U-RPT,C<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H
M=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7S,Y.&)B,3)B7V4X8V%?-&(W85\X
M9F$P7S(V,SED9C5A.#DQ,`T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#
M.B\S.3AB8C$R8E]E.&-A7S1B-V%?.&9A,%\R-C,Y9&8U83@Y,3`O5V]R:W-H
M965T<R]3:&5E=#`U+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z
M('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C
M:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-
M151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT
M+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V
M87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#
M;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B
M;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%1DQ!0SX-"B`@("`@(#QT<CX-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS
M1#(^/'-T<F]N9SY#3TY$14Y3140@0T].4T],241!5$5$(%-4051%345.5%,@
M3T8@0T]-4%)%2$5.4TE612!,3U-3("A53D%51$E4140I("A54T0@)"D\8G(^
M/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A
M;CTS1#(^,R!-;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^36%R+B`S,2P@,C`Q-3QB
M<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y-87(N(#,Q+"`R,#$T
M/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG
M/D-/3D1%3E-%1"!#3TY33TQ)1$%4140@4U1!5$5-14Y44R!/1B!#3TU04D5(
M14Y3259%($Q/4U,@*%5.055$251%1"D@6T%B<W1R86-T73PO<W1R;VYG/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.150@3$]34SPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XD("@Q,BPU.3`L,#4U*3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^)"`H.2PW
M,C@L,#,Q*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^/'-T<F]N9SY#:&%N9V4@:6X@9F]R96EG;B!C=7)R96YC>2!T
M<F%N<VQA=&EO;B!A;F0@;W1H97(@8V]M<')E:&5N<VEV92!I;F-O;64O*&QO
M<W,I(&9R;VT@97%U:71Y(&EN=F5S=&UE;G1S.CPO<W1R;VYG/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y5;G)E86QI>F5D(&QO<W,@;VX@
M97AC:&%N9V4@=')A;G-L871I;VX@:6X@9F]R96EN9R!S=6)S:61I87)I97,\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#4S+#,R,RD\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@Q,#0L-3DP
M*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^56YR96%L:7IE9"!G86EN+RAL;W-S*2!O;B!A=F%I;&%B;&4M9F]R+7-A
M;&4@<V5C=7)I=&EE<RP@;F5T(&]F('1A>&5S/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XS,S@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M/B@R+#8U,"D\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;W4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#3TU04D5(14Y3259%($Q/4U,\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#$R+#8T,RPP-#`I/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH.2PX
M,S4L,C<Q*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^3&5S<SH@0V]M<')E:&5N<VEV92!L;W-S(&%T=')I8G5T86)L
M92!T;R!N;VXM8V]N=')O;&QI;F<@:6YT97)E<W0\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C(L-#(R+#8X-SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L-C(Y+#`Q-SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0T]-4%)%2$5.
M4TE612!,3U-3($%45%))0E5404),12!43R!"24]424U%+"!)3D,N($-/34U/
M3B!32$%214A/3$1%4E,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^
M)"`H,3`L,C(P+#,U,RD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M/B0@*#@L,C`V+#(U-"D\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL
M/@T*#0HM+2TM+2T]7TYE>'1087)T7S,Y.&)B,3)B7V4X8V%?-&(W85\X9F$P
M7S(V,SED9C5A.#DQ,`T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B\S
M.3AB8C$R8E]E.&-A7S1B-V%?.&9A,%\R-C,Y9&8U83@Y,3`O5V]R:W-H965T
M<R]3:&5E=#`V+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U
M;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R
M<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!
M(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT
M;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C
M<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM
M96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@
M8VQA<W,],T1R97!O<G0@:60],T1)1#!%04Q"1SX-"B`@("`@(#QT<CX-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^
M/'-T<F]N9SY#3TY$14Y3140@0T].4T],241!5$5$(%-4051%345.5%,@3T8@
M0T%32"!&3$]74R`H54Y!541)5$5$*2`H55-$("0I/&)R/CPO<W1R;VYG/CPO
M=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0R/C,@36]N
M=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1H/DUA<BX@,S$L(#(P,34\8G(^/"]T:#X-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&@^36%R+B`S,2P@,C`Q-#QB<CX\+W1H/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY#05-(($9,3U=3
M($923TT@3U!%4D%424Y'($%#5$E6251)15,Z/"]S=')O;F<^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYE="!L;W-S(&%T=')I8G5T86)L
M92!T;R!":6]4:6UE+"!);F,N/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M/B0@*#$P+#$V-RPS-C@I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;3XD("@X+#`Y.2PP,30I/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.970@;&]S<R!A='1R
M:6)U=&%B;&4@=&\@;F]N+6-O;G1R;VQL:6YG(&EN=&5R97-T/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M/B@R+#0R,BPV.#<I/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,2PV,CDL,#$W*3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M/'-T<F]N9SY!9&IU<W1M96YT<R!T;R!R96-O;F-I;&4@;F5T(&QO<W,@871T
M<FEB=71A8FQE('1O($)I;U1I;64L($EN8RX@=&\@;F5T(&-A<V@@=7-E9"!I
M;B!O<&5R871I;F<@86-T:79I=&EE<SH\+W-T<F]N9SX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^1&5P<F5C:6%T:6]N(&5X<&5N<V4\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(V,BPV,#`\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR-38L.30U/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!
M;6]R=&EZ871I;VX@;V8@:6YT86YG:6)L92!A<W-E=',\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C$L,S$T+#`Y-#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L,S8W+#DY.#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^06UO<G1I
M>F%T:6]N(&]F(&1E9F5R<F5D(&-O;G-U;'1I;F<@9F5E<SPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C$V+#(W.3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^06UO<G1I>F%T:6]N(&]F
M(&1E9F5R<F5D(&QI8V5N<V4@9F5E<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,C<L,S<U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,C<L,S<U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!;6]R=&EZ871I;VX@;V8@9&5F97)R
M960@;&EC96YS92P@<F]Y86QT>2!A;F0@<W5B<V-R:7!T:6]N(')E=F5N=65S
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,C@P*3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^06UO<G1I
M>F%T:6]N(&]F('!R97!A:60@<F5N="!I;B!C;VUM;VX@<W1O8VL\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(Q+#$T-CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(Q+#$T-CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4W1O8VLM
M8F%S960@8V]M<&5N<V%T:6]N/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XQ+#DQ-"PT,#<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XX,#$L-34T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!;6]R=&EZ871I;VX@;V8@9&ES8V]U
M;G0@;VX@<F5L871E9"!P87)T>2!C;VYV97)T:6)L92!D96)T/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XT.2PV.3<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!8V-R=65D(&EN=&5R
M97-T(&]N(&-O;G9E<G1I8FQE(&1E8G0\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C,L-3,Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^3&]S<R!O;B!S86QE(&]R('=R:71E+6]F9B!O
M9B!E<75I<&UE;G0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XX
M+#4W-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^1&5F97)R960@:6YC;VUE('1A>"!B96YE9FET/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M/B@Q+#$W-BPX.#(I/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,2PS-#DL,#(V*3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1&5F
M97)R960@9W)A;G0@:6YC;VUE/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XQ+#0W-"PS,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D-H86YG97,@:6X@;W!E<F%T:6YG
M(&%S<V5T<R!A;F0@;&EA8FEL:71I97,Z/"]S=')O;F<^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%C8V]U;G1S(')E8V5I=F%B;&4L(&YE
M=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH-38L-3DX*3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#(T+#0T
M,2D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/D=R86YT(')E8V5I=F%B;&4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C(R."PQ.3$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XR,#(L,3(R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y);G9E;G1O<GD\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6T^*#,S+#(X-BD\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@U-RPX.30I/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0<F5P86ED(&5X
M<&5N<V5S(&%N9"!O=&AE<B!C=7)R96YT(&%S<V5T<SPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;3XH-C`L-S8Y*3QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#,W-2PR,C0I/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!8V-O=6YT<R!P
M87EA8FQE(&%N9"!A8V-R=65D(&QI86)I;&ET:65S/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M/B@S-C4L,3<U*3QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#$L,C<V+#(Q,2D\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D]T:&5R(&QO
M;F<@=&5R;2!L:6%B:6QI=&EE<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,3`L-S(W/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;3XH,3@U+#<Q-RD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/D1E9F5R<F5D(')E;G0@;&EA8FEL:71I
M97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#8R+#,Q,RD\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@U+#`T
M,"D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/D1E9F5R<F5D(')E=F5N=65S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M/B@R.2PX,3$I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;3XH-3<L-#`R*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O=3X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYE="!C87-H('5S960@:6X@;W!E
M<F%T:6YG(&%C=&EV:71I97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6T^*#DL,#8X+#@R,2D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M/B@Q,"PS-3<L,C<Q*3QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY#05-(($9,3U=3
M($923TT@24Y615-424Y'($%#5$E6251)15,Z/"]S=')O;F<^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!U<F-H87-E(&]F(&5Q=6EP;65N
M=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH-S<L,#`W*3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#(S,2PY
M,C$I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y087EM96YT<R!O;B!C;VYS=')U8W1I;VX@:6X@<')O9W)E<W,@*'-E
M92!.;W1E(#0I/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@R.38L
M,S@R*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/E!R;V-E961S(&9R;VT@=&AE('-A;&4@;V8@97%U:7!M96YT/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-"PP,#`\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-E8W5R:71Y
M(&1E<&]S:70@<&%I9"P@;F5T/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;3XH,CDY+#8Y-RD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R;W4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y#87-H('5S960@:6X@:6YV97-T:6YG(&%C=&EV
M:71I97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#,W,RPS.#DI
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH
M-3(W+#8Q."D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/CQS=')O;F<^0T%32"!&3$]74R!&4D]-($9)3D%.0TE.1R!!
M0U1)5DE42453.CPO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y0<F]C965D<R!F<F]M(&5X97)C:7-E<R!O9B!S=&]C:R!O<'1I
M;VYS/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS-#8L-S$S/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-3@L
M-3`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y0<F]C965D<R!F<F]M('-A;&4@;V8@<')E9F5R<F5D('-T;V-K/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,RPU,#`L,#`P/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0<F]C
M965D<R!F<F]M(&ES<W5A;F-E(&]F(&-O;6UO;B!S:&%R97,\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XX+#$X,BPU-3D\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D9E97,@<&%I9"!O
M;B!S86QE(&]F(&-O;6UO;B!S=&]C:SPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6T^*#(Q,BPP-#8I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y0<F]C965D<R!F<F]M('-A;&4@;V8@=')E
M87-U<GD@<W1O8VL@86YD('-U8G-I9&EA<GD@=V%R<F%N=',\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XU.3DL-#<R/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y296EM8G5R<V5M96YT
M(&9R;VT@;&%N9&QO<F0@;VX@8V]N<W1R=6-T:6]N(&EN('!R;V=R97-S("AS
M964@3F]T92`T*3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C@S
M+#<V-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/E)E<&%Y;65N="!O9B!C87!I=&%L(&QE87-E(&]B;&EG871I;VX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#$S+#DX,RD\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0<F]C
M965D<R!F<F]M('-A;&4@;V8@8V]M;6]N('-H87)E<R!O9B!S=6)S:61I87)Y
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU+#0Y.2PY.34\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y&
M965S('!A:60@;VX@<V%L92!O9B!C;VUM;VX@<VAA<F5S(&]F('-U8G-I9&EA
M<GD\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#0S,BPV,S$I/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,#QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')E=3X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/DYE="!C87-H('!R;W9I9&5D(&)Y(&9I;F%N8VEN9R!A8W1I=FET:65S/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU+#8X,RPX-3@\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,BPQ,C@L
M-#@U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y%9F9E8W0@;V8@97AC:&%N9V4@<F%T92!C:&%N9V5S(&]N(&-A<V@@
M86YD(&-A<V@@97%U:79A;&5N=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C$P,"PY-S8\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M/B@Q,#$L,C0P*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E=3X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DY%5"!#2$%.1T4@24X@0T%32"!!
M3D0@0T%32"!%455)5D%,14Y44SH\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6T^*#,L-C4W+#,W-BD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XQ+#$T,BPS-38\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^0T%32"!!3D0@
M0T%32"!%455)5D%,14Y44SH\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^070@8F5G:6YN:6YG(&]F('1H92!P97)I;V0\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(Y+#0X-BPY,#D\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU+#0Y-2PT
M-S@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/D%T(&5N9"!O9B!T:&4@<&5R:6]D/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XD(#(U+#@R.2PU,S,\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#8L-C,W+#@S-#QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^
M#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?,SDX8F(Q,F)?93AC85\T
M8C=A7SAF83!?,C8S.61F-6$X.3$P#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE
M.B\O+T,Z+S,Y.&)B,3)B7V4X8V%?-&(W85\X9F$P7S(V,SED9C5A.#DQ,"]7
M;W)K<VAE971S+U-H965T,#<N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O
M9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT
M;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@
M("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$
M)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X
M="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4
M:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@
M(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5-13X-"B`@("`@(#QT
M<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A
M;CTS1#(^/'-T<F]N9SY/<F=A;FEZ871I;VXL($)A<VES(&]F(%!R97-E;G1A
M=&EO;BP@86YD($QI<75I9&ET>3QB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XS($UO;G1H<R!%;F1E9#PO
M=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T:#Y-87(N(#,Q+"`R,#$U/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#X\<W1R;VYG/D]R9V%N:7IA=&EO;BP@0F%S:7,@;V8@
M4')E<V5N=&%T:6]N+"!A;F0@3&EQ=6ED:71Y(%M!8G-T<F%C=%T\+W-T<F]N
M9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3W)G86YI>F%T
M:6]N+"!"87-I<R!O9B!0<F5S96YT871I;VXL(&%N9"!,:7%U:61I='D\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQD:78@<W1Y;&4],T0G9F]N
M="UF86UI;'DZ("=4:6UE<R!.97<@4F]M86XG+"!4:6UE<RP@<V5R:68[(&9O
M;G0M<VEZ93H@,3!P=#LG/CQD:78@<W1Y;&4],T0G=&5X="UA;&EG;CH@:G5S
M=&EF>3LG/CQT86)L92!C96QL<&%D9&EN9STS1#`@8V5L;'-P86-I;F<],T0P
M(&-L87-S/3-$1%-01DQI<W1486)L92!S='EL93TS1"=F;VYT+7-I>F4Z(#$P
M<'0[(&9O;G0M9F%M:6QY.B`G5&EM97,@3F5W(%)O;6%N)RP@5&EM97,L('-E
M<FEF.R!W:61T:#H@,3`P)3LG/CQT<CX\=&0@<W1Y;&4],T0G9F]N="US:7IE
M.B`Q,'!T.R!F;VYT+69A;6EL>3H@)U1I;65S($YE=R!2;VUA;B<L(%1I;65S
M+"!S97)I9CL@=VED=&@Z(#$X<'0[('9E<G1I8V%L+6%L:6=N.B!T;W`[(&9O
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M=B!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G5&EM
M97,@3F5W(%)O;6%N)RP@5&EM97,L('-E<FEF.R!T97AT+6%L:6=N.B!J=7-T
M:69Y.R!M87)G:6XM;&5F=#H@,"XQ<'0[(&UA<F=I;BUR:6=H=#H@,"XQ<'0[
M('1E>'0M:6YD96YT.B`S-G!T.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE
M.B`Q,'!T.R!F;VYT+69A;6EL>3H@)U1I;65S($YE=R!2;VUA;B<L(%1I;65S
M+"!S97)I9CL@9F]N="US='EL93H@:71A;&EC.R<^1V5N97)A;"`F(S@R,3$[
M(#PO9F]N=#X\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M
M9F%M:6QY.B`G5&EM97,@3F5W(%)O;6%N)RP@5&EM97,L('-E<FEF.R<^0FEO
M5&EM92!I<R!A(&)I;W1E8VAN;VQO9WD@8V]M<&%N>2!F;V-U<V5D(&]N('1H
M92!F:65L9"!O9B!R96=E;F5R871I=F4@;65D:6-I;F4[('-P96-I9FEC86QL
M>2!H=6UA;B!E;6)R>6]N:6,@<W1E;2`H)B,X,C(P.VA%4R8C.#(R,3LI(&-E
M;&P@86YD(&EN9'5C960@<&QU<FEP;W1E;G0@<W1E;2`H)B,X,C(P.VE04R8C
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M:6UA<GD@=&AE<F%P975T:6,@<')O9'5C=',@87)E(&)A<V5D(&]N(&ET<R`\
M+V9O;G0^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A
M;6EL>3H@)U1I;65S($YE=R!2;VUA;B<L(%1I;65S+"!S97)I9CL@9F]N="US
M='EL93H@:71A;&EC.R<^2'E3=&5M/"]F;VYT/CQS=7`@<W1Y;&4],T0G9F]N
M="US:7IE.B!S;6%L;&5R.R!V97)T:6-A;"UA;&EG;CH@=&5X="UT;W`[(&QI
M;F4M:&5I9VAT.B`Q.R<^)B,Q-S0[/"]S=7`^/&9O;G0@<W1Y;&4],T0G9F]N
M="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)U1I;65S($YE=R!2;VUA;B<L
M(%1I;65S+"!S97)I9CLG/B!H>61R;V=E;"!T96-H;F]L;V=Y(&%N9"!I;F-L
M=61E(#PO9F]N=#X\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O
M;G0M9F%M:6QY.B`G5&EM97,@3F5W(%)O;6%N)RP@5&EM97,L('-E<FEF.R!F
M;VYT+7-T>6QE.B!I=&%L:6,[)SY296YE=FEA/"]F;VYT/CQF;VYT('-T>6QE
M/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=4:6UE<R!.97<@
M4F]M86XG+"!4:6UE<RP@<V5R:68[)SXF(S@T.#([(&$@<')O9'5C="!C=7)R
M96YT;'D@:6X@8VQI;FEC86P@=')I86QS(&EN($5U<F]P92!T;R!F86-I;&ET
M871E(&-E;&P@=')A;G-P;&%N=&%T:6]N.R`\+V9O;G0^/&9O;G0@<W1Y;&4]
M,T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)U1I;65S($YE=R!2
M;VUA;B<L(%1I;65S+"!S97)I9CL@9F]N="US='EL93H@:71A;&EC.R<^4F5'
M;'ED93PO9F]N=#X\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O
M;G0M9F%M:6QY.B`G5&EM97,@3F5W(%)O;6%N)RP@5&EM97,L('-E<FEF.R<^
M)B,X-#@R.R!A('!R;V1U8W0@=6YD97(@9&5V96QO<&UE;G0@9F]R('1E;F1O
M;B!S=7)G97)Y(&%P<&QI8V%T:6]N<SL@86YD(#PO9F]N=#X\9F]N="!S='EL
M93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G5&EM97,@3F5W
M(%)O;6%N)RP@5&EM97,L('-E<FEF.R!F;VYT+7-T>6QE.B!I=&%L:6,[)SY0
M<F5M=FEA/"]F;VYT/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@
M9F]N="UF86UI;'DZ("=4:6UE<R!.97<@4F]M86XG+"!4:6UE<RP@<V5R:68[
M)SXF(S@T.#([(&9O<B!W:&EC:"`U,3`H:RD@8V5R=&EF:6-A=&EO;B!H87,@
M8F5E;B!R96-E:79E9"!F;W(@=7-E(&EN('=O=6YD+6UA;F%G96UE;G0N($%S
M=&5R:6%S($)I;W1H97)A<&5U=&EC<RP@26YC+B`H)B,X,C(P.T%S=&5R:6%S
M+"8C.#(R,3L@/"]F;VYT/DY94T4@34M4.B!!4U0\9F]N="!S='EL93TS1"=F
M;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G5&EM97,@3F5W(%)O;6%N
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M86YC97(N($53($-E;&P@26YT97)N871I;VYA;"!0=&4@3'1D+B`H)B,X,C(P
M.T53228C.#(R,3LI+"!A(%-I;F=A<&]R92!P<FEV871E(&QI;6ET960@8V]M
M<&%N>2P@:7,@<')O=FED:6YG(&ET<R!.871I;VYA;"!);G-T:71U=&5S(&]F
M($AE86QT:"`H)B,X,C(P.TY)2"8C.#(R,3LI(&%P<')O=F5D(&A%4R!C96QL
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M22!"24\\+V9O;G0^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F
M;VYT+69A;6EL>3H@)U1I;65S($YE=R!2;VUA;B<L(%1I;65S+"!S97)I9CLG
M/B!D:79I<VEO;BX@3W)T:&]#>71E($-O<G!O<F%T:6]N("@F(S@R,C`[3W)T
M:&]#>71E)B,X,C(Q.RD@:7,@9&5V96QO<&EN9R!T:&5R87!I97,@=&\@=')E
M870@;W)T:&]P961I8R!D:7-O<F1E<G,L(&1I<V5A<V5S(&%N9"!I;FIU<FEE
M<RX@4F5#>71E(%1H97)A<&5U=&EC<RP@26YC+B`H)B,X,C(P.U)E0WET92!4
M:&5R87!E=71I8W,F(S@R,C$[*2!I<R!D979E;&]P:6YG('1H97)A<&EE<R!T
M;R!T<F5A="!A('9A<FEE='D@;V8@8V%R9&EO=F%S8W5L87(@86YD(')E;&%T
M960@:7-C:&5M:6,@9&ES;W)D97)S+"!A<R!W96QL(&%S(')E;&%T960@<')O
M9'5C=',@9F]R(')E<V5A<F-H+B!#96QL($-U<F4@3F5U<F]S8VEE;F-E<R!,
M=&0N("@F(S@R,C`[0V5L;"!#=7)E($YE=7)O<V-I96YC97,F(S@R,C$[*2!I
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M;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)U1I
M;65S($YE=R!2;VUA;B<L(%1I;65S+"!S97)I9CLG/B!D:79I<VEO;BX@3&EF
M94UA<"!38VEE;F-E<RP@26YC+B`H)B,X,C(P.TQI9F5-87`@4V-I96YC97,F
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M=61E<R`\+V9O;G0^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F
M;VYT+69A;6EL>3H@)U1I;65S($YE=R!2;VUA;B<L(%1I;65S+"!S97)I9CL@
M9F]N="US='EL93H@:71A;&EC.R<^1V5N94-A<F1S/"]F;VYT/CQS=7`@<W1Y
M;&4],T0G9F]N="US:7IE.B!S;6%L;&5R.R!V97)T:6-A;"UA;&EG;CH@=&5X
M="UT;W`[(&QI;F4M:&5I9VAT.B`Q.R<^)B,Q-S0[/"]S=7`^/&9O;G0@<W1Y
M;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)U1I;65S($YE
M=R!2;VUA;B<L(%1I;65S+"!S97)I9CLG/BP@=&AE(#PO9F]N=#X\9F]N="!S
M='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G5&EM97,@
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M<'0[(&9O;G0M9F%M:6QY.B`G5&EM97,@3F5W(%)O;6%N)RP@5&EM97,L('-E
M<FEF.R!F;VYT+7-T>6QE.B!I=&%L:6,[)SY-86QA0V%R9',\+V9O;G0^/&9O
M;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)U1I
M;65S($YE=R!2;VUA;B<L(%1I;65S+"!S97)I9CLG/B8C.#0X,CLL('1H92!H
M=6UA;B!D:7-E87-E(&1A=&%B87-E+"!A;F0@=&AE(&%N86QY<VES('1O;VQS
M(#PO9F]N=#X\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M
M9F%M:6QY.B`G5&EM97,@3F5W(%)O;6%N)RP@5&EM97,L('-E<FEF.R!F;VYT
M+7-T>6QE.B!I=&%L:6,[)SY687)%;&5C=#PO9F]N=#X\9F]N="!S='EL93TS
M1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G5&EM97,@3F5W(%)O
M;6%N)RP@5&EM97,L('-E<FEF.R<^)B,X-#@R.RP@82!P;W=E<F9U;"P@>65T
M(&5A<WDM=&\M=7-E(&%P<&QI8V%T:6]N(&9O<B!P<FEO<FET:7II;F<@9V5N
M92!V87)I86YT<R!R97-U;'1I;F<@9G)O;2!N97AT(&=E;F5R871I;VX@<V5Q
M=65N8VEN9R!E>'!E<FEM96YT<RP@86YD(#PO9F]N=#X\9F]N="!S='EL93TS
M1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G5&EM97,@3F5W(%)O
M;6%N)RP@5&EM97,L('-E<FEF.R!F;VYT+7-T>6QE.B!I=&%L:6,[)SY'96YE
M06YA;'ET:6-S/"]F;VYT/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P
M=#L@9F]N="UF86UI;'DZ("=4:6UE<R!.97<@4F]M86XG+"!4:6UE<RP@<V5R
M:68[)SXF(S@T.#([+"!A(&YO=F5L(&=E;F4@<V5T(&%N86QY<VES('1O;VPN
M($QI9F5-87`@4V-I96YC97,F(S@R,3<[('-U8G-I9&EA<GD@3&EF94UA<"!3
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M(#$P<'0[(&9O;G0M9F%M:6QY.B`G5&EM97,@3F5W(%)O;6%N)RP@5&EM97,L
M('-E<FEF.R!T97AT+6%L:6=N.B!J=7-T:69Y.R!M87)G:6XM;&5F=#H@,"XQ
M<'0[(&UA<F=I;BUR:6=H=#H@,"XQ<'0[('1E>'0M:6YD96YT.B`S-G!T.R<^
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M:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)U1I;65S($YE=R!2;VUA;B<L(%1I
M;65S+"!S97)I9CL@9F]N="US='EL93H@:71A;&EC.R<^15-)($))3SPO9F]N
M=#X@9&EV:7-I;VXN(%!R;V1U8W1S(&9O<B!T:&4@<F5S96%R8V@@;6%R:V5T
M(&=E;F5R86QL>2!C86X@8F4@<V]L9"!W:71H;W5T(')E9W5L871O<GD@*%5N
M:71E9"!3=&%T97,@1F]O9"!A;F0@1')U9R!!9&UI;FES=')A=&EO;B`H)B,X
M,C(P.T9$028C.#(R,3LI*2!A<'!R;W9A;"P@86YD(&%R92!T:&5R969O<F4@
M<F5L871I=F5L>2!N96%R+71E<FT@8G5S:6YE<W,@;W!P;W)T=6YI=&EE<R!W
M:&5N(&-O;7!A<F5D('1O('1H97)A<&5U=&EC('!R;V1U8W1S+CPO9&EV/CQD
M:78^/&)R("\^/"]D:78^/&1I=B!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[
M(&9O;G0M9F%M:6QY.B`G5&EM97,@3F5W(%)O;6%N)RP@5&EM97,L('-E<FEF
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M('1E>'0M:6YD96YT.B`S-G!T.R<^5&AE('5N875D:71E9"!C;VYD96YS960@
M8V]N<V]L:61A=&5D(&EN=&5R:6T@8F%L86YC92!S:&5E="!A<R!O9B!-87)C
M:"`S,2P@,C`Q-2P@=&AE('5N875D:71E9"!C;VYD96YS960@8V]N<V]L:61A
M=&5D(&EN=&5R:6T@<W1A=&5M96YT<R!O9B!O<&5R871I;VYS(&%N9"!S=&%T
M96UE;G1S(&]F(&-O;7!R96AE;G-I=F4@;&]S<R!F;W(@=&AE('1H<F5E(&UO
M;G1H<R!E;F1E9"!-87)C:"`S,2P@,C`Q-2!A;F0@,C`Q-"P@86YD('1H92!U
M;F%U9&ET960@8V]N9&5N<V5D(&-O;G-O;&ED871E9"!I;G1E<FEM('-T871E
M;65N=',@;V8@8V%S:"!F;&]W<R!F;W(@=&AE('1H<F5E(&UO;G1H<R!E;F1E
M9"!-87)C:"`S,2P@,C`Q-2!A;F0@,C`Q-"!H879E(&)E96X@<')E<&%R960@
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M+"!A;F0@8V%S:"!F;&]W<R!A="!-87)C:"`S,2P@,C`Q-2!H879E(&)E96X@
M;6%D92X@5&AE(&-O;G-O;&ED871E9"!B86QA;F-E('-H965T(&%S(&]F($1E
M8V5M8F5R(#,Q+"`R,#$T(&ES(&1E<FEV960@9G)O;2!T:&4@0V]M<&%N>28C
M.#(Q-SMS(&%N;G5A;"!A=61I=&5D(&9I;F%N8VEA;"!S=&%T96UE;G1S(&%S
M(&]F('1H870@9&%T92X@5&AE(')E<W5L=',@;V8@;W!E<F%T:6]N<R!F;W(@
M=&AE('1H<F5E(&UO;G1H<R!E;F1E9"!-87)C:"`S,2P@,C`Q-2!A<F4@;F]T
M(&YE8V5S<V%R:6QY(&EN9&EC871I=F4@;V8@=&AE(&]P97)A=&EN9R!R97-U
M;'1S(&%N=&EC:7!A=&5D(&9O<B!T:&4@9G5L;"!Y96%R(&]F(#(P,34N/"]D
M:78^/&1I=CX\8G(@+SX\+V1I=CX\9&EV('-T>6QE/3-$)V9O;G0M<VEZ93H@
M,3!P=#L@9F]N="UF86UI;'DZ("=4:6UE<R!.97<@4F]M86XG+"!4:6UE<RP@
M<V5R:68[('1E>'0M86QI9VXZ(&IU<W1I9GD[('1E>'0M:6YD96YT.B`S-G!T
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M;6ES<VEO;B`H)B,X,C(P.U-%0R8C.#(R,3LI(&5X8V5P="!F;W(@=&AE(&-O
M;G-O;&ED871E9"!B86QA;F-E('-H965T(&%S(&]F($1E8V5M8F5R(#,Q+"`R
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M;W)M(#$P+4L@9F]R('1H92!Y96%R(&5N9&5D($1E8V5M8F5R(#,Q+"`R,#$T
M+CPO9&EV/CQD:78@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A
M;6EL>3H@)U1I;65S($YE=R!2;VUA;B<L(%1I;65S+"!S97)I9CL@=&5X="UA
M;&EG;CH@:G5S=&EF>3L@=&5X="UI;F1E;G0Z(#,V<'0[)SXF(S$V,#L\+V1I
M=CX\9&EV('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ
M("=4:6UE<R!.97<@4F]M86XG+"!4:6UE<RP@<V5R:68[('1E>'0M86QI9VXZ
M(&IU<W1I9GD[('1E>'0M:6YD96YT.B`S-G!T.R<^/&9O;G0@<W1Y;&4],T0G
M9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)U1I;65S($YE=R!2;VUA
M;B<L(%1I;65S+"!S97)I9CL@9F]N="US='EL93H@:71A;&EC.R<^57-E(&]F
M(&5S=&EM871E<SPO9F]N=#X@)B,X,C$Q.R!4:&4@<')E<&%R871I;VX@;V8@
M8V]N<V]L:61A=&5D(&9I;F%N8VEA;"!S=&%T96UE;G1S(&EN(&-O;F9O<FUI
M='D@=VET:"!A8V-O=6YT:6YG('!R:6YC:7!L97,@9V5N97)A;&QY(&%C8V5P
M=&5D(&EN('1H92!5+E,N("@B1T%!4"(I(')E<75I<F5S(&UA;F%G96UE;G0@
M=&\@;6%K92!E<W1I;6%T97,@86YD(&%S<W5M<'1I;VYS('1H870@869F96-T
M('1H92!R97!O<G1E9"!A;6]U;G1S(&]F(&%S<V5T<R!A;F0@;&EA8FEL:71I
M97,@86YD(&1I<V-L;W-U<F4@;V8@8V]N=&EN9V5N="!A<W-E=',@86YD(&QI
M86)I;&ET:65S(&%T('1H92!D871E(&]F('1H92!C;VYS;VQI9&%T960@9FEN
M86YC:6%L('-T871E;65N=',@86YD('1H92!R97!O<G1E9"!A;6]U;G1S(&]F
M(')E=F5N=65S(&%N9"!E>'!E;G-E<R!D=7)I;F<@=&AE(')E<&]R=&EN9R!P
M97)I;V0N($%C='5A;"!R97-U;'1S(&-O=6QD(&1I9F9E<B!F<F]M('1H;W-E
M(&5S=&EM871E<RX\+V1I=CX\9&EV/CQB<B`O/CPO9&EV/CQD:78@<W1Y;&4]
M,T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)U1I;65S($YE=R!2
M;VUA;B<L(%1I;65S+"!S97)I9CL@=&5X="UA;&EG;CH@:G5S=&EF>3L@=&5X
M="UI;F1E;G0Z(#,V<'0[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P
M<'0[(&9O;G0M9F%M:6QY.B`G5&EM97,@3F5W(%)O;6%N)RP@5&EM97,L('-E
M<FEF.R!F;VYT+7-T>6QE.B!I=&%L:6,[)SY0<FEN8VEP;&5S(&]F(&-O;G-O
M;&ED871I;VX\+V9O;G0^("8C.#(Q,3L@0FEO5&EM928C.#(Q-SMS(&-O;G-O
M;&ED871E9"!F:6YA;F-I86P@<W1A=&5M96YT<R!I;F-L=61E('1H92!A8V-O
M=6YT<R!O9B!I=',@<W5B<VED:6%R:65S+B!4:&4@9F]L;&]W:6YG('1A8FQE
M(')E9FQE8W1S($)I;U1I;64F(S@R,3<[<R!O=VYE<G-H:7`L(&1I<F5C=&QY
M(&]R('1H<F]U9V@@;VYE(&]R(&UO<F4@<W5B<VED:6%R:65S+"!O9B!T:&4@
M;W5T<W1A;F1I;F<@<VAA<F5S(&]F(&ET<R!S=6)S:61I87)I97,@87,@;V8@
M36%R8V@@,S$L(#(P,34N/"]D:78^/&1I=CX\8G(@+SX\+V1I=CX\=&%B;&4@
M8F]R9&5R/3-$,"!C96QL<&%D9&EN9STS1#`@8V5L;'-P86-I;F<],T0P('-T
M>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=4:6UE<R!.
M97<@4F]M86XG+"!4:6UE<RP@<V5R:68[('=I9'1H.B`Q,#`E.R!B;W)D97(M
M8V]L;&%P<V4Z(&-O;&QA<'-E.R<^/'1R/CQT9"!S='EL93TS1"=B;W)D97(M
M=&]P.B`C,#`P,#`P(#)P>"!S;VQI9#L@=VED=&@Z(#(S+C(X)3L@=F5R=&EC
M86PM86QI9VXZ('1O<#L@8F]R9&5R+6QE9G0Z(",P,#`P,#`@,G!X('-O;&ED
M.R<^/&1I=B!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]D
M:78^/&1I=B!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY
M.B`G5&EM97,@3F5W(%)O;6%N)RP@5&EM97,L('-E<FEF.R!F;VYT+7=E:6=H
M=#H@8F]L9#L@=&5X="UA;&EG;CH@8V5N=&5R.R<^4W5B<VED:6%R>3PO9&EV
M/CPO=&0^/'1D('-T>6QE/3-$)V)O<F1E<BUT;W`Z(",P,#`P,#`@,G!X('-O
M;&ED.R!W:61T:#H@-3<E.R!V97)T:6-A;"UA;&EG;CH@=&]P.R!B;W)D97(M
M;&5F=#H@(S`P,#`P,"`R<'@@<V]L:60[)SX\9&EV('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+V1I=CX\9&EV('-T>6QE/3-$)V9O;G0M
M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=4:6UE<R!.97<@4F]M86XG+"!4
M:6UE<RP@<V5R:68[(&9O;G0M=V5I9VAT.B!B;VQD.R!T97AT+6%L:6=N.B!C
M96YT97([)SY&:65L9"!O9B!"=7-I;F5S<SPO9&EV/CPO=&0^/'1D('-T>6QE
M/3-$)V)O<F1E<BUT;W`Z(",P,#`P,#`@,G!X('-O;&ED.R!W:61T:#H@,3`E
M.R!V97)T:6-A;"UA;&EG;CH@=&]P.R!B;W)D97(M;&5F=#H@(S`P,#`P,"`R
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M<VAI<#PO9&EV/CPO=&0^/'1D('-T>6QE/3-$)V)O<F1E<BUT;W`Z(",P,#`P
M,#`@,G!X('-O;&ED.R!B;W)D97(M<FEG:'0Z(",P,#`P,#`@,G!X('-O;&ED
M.R!W:61T:#H@,3`E.R!V97)T:6-A;"UA;&EG;CH@=&]P.R!B;W)D97(M;&5F
M=#H@(S`P,#`P,"`R<'@@<V]L:60[)SX\9&EV('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(&QE9G0[)SXF(S$V,#L\+V1I=CX\9&EV('-T>6QE/3-$)V9O;G0M<VEZ
M93H@,3!P=#L@9F]N="UF86UI;'DZ("=4:6UE<R!.97<@4F]M86XG+"!4:6UE
M<RP@<V5R:68[(&9O;G0M=V5I9VAT.B!B;VQD.R!T97AT+6%L:6=N.B!C96YT
M97([)SY#;W5N=')Y/"]D:78^/"]T9#X\+W1R/CQT<CX\=&0@<W1Y;&4],T0G
M8F]R9&5R+71O<#H@(S`P,#`P,"`R<'@@<V]L:60[('=I9'1H.B`R,RXR."4[
M('9E<G1I8V%L+6%L:6=N.B!T;W`[(&)O<F1E<BUL969T.B`C,#`P,#`P(#)P
M>"!S;VQI9#L@8F%C:V=R;W5N9"UC;VQO<CH@(V-C965F9CLG/CQD:78@<W1Y
M;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)U1I;65S($YE
M=R!2;VUA;B<L(%1I;65S+"!S97)I9CL@=&5X="UA;&EG;CH@;&5F=#L@;6%R
M9VEN+6QE9G0Z(#<N-W!T.R!T97AT+6EN9&5N=#H@+3<N-W!T.R<^/&9O;G0@
M<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)U1I;65S
M($YE=R!2;VUA;B<L(%1I;65S+"!S97)I9CLG/D%S=&5R:6%S($)I;W1H97)A
M<&5U=&EC<RP@26YC+B`H/"]F;VYT/DY94T4@34M4.B!!4U0I/"]D:78^/"]T
M9#X\=&0@<W1Y;&4],T0G8F]R9&5R+71O<#H@(S`P,#`P,"`R<'@@<V]L:60[
M('=I9'1H.B`U-R4[('9E<G1I8V%L+6%L:6=N.B!T;W`[(&)O<F1E<BUL969T
M.B`C,#`P,#`P(#)P>"!S;VQI9#L@8F%C:V=R;W5N9"UC;VQO<CH@(V-C965F
M9CLG/CQD:78@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL
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M1"=B;W)D97(M=&]P.B`C,#`P,#`P(#)P>"!S;VQI9#L@=VED=&@Z(#$P)3L@
M=F5R=&EC86PM86QI9VXZ('1O<#L@8F]R9&5R+6QE9G0Z(",P,#`P,#`@,G!X
M('-O;&ED.R!B86-K9W)O=6YD+6-O;&]R.B`C8V-E969F.R<^/&1I=B!S='EL
M93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G5&EM97,@3F5W
M(%)O;6%N)RP@5&EM97,L('-E<FEF.R!T97AT+6%L:6=N.B!C96YT97([)SXV
M-RXU)3PO9&EV/CPO=&0^/'1D('-T>6QE/3-$)V)O<F1E<BUT;W`Z(",P,#`P
M,#`@,G!X('-O;&ED.R!B;W)D97(M<FEG:'0Z(",P,#`P,#`@,G!X('-O;&ED
M.R!W:61T:#H@,3`E.R!V97)T:6-A;"UA;&EG;CH@=&]P.R!B;W)D97(M;&5F
M=#H@(S`P,#`P,"`R<'@@<V]L:60[(&)A8VMG<F]U;F0M8V]L;W(Z("-C8V5E
M9F8[)SX\9&EV('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI
M;'DZ("=4:6UE<R!.97<@4F]M86XG+"!4:6UE<RP@<V5R:68[('1E>'0M86QI
M9VXZ(&-E;G1E<CLG/E5303PO9&EV/CPO=&0^/"]T<CX\='(^/'1D('-T>6QE
M/3-$)V)O<F1E<BUT;W`Z(",P,#`P,#`@,G!X('-O;&ED.R!W:61T:#H@,C,N
M,C@E.R!V97)T:6-A;"UA;&EG;CH@=&]P.R!B;W)D97(M;&5F=#H@(S`P,#`P
M,"`R<'@@<V]L:60[(&)A8VMG<F]U;F0M8V]L;W(Z("-F9F9F9F8[)SX\9&EV
M('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=4:6UE
M<R!.97<@4F]M86XG+"!4:6UE<RP@<V5R:68[('1E>'0M86QI9VXZ(&QE9G0[
M(&UA<F=I;BUL969T.B`W+C=P=#L@=&5X="UI;F1E;G0Z("TW+C=P=#LG/D)I
M;U1I;64@07-I82P@3&EM:71E9#PO9&EV/CPO=&0^/'1D('-T>6QE/3-$)V)O
M<F1E<BUT;W`Z(",P,#`P,#`@,G!X('-O;&ED.R!W:61T:#H@-3<E.R!V97)T
M:6-A;"UA;&EG;CH@=&]P.R!B;W)D97(M;&5F=#H@(S`P,#`P,"`R<'@@<V]L
M:60[(&)A8VMG<F]U;F0M8V]L;W(Z("-F9F9F9F8[)SX\9&EV('-T>6QE/3-$
M)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=4:6UE<R!.97<@4F]M
M86XG+"!4:6UE<RP@<V5R:68[('1E>'0M86QI9VXZ(&QE9G0[)SY3=&5M(&-E
M;&P@<')O9'5C=',@9F]R(')E<V5A<F-H/"]D:78^/"]T9#X\=&0@<W1Y;&4]
M,T0G8F]R9&5R+71O<#H@(S`P,#`P,"`R<'@@<V]L:60[('=I9'1H.B`Q,"4[
M('9E<G1I8V%L+6%L:6=N.B!T;W`[(&)O<F1E<BUL969T.B`C,#`P,#`P(#)P
M>"!S;VQI9#L@8F%C:V=R;W5N9"UC;VQO<CH@(V9F9F9F9CLG/CQD:78@<W1Y
M;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)U1I;65S($YE
M=R!2;VUA;B<L(%1I;65S+"!S97)I9CL@=&5X="UA;&EG;CH@8V5N=&5R.R<^
M.#$E/"]D:78^/"]T9#X\=&0@<W1Y;&4],T0G8F]R9&5R+71O<#H@(S`P,#`P
M,"`R<'@@<V]L:60[(&)O<F1E<BUR:6=H=#H@(S`P,#`P,"`R<'@@<V]L:60[
M('=I9'1H.B`Q,"4[('9E<G1I8V%L+6%L:6=N.B!T;W`[(&)O<F1E<BUL969T
M.B`C,#`P,#`P(#)P>"!S;VQI9#L@8F%C:V=R;W5N9"UC;VQO<CH@(V9F9F9F
M9CLG/CQD:78@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL
M>3H@)U1I;65S($YE=R!2;VUA;B<L(%1I;65S+"!S97)I9CL@=&5X="UA;&EG
M;CH@8V5N=&5R.R<^2&]N9R!+;VYG/"]D:78^/"]T9#X\+W1R/CQT<CX\=&0@
M<W1Y;&4],T0G8F]R9&5R+71O<#H@(S`P,#`P,"`R<'@@<V]L:60[('=I9'1H
M.B`R,RXR."4[('9E<G1I8V%L+6%L:6=N.B!T;W`[(&)O<F1E<BUL969T.B`C
M,#`P,#`P(#)P>"!S;VQI9#L@8F%C:V=R;W5N9"UC;VQO<CH@(V-C965F9CLG
M/CQD:78@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@
M)U1I;65S($YE=R!2;VUA;B<L(%1I;65S+"!S97)I9CL@=&5X="UA;&EG;CH@
M;&5F=#L@;6%R9VEN+6QE9G0Z(#<N-W!T.R!T97AT+6EN9&5N=#H@+3<N-W!T
M.R<^0V5L;"!#=7)E($YE=7)O<V-I96YC97,@3'1D+CPO9&EV/CPO=&0^/'1D
M('-T>6QE/3-$)V)O<F1E<BUT;W`Z(",P,#`P,#`@,G!X('-O;&ED.R!W:61T
M:#H@-3<E.R!V97)T:6-A;"UA;&EG;CH@=&]P.R!B;W)D97(M;&5F=#H@(S`P
M,#`P,"`R<'@@<V]L:60[(&)A8VMG<F]U;F0M8V]L;W(Z("-C8V5E9F8[)SX\
M9&EV('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=4
M:6UE<R!.97<@4F]M86XG+"!4:6UE<RP@<V5R:68[('1E>'0M86QI9VXZ(&QE
M9G0[)SY!9V4M<F5L871E9"!M86-U;&%R(&1E9V5N97)A=&EO;CPO9&EV/CPO
M=&0^/'1D('-T>6QE/3-$)V)O<F1E<BUT;W`Z(",P,#`P,#`@,G!X('-O;&ED
M.R!W:61T:#H@,3`E.R!V97)T:6-A;"UA;&EG;CH@=&]P.R!B;W)D97(M;&5F
M=#H@(S`P,#`P,"`R<'@@<V]L:60[(&)A8VMG<F]U;F0M8V]L;W(Z("-C8V5E
M9F8[)SX\9&EV('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI
M;'DZ("=4:6UE<R!.97<@4F]M86XG+"!4:6UE<RP@<V5R:68[('1E>'0M86QI
M9VXZ(&-E;G1E<CLG/C8R+C4E*#$I/"]D:78^/"]T9#X\=&0@<W1Y;&4],T0G
M8F]R9&5R+71O<#H@(S`P,#`P,"`R<'@@<V]L:60[(&)O<F1E<BUR:6=H=#H@
M(S`P,#`P,"`R<'@@<V]L:60[('=I9'1H.B`Q,"4[('9E<G1I8V%L+6%L:6=N
M.B!T;W`[(&)O<F1E<BUL969T.B`C,#`P,#`P(#)P>"!S;VQI9#L@8F%C:V=R
M;W5N9"UC;VQO<CH@(V-C965F9CLG/CQD:78@<W1Y;&4],T0G9F]N="US:7IE
M.B`Q,'!T.R!F;VYT+69A;6EL>3H@)U1I;65S($YE=R!2;VUA;B<L(%1I;65S
M+"!S97)I9CL@=&5X="UA;&EG;CH@8V5N=&5R.R<^27-R865L/"]D:78^/"]T
M9#X\+W1R/CQT<CX\=&0@<W1Y;&4],T0G8F]R9&5R+71O<#H@(S`P,#`P,"`R
M<'@@<V]L:60[('=I9'1H.B`R,RXR."4[('9E<G1I8V%L+6%L:6=N.B!T;W`[
M(&)O<F1E<BUL969T.B`C,#`P,#`P(#)P>"!S;VQI9#L@8F%C:V=R;W5N9"UC
M;VQO<CH@(V9F9F9F9CLG/CQD:78@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T
M.R!F;VYT+69A;6EL>3H@)U1I;65S($YE=R!2;VUA;B<L(%1I;65S+"!S97)I
M9CL@=&5X="UA;&EG;CH@;&5F=#L@;6%R9VEN+6QE9G0Z(#<N-W!T.R!T97AT
M+6EN9&5N=#H@+3<N-W!T.R<^15,@0V5L;"!);G1E<FYA=&EO;F%L(%!T92!,
M=&0\+V1I=CX\+W1D/CQT9"!S='EL93TS1"=B;W)D97(M=&]P.B`C,#`P,#`P
M(#)P>"!S;VQI9#L@=VED=&@Z(#4W)3L@=F5R=&EC86PM86QI9VXZ('1O<#L@
M8F]R9&5R+6QE9G0Z(",P,#`P,#`@,G!X('-O;&ED.R!B86-K9W)O=6YD+6-O
M;&]R.B`C9F9F9F9F.R<^/&1I=B!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[
M(&9O;G0M9F%M:6QY.B`G5&EM97,@3F5W(%)O;6%N)RP@5&EM97,L('-E<FEF
M.R!T97AT+6%L:6=N.B!L969T.R<^4W1E;2!C96QL('!R;V1U8W1S(&9O<B!R
M97-E87)C:"P@:6YC;'5D:6YG(&-L:6YI8V%L(&=R861E(&-E;&P@;&EN97,@
M<')O9'5C960@=6YD97(@8T=-4#PO9&EV/CPO=&0^/'1D('-T>6QE/3-$)V)O
M<F1E<BUT;W`Z(",P,#`P,#`@,G!X('-O;&ED.R!W:61T:#H@,3`E.R!V97)T
M:6-A;"UA;&EG;CH@=&]P.R!B;W)D97(M;&5F=#H@(S`P,#`P,"`R<'@@<V]L
M:60[(&)A8VMG<F]U;F0M8V]L;W(Z("-F9F9F9F8[)SX\9&EV('-T>6QE/3-$
M)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=4:6UE<R!.97<@4F]M
M86XG+"!4:6UE<RP@<V5R:68[('1E>'0M86QI9VXZ(&-E;G1E<CLG/C$P,"4\
M+V1I=CX\+W1D/CQT9"!S='EL93TS1"=B;W)D97(M=&]P.B`C,#`P,#`P(#)P
M>"!S;VQI9#L@8F]R9&5R+7)I9VAT.B`C,#`P,#`P(#)P>"!S;VQI9#L@=VED
M=&@Z(#$P)3L@=F5R=&EC86PM86QI9VXZ('1O<#L@8F]R9&5R+6QE9G0Z(",P
M,#`P,#`@,G!X('-O;&ED.R!B86-K9W)O=6YD+6-O;&]R.B`C9F9F9F9F.R<^
M/&1I=B!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G
M5&EM97,@3F5W(%)O;6%N)RP@5&EM97,L('-E<FEF.R!T97AT+6%L:6=N.B!C
M96YT97([)SY3:6YG87!O<F4\+V1I=CX\+W1D/CPO='(^/'1R/CQT9"!S='EL
M93TS1"=B;W)D97(M=&]P.B`C,#`P,#`P(#)P>"!S;VQI9#L@=VED=&@Z(#(S
M+C(X)3L@=F5R=&EC86PM86QI9VXZ('1O<#L@8F]R9&5R+6QE9G0Z(",P,#`P
M,#`@,G!X('-O;&ED.R!B86-K9W)O=6YD+6-O;&]R.B`C8V-E969F.R<^/&1I
M=B!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G5&EM
M97,@3F5W(%)O;6%N)RP@5&EM97,L('-E<FEF.R!T97AT+6%L:6=N.B!L969T
M.R!M87)G:6XM;&5F=#H@-RXW<'0[('1E>'0M:6YD96YT.B`M-RXW<'0[)SY,
M:69E36%P(%-C:65N8V5S+"!);F,N/"]D:78^/"]T9#X\=&0@<W1Y;&4],T0G
M8F]R9&5R+71O<#H@(S`P,#`P,"`R<'@@<V]L:60[('=I9'1H.B`U-R4[('9E
M<G1I8V%L+6%L:6=N.B!T;W`[(&)O<F1E<BUL969T.B`C,#`P,#`P(#)P>"!S
M;VQI9#L@8F%C:V=R;W5N9"UC;VQO<CH@(V-C965F9CLG/CQD:78@<W1Y;&4]
M,T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)U1I;65S($YE=R!2
M;VUA;B<L(%1I;65S+"!S97)I9CL@=&5X="UA;&EG;CH@;&5F=#LG/D)I;VUE
M9&EC86PL(&=E;F4L(&1I<V5A<V4L(&%N9"!S=&5M(&-E;&P@9&%T86)A<V5S
M(&%N9"!T;V]L<SPO9&EV/CPO=&0^/'1D('-T>6QE/3-$)V)O<F1E<BUT;W`Z
M(",P,#`P,#`@,G!X('-O;&ED.R!W:61T:#H@,3`E.R!V97)T:6-A;"UA;&EG
M;CH@=&]P.R!B;W)D97(M;&5F=#H@(S`P,#`P,"`R<'@@<V]L:60[(&)A8VMG
M<F]U;F0M8V]L;W(Z("-C8V5E9F8[)SX\9&EV('-T>6QE/3-$)V9O;G0M<VEZ
M93H@,3!P=#L@9F]N="UF86UI;'DZ("=4:6UE<R!.97<@4F]M86XG+"!4:6UE
M<RP@<V5R:68[('1E>'0M86QI9VXZ(&-E;G1E<CLG/C<U+C@E/"]D:78^/"]T
M9#X\=&0@<W1Y;&4],T0G8F]R9&5R+71O<#H@(S`P,#`P,"`R<'@@<V]L:60[
M(&)O<F1E<BUR:6=H=#H@(S`P,#`P,"`R<'@@<V]L:60[('=I9'1H.B`Q,"4[
M('9E<G1I8V%L+6%L:6=N.B!T;W`[(&)O<F1E<BUL969T.B`C,#`P,#`P(#)P
M>"!S;VQI9#L@8F%C:V=R;W5N9"UC;VQO<CH@(V-C965F9CLG/CQD:78@<W1Y
M;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)U1I;65S($YE
M=R!2;VUA;B<L(%1I;65S+"!S97)I9CL@=&5X="UA;&EG;CH@8V5N=&5R.R<^
M55-!/"]D:78^/"]T9#X\+W1R/CQT<CX\=&0@<W1Y;&4],T0G8F]R9&5R+71O
M<#H@(S`P,#`P,"`R<'@@<V]L:60[('=I9'1H.B`R,RXR."4[('9E<G1I8V%L
M+6%L:6=N.B!T;W`[(&)O<F1E<BUL969T.B`C,#`P,#`P(#)P>"!S;VQI9#L@
M8F%C:V=R;W5N9"UC;VQO<CH@(V9F9F9F9CLG/CQD:78@<W1Y;&4],T0G9F]N
M="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)U1I;65S($YE=R!2;VUA;B<L
M(%1I;65S+"!S97)I9CL@=&5X="UA;&EG;CH@;&5F=#L@;6%R9VEN+6QE9G0Z
M(#<N-W!T.R!T97AT+6EN9&5N=#H@+3<N-W!T.R<^3&EF94UA<"!38VEE;F-E
M<RP@3'1D+CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$)V)O<F1E<BUT;W`Z(",P
M,#`P,#`@,G!X('-O;&ED.R!W:61T:#H@-3<E.R!V97)T:6-A;"UA;&EG;CH@
M=&]P.R!B;W)D97(M;&5F=#H@(S`P,#`P,"`R<'@@<V]L:60[(&)A8VMG<F]U
M;F0M8V]L;W(Z("-F9F9F9F8[)SX\9&EV('-T>6QE/3-$)V9O;G0M<VEZ93H@
M,3!P=#L@9F]N="UF86UI;'DZ("=4:6UE<R!.97<@4F]M86XG+"!4:6UE<RP@
M<V5R:68[('1E>'0M86QI9VXZ(&QE9G0[)SY":6]M961I8V%L+"!G96YE+"!D
M:7-E87-E+"!A;F0@<W1E;2!C96QL(&1A=&%B87-E<R!A;F0@=&]O;',\+V1I
M=CX\+W1D/CQT9"!S='EL93TS1"=B;W)D97(M=&]P.B`C,#`P,#`P(#)P>"!S
M;VQI9#L@=VED=&@Z(#$P)3L@=F5R=&EC86PM86QI9VXZ('1O<#L@8F]R9&5R
M+6QE9G0Z(",P,#`P,#`@,G!X('-O;&ED.R!B86-K9W)O=6YD+6-O;&]R.B`C
M9F9F9F9F.R<^/&1I=B!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M
M9F%M:6QY.B`G5&EM97,@3F5W(%)O;6%N)RP@5&EM97,L('-E<FEF.R!T97AT
M+6%L:6=N.B!C96YT97([)SXH,BD\+V1I=CX\+W1D/CQT9"!S='EL93TS1"=B
M;W)D97(M=&]P.B`C,#`P,#`P(#)P>"!S;VQI9#L@8F]R9&5R+7)I9VAT.B`C
M,#`P,#`P(#)P>"!S;VQI9#L@=VED=&@Z(#$P)3L@=F5R=&EC86PM86QI9VXZ
M('1O<#L@8F]R9&5R+6QE9G0Z(",P,#`P,#`@,G!X('-O;&ED.R!B86-K9W)O
M=6YD+6-O;&]R.B`C9F9F9F9F.R<^/&1I=B!S='EL93TS1"=F;VYT+7-I>F4Z
M(#$P<'0[(&9O;G0M9F%M:6QY.B`G5&EM97,@3F5W(%)O;6%N)RP@5&EM97,L
M('-E<FEF.R!T97AT+6%L:6=N.B!C96YT97([)SY)<W)A96P\+V1I=CX\+W1D
M/CPO='(^/'1R/CQT9"!S='EL93TS1"=B;W)D97(M=&]P.B`C,#`P,#`P(#)P
M>"!S;VQI9#L@=VED=&@Z(#(S+C(X)3L@=F5R=&EC86PM86QI9VXZ('1O<#L@
M8F]R9&5R+6QE9G0Z(",P,#`P,#`@,G!X('-O;&ED.R!B86-K9W)O=6YD+6-O
M;&]R.B`C8V-E969F.R<^/&1I=B!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[
M(&9O;G0M9F%M:6QY.B`G5&EM97,@3F5W(%)O;6%N)RP@5&EM97,L('-E<FEF
M.R!T97AT+6%L:6=N.B!L969T.R!M87)G:6XM;&5F=#H@-RXW<'0[('1E>'0M
M:6YD96YT.B`M-RXW<'0[)SY,:69E36%P(%-O;'5T:6]N<RP@26YC+CPO9&EV
M/CPO=&0^/'1D('-T>6QE/3-$)V)O<F1E<BUT;W`Z(",P,#`P,#`@,G!X('-O
M;&ED.R!W:61T:#H@-3<E.R!V97)T:6-A;"UA;&EG;CH@=&]P.R!B;W)D97(M
M;&5F=#H@(S`P,#`P,"`R<'@@<V]L:60[(&)A8VMG<F]U;F0M8V]L;W(Z("-C
M8V5E9F8[)SX\9&EV('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF
M86UI;'DZ("=4:6UE<R!.97<@4F]M86XG+"!4:6UE<RP@<V5R:68[('1E>'0M
M86QI9VXZ(&QE9G0[)SY-;V)I;&4@:&5A;'1H('-O9G1W87)E/"]D:78^/"]T
M9#X\=&0@<W1Y;&4],T0G8F]R9&5R+71O<#H@(S`P,#`P,"`R<'@@<V]L:60[
M('=I9'1H.B`Q,"4[('9E<G1I8V%L+6%L:6=N.B!T;W`[(&)O<F1E<BUL969T
M.B`C,#`P,#`P(#)P>"!S;VQI9#L@8F%C:V=R;W5N9"UC;VQO<CH@(V-C965F
M9CLG/CQD:78@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL
M>3H@)U1I;65S($YE=R!2;VUA;B<L(%1I;65S+"!S97)I9CL@=&5X="UA;&EG
M;CH@8V5N=&5R.R<^*#(I/"]D:78^/"]T9#X\=&0@<W1Y;&4],T0G8F]R9&5R
M+71O<#H@(S`P,#`P,"`R<'@@<V]L:60[(&)O<F1E<BUR:6=H=#H@(S`P,#`P
M,"`R<'@@<V]L:60[('=I9'1H.B`Q,"4[('9E<G1I8V%L+6%L:6=N.B!T;W`[
M(&)O<F1E<BUL969T.B`C,#`P,#`P(#)P>"!S;VQI9#L@8F%C:V=R;W5N9"UC
M;VQO<CH@(V-C965F9CLG/CQD:78@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T
M.R!F;VYT+69A;6EL>3H@)U1I;65S($YE=R!2;VUA;B<L(%1I;65S+"!S97)I
M9CL@=&5X="UA;&EG;CH@8V5N=&5R.R<^55-!/"]D:78^/"]T9#X\+W1R/CQT
M<CX\=&0@<W1Y;&4],T0G8F]R9&5R+71O<#H@(S`P,#`P,"`R<'@@<V]L:60[
M('=I9'1H.B`R,RXR."4[('9E<G1I8V%L+6%L:6=N.B!T;W`[(&)O<F1E<BUL
M969T.B`C,#`P,#`P(#)P>"!S;VQI9#L@8F%C:V=R;W5N9"UC;VQO<CH@(V9F
M9F9F9CLG/CQD:78@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A
M;6EL>3H@)U1I;65S($YE=R!2;VUA;B<L(%1I;65S+"!S97)I9CL@=&5X="UA
M;&EG;CH@;&5F=#L@;6%R9VEN+6QE9G0Z(#<N-W!T.R!T97AT+6EN9&5N=#H@
M+3<N-W!T.R<^3VYC;T-Y=&4@0V]R<&]R871I;VX\+V1I=CX\+W1D/CQT9"!S
M='EL93TS1"=B;W)D97(M=&]P.B`C,#`P,#`P(#)P>"!S;VQI9#L@=VED=&@Z
M(#4W)3L@=F5R=&EC86PM86QI9VXZ('1O<#L@8F]R9&5R+6QE9G0Z(",P,#`P
M,#`@,G!X('-O;&ED.R!B86-K9W)O=6YD+6-O;&]R.B`C9F9F9F9F.R<^/&1I
M=B!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G5&EM
M97,@3F5W(%)O;6%N)RP@5&EM97,L('-E<FEF.R!T97AT+6%L:6=N.B!L969T
M.R<^0V%N8V5R(&1I86=N;W-T:6-S/"]D:78^/"]T9#X\=&0@<W1Y;&4],T0G
M8F]R9&5R+71O<#H@(S`P,#`P,"`R<'@@<V]L:60[('=I9'1H.B`Q,"4[('9E
M<G1I8V%L+6%L:6=N.B!T;W`[(&)O<F1E<BUL969T.B`C,#`P,#`P(#)P>"!S
M;VQI9#L@8F%C:V=R;W5N9"UC;VQO<CH@(V9F9F9F9CLG/CQD:78@<W1Y;&4]
M,T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)U1I;65S($YE=R!2
M;VUA;B<L(%1I;65S+"!S97)I9CL@=&5X="UA;&EG;CH@8V5N=&5R.R<^-S4N
M,R4\+V1I=CX\+W1D/CQT9"!S='EL93TS1"=B;W)D97(M=&]P.B`C,#`P,#`P
M(#)P>"!S;VQI9#L@8F]R9&5R+7)I9VAT.B`C,#`P,#`P(#)P>"!S;VQI9#L@
M=VED=&@Z(#$P)3L@=F5R=&EC86PM86QI9VXZ('1O<#L@8F]R9&5R+6QE9G0Z
M(",P,#`P,#`@,G!X('-O;&ED.R!B86-K9W)O=6YD+6-O;&]R.B`C9F9F9F9F
M.R<^/&1I=B!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY
M.B`G5&EM97,@3F5W(%)O;6%N)RP@5&EM97,L('-E<FEF.R!T97AT+6%L:6=N
M.B!C96YT97([)SY54T$\+V1I=CX\+W1D/CPO='(^/'1R/CQT9"!S='EL93TS
M1"=B;W)D97(M=&]P.B`C,#`P,#`P(#)P>"!S;VQI9#L@=VED=&@Z(#(S+C(X
M)3L@=F5R=&EC86PM86QI9VXZ('1O<#L@8F]R9&5R+6QE9G0Z(",P,#`P,#`@
M,G!X('-O;&ED.R!B86-K9W)O=6YD+6-O;&]R.B`C8V-E969F.R<^/&1I=B!S
M='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G5&EM97,@
M3F5W(%)O;6%N)RP@5&EM97,L('-E<FEF.R!T97AT+6%L:6=N.B!L969T.R!M
M87)G:6XM;&5F=#H@-RXW<'0[('1E>'0M:6YD96YT.B`M-RXW<'0[)SY/<G1H
M;T-Y=&4@0V]R<&]R871I;VX\+V1I=CX\+W1D/CQT9"!S='EL93TS1"=B;W)D
M97(M=&]P.B`C,#`P,#`P(#)P>"!S;VQI9#L@=VED=&@Z(#4W)3L@=F5R=&EC
M86PM86QI9VXZ('1O<#L@8F]R9&5R+6QE9G0Z(",P,#`P,#`@,G!X('-O;&ED
M.R!B86-K9W)O=6YD+6-O;&]R.B`C8V-E969F.R<^/&1I=B!S='EL93TS1"=F
M;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G5&EM97,@3F5W(%)O;6%N
M)RP@5&EM97,L('-E<FEF.R!T97AT+6%L:6=N.B!L969T.R<^3W)T:&]P961I
M8R!D:7-E87-E<RP@:6YC;'5D:6YG(&-H<F]N:6,@8F%C:R!P86EN(&%N9"!O
M<W1E;V%R=&AR:71I<SPO9&EV/CPO=&0^/'1D('-T>6QE/3-$)V)O<F1E<BUT
M;W`Z(",P,#`P,#`@,G!X('-O;&ED.R!W:61T:#H@,3`E.R!V97)T:6-A;"UA
M;&EG;CH@=&]P.R!B;W)D97(M;&5F=#H@(S`P,#`P,"`R<'@@<V]L:60[(&)A
M8VMG<F]U;F0M8V]L;W(Z("-C8V5E9F8[)SX\9&EV('-T>6QE/3-$)V9O;G0M
M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=4:6UE<R!.97<@4F]M86XG+"!4
M:6UE<RP@<V5R:68[('1E>'0M86QI9VXZ(&-E;G1E<CLG/C$P,"4H,RD\+V1I
M=CX\+W1D/CQT9"!S='EL93TS1"=B;W)D97(M=&]P.B`C,#`P,#`P(#)P>"!S
M;VQI9#L@8F]R9&5R+7)I9VAT.B`C,#`P,#`P(#)P>"!S;VQI9#L@=VED=&@Z
M(#$P)3L@=F5R=&EC86PM86QI9VXZ('1O<#L@8F]R9&5R+6QE9G0Z(",P,#`P
M,#`@,G!X('-O;&ED.R!B86-K9W)O=6YD+6-O;&]R.B`C8V-E969F.R<^/&1I
M=B!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G5&EM
M97,@3F5W(%)O;6%N)RP@5&EM97,L('-E<FEF.R!T97AT+6%L:6=N.B!C96YT
M97([)SY54T$\+V1I=CX\+W1D/CPO='(^/'1R/CQT9"!S='EL93TS1"=B;W)D
M97(M=&]P.B`C,#`P,#`P(#)P>"!S;VQI9#L@=VED=&@Z(#(S+C(X)3L@=F5R
M=&EC86PM86QI9VXZ('1O<#L@8F]R9&5R+6)O='1O;3H@(S`P,#`P,"`R<'@@
M<V]L:60[(&)O<F1E<BUL969T.B`C,#`P,#`P(#)P>"!S;VQI9#L@8F%C:V=R
M;W5N9"UC;VQO<CH@(V9F9F9F9CLG/CQD:78@<W1Y;&4],T0G9F]N="US:7IE
M.B`Q,'!T.R!F;VYT+69A;6EL>3H@)U1I;65S($YE=R!2;VUA;B<L(%1I;65S
M+"!S97)I9CL@=&5X="UA;&EG;CH@;&5F=#L@;6%R9VEN+6QE9G0Z(#<N-W!T
M.R!T97AT+6EN9&5N=#H@+3<N-W!T.R<^4F5#>71E(%1H97)A<&5U=&EC<RP@
M26YC+CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$)V)O<F1E<BUT;W`Z(",P,#`P
M,#`@,G!X('-O;&ED.R!W:61T:#H@-3<E.R!V97)T:6-A;"UA;&EG;CH@=&]P
M.R!B;W)D97(M8F]T=&]M.B`C,#`P,#`P(#)P>"!S;VQI9#L@8F]R9&5R+6QE
M9G0Z(",P,#`P,#`@,G!X('-O;&ED.R!B86-K9W)O=6YD+6-O;&]R.B`C9F9F
M9F9F.R<^/&1I=B!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M
M:6QY.B`G5&EM97,@3F5W(%)O;6%N)RP@5&EM97,L('-E<FEF.R!T97AT+6%L
M:6=N.B!L969T.R<^5F%S8W5L87(@9&ES;W)D97)S+"!I;F-L=61I;F<@8V%R
M9&EO=F%S8W5L87(M<F5L871E9"!D:7-E87-E<RP@:7-C:&5M:6,@8V]N9&ET
M:6]N<RP@=F%S8W5L87(@:6YJ=7)I97,\+V1I=CX\9&EV/B8C,38P.SPO9&EV
M/CQD:78@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@
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M<#H@(S`P,#`P,"`R<'@@<V]L:60[('=I9'1H.B`Q,"4[('9E<G1I8V%L+6%L
M:6=N.B!T;W`[(&)O<F1E<BUB;W1T;VTZ(",P,#`P,#`@,G!X('-O;&ED.R!B
M;W)D97(M;&5F=#H@(S`P,#`P,"`R<'@@<V]L:60[(&)A8VMG<F]U;F0M8V]L
M;W(Z("-F9F9F9F8[)SX\9&EV('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@
M9F]N="UF86UI;'DZ("=4:6UE<R!.97<@4F]M86XG+"!4:6UE<RP@<V5R:68[
M('1E>'0M86QI9VXZ(&-E;G1E<CLG/CDT+C@E/"]D:78^/"]T9#X\=&0@<W1Y
M;&4],T0G8F]R9&5R+71O<#H@(S`P,#`P,"`R<'@@<V]L:60[(&)O<F1E<BUR
M:6=H=#H@(S`P,#`P,"`R<'@@<V]L:60[('=I9'1H.B`Q,"4[('9E<G1I8V%L
M+6%L:6=N.B!T;W`[(&)O<F1E<BUB;W1T;VTZ(",P,#`P,#`@,G!X('-O;&ED
M.R!B;W)D97(M;&5F=#H@(S`P,#`P,"`R<'@@<V]L:60[(&)A8VMG<F]U;F0M
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M9STS1#`@8VQA<W,],T1$4U!&3&ES=%1A8FQE('-T>6QE/3-$)V9O;G0M<VEZ
M93H@,3!P=#L@9F]N="UF86UI;'DZ("=4:6UE<R!.97<@4F]M86XG+"!4:6UE
M<RP@<V5R:68[('=I9'1H.B`Q,#`E.R<^/'1R/CQT9"!S='EL93TS1"=W:61T
M:#H@,3AP=#LG/CPO=&0^/'1D('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@
M9F]N="UF86UI;'DZ("=4:6UE<R!.97<@4F]M86XG+"!4:6UE<RP@<V5R:68[
M('=I9'1H.B`Q.'!T.R!V97)T:6-A;"UA;&EG;CH@=&]P.R!A;&EG;CH@<FEG
M:'0[)SXH,2D\+W1D/CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O
M;G0M9F%M:6QY.B`G5&EM97,@3F5W(%)O;6%N)RP@5&EM97,L('-E<FEF.R!W
M:61T:#H@875T;SL@=F5R=&EC86PM86QI9VXZ('1O<#L@=&5X="UA;&EG;CH@
M;&5F=#LG/DEN8VQU9&5S('-H87)E<R!O=VYE9"!B>2`\9F]N="!S='EL93TS
M1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G5&EM97,@3F5W(%)O
M;6%N)RP@5&EM97,L('-E<FEF.R<^0FEO5&EM92P@07-T97)I87,L(&%N9"!%
M4TDN/"]F;VYT/CPO=&0^/"]T<CX\+W1A8FQE/CPO9&EV/CQD:78@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@;&5F=#LG/CQT86)L92!C96QL<&%D9&EN9STS1#`@
M8V5L;'-P86-I;F<],T0P(&-L87-S/3-$1%-01DQI<W1486)L92!S='EL93TS
M1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G5&EM97,@3F5W(%)O
M;6%N)RP@5&EM97,L('-E<FEF.R!W:61T:#H@,3`P)3LG/CQT<CX\=&0@<W1Y
M;&4],T0G=VED=&@Z(#$X<'0[)SX\+W1D/CQT9"!S='EL93TS1"=F;VYT+7-I
M>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G5&EM97,@3F5W(%)O;6%N)RP@5&EM
M97,L('-E<FEF.R!W:61T:#H@,3AP=#L@=F5R=&EC86PM86QI9VXZ('1O<#L@
M86QI9VXZ(')I9VAT.R<^*#(I/"]T9#X\=&0@<W1Y;&4],T0G9F]N="US:7IE
M.B`Q,'!T.R!F;VYT+69A;6EL>3H@)U1I;65S($YE=R!2;VUA;B<L(%1I;65S
M+"!S97)I9CL@=VED=&@Z(&%U=&\[('9E<G1I8V%L+6%L:6=N.B!T;W`[('1E
M>'0M86QI9VXZ(&QE9G0[)SY,:69E36%P(%-C:65N8V5S+"!,=&0N(&%N9"!,
M:69E36%P(%-O;'5T:6]N<RP@26YC+B!A<F4@=VAO;&QY+6]W;F5D('-U8G-I
M9&EA<FEE<R!O9B!,:69E36%P(%-C:65N8V5S+"!);F,N/"]T9#X\+W1R/CPO
M=&%B;&4^/"]D:78^/&1I=B!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^
M/'1A8FQE(&-E;&QP861D:6YG/3-$,"!C96QL<W!A8VEN9STS1#`@8VQA<W,]
M,T1$4U!&3&ES=%1A8FQE('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N
M="UF86UI;'DZ("=4:6UE<R!.97<@4F]M86XG+"!4:6UE<RP@<V5R:68[('=I
M9'1H.B`Q,#`E.R<^/'1R/CQT9"!S='EL93TS1"=W:61T:#H@,3AP=#LG/CPO
M=&0^/'1D('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ
M("=4:6UE<R!.97<@4F]M86XG+"!4:6UE<RP@<V5R:68[('=I9'1H.B`Q.'!T
M.R!V97)T:6-A;"UA;&EG;CH@=&]P.R!A;&EG;CH@<FEG:'0[)SXH,RD\+W1D
M/CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G
M5&EM97,@3F5W(%)O;6%N)RP@5&EM97,L('-E<FEF.R!W:61T:#H@875T;SL@
M=F5R=&EC86PM86QI9VXZ('1O<#L@=&5X="UA;&EG;CH@;&5F=#LG/DEN8VQU
M9&5S('-H87)E<R!O=VYE9"!B>2!":6]4:6UE(&%N9"!!<W1E<FEA<RX\+W1D
M/CPO='(^/"]T86)L93X\+V1I=CX\9&EV/CQB<B`O/CPO9&EV/CQD:78@<W1Y
M;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)U1I;65S($YE
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M;F-E<RP@3&EF94UA<"!38VEE;F-E<RP@3'1D+BP@86YD($QI9F5-87`@4V]L
M=71I;VYS+"!);F,N(&%S($)I;U1I;64@:&%S('1H92!A8FEL:71Y('1O(&-O
M;G1R;VP@=&AE:7(@;W!E<F%T:6YG(&%N9"!F:6YA;F-I86P@9&5C:7-I;VYS
M(&%N9"!P;VQI8VEE<R!T:')O=6=H(&ET<R!O=VYE<G-H:7`L(&%N9"!T:&4@
M;F]N+6-O;G1R;VQL:6YG(&EN=&5R97-T(&ES(')E9FQE8W1E9"!A<R!A('-E
M<&%R871E(&5L96UE;G0@;V8@<VAA<F5H;VQD97)S)R!E<75I='D@;VX@0FEO
M5&EM928C.#(Q-SMS(&-O;G-O;&ED871E9"!B86QA;F-E('-H965T<RX\+V1I
M=CX\9&EV/CQB<B`O/CPO9&EV/CQD:78@<W1Y;&4],T0G9F]N="US:7IE.B`Q
M,'!T.R!F;VYT+69A;6EL>3H@)U1I;65S($YE=R!2;VUA;B<L(%1I;65S+"!S
M97)I9CL@=&5X="UA;&EG;CH@:G5S=&EF>3L@=&5X="UI;F1E;G0Z(#,V<'0[
M)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY
M.B`G5&EM97,@3F5W(%)O;6%N)RP@5&EM97,L('-E<FEF.R!F;VYT+7-T>6QE
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M:"!A;F0@8V%S:"!E<75I=F%L96YT<R!O9B`D,C4L.#(Y+#4S,R!A<R!O9B!-
M87)C:"`S,2P@,C`Q-2P@=VEL;"!B92!S=69F:6-I96YT('1O(&9U;F0@:71S
M(&]P97)A=&EO;G,@870@;&5A<W0@=&AR;W5G:"`R,#$U+B!(;W=E=F5R+"!C
M;&EN:6-A;"!T<FEA;',@8F5I;F<@8V]N9'5C=&5D(&)Y($)I;U1I;64F(S@R
M,3<[<R!S=6)S:61I87)I97,L($%S=&5R:6%S(&%N9"!#96QL($-U<F4@3F5U
M<F]S8VEE;F-E<R!W:6QL(&)E(&9U;F1E9"!I;B!P87)T('=I=&@@9G5N9',@
M9G)O;2!G<F%N=',@86YD(&YO="!F<F]M(&-A<V@@;VX@:&%N9"X@268@07-T
M97)I87,@;W(@0V5L;"!#=7)E($YE=7)O<V-I96YC97,@=V5R92!T;R!L;W-E
M(&ET<R!G<F%N="!F=6YD:6YG(&ET(&UA>2!B92!R97%U:7)E9"!T;R!D96QA
M>2P@<&]S='!O;F4L(&]R(&-A;F-E;"!I=',@8VQI;FEC86P@=')I86QS(&]R
M(&QI;6ET('1H92!N=6UB97(@;V8@8VQI;FEC86P@=')I86P@<VET97,L(&]R
M(&]T:&5R=VES92!R961U8V4@;W(@8W5R=&%I;"!I=',@;W!E<F%T:6]N<R!U
M;FQE<W,@:70@:7,@86)L92!T;R!O8G1A:6X@9G)O;2!A;F]T:&5R('-O=7)C
M92!A9&5Q=6%T92!F:6YA;F-I;F<@=&AA="!C;W5L9"!B92!U<V5D(&9O<B!I
M=',@8VQI;FEC86P@=')I86PN/"]D:78^/&1I=B!S='EL93TS1"=F;VYT+7-I
M>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G5&EM97,@3F5W(%)O;6%N)RP@5&EM
M97,L('-E<FEF.R!T97AT+6%L:6=N.B!J=7-T:69Y.R!T97AT+6EN9&5N=#H@
M,S9P=#LG/B8C,38P.SPO9&EV/CQD:78@<W1Y;&4],T0G9F]N="US:7IE.B`Q
M,'!T.R!F;VYT+69A;6EL>3H@)U1I;65S($YE=R!2;VUA;B<L(%1I;65S+"!S
M97)I9CL@=&5X="UA;&EG;CH@:G5S=&EF>3L@=&5X="UI;F1E;G0Z(#,V<'0[
M)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY
M.B`G5&EM97,@3F5W(%)O;6%N)RP@5&EM97,L('-E<FEF.R!F;VYT+7-T>6QE
M.B!I=&%L:6,[)SY#97)T86EN('-I9VYI9FEC86YT(')I<VMS(&%N9"!U;F-E
M<G1A:6YT:65S/"]F;VYT/B`F(S@R,3$[(%1H92!O<&5R871I;VYS(&]F($)I
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M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\
M+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?,SDX8F(Q,F)?
M93AC85\T8C=A7SAF83!?,C8S.61F-6$X.3$P#0I#;VYT96YT+4QO8V%T:6]N
M.B!F:6QE.B\O+T,Z+S,Y.&)B,3)B7V4X8V%?-&(W85\X9F$P7S(V,SED9C5A
M.#DQ,"]7;W)K<VAE971S+U-H965T,#@N:'1M;`T*0V]N=&5N="U4<F%N<V9E
M<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T
M97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE
M860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT
M96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E
M/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E
M;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y
M/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5-13X-"B`@
M("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@
M<F]W<W!A;CTS1#(^/'-T<F]N9SY3=6UM87)Y(&]F(%-I9VYI9FEC86YT($%C
M8V]U;G1I;F<@4&]L:6-I97,\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^,R!-;VYT:',@16YD960\+W1H
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&@^36%R+B`S,2P@,C`Q-3QB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^/'-T<F]N9SY3=6UM87)Y(&]F(%-I9VYI9FEC86YT($%C
M8V]U;G1I;F<@4&]L:6-I97,@6T%B<W1R86-T73PO<W1R;VYG/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3=6UM87)Y(&]F(%-I9VYI9FEC
M86YT($%C8V]U;G1I;F<@4&]L:6-I97,\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQD:78@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=4:6UE<R!.
M97<@4F]M86XG+"!4:6UE<RP@<V5R:68[(&9O;G0M<VEZ93H@,3!P=#LG/CQD
M:78@<W1Y;&4],T0G=&5X="UA;&EG;CH@:G5S=&EF>3LG/CQT86)L92!C96QL
M<&%D9&EN9STS1#`@8V5L;'-P86-I;F<],T0P(&-L87-S/3-$1%-01DQI<W14
M86)L92!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G
M5&EM97,@3F5W(%)O;6%N)RP@5&EM97,L('-E<FEF.R!W:61T:#H@,3`P)3LG
M/CQT<CX\=&0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL
M>3H@)U1I;65S($YE=R!2;VUA;B<L(%1I;65S+"!S97)I9CL@=VED=&@Z(#$X
M<'0[('9E<G1I8V%L+6%L:6=N.B!T;W`[(&9O;G0M=V5I9VAT.B!B;VQD.R!A
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M;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G5&EM97,@3F5W(%)O;6%N
M)RP@5&EM97,L('-E<FEF.R!T97AT+6%L:6=N.B!J=7-T:69Y.R!T97AT+6EN
M9&5N=#H@,S9P=#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@
M9F]N="UF86UI;'DZ("=4:6UE<R!.97<@4F]M86XG+"!4:6UE<RP@<V5R:68[
M(&9O;G0M<W1Y;&4Z(&ET86QI8SLG/E)E=F5N=64@<F5C;V=N:71I;VX\+V9O
M;G0^("8C.#(Q,3L@0FEO5&EM92!C;VUP;&EE<R!W:71H($%30R`V,#4M,3`@
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M($)I;U1I;64@<F5C96EV97,@=7`M9G)O;G0@;F]N<F5F=6YD86)L92!L:6-E
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M/&1I=B!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G
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M(&QE<W,@=&\@8F4@8V%S:"!E<75I=F%L96YT<RX\+V1I=CX\9&EV/CQB<B`O
M/CPO9&EV/CQD:78@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A
M;6EL>3H@)U1I;65S($YE=R!2;VUA;B<L(%1I;65S+"!S97)I9CL@=&5X="UA
M;&EG;CH@:G5S=&EF>3L@=&5X="UI;F1E;G0Z(#,V<'0[)SX\9F]N="!S='EL
M93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G5&EM97,@3F5W
M(%)O;6%N)RP@5&EM97,L('-E<FEF.R!F;VYT+7-T>6QE.B!I=&%L:6,[)SY4
M<F%D92!A8V-O=6YT<R!A;F0@9W)A;G1S(')E8V5I=F%B;&4L(&YE=#PO9F]N
M=#X@)B,X,C$Q.R!.970@=')A9&4@<F5C96EV86)L97,@86UO=6YT960@=&\@
M87!P<F]X:6UA=&5L>2`D-C`U+#@P,"!A;F0@)#4T.2PS,#`@86YD(&=R86YT
M<R!R96-E:79A8FQE(&%M;W5N=&5D('1O(&%P<')O>&EM871E;'D@)#(V,"PS
M,#`@86YD("0T.3(L-C`P(&%S(&]F($UA<F-H(#,Q+"`R,#$U(&%N9"!$96-E
M;6)E<B`S,2P@,C`Q-"P@<F5S<&5C=&EV96QY+B!.970@=')A9&4@<F5C96EV
M86)L97,@:6YC;'5D92!A;&QO=V%N8V4@9F]R(&1O=6)T9G5L(&%C8V]U;G1S
M(&]F(&%P<')O>&EM871E;'D@)#$P,"PU,#`@87,@;V8@36%R8V@@,S$L(#(P
M,34@86YD($1E8V5M8F5R(#,Q+"`R,#$T(&9O<B!T:&]S92!A;6]U;G1S(&1E
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M+V1I=CX\9&EV/CQB<B`O/CPO9&EV/CQD:78@<W1Y;&4],T0G9F]N="US:7IE
M.B`Q,'!T.R!F;VYT+69A;6EL>3H@)U1I;65S($YE=R!2;VUA;B<L(%1I;65S
M+"!S97)I9CL@=&5X="UA;&EG;CH@:G5S=&EF>3L@=&5X="UI;F1E;G0Z(#,V
M<'0[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M
M:6QY.B`G5&EM97,@3F5W(%)O;6%N)RP@5&EM97,L('-E<FEF.R!F;VYT+7-T
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M>'0M86QI9VXZ(&IU<W1I9GD[('1E>'0M:6YD96YT.B`S-G!T.R<^/&9O;G0@
M<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)U1I;65S
M($YE=R!2;VUA;B<L(%1I;65S+"!S97)I9CL@9F]N="US='EL93H@:71A;&EC
M.R<^26YV96YT;W)Y("8C.#(Q,3L\+V9O;G0^($EN=F5N=&]R:65S(&%R92!S
M=&%T960@870@=&AE(&QO=V5R(&]F(&-O<W0@;W(@;6%R:V5T+B!#;W-T+"!W
M:&EC:"!I;F-L=61E<R!A;6]U;G1S(')E;&%T960@=&\@;6%T97)I86QS+"!L
M86)O<BP@86YD(&]V97)H96%D+"!I<R!D971E<FUI;F5D(&EN(&$@;6%N;F5R
M('=H:6-H(&%P<')O>&EM871E<R!T:&4@9FER<W0M:6XL(&9I<G-T+6]U="`H
M)B,X,C(P.T9)1D\F(S@R,C$[*2!M971H;V0N/"]D:78^/&1I=CX\8G(@+SX\
M+V1I=CX\9&EV('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI
M;'DZ("=4:6UE<R!.97<@4F]M86XG+"!4:6UE<RP@<V5R:68[('1E>'0M86QI
M9VXZ(&IU<W1I9GD[('1E>'0M:6YD96YT.B`S-G!T.R<^/&9O;G0@<W1Y;&4]
M,T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)U1I;65S($YE=R!2
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M3F]T92`T+CPO9&EV/CQD:78@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F
M;VYT+69A;6EL>3H@)U1I;65S($YE=R!2;VUA;B<L(%1I;65S+"!S97)I9CL@
M=&5X="UA;&EG;CH@:G5S=&EF>3L@=&5X="UI;F1E;G0Z(#,V<'0[)SXF(S$V
M,#L\+V1I=CX\9&EV('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF
M86UI;'DZ("=4:6UE<R!.97<@4F]M86XG+"!4:6UE<RP@<V5R:68[('1E>'0M
M86QI9VXZ(&IU<W1I9GD[('1E>'0M:6YD96YT.B`S-G!T.R<^/&9O;G0@<W1Y
M;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)U1I;65S($YE
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M971S('1H870@9&\@;F]T(&-O;G-T:71U=&4@82!B=7-I;F5S<R`H<W5C:"!A
M<R!T:&4@86-Q=6ES:71I;VX@;V8@87-S971S(&)Y($%S=&5R:6%S(&9R;VT@
M1V5R;VX@0V]R<&]R871I;VXI+"!I;B!A8V-O<F1A;F-E('=I=&@@=&AE(&%C
M8V]U;G1I;F<@<G5L97,@:6X@05-#(#@P-2TU,"P@<W5C:"!I;G1A;F=I8FQE
M(&%S<V5T<R!R96QA=&5D('1O(&EN+7!R;V-E<W,@<F5S96%R8V@@86YD(&1E
M=F5L;W!M96YT("@F(S@R,C`[25!2)F%M<#M$)B,X,C(Q.RD@87)E(&5X<&5N
M<V5D('5P;VX@86-Q=6ES:71I;VXN/"]D:78^/&1I=CX\8G(@+SX\+V1I=CX\
M9&EV('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=4
M:6UE<R!.97<@4F]M86XG+"!4:6UE<RP@<V5R:68[('1E>'0M86QI9VXZ(&IU
M<W1I9GD[('1E>'0M:6YD96YT.B`S-G!T.R<^/&9O;G0@<W1Y;&4],T0G9F]N
M="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)U1I;65S($YE=R!2;VUA;B<L
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M<B!T:&4@4V5C=7)I=&EE<R!!8W0@;V8@,3DS,RP@87,@86UE;F1E9"`H=&AE
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M('1E>'0M:6YD96YT.B`S-G!T.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE
M.B`Q,'!T.R!F;VYT+69A;6EL>3H@)U1I;65S($YE=R!2;VUA;B<L(%1I;65S
M+"!S97)I9CL@9F]N="US='EL93H@:71A;&EC.R<^5V%R<F%N=',@=&\@<'5R
M8VAA<V4@8V]M;6]N('-T;V-K/"]F;VYT/B`F(S@R,3$[($)I;U1I;64@9V5N
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M.B`S-G!T.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT
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M+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G5&EM97,@3F5W(%)O;6%N)RP@
M5&EM97,L('-E<FEF.R!T97AT+6%L:6=N.B!J=7-T:69Y.R!T97AT+6EN9&5N
M=#H@,S9P=#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N
M="UF86UI;'DZ("=4:6UE<R!.97<@4F]M86XG+"!4:6UE<RP@<V5R:68[(&9O
M;G0M<W1Y;&4Z(&ET86QI8SLG/E!A=&5N="!C;W-T<R`F(S@R,3$[/"]F;VYT
M/B!#;W-T<R!A<W-O8VEA=&5D('=I=&@@;V)T86EN:6YG('!A=&5N=',@;VX@
M<')O9'5C=',@;W(@=&5C:&YO;&]G>2!D979E;&]P960@87)E(&5X<&5N<V5D
M(&%S(')E<V5A<F-H(&%N9"!D979E;&]P;65N="!E>'!E;G-E<R!W:&5N(&EN
M8W5R<F5D+CPO9&EV/CQD:78^/&)R("\^/"]D:78^/&1I=B!S='EL93TS1"=F
M;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G5&EM97,@3F5W(%)O;6%N
M)RP@5&EM97,L('-E<FEF.R!T97AT+6%L:6=N.B!J=7-T:69Y.R!T97AT+6EN
M9&5N=#H@,S9P=#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@
M9F]N="UF86UI;'DZ("=4:6UE<R!.97<@4F]M86XG+"!4:6UE<RP@<V5R:68[
M(&9O;G0M<W1Y;&4Z(&ET86QI8SLG/E)E8VQA<W-I9FEC871I;VX\+V9O;G0^
M("8C.#(Q,3L@0V5R=&%I;B!P<FEO<B!Y96%R(&%M;W5N=',@:&%V92!B965N
M(')E8VQA<W-I9FEE9"!T;R!C;VYF;W)M('1O('1H92!C=7)R96YT('EE87(@
M<')E<V5N=&%T:6]N+B!4<F%D92!A;F0@9W)A;G0@<F5C96EV86)L97,@87)E
M(&YO=R!R97!O<G1E9"!S97!A<F%T96QY(&9R;VT@<')E<&%I9"!E>'!E;G-E
M<R!A;F0@;W1H97(@8W5R<F5N="!A<W-E=',N/"]D:78^/&1I=CX\8G(@+SX\
M+V1I=CX\9&EV('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI
M;'DZ("=4:6UE<R!.97<@4F]M86XG+"!4:6UE<RP@<V5R:68[('1E>'0M86QI
M9VXZ(&IU<W1I9GD[('1E>'0M:6YD96YT.B`S-G!T.R<^/&9O;G0@<W1Y;&4]
M,T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)U1I;65S($YE=R!2
M;VUA;B<L(%1I;65S+"!S97)I9CL@9F]N="US='EL93H@:71A;&EC.R<^4F5S
M96%R8V@@86YD(&1E=F5L;W!M96YT/"]F;VYT/B`F(S@R,3$[(%)E<V5A<F-H
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M/CQD:78^)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q
M-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[
M)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q
M-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[
M)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q
M-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[
M)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q
M-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[
M)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q
M-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[
M)B,Q-C`[(#PO9&EV/CQD:78@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F
M;VYT+69A;6EL>3H@)U1I;65S($YE=R!2;VUA;B<L(%1I;65S+"!S97)I9CL@
M=&5X="UA;&EG;CH@:G5S=&EF>3L@=&5X="UI;F1E;G0Z(#,V<'0[)SX\9F]N
M="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G5&EM
M97,@3F5W(%)O;6%N)RP@5&EM97,L('-E<FEF.R!F;VYT+7-T>6QE.B!I=&%L
M:6,[)SY'96YE<F%L(&%N9"!A9&UI;FES=')A=&EV93PO9F]N=#X@+2!'96YE
M<F%L(&%N9"!A9&UI;FES=')A=&EV92!E>'!E;G-E<R!C;VYS:7-T('!R:6YC
M:7!A;&QY(&]F(&-O;7!E;G-A=&EO;B!A;F0@<F5L871E9"!B96YE9FET<RP@
M:6YC;'5D:6YG('-T;V-K+6)A<V5D(&-O;7!E;G-A=&EO;BP@9F]R(&5X96-U
M=&EV92!A;F0@8V]R<&]R871E('!E<G-O;FYE;#L@<')O9F5S<VEO;F%L(&%N
M9"!C;VYS=6QT:6YG(&9E97,[(&%N9"!A;&QO8V%T960@;W9E<FAE860N/"]D
M:78^/&1I=CXF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF
M(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V
M,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF
M(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V
M,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF
M(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V
M,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF
M(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V
M,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF
M(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V
M,#LF(S$V,#LF(S$V,#L@/"]D:78^/&1I=B!S='EL93TS1"=F;VYT+7-I>F4Z
M(#$P<'0[(&9O;G0M9F%M:6QY.B`G5&EM97,@3F5W(%)O;6%N)RP@5&EM97,L
M('-E<FEF.R!T97AT+6%L:6=N.B!J=7-T:69Y.R!T97AT+6EN9&5N=#H@,S9P
M=#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI
M;'DZ("=4:6UE<R!.97<@4F]M86XG+"!4:6UE<RP@<V5R:68[(&9O;G0M<W1Y
M;&4Z(&ET86QI8SLG/D9O<F5I9VX@8W5R<F5N8WD@=')A;G-L871I;VX@9V%I
M;B!A;F0@;W1H97(@8V]M<')E:&5N<VEV92!L;W-S+"`F(S$V,#MF;W)E:6=N
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M<R!L;W-S97,@;V8@)#4R+#DX-2!A;F0@)#$P-RPR-#`L(')E<W!E8W1I=F5L
M>2!W:&EC:"!I<R!L87)G96QY(&9R;VT@9F]R96EG;B!C=7)R96YC>2!T<F%N
M<VQA=&EO;BX\+V1I=CX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&IU<W1I
M9GD[('1E>'0M:6YD96YT.B`S-G!T.R<^)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q
M-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[
M)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q
M-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[
M)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q
M-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[
M)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q
M-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[(#PO9&EV/CQD:78@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@:G5S=&EF>3LG/CQD:78@<W1Y;&4],T0G9F]N="US
M:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)U1I;65S($YE=R!2;VUA;B<L(%1I
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M964@;6]N=&AS(&5N9&5D($UA<F-H(#,Q+"`R,#$U(&%N9"`R,#$T+"!F;W)E
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M:6QY.B`G5&EM97,@3F5W(%)O;6%N)RP@5&EM97,L('-E<FEF.R!T97AT+6%L
M:6=N.B!J=7-T:69Y.R!T97AT+6EN9&5N=#H@,S9P=#LG/CQF;VYT('-T>6QE
M/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=4:6UE<R!.97<@
M4F]M86XG+"!4:6UE<RP@<V5R:68[(&9O;G0M<W1Y;&4Z(&ET86QI8SLG/DEN
M8V]M92!T87AE<R`F(S@R,3$[/"]F;VYT/B!":6]4:6UE(&%C8V]U;G1S(&9O
M<B!I;F-O;64@=&%X97,@:6X@86-C;W)D86YC92!W:71H($=!05`@<F5Q=6ER
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M($-A;&EF;W)N:6$L($%S=&5R:6%S)B,X,C$W.R!A8W1I=FET>2!F;W(@,C`Q
M,R!A;F0@,C`Q-"!H879E(&)E96X@:6YC;'5D960@:6X@0FEO5&EM928C.#(Q
M-SMS(&-O;6)I;F5D('1A>"!R971U<FXN($)I;U1I;64@<F5C;V=N:7IE<R!A
M8V-R=65D(&EN=&5R97-T(&%N9"!P96YA;'1I97,@<F5L871E9"!T;R!U;G)E
M8V]G;FEZ960@=&%X(&)E;F5F:71S+"!I9B!A;GDL)B,Q-C`[87,@:6YC;VUE
M('1A>"!E>'!E;G-E+"!H;W=E=F5R+"!N;R!A;6]U;G1S('=E<F4@86-C<G5E
M9"!F;W(@=&AE('!A>6UE;G0@;V8@:6YT97)E<W0@86YD('!E;F%L=&EE<R!A
M<R!O9B!-87)C:"`S,2P@,C`Q-2!A;F0@,C`Q-"X@0FEO5&EM92!F:6QE<R!A
M(%4N4RX@9F5D97)A;"!I;F-O;64@=&%X(')E='5R;B!A<R!W96QL(&%S('9A
M<FEO=7,@<W1A=&4@86YD(&9O<F5I9VX@:6YC;VUE('1A>"!R971U<FYS+B!)
M;B!G96YE<F%L+"!":6]4:6UE(&ES(&YO(&QO;F=E<B!S=6)J96-T('1O('1A
M>"!E>&%M:6YA=&EO;B!B>2!M86IO<B!T87AI;F<@875T:&]R:71I97,@9F]R
M('EE87)S(&)E9F]R92`R,#$P+B!!;'1H;W5G:"!T:&4@<W1A='5T92!I<R!C
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M:68[('1E>'0M86QI9VXZ(&IU<W1I9GD[('1E>'0M:6YD96YT.B`S-G!T.R<^
M)B,Q-C`[/"]D:78^/&1I=B!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O
M;G0M9F%M:6QY.B`G5&EM97,@3F5W(%)O;6%N)RP@5&EM97,L('-E<FEF.R!T
M97AT+6%L:6=N.B!J=7-T:69Y.R!T97AT+6EN9&5N=#H@,S9P=#LG/D%N(&EN
M8V]M92!T87@@8F5N969I="!O9B!A<'!R;WAI;6%T96QY("0Q+#$W-RPP,#`@
M=V%S(')E8V]R9&5D(&9O<B!T:&4@=&AR964@;6]N=&AS(&5N9&5D($UA<F-H
M(#,Q+"`R,#$U+"!O9B!W:&EC:"!A<'!R;WAI;6%T96QY("0Q+#(U,2PP,#`@
M;V8@=&AE(&)E;F5F:70@=V%S(')E;&%T960@=&\@9F5D97)A;"!O9F9S970@
M8GD@861J=7-T;65N="!O9B`D-S0L,#`P(')E;&%T960@=&\@<W1A=&4@=&%X
M97,N($9O<B!T:&4@<V%M92!P97)I;V0@:6X@,C`Q-"P@86X@:6YC;VUE('1A
M>"!B96YE9FET(&]F(&%P<')O>&EM871E;'D@)#$L,S0Y+#`P,"!W87,@<F5C
M;W)D960@+"!O9B!W:&EC:"!A<'!R;WAI;6%T96QY("0Q+#$U,2PP,#`@;V8@
M=&AE(&)E;F5F:70@=V%S(')E;&%T960@=&\@9F5D97)A;"!A;F0@)#$Y."PP
M,#`@=V%S(')E;&%T960@=&\@<W1A=&4@=&%X97,N/"]D:78^/&1I=CXF(S$V
M,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF
M(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V
M,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF
M(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V
M,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF
M(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V
M,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF
M(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V
M,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF
M(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V
M,#LF(S$V,#L@/"]D:78^/&1I=B!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[
M(&9O;G0M9F%M:6QY.B`G5&EM97,@3F5W(%)O;6%N)RP@5&EM97,L('-E<FEF
M.R!T97AT+6%L:6=N.B!J=7-T:69Y.R!T97AT+6EN9&5N=#H@,S9P=#LG/D%S
M=&5R:6%S(&5S=&%B;&ES:&5D(&1E9F5R<F5D('1A>"!L:6%B:6QI=&EE<R!P
M<FEM87)I;'D@<F5L871E9"!T;R!I=',@86-Q=6ES:71I;VX@;V8@8V5R=&%I
M;B!I;G1E;&QE8W1U86P@<')O<&5R='DN($ET(&ES(&UO<F4@;&EK96QY('1H
M86X@;F]T('1H870@=&AE($%S=&5R:6%S(&1E9F5R<F5D('1A>"!A<W-E=',@
M87)E(&9U;&QY(')E86QI>F%B;&4@<VEN8V4@=&AE<V4@:6YC;VUE('1A>"!B
M96YE9FET<R!A<F4@97AP96-T960@=&\@8F4@879A:6QA8FQE('1O(&]F9G-E
M="!S=6-H($%S=&5R:6%S(&1E9F5R<F5D('1A>"!L:6%B:6QI=&EE<RX\+V1I
M=CX\9&EV/B8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C
M,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P
M.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C
M,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P
M.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C
M,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P
M.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C
M,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P
M.R8C,38P.R8C,38P.R`\8G(@+SX\+V1I=CX\9&EV('-T>6QE/3-$)V9O;G0M
M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=4:6UE<R!.97<@4F]M86XG+"!4
M:6UE<RP@<V5R:68[('1E>'0M86QI9VXZ(&IU<W1I9GD[('1E>'0M:6YD96YT
M.B`S-G!T.R<^26X@2G5N92`R,#$T+"!!<W1E<FEA<R!S;VQD(#4L,#`P+#`P
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M>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G5&EM97,@3F5W(%)O;6%N)RP@5&EM
M97,L('-E<FEF.R!T97AT+6%L:6=N.B!J=7-T:69Y.R!T97AT+6EN9&5N=#H@
M,S9P=#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF
M86UI;'DZ("=4:6UE<R!.97<@4F]M86XG+"!4:6UE<RP@<V5R:68[(&9O;G0M
M<W1Y;&4Z(&ET86QI8SLG/E-T;V-K+6)A<V5D(&-O;7!E;G-A=&EO;CPO9F]N
M=#XF(S$V,#L\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M
M9F%M:6QY.B`G5&EM97,@3F5W(%)O;6%N)RP@5&EM97,L('-E<FEF.R!F;VYT
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M=&EF>3LG/CQB<B`O/CPO9&EV/CQD:78@<W1Y;&4],T0G9F]N="US:7IE.B`Q
M,'!T.R!F;VYT+69A;6EL>3H@)U1I;65S($YE=R!2;VUA;B<L(%1I;65S+"!S
M97)I9CL@=&5X="UA;&EG;CH@:G5S=&EF>3L@=&5X="UI;F1E;G0Z(#,V<'0[
M)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY
M.B`G5&EM97,@3F5W(%)O;6%N)RP@5&EM97,L('-E<FEF.R!F;VYT+7-T>6QE
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M(&9O;G0M9F%M:6QY.B`G5&EM97,@3F5W(%)O;6%N)RP@5&EM97,L('-E<FEF
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M+B!":6]4:6UE(&ES(&%P<&QY:6YG(&$@,3`@>65A<B!E<W1I;6%T960@=7-E
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M+B!3964@3F]T92`V+CPO9&EV/CQD:78^/&)R("\^/"]D:78^/&1I=B!S='EL
M93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G5&EM97,@3F5W
M(%)O;6%N)RP@5&EM97,L('-E<FEF.R!T97AT+6%L:6=N.B!J=7-T:69Y.R!T
M97AT+6EN9&5N=#H@,S9P=#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@
M,3!P=#L@9F]N="UF86UI;'DZ("=4:6UE<R!.97<@4F]M86XG+"!4:6UE<RP@
M<V5R:68[(&9O;G0M<W1Y;&4Z(&ET86QI8SLG/DQO<W,@<&5R('-H87)E/"]F
M;VYT/B`F(S@R,3$[($)I;U1I;64@87!P;&EE<R!T:&4@='=O+6-L87-S(&UE
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M('!E<B!S:&%R92!F;W(@=&AE('1H<F5E(&UO;G1H<R!E;F1E9"!-87)C:"`S
M,2P@,C`Q-2!A;F0@,C`Q-"!E>&-L=61E<R!A;GD@969F96-T(&9R;VT@-"PX
M.3,L.30R('1R96%S=7)Y('-H87)E<RP@-"PR-C8L-C`U(&]P=&EO;G,@86YD
M(#DL,3DT+#8W.2!W87)R86YT<R!A;F0@,3`L-30V+#$S-R!T<F5A<W5R>2!S
M:&%R97,L(#4L-#DQ+#,P,2!O<'1I;VYS(&%N9"`Y+#<U,2PV,34@=V%R<F%N
M=',L(')E<W!E8W1I=F5L>2P@8F5C875S92!T:&5I<B!I;F-L=7-I;VX@=V]U
M;&0@8F4@86YT:61I;'5T:79E+CPO9&EV/CQD:78^/&)R("\^/"]D:78^/&1I
M=B!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G5&EM
M97,@3F5W(%)O;6%N)RP@5&EM97,L('-E<FEF.R!T97AT+6%L:6=N.B!J=7-T
M:69Y.R!T97AT+6EN9&5N=#H@,S9P=#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M
M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=4:6UE<R!.97<@4F]M86XG+"!4
M:6UE<RP@<V5R:68[(&9O;G0M<W1Y;&4Z(&ET86QI8SLG/D9A:7(@=F%L=64@
M;V8@9FEN86YC:6%L(&EN<W1R=6UE;G1S/"]F;VYT/B`F(S@R,3$[(%1H92!F
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M<RP@<V5R:68[('1E>'0M86QI9VXZ(&IU<W1I9GD[('1E>'0M:6YD96YT.B`S
M-G!T.R<^)B,Q-C`[/"]D:78^/&1I=B!S='EL93TS1"=F;VYT+7-I>F4Z(#$P
M<'0[(&9O;G0M9F%M:6QY.B`G5&EM97,@3F5W(%)O;6%N)RP@5&EM97,L('-E
M<FEF.R!F;VYT+7=E:6=H=#H@8F]L9#L@9F]N="US='EL93H@:71A;&EC.R!T
M97AT+6%L:6=N.B!J=7-T:69Y.R!T97AT+6EN9&5N=#H@,S9P=#LG/CQF;VYT
M('-T>6QE/3-$)V9O;G0M=V5I9VAT.B!N;W)M86P[)SY296-E;G1L>2!)<W-U
M960@06-C;W5N=&EN9R!0<F]N;W5N8V5M96YT<R`F(S@R,3$[(#PO9F]N=#X\
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M.B`Q,'!T.R!F;VYT+69A;6EL>3H@)U1I;65S($YE=R!2;VUA;B<L(%1I;65S
M+"!S97)I9CL@=&5X="UA;&EG;CH@:G5S=&EF>3L@=&5X="UI;F1E;G0Z(#,V
M<'0[)SXF(S$V,#L\+V1I=CX\+V1I=CX\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*
M#0HM+2TM+2T]7TYE>'1087)T7S,Y.&)B,3)B7V4X8V%?-&(W85\X9F$P7S(V
M,SED9C5A.#DQ,`T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B\S.3AB
M8C$R8E]E.&-A7S1B-V%?.&9A,%\R-C,Y9&8U83@Y,3`O5V]R:W-H965T<R]3
M:&5E=#`Y+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E
M9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T
M/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT
M='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[
M(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP
M="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT
M("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA
M<W,],T1R97!O<G0@:60],T1)1#!%344^#0H@("`@("`\='(^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O
M;F<^26YV96YT;W)Y/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1H(&-O;'-P86X],T0Q/C,@36]N=&AS($5N9&5D/"]T:#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H
M/DUA<BX@,S$L(#(P,34\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/CQS=')O;F<^26YV96YT;W)Y(%M!8G-T<F%C=%T\+W-T<F]N9SX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^26YV96YT;W)Y/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\9&EV('-T>6QE/3-$)V9O
M;G0M9F%M:6QY.B`G5&EM97,@3F5W(%)O;6%N)RP@5&EM97,L('-E<FEF.R!F
M;VYT+7-I>F4Z(#$P<'0[)SX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&IU
M<W1I9GD[)SX\=&%B;&4@8V5L;'!A9&1I;F<],T0P(&-E;&QS<&%C:6YG/3-$
M,"!C;&%S<STS1$134$9,:7-T5&%B;&4@<W1Y;&4],T0G9F]N="US:7IE.B`Q
M,'!T.R!F;VYT+69A;6EL>3H@)U1I;65S($YE=R!2;VUA;B<L(%1I;65S+"!S
M97)I9CL@=VED=&@Z(#$P,"4[)SX\='(^/'1D('-T>6QE/3-$)V9O;G0M<VEZ
M93H@,3!P=#L@9F]N="UF86UI;'DZ("=4:6UE<R!.97<@4F]M86XG+"!4:6UE
M<RP@<V5R:68[('=I9'1H.B`Q.'!T.R!V97)T:6-A;"UA;&EG;CH@=&]P.R!F
M;VYT+7=E:6=H=#H@8F]L9#L@86QI9VXZ(')I9VAT.R<^,RX\+W1D/CQT9"!S
M='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G5&EM97,@
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M(&IU<W1I9GD[('1E>'0M:6YD96YT.B`S-G!T.R<^0FEO5&EM92!H96QD("0R
M.#8L-3$S(&%N9"`D,C4S+#(R-R!O9B!I;G9E;G1O<GD@;V8@9FEN:7-H960@
M<')O9'5C=',@;VXM<VET92!A="!I=',@8V]R<&]R871E(&AE861Q=6%R=&5R
M<R!I;B!!;&%M961A+"!#86QI9F]R;FEA(&%T($UA<F-H(#,Q+"`R,#$U(&%N
M9"!$96-E;6)E<B`S,2P@,C`Q-"P@<F5S<&5C=&EV96QY+B!&:6YI<VAE9"!G
M;V]D<R!P<F]D=6-T<R!O9B`D,3(L-SDU('=E<F4@:&5L9"!B>2!A('1H:7)D
M('!A<G1Y(&]N(&-O;G-I9VYM96YT(&%T($UA<F-H(#,Q+"`R,#$U(&%N9"!$
M96-E;6)E<B`S,2P@,C`Q-"X\+V1I=CX\+V1I=CX\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H
M=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7S,Y.&)B,3)B7V4X8V%?-&(W85\X
M9F$P7S(V,SED9C5A.#DQ,`T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#
M.B\S.3AB8C$R8E]E.&-A7S1B-V%?.&9A,%\R-C,Y9&8U83@Y,3`O5V]R:W-H
M965T<R]3:&5E=#$P+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z
M('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C
M:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-
M151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT
M+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V
M87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#
M;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B
M;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%344^#0H@("`@("`\='(^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R
M/CQS=')O;F<^17%U:7!M96YT+"!N970@86YD(&-O;G-T<G5C=&EO;B!I;B!P
M<F]G<F5S<SQB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T:"!C;VQS<&%N/3-$,3XS($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y-87(N
M(#,Q+"`R,#$U/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#X\<W1R;VYG/D5Q=6EP;65N="P@;F5T+"!A;F0@8V]N<W1R=6-T:6]N(&EN
M('!R;V=R97-S(%M!8G-T<F%C=%T\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^17%U:7!M96YT+"!N970L(&%N9"!C;VYS=')U
M8W1I;VX@:6X@<')O9W)E<W,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQD:78@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=4:6UE<R!.97<@4F]M
M86XG+"!4:6UE<RP@<V5R:68[(&9O;G0M<VEZ93H@,3!P=#LG/CQD:78@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@:G5S=&EF>3LG/CQT86)L92!C96QL<&%D9&EN
M9STS1#`@8V5L;'-P86-I;F<],T0P(&-L87-S/3-$1%-01DQI<W1486)L92!S
M='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G5&EM97,@
M3F5W(%)O;6%N)RP@5&EM97,L('-E<FEF.R!W:61T:#H@,3`P)3LG/CQT<CX\
M=&0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)U1I
M;65S($YE=R!2;VUA;B<L(%1I;65S+"!S97)I9CL@=VED=&@Z(#$X<'0[('9E
M<G1I8V%L+6%L:6=N.B!T;W`[(&9O;G0M=V5I9VAT.B!B;VQD.R!A;&EG;CH@
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M>'0M86QI9VXZ(&IU<W1I9GD[('1E>'0M:6YD96YT.B`S-G!T.R<^070@36%R
M8V@@,S$L(#(P,34@86YD($1E8V5M8F5R(#,Q+"`R,#$T+"!E<75I<&UE;G0L
M(&9U<FYI='5R92!A;F0@9FEX='5R97,L(&%N9"!C;VYS=')U8W1I;VX@:6X@
M<')O9W)E<W,@=V5R92!C;VUP<FES960@;V8@=&AE(&9O;&QO=VEN9SH\+V1I
M=CX\9&EV/CQB<B`O/CPO9&EV/CQT86)L92!C96QL<&%D9&EN9STS1#`@8V5L
M;'-P86-I;F<],T0P('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF
M86UI;'DZ("=4:6UE<R!.97<@4F]M86XG+"!4:6UE<RP@<V5R:68[('=I9'1H
M.B`Q,#`E.R<^/'1R/CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=F5R
M=&EC86PM86QI9VXZ(&)O='1O;3L@<&%D9&EN9RUB;W1T;VTZ(#)P>#LG/B8C
M,38P.SPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=V97)T:6-A
M;"UA;&EG;CH@8F]T=&]M.R!P861D:6YG+6)O='1O;3H@,G!X.R<^)B,Q-C`[
M/"]T9#X\=&0@8V]L<W!A;CTS1#(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ
M(&)O='1O;3L@=VAI=&4M<W!A8V4Z(&YO=W)A<#L@8F]R9&5R+6)O='1O;3H@
M(S`P,#`P,"`R<'@@<V]L:60[)SX\9&EV('-T>6QE/3-$)V9O;G0M<VEZ93H@
M,3!P=#L@9F]N="UF86UI;'DZ("=4:6UE<R!.97<@4F]M86XG+"!4:6UE<RP@
M<V5R:68[(&9O;G0M=V5I9VAT.B!B;VQD.R!T97AT+6%L:6=N.B!C96YT97([
M)SY-87)C:"`S,2P@,C`Q-3PO9&EV/CQD:78@<W1Y;&4],T0G9F]N="US:7IE
M.B`Q,'!T.R!F;VYT+69A;6EL>3H@)U1I;65S($YE=R!2;VUA;B<L(%1I;65S
M+"!S97)I9CL@9F]N="UW96EG:'0Z(&)O;&0[('1E>'0M86QI9VXZ(&-E;G1E
M<CLG/BA5;F%U9&ET960I/"]D:78^/"]T9#X\=&0@;F]W<F%P/3-$;F]W<F%P
M('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T
M=&]M.R!P861D:6YG+6)O='1O;3H@,G!X.R!T97AT+6%L:6=N.B!L969T.R<^
M)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W9E<G1I
M8V%L+6%L:6=N.B!B;W1T;VT[('!A9&1I;F<M8F]T=&]M.B`R<'@[)SXF(S$V
M,#L\+W1D/CQT9"!C;VQS<&%N/3-$,B!V86QI9VX],T1B;W1T;VT@<W1Y;&4]
M,T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@8F]R9&5R+6)O='1O;3H@(S`P
M,#`P,"`R<'@@<V]L:60[)SX\9&EV('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P
M=#L@9F]N="UF86UI;'DZ("=4:6UE<R!.97<@4F]M86XG+"!4:6UE<RP@<V5R
M:68[(&9O;G0M=V5I9VAT.B!B;VQD.R!T97AT+6%L:6=N.B!C96YT97([)SY$
M96-E;6)E<B`S,2P\+V1I=CX\9&EV('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P
M=#L@9F]N="UF86UI;'DZ("=4:6UE<R!.97<@4F]M86XG+"!4:6UE<RP@<V5R
M:68[(&9O;G0M=V5I9VAT.B!B;VQD.R!T97AT+6%L:6=N.B!C96YT97([)SXR
M,#$T/"]D:78^/"]T9#X\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O
M='1O;2!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!P861D:6YG
M+6)O='1O;3H@,G!X.R!T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X\
M+W1R/CQT<CX\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.B`W
M-B4[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&)A8VMG<F]U;F0M8V]L;W(Z
M("-C8V5E9F8[)SX\9&EV('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N
M="UF86UI;'DZ("=4:6UE<R!.97<@4F]M86XG+"!4:6UE<RP@<V5R:68[('1E
M>'0M86QI9VXZ(&QE9G0[(&UA<F=I;BUL969T.B`W+C)P=#L@=&5X="UI;F1E
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M97AT+6%L:6=N.B!L969T.R!B86-K9W)O=6YD+6-O;&]R.B`C8V-E969F.R<^
M/&1I=B!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G
M5&EM97,@3F5W(%)O;6%N)RP@5&EM97,L('-E<FEF.R<^)#PO9&EV/CPO=&0^
M/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#H@.24[('9E<G1I
M8V%L+6%L:6=N.B!B;W1T;VT[('1E>'0M86QI9VXZ(')I9VAT.R!B86-K9W)O
M=6YD+6-O;&]R.B`C8V-E969F.R<^/&1I=B!S='EL93TS1"=F;VYT+7-I>F4Z
M(#$P<'0[(&9O;G0M9F%M:6QY.B`G5&EM97,@3F5W(%)O;6%N)RP@5&EM97,L
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M=&]M.R!B86-K9W)O=6YD+6-O;&]R.B`C8V-E969F.R<^)B,Q-C`[/"]T9#X\
M=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.B`Q)3L@=F5R=&EC
M86PM86QI9VXZ(&)O='1O;3L@=&5X="UA;&EG;CH@;&5F=#L@8F%C:V=R;W5N
M9"UC;VQO<CH@(V-C965F9CLG/CQD:78@<W1Y;&4],T0G9F]N="US:7IE.B`Q
M,'!T.R!F;VYT+69A;6EL>3H@)U1I;65S($YE=R!2;VUA;B<L(%1I;65S+"!S
M97)I9CLG/B0\+V1I=CX\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4]
M,T0G=VED=&@Z(#DE.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!T97AT+6%L
M:6=N.B!R:6=H=#L@8F%C:V=R;W5N9"UC;VQO<CH@(V-C965F9CLG/CQD:78@
M<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)U1I;65S
M($YE=R!2;VUA;B<L(%1I;65S+"!S97)I9CLG/C0L.#<P+#4Q-CPO9&EV/CPO
M=&0^/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@<W1Y;&4]
M,T0G=VED=&@Z(#$E.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!T97AT+6%L
M:6=N.B!L969T.R!B86-K9W)O=6YD+6-O;&]R.B`C8V-E969F.R<^)B,Q-C`[
M/"]T9#X\+W1R/CQT<CX\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I
M9'1H.B`W-B4[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&)A8VMG<F]U;F0M
M8V]L;W(Z("-F9F9F9F8[)SX\9&EV('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P
M=#L@9F]N="UF86UI;'DZ("=4:6UE<R!.97<@4F]M86XG+"!4:6UE<RP@<V5R
M:68[('1E>'0M86QI9VXZ(&QE9G0[(&UA<F=I;BUL969T.B`W+C)P=#L@=&5X
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M+6%L:6=N.B!L969T.R!B86-K9W)O=6YD+6-O;&]R.B`C9F9F9F9F.R<^)B,Q
M-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.B`Y
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M;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B`C9F9F9F9F.R<^)B,Q-C`[
M/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.B`Q)3L@
M=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@=&5X="UA;&EG;CH@;&5F=#L@8F%C
M:V=R;W5N9"UC;VQO<CH@(V9F9F9F9CLG/B8C,38P.SPO=&0^/'1D('9A;&EG
M;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#H@.24[('9E<G1I8V%L+6%L:6=N
M.B!B;W1T;VT[('1E>'0M86QI9VXZ(')I9VAT.R!B86-K9W)O=6YD+6-O;&]R
M.B`C9F9F9F9F.R<^/&1I=B!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O
M;G0M9F%M:6QY.B`G5&EM97,@3F5W(%)O;6%N)RP@5&EM97,L('-E<FEF.R<^
M-#`U+#<S,#PO9&EV/CPO=&0^/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX]
M,T1B;W1T;VT@<W1Y;&4],T0G=VED=&@Z(#$E.R!V97)T:6-A;"UA;&EG;CH@
M8F]T=&]M.R!T97AT+6%L:6=N.B!L969T.R!B86-K9W)O=6YD+6-O;&]R.B`C
M9F9F9F9F.R<^)B,Q-C`[/"]T9#X\+W1R/CQT<CX\=&0@=F%L:6=N/3-$8F]T
M=&]M('-T>6QE/3-$)W=I9'1H.B`W-B4[('9E<G1I8V%L+6%L:6=N.B!B;W1T
M;VT[('!A9&1I;F<M8F]T=&]M.B`R<'@[(&)A8VMG<F]U;F0M8V]L;W(Z("-C
M8V5E9F8[)SX\9&EV('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF
M86UI;'DZ("=4:6UE<R!.97<@4F]M86XG+"!4:6UE<RP@<V5R:68[('1E>'0M
M86QI9VXZ(&QE9G0[(&UA<F=I;BUL969T.B`W+C)P=#L@=&5X="UI;F1E;G0Z
M("TW+C)P=#LG/D%C8W5M=6QA=&5D(&1E<')E8VEA=&EO;CPO9&EV/CPO=&0^
M/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#H@,24[('9E<G1I
M8V%L+6%L:6=N.B!B;W1T;VT[('!A9&1I;F<M8F]T=&]M.B`R<'@[(&)A8VMG
M<F]U;F0M8V]L;W(Z("-C8V5E9F8[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX]
M,T1B;W1T;VT@<W1Y;&4],T0G=VED=&@Z(#$E.R!V97)T:6-A;"UA;&EG;CH@
M8F]T=&]M.R!B;W)D97(M8F]T=&]M.B`C,#`P,#`P(#)P>"!S;VQI9#L@=&5X
M="UA;&EG;CH@;&5F=#L@8F%C:V=R;W5N9"UC;VQO<CH@(V-C965F9CLG/B8C
M,38P.SPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#H@
M.24[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&)O<F1E<BUB;W1T;VTZ(",P
M,#`P,#`@,G!X('-O;&ED.R!T97AT+6%L:6=N.B!R:6=H=#L@8F%C:V=R;W5N
M9"UC;VQO<CH@(V-C965F9CLG/CQD:78@<W1Y;&4],T0G9F]N="US:7IE.B`Q
M,'!T.R!F;VYT+69A;6EL>3H@)U1I;65S($YE=R!2;VUA;B<L(%1I;65S+"!S
M97)I9CLG/B@R+#8W,"PX,CD\+V1I=CX\+W1D/CQT9"!N;W=R87`],T1N;W=R
M87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.B`Q)3L@=F5R=&EC
M86PM86QI9VXZ(&)O='1O;3L@<&%D9&EN9RUB;W1T;VTZ(#)P>#L@=&5X="UA
M;&EG;CH@;&5F=#L@8F%C:V=R;W5N9"UC;VQO<CH@(V-C965F9CLG/CQD:78@
M<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)U1I;65S
M($YE=R!2;VUA;B<L(%1I;65S+"!S97)I9CLG/BD\+V1I=CX\+W1D/CQT9"!V
M86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=VED=&@Z(#$E.R!V97)T:6-A;"UA
M;&EG;CH@8F]T=&]M.R!P861D:6YG+6)O='1O;3H@,G!X.R!B86-K9W)O=6YD
M+6-O;&]R.B`C8V-E969F.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T
M=&]M('-T>6QE/3-$)W=I9'1H.B`Q)3L@=F5R=&EC86PM86QI9VXZ(&)O='1O
M;3L@8F]R9&5R+6)O='1O;3H@(S`P,#`P,"`R<'@@<V]L:60[('1E>'0M86QI
M9VXZ(&QE9G0[(&)A8VMG<F]U;F0M8V]L;W(Z("-C8V5E9F8[)SXF(S$V,#L\
M+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=VED=&@Z(#DE.R!V
M97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B;W)D97(M8F]T=&]M.B`C,#`P,#`P
M(#)P>"!S;VQI9#L@=&5X="UA;&EG;CH@<FEG:'0[(&)A8VMG<F]U;F0M8V]L
M;W(Z("-C8V5E9F8[)SX\9&EV('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@
M9F]N="UF86UI;'DZ("=4:6UE<R!.97<@4F]M86XG+"!4:6UE<RP@<V5R:68[
M)SXH,BPT,3@L-#`P/"]D:78^/"]T9#X\=&0@;F]W<F%P/3-$;F]W<F%P('9A
M;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#H@,24[('9E<G1I8V%L+6%L
M:6=N.B!B;W1T;VT[('!A9&1I;F<M8F]T=&]M.B`R<'@[('1E>'0M86QI9VXZ
M(&QE9G0[(&)A8VMG<F]U;F0M8V]L;W(Z("-C8V5E9F8[)SX\9&EV('-T>6QE
M/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=4:6UE<R!.97<@
M4F]M86XG+"!4:6UE<RP@<V5R:68[)SXI/"]D:78^/"]T9#X\+W1R/CQT<CX\
M=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.B`W-B4[('9E<G1I
M8V%L+6%L:6=N.B!B;W1T;VT[('!A9&1I;F<M8F]T=&]M.B`T<'@[(&)A8VMG
M<F]U;F0M8V]L;W(Z("-F9F9F9F8[)SX\9&EV('-T>6QE/3-$)V9O;G0M<VEZ
M93H@,3!P=#L@9F]N="UF86UI;'DZ("=4:6UE<R!.97<@4F]M86XG+"!4:6UE
M<RP@<V5R:68[('1E>'0M86QI9VXZ(&QE9G0[(&UA<F=I;BUL969T.B`W+C)P
M=#L@=&5X="UI;F1E;G0Z("TW+C)P=#LG/D5Q=6EP;65N="!N970L)B,Q-C`[
M86YD(&-O;G-T<G5C=&EO;B!I;B!P<F]G<F5S<SPO9&EV/CPO=&0^/'1D('9A
M;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#H@,24[('9E<G1I8V%L+6%L
M:6=N.B!B;W1T;VT[('!A9&1I;F<M8F]T=&]M.B`T<'@[(&)A8VMG<F]U;F0M
M8V]L;W(Z("-F9F9F9F8[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T
M;VT@<W1Y;&4],T0G=VED=&@Z(#$E.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M
M.R!B;W)D97(M8F]T=&]M.B`C,#`P,#`P(#1P>"!D;W5B;&4[('1E>'0M86QI
M9VXZ(&QE9G0[(&)A8VMG<F]U;F0M8V]L;W(Z("-F9F9F9F8[)SX\9&EV('-T
M>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=4:6UE<R!.
M97<@4F]M86XG+"!4:6UE<RP@<V5R:68[)SXD/"]D:78^/"]T9#X\=&0@=F%L
M:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.B`Y)3L@=F5R=&EC86PM86QI
M9VXZ(&)O='1O;3L@8F]R9&5R+6)O='1O;3H@(S`P,#`P,"`T<'@@9&]U8FQE
M.R!T97AT+6%L:6=N.B!R:6=H=#L@8F%C:V=R;W5N9"UC;VQO<CH@(V9F9F9F
M9CLG/CQD:78@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL
M>3H@)U1I;65S($YE=R!2;VUA;B<L(%1I;65S+"!S97)I9CLG/C(L.#8T+#8V
M.3PO9&EV/CPO=&0^/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T
M;VT@<W1Y;&4],T0G=VED=&@Z(#$E.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M
M.R!P861D:6YG+6)O='1O;3H@-'!X.R!T97AT+6%L:6=N.B!L969T.R!B86-K
M9W)O=6YD+6-O;&]R.B`C9F9F9F9F.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N
M/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.B`Q)3L@=F5R=&EC86PM86QI9VXZ
M(&)O='1O;3L@<&%D9&EN9RUB;W1T;VTZ(#1P>#L@8F%C:V=R;W5N9"UC;VQO
M<CH@(V9F9F9F9CLG/B8C,38P.SPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S
M='EL93TS1"=W:61T:#H@,24[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&)O
M<F1E<BUB;W1T;VTZ(",P,#`P,#`@-'!X(&1O=6)L93L@=&5X="UA;&EG;CH@
M;&5F=#L@8F%C:V=R;W5N9"UC;VQO<CH@(V9F9F9F9CLG/CQD:78@<W1Y;&4]
M,T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)U1I;65S($YE=R!2
M;VUA;B<L(%1I;65S+"!S97)I9CLG/B0\+V1I=CX\+W1D/CQT9"!V86QI9VX]
M,T1B;W1T;VT@<W1Y;&4],T0G=VED=&@Z(#DE.R!V97)T:6-A;"UA;&EG;CH@
M8F]T=&]M.R!B;W)D97(M8F]T=&]M.B`C,#`P,#`P(#1P>"!D;W5B;&4[('1E
M>'0M86QI9VXZ(')I9VAT.R!B86-K9W)O=6YD+6-O;&]R.B`C9F9F9F9F.R<^
M/&1I=B!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G
M5&EM97,@3F5W(%)O;6%N)RP@5&EM97,L('-E<FEF.R<^,BPX-3<L.#0V/"]D
M:78^/"]T9#X\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;2!S
M='EL93TS1"=W:61T:#H@,24[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[('!A
M9&1I;F<M8F]T=&]M.B`T<'@[('1E>'0M86QI9VXZ(&QE9G0[(&)A8VMG<F]U
M;F0M8V]L;W(Z("-F9F9F9F8[)SXF(S$V,#L\+W1D/CPO='(^/"]T86)L93X\
M9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&IU<W1I9GD[)SX\8G(@+SX\+V1I
M=CX\9&EV('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ
M("=4:6UE<R!.97<@4F]M86XG+"!4:6UE<RP@<V5R:68[('1E>'0M86QI9VXZ
M(&IU<W1I9GD[(&UA<F=I;BUL969T.B`P+C%P=#L@;6%R9VEN+7)I9VAT.B`P
M+C%P=#L@=&5X="UI;F1E;G0Z(#,V<'0[)SY%<75I<&UE;G0L(&9U<FYI='5R
M92!A;F0@9FEX='5R97,L(&%N9"!C;VYS=')U8W1I;VX@:6X@<')O9W)E<W,@
M870@36%R8V@@,S$L(#(P,34@:6YC;'5D92`D,3$U+#`P,"!F:6YA;F-E9"!B
M>2!C87!I=&%L(&QE87-E(&)O<G)O=VEN9W,@:6X@2G5N92`R,#$T(&%N9"`D
M-C`V+#8T,2!O9B!C;VYS=')U8W1I;VX@:6X@<')O9W)E<W,@9F]R($%S=&5R
M:6%S)B,X,C$W.R!&<F5M;VYT(&9A8VEL:71Y+B!$97!R96-I871I;VX@97AP
M96YS92!A;6]U;G1E9"!T;R`D,C8R+#8P,"!A;F0@)#(U-BPY-#4@9F]R('1H
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M<W1Y;&4],T0G=&5X="UA;&EG;CH@:G5S=&EF>3L@;6%R9VEN+6QE9G0Z(#`N
M,7!T.R!M87)G:6XM<FEG:'0Z(#`N,7!T.R!T97AT+6EN9&5N=#H@,S9P=#LG
M/CQB<B`O/CPO9&EV/CQD:78@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F
M;VYT+69A;6EL>3H@)U1I;65S($YE=R!2;VUA;B<L(%1I;65S+"!S97)I9CL@
M9F]N="US='EL93H@:71A;&EC.R!T97AT+6%L:6=N.B!J=7-T:69Y.R!M87)G
M:6XM<FEG:'0Z(#`N,7!T.R<^0V]N<W1R=6-T:6]N(&EN('!R;V=R97-S/"]D
M:78^/&1I=B!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!M87)G:6XM
M;&5F=#H@,"XQ<'0[(&UA<F=I;BUR:6=H=#H@,"XQ<'0[('1E>'0M:6YD96YT
M.B`S-G!T.R<^/&)R("\^/"]D:78^/&1I=B!S='EL93TS1"=F;VYT+7-I>F4Z
M(#$P<'0[(&9O;G0M9F%M:6QY.B`G5&EM97,@3F5W(%)O;6%N)RP@5&EM97,L
M('-E<FEF.R!T97AT+6%L:6=N.B!J=7-T:69Y.R!T97AT+6EN9&5N=#H@,S9P
M=#LG/D-O;G-T<G5C=&EO;B!I;B!P<F]G<F5S<R!O9B`D-C`V+#8T,2!A<R!O
M9B!-87)C:"`S,2P@,C`Q-2!E;G1I<F5L>2!R96QA=&5S('1O('1H92!I;7!R
M;W9E;65N=',@9F]R($%S=&5R:6%S)R!&<F5M;VYT(&9A8VEL:71Y+B!5;F1E
M<B!T:&4@=&5R;7,@;V8@=&AE(&QE87-E(&%G<F5E;65N="P@=&AE(&QA;F1L
M;W)D(&AA<R!P<F]V:61E9"!!<W1E<FEA<R!W:71H(&$@=&5N86YT(&EM<')O
M=F5M96YT(&%L;&]W86YC92!O9B`D-"PT,#`L,#`P+"!W:&EC:"!!<W1E<FEA
M<R!I<R!U<VEN9R!T;R!C;VYS=')U8W0@82!L86)O<F%T;W)Y(&%N9"!P<F]D
M=6-T:6]N(&9A8VEL:71Y('1H870@8V%N(&)E('5S960@=&\@<')O9'5C92!H
M=6UA;B!E;6)R>6]N:6,@<W1E;2!C96QL(&%N9"!R96QA=&5D('!R;V1U8W1S
M('5N9&5R(&-'35`N($]F('1H92`D-C`V+#8T,2P@)#4V,"PY-S`@<75A;&EF
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M,C`Q-2X\+V1I=CX\+V1I=CX\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM
M+2T]7TYE>'1087)T7S,Y.&)B,3)B7V4X8V%?-&(W85\X9F$P7S(V,SED9C5A
M.#DQ,`T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B\S.3AB8C$R8E]E
M.&-A7S1B-V%?.&9A,%\R-C,Y9&8U83@Y,3`O5V]R:W-H965T<R]3:&5E=#$Q
M+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN
M=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA
M<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U
M:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S
M970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,]
M,T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S
M8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R
M97!O<G0@:60],T1)1#!%344^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^26YT
M86YG:6)L92!A<W-E=',L(&YE=#QB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XS($UO;G1H<R!%;F1E9#PO
M=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T:#Y-87(N(#,Q+"`R,#$U/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#X\<W1R;VYG/DEN=&%N9VEB;&4@87-S971S+"!N970@
M6T%B<W1R86-T73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y);G1A;F=I8FQE(&%S<V5T<RP@;F5T/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\9&EV('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G
M5&EM97,@3F5W(%)O;6%N)RP@5&EM97,L('-E<FEF.R!F;VYT+7-I>F4Z(#$P
M<'0[)SX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&IU<W1I9GD[)SX\=&%B
M;&4@8V5L;'!A9&1I;F<],T0P(&-E;&QS<&%C:6YG/3-$,"!C;&%S<STS1$13
M4$9,:7-T5&%B;&4@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A
M;6EL>3H@)U1I;65S($YE=R!2;VUA;B<L(%1I;65S+"!S97)I9CL@=VED=&@Z
M(#$P,"4[)SX\='(^/'1D('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N
M="UF86UI;'DZ("=4:6UE<R!.97<@4F]M86XG+"!4:6UE<RP@<V5R:68[('=I
M9'1H.B`Q.'!T.R!V97)T:6-A;"UA;&EG;CH@=&]P.R!F;VYT+7=E:6=H=#H@
M8F]L9#L@86QI9VXZ(')I9VAT.R<^-2X\+W1D/CQT9"!S='EL93TS1"=F;VYT
M+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G5&EM97,@3F5W(%)O;6%N)RP@
M5&EM97,L('-E<FEF.R!W:61T:#H@875T;SL@=F5R=&EC86PM86QI9VXZ('1O
M<#L@9F]N="UW96EG:'0Z(&)O;&0[('1E>'0M86QI9VXZ(&IU<W1I9GD[)SY)
M;G1A;F=I8FQE(&%S<V5T<RP@;F5T/"]T9#X\+W1R/CPO=&%B;&4^/"]D:78^
M/&1I=CX\8G(@+SX\+V1I=CX\9&EV('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P
M=#L@9F]N="UF86UI;'DZ("=4:6UE<R!.97<@4F]M86XG+"!4:6UE<RP@<V5R
M:68[('1E>'0M86QI9VXZ(&IU<W1I9GD[('1E>'0M:6YD96YT.B`S-G!T.R<^
M070@36%R8V@@,S$L(#(P,34@86YD($1E8V5M8F5R(#,Q+"`R,#$T+"!I;G1A
M;F=I8FQE(&%S<V5T<R!A;F0@:6YT86YG:6)L92!A<W-E=',@;F5T(&]F(&%M
M;W)T:7IA=&EO;B!W97)E(&-O;7!R:7-E9"!O9B!T:&4@9F]L;&]W:6YG.CPO
M9&EV/CQD:78^/&)R("\^/"]D:78^/'1A8FQE(&-E;&QP861D:6YG/3-$,"!C
M96QL<W!A8VEN9STS1#`@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT
M+69A;6EL>3H@)U1I;65S($YE=R!2;VUA;B<L(%1I;65S+"!S97)I9CL@=VED
M=&@Z(#$P,"4[)SX\='(^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=V
M97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!P861D:6YG+6)O='1O;3H@,G!X.R<^
M)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W9E<G1I
M8V%L+6%L:6=N.B!B;W1T;VT[('!A9&1I;F<M8F]T=&]M.B`R<'@[)SXF(S$V
M,#L\+W1D/CQT9"!C;VQS<&%N/3-$,B!S='EL93TS1"=V97)T:6-A;"UA;&EG
M;CH@8F]T=&]M.R!W:&ET92US<&%C93H@;F]W<F%P.R!B;W)D97(M8F]T=&]M
M.B`C,#`P,#`P(#)P>"!S;VQI9#LG/CQD:78@<W1Y;&4],T0G9F]N="US:7IE
M.B`Q,'!T.R!F;VYT+69A;6EL>3H@)U1I;65S($YE=R!2;VUA;B<L(%1I;65S
M+"!S97)I9CL@9F]N="UW96EG:'0Z(&)O;&0[('1E>'0M86QI9VXZ(&-E;G1E
M<CLG/DUA<F-H(#,Q+"`R,#$U/"]D:78^/&1I=B!S='EL93TS1"=F;VYT+7-I
M>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G5&EM97,@3F5W(%)O;6%N)RP@5&EM
M97,L('-E<FEF.R!F;VYT+7=E:6=H=#H@8F]L9#L@=&5X="UA;&EG;CH@8V5N
M=&5R.R<^*%5N875D:71E9"D\+V1I=CX\+W1D/CQT9"!N;W=R87`],T1N;W=R
M87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B
M;W1T;VT[('!A9&1I;F<M8F]T=&]M.B`R<'@[('1E>'0M86QI9VXZ(&QE9G0[
M)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=F5R
M=&EC86PM86QI9VXZ(&)O='1O;3L@<&%D9&EN9RUB;W1T;VTZ(#)P>#LG/B8C
M,38P.SPO=&0^/'1D(&-O;'-P86X],T0R('9A;&EG;CTS1&)O='1O;2!S='EL
M93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B;W)D97(M8F]T=&]M.B`C
M,#`P,#`P(#)P>"!S;VQI9#LG/CQD:78@<W1Y;&4],T0G9F]N="US:7IE.B`Q
M,'!T.R!F;VYT+69A;6EL>3H@)U1I;65S($YE=R!2;VUA;B<L(%1I;65S+"!S
M97)I9CL@9F]N="UW96EG:'0Z(&)O;&0[('1E>'0M86QI9VXZ(&-E;G1E<CLG
M/D1E8V5M8F5R(#,Q+#PO9&EV/CQD:78@<W1Y;&4],T0G9F]N="US:7IE.B`Q
M,'!T.R!F;VYT+69A;6EL>3H@)U1I;65S($YE=R!2;VUA;B<L(%1I;65S+"!S
M97)I9CL@9F]N="UW96EG:'0Z(&)O;&0[('1E>'0M86QI9VXZ(&-E;G1E<CLG
M/C(P,30\+V1I=CX\+W1D/CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$
M8F]T=&]M('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[('!A9&1I
M;F<M8F]T=&]M.B`R<'@[('1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D
M/CPO='(^/'1R/CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=VED=&@Z
M(#<V)3L@=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO
M<CH@(V-C965F9CLG/CQD:78@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F
M;VYT+69A;6EL>3H@)U1I;65S($YE=R!2;VUA;B<L(%1I;65S+"!S97)I9CL@
M=&5X="UA;&EG;CH@;&5F=#L@;6%R9VEN+6QE9G0Z(#<N,G!T.R!T97AT+6EN
M9&5N=#H@+3<N,G!T.R<^26YT86YG:6)L92!A<W-E=',\+V1I=CX\+W1D/CQT
M9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=VED=&@Z(#$E.R!V97)T:6-A
M;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B`C8V-E969F.R<^
M)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H
M.B`Q)3L@=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@=&5X="UA;&EG;CH@;&5F
M=#L@8F%C:V=R;W5N9"UC;VQO<CH@(V-C965F9CLG/CQD:78@<W1Y;&4],T0G
M9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)U1I;65S($YE=R!2;VUA
M;B<L(%1I;65S+"!S97)I9CLG/B0\+V1I=CX\+W1D/CQT9"!V86QI9VX],T1B
M;W1T;VT@<W1Y;&4],T0G=VED=&@Z(#DE.R!V97)T:6-A;"UA;&EG;CH@8F]T
M=&]M.R!T97AT+6%L:6=N.B!R:6=H=#L@8F%C:V=R;W5N9"UC;VQO<CH@(V-C
M965F9CLG/CQD:78@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A
M;6EL>3H@)U1I;65S($YE=R!2;VUA;B<L(%1I;65S+"!S97)I9CLG/C4R+#4V
M,BPU-#D\+V1I=CX\+W1D/CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$
M8F]T=&]M('-T>6QE/3-$)W=I9'1H.B`Q)3L@=F5R=&EC86PM86QI9VXZ(&)O
M='1O;3L@=&5X="UA;&EG;CH@;&5F=#L@8F%C:V=R;W5N9"UC;VQO<CH@(V-C
M965F9CLG/B8C,38P.SPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS
M1"=W:61T:#H@,24[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&)A8VMG<F]U
M;F0M8V]L;W(Z("-C8V5E9F8[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B
M;W1T;VT@<W1Y;&4],T0G=VED=&@Z(#$E.R!V97)T:6-A;"UA;&EG;CH@8F]T
M=&]M.R!T97AT+6%L:6=N.B!L969T.R!B86-K9W)O=6YD+6-O;&]R.B`C8V-E
M969F.R<^/&1I=B!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M
M:6QY.B`G5&EM97,@3F5W(%)O;6%N)RP@5&EM97,L('-E<FEF.R<^)#PO9&EV
M/CPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#H@.24[
M('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[('1E>'0M86QI9VXZ(')I9VAT.R!B
M86-K9W)O=6YD+6-O;&]R.B`C8V-E969F.R<^/&1I=B!S='EL93TS1"=F;VYT
M+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G5&EM97,@3F5W(%)O;6%N)RP@
M5&EM97,L('-E<FEF.R<^-3(L-38R+#4T.3PO9&EV/CPO=&0^/'1D(&YO=W)A
M<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=VED=&@Z(#$E
M.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!T97AT+6%L:6=N.B!L969T.R!B
M86-K9W)O=6YD+6-O;&]R.B`C8V-E969F.R<^)B,Q-C`[/"]T9#X\+W1R/CQT
M<CX\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.B`W-B4[('9E
M<G1I8V%L+6%L:6=N.B!B;W1T;VT[('!A9&1I;F<M8F]T=&]M.B`R<'@[(&)A
M8VMG<F]U;F0M8V]L;W(Z("-F9F9F9F8[)SX\9&EV('-T>6QE/3-$)V9O;G0M
M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=4:6UE<R!.97<@4F]M86XG+"!4
M:6UE<RP@<V5R:68[('1E>'0M86QI9VXZ(&QE9G0[(&UA<F=I;BUL969T.B`W
M+C)P=#L@=&5X="UI;F1E;G0Z("TW+C)P=#LG/D%C8W5M=6QA=&5D(&%M;W)T
M:7IA=&EO;CPO9&EV/CPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS
M1"=W:61T:#H@,24[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[('!A9&1I;F<M
M8F]T=&]M.B`R<'@[(&)A8VMG<F]U;F0M8V]L;W(Z("-F9F9F9F8[)SXF(S$V
M,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=VED=&@Z(#$E
M.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B;W)D97(M8F]T=&]M.B`C,#`P
M,#`P(#)P>"!S;VQI9#L@=&5X="UA;&EG;CH@;&5F=#L@8F%C:V=R;W5N9"UC
M;VQO<CH@(V9F9F9F9CLG/B8C,38P.SPO=&0^/'1D('9A;&EG;CTS1&)O='1O
M;2!S='EL93TS1"=W:61T:#H@.24[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[
M(&)O<F1E<BUB;W1T;VTZ(",P,#`P,#`@,G!X('-O;&ED.R!T97AT+6%L:6=N
M.B!R:6=H=#L@8F%C:V=R;W5N9"UC;VQO<CH@(V9F9F9F9CLG/CQD:78@<W1Y
M;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)U1I;65S($YE
M=R!2;VUA;B<L(%1I;65S+"!S97)I9CLG/B@Q-2PP,C@L,C0W/"]D:78^/"]T
M9#X\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;2!S='EL93TS
M1"=W:61T:#H@,24[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[('!A9&1I;F<M
M8F]T=&]M.B`R<'@[('1E>'0M86QI9VXZ(&QE9G0[(&)A8VMG<F]U;F0M8V]L
M;W(Z("-F9F9F9F8[)SX\9&EV('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@
M9F]N="UF86UI;'DZ("=4:6UE<R!.97<@4F]M86XG+"!4:6UE<RP@<V5R:68[
M)SXI/"]D:78^/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I
M9'1H.B`Q)3L@=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@<&%D9&EN9RUB;W1T
M;VTZ(#)P>#L@8F%C:V=R;W5N9"UC;VQO<CH@(V9F9F9F9CLG/B8C,38P.SPO
M=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#H@,24[('9E
M<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&)O<F1E<BUB;W1T;VTZ(",P,#`P,#`@
M,G!X('-O;&ED.R!T97AT+6%L:6=N.B!L969T.R!B86-K9W)O=6YD+6-O;&]R
M.B`C9F9F9F9F.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T
M>6QE/3-$)W=I9'1H.B`Y)3L@=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@8F]R
M9&5R+6)O='1O;3H@(S`P,#`P,"`R<'@@<V]L:60[('1E>'0M86QI9VXZ(')I
M9VAT.R!B86-K9W)O=6YD+6-O;&]R.B`C9F9F9F9F.R<^/&1I=B!S='EL93TS
M1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G5&EM97,@3F5W(%)O
M;6%N)RP@5&EM97,L('-E<FEF.R<^*#$S+#<Q-"PQ-3,\+V1I=CX\+W1D/CQT
M9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I
M9'1H.B`Q)3L@=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@<&%D9&EN9RUB;W1T
M;VTZ(#)P>#L@=&5X="UA;&EG;CH@;&5F=#L@8F%C:V=R;W5N9"UC;VQO<CH@
M(V9F9F9F9CLG/CQD:78@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT
M+69A;6EL>3H@)U1I;65S($YE=R!2;VUA;B<L(%1I;65S+"!S97)I9CLG/BD\
M+V1I=CX\+W1D/CPO='(^/'1R/CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4]
M,T0G=VED=&@Z(#<V)3L@=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@<&%D9&EN
M9RUB;W1T;VTZ(#1P>#L@8F%C:V=R;W5N9"UC;VQO<CH@(V-C965F9CLG/CQD
M:78@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)U1I
M;65S($YE=R!2;VUA;B<L(%1I;65S+"!S97)I9CL@=&5X="UA;&EG;CH@;&5F
M=#L@;6%R9VEN+6QE9G0Z(#<N,G!T.R!T97AT+6EN9&5N=#H@+3<N,G!T.R<^
M26YT86YG:6)L92!A<W-E=',L(&YE=#PO9&EV/CPO=&0^/'1D('9A;&EG;CTS
M1&)O='1O;2!S='EL93TS1"=W:61T:#H@,24[('9E<G1I8V%L+6%L:6=N.B!B
M;W1T;VT[('!A9&1I;F<M8F]T=&]M.B`T<'@[(&)A8VMG<F]U;F0M8V]L;W(Z
M("-C8V5E9F8[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y
M;&4],T0G=VED=&@Z(#$E.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B;W)D
M97(M8F]T=&]M.B`C,#`P,#`P(#1P>"!D;W5B;&4[('1E>'0M86QI9VXZ(&QE
M9G0[(&)A8VMG<F]U;F0M8V]L;W(Z("-C8V5E9F8[)SX\9&EV('-T>6QE/3-$
M)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=4:6UE<R!.97<@4F]M
M86XG+"!4:6UE<RP@<V5R:68[)SXD/"]D:78^/"]T9#X\=&0@=F%L:6=N/3-$
M8F]T=&]M('-T>6QE/3-$)W=I9'1H.B`Y)3L@=F5R=&EC86PM86QI9VXZ(&)O
M='1O;3L@8F]R9&5R+6)O='1O;3H@(S`P,#`P,"`T<'@@9&]U8FQE.R!T97AT
M+6%L:6=N.B!R:6=H=#L@8F%C:V=R;W5N9"UC;VQO<CH@(V-C965F9CLG/CQD
M:78@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)U1I
M;65S($YE=R!2;VUA;B<L(%1I;65S+"!S97)I9CLG/C,W+#4S-"PS,#(\+V1I
M=CX\+W1D/CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T
M>6QE/3-$)W=I9'1H.B`Q)3L@=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@<&%D
M9&EN9RUB;W1T;VTZ(#1P>#L@=&5X="UA;&EG;CH@;&5F=#L@8F%C:V=R;W5N
M9"UC;VQO<CH@(V-C965F9CLG/B8C,38P.SPO=&0^/'1D('9A;&EG;CTS1&)O
M='1O;2!S='EL93TS1"=W:61T:#H@,24[('9E<G1I8V%L+6%L:6=N.B!B;W1T
M;VT[('!A9&1I;F<M8F]T=&]M.B`T<'@[(&)A8VMG<F]U;F0M8V]L;W(Z("-C
M8V5E9F8[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4]
M,T0G=VED=&@Z(#$E.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B;W)D97(M
M8F]T=&]M.B`C,#`P,#`P(#1P>"!D;W5B;&4[('1E>'0M86QI9VXZ(&QE9G0[
M(&)A8VMG<F]U;F0M8V]L;W(Z("-C8V5E9F8[)SX\9&EV('-T>6QE/3-$)V9O
M;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=4:6UE<R!.97<@4F]M86XG
M+"!4:6UE<RP@<V5R:68[)SXD/"]D:78^/"]T9#X\=&0@=F%L:6=N/3-$8F]T
M=&]M('-T>6QE/3-$)W=I9'1H.B`Y)3L@=F5R=&EC86PM86QI9VXZ(&)O='1O
M;3L@8F]R9&5R+6)O='1O;3H@(S`P,#`P,"`T<'@@9&]U8FQE.R!T97AT+6%L
M:6=N.B!R:6=H=#L@8F%C:V=R;W5N9"UC;VQO<CH@(V-C965F9CLG/CQD:78@
M<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)U1I;65S
M($YE=R!2;VUA;B<L(%1I;65S+"!S97)I9CLG/C,X+#@T."PS.38\+V1I=CX\
M+W1D/CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE
M/3-$)W=I9'1H.B`Q)3L@=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@<&%D9&EN
M9RUB;W1T;VTZ(#1P>#L@=&5X="UA;&EG;CH@;&5F=#L@8F%C:V=R;W5N9"UC
M;VQO<CH@(V-C965F9CLG/B8C,38P.SPO=&0^/"]T<CX\+W1A8FQE/CQD:78@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@:G5S=&EF>3LG/CQB<B`O/CPO9&EV/CQD
M:78@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)U1I
M;65S($YE=R!2;VUA;B<L(%1I;65S+"!S97)I9CL@=&5X="UA;&EG;CH@:G5S
M=&EF>3L@=&5X="UI;F1E;G0Z(#,V<'0[)SY":6]4:6UE(&%M;W)T:7IE<R!I
M=',@:6YT86YG:6)L92!A<W-E=',@9V5N97)A;&QY(&]V97(@86X@97-T:6UA
M=&5D('!E<FEO9"!O9B`Q,"!Y96%R<R!O;B!A('-T<F%I9VAT(&QI;F4@8F%S
M:7,N($)I;U1I;64@<F5C;V=N:7IE9"`D,2PS,30L,#DT(&%N9"`D,2PS-C<L
M.3DX(&EN(&%M;W)T:7IA=&EO;B!E>'!E;G-E(&]F(&EN=&%N9VEB;&4@87-S
M971S+"!I;F-L=61E9"!I;B!R97-E87)C:"!A;F0@9&5V96QO<&UE;G0L)B,Q
M-C`[9'5R:6YG('1H92!T:')E92!M;VYT:',@96YD960@36%R8V@@,S$L(#(P
M,34@86YD(#(P,30L(')E<W!E8W1I=F5L>2X\+V1I=CX\+V1I=CX\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B
M;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7S,Y.&)B,3)B7V4X
M8V%?-&(W85\X9F$P7S(V,SED9C5A.#DQ,`T*0V]N=&5N="U,;V-A=&EO;CH@
M9FEL93HO+R]#.B\S.3AB8C$R8E]E.&-A7S1B-V%?.&9A,%\R-C,Y9&8U83@Y
M,3`O5V]R:W-H965T<R]3:&5E=#$R+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M
M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X
M="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D
M/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N
M=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS
M1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO
M=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-
M"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%344^#0H@("`@
M("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O
M=W-P86X],T0R/CQS=')O;F<^4F]Y86QT>2!/8FQI9V%T:6]N(&%N9"!$969E
M<G)E9"!,:6-E;G-E($9E97,\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^,R!-;VYT:',@16YD960\+W1H
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&@^36%R+B`S,2P@,C`Q-3QB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^/'-T<F]N9SY2;WEA;'1Y($]B;&EG871I;VX@86YD($1E
M9F5R<F5D($QI8V5N<V4@1F5E<R!;06)S=')A8W1=/"]S=')O;F<^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E)O>6%L='D@3V)L:6=A=&EO
M;B!A;F0@1&5F97)R960@3&EC96YS92!&965S/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\9&EV('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G5&EM
M97,@3F5W(%)O;6%N)RP@5&EM97,L('-E<FEF.R!F;VYT+7-I>F4Z(#$P<'0[
M)SX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&IU<W1I9GD[)SX\=&%B;&4@
M8V5L;'!A9&1I;F<],T0P(&-E;&QS<&%C:6YG/3-$,"!C;&%S<STS1$134$9,
M:7-T5&%B;&4@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL
M>3H@)U1I;65S($YE=R!2;VUA;B<L(%1I;65S+"!S97)I9CL@=VED=&@Z(#$P
M,"4[)SX\='(^/'1D('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF
M86UI;'DZ("=4:6UE<R!.97<@4F]M86XG+"!4:6UE<RP@<V5R:68[('=I9'1H
M.B`Q.'!T.R!V97)T:6-A;"UA;&EG;CH@=&]P.R!F;VYT+7=E:6=H=#H@8F]L
M9#L@86QI9VXZ(')I9VAT.R<^-BX\+W1D/CQT9"!S='EL93TS1"=F;VYT+7-I
M>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G5&EM97,@3F5W(%)O;6%N)RP@5&EM
M97,L('-E<FEF.R!W:61T:#H@875T;SL@=F5R=&EC86PM86QI9VXZ('1O<#L@
M9F]N="UW96EG:'0Z(&)O;&0[('1E>'0M86QI9VXZ(&IU<W1I9GD[)SY2;WEA
M;'1Y($]B;&EG871I;VX@86YD($1E9F5R<F5D($QI8V5N<V4@1F5E<SPO=&0^
M/"]T<CX\+W1A8FQE/CPO9&EV/CQD:78@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M:G5S=&EF>3LG/CQB<B`O/CPO9&EV/CQD:78@<W1Y;&4],T0G9F]N="US:7IE
M.B`Q,'!T.R!F;VYT+69A;6EL>3H@)U1I;65S($YE=R!2;VUA;B<L(%1I;65S
M+"!S97)I9CL@=&5X="UA;&EG;CH@:G5S=&EF>3L@=&5X="UI;F1E;G0Z(#,V
M<'0[)SY":6]4:6UE(&%M;W)T:7IE<R!D969E<G)E9"!L:6-E;G-E(&9E97,@
M;W9E<B!T:&4@97-T:6UA=&5D('5S969U;"!L:79E<R!O9B!T:&4@;&EC96YS
M960@=&5C:&YO;&]G:65S(&]R(&QI8V5N<V5D(')E<V5A<F-H('!R;V1U8W1S
M+B!":6]4:6UE(&ES(&%P<&QY:6YG(&$@,3`@>65A<B!E<W1I;6%T960@=7-E
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M>'0M:6YD96YT.B`S-G!T.R<^07,@;V8@36%R8V@@,S$L(#(P,34L(&9U='5R
M92!A;6]R=&EZ871I;VX@;V8@9&5F97)R960@;&EC96YS92!F965S(&1E<V-R
M:6)E9"!A8F]V92!W87,@87,@9F]L;&]W<SH\+V1I=CX\9&EV/CQB<B`O/CPO
M9&EV/CQT86)L92!A;&EG;CTS1&-E;G1E<B!B;W)D97(],T0P(&-E;&QP861D
M:6YG/3-$,"!C96QL<W!A8VEN9STS1#`@<W1Y;&4],T0G9F]N="US:7IE.B`Q
M,'!T.R!F;VYT+69A;6EL>3H@)U1I;65S($YE=R!2;VUA;B<L(%1I;65S+"!S
M97)I9CL@=VED=&@Z(#4P)3LG/CQT<CX\=&0@=F%L:6=N/3-$8F]T=&]M('-T
M>6QE/3-$)W=I9'1H.B`S."4[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&)O
M<F1E<BUB;W1T;VTZ(",P,#`P,#`@,G!X('-O;&ED.R<^/&1I=B!S='EL93TS
M1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G5&EM97,@3F5W(%)O
M;6%N)RP@5&EM97,L('-E<FEF.R!F;VYT+7=E:6=H=#H@8F]L9#L@=&5X="UA
M;&EG;CH@8V5N=&5R.R<^665A<B!%;F1E9"!$96-E;6)E<B`S,2P\+V1I=CX\
M+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=VED=&@Z(#$E.R!V
M97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!P861D:6YG+6)O='1O;3H@,G!X.R<^
M)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H
M.B`Q,"4[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&)O<F1E<BUB;W1T;VTZ
M(",P,#`P,#`@,G!X('-O;&ED.R<^/&1I=B!S='EL93TS1"=F;VYT+7-I>F4Z
M(#$P<'0[(&9O;G0M9F%M:6QY.B`G5&EM97,@3F5W(%)O;6%N)RP@5&EM97,L
M('-E<FEF.R!F;VYT+7=E:6=H=#H@8F]L9#L@=&5X="UA;&EG;CH@8V5N=&5R
M.R<^1&5F97)R960\+V1I=CX\9&EV('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P
M=#L@9F]N="UF86UI;'DZ("=4:6UE<R!.97<@4F]M86XG+"!4:6UE<RP@<V5R
M:68[(&9O;G0M=V5I9VAT.B!B;VQD.R!T97AT+6%L:6=N.B!C96YT97([)SY,
M:6-E;G-E($9E97,\+V1I=CX\+W1D/CQT9"!N;W=R87`],T1N;W=R87`@=F%L
M:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.B`Q)3L@=F5R=&EC86PM86QI
M9VXZ(&)O='1O;3L@<&%D9&EN9RUB;W1T;VTZ(#)P>#L@=&5X="UA;&EG;CH@
M;&5F=#LG/B8C,38P.SPO=&0^/"]T<CX\='(^/'1D('9A;&EG;CTS1&)O='1O
M;2!S='EL93TS1"=W:61T:#H@,S@E.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M
M.R!B86-K9W)O=6YD+6-O;&]R.B`C8V-E969F.R<^/&1I=B!S='EL93TS1"=F
M;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G5&EM97,@3F5W(%)O;6%N
M)RP@5&EM97,L('-E<FEF.R!T97AT+6%L:6=N.B!C96YT97([)SXR,#$U/"]D
M:78^/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.B`Q
M)3L@=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@
M(V-C965F9CLG/B8C,38P.SPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL
M93TS1"=W:61T:#H@,3`E.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!T97AT
M+6%L:6=N.B!L969T.R!B86-K9W)O=6YD+6-O;&]R.B`C8V-E969F.R<^/&1I
M=B!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G5&EM
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M;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)U1I;65S($YE
M=R!2;VUA;B<L(%1I;65S+"!S97)I9CL@=&5X="UA;&EG;CH@8V5N=&5R.R<^
M,C`Q-CPO9&EV/CPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W
M:61T:#H@,24[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&)A8VMG<F]U;F0M
M8V]L;W(Z("-F9F9F9F8[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T
M;VT@<W1Y;&4],T0G=VED=&@Z(#$P)3L@=F5R=&EC86PM86QI9VXZ(&)O='1O
M;3L@=&5X="UA;&EG;CH@8V5N=&5R.R!B86-K9W)O=6YD+6-O;&]R.B`C9F9F
M9F9F.R<^)B,Q-C`[,3`Y+#4P,#PO=&0^/'1D(&YO=W)A<#TS1&YO=W)A<"!V
M86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=VED=&@Z(#$E.R!V97)T:6-A;"UA
M;&EG;CH@8F]T=&]M.R!T97AT+6%L:6=N.B!L969T.R!B86-K9W)O=6YD+6-O
M;&]R.B`C9F9F9F9F.R<^)B,Q-C`[/"]T9#X\+W1R/CQT<CX\=&0@=F%L:6=N
M/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.B`S."4[('9E<G1I8V%L+6%L:6=N
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M+6-O;&]R.B`C8V-E969F.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T
M=&]M('-T>6QE/3-$)W=I9'1H.B`Q,"4[('9E<G1I8V%L+6%L:6=N.B!B;W1T
M;VT[('1E>'0M86QI9VXZ(&-E;G1E<CL@8F%C:V=R;W5N9"UC;VQO<CH@(V-C
M965F9CLG/B8C,38P.S$P.2PU,#`\+W1D/CQT9"!N;W=R87`],T1N;W=R87`@
M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.B`Q)3L@=F5R=&EC86PM
M86QI9VXZ(&)O='1O;3L@=&5X="UA;&EG;CH@;&5F=#L@8F%C:V=R;W5N9"UC
M;VQO<CH@(V-C965F9CLG/B8C,38P.SPO=&0^/"]T<CX\='(^/'1D('9A;&EG
M;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#H@,S@E.R!V97)T:6-A;"UA;&EG
M;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B`C9F9F9F9F.R<^/&1I=B!S
M='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G5&EM97,@
M3F5W(%)O;6%N)RP@5&EM97,L('-E<FEF.R!T97AT+6%L:6=N.B!C96YT97([
M)SXR,#$X/"]D:78^/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$
M)W=I9'1H.B`Q)3L@=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N
M9"UC;VQO<CH@(V9F9F9F9CLG/B8C,38P.SPO=&0^/'1D('9A;&EG;CTS1&)O
M='1O;2!S='EL93TS1"=W:61T:#H@,3`E.R!V97)T:6-A;"UA;&EG;CH@8F]T
M=&]M.R!T97AT+6%L:6=N.B!C96YT97([(&)A8VMG<F]U;F0M8V]L;W(Z("-F
M9F9F9F8[)SXF(S$V,#LW,RPV-C<\+W1D/CQT9"!N;W=R87`],T1N;W=R87`@
M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.B`Q)3L@=F5R=&EC86PM
M86QI9VXZ(&)O='1O;3L@=&5X="UA;&EG;CH@;&5F=#L@8F%C:V=R;W5N9"UC
M;VQO<CH@(V9F9F9F9CLG/B8C,38P.SPO=&0^/"]T<CX\='(^/'1D('9A;&EG
M;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#H@,S@E.R!V97)T:6-A;"UA;&EG
M;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B`C8V-E969F.R<^/&1I=B!S
M='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G5&EM97,@
M3F5W(%)O;6%N)RP@5&EM97,L('-E<FEF.R!T97AT+6%L:6=N.B!C96YT97([
M)SXR,#$Y/"]D:78^/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$
M)W=I9'1H.B`Q)3L@=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N
M9"UC;VQO<CH@(V-C965F9CLG/B8C,38P.SPO=&0^/'1D('9A;&EG;CTS1&)O
M='1O;2!S='EL93TS1"=W:61T:#H@,3`E.R!V97)T:6-A;"UA;&EG;CH@8F]T
M=&]M.R!T97AT+6%L:6=N.B!C96YT97([(&)A8VMG<F]U;F0M8V]L;W(Z("-C
M8V5E9F8[)SXF(S$V,#LR-"PP.#,\+W1D/CQT9"!N;W=R87`],T1N;W=R87`@
M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.B`Q)3L@=F5R=&EC86PM
M86QI9VXZ(&)O='1O;3L@=&5X="UA;&EG;CH@;&5F=#L@8F%C:V=R;W5N9"UC
M;VQO<CH@(V-C965F9CLG/B8C,38P.SPO=&0^/"]T<CX\='(^/'1D('9A;&EG
M;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#H@,S@E.R!V97)T:6-A;"UA;&EG
M;CH@8F]T=&]M.R!P861D:6YG+6)O='1O;3H@,G!X.R!B86-K9W)O=6YD+6-O
M;&]R.B`C9F9F9F9F.R<^/&1I=B!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[
M(&9O;G0M9F%M:6QY.B`G5&EM97,@3F5W(%)O;6%N)RP@5&EM97,L('-E<FEF
M.R!T97AT+6%L:6=N.B!C96YT97([)SY4:&5R96%F=&5R/"]D:78^/"]T9#X\
M=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.B`Q)3L@=F5R=&EC
M86PM86QI9VXZ(&)O='1O;3L@<&%D9&EN9RUB;W1T;VTZ(#)P>#L@8F%C:V=R
M;W5N9"UC;VQO<CH@(V9F9F9F9CLG/B8C,38P.SPO=&0^/'1D('9A;&EG;CTS
M1&)O='1O;2!S='EL93TS1"=W:61T:#H@,3`E.R!V97)T:6-A;"UA;&EG;CH@
M8F]T=&]M.R!B;W)D97(M8F]T=&]M.B`C,#`P,#`P(#)P>"!S;VQI9#L@=&5X
M="UA;&EG;CH@8V5N=&5R.R!B86-K9W)O=6YD+6-O;&]R.B`C9F9F9F9F.R<^
M)B,Q-C`[,C`L,#@S/"]T9#X\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS
M1&)O='1O;2!S='EL93TS1"=W:61T:#H@,24[('9E<G1I8V%L+6%L:6=N.B!B
M;W1T;VT[('!A9&1I;F<M8F]T=&]M.B`R<'@[('1E>'0M86QI9VXZ(&QE9G0[
M(&)A8VMG<F]U;F0M8V]L;W(Z("-F9F9F9F8[)SXF(S$V,#L\+W1D/CPO='(^
M/'1R/CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=VED=&@Z(#,X)3L@
M=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@<&%D9&EN9RUB;W1T;VTZ(#1P>#L@
M8F%C:V=R;W5N9"UC;VQO<CH@(V-C965F9CLG/CQD:78@<W1Y;&4],T0G9F]N
M="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)U1I;65S($YE=R!2;VUA;B<L
M(%1I;65S+"!S97)I9CL@=&5X="UA;&EG;CH@8V5N=&5R.R<^5&]T86P\+V1I
M=CX\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=VED=&@Z(#$E
M.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!P861D:6YG+6)O='1O;3H@-'!X
M.R!B86-K9W)O=6YD+6-O;&]R.B`C8V-E969F.R<^)B,Q-C`[/"]T9#X\=&0@
M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.B`Q,"4[('9E<G1I8V%L
M+6%L:6=N.B!B;W1T;VT[(&)O<F1E<BUB;W1T;VTZ(",P,#`P,#`@-'!X(&1O
M=6)L93L@=&5X="UA;&EG;CH@;&5F=#L@8F%C:V=R;W5N9"UC;VQO<CH@(V-C
M965F9CLG/CQD:78@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A
M;6EL>3H@)U1I;65S($YE=R!2;VUA;B<L(%1I;65S+"!S97)I9CL@=&5X="UA
M;&EG;CH@8V5N=&5R.R<^)#0Q."PY-3@\+V1I=CX\+W1D/CQT9"!N;W=R87`]
M,T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.B`Q)3L@
M=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@<&%D9&EN9RUB;W1T;VTZ(#1P>#L@
M=&5X="UA;&EG;CH@;&5F=#L@8F%C:V=R;W5N9"UC;VQO<CH@(V-C965F9CLG
M/B8C,38P.SPO=&0^/"]T<CX\+W1A8FQE/CQD:78^/&)R("\^/"]D:78^/&1I
M=B!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G5&EM
M97,@3F5W(%)O;6%N)RP@5&EM97,L('-E<FEF.R!T97AT+6%L:6=N.B!J=7-T
M:69Y.R!T97AT+6EN9&5N=#H@,S9P=#LG/E1H92!C=7)R96YT('!O<G1I;VX@
M:6X@=&AE(&%M;W5N="!O9B`D,3`Y+#4P,"!I<R!I;F-L=61E9"!I;B!P<F5P
M86ED(&5X<&5N<V5S(&%N9"!O=&AE<B!C=7)R96YT(&%S<V5T<RX@5&AE(&YO
M;F-U<G)E;G0@<&]R=&EO;B!I;B!T:&4@86UO=6YT(&]F("0S,#DL-#4X(&ES
M(&EN8VQU9&5D(&EN(&1E9F5R<F5D(&QI8V5N<V4@86YD(&-O;G-U;'1I;F<@
M9F5E<RX\+V1I=CX\+V1I=CX\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM
M+2T]7TYE>'1087)T7S,Y.&)B,3)B7V4X8V%?-&(W85\X9F$P7S(V,SED9C5A
M.#DQ,`T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B\S.3AB8C$R8E]E
M.&-A7S1B-V%?.&9A,%\R-C,Y9&8U83@Y,3`O5V]R:W-H965T<R]3:&5E=#$S
M+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN
M=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA
M<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U
M:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S
M970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,]
M,T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S
M8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R
M97!O<G0@:60],T1)1#!%344^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^06-C
M;W5N=',@4&%Y86)L92!A;F0@06-C<G5E9"!,:6%B:6QI=&EE<SQB<CX\+W-T
M<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$
M,3XS($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y-87(N(#,Q+"`R,#$U/&)R/CPO
M=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D%C8V]U
M;G1S(%!A>6%B;&4@86YD($%C8W)U960@3&EA8FEL:71I97,@6T%B<W1R86-T
M73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!
M8V-O=6YT<R!087EA8FQE(&%N9"!!8V-R=65D($QI86)I;&ET:65S/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\9&EV('-T>6QE/3-$)V9O;G0M
M9F%M:6QY.B`G5&EM97,@3F5W(%)O;6%N)RP@5&EM97,L('-E<FEF.R!F;VYT
M+7-I>F4Z(#$P<'0[)SX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&IU<W1I
M9GD[)SX\=&%B;&4@8V5L;'!A9&1I;F<],T0P(&-E;&QS<&%C:6YG/3-$,"!C
M;&%S<STS1$134$9,:7-T5&%B;&4@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T
M.R!F;VYT+69A;6EL>3H@)U1I;65S($YE=R!2;VUA;B<L(%1I;65S+"!S97)I
M9CL@=VED=&@Z(#$P,"4[)SX\='(^/'1D('-T>6QE/3-$)V9O;G0M<VEZ93H@
M,3!P=#L@9F]N="UF86UI;'DZ("=4:6UE<R!.97<@4F]M86XG+"!4:6UE<RP@
M<V5R:68[('=I9'1H.B`Q.'!T.R!V97)T:6-A;"UA;&EG;CH@=&]P.R!F;VYT
M+7=E:6=H=#H@8F]L9#L@86QI9VXZ(')I9VAT.R<^-RX\+W1D/CQT9"!S='EL
M93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G5&EM97,@3F5W
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M;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G5&EM97,@3F5W(%)O;6%N
M)RP@5&EM97,L('-E<FEF.R!T97AT+6%L:6=N.B!J=7-T:69Y.R!T97AT+6EN
M9&5N=#H@,S9P=#LG/D%T($UA<F-H(#,Q+"`R,#$U(&%N9"!$96-E;6)E<B`S
M,2P@,C`Q-"P@86-C;W5N=',@<&%Y86)L92!A;F0@86-C<G5E9"!L:6%B:6QI
M=&EE<R!C;VYS:7-T960@;V8@=&AE(&9O;&QO=VEN9SH\+V1I=CX\9&EV/CQB
M<B`O/CPO9&EV/CQT86)L92!C96QL<&%D9&EN9STS1#`@8V5L;'-P86-I;F<]
M,T0P('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=4
M:6UE<R!.97<@4F]M86XG+"!4:6UE<RP@<V5R:68[('=I9'1H.B`Q,#`E.R<^
M/'1R/CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=F5R=&EC86PM86QI
M9VXZ(&)O='1O;3L@<&%D9&EN9RUB;W1T;VTZ(#)P>#LG/B8C,38P.SPO=&0^
M/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@
M8F]T=&]M.R!P861D:6YG+6)O='1O;3H@,G!X.R<^)B,Q-C`[/"]T9#X\=&0@
M8V]L<W!A;CTS1#(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@
M=VAI=&4M<W!A8V4Z(&YO=W)A<#L@8F]R9&5R+6)O='1O;3H@(S`P,#`P,"`R
M<'@@<V]L:60[)SX\9&EV('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N
M="UF86UI;'DZ("=4:6UE<R!.97<@4F]M86XG+"!4:6UE<RP@<V5R:68[(&9O
M;G0M=V5I9VAT.B!B;VQD.R!T97AT+6%L:6=N.B!C96YT97([)SY-87)C:"`S
M,2P@,C`Q-3PO9&EV/CQD:78@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F
M;VYT+69A;6EL>3H@)U1I;65S($YE=R!2;VUA;B<L(%1I;65S+"!S97)I9CL@
M9F]N="UW96EG:'0Z(&)O;&0[('1E>'0M86QI9VXZ(&-E;G1E<CLG/BA5;F%U
M9&ET960I/"]D:78^/"]T9#X\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS
M1&)O='1O;2!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!P861D
M:6YG+6)O='1O;3H@,G!X.R!T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T
M9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N
M.B!B;W1T;VT[('!A9&1I;F<M8F]T=&]M.B`R<'@[)SXF(S$V,#L\+W1D/CQT
M9"!C;VQS<&%N/3-$,B!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=F5R=&EC
M86PM86QI9VXZ(&)O='1O;3L@8F]R9&5R+6)O='1O;3H@(S`P,#`P,"`R<'@@
M<V]L:60[)SX\9&EV('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF
M86UI;'DZ("=4:6UE<R!.97<@4F]M86XG+"!4:6UE<RP@<V5R:68[(&9O;G0M
M=V5I9VAT.B!B;VQD.R!T97AT+6%L:6=N.B!C96YT97([)SY$96-E;6)E<B`S
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M,G!X.R!T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X\+W1R/CQT<CX\
M=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.B`W-B4[('9E<G1I
M8V%L+6%L:6=N.B!B;W1T;VT[(&)A8VMG<F]U;F0M8V]L;W(Z("-C8V5E9F8[
M)SX\9&EV('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ
M("=4:6UE<R!.97<@4F]M86XG+"!4:6UE<RP@<V5R:68[('1E>'0M86QI9VXZ
M(&QE9G0[(&UA<F=I;BUL969T.B`W+C)P=#L@=&5X="UI;F1E;G0Z("TW+C)P
M=#LG/D%C8V]U;G1S('!A>6%B;&4\+V1I=CX\+W1D/CQT9"!V86QI9VX],T1B
M;W1T;VT@<W1Y;&4],T0G=VED=&@Z(#$E.R!V97)T:6-A;"UA;&EG;CH@8F]T
M=&]M.R!B86-K9W)O=6YD+6-O;&]R.B`C8V-E969F.R<^)B,Q-C`[/"]T9#X\
M=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.B`Q)3L@=F5R=&EC
M86PM86QI9VXZ(&)O='1O;3L@=&5X="UA;&EG;CH@;&5F=#L@8F%C:V=R;W5N
M9"UC;VQO<CH@(V-C965F9CLG/CQD:78@<W1Y;&4],T0G9F]N="US:7IE.B`Q
M,'!T.R!F;VYT+69A;6EL>3H@)U1I;65S($YE=R!2;VUA;B<L(%1I;65S+"!S
M97)I9CLG/B0\+V1I=CX\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4]
M,T0G=VED=&@Z(#DE.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!T97AT+6%L
M:6=N.B!R:6=H=#L@8F%C:V=R;W5N9"UC;VQO<CH@(V-C965F9CLG/CQD:78@
M<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)U1I;65S
M($YE=R!2;VUA;B<L(%1I;65S+"!S97)I9CLG/C(L-S`W+#0S-SPO9&EV/CPO
M=&0^/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@<W1Y;&4]
M,T0G=VED=&@Z(#$E.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!T97AT+6%L
M:6=N.B!L969T.R!B86-K9W)O=6YD+6-O;&]R.B`C8V-E969F.R<^)B,Q-C`[
M/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.B`Q)3L@
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M:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.B`Y)3L@=F5R=&EC86PM86QI
M9VXZ(&)O='1O;3L@=&5X="UA;&EG;CH@<FEG:'0[(&)A8VMG<F]U;F0M8V]L
M;W(Z("-C8V5E9F8[)SX\9&EV('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@
M9F]N="UF86UI;'DZ("=4:6UE<R!.97<@4F]M86XG+"!4:6UE<RP@<V5R:68[
M)SXR+#(Y-BPV-#4\+V1I=CX\+W1D/CQT9"!N;W=R87`],T1N;W=R87`@=F%L
M:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.B`Q)3L@=F5R=&EC86PM86QI
M9VXZ(&)O='1O;3L@=&5X="UA;&EG;CH@;&5F=#L@8F%C:V=R;W5N9"UC;VQO
M<CH@(V-C965F9CLG/B8C,38P.SPO=&0^/"]T<CX\='(^/'1D('9A;&EG;CTS
M1&)O='1O;2!S='EL93TS1"=W:61T:#H@-S8E.R!V97)T:6-A;"UA;&EG;CH@
M8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B`C9F9F9F9F.R<^/&1I=B!S='EL
M93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G5&EM97,@3F5W
M(%)O;6%N)RP@5&EM97,L('-E<FEF.R!T97AT+6%L:6=N.B!L969T.R!M87)G
M:6XM;&5F=#H@-RXR<'0[('1E>'0M:6YD96YT.B`M-RXR<'0[)SY!8V-R=65D
M(&5X<&5N<V5S/"]D:78^/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE
M/3-$)W=I9'1H.B`Q)3L@=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R
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M<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)U1I;65S
M($YE=R!2;VUA;B<L(%1I;65S+"!S97)I9CLG/C,L,#DR+#`S,#PO9&EV/CPO
M=&0^/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@<W1Y;&4]
M,T0G=VED=&@Z(#$E.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!T97AT+6%L
M:6=N.B!L969T.R!B86-K9W)O=6YD+6-O;&]R.B`C9F9F9F9F.R<^)B,Q-C`[
M/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.B`Q)3L@
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M:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)U1I;65S($YE=R!2;VUA;B<L(%1I
M;65S+"!S97)I9CLG/C,L,3(U+#`R,SPO9&EV/CPO=&0^/'1D(&YO=W)A<#TS
M1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=VED=&@Z(#$E.R!V
M97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!T97AT+6%L:6=N.B!L969T.R!B86-K
M9W)O=6YD+6-O;&]R.B`C9F9F9F9F.R<^)B,Q-C`[/"]T9#X\+W1R/CQT<CX\
M=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.B`W-B4[('9E<G1I
M8V%L+6%L:6=N.B!B;W1T;VT[(&)A8VMG<F]U;F0M8V]L;W(Z("-C8V5E9F8[
M)SX\9&EV('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ
M("=4:6UE<R!.97<@4F]M86XG+"!4:6UE<RP@<V5R:68[('1E>'0M86QI9VXZ
M(&QE9G0[(&UA<F=I;BUL969T.B`W+C)P=#L@=&5X="UI;F1E;G0Z("TW+C)P
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M+6-O;&]R.B`C8V-E969F.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T
M=&]M('-T>6QE/3-$)W=I9'1H.B`Y)3L@=F5R=&EC86PM86QI9VXZ(&)O='1O
M;3L@=&5X="UA;&EG;CH@<FEG:'0[(&)A8VMG<F]U;F0M8V]L;W(Z("-C8V5E
M9F8[)SX\9&EV('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI
M;'DZ("=4:6UE<R!.97<@4F]M86XG+"!4:6UE<RP@<V5R:68[)SXR-#`L-C@Y
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M;&]R.B`C8V-E969F.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M
M('-T>6QE/3-$)W=I9'1H.B`Q)3L@=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@
M=&5X="UA;&EG;CH@;&5F=#L@8F%C:V=R;W5N9"UC;VQO<CH@(V-C965F9CLG
M/B8C,38P.SPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T
M:#H@.24[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[('1E>'0M86QI9VXZ(')I
M9VAT.R!B86-K9W)O=6YD+6-O;&]R.B`C8V-E969F.R<^/&1I=B!S='EL93TS
M1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G5&EM97,@3F5W(%)O
M;6%N)RP@5&EM97,L('-E<FEF.R<^.38T+#$X.3PO9&EV/CPO=&0^/'1D(&YO
M=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=VED=&@Z
M(#$E.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!T97AT+6%L:6=N.B!L969T
M.R!B86-K9W)O=6YD+6-O;&]R.B`C8V-E969F.R<^)B,Q-C`[/"]T9#X\+W1R
M/CQT<CX\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.B`W-B4[
M('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[('!A9&1I;F<M8F]T=&]M.B`R<'@[
M(&)A8VMG<F]U;F0M8V]L;W(Z("-F9F9F9F8[)SX\9&EV('-T>6QE/3-$)V9O
M;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=4:6UE<R!.97<@4F]M86XG
M+"!4:6UE<RP@<V5R:68[('1E>'0M86QI9VXZ(&QE9G0[(&UA<F=I;BUL969T
M.B`W+C)P=#L@=&5X="UI;F1E;G0Z("TW+C)P=#LG/D]T:&5R(&-U<G)E;G0@
M;&EA8FEL:71I97,\+V1I=CX\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y
M;&4],T0G=VED=&@Z(#$E.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!P861D
M:6YG+6)O='1O;3H@,G!X.R!B86-K9W)O=6YD+6-O;&]R.B`C9F9F9F9F.R<^
M)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H
M.B`Q)3L@=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@8F]R9&5R+6)O='1O;3H@
M(S`P,#`P,"`R<'@@<V]L:60[('1E>'0M86QI9VXZ(&QE9G0[(&)A8VMG<F]U
M;F0M8V]L;W(Z("-F9F9F9F8[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B
M;W1T;VT@<W1Y;&4],T0G=VED=&@Z(#DE.R!V97)T:6-A;"UA;&EG;CH@8F]T
M=&]M.R!B;W)D97(M8F]T=&]M.B`C,#`P,#`P(#)P>"!S;VQI9#L@=&5X="UA
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M8F]T=&]M.B`R<'@[('1E>'0M86QI9VXZ(&QE9G0[(&)A8VMG<F]U;F0M8V]L
M;W(Z("-F9F9F9F8[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@
M<W1Y;&4],T0G=VED=&@Z(#$E.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!P
M861D:6YG+6)O='1O;3H@,G!X.R!B86-K9W)O=6YD+6-O;&]R.B`C9F9F9F9F
M.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I
M9'1H.B`Q)3L@=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@8F]R9&5R+6)O='1O
M;3H@(S`P,#`P,"`R<'@@<V]L:60[('1E>'0M86QI9VXZ(&QE9G0[(&)A8VMG
M<F]U;F0M8V]L;W(Z("-F9F9F9F8[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX]
M,T1B;W1T;VT@<W1Y;&4],T0G=VED=&@Z(#DE.R!V97)T:6-A;"UA;&EG;CH@
M8F]T=&]M.R!B;W)D97(M8F]T=&]M.B`C,#`P,#`P(#)P>"!S;VQI9#L@=&5X
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M;F<M8F]T=&]M.B`R<'@[('1E>'0M86QI9VXZ(&QE9G0[(&)A8VMG<F]U;F0M
M8V]L;W(Z("-F9F9F9F8[)SXF(S$V,#L\+W1D/CPO='(^/'1R/CQT9"!V86QI
M9VX],T1B;W1T;VT@<W1Y;&4],T0G=VED=&@Z(#<V)3L@=F5R=&EC86PM86QI
M9VXZ(&)O='1O;3L@<&%D9&EN9RUB;W1T;VTZ(#1P>#L@8F%C:V=R;W5N9"UC
M;VQO<CH@(V-C965F9CLG/CQD:78@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T
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M.B`C8V-E969F.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T
M>6QE/3-$)W=I9'1H.B`Q)3L@=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@8F]R
M9&5R+6)O='1O;3H@(S`P,#`P,"`T<'@@9&]U8FQE.R!T97AT+6%L:6=N.B!L
M969T.R!B86-K9W)O=6YD+6-O;&]R.B`C8V-E969F.R<^/&1I=B!S='EL93TS
M1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G5&EM97,@3F5W(%)O
M;6%N)RP@5&EM97,L('-E<FEF.R<^)#PO9&EV/CPO=&0^/'1D('9A;&EG;CTS
M1&)O='1O;2!S='EL93TS1"=W:61T:#H@.24[('9E<G1I8V%L+6%L:6=N.B!B
M;W1T;VT[(&)O<F1E<BUB;W1T;VTZ(",P,#`P,#`@-'!X(&1O=6)L93L@=&5X
M="UA;&EG;CH@<FEG:'0[(&)A8VMG<F]U;F0M8V]L;W(Z("-C8V5E9F8[)SX\
M9&EV('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=4
M:6UE<R!.97<@4F]M86XG+"!4:6UE<RP@<V5R:68[)SXV+#,R,BPT,#<\+V1I
M=CX\+W1D/CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T
M>6QE/3-$)W=I9'1H.B`Q)3L@=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@<&%D
M9&EN9RUB;W1T;VTZ(#1P>#L@=&5X="UA;&EG;CH@;&5F=#L@8F%C:V=R;W5N
M9"UC;VQO<CH@(V-C965F9CLG/B8C,38P.SPO=&0^/'1D('9A;&EG;CTS1&)O
M='1O;2!S='EL93TS1"=W:61T:#H@,24[('9E<G1I8V%L+6%L:6=N.B!B;W1T
M;VT[('!A9&1I;F<M8F]T=&]M.B`T<'@[(&)A8VMG<F]U;F0M8V]L;W(Z("-C
M8V5E9F8[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4]
M,T0G=VED=&@Z(#$E.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B;W)D97(M
M8F]T=&]M.B`C,#`P,#`P(#1P>"!D;W5B;&4[('1E>'0M86QI9VXZ(&QE9G0[
M(&)A8VMG<F]U;F0M8V]L;W(Z("-C8V5E9F8[)SX\9&EV('-T>6QE/3-$)V9O
M;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=4:6UE<R!.97<@4F]M86XG
M+"!4:6UE<RP@<V5R:68[)SXD/"]D:78^/"]T9#X\=&0@=F%L:6=N/3-$8F]T
M=&]M('-T>6QE/3-$)W=I9'1H.B`Y)3L@=F5R=&EC86PM86QI9VXZ(&)O='1O
M;3L@8F]R9&5R+6)O='1O;3H@(S`P,#`P,"`T<'@@9&]U8FQE.R!T97AT+6%L
M:6=N.B!R:6=H=#L@8F%C:V=R;W5N9"UC;VQO<CH@(V-C965F9CLG/CQD:78@
M<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)U1I;65S
M($YE=R!2;VUA;B<L(%1I;65S+"!S97)I9CLG/C8L.#`S+#$W,SPO9&EV/CPO
M=&0^/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@<W1Y;&4]
M,T0G=VED=&@Z(#$E.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!P861D:6YG
M+6)O='1O;3H@-'!X.R!T97AT+6%L:6=N.B!L969T.R!B86-K9W)O=6YD+6-O
M;&]R.B`C8V-E969F.R<^)B,Q-C`[/"]T9#X\+W1R/CPO=&%B;&4^/"]D:78^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^
M#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\S.3AB
M8C$R8E]E.&-A7S1B-V%?.&9A,%\R-C,Y9&8U83@Y,3`-"D-O;G1E;G0M3&]C
M871I;VXZ(&9I;&4Z+R\O0SHO,SDX8F(Q,F)?93AC85\T8C=A7SAF83!?,C8S
M.61F-6$X.3$P+U=O<FMS:&5E=',O4VAE970Q-"YH=&UL#0I#;VYT96YT+51R
M86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT96YT+51Y
M<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*
M("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E
M(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T
M('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.
M;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@
M/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P14U%
M/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N
M/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/E)E;&%T960@4&%R='D@5')A;G-A
M8W1I;VYS(&%N9"!296QA=&5D(%!A<G1Y($-O;G9E<G1I8FQE($1E8G0\8G(^
M/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A
M;CTS1#$^,R!-;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^36%R+B`S,2P@,C`Q-3QB
M<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY2
M96QA=&5D(%!A<G1Y(%1R86YS86-T:6]N<R!A;F0@4F5L871E9"!087)T>2!#
M;VYV97)T:6)L92!$96)T(%M!8G-T<F%C=%T\+W-T<F]N9SX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4F5L871E9"!087)T>2!4<F%N<V%C
M=&EO;G,@86YD(%)E;&%T960@4&%R='D@0V]N=F5R=&EB;&4@1&5B=#PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/&1I=B!S='EL93TS1"=F;VYT
M+69A;6EL>3H@)U1I;65S($YE=R!2;VUA;B<L(%1I;65S+"!S97)I9CL@9F]N
M="US:7IE.B`Q,'!T.R<^/&1I=B!S='EL93TS1"=T97AT+6%L:6=N.B!L969T
M.R<^/'1A8FQE(&-E;&QP861D:6YG/3-$,"!C96QL<W!A8VEN9STS1#`@8VQA
M<W,],T1$4U!&3&ES=%1A8FQE('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@
M9F]N="UF86UI;'DZ("=4:6UE<R!.97<@4F]M86XG+"!4:6UE<RP@<V5R:68[
M('=I9'1H.B`Q,#`E.R<^/'1R/CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P
M<'0[(&9O;G0M9F%M:6QY.B`G5&EM97,@3F5W(%)O;6%N)RP@5&EM97,L('-E
M<FEF.R!W:61T:#H@,3AP=#L@=F5R=&EC86PM86QI9VXZ('1O<#L@9F]N="UW
M96EG:'0Z(&)O;&0[(&%L:6=N.B!R:6=H=#LG/C@N/"]T9#X\=&0@<W1Y;&4]
M,T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)U1I;65S($YE=R!2
M;VUA;B<L(%1I;65S+"!S97)I9CL@=VED=&@Z(&%U=&\[('9E<G1I8V%L+6%L
M:6=N.B!T;W`[(&9O;G0M=V5I9VAT.B!B;VQD.R!T97AT+6%L:6=N.B!L969T
M.R<^4F5L871E9"!087)T>2!4<F%N<V%C=&EO;G,@86YD(%)E;&%T960@4&%R
M='D@0V]N=F5R=&EB;&4@1&5B=#PO=&0^/"]T<CX\+W1A8FQE/CPO9&EV/CQD
M:78^/&)R("\^/"]D:78^/&1I=B!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[
M(&9O;G0M9F%M:6QY.B`G5&EM97,@3F5W(%)O;6%N)RP@5&EM97,L('-E<FEF
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M<RX\+V1I=CX\9&EV/CQB<B`O/CPO9&EV/CQD:78@<W1Y;&4],T0G9F]N="US
M:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)U1I;65S($YE=R!2;VUA;B<L(%1I
M;65S+"!S97)I9CL@=&5X="UA;&EG;CH@:G5S=&EF>3L@=&5X="UI;F1E;G0Z
M(#,V<'0[)SY);B!&96)R=6%R>2`R,#$U+"!!<W1E<FEA<R!R86ES960@87!P
M<F]X:6UA=&5L>2`D-2XU(&UI;&QI;VX@:6X@86=G<F5G871E(&=R;W-S('!R
M;V-E961S(&9R;VT@=&AE('-A;&4@;V8@,2PT,3`L,C4U('-H87)E<R!O9B!3
M97)I97,@02!#;VUM;VX@4W1O8VL@870@82!P<FEC92!O9B`D,RXY,"!P97(@
M<VAA<F4@=&AR;W5G:"!A;B!U;F1E<G=R:71T96X@<'5B;&EC(&]F9F5R:6YG
M(&%N9"!A('!R:79A=&4@<&QA8V5M96YT+B!"<F]A9'=O;V0@4&%R=&YE<G,L
M($PN4"XL($)R:71I<V@@)F%M<#L@06UE<FEC86X@26YV97-T;65N="!4<G5S
M="!03$,@86YD(%!E9')O($QI8VAT:6YG97(@<'5R8VAA<V5D(&%N(&%G9W)E
M9V%T92!O9B`Q+#`R-2PV-#`@;V8@=&AE('-H87)E<RX@0G)O861W;V]D(%!A
M<G1N97)S+"!,+E`N(&ES($)I;U1I;64F(S@R,3<[<R!L87)G97-T('-H87)E
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M($1I<F5C=&]R<RX@0G)I=&ES:"`F86UP.R!!;65R:6-A;B!);G9E<W1M96YT
M(%1R=7-T(%!,0R!I<R!A;B!A9F9I;&EA=&4@;V8@82!S=&]C:VAO;&1E<B!O
M9B!!<W1E<FEA<R!A;F0@0FEO5&EM92X\+V1I=CX\9&EV/CQB<B`O/CPO9&EV
M/CQD:78@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@
M)U1I;65S($YE=R!2;VUA;B<L(%1I;65S+"!S97)I9CL@=&5X="UA;&EG;CH@
M:G5S=&EF>3L@=&5X="UI;F1E;G0Z(#,V<'0[)SY);B!*=6QY(&%N9"!397!T
M96UB97(@,C`Q-"P@0V5L;"!#=7)E($YE=7)O<V-I96YC97,@:7-S=65D(&-E
M<G1A:6X@8V]N=F5R=&EB;&4@;F]T97,@*'1H92`F(S@R,C`[0V]N=F5R=&EB
M;&4@3F]T97,F(S@R,C$[*2!T;R!T=V\@0V5L;"!#=7)E($YE=7)O<V-I96YC
M97,@<VAA<F5H;VQD97)S(&]T:&5R('1H86X@0FEO5&EM92!I;B!T:&4@<')I
M;F-I<&%L(&%M;W5N="!O9B`D-#<P+#@W-BX@3VYE(&]F('1H92!#96QL($-U
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M(&EN($IU;'D@86YD(%-E<'1E;6)E<B`R,#$W+B!4:&4@;W5T<W1A;F1I;F<@
M<')I;F-I<&%L(&)A;&%N8V4@;V8@=&AE($-O;G9E<G1I8FQE($YO=&5S('=I
M=&@@86-C<G5E9"!I;G1E<F5S="!I<R!C;VYV97)T:6)L92!I;G1O($-E;&P@
M0W5R92!.975R;W-C:65N8V5S(&]R9&EN87)Y('-H87)E<R!A="!A(&9I>&5D
M(&-O;G9E<G-I;VX@<')I8V4@;V8@)#(P+C`P('!E<B!S:&%R92P@870@=&AE
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M('5N9&5R('1H92!P<F]V:7-I;VYS(&]F($%30R`X,34L/&9O;G0@<W1Y;&4]
M,T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)U1I;65S($YE=R!2
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M960@9F]R('5N9&5R($%30R`T-S`M,C`L/&9O;G0@<W1Y;&4],T0G9F]N="US
M:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)U1I;65S($YE=R!2;VUA;B<L(%1I
M;65S+"!S97)I9CL@9F]N="US='EL93H@:71A;&EC.R<^($1E8G0@=VET:"!#
M;VYV97)S:6]N(&%N9"!/=&AE<B!/<'1I;VYS+CPO9F]N=#X@56YD97(@05-#
M(#0W,"TR,"P@0FEO5&EM92!D971E<FUI;F5D('1H870@82!B96YE9FEC:6%L
M(&-O;G9E<G-I;VX@9F5A='5R92`H)B,X,C(P.T)#1B8C.#(R,3LI('=A<R!P
M<F5S96YT(&]N('1H92!I<W-U86YC92!D871E<R!O9B!T:&4@0V]N=F5R=&EB
M;&4@3F]T97,N/"]D:78^/&1I=B!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[
M(&9O;G0M9F%M:6QY.B`G5&EM97,@3F5W(%)O;6%N)RP@5&EM97,L('-E<FEF
M.R!T97AT+6%L:6=N.B!J=7-T:69Y.R!T97AT+6EN9&5N=#H@,S9P=#LG/B8C
M,38P.SPO9&EV/CQD:78@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT
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M;B!P<FEC92!O9B`D,C`N,#`@<&5R('-H87)E(&ES(&QE<W,@=&AA;B!T:&4@
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M-S`L.#<V(&]N('1H92!I<W-U86YC92!D871E<RX@5&AI<R!D96)T(&1I<V-O
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M9B!T:&4@0V]N=F5R=&EB;&4@3F]T97,@=V%S("0Q-CDL.3`X+"!C;VUP<FES
M960@;V8@<')I;F-I<&%L(&%N9"!A8V-R=65D(&EN=&5R97-T(&]F("0U,S0L
M.#$V+"!N970@;V8@=6YA;6]R=&EZ960@9&5B="!D:7-C;W5N="!O9B`D,S8T
M+#DP."X\+V1I=CX\+V1I=CX\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM
M+2T]7TYE>'1087)T7S,Y.&)B,3)B7V4X8V%?-&(W85\X9F$P7S(V,SED9C5A
M.#DQ,`T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B\S.3AB8C$R8E]E
M.&-A7S1B-V%?.&9A,%\R-C,Y9&8U83@Y,3`O5V]R:W-H965T<R]3:&5E=#$U
M+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN
M=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA
M<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U
M:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S
M970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,]
M,T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S
M8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R
M97!O<G0@:60],T1)1#!%344^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^4VAA
M<F5H;VQD97)S)R!%<75I='D\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^,R!-;VYT:',@16YD960\+W1H
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&@^36%R+B`S,2P@,C`Q-3QB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^/'-T<F]N9SY3:&%R96AO;&1E<G,G($5Q=6ET>2!;06)S
M=')A8W1=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/E-H87)E:&]L9&5R<R<@17%U:71Y/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\9&EV('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G5&EM97,@
M3F5W(%)O;6%N)RP@5&EM97,L('-E<FEF.R!F;VYT+7-I>F4Z(#$P<'0[)SX\
M9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&IU<W1I9GD[)SX\=&%B;&4@8V5L
M;'!A9&1I;F<],T0P(&-E;&QS<&%C:6YG/3-$,"!C;&%S<STS1$134$9,:7-T
M5&%B;&4@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@
M)U1I;65S($YE=R!2;VUA;B<L(%1I;65S+"!S97)I9CL@=VED=&@Z(#$P,"4[
M)SX\='(^/'1D('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI
M;'DZ("=4:6UE<R!.97<@4F]M86XG+"!4:6UE<RP@<V5R:68[('=I9'1H.B`Q
M.'!T.R!V97)T:6-A;"UA;&EG;CH@=&]P.R!F;VYT+7=E:6=H=#H@8F]L9#L@
M86QI9VXZ(')I9VAT.R<^.2X\+W1D/CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z
M(#$P<'0[(&9O;G0M9F%M:6QY.B`G5&EM97,@3F5W(%)O;6%N)RP@5&EM97,L
M('-E<FEF.R!W:61T:#H@875T;SL@=F5R=&EC86PM86QI9VXZ('1O<#L@9F]N
M="UW96EG:'0Z(&)O;&0[('1E>'0M86QI9VXZ(&IU<W1I9GD[)SY3:&%R96AO
M;&1E<G,G($5Q=6ET>3PO=&0^/"]T<CX\+W1A8FQE/CPO9&EV/CQD:78^/&)R
M("\^/"]D:78^/&1I=B!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M
M9F%M:6QY.B`G5&EM97,@3F5W(%)O;6%N)RP@5&EM97,L('-E<FEF.R!F;VYT
M+7-T>6QE.B!I=&%L:6,[('1E>'0M86QI9VXZ(&IU<W1I9GD[)SY0<F5F97)R
M960@4VAA<F5S/"]D:78^/&1I=B!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T
M:69Y.R<^/&)R("\^/"]D:78^/&1I=B!S='EL93TS1"=F;VYT+7-I>F4Z(#$P
M<'0[(&9O;G0M9F%M:6QY.B`G5&EM97,@3F5W(%)O;6%N)RP@5&EM97,L('-E
M<FEF.R!T97AT+6%L:6=N.B!J=7-T:69Y.R!T97AT+6EN9&5N=#H@,S9P=#LG
M/D)I;U1I;64@:7,@875T:&]R:7IE9"!T;R!I<W-U92`R+#`P,"PP,#`@<VAA
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M92`H8G5T(&YO="!B96QO=R!T:&4@;G5M8F5R(&]F('-H87)E<R!O9B!S=6-H
M('-E<FEE<R!T:&5N(&]U='-T86YD:6YG*2!T:&4@;G5M8F5R(&]F('-H87)E
M<R!O9B!A;GD@<V5R:65S(&]F('!R969E<G)E9"!S:&%R97,@<W5B<V5Q=65N
M="!T;R!T:&4@:7-S=64@;V8@<VAA<F5S(&]F('1H870@<V5R:65S+CPO9&EV
M/CQD:78^/&)R("\^/"]D:78^/&1I=B!S='EL93TS1"=F;VYT+7-I>F4Z(#$P
M<'0[(&9O;G0M9F%M:6QY.B`G5&EM97,@3F5W(%)O;6%N)RP@5&EM97,L('-E
M<FEF.R!T97AT+6%L:6=N.B!J=7-T:69Y.R!T97AT+6EN9&5N=#H@,S9P=#LG
M/D%S(&]F($UA<F-H(#,Q+"`R,#$U+"!":6]4:6UE(&AA9"`W,"PP,#`@;W5T
M<W1A;F1I;F<@<VAA<F5S(&]F(%-E<FEE<R!!($-O;G9E<G1I8FQE(%!R969E
M<G)E9"!3=&]C:R`H)B,X,C(P.U-E<FEE<R!!(%!R969E<G)E9"!3=&]C:R8C
M.#(R,3LI+B!4:&4@4V5R:65S($$@4')E9F5R<F5D(%-T;V-K(&-A<G)I97,@
M82!C=6UU;&%T:79E(&%N;G5A;"`S)2!P<F5F97)R960@9&EV:61E;F0@;W(@
M)#$N-3`@<&5R('-H87)E+"!I;B!P<F5F97)E;F-E('1O($)I;U1I;64@8V]M
M;6]N('-H87)E<RX@16%C:"!S:&%R92!O9B!397)I97,@02!0<F5F97)R960@
M4W1O8VL@:7,@8V]N=F5R=&EB;&4L(&%T('1H92!E;&5C=&EO;B!O9B!T:&4@
M:&]L9&5R+"!I;G1O($)I;U1I;64@8V]M;6]N('-H87)E<R!A="!A(&-O;G9E
M<G-I;VX@<')I8V4@;V8@)#0N,#`@<&5R('-H87)E+"!A(&-U<G)E;G0@8V]N
M=F5R<VEO;B!R871I;R!O9B`Q,BXU(&-O;6UO;B!S:&%R97,@9F]R(&5A8V@@
M<VAA<F4@;V8@4V5R:65S($$@4')E9F5R<F5D(%-T;V-K+CPO9&EV/CQD:78^
M/&)R("\^/"]D:78^/&1I=B!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O
M;G0M9F%M:6QY.B`G5&EM97,@3F5W(%)O;6%N)RP@5&EM97,L('-E<FEF.R!T
M97AT+6%L:6=N.B!J=7-T:69Y.R!T97AT+6EN9&5N=#H@,S9P=#LG/DEN(&%D
M9&ET:6]N('1O('1H92!P<F5F97)R960@9&EV:61E;F0L('1H92!397)I97,@
M02!0<F5F97)R960@4W1O8VL@=VEL;"!B92!E;G1I=&QE9"!T;R!P87)T:6-I
M<&%T92!W:71H($)I;U1I;64@8V]M;6]N('-H87)E<R!I;B!A;GD@9&EV:61E
M;F1S(&]R(&1I<W1R:6)U=&EO;G,@;VX@8V]M;6]N('-H87)E<R`H;W1H97(@
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M96YT.B`S-G!T.R<^06QL(&]U='-T86YD:6YG(%-E<FEE<R!!(%!R969E<G)E
M9"!3=&]C:R!W:6QL(&%U=&]M871I8V%L;'D@8F4@8V]N=F5R=&5D(&EN=&\@
M8V]M;6]N('-H87)E<R!O;B!-87)C:"`T+"`R,#$Y+"!O<B!I9B!H;VQD97)S
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M8F5R(&]F('-H87)E<RX\+V1I=CX\9&EV/CQB<B`O/CPO9&EV/CQD:78@<W1Y
M;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)U1I;65S($YE
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M:6YD96YT.B`S-G!T.R<^26X@=&AE(&5V96YT(&]F(&$@;&EQ=6ED871I;VX@
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M<F5S+CPO9&EV/CQD:78@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT
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M97,\+V1I=CX\9&EV/CQB<B`O/CPO9&EV/CQD:78@<W1Y;&4],T0G9F]N="US
M:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)U1I;65S($YE=R!2;VUA;B<L(%1I
M;65S+"!S97)I9CL@=&5X="UA;&EG;CH@:G5S=&EF>3L@=&5X="UI;F1E;G0Z
M(#,V<'0[)SY":6]4:6UE(&ES(&%U=&AO<FEZ960@=&\@:7-S=64@,3(U+#`P
M,"PP,#`@8V]M;6]N('-H87)E<R!W:71H(&YO('!A<B!V86QU92X@07,@;V8@
M36%R8V@@,S$L(#(P,34L($)I;U1I;64@:&%D(#@S+#(Q,"PW-S4@:7-S=65D
M(&%N9"`W."PS,38L.#,S(&]U='-T86YD:6YG(&-O;6UO;B!S:&%R97,N($%S
M(&]F($1E8V5M8F5R(#,Q+"`R,#$T+"!":6]4:6UE(&AA9"`X,RPQ,C$L-CDX
M(&ES<W5E9"!A;F0@-S@L,C(W+#<U-B!O=71S=&%N9&EN9R!C;VUM;VX@<VAA
M<F5S+B!4:&4@9&EF9F5R96YC92!O9B`T+#@Y,RPY-#(@8V]M;6]N('-H87)E
M<R!A<R!O9B!-87)C:"`S,2P@,C`Q-2!A;F0@1&5C96UB97(@,S$L(#(P,30@
M:7,@871T<FEB=71E9"!T;R!S:&%R97,@:&5L9"!B>2!":6]4:6UE('-U8G-I
M9&EA<FEE<R!W:&EC:"!A<F4@86-C;W5N=&5D(&9O<B!A<R!T<F5A<W5R>2!S
M=&]C:R!O;B!T:&4@8V]N9&5N<V5D(&-O;G-O;&ED871E9"!B86QA;F-E('-H
M965T+CPO9&EV/CQD:78^/&)R("\^/"]D:78^/&1I=B!S='EL93TS1"=F;VYT
M+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G5&EM97,@3F5W(%)O;6%N)RP@
M5&EM97,L('-E<FEF.R!T97AT+6%L:6=N.B!J=7-T:69Y.R!T97AT+6EN9&5N
M=#H@,S9P=#LG/D1U<FEN9R!T:&4@=&AR964@;6]N=&AS(&5N9&5D($UA<F-H
M(#,Q+"`R,#$U(&%N9"`R,#$T+"!":6]4:6UE(&=R86YT960@-#0P+#`P,"!A
M;F0@,2PR,#4L,#`P(&]P=&EO;G,L(')E<W!E8W1I=F5L>2P@=6YD97(@:71S
M(#(P,3(@17%U:71Y($EN8V5N=&EV92!0;&%N+CPO9&EV/CQD:78^/&)R("\^
M/"]D:78^/&1I=B!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M
M:6QY.B`G5&EM97,@3F5W(%)O;6%N)RP@5&EM97,L('-E<FEF.R!T97AT+6%L
M:6=N.B!J=7-T:69Y.R!T97AT+6EN9&5N=#H@,S9P=#LG/D1U<FEN9R!T:&4@
M=&AR964@;6]N=&AS(&5N9&5D($UA<F-H(#,Q+"`R,#$U+"`X.2PP-S<@;W!T
M:6]N<R!A;F0@;F\@=V%R<F%N=',@=V5R92!E>&5R8VES960N/"]D:78^/"]D
M:78^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B
M;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\S
M.3AB8C$R8E]E.&-A7S1B-V%?.&9A,%\R-C,Y9&8U83@Y,3`-"D-O;G1E;G0M
M3&]C871I;VXZ(&9I;&4Z+R\O0SHO,SDX8F(Q,F)?93AC85\T8C=A7SAF83!?
M,C8S.61F-6$X.3$P+U=O<FMS:&5E=',O4VAE970Q-BYH=&UL#0I#;VYT96YT
M+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT96YT
M+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL
M/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4
M>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R
M:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$
M;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-
M"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P
M14U%/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS
M<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/E-A;&5S(&]F($)I;U1I;64@
M0V]M;6]N(%-H87)E<R!B>2!3=6)S:61I87)I97,\8G(^/"]S=')O;F<^/"]T
M:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^,R!-;VYT
M:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&@^36%R+B`S,2P@,C`Q-3QB<CX\+W1H/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY386QE<R!O9B!":6]4
M:6UE($-O;6UO;B!3:&%R97,@8GD@4W5B<VED:6%R:65S(%M!8G-T<F%C=%T\
M+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4V%L
M97,@;V8@0FEO5&EM92!#;VUM;VX@4VAA<F5S(&)Y(%-U8G-I9&EA<FEE<SPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/&1I=B!S='EL93TS1"=F
M;VYT+69A;6EL>3H@)U1I;65S($YE=R!2;VUA;B<L(%1I;65S+"!S97)I9CL@
M9F]N="US:7IE.B`Q,'!T.R<^/&1I=B!S='EL93TS1"=T97AT+6%L:6=N.B!L
M969T.R<^/'1A8FQE(&-E;&QP861D:6YG/3-$,"!C96QL<W!A8VEN9STS1#`@
M8VQA<W,],T1$4U!&3&ES=%1A8FQE('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P
M=#L@9F]N="UF86UI;'DZ("=4:6UE<R!.97<@4F]M86XG+"!4:6UE<RP@<V5R
M:68[('=I9'1H.B`Q,#`E.R<^/'1R/CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z
M(#$P<'0[(&9O;G0M9F%M:6QY.B`G5&EM97,@3F5W(%)O;6%N)RP@5&EM97,L
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M:61I87)I97,\+W1D/CPO='(^/"]T86)L93X\+V1I=CX\9&EV/CQB<B`O/CPO
M9&EV/CQD:78@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL
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M<FEE<RX\+V1I=CX\9&EV/CQB<B`O/CPO9&EV/CQD:78@<W1Y;&4],T0G9F]N
M="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)U1I;65S($YE=R!2;VUA;B<L
M(%1I;65S+"!S97)I9CL@=&5X="UA;&EG;CH@:G5S=&EF>3L@=&5X="UI;F1E
M;G0Z(#,V<'0[)SY$=7)I;F<@2G5N92`R,#$T+"!!<W1E<FEA<R!S;VQD(#4L
M,#`P+#`P,"!O9B!I=',@0FEO5&EM92!C;VUM;VX@<VAA<F5S('=I=&@@=V%R
M<F%N=',@=&\@<'5R8VAA<V4@-2PP,#`L,#`P('-H87)E<R!O9B!!<W1E<FEA
M<R!397)I97,@0B!C;VUM;VX@<W1O8VL@=&\@='=O(&EN=F5S=&]R<R!F;W(@
M)#$R+#4P,"PP,#`@:6X@8V%S:"X@0G)O861W;V]D(%!A<G1N97)S+"!,+E`N
M+"!P=7)C:&%S960@,2PP,#`L,#`P(&]F('1H92!":6]4:6UE(&-O;6UO;B!S
M:&%R97,@=VET:"`Q+#`P,"PP,#`@07-T97)I87,@=V%R<F%N=',@86YD(&$@
M=')U<W0@<')E=FEO=7-L>2!E<W1A8FQI<VAE9"!B>2!'96]R9V4@2V%R9G5N
M:V5L('!U<F-H87-E9"`T+#`P,"PP,#`@;V8@=&AE($)I;U1I;64@8V]M;6]N
M('-H87)E<R!W:71H(#0L,#`P+#`P,"!!<W1E<FEA<R!W87)R86YT<RX\+V1I
M=CX\+V1I=CX\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'10
M87)T7S,Y.&)B,3)B7V4X8V%?-&(W85\X9F$P7S(V,SED9C5A.#DQ,`T*0V]N
M=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B\S.3AB8C$R8E]E.&-A7S1B-V%?
M.&9A,%\R-C,Y9&8U83@Y,3`O5V]R:W-H965T<R]3:&5E=#$W+FAT;6P-"D-O
M;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O
M;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*
M/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT
M96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G
M/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS
M/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H
M96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60]
M,T1)1#!%344^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L
M(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^4V5G;65N="!);F9O
M<FUA=&EO;CQB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T:"!C;VQS<&%N/3-$,3XS($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y-87(N
M(#,Q+"`R,#$U/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#X\<W1R;VYG/E-E9VUE;G0@26YF;W)M871I;VX@6T%B<W1R86-T73PO<W1R
M;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y396=M96YT
M($EN9F]R;6%T:6]N/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M9&EV('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G5&EM97,@3F5W(%)O;6%N)RP@
M5&EM97,L('-E<FEF.R!F;VYT+7-I>F4Z(#$P<'0[)SX\9&EV('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(&QE9G0[)SX\=&%B;&4@8V5L;'!A9&1I;F<],T0P(&-E
M;&QS<&%C:6YG/3-$,"!C;&%S<STS1$134$9,:7-T5&%B;&4@<W1Y;&4],T0G
M9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)U1I;65S($YE=R!2;VUA
M;B<L(%1I;65S+"!S97)I9CL@=VED=&@Z(#$P,"4[)SX\='(^/'1D('-T>6QE
M/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=4:6UE<R!.97<@
M4F]M86XG+"!4:6UE<RP@<V5R:68[('=I9'1H.B`Q.'!T.R!V97)T:6-A;"UA
M;&EG;CH@=&]P.R!F;VYT+7=E:6=H=#H@8F]L9#L@86QI9VXZ(')I9VAT.R<^
M,3$N/"]T9#X\=&0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A
M;6EL>3H@)U1I;65S($YE=R!2;VUA;B<L(%1I;65S+"!S97)I9CL@=VED=&@Z
M(&%U=&\[('9E<G1I8V%L+6%L:6=N.B!T;W`[(&9O;G0M=V5I9VAT.B!B;VQD
M.R!T97AT+6%L:6=N.B!L969T.R<^4V5G;65N="!);F9O<FUA=&EO;CPO=&0^
M/"]T<CX\+W1A8FQE/CPO9&EV/CQD:78^/&)R("\^/"]D:78^/&1I=B!S='EL
M93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G5&EM97,@3F5W
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M="X\+V1I=CX\+V1I=CX\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]
M7TYE>'1087)T7S,Y.&)B,3)B7V4X8V%?-&(W85\X9F$P7S(V,SED9C5A.#DQ
M,`T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B\S.3AB8C$R8E]E.&-A
M7S1B-V%?.&9A,%\R-C,Y9&8U83@Y,3`O5V]R:W-H965T<R]3:&5E=#$X+FAT
M;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B
M;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I
M:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78]
M,T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]
M=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13
M:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I
M<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O
M<G0@:60],T1)1#!%344^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^4W5B<V5Q
M=65N="!%=F5N=',\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&@@8V]L<W!A;CTS1#$^,R!-;VYT:',@16YD960\+W1H/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^
M36%R+B`S,2P@,C`Q-3QB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^/'-T<F]N9SY3=6)S97%U96YT($5V96YT<R!;06)S=')A8W1=/"]S
M=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-U8G-E
M<75E;G0@179E;G1S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M9&EV('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G5&EM97,@3F5W(%)O;6%N)RP@
M5&EM97,L('-E<FEF.R!F;VYT+7-I>F4Z(#$P<'0[)SX\9&EV('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(&IU<W1I9GD[)SX\=&%B;&4@8V5L;'!A9&1I;F<],T0P
M(&-E;&QS<&%C:6YG/3-$,"!C;&%S<STS1$134$9,:7-T5&%B;&4@<W1Y;&4]
M,T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)U1I;65S($YE=R!2
M;VUA;B<L(%1I;65S+"!S97)I9CL@=VED=&@Z(#$P,"4[)SX\='(^/'1D('-T
M>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=4:6UE<R!.
M97<@4F]M86XG+"!4:6UE<RP@<V5R:68[('=I9'1H.B`Q.'!T.R!V97)T:6-A
M;"UA;&EG;CH@=&]P.R!F;VYT+7=E:6=H=#H@8F]L9#L@86QI9VXZ(')I9VAT
M.R<^,3(N/"]T9#X\=&0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT
M+69A;6EL>3H@)U1I;65S($YE=R!2;VUA;B<L(%1I;65S+"!S97)I9CL@=VED
M=&@Z(&%U=&\[('9E<G1I8V%L+6%L:6=N.B!T;W`[(&9O;G0M=V5I9VAT.B!B
M;VQD.R!T97AT+6%L:6=N.B!J=7-T:69Y.R<^4W5B<V5Q=65N="!%=F5N=',\
M+W1D/CPO='(^/"]T86)L93X\+V1I=CX\9&EV/CQB<B`O/CPO9&EV/CQD:78@
M<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)U1I;65S
M($YE=R!2;VUA;B<L(%1I;65S+"!S97)I9CL@=&5X="UA;&EG;CH@:G5S=&EF
M>3L@=&5X="UI;F1E;G0Z(#,V<'0[)SY);B!!<')I;"`R,#$U+"!!<W1E<FEA
M<R!R96-E:79E9"`D,2PP-C(L,#(S(&9R;VT@=&AE($-A;&EF;W)N:6$@26YS
M=&ET=71E(&9O<B!296=E;F5R871I=F4@365D:6-I;F4@87,@<75A<G1E<FQY
M(&EN<W1A;&QM96YT('!A>6UE;G0@;V8@82`D,30N,R!M:6QL:6]N(')E<V5A
M<F-H(&=R86YT(&%W87)D960@9'5R:6YG(#(P,30N/"]D:78^/&1I=CX\8G(@
M+SX\+V1I=CX\9&EV('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF
M86UI;'DZ("=4:6UE<R!.97<@4F]M86XG+"!4:6UE<RP@<V5R:68[('1E>'0M
M86QI9VXZ(&IU<W1I9GD[('1E>'0M:6YD96YT.B`S-G!T.R<^3VX@36%Y(#@L
M(#(P,34L($]N8V]#>71E($-O<G!O<F%T:6]N)B,Q-C`[86-C97!T960@<W5B
M<V-R:7!T:6]N<R!F;W(F(S$V,#LS+#`P,"PP,#`@<VAA<F5S(&]F(&ET<R!C
M;VUM;VX@<W1O8VL@=&\@='=O(&9O<B`D,RPS,#`L,#`P(&EN(&-A<V@@9G)O
M;2!T=V\@;V8@:71S('-H87)E:&]L9&5R<RP@:6YC;'5D:6YG)B,Q-C`[82!S
M=6)S8W)I<'1I;VX@9F]R(#$L,#`P+#`P,"!S:&%R97,F(S$V,#MF<F]M($=E
M;W)G92!+87)F=6YK96PL(&$@8F5N969I8VEA;"!O=VYE<B!O9B!M;W)E('1H
M86X@-24@;V8@=&AE(&]U='-T86YD:6YG(&-O;6UO;B!S:&%R97,@;V8@0FEO
M5&EM92X@0V]N8W5R<F5N=&QY+"!":6]4:6UE('!U<F-H87-E9"8C,38P.S,L
M,#`P+#`P,"!S:&%R97,@;V8@3VYC;T-Y=&4@8V]M;6]N('-T;V-K(&EN(&5X
M8VAA;F=E(&9O<B!T:&4@8V%N8V5L871I;VX@;V8@)#,L,S`P+#`P,"!O9B!I
M;F1E8G1E9&YE<W,@;W=E9"!T;R!":6]4:6UE(&)Y($]N8V]#>71E+"!A;F0@
M3VYC;T-Y=&4@9&5L:79E<F5D('1O($)I;U1I;64@82!C;VYV97)T:6)L92!P
M<F]M:7-S;W)Y(&YO=&4@*'1H92`F(S@R,C`[3F]T928C.#(R,3LI(&9O<B!A
M;B!A9&1I=&EO;F%L("0S+#,P,"PP,#`@;V8@3VYC;T-Y=&4F(S@R,3<[<R!I
M;F1E8G1E9&YE<W,@=&\@0FEO5&EM92X@5&AE($YO=&4@=VEL;"!B96%R(&EN
M=&5R97-T(&%T('1H92!R871E(&]F(#$E('!E<B!A;FYU;2!A;F0@=VEL;"!M
M871U<F4@86YD(&)E('!A>6%B;&4@;VX@3F]V96UB97(@,S`L(#(P,38N($)I
M;U1I;64@=VEL;"!H879E('1H92!R:6=H="!T;R!C;VYV97)T('1H92!P<FEN
M8VEP86P@86UO=6YT(&]F('1H92!.;W1E('!L=7,@86-C<G5E9"!I;G1E<F5S
M="!I;G1O('-H87)E<R!O9B!/;F-O0WET92!C;VUM;VX@<W1O8VL@870@82!C
M;VYV97)S:6]N('!R:6-E(&]F("0Q+C$P('!E<B!S:&%R92!C;VUM96YC:6YG
M(&]N('1H92!E87)L:65S="!O9B!.;W9E;6)E<B`X+"`R,#$V+"!O<B!S:7@@
M;6]N=&AS(&%F=&5R($]N8V]#>71E(&-O;7!L971E<R!A;B!I;FET:6%L('5N
M9&5R=W)I='1E;B!P=6)L:6,@;V9F97)I;F<@;V8@:71S(&-O;6UO;B!S=&]C
M:RP@;W(@=7!O;B!T:&4@;V-C=7)R96YC92!O9B!A;B`F(S@R,C`[179E;G0@
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M96YT+CPO9&EV/CPO9&EV/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM
M+3U?3F5X=%!A<G1?,SDX8F(Q,F)?93AC85\T8C=A7SAF83!?,C8S.61F-6$X
M.3$P#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+S,Y.&)B,3)B7V4X
M8V%?-&(W85\X9F$P7S(V,SED9C5A.#DQ,"]7;W)K<VAE971S+U-H965T,3DN
M:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT
M86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S
M8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I
M=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E
M=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS
M1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C
M<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E
M<&]R="!I9#TS1$E$,$5*3$%%/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/E-U
M;6UA<GD@;V8@4VEG;FEF:6-A;G0@06-C;W5N=&EN9R!0;VQI8VEE<R`H4&]L
M:6-I97,I/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1H(&-O;'-P86X],T0Q/C,@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DUA<BX@
M,S$L(#(P,34\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/CQS=')O;F<^4W5M;6%R>2!O9B!3:6=N:69I8V%N="!!8V-O=6YT:6YG(%!O
M;&EC:65S(%M!8G-T<F%C=%T\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^4F5V96YU92!R96-O9VYI=&EO;CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/&1I=B!S='EL93TS1"=F;VYT+69A;6EL
M>3H@)U1I;65S($YE=R!2;VUA;B<L(%1I;65S+"!S97)I9CL@9F]N="US:7IE
M.B`Q,'!T.R<^/&1I=B!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M
M9F%M:6QY.B`G5&EM97,@3F5W(%)O;6%N)RP@5&EM97,L('-E<FEF.R!T97AT
M+6%L:6=N.B!J=7-T:69Y.R!T97AT+6EN9&5N=#H@,S9P=#LG/CQF;VYT('-T
M>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=4:6UE<R!.
M97<@4F]M86XG+"!4:6UE<RP@<V5R:68[(&9O;G0M<W1Y;&4Z(&ET86QI8SLG
M/E)E=F5N=64@<F5C;V=N:71I;VX\+V9O;G0^("8C.#(Q,3L@0FEO5&EM92!C
M;VUP;&EE<R!W:71H($%30R`V,#4M,3`@86YD(')E8V]G;FEZ97,@<F5V96YU
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M<F5A<V]N86)L>2!A<W-U<F5D+B!7:&5N($)I;U1I;64@<F5C96EV97,@=7`M
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M+CPO9&EV/CPO9&EV/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^0V%S:"!A;F0@8V%S:"!E<75I=F%L96YT<SPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/&1I=B!S='EL93TS1"=F;VYT
M+69A;6EL>3H@)U1I;65S($YE=R!2;VUA;B<L(%1I;65S+"!S97)I9CL@9F]N
M="US:7IE.B`Q,'!T.R<^/&1I=B!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[
M(&9O;G0M9F%M:6QY.B`G5&EM97,@3F5W(%)O;6%N)RP@5&EM97,L('-E<FEF
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M+V1I=CX\+V1I=CX\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/E1R861E(&%C8V]U;G1S(&%N9"!G<F%N=',@<F5C96EV
M86)L92P@;F5T/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\9&EV
M('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G5&EM97,@3F5W(%)O;6%N)RP@5&EM
M97,L('-E<FEF.R!F;VYT+7-I>F4Z(#$P<'0[)SX\9&EV('-T>6QE/3-$)V9O
M;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=4:6UE<R!.97<@4F]M86XG
M+"!4:6UE<RP@<V5R:68[('1E>'0M86QI9VXZ(&IU<W1I9GD[('1E>'0M:6YD
M96YT.B`S-G!T.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F
M;VYT+69A;6EL>3H@)U1I;65S($YE=R!2;VUA;B<L(%1I;65S+"!S97)I9CL@
M9F]N="US='EL93H@:71A;&EC.R<^5')A9&4@86-C;W5N=',@86YD(&=R86YT
M<R!R96-E:79A8FQE+"!N970\+V9O;G0^("8C.#(Q,3L@3F5T('1R861E(')E
M8V5I=F%B;&5S(&%M;W5N=&5D('1O(&%P<')O>&EM871E;'D@)#8P-2PX,#`@
M86YD("0U-#DL,S`P(&%N9"!G<F%N=',@<F5C96EV86)L92!A;6]U;G1E9"!T
M;R!A<'!R;WAI;6%T96QY("0R-C`L,S`P(&%N9"`D-#DR+#8P,"!A<R!O9B!-
M87)C:"`S,2P@,C`Q-2!A;F0@1&5C96UB97(@,S$L(#(P,30L(')E<W!E8W1I
M=F5L>2X@3F5T('1R861E(')E8V5I=F%B;&5S(&EN8VQU9&4@86QL;W=A;F-E
M(&9O<B!D;W5B=&9U;"!A8V-O=6YT<R!O9B!A<'!R;WAI;6%T96QY("0Q,#`L
M-3`P(&%S(&]F($UA<F-H(#,Q+"`R,#$U(&%N9"!$96-E;6)E<B`S,2P@,C`Q
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M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#;VYC96YT<F%T
M:6]N<R!O9B!C<F5D:70@<FES:SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/&1I=B!S='EL93TS1"=F;VYT+69A;6EL>3H@)U1I;65S($YE=R!2
M;VUA;B<L(%1I;65S+"!S97)I9CL@9F]N="US:7IE.B`Q,'!T.R<^/&1I=CX\
M9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G
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M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DEN=F5N
M=&]R>3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/&1I=B!S='EL
M93TS1"=F;VYT+69A;6EL>3H@)U1I;65S($YE=R!2;VUA;B<L(%1I;65S+"!S
M97)I9CL@9F]N="US:7IE.B`Q,'!T.R<^/&1I=B!S='EL93TS1"=F;VYT+7-I
M>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G5&EM97,@3F5W(%)O;6%N)RP@5&EM
M97,L('-E<FEF.R!T97AT+6%L:6=N.B!J=7-T:69Y.R!T97AT+6EN9&5N=#H@
M,S9P=#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF
M86UI;'DZ("=4:6UE<R!.97<@4F]M86XG+"!4:6UE<RP@<V5R:68[(&9O;G0M
M<W1Y;&4Z(&ET86QI8SLG/DEN=F5N=&]R>2`F(S@R,3$[/"]F;VYT/B!);G9E
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M/CPO9&EV/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^17%U:7!M96YT+"!N970\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQD:78@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=4:6UE<R!.
M97<@4F]M86XG+"!4:6UE<RP@<V5R:68[(&9O;G0M<VEZ93H@,3!P=#LG/CQD
M:78@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)U1I
M;65S($YE=R!2;VUA;B<L(%1I;65S+"!S97)I9CL@=&5X="UA;&EG;CH@:G5S
M=&EF>3L@=&5X="UI;F1E;G0Z(#,V<'0[)SX\9F]N="!S='EL93TS1"=F;VYT
M+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G5&EM97,@3F5W(%)O;6%N)RP@
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M('!E<FEO9"!O9B`S-B!T;R`Q,C`@;6]N=&AS+B!#;VYS=')U8W1I;VX@:6X@
M<')O9W)E<W,@:7,@;F]T(&1E<')E8VEA=&5D('5N=&EL('1H92!U;F1E<FQY
M:6YG(&%S<V5T(&ES('!L86-E9"!I;G1O('-E<G9I8V4N(%-E92!.;W1E(#0N
M/"]D:78^/"]D:78^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y);G1A;F=I8FQE(&%S<V5T<RP@;F5T/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\9&EV('-T>6QE/3-$)V9O;G0M9F%M
M:6QY.B`G5&EM97,@3F5W(%)O;6%N)RP@5&EM97,L('-E<FEF.R!F;VYT+7-I
M>F4Z(#$P<'0[)SX\9&EV('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N
M="UF86UI;'DZ("=4:6UE<R!.97<@4F]M86XG+"!4:6UE<RP@<V5R:68[('1E
M>'0M86QI9VXZ(&IU<W1I9GD[('1E>'0M:6YD96YT.B`S-G!T.R<^/&9O;G0@
M<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)U1I;65S
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M87-S971S('1H870@9&\@;F]T(&-O;G-T:71U=&4@82!B=7-I;F5S<R`H<W5C
M:"!A<R!T:&4@86-Q=6ES:71I;VX@;V8@87-S971S(&)Y($%S=&5R:6%S(&9R
M;VT@1V5R;VX@0V]R<&]R871I;VXI+"!I;B!A8V-O<F1A;F-E('=I=&@@=&AE
M(&%C8V]U;G1I;F<@<G5L97,@:6X@05-#(#@P-2TU,"P@<W5C:"!I;G1A;F=I
M8FQE(&%S<V5T<R!R96QA=&5D('1O(&EN+7!R;V-E<W,@<F5S96%R8V@@86YD
M(&1E=F5L;W!M96YT("@F(S@R,C`[25!2)F%M<#M$)B,X,C(Q.RD@87)E(&5X
M<&5N<V5D('5P;VX@86-Q=6ES:71I;VXN/"]D:78^/"]D:78^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y4<F5A<W5R
M>2!S=&]C:SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/&1I=B!S
M='EL93TS1"=F;VYT+69A;6EL>3H@)U1I;65S($YE=R!2;VUA;B<L(%1I;65S
M+"!S97)I9CL@9F]N="US:7IE.B`Q,'!T.R<^/&1I=B!S='EL93TS1"=F;VYT
M+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G5&EM97,@3F5W(%)O;6%N)RP@
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M06-T(&]F(#$Y,S,L(&%S(&%M96YD960@*'1H92`F(S@R,C`[4V5C=7)I=&EE
M<R!!8W0F(S@R,C$[*2!T;R!E;FAA;F-E('1H92!M87)K971A8FEL:71Y(&]F
M('1H92!S:&%R97,N/"]D:78^/"]D:78^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y787)R86YT<R!T;R!P=7)C:&%S
M92!C;VUM;VX@<W1O8VL\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQD:78@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=4:6UE<R!.97<@4F]M86XG
M+"!4:6UE<RP@<V5R:68[(&9O;G0M<VEZ93H@,3!P=#LG/CQD:78@<W1Y;&4]
M,T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)U1I;65S($YE=R!2
M;VUA;B<L(%1I;65S+"!S97)I9CL@=&5X="UA;&EG;CH@:G5S=&EF>3L@=&5X
M="UI;F1E;G0Z(#,V<'0[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P
M<'0[(&9O;G0M9F%M:6QY.B`G5&EM97,@3F5W(%)O;6%N)RP@5&EM97,L('-E
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M<R!O9B!-87)C:"`S,2P@,C`Q-2!I;F-L=61E(&$@8V]N9&ET:6]N86P@;V)L
M:6=A=&EO;B!T;R!I<W-U92!A('9A<FEA8FQE(&YU;6)E<B!O9B!S:&%R97,[
M(&YO<B!W87,@=&AE<F4@82!D965M960@<&]S<VEB:6QI='D@=&AA="!":6]4
M:6UE(&UA>2!N965D('1O('-E='1L92!T:&4@=V%R<F%N=',@:6X@8V%S:"X\
M+V1I=CX\+V1I=CX\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/D-O<W0@;V8@<V%L97,\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQD:78@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=4:6UE
M<R!.97<@4F]M86XG+"!4:6UE<RP@<V5R:68[(&9O;G0M<VEZ93H@,3!P=#LG
M/CQD:78@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@
M)U1I;65S($YE=R!2;VUA;B<L(%1I;65S+"!S97)I9CL@=&5X="UA;&EG;CH@
M:G5S=&EF>3L@=&5X="UI;F1E;G0Z(#,V<'0[)SX\9F]N="!S='EL93TS1"=F
M;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G5&EM97,@3F5W(%)O;6%N
M)RP@5&EM97,L('-E<FEF.R!F;VYT+7-T>6QE.B!I=&%L:6,[)SY#;W-T(&]F
M('-A;&5S/"]F;VYT/B`F(S@R,3$[($)I;U1I;64@86-C;W5N=',@9F]R('1H
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M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0871E;G0@
M8V]S=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQD:78@<W1Y
M;&4],T0G9F]N="UF86UI;'DZ("=4:6UE<R!.97<@4F]M86XG+"!4:6UE<RP@
M<V5R:68[(&9O;G0M<VEZ93H@,3!P=#LG/CQD:78@<W1Y;&4],T0G9F]N="US
M:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)U1I;65S($YE=R!2;VUA;B<L(%1I
M;65S+"!S97)I9CL@=&5X="UA;&EG;CH@:G5S=&EF>3L@=&5X="UI;F1E;G0Z
M(#,V<'0[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M
M9F%M:6QY.B`G5&EM97,@3F5W(%)O;6%N)RP@5&EM97,L('-E<FEF.R!F;VYT
M+7-T>6QE.B!I=&%L:6,[)SY0871E;G0@8V]S=',@)B,X,C$Q.SPO9F]N=#X@
M0V]S=',@87-S;V-I871E9"!W:71H(&]B=&%I;FEN9R!P871E;G1S(&]N('!R
M;V1U8W1S(&]R('1E8VAN;VQO9WD@9&5V96QO<&5D(&%R92!E>'!E;G-E9"!A
M<R!R97-E87)C:"!A;F0@9&5V96QO<&UE;G0@97AP96YS97,@=VAE;B!I;F-U
M<G)E9"X\+V1I=CX\+V1I=CX\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/E)E8VQA<W-I9FEC871I;VX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQD:78@<W1Y;&4],T0G9F]N="UF86UI
M;'DZ("=4:6UE<R!.97<@4F]M86XG+"!4:6UE<RP@<V5R:68[(&9O;G0M<VEZ
M93H@,3!P=#LG/CQD:78@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT
M+69A;6EL>3H@)U1I;65S($YE=R!2;VUA;B<L(%1I;65S+"!S97)I9CL@=&5X
M="UA;&EG;CH@:G5S=&EF>3L@=&5X="UI;F1E;G0Z(#,V<'0[)SX\9F]N="!S
M='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G5&EM97,@
M3F5W(%)O;6%N)RP@5&EM97,L('-E<FEF.R!F;VYT+7-T>6QE.B!I=&%L:6,[
M)SY296-L87-S:69I8V%T:6]N/"]F;VYT/B`F(S@R,3$[($-E<G1A:6X@<')I
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M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y297-E87)C
M:"!A;F0@9&5V96QO<&UE;G0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQD:78@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=4:6UE<R!.97<@4F]M
M86XG+"!4:6UE<RP@<V5R:68[(&9O;G0M<VEZ93H@,3!P=#LG/CQD:78@<W1Y
M;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)U1I;65S($YE
M=R!2;VUA;B<L(%1I;65S+"!S97)I9CL@=&5X="UA;&EG;CH@:G5S=&EF>3L@
M=&5X="UI;F1E;G0Z(#,V<'0[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z
M(#$P<'0[(&9O;G0M9F%M:6QY.B`G5&EM97,@3F5W(%)O;6%N)RP@5&EM97,L
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M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y'96YE
M<F%L(&%N9"!A9&UI;FES=')A=&EV93PO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/&1I=B!S='EL93TS1"=F;VYT+69A;6EL>3H@)U1I;65S($YE
M=R!2;VUA;B<L(%1I;65S+"!S97)I9CL@9F]N="US:7IE.B`Q,'!T.R<^/&1I
M=B!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G5&EM
M97,@3F5W(%)O;6%N)RP@5&EM97,L('-E<FEF.R!T97AT+6%L:6=N.B!J=7-T
M:69Y.R!T97AT+6EN9&5N=#H@,S9P=#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M
M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=4:6UE<R!.97<@4F]M86XG+"!4
M:6UE<RP@<V5R:68[(&9O;G0M<W1Y;&4Z(&ET86QI8SLG/D=E;F5R86P@86YD
M(&%D;6EN:7-T<F%T:79E/"]F;VYT/B`M($=E;F5R86P@86YD(&%D;6EN:7-T
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M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D9O<F5I
M9VX@8W5R<F5N8WD@=')A;G-L871I;VX@9V%I;B!A;F0@;W1H97(@8V]M<')E
M:&5N<VEV92!L;W-S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M9&EV('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G5&EM97,@3F5W(%)O;6%N)RP@
M5&EM97,L('-E<FEF.R!F;VYT+7-I>F4Z(#$P<'0[)SX\9&EV('-T>6QE/3-$
M)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=4:6UE<R!.97<@4F]M
M86XG+"!4:6UE<RP@<V5R:68[('1E>'0M86QI9VXZ(&IU<W1I9GD[('1E>'0M
M:6YD96YT.B`S-G!T.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T
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M87)C:"`S,2P@,C`Q-2!A;F0@,C`Q-"P@;W1H97(@8V]M<')E:&5N<VEV92!L
M;W-S(&EN8VQU9&5S(&QO<W-E<R!O9B`D-3(L.3@U(&%N9"`D,3`W+#(T,"P@
M<F5S<&5C=&EV96QY('=H:6-H(&ES(&QA<F=E;'D@9G)O;2!F;W)E:6=N(&-U
M<G)E;F-Y('1R86YS;&%T:6]N+CPO9&EV/CQD:78@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@:G5S=&EF>3L@=&5X="UI;F1E;G0Z(#,V<'0[)SXF(S$V,#LF(S$V
M,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF
M(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V
M,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF
M(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V
M,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF
M(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V
M,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#L@/"]D:78^
M/&1I=B!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G
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M;&]S<R!A;6]U;G1E9"!T;R`D,C`U+#$T.2!A;F0@)#$P+#(Q,BP@<F5S<&5C
M=&EV96QY+CPO9&EV/CPO9&EV/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^26YC;VUE('1A>&5S/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\9&EV('-T>6QE/3-$)V9O;G0M9F%M:6QY
M.B`G5&EM97,@3F5W(%)O;6%N)RP@5&EM97,L('-E<FEF.R!F;VYT+7-I>F4Z
M(#$P<'0[)SX\9&EV('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF
M86UI;'DZ("=4:6UE<R!.97<@4F]M86XG+"!4:6UE<RP@<V5R:68[('1E>'0M
M86QI9VXZ(&IU<W1I9GD[('1E>'0M:6YD96YT.B`S-G!T.R<^/&9O;G0@<W1Y
M;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)U1I;65S($YE
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M9R!A=71H;W)I=&EE<RX@0F5G:6YN:6YG($]C=&]B97(@,2P@,C`Q,RP@07-T
M97)I87,@8F5G86X@9FEL:6YG('-E<&%R871E(%4N4RX@9F5D97)A;"!I;F-O
M;64@=&%X(')E='5R;G,@8G5T(&5F9F5C=&EV96QY($)I;U1I;64@8V]M8FEN
M960@07-T97)I87,F(S@R,3<[('1A>"!P<F]V:7-I;VX@=VET:"!":6]4:6UE
M)B,X,C$W.W,@8V]N<V]L:61A=&5D(&9I;F%N8VEA;"!S=&%T96UE;G1S+B!&
M;W(@0V%L:69O<FYI82P@07-T97)I87,F(S@R,3<[(&%C=&EV:71Y(&9O<B`R
M,#$S(&%N9"`R,#$T(&AA=F4@8F5E;B!I;F-L=61E9"!I;B!":6]4:6UE)B,X
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M(&%S(&]F($UA<F-H(#,Q+"`R,#$U(&%N9"`R,#$T+B!":6]4:6UE(&9I;&5S
M(&$@52Y3+B!F961E<F%L(&EN8V]M92!T87@@<F5T=7)N(&%S('=E;&P@87,@
M=F%R:6]U<R!S=&%T92!A;F0@9F]R96EG;B!I;F-O;64@=&%X(')E='5R;G,N
M($EN(&=E;F5R86PL($)I;U1I;64@:7,@;F\@;&]N9V5R('-U8FIE8W0@=&\@
M=&%X(&5X86UI;F%T:6]N(&)Y(&UA:F]R('1A>&EN9R!A=71H;W)I=&EE<R!F
M;W(@>65A<G,@8F5F;W)E(#(P,3`N($%L=&AO=6=H('1H92!S=&%T=71E(&ES
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M:&4@;F5X="!Y96%R+CPO9&EV/CQD:78@<W1Y;&4],T0G9F]N="US:7IE.B`Q
M,'!T.R!F;VYT+69A;6EL>3H@)U1I;65S($YE=R!2;VUA;B<L(%1I;65S+"!S
M97)I9CL@=&5X="UA;&EG;CH@:G5S=&EF>3L@=&5X="UI;F1E;G0Z(#,V<'0[
M)SXF(S$V,#L\+V1I=CX\9&EV('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@
M9F]N="UF86UI;'DZ("=4:6UE<R!.97<@4F]M86XG+"!4:6UE<RP@<V5R:68[
M('1E>'0M86QI9VXZ(&IU<W1I9GD[('1E>'0M:6YD96YT.B`S-G!T.R<^06X@
M:6YC;VUE('1A>"!B96YE9FET(&]F(&%P<')O>&EM871E;'D@)#$L,3<W+#`P
M,"!W87,@<F5C;W)D960@9F]R('1H92!T:')E92!M;VYT:',@96YD960@36%R
M8V@@,S$L(#(P,34L(&]F('=H:6-H(&%P<')O>&EM871E;'D@)#$L,C4Q+#`P
M,"!O9B!T:&4@8F5N969I="!W87,@<F5L871E9"!T;R!F961E<F%L(&]F9G-E
M="!B>2!A9&IU<W1M96YT(&]F("0W-"PP,#`@<F5L871E9"!T;R!S=&%T92!T
M87AE<RX@1F]R('1H92!S86UE('!E<FEO9"!I;B`R,#$T+"!A;B!I;F-O;64@
M=&%X(&)E;F5F:70@;V8@87!P<F]X:6UA=&5L>2`D,2PS-#DL,#`P('=A<R!R
M96-O<F1E9"`L(&]F('=H:6-H(&%P<')O>&EM871E;'D@)#$L,34Q+#`P,"!O
M9B!T:&4@8F5N969I="!W87,@<F5L871E9"!T;R!F961E<F%L(&%N9"`D,3DX
M+#`P,"!W87,@<F5L871E9"!T;R!S=&%T92!T87AE<RX\+V1I=CX\9&EV/B8C
M,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P
M.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C
M,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P
M.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C
M,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P
M.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C
M,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P
M.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C
M,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P
M.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C
M,38P.R8C,38P.R`\+V1I=CX\9&EV('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P
M=#L@9F]N="UF86UI;'DZ("=4:6UE<R!.97<@4F]M86XG+"!4:6UE<RP@<V5R
M:68[('1E>'0M86QI9VXZ(&IU<W1I9GD[('1E>'0M:6YD96YT.B`S-G!T.R<^
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M9&EV/CQD:78^)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[
M)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q
M-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[
M)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q
M-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[
M)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q
M-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[
M)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q
M-C`[)B,Q-C`[)B,Q-C`[(#QB<B`O/CPO9&EV/CQD:78@<W1Y;&4],T0G9F]N
M="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)U1I;65S($YE=R!2;VUA;B<L
M(%1I;65S+"!S97)I9CL@=&5X="UA;&EG;CH@:G5S=&EF>3L@=&5X="UI;F1E
M;G0Z(#,V<'0[)SY);B!*=6YE(#(P,30L($%S=&5R:6%S('-O;&0@-2PP,#`L
M,#`P($)I;U1I;64@<VAA<F5S('=H:6-H(')E<W5L=&5D(&EN(&$@=&%X86)L
M92!G86EN(&]F(&%P<')O>&EM871E;'D@)#$P+C,@;6EL;&EO;B!A;F0@82!T
M87@@<&%Y86)L92!O9B`D,RXV(&UI;&QI;VXN($%S=&5R:6%S(')E8V5I=F5D
M('1H92!":6]4:6UE('-H87)E<R!F<F]M($)I;U1I;64@87,@<&%R="!O9B!T
M:&4@8V]N<VED97)A=&EO;B!F;W(@=&AE($%S=&5R:6%S(&-O;6UO;B!S=&]C
M:R!A;F0@=V%R<F%N=',@:7-S=65D('1O($)I;U1I;64@=6YD97(@86X@07-S
M970@0V]N=')I8G5T:6]N($%G<F5E;65N="!A;6]N9R!":6]4:6UE+"!!<W1E
M<FEA<RP@86YD($=E<F]N($-O<G!O<F%T:6]N+"!A('1A>"!F<F5E('1R86YS
M86-T:6]N+B!4:&ES(&EN8V]M92!T87@@;&EA8FEL:71Y('=A<R!O9F9S970@
M8GD@879A:6QA8FQE(&YE="!O<&5R871I;F<@;&]S<V5S+"!R97-U;'1I;F<@
M:6X@;F\@8V%S:"!I;F-O;64@=&%X97,@9'5E(&9R;VT@=&AA="!S86QE+B!4
M:&ES('1R86YS86-T:6]N('=A<R!T<F5A=&5D(&%S(&$@9&5E;65D(&1I<W1R
M:6)U=&EO;B!B>2!!<W1E<FEA<R!A;F0@<F5C;W)D960@86=A:6YS="!E<75I
M='DN/"]D:78^/"]D:78^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y3=&]C:RUB87-E9"!C;VUP96YS871I;VX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQD:78@<W1Y;&4],T0G9F]N
M="UF86UI;'DZ("=4:6UE<R!.97<@4F]M86XG+"!4:6UE<RP@<V5R:68[(&9O
M;G0M<VEZ93H@,3!P=#LG/CQD:78@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T
M.R!F;VYT+69A;6EL>3H@)U1I;65S($YE=R!2;VUA;B<L(%1I;65S+"!S97)I
M9CL@=&5X="UA;&EG;CH@:G5S=&EF>3L@=&5X="UI;F1E;G0Z(#,V<'0[)SX\
M9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G
M5&EM97,@3F5W(%)O;6%N)RP@5&EM97,L('-E<FEF.R!F;VYT+7-T>6QE.B!I
M=&%L:6,[)SY3=&]C:RUB87-E9"!C;VUP96YS871I;VX\+V9O;G0^)B,Q-C`[
M/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@
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M;VYS(&ES(&1E=&5R;6EN960@:6X@86-C;W)D86YC92!W:71H)B,Q-C`[1D%3
M0B!G=6ED86YC92P@8VAA;F=E<R!I;B!T:&4@<W5B:F5C=&EV92!A<W-U;7!T
M:6]N<R!C86X@;6%T97)I86QL>2!A9F9E8W0@=&AE(&5S=&EM871E9"!V86QU
M92X\+V1I=CX\+V1I=CX\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/DEM<&%I<FUE;G0@;V8@;&]N9RUL:79E9"!A<W-E
M=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQD:78@<W1Y;&4]
M,T0G9F]N="UF86UI;'DZ("=4:6UE<R!.97<@4F]M86XG+"!4:6UE<RP@<V5R
M:68[(&9O;G0M<VEZ93H@,3!P=#LG/CQD:78@<W1Y;&4],T0G9F]N="US:7IE
M.B`Q,'!T.R!F;VYT+69A;6EL>3H@)U1I;65S($YE=R!2;VUA;B<L(%1I;65S
M+"!S97)I9CL@=&5X="UA;&EG;CH@:G5S=&EF>3L@=&5X="UI;F1E;G0Z(#,V
M<'0[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M
M:6QY.B`G5&EM97,@3F5W(%)O;6%N)RP@5&EM97,L('-E<FEF.R!F;VYT+7-T
M>6QE.B!I=&%L:6,[)SY);7!A:7)M96YT(&]F(&QO;F<M;&EV960@87-S971S
M/"]F;VYT/B8C,38P.SQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@
M9F]N="UF86UI;'DZ("=4:6UE<R!.97<@4F]M86XG+"!4:6UE<RP@<V5R:68[
M(&9O;G0M<W1Y;&4Z(&ET86QI8SLG/B8C.#(Q,3L\+V9O;G0^($)I;U1I;64F
M(S@R,3<[<R!L;VYG+6QI=F5D(&%S<V5T<RP@:6YC;'5D:6YG(&EN=&%N9VEB
M;&4@87-S971S+"!A<F4@<F5V:65W960@86YN=6%L;'D@9F]R(&EM<&%I<FUE
M;G0@86YD('=H96YE=F5R(&5V96YT<R!O<B!C:&%N9V5S(&EN(&-I<F-U;7-T
M86YC97,@:6YD:6-A=&4@=&AA="!T:&4@8V%R<GEI;F<@86UO=6YT(&]F(&%N
M(&%S<V5T(&UA>2!N;W0@8F4@9G5L;'D@<F5C;W9E<F%B;&4N($EF(&%N(&EM
M<&%I<FUE;G0@:6YD:6-A=&]R(&ES('!R97-E;G0L($)I;U1I;64@=VEL;"!E
M=F%L=6%T92!R96-O=F5R86)I;&ET>2!B>2!A(&-O;7!A<FES;VX@;V8@=&AE
M(&-A<G)Y:6YG(&%M;W5N="!O9B!T:&4@87-S971S('1O(&9U='5R92!U;F1I
M<V-O=6YT960@;F5T(&-A<V@@9FQO=W,@97AP96-T960@=&\@8F4@9V5N97)A
M=&5D(&)Y('1H92!A<W-E=',N($EF('1H92!A<W-E=',@87)E(&EM<&%I<F5D
M+"!T:&4@:6UP86ER;65N="!R96-O9VYI>F5D(&ES(&UE87-U<F5D(&)Y('1H
M92!A;6]U;G0@8GD@=VAI8V@@=&AE(&-A<G)Y:6YG(&%M;W5N="!E>&-E961S
M('1H92!E<W1I;6%T960@9F%I<B!V86QU92!O9B!T:&4@87-S971S+CPO9&EV
M/CPO9&EV/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^1&5F97)R960@;&EC96YS92!A;F0@8V]N<W5L=&EN9R!F965S
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\9&EV('-T>6QE/3-$
M)V9O;G0M9F%M:6QY.B`G5&EM97,@3F5W(%)O;6%N)RP@5&EM97,L('-E<FEF
M.R!F;VYT+7-I>F4Z(#$P<'0[)SX\9&EV('-T>6QE/3-$)V9O;G0M<VEZ93H@
M,3!P=#L@9F]N="UF86UI;'DZ("=4:6UE<R!.97<@4F]M86XG+"!4:6UE<RP@
M<V5R:68[('1E>'0M86QI9VXZ(&IU<W1I9GD[('1E>'0M:6YD96YT.B`S-G!T
M.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL
M>3H@)U1I;65S($YE=R!2;VUA;B<L(%1I;65S+"!S97)I9CL@9F]N="US='EL
M93H@:71A;&EC.R<^1&5F97)R960@;&EC96YS92!A;F0@8V]N<W5L=&EN9R!F
M965S/"]F;VYT/B`F(S@R,3$[($1E9F5R<F5D(&QI8V5N<V4@86YD(&-O;G-U
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M9'5C=',N($)I;U1I;64@:7,@87!P;'EI;F<@82`Q,"!Y96%R(&5S=&EM871E
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M:&4@8V]N=&EN=65D(&%P<')O<')I871E;F5S<R!O9B!T:&4@,3`@>65A<B!E
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M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y,;W-S('!E<B!S:&%R
M93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/&1I=B!S='EL93TS
M1"=F;VYT+69A;6EL>3H@)U1I;65S($YE=R!2;VUA;B<L(%1I;65S+"!S97)I
M9CL@9F]N="US:7IE.B`Q,'!T.R<^/&1I=B!S='EL93TS1"=F;VYT+7-I>F4Z
M(#$P<'0[(&9O;G0M9F%M:6QY.B`G5&EM97,@3F5W(%)O;6%N)RP@5&EM97,L
M('-E<FEF.R!T97AT+6%L:6=N.B!J=7-T:69Y.R!T97AT+6EN9&5N=#H@,S9P
M=#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI
M;'DZ("=4:6UE<R!.97<@4F]M86XG+"!4:6UE<RP@<V5R:68[(&9O;G0M<W1Y
M;&4Z(&ET86QI8SLG/DQO<W,@<&5R('-H87)E/"]F;VYT/B`F(S@R,3$[($)I
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M=&AE('1H<F5E(&UO;G1H<R!E;F1E9"!-87)C:"`S,2P@,C`Q-2!A;F0@,C`Q
M-"!E>&-L=61E<R!A;GD@969F96-T(&9R;VT@-"PX.3,L.30R('1R96%S=7)Y
M('-H87)E<RP@-"PR-C8L-C`U(&]P=&EO;G,@86YD(#DL,3DT+#8W.2!W87)R
M86YT<R!A;F0@,3`L-30V+#$S-R!T<F5A<W5R>2!S:&%R97,L(#4L-#DQ+#,P
M,2!O<'1I;VYS(&%N9"`Y+#<U,2PV,34@=V%R<F%N=',L(')E<W!E8W1I=F5L
M>2P@8F5C875S92!T:&5I<B!I;F-L=7-I;VX@=V]U;&0@8F4@86YT:61I;'5T
M:79E+CPO9&EV/CPO9&EV/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^1F%I<B!V86QU92!O9B!F:6YA;F-I86P@:6YS
M=')U;65N=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQD:78@
M<W1Y;&4],T0G9F]N="UF86UI;'DZ("=4:6UE<R!.97<@4F]M86XG+"!4:6UE
M<RP@<V5R:68[(&9O;G0M<VEZ93H@,3!P=#LG/CQD:78@<W1Y;&4],T0G9F]N
M="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)U1I;65S($YE=R!2;VUA;B<L
M(%1I;65S+"!S97)I9CL@=&5X="UA;&EG;CH@:G5S=&EF>3L@=&5X="UI;F1E
M;G0Z(#,V<'0[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O
M;G0M9F%M:6QY.B`G5&EM97,@3F5W(%)O;6%N)RP@5&EM97,L('-E<FEF.R!F
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M;7,N/"]D:78^/"]D:78^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y296-E;G1L>2!I<W-U960@86-C;W5N=&EN9R!P
M<F]N;W5N8V5M96YT<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/&1I=B!S='EL93TS1"=F;VYT+69A;6EL>3H@)U1I;65S($YE=R!2;VUA;B<L
M(%1I;65S+"!S97)I9CL@9F]N="US:7IE.B`Q,'!T.R<^/&1I=B!S='EL93TS
M1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G5&EM97,@3F5W(%)O
M;6%N)RP@5&EM97,L('-E<FEF.R!F;VYT+7=E:6=H=#H@8F]L9#L@9F]N="US
M='EL93H@:71A;&EC.R!T97AT+6%L:6=N.B!J=7-T:69Y.R!T97AT+6EN9&5N
M=#H@,S9P=#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M=V5I9VAT.B!N;W)M86P[
M)SY296-E;G1L>2!)<W-U960@06-C;W5N=&EN9R!0<F]N;W5N8V5M96YT<R`F
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M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*
M("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?,SDX8F(Q
M,F)?93AC85\T8C=A7SAF83!?,C8S.61F-6$X.3$P#0I#;VYT96YT+4QO8V%T
M:6]N.B!F:6QE.B\O+T,Z+S,Y.&)B,3)B7V4X8V%?-&(W85\X9F$P7S(V,SED
M9C5A.#DQ,"]7;W)K<VAE971S+U-H965T,C`N:'1M;`T*0V]N=&5N="U4<F%N
M<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E
M.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@
M/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C
M;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T
M>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T
M(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB
M;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5-13X-
M"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS
M1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY/<F=A;FEZ871I;VXL($)A<VES(&]F
M(%!R97-E;G1A=&EO;B!A;F0@3&EQ=6ED:71Y("A486)L97,I/&)R/CPO<W1R
M;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q
M/C,@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DUA<BX@,S$L(#(P,34\8G(^/"]T
M:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^3W)G86YI
M>F%T:6]N+"!"87-I<R!O9B!0<F5S96YT871I;VXL(&%N9"!,:7%U:61I='D@
M6T%B<W1R86-T73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y":6]4:6UE)W,@;W=N97)S:&EP(&]F(&]U='-T86YD:6YG('-H
M87)E<R!O9B!I=',@<W5B<VED:6%R:65S/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\9&EV('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G5&EM97,@
M3F5W(%)O;6%N)RP@5&EM97,L('-E<FEF.R!F;VYT+7-I>F4Z(#$P<'0[)SX\
M9&EV/E1H92!F;VQL;W=I;F<@=&%B;&4@<F5F;&5C=',@0FEO5&EM928C.#(Q
M-SMS(&]W;F5R<VAI<"P@9&ER96-T;'D@;W(@=&AR;W5G:"!O;F4@;W(@;6]R
M92!S=6)S:61I87)I97,L(&]F('1H92!O=71S=&%N9&EN9R!S:&%R97,@;V8@
M:71S('-U8G-I9&EA<FEE<R!A<R!O9B!-87)C:"`S,2P@,C`Q-2X\+V1I=CX\
M9&EV/CQB<B`O/CPO9&EV/CQT86)L92!B;W)D97(],T0P(&-E;&QP861D:6YG
M/3-$,"!C96QL<W!A8VEN9STS1#`@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T
M.R!F;VYT+69A;6EL>3H@)U1I;65S($YE=R!2;VUA;B<L(%1I;65S+"!S97)I
M9CL@=VED=&@Z(#$P,"4[(&)O<F1E<BUC;VQL87!S93H@8V]L;&%P<V4[)SX\
M='(^/'1D('-T>6QE/3-$)V)O<F1E<BUT;W`Z(",P,#`P,#`@,G!X('-O;&ED
M.R!W:61T:#H@,C,N,C@E.R!V97)T:6-A;"UA;&EG;CH@=&]P.R!B;W)D97(M
M;&5F=#H@(S`P,#`P,"`R<'@@<V]L:60[)SX\9&EV('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+V1I=CX\9&EV('-T>6QE/3-$)V9O;G0M
M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=4:6UE<R!.97<@4F]M86XG+"!4
M:6UE<RP@<V5R:68[(&9O;G0M=V5I9VAT.B!B;VQD.R!T97AT+6%L:6=N.B!C
M96YT97([)SY3=6)S:61I87)Y/"]D:78^/"]T9#X\=&0@<W1Y;&4],T0G8F]R
M9&5R+71O<#H@(S`P,#`P,"`R<'@@<V]L:60[('=I9'1H.B`U-R4[('9E<G1I
M8V%L+6%L:6=N.B!T;W`[(&)O<F1E<BUL969T.B`C,#`P,#`P(#)P>"!S;VQI
M9#LG/CQD:78@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO
M9&EV/CQD:78@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL
M>3H@)U1I;65S($YE=R!2;VUA;B<L(%1I;65S+"!S97)I9CL@9F]N="UW96EG
M:'0Z(&)O;&0[('1E>'0M86QI9VXZ(&-E;G1E<CLG/D9I96QD(&]F($)U<VEN
M97-S/"]D:78^/"]T9#X\=&0@<W1Y;&4],T0G8F]R9&5R+71O<#H@(S`P,#`P
M,"`R<'@@<V]L:60[('=I9'1H.B`Q,"4[('9E<G1I8V%L+6%L:6=N.B!T;W`[
M(&)O<F1E<BUL969T.B`C,#`P,#`P(#)P>"!S;VQI9#LG/CQD:78@<W1Y;&4]
M,T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)U1I;65S($YE=R!2
M;VUA;B<L(%1I;65S+"!S97)I9CL@=&5X="UA;&EG;CH@8V5N=&5R.R<^0FEO
M5&EM93PO9&EV/CQD:78@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT
M+69A;6EL>3H@)U1I;65S($YE=R!2;VUA;B<L(%1I;65S+"!S97)I9CL@=&5X
M="UA;&EG;CH@8V5N=&5R.R<^3W=N97)S:&EP/"]D:78^/"]T9#X\=&0@<W1Y
M;&4],T0G8F]R9&5R+71O<#H@(S`P,#`P,"`R<'@@<V]L:60[(&)O<F1E<BUR
M:6=H=#H@(S`P,#`P,"`R<'@@<V]L:60[('=I9'1H.B`Q,"4[('9E<G1I8V%L
M+6%L:6=N.B!T;W`[(&)O<F1E<BUL969T.B`C,#`P,#`P(#)P>"!S;VQI9#LG
M/CQD:78@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO9&EV
M/CQD:78@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@
M)U1I;65S($YE=R!2;VUA;B<L(%1I;65S+"!S97)I9CL@9F]N="UW96EG:'0Z
M(&)O;&0[('1E>'0M86QI9VXZ(&-E;G1E<CLG/D-O=6YT<GD\+V1I=CX\+W1D
M/CPO='(^/'1R/CQT9"!S='EL93TS1"=B;W)D97(M=&]P.B`C,#`P,#`P(#)P
M>"!S;VQI9#L@=VED=&@Z(#(S+C(X)3L@=F5R=&EC86PM86QI9VXZ('1O<#L@
M8F]R9&5R+6QE9G0Z(",P,#`P,#`@,G!X('-O;&ED.R!B86-K9W)O=6YD+6-O
M;&]R.B`C8V-E969F.R<^/&1I=B!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[
M(&9O;G0M9F%M:6QY.B`G5&EM97,@3F5W(%)O;6%N)RP@5&EM97,L('-E<FEF
M.R!T97AT+6%L:6=N.B!L969T.R!M87)G:6XM;&5F=#H@-RXW<'0[('1E>'0M
M:6YD96YT.B`M-RXW<'0[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P
M<'0[(&9O;G0M9F%M:6QY.B`G5&EM97,@3F5W(%)O;6%N)RP@5&EM97,L('-E
M<FEF.R<^07-T97)I87,@0FEO=&AE<F%P975T:6-S+"!);F,N("@\+V9O;G0^
M3EE312!-2U0Z($%35"D\+V1I=CX\+W1D/CQT9"!S='EL93TS1"=B;W)D97(M
M=&]P.B`C,#`P,#`P(#)P>"!S;VQI9#L@=VED=&@Z(#4W)3L@=F5R=&EC86PM
M86QI9VXZ('1O<#L@8F]R9&5R+6QE9G0Z(",P,#`P,#`@,G!X('-O;&ED.R!B
M86-K9W)O=6YD+6-O;&]R.B`C8V-E969F.R<^/&1I=B!S='EL93TS1"=F;VYT
M+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G5&EM97,@3F5W(%)O;6%N)RP@
M5&EM97,L('-E<FEF.R!T97AT+6%L:6=N.B!L969T.R<^4F5S96%R8V@L(&1E
M=F5L;W!M96YT(&%N9"!C;VUM97)C:6%L:7IA=&EO;B!O9B!H=6UA;B!T:&5R
M87!E=71I8R!P<F]D=6-T<R!F<F]M('-T96T@8V5L;',L(&9O8W5S960@:6YI
M=&EA;&QY(&EN('1H92!F:65L9',@;V8@;F5U<F]L;V=Y(&%N9"!O;F-O;&]G
M>3PO9&EV/CPO=&0^/'1D('-T>6QE/3-$)V)O<F1E<BUT;W`Z(",P,#`P,#`@
M,G!X('-O;&ED.R!W:61T:#H@,3`E.R!V97)T:6-A;"UA;&EG;CH@=&]P.R!B
M;W)D97(M;&5F=#H@(S`P,#`P,"`R<'@@<V]L:60[(&)A8VMG<F]U;F0M8V]L
M;W(Z("-C8V5E9F8[)SX\9&EV('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@
M9F]N="UF86UI;'DZ("=4:6UE<R!.97<@4F]M86XG+"!4:6UE<RP@<V5R:68[
M('1E>'0M86QI9VXZ(&-E;G1E<CLG/C8W+C4E/"]D:78^/"]T9#X\=&0@<W1Y
M;&4],T0G8F]R9&5R+71O<#H@(S`P,#`P,"`R<'@@<V]L:60[(&)O<F1E<BUR
M:6=H=#H@(S`P,#`P,"`R<'@@<V]L:60[('=I9'1H.B`Q,"4[('9E<G1I8V%L
M+6%L:6=N.B!T;W`[(&)O<F1E<BUL969T.B`C,#`P,#`P(#)P>"!S;VQI9#L@
M8F%C:V=R;W5N9"UC;VQO<CH@(V-C965F9CLG/CQD:78@<W1Y;&4],T0G9F]N
M="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)U1I;65S($YE=R!2;VUA;B<L
M(%1I;65S+"!S97)I9CL@=&5X="UA;&EG;CH@8V5N=&5R.R<^55-!/"]D:78^
M/"]T9#X\+W1R/CQT<CX\=&0@<W1Y;&4],T0G8F]R9&5R+71O<#H@(S`P,#`P
M,"`R<'@@<V]L:60[('=I9'1H.B`R,RXR."4[('9E<G1I8V%L+6%L:6=N.B!T
M;W`[(&)O<F1E<BUL969T.B`C,#`P,#`P(#)P>"!S;VQI9#L@8F%C:V=R;W5N
M9"UC;VQO<CH@(V9F9F9F9CLG/CQD:78@<W1Y;&4],T0G9F]N="US:7IE.B`Q
M,'!T.R!F;VYT+69A;6EL>3H@)U1I;65S($YE=R!2;VUA;B<L(%1I;65S+"!S
M97)I9CL@=&5X="UA;&EG;CH@;&5F=#L@;6%R9VEN+6QE9G0Z(#<N-W!T.R!T
M97AT+6EN9&5N=#H@+3<N-W!T.R<^0FEO5&EM92!!<VEA+"!,:6UI=&5D/"]D
M:78^/"]T9#X\=&0@<W1Y;&4],T0G8F]R9&5R+71O<#H@(S`P,#`P,"`R<'@@
M<V]L:60[('=I9'1H.B`U-R4[('9E<G1I8V%L+6%L:6=N.B!T;W`[(&)O<F1E
M<BUL969T.B`C,#`P,#`P(#)P>"!S;VQI9#L@8F%C:V=R;W5N9"UC;VQO<CH@
M(V9F9F9F9CLG/CQD:78@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT
M+69A;6EL>3H@)U1I;65S($YE=R!2;VUA;B<L(%1I;65S+"!S97)I9CL@=&5X
M="UA;&EG;CH@;&5F=#LG/E-T96T@8V5L;"!P<F]D=6-T<R!F;W(@<F5S96%R
M8V@\+V1I=CX\+W1D/CQT9"!S='EL93TS1"=B;W)D97(M=&]P.B`C,#`P,#`P
M(#)P>"!S;VQI9#L@=VED=&@Z(#$P)3L@=F5R=&EC86PM86QI9VXZ('1O<#L@
M8F]R9&5R+6QE9G0Z(",P,#`P,#`@,G!X('-O;&ED.R!B86-K9W)O=6YD+6-O
M;&]R.B`C9F9F9F9F.R<^/&1I=B!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[
M(&9O;G0M9F%M:6QY.B`G5&EM97,@3F5W(%)O;6%N)RP@5&EM97,L('-E<FEF
M.R!T97AT+6%L:6=N.B!C96YT97([)SXX,24\+V1I=CX\+W1D/CQT9"!S='EL
M93TS1"=B;W)D97(M=&]P.B`C,#`P,#`P(#)P>"!S;VQI9#L@8F]R9&5R+7)I
M9VAT.B`C,#`P,#`P(#)P>"!S;VQI9#L@=VED=&@Z(#$P)3L@=F5R=&EC86PM
M86QI9VXZ('1O<#L@8F]R9&5R+6QE9G0Z(",P,#`P,#`@,G!X('-O;&ED.R!B
M86-K9W)O=6YD+6-O;&]R.B`C9F9F9F9F.R<^/&1I=B!S='EL93TS1"=F;VYT
M+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G5&EM97,@3F5W(%)O;6%N)RP@
M5&EM97,L('-E<FEF.R!T97AT+6%L:6=N.B!C96YT97([)SY(;VYG($MO;F<\
M+V1I=CX\+W1D/CPO='(^/'1R/CQT9"!S='EL93TS1"=B;W)D97(M=&]P.B`C
M,#`P,#`P(#)P>"!S;VQI9#L@=VED=&@Z(#(S+C(X)3L@=F5R=&EC86PM86QI
M9VXZ('1O<#L@8F]R9&5R+6QE9G0Z(",P,#`P,#`@,G!X('-O;&ED.R!B86-K
M9W)O=6YD+6-O;&]R.B`C8V-E969F.R<^/&1I=B!S='EL93TS1"=F;VYT+7-I
M>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G5&EM97,@3F5W(%)O;6%N)RP@5&EM
M97,L('-E<FEF.R!T97AT+6%L:6=N.B!L969T.R!M87)G:6XM;&5F=#H@-RXW
M<'0[('1E>'0M:6YD96YT.B`M-RXW<'0[)SY#96QL($-U<F4@3F5U<F]S8VEE
M;F-E<R!,=&0N/"]D:78^/"]T9#X\=&0@<W1Y;&4],T0G8F]R9&5R+71O<#H@
M(S`P,#`P,"`R<'@@<V]L:60[('=I9'1H.B`U-R4[('9E<G1I8V%L+6%L:6=N
M.B!T;W`[(&)O<F1E<BUL969T.B`C,#`P,#`P(#)P>"!S;VQI9#L@8F%C:V=R
M;W5N9"UC;VQO<CH@(V-C965F9CLG/CQD:78@<W1Y;&4],T0G9F]N="US:7IE
M.B`Q,'!T.R!F;VYT+69A;6EL>3H@)U1I;65S($YE=R!2;VUA;B<L(%1I;65S
M+"!S97)I9CL@=&5X="UA;&EG;CH@;&5F=#LG/D%G92UR96QA=&5D(&UA8W5L
M87(@9&5G96YE<F%T:6]N/"]D:78^/"]T9#X\=&0@<W1Y;&4],T0G8F]R9&5R
M+71O<#H@(S`P,#`P,"`R<'@@<V]L:60[('=I9'1H.B`Q,"4[('9E<G1I8V%L
M+6%L:6=N.B!T;W`[(&)O<F1E<BUL969T.B`C,#`P,#`P(#)P>"!S;VQI9#L@
M8F%C:V=R;W5N9"UC;VQO<CH@(V-C965F9CLG/CQD:78@<W1Y;&4],T0G9F]N
M="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)U1I;65S($YE=R!2;VUA;B<L
M(%1I;65S+"!S97)I9CL@=&5X="UA;&EG;CH@8V5N=&5R.R<^-C(N-24H,2D\
M+V1I=CX\+W1D/CQT9"!S='EL93TS1"=B;W)D97(M=&]P.B`C,#`P,#`P(#)P
M>"!S;VQI9#L@8F]R9&5R+7)I9VAT.B`C,#`P,#`P(#)P>"!S;VQI9#L@=VED
M=&@Z(#$P)3L@=F5R=&EC86PM86QI9VXZ('1O<#L@8F]R9&5R+6QE9G0Z(",P
M,#`P,#`@,G!X('-O;&ED.R!B86-K9W)O=6YD+6-O;&]R.B`C8V-E969F.R<^
M/&1I=B!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G
M5&EM97,@3F5W(%)O;6%N)RP@5&EM97,L('-E<FEF.R!T97AT+6%L:6=N.B!C
M96YT97([)SY)<W)A96P\+V1I=CX\+W1D/CPO='(^/'1R/CQT9"!S='EL93TS
M1"=B;W)D97(M=&]P.B`C,#`P,#`P(#)P>"!S;VQI9#L@=VED=&@Z(#(S+C(X
M)3L@=F5R=&EC86PM86QI9VXZ('1O<#L@8F]R9&5R+6QE9G0Z(",P,#`P,#`@
M,G!X('-O;&ED.R!B86-K9W)O=6YD+6-O;&]R.B`C9F9F9F9F.R<^/&1I=B!S
M='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G5&EM97,@
M3F5W(%)O;6%N)RP@5&EM97,L('-E<FEF.R!T97AT+6%L:6=N.B!L969T.R!M
M87)G:6XM;&5F=#H@-RXW<'0[('1E>'0M:6YD96YT.B`M-RXW<'0[)SY%4R!#
M96QL($EN=&5R;F%T:6]N86P@4'1E($QT9#PO9&EV/CPO=&0^/'1D('-T>6QE
M/3-$)V)O<F1E<BUT;W`Z(",P,#`P,#`@,G!X('-O;&ED.R!W:61T:#H@-3<E
M.R!V97)T:6-A;"UA;&EG;CH@=&]P.R!B;W)D97(M;&5F=#H@(S`P,#`P,"`R
M<'@@<V]L:60[(&)A8VMG<F]U;F0M8V]L;W(Z("-F9F9F9F8[)SX\9&EV('-T
M>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=4:6UE<R!.
M97<@4F]M86XG+"!4:6UE<RP@<V5R:68[('1E>'0M86QI9VXZ(&QE9G0[)SY3
M=&5M(&-E;&P@<')O9'5C=',@9F]R(')E<V5A<F-H+"!I;F-L=61I;F<@8VQI
M;FEC86P@9W)A9&4@8V5L;"!L:6YE<R!P<F]D=6-E9"!U;F1E<B!C1TU0/"]D
M:78^/"]T9#X\=&0@<W1Y;&4],T0G8F]R9&5R+71O<#H@(S`P,#`P,"`R<'@@
M<V]L:60[('=I9'1H.B`Q,"4[('9E<G1I8V%L+6%L:6=N.B!T;W`[(&)O<F1E
M<BUL969T.B`C,#`P,#`P(#)P>"!S;VQI9#L@8F%C:V=R;W5N9"UC;VQO<CH@
M(V9F9F9F9CLG/CQD:78@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT
M+69A;6EL>3H@)U1I;65S($YE=R!2;VUA;B<L(%1I;65S+"!S97)I9CL@=&5X
M="UA;&EG;CH@8V5N=&5R.R<^,3`P)3PO9&EV/CPO=&0^/'1D('-T>6QE/3-$
M)V)O<F1E<BUT;W`Z(",P,#`P,#`@,G!X('-O;&ED.R!B;W)D97(M<FEG:'0Z
M(",P,#`P,#`@,G!X('-O;&ED.R!W:61T:#H@,3`E.R!V97)T:6-A;"UA;&EG
M;CH@=&]P.R!B;W)D97(M;&5F=#H@(S`P,#`P,"`R<'@@<V]L:60[(&)A8VMG
M<F]U;F0M8V]L;W(Z("-F9F9F9F8[)SX\9&EV('-T>6QE/3-$)V9O;G0M<VEZ
M93H@,3!P=#L@9F]N="UF86UI;'DZ("=4:6UE<R!.97<@4F]M86XG+"!4:6UE
M<RP@<V5R:68[('1E>'0M86QI9VXZ(&-E;G1E<CLG/E-I;F=A<&]R93PO9&EV
M/CPO=&0^/"]T<CX\='(^/'1D('-T>6QE/3-$)V)O<F1E<BUT;W`Z(",P,#`P
M,#`@,G!X('-O;&ED.R!W:61T:#H@,C,N,C@E.R!V97)T:6-A;"UA;&EG;CH@
M=&]P.R!B;W)D97(M;&5F=#H@(S`P,#`P,"`R<'@@<V]L:60[(&)A8VMG<F]U
M;F0M8V]L;W(Z("-C8V5E9F8[)SX\9&EV('-T>6QE/3-$)V9O;G0M<VEZ93H@
M,3!P=#L@9F]N="UF86UI;'DZ("=4:6UE<R!.97<@4F]M86XG+"!4:6UE<RP@
M<V5R:68[('1E>'0M86QI9VXZ(&QE9G0[(&UA<F=I;BUL969T.B`W+C=P=#L@
M=&5X="UI;F1E;G0Z("TW+C=P=#LG/DQI9F5-87`@4V-I96YC97,L($EN8RX\
M+V1I=CX\+W1D/CQT9"!S='EL93TS1"=B;W)D97(M=&]P.B`C,#`P,#`P(#)P
M>"!S;VQI9#L@=VED=&@Z(#4W)3L@=F5R=&EC86PM86QI9VXZ('1O<#L@8F]R
M9&5R+6QE9G0Z(",P,#`P,#`@,G!X('-O;&ED.R!B86-K9W)O=6YD+6-O;&]R
M.B`C8V-E969F.R<^/&1I=B!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O
M;G0M9F%M:6QY.B`G5&EM97,@3F5W(%)O;6%N)RP@5&EM97,L('-E<FEF.R!T
M97AT+6%L:6=N.B!L969T.R<^0FEO;65D:6-A;"P@9V5N92P@9&ES96%S92P@
M86YD('-T96T@8V5L;"!D871A8F%S97,@86YD('1O;VQS/"]D:78^/"]T9#X\
M=&0@<W1Y;&4],T0G8F]R9&5R+71O<#H@(S`P,#`P,"`R<'@@<V]L:60[('=I
M9'1H.B`Q,"4[('9E<G1I8V%L+6%L:6=N.B!T;W`[(&)O<F1E<BUL969T.B`C
M,#`P,#`P(#)P>"!S;VQI9#L@8F%C:V=R;W5N9"UC;VQO<CH@(V-C965F9CLG
M/CQD:78@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@
M)U1I;65S($YE=R!2;VUA;B<L(%1I;65S+"!S97)I9CL@=&5X="UA;&EG;CH@
M8V5N=&5R.R<^-S4N."4\+V1I=CX\+W1D/CQT9"!S='EL93TS1"=B;W)D97(M
M=&]P.B`C,#`P,#`P(#)P>"!S;VQI9#L@8F]R9&5R+7)I9VAT.B`C,#`P,#`P
M(#)P>"!S;VQI9#L@=VED=&@Z(#$P)3L@=F5R=&EC86PM86QI9VXZ('1O<#L@
M8F]R9&5R+6QE9G0Z(",P,#`P,#`@,G!X('-O;&ED.R!B86-K9W)O=6YD+6-O
M;&]R.B`C8V-E969F.R<^/&1I=B!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[
M(&9O;G0M9F%M:6QY.B`G5&EM97,@3F5W(%)O;6%N)RP@5&EM97,L('-E<FEF
M.R!T97AT+6%L:6=N.B!C96YT97([)SY54T$\+V1I=CX\+W1D/CPO='(^/'1R
M/CQT9"!S='EL93TS1"=B;W)D97(M=&]P.B`C,#`P,#`P(#)P>"!S;VQI9#L@
M=VED=&@Z(#(S+C(X)3L@=F5R=&EC86PM86QI9VXZ('1O<#L@8F]R9&5R+6QE
M9G0Z(",P,#`P,#`@,G!X('-O;&ED.R!B86-K9W)O=6YD+6-O;&]R.B`C9F9F
M9F9F.R<^/&1I=B!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M
M:6QY.B`G5&EM97,@3F5W(%)O;6%N)RP@5&EM97,L('-E<FEF.R!T97AT+6%L
M:6=N.B!L969T.R!M87)G:6XM;&5F=#H@-RXW<'0[('1E>'0M:6YD96YT.B`M
M-RXW<'0[)SY,:69E36%P(%-C:65N8V5S+"!,=&0N/"]D:78^/"]T9#X\=&0@
M<W1Y;&4],T0G8F]R9&5R+71O<#H@(S`P,#`P,"`R<'@@<V]L:60[('=I9'1H
M.B`U-R4[('9E<G1I8V%L+6%L:6=N.B!T;W`[(&)O<F1E<BUL969T.B`C,#`P
M,#`P(#)P>"!S;VQI9#L@8F%C:V=R;W5N9"UC;VQO<CH@(V9F9F9F9CLG/CQD
M:78@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)U1I
M;65S($YE=R!2;VUA;B<L(%1I;65S+"!S97)I9CL@=&5X="UA;&EG;CH@;&5F
M=#LG/D)I;VUE9&EC86PL(&=E;F4L(&1I<V5A<V4L(&%N9"!S=&5M(&-E;&P@
M9&%T86)A<V5S(&%N9"!T;V]L<SPO9&EV/CPO=&0^/'1D('-T>6QE/3-$)V)O
M<F1E<BUT;W`Z(",P,#`P,#`@,G!X('-O;&ED.R!W:61T:#H@,3`E.R!V97)T
M:6-A;"UA;&EG;CH@=&]P.R!B;W)D97(M;&5F=#H@(S`P,#`P,"`R<'@@<V]L
M:60[(&)A8VMG<F]U;F0M8V]L;W(Z("-F9F9F9F8[)SX\9&EV('-T>6QE/3-$
M)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=4:6UE<R!.97<@4F]M
M86XG+"!4:6UE<RP@<V5R:68[('1E>'0M86QI9VXZ(&-E;G1E<CLG/B@R*3PO
M9&EV/CPO=&0^/'1D('-T>6QE/3-$)V)O<F1E<BUT;W`Z(",P,#`P,#`@,G!X
M('-O;&ED.R!B;W)D97(M<FEG:'0Z(",P,#`P,#`@,G!X('-O;&ED.R!W:61T
M:#H@,3`E.R!V97)T:6-A;"UA;&EG;CH@=&]P.R!B;W)D97(M;&5F=#H@(S`P
M,#`P,"`R<'@@<V]L:60[(&)A8VMG<F]U;F0M8V]L;W(Z("-F9F9F9F8[)SX\
M9&EV('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=4
M:6UE<R!.97<@4F]M86XG+"!4:6UE<RP@<V5R:68[('1E>'0M86QI9VXZ(&-E
M;G1E<CLG/DES<F%E;#PO9&EV/CPO=&0^/"]T<CX\='(^/'1D('-T>6QE/3-$
M)V)O<F1E<BUT;W`Z(",P,#`P,#`@,G!X('-O;&ED.R!W:61T:#H@,C,N,C@E
M.R!V97)T:6-A;"UA;&EG;CH@=&]P.R!B;W)D97(M;&5F=#H@(S`P,#`P,"`R
M<'@@<V]L:60[(&)A8VMG<F]U;F0M8V]L;W(Z("-C8V5E9F8[)SX\9&EV('-T
M>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=4:6UE<R!.
M97<@4F]M86XG+"!4:6UE<RP@<V5R:68[('1E>'0M86QI9VXZ(&QE9G0[(&UA
M<F=I;BUL969T.B`W+C=P=#L@=&5X="UI;F1E;G0Z("TW+C=P=#LG/DQI9F5-
M87`@4V]L=71I;VYS+"!);F,N/"]D:78^/"]T9#X\=&0@<W1Y;&4],T0G8F]R
M9&5R+71O<#H@(S`P,#`P,"`R<'@@<V]L:60[('=I9'1H.B`U-R4[('9E<G1I
M8V%L+6%L:6=N.B!T;W`[(&)O<F1E<BUL969T.B`C,#`P,#`P(#)P>"!S;VQI
M9#L@8F%C:V=R;W5N9"UC;VQO<CH@(V-C965F9CLG/CQD:78@<W1Y;&4],T0G
M9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)U1I;65S($YE=R!2;VUA
M;B<L(%1I;65S+"!S97)I9CL@=&5X="UA;&EG;CH@;&5F=#LG/DUO8FEL92!H
M96%L=&@@<V]F='=A<F4\+V1I=CX\+W1D/CQT9"!S='EL93TS1"=B;W)D97(M
M=&]P.B`C,#`P,#`P(#)P>"!S;VQI9#L@=VED=&@Z(#$P)3L@=F5R=&EC86PM
M86QI9VXZ('1O<#L@8F]R9&5R+6QE9G0Z(",P,#`P,#`@,G!X('-O;&ED.R!B
M86-K9W)O=6YD+6-O;&]R.B`C8V-E969F.R<^/&1I=B!S='EL93TS1"=F;VYT
M+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G5&EM97,@3F5W(%)O;6%N)RP@
M5&EM97,L('-E<FEF.R!T97AT+6%L:6=N.B!C96YT97([)SXH,BD\+V1I=CX\
M+W1D/CQT9"!S='EL93TS1"=B;W)D97(M=&]P.B`C,#`P,#`P(#)P>"!S;VQI
M9#L@8F]R9&5R+7)I9VAT.B`C,#`P,#`P(#)P>"!S;VQI9#L@=VED=&@Z(#$P
M)3L@=F5R=&EC86PM86QI9VXZ('1O<#L@8F]R9&5R+6QE9G0Z(",P,#`P,#`@
M,G!X('-O;&ED.R!B86-K9W)O=6YD+6-O;&]R.B`C8V-E969F.R<^/&1I=B!S
M='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G5&EM97,@
M3F5W(%)O;6%N)RP@5&EM97,L('-E<FEF.R!T97AT+6%L:6=N.B!C96YT97([
M)SY54T$\+V1I=CX\+W1D/CPO='(^/'1R/CQT9"!S='EL93TS1"=B;W)D97(M
M=&]P.B`C,#`P,#`P(#)P>"!S;VQI9#L@=VED=&@Z(#(S+C(X)3L@=F5R=&EC
M86PM86QI9VXZ('1O<#L@8F]R9&5R+6QE9G0Z(",P,#`P,#`@,G!X('-O;&ED
M.R!B86-K9W)O=6YD+6-O;&]R.B`C9F9F9F9F.R<^/&1I=B!S='EL93TS1"=F
M;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G5&EM97,@3F5W(%)O;6%N
M)RP@5&EM97,L('-E<FEF.R!T97AT+6%L:6=N.B!L969T.R!M87)G:6XM;&5F
M=#H@-RXW<'0[('1E>'0M:6YD96YT.B`M-RXW<'0[)SY/;F-O0WET92!#;W)P
M;W)A=&EO;CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$)V)O<F1E<BUT;W`Z(",P
M,#`P,#`@,G!X('-O;&ED.R!W:61T:#H@-3<E.R!V97)T:6-A;"UA;&EG;CH@
M=&]P.R!B;W)D97(M;&5F=#H@(S`P,#`P,"`R<'@@<V]L:60[(&)A8VMG<F]U
M;F0M8V]L;W(Z("-F9F9F9F8[)SX\9&EV('-T>6QE/3-$)V9O;G0M<VEZ93H@
M,3!P=#L@9F]N="UF86UI;'DZ("=4:6UE<R!.97<@4F]M86XG+"!4:6UE<RP@
M<V5R:68[('1E>'0M86QI9VXZ(&QE9G0[)SY#86YC97(@9&EA9VYO<W1I8W,\
M+V1I=CX\+W1D/CQT9"!S='EL93TS1"=B;W)D97(M=&]P.B`C,#`P,#`P(#)P
M>"!S;VQI9#L@=VED=&@Z(#$P)3L@=F5R=&EC86PM86QI9VXZ('1O<#L@8F]R
M9&5R+6QE9G0Z(",P,#`P,#`@,G!X('-O;&ED.R!B86-K9W)O=6YD+6-O;&]R
M.B`C9F9F9F9F.R<^/&1I=B!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O
M;G0M9F%M:6QY.B`G5&EM97,@3F5W(%)O;6%N)RP@5&EM97,L('-E<FEF.R!T
M97AT+6%L:6=N.B!C96YT97([)SXW-2XS)3PO9&EV/CPO=&0^/'1D('-T>6QE
M/3-$)V)O<F1E<BUT;W`Z(",P,#`P,#`@,G!X('-O;&ED.R!B;W)D97(M<FEG
M:'0Z(",P,#`P,#`@,G!X('-O;&ED.R!W:61T:#H@,3`E.R!V97)T:6-A;"UA
M;&EG;CH@=&]P.R!B;W)D97(M;&5F=#H@(S`P,#`P,"`R<'@@<V]L:60[(&)A
M8VMG<F]U;F0M8V]L;W(Z("-F9F9F9F8[)SX\9&EV('-T>6QE/3-$)V9O;G0M
M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=4:6UE<R!.97<@4F]M86XG+"!4
M:6UE<RP@<V5R:68[('1E>'0M86QI9VXZ(&-E;G1E<CLG/E5303PO9&EV/CPO
M=&0^/"]T<CX\='(^/'1D('-T>6QE/3-$)V)O<F1E<BUT;W`Z(",P,#`P,#`@
M,G!X('-O;&ED.R!W:61T:#H@,C,N,C@E.R!V97)T:6-A;"UA;&EG;CH@=&]P
M.R!B;W)D97(M;&5F=#H@(S`P,#`P,"`R<'@@<V]L:60[(&)A8VMG<F]U;F0M
M8V]L;W(Z("-C8V5E9F8[)SX\9&EV('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P
M=#L@9F]N="UF86UI;'DZ("=4:6UE<R!.97<@4F]M86XG+"!4:6UE<RP@<V5R
M:68[('1E>'0M86QI9VXZ(&QE9G0[(&UA<F=I;BUL969T.B`W+C=P=#L@=&5X
M="UI;F1E;G0Z("TW+C=P=#LG/D]R=&AO0WET92!#;W)P;W)A=&EO;CPO9&EV
M/CPO=&0^/'1D('-T>6QE/3-$)V)O<F1E<BUT;W`Z(",P,#`P,#`@,G!X('-O
M;&ED.R!W:61T:#H@-3<E.R!V97)T:6-A;"UA;&EG;CH@=&]P.R!B;W)D97(M
M;&5F=#H@(S`P,#`P,"`R<'@@<V]L:60[(&)A8VMG<F]U;F0M8V]L;W(Z("-C
M8V5E9F8[)SX\9&EV('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF
M86UI;'DZ("=4:6UE<R!.97<@4F]M86XG+"!4:6UE<RP@<V5R:68[('1E>'0M
M86QI9VXZ(&QE9G0[)SY/<G1H;W!E9&EC(&1I<V5A<V5S+"!I;F-L=61I;F<@
M8VAR;VYI8R!B86-K('!A:6X@86YD(&]S=&5O87)T:')I=&ES/"]D:78^/"]T
M9#X\=&0@<W1Y;&4],T0G8F]R9&5R+71O<#H@(S`P,#`P,"`R<'@@<V]L:60[
M('=I9'1H.B`Q,"4[('9E<G1I8V%L+6%L:6=N.B!T;W`[(&)O<F1E<BUL969T
M.B`C,#`P,#`P(#)P>"!S;VQI9#L@8F%C:V=R;W5N9"UC;VQO<CH@(V-C965F
M9CLG/CQD:78@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL
M>3H@)U1I;65S($YE=R!2;VUA;B<L(%1I;65S+"!S97)I9CL@=&5X="UA;&EG
M;CH@8V5N=&5R.R<^,3`P)2@S*3PO9&EV/CPO=&0^/'1D('-T>6QE/3-$)V)O
M<F1E<BUT;W`Z(",P,#`P,#`@,G!X('-O;&ED.R!B;W)D97(M<FEG:'0Z(",P
M,#`P,#`@,G!X('-O;&ED.R!W:61T:#H@,3`E.R!V97)T:6-A;"UA;&EG;CH@
M=&]P.R!B;W)D97(M;&5F=#H@(S`P,#`P,"`R<'@@<V]L:60[(&)A8VMG<F]U
M;F0M8V]L;W(Z("-C8V5E9F8[)SX\9&EV('-T>6QE/3-$)V9O;G0M<VEZ93H@
M,3!P=#L@9F]N="UF86UI;'DZ("=4:6UE<R!.97<@4F]M86XG+"!4:6UE<RP@
M<V5R:68[('1E>'0M86QI9VXZ(&-E;G1E<CLG/E5303PO9&EV/CPO=&0^/"]T
M<CX\='(^/'1D('-T>6QE/3-$)V)O<F1E<BUT;W`Z(",P,#`P,#`@,G!X('-O
M;&ED.R!W:61T:#H@,C,N,C@E.R!V97)T:6-A;"UA;&EG;CH@=&]P.R!B;W)D
M97(M8F]T=&]M.B`C,#`P,#`P(#)P>"!S;VQI9#L@8F]R9&5R+6QE9G0Z(",P
M,#`P,#`@,G!X('-O;&ED.R!B86-K9W)O=6YD+6-O;&]R.B`C9F9F9F9F.R<^
M/&1I=B!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G
M5&EM97,@3F5W(%)O;6%N)RP@5&EM97,L('-E<FEF.R!T97AT+6%L:6=N.B!L
M969T.R!M87)G:6XM;&5F=#H@-RXW<'0[('1E>'0M:6YD96YT.B`M-RXW<'0[
M)SY294-Y=&4@5&AE<F%P975T:6-S+"!);F,N/"]D:78^/"]T9#X\=&0@<W1Y
M;&4],T0G8F]R9&5R+71O<#H@(S`P,#`P,"`R<'@@<V]L:60[('=I9'1H.B`U
M-R4[('9E<G1I8V%L+6%L:6=N.B!T;W`[(&)O<F1E<BUB;W1T;VTZ(",P,#`P
M,#`@,G!X('-O;&ED.R!B;W)D97(M;&5F=#H@(S`P,#`P,"`R<'@@<V]L:60[
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M<SPO9&EV/CQD:78^)B,Q-C`[/"]D:78^/&1I=B!S='EL93TS1"=F;VYT+7-I
M>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G5&EM97,@3F5W(%)O;6%N)RP@5&EM
M97,L('-E<FEF.R!T97AT+6%L:6=N.B!L969T.R<^4W1E;2!C96QL+61E<FEV
M960@96YD;W1H96QI86P@86YD(&-A<F1I;W9A<V-U;&%R(')E;&%T960@<')O
M9V5N:71O<B!C96QL<R!T:&%T(&AA=F4@87!P;&EC871I;VYS(&EN(')E<V5A
M<F-H+"!D<G5G('1E<W1I;F<L(&%N9"!T:&5R87!E=71I8W,\+V1I=CX\+W1D
M/CQT9"!S='EL93TS1"=B;W)D97(M=&]P.B`C,#`P,#`P(#)P>"!S;VQI9#L@
M=VED=&@Z(#$P)3L@=F5R=&EC86PM86QI9VXZ('1O<#L@8F]R9&5R+6)O='1O
M;3H@(S`P,#`P,"`R<'@@<V]L:60[(&)O<F1E<BUL969T.B`C,#`P,#`P(#)P
M>"!S;VQI9#L@8F%C:V=R;W5N9"UC;VQO<CH@(V9F9F9F9CLG/CQD:78@<W1Y
M;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)U1I;65S($YE
M=R!2;VUA;B<L(%1I;65S+"!S97)I9CL@=&5X="UA;&EG;CH@8V5N=&5R.R<^
M.30N."4\+V1I=CX\+W1D/CQT9"!S='EL93TS1"=B;W)D97(M=&]P.B`C,#`P
M,#`P(#)P>"!S;VQI9#L@8F]R9&5R+7)I9VAT.B`C,#`P,#`P(#)P>"!S;VQI
M9#L@=VED=&@Z(#$P)3L@=F5R=&EC86PM86QI9VXZ('1O<#L@8F]R9&5R+6)O
M='1O;3H@(S`P,#`P,"`R<'@@<V]L:60[(&)O<F1E<BUL969T.B`C,#`P,#`P
M(#)P>"!S;VQI9#L@8F%C:V=R;W5N9"UC;VQO<CH@(V9F9F9F9CLG/CQD:78@
M<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)U1I;65S
M($YE=R!2;VUA;B<L(%1I;65S+"!S97)I9CL@=&5X="UA;&EG;CH@8V5N=&5R
M.R<^55-!/"]D:78^/"]T9#X\+W1R/CPO=&%B;&4^/&1I=CX\8G(@+SX\+V1I
M=CX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SX\=&%B;&4@8V5L
M;'!A9&1I;F<],T0P(&-E;&QS<&%C:6YG/3-$,"!C;&%S<STS1$134$9,:7-T
M5&%B;&4@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@
M)U1I;65S($YE=R!2;VUA;B<L(%1I;65S+"!S97)I9CL@=VED=&@Z(#$P,"4[
M)SX\='(^/'1D('-T>6QE/3-$)W=I9'1H.B`Q.'!T.R<^/"]T9#X\=&0@<W1Y
M;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)U1I;65S($YE
M=R!2;VUA;B<L(%1I;65S+"!S97)I9CL@=VED=&@Z(#$X<'0[('9E<G1I8V%L
M+6%L:6=N.B!T;W`[(&%L:6=N.B!R:6=H=#LG/B@Q*3PO=&0^/'1D('-T>6QE
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M/'1A8FQE(&-E;&QP861D:6YG/3-$,"!C96QL<W!A8VEN9STS1#`@8VQA<W,]
M,T1$4U!&3&ES=%1A8FQE('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N
M="UF86UI;'DZ("=4:6UE<R!.97<@4F]M86XG+"!4:6UE<RP@<V5R:68[('=I
M9'1H.B`Q,#`E.R<^/'1R/CQT9"!S='EL93TS1"=W:61T:#H@,3AP=#LG/CPO
M=&0^/'1D('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ
M("=4:6UE<R!.97<@4F]M86XG+"!4:6UE<RP@<V5R:68[('=I9'1H.B`Q.'!T
M.R!V97)T:6-A;"UA;&EG;CH@=&]P.R!A;&EG;CH@<FEG:'0[)SXH,BD\+W1D
M/CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G
M5&EM97,@3F5W(%)O;6%N)RP@5&EM97,L('-E<FEF.R!W:61T:#H@875T;SL@
M=F5R=&EC86PM86QI9VXZ('1O<#L@=&5X="UA;&EG;CH@;&5F=#LG/DQI9F5-
M87`@4V-I96YC97,L($QT9"X@86YD($QI9F5-87`@4V]L=71I;VYS+"!);F,N
M(&%R92!W:&]L;'DM;W=N960@<W5B<VED:6%R:65S(&]F($QI9F5-87`@4V-I
M96YC97,L($EN8RX\+W1D/CPO='(^/"]T86)L93X\+V1I=CX\9&EV('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SX\=&%B;&4@8V5L;'!A9&1I;F<],T0P
M(&-E;&QS<&%C:6YG/3-$,"!C;&%S<STS1$134$9,:7-T5&%B;&4@<W1Y;&4]
M,T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)U1I;65S($YE=R!2
M;VUA;B<L(%1I;65S+"!S97)I9CL@=VED=&@Z(#$P,"4[)SX\='(^/'1D('-T
M>6QE/3-$)W=I9'1H.B`Q.'!T.R<^/"]T9#X\=&0@<W1Y;&4],T0G9F]N="US
M:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)U1I;65S($YE=R!2;VUA;B<L(%1I
M;65S+"!S97)I9CL@=VED=&@Z(#$X<'0[('9E<G1I8V%L+6%L:6=N.B!T;W`[
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M9&EV/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A
M8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?
M,SDX8F(Q,F)?93AC85\T8C=A7SAF83!?,C8S.61F-6$X.3$P#0I#;VYT96YT
M+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+S,Y.&)B,3)B7V4X8V%?-&(W85\X9F$P
M7S(V,SED9C5A.#DQ,"]7;W)K<VAE971S+U-H965T,C$N:'1M;`T*0V]N=&5N
M="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N
M="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M
M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M
M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C
M<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@
M1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^
M#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$
M,$5-13X-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L
M<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY%<75I<&UE;G0L(&YE="!A
M;F0@8V]N<W1R=6-T:6]N(&EN('!R;V=R97-S("A486)L97,I/&)R/CPO<W1R
M;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q
M/C,@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DUA<BX@,S$L(#(P,34\8G(^/"]T
M:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^17%U:7!M
M96YT+"!N970L(&%N9"!C;VYS=')U8W1I;VX@:6X@<')O9W)E<W,@6T%B<W1R
M86-T73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y%<75I<&UE;G0L(&9U<FYI='5R92!A;F0@9FEX='5R97,\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQD:78@<W1Y;&4],T0G9F]N="UF86UI
M;'DZ("=4:6UE<R!.97<@4F]M86XG+"!4:6UE<RP@<V5R:68[(&9O;G0M<VEZ
M93H@,3!P=#LG/CQD:78@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT
M+69A;6EL>3H@)U1I;65S($YE=R!2;VUA;B<L(%1I;65S+"!S97)I9CL@=&5X
M="UA;&EG;CH@:G5S=&EF>3L@=&5X="UI;F1E;G0Z(#,V<'0[)SY!="!-87)C
M:"`S,2P@,C`Q-2!A;F0@1&5C96UB97(@,S$L(#(P,30L(&5Q=6EP;65N="P@
M9G5R;FET=7)E(&%N9"!F:7AT=7)E<RP@86YD(&-O;G-T<G5C=&EO;B!I;B!P
M<F]G<F5S<R!W97)E(&-O;7!R:7-E9"!O9B!T:&4@9F]L;&]W:6YG.CPO9&EV
M/CQD:78^/&)R("\^/"]D:78^/'1A8FQE(&-E;&QP861D:6YG/3-$,"!C96QL
M<W!A8VEN9STS1#`@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A
M;6EL>3H@)U1I;65S($YE=R!2;VUA;B<L(%1I;65S+"!S97)I9CL@=VED=&@Z
M(#$P,"4[)SX\='(^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=V97)T
M:6-A;"UA;&EG;CH@8F]T=&]M.R!P861D:6YG+6)O='1O;3H@,G!X.R<^)B,Q
M-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W9E<G1I8V%L
M+6%L:6=N.B!B;W1T;VT[('!A9&1I;F<M8F]T=&]M.B`R<'@[)SXF(S$V,#L\
M+W1D/CQT9"!C;VQS<&%N/3-$,B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@
M8F]T=&]M.R!W:&ET92US<&%C93H@;F]W<F%P.R!B;W)D97(M8F]T=&]M.B`C
M,#`P,#`P(#)P>"!S;VQI9#LG/CQD:78@<W1Y;&4],T0G9F]N="US:7IE.B`Q
M,'!T.R!F;VYT+69A;6EL>3H@)U1I;65S($YE=R!2;VUA;B<L(%1I;65S+"!S
M97)I9CL@9F]N="UW96EG:'0Z(&)O;&0[('1E>'0M86QI9VXZ(&-E;G1E<CLG
M/DUA<F-H(#,Q+"`R,#$U/"]D:78^/&1I=B!S='EL93TS1"=F;VYT+7-I>F4Z
M(#$P<'0[(&9O;G0M9F%M:6QY.B`G5&EM97,@3F5W(%)O;6%N)RP@5&EM97,L
M('-E<FEF.R!F;VYT+7=E:6=H=#H@8F]L9#L@=&5X="UA;&EG;CH@8V5N=&5R
M.R<^*%5N875D:71E9"D\+V1I=CX\+W1D/CQT9"!N;W=R87`],T1N;W=R87`@
M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T
M;VT[('!A9&1I;F<M8F]T=&]M.B`R<'@[('1E>'0M86QI9VXZ(&QE9G0[)SXF
M(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=F5R=&EC
M86PM86QI9VXZ(&)O='1O;3L@<&%D9&EN9RUB;W1T;VTZ(#)P>#LG/B8C,38P
M.SPO=&0^/'1D(&-O;'-P86X],T0R('9A;&EG;CTS1&)O='1O;2!S='EL93TS
M1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B;W)D97(M8F]T=&]M.B`C,#`P
M,#`P(#)P>"!S;VQI9#LG/CQD:78@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T
M.R!F;VYT+69A;6EL>3H@)U1I;65S($YE=R!2;VUA;B<L(%1I;65S+"!S97)I
M9CL@9F]N="UW96EG:'0Z(&)O;&0[('1E>'0M86QI9VXZ(&-E;G1E<CLG/D1E
M8V5M8F5R(#,Q+#PO9&EV/CQD:78@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T
M.R!F;VYT+69A;6EL>3H@)U1I;65S($YE=R!2;VUA;B<L(%1I;65S+"!S97)I
M9CL@9F]N="UW96EG:'0Z(&)O;&0[('1E>'0M86QI9VXZ(&-E;G1E<CLG/C(P
M,30\+V1I=CX\+W1D/CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T
M=&]M('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[('!A9&1I;F<M
M8F]T=&]M.B`R<'@[('1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/CPO
M='(^/'1R/CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=VED=&@Z(#<V
M)3L@=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@
M(V-C965F9CLG/CQD:78@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT
M+69A;6EL>3H@)U1I;65S($YE=R!2;VUA;B<L(%1I;65S+"!S97)I9CL@=&5X
M="UA;&EG;CH@;&5F=#L@;6%R9VEN+6QE9G0Z(#<N,G!T.R!T97AT+6EN9&5N
M=#H@+3<N,G!T.R<^17%U:7!M96YT+"!F=7)N:71U<F4@86YD(&9I>'1U<F5S
M/"]D:78^/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H
M.B`Q)3L@=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO
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M=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.B`Y)3L@=F5R=&EC
M86PM86QI9VXZ(&)O='1O;3L@=&5X="UA;&EG;CH@<FEG:'0[(&)A8VMG<F]U
M;F0M8V]L;W(Z("-C8V5E9F8[)SX\9&EV('-T>6QE/3-$)V9O;G0M<VEZ93H@
M,3!P=#L@9F]N="UF86UI;'DZ("=4:6UE<R!.97<@4F]M86XG+"!4:6UE<RP@
M<V5R:68[)SXT+#DR."PX-3<\+V1I=CX\+W1D/CQT9"!N;W=R87`],T1N;W=R
M87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.B`Q)3L@=F5R=&EC
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M+6-O;&]R.B`C8V-E969F.R<^/&1I=B!S='EL93TS1"=F;VYT+7-I>F4Z(#$P
M<'0[(&9O;G0M9F%M:6QY.B`G5&EM97,@3F5W(%)O;6%N)RP@5&EM97,L('-E
M<FEF.R<^)#PO9&EV/CPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS
M1"=W:61T:#H@.24[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[('1E>'0M86QI
M9VXZ(')I9VAT.R!B86-K9W)O=6YD+6-O;&]R.B`C8V-E969F.R<^/&1I=B!S
M='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G5&EM97,@
M3F5W(%)O;6%N)RP@5&EM97,L('-E<FEF.R<^-"PX-S`L-3$V/"]D:78^/"]T
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M;VQO<CH@(V9F9F9F9CLG/CQD:78@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T
M.R!F;VYT+69A;6EL>3H@)U1I;65S($YE=R!2;VUA;B<L(%1I;65S+"!S97)I
M9CL@=&5X="UA;&EG;CH@;&5F=#L@;6%R9VEN+6QE9G0Z(#<N,G!T.R!T97AT
M+6EN9&5N=#H@+3<N,G!T.R<^0V]N<W1R=6-T:6]N(&EN('!R;V=R97-S/"]D
M:78^/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.B`Q
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M="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)U1I;65S($YE=R!2;VUA;B<L
M(%1I;65S+"!S97)I9CLG/C8P-BPV-#$\+V1I=CX\+W1D/CQT9"!N;W=R87`]
M,T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.B`Q)3L@
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M9W)O=6YD+6-O;&]R.B`C9F9F9F9F.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N
M/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.B`Y)3L@=F5R=&EC86PM86QI9VXZ
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M965F9CLG/CQD:78@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A
M;6EL>3H@)U1I;65S($YE=R!2;VUA;B<L(%1I;65S+"!S97)I9CL@=&5X="UA
M;&EG;CH@;&5F=#L@;6%R9VEN+6QE9G0Z(#<N,G!T.R!T97AT+6EN9&5N=#H@
M+3<N,G!T.R<^06-C=6UU;&%T960@9&5P<F5C:6%T:6]N/"]D:78^/"]T9#X\
M=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.B`Q)3L@=F5R=&EC
M86PM86QI9VXZ(&)O='1O;3L@<&%D9&EN9RUB;W1T;VTZ(#)P>#L@8F%C:V=R
M;W5N9"UC;VQO<CH@(V-C965F9CLG/B8C,38P.SPO=&0^/'1D('9A;&EG;CTS
M1&)O='1O;2!S='EL93TS1"=W:61T:#H@,24[('9E<G1I8V%L+6%L:6=N.B!B
M;W1T;VT[(&)O<F1E<BUB;W1T;VTZ(",P,#`P,#`@,G!X('-O;&ED.R!T97AT
M+6%L:6=N.B!L969T.R!B86-K9W)O=6YD+6-O;&]R.B`C8V-E969F.R<^)B,Q
M-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.B`Y
M)3L@=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@8F]R9&5R+6)O='1O;3H@(S`P
M,#`P,"`R<'@@<V]L:60[('1E>'0M86QI9VXZ(')I9VAT.R!B86-K9W)O=6YD
M+6-O;&]R.B`C8V-E969F.R<^/&1I=B!S='EL93TS1"=F;VYT+7-I>F4Z(#$P
M<'0[(&9O;G0M9F%M:6QY.B`G5&EM97,@3F5W(%)O;6%N)RP@5&EM97,L('-E
M<FEF.R<^*#(L-C<P+#@R.3PO9&EV/CPO=&0^/'1D(&YO=W)A<#TS1&YO=W)A
M<"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=VED=&@Z(#$E.R!V97)T:6-A
M;"UA;&EG;CH@8F]T=&]M.R!P861D:6YG+6)O='1O;3H@,G!X.R!T97AT+6%L
M:6=N.B!L969T.R!B86-K9W)O=6YD+6-O;&]R.B`C8V-E969F.R<^/&1I=B!S
M='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G5&EM97,@
M3F5W(%)O;6%N)RP@5&EM97,L('-E<FEF.R<^*3PO9&EV/CPO=&0^/'1D('9A
M;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#H@,24[('9E<G1I8V%L+6%L
M:6=N.B!B;W1T;VT[('!A9&1I;F<M8F]T=&]M.B`R<'@[(&)A8VMG<F]U;F0M
M8V]L;W(Z("-C8V5E9F8[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T
M;VT@<W1Y;&4],T0G=VED=&@Z(#$E.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M
M.R!B;W)D97(M8F]T=&]M.B`C,#`P,#`P(#)P>"!S;VQI9#L@=&5X="UA;&EG
M;CH@;&5F=#L@8F%C:V=R;W5N9"UC;VQO<CH@(V-C965F9CLG/B8C,38P.SPO
M=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#H@.24[('9E
M<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&)O<F1E<BUB;W1T;VTZ(",P,#`P,#`@
M,G!X('-O;&ED.R!T97AT+6%L:6=N.B!R:6=H=#L@8F%C:V=R;W5N9"UC;VQO
M<CH@(V-C965F9CLG/CQD:78@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F
M;VYT+69A;6EL>3H@)U1I;65S($YE=R!2;VUA;B<L(%1I;65S+"!S97)I9CLG
M/B@R+#0Q."PT,#`\+V1I=CX\+W1D/CQT9"!N;W=R87`],T1N;W=R87`@=F%L
M:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.B`Q)3L@=F5R=&EC86PM86QI
M9VXZ(&)O='1O;3L@<&%D9&EN9RUB;W1T;VTZ(#)P>#L@=&5X="UA;&EG;CH@
M;&5F=#L@8F%C:V=R;W5N9"UC;VQO<CH@(V-C965F9CLG/CQD:78@<W1Y;&4]
M,T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)U1I;65S($YE=R!2
M;VUA;B<L(%1I;65S+"!S97)I9CLG/BD\+V1I=CX\+W1D/CPO='(^/'1R/CQT
M9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=VED=&@Z(#<V)3L@=F5R=&EC
M86PM86QI9VXZ(&)O='1O;3L@<&%D9&EN9RUB;W1T;VTZ(#1P>#L@8F%C:V=R
M;W5N9"UC;VQO<CH@(V9F9F9F9CLG/CQD:78@<W1Y;&4],T0G9F]N="US:7IE
M.B`Q,'!T.R!F;VYT+69A;6EL>3H@)U1I;65S($YE=R!2;VUA;B<L(%1I;65S
M+"!S97)I9CL@=&5X="UA;&EG;CH@;&5F=#L@;6%R9VEN+6QE9G0Z(#<N,G!T
M.R!T97AT+6EN9&5N=#H@+3<N,G!T.R<^17%U:7!M96YT(&YE="PF(S$V,#MA
M;F0@8V]N<W1R=6-T:6]N(&EN('!R;V=R97-S/"]D:78^/"]T9#X\=&0@=F%L
M:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.B`Q)3L@=F5R=&EC86PM86QI
M9VXZ(&)O='1O;3L@<&%D9&EN9RUB;W1T;VTZ(#1P>#L@8F%C:V=R;W5N9"UC
M;VQO<CH@(V9F9F9F9CLG/B8C,38P.SPO=&0^/'1D('9A;&EG;CTS1&)O='1O
M;2!S='EL93TS1"=W:61T:#H@,24[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[
M(&)O<F1E<BUB;W1T;VTZ(",P,#`P,#`@-'!X(&1O=6)L93L@=&5X="UA;&EG
M;CH@;&5F=#L@8F%C:V=R;W5N9"UC;VQO<CH@(V9F9F9F9CLG/CQD:78@<W1Y
M;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)U1I;65S($YE
M=R!2;VUA;B<L(%1I;65S+"!S97)I9CLG/B0\+V1I=CX\+W1D/CQT9"!V86QI
M9VX],T1B;W1T;VT@<W1Y;&4],T0G=VED=&@Z(#DE.R!V97)T:6-A;"UA;&EG
M;CH@8F]T=&]M.R!B;W)D97(M8F]T=&]M.B`C,#`P,#`P(#1P>"!D;W5B;&4[
M('1E>'0M86QI9VXZ(')I9VAT.R!B86-K9W)O=6YD+6-O;&]R.B`C9F9F9F9F
M.R<^/&1I=B!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY
M.B`G5&EM97,@3F5W(%)O;6%N)RP@5&EM97,L('-E<FEF.R<^,BPX-C0L-C8Y
M/"]D:78^/"]T9#X\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O
M;2!S='EL93TS1"=W:61T:#H@,24[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[
M('!A9&1I;F<M8F]T=&]M.B`T<'@[('1E>'0M86QI9VXZ(&QE9G0[(&)A8VMG
M<F]U;F0M8V]L;W(Z("-F9F9F9F8[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX]
M,T1B;W1T;VT@<W1Y;&4],T0G=VED=&@Z(#$E.R!V97)T:6-A;"UA;&EG;CH@
M8F]T=&]M.R!P861D:6YG+6)O='1O;3H@-'!X.R!B86-K9W)O=6YD+6-O;&]R
M.B`C9F9F9F9F.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T
M>6QE/3-$)W=I9'1H.B`Q)3L@=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@8F]R
M9&5R+6)O='1O;3H@(S`P,#`P,"`T<'@@9&]U8FQE.R!T97AT+6%L:6=N.B!L
M969T.R!B86-K9W)O=6YD+6-O;&]R.B`C9F9F9F9F.R<^/&1I=B!S='EL93TS
M1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G5&EM97,@3F5W(%)O
M;6%N)RP@5&EM97,L('-E<FEF.R<^)#PO9&EV/CPO=&0^/'1D('9A;&EG;CTS
M1&)O='1O;2!S='EL93TS1"=W:61T:#H@.24[('9E<G1I8V%L+6%L:6=N.B!B
M;W1T;VT[(&)O<F1E<BUB;W1T;VTZ(",P,#`P,#`@-'!X(&1O=6)L93L@=&5X
M="UA;&EG;CH@<FEG:'0[(&)A8VMG<F]U;F0M8V]L;W(Z("-F9F9F9F8[)SX\
M9&EV('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=4
M:6UE<R!.97<@4F]M86XG+"!4:6UE<RP@<V5R:68[)SXR+#@U-RPX-#8\+V1I
M=CX\+W1D/CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T
M>6QE/3-$)W=I9'1H.B`Q)3L@=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@<&%D
M9&EN9RUB;W1T;VTZ(#1P>#L@=&5X="UA;&EG;CH@;&5F=#L@8F%C:V=R;W5N
M9"UC;VQO<CH@(V9F9F9F9CLG/B8C,38P.SPO=&0^/"]T<CX\+W1A8FQE/CPO
M9&EV/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A
M8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?
M,SDX8F(Q,F)?93AC85\T8C=A7SAF83!?,C8S.61F-6$X.3$P#0I#;VYT96YT
M+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+S,Y.&)B,3)B7V4X8V%?-&(W85\X9F$P
M7S(V,SED9C5A.#DQ,"]7;W)K<VAE971S+U-H965T,C(N:'1M;`T*0V]N=&5N
M="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N
M="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M
M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M
M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C
M<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@
M1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^
M#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$
M,$5-13X-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L
M<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY);G1A;F=I8FQE(&%S<V5T
M<RP@;F5T("A486)L97,I/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C,@36]N=&AS($5N9&5D/"]T:#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1H/DUA<BX@,S$L(#(P,34\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/CQS=')O;F<^26YT86YG:6)L92!A<W-E=',L(&YE="!;06)S
M=')A8W1=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/DEN=&%N9VEB;&4@87-S971S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\9&EV('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G5&EM97,@3F5W
M(%)O;6%N)RP@5&EM97,L('-E<FEF.R!F;VYT+7-I>F4Z(#$P<'0[)SX\9&EV
M('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=4:6UE
M<R!.97<@4F]M86XG+"!4:6UE<RP@<V5R:68[('1E>'0M86QI9VXZ(&IU<W1I
M9GD[('1E>'0M:6YD96YT.B`S-G!T.R<^070@36%R8V@@,S$L(#(P,34@86YD
M($1E8V5M8F5R(#,Q+"`R,#$T+"!I;G1A;F=I8FQE(&%S<V5T<R!A;F0@:6YT
M86YG:6)L92!A<W-E=',@;F5T(&]F(&%M;W)T:7IA=&EO;B!W97)E(&-O;7!R
M:7-E9"!O9B!T:&4@9F]L;&]W:6YG.CPO9&EV/CQD:78^/&)R("\^/"]D:78^
M/'1A8FQE(&-E;&QP861D:6YG/3-$,"!C96QL<W!A8VEN9STS1#`@<W1Y;&4]
M,T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)U1I;65S($YE=R!2
M;VUA;B<L(%1I;65S+"!S97)I9CL@=VED=&@Z(#$P,"4[)SX\='(^/'1D('9A
M;&EG;CTS1&)O='1O;2!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M
M.R!P861D:6YG+6)O='1O;3H@,G!X.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N
M/3-$8F]T=&]M('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[('!A
M9&1I;F<M8F]T=&]M.B`R<'@[)SXF(S$V,#L\+W1D/CQT9"!C;VQS<&%N/3-$
M,B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!W:&ET92US<&%C
M93H@;F]W<F%P.R!B;W)D97(M8F]T=&]M.B`C,#`P,#`P(#)P>"!S;VQI9#LG
M/CQD:78@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@
M)U1I;65S($YE=R!2;VUA;B<L(%1I;65S+"!S97)I9CL@9F]N="UW96EG:'0Z
M(&)O;&0[('1E>'0M86QI9VXZ(&-E;G1E<CLG/DUA<F-H(#,Q+"`R,#$U/"]D
M:78^/&1I=B!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY
M.B`G5&EM97,@3F5W(%)O;6%N)RP@5&EM97,L('-E<FEF.R!F;VYT+7=E:6=H
M=#H@8F]L9#L@=&5X="UA;&EG;CH@8V5N=&5R.R<^*%5N875D:71E9"D\+V1I
M=CX\+W1D/CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T
M>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[('!A9&1I;F<M8F]T=&]M
M.B`R<'@[('1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/CQT9"!V86QI
M9VX],T1B;W1T;VT@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@
M<&%D9&EN9RUB;W1T;VTZ(#)P>#LG/B8C,38P.SPO=&0^/'1D(&-O;'-P86X]
M,T0R('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@
M8F]T=&]M.R!B;W)D97(M8F]T=&]M.B`C,#`P,#`P(#)P>"!S;VQI9#LG/CQD
M:78@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)U1I
M;65S($YE=R!2;VUA;B<L(%1I;65S+"!S97)I9CL@9F]N="UW96EG:'0Z(&)O
M;&0[('1E>'0M86QI9VXZ(&-E;G1E<CLG/D1E8V5M8F5R(#,Q+#PO9&EV/CQD
M:78@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)U1I
M;65S($YE=R!2;VUA;B<L(%1I;65S+"!S97)I9CL@9F]N="UW96EG:'0Z(&)O
M;&0[('1E>'0M86QI9VXZ(&-E;G1E<CLG/C(P,30\+V1I=CX\+W1D/CQT9"!N
M;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W9E<G1I
M8V%L+6%L:6=N.B!B;W1T;VT[('!A9&1I;F<M8F]T=&]M.B`R<'@[('1E>'0M
M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/CPO='(^/'1R/CQT9"!V86QI9VX]
M,T1B;W1T;VT@<W1Y;&4],T0G=VED=&@Z(#<V)3L@=F5R=&EC86PM86QI9VXZ
M(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@(V-C965F9CLG/CQD:78@<W1Y
M;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)U1I;65S($YE
M=R!2;VUA;B<L(%1I;65S+"!S97)I9CL@=&5X="UA;&EG;CH@;&5F=#L@;6%R
M9VEN+6QE9G0Z(#<N,G!T.R!T97AT+6EN9&5N=#H@+3<N,G!T.R<^26YT86YG
M:6)L92!A<W-E=',\+V1I=CX\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y
M;&4],T0G=VED=&@Z(#$E.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K
M9W)O=6YD+6-O;&]R.B`C8V-E969F.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N
M/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.B`Q)3L@=F5R=&EC86PM86QI9VXZ
M(&)O='1O;3L@=&5X="UA;&EG;CH@;&5F=#L@8F%C:V=R;W5N9"UC;VQO<CH@
M(V-C965F9CLG/CQD:78@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT
M+69A;6EL>3H@)U1I;65S($YE=R!2;VUA;B<L(%1I;65S+"!S97)I9CLG/B0\
M+V1I=CX\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=VED=&@Z
M(#DE.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!T97AT+6%L:6=N.B!R:6=H
M=#L@8F%C:V=R;W5N9"UC;VQO<CH@(V-C965F9CLG/CQD:78@<W1Y;&4],T0G
M9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)U1I;65S($YE=R!2;VUA
M;B<L(%1I;65S+"!S97)I9CLG/C4R+#4V,BPU-#D\+V1I=CX\+W1D/CQT9"!N
M;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H
M.B`Q)3L@=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@=&5X="UA;&EG;CH@;&5F
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M.R!B86-K9W)O=6YD+6-O;&]R.B`C8V-E969F.R<^/&1I=B!S='EL93TS1"=F
M;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G5&EM97,@3F5W(%)O;6%N
M)RP@5&EM97,L('-E<FEF.R<^)#PO9&EV/CPO=&0^/'1D('9A;&EG;CTS1&)O
M='1O;2!S='EL93TS1"=W:61T:#H@.24[('9E<G1I8V%L+6%L:6=N.B!B;W1T
M;VT[('1E>'0M86QI9VXZ(')I9VAT.R!B86-K9W)O=6YD+6-O;&]R.B`C8V-E
M969F.R<^/&1I=B!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M
M:6QY.B`G5&EM97,@3F5W(%)O;6%N)RP@5&EM97,L('-E<FEF.R<^-3(L-38R
M+#4T.3PO9&EV/CPO=&0^/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B
M;W1T;VT@<W1Y;&4],T0G=VED=&@Z(#$E.R!V97)T:6-A;"UA;&EG;CH@8F]T
M=&]M.R!T97AT+6%L:6=N.B!L969T.R!B86-K9W)O=6YD+6-O;&]R.B`C8V-E
M969F.R<^)B,Q-C`[/"]T9#X\+W1R/CQT<CX\=&0@=F%L:6=N/3-$8F]T=&]M
M('-T>6QE/3-$)W=I9'1H.B`W-B4[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[
M('!A9&1I;F<M8F]T=&]M.B`R<'@[(&)A8VMG<F]U;F0M8V]L;W(Z("-F9F9F
M9F8[)SX\9&EV('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI
M;'DZ("=4:6UE<R!.97<@4F]M86XG+"!4:6UE<RP@<V5R:68[('1E>'0M86QI
M9VXZ(&QE9G0[(&UA<F=I;BUL969T.B`W+C)P=#L@=&5X="UI;F1E;G0Z("TW
M+C)P=#LG/D%C8W5M=6QA=&5D(&%M;W)T:7IA=&EO;CPO9&EV/CPO=&0^/'1D
M('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#H@,24[('9E<G1I8V%L
M+6%L:6=N.B!B;W1T;VT[('!A9&1I;F<M8F]T=&]M.B`R<'@[(&)A8VMG<F]U
M;F0M8V]L;W(Z("-F9F9F9F8[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B
M;W1T;VT@<W1Y;&4],T0G=VED=&@Z(#$E.R!V97)T:6-A;"UA;&EG;CH@8F]T
M=&]M.R!B;W)D97(M8F]T=&]M.B`C,#`P,#`P(#)P>"!S;VQI9#L@=&5X="UA
M;&EG;CH@;&5F=#L@8F%C:V=R;W5N9"UC;VQO<CH@(V9F9F9F9CLG/B8C,38P
M.SPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#H@.24[
M('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&)O<F1E<BUB;W1T;VTZ(",P,#`P
M,#`@,G!X('-O;&ED.R!T97AT+6%L:6=N.B!R:6=H=#L@8F%C:V=R;W5N9"UC
M;VQO<CH@(V9F9F9F9CLG/CQD:78@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T
M.R!F;VYT+69A;6EL>3H@)U1I;65S($YE=R!2;VUA;B<L(%1I;65S+"!S97)I
M9CLG/B@Q-2PP,C@L,C0W/"]D:78^/"]T9#X\=&0@;F]W<F%P/3-$;F]W<F%P
M('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#H@,24[('9E<G1I8V%L
M+6%L:6=N.B!B;W1T;VT[('!A9&1I;F<M8F]T=&]M.B`R<'@[('1E>'0M86QI
M9VXZ(&QE9G0[(&)A8VMG<F]U;F0M8V]L;W(Z("-F9F9F9F8[)SX\9&EV('-T
M>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=4:6UE<R!.
M97<@4F]M86XG+"!4:6UE<RP@<V5R:68[)SXI/"]D:78^/"]T9#X\=&0@=F%L
M:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.B`Q)3L@=F5R=&EC86PM86QI
M9VXZ(&)O='1O;3L@<&%D9&EN9RUB;W1T;VTZ(#)P>#L@8F%C:V=R;W5N9"UC
M;VQO<CH@(V9F9F9F9CLG/B8C,38P.SPO=&0^/'1D('9A;&EG;CTS1&)O='1O
M;2!S='EL93TS1"=W:61T:#H@,24[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[
M(&)O<F1E<BUB;W1T;VTZ(",P,#`P,#`@,G!X('-O;&ED.R!T97AT+6%L:6=N
M.B!L969T.R!B86-K9W)O=6YD+6-O;&]R.B`C9F9F9F9F.R<^)B,Q-C`[/"]T
M9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.B`Y)3L@=F5R
M=&EC86PM86QI9VXZ(&)O='1O;3L@8F]R9&5R+6)O='1O;3H@(S`P,#`P,"`R
M<'@@<V]L:60[('1E>'0M86QI9VXZ(')I9VAT.R!B86-K9W)O=6YD+6-O;&]R
M.B`C9F9F9F9F.R<^/&1I=B!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O
M;G0M9F%M:6QY.B`G5&EM97,@3F5W(%)O;6%N)RP@5&EM97,L('-E<FEF.R<^
M*#$S+#<Q-"PQ-3,\+V1I=CX\+W1D/CQT9"!N;W=R87`],T1N;W=R87`@=F%L
M:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.B`Q)3L@=F5R=&EC86PM86QI
M9VXZ(&)O='1O;3L@<&%D9&EN9RUB;W1T;VTZ(#)P>#L@=&5X="UA;&EG;CH@
M;&5F=#L@8F%C:V=R;W5N9"UC;VQO<CH@(V9F9F9F9CLG/CQD:78@<W1Y;&4]
M,T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)U1I;65S($YE=R!2
M;VUA;B<L(%1I;65S+"!S97)I9CLG/BD\+V1I=CX\+W1D/CPO='(^/'1R/CQT
M9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=VED=&@Z(#<V)3L@=F5R=&EC
M86PM86QI9VXZ(&)O='1O;3L@<&%D9&EN9RUB;W1T;VTZ(#1P>#L@8F%C:V=R
M;W5N9"UC;VQO<CH@(V-C965F9CLG/CQD:78@<W1Y;&4],T0G9F]N="US:7IE
M.B`Q,'!T.R!F;VYT+69A;6EL>3H@)U1I;65S($YE=R!2;VUA;B<L(%1I;65S
M+"!S97)I9CL@=&5X="UA;&EG;CH@;&5F=#L@;6%R9VEN+6QE9G0Z(#<N,G!T
M.R!T97AT+6EN9&5N=#H@+3<N,G!T.R<^26YT86YG:6)L92!A<W-E=',L(&YE
M=#PO9&EV/CPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T
M:#H@,24[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[('!A9&1I;F<M8F]T=&]M
M.B`T<'@[(&)A8VMG<F]U;F0M8V]L;W(Z("-C8V5E9F8[)SXF(S$V,#L\+W1D
M/CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=VED=&@Z(#$E.R!V97)T
M:6-A;"UA;&EG;CH@8F]T=&]M.R!B;W)D97(M8F]T=&]M.B`C,#`P,#`P(#1P
M>"!D;W5B;&4[('1E>'0M86QI9VXZ(&QE9G0[(&)A8VMG<F]U;F0M8V]L;W(Z
M("-C8V5E9F8[)SX\9&EV('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N
M="UF86UI;'DZ("=4:6UE<R!.97<@4F]M86XG+"!4:6UE<RP@<V5R:68[)SXD
M/"]D:78^/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H
M.B`Y)3L@=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@8F]R9&5R+6)O='1O;3H@
M(S`P,#`P,"`T<'@@9&]U8FQE.R!T97AT+6%L:6=N.B!R:6=H=#L@8F%C:V=R
M;W5N9"UC;VQO<CH@(V-C965F9CLG/CQD:78@<W1Y;&4],T0G9F]N="US:7IE
M.B`Q,'!T.R!F;VYT+69A;6EL>3H@)U1I;65S($YE=R!2;VUA;B<L(%1I;65S
M+"!S97)I9CLG/C,W+#4S-"PS,#(\+V1I=CX\+W1D/CQT9"!N;W=R87`],T1N
M;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.B`Q)3L@=F5R
M=&EC86PM86QI9VXZ(&)O='1O;3L@<&%D9&EN9RUB;W1T;VTZ(#1P>#L@=&5X
M="UA;&EG;CH@;&5F=#L@8F%C:V=R;W5N9"UC;VQO<CH@(V-C965F9CLG/B8C
M,38P.SPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#H@
M,24[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[('!A9&1I;F<M8F]T=&]M.B`T
M<'@[(&)A8VMG<F]U;F0M8V]L;W(Z("-C8V5E9F8[)SXF(S$V,#L\+W1D/CQT
M9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=VED=&@Z(#$E.R!V97)T:6-A
M;"UA;&EG;CH@8F]T=&]M.R!B;W)D97(M8F]T=&]M.B`C,#`P,#`P(#1P>"!D
M;W5B;&4[('1E>'0M86QI9VXZ(&QE9G0[(&)A8VMG<F]U;F0M8V]L;W(Z("-C
M8V5E9F8[)SX\9&EV('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF
M86UI;'DZ("=4:6UE<R!.97<@4F]M86XG+"!4:6UE<RP@<V5R:68[)SXD/"]D
M:78^/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.B`Y
M)3L@=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@8F]R9&5R+6)O='1O;3H@(S`P
M,#`P,"`T<'@@9&]U8FQE.R!T97AT+6%L:6=N.B!R:6=H=#L@8F%C:V=R;W5N
M9"UC;VQO<CH@(V-C965F9CLG/CQD:78@<W1Y;&4],T0G9F]N="US:7IE.B`Q
M,'!T.R!F;VYT+69A;6EL>3H@)U1I;65S($YE=R!2;VUA;B<L(%1I;65S+"!S
M97)I9CLG/C,X+#@T."PS.38\+V1I=CX\+W1D/CQT9"!N;W=R87`],T1N;W=R
M87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.B`Q)3L@=F5R=&EC
M86PM86QI9VXZ(&)O='1O;3L@<&%D9&EN9RUB;W1T;VTZ(#1P>#L@=&5X="UA
M;&EG;CH@;&5F=#L@8F%C:V=R;W5N9"UC;VQO<CH@(V-C965F9CLG/B8C,38P
M.SPO=&0^/"]T<CX\+W1A8FQE/CPO9&EV/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^
M#0H-"BTM+2TM+3U?3F5X=%!A<G1?,SDX8F(Q,F)?93AC85\T8C=A7SAF83!?
M,C8S.61F-6$X.3$P#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+S,Y
M.&)B,3)B7V4X8V%?-&(W85\X9F$P7S(V,SED9C5A.#DQ,"]7;W)K<VAE971S
M+U-H965T,C,N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O
M=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S
M970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@
M:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M
M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R
M:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE
M;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C
M;&%S<STS1')E<&]R="!I9#TS1$E$,$5-13X-"B`@("`@(#QT<CX-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T
M<F]N9SY2;WEA;'1Y($]B;&EG871I;VX@86YD($1E9F5R<F5D($QI8V5N<V4@
M1F5E<R`H5&%B;&5S*3QB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XS($UO;G1H<R!%;F1E9#PO=&@^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M:#Y-87(N(#,Q+"`R,#$U/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#X\<W1R;VYG/E)O>6%L='D@3V)L:6=A=&EO;B!A;F0@1&5F97)R
M960@3&EC96YS92!&965S(%M!8G-T<F%C=%T\+W-T<F]N9SX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^06UO<G1I>F%T:6]N(&]F(&1E9F5R
M<F5D(&QI8V5N<V4@9F5E<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/&1I=B!S='EL93TS1"=F;VYT+69A;6EL>3H@)U1I;65S($YE=R!2;VUA
M;B<L(%1I;65S+"!S97)I9CL@9F]N="US:7IE.B`Q,'!T.R<^/&1I=B!S='EL
M93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G5&EM97,@3F5W
M(%)O;6%N)RP@5&EM97,L('-E<FEF.R!T97AT+6%L:6=N.B!J=7-T:69Y.R!T
M97AT+6EN9&5N=#H@,S9P=#LG/D%S(&]F($UA<F-H(#,Q+"`R,#$U+"!F=71U
M<F4@86UO<G1I>F%T:6]N(&]F(&1E9F5R<F5D(&QI8V5N<V4@9F5E<R!D97-C
M<FEB960@86)O=F4@=V%S(&%S(&9O;&QO=W,Z/"]D:78^/&1I=CX\8G(@+SX\
M+V1I=CX\=&%B;&4@86QI9VX],T1C96YT97(@8F]R9&5R/3-$,"!C96QL<&%D
M9&EN9STS1#`@8V5L;'-P86-I;F<],T0P('-T>6QE/3-$)V9O;G0M<VEZ93H@
M,3!P=#L@9F]N="UF86UI;'DZ("=4:6UE<R!.97<@4F]M86XG+"!4:6UE<RP@
M<V5R:68[('=I9'1H.B`U,"4[)SX\='(^/'1D('9A;&EG;CTS1&)O='1O;2!S
M='EL93TS1"=W:61T:#H@,S@E.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B
M;W)D97(M8F]T=&]M.B`C,#`P,#`P(#)P>"!S;VQI9#LG/CQD:78@<W1Y;&4]
M,T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)U1I;65S($YE=R!2
M;VUA;B<L(%1I;65S+"!S97)I9CL@9F]N="UW96EG:'0Z(&)O;&0[('1E>'0M
M86QI9VXZ(&-E;G1E<CLG/EEE87(@16YD960@1&5C96UB97(@,S$L/"]D:78^
M/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.B`Q)3L@
M=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@<&%D9&EN9RUB;W1T;VTZ(#)P>#LG
M/B8C,38P.SPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T
M:#H@,3`E.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B;W)D97(M8F]T=&]M
M.B`C,#`P,#`P(#)P>"!S;VQI9#LG/CQD:78@<W1Y;&4],T0G9F]N="US:7IE
M.B`Q,'!T.R!F;VYT+69A;6EL>3H@)U1I;65S($YE=R!2;VUA;B<L(%1I;65S
M+"!S97)I9CL@9F]N="UW96EG:'0Z(&)O;&0[('1E>'0M86QI9VXZ(&-E;G1E
M<CLG/D1E9F5R<F5D/"]D:78^/&1I=B!S='EL93TS1"=F;VYT+7-I>F4Z(#$P
M<'0[(&9O;G0M9F%M:6QY.B`G5&EM97,@3F5W(%)O;6%N)RP@5&EM97,L('-E
M<FEF.R!F;VYT+7=E:6=H=#H@8F]L9#L@=&5X="UA;&EG;CH@8V5N=&5R.R<^
M3&EC96YS92!&965S/"]D:78^/"]T9#X\=&0@;F]W<F%P/3-$;F]W<F%P('9A
M;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#H@,24[('9E<G1I8V%L+6%L
M:6=N.B!B;W1T;VT[('!A9&1I;F<M8F]T=&]M.B`R<'@[('1E>'0M86QI9VXZ
M(&QE9G0[)SXF(S$V,#L\+W1D/CPO='(^/'1R/CQT9"!V86QI9VX],T1B;W1T
M;VT@<W1Y;&4],T0G=VED=&@Z(#,X)3L@=F5R=&EC86PM86QI9VXZ(&)O='1O
M;3L@8F%C:V=R;W5N9"UC;VQO<CH@(V-C965F9CLG/CQD:78@<W1Y;&4],T0G
M9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)U1I;65S($YE=R!2;VUA
M;B<L(%1I;65S+"!S97)I9CL@=&5X="UA;&EG;CH@8V5N=&5R.R<^,C`Q-3PO
M9&EV/CPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#H@
M,24[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&)A8VMG<F]U;F0M8V]L;W(Z
M("-C8V5E9F8[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y
M;&4],T0G=VED=&@Z(#$P)3L@=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@=&5X
M="UA;&EG;CH@;&5F=#L@8F%C:V=R;W5N9"UC;VQO<CH@(V-C965F9CLG/CQD
M:78@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)U1I
M;65S($YE=R!2;VUA;B<L(%1I;65S+"!S97)I9CL@=&5X="UA;&EG;CH@8V5N
M=&5R.R<^)#@R+#$R-3PO9&EV/CPO=&0^/'1D(&YO=W)A<#TS1&YO=W)A<"!V
M86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=VED=&@Z(#$E.R!V97)T:6-A;"UA
M;&EG;CH@8F]T=&]M.R!T97AT+6%L:6=N.B!L969T.R!B86-K9W)O=6YD+6-O
M;&]R.B`C8V-E969F.R<^)B,Q-C`[/"]T9#X\+W1R/CQT<CX\=&0@=F%L:6=N
M/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.B`S."4[('9E<G1I8V%L+6%L:6=N
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M+6-O;&]R.B`C9F9F9F9F.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T
M=&]M('-T>6QE/3-$)W=I9'1H.B`Q,"4[('9E<G1I8V%L+6%L:6=N.B!B;W1T
M;VT[('1E>'0M86QI9VXZ(&-E;G1E<CL@8F%C:V=R;W5N9"UC;VQO<CH@(V9F
M9F9F9CLG/B8C,38P.S$P.2PU,#`\+W1D/CQT9"!N;W=R87`],T1N;W=R87`@
M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.B`Q)3L@=F5R=&EC86PM
M86QI9VXZ(&)O='1O;3L@=&5X="UA;&EG;CH@;&5F=#L@8F%C:V=R;W5N9"UC
M;VQO<CH@(V9F9F9F9CLG/B8C,38P.SPO=&0^/"]T<CX\='(^/'1D('9A;&EG
M;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#H@,S@E.R!V97)T:6-A;"UA;&EG
M;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B`C8V-E969F.R<^/&1I=B!S
M='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G5&EM97,@
M3F5W(%)O;6%N)RP@5&EM97,L('-E<FEF.R!T97AT+6%L:6=N.B!C96YT97([
M)SXR,#$W/"]D:78^/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$
M)W=I9'1H.B`Q)3L@=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N
M9"UC;VQO<CH@(V-C965F9CLG/B8C,38P.SPO=&0^/'1D('9A;&EG;CTS1&)O
M='1O;2!S='EL93TS1"=W:61T:#H@,3`E.R!V97)T:6-A;"UA;&EG;CH@8F]T
M=&]M.R!T97AT+6%L:6=N.B!C96YT97([(&)A8VMG<F]U;F0M8V]L;W(Z("-C
M8V5E9F8[)SXF(S$V,#LQ,#DL-3`P/"]T9#X\=&0@;F]W<F%P/3-$;F]W<F%P
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M<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)U1I;65S
M($YE=R!2;VUA;B<L(%1I;65S+"!S97)I9CL@=&5X="UA;&EG;CH@8V5N=&5R
M.R<^,C`Q.#PO9&EV/CPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS
M1"=W:61T:#H@,24[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&)A8VMG<F]U
M;F0M8V]L;W(Z("-F9F9F9F8[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B
M;W1T;VT@<W1Y;&4],T0G=VED=&@Z(#$P)3L@=F5R=&EC86PM86QI9VXZ(&)O
M='1O;3L@=&5X="UA;&EG;CH@8V5N=&5R.R!B86-K9W)O=6YD+6-O;&]R.B`C
M9F9F9F9F.R<^)B,Q-C`[-S,L-C8W/"]T9#X\=&0@;F]W<F%P/3-$;F]W<F%P
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M<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)U1I;65S
M($YE=R!2;VUA;B<L(%1I;65S+"!S97)I9CL@=&5X="UA;&EG;CH@8V5N=&5R
M.R<^,C`Q.3PO9&EV/CPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS
M1"=W:61T:#H@,24[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&)A8VMG<F]U
M;F0M8V]L;W(Z("-C8V5E9F8[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B
M;W1T;VT@<W1Y;&4],T0G=VED=&@Z(#$P)3L@=F5R=&EC86PM86QI9VXZ(&)O
M='1O;3L@=&5X="UA;&EG;CH@8V5N=&5R.R!B86-K9W)O=6YD+6-O;&]R.B`C
M8V-E969F.R<^)B,Q-C`[,C0L,#@S/"]T9#X\=&0@;F]W<F%P/3-$;F]W<F%P
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M;VQO<CH@(V9F9F9F9CLG/CQD:78@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T
M.R!F;VYT+69A;6EL>3H@)U1I;65S($YE=R!2;VUA;B<L(%1I;65S+"!S97)I
M9CL@=&5X="UA;&EG;CH@8V5N=&5R.R<^5&AE<F5A9G1E<CPO9&EV/CPO=&0^
M/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#H@,24[('9E<G1I
M8V%L+6%L:6=N.B!B;W1T;VT[('!A9&1I;F<M8F]T=&]M.B`R<'@[(&)A8VMG
M<F]U;F0M8V]L;W(Z("-F9F9F9F8[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX]
M,T1B;W1T;VT@<W1Y;&4],T0G=VED=&@Z(#$P)3L@=F5R=&EC86PM86QI9VXZ
M(&)O='1O;3L@8F]R9&5R+6)O='1O;3H@(S`P,#`P,"`R<'@@<V]L:60[('1E
M>'0M86QI9VXZ(&-E;G1E<CL@8F%C:V=R;W5N9"UC;VQO<CH@(V9F9F9F9CLG
M/B8C,38P.S(P+#`X,SPO=&0^/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX]
M,T1B;W1T;VT@<W1Y;&4],T0G=VED=&@Z(#$E.R!V97)T:6-A;"UA;&EG;CH@
M8F]T=&]M.R!P861D:6YG+6)O='1O;3H@,G!X.R!T97AT+6%L:6=N.B!L969T
M.R!B86-K9W)O=6YD+6-O;&]R.B`C9F9F9F9F.R<^)B,Q-C`[/"]T9#X\+W1R
M/CQT<CX\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.B`S."4[
M('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[('!A9&1I;F<M8F]T=&]M.B`T<'@[
M(&)A8VMG<F]U;F0M8V]L;W(Z("-C8V5E9F8[)SX\9&EV('-T>6QE/3-$)V9O
M;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=4:6UE<R!.97<@4F]M86XG
M+"!4:6UE<RP@<V5R:68[('1E>'0M86QI9VXZ(&-E;G1E<CLG/E1O=&%L/"]D
M:78^/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.B`Q
M)3L@=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@<&%D9&EN9RUB;W1T;VTZ(#1P
M>#L@8F%C:V=R;W5N9"UC;VQO<CH@(V-C965F9CLG/B8C,38P.SPO=&0^/'1D
M('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#H@,3`E.R!V97)T:6-A
M;"UA;&EG;CH@8F]T=&]M.R!B;W)D97(M8F]T=&]M.B`C,#`P,#`P(#1P>"!D
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M('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[('!A9&1I;F<M8F]T=&]M.B`T<'@[
M('1E>'0M86QI9VXZ(&QE9G0[(&)A8VMG<F]U;F0M8V]L;W(Z("-C8V5E9F8[
M)SXF(S$V,#L\+W1D/CPO='(^/"]T86)L93X\+V1I=CX\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*
M/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7S,Y.&)B,3)B7V4X8V%?-&(W
M85\X9F$P7S(V,SED9C5A.#DQ,`T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO
M+R]#.B\S.3AB8C$R8E]E.&-A7S1B-V%?.&9A,%\R-C,Y9&8U83@Y,3`O5V]R
M:W-H965T<R]3:&5E=#(T+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I
M;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL
M.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@
M(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T
M97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O
M:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI
M<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\
M=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%344^#0H@("`@("`\='(^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X]
M,T0R/CQS=')O;F<^06-C;W5N=',@4&%Y86)L92!A;F0@06-C<G5E9"!,:6%B
M:6QI=&EE<R`H5&%B;&5S*3QB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XS($UO;G1H<R!%;F1E9#PO=&@^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T:#Y-87(N(#,Q+"`R,#$U/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#X\<W1R;VYG/D%C8V]U;G1S(%!A>6%B;&4@86YD($%C8W)U
M960@3&EA8FEL:71I97,@6T%B<W1R86-T73PO<W1R;VYG/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!8V-O=6YT<R!P87EA8FQE(&%N9"!A
M8V-R=65D(&QI86)I;&ET:65S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\9&EV('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G5&EM97,@3F5W(%)O
M;6%N)RP@5&EM97,L('-E<FEF.R!F;VYT+7-I>F4Z(#$P<'0[)SX\9&EV('-T
M>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=4:6UE<R!.
M97<@4F]M86XG+"!4:6UE<RP@<V5R:68[('1E>'0M86QI9VXZ(&IU<W1I9GD[
M('1E>'0M:6YD96YT.B`S-G!T.R<^070@36%R8V@@,S$L(#(P,34@86YD($1E
M8V5M8F5R(#,Q+"`R,#$T+"!A8V-O=6YT<R!P87EA8FQE(&%N9"!A8V-R=65D
M(&QI86)I;&ET:65S(&-O;G-I<W1E9"!O9B!T:&4@9F]L;&]W:6YG.CPO9&EV
M/CQD:78^/&)R("\^/"]D:78^/'1A8FQE(&-E;&QP861D:6YG/3-$,"!C96QL
M<W!A8VEN9STS1#`@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A
M;6EL>3H@)U1I;65S($YE=R!2;VUA;B<L(%1I;65S+"!S97)I9CL@=VED=&@Z
M(#$P,"4[)SX\='(^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=V97)T
M:6-A;"UA;&EG;CH@8F]T=&]M.R!P861D:6YG+6)O='1O;3H@,G!X.R<^)B,Q
M-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W9E<G1I8V%L
M+6%L:6=N.B!B;W1T;VT[('!A9&1I;F<M8F]T=&]M.B`R<'@[)SXF(S$V,#L\
M+W1D/CQT9"!C;VQS<&%N/3-$,B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@
M8F]T=&]M.R!W:&ET92US<&%C93H@;F]W<F%P.R!B;W)D97(M8F]T=&]M.B`C
M,#`P,#`P(#)P>"!S;VQI9#LG/CQD:78@<W1Y;&4],T0G9F]N="US:7IE.B`Q
M,'!T.R!F;VYT+69A;6EL>3H@)U1I;65S($YE=R!2;VUA;B<L(%1I;65S+"!S
M97)I9CL@9F]N="UW96EG:'0Z(&)O;&0[('1E>'0M86QI9VXZ(&-E;G1E<CLG
M/DUA<F-H(#,Q+"`R,#$U/"]D:78^/&1I=B!S='EL93TS1"=F;VYT+7-I>F4Z
M(#$P<'0[(&9O;G0M9F%M:6QY.B`G5&EM97,@3F5W(%)O;6%N)RP@5&EM97,L
M('-E<FEF.R!F;VYT+7=E:6=H=#H@8F]L9#L@=&5X="UA;&EG;CH@8V5N=&5R
M.R<^*%5N875D:71E9"D\+V1I=CX\+W1D/CQT9"!N;W=R87`],T1N;W=R87`@
M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T
M;VT[('!A9&1I;F<M8F]T=&]M.B`R<'@[('1E>'0M86QI9VXZ(&QE9G0[)SXF
M(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=F5R=&EC
M86PM86QI9VXZ(&)O='1O;3L@<&%D9&EN9RUB;W1T;VTZ(#)P>#LG/B8C,38P
M.SPO=&0^/'1D(&-O;'-P86X],T0R('9A;&EG;CTS1&)O='1O;2!S='EL93TS
M1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B;W)D97(M8F]T=&]M.B`C,#`P
M,#`P(#)P>"!S;VQI9#LG/CQD:78@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T
M.R!F;VYT+69A;6EL>3H@)U1I;65S($YE=R!2;VUA;B<L(%1I;65S+"!S97)I
M9CL@9F]N="UW96EG:'0Z(&)O;&0[('1E>'0M86QI9VXZ(&-E;G1E<CLG/D1E
M8V5M8F5R(#,Q+#PO9&EV/CQD:78@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T
M.R!F;VYT+69A;6EL>3H@)U1I;65S($YE=R!2;VUA;B<L(%1I;65S+"!S97)I
M9CL@9F]N="UW96EG:'0Z(&)O;&0[('1E>'0M86QI9VXZ(&-E;G1E<CLG/C(P
M,30\+V1I=CX\+W1D/CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T
M=&]M('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[('!A9&1I;F<M
M8F]T=&]M.B`R<'@[('1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/CPO
M='(^/'1R/CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=VED=&@Z(#<V
M)3L@=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@
M(V-C965F9CLG/CQD:78@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT
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M86-K9W)O=6YD+6-O;&]R.B`C8V-E969F.R<^/&1I=B!S='EL93TS1"=F;VYT
M+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G5&EM97,@3F5W(%)O;6%N)RP@
M5&EM97,L('-E<FEF.R<^)#PO9&EV/CPO=&0^/'1D('9A;&EG;CTS1&)O='1O
M;2!S='EL93TS1"=W:61T:#H@.24[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[
M('1E>'0M86QI9VXZ(')I9VAT.R!B86-K9W)O=6YD+6-O;&]R.B`C8V-E969F
M.R<^/&1I=B!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY
M.B`G5&EM97,@3F5W(%)O;6%N)RP@5&EM97,L('-E<FEF.R<^,BPW,#<L-#,W
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M;&]R.B`C8V-E969F.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M
M('-T>6QE/3-$)W=I9'1H.B`Q)3L@=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@
M=&5X="UA;&EG;CH@;&5F=#L@8F%C:V=R;W5N9"UC;VQO<CH@(V-C965F9CLG
M/CQD:78@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@
M)U1I;65S($YE=R!2;VUA;B<L(%1I;65S+"!S97)I9CLG/B0\+V1I=CX\+W1D
M/CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=VED=&@Z(#DE.R!V97)T
M:6-A;"UA;&EG;CH@8F]T=&]M.R!T97AT+6%L:6=N.B!R:6=H=#L@8F%C:V=R
M;W5N9"UC;VQO<CH@(V-C965F9CLG/CQD:78@<W1Y;&4],T0G9F]N="US:7IE
M.B`Q,'!T.R!F;VYT+69A;6EL>3H@)U1I;65S($YE=R!2;VUA;B<L(%1I;65S
M+"!S97)I9CLG/C(L,CDV+#8T-3PO9&EV/CPO=&0^/'1D(&YO=W)A<#TS1&YO
M=W)A<"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=VED=&@Z(#$E.R!V97)T
M:6-A;"UA;&EG;CH@8F]T=&]M.R!T97AT+6%L:6=N.B!L969T.R!B86-K9W)O
M=6YD+6-O;&]R.B`C8V-E969F.R<^)B,Q-C`[/"]T9#X\+W1R/CQT<CX\=&0@
M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.B`W-B4[('9E<G1I8V%L
M+6%L:6=N.B!B;W1T;VT[(&)A8VMG<F]U;F0M8V]L;W(Z("-F9F9F9F8[)SX\
M9&EV('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=4
M:6UE<R!.97<@4F]M86XG+"!4:6UE<RP@<V5R:68[('1E>'0M86QI9VXZ(&QE
M9G0[(&UA<F=I;BUL969T.B`W+C)P=#L@=&5X="UI;F1E;G0Z("TW+C)P=#LG
M/D%C8W)U960@97AP96YS97,\+V1I=CX\+W1D/CQT9"!V86QI9VX],T1B;W1T
M;VT@<W1Y;&4],T0G=VED=&@Z(#$E.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M
M.R!B86-K9W)O=6YD+6-O;&]R.B`C9F9F9F9F.R<^)B,Q-C`[/"]T9#X\=&0@
M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.B`Q)3L@=F5R=&EC86PM
M86QI9VXZ(&)O='1O;3L@=&5X="UA;&EG;CH@;&5F=#L@8F%C:V=R;W5N9"UC
M;VQO<CH@(V9F9F9F9CLG/B8C,38P.SPO=&0^/'1D('9A;&EG;CTS1&)O='1O
M;2!S='EL93TS1"=W:61T:#H@.24[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[
M('1E>'0M86QI9VXZ(')I9VAT.R!B86-K9W)O=6YD+6-O;&]R.B`C9F9F9F9F
M.R<^/&1I=B!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY
M.B`G5&EM97,@3F5W(%)O;6%N)RP@5&EM97,L('-E<FEF.R<^,RPP.3(L,#,P
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M;&]R.B`C9F9F9F9F.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M
M('-T>6QE/3-$)W=I9'1H.B`Q)3L@=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@
M=&5X="UA;&EG;CH@;&5F=#L@8F%C:V=R;W5N9"UC;VQO<CH@(V9F9F9F9CLG
M/B8C,38P.SPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T
M:#H@.24[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[('1E>'0M86QI9VXZ(')I
M9VAT.R!B86-K9W)O=6YD+6-O;&]R.B`C9F9F9F9F.R<^/&1I=B!S='EL93TS
M1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G5&EM97,@3F5W(%)O
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M(V-C965F9CLG/CQD:78@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT
M+69A;6EL>3H@)U1I;65S($YE=R!2;VUA;B<L(%1I;65S+"!S97)I9CL@=&5X
M="UA;&EG;CH@;&5F=#L@;6%R9VEN+6QE9G0Z(#<N,G!T.R!T97AT+6EN9&5N
M=#H@+3<N,G!T.R<^06-C<G5E9"!B;VYU<V5S/"]D:78^/"]T9#X\=&0@=F%L
M:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.B`Q)3L@=F5R=&EC86PM86QI
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M<CH@(V-C965F9CLG/CQD:78@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F
M;VYT+69A;6EL>3H@)U1I;65S($YE=R!2;VUA;B<L(%1I;65S+"!S97)I9CLG
M/C(T,"PV.#D\+V1I=CX\+W1D/CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N
M/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.B`Q)3L@=F5R=&EC86PM86QI9VXZ
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M8F]T=&]M.R!T97AT+6%L:6=N.B!L969T.R!B86-K9W)O=6YD+6-O;&]R.B`C
M8V-E969F.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE
M/3-$)W=I9'1H.B`Y)3L@=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@=&5X="UA
M;&EG;CH@<FEG:'0[(&)A8VMG<F]U;F0M8V]L;W(Z("-C8V5E9F8[)SX\9&EV
M('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=4:6UE
M<R!.97<@4F]M86XG+"!4:6UE<RP@<V5R:68[)SXY-C0L,3@Y/"]D:78^/"]T
M9#X\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;2!S='EL93TS
M1"=W:61T:#H@,24[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[('1E>'0M86QI
M9VXZ(&QE9G0[(&)A8VMG<F]U;F0M8V]L;W(Z("-C8V5E9F8[)SXF(S$V,#L\
M+W1D/CPO='(^/'1R/CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=VED
M=&@Z(#<V)3L@=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@<&%D9&EN9RUB;W1T
M;VTZ(#)P>#L@8F%C:V=R;W5N9"UC;VQO<CH@(V9F9F9F9CLG/CQD:78@<W1Y
M;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)U1I;65S($YE
M=R!2;VUA;B<L(%1I;65S+"!S97)I9CL@=&5X="UA;&EG;CH@;&5F=#L@;6%R
M9VEN+6QE9G0Z(#<N,G!T.R!T97AT+6EN9&5N=#H@+3<N,G!T.R<^3W1H97(@
M8W5R<F5N="!L:6%B:6QI=&EE<SPO9&EV/CPO=&0^/'1D('9A;&EG;CTS1&)O
M='1O;2!S='EL93TS1"=W:61T:#H@,24[('9E<G1I8V%L+6%L:6=N.B!B;W1T
M;VT[('!A9&1I;F<M8F]T=&]M.B`R<'@[(&)A8VMG<F]U;F0M8V]L;W(Z("-F
M9F9F9F8[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4]
M,T0G=VED=&@Z(#$E.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B;W)D97(M
M8F]T=&]M.B`C,#`P,#`P(#)P>"!S;VQI9#L@=&5X="UA;&EG;CH@;&5F=#L@
M8F%C:V=R;W5N9"UC;VQO<CH@(V9F9F9F9CLG/B8C,38P.SPO=&0^/'1D('9A
M;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#H@.24[('9E<G1I8V%L+6%L
M:6=N.B!B;W1T;VT[(&)O<F1E<BUB;W1T;VTZ(",P,#`P,#`@,G!X('-O;&ED
M.R!T97AT+6%L:6=N.B!R:6=H=#L@8F%C:V=R;W5N9"UC;VQO<CH@(V9F9F9F
M9CLG/CQD:78@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL
M>3H@)U1I;65S($YE=R!2;VUA;B<L(%1I;65S+"!S97)I9CLG/C(X,BPR-3$\
M+V1I=CX\+W1D/CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M
M('-T>6QE/3-$)W=I9'1H.B`Q)3L@=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@
M<&%D9&EN9RUB;W1T;VTZ(#)P>#L@=&5X="UA;&EG;CH@;&5F=#L@8F%C:V=R
M;W5N9"UC;VQO<CH@(V9F9F9F9CLG/B8C,38P.SPO=&0^/'1D('9A;&EG;CTS
M1&)O='1O;2!S='EL93TS1"=W:61T:#H@,24[('9E<G1I8V%L+6%L:6=N.B!B
M;W1T;VT[('!A9&1I;F<M8F]T=&]M.B`R<'@[(&)A8VMG<F]U;F0M8V]L;W(Z
M("-F9F9F9F8[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y
M;&4],T0G=VED=&@Z(#$E.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B;W)D
M97(M8F]T=&]M.B`C,#`P,#`P(#)P>"!S;VQI9#L@=&5X="UA;&EG;CH@;&5F
M=#L@8F%C:V=R;W5N9"UC;VQO<CH@(V9F9F9F9CLG/B8C,38P.SPO=&0^/'1D
M('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#H@.24[('9E<G1I8V%L
M+6%L:6=N.B!B;W1T;VT[(&)O<F1E<BUB;W1T;VTZ(",P,#`P,#`@,G!X('-O
M;&ED.R!T97AT+6%L:6=N.B!R:6=H=#L@8F%C:V=R;W5N9"UC;VQO<CH@(V9F
M9F9F9CLG/CQD:78@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A
M;6EL>3H@)U1I;65S($YE=R!2;VUA;B<L(%1I;65S+"!S97)I9CLG/C0Q-RPS
M,38\+V1I=CX\+W1D/CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T
M=&]M('-T>6QE/3-$)W=I9'1H.B`Q)3L@=F5R=&EC86PM86QI9VXZ(&)O='1O
M;3L@<&%D9&EN9RUB;W1T;VTZ(#)P>#L@=&5X="UA;&EG;CH@;&5F=#L@8F%C
M:V=R;W5N9"UC;VQO<CH@(V9F9F9F9CLG/B8C,38P.SPO=&0^/"]T<CX\='(^
M/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#H@-S8E.R!V97)T
M:6-A;"UA;&EG;CH@8F]T=&]M.R!P861D:6YG+6)O='1O;3H@-'!X.R!B86-K
M9W)O=6YD+6-O;&]R.B`C8V-E969F.R<^/&1I=B!S='EL93TS1"=F;VYT+7-I
M>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G5&EM97,@3F5W(%)O;6%N)RP@5&EM
M97,L('-E<FEF.R!T97AT+6%L:6=N.B!L969T.R!M87)G:6XM;&5F=#H@-RXR
M<'0[('1E>'0M:6YD96YT.B`M-RXR<'0[)SY4;W1A;#PO9&EV/CPO=&0^/'1D
M('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#H@,24[('9E<G1I8V%L
M+6%L:6=N.B!B;W1T;VT[('!A9&1I;F<M8F]T=&]M.B`T<'@[(&)A8VMG<F]U
M;F0M8V]L;W(Z("-C8V5E9F8[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B
M;W1T;VT@<W1Y;&4],T0G=VED=&@Z(#$E.R!V97)T:6-A;"UA;&EG;CH@8F]T
M=&]M.R!B;W)D97(M8F]T=&]M.B`C,#`P,#`P(#1P>"!D;W5B;&4[('1E>'0M
M86QI9VXZ(&QE9G0[(&)A8VMG<F]U;F0M8V]L;W(Z("-C8V5E9F8[)SX\9&EV
M('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ("=4:6UE
M<R!.97<@4F]M86XG+"!4:6UE<RP@<V5R:68[)SXD/"]D:78^/"]T9#X\=&0@
M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.B`Y)3L@=F5R=&EC86PM
M86QI9VXZ(&)O='1O;3L@8F]R9&5R+6)O='1O;3H@(S`P,#`P,"`T<'@@9&]U
M8FQE.R!T97AT+6%L:6=N.B!R:6=H=#L@8F%C:V=R;W5N9"UC;VQO<CH@(V-C
M965F9CLG/CQD:78@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A
M;6EL>3H@)U1I;65S($YE=R!2;VUA;B<L(%1I;65S+"!S97)I9CLG/C8L,S(R
M+#0P-SPO9&EV/CPO=&0^/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B
M;W1T;VT@<W1Y;&4],T0G=VED=&@Z(#$E.R!V97)T:6-A;"UA;&EG;CH@8F]T
M=&]M.R!P861D:6YG+6)O='1O;3H@-'!X.R!T97AT+6%L:6=N.B!L969T.R!B
M86-K9W)O=6YD+6-O;&]R.B`C8V-E969F.R<^)B,Q-C`[/"]T9#X\=&0@=F%L
M:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.B`Q)3L@=F5R=&EC86PM86QI
M9VXZ(&)O='1O;3L@<&%D9&EN9RUB;W1T;VTZ(#1P>#L@8F%C:V=R;W5N9"UC
M;VQO<CH@(V-C965F9CLG/B8C,38P.SPO=&0^/'1D('9A;&EG;CTS1&)O='1O
M;2!S='EL93TS1"=W:61T:#H@,24[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[
M(&)O<F1E<BUB;W1T;VTZ(",P,#`P,#`@-'!X(&1O=6)L93L@=&5X="UA;&EG
M;CH@;&5F=#L@8F%C:V=R;W5N9"UC;VQO<CH@(V-C965F9CLG/CQD:78@<W1Y
M;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@)U1I;65S($YE
M=R!2;VUA;B<L(%1I;65S+"!S97)I9CLG/B0\+V1I=CX\+W1D/CQT9"!V86QI
M9VX],T1B;W1T;VT@<W1Y;&4],T0G=VED=&@Z(#DE.R!V97)T:6-A;"UA;&EG
M;CH@8F]T=&]M.R!B;W)D97(M8F]T=&]M.B`C,#`P,#`P(#1P>"!D;W5B;&4[
M('1E>'0M86QI9VXZ(')I9VAT.R!B86-K9W)O=6YD+6-O;&]R.B`C8V-E969F
M.R<^/&1I=B!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY
M.B`G5&EM97,@3F5W(%)O;6%N)RP@5&EM97,L('-E<FEF.R<^-BPX,#,L,3<S
M/"]D:78^/"]T9#X\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O
M;2!S='EL93TS1"=W:61T:#H@,24[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[
M('!A9&1I;F<M8F]T=&]M.B`T<'@[('1E>'0M86QI9VXZ(&QE9G0[(&)A8VMG
M<F]U;F0M8V]L;W(Z("-C8V5E9F8[)SXF(S$V,#L\+W1D/CPO='(^/"]T86)L
M93X\+V1I=CX\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'10
M87)T7S,Y.&)B,3)B7V4X8V%?-&(W85\X9F$P7S(V,SED9C5A.#DQ,`T*0V]N
M=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B\S.3AB8C$R8E]E.&-A7S1B-V%?
M.&9A,%\R-C,Y9&8U83@Y,3`O5V]R:W-H965T<R]3:&5E=#(U+FAT;6P-"D-O
M;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O
M;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*
M/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT
M96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G
M/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS
M/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H
M96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60]
M,T1)1#!%14A"23X-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#$^/'-T<F]N9SY/<F=A;FEZ871I
M;VXL($)A<VES(&]F(%!R97-E;G1A=&EO;B!A;F0@3&EQ=6ED:71Y("A$971A
M:6QS*2`H55-$("0I/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1H(&-O;'-P86X],T0R/DUA<BX@,S$L(#(P,34\8G(^/"]T:#X-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q-#QB<CX\+W1H
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y-87(N(#,Q+"`R,#$T/&)R/CPO
M=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3,\8G(^
M/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^3F]N
M8V]N=')O;&QI;F<@26YT97)E<W0@6TQI;F4@271E;7-=/"]S=')O;F<^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$9FX^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/D%C8W5M=6QA=&5D(&1E9FEC:70\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6T^)"`H,3DR+#,U-RPU-S4I/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&9N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;3XD("@Q.#(L,3DP+#(P-RD\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-H87)E:&]L
M9&5R<R<@97%U:71Y/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU
M-RPU,3$L-S@T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&9N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-C(L-S(R
M+#<V-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^0V%S:"!A;F0@8V%S:"!E<75I=F%L96YT<SPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,C4L.#(Y+#4S,SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1F;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C(Y+#0X-BPY,#D\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XV+#8S-RPX,S0\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU+#0Y-2PT-S@\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!A
M<F5N="!;365M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&9N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/DYO;F-O
M;G1R;VQL:6YG($EN=&5R97-T(%M,:6YE($ET96US73PO<W1R;VYG/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&9N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y!8V-U;75L871E9"!D969I8VET/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M/B@Q.3(L,S4W+#4W-2D\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$9FX^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/E=O<FMI;F<@8V%P:71A;#PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,C`L,S0Q+#0V,3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1F;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^4VAA<F5H;VQD97)S)R!E<75I='D\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4W+#4Q,2PW.#0\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$9FX^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-A<V@@86YD(&-A<V@@97%U:79A;&5N
M=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,C4L.#(Y+#4S
M,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1F;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^07-T97)I87,@0FEO
M=&AE<F%P975T:6-S+"!);F,N/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M9FX^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^
M3F]N8V]N=')O;&QI;F<@26YT97)E<W0@6TQI;F4@271E;7-=/"]S=')O;F<^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$9FX^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/D)I;U1I;64@3W=N97)S:&EP("AI;B!H=6YD
M<F5D=&AS*3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-C<N-3`E
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&9N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y":6]4:6UE($%S:6$L
M($QI;6ET960@6TUE;6)E<ET\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1F
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY.
M;VYC;VYT<F]L;&EN9R!);G1E<F5S="!;3&EN92!)=&5M<UT\+W-T<F]N9SX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1F;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^0FEO5&EM92!/=VYE<G-H:7`@*&EN(&AU;F1R
M961T:',I/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XX,2XP,"4\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$9FX^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-E;&P@0W5R92!.975R
M;W-C:65N8V5S+"!,=&0N(%M-96UB97)=/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$9FX^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS
M=')O;F<^3F]N8V]N=')O;&QI;F<@26YT97)E<W0@6TQI;F4@271E;7-=/"]S
M=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$9FX^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D)I;U1I;64@3W=N97)S:&EP("AI
M;B!H=6YD<F5D=&AS*3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M-C(N-3`E/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&9N/CQS=7`^6S%=/"]S=7`^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/D53($-E;&P@26YT97)N871I;VYA;"!0=&4N+"!,=&0N(%M-96UB
M97)=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$9FX^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^3F]N8V]N=')O;&QI;F<@
M26YT97)E<W0@6TQI;F4@271E;7-=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$9FX^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/D)I;U1I;64@3W=N97)S:&EP("AI;B!H=6YD<F5D=&AS*3PO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3`P+C`P)3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1F;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^3&EF94UA<"!38VEE;F-E<RP@26YC+B!;365M
M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&9N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/DYO;F-O;G1R;VQL:6YG
M($EN=&5R97-T(%M,:6YE($ET96US73PO<W1R;VYG/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&9N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y":6]4:6UE($]W;F5R<VAI<"`H:6X@:'5N9')E9'1H<RD\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C<U+C@P)3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1F;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^3&EF94UA<"!38VEE;F-E<RP@3'1D+B!;365M
M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&9N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/DYO;F-O;G1R;VQL:6YG
M($EN=&5R97-T(%M,:6YE($ET96US73PO<W1R;VYG/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&9N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y":6]4:6UE($]W;F5R<VAI<"`H:6X@:'5N9')E9'1H<RD\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`N,#`E/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&9N/CQS=7`^6S)=/"]S=7`^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DQI9F5-87`@4V]L=71I
M;VYS+"!);F,N(%M-96UB97)=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M9FX^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^
M3F]N8V]N=')O;&QI;F<@26YT97)E<W0@6TQI;F4@271E;7-=/"]S=')O;F<^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$9FX^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/D)I;U1I;64@3W=N97)S:&EP("AI;B!H=6YD
M<F5D=&AS*3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,"XP,"4\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$9FX^/'-U
M<#Y;,ET\+W-U<#X\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M3VYC;T-Y=&4@0V]R<&]R871I;VX@6TUE;6)E<ET\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1F;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^/'-T<F]N9SY.;VYC;VYT<F]L;&EN9R!);G1E<F5S="!;3&EN92!)=&5M
M<UT\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1F;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0FEO5&EM92!/=VYE<G-H
M:7`@*&EN(&AU;F1R961T:',I/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XW-2XS,"4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$9FX^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D]R
M=&AO0WET92!#;W)P;W)A=&EO;B!;365M8F5R73PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&9N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#X\<W1R;VYG/DYO;F-O;G1R;VQL:6YG($EN=&5R97-T(%M,:6YE($ET96US
M73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&9N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y":6]4:6UE($]W;F5R<VAI
M<"`H:6X@:'5N9')E9'1H<RD\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C$P,"XP,"4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$9FX^/'-U<#Y;,UT\+W-U<#X\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^4F5#>71E(%1H97)A<&5U=&EC<RP@26YC+B!;365M8F5R
M73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&9N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/DYO;F-O;G1R;VQL:6YG($EN
M=&5R97-T(%M,:6YE($ET96US73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&9N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y":6]4:6UE($]W;F5R<VAI<"`H:6X@:'5N9')E9'1H<RD\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/CDT+C@P)3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1F;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<CX-"B`@("`@("`@/'1D(&-O;'-P86X],T0V/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$:6YN97)&;V]T;F]T93X-
M"B`@("`@("`@/'1D('9A;&EG;CTS1'1O<#Y;,5T\+W1D/@T*("`@("`@("`\
M=&0@8V]L<W!A;CTS1#4@=F%L:6=N/3-$=&]P/DEN8VQU9&5S('-H87)E<R!O
M=VYE9"!B>2!":6]4:6UE+"!!<W1E<FEA<RP@86YD($5322X\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1&EN;F5R1F]O=&YO=&4^#0H@
M("`@("`@(#QT9"!V86QI9VX],T1T;W`^6S)=/"]T9#X-"B`@("`@("`@/'1D
M(&-O;'-P86X],T0U('9A;&EG;CTS1'1O<#Y,:69E36%P(%-C:65N8V5S+"!,
M=&0N(&%N9"!,:69E36%P(%-O;'5T:6]N<RP@26YC+B!A<F4@=VAO;&QY+6]W
M;F5D('-U8G-I9&EA<FEE<R!O9B!,:69E36%P(%-C:65N8V5S+"!);F,N/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1I;FYE<D9O;W1N
M;W1E/@T*("`@("`@("`\=&0@=F%L:6=N/3-$=&]P/ELS73PO=&0^#0H@("`@
M("`@(#QT9"!C;VQS<&%N/3-$-2!V86QI9VX],T1T;W`^26YC;'5D97,@<VAA
M<F5S(&]W;F5D(&)Y($)I;U1I;64@86YD($%S=&5R:6%S+CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*
M+2TM+2TM/5].97AT4&%R=%\S.3AB8C$R8E]E.&-A7S1B-V%?.&9A,%\R-C,Y
M9&8U83@Y,3`-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO,SDX8F(Q
M,F)?93AC85\T8C=A7SAF83!?,C8S.61F-6$X.3$P+U=O<FMS:&5E=',O4VAE
M970R-BYH=&UL#0I#;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M
M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB
M=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P
M+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C
M:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@
M<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J
M+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S
M/3-$<F5P;W)T(&ED/3-$240P14-+04D^#0H@("`@("`\='(^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O
M;F<^4W5M;6%R>2!O9B!3:6=N:69I8V%N="!!8V-O=6YT:6YG(%!O;&EC:65S
M("A$971A:6QS*2`H55-$("0I/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C$@36]N=&AS($5N9&5D/"]T
M:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#(^,R!-;VYT
M:',@16YD960\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N
M/3-$,3X\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&@^2G5N+B`S,"P@,C`Q-#QB<CX\+W1H/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T:#Y-87(N(#,Q+"`R,#$U/&)R/CPO=&@^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1H/DUA<BX@,S$L(#(P,30\8G(^/"]T:#X-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q-#QB<CX\+W1H/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY3=6UM87)Y(&]F
M(%-I9VYI9FEC86YT($%C8V]U;G1I;F<@4&]L:6-I97,@6T%B<W1R86-T73PO
M<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y4<F%D
M92!R96-E:79A8FQE/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD
M(#8P-2PX,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XD(#4T.2PS,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/D=R86YT<R!R96-E:79A8FQE/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XR-C`L,S`P/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-#DR+#8P,#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^06QL;W=A
M;F-E(&9O<B!D;W5B=&9U;"!A8V-O=6YT<SPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,3`P+#4P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C$P,"PU,#`\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^4')O<&5R='DL
M(%!L86YT(&%N9"!%<75I<&UE;G0@6TQI;F4@271E;7-=/"]S=')O;F<^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D9O<F5I9VX@8W5R<F5N
M8WD@9V%I;B`H;&]S<RD@:6YC;'5D960@:6X@8V]M<')E:&5N<VEV92!L;W-S
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@U,RPQ-C<I/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,3`W+#(T
M,"D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/D9O<F5I9VX@8W5R<F5N8WD@=')A;G-A8W1I;VX@9V%I;B`H;&]S<RD\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#(P-2PQ-#DI/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,3`L,C$R
M*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^/'-T<F]N9SY);F-O;64@5&%X97,@6T%B<W1R86-T73PO<W1R;VYG/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!8V-R=65D(&EN=&5R
M97-T(&%N9"!P96YA;'1I97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y$969E<G)E9"!I;F-O;64@=&%X(&)E;F5F:70\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6T^*#$L,3<V+#@X,BD\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@Q+#,T.2PP,C8I/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y$
M969E<G)E9"!I;F-O;64@=&%X(&)E;F5F:70L(&9E9&5R86P\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C$L,C4Q+#`P,#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L,34Q+#`P,#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1&5F
M97)R960@:6YC;VUE('1A>"!B96YE9FET+"!S=&%T92!T87AE<SPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-S0L,#`P/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3DX+#`P,#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3G5M8F5R
M(&]F('-H87)E<R!S;VQD(&)Y('-U8G-I9&EA<GD@*&EN('-H87)E<RD\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4L,#`P+#`P,#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5&%X86)L
M92!G86EN(&]N('-A;&4@;V8@<W5B<VED:6%R>2!S:&%R97,\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C$P+#,P,"PP,#`\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E1A>"!P87EA8FQE
M(&]N('-A;&4@;V8@<W5B<VED:6%R>2!S:&%R97,\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/B0@,RPV,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D9I;FET92U,
M:79E9"!);G1A;F=I8FQE($%S<V5T<R!;3&EN92!)=&5M<UT\+W-T<F]N9SX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^26YT86YG:6)L92!A
M<W-E="P@=7-E9G5L(&QI9F4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/C$P('EE87)S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y4<F5A<W5R>2!3:&%R97,@6TUE;6)E<ET\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY!;G1I9&EL=71I
M=F4@4V5C=7)I=&EE<R!%>&-L=61E9"!F<F]M($-O;7!U=&%T:6]N(&]F($5A
M<FYI;F=S(%!E<B!3:&%R92!;3&EN92!)=&5M<UT\+W-T<F]N9SX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^06YT:2UD:6QU=&EV92!S:&%R
M97,@97AC;'5D960@9G)O;2!C;VUP=71A=&EO;B!O9B!D:6QU=&5D(&QO<W,@
M<&5R('-H87)E("AI;B!S:&%R97,I/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XT+#@Y,RPY-#(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XQ,"PU-#8L,3,W/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3=&]C:R!/<'1I;VYS(%M-
M96UB97)=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O
M;F<^06YT:61I;'5T:79E(%-E8W5R:71I97,@17AC;'5D960@9G)O;2!#;VUP
M=71A=&EO;B!O9B!%87)N:6YG<R!097(@4VAA<F4@6TQI;F4@271E;7-=/"]S
M=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%N=&DM
M9&EL=71I=F4@<VAA<F5S(&5X8VQU9&5D(&9R;VT@8V]M<'5T871I;VX@;V8@
M9&EL=71E9"!L;W-S('!E<B!S:&%R92`H:6X@<VAA<F5S*3PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^-"PR-C8L-C`U/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-2PT.3$L,S`Q/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y787)R
M86YT<R!;365M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#X\<W1R;VYG/D%N=&ED:6QU=&EV92!396-U<FET:65S($5X8VQU9&5D(&9R
M;VT@0V]M<'5T871I;VX@;V8@16%R;FEN9W,@4&5R(%-H87)E(%M,:6YE($ET
M96US73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y!;G1I+61I;'5T:79E('-H87)E<R!E>&-L=61E9"!F<F]M(&-O;7!U=&%T
M:6]N(&]F(&1I;'5T960@;&]S<R!P97(@<VAA<F4@*&EN('-H87)E<RD\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/CDL,3DT+#8W.3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/CDL-S4Q+#8Q
M-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^5&5C:&YO;&]G>2!;365M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#X\<W1R;VYG/D9I;FET92U,:79E9"!);G1A;F=I8FQE($%S
M<V5T<R!;3&EN92!)=&5M<UT\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^26YT86YG:6)L92!A<W-E="P@=7-E9G5L(&QI9F4\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/C$P('EE87)S/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%<75I
M<&UE;G0@6TUE;6)E<ET@?"!-:6YI;75M(%M-96UB97)=/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^4')O<&5R='DL(%!L86YT
M(&%N9"!%<75I<&UE;G0@6TQI;F4@271E;7-=/"]S=')O;F<^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5Q=6EP;65N="!U<V5F=6P@;&EF
M93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^,S8@;6]N=&AS/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%
M<75I<&UE;G0@6TUE;6)E<ET@?"!-87AI;75M(%M-96UB97)=/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^4')O<&5R='DL(%!L
M86YT(&%N9"!%<75I<&UE;G0@6TQI;F4@271E;7-=/"]S=')O;F<^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5Q=6EP;65N="!U<V5F=6P@
M;&EF93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^,3(P(&UO;G1H
M<SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE
M/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?,SDX
M8F(Q,F)?93AC85\T8C=A7SAF83!?,C8S.61F-6$X.3$P#0I#;VYT96YT+4QO
M8V%T:6]N.B!F:6QE.B\O+T,Z+S,Y.&)B,3)B7V4X8V%?-&(W85\X9F$P7S(V
M,SED9C5A.#DQ,"]7;W)K<VAE971S+U-H965T,C<N:'1M;`T*0V]N=&5N="U4
M<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4
M>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-
M"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP
M92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP
M="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@
M3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@
M(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$4V
M04%#/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS
M<&%N/3-$,2!R;W=S<&%N/3-$,3X\<W1R;VYG/DEN=F5N=&]R>2`H1&5T86EL
M<RD@*%531"`D*3QB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T:#Y-87(N(#,Q+"`R,#$U/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1H/D1E8RX@,S$L(#(P,30\8G(^/"]T:#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^26YV96YT;W)Y(%M!8G-T<F%C=%T\
M+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^26YV
M96YT;W)Y(&]F(&9I;FES:&5D('!R;V1U8W1S(&]N+7-I=&4\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,C@V+#4Q,SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,C4S+#(R-SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^26YV
M96YT;W)Y(&AE;&0@8GD@=&AI<F0@<&%R='D@;VX@8V]N<VEG;FUE;G0\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,3(L-SDU/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Q,BPW.34\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-
M"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7S,Y.&)B
M,3)B7V4X8V%?-&(W85\X9F$P7S(V,SED9C5A.#DQ,`T*0V]N=&5N="U,;V-A
M=&EO;CH@9FEL93HO+R]#.B\S.3AB8C$R8E]E.&-A7S1B-V%?.&9A,%\R-C,Y
M9&8U83@Y,3`O5V]R:W-H965T<R]3:&5E=#(X+FAT;6P-"D-O;G1E;G0M5')A
M;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP
M93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@
M(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@
M8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@
M='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO
M="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\
M8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%5E-!
M13X-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A
M;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY%<75I<&UE;G0L(&YE="!A;F0@
M8V]N<W1R=6-T:6]N(&EN('!R;V=R97-S("A$971A:6QS*2`H55-$("0I/&)R
M/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P
M86X],T0R/C,@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&@@8V]L<W!A;CTS1#$^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&@@8V]L<W!A;CTS1#$^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DUA<BX@,S$L(#(P,34\8G(^/"]T
M:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^36%R+B`S,2P@,C`Q-#QB<CX\
M+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$T/&)R
M/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DIU;BX@,S`L(#(P,30\
M8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^
M17%U:7!M96YT+"!F=7)N:71U<F4@86YD(&9I>'1U<F5S(%M!8G-T<F%C=%T\
M+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^17%U
M:7!M96YT+"!F=7)N:71U<F4@86YD(&9I>'1U<F5S/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XD(#0L.3(X+#@U-SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@-"PX-S`L-3$V/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#;VYS
M=')U8W1I;VX@:6X@<')O9W)E<W,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C8P-BPV-#$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XT,#4L-S,P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!8V-U;75L871E9"!D97!R96-I871I
M;VX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#(L-C<P+#@R.2D\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@R
M+#0Q."PT,#`I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F5U/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^17%U:7!M96YT(&YE="P@86YD(&-O;G-T<G5C=&EO;B!I
M;B!P<F]G<F5S<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,BPX
M-C0L-C8Y/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,BPX-3<L.#0V/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y%<75I<&UE;G0L(&9U<FYI='5R92`L(&%N9"!F
M:7AT=7)E<R!I;F-L=61E9"!I;B!C87!I=&%L(&QE87-E(&)O<G)O=VEN9W,\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$Q-2PP,#`\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DQE87-E
M:&]L9"!I;7!R;W9E;65N=',@9F]R($%S=&5R:6%S)R!F86-I;&ET>3PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-C`V+#8T,3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1&5P<F5C:6%T
M:6]N(&5X<&5N<V4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(V
M,BPV,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XR-38L.30U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y);F-R96%S92!I;B!A8V-U;75L871E9"!D97!R96-I
M871I;VX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(U,BPT,CD\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/E1E;F%N="!I;7!R;W9E;65N="!A;&QO=V%N8V4@=6YD97(@;&5A<V4@86=R
M965M96YT/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT+#0P,"PP
M,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/D%M;W5N="!Q=6%L:69Y:6YG(&9O<B!R96EM8G5R<V5M96YT('5N9&5R
M('1H92!T96YA;G0@:6UP<F]V96UE;G0@86QL;W=A;F-E/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XU-C`L.3<P/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y296EM8G5R<V5M96YT(&9R
M;VT@;&%N9&QO<F0@;VX@8V]N<W1R=6-T:6]N(&EN('!R;V=R97-S/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#(X,RPW-C0\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#`\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B
M;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7S,Y.&)B,3)B7V4X
M8V%?-&(W85\X9F$P7S(V,SED9C5A.#DQ,`T*0V]N=&5N="U,;V-A=&EO;CH@
M9FEL93HO+R]#.B\S.3AB8C$R8E]E.&-A7S1B-V%?.&9A,%\R-C,Y9&8U83@Y
M,3`O5V]R:W-H965T<R]3:&5E=#(Y+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M
M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X
M="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D
M/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N
M=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS
M1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO
M=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-
M"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%64Q!0SX-"B`@
M("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@
M<F]W<W!A;CTS1#(^/'-T<F]N9SY);G1A;F=I8FQE(&%S<V5T<RP@;F5T("A$
M971A:6QS*2`H55-$("0I/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1H(&-O;'-P86X],T0R/C,@36]N=&AS($5N9&5D/"]T:#X-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^/"]T:#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H
M/DUA<BX@,S$L(#(P,34\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&@^36%R+B`S,2P@,C`Q-#QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T:#Y$96,N(#,Q+"`R,#$T/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#X\<W1R;VYG/DEN=&%N9VEB;&4@87-S971S+"!N970@6T%B
M<W1R86-T73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y);G1A;F=I8FQE(&%S<V5T<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^)"`U,BPU-C(L-30Y/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^)"`U,BPU-C(L-30Y/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!8V-U;75L871E
M9"!A;6]R=&EZ871I;VX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^
M*#$U+#`R."PR-#<I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;3XH,3,L-S$T+#$U,RD\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;W4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y);G1A;F=I8FQE(&%S<V5T<RP@
M;F5T/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS-RPU,S0L,S`R
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,S@L.#0X+#,Y-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^26YT86YG:6)L92!A<W-E=',L('5S969U;"!L:69E/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XQ,"!Y96%R<SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^06UO<G1I
M>F%T:6]N(&]F(&EN=&%N9VEB;&4@87-S971S/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XD(#$L,S$T+#`Y-#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,2PS-C<L.3DX/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D
M>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\S.3AB8C$R8E]E.&-A
M7S1B-V%?.&9A,%\R-C,Y9&8U83@Y,3`-"D-O;G1E;G0M3&]C871I;VXZ(&9I
M;&4Z+R\O0SHO,SDX8F(Q,F)?93AC85\T8C=A7SAF83!?,C8S.61F-6$X.3$P
M+U=O<FMS:&5E=',O4VAE970S,"YH=&UL#0I#;VYT96YT+51R86YS9F5R+45N
M8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O
M:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-
M"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0]
M,T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T
M97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E
M(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@
M("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P14Q,04,^#0H@("`@
M("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O
M=W-P86X],T0R/CQS=')O;F<^4F]Y86QT>2!/8FQI9V%T:6]N(&%N9"!$969E
M<G)E9"!,:6-E;G-E($9E97,@*$1E=&%I;',I("A54T0@)"D\8G(^/"]S=')O
M;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^
M,R!-;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&@^36%R+B`S,2P@,C`Q-3QB<CX\+W1H
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY2;WEA;'1Y
M($]B;&EG871I;VX@86YD($1E9F5R<F5D($QI8V5N<V4@1F5E<R!;06)S=')A
M8W1=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/DEN=&%N9VEB;&4@87-S971S+"!U<V5F=6P@;&EF93PO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^,3`@>65A<G,\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^06UO<G1I>F%T
M:6]N(&]F(&1E9F5R<F5D(&QI8V5N<V4@9F5E<R!;06)S=')A8W1=/"]S=')O
M;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/C(P,34\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@.#(L,3(U/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#XR,#$V/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,#DL-3`P/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#XR,#$W/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,#DL-3`P/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#XR,#$X/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XW,RPV-C<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/C(P,3D\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(T+#`X,SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5&AE<F5A9G1E
M<CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C`L,#@S/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F]U/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5&]T
M86P\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0Q."PY-3@\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!R
M97!A:60@97AP96YS97,@:6X@;W1H97(@8W5R<F5N="!A<W-E=',\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$P.2PU,#`\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D1E9F5R<F5D(&QI
M8V5N<V4@86YD(&-O;G-U;'1I;F<@9F5E<R!I;B!N;VYC=7)R96YT(&%S<V5T
M<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`S,#DL-#4X/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@
M(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\S.3AB8C$R
M8E]E.&-A7S1B-V%?.&9A,%\R-C,Y9&8U83@Y,3`-"D-O;G1E;G0M3&]C871I
M;VXZ(&9I;&4Z+R\O0SHO,SDX8F(Q,F)?93AC85\T8C=A7SAF83!?,C8S.61F
M-6$X.3$P+U=O<FMS:&5E=',O4VAE970S,2YH=&UL#0I#;VYT96YT+51R86YS
M9F5R+45N8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z
M('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\
M:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O
M;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y
M<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@
M4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O
M9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P139'04,^
M#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X]
M,T0Q(')O=W-P86X],T0Q/CQS=')O;F<^06-C;W5N=',@4&%Y86)L92!A;F0@
M06-C<G5E9"!,:6%B:6QI=&EE<R`H1&5T86EL<RD@*%531"`D*3QB<CX\+W-T
M<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y-87(N(#,Q+"`R
M,#$U/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L
M(#(P,30\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS
M=')O;F<^06-C;W5N=',@4&%Y86)L92!A;F0@06-C<G5E9"!,:6%B:6QI=&EE
M<R!;06)S=')A8W1=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/D%C8V]U;G1S('!A>6%B;&4\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/B0@,BPW,#<L-#,W/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`R+#(Y-BPV-#4\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%C8W)U960@
M97AP96YS97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,L,#DR
M+#`S,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C,L,3(U+#`R,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^06-C<G5E9"!B;VYU<V5S/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XR-#`L-C@Y/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^.38T+#$X.3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3W1H97(@86-C<G5E
M9"!L:6%B:6QI=&EE<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,C@R+#(U,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C0Q-RPS,38\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R;W4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y!8V-O=6YT<R!P87EA8FQE(&%N9"!A8V-R=65D
M(&QI86)I;&ET:65S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD
M(#8L,S(R+#0P-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/B0@-BPX,#,L,3<S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*
M+2TM+2TM/5].97AT4&%R=%\S.3AB8C$R8E]E.&-A7S1B-V%?.&9A,%\R-C,Y
M9&8U83@Y,3`-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO,SDX8F(Q
M,F)?93AC85\T8C=A7SAF83!?,C8S.61F-6$X.3$P+U=O<FMS:&5E=',O4VAE
M970S,BYH=&UL#0I#;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M
M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB
M=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P
M+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C
M:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@
M<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J
M+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S
M/3-$<F5P;W)T(&ED/3-$240P14M604<^#0H@("`@("`\='(^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O
M;F<^4F5L871E9"!087)T>2!4<F%N<V%C=&EO;G,@86YD(%)E;&%T960@4&%R
M='D@0V]N=F5R=&EB;&4@1&5B="`H1&5T86EL<RD@*%531"`D*3QB<CX\+W-T
M<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$
M,CXS($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H
M(&-O;'-P86X],T0Q/C$@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DUA<BX@,S$L
M(#(P,34\8G(^<W%F=#QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M:#Y-87(N(#,Q+"`R,#$T/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1H/D9E8BX@,C@L(#(P,34\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/CQS=')O;F<^4F5L871E9"!087)T>2!4<F%N<V%C=&EO;B!;
M3&EN92!)=&5M<UT\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^4F5N="!P97(@;6]N=&@\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/B0@-2PP-3`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/D%R96$@;V8@;V9F:6-E('-P86-E("AI;B!S
M<75A<F4@9F5E="D\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/CDP
M,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^4')O8V5E9',@9G)O;2!I<W-U86YC92!O9B!C;VUM;VX@<VAA<F5S/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^."PQ.#(L-34Y/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!<W1E
M<FEA<R!":6]T:&5R87!E=71I8W,L($EN8RX@?"!397)I97,@02!#;VUM;VX@
M4W1O8VL@6TUE;6)E<ET\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^/'-T<F]N9SY296QA=&5D(%!A<G1Y(%1R86YS86-T:6]N(%M,:6YE($ET
M96US73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y0<F]C965D<R!F<F]M(&ES<W5A;F-E(&]F(&-O;6UO;B!S:&%R97,\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4L-3`P+#`P,#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4VAA<F5S
M('-O;&0@*&EN('-H87)E<RD\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C$L-#$P+#(U-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^4W1O8VL@<')I8V4@*&EN(&1O;&QA<G,@<&5R('-H
M87)E*3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`S+CD\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYU
M;6)E<B!O9B!S:&%R97,@<'5R8VAA<V5D("AI;B!S:&%R97,I/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#`R-2PV-#`\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-E;&P@0W5R92!.
M975R;W-C:65N8V5S+"!,=&0N(%M-96UB97)=/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^4F5L871E9"!087)T>2!4<F%N<V%C
M=&EO;B!;3&EN92!)=&5M<UT\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^3G5M8F5R(&]F($-E;&P@0W5R92!.975R;W-C:65N
M8V5S(&EN=F5S=&]R<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^4W1A=&5D(&EN=&5R97-T(')A=&4@*&EN(&AU;F1R961T:',I/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS+C`P)3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V]N=F5R<VEO;B!P
M<FEC92`H:6X@9&]L;&%R<R!P97(@<VAA<F4I/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XD(#(P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y%<W1I;6%T960@9F%I<B!M87)K970@=F%L
M=64@*&EN(&1O;&QA<G,@<&5R('-H87)E*3PO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^)"`T,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^4')I;F-I<&%L(&%N9"!A8V-U;75L871E9"!I
M;G1E<F5S=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-#<P+#@W
M-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^06-C<G5E9"!I;G1E<F5S="!I<R!P87EA8FQE('!E<FEO9#PO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^,R!Y96%R<SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^169F96-T:79E(&%N
M;G5A;"!I;G1E<F5S="!R871E("AI;B!H=6YD<F5D=&AS*3PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,C,N,#`E/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#87)R>6EN9R!V86QU92!O
M9B!C;VYV97)T:6)L92!N;W1E<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,38Y+#DP.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^06UO=6YT(&]F(&-O;G9E<G1I8FQE(&YO=&4\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4S-"PX,38\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E5N86UO<G1I
M>F5D(&1E8G0@9&ES8V]U;G0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/B0@,S8T+#DP.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?
M3F5X=%!A<G1?,SDX8F(Q,F)?93AC85\T8C=A7SAF83!?,C8S.61F-6$X.3$P
M#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+S,Y.&)B,3)B7V4X8V%?
M-&(W85\X9F$P7S(V,SED9C5A.#DQ,"]7;W)K<VAE971S+U-H965T,S,N:'1M
M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L
M90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI
M(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS
M1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU
M=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H
M;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP
M=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R
M="!I9#TS1$E$,$4S1D%'/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/E-H87)E
M:&]L9&5R<R<@17%U:71Y("A$971A:6QS*2`H55-$("0I/&)R/CPO<W1R;VYG
M/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0R/C,@
M36]N=&AS($5N9&5D/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L
M<W!A;CTS1#$^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1H/DUA<BX@,S$L(#(P,34\8G(^/"]T:#X-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&@^36%R+B`S,2P@,C`Q-#QB<CX\+W1H/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$T/&)R/CPO=&@^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/E!R969E<G)E
M9"!3:&%R97,@6T%B<W1R86-T73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y0<F5F97)R960@<VAA<F5S+"!S:&%R97,@875T
M:&]R:7IE9"`H:6X@<VAA<F5S*3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,BPP,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,BPP,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y397)I97,@02!#;VYV97)T:6)L
M92!0<F5F97)R960@<VAA<F5S(&]U='-T86YD:6YG("AI;B!S:&%R97,I/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XW,"PP,#`\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XW,"PP,#`\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS
M=')O;F<^0V]M;6]N(%-H87)E<R!;06)S=')A8W1=/"]S=')O;F<^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-O;6UO;B!S:&%R97,L(&%U
M=&AO<FEZ960@*&EN('-H87)E<RD\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C$R-2PP,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,3(U+#`P,"PP,#`\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-O;6UO;B!S:&%R97,L
M('!A<B!V86QU92`H:6X@9&]L;&%R<R!P97(@<VAA<F4I/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XD(#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#`\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-O;6UO;B!S:&%R97,L('-H
M87)E<R!I<W-U960@*&EN('-H87)E<RD\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C@S+#(Q,"PW-S4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XX,RPQ,C$L-CDX/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#;VUM;VX@<VAA<F5S
M+"!S:&%R97,@;W5T<W1A;F1I;F<@*&EN('-H87)E<RD\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C<X+#,Q-BPX,S,\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XW."PR,C<L-S4V/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y4<F5A
M<W5R>2!S=&]C:R`H:6X@<VAA<F5S*3PO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^-"PX.3,L.30R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^-"PX.3,L.30R/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3=&]C:R!O<'1I;VYS(&=R
M86YT960@*&EN('-H87)E<RD\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C0T,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XQ+#(P-2PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/D]P=&EO;G,@97AE<F-I<V5D("AI;B!S
M:&%R97,I/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XX.2PP-S<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/E=A<G)A;G1S(&5X97)C:7-E9"`H:6X@<VAA<F5S*3PO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^4V5R:65S($$@4')E9F5R<F5D(%-T;V-K
M(%M-96UB97)=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS
M=')O;F<^4')E9F5R<F5D(%-H87)E<R!;06)S=')A8W1=/"]S=')O;F<^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-E<FEE<R!!($-O;G9E
M<G1I8FQE(%!R969E<G)E9"!S:&%R97,@;W5T<W1A;F1I;F<@*&EN('-H87)E
M<RD\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C<P+#`P,#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4')E
M9F5R<F5D('-T;V-K(&1I=FED96YD(')A=&4@*&EN(&AU;F1R961T:',I/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS+C`P)3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4')E9F5R<F5D
M('-H87)E(&1I=FED96YD("AI;B!D;VQL87)S('!E<B!S:&%R97,I/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#$N-3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4VAA<F4@8V]N=F5R
M<VEO;B!P<FEC92`H:6X@9&]L;&%R<R!P97(@<VAA<F4I/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XD(#0\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-O;6UO;B!S=&]C:R!C;VYV97)S
M:6]N(')A=&EO/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,BXU
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^
M#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\S.3AB
M8C$R8E]E.&-A7S1B-V%?.&9A,%\R-C,Y9&8U83@Y,3`-"D-O;G1E;G0M3&]C
M871I;VXZ(&9I;&4Z+R\O0SHO,SDX8F(Q,F)?93AC85\T8C=A7SAF83!?,C8S
M.61F-6$X.3$P+U=O<FMS:&5E=',O4VAE970S-"YH=&UL#0I#;VYT96YT+51R
M86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT96YT+51Y
M<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*
M("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E
M(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T
M('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.
M;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@
M/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P15=0
M04<^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P
M86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^4V%L97,@;V8@0FEO5&EM92!#
M;VUM;VX@4VAA<F5S(&)Y(%-U8G-I9&EA<FEE<R`H1&5T86EL<RD@*%531"`D
M*3QB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C
M;VQS<&%N/3-$,3XQ($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1H(&-O;'-P86X],T0Q/C,@36]N=&AS($5N9&5D/"]T:#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H
M/DIU;BX@,S`L(#(P,30\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&@^36%R+B`S,2P@,C`Q-3QB<CY);G9E<W1O<CQB<CX\+W1H/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY296QA=&5D(%!A<G1Y(%1R
M86YS86-T:6]N(%M,:6YE($ET96US73PO<W1R;VYG/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y.=6UB97(@;V8@<VAA<F5S('-O;&0@*&EN
M('-H87)E<RD\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4L,#`P
M+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^07-T97)I87,@0FEO=&AE<F%P975T:6-S(%M-96UB97)=('P@0FEO
M5&EM92!#;VUM;VX@4W1O8VL@6TUE;6)E<ET\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^/'-T<F]N9SY296QA=&5D(%!A<G1Y(%1R86YS86-T
M:6]N(%M,:6YE($ET96US73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y.=6UB97(@;V8@<VAA<F5S('-O;&0@*&EN('-H87)E
M<RD\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4L,#`P+#`P,#QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M3G5M8F5R(&]F(&EN=F5S=&]R<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^4')O8V5E9',@9G)O;2!S86QE(&]F($)I;U1I;64@<W1O8VL\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,3(L-3`P+#`P,#QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M07-T97)I87,@0FEO=&AE<F%P975T:6-S(%M-96UB97)=('P@07-T97)I87,@
M4V5R:65S($(@0V]M;6]N(%-T;V-K(%M-96UB97)=/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^4F5L871E9"!087)T>2!4<F%N
M<V%C=&EO;B!;3&EN92!)=&5M<UT\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^3G5M8F5R(&]F('-H87)E<R!P=7)C:&%S960@
M*&EN('-H87)E<RD\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4L
M,#`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^0G)O861W;V]D(%!A<G1N97)S+"!,4"!;365M8F5R72!\($)I
M;U1I;64@0V]M;6]N(%-T;V-K(%M-96UB97)=/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^4F5L871E9"!087)T>2!4<F%N<V%C
M=&EO;B!;3&EN92!)=&5M<UT\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^3G5M8F5R(&]F('-H87)E<R!P=7)C:&%S960@*&EN
M('-H87)E<RD\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L,#`P
M+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^0G)O861W;V]D(%!A<G1N97)S+"!,4"!;365M8F5R72!\($%S=&5R
M:6%S(%=A<G)A;G1S(%M-96UB97)=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/CQS=')O;F<^4F5L871E9"!087)T>2!4<F%N<V%C=&EO;B!;
M3&EN92!)=&5M<UT\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^3G5M8F5R(&]F('=A<G)A;G1S(&ES<W5E9"`H:6X@<VAA<F5S
M*3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PP,#`L,#`P/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y'
M96]R9V4@2V%R9G5N:V5L(%M-96UB97)=('P@0FEO5&EM92!#;VUM;VX@4W1O
M8VL@6TUE;6)E<ET\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M/'-T<F]N9SY296QA=&5D(%!A<G1Y(%1R86YS86-T:6]N(%M,:6YE($ET96US
M73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.
M=6UB97(@;V8@<VAA<F5S('!U<F-H87-E9"`H:6X@<VAA<F5S*3PO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-"PP,#`L,#`P/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y'96]R9V4@2V%R
M9G5N:V5L(%M-96UB97)=('P@07-T97)I87,@5V%R<F%N=',@6TUE;6)E<ET\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY296QA
M=&5D(%!A<G1Y(%1R86YS86-T:6]N(%M,:6YE($ET96US73PO<W1R;VYG/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.=6UB97(@;V8@=V%R
M<F%N=',@:7-S=65D("AI;B!S:&%R97,I/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XT+#`P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM
M+2TM+2T]7TYE>'1087)T7S,Y.&)B,3)B7V4X8V%?-&(W85\X9F$P7S(V,SED
M9C5A.#DQ,`T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B\S.3AB8C$R
M8E]E.&-A7S1B-V%?.&9A,%\R-C,Y9&8U83@Y,3`O5V]R:W-H965T<R]3:&5E
M=#,U+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP
M<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U
M<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M
M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H
M87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S
M<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO
M/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,]
M,T1R97!O<G0@:60],T1)1#!%,44^#0H@("`@("`\='(^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^
M4V5G;65N="!);F9O<FUA=&EO;B`H1&5T86EL<RD\8G(^/"]S=')O;F<^/"]T
M:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^,R!-;VYT
M:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&@^36%R+B`S,2P@,C`Q-3QB<CY396=M96YT/&)R
M/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/E-E
M9VUE;G0@26YF;W)M871I;VX@6T%B<W1R86-T73PO<W1R;VYG/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.=6UB97(@;V8@;W!E<F%T:6YG
M('-E9VUE;G1S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@
M(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\S.3AB8C$R
M8E]E.&-A7S1B-V%?.&9A,%\R-C,Y9&8U83@Y,3`-"D-O;G1E;G0M3&]C871I
M;VXZ(&9I;&4Z+R\O0SHO,SDX8F(Q,F)?93AC85\T8C=A7SAF83!?,C8S.61F
M-6$X.3$P+U=O<FMS:&5E=',O4VAE970S-BYH=&UL#0I#;VYT96YT+51R86YS
M9F5R+45N8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z
M('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\
M:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O
M;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y
M<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@
M4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O
M9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P14U.0D<^
M#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X]
M,T0Q(')O=W-P86X],T0R/CQS=')O;F<^4W5B<V5Q=65N="!%=F5N=',@*$1E
M=&%I;',I("A54T0@)"D\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&@@8V]L<W!A;CTS1#(^,R!-;VYT:',@16YD960\+W1H/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,CXP($UO;G1H<R!%
M;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T:#Y-87(N(#,Q+"`R,#$U/&)R/CPO=&@^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1H/DUA<BX@,S$L(#(P,30\8G(^/"]T:#X-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&@^07!R+B`S,"P@,C`Q-3QB<CX\+W1H/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T:#Y-87D@,#@L(#(P,34\8G(^26YV97-T;W(\
M8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^
M4W5B<V5Q=65N="!%=F5N="!;3&EN92!)=&5M<UT\+W-T<F]N9SX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4F5V96YU92!F<F]M(&=R86YT
M<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`V.3@L.#,Y/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`U
M-S4L-C4Y/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y3=6)S97%U96YT($5V96YT(%M-96UB97)=('P@07-T97)I87,@
M0FEO=&AE<F%P975T:6-S(%M-96UB97)=('P@0TE232!;365M8F5R73PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/E-U8G-E<75E
M;G0@179E;G0@6TQI;F4@271E;7-=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/E)E=F5N=64@9G)O;2!G<F%N=',\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L,#8R+#`R,SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1W)A;G1S(')E
M8V5I=F%B;&4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$T+#,P
M,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/E-U8G-E<75E;G0@179E;G0@6TUE;6)E<ET@?"!/;F-O0WET92!#
M;W)P;W)A=&EO;B!;365M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#X\<W1R;VYG/E-U8G-E<75E;G0@179E;G0@6TQI;F4@271E;7-=
M/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-A
M;&4@;V8@<W1O8VLL(&YU;6)E<B!O9B!S:&%R97,@:7-S=65D(&EN('1R86YS
M86-T:6]N("AI;B!S:&%R97,I/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XS+#`P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/E-A;&4@;V8@<W1O8VLL(&YU;6)E<B!O9B!S:&%R
M96AO;&1E<G,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-A
M;&4@;V8@<W1O8VL@8V]N<VED97)A=&EO;B!R96-E:79E9#PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,RPS,#`L,#`P/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#;VUM;VX@<W1O8VL@
M<'5R8VAA<V5D(&EN(&5X8VAA;F=E(&9O<B!C86YC96QA=&EO;B!O9B!I;F1E
M8G1E9&YE<W,@*&EN('-H87)E<RD\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C,L,#`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^0V]M;6]N('-T;V-K('!U<F-H87-E9"!I;B!E
M>&-H86YG92!F;W(@8V%N8V5L871I;VX@;V8@:6YD96)T961N97-S+"!V86QU
M93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,RPS,#`L,#`P/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3
M=6)S97%U96YT($5V96YT(%M-96UB97)=('P@3VYC;T-Y=&4@0V]R<&]R871I
M;VX@6TUE;6)E<ET@?"!'96]R9V4@2V%R9G5N:V5L(%M-96UB97)=/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^4W5B<V5Q=65N
M="!%=F5N="!;3&EN92!)=&5M<UT\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^4V%L92!O9B!S=&]C:RP@;G5M8F5R(&]F('-H
M87)E<R!I<W-U960@:6X@=')A;G-A8W1I;VX@*&EN('-H87)E<RD\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L,#`P+#`P,#QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3W=N97)S:&EP
M('!E<F-E;G1A9V4@;VX@;W5T<W1A;F1I;F<@8V]M;6]N('-H87)E<R`H:6X@
M:'5N9')E9'1H<RD\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4N
M,#`E/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y3=6)S97%U96YT($5V96YT(%M-96UB97)=('P@3VYC;T-Y=&4@0V]R
M<&]R871I;VX@6TUE;6)E<ET@?"!#;VYV97)T:6)L92!0<F]M:7-S;W)Y($YO
M=&4@6TUE;6)E<ET\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M/'-T<F]N9SY3=6)S97%U96YT($5V96YT(%M,:6YE($ET96US73PO<W1R;VYG
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#;VUM;VX@<W1O
M8VL@<'5R8VAA<V5D(&EN(&5X8VAA;F=E(&9O<B!C86YC96QA=&EO;B!O9B!I
M;F1E8G1E9&YE<W,L('9A;'5E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XD(#,L,S`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^1&5B="!I;G-T<G5M96YT(&EN=&5R97-T(')A
M=&4@*&EN(&AU;F1R961T:',I/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XQ+C`P)3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^1&5B="!I;G-T<G5M96YT(&UA='5R:71Y(&1A=&4\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/DYO=B`S,"P-"@D),C`Q-CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M1&5B="!I;G-T<G5M96YT(&-O;G9E<G-I;VX@<')I8V4@*&EN(&AU;F1R961T
M:',I/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#$N,3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\
M+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?,SDX8F(Q,F)?
M93AC85\T8C=A7SAF83!?,C8S.61F-6$X.3$P#0I#;VYT96YT+4QO8V%T:6]N
M.B!F:6QE.B\O+T,Z+S,Y.&)B,3)B7V4X8V%?-&(W85\X9F$P7S(V,SED9C5A
M.#DQ,"]7;W)K<VAE971S+V9I;&5L:7-T+GAM;`T*0V]N=&5N="U4<F%N<V9E
M<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T
M97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\>&UL('AM;&YS.F\]
M,T0B=7)N.G-C:&5M87,M;6EC<F]S;V9T+6-O;3IO9F9I8V4Z;V9F:6-E(CX-
M"B`\;SI-86EN1FEL92!(4F5F/3-$(BXN+U=O<FMB;V]K+FAT;6PB+SX-"B`\
M;SI&:6QE($A2968],T0B4VAE970P,2YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F
M/3-$(E-H965T,#(N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#`S
M+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970P-"YH=&UL(B\^#0H@
M/&\Z1FEL92!(4F5F/3-$(E-H965T,#4N:'1M;"(O/@T*(#QO.D9I;&4@2%)E
M9CTS1")3:&5E=#`V+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970P
M-RYH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,#@N:'1M;"(O/@T*
M(#QO.D9I;&4@2%)E9CTS1")3:&5E=#`Y+FAT;6PB+SX-"B`\;SI&:6QE($A2
M968],T0B4VAE970Q,"YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T
M,3$N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#$R+FAT;6PB+SX-
M"B`\;SI&:6QE($A2968],T0B4VAE970Q,RYH=&UL(B\^#0H@/&\Z1FEL92!(
M4F5F/3-$(E-H965T,30N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E
M=#$U+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970Q-BYH=&UL(B\^
M#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,3<N:'1M;"(O/@T*(#QO.D9I;&4@
M2%)E9CTS1")3:&5E=#$X+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE
M970Q.2YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,C`N:'1M;"(O
M/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#(Q+FAT;6PB+SX-"B`\;SI&:6QE
M($A2968],T0B4VAE970R,BYH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H
M965T,C,N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#(T+FAT;6PB
M+SX-"B`\;SI&:6QE($A2968],T0B4VAE970R-2YH=&UL(B\^#0H@/&\Z1FEL
M92!(4F5F/3-$(E-H965T,C8N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3
M:&5E=#(W+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970R."YH=&UL
M(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,CDN:'1M;"(O/@T*(#QO.D9I
M;&4@2%)E9CTS1")3:&5E=#,P+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B
M4VAE970S,2YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,S(N:'1M
M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#,S+FAT;6PB+SX-"B`\;SI&
M:6QE($A2968],T0B4VAE970S-"YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$
M(E-H965T,S4N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#,V+FAT
M;6PB+SX-"CPO>&UL/@T*+2TM+2TM/5].97AT4&%R=%\S.3AB8C$R8E]E.&-A
;7S1B-V%?.&9A,%\R-C,Y9&8U83@Y,3`M+0T*
`
end

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EYLAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Intangible assets, net (Details) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="2">3 Months Ended</th>
        <th class="th" colspan="1"></th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2015</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Intangible assets, net [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Intangible assets</a></td>
        <td class="nump"><a title="us-gaap_FiniteLivedIntangibleAssetsGross" onclick="toggleNextSibling(this);">$ 52,562,549</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_FiniteLivedIntangibleAssetsGross</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_FiniteLivedIntangibleAssetsGross" onclick="toggleNextSibling(this);">$ 52,562,549</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_FiniteLivedIntangibleAssetsGross</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated amortization</a></td>
        <td class="num"><a title="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" onclick="toggleNextSibling(this);">(15,028,247)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num"><a title="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" onclick="toggleNextSibling(this);">(13,714,153)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</span><span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible assets, net</a></td>
        <td class="nump"><a title="us-gaap_FiniteLivedIntangibleAssetsNet" onclick="toggleNextSibling(this);">37,534,302</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_FiniteLivedIntangibleAssetsNet</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_FiniteLivedIntangibleAssetsNet" onclick="toggleNextSibling(this);">38,848,396</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_FiniteLivedIntangibleAssetsNet</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Intangible assets, useful life</a></td>
        <td class="text">10 years<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangible assets</a></td>
        <td class="nump"><a title="us-gaap_AmortizationOfIntangibleAssets" onclick="toggleNextSibling(this);">$ 1,314,094</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AmortizationOfIntangibleAssets</span><span></span></td>
        <td class="nump"><a title="us-gaap_AmortizationOfIntangibleAssets" onclick="toggleNextSibling(this);">$ 1,367,998</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AmortizationOfIntangibleAssets</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 350<br><br> -SubTopic 30<br><br> -Section 45<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 350<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)(2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16323-109275<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 350<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16323-109275<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 350<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16323-109275<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 350<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16323-109275<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNetAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EVSAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Equipment, net and construction in progress (Details) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="2">3 Months Ended</th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="1"></th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2015</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetAbstract', window );"><strong>Equipment, furniture and fixtures [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Equipment, furniture and fixtures</a></td>
        <td class="nump"><a title="us-gaap_PropertyPlantAndEquipmentGross" onclick="toggleNextSibling(this);">$ 4,928,857</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PropertyPlantAndEquipmentGross</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_PropertyPlantAndEquipmentGross" onclick="toggleNextSibling(this);">$ 4,870,516</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PropertyPlantAndEquipmentGross</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConstructionInProgressGross', window );">Construction in progress</a></td>
        <td class="nump"><a title="us-gaap_ConstructionInProgressGross" onclick="toggleNextSibling(this);">606,641</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ConstructionInProgressGross</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_ConstructionInProgressGross" onclick="toggleNextSibling(this);">405,730</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ConstructionInProgressGross</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation</a></td>
        <td class="num"><a title="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" onclick="toggleNextSibling(this);">(2,670,829)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num"><a title="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" onclick="toggleNextSibling(this);">(2,418,400)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Equipment net, and construction in progress</a></td>
        <td class="nump"><a title="us-gaap_PropertyPlantAndEquipmentNet" onclick="toggleNextSibling(this);">2,864,669</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PropertyPlantAndEquipmentNet</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_PropertyPlantAndEquipmentNet" onclick="toggleNextSibling(this);">2,857,846</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PropertyPlantAndEquipmentNet</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeaseObligations', window );">Equipment, furniture , and fixtures included in capital lease borrowings</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_CapitalLeaseObligations" onclick="toggleNextSibling(this);">115,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CapitalLeaseObligations</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseholdImprovementsGross', window );">Leasehold improvements for Asterias' facility</a></td>
        <td class="nump"><a title="us-gaap_LeaseholdImprovementsGross" onclick="toggleNextSibling(this);">606,641</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_LeaseholdImprovementsGross</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
        <td class="nump"><a title="us-gaap_Depreciation" onclick="toggleNextSibling(this);">262,600</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_Depreciation</span><span></span></td>
        <td class="nump"><a title="us-gaap_Depreciation" onclick="toggleNextSibling(this);">256,945</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_Depreciation</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipmentPeriodIncreaseDecrease', window );">Increase in accumulated depreciation</a></td>
        <td class="nump"><a title="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipmentPeriodIncreaseDecrease" onclick="toggleNextSibling(this);">252,429</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipmentPeriodIncreaseDecrease</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_TenantImprovementAllowanceUnderLeaseAgreement', window );">Tenant improvement allowance under lease agreement</a></td>
        <td class="nump"><a title="btx_TenantImprovementAllowanceUnderLeaseAgreement" onclick="toggleNextSibling(this);">4,400,000</a><span style="display:none;white-space:normal;text-align:left;">btx_TenantImprovementAllowanceUnderLeaseAgreement</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_TenantImprovementAllowanceReimbursementUnderLeaseAgreement', window );">Amount qualifying for reimbursement under the tenant improvement allowance</a></td>
        <td class="nump"><a title="btx_TenantImprovementAllowanceReimbursementUnderLeaseAgreement" onclick="toggleNextSibling(this);">560,970</a><span style="display:none;white-space:normal;text-align:left;">btx_TenantImprovementAllowanceReimbursementUnderLeaseAgreement</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_ProceedsFromConstructionInProgress', window );">Reimbursement from landlord on construction in progress</a></td>
        <td class="nump"><a title="btx_ProceedsFromConstructionInProgress" onclick="toggleNextSibling(this);">$ 283,764</a><span style="display:none;white-space:normal;text-align:left;">btx_ProceedsFromConstructionInProgress</span><span></span></td>
        <td class="nump"><a title="btx_ProceedsFromConstructionInProgress" onclick="toggleNextSibling(this);">$ 0</a><span style="display:none;white-space:normal;text-align:left;">btx_ProceedsFromConstructionInProgress</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btx_ProceedsFromConstructionInProgress">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Refers to proceeds from landlord on construction in progress.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">btx_ProceedsFromConstructionInProgress</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>btx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btx_TenantImprovementAllowanceReimbursementUnderLeaseAgreement">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of quality for reimbursement under the tenant improvement allowance to lease agreement which use to construct a laboratory and production facility.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">btx_TenantImprovementAllowanceReimbursementUnderLeaseAgreement</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>btx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btx_TenantImprovementAllowanceUnderLeaseAgreement">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of allowance for tenant related to lease agreement which use to construct a laboratory and production facility.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">btx_TenantImprovementAllowanceUnderLeaseAgreement</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>btx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.14)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 14<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipmentPeriodIncreaseDecrease">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The change during the period, from the beginning balance of accumulated depreciation, depletion and amortization (relating to property, plant and equipment) to the ending balance.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipmentPeriodIncreaseDecrease</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeaseObligations">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount equal to the present value (the principal) at the beginning of the lease term of minimum lease payments during the lease term (excluding that portion of the payments representing executory costs such as insurance, maintenance, and taxes to be paid by the lessor, together with any profit thereon) net of payments or other amounts applied to the principal through the balance sheet date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 16<br><br> -Article 7<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6455398&amp;loc=d3e45280-112737<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CapitalLeaseObligations</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConstructionInProgressGross">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ConstructionInProgressGross</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_Depreciation</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseholdImprovementsGross">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount before accumulated depreciation of additions or improvements to assets held under a lease arrangement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 4<br><br> -Subparagraph (f)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6812-107765<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_LeaseholdImprovementsGross</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.13)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.13)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 13<br><br> -Subparagraph a<br><br> -Article 5<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 8<br><br> -Article 7<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNetAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNetAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0ELLAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Royalty Obligation and Deferred License Fees (Details) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2015</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueDisclosureAbstract', window );"><strong>Royalty Obligation and Deferred License Fees [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Intangible assets, useful life</a></td>
        <td class="text">10 years<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCostsAbstract', window );"><strong>Amortization of deferred license fees [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_DeferredLicenseFeesAmortizationExpenseDueInRemainderOfFiscalYear', window );">2015</a></td>
        <td class="nump"><a title="btx_DeferredLicenseFeesAmortizationExpenseDueInRemainderOfFiscalYear" onclick="toggleNextSibling(this);">$ 82,125</a><span style="display:none;white-space:normal;text-align:left;">btx_DeferredLicenseFeesAmortizationExpenseDueInRemainderOfFiscalYear</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_DeferredLicenseFeesAmortizationExpenseYearTwo', window );">2016</a></td>
        <td class="nump"><a title="btx_DeferredLicenseFeesAmortizationExpenseYearTwo" onclick="toggleNextSibling(this);">109,500</a><span style="display:none;white-space:normal;text-align:left;">btx_DeferredLicenseFeesAmortizationExpenseYearTwo</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_DeferredLicenseFeesAmortizationExpenseYearThree', window );">2017</a></td>
        <td class="nump"><a title="btx_DeferredLicenseFeesAmortizationExpenseYearThree" onclick="toggleNextSibling(this);">109,500</a><span style="display:none;white-space:normal;text-align:left;">btx_DeferredLicenseFeesAmortizationExpenseYearThree</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_DeferredLicenseFeesAmortizationExpenseYearFour', window );">2018</a></td>
        <td class="nump"><a title="btx_DeferredLicenseFeesAmortizationExpenseYearFour" onclick="toggleNextSibling(this);">73,667</a><span style="display:none;white-space:normal;text-align:left;">btx_DeferredLicenseFeesAmortizationExpenseYearFour</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_DeferredLicenseFeesAmortizationExpenseYearFive', window );">2019</a></td>
        <td class="nump"><a title="btx_DeferredLicenseFeesAmortizationExpenseYearFive" onclick="toggleNextSibling(this);">24,083</a><span style="display:none;white-space:normal;text-align:left;">btx_DeferredLicenseFeesAmortizationExpenseYearFive</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_DeferredLicenseFeesAmortizationExpenseAfterYearFive', window );">Thereafter</a></td>
        <td class="nump"><a title="btx_DeferredLicenseFeesAmortizationExpenseAfterYearFive" onclick="toggleNextSibling(this);">20,083</a><span style="display:none;white-space:normal;text-align:left;">btx_DeferredLicenseFeesAmortizationExpenseAfterYearFive</span><span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCostsCurrentAndNoncurrent', window );">Total</a></td>
        <td class="nump"><a title="us-gaap_DeferredCostsCurrentAndNoncurrent" onclick="toggleNextSibling(this);">418,958</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredCostsCurrentAndNoncurrent</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_PrepaidExpensesInOtherCurrentAssets', window );">Prepaid expenses in other current assets</a></td>
        <td class="nump"><a title="btx_PrepaidExpensesInOtherCurrentAssets" onclick="toggleNextSibling(this);">109,500</a><span style="display:none;white-space:normal;text-align:left;">btx_PrepaidExpensesInOtherCurrentAssets</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_DeferredLicenseAndConsultingFeesClassifiedAsNoncurrent', window );">Deferred license and consulting fees in noncurrent assets</a></td>
        <td class="nump"><a title="btx_DeferredLicenseAndConsultingFeesClassifiedAsNoncurrent" onclick="toggleNextSibling(this);">$ 309,458</a><span style="display:none;white-space:normal;text-align:left;">btx_DeferredLicenseAndConsultingFeesClassifiedAsNoncurrent</span><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btx_DeferredLicenseAndConsultingFeesClassifiedAsNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying amounts as of the balance sheet of noncurrent deferred license and consulting fees, which consists of the value of warrants issued to third parties for services and to the minority shareholder in BioTime Asia for consulting services, and deferred license fees paid to acquire rights to use the proprietary technologies of third parties.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">btx_DeferredLicenseAndConsultingFeesClassifiedAsNoncurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>btx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btx_DeferredLicenseFeesAmortizationExpenseAfterYearFive">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of amortization expense expected to be recognized after the fifth fiscal year following the latest fiscal year for deferred license fee.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">btx_DeferredLicenseFeesAmortizationExpenseAfterYearFive</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>btx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btx_DeferredLicenseFeesAmortizationExpenseDueInRemainderOfFiscalYear">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of amortization expense expected to be recognized during in the remainder of the fiscal year following the latest fiscal year ended for deferred license fee.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">btx_DeferredLicenseFeesAmortizationExpenseDueInRemainderOfFiscalYear</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>btx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btx_DeferredLicenseFeesAmortizationExpenseYearFive">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of amortization expense expected to be recognized during the fifth fiscal year following the latest fiscal year for deferred license fee.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">btx_DeferredLicenseFeesAmortizationExpenseYearFive</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>btx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btx_DeferredLicenseFeesAmortizationExpenseYearFour">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of amortization expense expected to be recognized during the fourth fiscal year following the latest fiscal year for deferred license fee.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">btx_DeferredLicenseFeesAmortizationExpenseYearFour</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>btx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btx_DeferredLicenseFeesAmortizationExpenseYearThree">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of amortization expense expected to be recognized during the third fiscal year following the latest fiscal year for deferred license fee.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">btx_DeferredLicenseFeesAmortizationExpenseYearThree</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>btx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btx_DeferredLicenseFeesAmortizationExpenseYearTwo">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of amortization expense expected to be recognized during the second fiscal year following the latest fiscal year for deferred license fee.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">btx_DeferredLicenseFeesAmortizationExpenseYearTwo</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>btx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btx_PrepaidExpensesInOtherCurrentAssets">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying amounts as of the balance sheet of related prepaid expenses which are classified in other current assets on the balance sheet.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">btx_PrepaidExpensesInOtherCurrentAssets</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>btx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DeferredCostsAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCurrentAndNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The carrying amount of deferred costs.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DeferredCostsCurrentAndNoncurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DeferredRevenueDisclosureAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0E6GAC">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>Accounts Payable and Accrued Liabilities (Details) (USD $)<br></strong></div>
        </th>
        <th class="th">
          <div>Mar. 31, 2015</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Accounts Payable and Accrued Liabilities [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
        <td class="nump"><a title="us-gaap_AccountsPayableCurrent" onclick="toggleNextSibling(this);">$ 2,707,437</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AccountsPayableCurrent</span><span></span></td>
        <td class="nump"><a title="us-gaap_AccountsPayableCurrent" onclick="toggleNextSibling(this);">$ 2,296,645</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AccountsPayableCurrent</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
        <td class="nump"><a title="us-gaap_AccruedLiabilitiesCurrent" onclick="toggleNextSibling(this);">3,092,030</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AccruedLiabilitiesCurrent</span><span></span></td>
        <td class="nump"><a title="us-gaap_AccruedLiabilitiesCurrent" onclick="toggleNextSibling(this);">3,125,023</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AccruedLiabilitiesCurrent</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedBonusesCurrent', window );">Accrued bonuses</a></td>
        <td class="nump"><a title="us-gaap_AccruedBonusesCurrent" onclick="toggleNextSibling(this);">240,689</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AccruedBonusesCurrent</span><span></span></td>
        <td class="nump"><a title="us-gaap_AccruedBonusesCurrent" onclick="toggleNextSibling(this);">964,189</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AccruedBonusesCurrent</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other accrued liabilities</a></td>
        <td class="nump"><a title="us-gaap_OtherAccruedLiabilitiesCurrent" onclick="toggleNextSibling(this);">282,251</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OtherAccruedLiabilitiesCurrent</span><span></span></td>
        <td class="nump"><a title="us-gaap_OtherAccruedLiabilitiesCurrent" onclick="toggleNextSibling(this);">417,316</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OtherAccruedLiabilitiesCurrent</span><span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accounts payable and accrued liabilities</a></td>
        <td class="nump"><a title="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" onclick="toggleNextSibling(this);">$ 6,322,407</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</span><span></span></td>
        <td class="nump"><a title="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" onclick="toggleNextSibling(this);">$ 6,803,173</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</span><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.19,20)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 20<br><br> -Article 5<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 19<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 19<br><br> -Subparagraph a<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.19(a))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedBonusesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying value as of the balance sheet date of obligations incurred and payable for incentive compensation awarded to employees and directors or earned by them based on the terms of one or more relevant arrangements. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 20<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Current Liabilities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6509677<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.20)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6911-107765<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AccruedBonusesCurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 20<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.20)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying value as of the balance sheet date of obligations incurred through that date and payable arising from transactions not otherwise specified in the taxonomy. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 20<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Current Liabilities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6509677<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.20)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6911-107765<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 9<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e7018-107765<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2015</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
        <td class="text"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="text-align: justify;"><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 100%;"><tr><td style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 18pt; vertical-align: top; font-weight: bold; align: right;">2.</td><td style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: auto; vertical-align: top; font-weight: bold; text-align: justify;">Summary of Significant Accounting Policies</td></tr></table></div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;">Revenue recognition</font> &#8211; BioTime complies with ASC 605-10 and recognizes revenue when persuasive evidence of an arrangement exists, delivery has occurred or services have been rendered, the price is fixed or determinable, and collectability is reasonably assured. Grant income and the sale of research products and services are recognized as revenue when earned. Revenues from the sale of research products and services are primarily derived from the sale of hydrogels and stem cell products. Royalty revenues consist of product royalty payments. License fee revenues consist primarily of subscription and advertising revenue from LifeMap Sciences&#8217; online databases and are recognized based upon respective subscription or advertising periods. Other license fees under certain license agreements were recognized during prior periods when earned and reasonably estimable. Royalties earned on product sales are recognized as revenue in the quarter in which the royalty reports are received from the licensee, rather than the quarter in which the sales took place. When BioTime is entitled to receive up-front nonrefundable licensing or similar fees pursuant to agreements under which BioTime has no continuing performance obligations, the fees are recognized as revenues when collection is reasonably assured. When BioTime receives up-front nonrefundable licensing or similar fees pursuant to agreements under which BioTime does have continuing performance obligations, the fees are deferred and amortized ratably over the performance period. If the performance period cannot be reasonably estimated, BioTime amortizes nonrefundable fees over the life of the contract until such time that the performance period can be more reasonably estimated. Milestone payments, if any, related to scientific or technical achievements are recognized in income when the milestone is accomplished if (a) substantive effort was required to achieve the milestone, (b) the amount of the milestone payment appears reasonably commensurate with the effort expended, and (c) collection of the payment is reasonably assured.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;">Cash and cash equivalents</font> &#8211; BioTime considers all highly liquid investments purchased with an original maturity of three months or less to be cash equivalents.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;">Trade accounts and grants receivable, net</font> &#8211; Net trade receivables amounted to approximately $605,800 and $549,300 and grants receivable amounted to approximately $260,300 and $492,600 as of March 31, 2015 and December 31, 2014, respectively. Net trade receivables include allowance for doubtful accounts of approximately $100,500 as of March 31, 2015 and December 31, 2014 for those amounts deemed uncollectible by BioTime. BioTime evaluates the collectability of its receivables based on a variety of factors, including the length of time receivables are past due and significant one-time events and historical experience. An additional reserve for individual accounts will be recorded if BioTime becomes aware of a customer&#8217;s inability to meet its financial obligations, such as in the case of bankruptcy filings or deterioration in the customer&#8217;s operating results or financial position. If circumstances related to customers change, estimates of the recoverability of receivables would be further adjusted.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;">Concentrations of credit risk</font> &#8211; Financial instruments that potentially subject BioTime to significant concentrations of credit risk consist primarily of cash and cash equivalents. BioTime limits the amount of credit exposure of cash balances by maintaining its accounts in high credit quality financial institutions. Cash equivalent deposits with financial institutions may occasionally exceed the limits of insurance on bank deposits; however, BioTime has not experienced any losses on such accounts.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;">Inventory &#8211;</font> Inventories are stated at the lower of cost or market. Cost, which includes amounts related to materials, labor, and overhead, is determined in a manner which approximates the first-in, first-out (&#8220;FIFO&#8221;) method.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;">Equipment, net and construction in progress</font>&#160;&#8211; Equipment is stated at cost. Equipment and construction in progress is being depreciated using the straight-line method over a period of 36 to 120 months. Construction in progress is not depreciated until the underlying asset is placed into service. See Note 4.</div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; text-indent: 36pt;">&#160;</div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;">Intangible assets, net</font> &#8211; Intangible assets with finite useful lives are amortized over their estimated useful lives and intangible assets with indefinite lives are not amortized but rather are tested at least annually for impairment. Acquired in-process research and development intangible assets are accounted for depending on whether they were acquired as part of an acquisition of a business, or as assets that do not constitute a business. When acquired in conjunction with the acquisition of a business, these assets are considered to be indefinite-lived until the completion or abandonment of the associated research and development efforts and are capitalized as an asset. If and when development is complete, the associated assets would be deemed finite-lived and would then be amortized based on their respective estimated useful lives at that point in time. However, when acquired in conjunction with an acquisition of assets that do not constitute a business (such as the acquisition of assets by Asterias from Geron Corporation), in accordance with the accounting rules in ASC 805-50, such intangible assets related to in-process research and development (&#8220;IPR&amp;D&#8221;) are expensed upon acquisition.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;">Treasury stock &#8211;</font> BioTime accounts for BioTime common shares issued to subsidiaries for future potential working capital needs as treasury stock on the consolidated balance sheet. BioTime has registered the BioTime common shares held by its subsidiaries for sale under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;) to enhance the marketability of the shares.</div><div style="text-align: justify;"><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;">Warrants to purchase common stock</font> &#8211; BioTime generally accounts for warrants issued in connection with equity financings as a component of equity. None of the warrants issued by BioTime as of March 31, 2015 include a conditional obligation to issue a variable number of shares; nor was there a deemed possibility that BioTime may need to settle the warrants in cash.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;">Cost of sales</font> &#8211; BioTime accounts for the cost of research products acquired for sale and any royalties paid as a result of any revenues in accordance with the terms of the respective licensing agreements as cost of sales on the consolidated statement of operations and comprehensive loss.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;">Patent costs &#8211;</font> Costs associated with obtaining patents on products or technology developed are expensed as research and development expenses when incurred.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;">Reclassification</font> &#8211; Certain prior year amounts have been reclassified to conform to the current year presentation. Trade and grant receivables are now reported separately from prepaid expenses and other current assets.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;">Research and development</font> &#8211; Research and development expenses consist of costs incurred for company-sponsored, collaborative and contracted research and development activities. These costs include direct and research-related overhead expenses including salaries, payroll taxes, consulting fees, research and laboratory fees, rent of research facilities, amortization of intangible assets, and license fees paid to third parties to acquire patents or licenses to use patents and other technology. BioTime expenses research and development costs as such costs are incurred.</div><div>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;">General and administrative</font> - General and administrative expenses consist principally of compensation and related benefits, including stock-based compensation, for executive and corporate personnel; professional and consulting fees; and allocated overhead.</div><div>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;">Foreign currency translation gain and other comprehensive loss, &#160;foreign currency transaction gains and losses&#160;&#8211;</font> In countries in which BioTime operates, where the functional currency is other than the U.S. dollar, assets and liabilities are translated using published exchange rates in effect at the consolidated balance sheet date. Revenues and expenses and cash flows are translated using an approximate weighted average exchange rate for the period. Resulting translation adjustments are recorded as a component of accumulated other comprehensive income or loss on the consolidated balance sheet. For the three months ended March 31, 2015 and 2014, other comprehensive loss includes losses of $52,985 and $107,240, respectively which is largely from foreign currency translation.</div><div style="text-align: justify; text-indent: 36pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </div><div style="text-align: justify;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; text-indent: 36pt;">For transactions denominated in other than the functional currency of BioTime, transactional gains and losses are recorded in other income and expense included in the consolidated statements of operations. For the three months ended March 31, 2015 and 2014, foreign currency transaction loss amounted to $205,149 and $10,212, respectively.</div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </div></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;">Income taxes &#8211;</font> BioTime accounts for income taxes in accordance with GAAP requirements, which prescribe the use of the asset and liability method, whereby deferred tax asset or liability account balances are calculated at the balance sheet date using current tax laws and rates in effect. Valuation allowances are established when necessary to reduce deferred tax assets when it is more likely than not that a portion or all of the deferred tax assets will not be realized. The FASB guidance also prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more-likely-than-not sustainable upon examination by taxing authorities. Beginning October 1, 2013, Asterias began filing separate U.S. federal income tax returns but effectively BioTime combined Asterias&#8217; tax provision with BioTime&#8217;s consolidated financial statements. For California, Asterias&#8217; activity for 2013 and 2014 have been included in BioTime&#8217;s combined tax return. BioTime recognizes accrued interest and penalties related to unrecognized tax benefits, if any,&#160;as income tax expense, however, no amounts were accrued for the payment of interest and penalties as of March 31, 2015 and 2014. BioTime files a U.S. federal income tax return as well as various state and foreign income tax returns. In general, BioTime is no longer subject to tax examination by major taxing authorities for years before 2010. Although the statute is closed for purposes of assessing additional income and tax in those years, the taxing authorities may still make adjustments to the net operating loss and credit carryforwards used in open years. Therefore the statute should be considered open as it relates to the net operating loss and credit carryforwards. Any potential examinations may include questioning the timing and amount of deductions, the nexus of income among various tax jurisdictions and compliance with U.S. federal, state and local and foreign tax laws. Management does not expect that the total amount of unrecognized tax benefits will materially change over the next year.</div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; text-indent: 36pt;">&#160;</div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; text-indent: 36pt;">An income tax benefit of approximately $1,177,000 was recorded for the three months ended March 31, 2015, of which approximately $1,251,000 of the benefit was related to federal offset by adjustment of $74,000 related to state taxes. For the same period in 2014, an income tax benefit of approximately $1,349,000 was recorded , of which approximately $1,151,000 of the benefit was related to federal and $198,000 was related to state taxes.</div><div>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; text-indent: 36pt;">Asterias established deferred tax liabilities primarily related to its acquisition of certain intellectual property. It is more likely than not that the Asterias deferred tax assets are fully realizable since these income tax benefits are expected to be available to offset such Asterias deferred tax liabilities.</div><div>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; text-indent: 36pt;">In June 2014, Asterias sold 5,000,000 BioTime shares which resulted in a taxable gain of approximately $10.3 million and a tax payable of $3.6 million. Asterias received the BioTime shares from BioTime as part of the consideration for the Asterias common stock and warrants issued to BioTime under an Asset Contribution Agreement among BioTime, Asterias, and Geron Corporation, a tax free transaction. This income tax liability was offset by available net operating losses, resulting in no cash income taxes due from that sale. This transaction was treated as a deemed distribution by Asterias and recorded against equity.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;">Stock-based compensation</font>&#160;<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;">&#8211;</font> BioTime follows accounting standards governing share-based payments, which require the measurement and recognition of compensation expense for all share-based payment awards made to directors and employees, including employee stock options, based on estimated fair values. Consistent with FASB guidelines, BioTime utilizes the Black-Scholes Merton option pricing model for valuing share-based payment awards. BioTime's determination of fair value of share-based payment awards on the date of grant using that option-pricing model is affected by BioTime's stock price as well as by assumptions regarding a number of highly complex and subjective variables. These variables include, but are not limited to, BioTime's expected stock price volatility over the term of the awards, and actual and projected employee stock option exercise behaviors; the expected term of options granted, derived from historical data on employee exercises and post-vesting employment termination behavior; and a risk-free interest rate is based on the U.S. Treasury rates in effect during the corresponding period of grant. Although the fair value of employee stock options is determined in accordance with&#160;FASB guidance, changes in the subjective assumptions can materially affect the estimated value.</div><div style="text-align: justify;"><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;">Impairment of long-lived assets</font>&#160;<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;">&#8211;</font> BioTime&#8217;s long-lived assets, including intangible assets, are reviewed annually for impairment and whenever events or changes in circumstances indicate that the carrying amount of an asset may not be fully recoverable. If an impairment indicator is present, BioTime will evaluate recoverability by a comparison of the carrying amount of the assets to future undiscounted net cash flows expected to be generated by the assets. If the assets are impaired, the impairment recognized is measured by the amount by which the carrying amount exceeds the estimated fair value of the assets.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;">Deferred license and consulting fees</font> &#8211; Deferred license and consulting fees consist of the value of warrants issued to third parties for services, and deferred license fees paid to acquire rights to use the proprietary technologies of third parties. The value of the warrants is being amortized over the period the services are being provided, and the license fees are being amortized over the estimated useful lives of the licensed technologies or licensed research products. BioTime is applying a 10 year estimated useful life to the technologies and products that it is currently licensing. The estimation of the useful life any technology or product involves a significant degree of inherent uncertainty, since the outcome of research and development or the commercial life of a new product cannot be known with certainty at the time that the right to use the technology or product is acquired. BioTime will review the continued appropriateness of the 10 year estimated useful life for impairments that might occur earlier than the original expected useful lives. BioTime will review its amortization schedules for impairments that might occur earlier than the original expected useful lives. See Note 6.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;">Loss per share</font> &#8211; BioTime applies the two-class method for calculating basic earnings per share. Under the two-class method, net income, if any, will be reduced by preferred stock dividends and the residual amount is allocated between common stock and other participating securities based on their participation rights. Participating securities are comprised of Series A convertible preferred stock and participate in dividends, whether declared or not. Basic earnings per share is calculated by dividing net income or loss attributable to BioTime common shareholders by the weighted average number of shares of common stock outstanding, net of unvested restricted stock subject to repurchase by BioTime, if any, during the period. For periods in which BioTime reported a net loss, the participating securities are not contractually obligated to share in the losses of BioTime, and accordingly, no losses have been allocated to the participating securities. Diluted earnings per share is calculated by dividing the net income or loss attributable to BioTime common shareholders by the weighted average number of common shares outstanding, adjusted for the effects of potentially dilutive common stock, which are comprised of stock options and warrants, using the treasury-stock method, and convertible preferred stock, using the if-converted method. Because BioTime reported losses attributable to common stockholders for all periods presented, all potentially dilutive common stock are antidilutive for those periods. Diluted net loss per share for the three months ended March 31, 2015 and 2014 excludes any effect from 4,893,942 treasury shares, 4,266,605 options and 9,194,679 warrants and 10,546,137 treasury shares, 5,491,301 options and 9,751,615 warrants, respectively, because their inclusion would be antidilutive.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;">Fair value of financial instruments</font> &#8211; The fair value of BioTime&#8217;s assets and liabilities, which qualify as financial instruments under FASB guidance regarding disclosures about fair value of financial instruments, approximate the carrying amounts presented in the accompanying consolidated balance sheets. The carrying amounts of cash equivalents, accounts receivable, prepaid expenses and other current assets, accounts payable, accrued expenses and other current liabilities approximate fair values because of the short-term nature of these items.</div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; text-indent: 36pt;">&#160;</div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; font-style: italic; text-align: justify; text-indent: 36pt;"><font style="font-weight: normal;">Recently Issued Accounting Pronouncements &#8211; </font><font style="font-weight: normal; font-style: normal;">There have been no recent accounting pronouncements or changes in accounting pronouncments during the three months ended March 31, 2015, as compared to the recent accounting pronouncements described in the Comany's 2014 Annual Report on Form 10-K that are of significance or potential significance to the Company.</font></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; text-indent: 36pt;">&#160;</div></div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for all significant accounting policies of the reporting entity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18726-107790<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18861-107790<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18743-107790<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18854-107790<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EKVAG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Related Party Transactions and Related Party Convertible Debt (Details) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="2">3 Months Ended</th>
        <th class="th" colspan="1">1 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2015

</div>
          <div>sqft</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2014</div>
        </th>
        <th class="th">
          <div>Feb. 28, 2015</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRent', window );">Rent per month</a></td>
        <td class="nump"><a title="us-gaap_PaymentsForRent" onclick="toggleNextSibling(this);">$ 5,050</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PaymentsForRent</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AreaOfLand', window );">Area of office space (in square feet)</a></td>
        <td class="nump"><a title="us-gaap_AreaOfLand" onclick="toggleNextSibling(this);">900</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AreaOfLand</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common shares</a></td>
        <td class="nump"><a title="us-gaap_ProceedsFromIssuanceOfCommonStock" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ProceedsFromIssuanceOfCommonStock</span><span></span></td>
        <td class="nump"><a title="us-gaap_ProceedsFromIssuanceOfCommonStock" onclick="toggleNextSibling(this);">8,182,559</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ProceedsFromIssuanceOfCommonStock</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=btx_AsteriasBiotherapeuticsMember', window );">Asterias Biotherapeutics, Inc. | Series A Common Stock [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common shares</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_ProceedsFromIssuanceOfCommonStock[us-gaap_RelatedPartyTransactionAxis=us-gaap_CommonClassAMember;us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=btx_AsteriasBiotherapeuticsMember]" onclick="toggleNextSibling(this);">5,500,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ProceedsFromIssuanceOfCommonStock<br>/ us-gaap_RelatedPartyTransactionAxis<br>= us-gaap_CommonClassAMember<br>/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis<br>= btx_AsteriasBiotherapeuticsMember</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Shares sold (in shares)</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction[us-gaap_RelatedPartyTransactionAxis=us-gaap_CommonClassAMember;us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=btx_AsteriasBiotherapeuticsMember]" onclick="toggleNextSibling(this);">1,410,255</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction<br>/ us-gaap_RelatedPartyTransactionAxis<br>= us-gaap_CommonClassAMember<br>/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis<br>= btx_AsteriasBiotherapeuticsMember</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Stock price (in dollars per share)</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_SharePrice[us-gaap_RelatedPartyTransactionAxis=us-gaap_CommonClassAMember;us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=btx_AsteriasBiotherapeuticsMember]" onclick="toggleNextSibling(this);">$ 3.90</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_SharePrice<br>/ us-gaap_RelatedPartyTransactionAxis<br>= us-gaap_CommonClassAMember<br>/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis<br>= btx_AsteriasBiotherapeuticsMember</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Number of shares purchased (in shares)</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_SharesIssued[us-gaap_RelatedPartyTransactionAxis=us-gaap_CommonClassAMember;us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=btx_AsteriasBiotherapeuticsMember]" onclick="toggleNextSibling(this);">1,025,640</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_SharesIssued<br>/ us-gaap_RelatedPartyTransactionAxis<br>= us-gaap_CommonClassAMember<br>/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis<br>= btx_AsteriasBiotherapeuticsMember</span><span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=btx_CellCureNeurosciencesLtdMember', window );">Cell Cure Neurosciences, Ltd. [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_NumberOfCellCureNeurosciencesInvestors', window );">Number of Cell Cure Neurosciences investors</a></td>
        <td class="nump"><a title="btx_NumberOfCellCureNeurosciencesInvestors[us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=btx_CellCureNeurosciencesLtdMember]" onclick="toggleNextSibling(this);">2</a><span style="display:none;white-space:normal;text-align:left;">btx_NumberOfCellCureNeurosciencesInvestors<br>/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis<br>= btx_CellCureNeurosciencesLtdMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (in hundredths)</a></td>
        <td class="nump"><a title="us-gaap_DebtInstrumentInterestRateStatedPercentage[us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=btx_CellCureNeurosciencesLtdMember]" onclick="toggleNextSibling(this);">3.00%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DebtInstrumentInterestRateStatedPercentage<br>/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis<br>= btx_CellCureNeurosciencesLtdMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion price (in dollars per share)</a></td>
        <td class="nump"><a title="us-gaap_DebtInstrumentConvertibleConversionPrice1[us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=btx_CellCureNeurosciencesLtdMember]" onclick="toggleNextSibling(this);">$ 20.00</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DebtInstrumentConvertibleConversionPrice1<br>/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis<br>= btx_CellCureNeurosciencesLtdMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_EstimatedFairMarketValue', window );">Estimated fair market value (in dollars per share)</a></td>
        <td class="nump"><a title="btx_EstimatedFairMarketValue[us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=btx_CellCureNeurosciencesLtdMember]" onclick="toggleNextSibling(this);">$ 41.00</a><span style="display:none;white-space:normal;text-align:left;">btx_EstimatedFairMarketValue<br>/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis<br>= btx_CellCureNeurosciencesLtdMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Principal and accumulated interest</a></td>
        <td class="nump"><a title="us-gaap_ProceedsFromConvertibleDebt[us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=btx_CellCureNeurosciencesLtdMember]" onclick="toggleNextSibling(this);">470,876</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ProceedsFromConvertibleDebt<br>/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis<br>= btx_CellCureNeurosciencesLtdMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Accrued interest is payable period</a></td>
        <td class="text">3 years<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective annual interest rate (in hundredths)</a></td>
        <td class="nump"><a title="us-gaap_DebtInstrumentInterestRateEffectivePercentage[us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=btx_CellCureNeurosciencesLtdMember]" onclick="toggleNextSibling(this);">23.00%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DebtInstrumentInterestRateEffectivePercentage<br>/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis<br>= btx_CellCureNeurosciencesLtdMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleNotesPayableCurrent', window );">Carrying value of convertible notes</a></td>
        <td class="nump"><a title="us-gaap_ConvertibleNotesPayableCurrent[us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=btx_CellCureNeurosciencesLtdMember]" onclick="toggleNextSibling(this);">169,908</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ConvertibleNotesPayableCurrent<br>/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis<br>= btx_CellCureNeurosciencesLtdMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebt', window );">Amount of convertible note</a></td>
        <td class="nump"><a title="us-gaap_ConvertibleDebt[us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=btx_CellCureNeurosciencesLtdMember]" onclick="toggleNextSibling(this);">534,816</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ConvertibleDebt<br>/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis<br>= btx_CellCureNeurosciencesLtdMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Unamortized debt discount</a></td>
        <td class="nump"><a title="us-gaap_DebtInstrumentUnamortizedDiscount[us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=btx_CellCureNeurosciencesLtdMember]" onclick="toggleNextSibling(this);">$ 364,908</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DebtInstrumentUnamortizedDiscount<br>/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis<br>= btx_CellCureNeurosciencesLtdMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btx_EstimatedFairMarketValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Refers to the price per share of the estimated fair market value feature embedded in the debt instrument.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">btx_EstimatedFairMarketValue</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>btx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btx_NumberOfCellCureNeurosciencesInvestors">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Refers to number of cell cure neurosciences investors.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">btx_NumberOfCellCureNeurosciencesInvestors</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>btx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:integerItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AreaOfLand">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Area of land held.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AreaOfLand</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:areaItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebt">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Including the current and noncurrent portions, carrying amount of debt identified as being convertible into another form of financial instrument (typically the entity's common stock) as of the balance sheet date, which originally required full repayment more than twelve months after issuance or greater than the normal operating cycle of the company.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 942<br><br> -SubTopic 210<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.9-03.16)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 16<br><br> -Article 9<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 210<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-03.16(a)(2))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 19, 20, 22<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ConvertibleDebt</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleNotesPayableCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying value as of the balance sheet date of the portion of long-term debt due within one year or the operating cycle if longer identified as Convertible Notes Payable. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 20<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.20)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ConvertibleNotesPayableCurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The price per share of the conversion feature embedded in the debt instrument.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 470<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 5<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928298&amp;loc=SL6031898-161870<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 835<br><br> -SubTopic 30<br><br> -Section 45<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6451184&amp;loc=d3e28551-108399<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 22<br><br> -Article 5<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.22(a)(1))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateEffectivePercentage</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Contractual interest rate for funds borrowed, under the debt agreement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 22<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.22(a)(1))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentTerm">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DebtInstrumentTerm</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscount">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of debt discount that was originally recognized at the issuance of the instrument that has yet to be amortized.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 835<br><br> -SubTopic 30<br><br> -Section 45<br><br> -Paragraph 1A<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6451184&amp;loc=d3e28541-108399<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 835<br><br> -SubTopic 30<br><br> -Section 55<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=34725769&amp;loc=d3e28878-108400<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscount</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Cash payments to lessor's for use of assets under operating leases.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 25<br><br> -Subparagraph (g)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3536-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PaymentsForRent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromConvertibleDebt">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 14<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3255-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ProceedsFromConvertibleDebt</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow from the additional capital contribution to the entity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 14<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3255-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Price of a single share of a number of saleable stocks of a company.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_SharePrice</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_SharesIssued</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=btx_AsteriasBiotherapeuticsMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=btx_AsteriasBiotherapeuticsMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=btx_CellCureNeurosciencesLtdMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=btx_CellCureNeurosciencesLtdMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EO1AG">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (USD $)<br></strong></div>
        </th>
        <th class="th">
          <div>Mar. 31, 2015</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>CURRENT ASSETS</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
        <td class="nump"><a title="us-gaap_CashAndCashEquivalentsAtCarryingValue" onclick="toggleNextSibling(this);">$ 25,829,533</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CashAndCashEquivalentsAtCarryingValue</span><span></span></td>
        <td class="nump"><a title="us-gaap_CashAndCashEquivalentsAtCarryingValue" onclick="toggleNextSibling(this);">$ 29,486,909</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CashAndCashEquivalentsAtCarryingValue</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_TradeAccountsAndGrantsReceivableNetCurrent', window );">Trade accounts and grants receivable, net</a></td>
        <td class="nump"><a title="btx_TradeAccountsAndGrantsReceivableNetCurrent" onclick="toggleNextSibling(this);">866,180</a><span style="display:none;white-space:normal;text-align:left;">btx_TradeAccountsAndGrantsReceivableNetCurrent</span><span></span></td>
        <td class="nump"><a title="btx_TradeAccountsAndGrantsReceivableNetCurrent" onclick="toggleNextSibling(this);">1,041,856</a><span style="display:none;white-space:normal;text-align:left;">btx_TradeAccountsAndGrantsReceivableNetCurrent</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory</a></td>
        <td class="nump"><a title="us-gaap_InventoryNet" onclick="toggleNextSibling(this);">299,308</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_InventoryNet</span><span></span></td>
        <td class="nump"><a title="us-gaap_InventoryNet" onclick="toggleNextSibling(this);">266,022</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_InventoryNet</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_TenantAllowanceReceivable', window );">Landlord receivable</a></td>
        <td class="nump"><a title="btx_TenantAllowanceReceivable" onclick="toggleNextSibling(this);">277,206</a><span style="display:none;white-space:normal;text-align:left;">btx_TenantAllowanceReceivable</span><span></span></td>
        <td class="nump"><a title="btx_TenantAllowanceReceivable" onclick="toggleNextSibling(this);">377,981</a><span style="display:none;white-space:normal;text-align:left;">btx_TenantAllowanceReceivable</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
        <td class="nump"><a title="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" onclick="toggleNextSibling(this);">1,271,895</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</span><span></span></td>
        <td class="nump"><a title="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" onclick="toggleNextSibling(this);">1,231,789</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</span><span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
        <td class="nump"><a title="us-gaap_AssetsCurrent" onclick="toggleNextSibling(this);">28,544,122</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AssetsCurrent</span><span></span></td>
        <td class="nump"><a title="us-gaap_AssetsCurrent" onclick="toggleNextSibling(this);">32,404,557</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AssetsCurrent</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Equipment, net and construction in progress (see Note 4)</a></td>
        <td class="nump"><a title="us-gaap_PropertyPlantAndEquipmentNet" onclick="toggleNextSibling(this);">2,864,669</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PropertyPlantAndEquipmentNet</span><span></span></td>
        <td class="nump"><a title="us-gaap_PropertyPlantAndEquipmentNet" onclick="toggleNextSibling(this);">2,857,846</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PropertyPlantAndEquipmentNet</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_DeferredLicenseAndConsultingFees', window );">Deferred license and consulting fees</a></td>
        <td class="nump"><a title="btx_DeferredLicenseAndConsultingFees" onclick="toggleNextSibling(this);">309,458</a><span style="display:none;white-space:normal;text-align:left;">btx_DeferredLicenseAndConsultingFees</span><span></span></td>
        <td class="nump"><a title="btx_DeferredLicenseAndConsultingFees" onclick="toggleNextSibling(this);">336,833</a><span style="display:none;white-space:normal;text-align:left;">btx_DeferredLicenseAndConsultingFees</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepositsAssetsNoncurrent', window );">Deposits</a></td>
        <td class="nump"><a title="us-gaap_DepositsAssetsNoncurrent" onclick="toggleNextSibling(this);">443,003</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DepositsAssetsNoncurrent</span><span></span></td>
        <td class="nump"><a title="us-gaap_DepositsAssetsNoncurrent" onclick="toggleNextSibling(this);">443,289</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DepositsAssetsNoncurrent</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other long-term assets</a></td>
        <td class="nump"><a title="us-gaap_OtherAssetsNoncurrent" onclick="toggleNextSibling(this);">7,916</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OtherAssetsNoncurrent</span><span></span></td>
        <td class="nump"><a title="us-gaap_OtherAssetsNoncurrent" onclick="toggleNextSibling(this);">9,985</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OtherAssetsNoncurrent</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
        <td class="nump"><a title="us-gaap_IntangibleAssetsNetExcludingGoodwill" onclick="toggleNextSibling(this);">37,534,302</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IntangibleAssetsNetExcludingGoodwill</span><span></span></td>
        <td class="nump"><a title="us-gaap_IntangibleAssetsNetExcludingGoodwill" onclick="toggleNextSibling(this);">38,848,396</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IntangibleAssetsNetExcludingGoodwill</span><span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">TOTAL ASSETS</a></td>
        <td class="nump"><a title="us-gaap_Assets" onclick="toggleNextSibling(this);">69,703,470</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_Assets</span><span></span></td>
        <td class="nump"><a title="us-gaap_Assets" onclick="toggleNextSibling(this);">74,900,906</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_Assets</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>CURRENT LIABILITIES</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accounts payable and accrued liabilities</a></td>
        <td class="nump"><a title="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" onclick="toggleNextSibling(this);">6,322,407</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</span><span></span></td>
        <td class="nump"><a title="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" onclick="toggleNextSibling(this);">6,803,173</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeaseObligationsCurrent', window );">Capital lease liability, current portion</a></td>
        <td class="nump"><a title="us-gaap_CapitalLeaseObligationsCurrent" onclick="toggleNextSibling(this);">57,500</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CapitalLeaseObligationsCurrent</span><span></span></td>
        <td class="nump"><a title="us-gaap_CapitalLeaseObligationsCurrent" onclick="toggleNextSibling(this);">57,500</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CapitalLeaseObligationsCurrent</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_RelatedPartyConvertibleDebtNetOfDiscount', window );">Related party convertible debt, net of discount</a></td>
        <td class="nump"><a title="btx_RelatedPartyConvertibleDebtNetOfDiscount" onclick="toggleNextSibling(this);">169,908</a><span style="display:none;white-space:normal;text-align:left;">btx_RelatedPartyConvertibleDebtNetOfDiscount</span><span></span></td>
        <td class="nump"><a title="btx_RelatedPartyConvertibleDebtNetOfDiscount" onclick="toggleNextSibling(this);">60,237</a><span style="display:none;white-space:normal;text-align:left;">btx_RelatedPartyConvertibleDebtNetOfDiscount</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_DeferredGrantIncome', window );">Deferred grant income</a></td>
        <td class="nump"><a title="btx_DeferredGrantIncome" onclick="toggleNextSibling(this);">1,474,300</a><span style="display:none;white-space:normal;text-align:left;">btx_DeferredGrantIncome</span><span></span></td>
        <td class="nump"><a title="btx_DeferredGrantIncome" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">btx_DeferredGrantIncome</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueCurrent', window );">Deferred license and subscription revenue, current portion</a></td>
        <td class="nump"><a title="us-gaap_DeferredRevenueCurrent" onclick="toggleNextSibling(this);">178,546</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredRevenueCurrent</span><span></span></td>
        <td class="nump"><a title="us-gaap_DeferredRevenueCurrent" onclick="toggleNextSibling(this);">208,357</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredRevenueCurrent</span><span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
        <td class="nump"><a title="us-gaap_LiabilitiesCurrent" onclick="toggleNextSibling(this);">8,202,661</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_LiabilitiesCurrent</span><span></span></td>
        <td class="nump"><a title="us-gaap_LiabilitiesCurrent" onclick="toggleNextSibling(this);">7,129,267</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_LiabilitiesCurrent</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>LONG-TERM LIABILITIES</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesNoncurrent', window );">Deferred tax liabilities, net</a></td>
        <td class="nump"><a title="us-gaap_DeferredTaxLiabilitiesNoncurrent" onclick="toggleNextSibling(this);">3,337,662</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredTaxLiabilitiesNoncurrent</span><span></span></td>
        <td class="nump"><a title="us-gaap_DeferredTaxLiabilitiesNoncurrent" onclick="toggleNextSibling(this);">4,514,362</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredTaxLiabilitiesNoncurrent</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRentCreditNoncurrent', window );">Deferred rent liabilities, net of current portion</a></td>
        <td class="nump"><a title="us-gaap_DeferredRentCreditNoncurrent" onclick="toggleNextSibling(this);">34,967</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredRentCreditNoncurrent</span><span></span></td>
        <td class="nump"><a title="us-gaap_DeferredRentCreditNoncurrent" onclick="toggleNextSibling(this);">97,280</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredRentCreditNoncurrent</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_LandlordLiabilitiesNoncurrent', window );">Lease liability</a></td>
        <td class="nump"><a title="btx_LandlordLiabilitiesNoncurrent" onclick="toggleNextSibling(this);">560,970</a><span style="display:none;white-space:normal;text-align:left;">btx_LandlordLiabilitiesNoncurrent</span><span></span></td>
        <td class="nump"><a title="btx_LandlordLiabilitiesNoncurrent" onclick="toggleNextSibling(this);">377,981</a><span style="display:none;white-space:normal;text-align:left;">btx_LandlordLiabilitiesNoncurrent</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent', window );">Capital lease, net of current portion</a></td>
        <td class="nump"><a title="us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" onclick="toggleNextSibling(this);">17,307</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent</span><span></span></td>
        <td class="nump"><a title="us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" onclick="toggleNextSibling(this);">31,290</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long term liabilities</a></td>
        <td class="nump"><a title="us-gaap_OtherLiabilitiesNoncurrent" onclick="toggleNextSibling(this);">38,119</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OtherLiabilitiesNoncurrent</span><span></span></td>
        <td class="nump"><a title="us-gaap_OtherLiabilitiesNoncurrent" onclick="toggleNextSibling(this);">27,961</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OtherLiabilitiesNoncurrent</span><span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrent', window );">Total long-term liabilities</a></td>
        <td class="nump"><a title="us-gaap_LiabilitiesNoncurrent" onclick="toggleNextSibling(this);">3,989,025</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_LiabilitiesNoncurrent</span><span></span></td>
        <td class="nump"><a title="us-gaap_LiabilitiesNoncurrent" onclick="toggleNextSibling(this);">5,048,874</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_LiabilitiesNoncurrent</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract', window );"><strong>SHAREHOLDERS' EQUITY</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Series A Convertible Preferred shares, no par value, authorized 2,000,000 shares as of March 31, 2015 and December 31, 2014; 70,000 issued and outstanding as of March 31, 2015 and December 31, 2014</a></td>
        <td class="nump"><a title="us-gaap_PreferredStockValue" onclick="toggleNextSibling(this);">3,500,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PreferredStockValue</span><span></span></td>
        <td class="nump"><a title="us-gaap_PreferredStockValue" onclick="toggleNextSibling(this);">3,500,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PreferredStockValue</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common shares, no par value, authorized 125,000,000 shares as of March 31, 2015 and December 31, 2014; 83,210,775 issued and 78,316,833 outstanding as of March 31, 2015 and 83,121,698 issued and 78,227,756 outstanding at December 31, 2014</a></td>
        <td class="nump"><a title="us-gaap_CommonStockValue" onclick="toggleNextSibling(this);">234,751,802</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CommonStockValue</span><span></span></td>
        <td class="nump"><a title="us-gaap_CommonStockValue" onclick="toggleNextSibling(this);">234,842,998</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CommonStockValue</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Contributed capital</a></td>
        <td class="nump"><a title="us-gaap_AdditionalPaidInCapital" onclick="toggleNextSibling(this);">7,145</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AdditionalPaidInCapital</span><span></span></td>
        <td class="nump"><a title="us-gaap_AdditionalPaidInCapital" onclick="toggleNextSibling(this);">7,145</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AdditionalPaidInCapital</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income</a></td>
        <td class="nump"><a title="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" onclick="toggleNextSibling(this);">238,820</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</span><span></span></td>
        <td class="nump"><a title="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" onclick="toggleNextSibling(this);">185,835</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
        <td class="num"><a title="us-gaap_RetainedEarningsAccumulatedDeficit" onclick="toggleNextSibling(this);">(192,357,575)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_RetainedEarningsAccumulatedDeficit</span><span></span></td>
        <td class="num"><a title="us-gaap_RetainedEarningsAccumulatedDeficit" onclick="toggleNextSibling(this);">(182,190,207)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_RetainedEarningsAccumulatedDeficit</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValue', window );">Treasury stock at cost: 4,893,942 shares at March 31, 2015 and at December 31, 2014</a></td>
        <td class="num"><a title="us-gaap_TreasuryStockValue" onclick="toggleNextSibling(this);">(19,889,788)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_TreasuryStockValue</span><span></span></td>
        <td class="num"><a title="us-gaap_TreasuryStockValue" onclick="toggleNextSibling(this);">(19,889,788)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_TreasuryStockValue</span><span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">BioTime, Inc. shareholders' equity</a></td>
        <td class="nump"><a title="us-gaap_StockholdersEquity" onclick="toggleNextSibling(this);">26,250,404</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockholdersEquity</span><span></span></td>
        <td class="nump"><a title="us-gaap_StockholdersEquity" onclick="toggleNextSibling(this);">36,455,983</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockholdersEquity</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Non-controlling interest</a></td>
        <td class="nump"><a title="us-gaap_MinorityInterest" onclick="toggleNextSibling(this);">31,261,380</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_MinorityInterest</span><span></span></td>
        <td class="nump"><a title="us-gaap_MinorityInterest" onclick="toggleNextSibling(this);">26,266,782</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_MinorityInterest</span><span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total shareholders' equity</a></td>
        <td class="nump"><a title="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" onclick="toggleNextSibling(this);">57,511,784</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</span><span></span></td>
        <td class="nump"><a title="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" onclick="toggleNextSibling(this);">62,722,765</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</span><span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY</a></td>
        <td class="nump"><a title="us-gaap_LiabilitiesAndStockholdersEquity" onclick="toggleNextSibling(this);">$ 69,703,470</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_LiabilitiesAndStockholdersEquity</span><span></span></td>
        <td class="nump"><a title="us-gaap_LiabilitiesAndStockholdersEquity" onclick="toggleNextSibling(this);">$ 74,900,906</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_LiabilitiesAndStockholdersEquity</span><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btx_DeferredGrantIncome">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The carrying amount of consideration received or receivable as of the balance sheet date on grant awards that were not recognized as revenue in conformity with GAAP, and which are expected to be recognized as such within one year or the normal operating cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">btx_DeferredGrantIncome</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>btx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btx_DeferredLicenseAndConsultingFees">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying amounts as of the balance sheet of deferred license and consulting fees, which consists of the value of warrants issued to third parties for services and to the minority shareholder in BioTime Asia for consulting services, and deferred license fees paid to acquire rights to use the proprietary technologies of third parties.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">btx_DeferredLicenseAndConsultingFees</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>btx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btx_LandlordLiabilitiesNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate carrying amount, as of the balance sheet date, of noncurrent liabilities related to a lease agreement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">btx_LandlordLiabilitiesNoncurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>btx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btx_RelatedPartyConvertibleDebtNetOfDiscount">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Convertible debt that the issuer (lender) can convert at any time before maturity. Convertible debt is a financial instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">btx_RelatedPartyConvertibleDebtNetOfDiscount</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>btx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btx_TenantAllowanceReceivable">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of tenant allowance due from lessor to lessee per the lease agreement to cover building improvements and or construction costs.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">btx_TenantAllowanceReceivable</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>btx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btx_TradeAccountsAndGrantsReceivableNetCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount due from customers or clients for goods or services that have been delivered or sold in the normal course of business within one year or the normal operating cycle, if longer, net of allowance for doubtful accounts, and the amounts due under the terms of governmental, corporate, or foundation grants.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">btx_TradeAccountsAndGrantsReceivableNetCurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>btx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.19,20)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 20<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 19<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 220<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 11<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=36458714&amp;loc=d3e637-108580<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 220<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 14<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=36458714&amp;loc=d3e681-108580<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 220<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 14A<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=36458714&amp;loc=SL7669686-108580<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 31<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 04<br><br><br><br> -Article 3<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 31<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.30(a)(1))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.18)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 12<br><br><br><br> -Article 7<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 18<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_Assets</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.9)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6801-107765<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 9<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeaseObligationsCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of capital lease obligation due within one year or the normal operating cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 19<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.20)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 840<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6455398&amp;loc=d3e45280-112737<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 840<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6455314&amp;loc=d3e45023-112735<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CapitalLeaseObligationsCurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Cash<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Cash Equivalents<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 1<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br><br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 4<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3044-108585<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 450<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=25496072&amp;loc=d3e14326-108349<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.25)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 25<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 19<br><br><br><br> -Article 7<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 17<br><br><br><br> -Article 9<br><br><br><br><br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 942<br><br><br><br> -SubTopic 210<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.9-03.17)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br><br><br><br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 944<br><br><br><br> -SubTopic 210<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.7-03.(a),19)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 30<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRentCreditNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>For a classified balance sheet, the cumulative difference between the rental income or payments required by a lease agreement and the rental income or expense recognized on a straight-line basis, or other systematic and rational basis more representative of the time pattern in which use or benefit is granted or derived from the leased property, expected to be recognized in income or expense, by the lessor or lessee, respectively, more than one year after the balance sheet date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 840<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 25<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=7501430&amp;loc=d3e39927-112707<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.26(c))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DeferredRentCreditNoncurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The carrying amount of consideration received or receivable as of the balance sheet date on potential earnings that were not recognized as revenue in conformity with GAAP, and which are expected to be recognized as such within one year or the normal operating cycle, if longer, including sales, license fees, and royalties, but excluding interest income.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 605<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SAB TOPIC 13.A.4(a).Q1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012821&amp;loc=d3e214044-122780<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 8<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Staff Accounting Bulletin (SAB)<br><br><br><br> -Number Topic 13<br><br><br><br> -Section A<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DeferredRevenueCurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of deferred tax liability attributable to taxable temporary differences, net of deferred tax asset attributable to deductible temporary differences and carryforwards net of valuation allowances expected to be realized or consumed after one year (or the normal operating cycle, if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 740<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 4<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=37586315&amp;loc=d3e31917-109318<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 740<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 6<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=37586315&amp;loc=d3e31931-109318<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 740<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 9<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=37586315&amp;loc=d3e31958-109318<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesNoncurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepositsAssetsNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment after one year or beyond the operating cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.17)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 17<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DepositsAssetsNoncurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 350<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 350<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph ((a)(1),(b))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16323-109275<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.6(a))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 330<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 35<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6386567&amp;loc=d3e3927-108312<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_InventoryNet</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.32)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 25<br><br><br><br> -Article 7<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 32<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.21)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 21<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of obligation due after one year or beyond the normal operating cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.22-26)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 22, 23, 24, 25, 26, 27<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of long-term debt and capital leases due within one year or the normal operating cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.20)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.31)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 27<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 20<br><br><br><br> -Article 7<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_MinorityInterest</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate carrying amount, as of the balance sheet date, of noncurrent assets not separately disclosed in the balance sheet. Noncurrent assets are expected to be realized or consumed after one year (or the normal operating cycle, if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.17)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 17<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate carrying amount, as of the balance sheet date, of noncurrent obligations not separately disclosed in the balance sheet. Noncurrent liabilities are expected to be paid after one year (or the normal operating cycle, if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.24)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 24<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 04<br><br><br><br> -Article 3<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.3-04)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.28)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 29<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 8<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 360<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.13)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 13<br><br><br><br> -Subparagraph a<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 8<br><br><br><br> -Article 7<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 31<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 04<br><br><br><br> -Article 3<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.31(a)(3))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 310<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SAB TOPIC 4.E)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Staff Accounting Bulletin (SAB)<br><br><br><br> -Number Topic 4<br><br><br><br> -Section E<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29-31)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 29, 30, 31<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 810<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 15<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=7656940&amp;loc=SL4568447-111683<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 810<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 16<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=7656940&amp;loc=SL4568740-111683<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 810<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 55<br><br><br><br> -Paragraph 4I<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=35736750&amp;loc=SL4590271-111686<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 4<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23315-112656<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_TreasuryStockValue</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EALBG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="2">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2015</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract', window );"><strong>CASH FLOWS FROM OPERATING ACTIVITIES:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss attributable to BioTime, Inc.</a></td>
        <td class="num"><a title="us-gaap_NetIncomeLoss" onclick="toggleNextSibling(this);">$ (10,167,368)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetIncomeLoss</span><span></span></td>
        <td class="num"><a title="us-gaap_NetIncomeLoss" onclick="toggleNextSibling(this);">$ (8,099,014)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetIncomeLoss</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net loss attributable to non-controlling interest</a></td>
        <td class="num"><a title="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" onclick="toggleNextSibling(this);">(2,422,687)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</span><span></span></td>
        <td class="num"><a title="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" onclick="toggleNextSibling(this);">(1,629,017)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss attributable to BioTime, Inc. to net cash used in operating activities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
        <td class="nump"><a title="us-gaap_Depreciation" onclick="toggleNextSibling(this);">262,600</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_Depreciation</span><span></span></td>
        <td class="nump"><a title="us-gaap_Depreciation" onclick="toggleNextSibling(this);">256,945</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_Depreciation</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangible assets</a></td>
        <td class="nump"><a title="us-gaap_AmortizationOfIntangibleAssets" onclick="toggleNextSibling(this);">1,314,094</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AmortizationOfIntangibleAssets</span><span></span></td>
        <td class="nump"><a title="us-gaap_AmortizationOfIntangibleAssets" onclick="toggleNextSibling(this);">1,367,998</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AmortizationOfIntangibleAssets</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_AmortizationOfDeferredConsultingFees', window );">Amortization of deferred consulting fees</a></td>
        <td class="nump"><a title="btx_AmortizationOfDeferredConsultingFees" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">btx_AmortizationOfDeferredConsultingFees</span><span></span></td>
        <td class="nump"><a title="btx_AmortizationOfDeferredConsultingFees" onclick="toggleNextSibling(this);">16,279</a><span style="display:none;white-space:normal;text-align:left;">btx_AmortizationOfDeferredConsultingFees</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_AmortizationOfDeferredLicenseFees', window );">Amortization of deferred license fees</a></td>
        <td class="nump"><a title="btx_AmortizationOfDeferredLicenseFees" onclick="toggleNextSibling(this);">27,375</a><span style="display:none;white-space:normal;text-align:left;">btx_AmortizationOfDeferredLicenseFees</span><span></span></td>
        <td class="nump"><a title="btx_AmortizationOfDeferredLicenseFees" onclick="toggleNextSibling(this);">27,375</a><span style="display:none;white-space:normal;text-align:left;">btx_AmortizationOfDeferredLicenseFees</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfDeferredCharges', window );">Amortization of deferred license, royalty and subscription revenues</a></td>
        <td class="nump"><a title="us-gaap_AmortizationOfDeferredCharges" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AmortizationOfDeferredCharges</span><span></span></td>
        <td class="num"><a title="us-gaap_AmortizationOfDeferredCharges" onclick="toggleNextSibling(this);">(280)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AmortizationOfDeferredCharges</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_AmortizationOfStockBasedPrepaidRent', window );">Amortization of prepaid rent in common stock</a></td>
        <td class="nump"><a title="btx_AmortizationOfStockBasedPrepaidRent" onclick="toggleNextSibling(this);">21,146</a><span style="display:none;white-space:normal;text-align:left;">btx_AmortizationOfStockBasedPrepaidRent</span><span></span></td>
        <td class="nump"><a title="btx_AmortizationOfStockBasedPrepaidRent" onclick="toggleNextSibling(this);">21,146</a><span style="display:none;white-space:normal;text-align:left;">btx_AmortizationOfStockBasedPrepaidRent</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensation" onclick="toggleNextSibling(this);">1,914,407</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensation</span><span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensation" onclick="toggleNextSibling(this);">801,554</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensation</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortization of discount on related party convertible debt</a></td>
        <td class="nump"><a title="us-gaap_AmortizationOfDebtDiscountPremium" onclick="toggleNextSibling(this);">49,697</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AmortizationOfDebtDiscountPremium</span><span></span></td>
        <td class="nump"><a title="us-gaap_AmortizationOfDebtDiscountPremium" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AmortizationOfDebtDiscountPremium</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_AccruedInterestOnConvertibleDebt', window );">Accrued interest on convertible debt</a></td>
        <td class="nump"><a title="btx_AccruedInterestOnConvertibleDebt" onclick="toggleNextSibling(this);">3,531</a><span style="display:none;white-space:normal;text-align:left;">btx_AccruedInterestOnConvertibleDebt</span><span></span></td>
        <td class="nump"><a title="btx_AccruedInterestOnConvertibleDebt" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">btx_AccruedInterestOnConvertibleDebt</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse', window );">Loss on sale or write-off of equipment</a></td>
        <td class="nump"><a title="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ImpairmentOfLongLivedAssetsHeldForUse</span><span></span></td>
        <td class="nump"><a title="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" onclick="toggleNextSibling(this);">8,576</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ImpairmentOfLongLivedAssetsHeldForUse</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred income tax benefit</a></td>
        <td class="num"><a title="us-gaap_DeferredIncomeTaxExpenseBenefit" onclick="toggleNextSibling(this);">(1,176,882)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredIncomeTaxExpenseBenefit</span><span></span></td>
        <td class="num"><a title="us-gaap_DeferredIncomeTaxExpenseBenefit" onclick="toggleNextSibling(this);">(1,349,026)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredIncomeTaxExpenseBenefit</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_ProceedsFromDeferredGrantIncome', window );">Deferred grant income</a></td>
        <td class="nump"><a title="btx_ProceedsFromDeferredGrantIncome" onclick="toggleNextSibling(this);">1,474,300</a><span style="display:none;white-space:normal;text-align:left;">btx_ProceedsFromDeferredGrantIncome</span><span></span></td>
        <td class="nump"><a title="btx_ProceedsFromDeferredGrantIncome" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">btx_ProceedsFromDeferredGrantIncome</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable, net</a></td>
        <td class="num"><a title="us-gaap_IncreaseDecreaseInAccountsReceivable" onclick="toggleNextSibling(this);">(56,598)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncreaseDecreaseInAccountsReceivable</span><span></span></td>
        <td class="num"><a title="us-gaap_IncreaseDecreaseInAccountsReceivable" onclick="toggleNextSibling(this);">(24,441)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncreaseDecreaseInAccountsReceivable</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_IncreaseDecreaseInGrantReceivable', window );">Grant receivable</a></td>
        <td class="nump"><a title="btx_IncreaseDecreaseInGrantReceivable" onclick="toggleNextSibling(this);">228,191</a><span style="display:none;white-space:normal;text-align:left;">btx_IncreaseDecreaseInGrantReceivable</span><span></span></td>
        <td class="nump"><a title="btx_IncreaseDecreaseInGrantReceivable" onclick="toggleNextSibling(this);">202,122</a><span style="display:none;white-space:normal;text-align:left;">btx_IncreaseDecreaseInGrantReceivable</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventory</a></td>
        <td class="num"><a title="us-gaap_IncreaseDecreaseInInventories" onclick="toggleNextSibling(this);">(33,286)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncreaseDecreaseInInventories</span><span></span></td>
        <td class="num"><a title="us-gaap_IncreaseDecreaseInInventories" onclick="toggleNextSibling(this);">(57,894)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncreaseDecreaseInInventories</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
        <td class="num"><a title="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" onclick="toggleNextSibling(this);">(60,769)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</span><span></span></td>
        <td class="num"><a title="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" onclick="toggleNextSibling(this);">(375,224)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued liabilities</a></td>
        <td class="num"><a title="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" onclick="toggleNextSibling(this);">(365,175)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</span><span></span></td>
        <td class="num"><a title="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" onclick="toggleNextSibling(this);">(1,276,211)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities', window );">Other long term liabilities</a></td>
        <td class="nump"><a title="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" onclick="toggleNextSibling(this);">10,727</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities</span><span></span></td>
        <td class="num"><a title="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" onclick="toggleNextSibling(this);">(185,717)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_IncreaseDecreaseInDeferredRentLiabilities', window );">Deferred rent liabilities</a></td>
        <td class="num"><a title="btx_IncreaseDecreaseInDeferredRentLiabilities" onclick="toggleNextSibling(this);">(62,313)</a><span style="display:none;white-space:normal;text-align:left;">btx_IncreaseDecreaseInDeferredRentLiabilities</span><span></span></td>
        <td class="num"><a title="btx_IncreaseDecreaseInDeferredRentLiabilities" onclick="toggleNextSibling(this);">(5,040)</a><span style="display:none;white-space:normal;text-align:left;">btx_IncreaseDecreaseInDeferredRentLiabilities</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredRevenue', window );">Deferred revenues</a></td>
        <td class="num"><a title="us-gaap_IncreaseDecreaseInDeferredRevenue" onclick="toggleNextSibling(this);">(29,811)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncreaseDecreaseInDeferredRevenue</span><span></span></td>
        <td class="num"><a title="us-gaap_IncreaseDecreaseInDeferredRevenue" onclick="toggleNextSibling(this);">(57,402)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncreaseDecreaseInDeferredRevenue</span><span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations', window );">Net cash used in operating activities</a></td>
        <td class="num"><a title="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" onclick="toggleNextSibling(this);">(9,068,821)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations</span><span></span></td>
        <td class="num"><a title="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" onclick="toggleNextSibling(this);">(10,357,271)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract', window );"><strong>CASH FLOWS FROM INVESTING ACTIVITIES:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of equipment</a></td>
        <td class="num"><a title="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" onclick="toggleNextSibling(this);">(77,007)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</span><span></span></td>
        <td class="num"><a title="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" onclick="toggleNextSibling(this);">(231,921)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForCapitalImprovements', window );">Payments on construction in progress (see Note 4)</a></td>
        <td class="num"><a title="us-gaap_PaymentsForCapitalImprovements" onclick="toggleNextSibling(this);">(296,382)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PaymentsForCapitalImprovements</span><span></span></td>
        <td class="nump"><a title="us-gaap_PaymentsForCapitalImprovements" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PaymentsForCapitalImprovements</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment', window );">Proceeds from the sale of equipment</a></td>
        <td class="nump"><a title="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment</span><span></span></td>
        <td class="nump"><a title="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" onclick="toggleNextSibling(this);">4,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_SecurityDepositReceived', window );">Security deposit paid, net</a></td>
        <td class="nump"><a title="btx_SecurityDepositReceived" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">btx_SecurityDepositReceived</span><span></span></td>
        <td class="num"><a title="btx_SecurityDepositReceived" onclick="toggleNextSibling(this);">(299,697)</a><span style="display:none;white-space:normal;text-align:left;">btx_SecurityDepositReceived</span><span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations', window );">Cash used in investing activities</a></td>
        <td class="num"><a title="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" onclick="toggleNextSibling(this);">(373,389)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations</span><span></span></td>
        <td class="num"><a title="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" onclick="toggleNextSibling(this);">(527,618)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract', window );"><strong>CASH FLOWS FROM FINANCING ACTIVITIES:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercises of stock options</a></td>
        <td class="nump"><a title="us-gaap_ProceedsFromStockOptionsExercised" onclick="toggleNextSibling(this);">346,713</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ProceedsFromStockOptionsExercised</span><span></span></td>
        <td class="nump"><a title="us-gaap_ProceedsFromStockOptionsExercised" onclick="toggleNextSibling(this);">58,500</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ProceedsFromStockOptionsExercised</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock', window );">Proceeds from sale of preferred stock</a></td>
        <td class="nump"><a title="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock</span><span></span></td>
        <td class="nump"><a title="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" onclick="toggleNextSibling(this);">3,500,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common shares</a></td>
        <td class="nump"><a title="us-gaap_ProceedsFromIssuanceOfCommonStock" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ProceedsFromIssuanceOfCommonStock</span><span></span></td>
        <td class="nump"><a title="us-gaap_ProceedsFromIssuanceOfCommonStock" onclick="toggleNextSibling(this);">8,182,559</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ProceedsFromIssuanceOfCommonStock</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_FeesPaidOnSaleOfCommonShares', window );">Fees paid on sale of common stock</a></td>
        <td class="nump"><a title="btx_FeesPaidOnSaleOfCommonShares" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">btx_FeesPaidOnSaleOfCommonShares</span><span></span></td>
        <td class="num"><a title="btx_FeesPaidOnSaleOfCommonShares" onclick="toggleNextSibling(this);">(212,046)</a><span style="display:none;white-space:normal;text-align:left;">btx_FeesPaidOnSaleOfCommonShares</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfTreasuryStock', window );">Proceeds from sale of treasury stock and subsidiary warrants</a></td>
        <td class="nump"><a title="us-gaap_ProceedsFromSaleOfTreasuryStock" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ProceedsFromSaleOfTreasuryStock</span><span></span></td>
        <td class="nump"><a title="us-gaap_ProceedsFromSaleOfTreasuryStock" onclick="toggleNextSibling(this);">599,472</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ProceedsFromSaleOfTreasuryStock</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_ProceedsFromConstructionInProgress', window );">Reimbursement from landlord on construction in progress (see Note 4)</a></td>
        <td class="nump"><a title="btx_ProceedsFromConstructionInProgress" onclick="toggleNextSibling(this);">283,764</a><span style="display:none;white-space:normal;text-align:left;">btx_ProceedsFromConstructionInProgress</span><span></span></td>
        <td class="nump"><a title="btx_ProceedsFromConstructionInProgress" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">btx_ProceedsFromConstructionInProgress</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeasesIncomeStatementAmortizationExpense', window );">Repayment of capital lease obligation</a></td>
        <td class="num"><a title="us-gaap_CapitalLeasesIncomeStatementAmortizationExpense" onclick="toggleNextSibling(this);">(13,983)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CapitalLeasesIncomeStatementAmortizationExpense</span><span></span></td>
        <td class="nump"><a title="us-gaap_CapitalLeasesIncomeStatementAmortizationExpense" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CapitalLeasesIncomeStatementAmortizationExpense</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromMinorityShareholders', window );">Proceeds from sale of common shares of subsidiary</a></td>
        <td class="nump"><a title="us-gaap_ProceedsFromMinorityShareholders" onclick="toggleNextSibling(this);">5,499,995</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ProceedsFromMinorityShareholders</span><span></span></td>
        <td class="nump"><a title="us-gaap_ProceedsFromMinorityShareholders" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ProceedsFromMinorityShareholders</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_FeesPaidOnSaleOfCommonSharesOfSubsidiary', window );">Fees paid on sale of common shares of subsidiary</a></td>
        <td class="num"><a title="btx_FeesPaidOnSaleOfCommonSharesOfSubsidiary" onclick="toggleNextSibling(this);">(432,631)</a><span style="display:none;white-space:normal;text-align:left;">btx_FeesPaidOnSaleOfCommonSharesOfSubsidiary</span><span></span></td>
        <td class="nump"><a title="btx_FeesPaidOnSaleOfCommonSharesOfSubsidiary" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">btx_FeesPaidOnSaleOfCommonSharesOfSubsidiary</span><span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations', window );">Net cash provided by financing activities</a></td>
        <td class="nump"><a title="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" onclick="toggleNextSibling(this);">5,683,858</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations</span><span></span></td>
        <td class="nump"><a title="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" onclick="toggleNextSibling(this);">12,128,485</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents', window );">Effect of exchange rate changes on cash and cash equivalents</a></td>
        <td class="nump"><a title="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" onclick="toggleNextSibling(this);">100,976</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents</span><span></span></td>
        <td class="num"><a title="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" onclick="toggleNextSibling(this);">(101,240)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents</span><span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease', window );">NET CHANGE IN CASH AND CASH EQUIVALENTS:</a></td>
        <td class="num"><a title="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" onclick="toggleNextSibling(this);">(3,657,376)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease</span><span></span></td>
        <td class="nump"><a title="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" onclick="toggleNextSibling(this);">1,142,356</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>CASH AND CASH EQUIVALENTS:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">At beginning of the period</a></td>
        <td class="nump"><a title="us-gaap_CashAndCashEquivalentsAtCarryingValue" onclick="toggleNextSibling(this);">29,486,909</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CashAndCashEquivalentsAtCarryingValue</span><span></span></td>
        <td class="nump"><a title="us-gaap_CashAndCashEquivalentsAtCarryingValue" onclick="toggleNextSibling(this);">5,495,478</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CashAndCashEquivalentsAtCarryingValue</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">At end of the period</a></td>
        <td class="nump"><a title="us-gaap_CashAndCashEquivalentsAtCarryingValue" onclick="toggleNextSibling(this);">$ 25,829,533</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CashAndCashEquivalentsAtCarryingValue</span><span></span></td>
        <td class="nump"><a title="us-gaap_CashAndCashEquivalentsAtCarryingValue" onclick="toggleNextSibling(this);">$ 6,637,834</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CashAndCashEquivalentsAtCarryingValue</span><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btx_AccruedInterestOnConvertibleDebt">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Refers to accrued amount unpaid interest on the convertible debt instrument for the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">btx_AccruedInterestOnConvertibleDebt</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>btx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btx_AmortizationOfDeferredConsultingFees">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate amount of recurring noncash expense charged against earnings in the period to allocate the cost of deferred consulting fees.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">btx_AmortizationOfDeferredConsultingFees</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>btx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btx_AmortizationOfDeferredLicenseFees">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate amount of recurring noncash expense charged against earnings in the period to allocate the cost of deferred license fees.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">btx_AmortizationOfDeferredLicenseFees</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>btx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btx_AmortizationOfStockBasedPrepaidRent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate amount of recurring noncash expense charged against earnings in the period to allocate the cost of amortization of stock based prepaid rent.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">btx_AmortizationOfStockBasedPrepaidRent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>btx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btx_FeesPaidOnSaleOfCommonShares">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash outflow associated with fee paid on sale of common shares during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">btx_FeesPaidOnSaleOfCommonShares</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>btx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btx_FeesPaidOnSaleOfCommonSharesOfSubsidiary">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash outflow associated with fee paid on sale of common shares of subsidiary during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">btx_FeesPaidOnSaleOfCommonSharesOfSubsidiary</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>btx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btx_IncreaseDecreaseInDeferredRentLiabilities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in the amount due that is the result of the cumulative difference between actual rent due and rental income recognized on a straight-line basis.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">btx_IncreaseDecreaseInDeferredRentLiabilities</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>btx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btx_IncreaseDecreaseInGrantReceivable">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period for amounts due under the terms of governmental, corporate, or foundation grants.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">btx_IncreaseDecreaseInGrantReceivable</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>btx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btx_ProceedsFromConstructionInProgress">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Refers to proceeds from landlord on construction in progress.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">btx_ProceedsFromConstructionInProgress</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>btx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btx_ProceedsFromDeferredGrantIncome">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow from deferred grant awarded during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">btx_ProceedsFromDeferredGrantIncome</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>btx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btx_SecurityDepositReceived">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The net cash inflow/(outflow) associated with security deposit received during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">btx_SecurityDepositReceived</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>btx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 835<br><br> -SubTopic 30<br><br> -Section 45<br><br> -Paragraph 1A<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6451184&amp;loc=d3e28541-108399<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.8)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 8<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AmortizationOfDebtDiscountPremium</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDeferredCharges">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of amortization of deferred charges applied against earnings during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AmortizationOfDeferredCharges</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 350<br><br> -SubTopic 30<br><br> -Section 45<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 350<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)(2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16323-109275<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeasesIncomeStatementAmortizationExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The charge for the use of long-lived depreciable capital leased assets for the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 30<br><br> -Section 45<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6455314&amp;loc=d3e45031-112735<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 980<br><br> -SubTopic 840<br><br> -Section 55<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6501752&amp;loc=d3e56872-110439<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CapitalLeasesIncomeStatementAmortizationExpense</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Cash<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Cash Equivalents<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 1<br><br> -Article 5<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 1<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3044-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 24<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3521-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 830<br><br> -SubTopic 230<br><br> -Section 45<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6450594&amp;loc=d3e33268-110906<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 6.I.7)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(h))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph h<br><br> -Article 4<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 6<br><br> -Section I<br><br> -Subsection 7<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Deferred Tax Expense (or Benefit)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6510177<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 9<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32639-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_Depreciation</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of increase (decrease) from the effect of exchange rate changes on cash and cash equivalent balances held in foreign currencies.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 830<br><br> -SubTopic 230<br><br> -Section 45<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6450594&amp;loc=d3e33268-110906<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=8077374&amp;loc=d3e2420-110228<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391110&amp;loc=d3e2921-110230<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 958<br><br> -SubTopic 225<br><br> -Section 45<br><br> -Paragraph 11<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28367520&amp;loc=d3e92212-112881<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Impairment<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6515133<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsHeldForUse</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredRevenue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period, excluding the portion taken into income, in the liability reflecting revenue yet to be earned for which cash or other forms of consideration was received or recorded as a receivable.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredRevenue</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in other noncurrent operating liabilities not separately disclosed in the statement of cash flows.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in the value of prepaid expenses and other assets not separately disclosed in the statement of cash flows, for example, deferred expenses, intangible assets, or income taxes.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of cash inflow (outflow) of financing activities, excluding discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 24<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3521-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 26<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3574-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of cash inflow (outflow) of investing activities, excluding discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 24<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3521-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 26<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3574-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 24<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3521-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 25<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3536-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Other Comprehensive Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6519514<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Net Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6518256<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.19)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.18)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.22)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 19<br><br> -Article 5<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 20<br><br> -Article 9<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1A<br><br> -URI http://asc.fasb.org/extlink&amp;oid=18733093&amp;loc=SL4573702-111684<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -Section 55<br><br> -Paragraph 4J<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35736750&amp;loc=SL4591551-111686<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForCapitalImprovements">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash outflow for acquisition of or capital improvements to properties held for investment (operating, managed, leased) or for use.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Investing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 13<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3213-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PaymentsForCapitalImprovements</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Investing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 13<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3213-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow from the additional capital contribution to the entity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 14<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3255-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholders and which takes precedence over common stockholders in the event of liquidation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 14<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3255-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromMinorityShareholders">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of cash inflow from a noncontrolling interest. Includes, but is not limited to, purchase of additional shares or other increase in noncontrolling interest ownership.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 14<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3255-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ProceedsFromMinorityShareholders</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Investing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 12<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3179-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfTreasuryStock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow from the issuance of an equity stock that has been previously reacquired by the entity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 14<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3255-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfTreasuryStock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow associated with the amount received from holders exercising their stock options. This item inherently excludes any excess tax benefit, which the entity may have realized and reported separately.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (j)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 14<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3255-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0E1E">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Segment Information (Details)<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2015

</div>
          <div>Segment</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Information [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments</a></td>
        <td class="nump"><a title="us-gaap_NumberOfOperatingSegments" onclick="toggleNextSibling(this);">1</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NumberOfOperatingSegments</span><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:integerItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Intangible assets, net (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2015</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Intangible assets, net [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock', window );">Intangible assets</a></td>
        <td class="text"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; text-indent: 36pt;">At March 31, 2015 and December 31, 2014, intangible assets and intangible assets net of amortization were comprised of the following:</div><div><br /></div><table cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 100%;"><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" style="vertical-align: bottom; white-space: nowrap; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; text-align: center;">March 31, 2015</div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; text-align: center;">(Unaudited)</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; text-align: center;">December 31,</div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; text-align: center;">2014</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td></tr><tr><td valign="bottom" style="width: 76%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Intangible assets</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">52,562,549</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">52,562,549</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="width: 76%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Accumulated amortization</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">(15,028,247</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">(13,714,153</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">)</div></td></tr><tr><td valign="bottom" style="width: 76%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Intangible assets, net</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">37,534,302</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">38,848,396</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;">&#160;</td></tr></table></div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 350<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16265-109275<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 350<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16323-109275<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EMNBG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Subsequent Events (Details) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="2">3 Months Ended</th>
        <th class="th" colspan="2">0 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2015</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2014</div>
        </th>
        <th class="th">
          <div>Apr. 30, 2015</div>
        </th>
        <th class="th">
          <div>May 08, 2015

</div>
          <div>Investor</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromGrants', window );">Revenue from grants</a></td>
        <td class="nump"><a title="us-gaap_RevenueFromGrants" onclick="toggleNextSibling(this);">$ 698,839</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_RevenueFromGrants</span><span></span></td>
        <td class="nump"><a title="us-gaap_RevenueFromGrants" onclick="toggleNextSibling(this);">$ 575,659</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_RevenueFromGrants</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Asterias Biotherapeutics [Member] | CIRM [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromGrants', window );">Revenue from grants</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_RevenueFromGrants[dei_LegalEntityAxis=btx_AsteriasBiotherapeuticsMember;us-gaap_MajorCustomersAxis=btx_CaliforniaInstituteOfRegenerativeMedicineMember;us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember]" onclick="toggleNextSibling(this);">1,062,023</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_RevenueFromGrants<br>/ dei_LegalEntityAxis<br>= btx_AsteriasBiotherapeuticsMember<br>/ us-gaap_MajorCustomersAxis<br>= btx_CaliforniaInstituteOfRegenerativeMedicineMember<br>/ us-gaap_SubsequentEventTypeAxis<br>= us-gaap_SubsequentEventMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrantsReceivable', window );">Grants receivable</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_GrantsReceivable[dei_LegalEntityAxis=btx_AsteriasBiotherapeuticsMember;us-gaap_MajorCustomersAxis=btx_CaliforniaInstituteOfRegenerativeMedicineMember;us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember]" onclick="toggleNextSibling(this);">14,300,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_GrantsReceivable<br>/ dei_LegalEntityAxis<br>= btx_AsteriasBiotherapeuticsMember<br>/ us-gaap_MajorCustomersAxis<br>= btx_CaliforniaInstituteOfRegenerativeMedicineMember<br>/ us-gaap_SubsequentEventTypeAxis<br>= us-gaap_SubsequentEventMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | OncoCyte Corporation [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock, number of shares issued in transaction (in shares)</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction[dei_LegalEntityAxis=btx_OncocyteCorporationMember;us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember]" onclick="toggleNextSibling(this);">3,000,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction<br>/ dei_LegalEntityAxis<br>= btx_OncocyteCorporationMember<br>/ us-gaap_SubsequentEventTypeAxis<br>= us-gaap_SubsequentEventMember</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_NumberOfInvestors', window );">Sale of stock, number of shareholders</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="btx_NumberOfInvestors[dei_LegalEntityAxis=btx_OncocyteCorporationMember;us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember]" onclick="toggleNextSibling(this);">2</a><span style="display:none;white-space:normal;text-align:left;">btx_NumberOfInvestors<br>/ dei_LegalEntityAxis<br>= btx_OncocyteCorporationMember<br>/ us-gaap_SubsequentEventTypeAxis<br>= us-gaap_SubsequentEventMember</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedPerTransaction', window );">Sale of stock consideration received</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_SaleOfStockConsiderationReceivedPerTransaction[dei_LegalEntityAxis=btx_OncocyteCorporationMember;us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember]" onclick="toggleNextSibling(this);">3,300,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_SaleOfStockConsiderationReceivedPerTransaction<br>/ dei_LegalEntityAxis<br>= btx_OncocyteCorporationMember<br>/ us-gaap_SubsequentEventTypeAxis<br>= us-gaap_SubsequentEventMember</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Common stock purchased in exchange for cancelation of indebtedness (in shares)</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_DebtConversionConvertedInstrumentSharesIssued1[dei_LegalEntityAxis=btx_OncocyteCorporationMember;us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember]" onclick="toggleNextSibling(this);">3,000,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DebtConversionConvertedInstrumentSharesIssued1<br>/ dei_LegalEntityAxis<br>= btx_OncocyteCorporationMember<br>/ us-gaap_SubsequentEventTypeAxis<br>= us-gaap_SubsequentEventMember</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Common stock purchased in exchange for cancelation of indebtedness, value</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_DebtConversionConvertedInstrumentAmount1[dei_LegalEntityAxis=btx_OncocyteCorporationMember;us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember]" onclick="toggleNextSibling(this);">3,300,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DebtConversionConvertedInstrumentAmount1<br>/ dei_LegalEntityAxis<br>= btx_OncocyteCorporationMember<br>/ us-gaap_SubsequentEventTypeAxis<br>= us-gaap_SubsequentEventMember</span><span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | OncoCyte Corporation [Member] | George Karfunkel [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock, number of shares issued in transaction (in shares)</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction[dei_LegalEntityAxis=btx_OncocyteCorporationMember;us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_MajorityShareholderMember;us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember]" onclick="toggleNextSibling(this);">1,000,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction<br>/ dei_LegalEntityAxis<br>= btx_OncocyteCorporationMember<br>/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis<br>= us-gaap_MajorityShareholderMember<br>/ us-gaap_SubsequentEventTypeAxis<br>= us-gaap_SubsequentEventMember</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership percentage on outstanding common shares (in hundredths)</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_EquityMethodInvestmentOwnershipPercentage[dei_LegalEntityAxis=btx_OncocyteCorporationMember;us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_MajorityShareholderMember;us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember]" onclick="toggleNextSibling(this);">5.00%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_EquityMethodInvestmentOwnershipPercentage<br>/ dei_LegalEntityAxis<br>= btx_OncocyteCorporationMember<br>/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis<br>= us-gaap_MajorityShareholderMember<br>/ us-gaap_SubsequentEventTypeAxis<br>= us-gaap_SubsequentEventMember</span><span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | OncoCyte Corporation [Member] | Convertible Promissory Note [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Common stock purchased in exchange for cancelation of indebtedness, value</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_DebtConversionConvertedInstrumentAmount1[us-gaap_DebtInstrumentAxis=us-gaap_ConvertibleNotesPayableMember;dei_LegalEntityAxis=btx_OncocyteCorporationMember;us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember]" onclick="toggleNextSibling(this);">$ 3,300,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DebtConversionConvertedInstrumentAmount1<br>/ us-gaap_DebtInstrumentAxis<br>= us-gaap_ConvertibleNotesPayableMember<br>/ dei_LegalEntityAxis<br>= btx_OncocyteCorporationMember<br>/ us-gaap_SubsequentEventTypeAxis<br>= us-gaap_SubsequentEventMember</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt instrument interest rate (in hundredths)</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_DebtInstrumentInterestRateStatedPercentage[us-gaap_DebtInstrumentAxis=us-gaap_ConvertibleNotesPayableMember;dei_LegalEntityAxis=btx_OncocyteCorporationMember;us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember]" onclick="toggleNextSibling(this);">1.00%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DebtInstrumentInterestRateStatedPercentage<br>/ us-gaap_DebtInstrumentAxis<br>= us-gaap_ConvertibleNotesPayableMember<br>/ dei_LegalEntityAxis<br>= btx_OncocyteCorporationMember<br>/ us-gaap_SubsequentEventTypeAxis<br>= us-gaap_SubsequentEventMember</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Debt instrument maturity date</a></td>
        <td class="text">Nov. 30,  2016<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Debt instrument conversion price (in hundredths)</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_DebtInstrumentConvertibleConversionPrice1[us-gaap_DebtInstrumentAxis=us-gaap_ConvertibleNotesPayableMember;dei_LegalEntityAxis=btx_OncocyteCorporationMember;us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember]" onclick="toggleNextSibling(this);">$ 1.10</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DebtInstrumentConvertibleConversionPrice1<br>/ us-gaap_DebtInstrumentAxis<br>= us-gaap_ConvertibleNotesPayableMember<br>/ dei_LegalEntityAxis<br>= btx_OncocyteCorporationMember<br>/ us-gaap_SubsequentEventTypeAxis<br>= us-gaap_SubsequentEventMember</span><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btx_NumberOfInvestors">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Refers to number of investors.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">btx_NumberOfInvestors</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>btx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:integerItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentAmount1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4332-108586<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4304-108586<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentAmount1</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or payments in the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4332-108586<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4304-108586<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentSharesIssued1</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The price per share of the conversion feature embedded in the debt instrument.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 470<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 5<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928298&amp;loc=SL6031898-161870<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Contractual interest rate for funds borrowed, under the debt agreement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 22<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.22(a)(1))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Date when the debt instrument is scheduled to be fully repaid, in CCYY-MM-DD format.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 22<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.22(a)(2))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DebtInstrumentMaturityDate</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:dateItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 323<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -Subparagraph (a)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6382943&amp;loc=d3e33918-111571<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrantsReceivable">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying amount as of the balance sheet date of amounts due under the terms of governmental, corporate, or foundation grants.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.8)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 8<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_GrantsReceivable</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromGrants">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Revenue earned during the period from non-repayable sum of money awarded to an entity to carry out a specific purpose as provided in grant agreements.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.1(e))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_RevenueFromGrants</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedPerTransaction">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of consideration received by subsidiary or equity investee in exchange for shares of stock issued or sold. Includes amount of cash received, fair value of noncash assets received, and fair value of liabilities assumed by the investor.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedPerTransaction</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Accounts Payable and Accrued Liabilities (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2015</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Accounts Payable and Accrued Liabilities [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock', window );">Accounts payable and accrued liabilities</a></td>
        <td class="text"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; text-indent: 36pt;">At March 31, 2015 and December 31, 2014, accounts payable and accrued liabilities consisted of the following:</div><div><br /></div><table cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 100%;"><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" style="vertical-align: bottom; white-space: nowrap; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; text-align: center;">March 31, 2015</div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; text-align: center;">(Unaudited)</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; text-align: center;">December 31,</div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; text-align: center;">2014</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td></tr><tr><td valign="bottom" style="width: 76%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Accounts payable</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">2,707,437</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">2,296,645</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="width: 76%; vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Accrued expenses</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">3,092,030</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">3,125,023</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="width: 76%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Accrued bonuses</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">240,689</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">964,189</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="width: 76%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Other current liabilities</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">282,251</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">417,316</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="width: 76%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Total</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">6,322,407</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">6,803,173</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;">&#160;</td></tr></table></div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/**
 * Rivet Software Inc.
 *
 * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved.
 * Version 2.4.0.3
 *
 */

var Show = {};
Show.LastAR = null,

Show.hideAR = function(){
	Show.LastAR.style.display = 'none';
};

Show.showAR = function ( link, id, win ){
	if( Show.LastAR ){
		Show.hideAR();
	}

	var ref = link;
	do {
		ref = ref.nextSibling;
	} while (ref && ref.nodeName != 'TABLE');

	if (!ref || ref.nodeName != 'TABLE') {
		var tmp = win ?
			win.document.getElementById(id) :
			document.getElementById(id);

		if( tmp ){
			ref = tmp.cloneNode(true);
			ref.id = '';
			link.parentNode.appendChild(ref);
		}
	}

	if( ref ){
		ref.style.display = 'block';
		Show.LastAR = ref;
	}
};

Show.toggleNext = function( link ){
	var ref = link;

	do{
		ref = ref.nextSibling;
	}while( ref.nodeName != 'DIV' );

	if( ref.style &&
		ref.style.display &&
		ref.style.display == 'none' ){
		ref.style.display = 'block';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '+', '-' );
		}else{
			link.innerText = link.innerText.replace( '+', '-' );
		}
	}else{
		ref.style.display = 'none';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '-', '+' );
		}else{
			link.innerText = link.innerText.replace( '-', '+' );
		}
	}
};
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Organization, Basis of Presentation, and Liquidity<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2015</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Basis of Presentation, and Liquidity [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Organization, Basis of Presentation, and Liquidity</a></td>
        <td class="text"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="text-align: justify;"><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 100%;"><tr><td style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 18pt; vertical-align: top; font-weight: bold; align: right;">1.</td><td style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: auto; vertical-align: top; font-weight: bold; text-align: justify;">Organization, Basis of Presentation, and Liquidity</td></tr></table></div><div style="text-align: justify;"><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; margin-left: 0.1pt; margin-right: 0.1pt; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;">General &#8211; </font><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">BioTime is a biotechnology company focused on the field of regenerative medicine; specifically human embryonic stem (&#8220;hES&#8221;) cell and induced pluripotent stem (&#8220;iPS&#8221;) cell technology. Regenerative medicine refers to therapies based on stem cell technology that are designed to rebuild cell and tissue function lost due to degenerative disease or injury. hES and iPS cells provide a means of manufacturing every cell type in the human body and therefore show considerable promise for the development of a number of new therapeutic products. BioTime and its subsidiaries are developing stem cell products for research and therapeutic use. BioTime&#8217;s primary therapeutic products are based on its </font><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;">HyStem</font><sup style="font-size: smaller; vertical-align: text-top; line-height: 1;">&#174;</sup><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> hydrogel technology and include </font><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;">Renevia</font><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">&#8482; a product currently in clinical trials in Europe to facilitate cell transplantation; </font><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;">ReGlyde</font><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">&#8482; a product under development for tendon surgery applications; and </font><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;">Premvia</font><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">&#8482; for which 510(k) certification has been received for use in wound-management. Asterias Biotherapeutics, Inc. (&#8220;Asterias,&#8221; </font>NYSE MKT: AST<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">) is developing pluripotent stem-cell based therapies in neurology and oncology, including AST-OPC1 neural cells in spinal cord injury, and AST-VAC2, a pluripotent stem cell-derived cancer vaccine. OncoCyte Corporation (&#8220;OncoCyte&#8221;) is developing products and technologies to diagnose cancer. ES Cell International Pte Ltd. (&#8220;ESI&#8221;), a Singapore private limited company, is providing its National Institutes of Health (&#8220;NIH&#8221;) approved hES cell lines, manufactured under current good manufacturing practices (&#8216;cGMP&#8221;), to pre-researchers focused on clinical applications through BioTime&#8217;s </font><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;">ESI BIO</font><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> division. OrthoCyte Corporation (&#8220;OrthoCyte&#8221;) is developing therapies to treat orthopedic disorders, diseases and injuries. ReCyte Therapeutics, Inc. (&#8220;ReCyte Therapeutics&#8221;) is developing therapies to treat a variety of cardiovascular and related ischemic disorders, as well as related products for research. Cell Cure Neurosciences Ltd. (&#8220;Cell Cure Neurosciences&#8221;) is an Israel-based biotechnology company focused on developing stem cell-based therapies for retinal and neurological disorders, including the development of retinal pigment epithelial cells for the treatment of macular degeneration. Research products and services are marketed through LifeMap Sciences Inc. and BioTime&#8217;s </font><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;">ESI BIO</font><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> division. LifeMap Sciences, Inc. (&#8220;LifeMap Sciences&#8221;) markets, sells and distributes </font><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;">GeneCards</font><sup style="font-size: smaller; vertical-align: text-top; line-height: 1;">&#174;</sup><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">, the leading human gene database and an integrated database suite that includes </font><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;">GeneCards</font><sup style="font-size: smaller; vertical-align: text-top; line-height: 1;">&#174;</sup><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">, the </font><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;">LifeMap Discovery</font><sup style="font-size: smaller; vertical-align: text-top; line-height: 1;">&#174;</sup><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> database of embryonic development, stem cell research and regenerative medicine, and </font><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;">MalaCards</font><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">&#8482;, the human disease database, and the analysis tools </font><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;">VarElect</font><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">&#8482;, a powerful, yet easy-to-use application for prioritizing gene variants resulting from next generation sequencing experiments, and </font><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;">GeneAnalytics</font><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">&#8482;, a novel gene set analysis tool. LifeMap Sciences&#8217; subsidiary LifeMap Solutions, Inc. (&#8220;LifeMap Solutions&#8221;) is developing mobile health software products in partnership with the Icahn Institute for Genomics and Multiscale Biology.</font></div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; margin-left: 0.1pt; margin-right: 0.1pt; text-indent: 36pt;">BioTime is focusing a portion of its efforts in the field of regenerative medicine on the development and sale of advanced human stem cell products and technologies that can be used by researchers at universities and other institutions, at companies in the bioscience and biopharmaceutical industries, and at other companies that provide research products to companies in those industries. These products are developed internally or in conjunction with BioTime&#8217;s subsidiaries and marketed through BioTime&#8217;s <font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;">ESI BIO</font> division. Products for the research market generally can be sold without regulatory (United States Food and Drug Administration (&#8220;FDA&#8221;)) approval, and are therefore relatively near-term business opportunities when compared to therapeutic products.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; text-indent: 36pt;">BioTime previously developed blood plasma volume expanders and related technology for use in surgery, emergency trauma treatment and other applications. BioTime&#8217;s operating revenues are now derived primarily from research grants, from licensing fees and advertising from the marketing of the LifeMap Sciences database products, and from the sale of products for research.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; text-indent: 36pt;">The unaudited condensed consolidated interim balance sheet as of March 31, 2015, the unaudited condensed consolidated interim statements of operations and statements of comprehensive loss for the three months ended March 31, 2015 and 2014, and the unaudited condensed consolidated interim statements of cash flows for the three months ended March 31, 2015 and 2014 have been prepared by BioTime&#8217;s management in accordance with the instructions from Form 10-Q and Regulation S-X. In the opinion of management, all adjustments (consisting only of normal recurring adjustments) necessary to present fairly the financial position, results of operations, and cash flows at March 31, 2015 have been made. The consolidated balance sheet as of December 31, 2014 is derived from the Company&#8217;s annual audited financial statements as of that date. The results of operations for the three months ended March 31, 2015 are not necessarily indicative of the operating results anticipated for the full year of 2015.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; text-indent: 36pt;">Certain information and footnote disclosures normally included in consolidated financial statements prepared in accordance with U.S. generally accepted accounting principles have been condensed or omitted as permitted by regulations of the Securities and Exchange Commission (&#8220;SEC&#8221;) except for the consolidated balance sheet as of December 31, 2014, which was derived from audited financial statements. Certain previously furnished amounts have been reclassified to conform with presentations made during the current periods. It is suggested that these condensed consolidated interim financial statements be read in conjunction with the annual audited consolidated financial statements and notes thereto included in BioTime&#8217;s Annual Report on Form 10-K for the year ended December 31, 2014.</div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; text-indent: 36pt;">&#160;</div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;">Use of estimates</font> &#8211; The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the U.S. ("GAAP") requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;">Principles of consolidation</font> &#8211; BioTime&#8217;s consolidated financial statements include the accounts of its subsidiaries. The following table reflects BioTime&#8217;s ownership, directly or through one or more subsidiaries, of the outstanding shares of its subsidiaries as of March 31, 2015.</div><div><br /></div><table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 100%; border-collapse: collapse;"><tr><td style="border-top: #000000 2px solid; width: 23.28%; vertical-align: top; border-left: #000000 2px solid;"><div style="text-align: left;">&#160;</div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; text-align: center;">Subsidiary</div></td><td style="border-top: #000000 2px solid; width: 57%; vertical-align: top; border-left: #000000 2px solid;"><div style="text-align: left;">&#160;</div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; text-align: center;">Field of Business</div></td><td style="border-top: #000000 2px solid; width: 10%; vertical-align: top; border-left: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;">BioTime</div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;">Ownership</div></td><td style="border-top: #000000 2px solid; border-right: #000000 2px solid; width: 10%; vertical-align: top; border-left: #000000 2px solid;"><div style="text-align: left;">&#160;</div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; text-align: center;">Country</div></td></tr><tr><td style="border-top: #000000 2px solid; width: 23.28%; vertical-align: top; border-left: #000000 2px solid; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; margin-left: 7.7pt; text-indent: -7.7pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">Asterias Biotherapeutics, Inc. (</font>NYSE MKT: AST)</div></td><td style="border-top: #000000 2px solid; width: 57%; vertical-align: top; border-left: #000000 2px solid; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;">Research, development and commercialization of human therapeutic products from stem cells, focused initially in the fields of neurology and oncology</div></td><td style="border-top: #000000 2px solid; width: 10%; vertical-align: top; border-left: #000000 2px solid; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;">67.5%</div></td><td style="border-top: #000000 2px solid; border-right: #000000 2px solid; width: 10%; vertical-align: top; border-left: #000000 2px solid; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;">USA</div></td></tr><tr><td style="border-top: #000000 2px solid; width: 23.28%; vertical-align: top; border-left: #000000 2px solid; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; margin-left: 7.7pt; text-indent: -7.7pt;">BioTime Asia, Limited</div></td><td style="border-top: #000000 2px solid; width: 57%; vertical-align: top; border-left: #000000 2px solid; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;">Stem cell products for research</div></td><td style="border-top: #000000 2px solid; width: 10%; vertical-align: top; border-left: #000000 2px solid; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;">81%</div></td><td style="border-top: #000000 2px solid; border-right: #000000 2px solid; width: 10%; vertical-align: top; border-left: #000000 2px solid; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;">Hong Kong</div></td></tr><tr><td style="border-top: #000000 2px solid; width: 23.28%; vertical-align: top; border-left: #000000 2px solid; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; margin-left: 7.7pt; text-indent: -7.7pt;">Cell Cure Neurosciences Ltd.</div></td><td style="border-top: #000000 2px solid; width: 57%; vertical-align: top; border-left: #000000 2px solid; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;">Age-related macular degeneration</div></td><td style="border-top: #000000 2px solid; width: 10%; vertical-align: top; border-left: #000000 2px solid; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;">62.5%(1)</div></td><td style="border-top: #000000 2px solid; border-right: #000000 2px solid; width: 10%; vertical-align: top; border-left: #000000 2px solid; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;">Israel</div></td></tr><tr><td style="border-top: #000000 2px solid; width: 23.28%; vertical-align: top; border-left: #000000 2px solid; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; margin-left: 7.7pt; text-indent: -7.7pt;">ES Cell International Pte Ltd</div></td><td style="border-top: #000000 2px solid; width: 57%; vertical-align: top; border-left: #000000 2px solid; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;">Stem cell products for research, including clinical grade cell lines produced under cGMP</div></td><td style="border-top: #000000 2px solid; width: 10%; vertical-align: top; border-left: #000000 2px solid; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;">100%</div></td><td style="border-top: #000000 2px solid; border-right: #000000 2px solid; width: 10%; vertical-align: top; border-left: #000000 2px solid; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;">Singapore</div></td></tr><tr><td style="border-top: #000000 2px solid; width: 23.28%; vertical-align: top; border-left: #000000 2px solid; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; margin-left: 7.7pt; text-indent: -7.7pt;">LifeMap Sciences, Inc.</div></td><td style="border-top: #000000 2px solid; width: 57%; vertical-align: top; border-left: #000000 2px solid; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;">Biomedical, gene, disease, and stem cell databases and tools</div></td><td style="border-top: #000000 2px solid; width: 10%; vertical-align: top; border-left: #000000 2px solid; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;">75.8%</div></td><td style="border-top: #000000 2px solid; border-right: #000000 2px solid; width: 10%; vertical-align: top; border-left: #000000 2px solid; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;">USA</div></td></tr><tr><td style="border-top: #000000 2px solid; width: 23.28%; vertical-align: top; border-left: #000000 2px solid; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; margin-left: 7.7pt; text-indent: -7.7pt;">LifeMap Sciences, Ltd.</div></td><td style="border-top: #000000 2px solid; width: 57%; vertical-align: top; border-left: #000000 2px solid; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;">Biomedical, gene, disease, and stem cell databases and tools</div></td><td style="border-top: #000000 2px solid; width: 10%; vertical-align: top; border-left: #000000 2px solid; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;">(2)</div></td><td style="border-top: #000000 2px solid; border-right: #000000 2px solid; width: 10%; vertical-align: top; border-left: #000000 2px solid; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;">Israel</div></td></tr><tr><td style="border-top: #000000 2px solid; width: 23.28%; vertical-align: top; border-left: #000000 2px solid; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; margin-left: 7.7pt; text-indent: -7.7pt;">LifeMap Solutions, Inc.</div></td><td style="border-top: #000000 2px solid; width: 57%; vertical-align: top; border-left: #000000 2px solid; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;">Mobile health software</div></td><td style="border-top: #000000 2px solid; width: 10%; vertical-align: top; border-left: #000000 2px solid; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;">(2)</div></td><td style="border-top: #000000 2px solid; border-right: #000000 2px solid; width: 10%; vertical-align: top; border-left: #000000 2px solid; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;">USA</div></td></tr><tr><td style="border-top: #000000 2px solid; width: 23.28%; vertical-align: top; border-left: #000000 2px solid; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; margin-left: 7.7pt; text-indent: -7.7pt;">OncoCyte Corporation</div></td><td style="border-top: #000000 2px solid; width: 57%; vertical-align: top; border-left: #000000 2px solid; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;">Cancer diagnostics</div></td><td style="border-top: #000000 2px solid; width: 10%; vertical-align: top; border-left: #000000 2px solid; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;">75.3%</div></td><td style="border-top: #000000 2px solid; border-right: #000000 2px solid; width: 10%; vertical-align: top; border-left: #000000 2px solid; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;">USA</div></td></tr><tr><td style="border-top: #000000 2px solid; width: 23.28%; vertical-align: top; border-left: #000000 2px solid; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; margin-left: 7.7pt; text-indent: -7.7pt;">OrthoCyte Corporation</div></td><td style="border-top: #000000 2px solid; width: 57%; vertical-align: top; border-left: #000000 2px solid; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;">Orthopedic diseases, including chronic back pain and osteoarthritis</div></td><td style="border-top: #000000 2px solid; width: 10%; vertical-align: top; border-left: #000000 2px solid; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;">100%(3)</div></td><td style="border-top: #000000 2px solid; border-right: #000000 2px solid; width: 10%; vertical-align: top; border-left: #000000 2px solid; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;">USA</div></td></tr><tr><td style="border-top: #000000 2px solid; width: 23.28%; vertical-align: top; border-bottom: #000000 2px solid; border-left: #000000 2px solid; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; margin-left: 7.7pt; text-indent: -7.7pt;">ReCyte Therapeutics, Inc.</div></td><td style="border-top: #000000 2px solid; width: 57%; vertical-align: top; border-bottom: #000000 2px solid; border-left: #000000 2px solid; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;">Vascular disorders, including cardiovascular-related diseases, ischemic conditions, vascular injuries</div><div>&#160;</div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;">Stem cell-derived endothelial and cardiovascular related progenitor cells that have applications in research, drug testing, and therapeutics</div></td><td style="border-top: #000000 2px solid; width: 10%; vertical-align: top; border-bottom: #000000 2px solid; border-left: #000000 2px solid; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;">94.8%</div></td><td style="border-top: #000000 2px solid; border-right: #000000 2px solid; width: 10%; vertical-align: top; border-bottom: #000000 2px solid; border-left: #000000 2px solid; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;">USA</div></td></tr></table><div><br /></div><div style="text-align: left;"><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 100%;"><tr><td style="width: 18pt;"></td><td style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 18pt; vertical-align: top; align: right;">(1)</td><td style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: auto; vertical-align: top; text-align: left;">Includes shares owned by <font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">BioTime, Asterias, and ESI.</font></td></tr></table></div><div style="text-align: left;"><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 100%;"><tr><td style="width: 18pt;"></td><td style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 18pt; vertical-align: top; align: right;">(2)</td><td style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: auto; vertical-align: top; text-align: left;">LifeMap Sciences, Ltd. and LifeMap Solutions, Inc. are wholly-owned subsidiaries of LifeMap Sciences, Inc.</td></tr></table></div><div style="text-align: left;"><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 100%;"><tr><td style="width: 18pt;"></td><td style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 18pt; vertical-align: top; align: right;">(3)</td><td style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: auto; vertical-align: top; text-align: left;">Includes shares owned by BioTime and Asterias.</td></tr></table></div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; text-indent: 36pt;">All material intercompany accounts and transactions have been eliminated in consolidation. The consolidated financial statements are presented in accordance with GAAP and with the accounting and reporting requirements of SEC Regulation S-X. As of March 31, 2015, BioTime consolidated Asterias, ReCyte Therapeutics, OncoCyte, OrthoCyte, ESI, Cell Cure Neurosciences, BioTime Asia, Limited (&#8220;BioTime Asia&#8221;), LifeMap Sciences, LifeMap Sciences, Ltd., and LifeMap Solutions, Inc. as BioTime has the ability to control their operating and financial decisions and policies through its ownership, and the non-controlling interest is reflected as a separate element of shareholders' equity on BioTime&#8217;s consolidated balance sheets.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;">Liquidity</font> &#8211; Since inception, BioTime has incurred significant operating losses and has funded its operations primarily through the issuance of equity securities, payments from research grants, royalties from product sales and sales of research products and services. At March 31, 2015, BioTime had an accumulated deficit of $192,357,575, working capital of $20,341,461 and shareholders&#8217; equity of $57,511,784. BioTime has evaluated its projected cash flows for it and its subsidiaries and believes that its cash and cash equivalents of $25,829,533 as of March 31, 2015, will be sufficient to fund its operations at least through 2015. However, clinical trials being conducted by BioTime&#8217;s subsidiaries, Asterias and Cell Cure Neurosciences will be funded in part with funds from grants and not from cash on hand. If Asterias or Cell Cure Neurosciences were to lose its grant funding it may be required to delay, postpone, or cancel its clinical trials or limit the number of clinical trial sites, or otherwise reduce or curtail its operations unless it is able to obtain from another source adequate financing that could be used for its clinical trial.</div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; text-indent: 36pt;">&#160;</div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;">Certain significant risks and uncertainties</font> &#8211; The operations of BioTime and its subsidiaries are subject to a number of factors that can affect their operating results and financial condition. Such factors include but are not limited to, the following: the results of clinical trials of their respective therapeutic product and medical device candidates; their ability to obtain FDA and foreign regulatory approval to market their respective therapeutic and medical device product candidates; their ability to develop new stem cell research products and technologies; competition from products manufactured and sold or being developed by other companies; the price and demand for their products; their ability to obtain additional financing and the terms of any such financing that may be obtained; their ability to negotiate favorable licensing or other manufacturing and marketing agreements for their products; the availability of ingredients used in their products; and the availability of reimbursement for the cost of their therapeutic and diagnostic products and medical devices (and related treatment) from government health administration authorities, private health coverage insurers, and other organizations.</div></div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 205<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35735333&amp;loc=d3e288-107754<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=18733093&amp;loc=d3e5614-111684<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 915<br><br> -SubTopic 235<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6472506&amp;loc=d3e38932-110933<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 272<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6373374&amp;loc=d3e70478-108055<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 205<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6359566&amp;loc=d3e326-107755<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EBAAE">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) (USD $)<br></strong></div>
        </th>
        <th class="th">
          <div>Mar. 31, 2015</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract', window );"><strong>SHAREHOLDERS' EQUITY</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockNoParValue', window );">Series A Convertible Preferred Shares, par value (in dollars per share)</a></td>
        <td class="nump"><a title="us-gaap_PreferredStockNoParValue" onclick="toggleNextSibling(this);">$ 0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PreferredStockNoParValue</span><span></span></td>
        <td class="nump"><a title="us-gaap_PreferredStockNoParValue" onclick="toggleNextSibling(this);">$ 0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PreferredStockNoParValue</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Series A Convertible Preferred Shares, authorized (in shares)</a></td>
        <td class="nump"><a title="us-gaap_PreferredStockSharesAuthorized" onclick="toggleNextSibling(this);">2,000,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PreferredStockSharesAuthorized</span><span></span></td>
        <td class="nump"><a title="us-gaap_PreferredStockSharesAuthorized" onclick="toggleNextSibling(this);">2,000,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PreferredStockSharesAuthorized</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Series A Convertible Preferred Shares, issued (in shares)</a></td>
        <td class="nump"><a title="us-gaap_PreferredStockSharesIssued" onclick="toggleNextSibling(this);">70,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PreferredStockSharesIssued</span><span></span></td>
        <td class="nump"><a title="us-gaap_PreferredStockSharesIssued" onclick="toggleNextSibling(this);">70,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PreferredStockSharesIssued</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Series A Convertible Preferred shares outstanding (in shares)</a></td>
        <td class="nump"><a title="us-gaap_PreferredStockSharesOutstanding" onclick="toggleNextSibling(this);">70,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PreferredStockSharesOutstanding</span><span></span></td>
        <td class="nump"><a title="us-gaap_PreferredStockSharesOutstanding" onclick="toggleNextSibling(this);">70,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PreferredStockSharesOutstanding</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockNoParValue', window );">Common shares, par value (in dollars per share)</a></td>
        <td class="nump"><a title="us-gaap_CommonStockNoParValue" onclick="toggleNextSibling(this);">$ 0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CommonStockNoParValue</span><span></span></td>
        <td class="nump"><a title="us-gaap_CommonStockNoParValue" onclick="toggleNextSibling(this);">$ 0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CommonStockNoParValue</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common shares, authorized (in shares)</a></td>
        <td class="nump"><a title="us-gaap_CommonStockSharesAuthorized" onclick="toggleNextSibling(this);">125,000,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CommonStockSharesAuthorized</span><span></span></td>
        <td class="nump"><a title="us-gaap_CommonStockSharesAuthorized" onclick="toggleNextSibling(this);">125,000,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CommonStockSharesAuthorized</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common shares, issued (in shares)</a></td>
        <td class="nump"><a title="us-gaap_CommonStockSharesIssued" onclick="toggleNextSibling(this);">83,210,775</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CommonStockSharesIssued</span><span></span></td>
        <td class="nump"><a title="us-gaap_CommonStockSharesIssued" onclick="toggleNextSibling(this);">83,121,698</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CommonStockSharesIssued</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common shares, outstanding (in shares)</a></td>
        <td class="nump"><a title="us-gaap_CommonStockSharesOutstanding" onclick="toggleNextSibling(this);">78,316,833</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CommonStockSharesOutstanding</span><span></span></td>
        <td class="nump"><a title="us-gaap_CommonStockSharesOutstanding" onclick="toggleNextSibling(this);">78,227,756</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CommonStockSharesOutstanding</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockShares', window );">Treasury stock (in shares)</a></td>
        <td class="nump"><a title="us-gaap_TreasuryStockShares" onclick="toggleNextSibling(this);">4,893,942</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_TreasuryStockShares</span><span></span></td>
        <td class="nump"><a title="us-gaap_TreasuryStockShares" onclick="toggleNextSibling(this);">4,893,942</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_TreasuryStockShares</span><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockNoParValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Face amount per share of no-par value common stock.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CommonStockNoParValue</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockNoParValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Face amount per share of no-par value preferred stock nonredeemable or redeemable solely at the option of the issuer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PreferredStockNoParValue</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockShares">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28,29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_TreasuryStockShares</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Segment Information<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2015</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Information [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">Segment Information</a></td>
        <td class="text"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="text-align: left;"><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 100%;"><tr><td style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 18pt; vertical-align: top; font-weight: bold; align: right;">11.</td><td style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: auto; vertical-align: top; font-weight: bold; text-align: left;">Segment Information</td></tr></table></div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; text-indent: 36pt;">BioTime's executive management team, as a group, represents the entity's chief operating decision makers. To date, BioTime&#8217;s executive management team has viewed BioTime&#8217;s operations as one segment that includes, the research and development of therapeutic products for oncology, orthopedics, retinal and neurological diseases and disorders, blood and vascular system diseases and disorders, blood plasma volume expansion, diagnostic products for the early detection of cancer, and hydrogel products that may be used in surgery, and products for human embryonic stem cell research. As a result, the financial information disclosed materially represents all of the financial information related to BioTime&#8217;s sole operating segment.</div></div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 280<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 29<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6534315&amp;loc=d3e8864-108599<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 280<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 32<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6534315&amp;loc=d3e8933-108599<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 280<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 26<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6534315&amp;loc=d3e8844-108599<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 280<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 10<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6534315&amp;loc=d3e8538-108599<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 280<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6534315&amp;loc=d3e8380-108599<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 280<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 34<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6534315&amp;loc=d3e8981-108599<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 280<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 35<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6534315&amp;loc=d3e8984-108599<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 280<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 41<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6534315&amp;loc=d3e9038-108599<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 280<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 30<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6534315&amp;loc=d3e8906-108599<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 280<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 42<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6534315&amp;loc=d3e9054-108599<br><br><br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 280<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 31<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6534315&amp;loc=d3e8924-108599<br><br><br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 280<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 40<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6534315&amp;loc=d3e9031-108599<br><br><br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 280<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 33<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6534315&amp;loc=d3e8971-108599<br><br><br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 280<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 12<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6534315&amp;loc=d3e8595-108599<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0E1GAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Document and Entity Information<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
        <th class="th" colspan="1"></th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2015</div>
        </th>
        <th class="th">
          <div>May 01, 2015</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_DocumentAndEntityInformationAbstract', window );"><strong>Document and Entity Information [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
        <td class="text">BIOTIME INC<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
        <td class="text">0000876343<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
        <td class="text">--12-31<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
        <td class="text">No<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
        <td class="text">No<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
        <td class="text">Yes<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
        <td class="text">Accelerated Filer<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="dei_EntityCommonStockSharesOutstanding" onclick="toggleNextSibling(this);">83,266,153</a><span style="display:none;white-space:normal;text-align:left;">dei_EntityCommonStockSharesOutstanding</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
        <td class="text">2015<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
        <td class="text">Q1<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
        <td class="text">10-Q<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
        <td class="text">false<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
        <td class="text">Mar. 31,  2015<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btx_DocumentAndEntityInformationAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">btx_DocumentAndEntityInformationAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>btx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>If the value is true, then the document is an amendment to previously-filed/accepted document.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">dei_AmendmentFlag</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:booleanItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>End date of current fiscal year in the format --MM-DD.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:gMonthDayItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:fiscalPeriodItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:gYearItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:dateItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word "Other".</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">dei_DocumentType</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:submissionTypeItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation 12B<br><br> -Number 240<br><br> -Section 12b<br><br> -Subsection 1<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:centralIndexKeyItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Indicate "Yes" or "No" whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:yesNoItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">dei_EntityFilerCategory</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:filerCategoryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation 12B<br><br> -Number 240<br><br> -Section 12b<br><br> -Subsection 1<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">dei_EntityRegistrantName</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:normalizedStringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Indicate "Yes" or "No" if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:yesNoItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Indicate "Yes" or "No" if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:yesNoItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Subsequent Events<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2015</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
        <td class="text"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="text-align: justify;"><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 100%;"><tr><td style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 18pt; vertical-align: top; font-weight: bold; align: right;">12.</td><td style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: auto; vertical-align: top; font-weight: bold; text-align: justify;">Subsequent Events</td></tr></table></div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; text-indent: 36pt;">In April 2015, Asterias received $1,062,023 from the California Institute for Regenerative Medicine as quarterly installment payment of a $14.3 million research grant awarded during 2014.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; text-indent: 36pt;">On May 8, 2015, OncoCyte Corporation&#160;accepted subscriptions for&#160;3,000,000 shares of its common stock to two for $3,300,000 in cash from two of its shareholders, including&#160;a subscription for 1,000,000 shares&#160;from George Karfunkel, a beneficial owner of more than 5% of the outstanding common shares of BioTime. Concurrently, BioTime purchased&#160;3,000,000 shares of OncoCyte common stock in exchange for the cancelation of $3,300,000 of indebtedness owed to BioTime by OncoCyte, and OncoCyte delivered to BioTime a convertible promissory note (the &#8220;Note&#8221;) for an additional $3,300,000 of OncoCyte&#8217;s indebtedness to BioTime. The Note will bear interest at the rate of 1% per annum and will mature and be payable on November 30, 2016. BioTime will have the right to convert the principal amount of the Note plus accrued interest into shares of OncoCyte common stock at a conversion price of $1.10 per share commencing on the earliest of November 8, 2016, or six months after OncoCyte completes an initial underwritten public offering of its common stock, or upon the occurrence of an &#8220;Event of Default&#8221; as defined in the Note. An Event of Default includes a failure of OncoCyte to pay any amount due on the Note or the commencement of bankruptcy proceedings by or against OncoCyte or the occurrence of certain insolvency related events, the dissolution or liquidation of OncoCyte, or any material breach or default by OncoCyte under any loan agreement, promissory note, or other instrument evidencing indebtedness payable to a third party. The conversion price is subject to pro rata adjustment in the event of a stock split, combination, reclassification, or similar event.</div></div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>35
<FILENAME>0001140361-15-018544-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001140361-15-018544-xbrl.zip
M4$L#!!0````(`!B(J$:R6Z"A?YP``#((!0`0`!P`8G1X+3(P,34P,S,Q+GAM
M;%54"0`#`"1-50`D355U>`L``00E#@``!#D!``#L/6MSXD:VWV_5_0^][,WN
MI`ILO7C9X]FRL9URQ6-[;6=S4ZE;4XW40&>$FK0DV^37W].M!Q(($`;Q,E/)
M#*#3YWU.GWZH^_._WOHV>B'<I<PY*ZE'2@D1QV06=;IG)=^M8->DM/2O+__]
M7Y__5JG\1!S"L4<LU!ZBJ\N?SA\[U`90%ST\WL-'@O0C_4@Y4E"+#8:<=GL>
M4IO-*JH@35&KZ,GO]ZF'KJF#'9-B&SUPZGB`H(QN;UM'Z-RVD6SE(DY<PE^(
M=52I".)O;6XCX-5Q3\1'>E;J>=[@Y/CX]?7U2/QRQ'CW6%,4_9@ZK@?H22F$
M!P:_SP`7C]O8C<'?)N!?=0D-@C2/Y=,8U*59@(!6/?[?K[=/9H_T<66<'T'>
M&C5,<E,[#AY&H-1EAJ;69PD;0,0-G!?B>FG<+C&/NNSE.'@&S52]HJ@578T:
M@9F[&`_B5AWLMB6%\(%H8J2;6(1F$X$'&>"^QZ?*T#R&IQ&@X_>S`2V/'WO#
M`3D&",*I&3=@3HXVS*F,M3.9[WA\F"U$^#!#5:;/.<3'M';ATPP-.)B:;G8K
M^4@T4=--7&IF-X`'6>#>@$^!AR<9#<B;V<MN()YDR-#VWF+X-F4>[1/JF$<F
MZPO@JJ+'H'FB$Z(:H<\BG$Y<&2B/I(-D>)T(HYV57-H?V")JY&\]3CIG)6"A
M$M$Z>G.M$CH.\,BD`%9U//+F(6J=E4P)IRJJQV+N)&P,32#U>,/PM_A7:HG?
M.Y1P)/DB*6$B%;5N?BY]4>!/HU[3#?WS\7CCB-1Q!JV0T@`<DEGC]$$]W+N$
M)/M%L"TLH*@1EM&SL4;$L1)-=##:B+"5:!#]FB`=_13J;K8Z0:$[H<3`R[Q0
M']6$"J,GJ]"'H6H[XE0)?1@554OXQRKUL3M!EO8/O2!]&''Z,79&,ZGT8RR>
M?HSBTH^^B^&F%Q=NN^-4J?136+C)]//MEG2Q?259.W^C[K=;VH'B8O!D4BC-
MB'OCF%])OTWX!A0W"C+2[9-8ZOB!!6R\#6QJ4B_@$5E08SG!V`PJZY,QV4I?
MH!XZF2;@Y^-,G"->CK.8V=9<FFW<BZ`,/7<IOJ4PM"36GAEWFH`?P;@M8MLM
MGY,[XG/FANY]Z^V;B6>+^1$,_4C,H4>>>X3C`?$]&`[O7Y:>(>-',/$]]WI,
M:*#%^(!Q[(&V]LS"TT7\"`8^=SW`AEW1826<?,]L/%/*CV#F*U=T5S<`RAWI
MX=A^\,C^=<ISY/P(IH[&%<SVA0+VL$^>*N%',.^]8^Y[ASQ-PH]@WK%9@?W+
MT-,$W$?C/GG8(X+;JS]]8*_%^@/FP%=7FOH!<_B\F^8-EYA/9DI8^A*!)47=
M-T.GEBJ_/7`&B+SA@PT4SAU+Z&4@Y+@8/@\')"C&HM\"R;\]8J<;//E*'=KW
M^[OM$SE4,/*,,5W,<XY%^(C5.J*6TN^Z''&K5X97ZKWX[>"]17IO4K\'[U4-
MI1:OT]9T92>6U,;7:6N+K]/6*KI2D#IW1(GI=<FD/HKLVJ^A\_#(+7TAUHT#
M5+JT;9-SUR6>>S'\BO]@O&5C-ZCMGHG9<YC-NL,+[$["[W:*7$`1H^252R.'
MI#;A=><@E$7%3,<+>2*FSZE'B7OU9MJ^1:QKSOJBZ/8].4Z^[UQA[HB=O0^$
M/_6@ZKX89B,(NO+^P&9#0IX\9GZ_'^SN7$+D9`4J*]'I3]/:P7O'MTX5ZKW/
MG&#7YT-IAX/?SO7;#'UMQ&.W:W?:.CWVD&]W/]]NE_>NLUHXY-O=S+?;52&L
MTV-_Q9SC79]B7XNOIC1U\-*U5@4'+]T=+]VVWE^+<ZFF-;X]$EN\Y?L`3`V?
M05,N-H6Z@UVYK-]G3C`Q$\W<9X.[%\/DD_W;)A9/L>>6?P6[R%;`6#H8)@VZ
MJ;RM+9ZWM8K6*"@B#G%PB(/UQ$%ZAT'2I8M<AEC`6_?K38SWNNMVO*BQQ<7N
MP:]VV*\VLI]-9MO[CIS9D![Q!%BA6G_@I$,X)]8>S!%-%7;4]<R0>M_,G^Z#
M#HZP=8ZPU?U+K@HF49XG]'>HSO>@.C_$0^YZ:W)*<)$(D+MO0$-R4JW';(OP
MO?3^)>8%BXJ]T2[-*2;8MY*@,">^I)R8'CMX[IH]-ZWWC^:N2U4>'S/O+MRY
M'W+O6IU9#E@N#G7TWM3128-^3)=^9W[>ZY)BA9WZYKN(77-;0U?"J0WXM-CQ
M*D'5T/)=C_4)#S:#M+!-.XP[%-\`F]3S/7+?>23=X`1O^D*^$@NTYI`0Q9/?
M=LF?/NCEZ@7^BM_2&_M]M_U^4D_A#/QBREJ%\Q=SQ,Q"TY'9%D],1F:9?E/3
M+D;BY:R<TRY&0>^W'2+T$*&'"!WK&(W"7IZL*HVP8X1/^8^Q^1CQ4HR++!4>
M&S]V9[SK@/\:"W8=R2:K/D'_?=Z\BCFDCQ$2:YWOV4RD;#Y#?)18/43H(4(_
M=H1.7*52T.;4=,=X2=J>J/2Y+Y@/Y^V<%\(]<=3#'?.(^X"'&#Z'@7.H"_?6
MDQ?A8-)ODE.(,QSHT.$=(N\0>?L<>>OJR-)[%`_A=`BGO0RG+=H7Z3LT",!?
ME(G["?OR[`3R)61,C![<"%7T+(E>X)J&6YN".[R$]>27I\OWHM;'4%OT!>)I
M7'VBQ1TX!+@]FW"KW/PD%9R-,4'NDCBL3YW9!.<I=YSB)-+H:4+N/&HS9EI[
M`!_?:Y#J%,R^QT_</SO>>_'6IN`5J>U&WM#+^'MQUV?@?@K"/1_JOU4JYP!M
MB1;HVL9=>0DS/!!9.7XB'J`P'!_%[:R95ZYVL.V"%29:QI1:\M9<<2NT:V(;
M_48P1U>.A40Z2-(-X0(P`745I(SY+%2B._AFH8GYN62FS+GH02:?3%XBF``D
M-R/)M#<53<Q(T/.A7XEM5[X[[-5!3V`UYA`+W;BN3WB2HP!8P/XL0"/(`'`^
M9W<LX&@FFG'._L-LWX%4/P3;V82[D_S$$`'`HGR,-1^G'WG.(X%*0%PCCL0K
M-GX&'R%D#!C`S6?G-Y'/YJ$99TLRBUI@RB[CPTEFY//H\7P>SDV3V.&UZ[)I
MDJ,4KG%&'DF70@4!I2VZPWTRR<D(0#R?S\K%S?WSS=<K='/72C*11C-A)=`8
MA\"^<2SRAGXF&1H)020$`,QG)%E]3D4SP8C<0H3D'J(RDA.)+KKW/5'\BPOO
M,_@:;3H*P!/0&4R*VY&1R*+R-UF,((N8M`\I\*RDE+XT=*U64ZMIIF?0F,Q)
MR21Y#3^Z65EIE-LD2+Z\E,Y(8RBF,A+FR#FL!%`YF?FWFL5*`L4D,Z(^SZ(N
M?I]/4%4J_TZ3%.U&/2$G&+$.N@6;1$3BTVK@V7U'/,D@(^]#3[I#=<P=FHKR
M^7@2U8BR*6^B=U%8X"-!!W[D/J2"6XK;U):'VY2C3#C!7H@@;'_N6&'K1.,H
MB>;@7QOCOZ9KFJ'4$S+DI[<=0@8W>,\6LJ'H:EU?CY#H$IS=9J(T0[\_BWF%
M"QL2P_^]1^81*H%(XID?"_^PO5.HP9'K#6T8_7<`OM+!?6H/3]`_GV&8ZJ([
M\HH>61\[_RPC^4L9N1"<G5,DH5WZ%SE!JC+P3DO_Z'JG8Q@%^0JV:=<Y07_X
MKD<[PQ&<)W4#W9T]P)9(@,("\KL[P&;\76Q>/BM=/CU<WT*_\RP:E5(<)WA`
MBXGP2BVO)YHJ/R38XO$G:\5T&J*I',Q#CHOTXK%!B.^5T&[/.T%M9ENG*'S,
MQ6\!=_4CP=6Q9Q7%(/8]EI_!J<;-Z_]CTAR/-'\L?2/^!AZUJ'.U.3J>TWY)
MG661#WZDCI@<.T%Z+0J+<P]]Q=SL(5TM(Q%_4B67Q`QFA,)?C3+"D>H&"=7A
M4'5V(G5`;+L0#O`K=%9>CP#SMLU>(6I.,D2>IY5\H;BNH'N16CTKM9GGL7Y,
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M^6<[^S`Y'B1O`^*XX3AZ/7U82B>;"_O5L+%\A!;F(A*C7E::6EG1E:V*T.)=
MX.!WF_8[5:N6%4W?/;\[C&YDS]!FCK_>CF$;Z\$-!FC!I9NAE&N-YE:%YV$4
MLN]>UZP99747O:Z`3B%S)FZ7QA#WXC`#9(8KY?;8HEP!?<:[-%9,'IDWK;TM
MM>!BC&ZJ6M0:6EFKJNM*"_GFP#?C60<?WU,?-]1Z65=K>^+C:^@/C2F>O[4C
MIV?F87M=?5\N[:PS+P!#R&)^VR;[/>^^H/B;JK1K95W3RH:RMG6F3`?=DF'?
M(7@.P;-8\#04O:S6US9[67#PS-T6N=AFY8R-PI,;EQ^)2>B+P%$&;7MS=V./
MX`%ZF3WF2K61VB8_`_^:N,ZQ:;QJ-/7W<QUN1)FSZ7L)]C2M6:L9U:EN4A!G
M.<RMU96ZH4]_I2"#L]3"9P9GJWL50%>UJJ*E7P68O_%_1?SE4)ZN-#5%5][#
MWT6P/#`K0`1<"+:$#ILU0VTT)UA,(RZ(O3S^9RBUA=CS^[X\L@I=D@$'3/)`
M@K+X9A/Q,=CIWA?O"_X5/GO@;``=QQ`^V>+=/`%Q]:=/!^+5HW+T2M6-8W*"
M78(^79+@TX\94D?DD]1CVB+;)RA'="55>!;3#"A&!"-R<U\6F:W(JF9H:446
MR.MJ+5).FZ0HM;_+/VMUI5&$7O=#@WGZ/L@_QEC?7)P&63"ISOJ`N"?.^'@A
MB#KP/:L/C5K)F?A6LLV-;'++7!?JAOO.,WY[E_/HC8:6+7D>DAL6,(=MU4:U
MH5>7%[`%I#EM^T)`$P^H!R7^N#10X0MWP/8#II"/6@'8>\Q25U.E6#;B(GC+
MH='%>#L7+QQAQQ3O'G%T"4-`K^/;*+,<G]:31RBN&8\03%;/2Q0@JJ)44^&_
M",'MD32'7ZU(TD3N$V^67897DZ)6#_-N1D6;@+_O1-`A\'(U15*66536Q+L1
M\V[,Y[VB-99FGSH>=KI4O@3HNL2;P_]-#'XNH9<30-5K]6:S,4V&<6)K$V(A
M#U)U$+5I+"V$.)U+OJLM@@=]>N"D3_W^9($^9N:V%[4)6RQGDAD.-4%I_:(L
M9!BC66O6WR6.X]&*16U?7`*!@B.H8+1MVKX%<=[AK"^+$]^+!9;`XMU9Z/G1
M0!QU)QJA3]0)F_]8D:=QH/N!/)48_1Z<H#;Y$CZ0CB@_$=/G<H1]%=*^!M*M
M$>7[SA7F#G6Z+HQ@Y$$?(*.?F=C3!P@N2>5BF(U`GA1XU1_8;$B(E#<0-SPM
M<.8Q)H96J]649%VP"DT4:])G+D^\&@;'OZS9IF-17:A-(T&3%Z;/M*:J5(V:
MFIISVWYS;C)"UVG-=T9HU6BJNCB/<8=,NM$(76?673A"C493;QK:3EDSO)!X
MC\V8NG)YM@&;:M.`ZOE@P*W*K8L8L%Y5:VIQ%4_V0&C*J"W'K(W15)2F4DOP
M.S:>681@GE7:9EW1C;HRA^#TN1#Y>)FE.<U0C&JU/L[`Q&S&,GSDF6)M5`U@
M5YO'QR,9X*&<PH9H#*?QD"V775C;IEWI-^/<A=-MMP+,#:8OQ0F41)X0G1@Q
M706+C2L;7"Y(=[-"+C3LK*AZLZ$O+VDK)5RT=WY8CK?3RP-#9PM['ZMD&0>L
MUE-S?K,)K)O_/#LGEN&_\H`EW6E]ULQ)^F^QI<62CCR8<\`<^!KT%@'JK,YB
M(@=`*E1A2#4AQ>A`TM%J;\>'GL$3Y_T%:V8=^B:^N6(1)>B_H4].QTZ;<2[/
M]9I(X%.TE9$(:KHR9Z8,E)+#$`D+N#TI@/P@!'S!ME!>&3TPFYI#]'OX[XQC
M#47;<\<2_R0P!.VVZ1##-9X3)R@+[*L\NTBB.D'"GM0,R,3F,\4',E*^W%8F
M6@DH%&Q):VBJ>HHN*!.X@W/G+'&Z,[9MU*/=GCV$%`(HA.^*$\V%IT.9Z7.S
M!]YCH5?J"6*(<=JE#OAU'WNB@AH&)]=Q0E`?*/9<@`"?AQ+58ZA-)G@[FMC/
M-['_+9='Y7+BW+LRII`L8(]%1:]5ZWJ]-E?<V7LF-B_U8@L1JJ'IU0*%QA[\
MR/E0'/+\'VS[$RO9V03/O:B5;/2NO0E-HU%K*LUYLHV1VJ!0N78"-;1F5==W
M1R@]UP;/JE%O[(Y,.0*K5M/K#=U8BTQS"[5W.^/JRK@E_?;.ET<10I?V&DPT
M0$TGKE&P9D^S_$08[Q+T,^8=W_E.[.DZ$L<@WW="!/?\4>RN#XC>=T9S$BWH
ME8EU,;S"9B\-.T5_4V[GG)PR6<F-IW-F/H,W"A(F6%;H9<USP1FV7AETBD(X
M!\J>,KI]V`\C75).3(_ELHQ:G&7$C0@T+!JCD_4ANHACTLDM&PE@$9I)T)P]
M\)M+3QQJGY4\[I,2.BZ>C^Q.<R8?+'+),G(8&F`NWD[Q25D<T-V#R/H+_%8>
MT:,HXO]H$AB[PL'S'#1]BAIZ65.5<KU>C0)!`-8;XC77<D/7$4M<?C$5<4,<
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M`1ZI^[V,6IQ8U`N_+#!7GT0E&@=XQ*<-SM"O<\H\J0!9H)F!)CFH8/JT^35U
M,`P+L(UH?+VOB[P>%HML'GR!1_80N7[[#QB,Q;/LX&$N[3JT0TT<K*Q-)QY=
M!8,&'!R&@YC!`NR4*?ZCF(A-80SCRLMC<+`_8X28O`V">ZDB5&ULBY<)7-0>
MHCX6V[JIV..`!(;XTAI(9V)%($+RIX_%NB+JI)1`/5^*<11,'8U8`Y<'H@*A
M7#+(;@7$03X3>))OIH"PY,TDT.<+,4*)Y+YSX%Z^L0&>W\;.]QCY*>JQ5_)"
M>#E61`\J;H=)H<$)8!@G*^NAW"\#$HOD[4,M'HF98QUB>K0D@U,><!2^4G<K
M%SYZV$&_]I@0Z_Y57/TI;IZF%L5<O&L7S**)!]SMT0'D*X]`WO;*Z*K3`?>1
MDK<`1U<XM$A?O\OKLN8$]H@-P<0SM`]8D!R,&`C(Q]0CXB'I^TY(&,ANP^*=
M/-,G>2T2"G(W)QU;JBHT?ARL]5-07R1<&5ER=D3$$A>+5,P'MV8.$5_[#.+"
MC?0B+ZL+[V!*]NWA*%'X(E!+@F<.\"96MW+?VA0<RQ%?V+3>"YRB0T%,43<.
M7,`8?9IRMU/(0MC,8X/,,[]"$II^I#4R3MZ0-Y*%*(+CG?+=39/KJI1-WR(S
MBKC9!Y@LI,EJ_:.I\9H26UZ.=N&[U('$MD)MJLH*M;G"[05)^:/\5I@MIA&.
M>XA5*#Q\S`.+K\DB.^'?+5&+S,P1TX[Y6UL*WK(#`.M9!P#6B]EZ$YS&[H*U
M*):UAG@A'0\(%+$F`,&`[0A]2@T;[GY[ND)??WX^0>=/SW-NKUM/ZM^P^22-
M1^(242=!008UN\V"@R""]9E^GW`Q/DB\WMCS`35*Z!H&1<SR1;TG-\:#0?I!
M550&]DS?E3ON:#@*HTYPDZ;H.62)YA"?@^#=H:0(1;W\L@T=R>9LD\Q!M?I1
M]8>=2//;H:]?GLYW+5]O\`#SV?DZ&KR?NQ3#\%F,_(FUK6ESC5K\__;>_KEM
MY%@4_?U5W?\!S]>IV%40EP2_XY-4R;*]JQ/;TK7LG'<J=2L%$D,):Q!@`%`R
MSU__^F-F,``!$J1(BO(RJ=VE2&"FIZ>GI[^;=0C%YPS^!YIK++GIL7*PPZ#)
M/)&#UO/E7X?'UF]1>&O]'?[UW+C8T4J=%WA&+]#0^AEEC61,YL?$^IAZR_'.
M1\+,#BT#GM^*LYBCEP"YXWG@QB`-W@I0,TGP.U9N]@3RF`/RV*O63K2'/XA(
M=IG$KEA5^/TH^=G12F7O;RQB:>0="%TN'V9=IP(YVK$RM".3SFR9#4:>_@#4
M4UBB=1N[GN"7`C1GRE>!)<)*L";?KY^NCY41'EY00=_$LV6"AT?7#9":.XOB
M5=W0CY(/'JU<]]&?B$_NS+J1`AV;_(Z5`1Y:H@/=?2H\A-RV4(Y#=VN""5N<
M%:NM=);GINX(L[/I^S2*@J-PXQR'Z-+O-@;/E\N=K&]'<Q7LA+\=L\9Z:`'O
M9^1OAY=*7CG/5Y$]/+:>IR)[_`)<%'#@X4F",SG<IVCD!\*Z$VZ0W@%<D_3!
M7:D^_,%DL^?,NTZ2V=$P^"T8UU4XCBX6J;`NHAA4^EU;R)^U7':!$>$Q"&/N
M;1@E&(ISK!SK\/(#:)/MYZM-'AY?SY!G':VP=16G=\^&:1U:U"+DS%"=5%ID
MDO,0W,51"+\AI-;,];E?$W`W$;GP)M9A.%HN=WA)`QT#K]HGV>S9\;D5#>*/
M]KK8@A-^$<0&ORY%"Q^2&SY;7-,<_W`3&2/B)P1MGEVZL>=']_(9'5=B<-9D
M?">FP%#'4<C]K^!+]3P,]/L<<[B*VZ$^'B!'8(U/^0Q6[-]C$]+0PZCS`#,H
M.1'47+FE5CZ+HUL1^FD4<V`T)Z?>N??"<F>S`&B$\R[A8LD<U%X\OP5`$BQ[
MPS9-,[[]D-?-<Z15D[T..\?FQ'GN&*U]8>6[:=?(MUR?(A2HI,QUF9ACK)_U
MUQ?O;JX_?/23E-)T]Y&?N3()4STX,'-@2FEO1Q#A1.6TE^L9SQ8T&<:V/W#<
M>1I5@%.^O9=<I#G1N;V4HCU:6`C=CG.'9'B[;:DD(MED]>:210&5-E27O$]T
M_%1T[!P='9<[;XF^*MP>%O8+>:"J`&=,];F$]FABK0AX.5'G$5-G^^BHLY++
MJHP?ZD<MN>)6%%9:L&-_53!R)3_2>$X5.5&>1M$;7BZI+ID]=XDMJ.FI7V-L
MW[-%A;Y.L]MO-_.+K1A^KZ#6Z2S3[/4ZK<U`/<]JUT0AT1FRAC!*Q5E%=H7D
M=Y557+-AJ%WF1C59RRJM(A@(10X(`*%.7>)NNS-HY4J.Y8`SZC'+BLM<RZT$
M&\GCT?$9A[EV%VM;%1\*.ZW><-@<E&*G!%:#NA,BF,0-RFJ[)NG5Y`9_.O6B
MV)E0NZ*PEK$7.=&VM/^$KC4UH<(\6'F0WU?&B2RFWAW_>^YC_V=\%(>GFP,+
M.\71P@VP/C$:S#VLQ^/B^_.`1J(GQ+T(Y]28A::,/2HF186I<%;@^M-$E?V!
M5V?`_;&$'"P+2[)A_55@54*6$TXTE+1*K"C%H*M;!P4J5<@<'XMF0A7[DKGN
M1IDZ+$M5IQE&)1TOG8,OO-KRDR!_?%Q]/@?8>J]?!$X.O1MX-NQOW1JV.NOA
MX=*-U*(RZV@"-"%^C.FB)]H:(VT$1L]K#SBS\+#H3+Z-*4@1XM]SW./W][F"
M^&5.^TJ&C'R?&1W60),L3WB7NL"<61^V5;)OW>9`[AM\^M='<>L&[\/4E_P8
M81D#+`8HLKAX!C^!_W4Q$_1&X?LZ!<7;;#S*-F"S1>UPAVR^,==L0?76&5>.
M17>.)2^=[?>/)9KU.X<#&6_195I^`<H-/,A6+S7K:V^ZU7+]>]CD0YW`NCOX
M3#?D?#R.Y[0#K/U8/MZD3/4SZL2SI:R9I^BO<,FN;?JZ.TGS;]?M_\XC)0^*
MJ1Q)7&'-S7%EY>1=X,`XT-FTUSAK&77M4?3.E6]VL.]=HTA#M:#>&(N'9<S;
M8OYX^7%QXUJ-UJ/VC4T=*(BZ83BG\JR2"P#$O(MW\]`#P3N]2W9S")25Y0M,
MH*>_%C&Z?=S;JM9`>SH(G>4ZY@VG7871-:!KK'X+7>XXBLYHM#IX?D*:SDX0
M:(S^3H[[M(I[N]?)*>YKP=6(HH9/WH&)CB<])HIKUJ*X(MR;8?&I..^&F#]>
MUENZ<:U';1Q9)+-:XEDS3;0B/-F.?9)0O$,R6B>Q'<U>@0S3ZIVU6F?MR@O1
M7)BQ!Q,1HV$)K09+]D/U*_TH+8_GH?<Y"L?;-WKNM`;#;HY?KIFD!%@0IZ@P
M>/VJ_WH6?O5D#MV_.51O%UL2A>I%AL9)-"M.Q"HK:9VW=;\`:;W4#H-B9[PT
M@M_]V,,6,60L)3NJB.]]NDIQ:*\X'TU`1E5X6QI@V=](;7WG\`C..8LCD/E%
MZL8+P/?X+L3"FM*3G)NS@:&0&8CXK@&F-1)D:M624P1<A"?@5K;X44%,/FQ^
M`::_]SWAZ="U//S9@R4C8]#;E"Y/6,QDCN58[H4V!<MQO,*JXNR')3MUUI`!
M%H0A=^3&<8&JK`4\63;A1/#FB/PTN!AM_:8P/I]4<\D2J%&S-$\S7N70TF""
MXYE3H!U<CT^%\.7@V.@Y"G#5;JY-A2?0YLVVESM!K&Z."3?8*P+;R\/$8Z$*
MY5.K%=-NS_24%7G5]GU5YY6A0@.]%<*Y4L#`U-B\822L[V'T$+*-7L^*?=`(
M48A@P@E9[*G9HD&0%>O,G`C9+CWX(%O&XMX'&*05'\X6=6.;,5W#9I'M5^)T
M]4;BH?*G<&1BHS?(E."+QK!S%KP:^$1\7-HV:Z2-_2K&14HL!Y3:=#`Q\WYC
ME*LW#^2IWBT`-X*E"*M7PTVQ^HY9OL8^"$_$;J":]6!KG?<`!A[>5V\![Q,_
M76JFI%Z6[_*K\*9\4;[VV$;5W5;!JE9GTB==X$8NG):SHP7ZO+`4%C;B9ZJ6
MLY>-.FNU0?=T>LL+><(5;-CLJM7O#0;.(U9`^@5'?$7C+8F-Q@"ADT;8SYD:
M#DHIKL[,1[3FC3:WW]GADND.#GQWY`?4C]>&FY-#9:0J,L,K(0JKEOL%;8+4
MNVB%^E(C!&G8=P8EBRH;_HD646-G@&V8+NS-%J&\UFC/"KBUUC]K:%[RM>RM
M8]*^RM2GYQBAN?>X2QHOW]9C.12S5XQE/&`D9@F`E9O[A8)G%M;5"'YD89*[
M'DM*_RA5J0]*4]U-_.\2@=7(TCB@>4#')TF-,:G0C?^`>J0,J3H^5?)X],A#
MJF=5J8M'=Z3.2]KDV=9DGN+EF<,6/%9^VCR1C&-_A+KY"$Z>]>!2-!XW!4S^
ML@4J^%JC%<"U2VEG+YZL!5^W\F:[EQ!R,M^+0BY"NRS;FA^MD0:X!T/LFOO'
M3._[;^1E[X%8O%Q_^]4IE*O1T5J!#;F7&AV`AC=E[<`VF:XL`_.98%_=\OOC
M$!L`LR1I5.X_,/38G?WU!?_WQ8[IH2*1I9)"JHHF/.;0'D.I"&30^SJ'ZQ:X
MG].X7,WA*!#]<N#8+6<-KG='\YMCH1;E*PCNY&%O]31OW<=Y.'PF.KJ7#W@>
M<@O<_WF0*ZT/2:LYM+O-YI-3:BT\_<0\NO_S\N@5-%D.R;'0Y.;<\^?BDX,3
MG]20]-MVK]=_<I+\H[/)X8E-:DB<CMT<M)^<))^*2Y8J?4?!.K%0G'`G\/<A
M#2!/Q%77%ZAZ%-]UFOLF\GK&@V-BQD6(.Q6[?W@._35*W57M#G9*]+66?5"B
M!X@L+YJ/`G&\5HI.:V`/NVM$N_V=KD[MT[7IO?*8RG$'=*"@:ZX0(Z%ZW+NZ
M:,I+J0*ADXK+9')J[2P6%,<K.,2$O8)84#+68[I)(E(9HAMFH1754[5AJDYW
M4)QJR7=3$K6\021A=<S$<EB&.2.6M!K'_HR`EP4@[/I!)O1\5564&C$R#EP^
MW=+X$G/DIUM"G1#!_J#;*0FL6[<$#*0K!OA40?G5_?$Q>_21$3WM=K_7*XFC
MJYKD0*#7*>K4;77:6X(^BQ)T.)_3\;6M[)EEP/E1?O*1&2R==C.?M%8^]E[A
MK(/83ML9##>#,X8!V!,MN64)@-DSCPJ)=+J]8:>;`T^/O#N0-JSMXO3R(8LE
M(+T]O[F\L,X_O[/>77[\]O7].^OS^Z_6QZN;&^OZ_1?KXNK3IZO/ULUOYU_>
M5R6"%Q;PWHU#N!V2:Q%3;9"W;N*/ST/OG1_,,>AAHS45DZ3/FHV60:QKYCJB
M5:XDIK)5=C9?I7K.@@<M>G*3I++B+*>LLOUGE7W$>GR:R$A\6EUE"RM_BX1#
MFAZB,PK3M*8BO8L\66LEP#+B))Z-D$PP#(F)0D_3L+Y1:^JR03B&E^/H;<NG
M"#&;0Z)&6%"+6UN/%BB&RIN6R[_`-OF`1"_1J5NQ2'P/ZQ!(01.#K0*@)`IU
M&XGT08B00K]T"9E,DJ4LL[$_XX4D8HS)GKCP$568X3I=?NXY%*PHGZUA75>]
MC0ED5+/+IU$FUHV@.JGGN:)\Q:51V)T>4I!DK%8+N+D3!#(<8&`9.&R,9?T:
MUML*]%/$GMPFQB6-AJ!FN*>00B0.-TUC?S3G\*8TTI2@$(<CWD4!EM/'H2@1
MC_RV&%L%2\+4['!.T3A8YDR6[ISD$1_-TR2%95+5>!G$/0>$)"D'-`((XU3C
M`X39W\68PNM`%Y%E?XQ"H!G=>(!X6%:6^->P/F#X'7VF&FX/=_[X3B\*AHMB
M@IR@0`38_/:J'<7H0&1.L3M.@=Z"A15Q""SG2DJDL]*#0S("-+!4?(Y*R<'8
M`4`=1NHQJK8_0CK-*%<&9E9!U+#4#;#1SN.0>]]]\ZTDO^FNAQQ1UN2C,%@N
MG(JOS:(4N*-/F/5P<5ACQ*0?6V[CTO&2U#7+*N:I)%';FB=JW6DL7%`'%V?\
MN&)$4MFL.I;F"/[D;*RJ(\GWX?R)L8OAGTO$)3>WB%MS10JGB`U8MZ;8&8:R
MPC6(X.'7ZS!#*('U^OI7QF^4J!-A$(PB>8-@U&ZD=QAU"\.F=PDVD("G\_&7
MA"T4+K#T%I?IQ=A>WD5K$D=3JV,/AFU[V'$TPB4EV/"3T^O9O68WMU=#NS7L
MV+W^,$OMQ:];31N42;O5[B\/U+4[PY;=;K8*`_6[+;L'4&;;G]5FQ",WDGO%
M7)UL$%2`Z"&:!WA9Y'!8P^2P1I8IU,Q!4M45RZCB!G^F@I!C-[F3?3K@@_CW
MW+]W`XSX79*?:*RKR7LY$I:+N`HOX"T0U?`_[[-W'YLIUVPY'4.RWV3JXUO[
M9MF.S>:PWWODTG69:#QJJH`)QBMG++'`+(LE6'X540SO_-V-)_/PNPCJ%JRK
M+O51Q"B`G2X^$2^[I*L8P\PUX&L+K]2OS;%!<9Q/[N\15MVXR>Z='1=C<:@4
MBZ%'U\:#WMP/+K"0?ZC*!!_\T`TIM2`K'K)1K0T<CD:[FNBQC*'D`"?E:/?*
M$6VD+C$QT1N95=E947$#;=^3W`!2#M`/]=\DTE).+"YG+&1YYM\@30(>*#.A
M;'8@8]2C/IS?O+5NYSZ7(H[AX)$H297"V-"=8)K#/"T`5#JFS=4*?E!*$&?'
MJ`KBK$<90HBVY(]1ZH+[GOF64;QXY`8$5'(GM$=@:3R4#`O\W<[J.<=B+.!K
M$)+L^KX'XWU9?Y*^H>*4*UXV]B"'A@QOB1859$)3<@="W1F6?;9"ES)0^`=X
MPD_%M(Y_HM8)U^SE$KA->$L2J5JKD51U]C5+-*IB[3`)@/81FX%E@Y$9\QL-
MA"T[UA9KJAX$&#?QZ0M4ZXD)9S"]1?6Y^+PNL]EJ&G4VZT!9%RE[0,"CP.6'
MS^AIRX!=6;2ID4%]J+?OJ]!UNCVGVQG664>AO<)AUE##,+_'-9R/Q_.IU);/
MC<2R#99E#&&.L,U"0>.!Q[KM6@NMF/<8EUY'ZNXVG8'3Z1]DZ9^7/74K9H.G
MMW(Q]KOM3KOIU%H1S'%`Z&N08GLPZ`S:P][FT$>Q`!E/WK@@N*8H\<OBW+>Z
M2S'?RDO=#986QJ-=R,%,[0&TKZ_9T*<2=8>0EQ^UM[:51=A,2D?BG:61I,A,
MAC0C,">3O_."^24R'9`&R=B^9/7EIAHL=HN8A5[0JFDV$(XU$'XB@=<9U=\:
M-PWIJ[,K9'FRP"E$4,HU%9J;CP(?A&(O;_L@X*3-3&:25XO35-FSH0J(\,0Y
MV9:$Z@DF-)<#`8LPA=PEPVW>+*-,@<J0_D6H,!QSF]F.*]N;8(D_@89M(7NI
MX*Y'H>"H']>X8<J(HF"*+NN-DL,'V_8WLU;:E>2H`I$2PV3_LNO8PP&__;+5
M[-M.IYFW)$K*`DH)L&H9?$&FSW)Z9I25Y=VOJG-1><@+Q^#TZ8_^R3J.:$,Z
ME<;-#))$&$U!T946A`)/+>.\IKO,&`H>*5X&>::C1Y>\Q&"1N4##ZJ9+2;[K
MTG8\9N5UQGXV,H6P=^^ET^S:K<Y0L1G;:3EY+E/'IK"M9+0DJ:DA+&,,ZU>\
MS5]A],!K=)[@`K%>6GWY#`?`U]_2NUAJ[7&5[P!GK9P*6'_FHUGQICX8H(O'
M+?A7$5)%2?)`>W`D_21%0K]?LIC()X%TSG//J?IXC]J\;JL_&)B!8FMF.P#\
M&VU%N]?KM_JM+>"/(H]"6W`!):I<?2>!&@FF+&I?)\UG_YI/B?DQ%&FU<V#I
M>2XJ-2$=.E_WR\UJ&AG5IOW2LEWW4O#WRX='],@ILK$Q>"4;?S2GE@]X99+*
MP!$XH(H$PDU2V=@%I=I<\:F&=:Y:*OKA&6@48ZQR7%EU:QD\6B0;[&4(B"?@
MJ)`7`[WP,L0)_@42MJ"'Y7QN0I$P7$N,OTY\5?O)A?6`ID-]OC"00OM;J%:6
M%ZG('<!D.L<2H/KYAO5?=R+,IO'):O6[%$VR=H\K)F0?@+%`*J_NB9AO^9$P
M]N,L(&L.+-\/5$6R62!X6`!\!"B,0M4$DB9.D@A#:<V";T4\@R()^\HD00"X
M,R+:_Y'J6,C0-:S+"<?&X))S&Y4H0(1=G%41E@J0\+"II6?EUD.#T@,I#CTR
M*;D02&>TRJPB[)2W;1;Y1$-4<:UA_18]`,2QS="OW+`2`JE)#M:K9(X(3DHW
MG0<9+73S:5;Z?A4Q/&#XNT%PJ.@:*FD?R3VFXF[PW/G-A35H=L^ZH&+2[,O'
M)F;_.))3G7/W2K$@I_GF\OH+_87_O-/?M]Z\)DJ1,C+LP"S*(:V&Y%G_*LKN
M00[N^6)X^B[*`_KYR>S!1Z35=(;YZ/2*H?<(9*T0^F;[44">7:`+.8I#WZ4`
M!*9L:J5Z2U(*';E/PO/'0.F9RU"3,NA=R'O=F9BG_CC9(I*D"',)'CKMYE+`
MB(*@`(",]V`/(]S^H-;%[&7,5JH7BIU;LV6J5>ZX<^)9]\7?6IUB[\3BJHTM
M0H7O.HY*JH/3;_S3HZ.4FLZ@;X*C1WXT)!L)Q\-VI^^T5@-RJ24)O.W>^<DL
M2D"L!RK]&(6WTM6QN5"<#7L5JT&O)C@DC7@2CP\F'AO[.[$"W%,I(-`6Y.3D
M?)KM`8"K=!J4Q>LLP6Y+.Q)>W4L7M"VM45C*E<2A4NE9RUXHQUAHS4^IHJ^*
M@T11QH_'\RF&!H[I"^!C')VCG`3YD!HE#2,0UM1=6+)^+0A3P8*L8VCA!SBE
MZ&<"(P='"'6DCYVO32LP$@;GUR.AKV.!$A";^-W83[*2OR7`25E2</,?6;EU
M'JK6AC(6V?!?Z(JU+#E+GLXQ[-E@M!QC;`IYIZ5AP#0%:F<+1>!O0Y)%?<P^
MP4!B8T"&=:0L^F4+$3_&0GA)H6IS/L;*`&Z]Z+0-P]),]*-TDE!#>]B^AQ@%
M\6@RH0A;D.!("%S!(XL3_28"[T,4?WNL>630->-E:TWX)(O:Z()M;KLBV5R"
M+8FL*%Q$U"@(*>M*6YJ5C3%K1H&\[/V/-'8I4P0[9%UB@!GGOV+Z210$.(9J
M%[B$%1H)Y_T`LV:39G.RA5`WD1!);CJ:+3^7FNJQILQ6L]]OFCGN>X3U#[83
M&S:0P;SW8?MI=@)>WDB\4S.>1+A#6#A59R-X?9W(E`7?DJ1COEIB`/GU_/P:
M;F,RW,@09+YS4?J@*NVJ<T#N0LT%6BQTUA:%<&!FFUF(@5^@+@GJ>0FB"B&0
M)KHL.4Y*5LL1%S)X0H4,4YT']X&M;(48C@:E`<C`"*PLG\T$Y.^J$!"R7(4"
MC3?4]S"2>:XE:TCX86Z[,$6N%/C?,<R`W*<HYI%,Z.I:*S)_3"*N=$`4Z:2`
M&`LV#W*@=CZN''A$E&T)1G-("8KF07=H@AD9;&U4\A3+MS+1+8LAR2+/M:,U
M-QJ.88Z`X`/$5'"!6'+J?A>TN()@R-\CD=$+L0#),E1.6TQZDVVY$OE\)@3:
M\A4UAS6%@X>/();/&,MGB.4SQ%4"/[JP")3UR48F?KCDTL8W481T?Y"@.(=9
M55[F6W'KAR'=+>,TPI1(]A2W[<QP.!*WL(\3/^"D3I"DD>(HS&@BV[\9/<9X
M>0E9[87J(1XLS"S-D1^2[LSC&[H,+Q;[72;:0%JF\>3<XB7[)EWBF?'%+IT-
M79'W>.Z0!'#16<)@EN1JNN3+89'K,?<V2Z^46YGH2'_=Q9HRJ$7H!A2199A-
MYZ&A!AAMVQ*=0YSIHVYBXEZ:2&WK3AF@PTAG-$@?!4.A`Z?<A2+F"L#<DL86
M&D_92H$\Z/RM)@L<[0';G<-_[T$CB^8)[QJ-J$(2EJFI@=%RK&`%F>('[(;2
MDD$CC<T$;$9%CO:G:)HK.0&$".PXHR4J6%:S89T'\,C\EG4LA!`Y!;H>@BB1
MZ)O-8SB7'(2%;"OA^#7/\V48B!'?@1!12`<>=YJ.5;\2@%`UAML5<#0%OI&+
M79-9UI2+SI(.O,NA&AA91VV]6"$$^![<&-3`>2(C3F!#>6)BHS&OU5P<,$KI
M-3%\0O0:TE@J"70;(`";X2)+"S:WAI<KCYCU[SEJK%&H<Z#]*8<$>H::[N$U
M1._:$I`?\X3IE]$]!7K0Q(6(_WT.JK_GC[/<6W(@^=EM;Q*M;1!D0*WW3-)4
M-VL#3D3HWO)-X$4BH=N*&7]F`DFQ[)\!>^7)Y@L/=?68$Z=ED*-NP!2BR(G[
MMRHR[Y`27K[PW)/#<Y[C&A*M=#*S8%)`Z\N6W>KW;:Q)B-UU=$Q6[91RFWI/
M<V)_<62GVZ*1I5RC@.")-'=7O#&:3%#^0_N4/N(4S]GOT"C&*TR0)*MFL5Z)
M.]6=H^&`<U"76QL-[<YP&0VK5M?::'4<)C8<&'.4+J>$>DYQHZ=/IT]'$B>K
ME0!3-_0JZ@F"Z`X,(_;)GI]%`:1),3I!-JHCD3,(!%6H0;D?V%FZ`%EOC2:)
M_$<#5J8^4I40Z5=`Y9%4(MV%+Q$E3#+1,0:&YN;>NWZ@2J%(ADUA#^6S&Z@X
M,;;3IR=D',=5VA=TM_^<AT+**/KL)&B9Z:*$0%*"TNID<1$60V)*Z&$=AFPA
M=!HI;ZM$JFDVVA;`'RASC;2><+(]%_5M]-03C0P23N<77**M``?9X+4-,8OL
M4^'YJ"FQFJF$2#WL4ATW73+(3Y(Y<QDU,E=-`"Y'3AHR^I-]"@<^Q_:B;+4B
MY4:G':B9N"[44FR7,A]-4*@UPOM1!?1SAH/,!/E`^KX6334#7-;W!!<LDOE6
M/O)G]H[F;*O>7#`*B7.CRTS.;J8;X*18-BE5.5DR<,_#*&6%!3.6C>R:.HN+
M\BU2<KVE=?(0JHSTINT?BS@)Z]4[P9]>4_2;LB`;H4S+]G]Z7KUW&:J75L8:
M;1*8WNL.![FUK)WPJ=:U6:W83J?3VG)=5Q2)BX8@BXI>&!?Q^H70RUFI7*,>
M\6,]B(-NO]5?M:3JJ0^^M`TCN?K.8Q=V7JB%HDH.DGERHU6JD:YY(,QPX&%V
MN)5.O^>T:I'G*BB.9?&;^5_;O6ZKW]W9VG4U<EGRO<8B"Z79'YN6-1RLWLK"
M=/N$?#,R[/8[9G&&^I!7,'ZL'1:F45R+THR''[>,;G\P[*Q:A3'3P5:P$0FU
MV\Z@MZ,57,OR42KK"SD!,WT.UUF_+#F"VGLY$!Q"&H9'>60R6;_K."NWK`X,
M1XJ)C7:^U^SWACM$1%FE%.O5^Q\J?%,E+BR56B^I9Z+?TBE\.RD!4V>F)UO1
M5F5A'K<B*^O58OUS92A0?I:2%B]'$!54IL=G;8U9K!=!(-L5(4+I[V3FCO7?
M6%/MKR_>W5Q_^`@*VU=\Z<6.S`RZZ53S3P989K^PW<XSP%>+/9O2:%;:ZEW^
M3!76&;IN8[EGU$X!=.=I5!_`RLU=D1M:HX=4F5WSZ(Q.YVE9T`(P:DJ=4=]V
M[++,S])T55D"WC6KAE%,1:ZZ-T4211A7!<?C+UM@J]Z9.]3IJFAPMDG/P&W[
MS>UTCG&$Z`NQENZZ\1_N,)P;D0U8Y49O-;HY[B'B<LV!-KO7Y2E]?P=P`Y!>
M?0M=N%%3X;W>24^]Q[6I/#HBW'"^(Z<_DZT>!?4A:S]ZLMNN!6J_=XS]J+E=
MY=2-;_WP#/\`0!L.CIF[G\_XRW(A9%\-4O?7"W6G/:)WN3?<T_0Q"!W67!M+
MOX=?7->QNSWXI[.F]?DQ=OT^4?.)FG\>:M[#-79</>RWN-O,2M6FQKBO*^[`
MC>]WUO?^<3WD'W7L-P.TFC'LC099C6IU[:8SL)U._U"<H9YH>WA4K-$C3X?G
M='B6#D_;[K<Z=JO;/AV>:@0<X`+O5!RIYZ.<9A;R`W"@6N@Z)`<"@"POF@,Z
M?FY=8,/E/Y6ZT.[;W7;';C>=I^)KG=I\;?\T>SH]I].ST>D9V(/.P&X/>S_)
MZ:GTU-9U]!^7ZU9'V\O"K`GE$"U[9&5"./:VON?@^:SBE<R,C"8`K4SPQJ0`
M"\M>(]E9`9:6Q&[P24FZOD<IDB`Y-H<=F<MHMWM]>S@<4":"Z0-6M?LYA;XH
M-)CE`ZJ*H!KY_$9S\$V*^6]8B+]&:,JJB)Z+*`'L7W)T+V4Q?(&=>,#2%^]_
MI`#J9A5S\K`8/9OX99I-3?8UHJFN8I[H"`)H?KZR.M=NRI5A<9>9-$O*ZC`1
M&,67*9,^&F%B'W43HE'HU,WB"'/VJ8!@FK6"E"=`>/GRONZ*:L&ZE1!7G)%$
ML07%;T1EYEG@$AFZT$:XW-A,/<19)C(`L+2EV4:QOX/V(!>!63[)GD#=,,"Z
MV^FU-H*5HV47R_#)'[;L".?T>DTG%\J8C??(V>O421X.V\U!W=DWXYGRI5.5
ML4-4&9/(KN:%9F`Y\C*J<*#+=071`T@GF/8,/`9YX-2-OV.)>^0YJJZ8[NRE
MRO48&=2J+@C`&K@@8W.Z'\H\=\*%R];'/&3,#J(Z1)0I"0L$V6BYED,B2UW%
M"6+4EI^P#;-9B/W#Y8<K_2?67^="9K7X;#EEEM$[\F#*)\>86QDH3$7`84/N
MR^+YY9OJ/7H-7L*"VOS*5J=TT.NVVB4KJ)[FB193A^%UVTX^,VN+Q=0/<)8O
MG"*;?_[(YO:SB6R61%E71=Z@R^&1J\MW(@!%%?B9W96E[%X"/["!(;!NJHXW
M_#%1W"H3S4.`%LM>I:1LCV46.8[J>O^>NS'<+]P")'"GPG-MH[H>OE0OUCJG
MIV8\\Q:YD@'+!/1MQ^X/NQQ@30NC0M[IG1][E(*_L+AI<P(HD@4=:\&PR1VV
M2BW^B.D^5%O2GV+%0MF8#VL`J"SU/UL38"6855_DG/KE2^/=K?NE]YJ]GIDZ
M73UZ!GV6EUG9,<1XYA$=3?HM9^CTC"MI>=A=0U4#90.G";I!:U.HB*3>4YF!
M%7"=A]X-EGS`+8!#P\]OA;O.L-D<-GNE8);.LF^@ZU#CL-]L=_K-QP'-9:O7
MDD#VT%:Y;L/!L.ET2R'-1MX/>#6VO]OL#`;]3GWPQF2'G(AE<5/^ENPD@;K=
M&K8Z.:+,#;X3@#8K'3'L`*[6`W3!O<:H;QP;1$@KDSLDJQ,O01J%MU]!MWHG
M1BF0KQR#>.S5""YHKF/Y"`[9!@YIGI9-YGO*I=6I$]%O-_N/79H2;ZX>0*--
M[OR9]0K$D+MYZ,4"),?D-1#:1'QR9];-V!=8S-I&VW2CLO?3)S_$8JL+99?2
M`U^+&',(W%OQ=G'M5B]ZJ2T4`C!U9VI^F+VL05/'Q$[[Q=^:C7[7,`]M`-8&
MN%%/G"=8!?FC/\6,G`.B!CMEP?PXO9Q\+6H<1,V@M6_,7&`=X@M4<C^+.4A'
MFG@^IMXAB0?A0#!R4``,-4C(\KV_OL!F!F<MQ%G/O,OV@[0OXF(!2L%7H_G9
MP4_;%S$&&$P0:A^X86?O!^XJ3N\B0I)1B>N`V*'Y$4'&]&N1TS1("8[?WL_>
M^DY^>\?3RE9^Z^BHU]_[27M_8Q&'HE&Y6C;<[]>I:!R<0[U/$)(<(`!''1;5
M/``MZ=L_"N:R+CCP@R>X_=7\=;B1>>#:N<Y->^)*X?A)F1),ORE/DA)2^V#T
M\U0"0$%ZK'>N,O+I/)I\0)D\,UM$J4X0ZY:^E<[=<GJM]F`%Q+L'JY:GV.GU
M^@.G#EB@6W&_`]E"1A4(UF4Y41XJ`@EO95VK'ML0J]GJ]=L]0Y3)C;Y72#<,
M6F@.A_!D'4#SG<_.S<K+%UQ'U;0<V=9;-_''*V'78WR->`1S`'I]O_NP?O[C
M0\`NMW?#]5]@[=AK;/[C<<O+5]^X><EKU?<.>,`YM^QA"W%4TABO!"$XL!KW
M[0('O0SUB-F`96WD'DD@PV9O,#`;#3\.FN>'K@VK;#;;W;[3/SB^/G`'J1WB
M2X^X3WRUG)8SZ`RZ:]%5$YKGAZX-"R</VH/NX-#80F]BLM/#J$?<ZV'L.OU>
M:SVV:@+S_+"U88W<?KL]&.X%6Z427%A3-LY?R,8@7Z-]=,UM]1P0"/I5`D&-
M^8]IZ1N1@--QG-Y@1TM_4#79<8%`1"%\'JM&I/7C1&&@;)S\,/SR3Q<_6A(J
M5!+7^?@P4S4%Z(A``?P@%J8/TV!A77)WA\HM-`-)K5PD:9VY<@LRYZ>^?D;G
MRC"BQA88&Y-!,LM#$L6RU9SN@EMXCA_;)"W%MKCUQ<R5R2'XUEI`/-G#U>,^
MB6BH@OU=_#GA?ISG88@]@KX(=&5BZ,\'6#A0R-G?97/9F!)P,!K(G_AC:NV'
M/1IUT\'<+Q*H"P0RE`DSYA:LC@_:]%29!HVLA892]V0\_%(Y7//A7.3\XSAT
MK]DW2U=7SK)OH#?,*.AUACD]<SW8<PK[`IK(H$_$+>W2$M3T[-5$JQ4W\L'-
MH.Z;4%]^_I"S?5?.D75ZT'#*M2S!J9]0#SQ6?VCVG6[/0.O2!#L%;K,6$YUN
MTVFWFIL!E[.A5$*X,_-6J]5J]P>==@F0)5:N'8*YH9VJ#;@$;-8$,[YU0YG<
M2**W;+6LFBI=8W96F+JJF=L'W7_Y1O=?KAM";LZ5F^D\],QYKB9ZEFR24]CY
MSQ]VWGHF8>?Y0X/&30IC-FF8LW8^^O^>^YZ?_HSQZ;D"*\U&:Y8578D9B_++
MITWH^I73QC>4PA]7<L!H6>Y:(S\RTF#'+(7"H&/JUAV%,D<+H]Z!AF+!>>X8
M-6]-A><#GQ!O+`RD)X$6\]_OYE/,?I^.XD44^F,`7$QS&5UW[V]R"5UC:L).
M=<Z]^1@3`0(0\5E<7G[;ORYY.UM"`^3R$A@!\@DF#;"T';LS#$8>N7*--$EA
MH$R6!W4`:(OUAUB,YC[@0L.<4OL\:P)B-UU"`>;58:,Y>-@S(?'\A/J,@";@
MA[_/8X`4$,'KOKYAOHN*"-IH,&E.N"$=6T#F?.*.4]9Z!'"'A01U,1-*06&<
MCR)OP4#IKNK)7?20M09$A@]33'V,A)4=`LV49BPI;X5:6L4\>B,>12=%9$4*
M"'JX8I/Y"&;P79UU*$<E25<C5R=5X-RYO&IS%B`\/8$^%OTWJJ/KHA0DFE3O
M)X*TQU-4>9I_6]S`8I=F3N:SDHD3$(H"$9<P?.1(Q/6Q+L39G>3ZK5SAC7Z'
M.2J,O2<V8=TMO#BZ%;E#P<>4TD.?!,.8"W_ON_MFD9+N.@,'!`%%9"J$&7@<
M'+LQ;`[NFI52.BQ^]7Z.;8.I]3@GVV#.$I]5;#`Y"UQY_>Z5QZ_`W:_!PA-/
M@SON*6HR&V)`(O20_\[C6^1K[FP&T++=^0W1VE/@"02EZ8%I#''!^='=5O/5
M]]?4E9IN5+I4[MR$S6BZ.2R^,*?FT=8#U>B!6=Q;TD6,7K*%>$(9'6O>IKIK
MJW&GYI'^^;]OWEN?_O[U+];YS=<]H.$UIXSKZZ)X^9_1`6+6GEW=V.(58Y0U
M4T(K-OZAJMR0V^;FZ]G5]46+'H63RG<LO)K`3/AW%'OR,F:!&%_XQ_F%@\UJ
MEX00?/L,B)CP3[:[V+IWQRA=-*S2F#83T>J!G.Q26+F^R_!&5#P75XNRA._>
MAA$:KVCFAE49D\DA8^;<[V\NS6EQ=3<PH3M#"0%NU7OD4X$,QY<B(&7RLSA"
MC@T`Z[.:Y#($(3N=8P8_2`F_"3=([W(3?K[\+;=.2OI'M*'$0_N)-QO002;<
MP(_,(E2>".9A%H2?68P]>L<PK9ZLU7LS_O73=7YY@*Y9+,Z4A(%RGR'0:L9M
M<ALT)4?SV[M2P>,IF!#LF?7V\FK?3`CHZMY/J`]S>;!XCH;5$RN(.#NB*&IC
M'V60>.&U&0KB*`13638`0LK#JL,1'$)L56]5!_6;D)0\M1E,+AQ=F#"E#.2Q
M&WM^=.\FXWG@QK*A,U>\\!.@GVD><F"L#R3^9X4Q2B7;AE61UK%\0BL>+*X)
M9/S+)'9%<,;\<*WR5B:&GQ5Y*<.<$DO$M2O&2H?$6'?&6$OT!C7`S+_EZD@S
M'YX*?,UVE;Y!^%=O35U&>:8I(25^4:I!CB-BB0@Z_"CJ<]D26@:?VV+D+-,,
MOO?'/=$5N6@FX14?R5=:(233\+B#5`!+=4$73X-$M)=<P'%-?A(ER^:J/,*E
M<\5J/!X%RW-3%P\J=V,.*;+@-B9FHW]*YE@E@>P4NF3/:5-VM2E/@4EU'-&=
M@#65%C\)1C.:!::?F0;-NI.&G2AG&BHU.=I/IAQ^<@.WG-;WIQ[:AHU/F1$5
M0FUE/X/_NL$";?UI%`5/PPC^X<;O`S%.#XH;4-6PJ-ED'MC60H#DX28+(/DS
M5(\-$9\$$%!V,)'"_Q_DML1G40QTN<99,@_((SJ)HRD(03]2*Q-*8/9_SP5'
MFF(5P]B7`5!/18?(<\]QQTGV/2R^0V!-`:,O`83G"&]9ZC`$K\Q.O+#*4^4J
MI!/US`HA?QJ-_(!*!*$VFD23],$E]5:*D*#V8ZT>E7E%%4+QV%R.W;LP4VF)
M3`"YT1130'%W/R%9),!3!8J2Y&-8&:3S]%UH'^O[,AQ$I$L@>EU5N('J-P$^
MQ00PQ7A=[R)2CB13:2"9'K&*7@?O'LT:GF1R)2Z#99L(BCUC]'H(B]2=T<(R
M-7X7;8X`0YQDE6?(&@80\UXST>$HI#A)LQ*""7J55,'H-?AS=N?&H*R0J@DJ
M#7JJ4!`6D@.@EDMC9T,1?,J?$R]I-*")%J:-R)RGQFV@<IN(O(,CJU+KL]6'
MZDW'9(Z.0(66/BBB[3*U)^^F";UE-:I*67HB_<A09JY-%9O#^"1.>1%&!6Y)
M%0E6Q$)<8$E)($ML@84UQUY]"\G21=$;B?4!#4U4GRN>WUKGWA0K@:4EYH\/
M[\Y-_J/,6FX@:2`6AN.-+`-46PRN$C<^PY*8U@C/DD@2*YKA:<)`&5\5$"Y$
M*2X[W8Z/SZQA'[-8W/O1/`G,\LJC`-$]"UP06:U[X.M3*K?LHNTOR9E>#,N&
M8>V6K@(;I$@!G\+Q`ITKP#4,PT)VU$T37[E3,8O(B[E"#Y^T,'JPE*V7_8Z`
M)Y8,--V!.D8B`'T;4)T?$A^$/%S`U%`:3[1,@53+Q(I?R0;=2X8++2JKG6?R
MTB,HGEEN<WHV5`+L#1BT;,N,[,OCDMMC'7JEV)P/!P>D;N3&R9U`@8/LSL5(
MWW23`9,L/"P+RT0[,-U*N1^II;JXP]V]%YP&H&U9&Y3%5V+ZEB".,4]E$D0/
MV\QN!&+#4IC-P'59=AXR/Y(*PHX]0KT6F/#ZC.=C1A=1I8I__C\TX1?FM,@]
M;\[^OP:(5O0:2FE2?,CF`+2@(=5#8N&EOJ)@!4Z[B<*`[+,<6([.KWE,C@#C
MA=?`7N'4)!080';_A)R+KA\'"RF9J)C`682R`$8_L;!?V'O>(P/1RV4<,SQ.
M74_0'9W?O#)"7:K[R)(K,Q=]K&4`>&XS7(XT5P23K<2@#9Z#I`T$@6$J7=\F
MA$,L,-6X]<GG[1$KO1>*=9F\D^<#A@CRWHQ0H68#Q2R@KA?X&H[^?'C4!?!O
MUT?CVP1)4(>=3J(H!?104(\,^TPDE1*BLC8;.>(HW3]]($N.V[?&3<.0:^!G
M,:-BWF;J`DSGSP(`("/.C+/`'H`FDZ;<RV"&=;GI#Q*6U3E-U(;>X`DS"C7^
MX'P,ROGVDZ0H$-V\O\@I9.('PJ<W?O.#H0J0/[B%`[+J!*";A;?)$#@F\UC6
M<U4US#/L`!_!H%8?5!:/Y7#:7D;YS(B23.B4FPDGNH@==72!J2]3/,S)_/96
M)"Q'<Z%USC)8Q=Y+B6&$1]?U2@5ZMO'D&,)ZZB)_3B1KK<<"5FM29]D%L"*[
M16TL'6;F&^MKVCY1/?Y\>Z*GA^<P.M0W:6&5K8?RAJ%<D"G>$LQZ=/#\>FIB
MLL3#@@59B2K+65$)SY*J-;&T5R]^/3^_?O$:B/W?<Q^9IR%V4).![R);!`O3
M23*?SI2O'CVXDXD8IU(31%HUSCI:%+@M$[X:%.K/9DQ;KAJA)[VAXAV>!?&B
M&&6]@U<%6Z9IP$.ZC8S!9O@EPBDQF@9F(,])!.)[%G`>X$(`![$2(=!^H''V
M?.[8@P5U:>+,D;KJ@UUZ2,KX8YU3PO&1Q+#Y>"3*:F9:8%A4FT0!")NT\Q2?
M&XL)FM"3<FU555#"^`FXQU*V_RCK3112?/&4(G^-F6PML<U3`#0D9V-RY\:B
M%+!2!6L;BN(5<2<^G5VR*MMD]WDEJ@_@&-#LSA(847U:G7(B7TNC66E'83F%
MTVXX@Y)>>^1QDT.P&79YC'4).]2&[V"7&3U=G6""&;,B9G!NM!%_*3^U+#>F
M'B:[_3\:&C\HB_E;:17<(39;S1UB<X>7@;E^Q=\.<@N9$^LR=+M`N/Q9^E4.
MM"//@KXO\.);R2.J>GT?C`4?61?P?ED7\/Y^!"4:<FV@>&4@^*H6[@=C_4^\
M?3*I@@WO]I)O<QQ-IR)&X5!U9P5>S_[-T@PF$N.UYQ/]"C*.$]M#^M*RE/E:
M$\[0*HN!/X:+Y.GVQN1!O7ZC^Z=GP>:/`U_?;LZ?&[^>T/^.D%^7=CLX5K9Y
M0"RR#K$Z*?18.=AAT&2>R$'K^?*OPV/KMRB\M?X._WIN7.QHI<Y5*2S'RLP.
M+0.>WV*R&4>ME&6T'"LW>P)YS`%Y[%5K)]K#'T0DXX2OY\;/CE8J6YDV>ZP,
M[<BD,S,54&?3WL;H*\^2>^6K65XOIND>*2,\O*""OHEGRP0/CRZ=KO[<^.#1
MRG7EN:''R@`/+=&![DZI"QC;C7*<3E>W98"HXH\J6%<Z_#'SZEB9W.%%EWZW
M,7B^7.YD?3N:JV`G_.V8-=9#"W@_(W\[O%3RRGF^BNSAL?4\%=GC%^#R^;/'
MRN$.+<%]*DT'/E;>=7A9XSGSKI-D=C0,?@O&558J[UBYUJ'EL@LN*RB+_>G2
M#D?(L0XO/X`VV7Z^VN3A\?4,>=;1"ENEM1&/E6D=6M2ZRM5WI**..0_!74S%
MGA!2:X9Y>A2K!CIFY,*;F&]XM%SN\)(&.@9>M4^RV;/C<Z,H3:/IJHTXONMB
M"TY869_UD-SPV>):5DF3A69+:ZOFB]'JN!*#LZJ2M)A@[$O57Q>O595TB]NA
M/AXX+[;$IZQK:&/M=U4CEBLOY,KP&K5U;T7HI]@>D.J04OHGI7/G*CC[H>&@
M]K"63\K]377MC:Q6\`&OF^=(JR9['7:.S8GSW#%:^\+*-U_:+(.W(D4H>%9]
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M1BLVWI9V59>0;)I<!EFN`I?YA%F*RRYA=^5,U5[-5749$NI!1>BDNC@+63@K
MC:,`O_9CHQH<E4C3NX?]?Q-=6W&&_<BY/B[7+,'B(T99$U4W)XS",SE^0`V(
MD-A`G\-R6[)$"M<T<X&.J8J1`/H2JK$('4VX#E"[_K.%&XVM7LHK7E77*3N5
MT5EN4&"VC%4R7JYHSHV/^,-_S60'6H."X&LLH08L'%9%#<YPOS3E8'5-&6N$
M3T_F5&2,2"0K8YC58U4T1&4IDV1..X?UKWB_$UW.SK9F[H(/>GD-USA:N`%5
M>Z+?5=<ZK+6:Z$K5LGC3JN8TP#&*12--!%`K#V!(\^E<FG4$X,`GDGW9&CIV
MN]NWNWUXYR&*O[,Y:(;XIP><IMWNM.Q.K\5S&C1N%EE7U`YOX&BMEMT?=!JY
M;1#W;C!G1DPE"*/?^3P5JHSZ:46'3RR*#=Q<W*M"U_@(O:Q+:"(4,(MBKB^=
MKCUPAG:WW:ZHW_K@8Y\W+%PT09S(4F!(`D4"@/D"X2:IWG^J3V3]%CU@>U1[
MJ37C2!`F(VPOFU:7/LU73-*U$7!%55EP"F9%J%QCGN\>_$Z2$U.9*L;'WQ&2
MJ+=?"*+MY22;$!!?.9^(J;]D0,7"84@:F:;B+FUP.R^XBB#=;1ZWH0W<A8W5
M3]-9A+%^:$G#HQ+PMA6P!;]2+SAFP[H9;/XQ.+\IU96*N=+R`[:4A?GF8ZI`
M!><N=?V@N''S,,#JUSYQ<1*0`;QH1,4;N<YCR'6;DV@>8_%U#Y:!G%W>)E0>
MC0JV8_DS5?B=*;6XD%,APJ>\)U1)3I/-QW[RG0_!'*,<\/?47U>CT*`>+)6T
MKN\P?/$[E06,<IV,L8=@%!M-`[+J@3G)):MC:THPVM#>L&[FP+/4:*K0VVB>
MZHJYJHUB&G%%:EW>[2^J:+TJS+MT[B82''AF!L!AH=V20B%<MY^#=['F"-PZ
MN"*/Y)?DC1S#D-+D^?KP[ES6KHT%;(I9$%_5L>?2BU1,?R4D)1#H%KFK()$5
M4JBO=$FWG\I>#V^H!K=(?>[C8ES02;Z#)-V*6/4?.`(S?:/P_*+8HH$@1&E"
MMGGPQ%0B2(*N)JE&*JKV,H4P8U%*A,62_UR+$O2CA`@GS\8DK^:QA%<R32AN
MH]0G#NC>1]S`.ZLTKYAOH4UFUMB!_KJ-A=1Q*E9FN??`J]6L6`\PA'<\G]Z1
M%6B6WM-=APKO`G%-1_,X$5F/7U+LDC0C\"(M9>%.>1K(TUABO<JU!U#E_E_+
M.Q;[984TJPSZ=/.M'$#/OXNT."B[GLI'J=F6>TO%S8&28FG,9.Q&\2W0R__(
M+@)+IGOY^3]^F2=GMZX[^\N5\?R%J>2>A]ZU45[X:O)!L9@;K>&^T\5)OP(#
M?QM$X^]_^U__CV7]Q_][=G9%X%SDZM&#FA8!0WSU$21G4/L^R--]086*QPOK
M:Z:*TY+H;ZGAGNLRZC:P>-J@K^Z/LS.>4"\'9\U-RG/BC'(Z-9LQ&:S5F"J;
M">:YFL`LI#S""K^(R5]?C+%R<+/5;*41?6JW6R^P>PO_^JW9=%Z0&CD%/HEV
ML[^=M9I]I],T<+X7(/\8F.]JS'=K8+[;;O7Z!T;\.17F!51%H:S`78HJ?BQ[
MJ&2E:]?7'[9ZA=45A]T3<)V6LPZXX7#0W0RXW9'LKWC?\9O6><Q=3=[QA7--
M18JWH>2Z%(*3X]1R8IZ7I]T90^ETAS48R@XA/FW5MARH[;2/=J>^A2"8!*!0
M>=9O((HBTLW]0,-RUF5A9[N3S2HG5:NZ"K/I]G=ZG%ZWQMEY+)!_P&W8Z&2T
MVX.#;X)/@_[R2I:Q!\R'HOP"A#M**]IRLQ['!YSVL-,M,H+E6?8)\$:GI#=L
M]8NG9"VX'[-&!&M%#./9Q\D93G_8:Q4@+1U\[\#6H?I!JS7<`MC+\!Z^C+"7
MW"?IT@2H;^884RAMW)]$C!UP,/925K%!?0XN%9;<?XWAV)0N3H^M1U;CPMUC
MC/H-!S7&W&;]+=BMHE2X[?S/$44UZ'F/*#H?C^.Y\/*D?[%*#^`7C.<OMJ=]
M9^`XW>))K9SA<*#7V)-.J]]>5K76@GYQ]>GZR_O?WG^^N?S'>^OCU<V-=?[U
MZY?+M]^^GK_]^-[Z>H5-1+]>?GIO6Y>?+QH6O/#IZK-U\]LYO';U\=W[+S>;
MZ-GJVKOF[K?G:1K[HSE%;GR-D+=D/NI+Y:)^G"PU<)H]I]NIIV)O`=ZS1N5F
M$D*KZ3C-]I*,L`=<7FOW<A1;7TH.D'H`M)(OY8=]@X5UFZ:X71BZ'*8+Z4>^
MG**MGVV-*V"4CYM//XZLR^$MF>9@X&^$<6?8:P^<[=>01L!NR26+C8Q!XDOA
M3KT.7&J!B6&S\!N5CJ]:U-=(OJ]>IY?AJM)O/FY_@%\/G=;R`M?/>QR+W6@W
M^_UFL_^HM=X(<CF>H[1#H8/HF;F.Q410=,L-109BU$EL8:@%Z*6@>WK8>2BF
M-HP<O/%Z"0%JA)LT&G__'%V[\3_H]1JR0=M<Y.7G#_DS5S'PT2RH1&)XW((R
MV!-\@CJ)>P(=2.CW0>CO0%Z%W].[Y'6V?&/)]-H_/U%_P_^[>F'OY.!?8&Q0
MES';`[U):XCT7]KM<X%QP%<3&NO\AY_\B^$YS\_"H.21U%E&4J/9KL)3.9QU
MB2"11!!&&1W8RJ^&EA;';C:;^(\*C2V+].%>Z\6^D6^L/K^)<5S2E6MV*ZL_
MTNJ=JDU]2VIFE[*)JC"[T6GZ>1%91U_?(2(56Y)KQ5/-"%O#B/B]2WZK!C&T
MBA?(JA68@S_I0DHVXV`+,8AYP\6<9V]NL3-.<R5U%:<XBF75V*=MEU7@.=DM
M6'I][_PB?$<SG%/KTT/<ALLB0ZO1K<3:"F`WX^0Y!KLA75P9K^[G`!LS',>R
M=L-@=[^L1])^S?W<!9WO"%W7V`#:-WH09T%/RB#//9%+%HXOON?W0$,R8A$>
M8<YL.?W6P+34UICG:193R^C<;O4'P^T6\T7WJ.?R!J`_8^+,POJG_"]&AUD4
M'E9"E7X4L].N.$P6:?-.)./8IPR-M;KTW\K"E3<,$<XBC/><:7\D`=!%S%='
M.:M0Z1ENF[40H!"H7N%9ZERLA^.8?MF&'3]2?*4D4WI[9L08-C`PQ./X5LX5
M@)&$?X]&S40&+3]D3<I5*E6P4&&V-<_4-HE2RY&3FU*N<?:IN[<L)&(FV*B\
ML;/*+#M*+:[F\-%8""_Y`-@P[I1W8K1>GOG"D:K7;IR:T2?)VX7Y"S%^!`YA
MRX$&@)7Q_B5'2K\YZ/=,)%:";."+GY%-)]U`<%?TZ30*C<;@.KQ^L0HOG_P0
MXVH7-T8^TNZ,Q6LF>L(E;6:R[PSA?]V=+6R6-V^M6LRES(R[FN3E`@Y'AB^0
MVEC0>=02*W:M_O1'L>2-"+7$EK'#A9LIC3E"KK?T"WIE!ZL<M`9.MSM<MTIC
MOL,O:+>4^IBE5#55SNX8'MTB\1^TC3IW3UTD.!H)CC.HNH'XRJ%Q"(9S!F"3
M"TLMLK#&M??561=88;U#LWX/&`E7,TX/>_\#NRTGPEN%1WI%OJ%?>-SIZ`ZZ
M58LIG>W0B]DLA+#3Z[?:CU^-XMDJ88\Y]OJCH9Z71V2=^FT`!Q->3<XY&RG`
MX%_\)HMH?,])T5O*;,:),73R0QP84B17'9AZ"U^S39A,E<SCA?2541Z=%I2L
M!S>F!.;U^/\JQ]G!I=,=#CM]9]6:<Y,=Q0)W<0G57QLJ?FI]HM*EOC3TGGSJ
M*Y=3(WC@L$O;B!0[:P[?^M5]?O^5`JQ*EC#Q4PP^>F30V+#O#)KM5@Y*.?)C
M@-@PW,KI#IO-;G<E%(6(D'Q`R&9FK@JL\ZLZ??)DWMJ#><O8L5#P)F(9G32>
M<TH2V;.B6Y"'\_G]1CD$PP26G5,_X6I/GD5E'I*T8?RX:A9\4Z5\@Z(X]FF0
M><+)UBB`Q"Y6%3O#YJ365*1WD6=AUJ_EHO_+Q[\F@$>TJ+6<I@4W?7J7-"B:
MN6H^S/?/S1:F/E5#XDCH8,'^]D30NF:!.V:#5*3*Q32L&R&LSU$JK$Z-Q.*Z
M%%_WK'U+Q&0>4/&GLPS+6MKZY(?^=#Y=)7Z5@\/CXK!KY:W*,=XNOBYF@D0G
M_9V2NMSPEG^1$$HAZF_7[=ZG&MC*P-L5HMP?QXXHAE`C"BA\/Y@JC?>O')^>
MWL91U!DZ@T&W7V,)-,4AH:\3^C[H-[NMWL;0;\!TK5>)YBPE_MJ*Z3#A;9MT
M(=B*0:?.>F""IUU-K9R*7J?7&VZXFI649?V3*GMN)<W\0>68I3)JY3%J=J8>
MV-9D'L.^HHN'Z_?\P,^RE$<E:5%)K3%F!)#UA(N4&&5[MG!LU:O]>J@JK_>$
M<2S/CF73];S%@J?\\QM+@JRKK#NS'Z65K'(%60\QQSA"],$DSMKQ'^[\5)PA
ML@&K8?00NW6JQ^^!XNGI!\$E[T=1X%57A<]3^_Z*A6T`TJMOH3OWL)S5FGXT
MC.*_ON#_OM@%.534WCTF(MQPOB.G/Y.U'@7U(7L_>K*K:B]4`8KDUOU>28L+
M32='U1?-*>L&Y*A;^OVZRW?U!J[&4NL12-J<3=28=!E9A]PK&O'E8Q`ZK+DV
M+K]^^,5U;%#K;%`F=G+L][*A>Z&K$S'_E,0,6KX-:O[S(^;#7&I/V.)N]:56
M9?(]X%V6P\W3'?_=@/'XD[HW4J$1>\V>W>NTCNJ<[I\`3E3WM%37:7;M?KOY
M_*AN#[=#J2;VG/2@\UQ+!^D17-LB>OO=W`IA^V$C:WLR'E#(7G7F-P/TJ:3&
M5X[=`[%QX`P/Q1CJ64$.CXDU)L?3V3F=G>6STVD-[$[S8)?J<SP[![B^.Q4G
MZF@UOLQ1&XK4SL[0VK"F`["G6L@\)'L"@"POFH\"L8U4^7R,2!LN_ZGT",<>
M]#IVK_=D`D.G-M/;/\F>#L_I\&QX>+I]>]`YF)%VSX=G;7?9&E%-&X:16EG'
M&NN?VP0XE72\.8)0I[)8I>?8W'GO+9M+//JY0\W&KF(;Y`,V<5X3<I#;W$W#
MVG?3.7R)OHZKM>PI%.\4BG<*Q3N%XIU"\4ZA>$=,=J=0O%,HWBEZZ12*=R+F
M$S&?0O%.H7BGH*CG%Q1U"L4[4=TI%.\4BG<*Q3N%$SVUU'@*Q3N%XIW.SBD4
M[Q2*=PK%.T43G:*)3J%XI\-S.CRG4+S'AN(=>1!0[K9N-EJS[`:/V5<LOZR(
M%EKKAUP3!.0N11OYX3B8>\)ZV6IUJ;/EQ`^Q1+QGC1;66#:&#H2;"*3UF&*%
M$ASS/^>AH-`DFO&E-"YRQ?Z*V;'7M"K5K2N4]M]8'V*!%4&MB3O&QO2+AO7.
ML"VH_CBR<0^WZ'GI]$"#!'!I<J?;LX>=+DV`44WI72R$K#)J"<"B5Q9DQ7%5
M`-E,`*SW(H")O]YA&[^)[!]AC43Z@!V"<%"O#";X)KH-J?&@SX_AZE%7(!M)
MHKJ1(5XP1-/E"O0X/3X,V(\)M_"R6V%;P5=AA2#T.\/2249N0,T2DCLABZ&Z
M<"C=(%C`?G.;=4::6?@Y>\8LLLK]AIBBHE@`\<I61.,%M?8M;46TZL`]FN(/
M<UA+*O&N/,`YT#=RIOP<^-HDPK&RR"_2M6(;I8US82`_QG99,17\3Q0-^V;G
M>9.I_+F$E7S#:L',%40\353@([,T%R`1S$_I2R!\N(4\ZP[@P3E\9!VZL<*#
MG]Y9+HP38J"V`87E8A2EZECRLH.Z.349Q@@]6)$>`0ZGK)H<96P2A@Q<8*YN
M&L4+.GLPL"<1IA8"\&'19C<$G@1C\('FYX1U-X=-LL1T%"^BT!_#)HLIQ6'2
M:(P]/6K"!92M\:^?KAO6%:-#;81MO>SVFO:PW[3^/8<-GBP(P<`*IJ-YG/!J
MYP9*JU'1@&4O;RJ@1,@V:0(Y]Z!M]WN=K#"]V@)FQ7KU@#ADN6/)R0`'V&$@
MA<F9B6%@:R!2V9*YI!JTXISIG0_["VN+84L0/`3J,>6A2R+LC4:#C'GJ5&&9
M32SJ!O97-<$X_KA^(Z@L.`7U2Z34#^H?'&]0?[:S*^@;CV'^9[-K+/;+JRO2
M;QB4_C27G&JM(QLW`D>:N8L$F*G=[#:I!S1)HUI"!0Z.S,>=`>/\X4^Y*^00
M6](C:P+&AZ(<RHR3"3(O"O%&%H;0_G<4?[<N?$P9XNL%F..4^E"J/C7((A5$
M<(>X//G9:''&4(S<!"OZ+^!'`L.'2\&#JW8,-Q`I"7=^0@T""-XYRZ?`7NA2
M@MMK"M"1'I!UK!SAO48JQF3B^O%6/2N?9NLN0^N#&,5S[%7#-Y2^KF.7<B7R
MN_2RV^A:`$<@Y1GW%H2(6_C-NJ6:Y;/*9BLMN]-JVDZW:[1,-)HJ&TV97!0*
M9K$O!8IV8]C,&HFC>A/-;T$4"?DJ?HC]%&YB:S8?@>2*-`.#8G<$;->)P]PC
M='0IXHW5L-[&D>L]1!$?S5#$V*FS<=VPX1<_]9,[[J&*_UCG4Q@,Y8Y+.+[<
M)!1..N#4NOYX05-<"R^.K(]`B4@4`.5L#C>^2Y@ST4,8:#I=D#.:2@QC1%1#
MA+0M*=G0&!,0$^);@(;?YZ:.3(PE!&T#H8`2>X&SN!YH2;&-PU[#Q-BA/+7-
M-\OT4V.D+[!*%P2(KPWKHW@[OPMIJ!L18GO9?^!^&<-BBRZ]K@O6I6W`X[AA
M2^U/8Q2(V+UE@:02%4MXAIG+P+VX\\4$FYR-YZC6@HB'/"26Y##EZ'>)I+<1
MK@;^>*?6V-B8!OR$]AEF"7RYSZY%K:#DQAAH)2#DACXK%O&?\X!E\QLQ2QF%
M;#^H:'U+/0RQ89QL0#PV;K\P0F7F%9*`VC>G^<:\'[$:O]Y3I_7F-:D^#U'E
M;(G92Y4Y,B@,H;X%I/0[RUKYDC&%U15TQ/=[H`OP$<`':\WS<!=9[A@$86P;
MN@2^17=(B(<!?W<S/03%@4:Q60U^8IE_'I(,`4!JVP-`58UG`O@RB5T1^+3A
M-W?BNX"3=A<]B'NIJ2R#AYP4+FFZ+P$]WT),`+*H?SPPCR@`%I.P%K+\[H@:
M25NRFXYJ@TPF$NIT\R?BUFX8SJ<\1!JA'2TRVM=G6Z'L-PKUQ=ELJ7B.Q_'<
MF(TXCS=G^Y]:"-P@]V[L1W,4"5+L4K>P/%J17T7#?89P.]C*09-;KQ\E1:QJ
M`T'9\T.\?.6E2'??Q/_!W19AC`0OVNPR=)J-IG$;VO@"PB8",5;V,OR;J91^
M=D/0G_$8<!MP`$8A!Y34<&'.4[G0*;([U#M%F@8`&RV\]II"CQH:T4MC-[EC
MG!OS3H1+QMS*^65+)$"UM(*B:$8,%15_X7ED-J2['IE^IJ.3'2,AH1P9\<V%
M-0`A!YDI,LS]&="(<X*DKT!B+/PFO%L@,>+K^!(]!*(CBK>I7B3(3D)H<F23
M-"CZ0$AH,M']J@K=H&KO!G5FQV[MKN<'BV52Y1TZ!U3CF[?!PE[!0_([PGA'
M+`-;/7.:!T3T2-+71495B*0KN@UD:]%&'O'?BM#J"\,3:"X#D=YCRY,+M!\*
M$"1P&TKH]I5QD[V]^)"[NQ[(FB82LH/S1:0[_#)SJJ+Z5>;F`][_!3_4D\-S
M7K8#U*--;Y$_L<MQS:0L0$<@I\<RCX5Q`E3D2'Z@'''0Y]`5.-?<B62;.">0
M*U<1R7T-ZX9.])J92KCY\NS`!DCS\D!0:>6?S0-6]_1+K##A55QJ(I:+].RU
ME"_04*I-TV$*=V<"6AC#Y6O*;X#P3+PB]F@SZ*AF)^^LW3P;P)4^*1U&XAT.
M%HX("I6;*@E/LGA6.='X.G8-=T^>M2GFR320B8"$#S\A/H8^("#";`@Y:>!/
M?6/@_,N;`L#7GQP9?6BQ1]XG4B0\SZ=['$80W%A8&M[A,?3617PK@%`I;>1J
M*C>.Z1[(X<P$P$,>:4)Q*=UI;K)*_$KO"$HU72SDE@*X/*3&78X65@G;Y6<3
MT8)"76[,!Q_H>D08![#^AU&K)2WEB,R:,68'3C]D=F34_M&S!0JQR.4U"<"\
M=K8\-B&8U@]C;)1MZ4(NB+Y.^T]5AO_J/2HY@4`++UN]H3ULPJG(E:TPT(H*
M;5'T1"1WVQU[T.IQG1'X8AYFR,LCEZPKO0Y.4\,)L($UWO`!)((0@=!ZH(\$
M46G#7?7<>>B]RYYZ+[?W4;UCAVVGW6TUS76LF&O/D&_4>G?0:7;;P_:C(#>>
ML^2#FW3"73FC?/WI/2^'%(8.(]!645]>@-4R2.N-5?6&XI'2',$\`JW;J!23
MB8%%=^0RH"F>X0V31#'>_6,T`Y!KEGD>J:1I[)(?,JZ:#[G"/?6'IWN.#H&<
MC6)MV)XH?;,\QIDRCB"/O@.])`.:WT*>F8`RCM9B&]7]&$"S4O<'_HGKF@?$
ML"<"O\B!9CB7U:_,^?13TLU*0TM.J4-/@+&ZX2VQ9HX.87,I[!,=;QP1P/'E
MA8_.50HM86^]M`[!5RG=EX!E^2+]C)X%]5/F2DC%^"Z,@N@6M'.ECFAL5"*=
M40S71C*'7^5?L=!;7(N]KSWJFL7D,Z%0.BSABVCY$]Y[-P[16V*\\H[?V*8?
MZ%D+J'W8=)I]$_!U,^T9[EH-S(=P"_7A_SN#&^[A7*O@':WC7S<J:NL]B9\7
MP!>B$(F4VOWRK++;[SZ7_&M,L14A\"6QO+9[$<[%ASB:TF./["[?&PX&[:$)
M96'X'0&UT>4/>.MU-P?J`L-6(L"N"^(]7&7IG"73+^(6]#C)RC\)#W`=BHQX
MM(<"6`ZR(7<FYJD_3K(G;N:C!`1\DB/N5Q/>^LWIM)MR<^#3OSZ*6S=X#R)W
MNB`:4\`48)&MIS^YOT?Q!5S3L-R8B3);M%[SU<1<L5JP'");"RU%=[DN?%^'
MREO-GM-TVG7V2?X"6T%1DWC%;":*T>O&VX7>["=!;"^"&&]:G*&]6@;3<1`8
MC^4K_P":.7K-[EFK*84>&32+USD/_G"'_FN@YKF;X/D4&'HG'0^H@\8QMEN7
MTAR(<`"V)P)X$H0:#-:+QE*0`PE#1GPE\,,]AO`*5-E#\D+92C%G.Q=[&>`5
M9>U$'XH*H0[0G^".=/P9!NI&^,0"!:$YBA26R7BT15JY^[6HH@/O\`D-'0HG
M1OBP6T`&O!KB%!+])>$$-<:'E4Y!9*0HWY@B[I9&N5MX<70K`OFVCAQ4@P($
MT<(-TH4"+R=&RZ>L6#X#@BF%93;03ZT$Q.4W,[A@#(SD&\<^&:A9I_?(&I"P
ME8=Q0G!_]"?BDSNS;J1MS_1Z1V&`_-QS8<_<1'H;"C@>45#"?$9&'!7VG9\?
MG2K&]$"2?N3!<MB*GI-Z91BE=/"JGW1(J30C&M-[\UAZUV`6.;*YV?)P:#)C
MTR>0I-H#/%#R43*B,NYQ)U>1D_3]JIA'^)/#AO#+6._M#,1^/8K(TXI<&QP-
MN$SN3,MCZ:`,4!I%WSGHI&']%RY2^Z(3BNPE+QHH`7(ZV)8SF!!S$Z,P%A/`
M+GDT>6[$&QYM'YB9&TNM8X[L`EY`12/#.F\+0Z.F1!814L@M*$ESN;%P7T[9
MN3D"ALN1^<P@:/A*A,H]DQR"HH#*N4-NU7*9R5[7Z46*[6V\5!"J!7%0.C?:
M7!;C><)SJFR'YFA,PPWK<E+Q$P8LHZ=M));I.D5VK`!7$R8%K!!X>FZ0<4R[
M+BGB@(?4#UCK(Q\ON:NJP4%88+)R@!K6)Q]H-\5@(,7*R"COA@M;!S!@5#%R
M(+B=,=Q*:JP81@D*[YTO5&AZ@8+\4-T41#\(XE3/AD$T8[XUDSM\>&*]<E]G
M4<[W9'P%))%I-!8RZH)T;)HR/YYMO1J]+C'43XO+0_,NL)0<`0,8\!,0,=IT
MZ0*7=F6<GC1QCQPC0"BOQJ_-@Z#<`7+L\G-11Q%?(^AE$J7FB\2L<BQQ27QD
M7J?DF4<I3"U03;JF134W]C[`VTAU&O8'@]Y:Z&ZD"$`^.]L*YRHR3'K*9`@3
MWA^9L=MZ!7_S`Z]K*$TRK/$"([NM\TJ5"4&YFE#PXV<"`_Z@.2X)ALO0,+>7
M[)RC=\YQ!O^J,-.SHD3P$#CG4A>JLNJ_79B_K-?+\EO2*E),I]5TNH8E8),E
M[W#+JK78*V!.%XL4W3'Q+.)4M7UM6+<YD!L&GY;47X1D#)`8@#Q>;RUN2)MS
M=9]\0WX547PKK+^[,=QZWT50=T-JFR.>:*LV.%9DT(`1;[+HPMWO=VOW^ZWC
M&UWI&&;!>0]G[,*<Z(N<YUK$1W?*BC=1NUV-]1J+6L+[:J6W#(.)O/9^C4#=
M^BQ*C.X;W:R#KGFSEDUP")@W$E8&PV%K6!-F^3W&S"\Y!LP7'PU4R^EU.MU.
M.5B[@FBCK6TU>[U>N[L>HILQ2.ASWMMSCOY+K&L9@8M;>RZ#$C[Z;#]"`?"?
ME,VVRKRIAKV:J$'EF.>A)T<T!J3A_J"6S]I-4URU.S-C=U3(2&#LCC1,G1JC
MG!JC[+ZPP*DQRJDQRJDQRJDQRD_8&.6\<,'NJUK@J77$C@N7'4,A4\?N-_MV
MIWWJ@W(BYI^`F)TAEM!9DMR.GYC_X'U0E+:N8DP/>(>=.E$<L`AFVVX.';OY
M''M1G.CN6=-=R^G:3:?]_.CNI-W0S3"*POEA+X9CE`>?\(#N673K-.W>X&"%
MQ4]:R(GJ8,1AKV.WGB/5/6%CK*/5(3@\6%;_,SU+^[HSML+8,7?WV;\LN*ON
M/GLNU3]P;*=[L"Z-V[?V.7R7BQ.-_R0TWFGU[?;A.@;OF<:?L-/4T6I.7['>
MW:'NOEK8.>KN-\_4[KZS[C?[77_/;CN.W6D>S,^T??>;_9/LZ?"<#L]FAV?0
M;-NM_L&LEWL^/&OKS!OQGX\(R"P-%OW@8Y'9LX^477F9%58YY[8[FX2(\E`T
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M@'-[<5IV*MRI3:WVL%_]?&8T?.-VB%2;>P&OCZF/>#2C`GUP[+%8&G4^G+K?
M!?5&CJAMG5W:H;UR<BK&?>^+!^&5OB@GQ'ZU6-@_Q):[O&-4V5DV49+EJRO;
M`7%0AJK0FE7>PT9/43BF]D*V!8SI#N;S_#&U18)ERK9R(;:0A&>HJ+/GPR2J
MI#S\0?<=O#`*L$L[?GGO)N,Y%NQ.%E1!?_4;,V`94]>ZCX(YMS9RPX1:87B^
M>QM&R1+`M"UN3&7\TZS4\AA+6\=<B%F5\<]>)&Q-W046O)XG7(,4F.^MB!?\
M2FZ*N_F4.PG'BRB$^;-&``K%U-8/NWACJRE9/-QHS*L/$S77`SX/,V)-[1A^
M#A:YIHDPJ(J9*1W`J+-=1B!)A-%4FBPE==0H*UWC0C)NO2"`1VSK5VJAPE1Q
M[DWA^DQ2V41&=H9*-NEA(L>5HV(@66Y,->2IL4FT]\8FYLZZN5T@\M']3<ZL
MZB>7>\OI]I3<W`+#Q.`!5S>W4,3-366IO'S6X`VKHIYQEPKS19N.:,91N4$)
M5VVEVO9)%(8B>(-'>B(29"82VD)GN#>\!-VD576;JW5XMB'<[#Q5+&WI?&`%
MWK?XV(6)N<>5&AVV.AVS7UKY)/N"=;..E["B7%74-:#BSQ+4'!#G1L><T<(R
MG[N6U?G/']S8LU5G<-N2O:K@FKBF;@GX390LUZ<MA<B8[^TB>T3.15/)B7B:
MRY`GH2DVV]YB86?8VWR%X=T#^+/C>R6)+A72=IK=PR+<NL:.33OL-H"#TIAE
MO02.I8-`V\2[\^)O[<:PB'1:PUKB5#1'S/\RQ(@YO$6N`X!T$]&E=)MY:+@/
M],`T[JDS[M[DEJKK*2>UY*U&!X#*Z`*7%Y]4BQ^.CT]436:6=X`B@0\DUBU*
M(B%]9Q!QUH*'VQS)MC?<R084+)#<N8=-UE1.ZT8F<U9-TE&*0NVC9`[+?2!`
MIJXG4/'@'KU1S"J<F,Z":$'-<S-I37W)8AMH))*O\[@XK6HK9$U</^:6YZ`V
M7\A:T]3;/;VS/IS?O+5NYSXVM`MQ"H4QX`P!]43"];X-7-CUF_%=A,VU/HDX
MQ87RN<:&=@C1-((Q:)4X5P4VY4IU;]T_)UG[.X6]#%[=RJ(<7;*-O2>[O]]2
M/SS5BQ[T3P;P+`\@]CJB1O(H!B\,.!B1W)[/Q?YIL%?PWQ'W#IHR@F&G;V%N
MZDYO]-NX\V_ON'?1+!`_N,+^?/2[[/%V[P+3'0591V;]A3(HP+[-4VK9A`VK
M`G_JLPIJ6Z9!9<90FX""&N^FW"50-ZI"="H=ES%ER]+CZ5Q*YB"J_\Z#E=(1
M2OOQV$^P@>&=>^\#);YA.X""0<TAZ8YQCWV9<JW^[H#2HIC-&&[J$EFJ^=04
M3..S*$G/[I%F-6U+FTU&&@H6J4=8L9]\/YO$`IO,P7/PLD4J">RP/@4(]+?&
M#2`^IB.[H$=([A%$!:HO'G?UBK$S7Q1Z6?<]35@-ZSQ([Z+Y+3>DRA-I^6E$
M2!1ULPD$V4_L45,P/'T9G]3'$'^SK?$=2B^)ZIYGT)))B]A0S+!R,%GS/NG#
M3R#6T;`VOU_UU?^YV'=F-H]A!;@%^^G79#1*.689:KD)C-/M=8IBE%S(IMA4
M?%KBC.[E#&/5?7TVPR5VI%Z/2YI\AYUWUJA<2[UT'H'&]42IG[B!_\`X;RM0
MO@_$$I&^/2B1=G>)W;=QY'H/:'9&V$(R0W^\SG"VFHB/B%3?28ELNUY/91B\
MF4^G;DQFNAL0\+&;(XHOYYF`2ES6+^G1DSV>/:T>/B:K;9GZ<G)P;NO@=([7
MOYG;W/J$_5-Y/@^DZ9X:HI\:HI\:HI\:HI\:HI\:HI\:HI\:HN^\(?H?7<"Z
M<!,.Z!KC!]S9>V"@H2P5L$;,XI:R'&4D;<*!#T,@N:%UDRDQTY5I.UV\Y_Q;
M"O\"NI_'9,W%O4/;)NBLZ5V"=`VT@GP<CTP1MM,N%G81U'E/9!TX<3]OV>/-
MG)]%2Y5>4[JKV-(UI6&R5Q)Y@.59G\&E_X-X%6ST2Y"I[4&3A>J7W<[0;LL_
MEF9>-8K3:^H77W:&CMW#/Q(DB'K%I3)9*E@T*E8AW0X4C/-`+!G]-A@PGT[F
M088WE/?SX(&V;'<W@D@&$4:)6C8:Q8$G@^@7*F:%.,F<,=H[!(J'&\S)8,^7
M3$X+@/G]'%H-N[]+/A;!3TU<<J:9[C.ZOT1X"\</3UHF$LA=1FG=3=`[P)I$
M8FBRP*_/4H9.*.(R/!W(DF.2B!O6.4#B>:2EN1S,&-\SKN%D^*!5D4-&8?O!
M![8QXELJ]OC:49@8";RK$G+HL!YFC>&HP7=Q+CX1M29&#Y#65,#N(XZR4,><
MR$'7M*O=#,!5:.B1&WZ/Y[-TO(`7,>XJT5J9K]J&JU?*8,C"(SE>DU[/0)A%
M"6&$))6Q'X_G4[Q5QZ2`ZCM=C9Q(9XBMY8)$76R()Q!&#'HP]_`AF@<8Z69-
MYC&)R:Z'S.ETY2U?>1%Y=U3@,SJP03+P4_*P53/(#T;\;)+&\ZF,X@:!;Q:A
MAYG=4M)YI2D9Y37C-(U735ZNHHZKKNB,<9`+-2F(7')@.*"</Z*&&KD!DQ^P
MH*F+9?A\B@;`$?3A!(+'&UT-`JH6$=TDAP0_G=,R&M9%'C0X/43VT@13_A8%
M3$=C@(GX!8K"/\9">%+:IA4ATR-AD/2'D,ZJ'OR-=1<]`%>*[8*NE1I<"74*
M$$NB!-7R*)1,0"[S=#8*9^,R1"8?Q0NK,L9$/>++BP.8&=7@8+T'+EAVE(PC
M--+$F!/\7:08B9&D*K9$Y17H&])@A,K#"[`&[BB2(?<J>-8N<3)CTD.HM5'C
M`D]DW'N<($9M^2F:I]8KM3JG^>;#Y8<K_6?KS6NX1N#Z/K'-(FF\A]--^1XD
M2.J(9^"$8W5%`N9OX0[,ZPY&=)3!3?5HN*$9"2'5-(P?5\U"D0^"LV5F<!7Z
M-(@*B$'"C%TTX9^1;8YWE=5YUXAV:/>0ZEI.4ZH>'#-4-1_REMQLI/_C;&01
M"184*H,I?O@T&:"HTFFD3*,-ZP:TG,]P85B=,A)["OK))ST^/3R'8G65]0=*
M[_^EY_7=YJ>4]8.J1$!6-F2+F15+69#\V`A4R3]?6@Z7AD?TR"FRL9$*L_$Q
MEDJ:1O%'X'OR,`4"97I@CG.Z74D.G\Y</Z8<'NM\+.TX/@:-16,D\<H<KY(:
MOK'6.-%<2R(S6F?(BH@662&MM6+!QFA7S>=B"^LX5>X5_#K1P80NK"?!V+S$
M)GMXHN8C2<N+:/'$$E".$,;STN;I9LO"YWX'M8LK"2M;THH)4XI7,Q:H;!Q\
M-XV$L1]G`=FI,P[`X7#:D`^BBA>%1H(<CAM)OE&)9S9T90Z$L3LCHI568,07
M0D?*!#Y#UKS<1B4*$&$79U6$I50%J9CFUD.#T@,I#CTR*=F,,P-J-MP8582=
M*@'9)QHBU;-A_:;$MH>U&U9"(#7)P7JE]+VR3>=!0`+6\2[D</A5Q!B1)?-]
MX.'7=DD@FQQ1>WCC.5L9R-<X:';/NDVI;2X?&T/4J7/N3$GE\OH+_87_O,N)
M+$@I,O!6NIB,]9XDF25KF0R.Y/#%M='46BE")F<XF3&&1\8#^1RF@_?\?`0<
MPW=)/L87)O,4M2^M(\+IBK\CU<BC#;>.\"C_-LW#)>,YD;BQX!-GLK'N!M,*
M9`*FVA.+6XQTCJ4"50[GG0@H#AAUJR5(R2O+GAT<X4:,T3B+OYZ/B8FUANTV
MYS-/R0QOO<+G#`K-OY(C44"-".\(>/(%D%I@V#)(8B,@5XE%*V-L_I#$_%\4
MGI"2J5Q9VO6F(QVM-^3?<IXA>DE,2G]0(TOB9O8<"H,[H\:?6070<D;)[G@!
M1:&\^?B9!LB\H?:?%8?.C*'EEE9MP$4(M($Q,^X1-\6AI"64K,YA(6CO#=P5
M,7FP4##!1^7]-XN2Q%=F1+Q6%"QHH`B%/-<B30-1@#XDB\J)P2Y9V#A`@WSQ
MZ^DO1W7,\OC]DB`3)2MH?D6"4KB0P03(>4#"95E)VF-9SC1"2"HN=#0J&,96
M+=MDSG'#`>XF&DJ.."CCUJ37*@G0K+40<C91+.YP9)P#2/!$1@4RNG8I<0?Q
MG%3?TA?TLR'ETH9&(V76G-$HB1&TDFBW.96F4/*6\/)RE+M"+-.IZ"3!`GNB
M`+#3#BZ%[U%$*QF_5\?N7<A()HY/6@#6M7'0C*13PTFG2425+/`C>V>X)2R]
M+4M@N.QZD0Y2Y9U<\GZ%T8,,0\)C*T`]90<@*04P%/$4O>EDD<QUH67A_K3_
M2_M??GZJZ:#JC>7B#]+&G.C31W<"LE5@]F>8UY1$%'6)?E2T)+M&/0<.WUFE
MB&-P_#V)LBJ-3<]&H@@G+<JH.1[C3.EVREJ=`6W4G0`)'B5N&P-58@#-2MT?
M^&>A?(2=!TVN`"WSZM<P?T=.W+'LCF7G6RB1#V7)UD6#FA&%1.)TDOS8(P.-
M3X%TZL[-&*D.1:2?0>'7/V4'(V.OAGM;8:,2Z6/)RUEYEG_%8CV#+=B83Y].
MGW[>3]8?Z@XYE0ZJ+AUT8G^G3W_@3W\L1O@!Q%F`1^H<XP4&.H9)P#SK%I4G
M0R]9LB[85H:W2>E(G`Y*([$DQT$S1<27AH189,$A2[+.QE!B'QL^!%46$;*B
MR$0Z>8#_:2#\1,F.*L&#2AEX*+YC&$C6.C3(.L&RRU,B0KO_9_.1#&47/SB>
M;JD0@HQ7J;:N4Z$-(P6*:I.8&B`%4TVXSDH9$.BZRH)1+,XG1+L"!O'=BCQH
MVO:ETAJ^"'4CF-O,07WY"'^*G5RVN[I&@YPRHI#I`"C-8YFJ&MZ&#Q+$7*0V
M.P)*(F,Y/+>*'+,8(!6:-;%>=AU[.."W7[::?=OI-/,!OBI^"-YRXUNMH)?3
M,Z-L4V]"C2B)TZ?3IS6WSTH_U=/<4G1ZC;1_4+S#B*K-L&^GP'O+.'2D`[1M
M<RAXI'AIY)F3'MU(5E5UHB0?\'2(=:D!/<E;T+?C12NO/6)*9J+"2Z?9M5N=
MH6)'MM-R"ND&AQ4_3FSH].DH/RTQPC^,2'[)_(PLN!O&D?CFJR4>R5_/SZ]5
MJF6N,!\Z-L:Q/V)!>IX(([Q,QN4J^7@AHUZEY#U:9(FV,*]\@<RYZGD)8I8C
MP#%HP5AU6F2I>5E0EC*O\H?@\('[P%="0?1N6/^@-">29U5&%L\D$DSX9<F=
M/&NAP/`HK*]!R=K>?"Q*UJ#<<!3]1OFU@?\=I4.ZS3!"C-SZKD7%R&5\7E89
MO71`3$[*LH<I`(\<`5:N=AD,DT39EK#3.2N.B+=3@J6>9`VW7"'%%/2ET=P0
M_;,TB<QQ;(Z&8Y@C(/@`L4HP2N"O[X(6EQ6NHZ!%_IYBY?&%6*3S.%1W:$1U
M[]C*)9_/\H9M^8J:PYK"P5-9S&>,Y3/$\AGB*H$?72YDP5%HXH>;U;-;X$BD
M&,UAUECZ5MZ*6S\D1^W5.(TP8(,O[K:=A>:-Q"WL(R=G:>\<:X<3X9'-+SM.
M<GD)Q<4RQ;'N8$1$C2AY0(VO#V[_#2\VCNZY^P*=Q+*Z^#DII63?I(1R`80#
MNQOZKETZFW0R<6PN+EI+*X;7TY20RF&1ZS'WULC\5^5.X&S'',<CRP=2)4(1
MRK`)(S!Q'AJ9XSBJ807E=/2,^5,^G<:]E.KL+#,GC+0C5T8!,Q1:WY7IVNRE
M*@.L,O<2\92M=.*3,W<-69BU+C%2*)K+]`,:44F(R]340".'#)3*THTH(P!$
M1]#B8YWYA3XT0D6.]J=8_:WD!!`B%I0%/Q(X/RZK62B_B!#.N=:C;/>`;\WF
M,9Q+UIV1;25L=L@R,,W:,``12=AXW&DZC@XN`0BCGN!V#0)J/I(S.4A'.^9_
M9%F/+#FC081SQ<9N'"\`/JY:JMIAP/,A3TQL-.:UFHL#1BGCDHVH:WH-:2R5
M!+H-$)B9NC`B,(VMX>4JI^Z_YQC('(4JA23UIVS)\8R\.@^O(:.*12A^S&6F
M&J,;M)%;35R(^-_GL9]X_C@?_0.WKK[M3:*U#8)$#T"0(TUULS;@1.A>+U1Z
M0^6]C=.L#$4:881I!GOER>8+SRBO*6U3NOQ%B,6J<?].62NE\)SGN(9$:UE&
MN=WJ]VULVL:U-*2*/*FKS]HXYE*J&X_L=%LTLI1K%!`\D>;NBC=&DPG*?UCQ
M5Q]Q,L/U.S2*67&$"))DU4SU3MRIKFT"!YQU;+<V&MJ=X3(:5JVNM='J6&L?
M#HPY2I=S<JF=/IT^U='JGXBO*B7`U`US&IOI#<H2Y\T\&Q4XG.7_J,)I*')2
ME0VL3`'\!M@9QJI?KM$DD?]HP,K41U1F)W-NQH7*(ZE$()YQ]D,B2IADHJ-/
M#<W-O7?]@%Z&OR7#IMBH\MD-5)P8V^G3$S*.XPIW!=WM/^>AD#**/CL)6F:Z
M*"&0E*"T.IDKI?I@H!]6E1J`0T:GD=SM9>6"&FTL<Q;H:I)L4'`7]!8*5^U&
M3SW1R"#190_-U"T)![DXC?08E3NKO"6H*;&:J81(/:R9!\29G87$FZSMGTS\
M`BY''6HQ"Y[M4]1Q224^2.5&>X'43!Q/NI0]J<Q'U+;`\+:@"NCG#`>9"?*!
M]'TMFFH&N*SOR2!9Z2;W0ZJRB$[YG&W54P4\B7-CLH:<W?3^/,CTNU2YTF5J
MD(<A9`H+9K:H*B7+SG=R?Z4JU>D4!7YJHG-JHG-JHG-JHG-JHO/S--$Y96&O
M<@3KNBJXM>@04.4T2!\\[IM._X[>I"78S1ND+(^(`GUDC_&*6C.Z4@FZA%0=
M24S6RD@V7Q@1RT6.R4:GM&VRYQ,+U;9L50N%T[395:MT;EDI$64]*I1B`B,'
M1P@3E2:8W6%D!U>%.(LU%Y&Q<XH9,)*LY'`)<-HA3_X*60,"1&P_415S4)XU
M0D@+BC^[FN2%DPVFRUT;=@9>FNHO8"S4+/^<*/DC&Y!A'2V,XNG%A7!!OJ3`
M'_)\S`#N)/CF#]X[99O1]?F7<SVJ4R'KO&UF0^)&Z%TI4?3RB7T3HUF%+1/Q
M"O/ET@)5%B"U:-&)?^3!C:,9%I^E*`V5]N>KNJ7&G!P_D2,<`TQ9RVVY;I:Z
M5>E6,QM,\`ODK=<UP8V.`5EY^<J1*\H62>#D.%YA57'VPU*!@H;I&G9G,UD0
M#JB*LY)+)IP(Y=',32-%+LY7)S;(X2TRPH9*;<NZ!(Q7.;11"=V<`@L@&"GO
MZ#V6'1S\$`1"*M:4*U3J"=3YV:V)[EH4DT-I-DT7=F;,M*)YRI'D1C)J,;%3
M%W:83E&$<P-=3A]$8CA7"IBL9/_W,'J0`1AZ5A5^E/IFJ7VB2),@*]:958]H
MY+D]7U_*GH*="_`JFS%=8V8K5FB2.%V]D?EK3^[;E."C)C'80"/PS3!;70I=
M\W^3$LL!)5NQF>&;C.^$1S6H=@^`+E?8.['W`GO_B#$',XS\0'VS1IV3&;<E
M(AI]B,ZHF($J3$G)ZS+0#GD&J"/^F!JN4%T=/4W#^J8K-!4'X<J<;/W*.D=D
M=;8Q?([N?Y!Z)*]GY8.*<XO02S0/A9,LRW6S).`G1C[B2*0/@KJ0%,R+'.5-
M[!Z3*]EFDM6$*M2/,Y[#ICATL32H=5[IVUR/;PIGDD:9J`Z%YWAJJ6L.RJ7%
MI1$?U4-20QJ]6EM7*?2PLH1LX00,",Y=!?J)!6?QD!A2B:,AJ!GN=5*-BO%3
M'IRRHES<"3)18ME2FE"QC)$T%F6(!_Y+=BF`@0F`XCSNN0PDJKB@36<V`"-*
M*1:Z8%1FU<CHQM!R55+2!Z-WT%*>EZZ?X1(4G'3&(5XK=E36[Z-Z#*P[R+).
MTE7/2&=>E:4*:6#92($:,HP=+&R.QZ+'L@BZC'+E35L%4<-ZYP=SLG%LLO,J
M'&FONY\OY);;=%7J73L`V$Y!F#)KDWNX./\^7Q],V2J7CE?>+F%Z#VRCRJXJ
M6G?&CRM&)&75JF-ICN!/SN23PE/%EZVW8NSB?;Y$7"J_I(!;<T4*I\IZJBA6
MZGHD*N+7ZS##)4[A$?UKUMM!]^92!*-(WB"8VC$]6=0G*%RR,C;(:]+:1&:Q
MCCT8MNUAQS&J!!(EV/"3T^O9O68WMU=#NS7LV+W^,).Q\>M6T^YV>G:KW5\>
MJ&MWABV[W6P5!NIW6W8/H,RVW\R"L;%9@RME+S]F:P%'SZIX/A.')RFBF-:;
MTZ8G95T&JD6+KTMFQ3*;3GGJK#KX5-M_@B;K\MFE9S`?]Y[9M-&D$5"'`9AA
MA-75)^M79.=28TM,#\9I5=R?6U3!P:!$@\H\5:EF+HVGVA\8#13L+"7#[)-3
MN]Z3\;YT\=HZOGG%R[GT90,-AM-%GRE=&1.XWQE9T$,WE=T<9"1)*J8K:V;^
M9$&9]'2^.6O)T7K\25=3A-C&+=#US%CWEFV9S2ZO<11&J"'SF3$/:=[Z6V.N
MW(+,^2EPVA!L0NY@2.6J-"2S/"1Y.VO)<_R8(>W5B$'EV(*9&V<RU5I`/)DD
MHP_T!>[OXL\)7WWG9#NVOM!%CTK"!RSMUFJ>_5UF[S#19S:*,4E:651W[A<)
MU`5SC,;2%ASS65&?C9;:M7I@9\VV#?_GA>E7/C=:V8+$:3YW+?VDY^C]LZTK
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M671-U4`COIV]K"^XM=?&W\JN\PTUM.SR+RO8L3+T@>D).YC/,`LOO,4-H+^3
MF3O6?Z/%]J\OWMU<?_CH)^E7?.G%C@20!]]+[_#5YI\,L&+]R=OQ/`-\E8P\
M8S=0>$FC6:F8+G\F0R]#-V3!+/7V!:`[3Z/Z`%9N[HUAJE,D7H#\EPS+OQ`=
M5$B:A[-UU-6*N-:VML^QW/1S1/^8SEC.</T?F1)"S0(<'?J=F=8+ADHV)AA?
M\H,8<H+=@'1G!&IN$'/*2,)^"=EY9A2!0$UYHSI"D][&,)4D"CBT6(=\\7PE
M[RPM8>+_8,-SB7\`K8<2BOR2^`ER\D39I%P/(95>)7;$V/(U[*%(?_CW?B!N
M5;"`\BN8D7R4HT+^Q\@(I5N>G4J5(1.D#D_<KB;$,)0(3;%PES%6LP7@K\5A
M*A$%R+7SV*4()C1V"F[L*C^_POA)]C8'T4,E+BG=1L*28ID)P_3^>ML=P-XK
MXM]S"E=D394I,C<&!ZS3(,_':GI>DJUO]N?TK#X?.0.-QIJU3^_"<!X8S(GL
M\F93)/U"X2']2.O-:Z:5JB?)5$@'UI(5\[AX*YDCVG\R-D\Y#I&,7K8:W69F
M[+>Y4Z`Z,57N'B#;]R[2TYTT9U0"17V\-`IL%?H@"MWN^5*RN<=@><\?JGS"
M8R4J^)IS43J-9FX)KC91&H]3)@=U_W$:W<+05.^VUGJ>#P%?9DVLM;MPB0+8
ML5FY><KECI:I-&#.:#JAS;HBQ4Y2S`PSCSRR+",+A4+8\Z^\,DJWY3WYA1>+
M3L1<\HP;%O+`93Q,CFQ>4RV&29:4D*PDX@=9[S.T,@\?46K^3#P;VCC'HD$&
MWUI-`"A\8D36F%R,([$2";BMS#4[Q#2'=#D"JI4WDV*EJ(J(T3%K#1,M@&5;
M]U'*'4JS*Y@\$/=T-:)315Y))L>0#I4B!_$3,Y@`!HDQ7M^@(6GFI7A?!A^>
M1P)-9`VFN-`>)*.Z_(D@>&XI/2M>NFV1;>6C6#AFT2\<$VXG*1_EFCENN@T@
M":C600D@SX>,5]Z&9;SK/E),:XEF72X;DB*)PO9._51UM"^)<B"//-&;&]2^
M"<L`,A-I$+@$W7IP7:O:,!51$[2#LH8L7G)FFTM].-=("WRTL>P7886.DJY)
MQ=%8R*%E@KE"#2=:L(<%XP>>&\E<+IWEP/\W.H/5$8*K1FLS9H".P;XVVF&9
M$6O6A\)[4;E747:?AW30EV]G74J)WF#GM]38](W(LQC0%<2T\TE*H6P+\SI4
MLQL19.OE@*6+OXRS<%::F6VJ%BQ]]V8A`/-,V?)&7@V'FVQW#1^57^R)3",7
MC*1*N\AQ'M@UIH^6D^6]YVF12#0D>55F@EGK=;I!VW9:3;O?[RJ;"(J?_8'=
M;O7L0;N=$U2*)XU&?P?GG9BVG*"S-$'+:=F]X:`P@>/T[7ZWMVJ"KW2T)DHU
M@\FR:*J"JE15:FX).L)K:K*20H=5G<1O=EG-(NWRG;-7-7_U.-5@16'V9T.3
M[S:(,3#J-NL^I=+,U.DPW5(\FXUEFLF>H#S6^>`T#E["D'D8S%'NB<L0@Q7P
M?KD&3/Z<&+2MP=!N]ONY:#XXV#H>D+0SE5.[W%RF)`RAKJ,F\PUE=J[WG/:W
MTA&DG^:'3XZ?G]7QTW*>B^>G2,!'[_;94*H_!V4^D/QBN1S-RY;=[#EVTVFK
M&BK"*&H+;!3&3U4-XR]"9JTB7_TD/"RA0`H2J&8@<\;!@D)`06,DF=J4[&&B
MCE$Z1^>1<7T&JDB`8C=S/ZK[^FQP?(5VG84U4$SY*AQ'%XM4F'5R,ID7Y`(Q
MHVP-(+QQ[$O6#>C-GFF7N*WP@LO%KJ,F_!#1OKQLVVWY@NQ8+3?S(5*OYC4*
MG?!MP)4#B(9M%<#('J;1?Q51?"NLO[OQ9!Y^%P'::;C4&04#1P\A:^A3K@/K
MAE;W3V5FK8+%0:N65)=$9T-F4H+*:?%6(TQO0PYK6.-!M>71W:A1U`JT7<C`
M)B5'>F($^\4Y@@\B5U()Q$`U#7O-]*18.N5>Q/G'E<U-94Q$4]2I8TIN%]8K
MA,5P?.#5:SHY6)`,S?J_>5#5Y+G0\!S\&2PL-']FLP\IYVYLU&>6B9>RB$KK
M3^1$0(_)E/-$9"W9><Q)RR.1E<`*8=1[*4LWZ4ST"EF.%-Z:2^R4:)&V>-FX
MKY!L3[#.@GE)G6M2==?M?+67I-5H&5X2SF&E;O=*2.><2D["UHOC\]XCJV/B
M_U""FDMF!1.$62!2\LD"G#X%LI+(^A"C)2WD5E9CK(@EB/F5G/7,C4IG9RS[
MFPA9),&@F??*?/-.3-QYD!KT8W$M055U1*$42R=;Q=>RYDTN!JT',AY=KXJ\
M'0LV7_`F81&N*!LUEP\L`X1QA)$;?H_GLW2,_MX(:P]0#M:($GE5E2T]C1PD
MO^"LLF.":<W8YD65@N3"$[8RM63FJCAOS)H8IY;.U$*73+%&,?F[R(_,N#`.
MN:ZAMK"""(^B*IMF%T\S#:QZXJBL"``0K4IC=L@8YU(='C)\9BGUB[J&>:N&
M99Z3`V>!G]JF==Q>LHU+BH:;TI6U/.IH#E62O=849(=NE4^A6W7G4S-"L13.
M2"^>A]X58E-&1R=?]#L4)5T6FWMH!>+GRURJO675^4N?18IU^#R1[\ANM&$J
M5%CL@;8_D+K_RVYGB!=<^<RK1G%Z3?WBR\[0L7OX1VWC3Z$-5,4J5%%YW>.$
M;F@OFH]2S*_7>"LK(]FTNQM!9&0FJGPG6<%P'F+_<X05<9(9IHRVW++832)9
M,CVM*M[(Z\9<E\[B=JDHF>"G)BZ%WYC5@BAE5X2WZ1U=TIS&:>PR]11/^'*@
M\F=&^8DH%&<I0Z<[BQNEP3"["J8&I-(%9<@\J#K$,E43*_W<RS1VA>TL&UXU
M)YMD\IK`_-V$]`U9G&(,1PV^BPM"DT(/D-846^`@CK)$-YG!S.8HBA]RM8U_
M[')6EW'5<6,3]O1C2)8OM0+]2AD,62E,]N+3ZQD(JF$+%0S*%U<R*B.KD1.9
M(F3KNA:ZX$6A`A(5^<CV4*=X3N8QW68J%;G&G5"+<1OW0\X^^LI7*L'KY0N!
MGR1K%5OMZX3Y%[-,.H-A>]AQ3'B7QMT3=#5R8+:#3D8!8/\EL1(P>F*;$/_6
M<#`8]@>#"L!HW)W#52-I8R.XOIE=,KZZ/ZRWNO^-[/B%7UYG'6J`.>EH_G-6
M/XK+,,>$M]6(/!Y\H4>#$Z'&DD,MKW?]/C2SA3YBYF>#D1J4N6.,_)>JU'`N
M*S5\UC$'\E1?F24:N)X(W=U<,*"(#36>'(Y'NYK06,9(-`Z`I<H./"J1KC]P
M>JW<H=@.BF-'2D<CI>3D%)'2'3C=?L?I[PPI-[(ZDW4UL=ZK(DOG9OTF7>GM
MHZQ<]E[6__TG^0BL$I?)*/WQ%S7PU40-:XZJ!I5CRB%IP&/RJSQY:+*LS9@K
MJ(4!Y:75\+(<9G>$07,86(%U$[A4]%^V,$JSZXA6`%N`!0_B%]8(1=-8.Y%6
M.95VZC3I5GJ/[B6$HR@%B5%/*]]K#_ZT[&OA1]_(Q9SQGW^Q_G>3_F<YLQ\6
M>;3W019K7#R,9Y[XO]&T^9[\IZ9:M22_YEQ5J]'16H$-N9<:'8"&TKB73:9K
M/E_L*RYUT'H15<`H]OM!+`?ZY#<DC!YB=_;7%_S?%SNFAQR`@9B41T:5.B%W
M=FC=\??;&%0R[VP<!5$,E#,>"S&9[)N)F_N!#'I?YW#=`O=S&I<V]C@0_7+@
MV"UG#:YW1_.;8Z$6Y2L([N1A;_4T;]W'>9C0_PY\'GH'/`^Y!>[_/,B5UH>D
MU1RBF?3)*;46GGYB'MW_>7GT"IHLA^18:')S[OES\<G!B4]J2/IMN]?K/SE)
M_M'9Y/#$)C4D3L=N#MI/3I)/Q25+E;ZC8)U489""E`YI`'DBKKK6-O(XONLT
M]TWD]8P'Q\2,BQ!W*G;_\!SZ:Y2ZP:&(OM:R#TKT`!'%I@3B>*T4G=;`'G;7
MB';[.UV=VJ=KTWNE/'7@/W[9C9='>Z+J=122T7Z".J&&.L;:]#P59CT/O0L]
M"AI/+_08Y\EG/<(V7MMV<]CI#A@3V\VJ5W]=+.N,99MRA9FI\VUB+E2^(]&:
M7(84K'+!S_/C6T5)-(>@)/*J:DRQO(&FI3KO2U2N0W)K?'V(5FP;OFR^*U_%
M-^'%QZYKH\FV7R%FP6VY1DJ@.]PJ<;IMUOEN+JS+T/HBIJY/\<57$^N#GV`8
M'(Z[^>)AP,M0#W<UX<$(G5M@8^"TG.XFR*B>?AOL<)X^`?_!O]^"%&@`?/\#
M]W_8O(9OLXDE<;><<6O*_Q#-M]A[FA;>W&:A_7:OU]^4['&R[=>XU8X^:C,[
M&V[FTCX60@'_*0/0*V(X<E%H_.@?-#KC8$'KN>U9VP5<!PYC0'%%R2[=8C&7
M[(\OR."2K$C]0Q1_IZPV=X9062'UUUR5_U^5]6^41Z`6T]BAFQ+*[D0%G*HT
M`27\%2%-W$#EKW`I$=VEZ7Q,.2*M8;M-Q4;<*6>;%Q/2\J_D4M,`-2*\<U7'
MP*D;?Q=FB#FWN"@M0I(7AE<=ERP*326X8_:+ZG"52_9:<RC5`%^C:_DZUP`Y
M'=(#'=*U.UB=4:*+15`J,O6X-D]PL2\J50D+0UE4D6J?""X1(6/I,3"?RZ6I
M`MS4O)N>:6#A\+)>IC2T402D-)%#YX=0E0^5OY#E#F3%6ES=_7VIZ-@;[`^B
MZOM@&)O*^YA%H`NI+`4L)*I@H6[)0O(KD::!*$#/*<)K#N(F1R2[&MT?9B(H
ML1RJL"IYD6I%E;L@W1_7_,I5>..B&GRC'Z\*[F_VVLT5U_Q9%UL9D-E#<I6U
M<YA+(/!_Q1S#J]#"QU$@SUZ0D:Z%->!+^,Y.%]%JMO.K6#>+7L;[?#-G9LA<
M[N?L0@2!=8'7UF<QCZ-D[,L:P!]3K[%4"Q]GUJ-A+ZM/-%95`D&.-_[K"Z>B
M8,O'Q5>@I\3EBL)O%^8O5/`>H4*@<C`!1&4E\-LFHIP7?^NT&@I)5:!JS&01
MRQ5XP(:Y`A.1DBTPI6*'2U=SJ09^*KSU3+Q=?OX`XC!CK1[8IJ4E5^[8-JOY
MJC\H8?4+<KJSRKIE92C4SS!)&R-GX]*P:[&H.RR0X0A."\Y)2&.`SK.I\)<R
MC'5,C,%=CS5RM5FG'ICYKCW+V;R82^1%0>#&1F_!UYOB#$:Z%C&'K$]D/YP<
M[\8V2>LZ46R/I_82974:F0&L%G#+XITN750FN^VHUU`S?]TMMQ"2!XX3LG,%
M'#"!6S=DQ2YY*(68H)IGU:"/=_#>9Y%>3=[)=[9J4M-TVE)7KSO-DRZICMFM
M-QPV!UNNJ4ZN,BVLQ-K-B8KRU?/0^Y5>S#(58<:+[2W<@UZO-5!7>.V9GGIA
M=5+NFIW6H-O;>F5UO!6;."7V[7XX'.!U6G6U>X-VN2&K&O"/`&@0Q6B>RSI4
M?B[U`*E'C2<?Y^CI]IK#OCP&*P??/[1UT-OO#P>M3:#51,$EK;A5=!D5T,F0
M297;<,E.O],N>B>,,7<+4`U4U0#EJP@1A'-=*"'C"SEV18_II[*'MC+T]OM.
M4S&GJH'W!^&&-%8;PLLI57/G5HX&M/YT-(\3_OX;6?D^4A.4<U6B9GD9QE#&
MQ,9`-`X-HT=Y[,G??N9ZB'C$TG>TVD['5-DWF4VOD.X$<F4;1I2E,FF95<5<
M'[Y[#:\J"X&TVM!;IKU@LQS:BC-?=[*G7=E*?6!I^]I.K]W:<GGGA1Q35MC>
M<O]5&9WPI4"0YCM2]:(7Y/-?RLEP@Q4YK59'\L$:<QU\+1O1W;9K*5:,B\(E
MM2>W#GY>E0:X"@LJR$X.S[I)#@?]1N1TUNZJ\U%_!75RKZL)J<11^\@CT6_W
MNV5D5#+3(1>QV5G89A&7JE':*]4F[34Z!$AH,Q1*<QGJE7?RA<N0GEXIG6U"
M3XXS:`TE1:V=Z[`+V6@_SIRFTW*<31=2258K%,KR_5ZK#6^P*\U5A%6A71YL
M)1MM2ZOG](=;K"8CL'<F@6FMBBXS0R5<36GJ-7S+5&<?M33L+%Y%;A43/O'R
M-J+!'FA0[6W7=\WE11/K`]8JULMB_G"YI`NKQ_'I>HKZ!@O)J>QK9CK4`K:1
M6#8&G>I$X_E*X_E85;R#7T'C29(JZ,WG+T/U],X74#[-8=>PF=`R:/=[G8T7
M(J-V%C`8U0S4M=]SE8;D0^_XF2^J//PN[I"*L?<#X(8W]G#8&_;K@;E>=:VK
MK.X$JZLF.`3,&ZIM3E/I;;4`EY,F$0>T&261<T1!3]W`0V\77_&1:^70*D9:
M:%"78BZ6JH,U#?--^01UH-2=%M[ZE(+@SL0\]<=)YKU5X3JJ^U2E;[?F*FN&
M$'#,0!;*PQ-N$G"@EE9869E7^#'(S>(T=/S!+K&J(AX>'9-Q4(2N#>!8CM4H
MPV.QZ4F&H;+F%5OCK]L<2/S!IW]]%+=N\!X[`/*R<:HQ3&7,)'%7*";^=3$3
M'(V0_WY'"$(V9/:=T+3#IQL.]HT92UO6WXC(&8>YFN`FPB`F5WN[,`<XIL#2
MBC)4NFK=J>%1_89'S>-M>)1M[6:TOFD^HZ0N]?&XVO1<R+X1I7W[L#-.15`]
MQ=92_+KY@FZ@1.J![L58Z"ZCD@!T[YGB.-S@874T?VY>C"!+J5&R5Y)48$8D
MA]F"O$A@HB=)UEP5%]LM(S*P,T;$#6T)-"DBFBULRQ(*GD]S)ME/[S_GH9"5
M_;4,06);UB13%L(OWPN*&W\H"UKOEK0>TE/(&+ZWI9V;=)@I]W!J.5A7R&SB
MU+#>QI'K/4219Z&T$%+OIH^-ZX:=-4$RNC3),/45*\B>U2#J12'!N$!0@%#L
MN'OO1_,D6&"]>#CJ?G+'`>_%ID\&()T-`.E4`[(F+GWC:Y9OZ,`/O_]E$D4I
M-F?Y"']8/^BK.**"<FDZ^\LOOSP\/#1^C.*@`6O\Q6DVV[_@S[_@@R_D\RG(
M(G]]`6-3BLP+&KPXO'PT<$<B^.N+#_+;L\M43,]:+S:86`V8GQR6&@'2\=MI
M`+/@72S"LV\W+_YVJ=KV*%I\"'-Y"AGU<[NJ]S>7C?_X)0=\;D6`/SGU78Q2
MRO_.KT&ND+_\5S`*\H#"VR[0]POKEU(TG<=C2Y;!;36:ZE4W'J]!C7SB%VQ(
M<59$$;+C4HBBRIU@8&'4*D!7[:?SI/M)FZBV=(N==,IVTCFZG716[Z2SDYUL
M[W4G/_H3\<F=63?Y%`+</_V3;%?%)?<;=-4_@&`2+,YXWW."`/#8Y3'QO<VI
MH%U&!>VCHX+V:BIHKZ6"\M5WRE;?.;K5=[9=?8$>\.Z#[__C%P0#/OS_4$L#
M!!0````(`!B(J$8OA2CYC!(```L$`0`4`!P`8G1X+3(P,34P,S,Q7V-A;"YX
M;6Q55`D``P`D354`)$U5=7@+``$$)0X```0Y`0``Y5U9<^.X$7Y/5?Z#XGV-
M?(QG=C-3.]G2^)A5E2=2V9Y4\K1%D9",6HI00,JV]M<'H$!1)'$T*%*$N2]S
MB(U&=^-#=^/^^9?793AX1C3&)/I\<G%Z?C)`D4\"'"T^GZSCH1?[&)_\\L^_
M_N7GOPV'7U&$J)>@8##;#&ZNOX[NYSADI/%@>C]A_T2#R]/+T_/3\\$566TH
M7CPE@XN/'S\,AH-WYQ<?!@_KY1(G@UL<>9&/O7`PI3A*&(._#^[NKDX'HS`<
MI*7B`44QHL\H.!T.>>6LEM\_\3]F7HP&3.@H_O0:X\\G3TFR^G1V]O+R<OIR
M>4KHXNS=^?G%V7^^W3WX3VCI#7$4)ZPV=#)@])_B],<[XGM)JO%>\=<9#3,&
MEV>[NI04_'_#C&S(?QI>O!M>7IR^QL&)$)%_!E22D;]6Z(5.S(@?S]*O.U+&
M"&M8[]1FUAL,MO:C)$3W:#[@?W^_'^]*SS!)\!+AR#_UR?*,?SX;^3Y91TD\
M]3;>+$2C*&"_T#4*[K`W8XV>8!1?H\3#8<Q$2MDGFQ7Z?!+CY2I$V6]/%,T_
MG\R2UR$'P/GEUCP_6'$_JZG"/=EX8;*9S$*\2)N;57.-YHA27H^/HAC=HD.T
ML*V@KB+CB#7E`G-#Q3%*XG^AI+[0.F9U!;SYWQJOEBA*&#-F@RO"P$?7/C?)
M.)I2LF"]^0`[V[&OJP1C&_`F2_F3$`?<T3TD[$]>=3R97WGQTVU(7N+OD;<.
M,/M:0Y=:M;2G$EFN*'IB-/@9W9&X9=4TM;6FXF3%0Q:#2KNZ2:MI5*DO7L@=
M^L,38KVV<5U4W/=5\+W07X>IEG?L_X6:T6N"&-N=/%R/QG1,9<BD"(E?J#GD
MP9S0HM*BXC0FSKUXE@9&EL\L/&_%`N3%^S,4)G'V"[?/^^'YA8C>/XB??]MZ
MR(QSZ,U0^/FD^&."$ZYH]N.9O:B5]F$__%8*(\+KK4.>+/&84I()2BZD-9,7
M]=AK^!$MJN11/V/._EEH]6I2(BC.8I8'IMR&K'F76?DY)<N*>8FU<GO"?AIL
MN0T2,C!S(31`]//))4^"7Q!/0T5&7*-1F\&?)%;?O/KAFJ?G7PD)7G`8EI!@
M4T08#%;$)4344%*!"A@G@8P?W4'&)'E"5(A,(G_-D!TE)2AH:819%#0N-39$
M#47K*HJ*YGSO3G.R));E#\EFRL(?3W'W,]Y2JT)(A57TI"ZUL852BJ;6<Q`M
M_LZ=%M]*?B7MN-)OA43C2MY1Z^<;CRCB=@O9P(,G8/?(1_B9#\U+HAGIA)@:
MNJYQ5[8K@6LEP9[@QB&HX>)>:C&E:.7AX.9U);*A/5\I1Z5%B9W_`91P$`[V
MFNJ!`>+G7E#B,Q$\369_<6_Z[(5\J#M*KCQ*-RP_^K<7KLO^P:J,,!ZPC(-`
MJ:.M'BI`C@(LY^Z`91P],TD)W50S%MFGW=!C_Y.#+:R17=^0Q8)-YA_R^$V]
M`&6SZ@Q`7RD+17$>@I@4<J]N7S"+\!8%'6S8VGH;<@`+M@(4%P90=)N96T8]
M;@-Y8#.I>41?=8U6),:L??3C9Q/9;C)-1>92.P*544Z>J4J+UOW@3NON+2&R
M#OB0$/_W)Q(R*6,>49--J96AY,)`9G(7%)?[>C5!5;G&1YCW*.0S_%./#=*O
M"(N.-.'3;M=HQH?HD_DUCE.O69+9MIC0!%ZLNTZJ:0Y26_%"!Z[6P#LSG+-[
M8Q+(Q@'%I(I]R6S*Q::DJW"JKSX`45;,7<P'MDM#]XCE[&LDQX^>J+2P5B9R
M%14@I0``4/%Q;][KREOAQ`OOD!>C?...PF?`B'?3&'IB5S%@I20`"R9^K8^%
M,S"F8Z]QY)-E>99*0U'JR`4*5UO0K(Y%%RXP`6;W'9E"GZ\30,*KLHN4,[?2
MVPAH5=E9@VX7M:>$ILV4)!3/U@D/UX^$#^A(E##;,U$6XRA!%,5E9]@L4]$`
M33%UR-1&LQE-T*$ZCY2Y[37=I$+))OC5!+MYP2I!=]Y"[Q^,RA3\@]PCR'C(
M]HL,NW4)]WQ[;(2"&X]&?,<^2]#7RW4Z$&2>'_NX.O"&%M@-N<T%7`6"M;(`
M8$!XNC=[=D662Q(IN[_J<Y8#5SZ[VN(&10#M6^7@X"Z3''/IFG-A!_8VR>/[
ML--IGT?OM3IE4J=T/FUB5]I5J!QF!@"2K"MP<%XN"#!7T0NG'@[&D1@$E@&E
MI\J`HZ)R%B`@M2!`4#%R;QYE2L5X41DJ-!3Y_J`JA:N-;%8'T,!2)@ZN`S<\
MUB.`89#!>G7JYQ:7U>O>@/T;C@A-M90.O56?A>FJG_N$'(/R+>&F6BLPNW-U
M+JR5Z1OK^;.FI'`O(.YIK]Q1HJ6IKL&K]Y+4GQR_\Z(@9-8#B0NAS<36TSK1
M1R3"$SLM57C/"Z23Q'J.[@T3\^6[*+EB?^-$LRG*3%I9#)61.HP("QUA@-`S
M="\=N2/1XA'1)=\2DNY&ME@SK54V<R)V91V&T"%6`#H9NQK<"YA9IWCT7B'!
M"$I><CYJ<H?18ZFKG1-2,W7O5$$Z'09!AYEP_\#KVT,$6#\8%G3L@).+KHYS
M#C$29-G?(I/[^:QLJ3OV_Z->J&&ZHJ3#`\]SG/!9[<JL8?E#?IAY]Z'SF+6=
ME&>>5)SI^X(B-*\LH0*I2Q%+2=U=_Y,T"K%5K]#G<H;[D4G)2!:8.EY/SY=E
M;IF)6)=+<+3&T2+O9%_0G%"TTPG%-Z\)]9@J./+H9LR,'(/VW1RAIMUIO!9K
MZBZ'V$K/9<G4*R</:HHL:Y!1=*^1Z"=*?<K?R]KDWSO<EQ(CYH*>TJOSGE%(
MTDL;A&"5+2D`VMUN%"UM=[Y4W3C$3L."0ZUPW>Y`T7)S+]W?WB\:\O,#P1)'
M.$ZX4L](#@<@M3"7D=I12-AI:0:%D9^#RY$Z!TW,_DYNE)Q7.B*J\G`PZ_A*
MF;C;Y*G<&:I?,N#O?^ENGZP7HE@<#ZE>$:#XFNV0+7_M<)$GO3PN$Z:RO"/]
MNEO8*7WM<)%686YBTJ&XV%KDLATGETJ[%V.$:#S#W1[.KR09BN^[Q*+RW<F&
M-.EA:DI)>?<6KO;EYM?UQ7K74B:1^)><Q,E6!6AC:E@Y"_?6!\3MVG)7*_^8
M=='21R=;4JN!L7.6"CN8L\D2$F**]`6]]SB4<;L/68=BRQ6)D\E<CECIM]VV
M^<(WYQI-)[NNR4KE9"B5)=0.#2W4:35D4%$H[6`?/<;4(H',KQ6,V:)4A9'>
MOC3N^1*F`"E**I\%,=()$VOHNKS?.FV6@CRR"^3T9/D]U@JR[GJ8N74(6+]"
M)U$R%K=:*QBZA_-T*;JJC6Q]7TVUO[@OHW(<`##MX.VOY/?GC4%0-WG,2*21
MR<&&DB\"'V]U4K.`W*H0AJ9P;).'YHV=#H\4EX\S*@Z<`BCS@\9JRBZO\6]L
M5\LQNS;$[D2C1:%K:IB)B_IW3!S-1B0:W#+O@1?1=CNMOWFD7A1[Z0MDHRA(
M_[=5_ZN'(Z[;B.*8>9'K->4G6Q#%)%!@_H@U[F=);=?H/)B/;W>;7G(4Z=P[
M>*!2^WM$D1?B/U#P*PG3MWF$?I/H`?E,N73WYL%]KJEJ#!WM\&K>;.]JV,)-
M=*G#17I;VX`E#TRZ]<+$UKRL<?C-2N@:;?\NIXHUBFK?FU`5[6X"$"5<1)8O
M/6,&@"^;[S'?(KN;OAPQM_^\O8E.,N`ISQ(VPBR;2CR069<FS8>*-:[`JUT^
M-YQM^0YGKIJ!##G<;,6)KX/$2J==[,7),J4/C>P%DQ[,'BWY^?<_4C$G\_08
MRA?F@`+Q>-"]Y$9K>(GL9AU(B3X@SMXT#6,,)$"&*H<V7?Q)#[@TA[P##L4<
MCCKH09J+GUQ"'$O(?9PJ48%7]5/^Z,K>IWX`1ZELXRC9KZGUZ[C+*?4X2O<3
M*I^8!-/GIY9,]'W`AZU9&@8-H/H,2>\:29):R/AUV;PN4^\'@'3JMIEANSC-
M7TS/LK!Y]>311>4T'8A6FF!7:/L`(QMSM)I45ZK.DAN'YK.K7A/R5(XQ(-HP
M449)&),^0+81`[8>3V$R94'VQ[<`<HL<3UW$".#^9WI&XQP-G+)\S[B?N\/`
M/DNRU^RF%"WQ>FD([DIZ18"7T/<!@K9F:3G02ZIW[PKT\7+E8<H7V29S?CG;
M'7Y&P?;!U%]1&-P2^KVRBF55)G.$L#)]@&$=\S3M"F$B9+GGQ]:F4>3)KSAP
M>XN`PQ8)O7;H4J#O`Z1LS7*4(4RA>@&E1I#45H*7;3`7-Z'9C%W,194)GZYH
M'[!Y@+%:3P!UDF2)X#_<@6RQGXVCQ(L6_)'CXL/H4E>I(I;ZR2IQ'X!H99!6
M/62U;O<.JE<[RSAZ9GV$4(@_E-`J'6"!M@]`LS%'ZRZN4'7FTRX=&MQ612Z]
MNVP$FX)>";@*?3]!IS=+Z\"K5)^!SZ%E^JK48BM+)KS8:C"*MF^820/M84R4
M*(4QZ2=T:QBP=3S#9,I`_OY8>^IV"T9,\'7(E0,/F^5%](M^I2)]@%\-XQQG
M";`D@8"60^.1AR>/HG0'(#^!P+I#89]/=E65EBB[K$I!U`=\@0S0,*)4=68S
M>HTLM,F]TW9Y+]ME/(F8B,^(P9N-=OB<=]DS`<GSYU<-Y'U`C*51FO9&QMH;
M?0D<N+UN_[4AFYDY0SG`(.%/,2<',],1!PWRV;B+9K;A23''%/$1"M+;%C(Y
MTNV`TKM;@-3YB7@]=1]096>2AK%DK#Q#D$M/P-0Z[T<:/OA6/&YJ(9'8%'F0
M).Z=UE9HQ.?1XJ9.*%HRTY]0!#-KRE&*`\2;:[0B,1:[I?/#O%G>KZ?*$G\5
ME7,.T;;-"-0$$$<(K#Q-_565NK>Y9.IMTN/;CV3D,V=#$5.;Z9)LIB%SW,P-
M<1>4/N]0#K[6!;,X;%&P#PBL;:B&06DC!_1"U>->@;1++OB-O9,Y&*GV)24I
MH[%D+[!:VU1-@]5&$/>NC\_ZVBVAXOW4\7+%K+&]*D/A2?7$)>^I(NX%"FT,
MTI*75-4ML&8\K_^&AS#U,N,VAC!@2=SS`#?S.?*3R?SFU7_RH@6Z]Q(TB>1V
M*?F#.D5%(]@5?7N(/<`T!^'3KE[WLGQ%_[K%D1?Y#0VH+9GI!]1@9FW,//)5
MOX2NT]OO^*(S65`DNWD36$"23*H*.!>];1N5U#`,)((#Y2BGCJKZ9:LGK@UO
M'KGW6=-->L>+<4@CI58.8TK4?8.=V20M8DY:N7LAH2`R%W*R2M6Y>474QW%E
M+A%,+P.=G+YWL`.8I4W@R:MW[Y*$?:''<;QFRJ+T@O$EB4S>3DLO@9Z"OF_0
M@YBE1>@IJG=O6";&]'<\L8^WRY*[*TSWMX#)G\2I67IW/:AEZ3Z`]#"3-0Q9
M:V&:W.\G'7;P;853#P>3:)LVB.[#MX[%D_G#>A;C`'MT4P*B;3%A3GBQ/D"O
MII$:QAQ<"@&VGQQ==/F&(\(7-5/1GTC(A-6-B77DDC@M)^\##"V-TF*4EM<N
MF]%V!W5Y9C&E8DM1FER,HF#[`V(?X4DCE(DVDS0SZ1MN:QOP*#FG6:8FMSA9
MQW&+V&T1K_L!,@MC'#$NRP\#]VR9K]Y\?1O+?&!)#$>TC_L>QFX#`M.*&T$Z
MU7R-$@^'<6</82AW350?0X60YF%10]IEWB`7*WTN&:IN@=BDL"#N]/%$<ZL1
M2W7++R(J:Q`Q6<O9O>W%\JXJ`PF`<O=NH(;2?7C`%;7"AI:M>Q/3(]]?+[ER
M*-B_RYS].T1I<T7!_C01=`-BTVSS@W@-L74?GRV9T`K,S<D@FQ<?=I;(E*_"
M8>IVG;:PC)!A);T23R)=>4`%(LZ&5`;BSGR/1K`]X.T##&X&`P.S:90,NO,<
MP%8G#1BFX"7T]:8CRQKUF3R"6X"4I4I0<C/8.D^:&H&6,7<Z"$BPW/JX<>2>
M;+PPV4QF(5YX(B!*+J+L.K;D=WO$2;Q][Y:'Y_P*PA*PP?2EUZ@T]$W-.DJL
M*UG&O%ZC<72/EAYFS4DG\UL<LW;_+_*H0M-#V94,49]==RX`WNBD<;L5O(11
MD/WGN>H+T.18[`"H<F%NR;H>,,N%K6"8%^X5Z!0V:0MB>75-WJ9Y(*`>&9?R
M3IZ:I:TA)4KW#E,RJ[0)*E%?ZV_*P20:S1-$4ZRSW*P6LJ0<K-!5XM`KA.FL
MTQ;*2G4VN2OBT(!8%V0'X:NGT#HRJBJ`:N0$P*$!\874#X=Y6?M@R,OV#DU5
MB[0:"'EM3@W[(<^+=3WFA\AX)1W]URB9+\_`2W:YY,5E^D*B=:RQ@9JF>"MD
MF::[WEZGX0A,UT+_MJAG[V;',G_W'A_87JD,["4P8F$^$_&;PXR5]H>`QU21
M>Z<,2PJ"?"S(G;Y=M("T/=#%2"MP;R..11"&AMS>.)5C^!.S*U'-M"A33/&!
M_S'S8L1^^3]02P,$%`````@`&(BH1OKX,[):&P``QY<!`!0`'`!B='@M,C`Q
M-3`S,S%?9&5F+GAM;%54"0`#`"1-50`D355U>`L``00E#@``!#D!``#M75ES
MXSB2?M^(_0]:S^OZJIJ>GJ[HV@GYJ`Y'V"6'[9[9MPZ:A"1,4X0;)%W6_/H!
M>$@\$B=)$:SQ2QUB(@]\"2`!)("?__:V"6>OB,:81)^/SD_.CF8H\DF`H]7G
MHS0^]F(?XZ.__=]__]?/_W-\_`N*$/42%,R>M[/KJU_F#TL<,M)X=O^P8/]$
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M03DQ+VOUO!#%B^5%_NF2;#8D>EQ[S.\OMKPN<(`]BE&7&C658&T*9[HF8<#Z
MD>L_4IQL.R@MYF6KW@,*>9]U[]%D^T2]*/9\CF`\CX+JITL2L8XPP<\AND+/
MB;T)'>79FCGW?9*RAG/O;3W&DTECO]`4!;?8>V;==-+)F8RX6R-%MEZ8;!?/
M(5YEK8R)N4)+1"F7XZ,H1E]0%RM,!=@:<A.QSG?%H9W',4KBKZB#/\F8V2K(
MF]8+[](8,U8'S!?CA*:9G]Y$]Y2L6"_1H9[-V-O7,A\I".W0W;196'>"++;Q
MZ':Q?,2K""^Q[T5)T6A8@'-/0NQWZ\W-^-N:L:`K+\+_RAK'A1=C-H#<\UB,
M^6#17FXQ`S?HU,G;"!FR6WSB7X;J%4OF`W>*UC88\N^Q2[166<)KT`[16F$C
M[@=HNM:&6,@8MD,M_QZL1]T+L#>D/K/I87+4YZRHE^G0\/.@`2=`?<Y\>IGR
M''JN<[!)SK##^$`#^.!#]W"#=J_#=3\#]<!#]%"#<P^SE"[3DZ&'T<&&SX.$
M,\,&,O8F,%<*>%/,?(I52,#[Q4<F`7%W8R(OO7C])23?XE\C+V6R4&!ABI64
MX4PBFQ<VG#$:_(IN23RP:1)I@YFX>.&[('RT&]0V4$RO1EUX(=\C>%PCUC?O
MA+"!FRFP1@EKTF%?AFF).H!QP]IC;\(5\5...^MXKED'FFR[1>AR=E4E/>J7
M>A;_K*JZVRO"47(:X,UI07/JA1JN(=B=*C>=^*;9#YFZ&;<>M&+_YET!B8X#
MM/324"-FT=81X-VOQF3C80VL;10N6/>A;\;J>(,VSXCVJ6R=;P^:KIE2U$^?
MT?&N(GK4%^1>U9HY"8XP;V^W[+\UP>@M0:Q+V?5%7-T.G<-04JW[O9&4D`PF
M@VMD-&X?5!O=".FP2BDBTCZ5L8[T^U3"9K+4IWS!1+)/$1;3Z'XM5"PU]"G,
M:OFE3P7,UZUZ-;^'Q;]>6Y=B!;5765:+RKUJH%A][[??DFT\'+Z''+ZG[+C#
M=?`>=6@E-/=:1^A=AU;#=G-_)&\L,R4R34I=0N+7%`AYYBNAX*0GF_`LO?@Y
MF_6D\?'*\U[8[.?\SZ<H3.+R%[[0\.?CL_,BU?5/Q<^_W>&(T&QNDB"F8L*,
M1S<LXMNM+8?>,PH_'RGIV`2'UXJ$[M05&Q??(C;DK/'+/9L,<E!6Z&*;ST,4
M5FN4%-2#M&2]9O:>.*?U.F*3Y%),,5^VG/HO*=GH8$JZ5,'>CD\SH:A90EH?
MI2((9?%"D?0^FD<]\%8;H>#:HQ'/I&==3+I)LQB*=7ELK&LZDGZ!HO)T"KCL
M-L8&:WN+#N?"23Z,ZB27W@M.]FOQA2<T?BVLW_WJ,J:PZMK`[8H7Z'P<%9W'
MA/B_UV8?-Y$?ID$6MM*LRI.$XN<TX<'"$_E*(I]$":M(ILJJ-+`!;K],BPKN
MBZG+KC5(Q6E[9E_2"\?^\\C=3KSF\P[V%[?EE<U\63@\3RX]2K=,W;][88I:
MG9)!F5V7I57&9:^S,=N@N]-B7OC,#Z/Z3-.0;(*DB(5K-(*HMZ`9T@<J6YH=
MHEK(&.OXM6!6(/L7CFQR_LD/28R"ST<)Y;#S'U@7PJ:6UV&VOO[Y*,Y7B#J[
M08S\DQ5Y/0T0SCV`_:,)//OIMUNT\L)\9VK^AIL3/L'7HFY:7X>$6+(G"$->
M1Y.HC)$!G;'B(+=8]#@1T44L%W]5VW(NX((^%>;5/PW:'PNVQ7.41"`0J?95
M<!H<."SUDNYB\ML'%U"IIU<8P=(RP``87K;CE*R5*\-^^&T>LT:*O9@OZZ\1
M]5Y0FF`_OJO%`P486K2%:0K:D4(:L)$0,\NJH%7Y<<04?#JV+1#`8C]F'F/O
M%F_XCC*(G8JL,$Y,YAABFO;(P!*S&**A7:(PO$PI^HI22F(?H\A'\6T"HZ5'
M7,XB%,2.(6=DFPP_%:..:R0@BM<QEYI%-E&V$>&%]PD2P:A)70YG*FK'@#2S
M3H:DDE/'50$0REN\1!OOY;%PG)O(!S%4D971O)#,,=0T[9'!)6;1<2:N@Y.H
MK:G(8)S<;5V:]AC@U&Y/?QD")Q*F64Z,JD$)Z1I(`72.0J6R2`<K@$<!UH]]
M@K6(?.)O$W1)Z`O)DS9!L)1TA6D2.L?`TK5(!I:$1P'67WL%BR9K/;24A"5<
M$D+7\-*U20J8A$F!V$]](O:`N+"GRA10U!MJ4.ZVLR64CH&F;Y4,-2F7<BY]
M-NX6:"7Q$<173%!N30($CJ&IM$$&(E2XQ&[<#)1=7GZ^7\G/"Y`HVV!J+^5K
MT>XVFZ6T;B_SFQBJM>BO8.A$FDE#-7@E6D93SN!AFO'V"_30)'K65>&6,LZF
M]#!#)U+/K.%N[T","CBT%=$-<>D.A1WF/6Q<](-ZGOT(#M+0IZ("ZI_&&IBE
MK9-(#:B-S1`?CER]?+N1_GS:,/B6_7?4\Q!C)WW/F38!YI/U5_2(_)1F6?'7
M;SSG"05?&&R\FM,\6WVQ+#,M[Q'-SLS<"G+$^V9;[L;UQG:TYMO1A/F&.U"_
MM5WGV4]5ESQ'ZFEZ]S\R3"U7>[6^=,XV</O1U8DPA]\#'Z0A6BP[6@6EL@W#
MO)Q!]<S\H,ES0S2A06M[J+;4M]+5*/*0R8"CC5D76Y@!L#YQ`$G]C&]R2:.N
MC0S4R+J/@`;HU.9KO=K3P^@HM\.),1-6\*NW0>`J@2ZYM.U4R<=;*CJ$CPJ;
M@K#&>AR;9!J*G;NJV??HH:T5'V=\%%K=<L1)I<MD([NI,^MM3Q1Y<4JWV<DP
M<-E-0E'4*TCAU-08Z+F(CF5JC]ESYK"#')WHD*XW+R'9(I1IMG@1)B<HZ<HU
M=3'=!)#7M=(4?PE?)UK[/SQ*/<'R.OBMJ(?&MPD@++/&%-4&+R=.=7_A%K"9
M_"L*FE?@B%:M38H4-:57Q,%*^#5&RS3DZ7K:E=`NHJR$:I&1VH01J,3*_FIS
MT1''FXR>&"=&QOT$7&*<?'%5MV!KX51=\*"+HJ;.9%T#-BYE(FQZBY`2FRZV
M=]X_";T,O1A:5+0HJ>[=VR4=6?33=C1I7Z>J&7B!3B5;WO$!,IWH_R0:[_45
MKEQ8EE9[(%QZO)4W&V>2^Z!&_6CVDTT%%(X("_[/<\;6`I&K[@@MLAW&'Z5K
M:,-ZI#M+9,A?1R0DJ^V%%P.Z@XMF)F7*932],NY--*0=&;&K#$T_@T1G"W%Z
M(IWH\^XI8>%/LKT/O?P-A?)>7=%$7K]`F1ZI4<`]\X5S>(,2J@IP8`9O@":Q
ML;W:DM2RLCQ3'1E.-)U];"[463YSURO6FK>KBAUTUF[F0):VFWN1OJ#IS=:%
M%EULGYAL8)9N4$+59U5+.#(KUW0E6?\EK`=X+BZ7*.W%JI*<Z,7$MC#)X$3'
MH(3*FZHEQIM=F[B%S(N$]FOU7WMA4@>J"OE^':@U]7/)A:`9<?\^))W]]N=%
MSLQT=[K!J0'PU\HAN]I7U\)IH&L@*J.T\-XS+H_7U1@ZT4,\L.DO%):T?B^O
M,=C_/KD00V23;2!1X>=$*\WT@:^I:'^IXGF0EBD=YMO0$)G65<1V17>0N-?`
M5*"TQI,Q8(&&3A4NTH%0A(PSP]H=4W63;D!TP&_[2[ZKWT8:T*#F0>2*M]#)
MJ8HKO*O%G&@[=]Z;&!_H6XE/_9MC^$@4E^%3+]9N/X<\Y+U[EK,\QSWN6W*#
M:]'<)F#*#"Y3\S6YP?70>4YN^,JP>KES[%L&!%K?"K9O=,EW-XJIR$>\K&.;
MO9C\A=`'U#JW+_BZN[*C\76L[EL7#:*RJ-:K*[CFUWDTN#DQ&,\I\A;+6R\*
M&G"V/Y1GD2H?)@"BT`Y3_*J,G(ASV3CI(Q3$_/3231RG_!'Z[(5U_@8P/Y'0
M7@34H]\O`*KH)X"_J=7&S5K-WXD3!/REZ,4RT^AKRJN4_2=[*)HKS5,F*@8V
M]T\MBI9[J$9%)^!.'>K"U+/,1#GQ1ENFWSUE<6S3A5H?2@>I?)@"_"([C,&M
M,'+BJ;2J:T'@-3Y5X=M]F@J`L"U6$.Y8#7%[>]GLP4<U^&P]9GR:\PVS0H7M
MNH4F@+"5_:;8ZPKI>$U\/TV;3YIOLA46/@$I+X-]8$9FMT<&^^>H&ZYD7K"H
M3I."$W`IZWHP=2L301TOM1_"M2H+-?D_^19$-LB=2SU+HQSH6-)RD_,K_5KH
MYE92.4-<O'\=)WC#E?SB87KGT=]1`CW6JR+;O<@D(IL`XIHVF@(L9NO&C?S5
M27)C-5>R2"&@!)8G6I03<`5]2[LL2;0XNW'-?[U'>D)T(QT@J@3@2)`33`!U
MI5W=^O:<88GQN.N3XF#F>KE$/K^"PR+RE)15!I]@V<DYC5EM]!>"@K)*5QMW
M<;/2RWTE"2IW-=G,C+8WJO2(RW<\%<03\!XC>TW=1<6\](]QUR7E,8=\])UB
M;-%O/"&,(<9=L:SW5+]&WH8P)?^%@BL<^\#%\MKTX#@"TD_`%4RM[C9>@/Q+
M=[%=&^W[\*`H[>1B6_LB/4EHP:-UK-"(QT'/&!JMJ/=0)\9+[W8R2T?\<3I'
M#_7L@U+]C0O*$Y#`@HX<%K!Q/-*ABN"C!09:Y`\IZDMW(E6HJA9XRDQ,`+C6
M^(<0+>`G&D9J]&6`B*9'.'7@T`+Y]MF'\;`'CT#T!+[\J$1'^'LX4@$NR,]C
M-JO'7GR!25)YR!7,R->B+5,#Y;0.1,OM$X$F]HFPW1\'5'#KV)I!,,$MZ-;+
M].545XNXG/DJB)W$T\A"-:`J=DYD@@KZ&?VH4#\,_([CO@,'>BX=,84U5`[U
M0EJY#SD;^LF&>Y6M&N,^--`#;)T+^3JYA#00',\I#&)"(Z^PB0>U_,*9X[5Y
M:GM^U2,<8P@)=BOJ;0('8@EQ"R<:1FG@7(DJ`&XC/_#+DUG7)&0ZQ/F+Q&,?
ML\MJI\A_;RT\EJXFHRF]#:89,1>F..X)9/8SC\GR=N91L.#S![Z&'I*8Q9_Q
M_#E.*/.C5KY,+]QV.34=N8W4C.5^0/JNIFI;!T7G63@=13H1!U0.,G5UU3Y8
MU4:0[\U)>ZP@+0_M)L^A8"0S(5=]GB9K0OG^H]C[1)1MYVI33L!W%.:9ND:;
MG1/G&:O.2TJ'E?0X+1J@*ZG03`!GH4G&C;_"R(ECA"WO`X^E*:A$K7GDPVKF
M+5EY6$V_%3<.JXV;O]/2;I$F<>)%`8Y6*J@!4A'>-=+)@"XVT`[Y&K^.9Q4'
M>(HT5[*!NH0">HJTI'`58[4Y6M"";)PX9Y@_E<L?8."/Z:(HSB\XXJ\IKE!^
M5>J>I+@.9?[-HT'^=&;\"W]V,;Z)[A'%)/B%DKCI$0-*J!YH[EN"JQXY?'5J
M>?0@:CAQ/#*S-1]TKU+*^MY<Q;S55EZ-C:_?$/5QW#YZ;\V@]&<+!LZZ:]?*
MT/-&"RE#G)HLGJ$5NH;P>_T1WRD`JS)%"S>`B2N''ZL+@8IE"CUB<+EV.HL5
M1D9:++8*ERQ&/O4(:2F>]&A22WQA$E,?,S.MO0&:`(U\0+*NYA5^Q0&*`G[4
M3G@NTJ0(Z!BB(M/P#BV#+5Q$Q->-TXU27:](&'ITO@$./!F7T_&8>KE)NHW$
M].Z^4V?>]?@C&!EF=W4P45G'ME@6X>@3N4^IOV9S)#Z+\J)MRQN,2NU\0;.4
MNYY@8[:F'VBR[GI>4N`%I1=FXQMXJ\L#GTD+>P7-<JU>05G.75^P,]VP5U`R
M=^U`9&;,Q38S37[L44C9.MP(4![T"*-Z-4';*+UE`QF["1X\S"X<RZZ+JE@,
M9)0KZ78+44(Z1[+)Q6Y`],V$,\9;K/.%)B%+-U)_*FJ!>;]B`B#U;ORD;S6$
M1,.F&L`BCMD6',!IJKBVLII'1!;*W+:$5IJL;0BN,_G9CXAB%,_KDQ0P45N#
MLNR\990.1'OM?&U]VT2C^SY;6\JKQR8=(_]D15Y/`X1SN-D_FBBSGWZ[12LO
MO(Z8_M#!?\'7PMK6URD,OG*3#(;<%J,>6ZPN>KEXL..%/I6W7M8^C3>(BJ`@
M4NVK$#4X9-=7UDJ.T*(T,6F-%Z.@`@V`FK!(!SP%,.^'T?L8M<!&TN$8>I7?
M2`?0%S19$W^;H$M"7PC-DC=`]-2$A8$R0L=PT[9)!IJ,R1!-;A'Y>H"IZ$J\
MQ'2NP:5ID10M,8^.F?$@6`^("WNJ-.:;R(>?GE53[L[@2B@=@TS?*AEH4BX=
MD]Y!V&[Q$FV\E\?=FQ`P9BJR,FP7DCF&EJ8],JC$+#JFK8,X7>2'8><Q]F[Q
M!B<(OCA%15;8)29S#"=->V0XB5FXD5_.+5@L;Z*`;]"F7@C,E:4T98XY3#.%
M>;..>0:S9P$[)XZ#M73[!T[6V3E\OB>[QB]/1#+)LRPM\A!5Z?&F[W*/@%S&
MJ":JS@2*`MU()<*)5?.#.EAKGNZJBT%K$7W[F'31HB\O<V;Y_G*-T?+Z#?DI
MOVI_L5QB'U'XGA4U9;E;(Z,<*3"Q[6B(B>%23Y$+S'9Y9(*<Z)5VROV=IR)1
M%/-4M`1T%QW2<EE32CH]AS$PO:/'R"4YT<'<AU[TU6-Q>SL<ACZ5V5^U3U,(
M?B7&&,2\=2Y.G(XO50(##?AC`\3QXU`0'*)0OPI;E4$5)Z=B1@.D6D'.2%A!
M`9T>6-(P30[74%M+^45F-Q'/Y^?O%C&A\-"HHBO'13'=2(.BH+T0?9L@E"KC
MF9C+$%M)E>.57-2'L[,/<.:*BFZ7="BD<PXP79OD@$FX.!%]9.>VGY@4(/P`
MOY6[N?5O4PA`9.881"`--DY<W:(\L1^+CNSOK8D"Z?`XI(BR=QA$Q'A!%>QP
M.O<\=*_+JD/7]-"ZX,%*OA,AWD1;0BM8FW1;@(+6@S8&:>Q[D.;@S/KE`XH3
MBOU$EG@LI=FE*(`T(X5M@_:@1*]&:C'#`/KD:1*@'DYTM<4%'Z!'@=^2VD4H
MW[D'R6K@$)[3D-_NBPYZF[D7HGBQ+#(4BLOPLF.9S+CT.<8!]GA._]AWG.N^
MLRA_:*%%ONM"5>2]S=OSRY%(&%QLG]:8YC*A.$9(5(U#`"*WW@=HUSC1M,_X
MI4L!TR%67\I+H&^B5S8,$-IT/^'WPC;@^P1@4UEEBAC`SXG`[)X2'Z$@_L)J
MB/>/B^7\E75^?)GA"Z'\ET?DIY19BHH7()H+UM8,RB5M"P83<*#.]6+J838"
MG4C2*H[7%:'"@C[@U3K973V_T_G2"T/$^KMKSU_7:9L9$'WQJY]J[<)O`O[:
M=ZV9NF\/\IW8AY5<32ZYN-N)2\C-PQKE)>3ZP8Q3EY"_OPK__BI\)5M]&G>S
MO#\*__XHO".+<N^/PK\_"O_^*/S[H_!3.X?__3P*WT]KOL(4^8PW"#?\L;"_
M^=%)0*46J!%L%G=B0>_.^R=A4^5MY>E6$#TE75$-$CHG,=6U2PVOA),3ZV8:
M#U/+`WS]B/X[#N$/'+/W?L&4`X^YZ_F0LU&\T4ONYB&<UCONCHSWO;F$-*8?
MSRD,PGLCK[`)[;7\PID$KLK3@?"Q4]'W<A.E_=V!\$'<O(G:)`V,*X=&V\R<
M:/&Y7MGFRX4$6(B@AFR=8!K02HRRP+;.S8E&.^W<.&TT=9/<E$#"V6H?1\I6
MRS<4;J(EH9LL':_,2RN5Z5]D^ARC/U(F]?J5Y_R-G0C7T.=6D`"G(BLWTX1D
M(\9;3),4\92-_+G*5HPE^+Z+JEK?QTID56%`U-;4YET"?GG$U.+CQ%B:*_.`
M?(1?@0UAT>?"^O9GAZ%4V**+9)N-$^-FGCZ5!6N[#)1*DL)-5!D]FGV11=&R
M?S(JZK!S=*@#7<<Q$S'$!9S?3UJL#J0FZ;`RW,1IL"-G;>W]Z9)$_'Z6_`K7
MO&MB,2.B6FW>H'"[U6L5=MA).M6#1<O7$N)$/EF>;WN'DC4)<M?GH?WB6X0H
MOS%(^+"G<;G:E11:Y1SV)UOK=5W)@+\3=Y=>H>=D_VI<\90<'^SBA*9<]>H0
M>-[<K;4J7.[F&A9VV*DZU8.N9YD**=SK1[?=*W^^U-BQ&L5T76I7;,K.!-O>
MFQOMV!<.]-?1'6BOVTV4(.;C"7\!-WLU*Q`.<^8%*TZD6]!Q-[*RW\21=`44
MKO230ZYTYR7\^,?VBNDJ=1V($'25.N%D7$-BGYTKU!F6JVAG#F$/OIB;O;$,
M#41&Y4#/D):;C*/H6V_G-U+^I1N-?`=/W1CPB(Z$!-XT&..`C=;46VV)]@0;
M9%5B^F$ZYV&:AL#7RRFH!&[@R)5S,M0!K]"X=0[@"#E%\^(YMYHZDP??F:6B
M$Z,]?O::"DP8;V76FH"M`'2GLM4ZP]Z^[VQTX,%WC#L@+W_,V`)[9S+2&AK"
M-\+*:&#,Q[X02MF$VVBK;W<2,060'B`[[3_P!6/%P&SP=+%@0'Y_L_C]S>+W
M-XOM@'D_*]G'2`4VDHF_6?S^`NZ@+^`Z<#+R,HT3LD$T!B(,,4'U+&2#P.DX
M0VF13J@!,7'B`"2_:G2QK*D'#GQ*NC(E2TPW7I@B@9#HFU;%N<TQR\P2<W)B
MLM\9[%;$,#[<4/QCB;<T'C)$?*CXZ-(+\9+0"'M\(P$G:9(=JUVA*,OA>D5W
M*,`^CA!\$,FN='E*R;3T2`.TND&3KE51]0RAN.Q<DZD8)SJ*^D85,,R+"<`-
MP0D,\TJ+=(9YB(D3N;EUQ80/8JC(0'#=>*)%@E\+7:VW5MH,VP@[]VA*1YQ;
M(^#H2$/#NQW4TM'=#&QGUN\K*01?28+B>V_+NR+!(60-VMUY9"GM2..ZLA$3
M,RO%#E!_@$'!TXF&_WYQI?7(W\^]E(*(P.+:R7&/6;Q?._E^[>3[M9,3NW;R
M_=J[J5U[5VGJH@LQBM_Y'\]>C-@O_P902P,$%`````@`&(BH1M'K2BSZ@```
M!D\'`!0`'`!B='@M,C`Q-3`S,S%?;&%B+GAM;%54"0`#`"1-50`D355U>`L`
M`00E#@``!#D!``#MO6MOY#B6-OA]@?T/W'JQZ"S`655V=4]/U3L3+\*7S#+&
MZ?#8SNH9)!8#.8)AJRM"C)843KM__9+4)73A53P,T78",UUIZ5P8XO,<'M[_
M[?\\K5?H$:=93))__^[PAY^^0SB9DT6<W/_[=]OL?93-X_B[_S/YO_^O?_M_
MWK__B!.<1CE>H+MG=';Z<7J]C%=4-$-7US/Z3XQ^_N'G'W[ZX2=T0C;/:7S_
MD*/#7W[Y"WJ/CGXZ_`NZV:[7<8X^Q$F4S.-HA:[2.,FI@0-T<7'R`YJN5HAK
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M"JKP-WF4[@$J?6?N/\!_J05%7;%'%_1?+;_X*<?)`B\JS\RV(G9RUSS8<LNU
M;3)O65VQ5H2DPI_##69X_L,]>?QQ@6-J^/#/[!_OV3_>_W18-A3_BS[ZG^F:
MEH[^?_YA%=U7YO@O^??OA._R.&<_H//NQW9IF7ZKO+1))=MTCCL>>B7XG]7=
MRNI+M2JZ*)K,Z'I%W;+<`B?O/]]\A^*%3'92/T+LV;_]N"MS_W=.TW;51.F\
M*A#]I^9'E!(_S@EM+S?Y^];O6:9D+:L%HOEXY;?@]GY%+3&4$R31_7$_H#O9
MIBGS&V?S:/7?.$II\#JEK.J@0R=6_D:YF`,J94:A`*JQ+\.J4FU2OD7%:\3>
M(RJ`F,2X(-96)3'_[&UHRS0JE*LM[@GPIV2^94RKFVH!VI4RY6^6R#C@7&@1
M"N0JXS*$RW4FU2M4O`L$VNIZ(X:?N0UJH7B%:(6M/<'YC':<\^=3LH[BI(,I
MT:ORM[5?.6"V:0@*J@*;,H3V1"?%$_2E>/;_C8M'80T0]9=KHZ\I58&NK[E7
MK/T-KU;_D9"OR0V.,I+@Q7F6;7$J!)]&MH5&J:PS/"668?&J=J(&L$JW0C23
M>?\'$T*5%"K$0L"XKJ*)97V(6"!1:]-":7NO//F=K+8)[4H_?XA7.,V$_)#(
MM'C1DW'F0\<B+`_$QM7X%^E4N*_?H>)E"&B751LQ_,HB='?$VZ@6VMHKFLO<
M_1IO2,J&ZF_R*-^*0:T6;6%;)NH,<;%A6*0K?:@!KU"M<%]U(&L95`B%@']-
M#1.[FA"Q0:S5)H7*\EZYP4EY0C/_>Y(^"RDAE&@QH2/A3("6/5C<BTRKX=[7
MJ%#.WZ#J50C8%E<5,?JV(B2WA-L`%MC9*VZO\7V<Y6F4Y)?1N@LEE4@+N5T1
M9^BV#<)B5VA;#5Z!2H7>W2O$WH4`7TF%$;,/+`)P6[J-8)&E_:8EM`%(H]5Y
MLL!/_X'%P5<BTTY$NC+N&4C;(G#J(32NR3D$.G6R4;Q#_"6B;T.`LJS>B.%G
M%N85;?%.0B&RM5\XD_6:)#<YF?]Q\Q!1C,VV.5O`P1;BB+%MH-`&NE+!'?4*
M\\`4T'O2\$%GH"8'%T1<\@`5LJ@A'`173'!`AM24D$4*W0ZEM%[V/.VSFWSZ
M0)]T.[`:J<[43T\*8/*G8Q-Z^D=L7C<!)-+:30$UISCY^S`F@61U2(P_N'@B
MJ*/0G0H2VAL%Y,6DE![F`CDAT%MR8%!O6/4#]KX#,[AW]7J`+Z<^@X.\J#Z%
MH)=\>A7L&RIBX/=L[@GZ%_@^6A5MSO0I[@)>\K;\I;VW#N#NV(*"M-BL#,@B
MZ0E_6#;@Z`M[/O+LJ*Q2B/9+MA':$:QP*=3?<R"^I68EL;?YJA-NBU<`$989
M@@ZJ#9NZ.%J+[D(G>Q1&K&Q]?Z+^;N*(R*2Z07"GZ8BT993=\=^US=[?1]&F
M@!M>Y5GUI(N[\O'_3%,<S987-,?N(*/_HOQ=S1<#4==W;HN[O+^TO"B=U+0(
M?A+A"?L;D27]OV4\QRC;1/1_W\4)ROZQI=T2M,0X_W[DQ:7]ZB&Z#]L&YDZ&
MP5*F"5K#AZZA16[6O'H/=_7+'KV<:CP<7H^'8T:8KU&Z8)%.D&D)WU5QIOW.
M%8A-:Q"MG,JP$HP]^0E_Q!N[(#(M<:40@V_9`693K(7-OOYXZ)S/R99O)[PB
MJW@>XVQZQ^8HYGD7JEK!"K<*05<02TV#(EKG10EOM?*$[>9DRW-H]+V)[Y.8
M-K!L0FRGABH]RH52<VP^Z&N>V-91ARE2G19M-):]@LNJZ=9G9UI?PS%V^.9!
M)DL4`%`V:B)1E"R[BIZCNQ6>)@OZ)-WBQ44<W<6K.*=E+5?YB&.WC68[F)MI
MPA#0Q)=U=ZF_WUE(2`O?!@0UMC:I%-"FT$`LFXT*';3:*07!42L8]4EK6[]"
M$IL8$;#:W/=^L6S5NCSB](X8M2\V[@'Q?/@-T,I*'@/1_8;+,Z2/@--Q&[^`
M6#YJ8/FJ@>52"36T#JI5R&\)U$=C@OHH\&SL-,[F*Y)M4WR+G_)C6IH_!F1F
M"BL669K0RAY"@L"O;?8&U.#)2^(:+V26C4-'^!%#!4++Z*%!A'T@$1BT#2K2
M,HW'$+C)`K<R>"+'H3D[T,X$^L*,(&XEC!&+D5GCD%3ZHTT(HR37>([C1U;R
M2YRKAT54HIT65BP*%"1$QN$GAO7.3!@O59_<IM$"H[1^'P9+E74LH**N+L1T
M$VF)."6W[AE*X(V*RI$+CIK-PT[F`%&IP/I94,C21')7:(40D\NFQ&B0VF@\
MVM/0\\#8:Y&$#1Y+5@X;AT$(207*\QW;05_]P($JI.X5]J;3,Z:3,?ZF7F`F
M6C04<)E1T<R?\$X#?MK@)`N@/VTUWC9@#L1H*,UB?F/OI#@FR3;3$$(LTR9#
M5P:&"&VK/G)PJ1<#%@CT:@;<%>^"(("D_OK@EW]N(?#;X@+0B^SY`@9D1BWW
M,`@5ASM8E"_#29T=\2%/E@<"9.3T>+O>KMCIS*=X0WO.,3]HG_Y[A=D_V-#+
MFIW:\D_^_"HE&YSFSU<4$3E]=_:/;;S9G:MXGLQ3'&7X%!?_[<?6/3C;!6FO
MSMQ)[;%X/IH-_\751!K?!9A43U&<L`4#E3^T:#@</7KM@T%D#)SVPJE'OYVX
M[/T7!A\L(%.)/11UW$A1)#=U>&AZ.4"UGV)*J>'I`%6^Z+^8-RY1^SNH]BG7
M8>A=Y73L#4^O,.K(L[A7$W9>0U[I*8/TE"L&$^B-\S_5%3!^`OL><[UZ>.(5
M9W(^HZ?_[,Q'0`PJXPHRM]IG%@69+QVT$Z9O!+9"W\MB<"#)RRQ_P.D)6=-?
M\X"3+'[$--,B:WQ!LNP2Y[/E;?0DSU%LM/NIB)DV7*`S\0<\*3?`M6'0,K;8
M"DV$::%Y4PW%7"^88&.%*7%,L:UH:>0P,20)$.9E&"\,+!8QBU/1ZBJ*:0_K
M)-K$>;3JTETM5=%:)N5*7[%=4)HJ72CIJ-"<G)`D3^.[+:/=O'@Q,L<T%4FL
MOGJ',V*%%C=4-D?DP-^W6<X:Y>R67&/V^6*^O&O'UEMR$F4/M#%_C!=X<?S\
M.<.T^+,-NWDZ3NZG\SQ^Y(L`9*<[>'11L\^'"V?JPA<*EO?>RJ<.&I[<3AJ6
M&?'2RC9*<(Y6U"Z*\B(D\1T!5.0X)K?Q&A^P(=D?V`,F.:>^*6MIV(H31"JG
M**J]_CIV'//()[(__'8C*+RW=OCU]6O&B]VK%?G*[I3_0-)3LKW+E]M5?ZFN
M9!G4$-TJVMKINH91&V_P\^(#O"NCG[6]2:V"EB1%BU*)36!SK9&#T2`<$8#J
M[80/&S.MN&#O?]^`AAM?'.(9%,V'73A76O4Z[-:.C#!6E.T=XK(AO;UA?-3!
MN<8(XFQYBI>8%FMQ\A"E][AWQJ&);-5JJ65=2:VR#M\J&7A3\E:K/VF*L,.^
M%J406L5SM@[^`*7D.5KESWS,/MO>9?,TWG#I%#_B9#OZ0F$C;)`!5=AAI4JM
MQ4*]?=\@A&M)3#PY(?"P#\%*"I5BKPU?LK`/!K!PPOIYDE-DQ&SO=Y;A7!W7
M9<+"P-X7!B55USSH@(R))W-2"0WT2!774BCB8B&Q2EKS4EJIZD=%JZZ>G%=B
M#X'PZA3?Y>S@!);:7:5X'6_7FI1)*B])FP3RP*U6SX/W]$GFT:8!$]OHIU&E
M$.)Y4C$IN8E2FD914CQB*LN8N*#F0N*A"B:*%DY9D^I&KJ>J:N@D?O:!2V\9
ME=2;,RB%F=5=CBI1]*X4'GM5LC<(&B9:[A@<->%*\G@1K[9Y_(AO\'R;\J'K
MLZ?Y:KO`BP_T$[/9^6U>_H*S*$WBY#Z[PBF_'_#X66Q`=-.`?T]58^33DVNX
M\%<VT"33>S&5`<JS]TGS/=H)A''YPQYX0O8.R$X,]>>T%7U]_[:7&K8OX@2?
MYW@-'*-[9F$"<L/LN-&W+DA`H;9;)H]QM>U*&D0K>XC%,]2PR'+(RB;;Y5;<
MS8R^,+N(&W[9H;</?[@X*X0>:%"M/0!&T$ZI`PN7E]$:GY)U%"=&8;`OK@QO
M37$O86OGP'\XZOFR#S,=$[+P<8"8(/I2B`89$`1`T!)=7%DF!-YIZHG9]1(8
MX8SC!NTV;_N+D2!MPF0FE<UQTY*B%`'E)*T">4Q(&GYX.'E?QY.,O<X0;J4B
M\W8JPH795#5;\[FAZ0A7*FX9Y>ICCVR!XATN%>G##30/*<P#)B'-\HX7$(43
MF,*)2J`)R4$3C_IKJHQG&1NSB;>SV^D%FM[<G-W>C,PI^02A;B*P/^$GG]@;
M7EEP,P4MDV8UQ<;\0YC=-:@DV>"\HI9&'6;GI2C7SLEVP*AD6L&A)P,"OXY5
MT'Q"X4`/39'>Y.3S]?79Y6U`4456<SW\*CZT",T=\3ZXA?9&AKH2XTIP`Z-Z
M*)SURP-$YO5@[FQ&"@:]>MB:XE4.5-C;<GLF@=M.JPMQ!1IE6QK.!;<#ZEG9
MS)I5=##-KJJY536SL,VKIXS<8F]13WYRRWR@>;DE((@%?L+*D;6DABVHM.4$
MC$=>-N2(+%M5<1V,0MDL8UV]RD!D4K]CAJ%R$_\%.Y(O*W:2WN11CMD^T^8*
MH;/B\H`.P`9JEQ_*6MN1!I;^('L9PURKB#3$XN0:;Z)G?B@2659G6J`5/_B1
MW*WB^P".G1L**0)2SVT*6QIJDGQ0&8*(`K,:")+LQ$Q8P'&1,""E^^9],5CJ
MR92P$@.3DQ8EJZO`GP_J!&C#D!,2114`D#!274UR`O;U9'R3>1B;7F(>B0D#
MQ0SPL07SPY5:ARG]C:1_L$-(@CA(27%PDO:@),'!2*J#D!RJ#2Q)[]@TK+/#
M.AR]A,J2).'JV@HE\6X$++.VUJR1]=6Z[J%9'=Z>%N&F<6;]<ILF<<ZN1RY.
M9UW&3^ROC!V;6,S`QTDG%[XC:4J^LHG:(*`OK7U]"VO=M!JTJ:,WIMG#-%FP
M_[!:?HQ6[$BD*[**Y\^]BZ1K&EGHU*0RTG&FF($7#XVXN5<U!TWM3)@,YQ\_
MG0SOI,>FF`TRB$/%=>EGH-XFH[&_?4$2,$&Q\`B"Q\,&(/D_&N('J%!`7\K_
M,DW$54>>)O$/5FD:Y0NMXZ9@PD*:7!0W1%7=KOBYQ,W&&?CTSP#G`\BMN"[M
M\NP6G?PVO?QXALXOT<GTYC<TO3PM_G'VGY_/?Y]>G%W>WHQ\'.8@+.G);7F=
MF8T5`Z;[NVK,UJ'O5FKP-6#V]I1M5J!7<^T;W78M&#B\PVO/IOE)E*;/M#?[
M>[3:FC5D$AUE"];3\<+SCA?;-FO#*^XL45XD9>/9GN`B.Y-ICC"E-5FB_`&C
MHI0A\E8&#"UA%?5F0M2.NIZA0G_[0J15DU-4]DT>I3D(*(<U.T)##)9W^#Y.
MV*:%MP5.JV8$`IW]AL,;/(_V,)8D<0L"S*,7-IH$B<NC?>/R:'^X_-EOIB[Q
M"`+)GY6Y>92C2@-QE=>.TI_WC=*?PTN[Q;L,S(35B3;4+@2U>=A9/@-/`XC8
MWG;SHL9W5(O=S2O&B%^"M?`F'L8CU$.,EV=/>,ZWU<Z6RWB.TT]X?8?3+IOT
MDA655)*N/)+;!B61UHV201KMR:=X_A#1'W[Z`_H;SG+TI7@Y]I2'00T3ZZKH
MT$:NU.*,SO9XA%E%639;WN1D_L>%Y/PLI4Q%$K&,*SU$5D&)H7"@I(14;\)?
ML1XO?QG0.5#J:B067[W#`9%X"_UR>V/C_F\T&XR2?)9>Q_</^>66,9*6M#Z.
MX21:K=AU6&?1_*$M*^:(N[TVGUSLP7!O>`D\\-2Y,`:<=O0Q*318`/A:O,U0
MG&5;O`CG#!8XL/:C!@Q>A!%FN&E!-'(MY]B1BT=3X3EO<@%!6PUTEEO?I*]6
MVOB\-HE2KWT.XD@V19U)&F;=L6M]65F3',31:B=DO8Z+*RI9YY(D[-9)G,SC
MWKU7!I(5SE62KH"7VP9%OM:-D@(:[4E#H!@2;XJ,S`B#:B;6]='AB%RI11:=
M[5%90Q).YJEXE$,JT.!(5P"`&FV3\(N092YT;!`H36YPRBI\B@J!JET(8PQ#
M7G_$](OW,=^6[4)=9,D+)."65TG-V^/AL(B*%`=%HC!]!4B0S4@/@,*HBY1X
MB3@]%<%.\+X5ZUKO07#=L`C=]HN,ZS'=U9F4=[V'&^%$E=:#M>0[BT#=$.UC
MNF<G!$0+5]A)7O?Q#+1NKF/0$YJ-%\&)5*KH7`RD'*"$L#O$T",3.$#1-G\@
M:?Q/O$"'1W\Y^.FGG]C_5P?G1KS?]XFB\@']?'B`:*W\A>>]IWA>8*5\^N?_
MC?[UYX.CPY\._OK7OU3#-TSPK_]Z\//AOQS\Z\\_([+-LYP^8S/S4L/4RN'1
MX<&__/*O'2M'1W\]^.M?_J5M)>\7)!ARRF?V%:"14K,_72^T$@(Q^6F[V3FO
M/3D_15)]FK:EX-C:M.LIV9;Y,21P3[/+XY*BP0V5:JI83`19?4CYT%20T*)O
MTQ]^@#-SJ8^!X#GLH>=UPD:9MP_%S?@9/.]3'.O&*XYUXQ7'\.,5Q[ZR>(%U
MPZYI4VDRS6BTCFFV48Y9'(>;T0OK4-Q3%7QU:4?U6-E1/0XMJR_(-ZVS4ET"
MT9>4)1%-2>B&8&?;4P]`XL:J.>AH=UN$1D\@W%9!4-VJED%<+YK&8:>D;""Z
MMD-@SR6YBE)-Q[@OTV=,4P:.*SNKGEC2<V#(CXY>EQEU=YD38T%6JRAM7!43
M#D<$52MFA[@FI+S8B4L8T;47`A<*ELYVPP6ZID0@*FM+6J+0C4G#N-?6I._'
MJCGIJG=9TQRH";=!$56ZJD615(ZF26EH*=N4GG7/V++JMMJ/>PB\N4"LWXLM
MQT#>!-1,^[8#L39^+[=H2:IU9;R,5:LR31:S_`&GIW$V7Y&,'2DGV_,#8$J0
M#]F;`DR;;)W['-`<6AC33&R0^2HL%%K!W+0!@D5)`N>""7F>9VM5E@X.*]W(
ME/$QACNX(#[YLFM'N8T#M%N!?5,VK-12L7N63[]Q8ZAA[1O%=!@*DV,C-_*;
M%#_@)(L?<7%*_R7.9\O;Z*G?ANLD=TVT7-(]G,ALPY_>IO6EB0=*[<G)[-/5
M]=EO9Y<WY[^?H8O9S<A7C9E4,+&NB1[E9$H=1JEM^T419)NC\^,`H:+%V$F@
M0@2]NR!9]CUM0#"_Y81*'Z!IGJ?QW3:/[E9\N(B&IM$O&H(%G#S(`R!NW!!-
MOV!"6PMV]O1UG/UQDN)%G+-_]4*T5K(.T0I)9W));7OH`^E\J?FEUIZT!/CB
MJ#F70"D5&9L\^KHFUI72Y8Y4J<T=C6V_@`*,UEH_#F@Z[,`)L1<'J!`J_PCV
MV&50L$DC-03:1H[4&:VY!2_:!<ZRVX<H^=L#6:V>9U\3O+C9WF7Q(H[2YZ+Y
M90_3["'>G"<TTN$L/ULN\3S/9LL3JGB/,]H$20_TWX>O76OATY=[>/!7.A\M
MEO?2:J*49__5,OT_T0:S4F9-9W,^H)HB6*(XSU!6^0Q@N]X^6$5&`&\OUOIS
MVXG6OG]?Z.$#,C_Q7])18T>1(^U\'"#F!>54&A5^$'>$=IX.RJXLJIVARML!
M*OVQ.%-Z+'K%7VYY/SBD_.J5A1UYCO=*XL[8>6:>;N?LMYTG5RFYIR7./J8D
MZY\RH)5LY'A228`0*[$-NY9&YT87W%3:DZ8`NS%M4XJ,'SIT-4RLJZ+/6HE2
MEW-*VV,2YA&G>4R#_B7)V<3,,VL`)&OW#61WI%')NM-&;MU'QT3K3<,?C?ZD
M(8(H/-9QEI'T&3'Q8!;]FU0^&5!'/4;)U3J<TMGWC3+(_%7OR0EBAVV,<2%4
M2KU:A,E3+2"(C9SJ5(4[Q7?]=67"M_WH7+R%8PJS!YRZ"$P;<J'6F$S79)OP
M2;]Y@P8)K=5@0-^J)S',NQ]7BFLF*$'RSD8(T&WRJG-)O#KKZ-XHKTP[:F$_
M+8+@KGI/+4+;TX`6H6E@4E\\4.P6$9!C_!3>I.[U;8*@AHS:A%+/H%%H>1B1
M65D^6]Y$*ZR[]5@K6#-*+NC,)IEI6"9IO*A9I%2>L/>,-QF3&)LKVAHEMM^^
MRQ&93IL?:LLC<^,:/^)$L-]0\*[%@/H=".A+:\8X_Z7`>8+OHQRK+Z@3V-<C
MO"D?'JB[]=+#L>!SBJ!;BO71VM*'KF#`7J+`LE7='NXJMWSZTJI7VJ4SK=\Q
MNVPL]2[2ARPF29E(X,4Y'QQDQX\VC_(X[.!KF'+YF6R5'3E@YPZRM1_D6<6A
M`0;K77_\S(X-_4X/4887;&0</\WYI`E:DA3-(TJ,5;'DB<WW)POJ"R\2-K$7
MS+;`@;`C$&!H<]S.3C,(#"E!N$&B&,JP#@\=-=/`4*OY#@FEH[T&@[9/IS#0
M-`40``Z*/GG@W.]BRH;U@OJVY'MIP8KI+:^C<GQ7IEN<K@5L%@LT>-L5`&!H
MVR0T%X76=:P3*$VF\WFZY80JEB2@.$.;<C(CA#N(%=5'3#]XGPQMV2[L198"
M`?CT*>XNOY`+"`%>"(`"G)GT!_"&=7.`UTH3/GZ_>X&^L%<CS\\IJDP*ZNY'
M5H&:R<I!O;,4"*@;X\"[%N<JC>=8E)I9Z0DIH-0#98;"$_C:"EO/YF32V2HX
M%N\X-J^ET(:)\3[8PS99I'B1/X30#[,#D924AO6KXJK"A)S"6K_[1#'8J)RU
M5S`(UVLZ.I@-[<2W_4%7,CKH'[MCCRKN"EJMTKV.<ERLU(T?\15.V<ZPZ+Y+
MG4&ZPN9)JPM*;HTW?WF=F6-SBIO8F]0O4)0DVVBUZ_>D5"WD=LH445+"6U2T
MBO,:,W+>&_D/A/J7T1H++XS4B0D)W10#Y>[.L#^:]GR8,[*CVNV*'2`F$,BM
MDMJ*E?)*7`DJ"NTTY&SI6@V$&)^3:$UHX_U/O&`'#;$10"5#%/)"J@CE03DC
M\."//')GYBR2V9@T7B`VW(T6Y>N0F*0"@)12FCI2<4N@*B>9U$\@;&LVF3<Y
M6Z\R(/V4*6ISS[ZBM\2SZ\KSX(B!ZV%YI]!8;WCD1>:<4A@9)9RJ"C;--KLV
MS%)-L>>](MG3`(F)6S@8'WXW*1Y_@^^]:OW4/O`;SAC)IRC?IG'^?$H+J6R1
M1(+"%J@M",K3IFE_.9_`BSD+>\J]QF-=2J!%-/:.&X,:EK)+5A<J,C5UY.3I
M6QZ1*TN<TL#(EDYFY;:&:;*XI)]4N$''6+YFCE;>F4`:#]:9FNY`5%./:DZ9
MV)C<LK*,32'3&B<#*Z5+*(UJFU=&?O8!,<`4RM";,[X.6>PNY/BBZI'7__M#
MFC01@H;:N&E/6<"'*+W7;0DS$^X&<8DP%+V$YCUTM`W<&7%+;F#'*_H.)UEQ
M5#W%?K9=Y6P3YA*/O=O&$`$BJFGK24(SH9Z08PH/WL$&'\B5KMR0U@KAA52X
MYZ?Z@)PNM`-@+H2@7FYJVEV=(+EBR%B^$]H5\D"$DWJ`[>>:.3,AG=K&Y)H\
M1RO:R9W=K>+[8ED_B_$U&R_*P/\!!W0EB3D\!"0TJD$Q#:6J(B9J_(S.Q0]X
M@=-H51R/?QL]G3UM6$T?XP0O8QDAS90ZK-0I`5%3[<9;`F;DUH2I!H9VK61<
MW`Z11T_HKA`XH-D8-Q`&-PV1(B"H>3V*6:K6%U'5Q./>0`J>N)FYA$%H,Y$K
MI:N+3-@=':4">E>JC#Z+X1^KFLS.!UA#R/3X^((FNQ/*B$9<P;.XEE5_77.!
M%^/1KG::-BV63]3[+A?=CODRQ/Q,7,&R82_S/*PE+AW=`KWY4&K9SX"IS5V%
M"L7.P.@K`HC)6*@50D((FG:YN%T2[CO[!DJ[31CBGFH/S;'#8,V`/&5P,FV1
MF.PC?7;.F\U/I3)TZ0BWPS>'-TWDA@%<"-&<+RB:)HL+ZLIRF,5&M1/GS52!
MZ&CBS%MZ;>'<A*3&YM2#,%G.%\U$3Z',C%EA24!EVSH6T]K$BHCCYM[W#&GP
MO-_&,22>FRT0U^$3`%SK!0S=[`O=FE;+-[Q#:,^NV9[BE%W/J%U7IQ+M3=F)
M1,%FZ_K&_4S42?V8S=%)U'?,Y.MX5G%T%Z_B/&;3XTEQ(72UQF?#!HA($@8K
ME?4OG)-3UY-L.JZO)9Z)DUD/@%.=24+=2B>]@FY*''[%D]R%+=<><7I'S+(_
MK=-!D^.=]4\VL^.A,$^+#Y,Y<8OU4')=HUEQ/^NBU&[`<S>].W<T-O.TZM3@
MG2CZ$MSZ*!]0U*1AD%@,(^7B)13?,J(6$C<#4+>*B,UZ7`-E?HN(0E&\GI5=
M6#Q/XPT/[VFA=1!J7B6L:CF-M)>(B.45;`GCTI"J4+2S=+%+BK7]$IUXAS1R
M<2#ZR!SX()+&EPFEE"9VY&+C8=VN2AC\T=:_@$DF=23FE$Q3Q"ZUEQ%YMB%9
MG&?3+,.YBE]JL9I7,C%G/HD->^E_*%VI::10G51OQV:*IB:)W5?O,D.LT6:$
MRJI'H`#V"M1.AF+D<`<25+P_0#N)UX$;:8+O!IQQD_E-BN<Q'S[HQ\W>JUVL
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M,(UBDW%&/H*AH/H8!D-I"06A#V+0V`?/?\W\V?!0>!;#!<D:I`J+4P9[X"UJ
M1<TIQ29X(Q_^T066?AOZ<H063=(K*43%$)<+]_@%/]B3)/FPX!NS*U"<!#];
MGI6W^;$C#V?)290]T$:'_>?L']OX,5KA).]>?#5$M8KU5JJNU+1P!IJ(V?M5
M4M;67'G9`EL-5M_5R(\,+?Z=(=I!G5.]XO0>]@^\LS`RF8=`B[A7>8?E%E9:
ME+?V/A[]UYL5><;XAMWO.>-SW<)!`:U<16RYG"N+999!*:MQHN2G4G?"'Z/B
M>1;($(*^5HEE!70()%-IL45M=SQJ4))N^(&F0D*(WU8TZ+YU!7_;'BCDA::5
M0!=H3.J'H4!;4C_$Z*-V8-P6;(%79&-4R.;/DN,5Q"\;@&V^!,#KSAPT7'N6
M=6CM*$QX(OY`5@O:A_\3*B2"V00OJ2=B\G7[N-W)=6';M3`R:C_A_($LSI-'
MG.6,4+.O;+S](=Y(K]RPUFMAW4@/A`8&GN`98NY43QY36Y/Z!1N0JD[99R>3
M;/,LI[T,=C;HO+Q0GE$P"^OV`GM`]4AI6=<BOAJ8Z%/9V._(+#\AZPU):(&$
MM[LI95KL[<F`,+5C%9Z58@=Z!HKT)F6[5;\+Y"8W=27V&*/XYB)V=,3[3!#:
M&P_U3WB^91<M_A[/\14%8;R0]B@,1"L.*$5=J:`P#LH(O1\E,73JDVM"_YFC
MO_V`KG!T1Q;/H71-3"J:V%=(ARX*K19KM-9'(\^'*$Y_CU9;/%M^B),HF<=L
M,W1USTAYF'$'Q58ZY1<SU''DE9$7\%E(&Z\JNIG;F3!1],ADV=#SLI)N7*(S
M\NBR'4:(0Q6V*6FDWN2FA;]]@1-L$M/*(P@R#TMH_EY!LQ9O7(H;\`'S_F$K
MF>WTA]LQ9SYIR>(<7]"6C_:;:._T/KY;8;Y(_'.&E]O51;SLLL5&I6I;C%1<
MV6O@!#)UL_"G9*ZIF<GN-8K*'0Y;+H)65&9D6MJ`@@ROM`XG#;1;E#3VMB<L
M6C4D!ANP;/Q"@/*PC\HW!$I92^$)E6&V$]G'E&3=53&FXMKVH1+WQL?"`7R/
MP\SA,`XV3/0;A5`IUZEX([KU*\>4:86F&<N:7O:`,[C.@Z$S5Y"Q+@,7>\_E
M4`-RU4Y++OLZD6<=Y(=!+]#@?A$G^#S':XL`WU/1!_F&BC\"UD[VTPGH^1M(
MP[89#1/1%R:.N/S8'74;A)AQ4EB#QK2LM0VIV?$6(CNG\_EVO5VQT[J;EV"8
M<U5C0,]<J0%_/):X-&:U^2GG@PLQD.HJHY/&2Q0UW@;+<AVVS#AO4-O&$4!B
MRS`>*$LR"MSWD4EJW,,CW2#;;%)A^HT*@Y)4;UP(-)&]Q-VEH&;"^B:0"_OC
M/S5O/3I!\F@UL&';N1M([<J`:+AZ]+/.#.O<C(^=FC&F'M4SI%GMP3N\]M&4
M-%RY8<N@B;A\C4BSC_+64`LT>G^*_D[2DQ6-(Y?1&@N730[4UL=WL;8_1HK\
M[6G(0N%Z(&.E%K4,YIJ(JR*F&\C"SJ$P,R.ZKNZ-B2\R9!@)Y&4(,3(</^_*
M.WV*+<8I99KZB-#7]!<-NK[V%`DD;@=&`:$UW5#FW7,K!GQABN&27XHF,^*K
MJMF8]%TCAH07^PZ1[#1)D>SKLU,RZM2![0,T<[//*>B^V^$)>7M3H;C3%\RV
M0DN8&&?G^FV(9OKFR3KH!<[FKO;43[2YXMG&DDF_\4V!=5"7T@VMHW8Q28KC
M^Z2XIV'^?)M&24:+Q4ZCF"8+_N>*CV1FZD/=G.U4+=!P.ZZ4'^H9-`%U+(0R
M+#C9GI3JY54G;&7W3@/=L]X4.S"(Y`\X9;MY-RE^P$E&X8]6XR^%<48G`09*
M)[H,-=D*.&[E"C`$?:2H8@<9'N,EE;F-GHR#CE13&V8$FMX"2\\7?,IK[7M8
M!!%;D\2,0J6(&>]8<!AY@_\0&!G%`V7]FD:`GA$SSDM\[Q?+<,FQO5]`(!_N
MD%RIH(8.^LB1S-2^/T!W7)/=@OR64"U+F_<"ZS$3Z(\XP6FTHBWL=+&F*3]+
MZ]F^Z?)6Y@Z/#*7+CZB5=F2SQCYD8FOF2L59$PN34HBGHE%+;%PRFM8[&50Y
M;<YI%)L\,_(Q'K4(67R-5ZQXW1ZTNC-JKU@1SD+1E7O&KL"30FO72EK:&0MR
M$<P`O!#7FNQPUMA&B[Z6GO<*6;#<S]XM'%YIYE<I\#9%,$`:ZKD`^P2U)/O;
M!ZI'S?WD)=U=$RV9GQNDJV^F1+K^:-_W!IHS#G`\D/H2>Z'/W@T#D1G-U75K
M3/2^&4.NR_R/QW;:"\VS:SS'\6-$BRF^9UTC53%8)N7*5;%=^!12Z4=)0H7F
MI'B)TOKMR/32U"6Q^O`=RH@56N10V?0'%+C$3>UC($H.:YCL7A^4XW)C]R-`
M\")+IIP`,VJ:U"F6)F)J0B4X]+T'QP%1\46$0Q-<FP=`%9"]A#ROL6Y(D)-%
MMY=9ZX9A3%?MXP8NDF57*5G&_2RO]Z8.5XTWSHBM;8'O>.O;5D.U+3TICO0H
MGHR-SWY5$.TW[(*R%FKCL:,+6Y^`P:=GUZ(R#U]N;4ICC$EUCAE9SM>;*$[Y
MD?PI[>AN2!:M9LL+DMSS!8,FDQPN)LK/-<R$(PF&.`5/T1P*H6+68+.3G28[
M@G9%-=ZO^)+<8MAI7%(Z08W`57V;Y4.L-</!\-*,Q`"P]L*E`#[@?]C&?XHJ
M9<8%IEXN3P]]RF5LGDB:P[&($D@#VRWI;WBU^$#2S[W%.58Z_294I0,7,>1>
M(*=>;!P:1@2-G>+&<G8%5$0[A30&?$W9OA2R7/*;:JL+]8(AN`%"Q(PVJT`I
M@^7J$LKJ_(U'T61.UO@FCW+,"BJ9)]5(53242;D23VP7E&I*%TIR*30G)[/+
MT[/+F[-31/]U,[LX/YW>TC]N;NE_/IU=WMZ@V0<TNSJ[GMZ>4P'T[O/E]//I
M.97Y/ICI35W=$ZN*ZE!*K-`BD<KFR+1AT?(#_4@G),GC9!LG][,-3HOM'<7:
MV$+N-GK"V=D3+3A)%W$2I<_\!,=+^M&I)JT`6K[[\X1VF'`FIIY73RWZ>O($
M$@*\E`U\4,]_6?7QR)_WR<7LY@8=GWV879^A\\N3V:<S=#O]+_KD\NS#^>U-
M",'*+UMZ`<\[+$5!TXO3?N#U^-O"#@EP_7S_Y1PQ'O"K-IAFN?4&,1ZBG1NT
M\U-MRBGEN:L#U')6'!%]@-K^4.7P6VSQ@._7&%Q&'?2HBJQ=?6H@V4K-))(@
M<51H&[Z'I7*CCV)R[4DSJ`36=5)7<(_QVIH0$5:HU"><PO;X?-',M&G$NDP!
MGS&3&(:?%5,[,F*)9-,/ITC.*!((+TR&X0V^NX01JM%TI56/4`%.*^5.AN+D
ML!E+`Y[E`8*0,@T:CJ&1$Y`41QD^Q<5_SY/I?$ZVJM6?-BJ[0&N@XLXDK1/C
M`&Q^PX:%6PW-S,Q,JN>-5:8![,BT0@497FL]ZFFU.S0T]+8G,$*&>&.'$#@L
M0C\70>\JX>]1G*`:GZ&LA_4-37FSX`6;8347,W9\&.M<%SL7+N+H+E[%>8R[
MQQ@/494V'RI5<.;*G0'W>6W]VO%88V["W_.%;(CV.]9HM1,(C;\&R%'RV*Q&
M=7266U'36N<]('97$>@J>F;AAQT[,I^G6YH16?#<QH@V850;\=9JJ]SZC0(6
M)1C6KFL-[S+.32%:'-93"(<<)JR`9]3PF\+`-!-0V3/+#?0E"BB<G.(EIC%O
M<8T?<;+5=RPE\M(@T9,'CP<=#WZI+W9FQW*1C4GUD'8A^=/@F"NK>"5)%76C
MXV-'54T]H9^`6%;.BR7W)]$FSJ.5?$;)4E&>CDL5X9-QB2O/J;C:JV4BKC(V
M.7F@EFCTISUI4@F6>TIXN]MH;W\-C;9:`*FS<H.JU>;D$AN:C%SI.2!JGR<T
MY%!O)FFW0%9*X)8L.&<;UO<R`-OW9T?0KOZD>O`<&N%$=:SDF*0J=+1JJ*F9
MU+/O&TP>!U`%GIQP)!\R;0B^-H09#XX.A5A8PZ%7*=Y$\:)*$<MC66GOC`_Z
M%/LYM)';QH@TI)L9`:>GB=N]-`(6!;%CM;'A22F)<"&2->_;*,\""F*SL!L`
ME='`%@ZZ*&%B3QT^S$LT&C<\MFDV1?!#"WDK6-&E.O::L:68E)A^8XE=8[H_
MFHS;_/9NZ3I[FJ^V"]J3J\ZI[#6VYBIUTVJBXAPL]$X\K!XT=JJ.!89F@CQ*
MW`H19'B-=2FKUVX3U-3;GH`(V$:9.X1`X6$+ALU+$]_5\O7QN"/?<^0;F]+V
MQ`\X0VHK=DO;Y8O(C34D+850`YB?`A^V[<0C3N^(74LA]VI#49F5%]%.J."@
MH**FOM1$%"BK>"CUM1\,>FLB%/X`X"=J(-!.%GT):%V[3T@:-@XPF`RI:6C<
M`URLUC\A69Z=%^NU%K?D&B?XZRP]>\IQLM`T&H-L29H32UO`)+?R[KVK,J0T
M-K'!WO[D*LK9B-Z<"885%X:!4!$Q!F-!'4JLS*J"S(#RC<T6;XWEH))XI8JX
M!\:U4*7&:I<KLH/%"M60]Y>%QC?#MGL\PHW<WO/-_\6>O')DD_99^TVY4FS7
M2DO$W$.*T##L2B>E#TT8D*M.ZG,<RKFO,#IPZOHD=M^^1RVA1H<U"JLC\J%<
MW2+B0/]5C?OF*V>L[XS!XKMG5XWICG@X*W\$]4#TWZ^+T9U4&Y==[?&QJ#O@
M02W6Q2C\`0]BPQ[Z/4I'1F"6'/`0%K"-MN;K/[H$\,J=^2JK'G$"F/&KG0P%
MR6$#)2$GWS`(DJ;,;A`:-]$MR\72\^P!+]AD#)N=F2VO<8;31\$J8F.-;HA5
M:4"Q2.[#7^#5^C2BE\;*CFCL[.QE*8PV*5ELYSD[9?M]1CM8@3#-`!PBTIG5
MGH1^<F4A$W6^]H-(^!"O]P<`QW;@KV3YI'@Y54Y!6BF\9DSJV@104`;14IA,
MB^M%NVV#GXEPN7$O,^!:=T;,4\QYAY60&T\FFE6#A$':V4.==<\H@H_@@R>O
M=?J-'"+0V6I89.F"LR.T`@O'TDV\6DEY,`;<IBNU[64T;^"QL&KM!G_".1-6
M7[MJQICLH94J:>@2R"[9"[9@_8&L%N=KVE]ZY#=_9/SFR`Y:]8+EEU$).C)%
M;AJ2*%HO*IYHE"?U>Q0W!-"2L'T:M%\=1]F?T#*:LTWJ(R<S!C5.;.NFS1ZY
M3I,\.LOC<6=WF$!Y]7R7,U*!BBL"`5>.]$Q:C^[HKEV1NE`20ZPTN67>ZAU]
MP9R'I*@Z8OJQ.V#OR;9`+K'D!0U@>;G<O#T4:`[>>'&`RE<O%P:2%'L(#L9,
MIQLEFB:+FYQF^"P8XS0[^\>6-E+RF*<4[T=`B3@<`X0.?$9'E4-#@LA-3&YG
MM],+='$^/3Z_.+\]/[M!TTMVX]WLY#]^FUV<GEW?_`F=_>?G\]O_#H9#:D2(
M&:6M-2F]A)H2LBF\[`&`/@*RTIDK^MK!FF\V+EZ^3JCI0SD(U@()\[O35>6Q
MO2_3#^A-&3@2[:SZ#-T]+X:,Z>B5Z2V_X#ZL<X'5=2GFA_C32SFQ$Y<0H6O/
M%TA\A->^AT$(Z6:]N[<O'1[ZF&F)CT"B8YF62X:4]8+2KC_8@++<-.@PF<Z+
M71>P<X[CY^OKL\O;9G8;#!]D]:KL$.J'DN4ZZOYA*`/)(MKJ22*75>43/JC2
MM^Z)+5)'U@U(FS,7L\N/[V_/KC\%R1I%1>M:$RON]-6TC4MX#!+V$/1D,E(S
M''CQ03&E(_!%B):.7;K$'2)VAV1^FUZ?O:@A&4.*&M>G7;=90UP#KWN$[-Z&
M;KI.H?`J'<H)9B)_7V@=.,KC"M=Q^S5S?KBF^$X)R=NZ!>F\=69=RQYL]B4R
MK6907V-2/D1+//[HC;AFB-'G[.*[)=B&L<#&>&`ER?TM3M>G^"ZGK"J/F^?+
M`V9WJ_B^N,Y<,A4_1+<"NIVN*PULO(&29(!C)86L[4U*&;1B0GS7,ULL7PT2
M;4C*5$9FWB`@$8#Z[;#6QDR+T_;^1V/\I^CO)#W99CE9TZ9S^A1W5Z7)!<JO
M)1)P)&C?)"0+I=955),H3:I'-)6CST9.XQ1U14R_;IL#?=DFT&66QD4S3?YN
M'J(4%^G@)[R^PZD(U"JY)K;%<A`0%UD&1[K"B1;P4MW)1TR+@=%_1.ERF_Q!
M?_N7XFT(#%!6;)<(NCH0\$&DTJ.%W.Z(['B*U]NUA!&"=S4+6N^<D=^P!HOV
MOF$UPKORD_)1,&`6U0DQ^)1=T#;$VD#MZ8\'SCB1@U/TK@)G^YTK.)O60,$I
M,*P$9T]^4CX*!9S".B$&G[(#SJ98"YQ]_3'!R2-Z=4+219S@\QRO>\FR3FX'
M6IF<.X#%EH'!K'2B`;9"=\+FC$B2TR*LV$'G]3E=7Y@<XH+C`U]3Q\2R.GJ$
M$*MTR*&R&PQ1;MGEOQJ2M&0D!"EE@,G!K?HD1M.!#2EV>G)"<)G`N-"N2@4/
M>E]>S0$NKL)_PUXPV)]]36BO^"'>7&$*R22/[O'Q\U4D&#H=H"GAB5(3F#T*
M7SXYI7=KPS2=M<EQ3&[C-4:U('H7)^AAFRQ2O,@?LI&OX!@"'04O#>M4S5:%
M$16'M;Z#8;:&OAJ.@A/1)]L&4*INM]XW&ZZX?!L674PX80Y\%;I'AO!EM,:S
M96O`]I2LHSCI8$PK5WX!A9PCNJ66(6&N<Z+"NUJW,2-0/!TY1=-7*+'\]FT.
M2%6:9-#8'8\5.#^)LH>KE#S&"[PX?OZ<X<5Y\B%.HF1.H]9TGL>/Q5)@&LKB
M9$N?E9>QDR23+!>$-5KQ#<BH*SE!B@'*9,@2*6D/YVAR,KWY#7VXF/WM!GVX
MGGU"'\XOIY<GYY<?T?3D]OQWOK#QUY'C!BR*B4\,=2(2B/U6^`(L\9BQKCC8
M_:)_](SPW2[R--^Y!Y"=->`XT#.LH7-'?L).CERQHU&B/$_CNVU>C3J4?<`#
M=OW'#Z/34E!3Q.`#]TBR$^M@O:L?6O-<4@NV>1YH5-T\6QOUTSQ;%F,/S?.P
M$@UHGH<XZC7/LZNSZ^GM2VB>AZ)8WSP[8,BH>;:T;]`\#RIQ&,WS]#&*5ZSU
MN24G9+TF27-]^W&4Q7-5`VZN+6KB3;0ADP"]/_!]2\/\&V<3AA8GEV>WZ&)V
M<X.FM[?7Y\>?;Z?'%V?H=H:.SV>WYY_.:+YQ>1)2OF$!+%E&8E?;BIQ%;TB:
MU9B68?\H!]OJ--`W,,0/BYRZ4$/OF.+WJ%9E]5,HHZ;V`>+Z;Q'VDNU1^\7]
MF)NEW%IRT$0?-,$?.;$'/\8'I#C^LOE==WY.C5`RX`6*$T0J;135ZJ.'&0B(
M@F7OOK)VN&P=JF5V+`)D0PU0%+]4*IMQ9@559M#=,WKWN2#6]Z@VAG;6V)6Y
ME3VT,_B-<%(LA<NX`',"P\%WT+DYT#FYD>?B]I43V!7'WP1<)R?8-.+8LK(0
M>EY@"U.P23=?DVUPDVP^\P*+(OC."RR+XI=.^KR@-O9"\X)1"6>7%XS"N`#S
M`G813`8U5F!I3)T7&!OS$\4,W>\K+[`KSH!`9N-@<M(<)X@KS=#S`5MXZL/3
M`)`812=#NP;1R:J$HS/)=SY@612_--+G`[6Q%YH/C$HXNWQ@%,:]W'S`;K'0
M0*,@^8'OQ4*6Q=C#8J%A)?(7Z]2+A<XO?S^[>1&+A8:B&"RJ#5XL9&D?+L@%
MN5BHL5KUEK3W"TMVK`W6%RX8,M('74QAX-$X+OU2Q*4$WT<Y7I@O&S(O@_FJ
M"E.;\J7*29#;[H;C3;J@PA("JA45!J;D:RJ,RS$&`3RM)[+P#H[]PV_@MZ_^
ML='?[Q?L!?Y''E>-6A0!G`-'[);C+/N5+9_;I/@!)UG\B+]QP@H38W/B:-3\
M\>MT/B=;EN#>TU0XH?^<%]<^7Y%5/'\N_O<6/^7'M!A_]-+'8>IU]FBK[AP\
M[!QZ6'`^J`#JP#'`Y.0:LY,U5L\HSK(M7J"H-L%FQ!LVQ@X/`P%&8"J]&QOL
M++5#PY!2C(!WP%1QF'-HL/-$\2O:Z:&VX@$JE-"7\K],&W'UL8]L&`G]TG1Q
MO_`?=1"9EK!:%E<TZ6=/&W9!0[<%U,E539U<SI7C,LOP$[@:3TKB*G7+NUM)
M_H!3FIBRUS^^PX5`]CV_G6!D)FJKF5C62(=:,I46A]1V?>((KE'0>1D,HD-^
MU-1N:7^UV:@4&?EX-C@`R8*S,X*"#+>RZ3A3>5WXA9M$TWD`G1\S=#:(3.U9
MK=GM;V?7;/_I[-/9C^_._NOJ[/+F[.;[L2>RC.O?A%8&TT\Z52.6A3)IM&4G
M:<^6];K_&WS/,[$NR71R%;GD<JZDDED&)9/&B9)$2MU)\9I=K+1KE[)28F0"
M:>N66%9#AS`RE191U'9'(TA=GI*WLD4A6KGRFRCD'`DBM0Q)$)T3%4'4NI/=
M@2I5RS)RPZ*O4F+Y]=N\D*HT>:&Q&PXO='S0\0`>_^"=7ID'*]"W.KEU2U!U
M<`-#O!'2+1"N1#9(UU5H%:S+*K5N#0':1=UMD#U[X;4OZ8?:5_^8_<ZZ0-(3
M$142W:@&>#JBP*:_R&9U7*),:\+/#V2@JB+<Z&NW554G0K?)<8D"82'`-4<G
M`N$!/L;U[0\`0RO.M0[]><F`T`4\*T2,&O32^RB)_\DI>D)92E;Q@O\Q3197
M%(CLR@7VYVQ9[@",5C?T23%;(^L*0=JL`BN,35?J090"M#L&6"`EN<'\3)JF
MBF.],C8HTK1R@*)D@2[B?VSC19P_HR^5A9'G8&&!33SBJA.6(,RW`AE<>5]F
MY#N-L_F*9-L4RY9#^3(/$0^%YL<,C8("V4;)1YS>$?6"*T]%]!8W92X'A-`7
M'#=57(`*H1K\`493@2>PP"K]%0%2&ZZWXJEP^V;U89?6+<.<S4W3C.^U<;2S
MCG;FT9=@%J^]U``@Z^:]L`@P:@>3K>-J;4G8=7X_D!3']\G)-DUQ,G^^3:,D
M8Z=K\!_+_UH5/WWQ]VV6LU]XB?/9\C9ZZB9;7IU4*9<G)Z[1V4NQP%>[>RVF
M,EC[<SPI]=&\-(#NV1UG[U;\3.LXF:^VB^+TF'EO3\[(`=DO8<@^X=F)S5[\
MM2*TQU\4;"R`R]>\%G&<0,!R-[Y<N;WUKC7:?8"J8%$Y00TO/+]K^$$[1P=L
M&QI+]ZBS;T$##,>O)VJ,GMU-LPSG&=O4R']`;SI`)=/,K?HR$.&P:]5/9B/Q
MHHU'0KTRFJQ(<O^>NE^CB$L%P'YI-7;)J_KJ`NIUQ7O,$=OSA0_8UD[F81`X
MZK:F>'F`=J]?.CY4L7D00$:/C))X7T7O*YS&9$&?ISC*\"DN_BN;504S:-"?
M-37H,5\U*P+H9"I4:89FH19.RB#0[E=6N^561<*9%'EC'CV-O9`6#KJ&2:(]
M>,SS03/;IKF?34F#"V:BQ+6;JM+?9AG1!EK5A#5KJYYBFV4Y]A'@AA5I2)0;
MXFER\D#=L.B&EMWQMKS1969=:**+BL6J1/R/+5M74ISIS$?.`XV00ZE@$"8=
M<&@6*RT=F`3,065^$5%3U-W_&,4)/SPHC;,XN3_=INR\!-Y.6,Z#>/`X(-H.
M]KC'2#RPC#Y6J^RMU%"!W*44D\\)37A6\3_QHCBRC`9T_#0O(G\SRE>M`-L]
MN;W+XD4<I:,?Q;]/W@T,[0#`'A[V!SH?VB0X_=:7$6R\S\=X*&\`<<;#3,U'
M/N5;7F-<>$>%>U3X#W\"YW6$*<NIG9<=IT(<VMPUX;^1U8(6N_HML^0&TRX;
M/T#=/9F%<J/)8-W=>&I)7`NVQUP5J*A#&@X0U\VLE"WMJ0816#-0W9O^GJ:C
M[[-HA5%6VVV.O8::FX+1R"#20T+6++J[>C0)Z3"_*N`HX3W)A"KD6`'"+)UL
M!)'252MII,%DY_"EII`O+9I8)HLO)9R,GA;VSSL3975RJ692)I*"B)9]N^"3
M+%(7VD@ET2SC3#6741X7$\)QJ+H*[1):_?4%=.PK]-@DLSDN%R[BZ"Y><=JJ
M%\<I!9N,D`A"D$)HVE=70>5,RQ"Y<F/='.+KYE8[T0!(HJ[F+D^T%2*@BE"G
MQQ:%9:](@DTGE6Z&@ZA.Z1H2@2VR`\*1*@5R!-+H:0B[N2^A#IX_1300Q-$J
MN]EN-BN60"6+3SAE$TN+.*,YUX+E8C0+NT_6DNCL:JL9P(?;@F#F4.]^EDP[
MED9+<2?[DUH;/>`5O[$X?XC3!=I$:?[,^FSSG48`,<$9I-VP`8$506`9:K87
M>]S*-S:;8)M"UY)XI5+=H-9&#E!MY@!5AOB\6L,4VC);J&'L`'U,P]@X&139
M5,UX$&P;/1F8SN?I%B\:V<J)8J.23KBU8TDN#+(U16;>TQXFC3O]?A6E@3(,
M1(508'TS?;7W=K"85(YH)XM,K[^E1>W!.\*`=T'I7+G!:[<OJL17J_]V$DSG
M#1AHRCU3,$@;/7[K=DZ0E"^CL+_QW)-UF_U5-M;WL=G*O#Q[WWEE733G;5B6
M'B<GLT]7UV>_G5W>G/]^ABYF-S=H>GM[?7[\^79Z?'&&;F?H^'QV>_[I[(#=
MHO,#H@J?9I?HYK<I59M=G)Y=WP00HCPPPG;;UC`8#MC#9>[(>D.7[6\8+<A>
M12S4?\+L`I9.[!"]*K]R^Y5C;&H:@PPL`KNJJ-`3GQ1/T)?BV<C'J`EK@^B_
M8IL73:DFJ/O:(R+RF?&%=2YY:D+[FY(]A`:2-5X5DL[PE=J&1;/.C1K<:NU)
M>2EKADI)/B0C2*>#.8_9I/*)=2UUV2)5:I-'8WM,+O$=CA](>MT?\Y"\W7&F
M_=:=)TU[X,,88OL:4O0T)NQ?:$.CXYJVU0^C8UQ80<3HJ_:PW!3LX+=O`[ZV
MP884)+8MJ_J0-?#%4[:K#%V//D8PK+HEHP!V]3UF/[]1G)-H$^?1ZIPFU^01
MB^ZB-!/NAS"A,!S&!>:-`]PO!>(3?!_E>&$8XN0.#6D@,[`C13G/F:?;>;7[
MDLK>TX^2H7<9QNB2Y!C]>>2[7`P!(>:0IMJDC!+H20@F]>`=>S["K<*5&^RZ
MP;@40TVYUX<S?>AV!EH(@?V63.?_V,8IODK92LW\^8HB):?9\AE]NA$LO;%7
M[`1\$T4@`NI=>6P(C)V;L-/0V.1JRZ9\,\SV).#J51CDM`",@*AV52GFK-Z&
MB+^FGO>*6?`&Q-PM'%R;#0O]\*4*JG0.$-<J;DPY>WM@UK1`/M$\:LM$"W09
MK?$I64=QTFU]A"^K%J;STI61+7.@XX4BRTI>]14F[!EB#]&7XO'8@W[BJB$F
M'[2#\)9<"\4""Z,#=?H4]WK"@E<=D!:O@"#*C/D`:,.N"3QK\28XV<-`H-FJ
M#@$PNY]1#$LF)0+E3GL\2%);.$WQXB8G\S\NR564_AZMMEWXZ,0JJ$K%7&$K
M,0P*8;4/)9Q5JI,;G/+]P&P)["-M06,V(U.KH)N'*&4KFS91BAZ9%GI'8]B"
MK%91FO'!ZXQ)C#TRHT,`L:NM#E,D&BW6**T&PJ#3^#%>X&1Q33M]5Y@".LFC
M>S6;U"I"9LE40%DF=N*/<4I_YNQ3F)GL2)<Q4;0H95%*A3GM'K;)@K[/'\:^
MU=H*(U+NZ>M0Q4.QMIR3*F^!\%/?N.G;-1]-FN?6;%A#9MZ&964;EI!=,T:[
MX=O\@:3\N(RC@Y]^^HG]?RF*(G[1Z2?*A`?T\^$!HK7W%]YO/\7S8D%+^?3/
M_QO]M=",LXRM7^"G`V_S+&<;%9)["TLA,=JP\;1J-S5-9GBMY>66U<]L6:1`
M58,^319\6=[N#D3IFB$8:^+LU=X:;))KZQ]^#09(>2SRYD$>&HUZH1C.HB8@
M=,HS:Q>(*!-P6\.*/'U8&<>G$MR`.4Q9///HL$4D9N8`%898ZUKU4:DQ5+0R
MK($MMNDT#'ZCGAFD0N;>J"/YK>(7Q3[G69^RX1<)"MOTMB!HC&F:]I?'"[R8
MQX6>LNG(5)EXL_YQD;T'U3<6UKZ4N+)Z4E&RJ2-G6]]R4#R:UITQ`R[UA15\
M:@I[X-3.O&]>]3S9<JMCP)1?C7YRT!P3H$+#,W'=Z;FVT]/QK>O!.P"M\D++
M/I;,GQL.6ZE=-5)3#<.\$>@9I5YNV`LG<>J,PY[RJ:3IFFT)LIF)$.F93$>T
M]7S.230][6UB0N!T\.Q$SU:7J;LI"N&D8%A4-<&/Z52%K&HMYBN:)HPG+?I^
M`R%U$7)FNX%O@S1.(*W(XUK2'MK1AGW?F5S?E6T3VK5@-@/2FI@(ND$504/3
MHDKJ3]^B-A1U36K/QYCLVT3QXJPXG[D:-"DNIQ:?.F6AL6.A7L.=B3H?P&PT
M=*=AI)&522F(RF.TL^;=H>41.1'7&IV!QM`@@^NNQT2=<H>-9KY&9&1,TN*D
M_&L\7]%ZC9?QO'-IZ"G.YFF\80][]!RF7G/55MV9N'8./<S_#2J`FM<#3$ZZ
MHF-S>2"."$S==EEN9ZE-^2&E&`'6@'-QPYQ#8_JP#^H#=$56\?P9?2G_>XN?
M<G1,X^D?HT^FC0-XZ9C-?A$_[K@.F6.\R#[0BFCT.T[Q73_YU$K6#9E"TIG<
M4MNP2:;.C9JP:FV:5,;)/-Y$*YY-1O/Y=KU=L5V<*"[/^1J;D/JZ)M:5TF69
M5*E-*(WM(*CS*4Y(&N?/O(_Y0%8+FOHH^*,2%Y!(+`[())$#7W12^#+EE-3$
MI))"#,>(7[5(EFA.UFN2U",HR]UUX,_A\$R)"0G9=/4F9YQ(4T8[N9<@N,<F
MQ"/ZB6?+]G@/[6$6#S!]R9\H&&EO1,!3&R.`[#5WZXO3UB4P9;JE80G_-^U=
M&>%P?@#J))%@&`;D\<'<GBQJV)8HL%ARPML,\[`AD%=&B):\EV#0\."?]WUG
M]A3OVNBP.2X%>RUZB'P6P4%+74F-F;"TH:HG9,]/$-SCY9GQ7G%V]H33>9P)
MEI(9R@NX)Y$'Y)[0@X=14S./I@24V^@0$)<OBQ2:0XT4:N$P4`T*"0.U]29G
MH%!5QD"%GWV@$'"0T]";,P0/NQ@L(EPIBFK9UPI`Z0@E-`)#&8.\H2G[;#E]
MC.(5.R3Y`TG9D]VEUNQ,H/Q9U2I8&1`U$X8&(!EKY-)7$F?EW9C1YD8EG;;C
MF-S&:QQ:E\T27S+"6]>X(@`8V9)&!(N2!!0A;E,<9=OT6==!4TA+N=^1!B=Z
MR[Y?5HM<V5&X;T'"U[P4+#-#-K&Q&V9%7Z,TC<8_E=40&4K62JM/1]&6HIJ/
M`A\!D<_X8%9[32DI/1[-:N[++UF=3F6UM-8A<?Z`:R*'<DCK`/`H>3ODF%9S
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MD^+*,F3C3MF(B%U?^P&@_U:D[P\`??JVHY!'%Z\<D[9-A!,H@VP8+G$N/>+3
M7$77-+14?%&SX01X/-+4WR!J=LTT>QS+;9K$^38M3OU;QD]Y8(?]64#$A)V2
M*C1D9T/;B)X];^'1\V,J'((T$-91LA3V149N?G\Y6M/=(!;N#.CY%RCIVM5O
M0K=>)1D2C>L94:SAP3O2_"=C+5=N,-.G8%ST]4'--N4:@+50$RV+!,LBL?*:
M4/F8@-(Y&YI%=?O5"2XO))1=OQPHN9K5;Y@T#4N63),DO_&[=.`_>C<<N4#L
ML#LGH,182%=\`P/.-I);(B[(*&[;5[;M*/OO)>^UBPS1/Y9VCK7Q/?Q^\J!.
MLD,/V:I[''K?V'H.W7KV?`_SYB/,F(/,E<MGR5]4GWG89*/+9+G=_.*>)LCW
M/#4.,REN-1V.OMRR9?PO8!8<`)*VF9D#)H/,TFZI9_&=Y.8:VK:AH>&-EK6/
MO61K/7?#:-FVHAOF8N*A7(MN@0XC3@JKSY23M;(9*3N^PB/E\3,KH^@&=G,-
M'2F;&KY(N?.Q%U+VW`TB9<>*&2E#N`[>`ALFE!17GB$E=\I&E.SZ"H^2NXO(
MK/M2"E4=286JOM@J<&9+VT><WI&!?2VY^T$TEIFS&A8)E-$J1)E06U/3AAP7
M6#$BN]3[GH'MO_.F<`R):6V';J='^W;!]^H\H=NVIP<,[R![?Q=Q@L]SO#;.
M,WL*NA:LH>"+WK6+O22976^#B-PVHAN.8=*(BX=*V3XL3(@JK#A#=M:Z1ISL
M>!J-B-<4*:)^7>]Y^14:SQW94UN")$G7J(H+;=D)_S.(?E/_VQ/-9VM#M!9I
M(K&C-R[@/F%VQ;((<NTW3=!5;R!@5]@"!U[+K!9Z#>D*?$&,I(GJH0O`_@<4
M0+`0ZH&PJ3L>##$_FOXJHL'Y-HV2+.)=K4S?JQZ@6<'81M,5YN:^P"<O[7TK
MN6)I;5(J(*Z!FBH\C6F_;EY+QX[?'YEZ`[!%G"N]0UUS(RUJV_K>+\#!NM8#
M_`*B^U`)[R![U?O%M*1/O1]0C]FCEA15.)-J)*MNM(!F3Y760?,S`T<#>-J<
M*Y42,Y2\SJC6]=33S8HJU0S8%<1,J*1LHIZR7E)-)9C>M-SV'FADVN/6:*LH
M%$*_W*"F]?31]-WE2@;4":%_+RZ9;%S75%Q-(;@Q79V#/9#)9CS7R(2*5L&,
MY!H#0<\P@U%<G:8!UX(9P97DJ,?/S3?F#9="43..(5+TU,OKN]H#,>5>A_3P
M),8Z9`VXW5,!Q:`#IZY"L^Y;WX9)[TWF.0@*:SMLVEZ:AZZ9W_[8H$Z8O.<5
M7F_+K(METZ]2=Z9"[D%EDEUXIN*:-@AL#Y[.P3[:&XL=>$8FW(;&@]F19PP5
M@U9(OQ]/IVG2X@2R&^\:9YA^WX=ILCC%CWA%^%*$LZ<-3K(N#XQD:S(J99V9
MJ+`.2T.](S4'=?J32H33;;$3&IM0)G5-!E1)ETH*M3:/M/;#)%%QI*@-E=H:
M)H2J-'S2JO#A86;8U.=@GC6LO$2V=>!@RKE^?5DPKSQCV)1_35_[P2#@Y*VQ
M/P``'G80V)!%I7"X!SW[1:ETFM8'3,>=EJ697SS/RWNBQ0O?5#*[%D$DX\Z_
MOE7@E$KJ0,,PB=YD]ZJ\-_-+\79\OB@JD5A\\QXE^N(=$LCLC8CZ/(H3O#B+
MTB1.[K/I?+Y=;WG?Z!0OXWG<[_V;*M1\T"LXDT/GPD-^9.A2S1TC(Y/&<YH<
M\1=C4\@8!&1H-77)I=-M,\W,TUYP!Y@3F;IS!]WA&T.=-,V!A]VX2<XC3K:8
MW0SWD5^(V8ONDO=U,.^]=^90QZ*'4"WVH":)2&=2/BXN+;P/X$91>7T1PT_<
MQ7M'M`UOH1T?``",F1+KUK5/(R+_`\7)G*Q'OJ]A>+U+`YUMQ0<0QJ[QG-PG
M,1NX5]_W9BS?#G,J>1C4RSWX"H-:CP;$T-BHPV2ZDPN"+@;UWZ>/614)V217
M%;!+YV<?@(,.NWIOSF@[W,&M(1CR:)TO**HC.R`61XW\Y#E:Y<]E.;MA7OBR
MBNF=EZY\:ID#'8D365;RI*\P*9[%N+Q@>Y.2Q7:>\TNVQTY9Q95$3#YM!]DM
MN1:,!19&@VQQ!3<?\KO<LB$_^L=#1.%UGF5;O#A/&NL/.F`;HEI^(SM51S+8
M.(.DR@"_*B)9FYO<E)?69TSG`"5<BS_@>BCFBNQ8J+RQEOL=_;L0&/FL^D'X
M(N[UWN:QC94FR^V][QGF5NF4P?EG0_Q#XIWF6L5[E)'5XNW"6))I[0O'8^9?
MC;*>D"2+%SB-6+EHQHCC1[RXPJE1<V:AW&_0C)3AN&[@SE.C9N[9D.:F!ML-
M&S_CL%9CW7JN%PSI;<`DIKUE%4MY;V!'PGSC$HQ*_:Q,J3\2LLCZ=VVI1!HT
M[HL`D+5K%)J2$OLZX@G5:GJEU:JCLH-6K.[.</H8S\?NJ"DKDYA__#Y9NM)=
M2HBM!0%\->;5<(=&NH^+X\3V34%>X_N6^:'HYD\#PK$!A(W1JP`NU&UN`IM@
M0[02VY95O1M^/4#TT4NL:44V;U[58^?DC>)(MFUII,3Q"FR3EL2N;?PR["3+
M/5G`N[,AZ^SWL\O/9S>_!@5QU48J@T^N1+QHVY32IC^(^`IZ71\#T=$)@L%L
MOX,!BUE\M$3+J/%R_H`76];SFB9YO(A7VYQVMF[P?)O&;,KD[&F^VB[P@JUW
M."'KS3;GG;+9LEK71;ME?("&WW75#;->C%?1&=BX*V-!BP/:8?-1,F5T@'<X
MJ6RRCF+3*MJ9197=8IJO89DI5;81-8ZX]?)^MK'CDA^.D'T@LQ,$0?VT8J>'
M7Q!`Q/T0)W&.+]C@UGF24S:Q3>O3+,-YIHZFIHJ]2*E7!(N".E=^(IRA5[/H
M962L%9D*C?=<!>UT4*$46L`QAI$PF-A4L"Q0Z&R(@X"9YP`(/IW/R3;)LZOH
MF95KFBSHDW2+%Q=Q=!>O>.SB)9:MU80PU4^7!IB"2XZLG8,O_@0HC&'V,\S\
MI-)#FT*1CX-'A2I:[71#B2,.V!2G*4X8D28EUE8E*<C`THU,(;AA`X""^.3/
M8:>S4)'IJD&FT@YJ&`KNMN;0^"4;^@B$8&$,HNA2$WU#;VW!.LGWT:P;^_0Q
MR#VX%##=@$[KW4C[(RX42ABQ1]:@O-^J438V-JPGX*L)MO+KH>6U]N\!Z8<#
MNKXAMJYCT$+;ENZ3%V&TG&;'WJK'Q0;8Z+6>5C;``HJ%5S\#9_8%,`LIMG9;
M,45^\.<!NGONO`YL<&T(%H6!92`T9)'%PIPXMEB7)X#@(KW05!U/S-1Z(42G
M!A8UU([\!`HCGV:QP<!4*QQHKO<-B_^&V!%2WKQ>92Q76Q`3V\1K`%SF*\2/
MGT]6M'>EIJ]4LL=8@20827NV_?!2YL:,BF+M%ON*8^MHL\N%2KJ%PC9Y50L)
MIJP3&:=Z2F(:26R/QQQ\STA\C3<DS>/D7K8D4B-6<48JYDH8B6%0MJA]**FB
M4IV4;VF_=TG2=53>_17(PC==Q1*[2NC00Z+1XH;2:C#$T%^B;*$AH8N/2Y,-
M?/@8=37V:D,KZ?7(`H:%12O#BV$M*TM--LT]L,:^]@-`N'%0<W\`V#O<@:\6
M#?/.8K^0E(U9>L'DJ&.2>$5MWG_$"4ZC%9M^7*SC)&9M%EMV6![4G:E/67,S
M4K<>PXPX\WF(6_AU.B[%4!-_L.%)J50LR6FIC<U])[P1R-KO!H@A]MHQ8WB)
M1J,"8&OG4@0_/.!M(E<^0$U&M`U4UT5DX9Y`%P)MI`WK>+P9M_E-8YQ-KZA)
MG*:J&R@,).N&5"'I'"*DMF''+G1NU%17:T\*`31%M4A0]U285#6QKI,NX:1*
M;59I;(_''+;%Y3C*\()M@J'<CD3G#BF%*KY(A%RI(C0+RA*5!R5!Y(H37L/O
M[]A+-&^\'9D2ZHHD-I^]0P2A?(L#"HN!P7^:IK3.,>MT'C_O1*ZB9_9H^C5*
M%[,-G\`NCO,^3ZXHP<GB8TJR[HT`'CTHB>?HP0MKG<H$WU?T5D;[H.'NM8@X
MB!12Q>4*.*0S!CWR0!NWP(!G$O2<G.DC)L!O"9/<<+U??^4;@=G5H:%E,M%J
M7AO&V2Q[4ZYT@+B'`U3ZH%WOXG8*&A8*/^P)]?0M.```]S5$AU&[\:R\5VG<
MBSS]%\W<IWP!$=6X*3^91M.T-HSLA,MV?<,>\-9\05:K*,W0AG8Q><L>0L/>
MKILNY7I?54`4+M/#=T,3M'IAVYJ66?.ZK2([XD]>3BVJXIVF&D>/+KV`643#
M:;(XI]\F86.<;"UC)KS>W,&"LJ^FL>`E75/ZW%-?RZ0,]AF7WNJ+&ITQ@Y<V
MRS&N;Y,D1FE,GZ08E&4<S'ON@ACY]P!X11>BZAGPJ;A:GR^6S\*=@1N5*%;I
MOF^FA->@-GH@F:P+PO_GEI:/_C+V@RZC-3XEZR@VFWF`<6$Z?#K(A>\AE@&%
M\C]G`E(^IR&6H6XG;.-*_ER,EJ`OQ9L@HQP0]FU&11RQ9CDJ,L";U;#(X%\S
M;IPM+[,1Q<?.JV9<JU]!Q*/2&'@<:=O5\K\I/KGLWABVH;_B@:<Y84U]="NI
M2T#!QQ40IY3J`;ZE#5S75DFQ64^P8]VFR@]?9YVKDDJ#2A\U#8SODW@9S]D.
MT.(8ICBYYQDJ.W1)MM;92JD*:89*K@0P<@,:!FT\*MEB;FARLUVOH_29[]/<
MJ:&='JH41Z:2'52(2T5VV&>DW^*EA<?Q")M'.4^%9DO:K21KEO"P9"G%#S1?
MHGW,\JEDT^<P[8K"MMJN7+;S!TKJ0:Z5[!Y@<7(RNSP]N[PY.T7T7S>SB_/3
MZ2W]X^:6_N?3V>7M#9I]H*\^75V?_4;ESG\_0Q>SFQOT[O/E]//I.97]/IQ]
MJ0.Q1T``T0D.=H9:46)(&4((%R=1]O!A1;YF^M@@%>T'`H$H'.M[QCU17.;'
MD,]B=4/R3F]^0Q\N9G^CI-TFT781YW@1)&GEH!`S5%EY4CKVM"3<DU@?GVC%
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M:B[9&W`FF:U+^*5J0XN@YN8@HY/R*<+5XX!F.(;#BT!5>)?NMK;:<6!8249!
M/-Q"M<'NX>$.O-.ELMW8[/)V&2.;7QR!,J/.5;)"/9#5@K8"1>?U/&'W0/)9
MFI3GQ7F>QG?;G!]Y3RYI;9(DIS5+BW)_GM#6`V?2&\*]&&\VQH#&(<(66'%@
M4V@/)=,&.UB'DYO?IM=GO\TN3L^N;_Z$SO[S\_GM?P<0O.#!W0UL7B`EB'E@
M?GKQ$/@7!!0JM>%.&[(\A!WK_)_DT4J;_XM<V,6`@L?',;F-U_B`+:W_H<C;
M2ZD_(<SE0F.U&3-MV*5F"%P2W3,+FR0+S=MCXK#<?53#H%IYW(@,[(M=4:@D
M^<M%ARKAM(3'RT\8O22*7A+$0!)#/Z,Z4,7RGPV66>`+:"^<D`N>_?G.^N"S
M/4_MW]"BV"WVML^E7,JU']K1!OJ6_:X7D:V%QS[C=C\<^O7SB_'X=Q36,$A5
MI/U0[TB<&_/>4V$0E19[Z7+;**JL?N.K,>!>#E^/@NH/7)(<&UP#8ZLGS>JE
M>N`Q3.+)-C<WN1C&TK==.%+9ZN389T&V\CJH*`.#02WJJ"\QH6:WTN\^L>IQ
M&$CC%0RFLD$CIA+HO3)[`[%QP@F-XE&'I;9W&>V1L"6XCVSAK;39T<E5S8Q<
MSI6J,LL^FA&-+R4?E;J3W6M4O!^97MIZ)995T&&/3*7%%K5=G\"!B^DZ+X,Q
M<R@`34@!&@Q!L@#L#*&0`JQLR8=&3!)>X99A2`R#+JA0^[`A2&>10Y\>H2SO
MUU6K@AL&"Q`D&BIBA+(HH%TLX5W:"A$Q'8!NSQ88]4@#X_NR96H]^`=R&[VJ
M^N2PU]V(+9!6P#V(.[#;1;J($WR>XW5O8XI&3`SYAA@L[&O#'J'?]6$!_[:J
M@`),`'&)L'C0KU<Y%X1UH.1#K:'@1,=J*+P0W[*FDA$S`NIF-9%5CUPPOTU-
MJB=@01CWIRDK40Y_[9UI(G$%\,.X)ZW30%%_X@-+=7*2%*@A!YP'U99])D-=
M)S8945NWSP8F$,J1G-K:561(PHI0ITFUBBI7ZM@-B2*BC;QJ*3D]8#;QBNUZ
MIH;I!EZ%IHP6(>SBU=2HFA*:';QB!0T=0MB]2TL5+^*(W?LI39'$`@T*=`4`
MT-\V"0U\H74=Y@5*D^;S@/(A28T1TV_<1W=;M@MLD:71,'V+YP\)69'[9WYV
M\GF2TUJ-:4]]FF4X%\/<2J?\.H8ZCF0P\@+)#QN'*LJ8VYGL1`/AD!T<B$-M
MM9EFI-XDGX6_\?C(?B([0G`1/\:+;;02I%M*F8IO8AE7?HFL@O))X4#)'ZG>
MA+]B9Z3L7@:18JEKD5A\]`XM1.(M&LCMA0/[O\7YPS5>\8,"LH=X<TO.$OH[
MGX4=](':,JKHM*%)I/;GE5Y&KJV(9V!QTGS/D%E(!#(>,!1,*L::U["&RVI#
M2I:;E&$\_J?1@IV8.\L?<%J>LIU=XSF.']FTD?#F/BN=BNMF.JX,-_$"RFL+
MATHV&]N9<%$4E3+\JK'[XAKBM)8_0`D>>;F^'4B(0QUVF&NBWN*KN;\168JC
M;)L^\R65Q8DP/4Y*)6H&"B2<^=:S"<LNF7DUE\1:D^H%ROBA?<$<_J6J.V+\
ML;LTZ`FW02^Q%0;$Q:,?<@D1Q*%&-OHVP?=3RWT8X[PU4%'AO*SW0$8K%-4G
M0[EV)*(O+$6Y8I0!"!-@ZV@5]@<`XK")"![Y7@,@)`MEAR%BS,6QK2+]'JVV
M7=3)!41AKQ2`1#@W:1ST?BGPG>#[*,<+X[#7=&(,\IU2MW&/<C0G6?XK^O/!
MO_[R\\$O?SZJ[C>C;SY1=#Z@GP\/$*V3O_`4FCX]I3D?QTOYXL\!T:-=[3)V
M]"I*P0TN*Z5&PY(7)/D)E2WS]B#J!<H#Q-^]7!R8!$E#((P9(C\GM&M+[I/X
MGWAQ&ST=XP0OXSPK+O:A#ZYP$JWR&&?\;N?RX+?Y/.U?\0E@J?R43I8<.>7@
MV\-&,??2J*CJ:GU2_H'B:AL]"_>;2FM<;D/`D8#CHATL'(PVHXISV<;E#%B#
M!5`.CW2A36#3`J(:J++!3PZA5OC#V@ZG4WU$16GJ&ZL$R`F15F.VZG^+V#'D
MXC7OPG?E!^R\<XP++6L>6D>1?16!^_*3:4;K+8XR5+X+941'7$G$X-NVJ=`2
M:X);H`]=VV!Q76C9JJ)I["V?O=CZE<0Z\PIV/SVL9]+J$##M4*W0O%4U']75
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M>('Y0+8M]8+,M^S2+^Z@\S%`2R0*.H`.)O39=A6E:+$[Q(^&G?P!(YSE\9K-
M1Z+H_C[E4Y,H:OA`N+"*EH2JEP[1JO"(EIB&K6Q[]W=<G"O3TF0:.)H_5*Z6
M\2.FPO,YQOR0W24M3+1"SSA*LQ]&WG0%1Q7B`ZR=#5W.MEE=099R=%8[)P^P
M1?'+9W;F6VD(S9:H,H6:ME!E#)764&FN//\'A7-$7*#<DQTX%QCYA@\,P94!
M9B0)MCQ^*7CTW:3%-MK$"1O';]12XB5L:@T;BQ,F]QV7M!-Q0I)LN\II(O2!
MXH3?"AXO8UK0C!U)OTW9O5P=PKH9*;_U4",.06:82^ADW:D4LFCB8'1R$J7I
M,TN$:=9<[%C)JE3Y+J+>YC1;?L`X9P^36K<?9]@8P;SVRL/.`?KZ$-/,FSV.
ML[RV^\B7--$_OE8#[3&_5Y?Q)G^(TP7:1"F?O&;)>X;31^JCF,GF$ABMXX2D
M;&M<X]X:=O-Q>04AFF9QQ)4;):KL''!#XD[$)HJYCVC^CVU,NR<IZY&7*_,Q
M][Q)R2:-<1ZESRBO]DVSHO+?UBC[R'T)1Y82*,ZT8^LP>U4\=2G-*($#I#_@
MYAX^9-"\_]2`_&A>6V`A91<ZWC8O)/G\6,1PR]N'^[7*U17+.-Q+`4^0(T."
MT/:JT:!&_*R-MTT.248^%CD`,^^K%+/<HDSRL_.$;V<]*7P5QZQT^&6A47XM
M(PT'MAO8A\Z6S5W*:&QJP2H/3MEQ`93=F\)X-3J=E?DN34F;K1_E.6%.49OJ
MB';8>]9'SAIM0$<&H:+-;`/EBL;&?OPC'"2ML_#EB&V:L%UU@=K#Y#2`YL<?
M^B19%SS\W/(I0R=P`YT6#AU!>&0"PA!R('\@E&0W\"#T-V+(\J7F&&99DO_&
M47K[E:@'"LUTQ>.#.EVX/HS:D^?10"/GAAT6`UML\H"F.BRC$4ZVXVI*C\$/
MH\:^D\4V9:D22U\R^I1V;AK3Z&A)5BORM1)@J5*6=P3$L_AAC9D9`E;<ZS''
MD;*OHS8CZ>*8^-XG8WP,@YEY!>-*<]"KFLIF6NW9[FIRFRDBJOF6X&PVL.4)
MSZ##6'IW<`G8(-=@J*9)&6WQ_^4MP=1LB,D33,=)S*B5+NH':MLG9X7V?KC)
M?(V8H#7<`Q"TM@:2I!4SDV\L1VLAUSY>=.$T.&`P0P-"QL[_?NFS[VRMZ1>0
M.$,R-J;[UN#MGK<YXGMON5OE<)3LK>D<$.5%!O?7MP9:]RS.$;1[S^1.M_@\
MN<;L2.H%VQ7T@3?5K$R#4CN].:M<3V7..[GESL?)!K7E<>._QKQSOA@7TY)I
MY6&W<<8B>\14<_&R<T@#BE@%,#.8#@EH<LMV$4Y7PI&9O,?$5%\0GQRV2UVI
M+72>H-H:VXQ3V.-9[3>J27$4+M?VD1.K2^!Q@=[@\OCD7)%(_^4;6Z1`")<M
M>T_&ITO:+63>/\2/PX96A1:L4NZ.!>_AHN5OG,1:5`2WF-"W.#Q]CIBM,E->
MY@]O:+15#&:K&"1%UY"HTS)F%V@$Y=@_L_:8Z`I]`W/*+IWEZL5X+#/P5O'O
ME*1"$F`?J6C/Z?ZS3V$1@(E`<\S;!YQBWE*\56`[Y9.0P!YE,OX#)<K@N?BF
MLO54?*&\EYD6YFJ\B?B&=_>)EMH8R#3\DEI[4YEA#[764SY=+`V=\&%V[.=[
M=M[W2IP]3\$WW<)19L`$/%-]6[!VGGUWP_6^YMXK?V-,O3=]PZ&[&"_\U[>%
M5N=I=S>TCI.Q#1WB<QK=V^/`WKAC>J##>4`C><V,[8T-Y;EU]J`&\(;U\/8\
M;#?2B!WL8-WP<;H7-4('!VOWA,T)UWM+V(8,Q$$E;&`C<)W!-YH%_/*VT.J>
ML#FA%3!A:]UZ>45HN_HL.W'<1%1T-6]/U(%I*L/0B9:!+QF-M*J3T]99W=%\
MSG(JEOULN#3/=B*:5-&'^?.?,I2W[OD]0'$R7VWY0=MSLEZ3ZMJ-QHE_V?8N
MBQ=QE%8'_BVW.7.W(3FS2M.JKR3]@UN(-G%._TXP7HQ]OIX1R(@=&!2WP':T
M*DKJ+7O$,$C28^)D*'H/>]=.?RFDPCEV&A)&)K<)#\216]JALPZ79)AX&HJF
MHRZ:7@]R)&D"!'(`4X#J6K9;<D6!]A!E^(0W*08IP1#5]G66AJH.++%Q!)U"
M#/`MHY&U*>L4HSXUF$)P4_JHLXO7G74,PC%QPY?P#D$C*U6,L/>\1QJ!9#%#
MG$(1Z+!Q8:6,$>$E/OM$LOK:4Z]0=DN<;+W!)5)#/$,!^L@`T&\'O.J[7+V"
M%W+X)GJZBI[9W1:SY"9B5V+<5`WP<W'O8'<0QUBA&LHQ4'#IPVC-@P_KF'J4
M=FC,#$RNV;A>5EVMD$=/:%.HL1-JLVC%T[(Z7RKO7!@[$[+`!QE2@YV>D%:W
M[@\9>O$.19C1&6-7;B!D(S6&N'N=L).-W0#CSG$<Q\@'X&B.L3\W]!V]=?3)
MQG^`T;?'FZRF=UF>1G/;NZNZ:H:W5>W4/%ZF43GQM=Y`ZW#H31EM.V9W8WRI
ME$;NIEH#QO`.#&%EVMUZ49DPO>>BXW)/2/6V@$#K%0*NIE>YO"6X#KRDQ06N
ML!U1UDQ]C.+$O"=JJK'KBNHUW/(PG7T/G5%#EXI4S,A"OSO*D[+[B-T64!Q-
M%&YV9@P4,J@F>^F93KF1GYGY\8]*J'ZIJ2]'/!8]4PY!)HIF"6+"[)"=G3BZ
M>=7PDW=.@?'GW#TU<0+:/S5UZ(C"HQT*JT#XYH*@O),*C$+`;.,LR^,UNRKL
M0Q2GGZ+T#YS_SBZ_[:!7)U;^8KF8`VMD1J$S"(T?&4&4:IU<89/27!)M<%HP
MH3JX$%<FT)+:0&MNI+R$>(DC/NV/UW=XL2@N:V,Z"WR7TW_3%)3_J)$'N[7X
M(.9UV6:/3*.BC-JB)]B!I`@Z!T,`1Y.!,SF87CY&)`V]"TC<FG259<@S0G1^
MAH#E2`D6](Y&F@59K2(:O^J0]?W+QY"DF7;!$&"#?+FE@3Z=+4_P:G5"`_\E
MWJ8DF\>8?I/L/'FD;05)NR,`=DKE[S95<F"'F0OHAMS*JXPX%D8:C7S"M5B[
M/J=Z[-I`C)*F)FVR2]616VQ+R)"A%=HFF9E^13D;;WM!*4B[;^?.'9\T)[BL
M8<G$$9-'EV)8OFY42O('7[!TRRW,_<"-&-CY=`?GT3=P]FMQ/^"$G.PN6^1I
MLCCCB^#/DR5)U[R!EDUT6ZA4D]Q&*B[3A@8.X":W+9Q)9PJ-;4PJ43X[6`BC
MAG0X$X0VN"`#ZZTS,6B@7D\*FKN"(M=56DY$%@.`)X22.,WCNQ4N_IE1U]>L
M`!U$6^N57\5"S^TF<3,OT+T#6\>*:\4M[+!S-5'*_D319K.*BST^]4`>V]^S
MV:8;PFX=IRWA`M-6>ATGU2DNNWY%N4^H&CG\QY81.<.TI\'^$2?4ZM>'>/ZP
ML_TUIJWJ'5N=SDN(%R/W/.QQ21P@T[O*W,Q$XT)S&Y_[(@1("V3M$80*M"VJ
MY4LT'Z"&2O4'4T)<ZRW`5=(T^<6K6_?$RA5<#\7:+0AJ:3_EI+E=;;[#:/I6
M,"KIG_C%*&`OA>\BFFU87G!%$4$_[M$G-JW6/>]8*U?^?H6<`ZVD5J$3(9TC
M&6_4>I/+:%U,^W.>$"Z'-E00D32^CY,H+^]P8XHCIR+ZFB86E=*FA52EHH'&
MIB\(@:0.6@^#P$-3`_X>%0*(27"8H"^%T,A]4QBX2)IZ-[R`]C?C.;["*8_.
MLV7AL;TE<Q,ES[W>II56W=<TU'+*4XQ\P/<S;=S*DQ1S*Q,NS(^H0!D-LBN\
M6V82-;N0T0KSE5H\1&?%ZWEA:/2^H1V*R.`J[N8P1@9V&8R%O_U`%ZA':.4/
M`+0LY'.,-A+J8I54B,L/_,-3V@_TA4_`AJ/:O7_VA--YG.%%!]'2]YV#C!KO
M`8ZFJ*WY.I*HZT!WRD1;OC']51\;A"N)YD'/E`,Q6=!_1CF*,Q3E>1K?;7,>
MR-E0(E7-HCFO:#9A1E://,_.LFV4S!L9>4)RE.%-1+NM>/6,%L791J./"LK!
M00SJ4WST1"W:/5^B8P,:9:`G]O0L6^&K>?9.#:N76-.:(W+,JAKFL)N62?@3
M;7KFK2K\2%3AO#$MQEI';D&'5;[FB!FSRH=<-<^G7<[IKTSR^!&S[IAP)$DK
M5ZV;E\NYK$V5605?.:]Q)%V<JM2K1Y+*2:ZXDI.,)AT>\1=CKX375CFQJ)W.
M$E692KU&56W3%Y9@EL/K/`Q"T2$_5/VH_'2HEBK&EL(85H*!C&QIO!-F'!?'
MJTS#-9Q:-X.0<_1FD"-;$.^$',#6]B1:Q4N2)G%TGF2TC-N<]FFO\3U.,)M[
M>\2?\"*>QPD6ML$#M<MO8:WM0!=+7]"M^##W,FX-L3:YQAOZ?3#+74E2;X];
M1W\G*9IO:?]US=;95VM?^/JKD9O[H>@BSE7>)JNEH8K"@_SO%^(@R<5`OX#@
MIHG(3@O5:@S,3454:0;2PNP?WY(\9G\`=\MY!CB$RX0&.@>$.5LG<W[]Z<VB
M5Y)+[0^]@'G7-6:7!RZNHC1_;BS2.<5W^27.9TMV+#X[";_#`ENU\DN9JSFP
MT]0)=&YEZ5=&2"LSDX9$L1*8SQVPU(G?,I"B=RN<+'#Z/9K3'DVY/!A%;(O`
M,\KC-49WF**/)6`Y7U[\`^J99#,1:!DG43)G5Q+L#B0H5R$SRW?L*LOY`_U!
M;)\QNRL!91L\CY=L%72TNP,S(;1L:;V8^0#1ZHSGT6KUW,CW_I1U;E(H?U*Y
MT*C,#<L?2'VQOQ[(BO[,D3-%:UJ0X9!M!Q]3"U74L?.X)S:"I(&V#B%X>,BZ
M-5P<;9A\1;2:0P<HP9P`BU+K]>-4DN/Y!*I;5F?C"2Z=L_4*`=>C;W"5U^C^
MX`IZ,66TP-/BTJ)LFBP^\JFQ:SS'\2-;/4!]GVS3%/<2.7O%ZGA)"T6G6]M,
MW4"G<]:>Y5>Z61FJ;@Q?L(.A*/R;@V(IFJ]B/G3&4JQ[0A;\88;3QYAMHN;)
MWT/TR+(ZG%`JKVC_@>W!84(T0:H.EDK8=L85I?V61B;&\[MM1GL868:^QOD#
M/]H-%_>(E]E5J4`VO$_"[J-ZGK-M//$2K0C-^=(Z8D3L8G*^&H5?04ZV=_ER
MNZHNU,H.^-Y49K)("C/^.[<L12U.VL3IFH_^W1-:\H17T.J`EC3=$+::Y8"5
M:$DU%\66UGO^,<>^!L*>1,0%WIVSYXQM[*[+L_.Z-_X"7>9IZQ*&N?RB3ZI0
M8YU#O0`H2FLE3I1YH?8V8"N]$M0O;EVO"[7Q!7EYJ*U?&/0>F:&7Q_FW`5OI
M?:1^8;O'^RDZL#<5-[R/PNOI_M#9GJ&_H<?YEX-U49H^L^RIRGVB>J+S+EKQ
MI"E[P&7/R^#$_X-J`(X^CK.\-E:<[==<;;R[<I2F=VG1[:ON'*VS1YZ9%0<6
MK&.:\?%3!]B"PF)LC26/QS&Y98.&TRR.N'*C1)6=(L7KE9]?4;")8NXCFO]C
M&Z<8I?']0W'!WI:*%,>GDDT:XYP=)9SC^4-"5N0^KDY#:)1]Y)S/F"R&EQO(
M\SN=INE=!LZYG(F#O=P)HSTRQTC?Z%*-UP>R@1>]V*`,<+_)!:V3%4FIN^@N
M7L6,^)?T>PG',HQDRU^MD75@B=(R=+-EXDS&$KTN/]`FNK]/\3WM>J-YN_DZ
MD#9?BZ*COD1);8]RK/9"T\EB\)$U!&B%V;6J$76"`SCDV@Q#Q+*JVU13JE4\
M,[#M$Z0@<=S(RV!XT@A>R:"&$-I)O28H2<(V#);<NLI:\W"]8R-7@Q%%^\`7
M/!I5P>KY-2%(TI^%09"'7BOO)I\G<[+N@DXAT>F;MB0`4M^&/5\]T+X+79K;
MU>#-=J>QYL=5LV[B@H_@LR.-^/A#,3?0&)U4M>FH&G!'$>U9+LKYAJ^8'8!-
M<F:%W"?Q/]F*#];(/^*$=D-CONR$':#(^I-L?@%]G$ZOBEYBT7]E>\/QTP;/
MRZ3@#G=L95LJ-71J(I".H@BLQ`A=XD2](=S-S7MVX)$/VL\3V+;$?+,W5R`T
MYN]>:M5K.FGF=0_8%;O%"34]K>;W=N.7W2EEG5PU@RR7<QFWEUD%GQ_6.)(.
MRROUJME?%H.Y8&-"M9X17N$L(WP!*?L7+FX;8K&PTY=B$G,VCXKNMO%JP7=1
MKC<I?;+&U0A_.8:7IUM^K@#](QM_/E6+(&)1V9WA>YE*/5JOMND+FC!3GSH/
M@T#))C8++-8":"?Q&J`BFZ%TPHKC_*/*-.!TH\[-(,0<-;KFZ:M"BFQ2T`DI
M@)VG69H_D/ESCD_*%3,TI@NW3.H%RU^H$G3`M]PL=$.M]22#N$9Q,BT7LY?'
MJI6=F9@M7D]R6K057AR@14P)D*^>64,;)]5?!^CN&<4YFQ!C/>@?$.NR;;,M
M7Y1%I7A37,ZO,5/,*OF:4"8_Q)OB,#>^8Y)UJ=[Q%OXO/_V_WU<]-[+-LYSR
MCS7XCZ28G&,+Z0LW&_*UV'U2V5Y'SS3+R`CM@\597G31HB*U2%EJP?;^1O=\
M0K$NPP$O'7Z*UAO6V;I[+JQ%\_R@R$(.&FD(MU@N_&?E*.83^=(UKKA-:?\2
MSZGXR(F'`2F(#7S;04*N4T4)G55O?`/)/O0NAC&-YA]<X(0*H(9$(!O0H$`C
M24)<4>.6AJAMP^4A>C_#L'/T-K`C24M<L0-YP(/HKJ*+?"$^S\%(N#J^02/L
MLM%7:1K\<`83;])]O'KE;PG+JTM8#(E";.'<V=FLU*LW,AM8]\I%F%,DC-P,
M9R$[(T)\!=X!HH(_!-(P00-+=N(#$+(<SW/0V@<\OL'(UW!\';U-?,G.9`#"
M%V`B=!P3MN^>K:"]B-=QCL4ID$ZL_)UR,0<^R(Q")SP:/S(2*-6^)3FO+LG1
M4H&8P[8='F0:56!06_3$,)`T1N=@"+=HZM)<_T_;DT(BD"8%`B:2-,4%)VZI
MB<HR7%*B\S($+4>O'RV2I,,%+9!30<G<;"9()U=-!,GE7`8895;!IX$TCJ3C
MBTJ];^G&JTLW]'P@%M#M#,C*5.KQ6+5-7T2#F?_1>1A$,3;[0]^'.H`/`A;9
MU(\36APG?E2F`>=]=&X&8>;H#6!&-N7CA!G`].,B7N)UM+DIAU/.D[DP^]")
M5?OUI&(N&U<D1L%WZ:G]2/>KJ-2^)1ZO+O'04H&8P[:SQT>B46_O45KTQ#"8
M+88:!T.XQ386TM>?H@VZJ<?.J40H8^<0.)%M)W0`BN,F0H5EP/V#&B]#X'+T
M!N`BVSOH`!=_J89L58E.3)QJP*PDD1GUG&J8KAY1JGU+-5Y[JB&=>#6!K3(D
M].9:U18],<Q'JF&\)D2M)V@[`IJFA\")6:IA!1305,/30@^=ER%P$:8:KPPN
M9JF&%5P@;P7-V&*1\X16?<+;X&AUE6-9QF$H7=T0JI-VN:9/;1LZ#3%S)[VS
MST#[6U+RZI(24[80:TAW+CU4*]97'YK8]TM)F$M7S?PXD)%F,6<W?*T=:LDA
M*OA#4`T4/,1D5[*"8<SQ>E:]`\!+6LV<.2#MZ`TC37:%*QC20*\58U-,M+U+
MHPW>YO%<.O]C(%E?'J:0=+KW16H7.BW2NY)?[Z+6_)8.O;ITR(09Q`K"W:MM
MI$J[VVPT=OW1#N@N,*V/@83C-W[Q]05-D:#&_>'P([W*RQ5`KA=V*8U#WM&E
M=3001D=O"4;2*[9<8>1A*HFLMJS9TRY;D<IU)I,$<@`CF#VKOJ:39(YT@YAB
MO6_)RJM+5O1\(!;0%0_]]E2Z8[\2F[Z(!CJK)/4PB&+->:5*@+<J@30J,'#1
MS"P-PPO,W)+0-/SDDM3-(-0<R5`32BX"`QO-#-,PV$!>YLG/BCO?G=39.#8N
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M(KFWD+HZA0N@!'503-AO&CI.Y@F:;`[,+U]41ND#S=9Y(R2<?66'$`GA(T[O
MR)"4$#0+E"=^MZJ1B2+CZT3XMP1KZS0.$M:`R1J[(/@JBA>SY"9:X=GRA*S7
M)+EA=XQGL^7-]BZ+%W&4/G?H8:M6?B5S-0?:FCJ!3LPL_<JX:F6FO%@P>V#S
MI$N*&A1E&9G'/`?C4Y5+=AD5N^.=IE,9-5A<.\A,%C?)\\L%L]HJ6FQ3ULGC
M%[_C-":+D7,O:Z21X2AH<]G40D5C.X][`CA(BF7K$`+:-+'BEYQ;8/?U`U62
M3/E$JEL*9>/)+'OZI8!JPB]`7\BR)UN_$(@]^H981:7N#[&`V=%T3=(\_B=O
M\:D;MM[GF"9CBZL4LUJ^[@]@66B47\1(PX&"!O:A,R%SES+>F5K@^4]T3Y-C
M%@X:-RNGF%V%S3*9A!*`)4CL.N.$=E?F%#3W[!+C^RA.LASA*$VH7,:N1=YE
M/0QXK+LS9V;98W8+)Q_U:I2,DYF5#=VQPJ%-43K$E\&-RVT;'))!0&D3VD"Y
MXK*Q'_^@!\F.+'PYPOV0#[^VX,=E$1=&I32Z'KTO[@]]D@P('GYN>8^A$[@9
M1`N'CB`\ZH.P&?>*V^6+C(>9>*U`E"0V\$"$3&?F\W2+%WS+(<[R67)"DD=,
M"W&WPJ?XKI?+&(I7B8Q6W(50&N/@*8R9/RF73-0GU^R&^(RG&H5\E<!L$\ZG
MN%1GO8DB!ZF-H`6U@F(^B<;'$OD<7"B#-L;((?:UV^&;1K,FFY$'SP"%23<,
M';E`DR4:)2*;&.SB[_6!3)9>`*+,,;$P\``YD&+JSP5M1V\5;;(<`A!MW@9#
M3EG;E5+@Q'/6K68#-,JA$(6\<"!$*`^6D0NL^QT$D3LT2\=E^OL?`%F4)4&K
MHBALABD;.]\PAIHPR=>@097A"U3%^;W4AV],>QCC4'AR0K-@?$.(MM<(-J.!
M#5>T00YJ2%SX&M)0N'/"G&`XX\U@SF@,PQ5S@!G(>3)/V6*84US\]SSYF$9)
M?HWG.'Z,:-;3`:VQ?/G[#>0=Z*.U#IV!F#J4\<=,GV<@<2F*WBU*X>^;*TE2
MO&%(H7^5R04;K2ARE8S*X=8.@G3-9TGOV5$`"?]]JP.:?11WH^`#MM-^2347
M!5_O69'&SC_,@48&8*'-3JUJQ4Y#'[X1#9)_&'MRPC+-/\X%0*9Y,1=F.74I
M_1KA)LE`8/'FEH$8N8`<_C!VZ(0[FH.\!8!)T@U8@'D?\#@A2;9=L<;,>,Q#
MK*(<]NBJ@*?M;0?[&?P0^K3+W@4F1AP"F=>E"7<41`(^93]!#@Z3GD);6]U9
M$'G:`]8]#HJ(G;FB7#4TTD'AZP6AU1B)&PK[>0I@K[5RRZ;X+^+HCNUQC'MM
MB;6>M!<KU0--Q21>_/=JU8[-,S.5G4&]W+(U*5LDUL_-'Z*<G7]7B#/,5>?<
MT1^]7='?_(C1(E[2@K!+,]`=SK]BG*!HGK/S]/@"&V:'[9-->=>8%8JLF;4Y
MN4_B?V*^]CA"69Y&\?T#Y6B<8+8^,1Z[>;+'LS2Y-(":+L>4F)#GFDJ?^R*2
MI\ZTQB,(A5J=Z]-FY[I2X@L744/M+>#5N-<-"5CH7KC"E=_>N,8Q"'!I[[Q&
M*`_`J[>%4.-N.R1"`;OQ5RF98[S(/M!O5GGD`P?GO.7L`-Q0NOP66FD'FFEL
M0^=59NYDC#+1WFU6C1.^5Y6A>->-X2/Y*/H:I0OZ5VC[4$UQ0:PKKTTKC6)%
M)B/[?L$'DHL8^G&`'<T[*BG$Q';I1C'F6DB^-G!)T@HX=+FE$`8.X!82&#IS
MP%@S12C"6/PJ425)!>!0Y:G9/ZE.FZ)-WWE"W]Q3;';'6\P5!(V_3`&((V+S
M/E,`I4<3JB@,-#8^;*K0S',!:G2Q(NFB7/Y;Z[->XJ:T$%`>H$&)@%?Z>I0S
M2ZPK(I?*BW=`@J<%:E=N4&PF!QR!)QW45<*O$W0&60($ZN!R!;D//^F"VI\;
M]OA-0\UC5(U#('J788PN28[1G[]_G<@TR#0@D-G/-^"1^;,-,C6GPIE[=,/F
MSX.Q^3KA^/-^X/@S7/I[PQ8_Q/GS*=Z0+"X7R>!%!\4:J?+72J4<N".Q"9W2
MJMW(2*+2XJ-8"<Z;(UD_OBN/7_N^=_Y:5II"B\)6N<8KP!$N'1:(<<6U22)1
MJ)BAM.<'8"`IJL;^`&C19/1&AI:7#@U)ICD<&VXYI<(P7"*I<3(`(4<"A+"3
M`@Y80'KI$)&D?,,ALJ=C4COP,A$U.`[5V[%[T"VL@:\AI^MU9HR&'V\:6C-K
MA`^#D_;D#:Y*R^1`/>>F5V?<^Z&DND98KVMPE./K@=&`8T5-<>3O^%#HQ24F
MOH;B27<TZ/@'94'":<"9GZ9P@MS=D='D+8ZRXYC?YEM=8RV\6]I(MMK/H99U
M6=RNL@R^@\/`F711NU;WVWW3K^Z^:3..$$LH=U;ZJ]3J)?YZVSY)"+.UQ,3+
M8/JQS22E#.H(!7*M,"R89/M&0-#D>*:&SCS@>1HFK@9CZDB.J>+"ZM<$*-G!
M&2"`<IN3TIJ'G(XR<C884C^_L3`EF62"017DU!)/QV]H(G+\?/L0IXNK*,V[
M-P2IA:J))8F0R\BNT"3XM)+*BW1@5ZY43"IM>8VR0^6+3E%&15F6ES-AENX6
MZ^E[(UKESC,\]M"6ILZ):0UU!H"%\O7XK\*:%QC!3!XIS=L#B$T=23"3CWS+
MB"LH9#-'`U'A.&\DM0LX;:3T88\-FIE="B/+N[@:RAQY$9$K1&0S1P,AXI:`
MR>U"9EYJ+_8@^5D&$AI*&K?#O1K(2'*MH9`!S*Z*:I@MSY-'G%&5[ORB]'WY
M2P3O'=#<LP:=2<D<R"`LEF^L*-]E47$E,G):)*\Q8O"1VP#MB5;8E-B`KGJ0
M[$=JV:K2#YLAJW[S$JM:DN+8U;5;8B,T"9?32,U;U7@KDXE?<HU+,A:[&G?+
M4X0F(5,4J0.K.J>)R4TY6\KG/PZZW>1R0N0EHD"2A-BA`')@AW[H;+9D8TCQ
M&C?G7H^?ZSL68YS=XJ?\F)K]HSOF,U2_&@ZRUW=)U&V]@0\B#2R`-+L?9*^1
M.K%E"?SL76KBEII`A8TR*V9=@::9L0>;!H.-`-1_I]M@:ZKN40PKP[Y1#S/F
M-=0S*-X/B_;$'.;H"]-'W,#(TPWC0%XV`+=7S#L.VPUQ"3BB-]0]*/*/;)'_
M%L$N&TK<*]@!5[GM_-\J_4_O,KX"29K1V:GW$CI3=1"2FSGST+#9.=:SV\:>
M=;-6J0?3J%E"K$?S`=4N8[F9J3[)K8I08+WY]2_HO^C#ZA']'W:Q.'WR_P-0
M2P,$%`````@`&(BH1A6:D02!/P``2Q@$`!0`'`!B='@M,C`Q-3`S,S%?<')E
M+GAM;%54"0`#`"1-50`D355U>`L``00E#@``!#D!``#M?5F3XSB2YON:[7^(
MK7[=S*QC>K:KK6O'XLP)&V4J+"*J:^>IC$%!$KLH0LTC,M2_?@%>XH'#`8("
MH,R7RBC1X8`[/C@NA_O?_N-M%U^\HC2+</++=S^\__Z["Y2$>!4EFU^^*[)W
M019&T7?_\7__Y__XV_]Z]^XC2E`:Y&AU\7*XN+WY>/FXCF)"FET\/"[)G^CB
MI_<_O?_^_?<7UWA_2*/--K_XX>>?_WSQ[N+'[W_X\\53L=M%^<5=E`1)&`7Q
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M=`(M=ZJ9WN@'E$9X=9NLYF_XL"I3C7_*@_0$4!E7-EV`^5NMT-27".?1#D5)
M^#[$NXKY4_&2H7\6*,EO7\E_LAN4!U&<R9O\DK^]H_/9]S]5UOY/7$[:34.;
M'6%TGZQQNBNGJ@F-X_/2;EX0HVRYOJH^7>/=#B=/VX#,V5<'JHMH%05IA*9H
M5+4&;5$HTRV.5\3RW/ZSB/+#A$;S>>DV[Q'%Y?@D`_/PG`9)%H2T![/+9-7]
M=(T3LHC+HY<8W:"77%^$B?7IBGD9AK@@`^<A.`2$)ZF-_)(69(A'P0M98N:3
MP*3$7;NG\"&(\\/R)8XVY2@CU=R@-4I36D^(D@S=H2E2J%:@*\A]0A:.&]JU
MEUF&\HPL(_0;+6*FVT`ZM/;4I!%F1`<$BUF>%B5.[Y.'%&^(E9B@9S7V^EJF
M,P5.)YB;,0O]F7"W"]+#<OT4;9)H'85!DM>#AFS.'G`<A=.LN1I_73&6Z29(
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M=17$]'[S:8N(;6XK(1,W:<`6Y61(`RX?8(*!JCJ!<//*HR_"#0X+VN_$\-P2
M`YH?IJW0Q>RZC=QWK-Z"_-"K"[WEB`C?:HTV55^,LM:FWAB'O:IBZD^`4XE<
MY(??175<OI"YFRQ%&S8QO=[ZY3N5(N0S%1)6Y(.Z3+7VRHNZ#(7O-_CUPPI%
M'XB<_T;_H`+_V[OO?ZC=(/Y$?OJ]:L$CVD2T8K)2"79H(**(I!:)3=(7H0N'
MR[0O3I"&#4?R9P\+8^>)FN+#OASB[\)M%+<P6J=XI]@I&"1AM_5_O8!4<)'C
M"S9CG)(-V2_??4_]>0C?>FU=*9LK=2ERW+U3/1$VKHF<:1#?D]'Z]E_HP`0'
MAZ:'CA&-9_`0RS@%'R/.-4!^<!T@UT5*=7P79622_6\4I+=DKTCFL`%&9&2U
M"OEDWB`%**D>6/C,:[S\Z#I>*O%^0W'\7PG^DCRA(,,)6MUG68%2IF&1T/8,
M#)?6&_BHR#S%X'!KJ('TDQ]`^CN."Z*!]'`7Q2C-F`#BT/2`,Z+Q##!B&:<`
M9<2Y!LB_^0&0VF(^HCU.Z=$1W0,7;)R(2?L+&0ZI9Z@!23QI6<.IH,;0G_W`
M4(G\:S+-;CH'K3WH,"EZB!E0>`84D7Q3\#'@6\/BW_V`17WGE^/PC^KB;UGD
MU*>?OLU@&QA`@;Z9$1;P#$,*TD\R.<)J:H3]']<1ULA\7.G?D5^&\Y:$:G#8
M-*+R!D`P.?50P^5=0^4O?D&E>B@@!PN#C@F7'IVG@.'+:@(R/>XU:'[V!33/
MA"T')]U/`VA4G[Q#`T.B:0"H&#9'=<X?YEZ2-J]*X,;!<(7"_%8K:?#-FWX7
MR:37\0..3<\[?TK;R->^@F,<T0II!@9@0.,-(B`R3C,)`\X-0J:>R_[MPTBU
M"_+#;%>M*M?2TR"\#K*74O(B>[<)@GV%8Q3G6?/+$-#US[^W[@S+=?M@_0%G
MD>"J5J5(#0=8D8GC6%\)E>L;1USVQ\:J#SY:%J$^*A)*PJ'I"32BL287]8RB
M+G_D'^H%^!K$I%W997X=I.F![$;_'L3%Z)Y,I4QS:08K8\U(B_L.ZPG=M]+,
M*LH+,QAK_>OX?/0@?KH/RG,:K%#C/$Q:_Y'Z#62/*$1$@)<8?49Y+>H`/>H%
M:VVJ%'071]KB`\&DPE___GXBHLS8KM8WN..:78.,]:G68_^3NT`1B`"$0I^#
MC<MWMN5`"764CF/\A:[4CM`<&@H976,7^'3N]BY4..BHY[/3ORMW8I`_I&@?
M1*O;MSU=ZA.#MLRW*.TI8H`;A1*UDD$EW,62NL!`5($8V[YJ-[2F%ZWE16MX
MEX%A``+LSM:X$\]'H:^L:4RJ*L[>C:4RKJZ./&R[T4ZQO7B/TOSP$`?5X5+G
MG=C(Z,I)6VLK(G40&PJRR2`B9F7#GY;]P*#_D+)^$UC$U#VF^UZS.94%DC<'
MM%)R!T&@**,,"')VMIUE]<W&#=K3L\>L?O&*DY`YQ<K(6K3PR)Q$"4@F.3IX
M;/17\Z\H?<'VU_.=)207&4*:6H4<&@<Q`9%&!@@.#_VUMQ-[.\;C^-NW,"ZH
M&]1'C%=?HC@>0$.E2'O@`RGB('`T9)7A",9RPBK?!5A5HC$W=,R=G).=SVPO
M;`<RQ4?5B6V:T@THEEPA]G4&87W4I(E-G!-#HA/,A2PU2\?37KP=SHVF:K%:
MY?!B+BA$?*DK)QP+[<[U+B2Z#^<`3+UD8U152EJS,8!^Q5.TT#<[_-I*8Z-2
MB[XE<F0'<!WL(SK)H"!#Q_!-'!C"B%LG`S&QXV!3DE4%7S+&SIP["0*GD97J
M<GT39>5(&8!$M5BM0G@QQX&C*;\*A.!5Z)];S>&FTIRSE6X0]TF(1V%#!!2#
M\\H>A>.0D$NETOM,;K8?84\YH*P:^XA>45(@]LPC)AI`8TCD"3J$LND`9,C0
MW\MAZ0)9N@+T<+EK=%4K6+SZ>G^LO!]FZA1T4`&MBJWI<[A][DAU//.6[]+Y
MM.-QR:*U/BL]!V_,)G+F)QGY8*;BD[LPJ@2=AY5%Y@ZH<2W=.8S/W=^Q=)R?
MD_R:_!OE4ER)2$>K'Q:I/W@"B*J))39G9_;;BR!9Q:0U$'L#HFU,K)C6?62H
M"*L(#0EK:]MG0Y,V3C;/*-W1@X'R38O"69]6V09Q:F4]0.`$9:@B4JTJ?_?]
MI1<%Q-;)";M>*-Y:.;"8BH`2\=4_$7#D^@(T5T+F2%]1,\><*,3*5WI:(-W(
M&CDP8-5B.Z[OA+M%3'/#E^D#*I=:ZD^+DFZ"C^9B44[9W"J**+T"%UQF?6@)
MZ_#7IWDL]'U2^\T]T+"1I+_S/(U>BIS>X#]C.JR([*3MI"F;^X0LSE'&.[V:
MAWD;&\(L<YLO`2O`E!*Q`A,(*(XO_<84%OW<9NEW#-'$T"W.9$OJMX/C%OA[
M@-:)V,@,B<'YW)E"^I_/$',2'<P-N''U_BYC+E>KTB,UB!^":'6?U%ORH8N>
MF*IQQ^-1G2$$81J9&XG<5OB[_+D,PV)7E"Y`Y>:^EW6L<@BAN<=*5Z#GX&WL
M2ZI3^NA/JE;Z'($]28.S`UZU=?X>(3[2;.P)6MT&:4*TD75$OT'K*(S&OHG0
M`JU7HKS`&2)<64]S@QK2('_=FYY3%&1%>N"N:/D$;3BN,<$9XE*JA[EQR&J`
MQL'HSQ7N$K2A"+9]B#Y6D_1(1'JL<9;PD^IA;OBQ&C#'\\(3@N]3E."T5$TE
M[@!ZO,^UPL>?SQ!V$AW,#;IQ];9S8M@^.9[EQ'B6D^*S'`^SZ/OTIENOT?I)
M1KR]AIWU1D;_<LUTL_S=A\NTQG?($)(#'[![AF9%Z8WX%7`JFA"QQ@5;HAJ9
M0C.`@E[,"GAE)@,_.YSUX:'LQRW*HS"(OZ6`<"3>QK<`)-\<2AQT*/F,B;F0
M>Y6,R9BN)5VR,]P/`75R6B>3;C/\]33IRU2E![TL\BU.HW\=ITDF-GG$3(2.
MB<\>IQ+]G!:MX\;XZZ_"DNP^RPH07ON$`JPVA%\)3IEZL8'1IB'^NJ^PI.(G
MP@92"Y#J1@KLT\(5FBG[-)AE)=3V\)BKX]3(79\*:<8.J&>^,H5HXX2NJ(PU
MJ8?>(J-\]=P%*8!R#,FO8BD*U\P)X<E=A&J\N7,.I,P5J(2*!\XS7GO"-')R
M4`Y6G1K.)LX!DK_DA)#RH'GNBTT%W9P<I*QEIH<^*CT?PTHRD3MHGX+E#]I0
MG"$<Y9HXJ4=HTP)])PTF^!R_T?ZZ_#-,G6)_NRC7O"@WDO;!B8OR5D79<KW<
MH[2*[=/>F%N[)*]>";6MX]QK2JC:A#\<*GN7O4&,LCHV[F?$O;454S77KSPJ
MBW?[90Z[IE&C*WSFU_:F?O#5GL62:!_+1!G8(C:[ROP,V/A[6?F(#T&<']@]
MS_[8/',;?'2YWX6"@+M]R,7?Z[Y:A#NBOS(B_'"SP/W>/G$<?7>Z^R7BP!$P
M9N3OG5I73IHZ+ALG!1:1,&:S(XG+:``(!08$FY>_UU4#4<7K&_&ZQA\0&.K_
M;M?[ZAXM6Y^/-0?:UW'8,C1H8N?F2)S):YR1?2Q[9<7\UIX/][ZYC`61&&`$
M#)AHK*K<>AK],<59]I#B]2B4!.-+K:S>%Y=[G"\"N+][+"9$RW;A)7)]`I-L
M;M_VY9:0<S(@I6O"$?/I+&X6,D2PL[U,5C=DD,9X3WNT;N!HXP"@;3<10EIK
MHT#>5UA-T/[(X+*O-AA"MOZ>,WQ$"1$[IIDQ5[LHB:C(>?2*V#`"4C?&4T;M
M-I34A%4`DY2QOP<8([EE]E9F9UT'B4P@!5@P6,TQ"[NU;H%.P.!5C("AO]O_
M5JACS#?>P!I3#(=6E\(+:'!%4@=%E]4<1P(GQ,1GG."^6#7B.4M=,'VM7`"]
M-=F;"_U>N\;G8C*R]EJ31V9M>,`["X/%[(\6:0UTW/`Y^[OB+0-ICJ4?VE,Q
M53=+#8O*#^#`A-3`#9>QORM;KMQ0,PLUK[Z`!RJH!GP$K,]_1:PZ3X,700#&
M_KY1."[LZ"5PE1VE(((>7;&NT!JG==#DY^`-9;=O1&HB<90$Z>&>Z"L#18@[
M04T]=ZN9:G)Y")Q.Q>#!,VN3/`_[V>1D;66O[<H52M#XL@5(/<B$RZ5V&<=J
MHH*Q*&6K\5["K:NZZA:*<<PQ_M`^%C]^<!D27`'`O=_E,$<`R5.NJ5%^M*L:
MP5JURS=K</7R+F-KJCK@*TGUBFJD_NS?RK(O[&L0Q96DG2=K]1N'JR"+0B%$
MP:69``64]@>>JJK0!">@FN9,PLA;%`L`;?)H/*"T?+-6BD4OJJ.XR$?/M('4
MM=:EU"X#3DU4,,"D;!M`>7C*]1N*-ELBQ.4KV=9LT.=B]X+2Y;J4L_,D5PRQ
M:4SJ[M!EXC(@C2@&C%/=VAKXZIRQN?\VKY="BTX1]I_H=5Y75MU9YO<=9?J2
MA[15*3V.;@LK_6U/J/U>5ZE[X'M%Q1HX>TA?;_(8DG93XI%).L+TI(0^[4<W
MJ/J7YPUJC&'W?G`B0^?4>X=3,K,DUV5R^_#PG`9)%E=#:?6/(BM3E!.Y%'6L
MR56B:&6N7FB;M)1*D*PZ\GP,HJ3<\:111F;UFR*EL1%*;'&2AYZP1HU>TJ[1
MGK^@861C&UTT\%<T(U+K$C"W*-Z_3>)IZ=>$S`HQ#23WGSBFJ_9&'<OD"85$
M%V7(C<E#WU0UDO$^O9JO89`;[HR3C^SI[=?W%A(-9P?0HK&@5)P-X$LG&"[@
M+58U]L*6^KLY84C/,<8`RF.$0C[EF8`<KHTY@"NL?4)RIV^WK7[=MIK%M-F+
M63-(U[_#-7(N[-#:NJ<W[<2Q,W%7.4CR(I7L:99$9K1^RJ61=HL-OVKSXVC<
M^$GMY"-U$RTR]#K"O3NW(-O>Q?B+6W=M;:OD%VM<TO$M&H/4YHJ/-N<AQ:\1
MZ="KPZ\9]1IM7T->AGGT6F[#60[-O'>$1ID>UX9&F+JQN!8MG$6+8IM/?\SV
MZG#1*WX39*3NT:+6Y].#;WLU9Z`[>=TX$[R55H?^1NTZ'@QFS_@1$2'#*$8]
M33QCH'XY,]J<5=2(F*<*BR]^");"J$3HZ'G/^%/[EJ?[R9J]F+6[L5`#?<,P
M1T.J]T'=!O@["5[NZ#[X7Z4<=".6!\DF(M;N,LO0*#0RC+@9CA+BL\6FDI9.
M@U99DVR$#'C)WR@H__S]3S4DR0\#.#:/\.B>MXBI>'=H%.Y*I0@3FKPB7PE`
M01JS`5->PVQ$'5<`:YT@`8Q4!KT0ICWZKPRC?%W9!&BO5?I'Q4Y<X'"&X#9(
M-U#+VZ<5F]R&]BO#,5M'5HULTZ()$=NFX1=@8LN'A5<!D?(A1?L@6CT2[0A!
M*2S!A":GQ%<"4(B^;,"4TR[]6#I.&-OF:2,J+[[(',+:[(N)FLL1#M'9PA:D
ME=,@E=<4?W/_#J>(E_PFRD)<)#D9?;NHV$D6`EQZSF*`07^VP%75E9U%`:-5
M^@F"9UD8A&%:4,&J0_AE0G:)KXC(\!(CVOPA0H'D#4"EY.>+3S5-G0B>TD9I
M1.EQZP[F?D>6-6GEW[#`R681O:)5=3[WGRA>W>'TUU$<3*4R3<`[6)FSQ;>.
MSDX#<F#+_(WR\W7&L)O_*DP_`-Y\MV.PZ'DZ\8`,'^(2R4*$5F7(R:;997[+
MJNT#4`*IC\$1Q-1G"THU/9T&E-(V38@IY,1QPM#IM:.1ZV`?Y4',<<Y0+WB,
MG@LNZ)!:R'*2;FTR`BX4O5+G'JE"^$6XJF`5L1DY2;6+L98>^F,97FT=`!A0
MG8:SA:FE/G,&&;>ZM"H*X.+0<Y$UHO<>5F(-F,74J"[O_??&,MZ3[7%":HM&
MEW8@6B[R>K3>HXXON5G$]>K1<%]P'6WUG4RSJ&I2'B2K\L$.TY5L&A,N/F%,
MO`>NAJ[,(AK6``U?"->AWBQ('H(#G3QH?LGJ;'(1!2]17&XZP(M)"!/I\E+,
MQ'NH:^AJGB6HN`'Z;A.V3^48^JDS2X5E")%<!=GRHOR=HZ"H]R@&Z\4L=D75
MVLA#!-P_-=/*HR+Z).6XT..6\QYW,(V8!1VW3@V'"->7`T=9R0J_D._T.?0`
M9-;T9X1(E@;F0F)=E[X/@^TX#K-?B^H>`9_H;E2A>1-BJ]ON9?//;$_P[G*N
ME[CS--W&ZQ$7(DT,IB8SS(Q$ECBK\694KS.^<9_4R`EO7%Q($`L*.C.Y+U6#
M((V:,KVGSB'&)T<#]$@],QU?1Y.IV`HJ,[67_2,XU+/M9?C/(DH1$86T+S\\
MQ$&27R:K6_+K?C=^<Z->L'&042CHVB2A"Q8\05^@"4&Q8:5KC$*#+%Z_FX7Y
M'4[KO</];D]T6$52XT!;3#R`,X_X#"$,TLO<L.4UPON+_:[+VE,0H^4:;)+5
M2S*<%J4ESPG1VAJ;#=XJ+7(F*D*==^!P@_8XBVI'FU'^0@E5\ZR11W5&N(-I
M8BZ,<6OW/([!-`T9W2X8W2:<%?2-ZG6N$3*UD1,"*IS!8<FT+;61PQ+E)MB(
MAC6KU;N+DB`)#1^6:#(56T%EIFXLS6ETBN6^;-KM&TK#*!LM>,#TK&4XF]ZU
MF4`7$</%-T`[(&.OV)[1DIO=#OVC5"<61ET)[[.L(!HJ-Q:U(*709&=1_8#(
MQ_(7`9C5F3`0KL+D3&&OK<=3C`65QOD[?;(EOL:['4[@PX!!+T1\C_[LP<W7
MSFEQW&N',X<G-(;@0Q"MEDEUX%.WDD88&FY*(:2U9L6D9P0Y!9W,A39Q$[Q_
M$3$^DWRF#EE%>I`92`$U]^1Y0'U&2%73S$F6NZQ6V'C6(`W30`,"YVE1)K"F
M3Y'PAJAG='$'+L!`'Z_`F0(0I)]38)#7$,_C/-:7DPOJN9I5WHOM658W\EK]
MC&Z`9,W233Y;U=)GA/%IFIL+\,JM\C>09'=L?XH23&^:RJ70%L=$)I'-%I$S
M+#:;_(RPK*B;4UAK=C,,O[&89R^U7#\5+UFTBH+TH+"O8A4#[+'ZQ<X(E)JZ
MLK'WZC?'^W"1TY1F](;'Z,W.60T/HWJ=:]!,;:1^/,ISN-^>=@MJY'Y;N0G^
M/H&Z7:]12-1S^Q9N@V2#'HG"E@E5"DT>3?ZA#G&OQ/:/'7EUBM:]I%;4>21/
MT(0:7M4J,IQC_:3;>Y9$#\Q$Y*.]O7K1=F.O4M1Y5$[0A!HJU2J:PWO+.C0Y
MCCXP8B'\''#,X32,3)UI>B`SXM^#>!2H0:F,6`'#,M8&'K`WN4-/+'U_S(GK
MXH^Z41WZSC7[<@"3P9_FC@ZZZ0C\_<>O&X,C^>=%H88'2X7"VX1]/N#-M&MD
MNR)C;2@`U=\^C'2[(#]4WYB?>GI';SE*5D<'PY[F7R*<1SL4)>'[$.^JRI?I
M)DCJ(_JK((NRTB?JV*^D[R,B[BK*#]_9LD#=-M([-1Q'JZ9UW<8NU_7F,8C;
MWN2M#HSRK`%EB*<U2S^I_33#4HRS(D7/!(17\=A]8B[V)K3/9&_-W)D%)YY=
M]7U+:J3UU.2:;[7^@NP5I2]X</=^:EO]5.QV07I8KI^B31*MHY`^FZSB>9+9
M_H&H)Z21Z:SEV1LUA6-[Y83'Q&5<0GMI+D7*Y]D^M4+->U%@(7MAW.0=B35E
M'P1BXU94OOH$5F`H;,RIAWT3;]W>`JQMP=&H<G.O2"G;Z)`"2HLQ,4>MX@UI
M""E?5A>&+Z2SL)*@PX"77/Y5%$017[^GZC:4P6=$(QMP/`$M.C*Q`R]P1C68
M_NC*)*.WZ<3%;IM\Q.L4E6G$+8L`[V@\21U].R&MM7;54JC-;^MQ3S@E&YH.
MMLH]08R(-5OQ$>/5ERB.B<J'S9*N!K3*UA!1+&MQQ<!K''_A`"[1KA\`):P9
M#;U>QCJ*Z-L-I8JK%0>@0K]-QR,^!'%^6+[$T:8Y*VD"AR^BD+I@4[]":^9D
M$,1<:D+`](/,N0)ZZQF#1VWC60IX`9GT+M@)>%=B#='[ID%:5S>OKZ@.OZT!
M*-N/Q<B5M%%9TZH@YAT8`BB/,2OYE-8&/J0;Y-9@(I?^F:HZ%WN;$D#O8U/J
M&>Q,^%67,?UUJ_3;JCRBF#X:>`C(=NPY#9(L""N?W&35_72-$]+:G"ZW;M"+
MO1T,M[EL8P,EKP$C)[=F=GA-DYL:C9(2=;AE4L!]C*?HHF]+9'52@Z)4E\G0
M32>_RNP\LJ,G.1:]2ZKJ.<:`_;'QI!]\M'<E2<,;]+3Y&>>`_85RN>9B$E[.
MVA#G]!S6E[H_G/O\RVM(.%^_YW_Z'#%;KJ^J3]UGB5>']EFBWLZ"'8.YK>]9
M6!]G#.L6;\"N7-Q8[&F@GKG#6[?\2')P>7L>HKJ=C*?K:>!(JMB2TG2HM\#K
MV1]MZ,W-?;+&Z:[D:6WVKYORB/8T5$6RX=D0"5D;X9U'9F]M,&@28%4`+\$1
MVZV5@+3OL([,@T'/J:,*2@_@[?F*@-@H],^",+RE/AWVSA2'#>$-9PE9@VLN
MF;WA/&@2=Q#+Z#@B.C%@9;V#X?(-ABF'<SE,^1Q]'YP0M^%O[L.G.I0K+YMH
M!EC2&[2'R\8=^$=Q0/KV`$Y*[[B_L*K$*J["`-Z>1T3G/`@78DRIC/C!OF=8
MTY%<!6]`_OI/-)W`W',:K.CMUS+?HK2Y%*N2+]%[L4K<`>:4RM2:!Y9Q'',Z
MDJM@#LC?W[@YUS@)B3*J2$"/4?;'-6EYE-._AH9-3MF8,Q&EXX""2ZEDND1<
M/<^GUCX]$,^+,K+A\P[?9C^@?"JHX;.<$'O&!<AP_<_%$%(M)GLOX!O$-.57
M@1R\"L\#;PO\G<4@5"\H=\+W#8C:.E"!HDHE^G&P)X*1>=?8RY0@1A.$M%VP
MBT@=1XR"G&K+<Q%;_7C3<Z#BMR!-`WH6BA^*--P&67,W*4>)3M%:FVI%'4?1
M!#VHH$JM&HV`T2Y-A-<XRY?K\M)<<K`E)6RW?WQ"QP$&EE%M\\=GJA\BV?;!
MP7!.OHN2*$<+FB*\DI**39-8%%2D9_R($O1EF=Z6-RZCO:$!7ISW?8J\'`>H
M24VI;44GU=N<R?IZ$?"01CBM`L$^HC`.LJR\^RMAL?I'D>7EXVF4A6E49H4=
M;5SUBK<;6-7BCJ-XHC[4-K2J5358]?4"X9$HAW34MGRL^HIB7.[?ZY1!S.L#
MA1+MQ2B@A.,@5)=:[7(4P+V!FL:]@1-0>T(QX;GY2(Q]&M"-^N5J1R:&K#SH
M?D6UM))UY30FK=><'A/',6I$-TKAOS0K;)#LZR7&'4Y1M$FNZ?(E"8<O\<K_
MC4L%2L`\F4^3,TJ?C^.0-J4A%51/J+,!]DGSG)K:H=$$@L_!F^QB3DS6[JMX
M9(X##BB?VFZ(Q[*!BZ_7(N5#B:L@0ZMKO*.VO@H*NZ^CG]R7U]AD(J#W0QES
M,3F!0S.7ZW!P'(33M:(TB^O4UD#W])<HALS=;A]$:1EU/KV)LCW.@GBY7N!D
M4QY30.[VIK!HS*06"\?1:T`O2N95J[H&OZ>_[C$;T>B:#-Z-;-,$(QY$,N(1
M.XX^)5E5<"9CW"#*UZN=VR!-B.@T@U4Y(X@A!:1NWNO+J!T'E9JT*JB2<FY@
MI9,7TP58W1'C7*;#Z>0*N"]C\NZ.#MG#?;%*F68/#"OC.-!T)%?:V\+X-Q[*
MOM[`?$9?.GI(<4+^#%%'1+%QTRW>9BY6+>XX*B?J0P6@ZE4U6#5R`^-P$JCG
M,A[:MU109YX*JM?F!<JRYVV0_+;%<7Q8?DG0ZIA]_J$<U?3'--M&^_N$P!EE
M>94MEP#INDR62T-8\YUT3E#7\9G'G'6=3\:H4W9*WS(;2Q\ULP@^!V`!I:>P
M;.J_):E@M$WYF8GR`Q,7K)F9-!2G2#YQ)O:`D7#"\NC_EG9"<ND5;M&JB*L=
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MS,E:"$AF]]=1X2^S*%A$.[+_7S%[7D96*X9/YEQ_`R42=S6?B;6@B\Q>OD9Q
M?$TV89]1D>(LC%`2HFR1L_L:1MS<>4J(G>MW)>G$O2]CI1\$<0X,W&:TO>4D
MG90"!?%#CG@@`%(W4Y.,VCD8J,DGQH&4E[6`ADP@+*(UV@7[IQJP]TG(1(",
MK%E#<<F<ZW.@1.+.YC.Q%H,0TLN\<2XC8_>RRR,;*)%2+X_'\NG?LPE[&<=%
M^5Q3-IBY=(-^9M`YV]$RF6`]S>#B5A"]91+B\)"C:YSN<14XE]G54KKF^()/
MYUQ70V42=[6`BUN1\99IOH7UM92P/:OB$[K7VU"I)-TM8&,M1AVSOQ\1;>9S
MY["`9\<!E&U$&@&E<UT.ETO<YT(^^K'EG'CQT<W5QP0'GZ"3CVE(X!P4I%*(
M$<`J/B':&C-FQ0FUQ#O`QL*CXKZ*!CS*+6NOK/Z1I&WUB.\GL.P"H*\G)K-R
MC3AD8EAAIS0BS0U4E428AD/`27DA-;X\`=$VID5,:^_);[\Y[#L7$4USPL6F
ML>?$70X)YC3`^M1Z8'0_64Z?S5,X%HHPL/XL3J53=8^#OP8.-@8Q#,1]W0E9
MEY,$FZ6_RI3.%BH6#SAW2%CJWQ/9GDF&$B^B!-T348>SB)2.XT;0H7-&QO85
MUP-*:<B@8(.NZ@=>$JD!)3EZ$)9T9BB->Q5/48)X<+65T0&F5(F_"[='ZI65
MH%433>,R#(M=$1/C0GW7HS`:(A!>H#TQD!=P&V_*(BO`#,+;\TR+U\$^RH-X
MZ`[0_[6Y]V]^=1L1[,8K='O+P-IEOJE]'P[_V.*8")%5*Y'[)(R+51FC(BV[
M*\_3Z*7(2Z=7_!DG(4YR(@!IRJ91S6B#:))INY,TP]1M8,ZB.@5<FZK?\UR-
M[!2ZE_EUD*8'(F@92&AD$!7*M.825,9MS.H(KF1J0>SG<+-P:0\*W2\!]Y\"
M=H:3]/H<D03BYSY3)!%.U89V*J=^9_)4['9!>EBNGZ)-4F862?)Q."S;3TSD
M,<$:CW=Y\+#:W5U`:&UV&^?G_HSR*N@[1U`A:5]4#JGC<=X4Y%2)Z29F:\WE
MWU"XC#+YWU$T-H(D5$T(#!Z5X[B!2:<"&2Y'ST\1+N,8?R$3'KK#Z0TN7O)U
M$8^'!\<*Z91MS)):6<?Q-D432H9+K1[?3T':][_\H$N,5Y"JQ49ON&7%W(L%
M=G5X)G4SG`(42LBB@75+N*<!VC:FNX!""6D\M$X)JRX296O8#X'87SMN$;VO
M[H5U8_0*EHD%C.)V9-U<E_=8^GM1KC+(A5'R>","J.!C=>)`>9UJ_%6Z\BPC
MTCS7&@]\0(!U"M7?K<OC"U8:AI4QX8U^;ZY+C[_;;3/;47S\I=MNMKD^K6=%
MM"MVS+8SOQV]([K?K`U6EGZQN.G]D==A4)\"=@OZ.XP^!6_\CF5]:SJV_\VY
MCA4T7=RQ_8*&_;U.K9CAS,\W,PRE-/-XK]#7-5_S)A/]6;G#T5]?0JZ8"XY3
M(;R`;`NV<,#-D-NX7S.T+F+Z1!4J_[B$3`'=$NYM.,;]*5KU<J4'[C<6W?MH
M4"US'.T[;L.4Q]X,6X[%.=QB`S.EZAT^JAP"PZO0=_>Q/<4L:2PNZGV?HBU*
MLN@554F+%SC+^.FP^]FP+U?_*+*\3FVQ7#\';P.S/&\ES5ONF2IQ?!R<1+<J
MHV:N!EF+(V-FH/%%_QA$"57.%5H3FO'HT2A9=YM22<=QKJ\%%?`JU6(MYHT9
M1+;9Z:4Q]`&4M:Z%E-8D_35)48@W2?0OM")MNT()6D=YUC;V`25!3$,;5^DA
M2G^S.N[Q0!,&.-6:FL3)VEB%(`&;5%-_\`JJIZ-W4K5FDW=8S(S1BENG"*C5
M,$`RD'J0%8-+[3HBU<150IV4M;\'4(UH=XA(0/,%JR`+5F@`,%DA7W"F)+P6
MW&0U>.Z3U(A9>H?3./RD*D4`JA0=P!!6U!<P:BA""Y*P>MP*^_JT)5K.GG"\
MNCH\;Z-T]1"D^3`MO9BH\6OC$+F.$I!P2GC@<=3?PD]>8C'[G@A`S^_HUFZ9
M/`7TI.^8H+828@`$A1*UXD`E7(>(NMA*>`&Q=RO"+-U-5#ERX,@!%C@"1UK`
M`]RH":T*&RGW.8+5.G<V!C^?43D+$W+5UZO^GH8Y$`=I\>K,VD5,I:+I*B5I
M(:'%!NM#>3$'G/EEF4N'BQSE@B.'?GE!>^?O_*9='3X%_\#I=1QDK'A_&B6;
M\W>5DBYJYMC&S\&.[?:O65JN(79I:UIZ1N$VP3'>'*Z"C-%:EF.?4IEFVH>5
ML38CZ?8WUE-'?\)2K+Q<),`J]=??3L<\X:GC%MPMPR:4EVRJ5?O;.1ISJKAO
M)#,.SZ=(5KND6\:U^NN)+1!SP7&K5"DBG]@6#KA6\IO']:U4*2)5@A/>E4K=
M*AR60`=+2(7BD6C&QU)TFN:S<>0-QIFLXF+D;>GA^P7EC3">L%/L=P2TZKXO
MIKQ*?Y<+L.,>S;,+E;,?>!764@29/BVY),I8133=U2MZ0F&1ELG.;]]H^#^T
MNB/]0YT:BR9\51/P]`&EY5FC^$3%)//1J8L9YO8BHTQK_M6!S8!QDG."FIJH
M*W/6Y%A/<8^&H.1"G;EQ^).B("O20QD>E'W4PZ=H#G98%/9F&FC?8(AL@ZE%
MPKL\EF'Q]#P@V.UN'^,#0J5,R_TX/UL3.T1&UT01X=-Y@1NHG.KH$7#VU]GN
MMR"EL<^8D&%^J]4W^.8%-$3RJ,-AP&T.SS?K>C2[2L'*LS.D5XRTL0R_)FV;
MOWN\F38%W!Z=8WG+.U`Q(1&__PU)XN_1]42U\(ZW3;,ULP=RX9A\H@B7.WK$
M8E;;?9YF5-WP]'7*8Y[6SZ%GHY-@[\C?4&N_38O&IT752P5'YL"SN)Q0#04Q
MPS&K7L`(,PW13\=N-=G!??)*F.'T8#N?P;$A\A?.4LKVA;.`TN);[KI5]'8L
M(RC\B/$J*X,G/)*N35]'_N@*)8:2BTI8]$B7]R#6$7OHDLZMIO*9!K#W_)BS
M#/#1"OHI((V*@CA[*O;[N'I;_0FEX39(5E&&?B66(Z5WA]$FH?$\!B@TPJL;
M`$:?E^O(-:DJ)4Q/K-ADWH93SV1MG"<R@NL[\#PMRG@@]\E#BC>D-NM9>[C!
MJ3AS'9A>%B+/@7F/VS;:88KB,XK(--`KXIX2/J8X`X>([!'+!*^)W0N,R.I$
M47`^EM3`J(B=JH1!^>HJ/)_UV;:/A3``99/^443I#;;@\NH!2\C?W^O.7J9H
MTO0P*O5"_HY1'1'N<D=SKE;)!+G:&AZO&F9[S.YFB*TWN)Y)DWJ#P%QC-&Z'
M?ZY&3((VM'[;EEBD,H6UCL(:QR/0*DAL>)HO*Y@0VP3G06S;]0"^-9"H&N2"
M+*U-IN^1%[*'=[K7P3ZB/8^"#"U?XFA3*F>TIA)3M>FT.51^``HFI`:&N(S]
M73V5LM!$]?>[?8I?J_S)K-6XG+#6JXC0#_R`1=6`D(BWX5#K)PVR=EQ*#7##
M^M0&P>A^\@,;`G$TT-#G9BV@F5L;L0>41IA&P:2NW>@&5?_.M#T35V9XT\:K
MS`_HGU3E&H-I[O99"QS/#AR&$M+NSBS2IAHNKT[*>>9RDR+$.-O0*MO&%5$J
MZP>TIRA$`ZF*U>E'K)LIW"&W^8\HVKT4!.QE'I\).(0RDH)2SLAWA"JJRBA<
MY77/$3=/'[E$W!"A558Y3K&.P\<'7\`"Q^,O:0$_$*<LNMZAC+0._8?A+.MW
M>A^V?FB!SRBW?<]/78F^1'%<)2_HM4[JWZ95ML:'8ED'8]ID?&\`M4+RX#YN
M>`0(&L@Z(X*2R\6W?5ZDV)WB<#+RHR-8=9(P,N?A'R`0L+/!ZV[DX""4,)##
MDLO@/(`*T\\,T.56K'&P[M8EJU@]2I.(TN1Q+I"47;<:@5_WRE7GM;<+5ZYZ
M*S.I\D$7L$IUR_O"Q'6LXW/95Q0=<09@`L,D&H0E(UZBAY>]W;EUN1[J9'C#
M`B)N;D@DQ/ZA3TG\B;B3U67H8OC49Q^/^!#$^>'H*4$4,@@(2&,`VCX/:9KT
MB%Y14B#I&0B8?I#K04#_;8:R.4/!.]3$K"2M[121>VW/1(T2KG&6RU*K,&D&
M8VM`,U-2F#)B:<=6UQGI;@ITGSPB&E"(]`>-+)N%0?S?*!A&WS+%CIU$1H.=
M]2''[MMQ;-JIJF(/P5[MC'"U&K5:S/X[`<&T[<]?L!9<!V65L-F6]1V(;"48
M15U;A<F'L"<%&.$R7$QHEE8'657Z+&#&4(1YH%656,O].Q%J=[C0FWN'A96!
M5A4^!YPQU&`<9E4=;B7R56@]69[KHZQ36!UE9>&S0-E8#>915M;AEOLFK/67
M:U+W)*@Q.2CA;<#!=]")%&(4>8.*+#IQSK!EORY2VD^7R>HS3L+J?T3;=Q$]
M:RO/IG<?>U!A%9$F8#O!P=*%:TNELS?(B9#&81N'K5O[K(<4[8-H51N7[#XI
MPRDUF&!=X"B4:)U7`27\@(JZ\!K``57B]!YJE)"I3,T8K2.TNLRDIEV/"3`%
M-H^)'_@SHJ()MDRU7OT]F`M>UG4XU>PA.-"(I_2E5QBF!55#\!+%9=!4V]>,
M==NRIG%!S+OX`%`V!EM$:?,A:+<WKIDV1$QT?'C))++W@@+0-1@HW."]!)]S
M_;B1R='?*\#Q".4"14QWQ`J/S@.X@$1410R/J<<>3)505S@I,@E@V#1]L`QI
M/`&*4#0=D`P96ENS&HPL#+4O,.)N;&"/+8V2L$I(DG'V/[B%=(4)6NA`2K)7
M/^*2KB-/7PU3UDGB:B9<"8S.SD[N7(G*YS(/09H?GM,@R8+RY2S52_<3V?V1
M#5I.W<=NT(OUMZ?<5K-W0E#R&BER<@?R0_,:>77H?1&F@=;@,<KVK,3#FMY@
MK63D:%8O*`$1JZ`3:F'F3.83,,2<D!>9><AXF96Q_;,K8K?(JB#8HR*/PHR9
MD11$VTR(8EIK4Z!`V5A-POY<-^9;3G%B?M;>3#&A<(WBF,RWZ#,J4IR%$4I"
ME"WR%1,+,.(F2*6$V%$T*,D(@8.,X1S76):T";3C&&#^^)H55T(USF)^#@GS
M=%85>,),V^\#K78,NT-6O[_'I1PIX2L?^%+'H;5-IU7290Z75BSMA,6/J8P8
MNQU.RHNY2_:TR"5H\U^,"5PSV(R94"86R$9W)D(&OSD60_9U*9KM9*,`I%36
M3,=@_&W2`QC9>6>YWK3FX84.1ZP%)\4XE%QL\A<.I`1_"`YE[.\[G#Z.#XTY
M7X_7_OVOKAFH<7]@F4P@N[3HIKH>\?,\6LAEBH+E>A$DJP$8QA^:\Y#.!R\@
MP)5$O?>[K*QY:AI+Q--&P;S/LH)&5EVNJ^7,4X[#/T:.G4!Z1DQ2#KT7Z%&5
M6\.DR&OP-TG#4T"7':48GPNZ/";_0Y.$9U12&F>@HY7AS8-&T>;"0:FH%SB<
MH`UU2*I59M:-TP9(J6P/:12.+K]&'QJ`=3[X`1^>)!K@Z+"R]K[-8,?7H&9U
M_>!3M_/;3_YT/UL:30"TS/3?F,UQ]=.8*^8%!<T#GA$^PPV>6J%:;]!"7N!#
M2P/JR(%68RV`OZE7BR_Y?1E8GNX5[Q/2*"+9(U'/4U[J"*4A5=QF_+Q6M6#[
MK@5>T`M`:FM"'90J5>GG!;"]$.]+V?'0JO[,(IJ<B,SI/P@A"2C'1*2PG(>`
MA.MA*AZ%-=5P_,LIX<B<=F^S/-I1R>Z"*/T4I'^@_.]!7`SMFXRLUAF?S`NH
M`*541P:?<0V$G[W=@@V2LG3=1P4'41Q*=EJ</J472(++.NW8:<2[.=STT&>A
M;SZ?4;H3SFA=`N;451%X`1>I9%,GHXIE`PX/;_[X:[W;]1H1\5^1QN)<4%:Z
M/F>6]1!M:OHPN4IGUM9@U,,C\XXQ_HQS)'[1#"-N77;$Q%[`3DEB=9S)V#?`
MTCCM=@A8C'65>'WAY_K)])J)NT[2.`"WC8:^0?TU":IH8FA%8WS0YVS"Z4]`
MSYSRF/1>8$A5[JE3&[.&!F<:I^SGZO4V[JQ3N+YU:C5\*6\?_LPGM";>_\'>
M/71?U&K6:L@W]-3/:LL+M2V.2>,SFK(V/]A^,ENU@O-`EOVQ.;L;?'3@\6OI
MQW!U*)VTQ4]<N92CAZP,2GN2TFN*\JR8MJ9N&^.-AI2ND9)/9V_MVFD*\U$&
MGZ!9P3((['492B.473XT-JIL%?,=!H"RZ381I;6Y1M`O6$6Z_APRYEK.&B)N
M'K\;D(Y;#,#_8%W$XUEN<QB\/%8?P+QCN'7DK2]'S$M$\IG:?A68H?#]!K]^
M6*&HLEODCZ&Y(C_]OD";(+Y-\H@9\8#SM=;5Z.N)VEQ5R9PG6)^:I4OOT[>X
M!'K#C:G@21$)NAQGC45@^%)\F>9;'!YR=(W3/4Y+:9C=+B=L(H$)")WK<+!4
MXMX6L;'Q!(W=U4D(ZVD97=/1?#KW^ADHDZ2;^5QLO'Y@]O(CHBU\[MB<^R1D
M]C.`LGTM**!TKJ_A<HE[6\A'_SV!X?ZF"2]WP?ZI=5!E=[:,K%D,<<F<ZV:@
M1.(^YC/1?S5@N(.OJL.XRRP*%M$NRA$[1)",K%8'G\RY#@9*).Y@/I,YW@2<
M4&N\30T6;A_ZRAKP*-WW>F7/?D,MWAHJ;:-'K/R-/?!,Q:?YUE?1:[0J@IBQ
MJ1;2U/KCT+@CUV]1OBVO:.AMS3;:/V/!KERS-$\7LM+VCK&W$5K?OJ&PH`Y+
MR_4Z"E'*CK\CIVP.MD64UHR$;H]B%='[1D2QRO*D4U25[1.Z"==WC41_)_(\
M$"5%*Z(F)LX@I,WYF)#41Z0I"#\9:N*Z#$]H-M4_7#)-L^T2O3=K*^5*SG[Y
M!5E$*"W".`S]C4WQ$`?)YX!L8,8K,-:GYE5)[Y/UQC.74^R/`P%,7W14GA]D
MFT\01;VQ237L&4=&U_,D8=+9RSO`5BR&2]4?<GU^Y33!Y^-6D.721BSW5`[:
M2%+9CVP'!AE=ZW7"I7.PNZ%2R;I;P,??)0'3>F*)66)KJIG?AT7/?OH6S$!*
MLW:?CXVC=4.!ZKX$Z>J9U,*8K9G?FFOR_C>[H6:N@HQF_-W1U*TUUM(@V90>
M(MG5X4A3AQDL&W^4(%D)9_TYJ^B&OC%>A<5`H%F>1F$N<L`3TK27>$P:>S9F
M3B1@F$X&5FJ&%E47B<R6^'MT\UM`=<(^JV%^J]4]^':VT!/IX#20&[3`WV4:
M>]K$)YE(^EW5:TD;8LQX"\Y^T2A:""FM&@>,;%S8FW\WL.#$]Q;2,%X/=&@L
MQDOI^KCW@W0^!&D9%H:,@#)!YC%I.S?YMQEN;=R5B=P<T6K5XLLBW^*4/L<4
M*HU'S-3)F-C>7MU0UV-%A0RV^]-:4<6S$=?N>:!VEGC+(L_R(%E%R0:`30:U
M`)P]ZG-%)U\E)X%GKWI_75KZHMW0VR&4K&AH%FXL'94B3)#RBIP?4D'*F1FN
MO#9X?/<GDN\&QW&07NX843"4RT'0VR]W]A`6J.FT..XWQ!FW\S*Z)VE>*>AR
M7=T.9<_XH4C#+=GOTBUQD!Q&R%0JU>(26.H\4*FCHADP"6R&,W[R1Z%+.9DQ
M:1^I@KC6$EAN9"VEY<X#EWIJFM%:2AOBN8N_^,QG-(--/1+I]Q2S\O%LI5&I
MYYO<3M*CJ4=:)EBUL>^FL')!F9*3+`#E6!4.G6$9Z6NLHH?!>)Y0_S&)K/%S
M*]M[K*Y:<*,*P3`=T3#&7X?FG.#&E7TVH'5K]/?H:31RF+F<)%0\VV8]P]-L
M=@V0",JX31ODB](X,W)MB2([A(>0\K#GQO'[;`"$'KP;1R'KR%WCQ,<)*#ZG
M*"`2'SKB#1`HH&B>3K(HO,>;7&ZS,&/6YZ_3A-3[AN=\4Q]E?:3^4=E]\H#2
M"*\^IC@;A:*<KP:HIZI.#=X/C/GU;G9@S=)>:QDK385[)=JL5E,W14HFLDJX
M2J^=]R39[1M*PR@;IS;59M!]JJ/(P/^A,U5KAD>&1G.LI=5D7BK4?K1<F'*_
M]SV>SPID,IG-8HA1FWZ"2S^.]0T>"P//]*?5J'\TXT1_`/V6(1ZX2O[+'(;Z
M,[]M!W!.S'VL$KV^K\$^QW[2!08G7U,K!#'9]*_K4&7U6"R''UDY%B]9M(H"
M&C1</^$"^W%T6^VSL%K.Y95N\69]IES<@2P-&NE%1OD;]%.4:/*P^'(1TDK&
M6UGU@NT;1WA!)]3"?"/+)V"(^2T4^+1)2Z#L20'!QWP=#0MN*%-;E**0\&;B
MA/VQ5MOPHZ-($,H`Z?HA`W\O-#\%_\`I69=U4D(QNUU*5VM/0.<H&*"207`A
MX'5^V=L$,S@&3'Q\?8HK&2;+.Z?'MF8S%LK76+P]KIG<A<SZ_9T6.5+"U[SP
M1:Y#J]I.JZ0+7"ZM6%KK85DZ1V;LV+B\[V-O"J<F.WY_8+E0(/O<B6P[9N?O
M4*^$*8^CK@2(8!'T(-$G\`43`K&T0-'GY^]:V?=0.6`8P&/>2!'`#EZCL0I^
M1>D+MG_!`)G:^2LR_84P:^7+8/QM$0Q8=,V[ZO4]800T_;EX_3<B%R\!%Y-"
MW+"O1"K/!+()OSH\;Z.TJI/E%\8EZKIV,8A<,T)CG6.@A"`3M.C>,O/8NA4S
MN+D`OT]>44:*#,'+_5[KA?'=BTZ7R:7>WPR.<[@*G#0B`PX16F5W1+OT`G.Y
MOGP-HIA:]SN<TE^>4%BD41ZAK+J['H!'GT'[ZEB=@1?PFZP9=7SJ5.EO-)':
MW:1>7"_3QVBSS5MOGU;0ZR".$3'0MT&X[=,.M[.F^/6CUTWAYP703>M-'?<&
M6N!OC&[!$SS!NS-''MNI+^(`K^C@2[?!\SA3KT;.8,?(V[K,NVU<C+P&/;PJ
MU/8CPV:\J@9=I-B:OD^B4BM\]59$&_J"Y3Y9XW17\M3W2S1DTJL6/:(]3O,H
MV?`<%B5DC:GGDEF;LYJY>;E'-.MXLJG;R-N:<ND&6U0&G3TS(.L=#)=O,*0Y
MG+M;5`9'7X<G,5+HGP5A>/M*!;$^.`?MX0U."5DS.+ED]A:4_28QG7\%)&S!
M;+ON#IO#SFDCH>*(YD">FW&+V,EJ9'1\":W[)PS:Q$Y[)J)ARV;]0E+>)Q@F
MV&"2X+$M%WAL=AY?G$D&[EB%7.Q+U=BFR^`S/!]%#K>+,`LIUF&S">3RLNTS
MDZ'P_0:_?EBAJ+)/Y(^A62(__;Y`FR"^+3/<,B83SM=:1:.O)VKS+3\?/.M3
MDQ9T:B;W;T\S=AP%3WJ4<3O(=SW;<PR1YXD^`)9)B,-#CJYQ2O8RI4S,SI?2
MU<H1T#G7Z5"9Q!TNX.+Y*V:>^<1"0]77UH!'F>KW7!*22R9J\>P#FZ!'//QU
MZ"D?I5P768YW!-R,V9I/T'W4,R"P=X`6[-!RW6L2<TJ7TC4':'PZ4[;^.HBC
M-4Z3*+A/,E)MD9?GRQN4E"=5K^@36D5AE""VK[%>Z>8J5K6TM6$M[S`\51G]
ML<^ML+Q85:UH#L^G$VI?8`0P?##U%3SF69[3\GF=[YPDM;&P:8G%QE\WEAOT
MDM/1E19E'+7QS,0G:!X<,P@<$8>;-EM&QA3-B?35G?P,GW%.(PH=*#`Y+V0`
MM.UC&2&MM4$M[2FL)F=_C/.X5P]GA%P]GVL$PQJ#QX=(F<U4PV=UOC.-U&;"
M9AH6&W\]Q;Z%KW$[?,VW8!8^!K/PT'I^"V9A>7HR%:N",VUIA*+P,6!Z7_H%
MYVV>C(SM%K!P(-W\(R(M*1!]S5&%U![-2YSO[;0T^N[*B!CW`I;+(P3_HNO=
MS>#D>9*V2HQ'%*+HE>&0Q?M<:V[\V6D@2*2!XV#,R//W>M6K+D9<X^HEPWW2
M,?=#.ZA1M!/:%%[4:6A-T`(<=FJ5V#BZ//N'PA`LJ#T0%G4X_V&PQC'!9%<+
MXZ;FFJP=HQ6JW`LJ:TK6D"@%&1N%PF-S`RKL-,@F:4++Y("J\7?97SU<_H3R
M+5Y5XXV>S2V_)&1^WD9[(FA(5;89+I&4RS6N;_!R3@-15WXX!A5J,)P3X,3W
M6\>\W/45!9W3FU/B[DS_`^/62[UPYRY,I;#3:)RD"3@D5:O13];C/"XO=[A(
M<F5$#HI!L=@6\QN%;.D-XJ^M0#\'D`O(.PITGY"-,C']CT&.GO+RL)$W(ZL7
M9'H%B`LZCS\M#:@A$%I%C<&_>'HXTA?U4Y#3N!^'&R*E$'@L0B;0^H0>`4L@
MH2Z0^BQKX/SLN_'J>)P<K?9#&H6(-6\JE6,B2EC.(X#!Y=?%F["&YE#75U<@
MQ4=WXPZ9\.IN,0JYXF&B-NEC>\;+1=6+A7Z$%":SV2,LU%_H?UZ"#)%?_C]0
M2P,$%`````@`&(BH1DJ^0T@F#0``DX@``!``'`!B='@M,C`Q-3`S,S$N>'-D
M550)``,`)$U5`"1-575X"P`!!"4.```$.0$``.U=W7/B.!)_OZK['W2\W%S5
M$&`R,[M)37:+$#)+%1,H8';OGK:$+4"U1O9*<@+WUU]+ML$VQI_9C#/GIQB[
MN]7=O]9'MV7ET\^[K84>"1?49C>MWD6WA0@S;).R]4W+%6TL#$I;/__T][]]
M^D>[_9DPPK$D)EKNT?#N<W^VHA:0"C2=3>"2H,N+RXON11<-;&?/Z7HC4>_J
MZ@-JHW?=W@<T=[=;*M$]99@9%%MHRBF3(.`M&H\'%ZAO64AS"<2)(/R1F!?M
MMFI\)ZZ%L2%;C"3F:R(?\)8(!QODIK61TKGN=);4EG1+*#,N#'O;4>UU+R][
M8(]%MH3)>YMO[\@*NY:\:?WI8HNN*#%;"!S`Q/5.'`0]/3U=/%U>V'P-0KJ]
MSK^_C.>ZZ8!V*7?9K7JDX$&Y=\A1^`J+I18=/%$L[]O=7OO(!![](Z+-;LFM
M0)_+CGJ\Q((<5#^A][4'SU]U]-,#*0BB*:(I$Q*0(6%Z4QX8PL0?.M[#@)2R
M1R)BI((8%VO[L>,]4Y9>1BUE[C99&U/RCG)/!R@(I\:!P68Y>&S6CO&9A":K
M!@_""$"H(:2"#3-F2RRA5^A;_DW'H6QE^W?@GO+M=8#'C*R0]O:UTN*F)>C6
ML90K];T-)ZN;%H1..XB1WQU.+D"]@(+;%DG!1CWN.*I;,$^Q\;'=0`3FQHF4
MDV``(;9#N*00?,=8ZCR750:VBEH%+(9KU=DHDZR*&@4LE-$:VV3A95&;@(58
M?ZTY2LX"#$#JXNML=&ZDU?K<V8:KQO8^,X<PC\C]"+HGW^I(:B%JWK12*0Y-
M!XT?,?NI"T-_MPL35R`A?(F9B3QQ*"3O4R<N)"[?%<2<L)_T=;PK^]P^21IG
MK+OD9XR&9#*??S>`H0HZ`YN9A(%XN!"V14VU<KC%EIIAYAM"I/C*L&M2J:9A
M!581AE3L`#F-W1S<2WSP!I.'N^'#?'BGKN:3\>BNOX`?M_UQ_V$P1/-?AL/%
M'+TYM/"O!L[2<$XQ!U]LB*1@7&%LH]QA%\`2U'N(9J#1=7%,]6(R+6YZU>,&
MO8D8T,11GC@Z>%Q,5A-')1F@3J[Q(8LS%?!W^0>*^0+^?!D^`-B3>S29#F?]
MQ0@(`/J'_M>[$=`T4!>%>F!OP0L;H*&/9&R+PHBG"$@%_K(L\(/)E^EL^`O0
MC7X=HO%DW@1`I0#`8G-OV4_%@3]E3`7\?6G`^_-?T/UX\EL#=`K0$[[&C/Y7
M*WJ+!06$IB&C8?D]IG^Z%(#:>P`784@%]F.P3J?"L&SA<@(_PM+?(BT?V2L4
M;N&M7L4?&FD`C0*J2G68[R>K.5TSNH*5#"11AF&[NEXWA2YI0"+G89F3-@/&
M=Z<P^H(5="'1Z"@;!<(;^*+PC=@C&&ASO[<=?V:`<'D*PH&W\7'4QT,8.APU
ME3P055]0,Y7DKJ':'[$IM]?@`;^'Y"/-P.;]*38'N6\1(UY=P@C)1I0AQY?>
MH!?O(1*S-5U:I"\$I)^`3-!73A]D(/,AJ=<$4A#68C1"#0A1$&;V'EMR/UE:
M=!W,^W=D13@G,/\;:@5X3X)I)B]Q!E@?3\'R):.C:-V5`N'(EXZ4^`;"*(3^
M9"RF>(]5GV$FW.&N@@0OJ47E89F0BS(#O!].P0O$(E^NALZ7C$*B&^!B?8]8
MV*NVR?V"8R:PGC,$X!)^!'/5HZK:@V?OR-(?(TOR9H#[8T+/]*0A+0Z%F](P
M1Q^'FD.JO0;QV)I^@SG9V)9)N%`KAR`72[B?@=15PEH]).2?R!/3`!`#`%L$
M$MU;[]'`WFYMIOTF;O=S=RD@$\7\F%;EI4X'J]=-`$N)5FD5"%^`<.1)]T`4
M:G='N($&QAB,9*W6W"<O&Q/N9T"34+KPA30O%M-J$TM!_G3!R*%*30]5B-C=
M#-\GUAL"$<B3T7B^3%6H3'4HL4H4?]^7OQZ4\:+OAVK5)O0FN&H*P>4+P0NU
M6A>%R\$^6UJ<%"__9L3+CR6+S-%&T!M/]R9HRE32PN%2A"$M4`K4SS(CI%IY
MKHF-_'6Z<"2<?YR&>W)U+A/BW'6^!LUJ!;\PPL58TE`O4N;+C(6/W5Z5,F(3
M(17JB>'P*$"?%AMYJXB9<5&A0MG$1/5%Y1V1F%K%5Y4!WXLN*Z^>:5GI*]_$
M3:ET-1(RQ5A>)%F]JIJL-N&1L4DB$@$G=],7DCYQ)H9I.RL:B"IEAA'X"G&\
M3&YX53DW;,(C=W(8Z\MGGS][>GA5)#UL`*V4'T9`+LCS0AGBE=K26"U#;(*D
M?(H8B9`B#"^0)%Y52Q*;L'C.#2W1H:22B-21I<I&ELQX>NZ=,TV0Y=]#$TT?
MSSY.3143]LYD8IYS#TX#9=7=.%&`"S*EPEYH%TY60%3?Y].$2OX=/]&@./LX
M%?[3G3Z9&.?;,-0`F7?K4*SVE_PPO<H7VS*4"6&>?4?_%P!^ZL3.U/%N1$_>
M4>?NT*UC<XG8R9E/X=.4UA@[D<.4O/.BQK:AA46/_TED[!!+BN!.^RCJ8B?,
MX*"25'723A9*52?.HRXJ*Y!PZE(>'4)L_G7[***<)CJQX?O"JH3Y@A_5E7$A
MTV;&OC`X$<;#K\HPD9VQ*:S+@4E?5=:!86KHD\AZ190X<GF7[:.`<FH(:A16
M(N!1%V44B)]T=.7-$XRLL?X8_8P.$3:+\PA76\EI]]ZU>Q^KZR$+ZR#+M!]U
MJG1X<20")GWU'%B$#Z3+XP/-HGZU`S[EB4OEB0I:O.]P==)53@4TM6H6.N2/
M[5ZW&``GA^OE;#5@4`U_*&=I\O%Y>=H/<SYXC)5[P.D!@,4T*:]&^@F-Y1<5
M6E:9D?IT9/"/6P-5#=DF.\?"#*O7B/?P._]H$98R/`I)\9E_DJ;6,9P)+U(S
MX?Y22*XU4VOLI=S]7IS3.]).'U]Y#?<H6X\DV:JU)-@+'))*5UG[F=NN$Q!2
M(&DA1BU+U5-O6I*[0(Y]H<%OC]:!<+'-A6[&=+G_44>VZ>E%@`79R5O+-OY(
MLCTWJV>\=_3EM0SN/X,#5M@2)3T`_7Q)^&0UTBM$FXNCA0F/PO!1)LF:\&^K
MON?QN6V9M_O%AG*OK!M"Z<SS2!QJFF]K1U](H,="A=.&<.P0:-X07XB"X&A.
M!EDDP$Q[BRG[IMU+O?V:8@H9I.HM^I"G0R\Y&I5.%48*;D,VS?<O@Y7W;.D=
M;7?3,C@QJ4P)10*IA*X3.[:@<D8,0A^#8Y!T+)XCJ(V))EFF63CEMD&(*>ZY
MO4T[)$,9FX?V-=H=O.']S+&J$QKVEB0;G4CX6BP&?3G!@MP1[^^(!>;,@.CD
M0`!E>P&6VG@AJTOWM["2\W=P3E:!/2J<74MMS3L>::$'YUS4M3&^<`CH2/9&
M+:5#&O0GI+6QNASD)T>8G,<[0EH;LS/`]K<GC&!)!T.SG+#$PR*TT9F4M;&Y
M&-1S"6OQ6XA><\J)`\L1-6R=`_L,<6U,SX`[;<4%Q@79RS[?&BW*41L?9,&_
M($S-S%N'VX_Z?M^R["?%^Y69A(_52-:'E8I^=O1$0;:7=H=7,)//Z(T9H=NE
MRX6^6](UV3+JXJ>,GC.F*[+%#B246A<!4U\\1TLAJ5M^!C/T7I)%*)-,L">5
MJ&X6#<6`6):>G9@FQ=94DK$TXU9E$M;-LB"L#$H@4$6"2><I:FY+2B<ZI:B;
M+1-([50'&=C<L3WBN#$I)'6SQB]G]@7%8[I5IS''C3E/43=;5`<?N)P\$)?;
MXGR_R:*KFUT3+C>9(9="4S=[O&5#:*UPFF&FD+R2A4-JW:@6M:*R*\<Q9J9E
M\_`6_`>;>=LJ0HO##++78FTLS?<_3$LJ!V53UL7FC-!=<&R2X*L&,$-'J3CV
MP0<B!W&TB_"\$C>D?#<`UDQ6:B.@,C>\<L[+41<79$7_0/VW19LSBD?,4XE,
M5C.R]OZ=)'TD7X#?H(R<S+%%&>LV27E[\&%LAEN@[A0<=I)2G">IFS6_8:X[
MY'!'N$%%^"U5PJ.ZO2R=<AA2IX3K\I/Z9T$ZSU[84Y<;&RS4RW@'LWWXO4Q.
M!A\G`,GQJ5^D%YY]I:C*C)ZV*IK>=;OOXD&70E*WH)MR?T;TRH:A$=&[5/^Z
M=J9DA('+S1(.4L?]:X'+MC7MWQ6>[J/)1UVSO3/!]I#$]"EE.TD6?>WVF`RA
MQ:V:R.\QY5\P_X/(7['EDG`QZ1S%RPXH.7(MO%,R/\-8$)3RC\7[^,:,7,2O
M9>F2M1Q/Z)6Y.6K6,P$W_]OC7!AGTKX6B(.E2V1B5Z^IU!RI3]'9)VSD*\85
MF51KLH=OH=ZZNX!7JIWI5'6T*^&5>O@U['#GJ-O_(9C?PWK[;,?-Y*M+?.<L
M(>4PRW9Y*7=HON_*'?V5)+QLB,28ORO'W+EDQ&9$906F6I;=4V%@2QE;U$MI
MDKXKERF3%AM.2@TU/N/WYY`GNY0[GNQ7XPQ_CX^O/>0J$[7YVJ]?>N=115+6
M;.)78GC6"GA@82'HBA*SGUCS+\O_2MPS-S;$=-6:6:%M0/X7#O:8\7Y`Z(-A
MDSXG>099WWH-IS_[]KY:@E__`U!+`0(>`Q0````(`!B(J$:R6Z"A?YP``#((
M!0`0`!@```````$```"D@0````!B='@M,C`Q-3`S,S$N>&UL550%``,`)$U5
M=7@+``$$)0X```0Y`0``4$L!`AX#%`````@`&(BH1B^%*/F,$@``"P0!`!0`
M&````````0```*2!R9P``&)T>"TR,#$U,#,S,5]C86PN>&UL550%``,`)$U5
M=7@+``$$)0X```0Y`0``4$L!`AX#%`````@`&(BH1OKX,[):&P``QY<!`!0`
M&````````0```*2!HZ\``&)T>"TR,#$U,#,S,5]D968N>&UL550%``,`)$U5
M=7@+``$$)0X```0Y`0``4$L!`AX#%`````@`&(BH1M'K2BSZ@```!D\'`!0`
M&````````0```*2!2\L``&)T>"TR,#$U,#,S,5]L86(N>&UL550%``,`)$U5
M=7@+``$$)0X```0Y`0``4$L!`AX#%`````@`&(BH1A6:D02!/P``2Q@$`!0`
M&````````0```*2!DTP!`&)T>"TR,#$U,#,S,5]P<F4N>&UL550%``,`)$U5
M=7@+``$$)0X```0Y`0``4$L!`AX#%`````@`&(BH1DJ^0T@F#0``DX@``!``
M&````````0```*2!8HP!`&)T>"TR,#$U,#,S,2YX<V155`4``P`D355U>`L`
A`00E#@``!#D!``!02P4&``````8`!@`4`@``TID!````
`
end

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EZ3AE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="2">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2015</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueNetAbstract', window );"><strong>REVENUES:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LicensesRevenue', window );">License fees</a></td>
        <td class="nump"><a title="us-gaap_LicensesRevenue" onclick="toggleNextSibling(this);">$ 319,146</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_LicensesRevenue</span><span></span></td>
        <td class="nump"><a title="us-gaap_LicensesRevenue" onclick="toggleNextSibling(this);">$ 294,504</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_LicensesRevenue</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RoyaltyRevenue', window );">Royalties from product sales</a></td>
        <td class="nump"><a title="us-gaap_RoyaltyRevenue" onclick="toggleNextSibling(this);">156,550</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_RoyaltyRevenue</span><span></span></td>
        <td class="nump"><a title="us-gaap_RoyaltyRevenue" onclick="toggleNextSibling(this);">97,886</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_RoyaltyRevenue</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromGrants', window );">Grant income</a></td>
        <td class="nump"><a title="us-gaap_RevenueFromGrants" onclick="toggleNextSibling(this);">698,839</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_RevenueFromGrants</span><span></span></td>
        <td class="nump"><a title="us-gaap_RevenueFromGrants" onclick="toggleNextSibling(this);">575,659</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_RevenueFromGrants</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Sale of research products and services</a></td>
        <td class="nump"><a title="us-gaap_SalesRevenueGoodsNet" onclick="toggleNextSibling(this);">89,919</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_SalesRevenueGoodsNet</span><span></span></td>
        <td class="nump"><a title="us-gaap_SalesRevenueGoodsNet" onclick="toggleNextSibling(this);">98,586</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_SalesRevenueGoodsNet</span><span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueNet', window );">Total revenues</a></td>
        <td class="nump"><a title="us-gaap_SalesRevenueNet" onclick="toggleNextSibling(this);">1,264,454</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_SalesRevenueNet</span><span></span></td>
        <td class="nump"><a title="us-gaap_SalesRevenueNet" onclick="toggleNextSibling(this);">1,066,635</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_SalesRevenueNet</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">Cost of sales</a></td>
        <td class="num"><a title="us-gaap_CostOfRevenue" onclick="toggleNextSibling(this);">(264,167)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CostOfRevenue</span><span></span></td>
        <td class="num"><a title="us-gaap_CostOfRevenue" onclick="toggleNextSibling(this);">(131,914)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CostOfRevenue</span><span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross Profit</a></td>
        <td class="nump"><a title="us-gaap_GrossProfit" onclick="toggleNextSibling(this);">1,000,287</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_GrossProfit</span><span></span></td>
        <td class="nump"><a title="us-gaap_GrossProfit" onclick="toggleNextSibling(this);">934,721</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_GrossProfit</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>OPERATING EXPENSES:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
        <td class="nump"><a title="us-gaap_ResearchAndDevelopmentExpense" onclick="toggleNextSibling(this);">9,323,510</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ResearchAndDevelopmentExpense</span><span></span></td>
        <td class="nump"><a title="us-gaap_ResearchAndDevelopmentExpense" onclick="toggleNextSibling(this);">8,405,393</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ResearchAndDevelopmentExpense</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
        <td class="nump"><a title="us-gaap_GeneralAndAdministrativeExpense" onclick="toggleNextSibling(this);">5,178,800</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_GeneralAndAdministrativeExpense</span><span></span></td>
        <td class="nump"><a title="us-gaap_GeneralAndAdministrativeExpense" onclick="toggleNextSibling(this);">3,667,171</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_GeneralAndAdministrativeExpense</span><span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
        <td class="nump"><a title="us-gaap_OperatingExpenses" onclick="toggleNextSibling(this);">14,502,310</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OperatingExpenses</span><span></span></td>
        <td class="nump"><a title="us-gaap_OperatingExpenses" onclick="toggleNextSibling(this);">12,072,564</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OperatingExpenses</span><span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
        <td class="num"><a title="us-gaap_OperatingIncomeLoss" onclick="toggleNextSibling(this);">(13,502,023)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OperatingIncomeLoss</span><span></span></td>
        <td class="num"><a title="us-gaap_OperatingIncomeLoss" onclick="toggleNextSibling(this);">(11,137,843)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OperatingIncomeLoss</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>OTHER INCOME/(EXPENSES):</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNet', window );">Interest expense, net</a></td>
        <td class="num"><a title="us-gaap_InterestIncomeExpenseNet" onclick="toggleNextSibling(this);">(25,461)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_InterestIncomeExpenseNet</span><span></span></td>
        <td class="num"><a title="us-gaap_InterestIncomeExpenseNet" onclick="toggleNextSibling(this);">(8,384)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_InterestIncomeExpenseNet</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncome', window );">Other income/(expense), net</a></td>
        <td class="num"><a title="us-gaap_OtherNonoperatingIncome" onclick="toggleNextSibling(this);">(239,453)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OtherNonoperatingIncome</span><span></span></td>
        <td class="nump"><a title="us-gaap_OtherNonoperatingIncome" onclick="toggleNextSibling(this);">69,170</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OtherNonoperatingIncome</span><span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income/(expenses), net</a></td>
        <td class="num"><a title="us-gaap_NonoperatingIncomeExpense" onclick="toggleNextSibling(this);">(264,914)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NonoperatingIncomeExpense</span><span></span></td>
        <td class="nump"><a title="us-gaap_NonoperatingIncomeExpense" onclick="toggleNextSibling(this);">60,786</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NonoperatingIncomeExpense</span><span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">LOSS BEFORE INCOME TAX BENEFITS</a></td>
        <td class="num"><a title="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" onclick="toggleNextSibling(this);">(13,766,937)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</span><span></span></td>
        <td class="num"><a title="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" onclick="toggleNextSibling(this);">(11,077,057)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred income tax benefit</a></td>
        <td class="nump"><a title="us-gaap_DeferredIncomeTaxExpenseBenefit" onclick="toggleNextSibling(this);">1,176,882</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredIncomeTaxExpenseBenefit</span><span></span></td>
        <td class="nump"><a title="us-gaap_DeferredIncomeTaxExpenseBenefit" onclick="toggleNextSibling(this);">1,349,026</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredIncomeTaxExpenseBenefit</span><span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">NET LOSS</a></td>
        <td class="num"><a title="us-gaap_ProfitLoss" onclick="toggleNextSibling(this);">(12,590,055)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ProfitLoss</span><span></span></td>
        <td class="num"><a title="us-gaap_ProfitLoss" onclick="toggleNextSibling(this);">(9,728,031)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ProfitLoss</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net loss attributable to non-controlling interest</a></td>
        <td class="nump"><a title="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" onclick="toggleNextSibling(this);">2,422,687</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</span><span></span></td>
        <td class="nump"><a title="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" onclick="toggleNextSibling(this);">1,629,017</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">NET LOSS ATTRIBUTABLE TO BIOTIME, INC.</a></td>
        <td class="num"><a title="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" onclick="toggleNextSibling(this);">$ (10,167,368)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</span><span></span></td>
        <td class="num"><a title="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" onclick="toggleNextSibling(this);">$ (8,099,014)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">BASIC AND DILUTED NET LOSS PER COMMON SHARE (in dollars per share)</a></td>
        <td class="num"><a title="us-gaap_EarningsPerShareBasicAndDiluted" onclick="toggleNextSibling(this);">$ (0.13)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_EarningsPerShareBasicAndDiluted</span><span></span></td>
        <td class="num"><a title="us-gaap_EarningsPerShareBasicAndDiluted" onclick="toggleNextSibling(this);">$ (0.14)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_EarningsPerShareBasicAndDiluted</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">WEIGHTED AVERAGE NUMBER OF COMMON STOCK OUTSTANDING: BASIC AND DILUTED (in shares)</a></td>
        <td class="nump"><a title="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" onclick="toggleNextSibling(this);">78,261,788</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</span><span></span></td>
        <td class="nump"><a title="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" onclick="toggleNextSibling(this);">58,257,427</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</span><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfRevenue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate cost of goods produced and sold and services rendered during the reporting period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 2<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CostOfRevenue</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 6.I.7)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(h))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph h<br><br> -Article 4<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 6<br><br> -Section I<br><br> -Subsection 7<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Deferred Tax Expense (or Benefit)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6510177<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 9<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32639-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.4)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.1,2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_GrossProfit</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This element represents the income or loss from continuing operations attributable to the economic entity which may also be defined as revenue less expenses from ongoing operations, after income or loss from equity method investments, but before income taxes, extraordinary items, and noncontrolling interest.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 940<br><br> -SubTopic 20<br><br> -Section 25<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35710027&amp;loc=d3e41242-110953<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 10<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The net amount of operating interest income (expense).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 942<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.9-04.10)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 10<br><br> -Article 9<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNet</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LicensesRevenue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Revenue earned during the period relating to consideration received from another party for the right to use, but not own, certain of the entity's intangible assets. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, manufacturing process, software or trademark. Licensing fees are generally, but not always, fixed as to amount and not dependent upon the revenue generated by the licensing party. An entity may receive licensing fees for licenses that also generate royalty payments to the entity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.1(e))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_LicensesRevenue</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1A<br><br> -URI http://asc.fasb.org/extlink&amp;oid=18733093&amp;loc=SL4573702-111684<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -Section 55<br><br> -Paragraph 4J<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35736750&amp;loc=SL4591551-111686<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Net income after adjustments for dividends on preferred stock (declared in the period) and/or cumulative preferred stock (accumulated for the period).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 11<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7655603&amp;loc=d3e1377-109256<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.7)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 7<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The net result for the period of deducting operating expenses from operating revenues.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncome">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate amount of other income amounts, the components of which are not separately disclosed on the income statement, resulting from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business) also known as other nonoperating income recognized for the period. Such amounts may include: (a) dividends, (b) interest on securities, (c) profits on securities (net of losses), and (d) miscellaneous other income items.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.7)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 7<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncome</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -Section 55<br><br> -Paragraph 4K<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35736750&amp;loc=SL4591552-111686<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 19<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7656940&amp;loc=SL4569616-111683<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1A<br><br> -Subparagraph (a),(c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=18733093&amp;loc=SL4573702-111684<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -Section 55<br><br> -Paragraph 4J<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35736750&amp;loc=SL4591551-111686<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 985<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 730<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromGrants">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Revenue earned during the period from non-repayable sum of money awarded to an entity to carry out a specific purpose as provided in grant agreements.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.1(e))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_RevenueFromGrants</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RoyaltyRevenue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Revenue earned during the period from the leasing or otherwise lending to a third party the entity's rights or title to certain property. Royalty revenue is derived from a percentage or stated amount of sales proceeds or revenue generated by the third party using the entity's property. Examples of property from which royalties may be derived include patents and oil and mineral rights.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.1(e))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 1<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_RoyaltyRevenue</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesRevenueGoodsNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate revenue during the period from the sale of goods in the normal course of business, after deducting returns, allowances and discounts.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.1(a))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 1<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_SalesRevenueGoodsNet</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesRevenueNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total revenue from sale of goods and services rendered during the reporting period, in the normal course of business, reduced by sales returns and allowances, and sales discounts.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 1<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_SalesRevenueNet</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesRevenueNetAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_SalesRevenueNetAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Royalty Obligation and Deferred License Fees<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2015</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueDisclosureAbstract', window );"><strong>Royalty Obligation and Deferred License Fees [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueDisclosureTextBlock', window );">Royalty Obligation and Deferred License Fees</a></td>
        <td class="text"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="text-align: justify;"><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 100%;"><tr><td style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 18pt; vertical-align: top; font-weight: bold; align: right;">6.</td><td style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: auto; vertical-align: top; font-weight: bold; text-align: justify;">Royalty Obligation and Deferred License Fees</td></tr></table></div><div style="text-align: justify;"><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; text-indent: 36pt;">BioTime amortizes deferred license fees over the estimated useful lives of the licensed technologies or licensed research products. BioTime is applying a 10 year estimated useful life to the technologies and products that it is currently licensing. The estimation of the useful life of any technology or product involves a significant degree of inherent uncertainty, since the outcome of research and development or the commercial life a new product cannot be known with certainty at the time that the right to use the technology or product is acquired. BioTime will review its amortization schedules for impairments that might occur earlier than the original expected useful lives.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; text-indent: 36pt;">As of March 31, 2015, future amortization of deferred license fees described above was as follows:</div><div><br /></div><table align="center" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 50%;"><tr><td valign="bottom" style="width: 38%; vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; text-align: center;">Year Ended December 31,</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td valign="bottom" style="width: 10%; vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; text-align: center;">Deferred</div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; text-align: center;">License Fees</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td></tr><tr><td valign="bottom" style="width: 38%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;">2015</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 10%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;">$82,125</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td></tr><tr style="height: 16px;"><td valign="bottom" style="width: 38%; vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;">2016</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 10%; vertical-align: bottom; text-align: center; background-color: #ffffff;">&#160;109,500</td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="width: 38%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;">2017</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 10%; vertical-align: bottom; text-align: center; background-color: #cceeff;">&#160;109,500</td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="width: 38%; vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;">2018</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 10%; vertical-align: bottom; text-align: center; background-color: #ffffff;">&#160;73,667</td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="width: 38%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;">2019</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 10%; vertical-align: bottom; text-align: center; background-color: #cceeff;">&#160;24,083</td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="width: 38%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;">Thereafter</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 10%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: center; background-color: #ffffff;">&#160;20,083</td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="width: 38%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;">Total</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 10%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;">$418,958</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;">&#160;</td></tr></table><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; text-indent: 36pt;">The current portion in the amount of $109,500 is included in prepaid expenses and other current assets. The noncurrent portion in the amount of $309,458 is included in deferred license and consulting fees.</div></div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DeferredRevenueDisclosureAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for deferred revenues at the end of the reporting period, and description and amounts of significant changes that occurred during the reporting period. Deferred revenue is a liability as of the balance sheet date related to a revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 8<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 13<br><br> -Section A<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 605<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 13.A.3(b).Q1(c),(b).Q2,(c).Q3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012821&amp;loc=d3e214044-122780<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DeferredRevenueDisclosureTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Intangible assets, net<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2015</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Intangible assets, net [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsDisclosureTextBlock', window );">Intangible assets, net</a></td>
        <td class="text"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="text-align: justify;"><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 100%;"><tr><td style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 18pt; vertical-align: top; font-weight: bold; align: right;">5.</td><td style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: auto; vertical-align: top; font-weight: bold; text-align: justify;">Intangible assets, net</td></tr></table></div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; text-indent: 36pt;">At March 31, 2015 and December 31, 2014, intangible assets and intangible assets net of amortization were comprised of the following:</div><div><br /></div><table cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 100%;"><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" style="vertical-align: bottom; white-space: nowrap; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; text-align: center;">March 31, 2015</div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; text-align: center;">(Unaudited)</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; text-align: center;">December 31,</div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; text-align: center;">2014</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td></tr><tr><td valign="bottom" style="width: 76%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Intangible assets</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">52,562,549</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">52,562,549</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="width: 76%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Accumulated amortization</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">(15,028,247</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">(13,714,153</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">)</div></td></tr><tr><td valign="bottom" style="width: 76%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Intangible assets, net</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">37,534,302</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">38,848,396</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;">&#160;</td></tr></table><div style="text-align: justify;"><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; text-indent: 36pt;">BioTime amortizes its intangible assets generally over an estimated period of 10 years on a straight line basis. BioTime recognized $1,314,094 and $1,367,998 in amortization expense of intangible assets, included in research and development,&#160;during the three months ended March 31, 2015 and 2014, respectively.</div></div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for all or part of the information related to intangible assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 350<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16323-109275<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 350<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16265-109275<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 350<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16373-109275<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_IntangibleAssetsDisclosureTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Royalty Obligation and Deferred License Fees (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2015</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueDisclosureAbstract', window );"><strong>Royalty Obligation and Deferred License Fees [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_ScheduleOfExpectedAmortizationDeferredLicenseExpenseTableTextBlock', window );">Amortization of deferred license fees</a></td>
        <td class="text"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; text-indent: 36pt;">As of March 31, 2015, future amortization of deferred license fees described above was as follows:</div><div><br /></div><table align="center" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 50%;"><tr><td valign="bottom" style="width: 38%; vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; text-align: center;">Year Ended December 31,</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td valign="bottom" style="width: 10%; vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; text-align: center;">Deferred</div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; text-align: center;">License Fees</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td></tr><tr><td valign="bottom" style="width: 38%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;">2015</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 10%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;">$82,125</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td></tr><tr style="height: 16px;"><td valign="bottom" style="width: 38%; vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;">2016</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 10%; vertical-align: bottom; text-align: center; background-color: #ffffff;">&#160;109,500</td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="width: 38%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;">2017</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 10%; vertical-align: bottom; text-align: center; background-color: #cceeff;">&#160;109,500</td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="width: 38%; vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;">2018</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 10%; vertical-align: bottom; text-align: center; background-color: #ffffff;">&#160;73,667</td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="width: 38%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;">2019</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 10%; vertical-align: bottom; text-align: center; background-color: #cceeff;">&#160;24,083</td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="width: 38%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;">Thereafter</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 10%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: center; background-color: #ffffff;">&#160;20,083</td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="width: 38%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;">Total</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 10%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;">$418,958</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;">&#160;</td></tr></table></div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btx_ScheduleOfExpectedAmortizationDeferredLicenseExpenseTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of the estimated aggregate amortization expense for deferred license fees subject to amortization for each of the five succeeding fiscal years.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">btx_ScheduleOfExpectedAmortizationDeferredLicenseExpenseTableTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>btx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DeferredRevenueDisclosureAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EJLAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2015</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue recognition</a></td>
        <td class="text"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;">Revenue recognition</font> &#8211; BioTime complies with ASC 605-10 and recognizes revenue when persuasive evidence of an arrangement exists, delivery has occurred or services have been rendered, the price is fixed or determinable, and collectability is reasonably assured. Grant income and the sale of research products and services are recognized as revenue when earned. Revenues from the sale of research products and services are primarily derived from the sale of hydrogels and stem cell products. Royalty revenues consist of product royalty payments. License fee revenues consist primarily of subscription and advertising revenue from LifeMap Sciences&#8217; online databases and are recognized based upon respective subscription or advertising periods. Other license fees under certain license agreements were recognized during prior periods when earned and reasonably estimable. Royalties earned on product sales are recognized as revenue in the quarter in which the royalty reports are received from the licensee, rather than the quarter in which the sales took place. When BioTime is entitled to receive up-front nonrefundable licensing or similar fees pursuant to agreements under which BioTime has no continuing performance obligations, the fees are recognized as revenues when collection is reasonably assured. When BioTime receives up-front nonrefundable licensing or similar fees pursuant to agreements under which BioTime does have continuing performance obligations, the fees are deferred and amortized ratably over the performance period. If the performance period cannot be reasonably estimated, BioTime amortizes nonrefundable fees over the life of the contract until such time that the performance period can be more reasonably estimated. Milestone payments, if any, related to scientific or technical achievements are recognized in income when the milestone is accomplished if (a) substantive effort was required to achieve the milestone, (b) the amount of the milestone payment appears reasonably commensurate with the effort expended, and (c) collection of the payment is reasonably assured.</div></div><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and cash equivalents</a></td>
        <td class="text"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;">Cash and cash equivalents</font> &#8211; BioTime considers all highly liquid investments purchased with an original maturity of three months or less to be cash equivalents.</div></div><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TradeAndOtherAccountsReceivablePolicy', window );">Trade accounts and grants receivable, net</a></td>
        <td class="text"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;">Trade accounts and grants receivable, net</font> &#8211; Net trade receivables amounted to approximately $605,800 and $549,300 and grants receivable amounted to approximately $260,300 and $492,600 as of March 31, 2015 and December 31, 2014, respectively. Net trade receivables include allowance for doubtful accounts of approximately $100,500 as of March 31, 2015 and December 31, 2014 for those amounts deemed uncollectible by BioTime. BioTime evaluates the collectability of its receivables based on a variety of factors, including the length of time receivables are past due and significant one-time events and historical experience. An additional reserve for individual accounts will be recorded if BioTime becomes aware of a customer&#8217;s inability to meet its financial obligations, such as in the case of bankruptcy filings or deterioration in the customer&#8217;s operating results or financial position. If circumstances related to customers change, estimates of the recoverability of receivables would be further adjusted.</div></div><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentrations of credit risk</a></td>
        <td class="text"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;">Concentrations of credit risk</font> &#8211; Financial instruments that potentially subject BioTime to significant concentrations of credit risk consist primarily of cash and cash equivalents. BioTime limits the amount of credit exposure of cash balances by maintaining its accounts in high credit quality financial institutions. Cash equivalent deposits with financial institutions may occasionally exceed the limits of insurance on bank deposits; however, BioTime has not experienced any losses on such accounts</div></div><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventory</a></td>
        <td class="text"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;">Inventory &#8211;</font> Inventories are stated at the lower of cost or market. Cost, which includes amounts related to materials, labor, and overhead, is determined in a manner which approximates the first-in, first-out (&#8220;FIFO&#8221;) method.</div></div><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Equipment, net</a></td>
        <td class="text"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;">Equipment, net and construction in progress</font>&#160;&#8211; Equipment is stated at cost. Equipment and construction in progress is being depreciated using the straight-line method over a period of 36 to 120 months. Construction in progress is not depreciated until the underlying asset is placed into service. See Note 4.</div></div><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock', window );">Intangible assets, net</a></td>
        <td class="text"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;">Intangible assets, net</font> &#8211; Intangible assets with finite useful lives are amortized over their estimated useful lives and intangible assets with indefinite lives are not amortized but rather are tested at least annually for impairment. Acquired in-process research and development intangible assets are accounted for depending on whether they were acquired as part of an acquisition of a business, or as assets that do not constitute a business. When acquired in conjunction with the acquisition of a business, these assets are considered to be indefinite-lived until the completion or abandonment of the associated research and development efforts and are capitalized as an asset. If and when development is complete, the associated assets would be deemed finite-lived and would then be amortized based on their respective estimated useful lives at that point in time. However, when acquired in conjunction with an acquisition of assets that do not constitute a business (such as the acquisition of assets by Asterias from Geron Corporation), in accordance with the accounting rules in ASC 805-50, such intangible assets related to in-process research and development (&#8220;IPR&amp;D&#8221;) are expensed upon acquisition.</div></div><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_TreasuryStockPolicyTextBlock', window );">Treasury stock</a></td>
        <td class="text"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;">Treasury stock &#8211;</font> BioTime accounts for BioTime common shares issued to subsidiaries for future potential working capital needs as treasury stock on the consolidated balance sheet. BioTime has registered the BioTime common shares held by its subsidiaries for sale under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;) to enhance the marketability of the shares.</div></div><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_WarrantsToPurchaseCommonStockPolicyTextBlock', window );">Warrants to purchase common stock</a></td>
        <td class="text"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;">Warrants to purchase common stock</font> &#8211; BioTime generally accounts for warrants issued in connection with equity financings as a component of equity. None of the warrants issued by BioTime as of March 31, 2015 include a conditional obligation to issue a variable number of shares; nor was there a deemed possibility that BioTime may need to settle the warrants in cash.</div></div><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfSalesPolicyTextBlock', window );">Cost of sales</a></td>
        <td class="text"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;">Cost of sales</font> &#8211; BioTime accounts for the cost of research products acquired for sale and any royalties paid as a result of any revenues in accordance with the terms of the respective licensing agreements as cost of sales on the consolidated statement of operations and comprehensive loss.</div></div><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsFiniteLivedPolicyCostsIncurredToRenewOrExtend', window );">Patent costs</a></td>
        <td class="text"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;">Patent costs &#8211;</font> Costs associated with obtaining patents on products or technology developed are expensed as research and development expenses when incurred.</div></div><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription', window );">Reclassification</a></td>
        <td class="text"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;">Reclassification</font> &#8211; Certain prior year amounts have been reclassified to conform to the current year presentation. Trade and grant receivables are now reported separately from prepaid expenses and other current assets.</div><div><br /></div></div><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and development</a></td>
        <td class="text"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;">Research and development</font> &#8211; Research and development expenses consist of costs incurred for company-sponsored, collaborative and contracted research and development activities. These costs include direct and research-related overhead expenses including salaries, payroll taxes, consulting fees, research and laboratory fees, rent of research facilities, amortization of intangible assets, and license fees paid to third parties to acquire patents or licenses to use patents and other technology. BioTime expenses research and development costs as such costs are incurred.</div></div><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock', window );">General and administrative</a></td>
        <td class="text"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;">General and administrative</font> - General and administrative expenses consist principally of compensation and related benefits, including stock-based compensation, for executive and corporate personnel; professional and consulting fees; and allocated overhead.</div></div><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Foreign currency translation gain and other comprehensive loss</a></td>
        <td class="text"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;">Foreign currency translation gain and other comprehensive loss, &#160;foreign currency transaction gains and losses&#160;&#8211;</font> In countries in which BioTime operates, where the functional currency is other than the U.S. dollar, assets and liabilities are translated using published exchange rates in effect at the consolidated balance sheet date. Revenues and expenses and cash flows are translated using an approximate weighted average exchange rate for the period. Resulting translation adjustments are recorded as a component of accumulated other comprehensive income or loss on the consolidated balance sheet. For the three months ended March 31, 2015 and 2014, other comprehensive loss includes losses of $52,985 and $107,240, respectively which is largely from foreign currency translation.</div><div style="text-align: justify; text-indent: 36pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; text-indent: 36pt;">For transactions denominated in other than the functional currency of BioTime, transactional gains and losses are recorded in other income and expense included in the consolidated statements of operations. For the three months ended March 31, 2015 and 2014, foreign currency transaction loss amounted to $205,149 and $10,212, respectively.</div></div><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income taxes</a></td>
        <td class="text"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;">Income taxes &#8211;</font> BioTime accounts for income taxes in accordance with GAAP requirements, which prescribe the use of the asset and liability method, whereby deferred tax asset or liability account balances are calculated at the balance sheet date using current tax laws and rates in effect. Valuation allowances are established when necessary to reduce deferred tax assets when it is more likely than not that a portion or all of the deferred tax assets will not be realized. The FASB guidance also prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more-likely-than-not sustainable upon examination by taxing authorities. Beginning October 1, 2013, Asterias began filing separate U.S. federal income tax returns but effectively BioTime combined Asterias&#8217; tax provision with BioTime&#8217;s consolidated financial statements. For California, Asterias&#8217; activity for 2013 and 2014 have been included in BioTime&#8217;s combined tax return. BioTime recognizes accrued interest and penalties related to unrecognized tax benefits, if any,&#160;as income tax expense, however, no amounts were accrued for the payment of interest and penalties as of March 31, 2015 and 2014. BioTime files a U.S. federal income tax return as well as various state and foreign income tax returns. In general, BioTime is no longer subject to tax examination by major taxing authorities for years before 2010. Although the statute is closed for purposes of assessing additional income and tax in those years, the taxing authorities may still make adjustments to the net operating loss and credit carryforwards used in open years. Therefore the statute should be considered open as it relates to the net operating loss and credit carryforwards. Any potential examinations may include questioning the timing and amount of deductions, the nexus of income among various tax jurisdictions and compliance with U.S. federal, state and local and foreign tax laws. Management does not expect that the total amount of unrecognized tax benefits will materially change over the next year.</div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; text-indent: 36pt;">&#160;</div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; text-indent: 36pt;">An income tax benefit of approximately $1,177,000 was recorded for the three months ended March 31, 2015, of which approximately $1,251,000 of the benefit was related to federal offset by adjustment of $74,000 related to state taxes. For the same period in 2014, an income tax benefit of approximately $1,349,000 was recorded , of which approximately $1,151,000 of the benefit was related to federal and $198,000 was related to state taxes.</div><div>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; text-indent: 36pt;">Asterias established deferred tax liabilities primarily related to its acquisition of certain intellectual property. It is more likely than not that the Asterias deferred tax assets are fully realizable since these income tax benefits are expected to be available to offset such Asterias deferred tax liabilities.</div><div>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; text-indent: 36pt;">In June 2014, Asterias sold 5,000,000 BioTime shares which resulted in a taxable gain of approximately $10.3 million and a tax payable of $3.6 million. Asterias received the BioTime shares from BioTime as part of the consideration for the Asterias common stock and warrants issued to BioTime under an Asset Contribution Agreement among BioTime, Asterias, and Geron Corporation, a tax free transaction. This income tax liability was offset by available net operating losses, resulting in no cash income taxes due from that sale. This transaction was treated as a deemed distribution by Asterias and recorded against equity.</div></div><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-based compensation</a></td>
        <td class="text"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;">Stock-based compensation</font>&#160;<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;">&#8211;</font> BioTime follows accounting standards governing share-based payments, which require the measurement and recognition of compensation expense for all share-based payment awards made to directors and employees, including employee stock options, based on estimated fair values. Consistent with FASB guidelines, BioTime utilizes the Black-Scholes Merton option pricing model for valuing share-based payment awards. BioTime's determination of fair value of share-based payment awards on the date of grant using that option-pricing model is affected by BioTime's stock price as well as by assumptions regarding a number of highly complex and subjective variables. These variables include, but are not limited to, BioTime's expected stock price volatility over the term of the awards, and actual and projected employee stock option exercise behaviors; the expected term of options granted, derived from historical data on employee exercises and post-vesting employment termination behavior; and a risk-free interest rate is based on the U.S. Treasury rates in effect during the corresponding period of grant. Although the fair value of employee stock options is determined in accordance with&#160;FASB guidance, changes in the subjective assumptions can materially affect the estimated value.</div></div><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of long-lived assets</a></td>
        <td class="text"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;">Impairment of long-lived assets</font>&#160;<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;">&#8211;</font> BioTime&#8217;s long-lived assets, including intangible assets, are reviewed annually for impairment and whenever events or changes in circumstances indicate that the carrying amount of an asset may not be fully recoverable. If an impairment indicator is present, BioTime will evaluate recoverability by a comparison of the carrying amount of the assets to future undiscounted net cash flows expected to be generated by the assets. If the assets are impaired, the impairment recognized is measured by the amount by which the carrying amount exceeds the estimated fair value of the assets.</div></div><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredChargesPolicyTextBlock', window );">Deferred license and consulting fees</a></td>
        <td class="text"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;">Deferred license and consulting fees</font> &#8211; Deferred license and consulting fees consist of the value of warrants issued to third parties for services, and deferred license fees paid to acquire rights to use the proprietary technologies of third parties. The value of the warrants is being amortized over the period the services are being provided, and the license fees are being amortized over the estimated useful lives of the licensed technologies or licensed research products. BioTime is applying a 10 year estimated useful life to the technologies and products that it is currently licensing. The estimation of the useful life any technology or product involves a significant degree of inherent uncertainty, since the outcome of research and development or the commercial life of a new product cannot be known with certainty at the time that the right to use the technology or product is acquired. BioTime will review the continued appropriateness of the 10 year estimated useful life for impairments that might occur earlier than the original expected useful lives. BioTime will review its amortization schedules for impairments that might occur earlier than the original expected useful lives. See Note 6.</div></div><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Loss per share</a></td>
        <td class="text"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;">Loss per share</font> &#8211; BioTime applies the two-class method for calculating basic earnings per share. Under the two-class method, net income, if any, will be reduced by preferred stock dividends and the residual amount is allocated between common stock and other participating securities based on their participation rights. Participating securities are comprised of Series A convertible preferred stock and participate in dividends, whether declared or not. Basic earnings per share is calculated by dividing net income or loss attributable to BioTime common shareholders by the weighted average number of shares of common stock outstanding, net of unvested restricted stock subject to repurchase by BioTime, if any, during the period. For periods in which BioTime reported a net loss, the participating securities are not contractually obligated to share in the losses of BioTime, and accordingly, no losses have been allocated to the participating securities. Diluted earnings per share is calculated by dividing the net income or loss attributable to BioTime common shareholders by the weighted average number of common shares outstanding, adjusted for the effects of potentially dilutive common stock, which are comprised of stock options and warrants, using the treasury-stock method, and convertible preferred stock, using the if-converted method. Because BioTime reported losses attributable to common stockholders for all periods presented, all potentially dilutive common stock are antidilutive for those periods. Diluted net loss per share for the three months ended March 31, 2015 and 2014 excludes any effect from 4,893,942 treasury shares, 4,266,605 options and 9,194,679 warrants and 10,546,137 treasury shares, 5,491,301 options and 9,751,615 warrants, respectively, because their inclusion would be antidilutive.</div></div><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair value of financial instruments</a></td>
        <td class="text"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;">Fair value of financial instruments</font> &#8211; The fair value of BioTime&#8217;s assets and liabilities, which qualify as financial instruments under FASB guidance regarding disclosures about fair value of financial instruments, approximate the carrying amounts presented in the accompanying consolidated balance sheets. The carrying amounts of cash equivalents, accounts receivable, prepaid expenses and other current assets, accounts payable, accrued expenses and other current liabilities approximate fair values because of the short-term nature of these items.</div></div><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently issued accounting pronouncements</a></td>
        <td class="text"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; font-style: italic; text-align: justify; text-indent: 36pt;"><font style="font-weight: normal;">Recently Issued Accounting Pronouncements &#8211; </font><font style="font-weight: normal; font-style: normal;">There have been no recent accounting pronouncements or changes in accounting pronouncments during the three months ended March 31, 2015, as compared to the recent accounting pronouncements described in the Comany's 2014 Annual Report on Form 10-K that are of significance or potential significance to the Company.</font></div></div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btx_TreasuryStockPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for an entity's treasury stock, including common shares issued to subsidiaries for future potential working capital needs.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">btx_TreasuryStockPolicyTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>btx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btx_WarrantsToPurchaseCommonStockPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for an entity's warrants to purchase common stock, including common shares issued to subsidiaries for future potential working capital needs.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">btx_WarrantsToPurchaseCommonStockPolicyTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>btx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Cash<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Cash Equivalents<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4273-108586<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 305<br><br> -SubTopic 10<br><br> -Section 05<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6375392&amp;loc=d3e26790-107797<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 1<br><br> -Article 5<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Financial Reporting Release (FRR)<br><br> -Number 203<br><br> -Paragraph 02-03<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for credit risk.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 825<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28088331&amp;loc=SL29635902-196195<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 20<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35750535&amp;loc=d3e13531-108611<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 21<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35750535&amp;loc=d3e13537-108611<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 55<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6875567&amp;loc=d3e14489-108613<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 942<br><br> -SubTopic 825<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6480020&amp;loc=d3e61082-112788<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 942<br><br> -SubTopic 825<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6480020&amp;loc=d3e61044-112788<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfSalesPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for recognition of costs in the period which correspond to the sales and revenue categories presented in the statement of operations. The accounting policy may include the amount and nature of costs incurred, provisions associated with inventories, purchase discounts, freight and other costs included in cost of sales incurred and recorded in the period. This disclosure also includes the nature of costs of sales incurred and recorded in the statement of operations for the period relating to transactions with related parties.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 2<br><br> -Article 5<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 605<br><br> -SubTopic 50<br><br> -Section 45<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6408645&amp;loc=d3e63676-111659<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CostOfSalesPolicyTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredChargesPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for deferral and amortization of significant deferred charges.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.17)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 17<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DeferredChargesPolicyTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for determining the fair value of financial instruments.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35750535&amp;loc=d3e13279-108611<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 60<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 830<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 830<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6450222&amp;loc=d3e30840-110895<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 350<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35741047&amp;loc=d3e13816-109267<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 350<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16265-109275<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 5<br><br> -Section CC<br><br> -Subsection 3<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 05<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6390181&amp;loc=d3e202-110218<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 19<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32840-109319<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 30<br><br> -Section 05<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6423966&amp;loc=d3e40913-109327<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 954<br><br> -SubTopic 740<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6491622&amp;loc=d3e9504-115650<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 17<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32809-109319<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 25<br><br> -URI http://asc.fasb.org/extlink&amp;oid=37586315&amp;loc=d3e32247-109318<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=37586315&amp;loc=d3e32280-109318<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsFiniteLivedPolicyCostsIncurredToRenewOrExtend">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for the treatment of costs incurred to renew or extend the term of a recognized intangible asset.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 350<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16323-109275<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_IntangibleAssetsFiniteLivedPolicyCostsIncurredToRenewOrExtend</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for major classes of inventories, bases of stating inventories (for example, lower of cost or market), methods by which amounts are added and removed from inventory classes (for example, FIFO, LIFO, or average cost), loss recognition on impairment of inventories, and situations in which inventories are stated above cost. If inventory is carried at cost, this disclosure includes the nature of the cost elements included in inventory.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 6<br><br> -Subparagraph a<br><br> -Article 5<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.6(b))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 330<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28360613&amp;loc=d3e4492-108314<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 330<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28360613&amp;loc=d3e4556-108314<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Financial Reporting Release (FRR)<br><br> -Number 206<br><br> -Paragraph b<br><br> -Subparagraph i, ii<br><br> -Chapter 2<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for reclassifications that affects the comparability of the financial statements.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 205<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6359566&amp;loc=d3e326-107755<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PriorPeriodReclassificationAdjustmentDescription</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, basis of assets, depreciation and depletion methods used, including composite deprecation, estimated useful lives, capitalization policy, accounting treatment for costs incurred for repairs and maintenance, capitalized interest and the method it is calculated, disposals and impairments.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.13(a))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 13<br><br> -Subparagraph a<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 730<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Research and Development<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6523717<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for revenue recognition. If the entity has different policies for different types of revenue transactions, the policy for each material type of transaction is generally disclosed. If a sales transaction has multiple element arrangements (for example, delivery of multiple products, services or the rights to use assets) the disclosure may indicate the accounting policy for each unit of accounting as well as how units of accounting are determined and valued. The disclosure may encompass important judgment as to appropriateness of principles related to recognition of revenue. The disclosure also may indicate the entity's treatment of any unearned or deferred revenue that arises from the transaction.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18726-107790<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 13<br><br> -Section B<br><br> -Paragraph Question 1<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 605<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 13.B.Q1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012821&amp;loc=d3e214044-122780<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18823-107790<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for inclusion of significant items in the selling, general and administrative (or similar) expense report caption.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 720<br><br> -SubTopic 35<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6420018&amp;loc=d3e36677-107848<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for stock option and stock incentive plans. This disclosure may include (1) the types of stock option or incentive plans sponsored by the entity (2) the groups that participate in (or are covered by) each plan (3) significant plan provisions and (4) how stock compensation is measured, and the methodologies and significant assumptions used to determine that measurement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (b),(f)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TradeAndOtherAccountsReceivablePolicy">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for trade and other accounts receivables. This disclosure may include the basis at which such receivables are carried in the entity's statements of financial position (for example, net realizable value), how the entity determines the level of its allowance for doubtful accounts, when impairments, charge-offs or recoveries are recognized, and the entity's income recognition policies for such receivables, including its treatment of related fees and costs, its treatment of premiums, discounts or unearned income, when accrual of interest is discontinued, how the entity records payments received on nonaccrual receivables and its policy for resuming accrual of interest on such receivables.  If the enterprise holds a large number of similar loans, disclosure may include the accounting policy for the anticipation of prepayments and significant assumptions underlying prepayment estimates for amortization of premiums, discounts, and nonrefundable fees and costs.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 3, 4<br><br> -Article 5<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 310<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6378556&amp;loc=d3e10133-111534<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 310<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35738203&amp;loc=d3e5093-111524<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 310<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 15<br><br> -Subparagraph (d)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35738203&amp;loc=d3e5212-111524<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_TradeAndOtherAccountsReceivablePolicy</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Shareholders' Equity<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2015</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Shareholders' Equity [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Shareholders' Equity</a></td>
        <td class="text"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="text-align: justify;"><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 100%;"><tr><td style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 18pt; vertical-align: top; font-weight: bold; align: right;">9.</td><td style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: auto; vertical-align: top; font-weight: bold; text-align: justify;">Shareholders' Equity</td></tr></table></div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic; text-align: justify;">Preferred Shares</div><div style="text-align: justify;"><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; text-indent: 36pt;">BioTime is authorized to issue 2,000,000 shares of preferred stock. The preferred shares may be issued in one or more series as the board of directors may by resolution determine. The board of directors is authorized to fix the number of shares of any series of preferred shares and to determine or alter the rights, preferences, privileges, and restrictions granted to or imposed on the preferred shares as a class, or upon any wholly unissued series of any preferred shares. The board of directors may, by resolution, increase or decrease (but not below the number of shares of such series then outstanding) the number of shares of any series of preferred shares subsequent to the issue of shares of that series.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; text-indent: 36pt;">As of March 31, 2015, BioTime had 70,000 outstanding shares of Series A Convertible Preferred Stock (&#8220;Series A Preferred Stock&#8221;). The Series A Preferred Stock carries a cumulative annual 3% preferred dividend or $1.50 per share, in preference to BioTime common shares. Each share of Series A Preferred Stock is convertible, at the election of the holder, into BioTime common shares at a conversion price of $4.00 per share, a current conversion ratio of 12.5 common shares for each share of Series A Preferred Stock.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; text-indent: 36pt;">In addition to the preferred dividend, the Series A Preferred Stock will be entitled to participate with BioTime common shares in any dividends or distributions on common shares (other than dividends and distributions of common shares resulting in an adjustment of the conversion price) as if all shares of Series A Preferred Stock were then converted into common shares.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; text-indent: 36pt;">All outstanding Series A Preferred Stock will automatically be converted into common shares on March 4, 2019, or if holders of a majority of the outstanding shares of Series A Preferred Stock, voting as a class, approve or consent to a conversion. The conversion price is subject to prorata adjustment in the event of a subdivision or reclassification of the common shares into a greater number of shares, a stock dividend paid in common shares, or a stock combination or reclassification of the common shares into a smaller number of shares.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; text-indent: 36pt;">The Series A Preferred Stock will be entitled to vote with common shares on all matters submitted to common shareholders for approval. Each share of Series A Preferred Stock will be entitled to a number of votes equal to the number of common shares into which it could then be converted. The Series A Preferred Stock will also vote as a separate class on certain matters affecting those shares.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; text-indent: 36pt;">In the event of a liquidation or dissolution of BioTime, holders of Series A Preferred Stock will be entitled to receive payment of any accrued but unpaid preferred dividends before any assets may be distributed to holders of common shares. After payment of the accrued dividends, the Series A Preferred Stock will participate with the common shares in the distribution of any assets available to shareholders, as if the Series A Preferred Stock was then converted into common shares.</div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; text-indent: 36pt;">&#160;</div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic; text-align: justify;">Common Shares</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; text-indent: 36pt;">BioTime is authorized to issue 125,000,000 common shares with no par value. As of March 31, 2015, BioTime had 83,210,775 issued and 78,316,833 outstanding common shares. As of December 31, 2014, BioTime had 83,121,698 issued and 78,227,756 outstanding common shares. The difference of 4,893,942 common shares as of March 31, 2015 and December 31, 2014 is attributed to shares held by BioTime subsidiaries which are accounted for as treasury stock on the condensed consolidated balance sheet.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; text-indent: 36pt;">During the three months ended March 31, 2015 and 2014, BioTime granted 440,000 and 1,205,000 options, respectively, under its 2012 Equity Incentive Plan.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; text-indent: 36pt;">During the three months ended March 31, 2015, 89,077 options and no warrants were exercised.</div></div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(d),(e))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 4<br><br> -Subparagraph (SAB TOPIC 4.C)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187143-122770<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29-31)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 310<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SAB TOPIC 4.E)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 4<br><br> -Section C<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 4<br><br> -Section E<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Article 4<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21506-112644<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Preferred Stock<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6521494<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30, 31<br><br> -Article 5<br><br><br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br><br><br><br>Reference 15: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 11<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21564-112644<br><br><br><br>Reference 16: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21488-112644<br><br><br><br>Reference 17: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21484-112644<br><br><br><br>Reference 18: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph d<br><br> -Article 4<br><br><br><br>Reference 19: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23285-112656<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Accounts Payable and Accrued Liabilities<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2015</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Accounts Payable and Accrued Liabilities [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">Accounts Payable and Accrued Liabilities</a></td>
        <td class="text"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="text-align: justify;"><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 100%;"><tr><td style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 18pt; vertical-align: top; font-weight: bold; align: right;">7.</td><td style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: auto; vertical-align: top; font-weight: bold; text-align: justify;">Accounts Payable and Accrued Liabilities</td></tr></table></div><div style="text-align: justify;"><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; text-indent: 36pt;">At March 31, 2015 and December 31, 2014, accounts payable and accrued liabilities consisted of the following:</div><div><br /></div><table cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 100%;"><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" style="vertical-align: bottom; white-space: nowrap; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; text-align: center;">March 31, 2015</div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; text-align: center;">(Unaudited)</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; text-align: center;">December 31,</div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; text-align: center;">2014</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td></tr><tr><td valign="bottom" style="width: 76%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Accounts payable</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">2,707,437</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">2,296,645</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="width: 76%; vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Accrued expenses</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">3,092,030</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">3,125,023</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="width: 76%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Accrued bonuses</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">240,689</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">964,189</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="width: 76%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Other current liabilities</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">282,251</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">417,316</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="width: 76%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Total</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">6,322,407</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">6,803,173</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;">&#160;</td></tr></table></div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.19(a),20,24)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 19<br><br> -Subparagraph a<br><br> -Article 5<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 20, 24<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Related Party Transactions and Related Party Convertible Debt<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2015</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions and Related Party Convertible Debt [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Party Transactions and Related Party Convertible Debt</a></td>
        <td class="text"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="text-align: left;"><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 100%;"><tr><td style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 18pt; vertical-align: top; font-weight: bold; align: right;">8.</td><td style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: auto; vertical-align: top; font-weight: bold; text-align: left;">Related Party Transactions and Related Party Convertible Debt</td></tr></table></div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; text-indent: 36pt;">BioTime currently pays $5,050 per month for the use of approximately 900 square feet of office space in New York City, which is made available to BioTime on a month-by-month basis by one of its directors at his cost for use in conducting meetings and other business affairs.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; text-indent: 36pt;">In February 2015, Asterias raised approximately $5.5 million in aggregate gross proceeds from the sale of 1,410,255 shares of Series A Common Stock at a price of $3.90 per share through an underwritten public offering and a private placement. Broadwood Partners, L.P., British &amp; American Investment Trust PLC and Pedro Lichtinger purchased an aggregate of 1,025,640 of the shares. Broadwood Partners, L.P. is BioTime&#8217;s largest shareholder and one of its directors, Neal C. Bradsher, is President, and one of Asterias&#8217; directors, Richard T. LeBuhn, is Senior Vice President, of Broadwood Capital, Inc., the investment manager of Broadwood Partners, L.P. Pedro Lichtinger is Asterias&#8217; Chief Executive Officer and a member of its Board of Directors. British &amp; American Investment Trust PLC is an affiliate of a stockholder of Asterias and BioTime.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; text-indent: 36pt;">In July and September 2014, Cell Cure Neurosciences issued certain convertible notes (the &#8220;Convertible Notes&#8221;) to two Cell Cure Neurosciences shareholders other than BioTime in the principal amount of $470,876. One of the Cell Cure Neurosciences shareholders who acquired Convertible Notes is considered a related party.&#160;&#160; The functional currency of Cell Cure Neurosciences is the Israeli New Shekel, however the Convertible Notes are payable in United States dollars. The Convertible Notes bear a stated interest rate of 3% per annum. The total outstanding principal balance of the Convertible Notes, with accrued interest, is due and payable on various maturity dates in July and September 2017. The outstanding principal balance of the Convertible Notes with accrued interest is convertible into Cell Cure Neurosciences ordinary shares at a fixed conversion price of $20.00 per share, at the election of the holder, at any time prior to maturity. Any conversion of the Convertible Notes must be settled with Cell Cure Neurosciences ordinary shares and not with cash. The conversion feature of the Convertible Notes is not accounted for as an embedded derivative under the provisions of ASC 815,<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;"> Derivatives and Hedging</font> since it is not a freestanding financial instrument and the underlying Cell Cure Neurosciences ordinary shares are not readily convertible into cash. Accordingly, the Convertible Notes are accounted for under ASC 470-20,<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;"> Debt with Conversion and Other Options.</font> Under ASC 470-20, BioTime determined that a beneficial conversion feature (&#8220;BCF&#8221;) was present on the issuance dates of the Convertible Notes.</div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; text-indent: 36pt;">&#160;</div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; text-indent: 36pt;">A conversion feature is beneficial if, on the issuance dates, the effective conversion price is less than the fair value of the issuer&#8217;s capital stock. Since the effective conversion price of $20.00 per share is less than the estimated $41.00 per share fair value of Cell Cure Neurosciences ordinary shares on the dates the Convertible Notes were issued, a beneficial conversion feature equal to the intrinsic value is present. In accordance with ASC 470-20-30-8, if the intrinsic value of the BCF is greater than the proceeds allocated to the convertible instrument, the amount of the discount assigned to the BCF is limited to the amount of the proceeds allocated to the convertible instrument. The BCF is recorded as an addition to equity with a corresponding reduction to the carrying value of the convertible debt instrument. In the case of the Convertible Notes, this reduction represents a debt discount equal to the principal amount of $470,876 on the issuance dates. This debt discount will be amortized to interest expense using the effective interest method over the three-year term of the debt, representing an approximate effective annual interest rate of 23%. As of March 31, 2015, the carrying value of the Convertible Notes was $169,908, comprised of principal and accrued interest of $534,816, net of unamortized debt discount of $364,908.</div></div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 850<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39622-107864<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 850<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39603-107864<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 850<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph b<br><br> -Article 3A<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(k))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph k<br><br> -Article 4<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 850<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 850<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39678-107864<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Sales of BioTime Common Shares by Subsidiaries<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2015</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_SalesOfBioTimeCommonSharesBySubsidiariesAbstract', window );"><strong>Sales of BioTime Common Shares by Subsidiaries [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_SalesOfBiotimeCommonSharesBySubsidiariesTextBlock', window );">Sales of BioTime Common Shares by Subsidiaries</a></td>
        <td class="text"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="text-align: left;"><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 100%;"><tr><td style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 18pt; vertical-align: top; font-weight: bold; align: right;">10.</td><td style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: auto; vertical-align: top; font-weight: bold; text-align: left;">Sales of BioTime Common Shares by Subsidiaries</td></tr></table></div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; text-indent: 36pt;">Certain BioTime subsidiaries hold BioTime common shares that the subsidiaries received from BioTime in exchange for capital stock in the subsidiaries. The BioTime common shares held by subsidiaries are treated as treasury stock by BioTime and BioTime does not recognize a gain or loss on the sale of those shares by its subsidiaries.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; text-indent: 36pt;">During June 2014, Asterias sold 5,000,000 of its BioTime common shares with warrants to purchase 5,000,000 shares of Asterias Series B common stock to two investors for $12,500,000 in cash. Broadwood Partners, L.P., purchased 1,000,000 of the BioTime common shares with 1,000,000 Asterias warrants and a trust previously established by George Karfunkel purchased 4,000,000 of the BioTime common shares with 4,000,000 Asterias warrants.</div></div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btx_SalesOfBioTimeCommonSharesBySubsidiariesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">btx_SalesOfBioTimeCommonSharesBySubsidiariesAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>btx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btx_SalesOfBiotimeCommonSharesBySubsidiariesTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Refers to sales of BioTime Common Shares by Subsidiaries.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">btx_SalesOfBiotimeCommonSharesBySubsidiariesTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>btx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EWPAG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Sales of BioTime Common Shares by Subsidiaries (Details) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="1">1 Months Ended</th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Jun. 30, 2014</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2015

</div>
          <div>Investor</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_SharesSoldByThirdParty', window );">Number of shares sold (in shares)</a></td>
        <td class="nump"><a title="btx_SharesSoldByThirdParty" onclick="toggleNextSibling(this);">5,000,000</a><span style="display:none;white-space:normal;text-align:left;">btx_SharesSoldByThirdParty</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=btx_AsteriasBiotherapeuticsMember', window );">Asterias Biotherapeutics [Member] | BioTime Common Stock [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_SharesSoldByThirdParty', window );">Number of shares sold (in shares)</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="btx_SharesSoldByThirdParty[us-gaap_RelatedPartyTransactionAxis=us-gaap_CommonStockMember;us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=btx_AsteriasBiotherapeuticsMember]" onclick="toggleNextSibling(this);">5,000,000</a><span style="display:none;white-space:normal;text-align:left;">btx_SharesSoldByThirdParty<br>/ us-gaap_RelatedPartyTransactionAxis<br>= us-gaap_CommonStockMember<br>/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis<br>= btx_AsteriasBiotherapeuticsMember</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_NumberOfInvestors', window );">Number of investors</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="btx_NumberOfInvestors[us-gaap_RelatedPartyTransactionAxis=us-gaap_CommonStockMember;us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=btx_AsteriasBiotherapeuticsMember]" onclick="toggleNextSibling(this);">2</a><span style="display:none;white-space:normal;text-align:left;">btx_NumberOfInvestors<br>/ us-gaap_RelatedPartyTransactionAxis<br>= us-gaap_CommonStockMember<br>/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis<br>= btx_AsteriasBiotherapeuticsMember</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity', window );">Proceeds from sale of BioTime stock</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity[us-gaap_RelatedPartyTransactionAxis=us-gaap_CommonStockMember;us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=btx_AsteriasBiotherapeuticsMember]" onclick="toggleNextSibling(this);">$ 12,500,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity<br>/ us-gaap_RelatedPartyTransactionAxis<br>= us-gaap_CommonStockMember<br>/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis<br>= btx_AsteriasBiotherapeuticsMember</span><span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=btx_AsteriasBiotherapeuticsMember', window );">Asterias Biotherapeutics [Member] | Asterias Series B Common Stock [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Number of shares purchased (in shares)</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_SharesIssued[us-gaap_RelatedPartyTransactionAxis=us-gaap_CommonClassBMember;us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=btx_AsteriasBiotherapeuticsMember]" onclick="toggleNextSibling(this);">5,000,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_SharesIssued<br>/ us-gaap_RelatedPartyTransactionAxis<br>= us-gaap_CommonClassBMember<br>/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis<br>= btx_AsteriasBiotherapeuticsMember</span><span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_DirectorMember', window );">Broadwood Partners, LP [Member] | BioTime Common Stock [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Number of shares purchased (in shares)</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_SharesIssued[us-gaap_RelatedPartyTransactionAxis=us-gaap_CommonStockMember;us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_DirectorMember]" onclick="toggleNextSibling(this);">1,000,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_SharesIssued<br>/ us-gaap_RelatedPartyTransactionAxis<br>= us-gaap_CommonStockMember<br>/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis<br>= us-gaap_DirectorMember</span><span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_DirectorMember', window );">Broadwood Partners, LP [Member] | Asterias Warrants [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Number of warrants issued (in shares)</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight[us-gaap_RelatedPartyTransactionAxis=us-gaap_WarrantMember;us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_DirectorMember]" onclick="toggleNextSibling(this);">1,000,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight<br>/ us-gaap_RelatedPartyTransactionAxis<br>= us-gaap_WarrantMember<br>/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis<br>= us-gaap_DirectorMember</span><span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_MajorityShareholderMember', window );">George Karfunkel [Member] | BioTime Common Stock [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Number of shares purchased (in shares)</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_SharesIssued[us-gaap_RelatedPartyTransactionAxis=us-gaap_CommonStockMember;us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_MajorityShareholderMember]" onclick="toggleNextSibling(this);">4,000,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_SharesIssued<br>/ us-gaap_RelatedPartyTransactionAxis<br>= us-gaap_CommonStockMember<br>/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis<br>= us-gaap_MajorityShareholderMember</span><span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_MajorityShareholderMember', window );">George Karfunkel [Member] | Asterias Warrants [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Number of warrants issued (in shares)</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight[us-gaap_RelatedPartyTransactionAxis=us-gaap_WarrantMember;us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_MajorityShareholderMember]" onclick="toggleNextSibling(this);">4,000,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight<br>/ us-gaap_RelatedPartyTransactionAxis<br>= us-gaap_WarrantMember<br>/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis<br>= us-gaap_MajorityShareholderMember</span><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btx_NumberOfInvestors">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Refers to number of investors.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">btx_NumberOfInvestors</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>btx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:integerItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btx_SharesSoldByThirdParty">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The number of shares sold by third parities during the period reported.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">btx_SharesSoldByThirdParty</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>btx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow associated with the sale of equity securities classified as available-for-sale securities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Investing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 12<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3179-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 320<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 11<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6871852&amp;loc=d3e26853-111562<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_SharesIssued</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=btx_AsteriasBiotherapeuticsMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=btx_AsteriasBiotherapeuticsMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_DirectorMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_DirectorMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_MajorityShareholderMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_MajorityShareholderMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Equipment, net and construction in progress (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2015</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Equipment, net, and construction in progress [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Equipment, furniture and fixtures</a></td>
        <td class="text"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; text-indent: 36pt;">At March 31, 2015 and December 31, 2014, equipment, furniture and fixtures, and construction in progress were comprised of the following:</div><div><br /></div><table cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 100%;"><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" style="vertical-align: bottom; white-space: nowrap; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; text-align: center;">March 31, 2015</div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; text-align: center;">(Unaudited)</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; text-align: center;">December 31,</div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; text-align: center;">2014</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td></tr><tr><td valign="bottom" style="width: 76%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Equipment, furniture and fixtures</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">4,928,857</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">4,870,516</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="width: 76%; vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Construction in progress</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">606,641</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">405,730</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="width: 76%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Accumulated depreciation</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">(2,670,829</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">(2,418,400</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">)</div></td></tr><tr><td valign="bottom" style="width: 76%; vertical-align: bottom; padding-bottom: 4px; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Equipment net,&#160;and construction in progress</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">2,864,669</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">2,857,846</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #ffffff;">&#160;</td></tr></table></div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.13)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 13<br><br> -Subparagraph b<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0ECKAI">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="1">1 Months Ended</th>
        <th class="th" colspan="2">3 Months Ended</th>
        <th class="th" colspan="1"></th>
      </tr>
      <tr>
        <th class="th">
          <div>Jun. 30, 2014</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2015</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Trade receivable</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_AccountsReceivableNetCurrent" onclick="toggleNextSibling(this);">$ 605,800</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AccountsReceivableNetCurrent</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_AccountsReceivableNetCurrent" onclick="toggleNextSibling(this);">$ 549,300</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AccountsReceivableNetCurrent</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrantsReceivableCurrent', window );">Grants receivable</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_GrantsReceivableCurrent" onclick="toggleNextSibling(this);">260,300</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_GrantsReceivableCurrent</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_GrantsReceivableCurrent" onclick="toggleNextSibling(this);">492,600</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_GrantsReceivableCurrent</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent', window );">Allowance for doubtful accounts</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" onclick="toggleNextSibling(this);">100,500</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" onclick="toggleNextSibling(this);">100,500</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency gain (loss) included in comprehensive loss</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num"><a title="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" onclick="toggleNextSibling(this);">(53,167)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</span><span></span></td>
        <td class="num"><a title="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" onclick="toggleNextSibling(this);">(107,240)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax', window );">Foreign currency transaction gain (loss)</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num"><a title="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" onclick="toggleNextSibling(this);">(205,149)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ForeignCurrencyTransactionGainLossBeforeTax</span><span></span></td>
        <td class="num"><a title="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" onclick="toggleNextSibling(this);">(10,212)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ForeignCurrencyTransactionGainLossBeforeTax</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Taxes [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued', window );">Accrued interest and penalties</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued</span><span></span></td>
        <td class="nump"><a title="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred income tax benefit</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num"><a title="us-gaap_DeferredIncomeTaxExpenseBenefit" onclick="toggleNextSibling(this);">(1,176,882)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredIncomeTaxExpenseBenefit</span><span></span></td>
        <td class="num"><a title="us-gaap_DeferredIncomeTaxExpenseBenefit" onclick="toggleNextSibling(this);">(1,349,026)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredIncomeTaxExpenseBenefit</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit', window );">Deferred income tax benefit, federal</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" onclick="toggleNextSibling(this);">1,251,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredFederalIncomeTaxExpenseBenefit</span><span></span></td>
        <td class="nump"><a title="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" onclick="toggleNextSibling(this);">1,151,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredFederalIncomeTaxExpenseBenefit</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit', window );">Deferred income tax benefit, state taxes</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" onclick="toggleNextSibling(this);">74,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit</span><span></span></td>
        <td class="nump"><a title="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" onclick="toggleNextSibling(this);">198,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_SharesSoldByThirdParty', window );">Number of shares sold by subsidiary (in shares)</a></td>
        <td class="nump"><a title="btx_SharesSoldByThirdParty" onclick="toggleNextSibling(this);">5,000,000</a><span style="display:none;white-space:normal;text-align:left;">btx_SharesSoldByThirdParty</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_TaxableGainOnSaleOfSubsidiaryShares', window );">Taxable gain on sale of subsidiary shares</a></td>
        <td class="nump"><a title="btx_TaxableGainOnSaleOfSubsidiaryShares" onclick="toggleNextSibling(this);">10,300,000</a><span style="display:none;white-space:normal;text-align:left;">btx_TaxableGainOnSaleOfSubsidiaryShares</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_TaxPayableOnSaleOfSubsidiaryShares', window );">Tax payable on sale of subsidiary shares</a></td>
        <td class="nump"><a title="btx_TaxPayableOnSaleOfSubsidiaryShares" onclick="toggleNextSibling(this);">$ 3,600,000</a><span style="display:none;white-space:normal;text-align:left;">btx_TaxPayableOnSaleOfSubsidiaryShares</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Intangible asset, useful life</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">10 years<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_TreasuryStockMember', window );">Treasury Shares [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive shares excluded from computation of diluted loss per share (in shares)</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount[us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_TreasuryStockMember]" onclick="toggleNextSibling(this);">4,893,942</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount<br>/ us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis<br>= us-gaap_TreasuryStockMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount[us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_TreasuryStockMember]" onclick="toggleNextSibling(this);">10,546,137</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount<br>/ us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis<br>= us-gaap_TreasuryStockMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive shares excluded from computation of diluted loss per share (in shares)</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount[us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember]" onclick="toggleNextSibling(this);">4,266,605</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount<br>/ us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis<br>= us-gaap_EmployeeStockOptionMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount[us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember]" onclick="toggleNextSibling(this);">5,491,301</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount<br>/ us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis<br>= us-gaap_EmployeeStockOptionMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Warrants [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive shares excluded from computation of diluted loss per share (in shares)</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount[us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember]" onclick="toggleNextSibling(this);">9,194,679</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount<br>/ us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis<br>= us-gaap_WarrantMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount[us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember]" onclick="toggleNextSibling(this);">9,751,615</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount<br>/ us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis<br>= us-gaap_WarrantMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TechnologyBasedIntangibleAssetsMember', window );">Technology [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Intangible asset, useful life</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">10 years<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Equipment [Member] | Minimum [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Equipment useful life</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">36 months<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Equipment [Member] | Maximum [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Equipment useful life</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">120 months<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btx_SharesSoldByThirdParty">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The number of shares sold by third parities during the period reported.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">btx_SharesSoldByThirdParty</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>btx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btx_TaxableGainOnSaleOfSubsidiaryShares">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Refers to the taxable gain on the sale of subsidiary shares</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">btx_TaxableGainOnSaleOfSubsidiaryShares</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>btx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btx_TaxPayableOnSaleOfSubsidiaryShares">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Refers to the tax payable on sale of subsidiary shares.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">btx_TaxPayableOnSaleOfSubsidiaryShares</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>btx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.3-4)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 3<br><br> -Subparagraph a(1)<br><br> -Article 5<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 4<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>A valuation allowance for trade and other receivables due to an Entity within one year (or the normal operating cycle, whichever is longer) that are expected to be uncollectible.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 4<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 310<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35738203&amp;loc=d3e5074-111524<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.4)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Antidilution<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6505113<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Diluted Earnings Per Share<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6510752<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Contingent Stock Agreement<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6508534<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of deferred federal income tax expense (benefit) pertaining to income (loss) from continuing operations.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 6.I.7)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(h))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph h<br><br> -Article 4<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 6<br><br> -Section I<br><br> -Subsection 7<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Deferred Tax Expense (or Benefit)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6510177<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 9<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32639-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DeferredFederalIncomeTaxExpenseBenefit</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 6.I.7)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(h))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph h<br><br> -Article 4<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 6<br><br> -Section I<br><br> -Subsection 7<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Deferred Tax Expense (or Benefit)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6510177<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 9<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32639-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of deferred state and local tax expense (benefit) pertaining to income (loss) from continuing operations.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 6.I.7)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(h))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph h<br><br> -Article 4<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 6<br><br> -Section I<br><br> -Subsection 7<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Deferred Tax Expense (or Benefit)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6510177<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 9<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32639-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 830<br><br> -SubTopic 20<br><br> -Section 45<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6450189&amp;loc=d3e30690-110894<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 830<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6450222&amp;loc=d3e30840-110895<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 830<br><br> -SubTopic 20<br><br> -Section 45<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6450189&amp;loc=d3e30700-110894<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossBeforeTax</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrantsReceivableCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying amount as of the balance sheet date of amounts due under the terms of governmental, corporate, or foundation grants. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.8)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 8<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_GrantsReceivableCurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 220<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 10A<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=36458714&amp;loc=SL7669646-108580<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 830<br><br> -SubTopic 30<br><br> -Section 45<br><br> -Paragraph 20<br><br> -Subparagraph (b,c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6915805&amp;loc=d3e32211-110900<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 15<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32718-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_TreasuryStockMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_TreasuryStockMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TechnologyBasedIntangibleAssetsMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TechnologyBasedIntangibleAssetsMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EFLAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (UNAUDITED) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="2">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2015</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (UNAUDITED) [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">NET LOSS</a></td>
        <td class="num"><a title="us-gaap_ProfitLoss" onclick="toggleNextSibling(this);">$ (12,590,055)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ProfitLoss</span><span></span></td>
        <td class="num"><a title="us-gaap_ProfitLoss" onclick="toggleNextSibling(this);">$ (9,728,031)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ProfitLoss</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxAbstract', window );"><strong>Change in foreign currency translation and other comprehensive income/(loss) from equity investments:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax', window );">Unrealized loss on exchange translation in foreing subsidiaries</a></td>
        <td class="num"><a title="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" onclick="toggleNextSibling(this);">(53,323)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax</span><span></span></td>
        <td class="num"><a title="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" onclick="toggleNextSibling(this);">(104,590)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gain/(loss) on available-for-sale securities, net of taxes</a></td>
        <td class="nump"><a title="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" onclick="toggleNextSibling(this);">338</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</span><span></span></td>
        <td class="num"><a title="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" onclick="toggleNextSibling(this);">(2,650)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</span><span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">COMPREHENSIVE LOSS</a></td>
        <td class="num"><a title="us-gaap_ComprehensiveIncomeNetOfTax" onclick="toggleNextSibling(this);">(12,643,040)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ComprehensiveIncomeNetOfTax</span><span></span></td>
        <td class="num"><a title="us-gaap_ComprehensiveIncomeNetOfTax" onclick="toggleNextSibling(this);">(9,835,271)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ComprehensiveIncomeNetOfTax</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Less: Comprehensive loss attributable to non-controlling interest</a></td>
        <td class="nump"><a title="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" onclick="toggleNextSibling(this);">2,422,687</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</span><span></span></td>
        <td class="nump"><a title="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" onclick="toggleNextSibling(this);">1,629,017</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest', window );">COMPREHENSIVE LOSS ATTRIBUTABLE TO BIOTIME, INC. COMMON SHAREHOLDERS</a></td>
        <td class="num"><a title="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest" onclick="toggleNextSibling(this);">$ (10,220,353)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest</span><span></span></td>
        <td class="num"><a title="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest" onclick="toggleNextSibling(this);">$ (8,206,254)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest</span><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Other Comprehensive Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6519514<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Comprehensive Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35737396<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 220<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=36458714&amp;loc=d3e557-108580<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Net Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6518256<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1A<br><br> -URI http://asc.fasb.org/extlink&amp;oid=18733093&amp;loc=SL4573702-111684<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -Section 55<br><br> -Paragraph 4J<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35736750&amp;loc=SL4591551-111686<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount after tax, before reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 220<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 11<br><br> -URI http://asc.fasb.org/extlink&amp;oid=36458714&amp;loc=d3e637-108580<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 830<br><br> -SubTopic 30<br><br> -Section 45<br><br> -Paragraph 12<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6915805&amp;loc=d3e32022-110900<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 830<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 830<br><br> -SubTopic 30<br><br> -Section 45<br><br> -Paragraph 18<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6915805&amp;loc=d3e32157-110900<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 830<br><br> -SubTopic 30<br><br> -Section 45<br><br> -Paragraph 20<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6915805&amp;loc=d3e32211-110900<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 220<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 10A<br><br> -Subparagraph (a-c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=36458714&amp;loc=SL7669646-108580<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount after tax of other comprehensive income (loss) attributable to noncontrolling interests.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 20<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7656940&amp;loc=SL4569643-111683<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 19<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7656940&amp;loc=SL4569616-111683<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1A<br><br> -Subparagraph (c)(3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=18733093&amp;loc=SL4573702-111684<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount after tax, before reclassification adjustments, of unrealized holding gain (loss) on available-for-sale securities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 220<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 11<br><br> -URI http://asc.fasb.org/extlink&amp;oid=36458714&amp;loc=d3e637-108580<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 220<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 10A<br><br> -Subparagraph (e)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=36458714&amp;loc=SL7669646-108580<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -Section 55<br><br> -Paragraph 4K<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35736750&amp;loc=SL4591552-111686<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 19<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7656940&amp;loc=SL4569616-111683<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1A<br><br> -Subparagraph (a),(c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=18733093&amp;loc=SL4573702-111684<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -Section 55<br><br> -Paragraph 4J<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35736750&amp;loc=SL4591551-111686<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Equipment, net and construction in progress<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2015</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Equipment, net, and construction in progress [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Equipment, net, and construction in progress</a></td>
        <td class="text"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="text-align: justify;"><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 100%;"><tr><td style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 18pt; vertical-align: top; font-weight: bold; align: right;">4.</td><td style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: auto; vertical-align: top; font-weight: bold; text-align: justify;">Equipment, net and construction in progress</td></tr></table></div><div style="text-align: justify;"><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; text-indent: 36pt;">At March 31, 2015 and December 31, 2014, equipment, furniture and fixtures, and construction in progress were comprised of the following:</div><div><br /></div><table cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 100%;"><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" style="vertical-align: bottom; white-space: nowrap; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; text-align: center;">March 31, 2015</div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; text-align: center;">(Unaudited)</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; text-align: center;">December 31,</div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; text-align: center;">2014</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td></tr><tr><td valign="bottom" style="width: 76%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Equipment, furniture and fixtures</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">4,928,857</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">4,870,516</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="width: 76%; vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Construction in progress</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">606,641</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">405,730</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="width: 76%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Accumulated depreciation</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">(2,670,829</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">(2,418,400</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">)</div></td></tr><tr><td valign="bottom" style="width: 76%; vertical-align: bottom; padding-bottom: 4px; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Equipment net,&#160;and construction in progress</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">2,864,669</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">2,857,846</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #ffffff;">&#160;</td></tr></table><div style="text-align: justify;"><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; margin-left: 0.1pt; margin-right: 0.1pt; text-indent: 36pt;">Equipment, furniture and fixtures, and construction in progress at March 31, 2015 include $115,000 financed by capital lease borrowings in June 2014 and $606,641 of construction in progress for Asterias&#8217; Fremont facility. Depreciation expense amounted to $262,600 and $256,945 for the three months ended March 31, 2015 and 2014, respectively. The difference between the depreciation expense recognized in the consolidated statement of operations and the increase in accumulated depreciation of $252,429 in the consolidated balance sheet is partially attributed to the sale of partially depreciated assets and foreign currency rates.</div><div style="text-align: justify; margin-left: 0.1pt; margin-right: 0.1pt; text-indent: 36pt;"><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic; text-align: justify; margin-right: 0.1pt;">Construction in progress</div><div style="text-align: justify; margin-left: 0.1pt; margin-right: 0.1pt; text-indent: 36pt;"><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; text-indent: 36pt;">Construction in progress of $606,641 as of March 31, 2015 entirely relates to the improvements for Asterias' Fremont facility. Under the terms of the lease agreement, the landlord has provided Asterias with a tenant improvement allowance of $4,400,000, which Asterias is using to construct a laboratory and production facility that can be used to produce human embryonic stem cell and related products under cGMP. Of the $606,641, $560,970 qualify for reimbursement under the tenant improvement allowance. As of March 31, 2015, we received $283,764 from the landlord. The facility is expected to be substantially completed and placed into service in the third quarter of 2015.</div></div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, accounting policies and methodology, roll forwards, depreciation, depletion and amortization expense, including composite depreciation, accumulated depreciation, depletion and amortization expense, useful lives and method used, income statement disclosures, assets held for sale and public utility disclosures.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391110&amp;loc=d3e2921-110230<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 205<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6360339&amp;loc=d3e1361-107760<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.13-14)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0E6AAC">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>Inventory (Details) (USD $)<br></strong></div>
        </th>
        <th class="th">
          <div>Mar. 31, 2015</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoodsNetOfReserves', window );">Inventory of finished products on-site</a></td>
        <td class="nump"><a title="us-gaap_InventoryFinishedGoodsNetOfReserves" onclick="toggleNextSibling(this);">$ 286,513</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_InventoryFinishedGoodsNetOfReserves</span><span></span></td>
        <td class="nump"><a title="us-gaap_InventoryFinishedGoodsNetOfReserves" onclick="toggleNextSibling(this);">$ 253,227</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_InventoryFinishedGoodsNetOfReserves</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment', window );">Inventory held by third party on consignment</a></td>
        <td class="nump"><a title="us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment" onclick="toggleNextSibling(this);">$ 12,795</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment</span><span></span></td>
        <td class="nump"><a title="us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment" onclick="toggleNextSibling(this);">$ 12,795</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment</span><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoodsNetOfReserves">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.6(a)(1))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 330<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SAB TOPIC 5.BB)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 6<br><br> -Article 5<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 5<br><br> -Section BB<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_InventoryFinishedGoodsNetOfReserves</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Gross amount of inventory owned by the entity but in the hands of a customer, typically a reseller.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.6(a))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 6<br><br> -Subparagraph a<br><br> -Article 5<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 605<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 13.A.2.Q2 Response)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012821&amp;loc=d3e214044-122780<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<FilingSummary xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <Version>2.4.1.9</Version>
  <ProcessingTime />
  <ReportFormat>Html</ReportFormat>
  <ContextCount>49</ContextCount>
  <ElementCount>233</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>30</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>7</UnitCount>
  <MyReports>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000100 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biotimeinc.com/role/DocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
    </Report>
    <Report>
      <IsDefault>true</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>010000 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biotimeinc.com/role/CondensedConsolidatedBalanceSheetsUnaudited</Role>
      <ShortName>CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>010100 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biotimeinc.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical</Role>
      <ShortName>CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>020000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biotimeinc.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>030000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (UNAUDITED)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biotimeinc.com/role/CondensedConsolidatedStatementsOfComprehensiveLossUnaudited</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (UNAUDITED)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>040000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biotimeinc.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>060100 - Disclosure - Organization, Basis of Presentation, and Liquidity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biotimeinc.com/role/OrganizationBasisOfPresentationAndLiquidity</Role>
      <ShortName>Organization, Basis of Presentation, and Liquidity</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>060200 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biotimeinc.com/role/SummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>060300 - Disclosure - Inventory</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biotimeinc.com/role/Inventory</Role>
      <ShortName>Inventory</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>060400 - Disclosure - Equipment, net and construction in progress</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biotimeinc.com/role/EquipmentNetAndConstructionInProgress</Role>
      <ShortName>Equipment, net and construction in progress</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>060500 - Disclosure - Intangible assets, net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biotimeinc.com/role/IntangibleAssetsNet</Role>
      <ShortName>Intangible assets, net</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>060600 - Disclosure - Royalty Obligation and Deferred License Fees</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biotimeinc.com/role/RoyaltyObligationAndDeferredLicenseFees</Role>
      <ShortName>Royalty Obligation and Deferred License Fees</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>060700 - Disclosure - Accounts Payable and Accrued Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biotimeinc.com/role/AccountsPayableAndAccruedLiabilities</Role>
      <ShortName>Accounts Payable and Accrued Liabilities</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>060800 - Disclosure - Related Party Transactions and Related Party Convertible Debt</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biotimeinc.com/role/RelatedPartyTransactionsAndRelatedPartyConvertibleDebt</Role>
      <ShortName>Related Party Transactions and Related Party Convertible Debt</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>060900 - Disclosure - Shareholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biotimeinc.com/role/ShareholdersEquity</Role>
      <ShortName>Shareholders' Equity</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>061000 - Disclosure - Sales of BioTime Common Shares by Subsidiaries</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biotimeinc.com/role/SalesOfBiotimeCommonSharesBySubsidiaries</Role>
      <ShortName>Sales of BioTime Common Shares by Subsidiaries</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>061100 - Disclosure - Segment Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biotimeinc.com/role/SegmentInformation</Role>
      <ShortName>Segment Information</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>061200 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biotimeinc.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>070200 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biotimeinc.com/role/SummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>080100 - Disclosure - Organization, Basis of Presentation and Liquidity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biotimeinc.com/role/OrganizationBasisOfPresentationAndLiquidityTables</Role>
      <ShortName>Organization, Basis of Presentation and Liquidity (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>080400 - Disclosure - Equipment, net and construction in progress (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biotimeinc.com/role/EquipmentNetAndConstructionInProgressTables</Role>
      <ShortName>Equipment, net and construction in progress (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>080500 - Disclosure - Intangible assets, net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biotimeinc.com/role/IntangibleAssetsNetTables</Role>
      <ShortName>Intangible assets, net (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>080601 - Disclosure - Royalty Obligation and Deferred License Fees (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biotimeinc.com/role/RoyaltyObligationAndDeferredLicenseFeesTables</Role>
      <ShortName>Royalty Obligation and Deferred License Fees (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>080700 - Disclosure - Accounts Payable and Accrued Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biotimeinc.com/role/AccountsPayableAndAccruedLiabilitiesTables</Role>
      <ShortName>Accounts Payable and Accrued Liabilities (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>090100 - Disclosure - Organization, Basis of Presentation and Liquidity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biotimeinc.com/role/OrganizationBasisOfPresentationAndLiquidityDetails</Role>
      <ShortName>Organization, Basis of Presentation and Liquidity (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>090200 - Disclosure - Summary of Significant Accounting Policies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biotimeinc.com/role/SummaryOfSignificantAccountingPoliciesDetails</Role>
      <ShortName>Summary of Significant Accounting Policies (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>090300 - Disclosure - Inventory (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biotimeinc.com/role/InventoryDetails</Role>
      <ShortName>Inventory (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>090400 - Disclosure - Equipment, net and construction in progress (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biotimeinc.com/role/EquipmentNetAndConstructionInProgressDetails</Role>
      <ShortName>Equipment, net and construction in progress (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>090500 - Disclosure - Intangible assets, net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biotimeinc.com/role/IntangibleAssetsNetDetails</Role>
      <ShortName>Intangible assets, net (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>090602 - Disclosure - Royalty Obligation and Deferred License Fees (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biotimeinc.com/role/RoyaltyObligationAndDeferredLicenseFeesDetails</Role>
      <ShortName>Royalty Obligation and Deferred License Fees (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>090700 - Disclosure - Accounts Payable and Accrued Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biotimeinc.com/role/AccountsPayableAndAccruedLiabilitiesDetails</Role>
      <ShortName>Accounts Payable and Accrued Liabilities (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>090800 - Disclosure - Related Party Transactions and Related Party Convertible Debt (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biotimeinc.com/role/RelatedPartyTransactionsAndRelatedPartyConvertibleDebtDetails</Role>
      <ShortName>Related Party Transactions and Related Party Convertible Debt (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>090900 - Disclosure - Shareholders' Equity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biotimeinc.com/role/ShareholdersEquityDetails</Role>
      <ShortName>Shareholders' Equity (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>091000 - Disclosure - Sales of BioTime Common Shares by Subsidiaries (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biotimeinc.com/role/SalesOfBiotimeCommonSharesBySubsidiariesDetails</Role>
      <ShortName>Sales of BioTime Common Shares by Subsidiaries (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>091100 - Disclosure - Segment Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biotimeinc.com/role/SegmentInformationDetails</Role>
      <ShortName>Segment Information (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>091200 - Disclosure - Subsequent Events (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biotimeinc.com/role/SubsequentEventsDetails</Role>
      <ShortName>Subsequent Events (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Info">Element us-gaap_ProceedsFromIssuanceOfCommonStock had a mix of decimals attribute values: -5 0.</Log>
    <Log type="Info">Process Flow-Through: 010000 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)</Log>
    <Log type="Info">	Process Flow-Through: Removing column 'Mar. 31, 2014'</Log>
    <Log type="Info">	Process Flow-Through: Removing column 'Dec. 31, 2013'</Log>
    <Log type="Info">Process Flow-Through: 010100 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical)</Log>
    <Log type="Info">Process Flow-Through: 020000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)</Log>
    <Log type="Info">Process Flow-Through: 030000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (UNAUDITED)</Log>
    <Log type="Info">Process Flow-Through: 040000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)</Log>
  </Logs>
  <InputFiles>
    <File>btx-20150331.xml</File>
    <File>btx-20150331.xsd</File>
    <File>btx-20150331_cal.xml</File>
    <File>btx-20150331_def.xml</File>
    <File>btx-20150331_lab.xml</File>
    <File>btx-20150331_pre.xml</File>
  </InputFiles>
  <SupplementalFiles />
  <BaseTaxonomies />
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Organization, Basis of Presentation and Liquidity (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2015</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Basis of Presentation, and Liquidity [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTextBlock', window );">BioTime's ownership of outstanding shares of its subsidiaries</a></td>
        <td class="text"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div>The following table reflects BioTime&#8217;s ownership, directly or through one or more subsidiaries, of the outstanding shares of its subsidiaries as of March 31, 2015.</div><div><br /></div><table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 100%; border-collapse: collapse;"><tr><td style="border-top: #000000 2px solid; width: 23.28%; vertical-align: top; border-left: #000000 2px solid;"><div style="text-align: left;">&#160;</div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; text-align: center;">Subsidiary</div></td><td style="border-top: #000000 2px solid; width: 57%; vertical-align: top; border-left: #000000 2px solid;"><div style="text-align: left;">&#160;</div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; text-align: center;">Field of Business</div></td><td style="border-top: #000000 2px solid; width: 10%; vertical-align: top; border-left: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;">BioTime</div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;">Ownership</div></td><td style="border-top: #000000 2px solid; border-right: #000000 2px solid; width: 10%; vertical-align: top; border-left: #000000 2px solid;"><div style="text-align: left;">&#160;</div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; text-align: center;">Country</div></td></tr><tr><td style="border-top: #000000 2px solid; width: 23.28%; vertical-align: top; border-left: #000000 2px solid; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; margin-left: 7.7pt; text-indent: -7.7pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">Asterias Biotherapeutics, Inc. (</font>NYSE MKT: AST)</div></td><td style="border-top: #000000 2px solid; width: 57%; vertical-align: top; border-left: #000000 2px solid; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;">Research, development and commercialization of human therapeutic products from stem cells, focused initially in the fields of neurology and oncology</div></td><td style="border-top: #000000 2px solid; width: 10%; vertical-align: top; border-left: #000000 2px solid; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;">67.5%</div></td><td style="border-top: #000000 2px solid; border-right: #000000 2px solid; width: 10%; vertical-align: top; border-left: #000000 2px solid; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;">USA</div></td></tr><tr><td style="border-top: #000000 2px solid; width: 23.28%; vertical-align: top; border-left: #000000 2px solid; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; margin-left: 7.7pt; text-indent: -7.7pt;">BioTime Asia, Limited</div></td><td style="border-top: #000000 2px solid; width: 57%; vertical-align: top; border-left: #000000 2px solid; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;">Stem cell products for research</div></td><td style="border-top: #000000 2px solid; width: 10%; vertical-align: top; border-left: #000000 2px solid; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;">81%</div></td><td style="border-top: #000000 2px solid; border-right: #000000 2px solid; width: 10%; vertical-align: top; border-left: #000000 2px solid; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;">Hong Kong</div></td></tr><tr><td style="border-top: #000000 2px solid; width: 23.28%; vertical-align: top; border-left: #000000 2px solid; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; margin-left: 7.7pt; text-indent: -7.7pt;">Cell Cure Neurosciences Ltd.</div></td><td style="border-top: #000000 2px solid; width: 57%; vertical-align: top; border-left: #000000 2px solid; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;">Age-related macular degeneration</div></td><td style="border-top: #000000 2px solid; width: 10%; vertical-align: top; border-left: #000000 2px solid; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;">62.5%(1)</div></td><td style="border-top: #000000 2px solid; border-right: #000000 2px solid; width: 10%; vertical-align: top; border-left: #000000 2px solid; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;">Israel</div></td></tr><tr><td style="border-top: #000000 2px solid; width: 23.28%; vertical-align: top; border-left: #000000 2px solid; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; margin-left: 7.7pt; text-indent: -7.7pt;">ES Cell International Pte Ltd</div></td><td style="border-top: #000000 2px solid; width: 57%; vertical-align: top; border-left: #000000 2px solid; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;">Stem cell products for research, including clinical grade cell lines produced under cGMP</div></td><td style="border-top: #000000 2px solid; width: 10%; vertical-align: top; border-left: #000000 2px solid; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;">100%</div></td><td style="border-top: #000000 2px solid; border-right: #000000 2px solid; width: 10%; vertical-align: top; border-left: #000000 2px solid; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;">Singapore</div></td></tr><tr><td style="border-top: #000000 2px solid; width: 23.28%; vertical-align: top; border-left: #000000 2px solid; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; margin-left: 7.7pt; text-indent: -7.7pt;">LifeMap Sciences, Inc.</div></td><td style="border-top: #000000 2px solid; width: 57%; vertical-align: top; border-left: #000000 2px solid; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;">Biomedical, gene, disease, and stem cell databases and tools</div></td><td style="border-top: #000000 2px solid; width: 10%; vertical-align: top; border-left: #000000 2px solid; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;">75.8%</div></td><td style="border-top: #000000 2px solid; border-right: #000000 2px solid; width: 10%; vertical-align: top; border-left: #000000 2px solid; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;">USA</div></td></tr><tr><td style="border-top: #000000 2px solid; width: 23.28%; vertical-align: top; border-left: #000000 2px solid; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; margin-left: 7.7pt; text-indent: -7.7pt;">LifeMap Sciences, Ltd.</div></td><td style="border-top: #000000 2px solid; width: 57%; vertical-align: top; border-left: #000000 2px solid; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;">Biomedical, gene, disease, and stem cell databases and tools</div></td><td style="border-top: #000000 2px solid; width: 10%; vertical-align: top; border-left: #000000 2px solid; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;">(2)</div></td><td style="border-top: #000000 2px solid; border-right: #000000 2px solid; width: 10%; vertical-align: top; border-left: #000000 2px solid; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;">Israel</div></td></tr><tr><td style="border-top: #000000 2px solid; width: 23.28%; vertical-align: top; border-left: #000000 2px solid; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; margin-left: 7.7pt; text-indent: -7.7pt;">LifeMap Solutions, Inc.</div></td><td style="border-top: #000000 2px solid; width: 57%; vertical-align: top; border-left: #000000 2px solid; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;">Mobile health software</div></td><td style="border-top: #000000 2px solid; width: 10%; vertical-align: top; border-left: #000000 2px solid; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;">(2)</div></td><td style="border-top: #000000 2px solid; border-right: #000000 2px solid; width: 10%; vertical-align: top; border-left: #000000 2px solid; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;">USA</div></td></tr><tr><td style="border-top: #000000 2px solid; width: 23.28%; vertical-align: top; border-left: #000000 2px solid; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; margin-left: 7.7pt; text-indent: -7.7pt;">OncoCyte Corporation</div></td><td style="border-top: #000000 2px solid; width: 57%; vertical-align: top; border-left: #000000 2px solid; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;">Cancer diagnostics</div></td><td style="border-top: #000000 2px solid; width: 10%; vertical-align: top; border-left: #000000 2px solid; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;">75.3%</div></td><td style="border-top: #000000 2px solid; border-right: #000000 2px solid; width: 10%; vertical-align: top; border-left: #000000 2px solid; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;">USA</div></td></tr><tr><td style="border-top: #000000 2px solid; width: 23.28%; vertical-align: top; border-left: #000000 2px solid; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; margin-left: 7.7pt; text-indent: -7.7pt;">OrthoCyte Corporation</div></td><td style="border-top: #000000 2px solid; width: 57%; vertical-align: top; border-left: #000000 2px solid; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;">Orthopedic diseases, including chronic back pain and osteoarthritis</div></td><td style="border-top: #000000 2px solid; width: 10%; vertical-align: top; border-left: #000000 2px solid; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;">100%(3)</div></td><td style="border-top: #000000 2px solid; border-right: #000000 2px solid; width: 10%; vertical-align: top; border-left: #000000 2px solid; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;">USA</div></td></tr><tr><td style="border-top: #000000 2px solid; width: 23.28%; vertical-align: top; border-bottom: #000000 2px solid; border-left: #000000 2px solid; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; margin-left: 7.7pt; text-indent: -7.7pt;">ReCyte Therapeutics, Inc.</div></td><td style="border-top: #000000 2px solid; width: 57%; vertical-align: top; border-bottom: #000000 2px solid; border-left: #000000 2px solid; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;">Vascular disorders, including cardiovascular-related diseases, ischemic conditions, vascular injuries</div><div>&#160;</div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;">Stem cell-derived endothelial and cardiovascular related progenitor cells that have applications in research, drug testing, and therapeutics</div></td><td style="border-top: #000000 2px solid; width: 10%; vertical-align: top; border-bottom: #000000 2px solid; border-left: #000000 2px solid; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;">94.8%</div></td><td style="border-top: #000000 2px solid; border-right: #000000 2px solid; width: 10%; vertical-align: top; border-bottom: #000000 2px solid; border-left: #000000 2px solid; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;">USA</div></td></tr></table><div><br /></div><div style="text-align: left;"><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 100%;"><tr><td style="width: 18pt;"></td><td style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 18pt; vertical-align: top; align: right;">(1)</td><td style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: auto; vertical-align: top; text-align: left;">Includes shares owned by <font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">BioTime, Asterias, and ESI.</font></td></tr></table></div><div style="text-align: left;"><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 100%;"><tr><td style="width: 18pt;"></td><td style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 18pt; vertical-align: top; align: right;">(2)</td><td style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: auto; vertical-align: top; text-align: left;">LifeMap Sciences, Ltd. and LifeMap Solutions, Inc. are wholly-owned subsidiaries of LifeMap Sciences, Inc.</td></tr></table></div><div style="text-align: left;"><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 100%;"><tr><td style="width: 18pt;"></td><td style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 18pt; vertical-align: top; align: right;">(3)</td><td style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: auto; vertical-align: top; text-align: left;">Includes shares owned by BioTime and Asterias.</td></tr></table></div></div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The tabular disclosure of the effects of any changes in a parent's ownership interest in a subsidiary on the equity attributable to the parent if the ownership interests in a subsidiary changes during the period. The changes represented by this element did not result in the deconsolidation of the subsidiary.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1A<br><br> -Subparagraph (d)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=18733093&amp;loc=SL4573702-111684<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -Section 55<br><br> -Paragraph 4M<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35736750&amp;loc=SL4591554-111686<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
